CONTENTS

ABSTRACTS

Presidential Lecture ........................................... S2
Presidential Symposium ...................................... S2
Special Symposium .......................................... S3
Symposium ..................................................... S5
Educational Lecture .......................................... S32
Meet the Expert .............................................. S38
Luncheon Seminar ........................................... S45
Evening Seminar .............................................. S58
Annual Course Lecture Luncheon Seminar ................. S67
Workshop ....................................................... S67
International Concurrent Workshop ....................... S173
Poster Session ............................................... S211
English Poster Session ..................................... S393

AUTHORS’ INDEX ............................................. S403
President Lecture

PL
Talk about the future
Hisashi Yamanaka
Department of Rheumatology, Tokyo Women’s Medical University
School of Medicine, Tokyo, Japan

Conflict of interest: None

The 63rd Annual General Assembly and Scientific Meeting of the Japan College of Rheumatology will be held at Kyoto from April 15th to 17th, 2019. And, two weeks after this meeting, Heisei era will be terminated. During the 30 years of Heisei era, rheumatology has made a tremendous progress. MTX was approved in 1999, the first biologics was approved in 2003, and the management of rheumatoid arthritis (RA) has been remarkably changed. IORRA cohort study conducted in Institute of Rheumatology, Tokyo Women’s Medical University from 2000, has continuously recorded the changes of the patient’s outcome in these years. Remission, once was a dream in Heisei 1st, however, has become reality in 55% of patients in Heisei 30th. Indeed, a dream has become a reality. Over the last 15 years, we have discussed the methodology how to achieve remission (Toward Remission). However, nowadays when the remission rate become over 50%, we should discuss how to optimize the treatment strategy in patients who has achieved remission (Beyond Remission). These include the reduction/discontinuation of drugs, pharmacoeconomical issues and others. However, along with the EBM centered medicine, we may have weighted toward the feasible, short term outcomes. Now, it is quite important to verify the long-term outcome of patients, since all clinical practitioner wishes the patients who have unfortunately suffered from chronic illness can spend a happy life. Furthermore, we have come to a point to consider the essential questions, how can we cure RA or how can we prevent the onset of RA. These are dreams now, however, someday dream will become reality, just as the speech of Martin Luther King, Jr., as ‘I have a dream’. However, dream is a dream, reality cannot be achieved without the effort to have steps to the reality. First, we need to have dream, then to have steps toward the reality. As the president of JCR 219, I would like to take the opportunity of the Presidential Speech to emphasize the importance of the long-term outcome of patients, and the necessity to have dreams.

President Symposium

PS-1
Future rheumatology – evolution, revolution and disruption
Gerd R Burmester1,2
1Department of Rheumatology and Clinical Immunology, Charite University Hospital, Berlin, Germany, 2Free University and Humboldt University of Berlin, Germany

Conflict of interest: None

Medicine as one of the most important disciplines for the welfare of the human being is currently at the brink of major disruptive changes. Examples include automated reading and evaluation of CT and MRI images in radiology, detection of skin tumors via smartphones in dermatology, automated evaluation of the retina, e.g. in diabetes or macular degeneration in ophthalmology and investigation of the gene expression profile for the planning of optimal chemotherapy in pathology. Rheumatology is one of the most successful disciplines in medicine, especially with regard to integrating novel diagnostic and therapeutic tools, which has dramatically changed the course of especially inflammatory rheumatic diseases. Nevertheless, also in rheumatology many changes can be envisioned. These include the dramatic new developments in systems biology with new technologies based on “big data” for complex biological systems that we encounter particularly in the multifactorial rheumatic diseases. These address the high volume of data composed of clinical data, “omics”, sensors/wearables, speed of data generation and processing, variety (history, imaging, lab data, insurance data, omics, social media), velocity and value (utilizing the data to the interest of the patient). Novel approaches will allow insights into disease mechanisms and may lead to new diagnostic and therapeutic tools. The combination of clinical signs, novel biomarkers and imaging techniques will make diagnosis much easier, and telemedicine approaches will allow access to specialists around the world addressing also rare diseases. This lecture will cover some of these items and hopefully raise enthusiasm for the new developments in our exciting discipline.

PS-2
Rheumatoid Arthritis and the Mucosal Origins Hypothesis: Implications for Pathogenesis and Prevention
Michael V Holers1, Yuko Okamoto1, Kristine A Kuhn1, Meagan Chriswell1, Nickie Seto1, Mariana J Kaplan2, Ashley Visser1, Marie Feser1, Laura K Moss1, Jennifer Seifert1, Kristen J Polinski3, Jill M Norris1, Kristen M Demoruelle1, Kevin D Deane1
1University of Colorado School of Medicine, Denver, USA, 2Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, USA, 3Colorado School of Public Health, Department of Epidemiology, Aurora, USA

Conflict of interest: Yes

Individuals at high risk for the future development of seropositive rheumatoid arthritis (RA) can be identified by first-degree relative status to an RA proband or the presence in the serum of highly informative and predictive patterns of RA-related autoantibodies, including anti-citrullinated protein antibodies (ACPA) and/or at least two rheumatoid factor (RF) isotypes. Prior studies using HRCT imaging of the lungs have shown that a subset of serum RA-related autoantibody positive at-risk individuals exhibit small airways disease. Recent studies in at-risk individuals have demonstrated the presence of pulmonary mucosal inflammatory processes associated with local sputum ACPA production, as measured by cyclic citrullinated peptide 3 (CCP3) immunoreactivity. Sputum anti-CCP3 positivity was also associated with sputum hyper-cellularity as well as increased neutrophil extracellular traps (NETs). In further analyses, the proportion of sputum neutrophils undergoing NETosis containing citrullinated-histone H3 (cit-H3) was significantly higher in at-risk subjects. In addition, sputum ACPA and DNA-cit-H3 levels significantly correlated with local levels of key pro-inflammatory cytokines. Other mucosal sites in at-risk individuals, including the cervico-vaginal, periodontal and gut mucosa, also exhibited autoantibody production, inflammation and/or evidence of dysbiosis. With regard to environmental exposures, there was an apparent protective relationship of high levels of omega-3 intake on ACPA and RF positivity. A murine model has been developed.
that demonstrates several features relevant to human disease pathogenesis. Finally, CCP3+ at-risk individuals are being enrolled in the STOPRA prevention trial, which compares hydroxychloroquine to placebo on the development of biomarkers and classified RA. In sum, it is likely that future treatment of RA will include prevention and novel therapies targeting immune processes that are unique to the pre-clinical period of disease.

**PS-3**  
**How can we make discoveries in medicine? I learned from my experience**  
Naoyuki Kamatani  
Gout Foundation of Japan  
Conflict of interest: Yes

It is an important strategy to conduct medical research in accordance with consensus of the current academic society. However, it is equally important to aim for discoveries far away from it. I mainly conducted research following the latter strategy, so I will explain the method that can be recommended in such a case. The important thing is “to find a similar structure in different layers and discover a missing element in one layer”. The element that appears to be missing in one layer is often not actually absent, but is only difficult to recognize. Discovering it leads to big discoveries, and discerning its presence leads to good predictions. In 2015, I proposed a “six-layer structure” consisting of life, species, groups, families, individuals, and cells as a framework to make discoveries in medicine and biology. Each is a collection of elements with that layer’s name, and the previous layer is a set of subsequent layers. We reported MTAP deficiency of human cancer cells, the first reported result of a mutation of a tumor suppressor gene. That was based on the fact that genetic enzyme deficiency present in the individual layer and the species layer was missing in the cell layer. The first proposal for personalized treatment of cancer (for MTAP-deficient cancer) was based on the fact that antibiotics take advantage of the genetic difference between humans and bacteria in the species layer. Thus, we may be able to take advantage of the genetic difference between normal and malignant cells in the cell layer. A similar rationale was used in the development of cladribine, a drug for lymphocytic leukemia, and febuxostat, a drug for gout. Now I am developing a new drug ATP enhancer whose idea originated from a similar rationale that the importance of energy (ATP) is, unlike things (compounds) and information (gene), not sufficiently recognized in the cell layer despite the fact that the importance of the three items are well recognized in the society (population layer).

**Special Symposium**

**SS1-1**  
**From “The Lady of the Lamp” to “The Lady of the Stamp” – Nightingale’s life from the viewpoint of the “gender equality” era –**  
Oikiko Miyake1,2  
1Baika Women’s University, Japan, 2International Institute for Children’s Literature, Osaka, Japan  
Conflict of interest: None

As female role models, Florence Nightingale, Marie Curie and Helen Keller have enjoyed popularity beyond the times. Unfortunately, no such role models can be found in Japanese history, so I will consider Nightingale, who contributed to medical development, as a case for “gender equality”. Nightingale (1820-1910) worked with 38 nurses during the Crimean War. This lasted for about 2 years in the mid-30s, but has brought her international fame. She published “Notes on Nursing” at the age of 39 and established the Nightingale Nursing School the following year. However, she became ill after that and spent most of her time in bed until she passed away at the age of 90. Biographies aimed at children described Nightingale as something of a “saint”, however her work after becoming ill differs from her earlier work. Based on her experience, she recorded details descriptions of the hospitals and the life conditions of soldiers. Using these descriptions and statistical analyses, she gave an overview of the situation at the front lines. She proposed strategies for improving hygiene in military settings and hospitals. As such, she became a relentless “social reformer”. After her death, numerous biographies have been published based on the remaining records and about 12,000 letters. Mary Seacole (1805-1881), a Creole woman, was active during the same era as Nightingale. During the Crimean War, she opened the British Hotel near the frontline, where she served meals and provided folk remedies. These achievements have been largely ignored, but they are starting to be reevaluated now. I would like to investigate Nightingale as the pragmatist, from “saint” to “reformer”, while also considering Seacole’s contributions. [References] Sir Edward Cook: The Life of Florence Nightingale, 1913 Lytton Strachey “Florence Nightingale” Eminent Victorians, 1918 Cecil Woodham-Smith: Florence Nightingale, 1820-1920, 1950 Mary Seacole: Wonderful Adventures of Mrs Seacole in Many Lands, 1857

**SS2-1**  
**Systemic autoimmune response to modified proteins as a biomarker – ACPA and more**  
Gerd R Burmester1,2  
1Department of Rheumatology and Clinical Immunology, Charite University Hospital, Berlin, Germany, 2Free University and Humboldt University of Berlin, Germany  
Conflict of interest: None

One of the most important serological discoveries in the field of rheumatology in recent years has been the characterization of autoantigens in RA that contain the amino acid citrulline. The starting point for this discovery was the identification of the target antigen of the anti-keratin antibodies (AKA) first described in 1979, which have a high specificity for RA. The target antigen is fillagrin, a protein specifically expressed in keratin-producing epithelial cells with structure-forming functions. Since fillagrin is only expressed in epithelial cells and neither in the joint nor in other organs, this finding could not initially be interpreted pathogenically. Subsequent studies showed that only the citrullinated forms of fillagrine were recognized by the AKA. Citrullination of proteins takes place enzymatically by deamination of arginine to citrulline and represents a posttranslational modification, which causes a change in the charge state of the protein. This leads to changes in the three-dimensional structure of the proteins and the associated antigenic properties. Citrullination plays an important physiological and biochemical role in the regulation of cell differentiation and programmed cell death (apoptosis). Due to the difficulties in isolating the pure fillagrine, only the relevant citrullinated epitopes were used to develop a test using synthetic peptides as antigens, which were given a ring structure by an intramolecular disulfide bridge binding, giving the citrulline epitope a prominent position. With these cyclic citrullinated peptides (CCP) as antigens in the assay routinely
used today, an improvement in specificity to 96 to 98% could be achieved with approximately the same sensitivity. In the meantime, several studies have shown that anti-CCP antibodies not only have a high specificity but also a high predictive value for an erosive course of the disease and thus have a prognostic value. Other citrullinated antigens are fibrin and fibrinogen. Close cross-reactivity between fillagrin and citrullinated fibrin has been confirmed by investigations with citrullinated peptide derivatives of both proteins. Some publications have described a high diagnostic specificity and sensitivity for the detection of anti-citrullinated fibrinogen antibodies in RA patients. Using ELISA, a sensitivity of about 75% with a specificity of 98% for RA was achieved. Thus, the diagnostical properties of this antigen in rheumatoid arthritis are comparable to the CCP antigen.

In addition, citrullinated fibrinogen offers comparable sensitivity and specificity to CCP in early rheumatoid arthritis. Both markers have been described as good predictors of radiological disease progression. Furthermore, a close association with the occurrence of positive anti-CCP antibodies in patients with rheumatoid arthritis was confirmed. An interesting citrullinated autoantigen is the citrullinated form of α-enolase, an enzyme that plays a role in glycolysis. The citrullinated ε-enolase was found together with other citrullinated antigens in synovial tissue in patients with rheumatoid arthritis. In addition, citrullinated vimentin was described as a relevant autoantigen, interestingly with expression in synovial tissue. Citrullinylated vimentin is presumably the target antigen of the already known anti-Sa antibodies with a high specificity. Direct evidence that ACPA contribute to experimental inflammation is provided by showing that antibodies specific to citrullinated fibrinogen enhance arthritis in a mouse model. Moreover, the presence of anti-CCP antibodies and not RF was found to be correlated with the shared epitope (SE) containing HLA-DRB1 alleles. Interestingly, local production of ACPA in the synovium is inferred from 1.4-fold higher titer in synovial fluid versus serum. Recently, it was demonstrated that through a combination of intracellular protein citrullination of 99% for RA as well as autoimmune production of interleukin 8 (IL-8), ACPA can enhance osteoclastogenesis in human monocytes in vitro. Furthermore, in an IL-8 dependent manner, ACPA induced both bone loss and pain in mice. Another major post-translational modification of proteins in RA is carbamylation, where preferentially lysine residues are converted to homocitrulline in a chemical reaction mediated by isocyanate that interacts with the ε-amino group of lysine forming a new class of autoantigens with the induction of anti-Carb antibodies. In humans, isocyanate is formed by the decomposition of urea into ammonia and cyanate, which is consequently transformed to its reactive form, isocyanate. Thus, hyperuremia, which associates with chronic kidney failure, promotes the formation of isocyanate. In addition to hyperuremia, smoking also leads to isocyanate formation, and thus thiocyanate, a metabolite of cyanide that is present in cigarette smoke, represents another precursor for isocyanate. In fact, smoking has been identified as a prominent environmental risk factor for RA. During inflammation, myeloperoxidase is released from neutrophils and utilizes H2O2 to oxidize thiocyanate to cyanate that subsequently promotes protein carbamylation at sites of inflammation. In addition to RF and ACPA, anti-CarbP antibodies precede the onset of RA, and their presence is an independent risk factor in arthralgia patients for the development of RA. Moreover, anti-CarbP antibodies are associated with disease development - thus, the sensitivity for these antibodies in pre-symptomatic individuals is 13.9% and increased to 42.2% in established RA. This lecture will address the utility of anti-inflammatory agents. In axial structural damage follow-up, x-Ray is still the reference method. When peripheral SPA is suspected, US or MRI are used to detect peripheral enthesitis but also for assessing inflammatory activity. For axial structural damage follow-up, x-Ray is still the reference method. In OA, imaging is not required to make the diagnosis in typical disease presentation. However, in atypical cases, imaging is useful to confirm or make alternative diagnosis. Routine imaging in OA follow-up is not recommended, but it is used if symptoms rapidly change and disease unexpectedly progresses. If imaging is needed, x-Ray should be used as the first tool. However, soft tissues assessment is recommended by US and MRI while more useful information on bone involvement is given by CT and MRI.

SS2-2 Imaging in diagnosis and monitoring of rheumatic and musculoskeletal diseases
Anna Maria Iagnocco
Università Degli Studi di Torino, Italy

Conflict of interest: Yes

Imaging techniques are crucial tools in the diagnosis and monitoring of RMDs. X-Ray is the reference standard in many cases, particularly for structural damage assessment, but Doppler ultrasound (DUS) and MRI are increasingly utilized for both inflammatory and structural lesions evaluations. Recently, interesting results have also been obtained with the use of new modalities and hybrid techniques in specific RMDs. In RA, DUS or MRI are used to improve the diagnosis and monitor disease ac-

SS2-3 Treatment strategy for pre-RA and early RA
Johannes W Bijlsma
University Medical Center Utrecht, The Netherlands

Conflict of interest: Yes

The lecture will discuss two areas: prevention of RA and treatment of (very) early RA. In both areas we will focus on two main questions: A: Can we prevent RA? Question one: are we presently able to reliably diagnose pre-RA? Question two: if so, are we able to intervene in order to prevent RA becoming active? B: Can we treat early RA effectively? Question one: are we presently able to reliably diagnose early RA? Question two: if so, are we able to effectively treat early RA? Up to date evidence will be discussed. The main message will be that prevention is a good area for continued research, but not yet for clinical practice; on the other hand, early diagnosis and effective treatment should be clinical practice anno 2019. This message is in line with the EULAR campaign: Don’t delay, connect today.
The prevalence of therapeutic agents such as biologics has significantly broadened treatment options, allowing the implementation of T2T strategies with the goal of achieving remission. However, remission may not always be attained or sustained due to complications or a host of other reasons. Prevention and early detection of infection and maintaining adherence to treatment are crucial for implementing the appropriate treatment. Psychological and social support and physical care are another important factor in the treatment plan. In the past, rheumatic care focused primarily on providing medical treatment and dealing with symptoms; however, in recent years, the approach to treatment has taken on a broader scope. Patients must be considered not only as “patients” with a disease, but also as “people” who live their lives with the burden of an illness. Remission should be considered not only from the point of view of relieving symptoms, but also making sure that patients are able to live fulfilling lives. The overarching principles of EULAR recommendations for patient education are: “patient education is designed to support and enable people to manage their life and optimize their health and well-being” and “communication and shared decision making between people and healthcare professionals are essential.” Doctors alone are not able to provide such supports, making interdisciplinary cooperation crucial for providing effective treatment. As such, sharing information is vital for enabling multidisciplinary cooperation. According to the updated T2T recommendations, “the involvement of the patient in making decisions and the type of information provided should be recorded, along with the treatment target” and “the agreed and documented target should be visible in the patient records to every health professionals involved in the monitoring”. In this presentation, I would like to consider how we as health professionals can provide the best possible care to our patients.

S1-3
Physical therapy in the era of biological DMARDs –Preventing sarcopenia–
Shinichiro Fujita1, Ryozo Harada2, Kazuhiko Ezawa3, Koji Takasugi1, Misuzu Fujimori1, Kie Inoue1, Wataru Yamamoto4, Keichihiro Nishida5
1Department of Rehabilitation, Kurashiki Sweet Hospital, Kurashiki, Japan, 2Department of Orthopedics, Rheumatic Disease Center, Kurashiki Sweet Hospital, Kurashiki, Japan, 3Department of Internal Medicine, Rheumatic Disease Center, Kurashiki Sweet Hospital, Kurashiki, Japan, 4Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan, 5Department of Orthopedics, Okayama University Hospital, Okayama, Japan

Conflict of interest: None

Pharmacotherapy, surgical therapy, rehabilitation and care has been the basis of therapy for patients with rheumatoid arthritis. Exercise therapy, occupational therapy, patient education have been recommended for the treatment of the rheumatoid arthritis by the guidelines, Japan College of Rheumatology. Advanced drug treatment in recent years has improved the control of disease activity, and has been easier to achieve clinical remission. Likewise, advanced surgical techniques makes it easier to achieve structural remission, and has been improving physical function in patients with rheumatoid arthritis. In such situations, rehabilitation has been also changing to achieve functional remission. In recent years, the concept of senile syndrome such as frail, locomotive syndrome, sarcopenia etc. has been proposed for elderly people. In patients with rheumatoid arthritis, skeletal muscle mass decreases with low activity and inflammatory decompounding protein. Since patients with high disease activity have low skeletal muscle mass, they have been required to improve drug therapy. Decreasing skeletal muscle mass increases the risk of falling fractures. Life prognosis of patients with rheumatoid arthritis has improved and, frail and sarcopenia should be considered in rehabilitation treatment to the elderly patient with rheumatoid arthritis. Patients with rheumatoid arthritis often have joint deformity, decreased body function, decreased skeletal muscle mass, and decreased muscle strength, and are likely to become sarcopenia. Rehabilitation improve the physical function and activity of daily living of patients with rheumatoid arthritis and reduce the risk of falling fractures. As a part of treatment, we measure the muscle mass of patients. When the muscle mass value is low, we practice appropriate exercise for the patient and support nutritional status of the patient. By such treatment, we are trying to prevent sarcopenia and improve the physical function of the patient with rheumatoid arthritis.

S1-2
The best therapy for rheumatoid arthritis (RA) patients: A pharmacist’s view
Keiko Funahashi
Clinical Research, Matsubara Mayflower Hospital

Conflict of interest: None

The importance of team medical care is being recognized, and within each field, specialist pharmacists monitor side effects, avoid serious events and are expected to recommend prescriptions for best results. Team medical care is usually talked from an in-hospital perspective, but it is necessary to include drug dispensary pharmacists because most RA patients are managed by the outpatient department in use of self-injection or oral medicine. Adherence is if prime importance. Poor adherence causes lack of efficacy, and further medication by staff unaware of adherence issues and thus has a socio-economic effect a well. The pharmacist often must involve family or caregiver to reveal the causes of the poor adherence. Secondly, it is important to manage side effects. Monitoring the occurrence and severity is important, but just as important are team communication and patient education. For example, herpes zoster, which is induced by TMDARs, cause sequelae if treatment is delayed. It is necessary to confirm side effects at each examination, but also inform patients how to contact us on a holiday. Half of all RA patients aren’t examined by a rheumatic specialist. The pharmacist has to consult with the doctor, if there is a question about usage of drugs and suggest a change of drug to improve adherence. In addition, in the face of an aging society, the issues of polypharmacy, renal function decline, cognitive decline and frailty need to be addressed. It is important for the pharmacist to investigate the problem that is not clear on at the hospital side. The generalist pharmacist has knowledge of not only the anti-rheumatic drug but also other drugs. The aging RA patient has many problems, but pharmacists can offer a multi-faceted approach to drug use in team medical care.

S1-1
Optimal rheumatic care through a multidisciplinary approach -From the physicians’ point of view-
Hideko Nakahara
Division of Allergy, Rheumatology and Connective Tissue Diseases, Department of Internal Medicine, NTT West Osaka Hospital

Conflict of interest: None

The advancement of medicine drastically changed the course of treatment of rheumatoid arthritis. Nowadays specialists can diagnose and intervene rheumatism at an early stage and prevent joint destruction and deformity. Multidisciplinary team approach brought long term improvement of quality of life of the patients. However, current social welfare system has not been adequately updated to address the current needs of the patients. I would like to present the overview of transition of treatment after the year of 1983, the history of patients’ support group, and the changes of social security system and welfare policies and the relationship among them, based on literature review. I then will raise political subject from social worker’s perspective, especially on the need to improve medical service coverage.

S1-5
Psychological support to person with Rheumatoid Arthritis
Takuro Motonaga1, Mika Mori2, Mayuko Mabuchi3, Yoshie Saki4
1Teikyo University, Japan, 2Jikei University School of Medicine, Japan, 3Tokyo University of Agriculture and Technology, Japan, 4Aomi University
Various types of psychological supports are implemented to person with Rheumatoid Arthritis (RA). Psychiatrists might treat the person with comorbid psychiatric disorders. Clinical psychologists might approach when the person want to receive psychotherapy. But Various health professionals including medical doctors and nurses already implement various types of psychological supports through their professional intervention to the disease. We developed multidisciplinary educational programs for nurse concerning psychological support on this view point. The program focuses on nurses’ practices that may have good effect for their mental health. The program also considers how to implement psychological support on very busy practice environments. The psychological supports have a goal to enhance their QOL. The supports also have a goal to higher quality of medical treatments of RA in medical facilities. Clear and high goal setting, for example ‘Treat to Target, needs good relationship between person and medical staffs, which may be provided through patients’ participations. Psychological supports become more important when medical staffs will implement ‘Treat to Target.’ We would like to share the supposed to be ideas among medical doctors and other health professionals including nurses. Psychological support is an important concept when various health professionals collaborate each other on the treatment of RA.

### S1-6 Knowledge and Skills to Support People Living with Chronic Illness
Yuriko Kuroe
Gifu College of Nursing, Japan

Conflict of interest: None

No one can avoid the eternal themes of birth, aging, sickness, and death even if our situations change dramatically. We all face the prospect of getting sick, and any illness can become chronic, so anyone living in modern society has the possibility of living with chronic illness. In this situation, we must continue over the course of our lives to manage our illnesses with various measures 24 hours a day, 365 days a day, not resting even for a day. At times, life with illness seems lacking in color, quality and enjoyment. It is necessary to make correct judgment and judgment correction for seronegative cases. I used to be a Rheumatologist mentioned above and I have detailed knowledge about anatomy as well as Orthopedics and Rheumatology. I introduced this topic to junior resident, especially about musculoskeletal anatomy, to have left the assessment to Orthopedics because I believed the knowledge of anatomy is for surgeons until my study abroad for musculoskeletal ultrasound (MSKUS) to Spain. The fact that Rheumatologists in Europe have detailed knowledge about anatomy as well as Orthopedics revealed the importance of filling up the upper moat. As MSKUS based on anatomy is called sonoanatomy, sonoanatomy make it possible to make an unexpected diagnosis, have the conference for minute part surgery in Europe. In this symposium, I am going to introduce the educational system of sonoanatomy in EULAR and the utility of MSKUS for our daily medical practice with actual cases. Additionally, I want to emphasize that Sonoanatomy never fail to improve our comprehension of CTD and assessment to differential diagnosis.

### S2-1 Sonoanatomy make it possible to improve the comprehension of musculoskeletal disease of connective tissue disease
Kenta Misaki
Department of Rheumatology, Kita-Harima Medical Center

Conflict of interest: Yes

There is a traditional dictum from famous general (Shogun): ‘Fill up the outer moat first’ means that it is necessary a roundabout approach to achieve the aim. We Rheumatologist have been also faced the challenging of combating to refractory connective tissue disease (CTD) as well as invulnerable castle. Biologics (Bio) was approved under our medical insurance in 2003. Additionally many useful examination tools or makers have been applied in clinical setting. Thanks to those, it is possible for Rheumatologist to rival intractable CTD more directly, and to proceed the daily medical practice in a favorable environment. However it seem that there are some trends to capture the tower keep first for the purpose of achievement: for example meaningless abuse of Bio, exhaustive measurement of specific antibody and overconfidence of radiographic imaging procedures. Systematic assessment based on physical examination is crucial to make a diagnosis and manage the disease activity in particular for seronegative cases. I used to be a Rheumatologist mentioned above just after junior resident, especially about musculoskeletal anatomy, to have left the assessment to Orthopedics because I believed the knowledge of anatomy is for surgeons until my study abroad for musculoskeletal ultrasound (MSKUS) to Spain. The fact that Rheumatologists in Europe have detailed knowledge about anatomy as well as Orthopedics revealed the importance of filling up the upper moat. As MSKUS based on anatomy is called sonoanatomy, sonoanatomy make it possible to make an unexpected diagnosis, have the conference for minute part surgery in Europe. In this symposium, I am going to introduce the educational system of sonoanatomy in EULAR and the utility of MSKUS for our daily medical practice with actual cases. Additionally, I want to emphasize that Sonoanatomy never fail to improve our comprehension of CTD and assessment to differential diagnosis.

### S2-2 Does the musculoskeletal ultrasound examination improve the physical examination skill?
Michihiko Ogasawara
Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan

Conflict of interest: None

The physical examination technique is a basic technique used for diagnosis and disease evaluation in musculoskeletal diseases typified by rheumatoid arthritis. Diagnosis, treatment strategy and outcome could be differ depending on the judgment result, so its technical capability and the judgment result must be more accurate and highly reproducible. In the evaluation of synovitis of rheumatoid arthritis, presence or absence of joint tenderness and swelling, and these numbers are regarded as useful activity judgment findings. The causes of joint pain are roughly classified into inflammatory, degenerative and psychogenic, but since either can cause tenderness, it is difficult to distinguish the three from the tenderness. However, as an advantage of tenderness judgment, it is possible to identify an anatomical lesion site by searching for a tender portion by using the pain awareness as a guide. On the other hand, swelling joint includes synovial fluid accumulation and synovial thickening. Synovial fluid accumulation is not seen in psychogenic joint pain, but since it is recognized in both degenerative as well as inflamed joint pain, discriminatory ability in differential diagnosis of the two is insufficient. Therefore, in order to judge whether it is inflammatory or not by clinical examination, it is important to not only detect the presence or absence of joint swelling, but also to detect the presence or absence of specific synovial thickening due to inflammatory arthritis. However, in fact, the sensation of synovial thickening is difficult to distinguish from soft tissues such as subcutaneous fat, compared to the sensation of synovial fluid which is more easily judged, so it is often difficult to make judgments. On the other hand, the sensation of hotness and redness of the joint suggests the presence of synovitis with high sensitivity if it is in the acute phase, but the sensitivity decreases after the acute phase, and the detectability of synovitis becomes insufficient. Therefore, in some cases / joints that are difficult to judge synovitis, in order to more accurately judge synovitis, it is necessary to make correct judgment and judgment correction of clinical assessment using musculoskeletal ultrasound examination. We reported in the past that autofeedback of ultrasound image after physical examination will improve the examination technique. In order to utilize the musculoskeletal ultrasound as a learning tool for improving the physical examination and to contribute widely to the examination procedure improvement, it is considered that future identification and dissemination activities of higher utilization methods with higher relevance are needed.
S2-3
Is Musculoskeletal Ultrasound Necessary for Monitoring in Patients with Rheumatoid Arthritis?
Shin-ya Kawashiri1,2, Yushiro Endo1, Atsushi Kawakami2
1Department of Community Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Conflict of interest: Yes

Musculoskeletal ultrasound (US) is excellent in the detection of synovitis in patients with rheumatoid arthritis (RA) and the synovitis score, especially the power Doppler (PD) score by US well reflects the clinical disease activity. We have used US for therapeutic monitoring from 10 years ago. In many patients, clinical disease activity and US synovitis score fluctuate in parallel, but deviations of each score are observed in some patients. It is also known that residual synovitis is detected by US at a constant frequency in patients achieving clinical remission. In addition, residual synovitis is a risk of joint destruction and relapse. Therefore, accurate evaluation of disease activity using US seems to be important for improving patient’s prognosis. However, in the ARCTIC trial1 and the TaSER trial2 conducted in Europe, additional value in strengthening treatment according to disease activity by periodic PD evaluation compared with clinical evaluation was not demonstrated. In the first place, there are still many issues in monitoring, such as patients requiring monitoring, scoring system (assessment joint/ assessment lesion), assessment timing (periodic or necessary), assessment frequency and so on. We have been promoting the cohort study for patients who introduced molecular targeted therapeutic drugs (bDMARDs and tsDMARDs) in collaboration with multi-center of hospitals in Kyushu region from 2013.3,4 In this study, we have evaluated disease activity every 3 months by US, and have analyzed associations between US score, clinical disease activity, radiographic change, and serum biomarkers. In this symposium, we will outline the usefulness of monitoring by US in patients with RA based on the results of our cohort study and latest evidence. References; 1) BMJ 2016; 354: i2405, 2) Ann Rheum Dis 2016;75:1043, 3) Arthritis Care Res (Hoboken). 2018 Feb 26. doi: 10.1002/acr.23551.

S2-4
Ultrasonographic pathological findings and treatment strategies in patients with psoriatic arthritis
Tadashi Okano1, Kentaro Inui2, Koji Mandai1, Yutaro Yamada1, Setsuko Takeda2, Yuko Yoshida2, Emi Yamashita2, Asami Fujii3, Yuko Sugio3, Tatsuya Koike3, Hiroaki Nakamura1
1Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Central Clinical Laboratory, Osaka City University Hospital, Osaka, Japan, 3Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan, 4Shirahama Foundation for Health and Welfare, Wakayama, Japan

Conflict of interest: None

CASPAR classification is usually used for the diagnosis of psoriatic arthritis (PsA), but it is defined that there are inflammatory conditions such as arthritis/enthesitis/spondylitis as the premise. However, it is sometimes difficult only by clinical examination to distinguish whether joint symptoms are due to inflammation or degenerative change. The usefulness of ultrasonography (US) in the diagnosis of PsA has been reported, especially in early diagnosis and differential diagnosis with other rheumatic disease. Moreover, by using US, physicians can detect subclinical inflammation even in patients without obvious swelling or positive inflammatory findings. There are some specific findings to make differential diagnosis with rheumatoid arthritis (RA). In RA, intra-articular synovitis is the main pathology, whereas intra-articular synovitis occurs secondary to tendon and ligament enthesitis in PsA. Reflecting this mechanism, in peripheral joint of PsA, US inflammatory findings with Doppler signals are often found not only in the intra-articular synovium but also in the tendon enthesis or subcutaneous tissue. In addition, inflammation around the flexor tendon and extensor tendon is also found in patients with PsA. In extensor tendon, inflammation may be observed around the tendon at the MCP joint level and slightly proximal to the metacarpal head. It is called PTI (peritenon extensor tendon inflammation) pattern. Furthermore, inflammatory findings of large enthesis such as enthesis of the extensor carpi radialis brevis tendon to the humeral lateral epicondyle and enthesis of the Achilles tendon to the calcaneus are the most important findings in US examination for PsA. US has huge utility comparing with traditional methods for diagnosis such as clinical examination, laboratory test and conventional radiography. In this presentation, we demonstrate the pathological specific findings and treatment strategy of PsA with typical US images.

S2-5
Present practice and future prospects of joint ultrasonography by sonographers
Motsumi Nishida1, Hitoshi Shibuya1, Takanori Teshima2
1Diagnostic Center for Sonography, Hokkaido University Hospital, 2Division of Laboratory and Transfusion Medicine, Hokkaido University Hospital

Conflict of interest: Yes

[Objectives] Early detection of synovitis is critical for arthritis clinic. Ultrasonography (US) is capable to detect early rheumatoid synovitis. The aim of this study was to report present practice and future prospective of joint US by sonographers. [Methods] Questionnaire survey was done for medical practitioners according to the following items; 1. Professions, 2. Scale of facilities, 3. Presence or absence of performing joint US, 4. The number of joint US per month, 5. Professions performing US, 6. Available or not available of performing US in the future, 7. Interest for joint US, 8. Problems [Results] Response rate was 8.9% (82/926). 1. Clinical technologists / Radiographers 91.5 / 7.3%, 2. Medical centers / Clinic / Hospitals (<200) / Hospitals (≥200) / Others 14.6 / 14.6 / 13.4 / 28 / 40.2 / 3.7%, 3. Joint US Presence / Absence / Do not know 45.1 / 25.2 / 2.4%, 4. The number of joint US; <50 exams / ≥50 exams 95/5%, 5. Sonographers / Physicians / Sonographers and Physicians 48.6/24.3/27%, 6. Available / Not available / Do not know 9.1/41.9/50%, 7. Interesting / Not interesting / Do not know 52.3/11.4/36.4%, 8. Problems; No trainers/ No knowledge of disease / Poor understanding of anatomy and scanning methods/ No order of US / No certified system for joint US sonographers / Time consuming / Others 46 / 43 / 31 / 25 / 8 / 8 / 4. [Discussion and Results] The ratio of facilities performing joint US were nearly half of them, the number of US was <50month. Half of US were performed by sonographers, and physicians, and sonographers showed nearly 30%, and physicians performed the rest of them. Even not available US in the present, more than half of sonographers interested in joint US. Once problems are solved, sonographers can perform joint US in the near future. Establishing training and certification systems for sonographers and make the exam time shorten are needed to be solved.

S2-6
Development of the guidelines for clinical management using musculoskeletal ultrasound
Kei Ikeda
Department of Allergy and Clinical Immunology, Chiba University Hospital

Conflict of interest: None

Japan College of Rheumatology-Committee for the Standardization of Musculoskeletal Ultrasoundography (JCR-CoSMUS) has published the guidelines of musculoskeletal ultrasound scanning for rheumatoid arthritis (RA) in 2011 and the guidelines of interpreting musculoskeletal ultrasound images for RA in 2014. However, for the further spread and advance of this technique, a larger number of technicians/technologists need to perform musculoskeletal ultrasound as they do in the other areas such as cardiac and abdominal ultrasound in Japan. For this purpose, a simple core set that can be easily learned and performed in daily practice needs to be developed. This core set should focus on the synovial Doppler signal, which is shown to be reproducible, and should be comprised of a small number of joints with simple anatomical structure, in which synovitis frequently occurs in RA. Moreover, strategies based on this ultrasound core-set need to be established, which rheumatologists can utili-
lize in the diagnosis and the treatment guide. Therefore, the Japan Agency for Medical Research and Development (AMED) project “Optimization and standardization of ultrasound-based management of rheumatoid arthritis”, together with JCR-CoSMUS, is now developing the guidelines for the management of RA using musculoskeletal ultrasound in order for the technicians/technologists to be more deeply involved in this technique. In this presentation, the current progress will be reported.

**S3-1**

**Treatment strategies of the rheumatoid foot based on its pathological condition**

Takumi Matsumoto  
Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo

Conflict of interest: None

Improvement in rheumatoid arthritis (RA) control due to the development of powerful disease-modifying anti-rheumatic drugs has led to a decreased involvement and surgery of the large joints. This shifting allows us to focus on the foot, which has been prone to being put aside behind other priorities. Appropriate control of the disease activity and improvement of bone fragility in RA patients enable the surgeons to adopt the joint-preserving surgeries nowadays, which was generally not applicable before the era of biologic agents. In other words, we are facing an era of being able to apply a variety of techniques, which has been accumulated through the experience in treating foot and ankle of other pathologies than RA, to RA foot. Stereotypical strategy such as resection arthroplasty for foot deformity and tibiotalocalcaneal fusion for hindfoot deformity, which were the gold standards in a couple of decades ago, has become a thing of past. On the other hand, a wide variety of involved sites and deformities make surgeons feel it difficult to select an appropriate treatment plan for individual cases. Other difficult point that makes it difficult to comprehend RA foot is that the progression of RA foot deformity is affected by both factors including disease activity and mechanical load. In addition to the knowledge about the pros and cons of each surgical technique, understanding the pattern of destruction and its future prospect is essential to construct an appropriate strategy for RA foot. This lecture will give an outline about the patterns of destruction in RA foot and their characteristics, and will provide a treatment strategy based on estimated prognosis of each pattern. Especially, this lecture will highlight the destructive pattern starting from midfoot joints as a pattern worth heeding because this pattern generally progresses to flat foot in just a couple of years since its involvement without foot joints as a pattern worth heeding because this pattern generally progresses to flat foot in just a couple of years since its involvement.

**S3-2**

**Total assessment and management of loading alignment against rheumatoid foot deformity**

Makoto Hirao 1, Moto Kobayashi 1, Natsuo Komishii 1, Masakazu Urayama 2, Hiroki Ito 1, Takayuki Tanizaki 1, Toshiaki Aizawa 2, Hidekazu Abe 1, Norio Suzuki 1, Keiji Kamo 1, Hiroshi Aonuma 1, Yusuke Sugimura 1, Tetsuya Kawanami 1, Yosuke Iwamoto 1, Yoshiaki Kimura 1, Manabu Akagawa 1, Ikuko Wakahayashi 1, Koji Nozaka 4, Naohisa Miyakoshi 1, Yoichi Shimada 1  
1Department of Orthopedic Surgery, Akita City Hospital, 2AORA (Akita Orthopedic Group on RA), 3Department of Rehabilitation Medicine, Akita City Hospital, 4Department of Orthopedic Surgery, Akita University Graduate School of Medicine

Conflict of interest: None

Along with advances in drug therapy, the prognosis of patients with rheumatoid arthritis (RA) is also prolonged. In RA, besides having bone fragility in the disease itself, it further exacerbates with aging, so the ADL improves, the risk of injury to fractures increases. Fractures around the ankle often occur, and in RA cases it becomes more complicated. We experienced a case in which lizarov external fixation was used for a distal tibial fracture of an elderly RA patient. There are 3 cases, all cases are females. Surgery by external fixation was chosen due to small distal bone fragment, during biologic administration, complications and internal anti-thrombotic drugs, and having bone fragility. In two cases, the MATILDA method was used, in one case closed restoration using Olive wire was performed, and it was fixed using lizarov external fixation. After the operation patients walked according to the pain, leaving bed on average 3.3 days, parallel bar walking 5.3 days, discharge from 70.7 days. Bone fusion was obtained in all cases. In the case of RA, it has bone fragility, strong fixation is necessary, there is symmetrical joint disorder, there is a concern of contralateral joint disorder at one side therapy release, because of many mergers of obstacles, it can be cited that it is difficult to adjust the load using crutches. By preliminary combined loading at the early stage, functional deterioration can be minimized. In many cases, ADL declines with trauma as a trigger, and it is useful to aim for early exit from the bed to prevent further exacerbation in cases already having dysfunction like RA. External fixation surgery is entering a super aged society, it becomes a powerful option of injury of lower limb in RA.

**S3-3**

**Combination with EF-Fix for distal tibial fracture of Rheumatoid arthritis**

Takeshi Kashiwagura 1, Moto Kobayashi 1, Natsuo Komishii 1, Masakazu Urayama 2, Hiroki Ito 1, Takayuki Tanizaki 1, Toshiaki Aizawa 2, Hidekazu Abe 1, Norio Suzuki 1, Keiji Kamo 1, Hiroshi Aonuma 1, Yusuke Sugimura 1, Tetsuya Kawanami 1, Yosuke Iwamoto 1, Yoshiaki Kimura 1, Manabu Akagawa 1, Ikuko Wakahayashi 1, Koji Nozaka 4, Naohisa Miyakoshi 1, Yoichi Shimada 1

Conflict of interest: None

The treatment for the rheumatoid arthritis (RA) has been significantly developed. However, surgery for the damaged joint is still performed to improve the activities of daily living. Although joint preservation surgery for the fore foot deformity in RA has been widely recognized, arthrodesis or total ankle replacement still plays an important role in the ankle joint of RA. For osteoarthritis (OA) of ankle, various surgical treatments are chosen depending on age, activity and stage. Arthrodesis and total ankle arthroplasty are usually performed for the end stage of OA. Especially, arthrodesis is often performed for highly active cases, but there are many problems as it may interfere with daily living due to limitation of range of motion. Distraction arthroplasty (DA) is the method to enlarge joint space by external fixator with articulation and combined with arthroscopic microfracture. This technique has been performed for the end stage of OA ankle, but we performed DA for RA patients who denied to be performed arthrodesis. [Case 1] A 34-year old female who was treated by...
methotrexate, etanercept for 5 years. Her left ankle pain increased and joint space of ankle was disappeared. DA was performed, and her symptom was significantly improved. [Case 2] A 39-year old female who was treated by methotrexate for 5 years. She had severe left ankle pain, so she was recommended to have ankle arthrodesis. She denied to have arthrodesis, so DA was performed. Her symptom was significantly improved and joint space enlarged. Also range of motion improved. Even for RA patients, DA was able to obtain good results in the short term. DA may be a one surgical option in order to preserve the ankle joint in RA.

S3-5
Reconstructive surgery using total talar prosthesis for end-stage hindfoot arthropathy in patients with ankle osteoarthritis and rheumatoid arthritis
Ryota Hara¹⁺², Hiroaki Kurokawa², Akira Taniguchi², Yasuhiro Tanaka¹⁺²
¹The Center for Rheumatic Diseases, Nara Medical University, ²Department of Orthopaedic Surgery, Nara Medical University

Conflict of interest: None

The talus does not have the origin and insertion of the muscles and is responsible for the center of the dorsiflexion planar flexion of talocalcaneal joint and varus-valgus motion of talocalcaneal joint due to the passive movement. Through such anatomical characteristics, replacement of artificial implant on the talus is reasonable and we developed an artificial talus designed as a custom made implant using alumina ceramic excellent in affinity at the joint surface in 1999. Since 2005, we have used third-generation implant replaced the whole talus with a total talar prosthesis and the clinical results were generally good in patients with osteonecrosis of the talus. In cases of failed TAA with subsidence of talus component, we have often used total talar prosthesis in combination with tibial component (combined TAA). Arthrodesis and exchanged TAA are indicated as revision surgery of TAA in many cases, but the former have some problems of immobility, pseudarthrosis and leg length shortening due to bone defect, and the latter of low survival rate. Combined TAA is an ideal surgical procedure to solve these problems and good clinical results have been obtained. In recent years, we have indicated combined TAA as a primary surgery for end-stage arthropathy of AOA and RA with collapsed talus and good clinical results have been obtained for a short term. Careful consideration of indication can lead primary combined TAA to one of the options for hindfoot reconstruction surgeries for AOA and RA. As for the indication of combined TAA in the primary surgery at the present time, age and alignment need to satisfy the indication criteria of TNK ankle in addition to talar collapsing. We consider that it is desirable that cartilage of the articular surface preserves to some extent on the side of the calcaneus and the navicular. In the future, we need to study the limits of indication to cases of preoperative calcaneofibular ligament disfunction and malalignment of hindfoot.

S3-6
Experience of and future prospects for a new ankle prosthesis
Koichiro Yano¹, Haruki Tobimatsu¹, Yu Sakuma¹, Koei Ohi¹, Katsunori Ikari¹, Ken Okazaki²
¹Department of Orthopedic Surgery, Institute of Rheumatology, Tokyo Women’s Medical University, ²Department of Orthopedic Surgery, Tokyo Women’s Medical University

Conflict of interest: Yes

For the first time in 15 years, a new ankle prosthesis, the Trabecular metal ankle system® (TM ankle, Zimmer-Biomet), was released in Japan in August 2018. The two prostheses which had been used in Japan require an anterior approach while the TM ankle prosthesis is based on a new concept using a lateral approach with lateral malleolar cutting. An anterior approach occasionally causes delayed wound healing and wound dehiscence after surgery because of pressure on the wound from the anterior fibula muscular and extensor hallucis longus muscle tendon. Deep infection from wound complications is a substantial problem of the anterior approach. The biggest advantage of a lateral approach is that such a subsequent wound complication does not occur. In addition, the amount of bone cutting can be minimized by performing a semicircular osteotomy according to the shape of the talocrural joint. Moreover, implanting the prosthesis on solid cancellous bone may improve the long-term outcomes. Furthermore, improvement of long-term outcomes is expected because the bone contact area of the prosthesis is made with trabecular metal, which has reported good outcomes from the studies of hip and knee prosthesis. Correct osseointegration is possible because surgeons can visualize the anatomical rotational center of the talocrural joint using a rigid alignment stand device. However, there are some disadvantages. Many pins are needed to fix the lower leg on the alignment stand device. In addition, a lateral malleolar osteotomy is needed to expose the talocrural joint. As a result, surgical invasions are bigger and operation time is longer than those with anterior approach. Although an improvement of long-term outcomes is expected in theory, it currently remains unclear because the TM ankle prosthesis was only recently released globally. Since August 2018, we have performed 11 total ankle replacements using the TM ankle prosthesis. We will discuss their outcomes and future prospects for the TM ankle prosthesis in this session.

S4-1
Central Nervous System Lupus
John G Hanly
Dalhousie University, Halifax, Nova Scotia, Canada

Conflict of interest: None

Systemic lupus erythematosus (SLE) has the potential to cause autoimmune mediated inflammation and dysfunction in all organ systems including the nervous system. Case definitions for 19 neuropsychiatric (NP) syndromes, compiled by the American College of Rheumatology (ACR), is the most widely adopted classification of neuropsychiatric SLE (NPSLE). In the assessment of individual patients and events, attribution rules are needed to determine whether a NP event is due to SLE or a competing co-morbidity or both. Overall, approximately 35% of NP events are attributed to SLE but this varies between 0% and 100% for individual manifestations. Regardless of attribution, NP events are associated with a significant negative impact on health related quality of life, even when other factors such as global SLE disease activity, cumulative organ damage and medications are taken into account. Ischemic and inflammatory mechanisms are key components of the immunopathogenesis of NPSLE. Microangiopathy, intravascular thrombosis, increased permeability of the blood-brain barrier and autoantibody mediated production of pro-inflammatory cytokines likely all contribute to the disease. Advances in brain neuroimaging provide a platform to assess these and other novel disease mechanisms in a non-invasive way. In the absence of controlled clinical trials, large observational cohort studies with careful documentation of NP events and their attribution, treatment and outcomes provides insight into this complex aspect of SLE. In the future, the convergence of more rigorous clinical characterization, validation of biomarkers and brain neuroimaging will provide opportunities to determine the efficacy of novel targeted therapies in the treatment of NPSLE.

S4-2
Treat to target: Endpoints and strategies for SLE
Eric Morand
Monash University, Melbourne, Australia

Conflict of interest: None

In contrast to other rheumatic conditions, only one successful target-ed therapy has emerged for Systemic lupus erythematosus (SLE) in recent decades, with a lack of validated endpoints a major contributor to trial failures. As management continues to rely on glucocorticoids and non-specific immunosuppression, inadequately controlled disease activity and adverse effects of glucocorticoids contribute to irreversible end organ damage, in turn leading to early mortality. Treat to target (T2T) approaches have yielded clear benefits in many chronic diseases, especially those whose endpoints are easily measurable, such as hypertension or diabetes. T2T approaches in rheumatoid arthritis (RA), resulting in improved outcomes even without biological therapies, have been adopted in guidelines and the assessment of novel therapies. In contrast, the clinical complexity and heterogeneity of SLE has previously hindered the development of treatment endpoints and hence adoption of T2T strategies. Sustained remission in SLE is rare, and remission definitions remain in
evolution. In contrast, the Asia Pacific Lupus Collaboration (APLC) proposed the Lupus Low Disease Activity State (LLDAS), subsequently defined operationally via a nominal consensus approach. LLDAS includes domains capturing the absence of threatening disease activity and harmful treatment burden. LLDAS has begun to be tested as an outcome measure in SLE clinical trials, and evidence that its attainment is associated with improved patient outcomes has been adduced in multiple cohort studies. It is proposed that LLDAS form the basis of a T2T strategy for SLE.

S4-3 Current problems and future direction of management of systemic sclerosis
Masataka Kawana
Department of Allergy and Rheumatology, Nippon Medical School

Conflict of interest: Yes

Systemic sclerosis (SSc) is the most difficult-to-treat rheumatic disease today. There is only a few disease-modifying treatment helpful in improving the natural course of SSc, including cyclophosphamide and mycophenolate mofetil, which were proven to show limited efficacy in interstitial lung disease (ILD). Two trials reported autologous stem cell transplantation superior to intravenous cyclophosphamide, albeit at the price of significant procedure-associated early mortality. Several reasons may explain lack of fully adequate therapies. First, it is difficult to identify “active and progressive” patients eligible for disease-modifying treatment. The majority of patients with diffuse cutaneous SSc (dcSSc) assigned to the placebo group in clinical trials experienced improvement of modified Rodnan total skin thickness score (mRSS). In addition, a number of observational studies have revealed that only 20-30% of SSc-ILD at diagnosis progress to end-stage lung disease, and the remaining patients show stable lung function throughout the disease course without treatment. Second, outcome measures that reflect long-term outcomes are not yet established. In clinical trials, mRSS (for dcSSc) or forced vital capacity (for ILD) is used as a primary endpoint, while ACR Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis (CRISS) has been proposed as a new composite measure. Finally, there is almost no drug proven to prevent excessive fibrosis. A much greater understanding of SSc pathophysiology has developed by tremendous efforts of basic researches, leading to clinically testable hypothesis. Accordingly, novel therapies towards specific molecular and cellular targets have been tested in clinical trials. These include rituximab, tocilizumab, abatacept, nintedanib, pirfenidone, riociguat, and nabasum. This lecture features future approach to the management of SSc based on recent promising knowledge.

S4-4 Role of Jo-1 in the immunopathogenesis of the anti-synthetase syndrome
Dana P Ascherman
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA

Conflict of interest: None

Antibodies targeting histidyl-tRNA synthetase (HRS=Jo-1) are a hallmark of the anti-synthetase syndrome, one of the most prominent subsets of idiopathic inflammatory myopathy (IIM). Although there is little evidence that these antibodies directly mediate tissue pathology, a range of clinical and epidemiological data strongly implicate Jo-1 in the immunopathogenesis of the anti-synthetase syndrome. Beyond in vitro studies and animal models that underscore the contribution of antigen-specific T cells to muscular as well as extra-muscular complications of this disorder, immunohistochemical studies and gene expression profiling of human muscle biopsy specimens point to an equally important role for innate immune signaling cascades. Newer animal models support these findings, demonstrating an important role for cell-surface and endosomal Toll-like receptors (TLRs) that ultimately drive NF-κB activation and the elaboration of pro-inflammatory cytokines. Importantly, these models have begun to elucidate the pathogenic connection between dysregulated innate and adaptive immune pathways in the anti-synthetase syndrome—highlighting novel “checkpoints” that can be targeted through more selective immunotherapy.

S5-4 Recent Advances in the Treatment of Large Vessel Vasculitis
Yoshikazu Nakaoka
Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Japan

Conflict of interest: Yes

Large vessel vasculitis (LVV) consists of Takayasu arteritis (TAK) and giant cell arteritis (GCA) according to the classification criteria of Chapel Hill Consensus Conference 2012 (CHCC2012). Glucocorticoids (GCs), the first-line therapy for the treatment of TAK and GCA, are often associated with adverse effects when used long-term in high dose, and patients frequently relapse during GC tapering. Other immunosuppressive agents, such as methotrexate, azathioprine and mycophenolate mofetil, may be used if relapse occurs while the patient is receiving GCs; however, these agents have not demonstrated consistent clinical benefits or steroid-sparing effects. We previously reported efficacy of anti-interleukin-6 receptor antibody, tocilizumab (TCZ), for refractory TAK via conducting a pilot study in Japan (Nakaoka et al. Int Heart J. 54, 406, 2013). Based on these findings, we performed a phase III, double-blind, placebo-controlled multi-centered, randomized clinical trial. Thirty-six patients were enrolled in this study, and all of them were randomized to 1:1 (TCZ-SC group N=18, placebo group N=18). The number of relapses were 8 (44.4%) and 11 (61.1%), the estimated relapse free rates at week 24 were 22.9% and 50.6% in TCZ-SC group and placebo group, respectively. There was no statistical significance in the primary endpoint, time to first relapse between the two groups (p=0.0596, log-rank test). Although the primary endpoint was not met, TCZ seemed to show favorable tendency to suppress relapses of TAK compared to placebo (Nakaoka et al. Ann Rheum Dis, 77, 348, 2018). In 2017, TCZ was approved for TAK in Japan. In addition, based on the results from GACTA study, TCZ was also approved for GCA in the United States, Europe, and Japan. Like rheumatoid arthritis and inflammatory bowel diseases, new era with biologics may totally change the therapeutic scheme for LVV. In this talk, I will review the recent progress and the current perspective for the treatment for LVV.

S5-5 The Immunogenetics of Inflammatory Mechanisms by Fibroblast-like Synoviocytes formRheumatoid Arthritis Patients
Haruka Tsuchiya1, Mineto Ota1, Shuji Sumitomo2, Kazuyoshi Ishigaki2, Akari Suzuki, Yuta Kochi1, Yumi Tsushima1, Hirofumi Shoda1, Hiroshi Inui1, Shuji Taketomi1, Yuto Kadono1, Sakae Tanaka1, Kazuhiko Yamamoto1, Keishi Fujio1

Conflict of interest: Yes

Sustained clinical remission (CR) without drug treatment has not been achieved in patients with rheumatoid arthritis (RA). This implies a substantial difference between CR and the healthy state, but it has yet to be quantified. We report a longitudinal monitoring of the drug response at multi-omics levels in the peripheral blood of patients with RA. Our data reveal that drug treatments alter the molecular profile closer to that of healthy controls at the transcriptome, serum proteome, and immunophenotype level. Patient follow-up suggests that the molecular profile after drug treatments is associated with long-term stable CR. This high-dimensional phenotyping provides a quantitative measure of molecular remission and illustrates a multi-omics approach to understanding drug response. In this symposium, we introduce our multi-omics analysis data of drug response in RA and discuss some clues for elucidation of pathogenic mechanism of autoimmune disease.
Fibroblast-like synoviocyte (FLS) cooperatively expresses a wide range of inflammatory mediators (i.e., IL-6) under the complex inflammatory environment, which leads joint destruction in rheumatoid arthritis (RA). The objective of this study is to elucidate the genetic responsibility of FLS in RA pathogenesis, and to explore potential novel therapeutic targets in FLS. FLS from RA and Osteoarthritis (OA) patients (n = 30 per disease) were stimulated with cytokines (TNF-α, IL-1β, IL-6/IFN-γ, IL-17A, IL-18, IFN-γ, IFN-α, TGF-β1 and combination of all 8 cytokines [8-mix] which simulated the mixture of stimuli in the joint) for 24 hours. Five subsets of peripheral blood mononuclear cells were collected from the same patients. The comprehensive analysis including expression quantitative trait loci (eQTL) was performed with genome (SNP typing), transcriptome (RNA-seq) and epigenome (ChIP-seq for H3K27ac, H3K4me1, H3K4me3, H3C-C) data. By the analysis of overlapping between RA genome-wide association study (GWAS) SNPs and enhancer regions of each dataset, disease susceptibility loci were enriched in super-enhancers (SE) of 8-mix stimulated FLS and known CD4+ T cell and B cell. SE were related to high level expression of targeted genes compared with typical enhancers (TE), and SE of 8-mix stimulated FLS (8-mix SE) formed 3D loops with the promoter of some inflammatory mediators (i.e., IL-6, chemokines). Furthermore, candidate transcription factors which bind to 8-mix SE were extracted by the motif analysis, and some of these were suggested to be regulated by disease susceptibility loci and 8-mix SE. From our research, FLS could contribute to the genetic risk of RA under the complex inflammatory environment and the control of inflammatory mediators by SE would be important for the disease course of RA modulated by the genetic background. The identification of transcription factor complex of 8-mix SE and functional analysis would lead to the development of FLS targeted treatment.

SS5-3
Type I Interferon-producing mechanism in SLE
Hyota Takamatsu1, Yasuhiro Kato1, Jeong Hoon Park2, Hachirou Konaka1, Eri Itotagawa1, Atsushi Kumanogoh1
1Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Japan, 2School of Medicine, Osaka University, Japan

Conflict of interest: None

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes systemic organ dysfunction and occurs mostly in young women. For its pathogenesis, the failure of tolerance to nucleic acid and the accompanying excessive production of type I interferon (IFN-I) via the nucleic acid sensors including TLRs are important. Measurement of IFN-I concentration in SLE serum was difficult due to low sensitivity of ELISA. However, we successfully measured the IFN-I bioactivity in sera of SLE patients by using IFN-I-responsive reporter cells. And we found that serum IFN-I bioactivity is very high in SLE compared to other autoimmune diseases, and IFN-I bioactivity correlates with SLE disease activity. It was also found that IFN-I production is further induced by the membrane vesicles that contain dsDNA in SLE serum via the intracellular nucleic acid sensor cGAS-STING pathway in addition to IFN-I itself. Therefore, as a cell-extrinsic mechanism of IFN-I production in SLE, we have proposed an alternative mechanism, that is, the nucleic acids in extracellular vesicles induce IFN-I production via cGAS-STING pathway. Meanwhile, as an alternative mechanism of cGAS-STING pathway during the development of Tfh cells characteristically as Tfh1 like cells. The loci of Bel-6 and Tbet (master transcription factor for Tfh and Th1) were marked by bivalent histone modifications. After IL-12-stimulation, both STAT1 and STAT4 directly bind on BCL6 and TBX21 gene loci accompanied by suppression of repressive histone mark trimethylated histone 3 lysine 27. The findings suggest that IL-12-mediated co-activation of STAT1 and STAT4 alters histone modification, resulting in development of Th1 like cells. This could be one of underlying mechanisms responsible for the pathogenesis of Tfh cells in SLE. Recent studies have also shown that various types of SNPs, TETs and miRNAs control phenotypic change of Tfh cells. These findings argue that the epigenomic regulation of T helper cells is a key event for the development of SLE. Thus, better understanding of the extrinsic and intrinsic signals that control stability and plasticity of Tfh cells will have important therapeutic applications to control this disease. In this symposium, we would like to highlight recent advances that pertain to this topic and the mechanisms that contribute to Tfh differentiation and the potential in the treatment of SLE.

SS5-5
The role of WDFY4 gene in clinically amyopathic dermatomyositis
Yuta Kochi
Laboratory for Autoimmune Diseases, IMS, RIKEN

Conflict of interest: Yes

The progress of genetics in autoimmune diseases has enabled the identification of hundreds of loci associated with the disease susceptibility. However, unlike common autoimmune diseases such as rheumatoid arthritis, the etiology of rare autoimmune diseases is yet unknown. Among them, clinically amyopathic dermatomyositis (CADM), a subset of dermatomyositis, is of clinical importance, because this disease is often accompanied by rapidly progressive interstitial lung disease. In order to dissect the mechanism of disease, we performed genome-wide association study of CADM in Japanese and identified a significant association at the WDFY4 locus. We studied candidate causal variants and identified variants having splicing quantitative trait locus (sQTL) effect for its truncated isoform (tr-WDFY4). Moreover, we demonstrated that both WDFY4 and tr-WDFY4 interacted with pattern recognition receptors such as TLR3, TLR4, TLR9, and MDA5 and augmented the NF-κB activation by these receptors. Because CADM is characterized by the appearance of anti-MDA5 antibody, WDFY4 may have a critical role in the autoimmune response in CADM. Interestingly, the association signals were different between Japanese and European populations, suggesting that the causal variants were different. Furthermore, the association of the WDFY4 locus was also observed in systemic lupus erythematosus and rheumatoid arthritis, but the association signals were different compared to CADM. Therefore, WDFY4 may play important roles in the regulation of innate immune responses as well as the onset of autoimmune diseases, where the causal mechanism would be different among different environ-
S6-1
Mechanisms of action of JAK inhibitors
Akio Morinobu
Rheumatology and Clinical Immunology, Department of Internal Medicine, Kobe University Graduate School of Medicine

Conflict of interest: Yes

Cytokine binding to its receptor activates the down-stream signaling cascade. Type I and II cytokines utilizes JAK-STAT pathway as intra cellular signaling. JAK inhibitors (JAKi) block JAK activity by binding to JAK’s ATP binding pocket. JAKi are small compounds, which are orally available. JAKi suppresses lymphocyte functions primarily, but also act on myeloid cells and synovial fibroblasts. The major difference between JAKi and biologics is that JAKi suppress multiple cytokinals partially whereas biologics blocks single cytokine completely. Considering that multiple cytokines work at the site of inflammation, this property of JAKi may have the advantage to treat immune and inflammatory conditions. On the other hand, adverse events may occur due to this characteristic. Until now, however, clinical experiences have shown that JAKi are well tolerable, probably because JAKi partially inhibits JAK-STAT pathway. Cytokines that use JAK-STAT pathway involve IL-6, IFNs, IL-2, GM-CSF, and JAKi are expected to be useful in many immune and inflammatory conditions. Today JAKi are clinically used for RA and UC, and now under clinical trials for various other diseases. Broad spectrum of application of JAKi is remarkable and could be comparable to glucocorticoids, and that JAKi may change the whole concept of immune suppression strategy. JAK family consists of four members; JAK1, JAK2, JAK3, Tyk2. The current JAKi suppress couple of these, thus called pan-JAKi, while selective JAKi are being developed into clinical stages. So far selectivity depends on how they are assayed, and does not make much differences when clinically used. However, once they are tried on many diseases other than RA, selective JAKi may help understanding the cytokine regulations of each disease. In conclusion, JAKi is a new class of drugs with novel mechanisms of action. JAKi may pave the way to new strategies for the treatment of various immune and inflammatory diseases.

S6-2
Characteristics of clinical trials of JAK inhibitors in patients with rheumatoid arthritis
Tomonori Ishii
Clinical Research, Innovation and Education Center, Tohoku University Hospital

Conflict of interest: Yes

In recent years, new compounds that target specific molecules have been proposed as therapeutic agents against several systemic autoimmune diseases. In order for these compounds to be recognized as drugs, their safety and effectiveness need to be confirmed based on objective data. Clinical trials are useful for confirming the efficacy and safety of drugs. Several clinical trials have failed to establish safe and efficient drugs for most systemic autoimmune diseases, such as systemic lupus erythematosus and systemic scleroderma. One of the underlying reasons for this failure is the inability of the trial design to identify the efficiency of an effective drug. Under these circumstances, clinical trials for rheumatoid arthritis (RA) have been well organized and established among clinical trials of systemic autoimmune diseases, and several drugs have been approved in clinical practice. In clinical trials of RA, methodology is established for basic structures, such as the inclusion criteria, exclusion criteria, treatment protocols, and evaluation methods. Therefore, in most tests, the test method does not significantly change. However, in order to obtain approval for a new drug, additional usefulness beyond that of existing drugs is necessary. Therefore, new evaluation items should be added. In recent years, patient reported outcome (PRO) has been actively used as a criterion for RA evaluation. It has been adopted as an item in clinical trials that can evaluate more subjective symptoms in addition to objective data, such as joint swelling in patients and inflammatory findings on blood tests (C-reactive protein, erythrocyte sedimentation rate, etc.). In the clinical trials of JAK inhibitors targeting RA, evaluation using PRO has been adopted, and JAK inhibitors are shown to be more useful than older drugs. Recently, several clinical trials on RA have been conducted as global trials; patients selected using the same inclusion criteria are treated with the same protocol and assessed using the same evaluation methods worldwide. Thus, it became possible to compare data obtained from patients in other countries with those from Japanese patients, clearly demonstrating the characteristics of Japanese patients.

S6-3
Future perspectives for JAK inhibitors from the Japanese all case post-marketing survey
Kunihiro Yamaoka
Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Japan

Conflict of interest: Yes

JAK inhibitors (JAKi) have shown similar anti-rheumatic effect with biologics. JAKi and IL-6 inhibitors gathered attention with monotherapy and is currently recommended for patients with methotrexate contraindication. The Japanese all case post-marketing survey (PMS) has revealed that JAKi is initiated as monotherapy in a fairly large amount of patients with long disease duration and failed multiple anti-rheumatic drugs. Tapering is something to consider. Tapering is something to consider though information is limited. In a study that discontinued tocilizumab at the time of completion of the clinical trial, 60% had flared by 52 weeks. Whereas, a tapering study with baricitinib resulted in majority maintaining their low disease activity. Due to side effects with methotrexate (MTX) especially in Japanese population, MTX-tapering is something to consider though information with JAKi is lacking. Studies with patients under control with MTX and tocilizumab (Tcz) would be suggestive. In a study that discontinued MTX, the effect was minimum and another study that discontinued Tcz, approximately half maintained disease activity under control. Taking these results in to account, tapering/discontinuation of MTX or tapering JAKi would be realistic. However, majority were treated with concomitant MTX. Depending on the report of PMS, tapering/discontinuation would not be suggested with those treated with monotherapy. JAKi share the fate with other anti-rheumatic drugs such as infections as their negative side. Herpes zoster is a characteristic side effect and the incident rate is doubled in the Japanese population compared to Western countries. Another concern is carcinogenesis owing to the effect of JAKi on the adaptive immunity. Ten-years follow up of the tofacitinib clinical trial revealed no increase in carcinogenesis. From the PMS, patients diagnosed as cancer with metastasis was occasionally observed within 6 months following initiation, suggesting the importance of screening. Recent concern of venous thrombotic event (VTE) has been raised. Currently the incident rate is similar to that with preexisting anti-rheumatic drugs and long-term follow up is necessary. Future perspectives of JAKi will be discussed based on the observations from the PMS and previous clinical trial.

S6-4
Management of herpes zoster induced by Jak inhibitors
Shinichi Imafuku
Department of Dermatology, Faculty of Medicine, Fukuoka University, Japan

Conflict of interest: Yes

Herpes zoster is an endogenous recurrent infection of varicella-zoster virus (VZV), which develops in about 5 people / 1,000 patient-year in the whole population, but its frequency increases in immunocompromised individuals. Our study using Japanese claim database revealed that in rheumatoid arthritis patients, the incidence was as high as 9.18 / 1,000 person years. Furthermore, in rheumatoid arthritis patients treated with tofacinib, one of the Jak inhibitors, pooled analysis of all trials including phase 2, phase 3, and open extension trials found that the incidence was extremely elevated to 39 / 1,000 PY (Cohen SB et al). In addition, severe cases (disseminated or multi-branched lesions) is 3 / 1,000 PY, thus Jak inhibitor treatment causes significant increase of incidence and severity of herpes zoster. Incidence of non-melanoma skin cancer also increases dose-dependently with other skin infections, but they are also known for other immunosuppressants such as MTX and cyclosporine.
Therefore, herpes zoster is a very specific infection characteristic of Jak inhibitors hence special attention needs to be paid to skin eruptions. Two types of vaccines have been approved for the prevention of herpes zoster in Japan, but as of November 2018, only the attenuated live vaccine, the varicella vaccine, is distributed in the domestic market. Varicella vaccine are contraindicated in immunosuppressed patients, and efficient prevention can not be expected at this point. Therefore, it is very important to diagnose herpes zoster early and treat with antiviral reagents.

S6-5
JAK-inhibitors – From targeting just another kinase to novel treatments
Gerd R Burmester1,2
1Department of Rheumatology and Clinical Immunology, Charite University Hospital, Berlin, Germany, 2Free University and Humboldt University of Berlin, Germany

Conflict of interest: Yes

For a long time, many approaches have tried using novel oral compounds to achieve similar efficacy and safety as biologics. Most of these trials have failed, especially those aiming to inhibit the MAP (mitogen-activated protein) kinase pathway where evidence suggests importance in the pathogenesis of rheumatoid arthritis (RA). However, drugs inhibiting the Janus kinase (JAK) pathways have resulted in a significant breakthrough in RA treatment. While efficacy could be anticipated due to the many cytokines that use JAKs for intracellular signaling, safety concerns were expressed, since knocking out JAK 1 or JAK 2 in rodent models were lethal and there is a human severe combined immunodeficiency disease where the gene for JAK 3 is malfunctioning. However, it appears that these doses approved in RA are usually safe, since apparently only the pathologically increased levels of JAK enzymes are reduced so that physiological functions remain – quite analogous to the situation with biologics where the complete absence may also lead to severe diseases, yet the amounts used for treatment usually do not lead to major deficiencies (1).

In many countries including the USA tofacitinib targeting JAK 1, 2 and 3 was the first drug to be approved. Finally, also EMA (European Medicines Agency) gave a positive opinion for this drug which “in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs” and “can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.” EMA also granted market authorization to baricitinib, a JAK 1 and 2 inhibitor where baricitinib “is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti-rheumatic drugs” and may be used as monotherapy or in combination with methotrexate.

Both tofacitinib and baricitinib have been investigated in extensive clinical trial programs ranging from MTX naïve early RA to csDMARD inadequate responders and patients failing biologics, most notably TNF inhibitors. One trial was powered to compare baricitinib and the TNF inhibitor adalimumab in a head-to-head design showing a modest, nevertheless significantly better efficacy of the JAK inhibitor. Also, both JAK inhibitors in monotherapy were clinically more effective than MTX in early RA including the analysis of radiologic progression. In addition, the major development programs of new compounds such as upadacitinib and filgotinib (selective JAK-1 inhibitors) and peficitinib support the positive benefit/risk ratio of JAK-inhibitors. Will these novel oral anti-rheumatic drugs lead to a paradigm shift in the treatment of patients with RA? While the current EULAR recommendations place these csDMARDs somewhat behind the biologics (Recommendation 8: “If the treatment target is not achieved with the first csDMARD strategy, when poor prognostic factors are present, addition of a bDMARD or a tsDMARD should be considered; current practice would be to start a bDMARD”), practice may change with more clinical experience, especially since the safety signals of the JAK inhibitors do not differ significantly from biologics with the exception of more herpes zoster cases, most notably in Japanese and Korean patients. Tofacitinib has safety and efficacy data from open label extension studies for more than 9 years. Nevertheless, the significant costs of these drugs will make early use in csDMARD naïve patients unlikely, and the very long experience, the extensive registry data and the availability of less expensive biosimilars with biologics may still result in a preferred use of biologic agents in the near future. However, patient preference of oral drugs instead of injectable compounds, the possibility to use them in monotherapy and the potentially superior efficacy compared to TNF inhibition might lead to a paradigm shift in the future. Reference (1) Burmester GR, Pope JE. Novel treatment strategies in rheumatoid arthritis. Lancet. 2017. 389:2338-2348.

S7-1
Recent activities of the research group for the systemic autoinflammatory diseases funded by the Ministry of Health, Labour, and Welfare
Ryuta Nishikomori
Kyoto University Hospital

Conflict of interest: None

The systemic autoinflammatory diseases (SAID) are one of intractable diseases, which cause systemic inflammation resulting in damage on multiple organs. The symptoms include fever of unknown origin, rash, and arthritis which could be misdiagnosed as rheumatic diseases. Since it has been known that some of SAID show great response to certain biologics, it is very important for rheumatologists to properly diagnose and treat SAID patients. Canakinumab, or anti-human IL-1β mAb, was approved for cryopyrin-associated periodic syndrome in 2011 and the approval was extended further to TRAPS, Hyper IgD syndrome, and colchicine-resistant or -intolerant FMF in 2016. Canakinumab has provided these patients much better QOL, but at the same time the canakinumab treatment has raised some issues on its long-term effectiveness and safety.

On the other hand, the diagnosis of SAID heavily relies on the genetic analysis, since SAID lack disease-specific biomarkers for diagnostic purposes. Thus, it requires nation-wide cooperation of experts on SAID in terms of clinical as well as genetic aspects. Finally, the number of SAID has been still increasing, which needs more efforts for the newly-diagnosed SAID on proper diagnosis and establishing standard patient care. To tackle these issues, we organized research group for SAID funded by the Ministry of Health, Labour, and Welfare in 2014. We have been working for patients with SAID regarding nation-wide patient care system, patient registration system, clinical guidelines, and seriousness classification. In this review talk, I will focus on the recent activities of the research group for SAID, such as introduction of genetic diagnosis system based upon newly-established genetic tests covered by health insurance, elimination of disparities on genetic diagnosis on SAID, and embarking on the “Nanbyo platform” registration system supported by AMED.

S7-2
Immunogenetics of Behçet’s disease from recent genetic findings
Masaki Takeuchi
Department of Ophthalmology, Yokohama City University

Conflict of interest: None

Behçet’s disease (BD) is a systemic inflammatory disorder vasculitis that manifests with oral ulcers, uveitis, skin inflammation, genital ulcers, and inflammation in other organs. Multiple genetic and environmental factors are believed to contribute to BD susceptibility. In 2010, we conducted the first genome-wide association study (GWAS) for BD in a Japanese population was conducted. In addition, Korean and Turkish populations were studied in the replication phase. Other genetic studies have also identified susceptibility loci. However, these genetic findings do not fully explain pathogenesis of BD. To further clarify the genetic factor of BD, we conducted the largest-ever genetic study for BD by genotyping with the Immunochip (Illimina), which is a custom genotyping array designed for dense genotyping of immune disease-associated loci. We genotyped 2,014 Turkish BD cases and 1,826 control subjects on the Immunochip and replicated the genetic findings in Japanese including 608 cases and 737 controls, and Iranian including 969 cases and 826 controls. This largest-ever genetic study with multiple populations for BD identified 6 novel loci (IL1A-IL1B, RIPK2, ADO-EGR2, LACC1, IRF8, and CEBPBP2PTPN1). Our results have significantly helped expand the list of genes with common variants that influence BD susceptibility and implicate variants influencing both innate and adaptive immunity in disease patho-
genetic risk. The risk allele of the lead SNP in the *IL1A-IL1B* locus was associated with both decreased interleukin-1α and increased interleukin-1β production. Our findings suggest the possibility that a combination of the decreased barrier function of IL-1α and increased inflammatory response of IL-1β increases the disease risk. ABO non-secretor is due to homozygosity of non-secretor SNPs for FUT2 revealed a strong disease association. These genetic findings implicate genetic determinants of mucosal barrier function and the host response to pathogens in BD susceptibility.

**S7-3**

**Update in clinical researches of intractable vasculitides by JPVAS**

Masayoshi Harigai
Department of Rheumatology, Tokyo Women’s Medical University

Conflict of interest: None

Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitis (JPVAS) is in charge of the following designated intractable diseases: Takayasu arteritis (TAK), giant cell arteritis (GCA), polyarteritis nodosa (PAN), microscopic polyangiitis (MPA), granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with polyangiitis (EGPA), rheumatoid vasculitis (RV), anti-phospholipid antibody syndrome (APS), and Burger disease. As for ANCA-associated vasculitis, three cohort studies revealed the genetic background, clinical characteristics, response to treatment, safety, risk factors for relapse, and association between ANCA positive conversion and relapse. JPVAS released the 2017 Clinical Practice Guidelines for ANCA-associated Vasculitis in February 2017, and published it in Modern Rheumatology. Two cohort studies for TAK and GCA are in progress, which clarified clinical characteristics and response to treatment of these diseases in Japan. JPVAS collaborated with Japan Circulation Society and revised 2017 Clinical Practice Guidelines for Vasculitides, and revised diagnosis and treatment of TAK, GCA, and Burger disease. Pediatricians are also participating in the subcommittees for large-sized vessel vasculitis and small and medium-sized vessel vasculitis. Subcommittee for clinical pathology is accepting consultation for pathological diagnosis for vasculitides from medical institutions at large. Subcommittee for international cooperation research has implemented DCVAS and PEXIVAS. It also collaborating with the Study Group on Diffuse Pulmonary Disorders to study ANCA-positive interstitial lung disease. Cross-collaboration research subcommittee has convened a series of public lectures for vasculitides and joint symposium with relevant medical societies. In this symposium, recent progress of JPVAS will be reviewed to provide a bird’s-eye view of the progress and challenges of management of vasculitis.

**S7-4**

**Efforts of research study group on autoimmune disease**

Masaaki Mori1, Takayuki Sumida1, Tatsuya Atsumi1, Yoshiya Tanaka4, Manabu Fujimoto1

1Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 2Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, 3Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, 4Department of First Internal Medicine, University of Occupational and Environmental Health, 5Department of Dermatology, Faculty of Medicine, University of Tsukuba

Conflict of interest: Yes

**Objectives** The aim of the research is to further improve its medical level with respect to 6 designated intractable disease such as systemic lupus erythematosus (SLE), polymyalgia/dermatomyositis (PM/DM), mixed connective tissue disease (MCTD), Sjögren’s syndrome (SS), adult onset Still’s disease (AOSD) and juvenile idiopathic arthritis (JIA).

**Method** Experts from the multiple medical fields are gathered to form a subcommittee and the following various projects are carried out in an integrated manner for children and adults; 1) verification and revision of diagnostic criteria and severity classification, and validation of international classification standards, 2) formulation and revision of clinical practice guidelines (GL), 3) educational activities for early diagnosis and treatment and medical treatment network construction for autoimmune diseases, 4) collaboration with AMED practical research projects, and so on. <Results> 1) All diseases were verified based on diagnostic criteria and severity classification of domestic and foreign countries so far. Especially, MCTD, which resumed policy research for the first time in several years, clearly defines the concept of disease again and is discussing classification criteria and severity classification. 2) As for SLE, we decide all CQ recommended sentences, and the first comprehensive clinical practice guidelines in Japan will be released in FY 2019. Additionally, PM / DM, SS, AOSD and JIA are conducting verification for revision based on recently published criteria. 3) In cooperation with patient associations and academic societies, we are trying to hold open sessions for patients or medical consultation sessions at least every year at each subgroup and we are devoting efforts to closeness with patients. As this consultation meeting is well received, we will consider regularly and continuously holding events. 4) By coordinating with AMED practical research projects, we collect clinical information and specimens from each facility and formulate a plan for new research projects. In addition to these, from April 2018, “ JIA” was registered and treated as one of designated intractable disease. <Products obtained to date> In this research, we conduct indispensable research on the above 1) ~ 4) and express outcomes leading to the future. Particularly, we were able to study children by integrating pediatric and adult cases. It is one of the results of consciousness of transition medical treatment, which is regarded as important for measures against intractable diseases.

**S7-5**

**Investigation of the Japanese Scleroderma Research Group**

Hironobu Ihn
Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Japan

Conflict of interest: None

The Japanese Scleroderma Research Group is working on “Study of diagnostic criteria, severity classification, and guidelines of systemic sclerosis and other cutaneous fibrotic diseases” supported by Japanese Ministry of Health, Labor and Welfare, and “The investigation on the efficacy of new low molecular compound for systemic sclerosis” supported by Japan Agency for Medical Research and Development. I would like to introduce the diagnostic criteria, severity classification, and guidelines of systemic sclerosis, localized scleroderma, eosinophilic faciitis, and lichen sclerosus et atrophicus. I also would like to talk about new low-molecular compound for systemic sclerosis.

**S7-6**

**The current status of the research committee for IgG4-related disease in Japan**

Kazuichi Okazaki
Department of Gastroenterology and Hepatology, Kansai Medical University, Japan

Conflict of interest: None

IgG4 related-disease (IgG4-RD) is a fibroinflammatory disorder recognized as a novel clinical entity originally proposed from Japan, and has become specified as an intractable disease in 2015. The patients with IgG4-RD show diffuse or focal organ enlargement and mass-forming or nodular/thickened lesions with abundant infiltration of IgG4-positive plasmacytes and fibrosis in various systemic organs, and respond well to steroid treatment. The research committee for IgG4-RD consists of eight subcommittees; gastrointestinal, lacrimal and salivary (Mikulicz disease), ophthalmic, renal, pulmonary, endocrine and neural, cardiovascular, and pathological one. The committee has performed epidemiological studies, and made/updated the comprehensive and individual organ diagnostic criteria, classification of disease severity, and therapeutic guidelines. We also have established and started the registry system for the patients with IgG4-RD.

**S8-1**

**Current and Future Osteoporosis Treatments: Mechanisms of Action**

Roland E Baron

...
Department of Medicine, Harvard Medical School, Boston, USA

Conflict of interest: Yes

Novel therapeutic approaches for osteoporosis provide better treatment but also new insights on the cellular and molecular mechanisms by which skeletal homeostasis is regulated. Skeletal homeostasis is ensured by the balanced activities of bone resorption and bone formation in bone remodeling. Osteoclasts resorb bone, but also recruit osteoblasts (coupling) ensuring repair of resorbed areas. In turn, osteoblasts form new bone at these sites and regulate the differentiation of osteoclasts via RANKL and OPG. Consequently, inhibition of bone resorption leads also to a decrease in bone formation and remodeling. Unlike bisphosphonates, Denosumab allows continued increase in bone density and reduction in fracture risk over time, in part via bone modeling, during which bone formation continues independent of resorption, particularly in cortical bone. One can also stimulate bone formation by activating the PTH/PTHrP or Wnt signaling pathways. Daily PTH1-34 (Teriparatide) injections increase bone formation but also resorption and turnover, with a positive balance. Bone density increases, but the increase in bone resorption affects intracortical remodeling and porosity, limiting the benefits of PTH treatment. PTHrP analogs (AlabaParatide) or the combination of PTH with Denosumab partially avoids the increase in resorption, increasing bone density further. The Wnt signaling pathway is a key regulator of osteoblasts as well as their cross-talk with osteoclasts. Blockade of the inhibitor Sclerostin, secreted by osteocytes, leads to major increases in bone formation and production of OPG, reducing also resorption. Sclerostin antibodies (Romosozumab) enhance Wnt signaling and has both an anabolic and an anti-resorptive effect that, albeit limited in time, increase bone density at trabecular and cortical sites, in large part via bone modeling. Taken together, these therapeutic developments provide promising prospects for osteoporosis treatment but also insights into bone biology.

S8-2 Epidemiology of Osteoporosis, Sarcopenia, and Frailty in Japan
Noriko Yoshimura
Department of Preventive Medicine for Locomotive Organ Disorders, 22nd Century Medical and Research Center, University of Tokyo, Japan

Conflict of interest: None

Purpose: To clarify the prevalence, incidence, and mutual association among osteoporosis (OP), sarcopenia (SP), and frailty (FR) using a 4-year follow-up assessment of a population-based cohort study entitled ‘ROAD.’ Methods: The second survey of the ROAD study was conducted between 2008 and 2010; overall, 1,083 subjects (aged ≥60 years; 372 men, 711 women) completed all examinations on OP, SP, and FR, which were defined using the WHO criteria, AWGS, and Fried’s definition, respectively. The third survey of the ROAD was conducted between 2012 and 2013; 749 of 1,083 individuals who were enrolled on the second survey (69.2%; 248 men, 501 women) completed assessments identical to those in the second survey. Results: The prevalence of OP, SP, and FR in the second survey were 25.0%, 8.1%, and 5.6%, respectively. The cumulative incidences of OP, SP, and FR were 1.9%/year, 2.0%/year, and 1.2%/year, respectively. After adjusting for confounding factors, logistic regression analysis indicated that OP was significantly raised the risk of the occurrence of SP, and FR. Conclusions: Preventing OP may help to reduce the risk of subsequent occurrence of SP and FR.

S8-3 Management of osteoporosis in diabetic patients
Ippei Kanazawa, Toshitsugu Sugimoto
Internal Medicine 1, Shimane University Faculty of Medicine, Shimane, Japan

Conflict of interest: None

Previous studies have shown that not only type 1 but also type 2 diabetes mellitus (DM) increase risk of fragility fractures. Because the estimated fracture risks based on their bone mineral density (BMD) are higher than actual fracture risks in patients with DM, the deterioration of bone quality should be a major cause of DM-induced bone fragility. Accumulating evidence reveals the underlying mechanism of the increased risk of fractures in patients with DM; accumulation of collagen cross links of advanced glycation end products (AGEs), low bone remodeling with impaired bone formation, and microstructure alteration such as cortical porosity. Although the mechanism of DM-induced bone fragility remains unclear, we previously demonstrated that AGEs and homocysteine induce dysfunction of osteoblasts and osteocytes, which may lead to low bone remodeling and decreased bone formation. On the other hand, the increased risk of falls is also important for the incidence of osteoporotic fractures in DM patients. We previously showed that AGEs were associated with decreased myostatinogenesis and muscle reduction in type 2 DM. In clinical settings, if all of the focus is given only to BMD values, we might underestimate the fracture risks in DM. However, there are no useful markers to evaluate bone quality thus far. Therefore, we need to choose patients with a high risk of osteoporotic fracture based on clinical risk factors, and to consider intensive treatment including anti-osteoporotic drugs. Previous studies have shown that higher HbA1c levels, longer duration of DM, insulin use, and thiazolidine use (if postmenopausal women) increase the fracture risk in patients with DM. However, further studies are needed to determine a suitable assessment tool for fracture risk that supplement the insensitivity of BMD and assess fracture risk in patients with DM. In this symposium, we will review the management strategy of DM-induced bone fragility.

S8-4 Management of osteoporosis in RA patients
Tatsuya Koike
Center for Senile Degenerative Disorders (CSDD), Osaka University Medical School

Conflict of interest: Yes

Patients with rheumatoid arthritis (RA) are known to be at higher risk for disorders of bone metabolism due to inflammation, glucocorticoid (GC) use and inactivity resulting from joint destruction. Previous researchers have reported that patients with RA had the risk of hip and vertebral fractures by about two- to six-fold compared to controls. RA is an independent risk factor for fragile fractures that has been assessed using the Fracture Risk Assessment Tool (FRAX). However, is the situation unchanged even in a new era when RA treatment has made remarkable progress? To reveal the real risk factors for osteoporosis in RA, we launched a ten-year prospective cohort in 2010, the TOTal Management Of Risk factors in Rheumatoid arthritis patients to 10Wer morbidity and mortality: the TOMORROW study including 208 RA patients and age- and sex-matched 205 volunteers. The most involved in fractures is a fall. When comparing the number of falls in both groups, the percentage of subjects experiencing falls increased in the same way year by year in both groups, but the average falling number was significantly higher in RA. Moreover, a positive correlation was found between the number of falls and the amount of administered GC. Comparing the 25 (OH) D levels related to the fall, it showed a significantly low value in RA. However, there was no significant relationship with the fall. The number of existing vertebral fractures was significantly larger in RA patients and the risk factors for clinical fractures were falls and GC use. RA was not extracted as a risk factor for clinical fractures. In addition, although the risk of fracture did not decrease by reducing GC dosage, a significant reduction in fracture risk was observed in the group where GC administration could be stopped. Based on the above, we believe that administration of GC rather than RA per se is an important risk factor in fragile fractures.

S8-5 Glucocorticoid-induced osteoporosis in rheumatic diseases and other inflammatory joint disorders
Nicholas C Harvey
MRC Lifecourse Epidemiology Unit, University of Southampton, UK

Conflict of interest: None

Glucocorticoids are widely used to treat disorders such as polymyalgia rheumatica and inflammatory arthritides. The impact of glucocorticoids on fracture risk is well documented, with a rapid rise in risk follow-
ing commencement of therapy and a corresponding decline in risk after cessation. Glucocorticoids adversely affect both bone formation and bone resorption, resulting in the observed risk-time relationships. The increased fracture risk appears partly independent of BMD. Importantly epidemiological studies have demonstrated that there is no safe minimum dose below which fracture risk is not raised. National and international guidelines have been developed to address fracture risk assessment, and bone protective therapy, in patients commencing glucocorticoid treat- ment, for example from the International Osteoporosis Foundation and, in the UK, the National Osteoporosis Guideline Group (NOGG). Such approaches incorporate the use of the FRAX Fracture Risk Assessment Tool, which includes glucocorticoids as an input variable. Given that dose information is not considered by FRAX directly, methods for modi- fying the output fracture probability have been derived, and are incorpo- rated in the UK NOGG website. In this presentation, the epidemiology and pathophysiology of glucocorticoid induced osteoporosis will be re- viewed, together with current approaches to assessment and treatment, including practical messages for the clinic.

S9-1
Actual state of support system, problems, and preparation of guid- ance for transition support in patients with juvenile onset rheumatic diseases
Toshihiro Matsui
Department of Rheumatology, National Hospital Organization Sagamihara National Hospital

Conflict of interest: Yes
Following the announcement of “The recommendation for the transition medicine in patients with juvenile onset disease” by the Japan Pedi- atric Society in 2013, “Transition support WG for pediatric patients with chronic diseases” was started to prepare guidance for transition support. In 2014, Transition support WG was established at the Pediatric Rheuma- tology Association of Japan. Recently, guidance for transition support for juvenile onset rheumatic diseases has been under preparation by the re- search project supported by the Ministry of Health, Labor and Welfare started since 2017. Interest in transtion medicine is increasing year by year. In the past, places where pediatricians and adult physicians interacted were limited, but now both are participating in the same research proj- ect, cooperating with each other and discussing actively for preparing guidance for transition support in patients with juvenile onset rheumatic diseases. Nowadays, medical treatment and research on rheumatic diseases have entered a seamless era beyond the boundaries between children and adults in various aspects. At this symposium, speakers will talk about the differences between children and adults in rheumatic diseases, prob- lems and efforts related to the transition support for patients with juvenile onset rheumatic diseases, and problems of pregnancy and childbirth. In addition, we would like to think about the medical care system in transi- tion medicine.

S9-2
Differences between pediatric and adult rheumatic diseases
Kimio Kawahata
Division of Rheumatology and Allergy, Department of Internal Med- icine, St. Marianna University School of Medicine, Japan

Conflict of interest: None
Clinical differences between children and adults with rheumatic dis- eases are unclear. Even though the names of the diseases are the same among children and adult patients, the symptoms, treatment, and prognosis of these diseases are different. To understand these differences are critical in several clinical settings. The first is the need for long-term follow-up of patients with rheumatic diseases from childhood to adulthood in the departments for adults. For example, attention to ocular complica- tions may be required in patients with juvenile idiopathic arthritis. Fur- thermore, since the disease pathology does not merely change at when a patient turns 16 years old, the treatment for children may be desired for some adult patients although the symptoms start in adulthood, or like- wise, the treatment for adults may be desired for some child patients even when the symptoms occur during childhood. Such phenomena have yet to be shown in rheumatic diseases yet but are known in other diseases. For example, in acute lymphoblastic leukemia, it has been shown that it is better for an adult patient to be treated with pediatric protocols until the patient reaches 25 years of age. Furthermore, even when the same symp- toms and severity are observed in children and adults, it is essential to understand the variation of the influence of the treatment on living func- tions by performing long-term follow-ups. Future clinical studies are expected to provide insights, not only based on the differences and similari- ties the symptoms and complications, but also on the influence of the treatment on daily living functions in adults that have gone through the process of growth, in order to clarify the differences in the meaning of treatment for diseases with seemingly similar activities and severities. In this talk, I would like to introduce the differences between children and adults with rheumatic diseases based on the points mentioned above.

S9-3
Pathology of transitional stage of juvenile idiopathic arthritis and guidance for clinical practice
Hiroaki Umebayashia, Masaaki Morib
aDepartment of Rheumatology and Infectious Diseases, Miyagi Chil- dren’s Hospital, Sendai, Japan, bDepartment of Lifetime Clinical Immu- nology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Conflict of interest: None
Juvenile idiopathic arthritis (JIA) is the most common chronic rheu- matic disease in children and young people. In a recent national epidemi- ological survey, it was estimated that the actual number of patients of JIA was about 3000. JIA is thought to be remission about 30% in about 10 years after onset, and many cases require an outpatient even after adult- hood. Prognosis, treatment, complications and so on, are different de- pending on disease type. Treatment of systemic JIA is based on steroids, sometimes the treatment is completed only by that, but there are many cases that easily recur. In patients with high steroid dependence, various adverse effects become apparent and the quality of life in transition may be affected. In a polyarthritis, MTX becomes an anchor drug like a rheu- matoid arthritis in adult. Among them, in particular RF positive polyar- thritis often uses biological drugs, many cases continue even in the transi- tion period. In children who are physically and mentally growing, symptoms of JIA and long-term hospitalization may inhibit healthy growth, with self-reliance as a person. To support JIA patients and families in transition, it is necessary to cooperate with pediatricians, adult medical specialists, nurses, pharmacists, psychologists etc.

S9-4
Transition support for Sjogren’s syndrome and problems related to “sex”
Yuzaburo Inoue
Department of Allergy and Rheumatology, Chiba Children’s Hospital, Chiba, Japan

Conflict of interest: None
Sjogren’s syndrome (SS) is a chronic disease requiring medical treat- ment tailored to the life stage of the patient. In particular, during the transition period from childhood to puberty, adolescence, and adulthood, vari- ous problems exist including not only the simple change in medical care from pediatrics to adult healthcare, but also problems in the transition from guardian-based to self-based medical care, the influence of the physical, mental and sexual maturity of patients, and problems due to dif- ferences in the medical system for children and adults. The guidelines for transition support include a “core guide,” laying out a series of support processes necessary to satisfy the individual needs of patients as they grow, along with a “guide by disease,” demonstrating a method of pro- viding medical support to patients based on the characteristics of individ- ual diseases. As created in cooperation with pediatrics and adult health- care in health labor science research, we herein introduce the guidelines on support and education for the following six categories, as the “guide by disease” to childhood SS patients: 1. psychological support; 2. self- support; 3. self-reliant medical behavior; 4. educational and occupational plans; 5. health and lifestyle, and 6. sexual health. Moreover, it is not un-
common to experience patients suffering from problems and concerns related to “sex” in the treatment of pediatric rheumatic diseases. According to a questionnaire survey targeting members of the Pediatric Rheumatology Association of Japan, approximately 60% of respondents had patients who had “troubles/issues related to sex,” while 11%, 29% and 37% of pediatric rheumatologists had patients with anxiety when it came to love, marriage, and pregnancy, respectively. Many pediatric rheumatologists had trouble regarding how to deal with this anxiety or how to talk about sexual intercourse and pregnancy originally in the clinic. Furthermore, 28% of them had experience dealing with patients who become pregnant in their teens, while 11% had experience dealing with patients who gotten married in their teens, making it by no means rare to respond to young pregnancy and young marriage. Support for troubles and problems related to “sex” is also an important issue for transition support medical care.

S9-5
Pregnancy in patients with childhood onset rheumatic disease patients
Mikako Goto1, Kayoko Kaneko2, Atsuko Murashima1,2
1The Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, 2Division of Medicine, Center of Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development

Conflict of interest: Yes

Treatment for pediatric rheumatic diseases has advanced remarkably; however, there are a certain number of cases in an adult department in which the disease developed during a patient’s childhood and continues to require treatment even after they’ve become adults. Therefore, medical care in a transitional period is an avoidable issue. Pediatric rheumatic disease is comparatively similar to its form in adults. Therefore it supposed not to be difficult to be transitioned to department of Rheumatology. However, special attention should be made to those patients. Here, we would like to consider patient’s pregnancy in this setting. First, it is necessary to check their disease condition and also to check whether or not there are any serious complications. If the patient’s condition is stable, we have to consider if it is necessary to continue the medication they are taking and also consider if the medication is possible even after pregnancy, in case they will need to continue taking it. If the disease is not stable, we have to tell the patient to concentrate on treatment, and advise them to plan to get pregnant when they are in good condition. The checklist written by Dr Ishizaki on the transition to adult includes questions on whether or not patients have consulted physicians, etc. about issues of pregnancy and young marriage. Support for troubles and problems related to “sex” is also an important issue for transition support medical care.

S9-6
Experiences of care for patients with rheumatic disease in transitional generation
Ken-ichi Yamaguchi, Masato Okada
St. Luke’s International Hospital, Immuno-Rheumatology Center, Japan

Conflict of interest: None

When a physician treats pediatric patients with chronic diseases, he may be involved various problems arise in their translational generation. Considering the importance of transitional medicine, Japan College of Rheumatology had started to create of the guideline about transition in rheumatic diseases under the cooperation of adults’ and pediatric rheumatologists. In the near future, we will provide guideline-based translational care. Even if it becomes such a time, we need solve about problems arises to patient case-by-case way in clinical medicine. This is “practical translational medicine”, which is the theme of this symposium. We treat patients from a baby to elderly people with rheumatic diseases in Immuno-Rheumatology Center, St. Luke’s International Hospital. We had been faced with various problems while treating patients in transitional age. Some patients had problems about medication under pregnancy, and some patients had problems in school life, and other patients had poor health derived from mental problems. If a medical subject like change of the medicine accompanying pregnancy hope also occurs, a subject called the poor health which arose from the subject which arises in school life, or the mental problem is included. I hope our experiences help you in this symposium about practical translational medicine.

S9-7
What I thought in rheumatologic training of both childhood and adulthood
Mariko Mouri, Takumi Matsumoto, Fumio Hirano, Masaaki Mori
LifeTime Clinical Immunology, Tokyo Medical Dental University

Conflict of interest: None

I am a pediatrician. I could luckily have a rheumatology training in both childhood and adulthood, four years in total. During the training period, I could think about pathologic differences in childhood and adulthood. Another large crop was that I could see “pediatricians” objectively. As a pediatrician is primary physician of children, so patients will come to feel a specialist, a like pediatric rheumatologist, with a family doctor. On the other hand, the period when the pediatrician sees growth of children at the side becomes long, the bonds might be strong, and they might not want to part with the patients. There are three different points from pediatric rheumatology when I trained in outpatients of adulthood rheumatology. First, the number of patients. Second, there are many problems in one patient, but third, they have a family doctor. It is not necessary for the rheumatologist to support all of the problems, and they can concentrate on rheumatologic problems. Whereas the burdens on adult department physician come to continue increasing with of the number of patients, because there are a lot of patients whom condition is stable does not to accept with introduction to rheumatic clinic of their neighborhood. Furthermore, the adult medical care may collapse when transition patients are added. In transition medical care, it is important that pediatricians and adult internal medicine should deepen understanding of each other. A pediatric rheumatologist does not have to completely treat adult rheumatic patients, and vice versa. It is necessary for the pediatrician to realize it again about an important role to promote the independence of children.

S10-1
Overview
Yasuhiro Kondo1, Masataka Kuwana2
1Department of Respiratory Medicine and Allergy, Tosei General Hospital, 2Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine

Conflict of interest: None

Interstitial lung disease associated with the connective tissue diseases (CTD-ILD) is a challenging and crucial issue for both pulmonologists and rheumatologist. Here’s an overview of CTD-ILD. 1) Early diagnosis Pulmonologists and rheumatologist see patients with some different populations of CTD-ILD. Pulmonologist see not only ILD patients with established CTD but also see ILD with subtle or not definitive features for CTD. On the other hand, rheumatologists see patients with established CTD and then find ILD, therefore, they have chance to see mild or asymptomatic ILD. Because of these differences, collaborations of pulmonologists and rheumatologist is useful. 2) Classification The clinical course of CTD-ILD is heterogeneous; some experience stable or slowly progressive ILD; however, a significant group exhibits a more severe and progressive decline. CTD-ILD is the leading cause of death. It is crucial to make a classification with primary disease, autoantibodies, HRCT pattern, histological patterns, and biomarkers. 3) Treatment Mainstay therapies for CTD had been corticosteroids and immunosuppressants, but recently, molecular targeted drugs for CTD are available. In patients with IPF, antifibrotic drugs roughly half the relative rate of decline of FVC. In patients with NSIP, corticosteroids and immunosuppressants are usually effective, however, they are harmful in patients with IPF. In patients with RA-ILD, DMARDs may be harmful with histopathological UIP in RA. Further studies are needed to evaluate the efficacy of these drugs in patients with CTD-ILD. 4) Future directions Many genetic factors have been identified through GWAS in CTD as well as in IPF, and evaluations
of similarities and differences of them may lead to an individualized medicine. Some molecular targeted drugs for CTD may be effective for CTD-ILD. Both pulmonologists and rheumatologists are now in desperate need for novel therapies with multidimensional approach among the broader spectrum of CTD-ILD.

S10-2
Diagnosis and treatment of interstitial lung disease associated with dermatomyositis
Shinji Sato
Tokai University School of Medicine

Conflict of interest: Yes

Interstitial lung disease (ILD) is the one of most important prognostic factors in patients with dermatomyositis (DM). Clinical course, response to treatment and prognosis of complicating ILD with DM is well known to be extremely diverse. Some are seldom progressive with no need of treatment, some are slowly progressive in a long period of time resulting in respiratory failure and some show sub-acute or acute progressive course some of which is fatal. Response to treatment is also different in each case. Therefore, correct evaluation of ILD types is very important in terms of the treatment of DM and ILD and this would lead to selection of appropriate treatment regimen and complete control of disease progression. In this aspect, autoantibodies found in patients with DM are useful for the diagnosis and treatment decision in clinical setting as well as serum ferritin or KL-6. Anti-aminocyl transfer RNA synthetase (ARS) antibody and anti- melanoma- differentiation associated gene 5 (MDA5) antibody (anti-CADM-140 antibody) is well known as major antibodies that are closely associated with ILD accompanied by DM. Anti-ARS antibody is closely associated with ILD that shows chronic course, whereas anti-MDA5 antibody demonstrates acute or sub-acute type of ILD that is refractory and has poor prognosis. The treatment regimens of ILD with DM are still controversial and do not reach the agreement among the specialist because large multicenter prospective randomized control studies were not available in this area. In this symposium, clinical characteristics, laboratory and imaging findings, diagnosis, recommended therapy and prognosis of ILD associated with DM are reviewed.

S10-3
Interstitial lung disease in patients with systemic sclerosis
Yoshio Yamasaki
Rheumatology and Allergology, St. Marianna University School of Medicine

Conflict of interest: None

Interstitial lung disease (ILD) is one of the common complications in patients with systemic sclerosis (SSc). ILD is detected by HRCT in up to 60% of SSc patients. Though the clinical course of ILD associated with SSc (SSc-ILD) varies from mild to severe, the disease is potentially progressive. Previous report shows that patients having extensive pulmonary disease of >20% by HRCT were associated with poor prognosis. The survival rate of 43% at 10-year. Additionally, the survival in patients both with ILD and pulmonary hypertension is extremely poor (30% at 3-year). To improve the outcome in patients with SSc-ILD, proper assessment in patients having potential risk for progressive ILD and appropriate therapeutic intervention for those patients is necessary. Randomized controlled trials showed both oral cyclophosphamide and mycophenolate mofetil had the therapeutic efficacy on SSc-ILD (SLS-I and SLS-II, respectively). In stead of oral cyclophosphamide, IV cyclophosphamide is often used in clinical practice. One recent study showed that IVCY was as effective as oral cyclophosphamide. Unfortunately these traditional immunosuppressive therapies may not be enough to sustain pulmonary function in some patients with SSc-ILD. Significant interests are taken in developing new therapies based on the pathogenesis of SSc or SSc-ILD, which are now under clinical trials. Antifibrotic medications such as pirfenidone and nintedanib, which have been recently approved in patients with idiopathic pulmonary fibrosis, are included as investigational treatments. Additionally, investigation on the efficacy of pirfenidone in combination with mofetil also under way (SLE-III). Tocilizumab, a humanized IL-6-receptor antibody, is now in a Phase 3 trial as a possible treatment for SSc and its associated ILD. Rituximab might be another candidate for the treatment of SSc-ILD. In this session, the overview of SSc-ILD including recent progress in treatment will be provided.

S10-4
Statement for the diagnosis and treatment of interstitial lung disease in primary Sjögren’s syndrome
Takashi Ogura1, Noboru Kitamura2
1Division of Respiratory Medicine, Kanagawa Cardiovascular and Respiratory Center, Japan, 2Department of Internal Medicine, Division of Hematology and Rheumatology, Nihon University, School of Medicine, Japan

Conflict of interest: Yes

Patients diagnosed with an Idiopathic interstitial pneumonia (IIP) often have clinical features that suggest an underlying autoimmune process, and do not meet the established diagnostic criteria for any characterisable CTD. It has been proposed that the criteria and terms to describe these patients, including “undifferentiated CTD associated ILD” (UCTD-ILD), “lung-dominant CTD” or “autoimmune-featured ILD”. Each term is controversial, and the lack of consensus over classification criteria limits the ability to conduct prospective studies for answering fundamental questions about these patients. The recent joint task force of the European Respiratory Society (ERS) and American Thoracic Society (ATS) proposed “interstitial pneumonia with autoimmune features” (IPAF) for this condition. A patient must meet criteria from two of the three prespecified domains to fulfill criteria for IPAF. These domains are clinical features of extrathoracic autoimmune disease, serologic evidence of autoimmune disease, and morphological criteria based on chest imaging, histopathology, or other multicompartment involvement. The concepts discussed in this research statement are intended to provide a platform for the prospective study of these patients and are not intended as guidelines for clinical care. According to the recent retrospective studies, current IPAF criteria seem to include a rather heterogeneous population. To overcome this issue, some researchers suggest requirements of multi-department with multi-center studies, and the exclusion of some specific autoantibodies. One of the main purposes of this criteria is to clarify the management and treatment of the IP patients with autoimmune features. We need prospective trials to investigate the efficacy and safety of disease-modifying antirheumatic drugs, biologic and antibiotics. For a future progress in the field, there is definitely need for close collaboration between pulmonologists and rheumatologists.

S10-5
Interstitial Pneumonia with Autoimmune Features (IPAF)
Yutaro Nakamura, Katsuhito Yoshimura, Takafumi Suda
Second Division, Department of Internal Medicine (Respiratory Medicine), Hamamatsu University School of Medicine

Conflict of interest: None

Patients diagnosed with an Idiopathic interstitial pneumonia (IIP) often have clinical features that suggest an underlying autoimmune process, and do not meet the established diagnostic criteria for any characterisable CTD. It has been proposed that the criteria and terms to describe these patients, including “undifferentiated CTD associated ILD” (UCTD-ILD), “lung-dominant CTD” or “autoimmune-featured ILD”. Each term is controversial, and the lack of consensus over classification criteria limits the ability to conduct prospective studies for answering fundamental questions about these patients. The recent joint task force of the European Respiratory Society (ERS) and American Thoracic Society (ATS) proposed “interstitial pneumonia with autoimmune features” (IPAF) for this condition. A patient must meet criteria from two of the three prespecified domains to fulfill criteria for IPAF. These domains are clinical features of extrathoracic autoimmune disease, serologic evidence of autoimmune disease, and morphological criteria based on chest imaging, histopathology, or other multicompartment involvement. The concepts discussed in this research statement are intended to provide a platform for the prospective study of these patients and are not intended as guidelines for clinical care. According to the recent retrospective studies, current IPAF criteria seem to include a rather heterogeneous population. To overcome this issue, some researchers suggest requirements of multi-department with multi-center studies, and the exclusion of some specific autoantibodies. One of the main purposes of this criteria is to clarify the management and treatment of the IP patients with autoimmune features. We need prospective trials to investigate the efficacy and safety of disease-modifying antirheumatic drugs, biologic and antibiotics. For a future progress in the field, there is definitely need for close collaboration between pulmonologists and rheumatologists.

S10-6
Progressive Fibrosing Interstitial Lung Disease: PF-ILD
Yoshikazu Inoue
Clinical Research Center, National Hospital Organization Kinki-Chuo Chest Medical Center, Japan

Conflict of interest: Yes

Interstitial Lung Disease (ILD), also referred to as Diffuse Parenchymal Lung Disease (Diffuse Parenchymal Lung Disease), encompass a large group of over 200 pulmonary disorders including connective tissue diseases, most of which are rare diseases. Patients with ILD have similar respiratory symptoms, pulmonary dysfunction, chest image findings, and/ or pathological features, and the presence of patients who develop a progressive fibrosing phenotype instead of appropriate treatment during their clinical course has been reported. In addition, those patients can develop acute exacerbation, resulting in early death from respiratory failure. Patients with Idiopathic Pulmonary Fibrosis (IPF), a representative pulmonary fibrosis, have heterogeneous clinical features. But the prognosis of
the patients with progressive fibrosing phenotype are considered to be poor. Recently, a large-scale clinical trial for IFP using anti-fibrotic drugs (nintedanib or pirfenidone) had been conducted with the positive results. Their efficacy and safety have been also reported in a real-world setting. The effects of these anti-fibrotic drugs on the phenotype of progressive pulmonary fibrosis other than IFP are expected. “Progressive Fibrosing Interstitial Lung Disease (PF-ILD)” is a disease concept defined in the clinical trials confirming the efficacy and safety of nintedanib for such patients. PF-ILD was defined as combination of evidence of worsening lung function, worsening respiratory symptoms and/or evidence of increasing fibrosis on chest imaging, despite adequate treatment in 24 months. The clinical trial is ongoing and the results are highly expected (Flaherty KR, et al, BMJ Open Respir Res. 2017). Patients with connective tissue disease associated with progressive fibrosing phenotype of ILD could not be sufficiently controlled by conventional treatments and managements of underlying connective tissue disease. In order to improve QOL and prognosis of those patients, treatments and/or managements of IFP, such as anti-fibrotic drugs would be helpful.

**S11-1**

Joint surgery for rheumatoid arthritis aimed at improving physical function

Toshihisa Kojima

Nagoya University, Graduate School of Medicine

Conflict of interest: Yes

Drug therapy with methotrexate (MTX), and biologics (Bio) had made great progress in treatment of rheumatoid arthritis (RA) during two decades. A strategic Treat To Target aiming at a clear numerical target, that is, “remission; symptoms of arthritis remain at most one joint” is the most important for improving the outcome. Early patients with minimal joint destruction can sufficiently prevent the occurrence of ADL disorder by medication therapy. On the other hand, there are many patients who already have joint destruction and ADL disorders. Surgical therapy is an important option for these patients. According to a multi-center cohort study for the RA patient with joint surgery, which was supported by a grant from Ministry of Health, Labor and Welfare, more than half cases were operated with inflammation being almost calm. Also, approximately one third of cases were undergoing surgery in functional remission status. Therefore, current RA surgical therapy is performed not only to relief from pain but also to re-acquire physical functions. It is essential to set concrete numerical targets to achieve high therapeutic goal of improving patient’s physical function. The target needs to be a daily, familiar numerical value for the patient, the medical doctor, and both. Now, we are paying attention to the range of motion of the joint and the activity speed as outcome measure to set the target. The targets should be useful for shared decision making of surgery, daily care and rehabilitation.

**S11-2**

Evidences of surgeries for upper extremity (Elbow/Shoulder) to improve QOL of RA patients

Yoshihisa Nasu1, Ryozo Harada1, Keiichiro Nishida1, Minami Matsuhashi1, Masahito Watanabe1, Shunji Okita2, Yohei Kiso2, Hideki Ohashi2, Ryuichi Nakahara1, Toshifumi Ozaki2

1Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 2Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science, 3Department of Intelligent Orthopaedic System, Okayama University Graduate School of Dentistry and Pharmaceutical Science

Conflict of interest: Yes

The advancement of recent pharmacological therapy has dramatically changed the patients’ disease characteristics of rheumatoid arthritis (RA). As results, decreasing incidence of orthopaedic surgeries have been observed in many registered populations. On the other hand, small joint surgeries for hand / foot disability have been performed more frequently in Japan. Regarding to function of upper extremity, the reconstruction of ability to reach, that is mainly affected by shoulder and elbow function is essential to improve the QOL of RA patients. Synovectomy is rarely performed today but still important option for persistent synovitis despite of adequate therapy. Long term result should be re-evaluated in this bio era. The clinical result of shoulder arthroplasty has been remarkably improved mainly by the advancement of prosthetism design. Reverse shoulder arthroplasty is widely indicated cuff tear arthropathy. However rheumatoid shoulder with rotator cuff disorder can be also indication of reverse shoulder arthroplasty, we need careful consideration for poor bone quality and bone stock of them. Intensive drug therapy for joint inflammation and osteoporosis is expected to reduce these problems in RA patients. Total elbow arthroplasty is also important procedure for reconstruction of RA elbow. We still have to treat many patients who already have destructed elbow with severe pain, contracture, or instability. Surgeon have to select adequate implant to each case regarding to patient’s factors (e.g. condition of soft tissues, age, bone stock, daily activity level). Our previous studies revealed that clinical result of TEA is significantly affected by adjacent joint involvement. In this symposium, we outline the clinical result of our TEA evaluated by several patients reported outcomes (PREE, DASH, HAND20, Boddy image assessment tool).

**S11-3**

Evidence that surgery for rheumatoid arthritis patients improves their quality of life Wrist and Hand

Asami Abe

Department of Rheumatology, Niigata Rheumatic Center, Shibata Niigata Japan

Conflict of interest: None

**Objective:** The disease activity of rheumatoid arthritis (RA) patients is improved by treatment with biological agents (Bios). We examined the surgical sites and procedures that afforded high satisfaction (EuroQol 5 Dimension [EQ-5D], Beck’s Depression Inventor-II [BDI-II], Japanese version of the Stanford Health Assessment Questionnaires [J-HAQ]) and Disability of the Arm, Shoulder and Hand [DASH]) in RA patients after surgery. **Methods:** We evaluated 123 RA patients for their duration of disease as well as disease stage and class. We also assessed the surgical site and type of procedure performed. The EQ-5D, BDI-II, J-HAQ and DASH were measured before surgery and at six months and one year after surgery. **Results:** A total of 123 RA patients (average age: 63.2 years old) had been affected for a mean of 16 years with a mean stage of 3.16 and class of 2.33. The surgical sites were the wrist in 76 and finger in 47. The procedure was synovectomy in 21, arthroplasty in 39, arthrodensis in 33 and joint replacement in 30. There were significant differences in the EQ-5D, BDI-II and J-HAQ scores of the wrist before and after surgery. There were also significant differences in the EQ-5D, BDI-II and J-HAQ scores between arthroplasty and arthrodensis. At all surgical sites and for all procedures, the DASH score improved after surgery. **Conclusions:** The postoperative satisfaction of RA patients was shown to be quite high at the wrist joint. The surgical procedures of arthroplasty, arthroplasty, arthrodensis and joint replacement showed a high postoperative satisfaction among RA patients. Surgeries at the wrists and fingers for RA were shown to enhance the quality of life of RA patients.

**S11-4**

Evidence of the knee and hip surgery for the patients with rheumatoid arthritis improved their quality of life

Yuya Takakubo1,2, Michiaki Takagi1

1Department of Rehabilitation & Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan, 2Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan

Conflict of interest: None

Knee and hip joints play important roles for standing and walking as a human being. Reconstruction of their joints is one of beneficial therapeutic targets in surgical interventions (Ito H, et al. 2018). Biologic (BIO) therapies have been developed dramatically the treatment in RA patients. Decreasing of total numbers of surgeries for RA in BIO-era, especially synovectomy of joint and total knee and hip arthroplasties (TKA, THA) (Weiss RJ, et al, 2008, Shourt CA, et al, 2012, Momohara, et al, 2010). In our registry, the rate of orthopaedic surgeries for RA patients were de-
creased year by year compared to the trend of whole orthopaedic surgeries (Takakubo Y, et al. 2015). However, 20-30 % of RA patients using biologics are non-responders or show only minor improvement. The residual joint inflammation indicates a risk for progression of the joint destruction with osteoarthritis changes and osteoporosis (Nystad TW, et al, 2016). It has reported not to stop and prevent the progression of joint even using biologics who already has changed the joint destruction over Larsen grade 2 (Matsushita I, et al, 2017). TKA and THA is an important intervention for RA patients, because they have related the improvement of ACR core set and HAQ scores (Tanaka E, et al, 2005, Ishikawa H, et al, 2018, Kojima T, et al, 2018). Because pre- and postoperative modified Harris Hip Score values were influenced by preoperative disease activity of RA due to multi-joint disorders, it is so important total management of whole joints of lower limbs for the surgical interventions (Imagama T, et al, 2018). In future, when it is possible to prevent joint arthritis and destruction at the early stage of RA, the joint preserving and re-construction surgeries which are relative contraindication until now is applied similar to non-RA patients (Yoshitomi H, et al. 2018). We will show the evidence of knee and hip surgeries for improvement of QOL in the patients with RA at this symposium.

S11-5 Foot and ankle surgery with evidence for higher QOL of rheumatoid arthritis patients
Makoto Hiraot, Kasuke Ebina, Hideki Tsuboi, Takaaki Noguchi, Shigeiyoji Tsuji, Yasuo Kunugi, Koichiro Takahashi, Hideki Yoshikawa, Jun Hashimoto
1Department of Orthopedics, Osaka University Graduate School of Medicine, Orthopaedics/Rheumatology, Osaka Rosai Hospital, Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, 2Department of Orthopaedics, JCHO Hoshiyauko Medical Center, 3Orthopaedics/Rheumatology, National Hospital Organization, Toneyama Hospital
Conflict of interest: None
As a general-purpose rating system of the QOL, Medical Outcomes Study 36-Item Short Form-36 (SF-36) and EuroQol. (EQ-5D) are popular. These are evaluations including the mental health not only to mention an item of a function, pain, a daily living activity, the social life. There are the AOFAS score of the surgery society of the American foot and the JSSF score of the surgery society of the Japanese foot, and it is used frequently, but it is all the evaluation of pain, the function, however mental health index is not included in the treatment result criteria of a foot part, the ankle. Rheumatoid arthritis is a systemic disease, and chances for a remission state increase by dramatic progress of the medical treatment, but there is certain pain subjectively in 90%, latitude in 70%, and stiffness in 40% of a case said to be remission from a doctor notes [Rheumatic communication book, Copyright © 2018 Eli Lilly Japan K.K. All rights reserved]. The rating system that the mental health side such as SF-36 or EQ-5D included was important, but it was said to check systematic body and metal health, and the surgery of the foot part was local treatment and focused on a foot. From these, it was able to use an evaluation using SAFE-Q rating system including the items of the mental health index. Validity and responsiveness of SAFE-Q in the rheumatic case is proved [Yano et al. Mod Rheumatol. 2015]. We introduce this SAFE-Q from 2014, then we compared even the severe case example such as Larsen classification 4-5 with the mild case when we performed the modified Scarf osteotomy+metatarsal shortening offset osteotomy for rheumatic forefront deformity. There was no inferiority in severe group [JBJS.2018]. On the other hand, we knew that score was higher than case group of the biological treatment in a score of the postoperative social life-related index, as compared with non-biological group, after total ankle arthroplasty (TAA) [JBJS open access. 2017]. With progress of the medical therapy, we feel a duty and challenge for the durability improvement of the artificial ankle joint for the rheumatic case that have more activity.

S11-6 Surgical treatment of spinal lesions associated with rheumatoid arthritis
Hirotaka Chikuda
Department of Orthopaedic Surgery, Gunma University
Conflict of interest: None
Spinal lesions associated with rheumatoid arthritis (RA) commonly affect the cervical spine with reported incidences ranging from 40 to 80 %. Progressive destruction of the spine may cause intractable pain, loss of natural motion, and instability of the spine. Further destruction may result in compromise of spinal cord and subsequent paralysis. Recent advances in medical treatment have greatly improved care of patients with RA. Modern biologics not only suppress the progression of joint destruction but also have the potential to reduce the occurrence of spinal lesion. Nevertheless, surgical treatment will remain as treatment of choice for those presenting with advanced destruction of the spine. For the last few decades, surgical treatment of spinal lesions in RA patients has been becoming increasingly safer; the primary factors include 1) wide-use of computer navigation-assisted surgery, 2) advances in spinal instrumentation, and 3) increased awareness of potential complications. Surgical treatment of spinal lesions has the potential to substantially improve outcomes and patients’ quality of life if provided at the right time.

S12-1 Trans-layer omics analysis reveals disease biology
Yukinori Okada
Department of Statistical Genetics, Osaka University Graduate School of Medicine
Conflict of interest: None
Recent development of genome sequencing technology changed the bottleneck of genomic studies from genome sequencing into interpretation of the sequenced genomes. Trans-layer omics analysis is a type of the bioinformatics analysis which integrates omics data from different samples or populations. Compared with multi-layer omics analysis which handles omics data form the same individuals, trans-layer omics analysis can handle more omics layers and larger samples with lower costs. Integration of large scale genome-wide association study results with tissue-specific epigenome information can identify key cell types causally related to disease biology. Previous trans-layer omics analysis mainly handled epigenome information such as gene expression (by RNA-seq) and chromatin information (by Chip-seq and ATAC-seq). Recently efforts focus on integrating additional omics layers. We developed a novel statistical genetics method named MIGWAS (mirRNA-target gene enrichment analysis in GWAS), which integrated large scale disease genetic data with tissue-specific expression profiles of microRNAs. Application of the non-linear machine learning method to the HLA gene variants revealed clustering patterns of white blood cell types of the Japanese population. We would like to introduce our recent researches on trans-layer omics analysis.

S12-2 AI-based drug discovery: data-driven approach to predict therapeutic effects and side-effects
Yoshihiro Yamanishi
Department of Bioscience and Bioinformatics, Kyushu Institute of Technology
Conflict of interest: None
Recent developments in biotechnology have contributed to the increase in the amounts of high-throughput data for compounds and proteins in the genome, transcriptome, proteome, metabolome and phenome. These biomedical big data can be useful resources for drug discovery and repositioning. Drug repositioning, or the identification of new drug indications (new applicable diseases of existing drugs), is an efficient strategy for drug development. The drug repositioning approach has received remarkable attention in pharmaceutical industry, because it can increase the success rate of drug development and to reduce the cost in terms of time, risk, and expenditure. In this study, we developed novel machine learning methods for predicting potential target proteins of known drugs or drug candidate compounds toward automatic drug discovery and repositioning. We performed the prediction of unknown therapeutic effects or side-effects based on various large-scale omics data of drugs, compounds, genes, proteins, and diseases in a framework of supervised network infer-
ence. Our results show that the proposed method outperforms previous methods in terms of accuracy and applicability. We performed a comprehensive prediction of new indications of all approved drugs and bioactive compounds for a wide range of diseases defined in the International Classification of Diseases. We show several biologically meaningful examples of newly predicted drug indications for cancers and neurodegenerative diseases. The proposed methods are expected to be useful for predicting therapeutic effects and side-effects of drug candidate compounds in practice.

S12-3
Cancer immunology research with novel experimental approaches
Hiroyoshi Nishikawa
Research Institute, Division of Cancer Immunology, National Cancer Center

Conflict of interest: Yes

Upon the clinical application of cancer immunotherapy, particularly immune checkpoint blockade (ICB) in which treatment efficacy is dependent on the immune system, more than half of treated patients yet fail to respond to immune checkpoint blockade, even in combination, uncovering a limited window of clinical responses. It is therefore required to develop more effective cancer immunotherapies and define biomarkers for stratifying responders and non-responders via the detailed analyses of immune responses in the patients. According to the cancer immunomodulating hypothesis, cancers select low-immunogenic tumor cells such as cells with decreased immunogenic antigens and employ multiple immune suppressive mechanisms including immune checkpoint molecules to create an immunosuppressive tumor microenvironment (TME) to escape immunosurveillance. Thus, cancers in the clinic can be divided in immunologically hot and cold tumors, and clarifying the immunological phenotypes with comprehensive genomic and immunological assays is necessary to optimize cancer immunotherapies with suitable predictive biomarkers. Certain oncogenic signals such as WNT signal reportedly control immune responses in tumors. We have found that driver mutations in EGFR promote Treg-infiltration and inhibited effector T-cell infiltration into the TME by directly targeting chemokine expression to establish the immunosuppressive TME. Thus, integrated analyses of immunological and genomic assays revealed the comprehensive immune suppressive network in the TME, leading to the optimal cancer immunotherapies.

S12-4
SKG mouse as a model of autoimmune arthritis
Keiji Hirota
Laboratory of Integrative Biological Science, Institute for Frontier Life and Medical Sciences, Kyoto University

Conflict of interest: None

The SKG strain of mice, carrying a point mutation in the gene encoding the TCR-proximal signaling molecule ZAP-70, develops CD4+ T cell-mediated autoimmune arthritis, which clinically and immunologically resembles rheumatoid arthritis (RA) in humans. The mice spontaneously develop the disease in a microbiologically conventional environment but not under a specific pathogen-free (SPF) condition. Yet the disease can be induced in SPF SKG mice by stimulation of innate immunity via TLRs, the Dectin pathway, or complement activation pathways. We previously demonstrated using SKG mice how self-reactive T cells are generated in the process of thymic positive and negative selection, become activated in the periphery by recognizing self-antigens, differentiate into arthriticogenic Th17 cells upon stimulation of innate immunity, migrate into the joints, and aggress self-antigens expressed by synoviocytes. These features make this spontaneous model of autoimmune arthritis suitable for elucidating how Th17 cells mediate autoimmune diseases, especially RA, via interacting with other lymphoid and non-lymphoid cells at the inflammation site and controlling their production of inflammatory cytokines.

S12-5
Research on diseases and drug discovery by intravital imaging
Junichi Kikuta

Department of Immunology and Cell Biology, Graduate School of Medicine, Osaka University, Japan

Conflict of interest: None

Bone is the hardest tissue in the body; for this reason, it is technically difficult to visualize cellular interactions in the bone marrow of living animals. The morphology and structure of bone tissues can be analyzed using various conventional methods, including micro-computed tomography, histomorphological analyses, and flow cytometry. These methods yield information on cell shape and gene expression patterns, but not on dynamic cell movements in living bone marrow. The recent introduction of fluorescence microscopy has enabled imaging of the cellular dynamics of organs and tissues in vivo. Therefore, we have originally established an advanced imaging system for visualizing living bone tissues with intravital two-photon microscopy. By means of this system, we revealed the in vivo behavior of bone-resorbing osteoclasts and could grasp the real time-course of osteoclastic bone resorption which was finely regulat ed by cell-cell contact with bone-forming osteoblasts. We also found that various anti-osteoporosis drugs acted directly on mature osteoclasts during bone destruction, with different efficacies. Here we show the latest data of intravital bone imaging, and also discuss its further application. This technique facilitates investigation of cellular dynamics in the pathogenesis of bone-destructive disorders, such as osteoporosis and rheumatoid arthritis in vivo, and would thus be useful for evaluating the efficacy of novel anti-bone-resorptive drugs.

S13-1
Current concepts and future perspective of the treatment of rheumatic diseases
Josef Smolen
Medical University of Vienna, Austria

Conflict of interest: None

Treatment of IMIDs of joints and spine has reached an unprecedented success, owing to early diagnosis, a strategic treatment approach and the availability of targeted therapies. Since end of last century, pathogenetic information was used to develop novel therapies, but pathogenetic information does not equate knowing pathogenesis. True pathogenetic insights come from success or failure of agents deemed to be effective by ex-vivo data or from preclinical models, thus, still from empiric approaches. TNF inhibition is effective across many IMIDs while IL-6 inhibition is not and IL-1 inhibition fails in most. IL-17 and IL-23 directed therapies fail in RA, but are effective in psoriasis with less efficacy in PsA; IL-17 inhibition fails in Crohn’s (CD), while IL-23 inhibition is inefficacious in AS. Given relationship between IL-23 and Th17, the IL-17 source and the role of IL-23 is upregulated and enigmatic. While this information allows to develop a “cytokine map” of IMIDs, it does not allow drawing a “cellular map”. Inhibition of pathways involved with various pathogenic cytokines, such as 38-MAPK and Syk, is not efficacious where tested, while Jak-inhibition is efficacious across many IMIDs. We still do not understand which cytokines are those whose pathway is inhibited. Activation of the interferon pathway has been assumed to be critical in SLE, but recent data shatter the interferon theory. This list reveals that we have to learn which findings constitute an epiphenomenon and which ones are of true pathogenetic relevance? this will be a major challenge of the future. Recent developments, like single cell analysis or?omics approaches, may help in this regard, as might information on the role of microbiota. The fact that autoimmunity starts many years before the onset of clinical manifestations, a time point that cannot be accessed at present, reveals the complexity of approaching a true understanding of pathways to these diseases. Future perspectives will be drawn.

S13-2
Safety management of biologics learned from multiple big data in the real world
Masayoshi Harigai
Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Conflict of interest: Yes
Safety data of biologics are collected during and after clinical development programs, and post-marketing surveillance programs with predefined objectives have been implemented for many biologics in Japan. TNF inhibitors are approved for a series of rheumatic diseases, and their safety profiles have been investigated in detail. Infection is the most frequently observed serious adverse drug reaction (sADR) of TNF inhibitors, and should be paid attention in all diseases for which TNF inhibitor is used. Risk for serious infection is strongly affected by patient background of each disease, including age, comorbidities, and concomitant drugs, especially glucocorticoid. Safety profiles are basically similar across all indications. Among non-TNF inhibitors, tocilizumab has recently been approved for Takayasu arteritis and giant cell arteritis. Clinical trials of the drug for adult-onset Still’s disease and systemic sclerosis has been completed, and that for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) is currently underway. Rituximab is already approved for MPA and GPA. Infection is also the most frequently reported sADR in patients treated with tocilizumab and rituximab. When these biologics are used for systemic rheumatic diseases such as vasculitides, it is pertinent to taper concomitant glucocorticoid as fast as possible and reduce the risk for infection as much as possible. Appropriate regimens of glucocorticoid including initial dosage and tapering speed is under investigation. No new ADRs of tocilizumab and rituximab have been reported in patients with vasculitides or systemic sclerosis in clinical trials. Belimumab and mepolizumab are now available for systemic lupus erythematosus and eosinophilic GPA, respectively. All-cases post-marketing surveillance programs are in progress for these biologics and the results are awaited. I would like to take this opportunity to sort out the relevant data and reflect for future challenges.

**S13-3**

**Prevention of Inflammatory RA**

Paul Emery

1University of Leeds, Leeds Institute of Rheumatic & Musculoskeletal Medicine, Leeds, UK, 2Leeds Teaching Hospitals NHS Trust, Leeds, UK

Conflict of interest: Yes

That the RA phenotype is the end-point of a continuum and that patients can be identified at a phase when they are at risk, has been a major advance for RA management. There are several ways of identifying patients, including identifying those with clinically suspicious symptoms but also asymptomatic patients with presence of CCP-2 (an anti-citrullinated protein antibody). Finding these patients in primary care has been a challenge, but there is now, through a national network, a process by which patients are referred with ACPA positivity and who have a relatively short period before they progress to inflammatory arthritis. It is possible through a clinical risk score to identify those likely to progress. This score can be further improved by the use of the imaging including ultrasound. Furthermore MRI has identified that the first musculoskeletal involvement may frequently be outside the joint and unique structures involved have been defined. The presence of abnormalities of T-cell subsets (particularly reduced naive cells corrected for age) provide further sophistication. We are now in a position to accurately stratify patients for risk. Alongside this development, there has been evidence that the primary site of initiation of autoimmunity involves the mucosa. This has been studied in the mouth, the lung and the gut. We have had a particular interest in identifying abnormalities of the oral microbiome in patients at risk and have shown that p.gingivalis is highly prevalent in those with autoantibodies (without synovitis) and this is true of both diseased and healthy periodontal sites. Thus, we are now in the position that clinical trials can be logically undertaken to identify the best strategy for reducing the rate of progression.

**S13-4**

**New perspectives on non-TNF biologics for RA and other autoimmune diseases**

Yoshiya Tanaka

The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan

Conflict of interest: Yes

Autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are characterized by acute and chronic inflammation leading to multiple organ manifestations and various immunologic abnormalities are involved in the diseases processes. The development of biologics targeting IL-6 and T cells as well as TNF have revolutionized treatment of RA and clinical remission and prevention of structural changes are a realistic goal for the treatment. Moreover, the indication of anti-IL-6 receptor antibody has been recently expanded to other autoimmune diseases such as idiopathic juvenile arthritis, Takayasu’s disease and giant cell arteritis. In contrast, there has been less evidence of effective targeted therapies in other autoimmune diseases and corticosteroids and immunosuppressants are still the standard of care which are often associated with adverse events. Several clinical trials have demonstrated less improvement in SLE due to the clinical and molecular heterogeneity among patients. By recent genome-wide association studies, disease-associated risk loci locate not only in acquired immunity but also in innate immunity. Biologics targeting BAFF, IFN, IL-12, etc. which are produced by dendritic cells and activate T cells and/or B cells, have been emerging for the treatment of SLE. On the other hand, how multiple biologics are differentially used for the treatment of autoimmune diseases remain unclear. Psoriatic arthritis (PsA) is a chronic and progressive inflammatory arthritis and biologics targeting TNF, IL-17, IL-12/IL-23, IL-23 are approved for the treatment. Because PsA is heterogeneous, we have tried to classify PsA by phenotypic differences of peripheral lymphocytes using 8-color flow cytometry and found that PsA was divided to four types, activated Th17-dominant, Th1-dominant, both of them and neither of them, which resulted in precision medicine via the strategic selection of different biologics based on the phenotypic differences in T cells in individual patients with PsA. Taken together, a treatment strategy should be guided by molecular, cellular and/or immunological mechanisms and biomarkers and a systematic approach to design a precision medicine to autoimmune diseases should help to achieve the goal.

**S13-5**

**Further development beyond RA and beyond biologics**

Tom WJ Huizinga

Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands

Conflict of interest: None

Rheumatoid Arthritis (RA) is a chronic inflammatory and destructive disease. During the last decades insight in pathogenesis and subsequent development of targeted therapies (especially monoclonal antibodies against cytokines and surface receptor on white blood cells) have dramatically improved outcomes for patients, the major developments will be reviewed. The phases of RA development are now well defined ranging from the mere presence of genetic risk factors to full-blown persistent RA. We expect that the management of RA will change by testing intervention strategies designed to prevent the development of persistent RA. The likelihood of an individual at risk in different pre-RA phases progressing to RA is currently being defined. The subjects at the highest risk of developing arthritis (i) suffered from joint pain prior to showing typical joint swelling; (ii) experienced sick leave rising sharply already 6 months before the diagnosis; (iii) displayed elevated levels of systemic markers of inflammation and autoantibodies; and (iv) showed anatomical changes detected by advanced in vivo imaging. Most inside has been gained in the development and maturation of the autoantibody response in RA. Subsequently, the strategies to detect patients at risk have been developed. Interventional studies in undifferentiated arthritis and early RA patients aiming to reach clinical remission as defined by the absence of signs and symptoms, already showed that drug free remission can be achieved if patients are treated very early. The development of specific autoantibody profiles and the selection of B-cells specific for citrullinated antigens and subsequent specific mutations from germline sequences are now identified, opening the possibilities for more specific interventions in early disease. Examples of such interventions will be reviewed. An ideal intervention would be one that prevents the expression of the clinical entity we recognise as full-blown RA. Such intervention will halt the disease process in individuals from the “phases” from the pre-clinical status [an individual with genetic risk factors & environmental risk factors that develops systemic autoimmunity] through the clinical phases [an individual will develop symptoms e.g. joint pain and stiffness, then arthritis f-
nally to a disease to classified as RA.

S14-1  
Guideline for management of hyperuricemia and gout in Japan 3rd edition: Important issue of revision  
Ichiro Hisatome  
Division of Regenerative Medicine and Therapeutics, Tottori University Graduate School of Medical Science  

Conflict of interest: Yes  

Evidences showing that hyperuricemia could be an independent risk factor not only for gout but also for life-style related disease, renal failures as well as cardiovascular events have been enormously accumulated since 2010 when the 2nd edition of the guideline for the management of hyperuricemia and gout has been published. Thus, the 3rd edition of the guideline for the management of hyperuricemia and gout has been published in 2018. Using the systematic reviews on reports related to outcome of 7 clinical questions, bias risk of each evidence has been estimated. Taken together with the estimation of body of evidence, patients’ opinions and medical economics, the recommendation for each clinical question has been determined as follows: 1) NSAIDs, glucocorticoid and colchicine are equally recommended to be used for gout attack, 2) Lowering serum urate less than 6mg/dl is recommended to treat tophus, 3) Long term colchicine cover is recommended to treat gout patients after administration of urate lowering agents (ULAs) than short period colchicine cover, 4) ULAs is partially recommended to use for hyperuricemic patients with CKD in order to suppress their deterioration of renal function, 5) ULAs are not partially recommended to use for hyperuricemic patients with hypertension in order to improve their prognosis and suppress their cardiovascular events, 6) ULAs are not partially recommended to use for hyperuricemic patients with heart failure in order to improve their prognosis and suppress their cardiovascular events, 7) Dietary education including restriction of alcohol abuse is recommended for management of hyperuricemia and gout. In addition to recommendation against clinical questions, review papers regarding the clinical issues of hyperuricemia and gout have been published. Thus, this guideline is expected to cover the decision making against the important clinical issues on hyperuricemia and gout.

S14-2  
Guidelines for management of Behçet’s disease  
Mitsuhito Takeno1,2, Shunsai Hirohata3,1, Hirotoshi Kikuchi2,4, Masataka Kuwana2,12, Kazuyoshi Saito2,3, Yoshiya Tanaka2,16, Hiroko Nagafuchi2,17, Tetsuji Sawada2,4, Toshihiro Tone3,16, Yohei Kirino2,16, Ryusuke Yoshimi2,16, Hiroki Dobashi2,16, Ken-ichi Yamaguchi2,16, Kayoko Kameko2,13, Shuichi Ito2,14, Masaki Takeuchi2,18, Yoshiaki Ishigatsubo2,16,17, Nobuhisa Mizuki19  
1Department of Allergy and Rheumatology, Nippon Medical School, 2Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Japan  

Conflict of interest: Yes  

Behçet’s disease has a broad spectrum of clinical features including serious organ involvement in the eye, central nervous system, vascular system, and gastrointestinal tract. The Behçet’s Disease Research Committee of the MHLW, Japan generated organ based management guidelines for Behçet’s disease, consisting of a total of 162 clinical questions based on the concept of “all in one”. Topical steroids, colchicine, antibiotics, NSAID, and oral corticosteroid are listed for mucocutaneous lesions. Topical steroids are also recommended for ocular attacks, whereas colchicine, a small amount CS, cyclosporine (CsA), and anti-TNF antibody are recommended along the severity to prevent attacks in the posterior uveitis. Early introduction of anti-TNF antibody is encouraged for patients having poor prognostic factors such as gender and young aged onset. CS and immunosuppressants are recommended for both arterial and venous lesions. IVCY and anti-TNF antibody are suggested for serious cases. At surgical or endovascular interventions for impending rapture of aneurysms, concurrent immunosuppressive therapies are recommended. The Japan guidelines recommend anticoagulants for deep vein thrombosis, unlike the EULAR recommendations. The guidelines recommend 5-ASA for all intestinal lesions, and steroids and anti-TNF antibodies for refractory or severe cases with or without immunosuppressants. Gastrointestinal bleeding and perforation require surgical operations followed by postoperative immunosuppressive therapy. CS and methotrexate are recommended for acute type and chronic progressive type of parenchymal neurological involvement, respectively. Anti-TNF antibody is recommended for refractory or recurrent cases. CsA is prohibited for the neurological involvement because of the neurotoxicity. The management is tailored to each patient, considering disease phenotype and severity. The guidelines would be helpful for improving medical care for Behçet’s disease in Japan.

S14-3  
SLE guideline by JCR/MHLW  
Tatsuya Atsumi  
Department of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan  

Conflict of interest: Yes  

Systemic lupus erythematosus (SLE) is a prototype of systemic autoimmune disease. Multiple organs and tissues are affected in patients with SLE in a different way, and such heterogeneity of clinical aspect is making difficult to standardise the management of lupus patients in clinical practice. In the history, corticosteroids (CS) dramatically improved the mortality of lupus patients; on the other hand, major or minor adverse events of CS would significantly affect to their morbidity. Recently, the potent immunosuppressants are efficiently used for the remission induction in patients with SLE. Amongst the lupus organ involvements, lupus nephritis (LN) is one of the most common and important manifestation, and the better use of immunosuppressants are described in two major guidelines for lupus nephritis. Hydroxychloroquine was described as the basic drug for all LN patients, Mycophenolate mofetil (MMF) has been recommended for the initial and maintenance treatment. Cyclophosphamide (CY) and tacrolimus (TAC) are commonly used immunosuppressants. TAC has been approved for LN in a maintenance phase of the treatment in Japan. In clinical practice, however, TAC is often considered as a partner for MMF or CY in the induction phase for cases with insufficient response for MMF or CY. JCR and MHLW have collaborated to established SLE guideline according to the GRADE method. In this guideline, recommendation statement was classified into 3 categories; recommended, suggested and proposed. Referring another SLE guideline for British National Health System, established by BSR, we discuss the significance of the Japanese SLE guideline for our daily clinical practice.

S14-4  
Treatment guideline for pregnancy/delivery of female patients complicated with SLE, RA, JIA, or IBD  
Yohko Murakawa, Shiigeru Saito  
1Department of Rheumatology, Shimane University Faculty of Medicine, 2Department of Obstetrics & Gynecology, University of Toyama  

Conflict of interest: Yes  

Recent paradigm shift in the treatments of rheumatic diseases and
S14-5
A Clinical Practice Guidance for Pediatric Rheumatic Diseases
Kazuko Yamazaki1, Syuji Takei2, Ichiro Kobayashi3, Minako Tomiita4, Daisuke Komura5, Masaaki Mori6
1Department of Pediatrics, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan, 2Department of Pediatrics, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan, 3Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center, Sapporo, Japan, 4Department of Allergy and Rheumatology, Chiba Children’s Hospital, Chiba, Japan, 5Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 6Department of Pediatrics, Shimoshizu National Hospital, Yotsukaido, Japan

Conflict of interest: None

Rheumatic diseases often involve multi-organ systems and, accordingly, should be managed by rheumatologists who have enough skills as general physicians. The number of certified pediatric rheumatologists is as few as 80 in Japan and it varies from one region to another. Therefore, standardization of disease management and establishment of uniform accessibility to pediatric rheumatologists are difficult. In the absence of a pediatric rheumatologist, a pediatrician with other subspecialty may have a responsibility to the management of patients with pediatric rheumatic diseases. Also, rheumatologists take the role of consultants for pediatricians and take over the treatment when the patients come of age. In medical care for pediatric rheumatic patients, it is critical that a team of specialists share clinical information and have common clinical goals. To achieve this, four clinical practice guidance for juvenile idiopathic arthritis (2015), childhood-onset systemic lupus erythematosus (SLE) (2018), juvenile dermatomyositis (JDM) (2018), and childhood Sjogren’s syndrome (SS) (2018), have been published. The three guidance (SLE, JDM and SS) were created by “Pediatric Rheumatic Diseases Research Group” under the financial support by Health and Labour Sciences Research Grants (#201610070B) in collaboration with Japan College of Rheumatology, Pediatric Rheumatology Association of Japan, and Japanese society for Sjogren’s syndrome. They provide comprehensive guidance for diagnosis, treatment corresponding to the activity and severity of the diseases, and management of complications. At this symposium, we would like to describe the three guidance (for SLE, JDM and SS), emphasizing the differences between clinical features, complications, and treatment strategies in children and adults, and making comparisons with guidelines in other countries.

S15-1
Vascular Endothelial Growth Factor A (VEGF) in Osteoimmunology
Bjorn R Olsen
Harvard School of Dental Medicine/Harvard Medical School, USA
Conflict of interest: None

Vascular endothelial growth factor A (VEGF) has critical roles in cardiovascular, hematopoietic, musculoskeletal and nervous systems. The name reflects its role in endothelial-based angiogenesis, but it functioned in multicellular organisms for millions of years before cell transport channels acquired endothelial cells. To obtain insights into VEGF-dependent regulatory mechanisms, the Olsen-lab has studied endothelial, cartilage and bone disorders that include altered VEGF functions. This led to identification of the matrix-binding receptor ANTXR1 as a negative regulator of VEGF expression. Loss-of-function mutations in ANTXR1 cause high levels of VEGF in several cell types associated with a severe early aging disorder (GAPO syndrome). VEGF contributes to pathogenetic mechanisms either by interacting with cell surface receptors on target cells (paracrine signaling) or by interacting with protein complexes in nuclear or cytoplasmic compartments of the cells that produce the growth factor. Intracellular VEGF mechanisms may explain how cells in vascular-free condensations express VEGF, but angiogenesis is not induced, at early stages of endochondral ossification. In differentiated chondrocytes, VEGF expression contributes to survival in hypoxic environments and the differentiation of articular chondrocytes and is required, as a paracrine factor, for growth plate and joint development. However, once established, articular cartilage expresses low levels of VEGF, until the levels increase with age and reach disease-promoting heights in osteoarthritic joints. Differentiation of Osterix-positive bone marrow-derived stromal cells to osteoblasts during postnatal bone growth requires intracellular mechanisms. These data have led to current studies of the molecular mechanisms that may be responsible for intracellular effects of VEGF in osteoblastic and hematopoietic lineage cells.

S15-2
Mesenchymal causalties in immunity and disease
George Kollias
BSRC ‘Alexender Fleming, Greece
Conflict of interest: None

Mesenchymal cells (MCs) refer to a variety of cell types, most commonly tissue fibroblasts, pericytes and mesenchymal stromal cells, which form tissue microenvironments, mediate tissue structure and function and regulate immune responses. Understanding the physiological significance of MCs, in immunological homeostasis and the pathophysiology of chronic inflammatory disease remains a great challenge. We have identified a causal role of synovial fibroblasts and tissue MCs in the development of chronic inflammatory joint diseases and comorbidities, by showing in animal models that MCs responding to TNF become necessary and sufficient orchestrators of pathophysiology. Moreover, we gained interesting new insights into the lymphoid tissue organizing role of specific subpopulations of MCs and their functions in the development of secondary lymphoid tissue. Our recent studies have also uncovered a physiologically dominant innate sensing character of MCs responding to TLR4/MyD88, NFκB and MAPK signals and mediating tissue homeostasis, inflammation and tumorigenesis. The uncovered multi-layered functions of mesenchymal cells offer exciting new links between tissue homeostasis, immunity, chronic inflammation and cancer and prove essential for the discovery of novel mechanisms in complex disease pathogenesis, patient stratification and treatment.

S15-3
Integrated bioflow in inter-organ communication between skeletal and hematopoietic systems
Yoshio Katayama
Department of Hematology, Kobe University Hospital, Kobe, Japan
Conflict of interest: None

The hematopoietic organ, bone marrow (BM), is located inside the

IBD has brought about great changes in the managements of the woman of childbearing age (WoCBA). Since active disease harms not only the patients but also their fetuses, treatment of the WoCBA should aim to prevent disease activity with safe drug therapy for exposing fetus/child. The study group (chaired by Prof. S. Saito) published the Treatment Guideline for pregnancy/delivery of female patients complicated with SLE, RA, JIA, or IBD, in March 2018. This was developed for clinicians treating WoCBA patients with these diseases and gynecologist/obstetrician managing pregnancy. The guideline was also described for the patients. The consensuses of 17 committee members were described in the guideline in light of the knowledge from manuscripts published until December 2017. Eleven clinical questions (CQ) were set and the recommendation of each CQ was described. Three levels of recommendation grade and the median value voted by Delphi method as an agreement level were described. CQs were described on i) preconception managements, ii) managements during pregnancy, iii) delivery management and newborn risks, and iv) drug information during pregnancy/lactation. CQ1: How to explain to a patient hoping pregnancy. CQ2: State to permit a patient pregnant. CQ3: Fertility in patients with these diseases. CQ4: Effect of pregnancy/delivery on disease activities. CQ5: Laboratory tests to examine and patient obstetric management for these disease patients should be treated in advanced treatment hospital? CQ7: Delivery management of the patients. CQ8: The points to consider for neonatal care. CQ9: Use of rheumatic medications during pregnancy. CQ10: The points to consider for using biologics during pregnancy. CQ11: Use of rheumatic medications during lactation. We hope the guideline would help the clinicians and make more patients happier.
Bone, and the hematopoietic and skeletal tissues contact directly in the endosteal region. We have been working on the mechanism how the BM hematopoiesis is regulated by the skeletal system. Through this activity, we found that bone biology is critically important to explain the phenomenon observed in clinical hematology. I would like to introduce the relay of multiple biological factors in different classes (e.g., cytokine, neurotransmitter, lipid mediator, hormone) and cellular players (e.g., sympathetic nerve, osteoblast, osteocyte, macrophage, neutrophil) that regulates the transient and irreversible distortion of inter-organ network between hematopoietic and skeletal systems.

S15-4
The osteoimmune regulator, RANKL
Kazuo Okamoto
Department of Osteoimmunology, Graduate School of Medicine and Faculty of Medicine, The University of Tokyo, Tokyo, Japan

Conflict of interest: Yes

Bone is a crucial element of the skeletal-locomotor system, but also functions as an immunological organ that harbors hematopoietic stem cells and immune progenitor cells. Additionally, the skeletal and immune systems share variety of molecules, including cytokines, receptors and signaling molecules. Osteoimmunology was created as a new interdisciplinary field to explore the shared molecules and interactions between the skeletal and immune systems. In particular, the importance of an inseparable link between the two systems has been highlighted by studies on the pathogenesis of rheumatoid arthritis, which is one of the most representative skeletal disorders triggered by an abnormal immune response. RANKL is one of the most important factors explicitly linking the two systems. RANKL plays crucial roles in not only osteoclast differentiation but also the immune system, including lymph node development, thymic epithelial cell differentiation and M cell differentiation. Furthermore, bone resorption by excessive RANKL signaling lies at the core of the pathogenesis of various inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis and periodontal disease. A fully human anti-RANKL neutralizing antibody denosumab is now used in the treatment of osteoporosis and skeletal-related events by bone tumors. Furthermore, it was approved in Japan for the treatment of bone erosion associated with RA last year. Recently, the importance of RANKL inhibition has been recognized in the oncology field. RANKL biology has been widely spreading beyond the conventional framework of osteoimmunology. It can be said that it is necessary to keep the osteoimmune system in mind when we think about anything related to either the bone or immune system.

S16-1
Empower Our Society using Microsoft Technologies
Akira Sakakibara1,2
1Microsoft Japan Co., Ltd., Japan, 2Microsoft Development Ltd.

Conflict of interest: None

Artificial Intelligence (AI) that began to transcend human cognitive ability, the world where everything is connected to the Internet and can analyze various data acquired from them (IoT), and a Mixed Reality (MR) begins to penetrate all aspects of entertainment, industry, education, medicine and life by mixing up real and virtual world. We are currently changing our society drastically using these technology innovations. On the other hand, we still have big concerns such as privacy information protection issue, security risks caused by platform vulnerability, ethical perspective on AI social implementation. In this session, we can discuss how we build innovative world and how we tackle concerns that were occurred as a side effect of innovation through the prospects of technology and social future trend.

S17-1
Design Determines the Quality of Research
Shunichi Fukuhara
Kyoto University, Kyoto, Japan

Conflict of interest: None

Publication of research has been very sluggish especially in the field of clinical research (Japan’s share in the number of articles published in world top journals are on averages 8% in basic medicine, whereas only 2.5% in clinical research). So, it would be fair to say that the medical academia in Japan is now standing at the turning point. Some say low productivity in clinical research can be attributed to the lack of knowledge in statistical analysis or poor English competency. However, I think this is not as a serious problem as the absence of systematic education in “reproducible research”, which is the most fundamental and serious problem. Promotion of Clinical Research is needed not just for improving the ranking in publication of articles or accumulation of evidences from Japan. It is necessary because it could animate clinicians and improve quality of health care. This would be the most important reason for promoting clinical research in Japan. Now is the time for medical academia to start encouraging clinically and socially meaningful clinical research. To do this, it is absolutely necessary to promote the education of young researchers, and at the same time, to activate the database research.

S17-2
Statistical significance and its interpretation: Understanding from clinical research papers of New England Journal of Medicine
Hisashi Noma
Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics

Conflict of interest: None

I guess many clinicians are still suffering with “statistics” of clinical research papers. However, in modern medical researches, many advanced statistical techniques, e.g., significance tests, confidence intervals, logistic regression, Cox regression, have been commonly used, and we cannot understand clinical evidence from these research articles precisely if we do not have sufficient knowledge about them. In this talk, I will provide a gentle introduction for significance tests and p-values that are said as the most difficult concepts to understand “statistics” of clinical researches. The significance test is a statistical method to assess two hypotheses, null and alternative hypotheses, e.g., “the investigational drug is efficacious” and “not efficacious”, and provides a reasonable answer which hypothesis is true from observed data. However, the significance test does not pro-
vide certain information concerning the magnitude of effect, e.g., efficacy of the investigational drug. From a pragmatic point of view, the concept “effect size” is also important, which measures the magnitude of effects. In this talk, I also explain its relevance in clinical researches with a related important concept “minimally important clinical difference.”

S17-3
The stumbling point of clinical research and dealing
Nobuyuki Yajima
Division of Rheumatology, Department of Medicine, Showa University School of Medicine

Conflict of interest: Yes

Unfortunately, in clinical research, the publication of Japan facilities to the top journal is not often compared to basic research. This trend is the same as in diabetes, the care and kidney area. In the Japan, there is no education of the clinical research which was systematic in the education after graduation, and there are few who go on to the public Health Graduate School to study the clinical research literacy, absence of the leader of the clinical research, lack of the consultation opportunity with the statistician. There are many possible causes, such as the lack of available databases. It seems that there are a lot of people who were not able to overcome it as a result in the road of the clinical research from the research design to the thesis in the way. As the main hurdle, I do not know the entrance of research, the complexity of the literature search, the number of samples, statistical analysis, the writing of papers, the high wall of English papers, etc. will not rise. In this lecture, we will explain the overall image of the research project, and explain how to deal with the stumbling points of the theory culture such as the liver of research planning, how to search literature, and the knack of building a multi-facility registry. It introduces the type of the thesis creation while planning it in the liver of the research design, and touches the importance of consideration of the thesis making from the time of the design. In the literature search method, I will introduce how to search in “MESH + keyword” which is a general method of the search in PubMed. In building a multi-facility registry, I would like to talk about the actual experience of building flow, rule setting, and expansion method. In April 2018, the Clinical Research Promotion Subcommittee was established in the Japan Rheumatic society. The mission of this Committee is to promote literacy and clinical research for clinical research by the members of the Society in order to disseminate high quality clinical research from Japan. We are planning to launch seminars, lectures and consulting sessions organized by the Committee in the future, and I would like to inform you about the activities of the Committee.

S18-1
Appropriate understanding and management of axial spondyloarthritis (Axial SpA) - Overview
Shigeto Kobayashi
Department of Medicine, Juntendo University Koshigaya Hospital, Saitama, Japan

Conflict of interest: None

The statement “With increased interest in ankylosing spondylitis and awareness that the majority of cases are misdiagnosed and inappropriate treated” by Andrei Calin in 1977, JAMA 237:24:2613-2614, is of critical relevance even at present. Despite remarkable advancements in the understanding and management of spondyloarthritis (SpA) recently established, some controversies, pitfalls, and inappropriate comprehension have been experienced and reported in the field of clinical practice and academic research for SpA. In this symposium, the recent understanding of axial SpA will be reconfirmed, and the controversies and unexpected pitfalls will be discussed since the time Dr. Calin warned us about 40 years ago as an initiative toward the introduction of appropriate management of axial SpA in Japan.

S18-2
Ankylosing spondylitis--key points of clinical practice--
Kurisu Tada
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine

Conflict of interest: None

Ankylosing spondylitis (AS) is a prototype of spondyloarthritis (SpA) which is mainly affected axial joints and enthesis and is highly associated with HLA-B27. In advanced cases, it may interfere of activity of daily life due to spinal ankylosis. In AS patients, 80 to 90 % of patients have HLA-B27 positive, but in Japanese population HLA-B27 positive people is very rare, about 0.3%, so the prevalence of AS in Japan is very small compared to overseas. The modified New York criteria which is widely used for diagnosis of AS has high specificity but low sensitivity and it is difficult to diagnose correctly in early patients who do not meet the X-ray criteria. Additionally, it is difficult to interpret the X-ray findings of the sacroiliac joints, but it also hinders correct diagnosis. To diagnose SpA patients earlier, the Assessment of SpondyloArthritis international Society (ASAS) established classification criteria for axial SpA in 2009. In this criteria, MRI of the sacroiliac joint, which can visualize inflammation from earlier than X-ray, is added as imaging arm, and other SpA features such as psoriasis and inflammatory bowel disease, is included in clinical arm. Attempts have been made to diagnose axial SpA from early stage, non-radiographic axial SpA, and to lead them to therapy earlier, but the problem of this classification criteria was discussed in recently. It is a problem to diagnose as axial SpA only by applying and meeting this classification criteria without adequate discrimination or exclusion diagnosis. At Juntendo University hospital, AS specialized outpatient clinic was established in department of orthopedic surgery and sports medicine about 25 years ago, and about 10 years ago, SpA specialized outpatient clinic was established also in department of internal medicine and rheumatology. In this session, I would like to share knowledge about this disease, the diseases to be discriminated or exclude and important point of treatment.

S18-3
What is non-radiographic axial spondyloarthritis -- precautions for treatment--
Yuu Kodono, Atsuko Kanno, Hiroyuki Yoshioka, Hiromi Oda
Orthopaedic Surgery, Saitama Medical University

Conflict of interest: Yes

Recently, it becomes well known that spondyloarthritis (SpA) is a kind of umbrella inflammatory disease concept including ankylosing spondylitis (AS) and psoriatic arthritis. SpA exhibits not only arthritis or spondylitis but also enthesitis. SpA which shows sacroiliac joint or spine involvement like AS, is roughly classified into axial SpA (axSpA). We use ASAS criteria to classify axSpA, and call it a ‘non-radiographic axSpA’ when we can detect just a small radiographic change. Although there is the classification criteria, we sometimes have a difficulty to diagnose. We should distinguish inflammatory back pain from mechanical pain or fibromyalgic pain. When we find spinal fusion or hyper ossification, we should distinguish axSpA from degeneration, diffuse idiopathic skeletal hyperostosis or osteitis condensans illi. When we find STIR high lesions, we should distinguish axSpA from overuse, injury or infection. We should be careful and judge by not only cross-sectional but also longitudinal points of view.

S18-4
The prevalence of non-radiographic axial spondyloarthritis in Japan
Tetsuya Tomita, Yuri Matsubara, Yoshikazu Nakamura
1Department of Orthopaedic Biomaterial Science, Osaka University, Osaka, Japan, 2Department of Public Health, Jichi Medical University

Conflict of interest: None

The accurate prevalence, incidence rate or natural course of non-radiographic axial spondyloarthritis has been still remains unclear all over the worlds. The objective of this study is to clarify the prevalence of non-radiographic axial spondyloarthritis in Japan. A national-wide mail survey was conducted in about 20% of hospitals with beds and having orthopaedic Surgery, rheumatology and pediatrics department. The survey
required the number of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis during last year (2017/January - December). If the hospital answered yes, we conducted the secondary mail survey in terms of the detail of the patients with AS and non-radiographic axial spondyloarthritis. In total 8459 departments, 2222 departments were extracted (the extracted rate: 26.3%). And 1344 departments responded (the response rate: 60.5%). The reported patients number for last year were 649 AS and 164 nr-ax SpA in orthopedic surgery, 472 AS and 149 nr-ax SpA in Rheumatology, and 11 AS and 12 nr-ax SpA in pediatrics. Based upon the established survey methods, the estimated patients number of AS and nr-ax SpA in Japan were 3200 and 860 respectively. In Japan patients number of nr-ax SpA was much less compared to AS.

S18-5
Axial involvement of Psoriatic arthritis
Atsuo Taniguchi
Department of Rheumatology, Tokyo Women’s Medical University

Conflict of interest: None

Axial involvement of psoriatic arthritis was reported to be 5%. However, it has been indicated that half of the patients with axial involvement did not show symptoms suggested spondylitis. The previous studies showed how the differences between axial involvement of psoriatic arthritis and ankylosing spondylitis. Asymmetric sacroiliitis, non-marginal syndesmophyte, and paravertebral ossification were more often seen in axial involvement of psoriatic arthritis. Other studies showed that the frequency of cervical spine involvement in psoriatic arthritis was more often than that in ankylosing spondylitis. The random spinal involvement has reported to be one of the characteristic findings of psoriatic arthritis. Axial involvement is important as one of the key domains of psoriatic arthritis.

S18-6
Problems involved in the treatment of axial spondyloarthritis on the standpoint of a patient-physician
Hisashi Inoue
Department of Orthopaedic Surgery, Juntendo University School of Medicine

Conflict of interest: None

Japan has been considered to be an ‘underdeveloped country’ for axial spondyloarthritis (AS) in view of the low incidence of this disease among Japanese. However, the academic achievements made for the disease in recent years have been quite remarkable in Japan. Through my personal experiences in the past 25 years as an AS patient myself, having been in charge of the Japan AS patients’ association as well as a physician running a special AS clinic at the Juntendo University Hospital in Tokyo, I must admit that there still is a long way to go in terms of clinical aspects of the disease, namely diagnosis and treatments, especially on psychological care of the patients. The problems include erroneous diagnoses, over-diagnosis, excessive treatments, lack of tender and mindful approach to the anxious patients, etc. It is a pity to see some of the unfortunate patients tend to seek for inappropriate treatments and to become doctor shoppers, resulting in unfavorable outcomes. It is a sort of vicious cycle. Presuming that I would have been appointed as a symposist based on the above experiences, I will report the results of a questionnaire study I performed to my AS patients, and summarize my personal opinions regarding AS along with the patients’ voices expressing their hope and dissatisfaction toward their physicians and treatments.

S19-1
How should we manage pneumonia in patients with Rheumatoid Arthritis?
Hiroshi Mukae
Nagasaki University Graduate School of Biomedical Sciences

Conflict of interest: None

Biological agents, such as DMARDs, now plays a vital role in caring for Rheumatoid Arthritis (RA) patients, and respiratory tract infections (RTI) have been major prognostic factors for RA, or disturbance for RA treatment. Pneumonia accounts for 23% of total death with RA patients, which is equivalent to malignancies, by Ninja Study reported in 2014. RTI screening is necessary when RA patients is scheduled the biological treatments, and sampling lower respiratory specimen is essential when airway or lung abnormalities are detected in chest CT scan. In our bronchoscopic study in RA patients, *Pseudomonas aeruginosa* accounts for 21% of pathogenic microorganisms detected in lower respiratory tract. Our findings were supported by a recent pneumonia study in RA patients, which showed that *P. aeruginosa* amount to 14% of causative microorganisms, following *Streptococcus pneumoniae*. Colonization of *P. aeruginosa* in the airway might be a risk factor for developing pneumonia and worsening prognosis of RA patients. Furthermore, those chronic RTI cause NETosis and might worsen the RA activities itself. Immunomodulatory drugs, such as macrolides may contribute to manage those diseases. Pneumocystis pneumonia (PCP) has also been increased in RA patients. It usually progresses rapidly and has high mortality. The definitive diagnosis of PCP in RA patients is difficult because the trophic forms or cysts in bronchoalveolar lavage fluid are usually undetectable, and DNA PCR result is hard to discriminate contamination. Moreover, PCP in RA is often accompanied by connective tissue disease-related interstitial pneumonia, or drug-induced pneumonia, representative by methotrexate (MTX). Our recent study indicated that PCP in MTX-treated RA expressed significantly higher serum soluble IL-2R compared to PCP in MTX-unreated RA. New diagnostic markers and treatment programs specific for RA-related PCP are required in future management. In this symposium, I would like to introduce recent findings in the field and also to share our data, discussing the future management of pneumonia in RA.

S19-2
Risk and management of nontuberculous mycobacterial infection in rheumatoid arthritis patients receiving biological therapy
Shunsuke Mori
Department of Rheumatology, NHO Kumamoto Saishunsou National Hospital

Conflict of interest: None

Nontuberculous mycobacteria (NTM) are opportunistic pathogens that are ubiquitous in natural environments such as soil and water. Although over 150 different species are described, most NTM do not cause human disease. In susceptible individuals, NTM species infect the airway and lung tissue, leading to slowly progressive and destructive disease. NTM lung disease is most commonly due to *M. intracellulare* and *M. avium* (MAC). NTM disease occurs in the context of lung problem like COPD, bronchiectasis, and lung damage due to previous tuberculosis infection. The incidence of NTM disease is increasing worldwide, but there are no bactericidal anti-NTM drugs. Currently, multiple combined bacteriostatic antibiotics therapy is recommended, however, its effect is limited. The prognosis of NTM lung diseases is poor as indicated that the 5-year all-cause mortality exceeds 25%. Rheumatoid arthritis (RA) affects the immune system and is associated with lung diseases such as interstitial pneumonia and airway disease. The weak immune system and underlying lung disease are significant risk factors for NTM lung disease. Therefore, RA patients are much susceptible to NTM infection compared with the general population. In addition, biological agents, especially tumor necrosis factor inhibitors, are known to increase the risk of NTM disease. The use of biological agents has not been recommended for RA patients who have developed NTM diseases. However, we often encounter patients whose RA activity is uncontrollable without the introduction of biological therapy. Recent case reports demonstrated that under strictly supervised anti-NTM therapy, biological agents were successfully used for intractable RA patients who had NTM infection. Here, we discuss the safety of simultaneous use of biological agents in RA patients who have NTM lung disease. We also present cases of NTM disease caused by rapidly growing mycobacteria during biological therapy.

S27
S19-3
How to assess acute-onset diffuse lung diseases in patients with rheumatoid arthritis?
Hitoshi Tokuda
Faculty of Medicine, Toho University, Tokyo, Japan

Conflict of interest: Yes

Lung is a vital organ where autoantibodies such as anti-citrullinated protein antibody are produced and are produced and pathological lesions including interstitial lung disease (ILD) and rheumatoid nodules develop. Among pulmonary complications, acute-onset diffuse lung diseases (AODLD) are frequently fatal, requiring the treatment in advance to the sufficient differential diagnosis procedures: they often develop as a result of immune disorder by RA, complicated by their modification by RA treatments and microorganisms. Therefore, major differential diagnoses for AODLD such as RA-ILD, drug-induced lung injury and pneumocystis pneumonia were not always mutually exclusive, and those diagnoses, including their overlap and transition, should be consistent with the treatment. Further, the concept of immune reconstruction (inflammatory) syndrome has been widely recognized, which leads to concerns about the risk of discontinuing immunosuppressive drugs upon infectious complications in patients with RA. Thus, the optimization of RA treatment discontinuation should be intensively discussed. In this symposium, the pathophysiology, diagnosis and treatment of AODLD will be discussed with recent findings and evidences.

S19-4
Pathological study of the consequences of interstitial pneumonia in the patients with rheumatoid arthritis
Tamiko Takemura
Department of Pathology, Japanese Red Cross Medical Center

Conflict of interest: None

Histopathological features of the lung with rheumatoid arthritis (RA) are very variable composed of interstitial pneumonia (IP), airway and pleural diseases. Among them, IP and bronchiolitis are thought to be the important prognostic factors of RA patients. The histological patterns of RA-IP has been applied by the classification of idiopathic interstitial pneumonias (IIPs), and the prognosis of RA-IP has been considered based on IIPs classification. However, whether this IIPs pattern exactly reflects the consequence of RA-IP has not been discussed until now. In this symposium, we present the characteristics of IP and bronchiolar disease of RA patients, and clarify the present issue. 1) Interstitial pneumonia in RA mainly consist of NSIP showing lymphocyte and plasma cell infiltration with alveolar wall fibrosis, and UIP with peribronchiolar fibrosis, alternating normal alveoli and fibroelastic foci. There are some cases of UIP in RA showing cystic lesion in the lobule developed from chronic bronchiolar inflammation, resembling as honeycombing. These cystic lesions are lined by bronchiolar epithelium. Marked inflammatory cell infiltration also induced destruction of lobular structures. 2) Bronchiolar disease Hyperplasia of BALT frequently can be seen along the airways with follicular bronchiolitis. Cellular and destructive bronchiolitis, which shows loss of elastica of the bronchiolar walls, fibrosis and destruction of alveolar structures around the bronchioles, resulting in cystic change of the lobule. Sometimes, peribronchiolar metaplasia is prominent, inducing the cystic lobular change. Chronic and destructive intralobular bronchiolar inflammation in the lung with RA may induce destruction and cystic change of lobular structure. Here, we emphasize that intralobular bronchiolar inflammation and cystic consequences are important for the prognosis and treatment of RA-ILD.

S19-5
Management of rheumatoid arthritis associated with interstitial lung disease
Hitoshi Tokuda
Department of Respiratory Medicine, Tokyo Yamate Medical Center, Japan Community Health Care Organization (JCHO), Tokyo, Japan

Conflict of interest: None

Biologic agents have substantially advanced the management of rheumatoid arthritis, including its extra-articular manifestations. The only exception is lung complications, especially interstitial lung disease (ILD). RA-ILD is increasing in incidence and prevalence worldwide and now is the commonest cause of mortality of RA patients in Japan. RA-ILD includes those of slow progression (chronic ILD) and those of rapid progression (acute ILD), the latter may sometimes be caused by drug therapy or occult as an acute exacerbation of chronic ILD. The basic pathogenesis has much in common, so both should be discussed together. Chronic RA-ILD is usually classified according to the classification of idiopathic interstitial pneumonia, such as UIP pattern, NSIP pattern, and COP pattern. The latter two are usually responsive to corticosteroid therapy, resulting in favorable clinical course. UIP pattern is the problem. No effective treatment has been established in controlling the deteriorating course in some proportion of patients of this category. As for the pathogenesis of deterioration, many immunological studies have elucidated the possible participation of host immune response to pulmonary tissue containing RA specific substances such as ACPA. Thus treatment strategy should be formulated upon this knowledge including suppression of excess immune response in the pulmonary tissue. We have clarified pathologically and radiologically that in some cases of RA-UIP, the honeycomb-like structural derangement are caused by persistent inflammation and destruction of the bronchioles and surrounding lung parenchyma. Thus we propose the possibility of treatment through proper control of inflammation of the airway, utilizing inhaled corticosteroid and tacrolimus if necessary, with agile use of antibiotics in case of infection. Other immunosuppressive treatments, such as mycophenolate, rituximab, abatacept are also reported to be effective in case reports and in small case series.

S20-1
Environmental factors and rheumatoid arthritis
Yoshihiro Miyake
Department of Epidemiology and Preventive Medicine, Ehime University Graduate School of Medicine, Japan

Conflict of interest: None

In Japan, there are several clinical epidemiological investigations among patients with rheumatoid arthritis to assess prognostic factors, while no epidemiological study was performed to examine the relationship between environmental factors and the risk of rheumatoid arthritis. Some meta-analyses showed that obesity, coffee consumption, and smoking are associated with an increased risk of rheumatoid arthritis and that moderate drinking and vitamin D intake are preventive against rheumatoid arthritis. Antioxidant intake such as vitamins C and E, higher socioeconomic status, pregnancy, and statin use may be inversely related to the risk of rheumatoid arthritis. Meat intake and stress may increase the risk of rheumatoid arthritis. In a recent case-control study conducted in China, intake of mushroom, citrus fruit, and dairy products was associated with a reduced risk of rheumatoid arthritis, while intake of potato and other fruits except for citrus was positively related to the risk of rheumatoid arthritis. It is necessary to accumulate epidemiological evidence regarding risk and preventive factors for rheumatoid arthritis in Japan.

S20-2
Periodontal disease as an environmental factor in the onset of rheumatoid arthritis
Tetsuo Kobayashi1, Satoshi Ito2, Akira Murasawa2, Hajime Ishikawa2
1General Dentistry and Clinical Education Unit, Niigata University Medical and Dental Hospital, 2Department of Rheumatology, Niigata Rheumatic Center

Conflict of interest: None

Oral cavity has been considered to possess the second most complex microbiota and several different niches in human body. Dental plaque is the most microbial biofilm and causes periodontal disease (PD). PD is a chronic inflammatory disease characterized by the destruction of periodontal tissue and is classified as a lifestyle-related disease due to its association with oral hygiene and smoking. Recent evidence suggested a role for PD in systemic diseases including diabetes mellitus, vascular disorder, and rheumatoid arthritis (RA). RA is a systemic autoimmune dis-
ease triggered by a combination of genetic and environmental factors that lead to the breakdown of immune tolerance. Recently, a role for oral microbiome and PD was proposed as an environmental risk factor for RA. Studies suggest the potential mechanisms linking PD to RA as follows: 1) citrullination by oral bacteria and host peptidylarginine deiminase (PAD); 2) neutrophil extracellular traps (NETs) formation and host PAD activation by PD; 3) carbamylation by NETs components. We evaluated if Porphyromonas gingivalis (Pg) contributes to RA through its PAD activity. The results showed that serum antibody titers to Pg and Pg PAD increased and correlated with serum titer to cyclic citrullinated peptide (CCP) in patients with RA. Periodontal therapy reduced the Disease Activity Score in 28 joints (DAS28) and serum levels of anti-Pg titer and citrulline. The patients with high anti-Pg PAD titers also exhibited an inhibition in DAS28 improvements after RA medication. These suggest an association between Pg infection and RA. The patients further showed that serum levels of NETs and carbamylated protein (CarP) increased and correlated with PD severity. The NETs levels were related to DAS28 and serum anti-CCP titer, while the CarP levels were not. These suggest an association between serum NETs levels and PD severity, implicating a role for NETs in citrullination and autoimmunity response in patients with RA.

S20-3 Supports of oral care for patients with rheumatoid arthritis by multidisciplinary team approach
Yasushi Miura
Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences

Conflict of interest: None

Most of the anti-rheumatic drugs including methotrexate, steroids, biologics, and JAK inhibitors, suppress immunity. In contrast, NSAIDs render patients with RA less sensitive to dental pain. Further, the disability of upper limbs caused by joint destruction and the limited mandibular opening prevent plaque control by patients with RA. Due to these factors, patients with RA often develop and complicate periodontal diseases and dental caries, especially with lack of saliva when accompanying Sjögren’s syndrome. The patients who lost their teeth by these diseases have difficulties on biting, speaking, getting proper nutrition, and swallowing and suffer from lower quality of life. Recently, Porphyromonas gingivalis, bacteria causing periodontal diseases, was reported to produce peptidylarginine deiminase solely and suggested to produce anti-cyclic citrullinated peptide antibody (ACPA), resulting the onset of RA or worsening the disease condition. Therefore, it is important to keep good oral condition for patients with RA to keep good treatment effects and high quality of life. For the purposes, both the professional oral care by dentists and dental hygienists and self-care by patients with RA. In addition, patient education, encouragement to visit dentists, the improvement of upper limb function by surgery, rehabilitation, and the self-help device by the multidisciplinary team are also necessary. We have been educating patients by a dental hygienist in the patient’s class periodically and encouraging to visit dentists. In this symposium, the growing roles of the oral care supports by multidisciplinary team in aging society are reviewed by illustrating our experiences including the survey of oral condition of patients with RA evaluated by Adult Dental Examination Program and a study of the relationship between oral condition evaluated by Oral Health Assessment Tool (OHAT) and upper limb functions in patients with RA.

S20-4 Influence of smoking on the pathogenesis of rheumatoid arthritis
Masanori Funauchi
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine

Conflict of interest: None

Relationship between smoking and rheumatoid arthritis (RA) has long been discussed, although RA has not been recognized enough as a smoking-related disease. Cigarette smoke contains various toxic substances including carcinogens and reactive oxygen species (ROS) such as hydroxyl radical, peroxynitrite and nitric monoxide which are associated with onset or progress of various smoking-related diseases including malignancy (laryngeal, pulmonary, gastric cancers, etc.), respiratory diseases (chronic bronchitis, emphysema, etc.), cardiovascular disorders (myocardial infarction, cerebrovascular disorder, Buerger’s disease, etc.), obstetrical diseases (infertility, abortion, premature birth, etc.), or periodontal disease. It is noteworthy that most of these diseases are also important as the complications of RA. Smoking is known to accelerate the onset and increase the incidence of RA as well as to exacerbate the disease activity and reduce the efficacy of anti-rheumatic drugs. Toxic substances of tobacco not only give rise to inflammation of the tissue but also modify autoantigens by activation of peptidylarginine deiminases (PAD), leading to production of anti-citrullinated peptides antibody (ACPA). On the other hand, smoking increases oxidative stress to stimulate signal transduction and apoptosis of the cell. And, it also causes changes of the microenvironment through ischemia-reperfusion injury (IRI) which increase the oxidative stress to aggravate the pathogenesis of RA. Furthermore, smoking affects the prognosis of RA by increasing the incidence of complications of the above smoking-related diseases. Since RA is influenced by smoking in many phases such as onset, disease activity, complication and prognosis, RA is absolutely one of the smoking-related diseases. Here, influences of the smoking on the pathogenesis of RA, in addition to the relationship to genetic factors, are discussed, and the effect of cessation of smoking are referred.

S20-5 Dysbiosis in rheumatoid arthritis patients
Yuichi Maeda
Department of Respiratory Medicine and Clinical Immunology, Osaka University

Conflict of interest: None

Rheumatoid arthritis (RA) is a systemic autoimmune disease, caused by both genetic and environmental factors. Recently, researchers have focused on the gut microbiota, which is thought to be one of the environmental factors affecting the development of RA. We review here the evidence from animal and human studies that supports the role of the gut microbiota in RA. We and others have demonstrated that the relative abundance of Prevotella copri is increased in some of RA patients. We have also produced gnotobiotic experiments to show that dysbiosis in RA patients contributed to the development of Th17 cell-dependent arthritis in gut microbiota-humanized mice. Recently, we have successfully isolated P. copri from rheumatoid arthritis patients. From these experiments, we could analyze precise mechanistic link between gut microbiota and human arthritis development. We believe that the endeavors to remediate dysbiosis would serve as a novel therapeutic or preventive approach in RA patients.

S20-6 Obesity, nutrition and rheumatism
Tokuruto Tsuda
Immuuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan

Conflict of interest: Yes

According to ancient Chinese historical book “The Rites of Zhou”, there were four medical professions: internalist, surgeon, veterinarian, and food physician, which is the superior to the others. The traditional Chinese medicine told that daily meals with temperature, regular lifestyle and peace of mind without greed make you live out your allotted span of life, but excessive drinking and eating, self-indulgent lifestyle and violations of the hygiene make you ill, then you would need “toxic drugs” for the treatment. The therapies for the illnesses caused by bad lifestyles must be accompanied with considerable risks, but they were regarded as a lower medicine. On the other hand, the disease preventions through improvements of whole lifestyle including daily meals were regarded as the genuine medicine. In modern rheumatology, the pathophysiology and therapeutics have made remarkable progress for these several decades. While our “weapons” such as biologics and dMDARDs are getting much stronger day by day, the risks and economical burden we take are also
getting heavier. However, the knowledge about feasible preventions remains insufficient. Recently, the comprehensive fundamental studies revealing the linkages between immunity and metabolism, and the epide-miological studies of large-scale cohorts present some evidences about the prevention. Especially, the fact that obesity has a feature of chronic tissue inflammation draws many researcher’s notice. Its influence affects on the various organ systems: liver, pancreas, gut, adipose tissue, muscle and central nervous system. Among these organs, there is crosstalk mediated by cytokines, exosomes, free fatty acid, lipopolysaccharide, and so on. Based on these researches, novel promising therapies are expected to emerge. In this lecture, I will try to discuss about the prevention of rheumatic diseases which is validated by current evidences and feasible into our clinical practice.

S21-1
Overview
Kazuyuki Yoshizaki
Graduate School of Information Science and Technology, Osaka University

Conflict of interest: Yes

Since Benjamin Castleman, a pathologist in USA, had reported the enlarged lymph node, resembling thymoma with special pathological feature in 1956, it has been passed for sixty years. Pathological analysis is gradually increased. However, neither etiological and pathogenic analysis, epidemiology, treatment guideline, nor therapeutic algorithm are still unclear. Therefor, in 2015, the research study team of intractable disease on Castleman disease governed by the ministry of Health and Labor was started, and in 2017, to clear the classification of analogous diseases amongst Castleman disease, TAFRO syndrome, IgG4-related disease and POEMS syndrome, the another study group on related disease has been established. Then, we are discussing about the difference and similarity among those diseases with the other study groups on IgG4-RD and POEMS syndrome. Today the professional doctors of each disease present the out line and specificity of each disease. And we propose the some cases who were hardly diagnosed. We hope you will be interesting in these rare and unclear disease. Knowing the problems and analysis of those diseases in this symposium, you will be of use in your daily clinical activity.

S21-2
Castleman disease
Hiroshi Kawabata, Nozomu Kurose, Shino Fujimoto, Yasufumi Masaki, Tomohiro Koga, Atsushi Kawakami, Toshio Kitakawa, Akifumi Takaori-Kondo, Hajime Yoshifuji, Tsuneyo Mimori, Kazuyuki Yoshizaki
1Department of Hematology and Immunology, Kanazawa Medical University, 2Department of Pathology and Laboratory Medicine, Kanazawa Medical University, 3Department of Immunology and Rheumatology, Nagasaki University, 4Department of Hematology and Oncology, Kyoto University, 5Department of Rheumatology and Clinical Immunology, Kyoto University, 6Graduate School of Information Science and Technology, Osaka University

Conflict of interest: None

Castleman disease (CD) is a rare non-clonal lymphoproliferative disorder, interleukin-6 plays an essential role in its pathogenesis. Clinically, CD is divided into two categories; unicentric CD (UCD) with a single lymph node lesion, and multicentric CD (MCD) with multiple lesions and systemic inflammatory symptoms. MCD is further categorized into at least 3 types; HHV-8-associated MCD commonly observed in HIV-positive individuals, POEMS syndrome-associated MCD manifesting polyneuropathy and M-proteinemia, and idiopathic MCD (iMCD). The affected lymph nodes in UCD usually show hyaline-vascular type histology, and those in MCD usually manifest either plasma cell type or mixed type histology. In Western countries, UCD is commoner than MCD, but a majority of CD in Japan are iMCD. Patients with iMCD manifest fever, malaise, anemia, lymphadenopathy, and splenomegaly; their blood tests show microcytic anemia, hypoalbuminemia, polyclonal hypergammaglobulinemia, and increased CRP levels. For making diagnosis of CD, histopathological diagnosis is essential and excluding infectious diseases such as non-tuberculosis mycobacteria infection, neoplastic diseases such as lymphomas, and autoimmune diseases is mandatory. A proportion of patients with iMCD manifest anasarca and thrombocytopenia; these symptoms are consistent with TAFRO syndrome. Thus, MCD seems to include multiple clinical entities; identification of specific markers for each entity is desired. As for treatments, UCD can be cured by complete resection of the lesions. Symptomatic patients with iMCD, especially those with pulmonary or renal involvement, should be treated with corticosteroids and/or tocilizumab (or siltuximab in US). In 2018, iMCD was registered as a designated intractable disease by Japanese government. Researchers in CD Collaboration Network are promoting researches internationally on iMCD. Further clarification of pathogenesis of iMCD and development of its novel treatments are awaited.

S21-3
TAFRO Syndrome
Yasufumi Masaki, Hiroshi Kawabata, Kazue Takaikori, Norifumi Tsukamoto, Shino Fujimoto, Yasuhito Ishigaki, Nozomu Kurose, Shigeo Nakamura, Sadao Aoki
1Department of Hematology and Immunology, Kanazawa Medical University, 2Department of Hematology, Niigata City General Hospital, 3Oncoology Center, Gunma University Hospital, 4Medical Research Institute, Kanazawa Medical University, 5Department of Pathology and Laboratory Medicine, Kanazawa Medical University, 6Department of Pathology and Laboratory Medicine, Nagoya University Hospital, 7Department of Pathophysiology, Faculty of Pharmaceutical Sciences, Niigata University of Pharmacy and Applied Life Sciences

Conflict of interest: Yes

TAFRO syndrome is a systemic inflammatory disorder manifesting as thrombocytopenia; anasarca including pleural effusion and ascites; fever; reticulin fibrosis/renal insufficiency; and organomegaly including hepatosplenomegaly and lymphadenopathy. Its onset may be acute or sub-acute, but its etiology is undetermined. Although several clinical and pathological characteristics of TAFRO syndrome resemble those of idiopathic multicentric Castleman disease (iMCD), other specific features can differentiate between them. Some patients have been successfully treated with glucocorticoids and/or immunosuppressants including cyclosporin A, tocilizumab and rituximab, whereas others are refractory to treatment, eventually succumbing of disease. Early and reliable diagnoses and early treatments with appropriate agents are essential to enhance patient survival. We reported the 2015 updated diagnostic criteria, disease severity classification and treatment strategy for TAFRO syndrome, as formulated by Japanese research teams. We are now collecting data of patients with TAFRO syndrome, iMCD, and similar disorders, retrospectively. Establishment of appropriate medical treatment guideline is urgent business about the TAFRO syndrome which a diagnosis is difficult, and progress rapidly.

S21-4
Autoimmune Pancreatitis and IgG4-Related Disease
Shigeyuki Kawa
Department of Internal Medicine, Matsumoto Dental University, Shiojiri, Japan

Conflict of interest: None

IgG4-related disease (IgG4-RD) is a recently established systemic disease that is characteristically associated with elevated serum IgG4 levels and believed to be caused by autoimmune mechanisms. The clinical features of IgG4-RD include (i) systemic distribution, (ii) imaging findings of swelling, nodules, and/or wall thickening, (iii) high serum IgG levels, (iv) abundant IgG4-bearing plasma cell infiltration in affected organs, (v) a favorable response to corticosteroid therapy, and (vi) coexistence with other IgG4-RD manifestations simultaneously or in a monochronous fashion. The concept of IgG4-RD was established based on the culmination of specific discoveries, including a close association between autoimmune pancreatitis (AIP) and high serum IgG4 levels, massive IgG4-bearing plasma cell infiltration in pancreatic tissues affected by AIP, and systemic other organ involvements in AIP with similar IgG4-
bearing plasma cell features, which opened the gateway from AIP to IgG4-RD. 1 Protein electrophoresis of sera of patients with AIP showed β-γ bridging, which was a polyclonal band in the rapidly migrating fraction of γ-globulins. This abnormal band was confirmed by immunoelectrophoresis to be caused by elevated serum IgG4 levels. We observed elevated IgG4 levels in 90% of patients with AIP but scarcely in other conditions, which nominated IgG4 as a sensitive and specific marker for AIP. We also described the characteristic histological features of abundant IgG4-bearing plasma cell infiltration in affected pancreatic tissues and other organs, indicating that AIP and systemic other organs shared a common pathological background. The disease spectrum of IgG4-RD seems to be capable of spreading every organ, including well-established members of AIP, lacrimal and salivary gland lesions, respiratory diseases, sclerosing cholangitis, kidney diseases, and retroperitoneal fibrosis, and other additional new members.

S21-5
POEMS syndrome
Satoshi Kuwabara
Department of Neurology, Chiba University Hospital, Chiba, Japan

Conflict of interest: None

POEMS (polyneuropathy, organomegaly, edema/effusion, M-protein and skin changes) syndrome is a rare generalized disorder characterized by plasma cell dyscrasia, characterized and overproduction of vascular endothelia growth factor (VEGF). Japanese national survey have revealed the prevalence of 0.4: 100,000, and mean onset age is 49 years. Most of the symptoms are likely to be explained by neovascularization and increased vascular permeability of VEGF, whereas multiple pro-inflammatory cytokines are upregulated in POEMS syndrome. To facilitate precise and early diagnosis, comprehensive systemic survey is essential, and we propose that current diagnostic criteria. The current first line therapy is high-dose chemotherapy with autologous stem cell transplantation (HDT with ASCT), whereas patients who are not eligible for transplantation because of high age or poor general condition, are treated with immunomodulatory drugs, such as thalidomide or lenalidomide. Diagnosis of POEMS syndrome has been substantially improved by these novel interventions. This review focuses on recent advances in diagnosis, pathophysiology, and treatment of POEMS syndrome, and discusses future perspectives of therapeutic strategy.

S21-6
Differential diagnosis of IgG4-related disease, multicentric Castleman disease, TAFRO syndrome, and POEMS syndrome
Mitsuhito Kawano
Department of Rheumatology, Kanazawa University Hospital

Conflict of interest: None

Fever and thrombocytopenia, which are representative features of TAFRO syndrome, are rarely seen in IgG4-related disease (IgG4-RD). Similarly, M proteinemia and polynuropathy, which are important features of POEMS syndrome, rarely present in IgG4-RD. In contrast, some patients with multicentric Castleman disease (mCD) show some clinical features very similar to those seen with IgG4-RD. Frequently lymph nodes (LNs) are involved in IgG4-RD, and marked infiltration of IgG4-positive plasma cells in the LNs is a common feature between mCD and IgG4-RD. In such mCD cases, serum IgG4 levels are generally elevated. Moreover, hypergammaglobulinemia or hyper-IgGemia is a common feature shared by IgG4-RD and mCD. On the other hand, serum IgA and IgM levels are usually normal in IgG4-RD, but elevated in mCD. Although erythrocyte sedimentation rate is moderately elevated in IgG4-RD, serum CRP levels were normal or only slightly elevated (less than 1.0 mg/dL) in about 90% of patients in an analysis of 334 Japanese cases. In contrast, serum CRP concentrations are continuously elevated in mCD, and delayed treatment sometimes leads to secondary amyloidosis. Glucocorticoid responsiveness is also different between these two diseases. Good responsiveness is an important feature in IgG4-RD, while glucocorticoid responsiveness is partial, with the addition of tocilizumab therapy sometimes needed in mCD. Lungs, kidneys, skin are common extra-LN lesions in both, while pancreas, lacrimal gland or salivary gland involvement is rarely seen in mCD. The above-mentioned features are useful for differentiating these two diseases. Finally, recently we found that serum IL-6 concentrations are continuously markedly elevated in mCD during treatment with tocilizumab. This may provide a hint to the pathogenesis of mCD.

S21-7
Approach and future prospects to clarify the pathology of idiopathic multicentric Castleman disease
Tomohiro Koga1, Reni Sumiyoshi2, Atsushi Kawakami2, Kazuyuki Yoshizaki1
1Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 2Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 3Department of Biomolecular Science and Regulation, The Institute of Scientific and Industrial Research, Osaka University

Conflict of interest: None

Castleman’s disease (CD), a heterogeneous group of lymphoproliferative disorders, is divided into unicentric CD and multicentric CD (MCD) based on the number of regions of enlarged lymph nodes with characteristic histopathologic features. The etiology of MCD remains largely unclear. The observed clinical symptoms of MCD are attributed to hypercytokinemia, including elevated levels of interleukin-6 (IL-6). The standard treatment of iMCD is glucocorticoid and humanized anti-IL-6 receptor antibody (tocilizumab), but some iMCD patients may present life-threatening complications such as respiratory failure, renal failure, liver failure, pancytopenia despite treatment with combined use with IL-6 inhibitor, high-dose glucocorticoid, and systemic chemotherapy. In addition, systemic chemotherapy is highly cytotoxic, leading to severe infection and organ disorder. Therefore, treatment development in iMCD according to the pathology is desired. Cyclosporin, a calcineurin inhibitor that suppresses activation of T cells as an immunosuppressive agent used in iMCD, is effective. In a report that examines the lymph nodes of iMCD, the percentage of T cells is higher than that of UCD, whereas the proportion of B cells is lower in iMCD suggesting the importance of T cells in the pathology of iMCD. Recent studies of the Castleman Disease Collaboration Network (CDCN) have suggested that the PI3K / Akt / mTOR pathway may be a therapeutic target for iMCD. The PI3K / Akt / mTOR signaling cascade is well known for its role in promoting cell growth and metabolism in response to growth factors by modulating S6K and 4EBP1. Accordingly, vascular endothelial growth factor: VEGF), T cell activation, and cellular proliferation can be candidates for the treatment of severe MCD. In particular, rapamycin, an inhibitor of mTOR, effectively inhibits cell proliferation of T cells and B cells. In this lecture, we will outline the latest findings on the pathology of iMCD and the possibility of mTOR inhibitor for iMCD patients.
Educational Lecture

EL1
An overview of cancer immunotherapy
Naoki Hosen
Osaka University Graduate School of Medicine
Conflict of interest: Yes

Cancer immunotherapy has become an important tool in treatment of many types of cancers. Managing of immune-mediated side effects is essential for effective and safe cancer immunotherapy. In this lecture, I will summarize the state of art of cancer immunotherapy including checkpoint antibody therapy and CAR T cell therapy. In addition, I will discuss what we learn from autoimmune disease occurred after cancer immunotherapy.

EL2
Immunodeficiencies and autoimmunity/autoinflammation : the two sides of a coin
Ichiro Kobayashi
Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center
Conflict of interest: None

Autoinflammatory and autoimmune diseases reflect excessive immunity, whereas primary immunodeficiency syndromes are generally characterized by susceptibility to infection based on the defect of genes related to host defense. However, current classification of PID includes “diseases of immune dysregulation” which is characterized by autoimmunity or predisposition to macrophage activation. For example, defect in autoimmune regulator (Aire) gene which is critical to central T cell tolerance in the thymus causes multiple organ-specific autoimmunity, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED). On the other hand, mutation of Foxp3 gene, a master key gene for regulatory T cells (Tregs) which play a critical role in peripheral T cell tolerance, causes immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. Haploinsufficiency of CTLA-4, a functional molecule of Tregs, is clinically similar to IPEX syndrome. Defect in Tregs leads to autoimmune diseases and massive tissue inflammation. Therefore, the association between frailty and dementia is necessary for all the medical providers.

EL3
Treatment strategy for elderly rheumatic diseases
Takahiko Sugihara
Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan
Conflict of interest: None

Elderly-onset is common in polymyalgia rheumatic (PMR), giant cell arteritis (GCA), and microscopic polyangiitis (MPA). The age of onset also shifted to elderly side in rheumatoid arthritis (RA). The prevalence rates of elderly rheumatoid diseases such as systemic lupus erythematosus and dermatomyositis/polymyositis will increase in line with the increasing life expectancy. Elderly-onset cases are not rare in these rheumatic diseases. Induction therapy of elderly rheumatic diseases is challenging, because adverse events are common in elderly patients receiving corticosteroids, immunosuppressive drugs, or biologics. Maintenance therapy is also critical problems for elderly patients. Abrogation of disease activity and its maintenance are main goal of rheumatic diseases. The pitfall of treatment of elderly patients is that drug-associated damages had great impact on the physical function and frailty, especially, long-standing corticosteroids therapy. The primary physicians are balancing risk of adverse events and relapse / recurrence of disease activity in the elderly patients with rheumatic diseases, however there are no clinical data of randomized controlled studies and observational studies are few. In this seminar, I will discuss these challenging clinical questions, mainly about treatment of PMR, GCA, and RA.

EL4
Frailty and dementia
Hiroyuki Umegaki
Department of Community Healthcare & Geriatrics, Nagoya University Graduate School of Medicine, Aichi, Japan
Conflict of interest: None

In Japan the aging of the population has progressed rapidly and the ratio of the older (>65 years old) has reached 27.3% in 2017. With aging muscle mass and performance decrease, which is called sarcopenia. Basises on sarcopenia older subjects tend to decrease physical functional reserve and lead to be frail. Frailty is a syndrome that results from the accumulation of multiple age-related organic types of decline with an impairment of physiological reserve, thus increasing vulnerability to adverse health outcomes including falls, hospitalization, institutionalization and mortality. Several models for frailty have been developed and so far one of the most frequently applied is the one developed by Fried et al. According to Fried criteria the diagnosis of frailty requires three or more of the following characteristics: unintended weight loss, exhaustion, weakness, slow gait speed, and low physical activity. A number of studies have reported that frailty is associated with cognitive decline cross-sectionally and is also a risk for future cognitive decline or incidence of dementia. Although the underlying mechanism of the association of frailty and dementia have not been fully elucidated, inflammation, oxidative stress, and physical inactivity may be involved. While frailty is a risk of dementia, demented subjects often have malnutrition which may induce frailty. Therefore, the association between frailty and dementia is bidirectional. Considering the aging of the population in Japan, the understanding of frailty and dementia is necessary for all the medical providers.

EL5
Immunology Update
Sachiko Miyake
Department of Immunology, Juntendo University Graduate School of Medicine, Japan
Conflict of interest: None

Updated basic immunology will be shown and discussed. They will help you to understand the mechanisms of molecular targeted drugs for rheumatic diseases.

EL6
Two different approaches to patient safety: Safety-I & Safety-II
Kazue Nakajima
Department of Clinical Quality Management, Osaka University Hospital, Japan
Conflict of interest: None

Remarkable advances in health care have contributed to less invasiveness and improved prognosis and quality of life for patients. However, physicians are performing more difficult techniques and treating more elderly patients with multiple comorbidities, which poses new risks for patient safety. In recent years, a new approach to safety based on resilience engineering in high reliability industries such as health care and aerospace had developed because of limitations in current safety management, the enormous cost of redundancy as preventive measures, and progress in complexity science. In conventional safety management, the
objective is the reduction of failures. Events such as incidents are analyzed, related factors (e.g., people, technology, organizational culture) are identified, outcomes are explained by a linear cause-and-effect model, and preventive measures are taken for specific failures. Such an approach is called Safety-I. By contrast, Safety-II pursues proactive safety management based on resilience engineering, with the goal of promoting resilient performance of the system (e.g., health care teams, organizations), which can continue to function in varying environments with perturbations and constraints. In Safety-II, we need to understand how everyday clinical work is carried out from dynamic, non-linear perspectives, rather than to explain why things went wrong from static, linear perspectives. We also need to analyze relationships between the behavior of system components (micro level) as well as the behavior of the system as a whole (macro level), instead of capturing the performance of individuals as snapshots for retrospective evaluation. In this presentation, I will explain the theory of resilience engineering with some examples from health care. Using Safety-II, we would be able to proactively manage a dynamic and complex adaptive system and control it with more stable and responsive manners.

EL7 Recent progress in pathogenic analysis, diagnosis, and treatment for Sjögren’s syndrome: 2019 Update
Hiroto Tsuboi, Fumika Honda, Saori Abe, Yuko Ono, Hiroyuki Takahashi, Yuya Kondo, Isao Matsumoto, Takayuki Sumida
Department of Internal Medicine, Faculty of Medicine, University of Tsukuba
Conflict of interest: Yes

Sjögren’s syndrome (SS) is an autoimmune disease which affects salivary and lacrimal glands accompanied with various autoimmune extra-glandular manifestations (EGM). In this lecture, we introduce 1) pathogenic roles of T cells in SS, 2) comparison of different sets of diagnostic and classification criteria, 3) clinical practice guidelines for SS in all over the world, and 4) evidences of diagnostic methods and therapies for SS shown in “clinical practice guideline for SS 2017” in Japan. 1) Th1, Th2, Th17, and Th19 could induce B cells activation and plasmacytes differentiation in affected organs of SS. Moreover, infiltrated T cells directly contribute to destruction of exocrine glands via FasL and perforin. We detected anti-M3 muscarinic acetylcholine receptor (M3R) antibodies and M3R reactive Th1 and Th17 in peripheral blood of SS patients. 2) The research team of Japan MHLW (chaired by Takayuki Sumida) revealed that ACR-EULAR criteria had significantly higher sensitivity and lower specificity in diagnosis of Japanese primary SS patients, compared with the revised Japanese Ministry of Health, AECG, and ACR criteria. 3) The treatment guideline by SS Foundation in USA, the management guideline by British Society for Rheumatology, and “clinical practice guideline for SS 2017” by the guideline committee of MHLW are currently available. 4) In “clinical practice guideline for SS 2017”, unstimulated whole saliva, Saxon and Gum test, labial salivary gland biopsy, and anti-SS-A/B antibodies are recommended for diagnosis of SS. Salivary gland swelling, purpura, and low C3/C4 levels are recommended as significant risk factors for development of malignant lymphoma in SS. Although cevimeline and pilocarpine are recommended for the treatment of gland swelling, purpura, and low C3/C4 levels are recommended as significantly available. 4) In “clinical practice guideline for SS 2017”, unstimulated whole saliva, Saxon and Gum test, labial salivary gland biopsy, and anti-SS-A/B antibodies are recommended for diagnosis of SS. Salivary gland swelling, purpura, and low C3/C4 levels are recommended as significant risk factors for development of malignant lymphoma in SS. Although cevimeline and pilocarpine are recommended for the treatment of dry mouth, it is suggested that corticosteroid cannot improve salivary and lacrimal secretion. For biologics, it is suggested that rituximab and abatacept can improve both glandular and EGM, while belimumab can improve only EGM.

EL8 Mechanism, prevention and treatment of herpes zoster
Shinichi Imafuku
Department of Dermatology, Faculty of Medicine, Fukuoka University, Japan
Conflict of interest: Yes

Herpes zoster (HZ) is an endogenous recurrent infection of varicella-zoster virus (VZV). Most of the HZ presently seen are seen as unilateral painful erythema and vesicles in adults who were infected with natural varicella at childhood. HZ develops at about 5/1000 person year, but the incidence doubles in elderly people. Also, in immunosuppressed patients, the incidence increases. Our claim database study revealed that incidence of HZ tripled in SLE patients and doubled in rheumatoid arthritis patients. Although HZ heals spontaneously, HZ burdens patients with severe pain, skin lesions such as vesicles, crusts, and ulcers, and the like, involvement of important adjacent organs (ocular complications and facial nerve palsy, etc.), and most importantly postherpetic neuralgia (PHN). It is known that the incidence of PHN is proportional to the age, severity of eruption at first visit. In immunosuppressed patients, the frequency of hospitalizations due triples and PHN and other complications significantly increase. Herpes zoster is easily diagnosed from clinical symptoms. Acute onset, unilateral edematous erythema, mononuclear papules/vesicles, etc. However, in atypical cases needs to be distinguished from herpes simplex, impetigo, or contact dermatitis etc. In 2018, a quick kit with excellent sensitivity and specificity was released, and definitive diagnosis became available on the spot. Serologically, it is difficult to diagnose. Almost all adults with a history of varicella has serum anti-VZV-IgG antibody but the titer is low. VZV-IgG become elevated after onset of herpes zoster, but it rises immediately or as late as 2 weeks after onset, depending on cases. Elevated antibody confirms the diagnosis, but it is important that low titer does not deny the diagnosis. Early administration of antiviral drugs is most important in treating HZ. Representative antiviral drugs such as valacyclovir, or famciclovir were a nucleic acid analog and its serum concentration is dependent on renal function. Amenamevir is a helicase primase inhibitor, appeared in 2017 in Japan, and is metabolized in the liver, therefore, safe options for those with impaired renal function. Incidence of HZ was proved to be suppressed by the same vaccine against varicella in a large clinical trial in US and labeled for prevention of HZ in Japan, too. But because it is a live vaccine, its administration to immunosuppressed patients is contraindicated. Meanwhile, a subunit vaccine against HZ was also developed and approved. Clinical trials have demonstrated that the subunit vaccine have an extremely high preventive effect on HZ, and it is expected for immuno-compromised individuals.

EL9 Approach to the Patient with Fever/Inflammation of Unknown Origin
Noboru Hagino
Division of Hematology and Rheumatology, Teikyo University Chiba Medical Center, Japan
Conflict of interest: None

Rheumatologists sometimes act as a “last resort” to diagnose difficult case of prolonged fever or inflammation. To diagnose a rheumatic disease, physician must rule out other conditions which may mimic rheumatic disease before applying “classification criteria”. Thus, exclusion of infectious diseases, oncologic diseases, and other “mimickers” is of paramount importance for the diagnosis of fever/inflammation of unknown origin. For example, infectious disease such as tuberculosis or syphilis is an “old foe” as they are difficult to prove via culture. Chronic infectious diseases also make the diagnosis of rheumatic disease the difficult one. In the field of oncology, various types of lymphoma present with fever, and some of them, including intravascular lymphoma, mimic rheumatic diseases such as adult-onset Still’s disease. In our field, autoinflammatory diseases have attracted attention as the cause of fever/inflammation of unknown origin, and adult-onset cases are more common than ever believed. This lecture aims to provide overview of the approach to fever/inflammation of unknown origin from the adult rheumatologist’s viewpoint, in the form of case-based discussion.

EL10 Antiphospholipid syndrome: diagnosis and treatment
Shinsuke Yasuda
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University
Conflict of interest: Yes

Antiphospholipid syndrome (APS) is an autoimmune disorder in which the persistent presence of antiphospholipid antibodies (aPL) is associated with recurrent thrombotic events and pregnancy morbidities.
Pathophysiology of APS has been intensively investigated since 1990. aPLs play a role in activating monocytes, endothelial cells and platelets, being recognized as pathogenic autoantibodies. Complement activation is also one of the pathogenic features observed in patients with APS. We recently found elevated anti-C1q antibodies that activate classical pathway of complement system, as well as decreased factor H that results in activation of alternative pathway. T/B cell subpopulations are also altered in APS patients, characterized by increased Th2, Th17, and plasmablasts and decreased Tregs, Bregs, and memory B cells. Diagnosis of APS is made based on clinical symptoms such as arterial thrombosis, venous thrombosis, and/or pregnancy morbidity, with persistent presence of the following aPLs: IgG anti-cardiolipin antibodies (aCL), IgG anti-beta2-glycoprotein I antibodies (aβ2-GPI), and lupus anticoagulant (LA) (the Sydney-revised Sapporo criteria). To make aPL screening simple, we propose the measurement of non-criteria aPLs: anti-aβ2-GPI domain I antibody (aβ2-GPI) and phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) tests for the diagnosis of APS. Treatment strategy for APS focuses on the prevention of recurrences, in which anticoagulation and/or anti-platelet therapies are mainstay. For the prevention of arterial thromboses, our retrospective analysis suggests dual antiplatelet therapy (DAPT) has an advantage comparing to anticoagulant, single antiplatelet therapy or combination of anticoagulant and an antiplatelet agent. A inhibitor may not be sufficient for the prevention of thrombotic events in patients with high-risk APS. I would like to discuss recent advancement in the clinical and translational aspects of APS.

EL11
How to improve patient satisfaction after total knee arthroplasty
Ken Okazaki
Department of Orthopedic Surgery, Tokyo Women’s Medical University

Conflict of interest: Yes

Although the long-term results of total knee arthroplasty (TKA) has significantly improved, patient-reported satisfaction after TKA is not always high. It has been reported 10 to 20% of patients were not very satisfied with their replaced knees. Number of studies have been reported with factors affecting patient satisfaction using patient-reported outcome measures (PROM). Coronal alignment, rotational alignment and range of motion after TKA correlate with the PROM. As the coronal alignment, severe varus or valgus alignment after surgery would deteriorate the PROM whereas slight varus would show the comparable results with the neutral alignment. Regarding the ligament balancing, loose medial tension in flexion would deteriorate the clinical results whereas slight loose tension at the lateral side would be accepted. Therefore, care should be taken to obtain the medial stability in all the range of motion and not to extensive release the medial ligaments. Pain control after TKA is also important factor to reduce the residual pain. Although residual pain can be caused by many factors such as, malposition of the component, inappropriate soft-tissue balancing, infection, subcutaneous nerve injury, unexplained pain after TKA still exists. Pain sensitization may present in some patients, characterized by increased Th2, Th17, and plasmablasts and decreased Tregs, Bregs, and memory B cells. Diagnosis of APS is made based on clinical symptoms such as arterial thrombosis, venous thrombosis, and/or pregnancy morbidity, with persistent presence of the following aPLs: IgG anti-cardiolipin antibodies (aCL), IgG anti-beta2-glycoprotein I antibodies (aβ2-GPI), and lupus anticoagulant (LA) (the Sydney-revised Sapporo criteria). To make aPL screening simple, we propose the measurement of non-criteria aPLs: anti-aβ2-GPI domain I antibody (aβ2-GPI) and phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) tests for the diagnosis of APS. Treatment strategy for APS focuses on the prevention of recurrences, in which anticoagulation and/or anti-platelet therapies are mainstay. For the prevention of arterial thromboses, our retrospective analysis suggests dual antiplatelet therapy (DAPT) has an advantage comparing to anticoagulant, single antiplatelet therapy or combination of anticoagulant and an antiplatelet agent. A inhibitor may not be sufficient for the prevention of thrombotic events in patients with high-risk APS. I would like to discuss recent advancement in the clinical and translational aspects of APS.

EL12
Assessment and management of the rheumatoid foot
Takumi Matsumoto
Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo

Conflict of interest: None

Dramatic improvement in rheumatoid arthritis (RA) control due to the development of powerful drugs has significantly changed the therapeutic strategy for joint destruction and deformity in RA patients. Especially, decreased involvements of large joints in lower limbs have come to shed light on the magnitude of functional impairment by foot deformity and wide range of needs for resolution of foot trouble. For human being achieving bipedal walking, the defect of foot could be directly linked to gait impairment. In the first place, the foot lesion is one of the most favored sites of joint involvements in RA from its early stage. Foot and ankle involvement increases with duration of the disease process, and more than 90% of patients with RA have foot and ankle symptoms at later stages. It is not surprising that more focus has been on the foot as a result of decreased involvements of large joints. Higher demand for quality of life by patients than ever before also highlight the problems in foot. The most common RA-related foot deformities are splayed foot, flat foot, and hindfoot valgus; however, in practice, we face a wide variety of deformities which cannot be expressed only with these words. Moreover, the intensity of symptoms and the severity of deformity do not necessarily correlate with each other. Because of these situations, there might be a lot of physicians who feel difficulty in assessing RA foot deformity. In addition to the knowledge about the pros and cons of each intervention, understanding the pattern of destruction and its future prospect is essential to construct an appropriate treatment strategy for RA foot. This instructional lecture will present the way how to grasp the characteristic foot deformity and patients’ complaints dividing the foot lesions into forefoot, midfoot, hindfoot, and ankle. And also, the cross relationship of deformities among these lesions and the pattern of deformity progression will be discussed. It is essential to understand that the progression of RA foot deformity is affected by both factors including disease activity and mechanical load. This concept will help you to select the way or timing to intervene in RA foot deformity.

EL13
Actual use of biological products in pediatric rheumatic diseases
Masaaki Mori
Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University

Conflict of interest: Yes

The fact that this common inflammatory pathogenic factor is an inflammatory cytokine was proved by inhibiting a single inflammatory cytokine function leading to inflammation with monoclonal antibodies against specific inflammatory cytokines or specific receptors as therapeutic agents. At the same time, it was also found that the type of cytokines leading the inflammatory pathology is different depending on the disease, even in the same inflammatory condition. In juvenile idiopathic arthritis (JIA), a typical disease of rheumatic diseases of childhood, there are various inflammatory cytokines production and mechanisms for mutual induction have been found, but in fact it is thought that there is a leading cytokine specific to disease, and by blocking that cytokine, inflammation can be brought to the end. Systemic JIA is forced to use a long-term massive amount of steroid against strong systemic inflammation and is suffering from side effects such as obesity, growth disorder, osteoporosis, compression fracture of the vertebral body, femoral head necrosis and steroid diabetes. In this way, the life of patients was extremely restricted. As a treatment with biological preparation, it was found that tocilizumab as an anti-IL-6 inhibitor was approved through clinical trials earlier in the world, it was found that it had high effectiveness and side effects were relatively slight, and it is used as an essential therapeutic agent. Also, in July 2018, canakinumab, which has a proven anti-IL-1 inhibitory action in Europe and the United States, has been approved in Japan and has been shown to be effective in clinical practice. Anti-TNF therapeutic agents such as etanercept / adalimumab are used for types in which arthritis remains even if systemic symptoms improve. On the other hand, in articular JIA, the anti-TNF inhibitor etanercept / adalimumab and the above tocilizumab were approved in Japan and abatacept, which inhibits costimulatory signals between antigen presenting cells and T cells located upstream of the onset of inflammation, has also recently received approval as a result of clinical trials. In this lecture, I focus on systemic JIA in which an abnormality of innate immunity is involved in pathogenesis, and articular JIA in which excessive adaptive immunity induces arthritic symptoms, and finally I will outline the actual use of biological preparation and the mechanism that has been elucidated so far.
I am going to speak on Basic Philosophy of Research Ethics and Regulation Rules in Japan. The main subjects are “Clinical Research Act” and “Ethics Guideline on Medical Research.”

**EL15**

**Mechanism of the rheumatoid hand deformity**

Ryuichi Nakahara
Department of Intelligent Orthopaedic System Development, Okayama University Graduate School of Medicine Dentistry and Pharmaceutical Sciences, Okayama, Japan

Conflict of interest: Yes

Due to the remarkable improvement of drug therapy of rheumatoid arthritis (RA), severe rheumatic hand deformed patients are decreasing. However, the patient with rheumatic hand deformity does not disappear. Rheumatoid hand deformity often progresses asymptomatically and starts with minute image changes that are difficult to evaluate clinically. If we know the mechanism of the rheumatoid hand deformity, we can predict the progression of deformity from radiographic and ultrasonographic findings. Synovitis of the wrist joint occurs in all of the distal radioulnar joint, radiocarpal joint, intercarpal joint, carpometacarpal joint, and tenosynovitis may also develop in extensor tendon and flexor tendon. For examining these findings, guideline for musculoskeletal ultrasound in rheumatology published by college of rheumatology is useful. These lesions progress to wrist deformity via carpal rotation, supination deformity, ulnar carpal shift, dorsal dislocation of the distal ulna and palmar carpal subluxation. Synovitis of radioulnar joint and mechanical irritation by bone deformity progress to tendon rupture. Ulnar deviation derived from synovitis of MCP joint and carpal rotation (zig-zag deformity). Attention should be paid because the ulnar deviation may progress gradually even once occurred. Boutonniere deformity results when the central slip of the extensor tendon of a digit are disrupted. Swan neck deformity develops from either tightening of intrinsic muscle or overpull of the extensor mechanism on the proximal phalanx or instability of the distal phalanx. In this way, the synovitis and bone destruction of each joint are closely related to the rheumatoid hand deformity. In this lecture, we outline the rheumatoid hand deformity focusing on image finding and anatomical structure.

**EL16**

**The treatment of glucocorticoid-induced osteoporosis**

Ikuko Tanaka1, Shigenori Tamaki2
1Imaging Center, Nagoya Rheumatology Clinic, Japan, 2Nagoya Rheumatology Clinic

Conflict of interest: None

Glucocorticoid-induced osteoporosis (GIO) is the most important adverse effect caused by the glucocorticoid therapy, as bone fractures occur in 30 to 50% of the patients receiving long-term glucocorticoid therapy. The loss of bone mineral density is as high as 8 to 12% in the first few months after initiation of glucocorticoid therapy. Fracture risk already increases before bone mineral density decreases. These findings suggest that it is necessary to cope with GIO promptly after starting glucocorticoid administration. The primary prevention is to be considered. For autoimmune diseases, there are many patients in adolescence from young people, and many patients with childbearing age. In the treatment of autoimmune diseases, glucocorticoids are drugs that are still used in large amounts and for a long time. It is necessary to choose treatment for GIO while considering the characteristics of the original disease, the characteristics of glucocorticoid treatment, and the patient’s own needs. Since the appearance of Methotrexate and biologics, glucocorticoids were less used for treatment of rheumatoid arthritis. However, in the EULAR Update of 2016, it is recommended that glucocorticoids be used in the initial treatment. Guidelines and recommendations about glucocorticoid treatment in many inflammatory and autoimmune diseases have been published in Europe, United States, and other countries. Glucocorticoid will continue to be a frequently used drug for rheumatoid arthritis in the future. The pathophysiology and the treatment of GIO will be discussed in this lecture.

**EL17**

**Molecular mechanism of osteoclast differentiation and function**

Naoyuki Takahashi
Institute for Oral Science, Matsumoto Dental University, Japan

Conflict of interest: None

We have established a mouse co-culture system of osteoblastic cells and hematopoietic cells to examine osteoclast differentiation in vitro. In 1992, we proposed a hypothesis that osteoblastic cells express osteoclast differentiation factor (ODF) in response to bone resorption-stimulating factors. In 1998, RANKL [receptor activator of NF-κB (RANK) ligand] was discovered as an osteoclast differentiation factor ODF. This discovery of RANKL triggered the identification of nuclear factor of activated T cells c1 (NFATc1), a master transcription factor for osteoclast differentiation. Furthermore, the significance of immunoreceptor tyrosine-based activation motif (ITAM) signal as a costimulatory signal of RANK has been demonstrated. Thus, understanding of the molecular mechanisms regulating osteoclast differentiation has greatly progressed over the past 20 years. On the other hand, the analysis of osteoclast function started from experiments using osteoclasts isolated from bone tissue in the 1980’s. Experimental systems to obtain a large number of osteoclasts were established in the 1990’s, and the mechanism of osteoclast function has been analyzed in more detail. Osteoclasts adhere to bone via αvβ3 integrin and p130Cas in osteoclasts recognizes the hardness of bone as a mechanosensor. It is proposed that p130Cas recognizing bone hardness is phosphorylated by c-Src and its phosphorylation sends a signal to induce ruffled border formation. In addition to the adhesion signal, signals from RANKL and Wnt5a have also been shown to be necessary to promote ruffled border formation in osteoclasts. In my presentation, I would like to summarize the molecular mechanisms that regulate osteoclast differentiation and function.

**EL18**

**Diagnosis and Treatment in Idiopathic Inflammatory Myopathies**

Takahisa Gono
Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine

Conflict of interest: None

Idiopathic inflammatory myopathies (IIMs) is one of the autoimmune diseases, characterized by muscle weakness and extramuscular lesions including dermatitis, arthritis, interstitial lung disease (ILD) and cardiomyopathy. IIMs is classified into the followings based on the new EULAR/ACR IIM classification criteria: dermatomyositis (DM), amyopathic DM, polymyositis (PM), immune-mediated necrotizing myopathy (IMNM) and inclusion body myositis (IBM). The important things which physicians should pay attention to in diagnosis of IIMs are presence or absence of cutaneous features associated with DM, distribution of muscle weakness and muscle atrophy, clinical course of muscle symptoms, and pathohistological finding of the muscles. First of all, physicians should carefully examine the skin. When patients have no any skin rashes related to DM, infection, drug, thyroid diseases, muscular dystrophies and metabolic myopathies should be considered as differential diagnoses beside IIMs. The distribution of muscle involvement is usually proximal predominant in PM/DM and IMNM. On the other hand, finger flexor muscles are involved in IBM. Muscle atrophy is also often revealed in patients with IMNM or IBM. Clinical courses of myositis depend on each form of IIMs; muscle weakness develops in months in PM/DM, in weeks in subacute form of IMNM, and in months/years in chronic form of IMNM or in IBM. Pathohistological evaluation of the muscles is critical to diagnose in myositis patients. Infiltration of CD8-positive T cells which surround and invade non-necrotic muscle fibers, necrosis and regeneration of muscle fibers with pauci-infiltrating lymphocytes, and accumulation of proteins in vacuoles within muscle fibers are specific for PM, IMNM and IBM, respectively. In addition, physicians should also investigate complications of ILD, cardiomyopathy and malignancy in IIMs patients. I will give a lecture regarding diagnosis and treatment for IIMs, focusing on clinical issues in daily practice.
Ten common mistakes in the management of systemic sclerosis- part 2

Masataka Kuwana
Department of Allergy and Rheumatology, Nippon Medical School

Conflict of interest: Yes

Systemic sclerosis (SSc) remains an intractable disease with poor outcomes because of underlying mechanisms mainly caused by excessive fibrosis, which is often irreversible, and almost lack of treatment proved to be effective by randomized clinical trials. In addition, adverse outcome is attributable, in part, to poor understandings of natural disease course and highly variable clinical presentation of the disease by healthcare providers. It is useless and meaningless without full understandings of unique clinical features of SSc, and discussion of treatment responses in observational cases without adequate controls is always inadequate and often leads wrong prejudice. Recent advances in basic researches successfully lead to implementation of a number of clinical trials of potential anti-fibrotic agents in SSc patients. Before the dawn of SSc-treatment era, this lecture features fundamental knowledge required for daily clinical practice of SSc patients, highlighting 10 common mistakes in the management of SSc, listed below: 1. The absence of Raynaud’s phenomenon judged solely by history taking of color changes of fingers 2. Skin thickness scoring based on whether skin can be easily pinched or not 3. Exclusion of SSc diagnosis based on the absence of skin thickness 4. Exclusion of SSc diagnosis based on negative anti-nuclear antibody test 5. Transition of patients with limited cutaneous SSc to diffuse cutaneous SSc 6. Treat sicker patients more intensively 7. Evaluation of upper gastrointestinal involvement using endoscopy 8. Initiate upfront combination of pulmonary vasodilators in patients diagnosed as having pulmonary arterial hypertension 9. Wait for initiating disease-modifying treatment until functional impairment becomes apparent 10. Avoid high-dose corticosteroids to treat overlapping myositis or vasculitis because of increased risk of renal crisis Extra. Use of tocilizumab to treat patients with early dcSSc

Updates of genetic studies of rheumatoid arthritis

Chikashi Terao
Laboratory for Statistical Analysis, RIKEN Center for Integrative Medical Sciences

Conflict of interest: None

Rheumatoid arthritis (RA) is a complexed disease and both genetic and environmental factors are associated with onset of RA. Twin studies have revealed heritability of rheumatoid arthritis (RA) as around 60% in both European and Japanese, supporting significance of genetic studies in RA to identify susceptibility genes beyond populations. Enormous progress has been made since completion of the Human Genome Project in 2003. Genetic association studies especially genome-wide association studies (GWAS), where we comprehensively genotype single nucleotide polymorphism (SNP) throughout the genome in a hypothesis-free manner, have greatly contributed to this progress. As far as we focus on inherit variants in genetic studies, significant signals indicate that they are causes of the diseases and not results of the diseases. This is a big advantage of genetic studies over non-genetic studies. Genetic studies have revealed that there are more than thousands of associated variants with weak effect sizes. The HLA region is an exception and shows strong multiple signals. Previous studies have identified significant amino acid positions of HLA proteins and showed that significant amino acid positions were different in subsets of RA. Genetic studies have identified more than 100 susceptibility loci for RA. With the use of summary statistics of GWAS results, critical cell types, molecular networks and pathways in RA were identified. While next-generation sequencer (NGS) can identify variants not in GWAS arrays and difficult to impute, association studies to focus on rare variants with the use of NGS were not successful so far. Aside from onset of diseases and its genetic associations, numerous efforts have been made to analyze genetic components associated with disease progression or responsiveness of treatment and some of which are successful. Some researchers are trying to combine latest technologies such as CyTOF with sequence results by NGS to understand the basics of RA.

Physical joint examination: what we learn from ultrasound

Kei Ikeda
Department of Allergy and Clinical Immunology, Chiba University Hospital

Conflict of interest: None

Physical joint examination for arthritis provides information on both the current inflammation and the structural damage but this lecture focuses on the inflammation. 4 signs of inflammation (i.e. redness, warmth, tenderness, swelling) are important in physical joint examination; however, each sign has its advantage and disadvantage. Redness and warmth are highly specific to inflammation but are detected only when acute, severe inflammation is present, and their sensitivity is very low. Tenderness is more sensitive but less specific to inflammation and may reflect non-inflammatory (e.g. mechanical, neuropathic, psychosocial) pain. Swelling, on the other hand, has well-balanced sensitivity/specificity and plays an important role in the assessment of chronic inflammation. In addition, joint swelling has been shown to correlate with joint inflammation in patients with rheumatoid arthritis in a stable state. In inflamed synovial tissues, the amount of synovial fluid increases and the volume of synovial tissues also increases due to cellular infiltration and angiogenesis. We need to discriminate between these synovial changes and other soft tissues by physical examination. In addition, we may want to discriminate synovial fluid from synovial hypertrophy, the latter is more specific to inflammation. Ultrasound visualizes the extent of synovial fluid and hypertrophy and dynamic scanning can further differentiate their properties (i.e. compressibility and displaceability). These pieces of visual information help with improving physical examination skills. In this lecture, real ultrasound images/videos of synovitis will be presented and general/joint-specific tips in palpitation will be provided. In addition, how to guide treatment based on these physical examination findings will be discussed.

Update on Diagnosis and Assessment of Systemic Lupus Erythematosus

Yasuhiro Katsumata
Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan

Conflict of interest: None

The most widely used classification criteria for systemic lupus erythematosus (SLE) are those developed by the American College of Rheumatology (ACR). These classification criteria were published in 1982 and revised by a committee in 1997. The 1982 ACR criteria have been validated, but not the 1997 revision. In addition, multiple concerns have arisen in the current ACR classification: possible duplication of highly correlated cutaneous lupus terms (such as malar rash and photosensitivity) and the absence of inclusion of many other lupus cutaneous manifestations; omission of many SLE neurologic manifestations; the need to utilize new standards in the quantification of urine protein; and the omission of low complement (Arthritis Rheum 2012;64:2677). Most of all, there were concerns about patients without any immunologic criteria being classified as SLE. The Systemic Lupus International Collaborating Clinics (SLICC) group revised and validated the ACR criteria in 2012. We also evaluated the performance of the SLICC criteria on classifying SLE in an uncontrolled multi-centered study with real-life scenario of the patients in Japan (Mod Rheumatol 2018;28:642). Compared to the ACR criteria, the SLICC criteria had a higher sensitivity (0.88 vs. 0.99) and lower specificity (0.85 vs. 0.80). However, the SLICC criteria has never been used in clinical trials or officially approved. On the other hand, at the 2017 ACR Annual Meeting, a draft of new EULAR/ACR endorsed criteria for SLE were presented. Although the criteria were based on the SLICC criteria, they were fine-tuned and simplified, using ANA of ≥1:80 as entry criterion and a classification threshold of 10. In this seminar, update on diagnosis and assessment of SLE, including the pitfalls of the SLEDAI and SLICC damage index, is to be discussed. The Asia Pacific Lupus Collab-
Patients with rheumatoid arthritis have a high risk of infection. This is considered to be due to the use immunosuppressive drugs such as steroids and methotrexate in treatment. Rheumatoid arthritis patients also have opportunistic infections such as legionellosis, nocardiosis and pneumocystis pneumonia. Decrease in cellular immunity due to the effects of rheumatoid arthritis therapy is thought to contribute to this. In order to appropriately treat these infectious diseases, the causative microorganisms must be identified. However, these microorganisms are often difficult to detect by common bacterial tests. Therefore, it is necessary to accurately list up the possible causal microorganisms from the condition of the patient’s immunity and lung lesions, etc., and to individually select examination methods for identifying those microorganisms. Prevention of infectious diseases is important because respiratory virus infections such as influenza can become severe in immunocompromised individuals. First, they should be advised to maintain the rhythm of life as far as possible and to manage their physical condition. Patients’ wearing a surgical mask is effective in preventing acute respiratory tract infections. Oral care will also become more important from the viewpoint of preventing infections such as pneumonia. Immunization is also important, such as influenza and pneumococcal vaccines. Although there is a view that the effect of a vaccine is insufficient in immunocompromised patients, even so, for the surrounding family and others try to prevent infection by getting vaccinated is a useful measure against infection of the patient. Oral administration of TMP/SMX is effective for prevention of pneumocystis pneumonia, but the conditions of patients vary and it is necessary to consider individually which patients need it. Patients using biological products also have an increased risk of developing tuberculosis, so evaluation beforehand and treatment of any latent tuberculosis are necessary.

Conflict of interest: Yes

The International Classification of Diseases and Related Health Problems (ICD) was originally adopted in 1900. It has been implemented in Japan since the same time and applied to various statistical studies, including mortality statistics. In Japan, the “Statistical classification of diseases, injuries and causes of death” is stipulated as a statistical standard under the Statistics Act, and is applied to producing official statistics in Japan since the same time and applied to various statistical studies, including the Vital Statistics or the Patient Statistics and used in management of medical records in medical institutions. In the global ageing where especially Japan enters a high-mortality society, it is important to prepare effectively by constructing a sustainable health and medical system. Statistics and information foundation constitutes the basis of this and its maintenance and utilization will become required even more while the newly released ICD-11 and related international classifications are expected to fulfill its role to assist such framework. From now on, we would like to verify the legal system issues and the usage environment in cooperation with stakeholders and work toward the implementation in Japan smoothly.

Conflict of interest: None

Conflict of interest: None

Classification of rheumatic diseases have been drastically changed through the revision of International Classification of Diseases-10 (ICD-10) to ICD-11. Rheumatic diseases has been assigned to Chapter XII, Disorders of the musculoskeletal system or connective tissue, in ICD-10, but has been separated into two chapters, Chapter IV Diseases of the immune system and Chapter XV Disorders of the musculoskeletal system or connective tissue. Rheumatoid arthritis, psoriatic arthritis, polymyalgia rheumatica, Adult-onset Still’s disease, Juvenile idiopathic arthritis, gout, other crystal-induced arthropathies were categorized into ‘Inflammatory arthropathies’ and belong to Chapter XV together with osteoarthritis and infection-related arthropathies, which include infectious arthritis, reactive arthritis, and others. Chapter IV has primary immunodeficiencies and acquired immunodeficiencies, followed by non-organ specific systemic autoimmune disorders (NOSSAD) and Autoinflammatory disorders. NOSSAD includes major collagen diseases such as systemic lupus erythematosus, idiopathic inflammatory arthritis, systemic sclerosis, vasculitis, mixed connective tissue disease, and anti-phospholipid syndrome. Autoinflammatory disorders contains monogenic autoinflammatory syndromes, SAPHO syndrome, Behcet’s disease, and others. In this educational lecture, classification of rheumatic diseases in ICD-11 will be reviewed and some tips and traps will be provided.

Conflict of interest: None

Conflict of interest: None

The International Classification of Diseases and Related Health Problems (ICD) was originally adopted in 1900. It has been implemented in Japan since the same time and applied to various statistical studies, including mortality statistics. In Japan, the “Statistical classification of diseases, injuries and causes of death” is stipulated as a statistical standard under the Statistics Act, and is applied to producing official statistics including the Vital Statistics or the Patient Statistics and used in management of medical records in medical institutions. In the global ageing where especially Japan enters a high-mortality society, it is important to prepare effectively by constructing a sustainable health and medical system. Statistics and information foundation constitutes the basis of this and its maintenance and utilization will become required even more while the newly released ICD-11 and related international classifications are expected to fulfill its role to assist such framework. From now on, we would like to verify the legal system issues and the usage environment in cooperation with stakeholders and work toward the implementation in Japan smoothly.

Conflict of interest: None

Classification of rheumatic diseases have been drastically changed through the revision of International Classification of Diseases-10 (ICD-10) to ICD-11. Rheumatic diseases has been assigned to Chapter XII, Disorders of the musculoskeletal system or connective tissue, in ICD-10, but has been separated into two chapters, Chapter IV Diseases of the immune system and Chapter XV Disorders of the musculoskeletal system or connective tissue. Rheumatoid arthritis, psoriatic arthritis, polymyalgia rheumatica, Adult-onset Still’s disease, Juvenile idiopathic arthritis, gout, other crystal-induced arthropathies were categorized into ‘Inflammatory arthropathies’ and belong to Chapter XV together with osteoarthritis and infection-related arthropathies, which include infectious arthritis, reactive arthritis, and others. Chapter IV has primary immunodeficiencies and acquired immunodeficiencies, followed by non-organ specific systemic autoimmune disorders (NOSSAD) and Autoinflammatory disorders. NOSSAD includes major collagen diseases such as systemic lupus erythematosus, idiopathic inflammatory arthritis, systemic sclerosis, vasculitis, mixed connective tissue disease, and anti-phospholipid syndrome. Autoinflammatory disorders contains monogenic autoinflammatory syndromes, SAPHO syndrome, Behcet’s disease, and others. In this educational lecture, classification of rheumatic diseases in ICD-11 will be reviewed and some tips and traps will be provided.

Conflict of interest: None

Conflict of interest: None
In 2009, it was proposed that Takayasu arteritis (TAK) and giant cell arteritis (GCA) are the same disease with a spectrum by age of onset (Maksimowicz-McKinnon, Medicine, 2009). However, TAK and GCA are different in geoepidemiology (Asia vs. Western countries) and comorbidities (ulcerative colitis vs. polymyalgia rheumatica), and the difference can be explained by the difference of associated HLAs. In histopathology of the aorta, it is pointed out that the outer layer of the media and the adventitia are dominantly affected in TAK, whereas the middle or inner layer of the media are dominantly affected in GCA (Stone, Cardiovasc Pathol, 2015). TAK and GCA have different responsiveness to several drugs. A randomized controlled trials (RCT) with abatacept for TAK and GCA were performed, and it showed significant relapse-prevention effects on GCA, whereas, disappointingly, real drug is inferior to placebo for TAK. Three single-arm tests with TNF inhibitors for TAK showed favorable effects, whereas three RCTs with TNF inhibitors for GCA all failed. The importance of Th1 and Th17 cytokines is known for both diseases. In the analysis of PBMC from TAK and GCA with the same protocol performed by Saadoun et al. (Arthritis Rheumatol, 2015), the expression of both Th1 and Th17 cytokines is markedly enhanced in TAK, whereas both the cytokines showed relatively milder elevation in GCA; only expression of IL-23 was significantly more enhanced in GCA. Taken together, it is reasonable that TAK and GCA are distinct diseases which differ in epidemiology, histopathology, symptoms, and cytokine profiles. In ACR2018, separated drafts of revised classification criteria for TAK and GCA were presented. Regarding the age, the committee proposed inclusion criteria, in which the criteria of TAK is considered when the age at diagnosis ≦ 60 years, and the criteria of GCA is considered when the age at diagnosis ≥ 40 years. They also proposed new items that have not adopted before. The strengths and weaknesses of the proposed drafts are discussed.

Meet the Expert

MTE1
Lumbar lesions in patients with rheumatoid arthritis: An underrecognized problem
Hirotaka Chikuda
Department of Orthopaedic Surgery, Gunma University
Conflict of interest: None

Rheumatoid arthritis (RA) is a chronic systemic inflammatory disorder characterized by polyarticular synovitis that can lead to structural damage and deformation of joints. While the involvement of the cervical spine in RA has been well documented, lumbar lesions have received much less attention. Recent studies have revealed that half of RA patients have lumbar lesions, including disc narrowing, spondylolisthesis, and scoliosis. Despite its high prevalence in aged populations and the potential impact on patients’ quality of life, lumbar lesions in RA patients remain underrecognized, which might lead to a misdiagnosis or a delay in treatment. Lumbar lesions in RA patients are categorized into three groups according to the underlying pathology. First, inflammation due to RA itself can cause erosion of the lumbar spine, especially in the facet joints and endplates, which may destabilize the spine. Second, severe osteoporosis, particularly in patients receiving glucocorticoid therapy, may result in multiple vertebral fractures and consequent spinal deformity. Finally, with the improved life expectancy, RA patients are increasingly presenting with common degenerative spinal disorders, such as canal stenosis. A patient with RA may present with one or a combination of these three categories. Physicians encountering RA patients who present with gait disturbance or leg pain are advised to be alert for not only arthritis in the lower extremities but also potential lumbar lesions.

MTE2
Footwear and custom orthotic interventions for rheumatoid foot in combined-modality therapy of surgical, pharmaceutical and rehabilitation
Jun Hashimoto
Department of Rheumatology and Allergology, National Hospital Organization Osaka Minami Medical Center
Conflict of interest: Yes

Principle of footwear and custom orthotic interventions for rheumatoid foot is simple. Cautious selection of shoes, prevention of concentrated plantar pressure and the friction due to planter sliding, stabilization of damaged joints and realignment of the shifted mechanical axis are required. Principle of shoes selection is also simple. Large toe box that is provided by shoes 2-3 cm bigger than foot length, well-fixation of foot in shoes by fixing belt or shoestring and well-fitting of heel to quarter are required. After cautious selection of shoes, we prescribe the insole for various pathological condition of rheumatoid foot. The difficulty of footwear and custom orthotic interventions lies in point other than these principles. Despite the prevalence of footwear and custom orthotic interventions, unrecovered or remaining gait disturbances are frequently overlooked. Their poor functional prognosis due to overlapping age-related disability could burden them sooner or later. In the case of disabled patients using foot orthosis, we must return them to a lifestyle with less disability with timely indicated appropriate surgical intervention. Since we are now short of the specialists of foot and ankle surgery whose techniques catch up with rapidly advanced pharmacotherapy, the well-organized cooperation with foot and ankle surgeon who have high expertise in rheumatoid foot is possible solution. On the other hand, some patients tolerate the improper footwear or orthotics and are led into reduced walking distance and impaired health-related quality of life. Patients’ reasons for this tolerance are complex but include high price of custom foot orthotics, difficulty in size and shape adjustment after purchase of ready-made shoes, strongly opinionated shoes size choice of foot length and low demand of recovery from disability. Provision of dedicated foot care service including shoes adjustment is required, however that remains to be prepared in our team. Rapidly advanced pharmacotherapy and rapid improvement of longevity in the elderly including aged patients with RA inevitably increase the importance of non-pharmacological management such as rehabilitation and surgery. This course aimed to improve skill in
footwear and orthotics fitting and interpretability of the whole series of rheumatoid foot treatment for increasing daily steps counted by pedometer in patients with RA.

**MTE3**

**Chasing molecular and cellular dynamics using genome editing and robotic technologies**

Nozomu Yachie

RCAST, The University of Tokyo

Conflicts of interest: None

Mammalian development, tumorigenesis and other dynamic progressions of heterogeneous biological systems remain largely unclear. The molecular landscapes of cells have been rapidly unveiled by fast-developing sequencing and mass-spectrometry technologies, which however all require destruction of the samples and limit us to analyze the dynamics of single cells or individuals. One can analyze the spatiotemporal dynamics of molecules and cells by microscopic observation with fluorescent proteins or probes, but only for a limited number of objects. Not surprisingly, the above-mentioned technologies only allow us to examine the events that occur at the time of observation. This fact prevents global analyses of heterogeneous molecular dynamics in a complex system. We do not have a time machine. To address this kind of issues, our team has been developing several cell-embedded dynamic DNA memories using genome editing and DNA sequencing technologies. I will first talk about our progress in developing a dynamic DNA memory that continuously records cellular lineage and molecular event information, and then another DNA memory that enables time-course omic analyses of a target clone buried in a complex cell population. I will also briefly discuss the need for robotic technologies to promote biology of the next decades.

**MTE4**

**Giant cell arteritis and Polymyalgia rheumatica**

Eiichi Suematsu

Division of Internal Medicine and Rheumatology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

Conflicts of interest: None

Polymyalgia rheumatica (PMR) is an inflammatory disorder characterized by pain and stiffness in shoulders, neck as well as girdles. The markedly significant uptake of FDG has been reported in ischial tuberosities, greater trochanters, ilipectineal bursas and spinous processes, suggesting the great value of FDG-PET/CT for the diagnosis with PMR. Giant cell arteritis (GCA), previously known as temporal arteritis is classified as a large-vessel vasculitis. Almost all patients who develop GCA are over the age of 50. Common signs and symptoms of GCA due to the involvement of the temporal arteries and other medium-sized arteries of the head and the neck are visual disturbances, headache, jaw claudication, neck pain, and scalp tenderness. General manifestations, such as fatigue, malaise, and fever, are also present. GCA is diagnosed based on the American College of Rheumatology 1990 classification criteria. Because the disease is relatively uncommon, and the disease can cause so many different symptoms, the diagnosis of GCA can be difficult. Actually, GCA is classified into three types: classic temporal arteritis type (cranial GCA); large-vessel type (LV GCA), affecting the aorta and its major branches without temporal arteries; generalized type, affecting both temporal arteries and large vessels. ACR 1990 classification criteria for large-vessel GCA were satisfied in only small portion of LV GCA patients. Recently new classification criteria for GCA has been proposed. PMR occurs in 30–50% of patients with GCA, and 15–30% of patients develop GCA, thus these two diseases might be the same disease with different clinical aspects. In this section, we would like to discuss the clinical subtype and characteristic manifestations of GCA, and the relation between GCA and PMR.

**MTE5**

**Diagnosis and treatment for pain in extremities in children**

Shuichi Ito

Department of Pediatrics, Yokohama City University Graduate School of Medicine

Conflict of interest: Yes

Pain in extremities in children is common chief complaint in outpatient clinic. However, diagnosis and physical examination is often challenging. Orthopedic trauma and growth pain are major causes, but infection, rheumatic diseases, metabolic diseases, hemato-oncological diseases, congenital bone, cartilage and connective tissue diseases could be the cause. Anatomically-based careful physical examination and radiological evaluation are useful to focus on site of the pain, leading to the diagnosis. Additionally, family and developmental history taking is essential to diagnosis inborn disorders. Meanwhile, somatoform disorder, malingering and fibromyalgia syndrome are also put in the list of differential diagnosis. Psychosocial problems are frequently associated with such disorders, so-called “heart pain”. In this lecture, you can learn physical examination, differential diagnosis and treatment of pain in extremities in children.

**MTE6**

**Clinical and immunological characteristics of macrophage activation syndrome: From the results of serum cytokine profile analysis**

Masaki Shimizu

Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University

Conflict of interest: Yes

Macrophage activation syndrome (MAS) is defined as secondary hemophagocytic lymphohistiocytosis related to rheumatic diseases. Excessive activation and expansion of cytotoxic T cells and macrophages, and overproduction of proinflammatory cytokines play a central role in the pathogenesis of MAS. Although MAS has been associated with most rheumatic diseases, in pediatrics it is most common in systemic juvenile idiopathic arthritis (s-JIA). The genetic defects contributing to the development of cytolytic dysfunction including perforin, and chronic interleukin (IL)-6 and IL-18 exposure inducing secondary suppression of cytolytic function are also closely associated to the development of MAS. A trigger of MAS such as infection activates macrophage by interferon-γ, further amplifies the inflammatory response, leading to excessive production of cytokines and ultimately creating cytokine storm. Clinical features of MAS are characterized by fever, hepatosplenomegaly, lymphadenopathy, profound depression of all 3 blood cell lines, deranged liver function, hyperferritinaemia and evidence of intravascular coagulation. Bone-marrow examination reveals numerous morphologically benign macrophages exhibiting hemophagocytic activity. MAS is a potentially fatal complication, and a proper diagnosis of MAS is essential to start appropriate therapeutic interventions. Once the complication of MAS is suspected, careful monitoring of platelets counts, serum AST, ferritin levels and coagulation test is necessary. We analyzed serum cytokine profile in patients with MAS associated with s-JIA. Serum IL-18 levels in patients with s-JIA were extremely high, in particular, in those with MAS. These levels reflected disease activity of s-JIA and MAS. Serum IL-18 levels were useful to predict MAS development. There were two distinct subsets on the basis of serum IL-6/IL-18 levels in s-JIA. Serum neopterin and sTNFRI/II ratio were useful for the diagnosis of MAS. In this lecture, we will learn the pathogenesis of MAS. Furthermore, we will discuss how we should diagnose MAS and how we should treat the patients with MAS through the case presentations.

**MTE7**

**Psychiatric symptoms in patients with neuropsychiatric systemic lupus erythematosus (NPSLE): A management strategy for rheumatologists**

Katsuji Nishimura

Tokyo Women’s Medical University, Japan

Conflict of interest: None

Neuropsychiatric systemic lupus erythematosus (NPSLE) is associated with poor prognosis, extensive cumulative organ damage, and low quality of life. Therefore, rheumatologists consider adequate management
of NPSLE important for patient outcome. However, it is often difficult to evaluate and manage psychiatric symptoms in patients with SLE. Typically, the psychiatric differential diagnosis of medically ill patients includes syndromic and etiologic components. Regardless of the etiology, psychiatric manifestations are classified into 4 major syndromes: cognitive, including delirium and dementia; psychotic; mood; and anxiety. These categories were adopted by the American College of Rheumatology in 1999 to define NPSLE cases. The second step, the etiologic differential diagnosis, is often very difficult in SLE patients for the following reasons: (1) it is difficult to distinguish NPSLE from psychiatric disorders due to other etiologies, such as corticosteroid-induced psychiatric disorders, solely on the basis of symptoms; (2) no disease-specific diagnostic markers or gold standard for NPSLE has been established; and (3) NPSLE may occur independently of the systemic activity of SLE. Therefore, the first step of the etiologic diagnostic work-up should involve excluding non-SLE-related conditions. The correct diagnosis is derived from careful analysis of the clinical, laboratory, and imaging data on a case-by-case basis. The choice of psychotropic drug for symptomatic treatments is based on the above-mentioned syndromic diagnosis. However, patients with SLE often develop stress-related psychological distress that manifests as depression or anxiety and requires stress management or supportive psychotherapy. This program reviews the status of stress that manifests as depression or anxiety and requires stress management or supportive psychotherapy. How is it different from the significance of HLA-B27 in ankylosing spondylitis? 11. How is the disease activity assessed? 12. Which should be selected, steroids or anti-TNF antibodies, in given conditions? 13. Is the disease activity assessed? 6. Is it appropriate to pick up gastrointestinal lesions other than ileocecal ileum at the diagnosis? 7. What vascular lesions are associated with poor survival prognosis? 8. When should CSF IL-6 be measured to make the diagnosis of neurologic chronic progressive type? 9. What are the differences between the Japan criteria and other sets of International criteria? 10. Why is HLA-B 51 a reference finding on the diagnosis? 11. Is it appropriate to pick up gastrointestinal lesions other than ileocecal ileum at the diagnosis? 7. What vascular lesions are associated with poor survival prognosis? 8. When should CSF IL-6 be measured to make the diagnosis of neurologic chronic progressive type? 9. What are the differences between the Japan criteria and other sets of International criteria? 10. Why is HLA-B 51 a reference finding on the diagnosis? How is it different from the significance of HLA-B27 in ankylosing spondylitis? 11. How is the disease activity assessed? 12. Which should be selected, steroids or anti-TNF antibodies, in given conditions? 13. Is antiocoagulation therapy acceptable for deep venous thrombosis? 14. How have been the clinical pictures of Behçet’s disease changed in Japan? MTE8 Questions in daily clinical practice for patients with Behçet’s disease Mitsutoki Takeno Department of Allergy and Rheumatology, Nippon Medical School Conflict of interest: Yes The Guidelines for management of Behçet’s disease released from Behçet’s Disease Research Committee, MHLW and 2018 update EULAR recommendations for the management for Behçet’s syndromes would be helpful for daily clinical care of the patients. Although a number of the disease susceptible genes have been identified, the cause is still unknown. The diagnosis remains dependent on symptomatology with no disease-specific biomarker. Of note, it is important to assess individual symptoms appropriately, as the criteria mention “atypical findings in both major and minor symptoms should not be counted.” This session discusses issues of Behçet’s disease in daily clinical practice. 1. What is the definition of “recurrent” oral aphtha? 2. What conditions should be excluded from folliculitis- and acne-like eruptions? 3. What relation is found between genital ulcer and menstrual cycle? 4. What features are found in uveitis of Behçet’s disease? 5. When should visual acuity be assessed? 6. Is it appropriate to pick up gastrointestinal lesions other than ileocecal ileum at the diagnosis? 7. What vascular lesions are associated with poor survival prognosis? 8. When should CSF IL-6 be measured to make the diagnosis of neurologic chronic progressive type? 9. What are the differences between the Japan criteria and other sets of International criteria? 10. Why is HLA-B 51 a reference finding on the diagnosis? How is it different from the significance of HLA-B27 in ankylosing spondylitis? 11. How is the disease activity assessed? 12. Which should be selected, steroids or anti-TNF antibodies, in given conditions? 13. Is antiocoagulation therapy acceptable for deep venous thrombosis? 14. How have been the clinical pictures of Behçet’s disease changed in Japan? MTE9 Ultrasound assessment of disease activity in rheumatoid arthritis patients Michihiro Ogasawara Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan Conflict of interest: None In routine practice, we mainly refer to the number of tender and swollen joint, CRP, ESR, patient’s VAS, which are components within the composite measure such as DAS, SDAI, CDAL and investigate the condition of rheumatoid arthritis. It is common to judge roughly, however, each component cannot judge the disease condition of RA properly, such as when the findings of affected joints are mild, when suffering from infection, individual difference in pain range value, etc. In such a case, using joint ultrasound examination, it becomes possible to detect abnormal findings such as synovitis with high sensitivity through high-resolution ultrasound images and correct disease activity judgment. On the day of lecture, tips and pitfalls of ultrasound examination, how do you select and judge joint position and number of ultrasound examination necessary for RA activity evaluation? The inspection timing and interval? How do you interpret the obtained findings? How to strengthen treatment using ultrasound image? We will acquire the fundamental knowledge that is indispensable for exploiting the joint ultrasound examination in RA monitoring. MTE10 Methods for evaluating idiopathic inflammatory myopathies Ken Yoshida Division of Rheumatology, Department of Internal Medicine, Jikei University School of Medicine Conflict of interest: None Idiopathic inflammatory myopathy (IIM) is an autoimmune disorder with a diverse phenotype characterized by chronic inflammation of the muscle, skin, or lung. The treatment response and prognosis depend on the phenotype. It is thus important to comprehensively evaluate the disease condition early for an appropriate treatment. I will first describe the differences between the latest 2017 EULAR/ACR IIM classification criteria and conventional classifications, such as the Bohan & Peter criteria for polymyositis (PM)/dermatomyositis (DM), 2015 diagnostic criteria for PM/DM set by the Ministry of Health and Welfare in Japan, and European Neuromuscular Centre classification criteria focusing on muscle pathology. Furthermore, for the treatment of IIMs, clinicians must evaluate the disease activity, extent of disease, complications, and prognostic factors using various evaluation methods including imaging tests. Magnetic resonance imaging (MRI) and ultrasonography are particularly useful noninvasive modalities, in contrast to the more invasive electromyogram and muscle biopsy, and allow for the accurate assessment of myositis and fasciitis. I will therefore show the utility of imaging tests in IIMs and discuss the relationship between the MRI findings and myositis-specific antibodies. Finally, I would like to describe the prognostic factors in clinically amyopathic DM (CADM). Anti-MDA5 antibody-positive CADM with rapidly progressive interstitial lung disease leads to a poor outcome. Therefore, it is critically important to assess the prognostic factors in CADM for early intervention. MTE11 The assessment of nailfold capillary changes in clinical settings Yoshihide Asano Department of Dermatology, University of Tokyo Graduate School of Medicine Conflict of interest: Yes Systemic sclerosis (SSc) is a multisystem autoimmune disease characterized by vasculopathy and fibrosis of the skin and various internal organs. Although its etiology still remains unknown, recent clinical and basic studies have achieved a progress in the understanding of its developmental process. SSc-associated organ fibrosis occurs as a result of constitutive activation of dermal fibroblasts followed by vasculopathy and autoimmune inflammation; therefore the assessment of vasculopathy is quite useful for the early diagnosis of SSc without fibrotic changes, as well as for evaluating its disease stage and severity. SSc vasculopathy consists of the functional and structural abnormalities, the latter of which can be evaluated by looking at nailfold capillaries. Generally, skin vasculature forms capillary loops in the papillary dermis, which runs parallel to the epidermis in the areas around nailfold. The nailfold capillary changes associated with SSc vasculopathy is characterized by capillary dilation or loss, which can be observed by naked eyes when the changes are severe. Dermoscopy and capillaroscopy help us observe the nailfold capillary changes much more precisely. Especially, there is a scoring system of
naifld capillary changes, and also the evaluation of blood flow velocity is possible in capillaroscopy-based evaluation. Indeed, we experienced the improvement of numeric parameters in capillaroscopy-based assessment in SSC patients treated with disease-modifying drugs, suggesting that capillaroscopy may be useful for evaluating disease modifying effects of new drugs against SSC. In my talk, I will present our cases who were longitudinally followed up with capillaroscopy, and also explain the underlying pathogenesis of SSC vasculopathy.

**MTE12**

*Synovial fluid hands-on workshop: “one-drop assessment” by physicians*

Naoto Yokogawa1, Takayasu Kise1, Yuji Miyoshi1, Yoshiki Nagai1, Masako Utsunomiya1, Ikuko Masuda1
1Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, 2Jujo Takeda Rehabilitation Hospital, Center for Rheumatic Diseases

Conflict of interest: Yes

Crystal arthritis is the most important differential diagnosis in the assessment of inflammatory arthritis but misdiagnosed very frequently. Crystal identification by microscopy is a classic, simple diagnostic procedure but remains to be a gold standard for the definitive diagnosis. Microscopic examination of a drop of synovial fluid can provide a prompt assessment of the presence or absence of inflammation and crystals and help avoiding excessive tests and treatments. In Japan, crystal identification is not performed routinely and often sent outside laboratories. In cooperation with ACR and EULAR synovial fluid workshop, we organized the first JCR synovial fluid workshop for rheumatologists. Teaching points 1) A clinical diagnosis of crystal arthritis is provisional. The definitive diagnosis of crystal arthritis should be made by microscopic examination of the synovial fluid. 2) Physicians should look at every synovial fluid by microscopy. It is very important that rheumatologists become acquainted with crystal analysis; besides becoming able to diagnose crystal arthritis at the first visit, they search with knowledge of the clinical picture, and their interest in the search is clearly higher than that of a lab technician. Centrifuging is not necessary. Important clinical information such as presence or absence of inflammation, monosodium urate (MSU) and calcium pyrophosphate (CPP), will be obtained immediately. 3) Optimal microscopy is acceptable. By the ordinary microscope, crystals are well distinguished and identified as MSU or CPP easily by shape. There is always a microscope fitted with polarized filters in Pathology departments. The polarizing light observation is helpful, showing the strong brilliancy of most MSU crystals and the weak to absent of CPP. Use of the compensator may be useful for isolated or very occasional crystals. Acknowledgement: Dr. Eliseo Pascual (EULAR), Dr. Brian F Mandell (ACR), Dr. Ralph H Schumacher.

**MTE13**

*Pathological aspects of vasculitides*

Akihiro Ishizu
Department of Medical Laboratory Science, Hokkaido University, Faculty of Health Sciences

Conflict of interest: None

Vasculitis is a disease in which vessels are affected primarily. Since vasculitis is apt to affect vessels segmentally, it is desirable to cut the vessels in round slices as many as possible for histological examination. By the same reason, it is recommended to examine deeper sections when there is no remarkable finding in the first section in spite of the clinical suspicion. The major histological aspects of vasculitis are granulomatous vasculitis and necrotizing vasculitis. The specific stain of elastic fibers can be useful to elucidate the vascular injury. Granulomatous vasculitis is characteristic of Takayasu arteritis (TAK) and giant cell arteritis. Multi-nuclear giant cells that capture the degraded elastic fibers in the cytoplasm are sometimes present in the lesion. In TAK, the granulomatous inflammation characteristically invades the tunica media from the adventitial side. On the other hand, necrotizing vasculitis occurs in polyarteritis nodosa, anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, anti-glomerular basement membrane disease, IgA vasculitis, etc. Infiltration of neutrophils (eosinophils in case of eosinophilic granulomatosis with polyangitis) is present, and leukocytoclastic is sometimes observed. Additionally, the presence of neutrophil extracellular traps in the lesion is the feature of ANCA-associated vasculitis. These histological characteristics are considered to reflect the pathogenesis. Thus, an exact recognition of pathological findings is important for understanding the pathophysiology of vasculitides. In this lecture, I will introduce the textbooks of vasculitis, the consultation system of Pathological Diagnosis of Vasculitides, which have been established by the Subcommittee of Clinical Pathology in the Japan Research Committee of the Ministry of Health, Labour, and Welfare for Intractable Vasculitides, and the workshops of vasculitis. I hope to contribute useful information for diagnosis of patients with vasculitis.

**MTE14**

*Approach to SpA diagnosis for rheumatologists*

Shigeyoshi Tsuji
NHO Osaka Minami Medical Center

Conflict of interest: None

SpA is classified into Axial SpA (axSpA), Peripheral SpA (pSpA) by the ASAS classification (Assessment of SpondyloArthritis international Society) from the superiority of its body axis lesion, peripheral lesion, and non - radiographic axial SpA nr - axSpA has been proposed. On the other hand, from the concept of disease / diagnosis, prototypes such as ankylosing spondylitis (AS), reactive arthritis (ReA), psoriatic arthritis (PsA), juvenile SpA, enterocolitis related spondylarthrits (IBD - SpA) SpA (uSpA), and ReA, IBD-SpA, uSpA, etc. are representative, mainly PsA, as diseases classified as pSpA. This seminar will outline the physiological findings and image findings which are important findings in the process of conducting PsA diagnosis in “SpA diagnosis by rheumatologist”.

**MTE15**

*Clinical utility of anti-nuclear antibody testing in patients with connective tissue diseases*

Takao Fujii
Department of Rheumatology and Clinical Immunology, Wakayama Medical University

Conflict of interest: None

Connective tissue diseases (CTDs) are well known as systemic autoimmune disorders, because high tiers of anti-nuclear antibodies (ANAs) are frequently observed in sera from CTD patients. Actually, lots of ANA tests, of which clinical significance is clearly identified, are available in clinical practice. 1) ANAs associated with disease diagnosis Anti-Sm and dsDNA antibodies (Abs) in systemic lupus erythematosus (SLE), and anti-topoisomerase I Abs in systemic sclerosis are ‘marker ANAs’. These Abs are highly specific and included in the international classification criteria. 2) ANAs associated with specific manifestations Anti-U1RNP Ab may be one of the critical risk factors for pulmonary arterial hypertension and aseptic meningitis. Anti-aminocyan RNA synthetase (ARS) Abs including anti-Jo-1, autoantigens of which are cytoplasmic proteins and are usually recognized in polymyositis/dermatomyositis. Patients with anti-ARS Abs, however, often show the similar clinical manifestations (anti-synthetase syndrome), which include fever, Raynaud’s phenomenon, polyarthritis, interstitial lung disease (ILD) and/or myositis. 3) ANAs associated with disease activity Anti-DNA Ab titer correlate with disease activity in SLE and should be repeatedly determined until clinical remission. 4) Autoantibodies associated with severe and/or life-threatening manifestations Anti-U1RNP Ab in systemic sclerosis are ‘marker ANAs’. These Abs are closely associated with life-threatening ILD, particularly in clinical practice. In the present seminar, we can discuss the best way to use autoantibody testing according to the International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies (Agmon-Levin N, et al. Ann Rheum Dis 2014;73:17-23).
MTE16
Statistical Analysis for Clinical Research based on Database
Eisuke Inoue
St. Marianna University
Conflict of interest: None

There is a type of clinical research that utilizes a database as its platform (DB-research). For example, a research following up a group of subjects with a specific medicine, capturing a natural course of a certain disease for a long period of time, building a registry of a rare disease along with clinical information are included as this type of research. Results from DB-research have great influence on various aspects and have contributed to progress in medicine in various forms since sample size and observation period of DB-research are often enormous. In order to publish correct results from DB-research, there are two key components: designing appropriate data collection system and conducting reliable statistical analysis. In this session, we consider and discuss methods of statistical analysis to report information appropriately from DB-research. Analysis of DB-research requires attention to confounding. One solution is to collect lots of factors of possible confounding and incorporate them into the analysis. However, imposing an impossibly large amount of data collection will affect increasing missing data or continuity of research project. It is inevitable to discuss the data collection first enough. In DB-research, it is necessary to deal with missing values appropriately. In multivariate analysis, missing data will affect loss of information directly since a subject with even one missing data item will be excluded from analysis. There is no gold standard method to handle missing values. Therefore, it is necessary to analyze data from various aspects using several currently available methods and evaluate sensitivity to those methods.

MTE17
Pharmacoeconomics in Rheumatoid Arthritis
Eiichi Tanaka
Institute of Rheumatology, Tokyo Women’s Medical University Hospital, Tokyo, Japan
Conflict of interest: None

The recent introduction of biologics has resulted in significant advances in treatment strategies for rheumatoid arthritis (RA). On the other hand, rising healthcare costs have caused concern, placing a heavy burden on society as well as RA patients. The IORRA study has also shown that RA patients’ financial burden is increasing and that direct and indirect costs associated with progression of functional impairment or decline in quality of life (QOL). This suggests that inhibiting the progression of functional impairment through aggressive control of RA may help reduce lifetime healthcare costs. Pharmacoeconomics is the scientific discipline that evaluates both the clinical benefits and economic efficiency of a drug to determine whether it is worth the cost. Mainly in Europe, pharmacoeconomic evaluation of expensive drugs has been widely used. In Japan, cost-effective assessment was started on a pilot basis for some expensive oncologic in the treatment of RA and found that the use of biologics in Japanese RA patients is justified in the long term from a health economic perspective. These results suggest that, although biologics are expensive, their proper use in eligible RA patients may also be socially beneficial by helping maintain QOL for a long period of time and allowing patients to have a social life including workforce participation without difficulty. At this Meet the Expert seminar, I will first share health economic issues and the importance of pharmacoeconomic evaluation and then explain cost-effectiveness in real-world settings.

MTE18
Basic knowledge of orthopedic diseases for RA treatment and diagnosis
Toshihisa Kojima
Nagoya University, Graduate School of Medicine
Conflict of interest: Yes

Rheumatoid arthritis (RA) is characterized by multiple arthritis which causes bone destruction. There are many orthopedic diseases that cause pain in the hand fingers, wrist joints, feet, and other limb joints that are particularly frequent in arthritis by RA. Along with advances in drug therapy, an early diagnosis before the appearance of bone destruction and tight control of inflammation is required. Therefore, in order not to misdiagnose these conditions as RA and also to evaluate the disease activity correctly during treatment, it is necessary to know representative orthopedic diseases. The following are representative orthopedic diseases due to routine medical treatment that causes pain in the limb joints. These diseases can understand pathology from the anatomical structure and function of the site. Hand fingers, wrist joints: 1) finger tendonitis and de Quervain tenosynovitis, 2) osteoarthritis (Heberden nodule, Bouchard nodules), 3) RA hand in the form (DB-research). For example, a research following up a group of patients- Ryumachi Hakusho, initial symptoms of RA are mainly wrist joint arthritis (37.7%) or finger joint arthritis (52.1%). Persistent arthritis are particularly frequent in arthritis by RA. Along with advances in drug therapy, an early diagnosis before the appearance of bone destruction and tight control of inflammation is required. Therefore, in order not to misdiagnose these conditions as RA and also to evaluate the disease activity correctly during treatment, it is necessary to know representative orthopedic diseases. The following are representative orthopedic diseases due to routine medical treatment that causes pain in the limb joints. These diseases can understand pathology from the anatomical structure and function of the site. Hand fingers, wrist joints: 1) finger tendonitis and de Quervain tenosynovitis, 2) osteoarthritis (Heberden nodule, Bouchard nodules), 3) RA hand in the form (DB-research). For example, a research following up a group of patients- Ryumachi Hakusho, initial symptoms of RA are mainly wrist joint arthritis (37.7%) or finger joint arthritis (52.1%). Persistent arthritis could cause joint destruction or deformity. For this reason, the treatment of RA hand has become essential recently. (Examination of RA hand) As it is required to confirm the presence of finger or wrist joint synovitis, careful examination is essential. In addition, it is necessary to get in-depth information, joint destruction, range of motion, pinch power, and grip power. As the joint synovitis that is not detected by palpation may be confirmed by ultrasound test, it is necessary for additional inspection. As checking if tenosynovitis exist is important because of the risk of tendon rupture, it should not be missed. (Conservative treatment of RA hand) Joint steroidal injection makes some synovitis improve, therefore it...
is important as conservative treatment of RA hand. It is desirable to consider resting-purpose orthotics for arthritis. If an orthotic suitable for individual hand deformity is considered, the benefits were significant. (Surgical treatment of RA hand) Small joint surgeries are predicted to increase, and joint-preserving RA hand surgery has been more indicated recently. If conservative treatment such as a joint injection is not effective, the synovial resection is recommended. For destructive joint cases surgical intervention is needed. Especially for RA patients, hand deformity is a big problem. Therefore, we need to explain that surgical treatment is also effective for advanced hand deformity. (Conclusion) In addition to drug treatment, a local approach to remaining arthritis is also thought to be essential. Especially for the problem of RA hand, combination of conservative and surgical treatment is thought to be even more important.

MTE21
How to assess plain X-ray imaging for rheumatic diseases
Shintaro Hirata, Eiji Sugiyama
Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital

Conflict of interest: Yes

Recent progress in clinical imaging technology with novel modalities have contributed to diagnosis and management, as well as investigation of pathophysiology in rheumatic diseases. Indeed, plain X-ray is a “legacy” modality utilized for more than 120 years since discovery of X-ray by Wilhelm Conrad Röntgen in 1895. Nevertheless, plain X-ray is the most frequently used modality at both diagnosis and follow-up, especially for bone/joint and chest, in rheumatology to date, since plain X-ray is simple, inexpensive, and suitable for repeated test. Various findings are identified on bone/joint X-ray in rheumatic diseases. Erosion, joint space narrowing, and luxation/subluxation are common in rheumatoid arthritis (RA); especially, erosion is highly diagnostic. van der Heijde’s modified total Sharp score (vdH-S score, mTSS) has been the standardized index for joint destruction in clinical trials for RA. Pencil-in-cup appearance, sacroiliitis, or bamboo-spine are characteristic for spondyloarthritis (SpA) including psoriatic arthritis (PsA) and anklyosing spondylitis (AS). Linear calcification in joint space is characteristic for pseudogout. Various findings are observed on chest X-ray, as well. Interstitial lung diseases (ILDs) are common in several connective tissue diseases; however, diffuse lung disease (DLD) is most frequently used modality at both diagnosis and follow-up, especially for bone/joint and chest, in rheumatology to date, since plain X-ray is simple, inexpensive, and suitable for repeated test. Various findings are identified on bone/joint X-ray in rheumatic diseases. Erosion, joint space narrowing, and luxation/subluxation are common in rheumatoid arthritis (RA); especially, erosion is highly diagnostic. van der Heijde’s modified total Sharp score (vdH-S score, mTSS) has been the standardized index for joint destruction in clinical trials for RA. Pencil-in-cup appearance, sacroiliitis, or bamboo-spine are characteristic for spondyloarthritis (SpA) including psoriatic arthritis (PsA) and anklyosing spondylitis (AS). Linear calcification in joint space is characteristic for pseudogout. Various findings are observed on chest X-ray, as well. Interstitial lung diseases (ILDs) are common in several connective tissue diseases; however, degree of infiltration and fibrosis varies; infiltration is dominant in polymyositis/dermatomyositis (PM/DM) whereas fibrosis is dominant in systemic sclerosis (SSc). Pleuritis and pericarditis are often observed in systemic lupus erythematosus (SLE), airway lesions including bronchiolitis are often found in RA. Indeed, chest X-ray is quite important for screening infectious disorders including tuberculosis and pneumocystis at initiation and follow-up of immunosuppression with DMARDs or glucocorticoids, etc. In the session, active discussion with attendees will be encouraged about assessment of plain X-ray imaging for rheumatic diseases, viewing representative images.

MTE22
Early treatment of tenosynovitis with conventional synthetic disease-modifying antirheumatic drugs other than methotrexate prevents the progression of preclinical rheumatoid arthritis
Tomomasa Izumiya
Higashisendai Rheumatic Disease Clinic

Conflict of interest: None

I have a dream that oneday Japan would lead the world in treating preclinical rheumatoid arthritis (pre-RA). However, there is a theoretical dilemma in treating pre-RA: As pre-RA can only be retrospectively defined in the absence of currently available clinical definition, presumable cases cannot be verified as being pre-RA when the treatment is effective and the would-be RA resultant stops progressing to established RA. Mankia et al. have reported that many patients who possess a risk to progress to established RA actually do not. I have experienced a case in which the patient progressed to established RA after a very long period of 37 years from his seroconversion of rheumatoid factor. Such a case indicates us that it is impossible to distinguish those who progress from those who don’t. Therefore, a revolutionary change in the definition of pre-RA is required. Since RA is a syndrome of systemic synovial inflammation, arthritis is not necessarily its essential component. Accordingly, its treatment must aim at systemic synovitis instead of just arthritis. For example, tenosynovitis can be an initial symptom and can cause erosions of adjacent bones. Thus, this pathology can be useful in making an early diagnosis of RA and itself can be a treatment target in the pre-RA stage. Tenosynovitis can cause severe pain and morning stiffness especially when it affects flexor tendons of hands. At our clinic conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) other than methotrexate (MTX) are effective in treating such cases. Ultrasonography is especially useful in diagnosing tenosynovitis and this technique is widely available in Japan. Further, many csDMARDs other than MTX including Bucillamine, Igarutimod and Tacrolimus can be used in this country. Taking advantage of these, I hope that we can lead the world in detecting and treating pre-RA and preventing its progression to established RA.

MTE23
Treatment of Shoulder Pain in Patients with Rheumatoid Arthritis
Kazuya Tamai, Yuichi Nagase, Masashi Naito, Sakae Tanaka
1Department of Orthopedics, Tohto Bunkyo Hospital, 2Rheumatology and Connective Tissues Department, Tokyo Metropolitan Tama Medical Center, 3Department of Orthopaedic Surgery and Spinal Surgery, The University of Tokyo Hospital

Conflict of interest: None

The goal of this lecture is to provide knowledge for: 1) functional anatomy of the shoulder, 2) possible causes of shoulder pain in patients with RA, 3) intraarticular injection, 4) physical therapy, and 5) surgical options. <Functional anatomy> The basic function of the shoulder is to move the hand to a specific position in the space. The shoulder motion is a sum of scapulothoracic and glenohumeral motions. The stability of the glenohumeral joint depends on the rotator cuff. <Shoulder joint in RA> In advanced RA, the glenohumeral as well as the acromioclavicular joint show destructive changes in half of cases. Rotator cuff tear occurs frequently in RA because the insertion of the rotator cuff is located close to the bare area. The impairment of shoulder function has a great impact on the health-related QOL in RA patients. <Treatment of shoulder pain in RA> The JCR clinical guideline (2014) describes intra-articular corticosteroid injection, physical and occupational therapy, and total shoulder and hemiarthroplasty as a recommended treatment for RA patients. 1) Intraarticular corticosteroid injection: This is known to improve pain VAS and active shoulder flexion, and to decrease inflammation/hypervascularity in the synovium. My preference of injection technique is from posterior in a sitting patient. 2) Rehabilitation: It is known that aerobic exercises and resistance muscle training are useful for RA patients. For the shoulder joint, isometric exercises of the rotator cuff muscles and relaxation of the scapulothoracic muscles are recommended. 3) Surgery: Anatomical total shoulder arthroplasty is recommended when a rotator cuff function is preserved because it shows satisfactory clinical outcome as well as longevity of the implant. In contrast, hemiarthroplasty is not preferred now because it often causes glenoid erosion. Reverse total shoulder arthroplasty is now an attractive option in patients who have both joint destruction and rotator cuff insufficiency.

MTE24
Musculoskeletal ultrasound makes our RA practice style aggressive one!—Excellent procedure for Rheumatologist make it possible to depict the sharp answer in clinical setting—
Kent Misaki
Department of Rheumatology, Kitu-Harima Medical Center

Conflict of interest: Yes

Ultrasound technique have played a pivotal role for diagnosis and evaluation of treatment efficacy since 1949 when K.T. Dussik firstly introduced it in clinical settings. The reason why ultrasound is surprisingly spread in clinical field is that it is easy and non-invasive imaging procedure to patients. Remarkable innovative revolutions for ultrasound probe make it possible for Rheumatologists to put into clinical setting. However, many patients also including co-medicals are no where insight about adaptations of ultrasound to connective tissue disease (CTD). Muscule-
skeletal ultrasound (MSKUS) is mostly used for Rheumatoid arthritis (RA) in Rheumatology. The contribution of MSKUS for both diagnosis and evaluation of treatment efficacy is quite high as expected. In particular, high specificity (93.7%) in 2010 ACR/EULAR-RA classifications was shown by using MSKUS compared with that (79.4%) of palpation method from our country. The algorithm for RA diagnosis also including the validation of both therapeutic effect and remission, and the final definition of enthesitis were reported from EULAR recently. These excellent reports suggested that MSK is crucial examination for daily medical practice, moreover MSKUS is very useful to not only RA but also the differential diagnosis similar to connective tissue disease. In this session, I am going to introduce the latest evidence of MSKUS in addition to the real-cases diagnosed by MSKUS, and focus upon the educational systems to sonographers and nurse in our institution.

MTE25
An introduction to statistical analysis for clinical researches using R and EZR
Hisashi Noma
Research Center for Medical and Health Data Science, The Institute of Statistical Mathematics
Conflict of interest: None

In the Symposium 17, I provided an introductory talk about the worrisome “statistics,” and I’d ask again, “Are you still suffering with “statistics” of clinical research papers?” However, in modern medical researches, many advanced statistical techniques, e.g., significance tests, confidence intervals, logistic regression, Cox regression, have been commonly used, and we cannot understand clinical evidence from these research articles precisely if we do not have sufficient knowledge about them. In addition, we cannot write a clinical research article if we can use statistical software actually. It is said that these software cannot be used if the user is not familiar with programming skills and most of these software are expensive. In this session, I conduct a hands-on seminar about a free statistical software R (R Foundation for Statistical Computing, Vienna, Austria) and its add-in EZR for statistical analysis for clinical researches, which resolve all of the problems mentioned above. R is a well-known statistical software that has been widely adopted in clinical researches published in international medical journals, and has rich and reliable functions for data analyses. R itself is difficult to use if the user acquires programming skills for the R language, but EZR enables easy-to-conduct statistical computations like as spreadsheet software, e.g., Microsoft Excel. In this seminar, you can experience statistical computations of p-values, confidence interval, and multivariate analyses that are widely used in international medical journals actually.

MTE26
How to Write a Paper in English 2 - The Structure of Logic and Figures -
Tetsuo Koyama
Department of Rehabilitation Medicine, Nishinomiya Kyoritsu Neurosurgical Hospital
Conflict of interest: None

In medical science, research papers are published primarily in English. I provide some useful ideas to write a research paper in English in terms of the structure of logic and figures. In both English and Japanese, logical composition is most important in writing a paper. Scientific papers are not highbrow literature, esoteric philosophy, or advanced mathematics. The required logical composition is therefore very simple; the keys are “abstract and specific,” “parallel and contrast,” and “comparison and integration.” Japanese sentences often put main focus on predicates and allow null subjects, whereas English sentences require definite subjects and predicates in principle. English is thus beneficial in providing a well-organized logical structure. A good hint for writing a paper in English can be found in modern/contemporary artworks. Not a few modern paintings, including those of Édouard Manet, are based on past artworks. Scientific papers are similar to these artworks in that they are prepared referencing past papers. Another hint comes from the use of ready-mades in artworks. For instance, Marcel Duchamp placed a mass-produced porcelain urinal in an art museum as Fountain (1917), and Andy Warhol attracted public attention with Campbell’s Soup Cans (1962). Similarly, most figures and tables presented in a beautiful array in scientific papers are prepared using the format of Excel and other statistical software. The use of “ready-mades” in modern/contemporary art gives a great hint on the preparation of figures and tables, which have pivotal roles in scientific papers. In summary, the keys to write a research paper in English are: 1) to find a point for discussion in the context of past papers; 2) always to be mindful of subject-oriented logical structure; and 3) to create a beautiful array of figures and tables using “ready-mades.”
Luncheon Seminar

LS1-1  Current treatment for spondyloarthritis
Naoto Tamura
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine

Conflict of interest: Yes

Spondyloarthritis (SpA) is a group of diseases showing common clinical features, such as axial and peripheral arthritis, enthesitis, dactylitis, and extraarticular involvement, including uveitis. There are now two types of SpA, peripheral dominant peripheral SpA and axial dominant axial SpA, and psoriatic arthritis and ankylosing spondylitis are representative diseases, respectively. Patients with psoriatic arthritis often have enthesitis and/or dactylitis other than peripheral arthritis that are critical for the diagnosis. Family history of psoriasis, examination of nail disease, and finding hidden psoriatic lesions, in scalp, buttocks and other places, are also important. Axial disease is not rare in psoriatic arthritis. It usually can be distinguished from ankylosing spondylitis due to asymmetrical appearance, lack of sacroiliac involvements, and non-marginal ossification. Modified New York criteria has been used for classification of ankylosing spondylitis and also for diagnosis of an intractable disease supported by Ministry of Health, Labour, and Welfare. On the other hand, a classification criteria for axial spondyloarthritis proposed by ASAS is now commonly used. It includes MRI and HLA-B27 to classify early disease as non-radiographic axia SpA. However, only a part of non-radiographic axial SpA becomes to ankylosing spondylitis. Although early in-enthesitis is non-radiographic other than peripheral arthritis that are critical for the diagnosis. Family history of psoriasis, examination of nail disease, and finding hidden psoriatic lesions, in scalp, buttocks and other places, are also important. Axial disease is not rare in psoriatic arthritis. It usually can be distinguished from ankylosing spondylitis due to asymmetrical appearance, lack of sacroiliac involvements, and non-marginal ossification. Modified New York criteria has been used for classification of ankylosing spondylitis and also for diagnosis of an intractable disease supported by Ministry of Health, Labour, and Welfare. On the other hand, a classification criteria for axial spondyloarthritis proposed by ASAS is now commonly used. It includes MRI and HLA-B27 to classify early disease as non-radiographic axia SpA. However, only a part of non-radiographic axial SpA becomes to ankylosing spondylitis. Although early intervention is required for SpA to improve its outcome, appropriate diagnosis is necessary. In axial disease and enthesitis, conventional anti-rheumatic drugs are not effective and then biologics should be used in case of active diseases with NSAIDs. Recently, “Treat to target (T2T)” is recommended as a therapeutic strategy for SpA, and new medicines for SpA have been appearing. In this session, we will discuss about update of diganosis and treatment of SpA.

LS1-2  Pathophysiology of Spondyloarthritis : the role of IL-17A in inflammation, enthesitis, and new bone formation
Dirk Elewaut
VIB Inflammation Research Center, Ghent University and Department of Rheumatology, Ghent University Hospital, Ghent, Belgium

Conflict of interest: Yes

Enthesitis is a hallmark of spondyloarthritis. Despite this, relatively little is known about the immunobiology of enthesitis. The enthesis is composed of stromal cells, tendon structures and a rare population of inflammatory mediators leading to enthesitis. It should be noted that there may be other means how enthesitis occurs including by tissue resident cells. The overall immunobiology of enthesitis will be discussed with special emphasis on IL-17A as a key driver of inflammation and tissue remodeling.

LS2-1  Clinical features of eosinophilic granulomatosis with polyangiitis compared to other ANCA-associated vasculitis
Ken-ei Sada
Dentistry and Pharmaceutical Sciences, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine

Conflict of interest: Yes

Eosinophilic granulomatosis with polyangiitis (EGPA) is classified into antineutrophil cytoplasmic antibody (ANCA) associated vasculitis along with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) in Chapel Hill Consensus Conference 2012. EGPA is characterized by eosinophil-rich and necrotizing granulomatous inflammation and necrotizing small vessel vasculitis, and hypereosinophilia, and occurs in individuals with asthma and allergic rhinitis. A previous national survey in Japan reported that younger disease onset than patients with other ANCA associated vasculitis, high frequency of neurological manifestations, and 50% of positivity of myeloperoxidase- ANCA. This report also showed that ANCA-positive patients had renal involvement, mucous membrane or ophthalmological symptoms, and ENT symptoms more frequently, whereas cutaneous lesions and cardiovascular involvement were less common. Interestingly, neurological symptom revealed no dependence on ANCA positivity. Glucocorticoids generally showed good treatment response for EGPA. For refractory cases, cyclophosphamide and azathioprine have been used concomitantly as with the treatment of other ANCA associated vasculitis. Recently, B-cell depleting therapy with the anti-CD20 antibody rituximab has proved beneficial for the treatment of MPA and GPA, and avacapan, selective C5a receptor inhibitor, has been developed as a new treatment option. For EGPA, the efficacy of IVIG for refractory neurological symptoms and efficacy of mepolizumab, anti-IL-5 inhibitor, for refractory EGPA were reported additionally. In this seminar, we focused on the clinical features of EGPA compared to MPA and GPA based on recent epidemiological studies and clinical trials.

LS2-2  Mepolizumab, an anti-IL5 monoclonal antibody, improves disease outcomes in Eosinophilic granulomatosis with polyangiitis
Peter Howarth1,2
1Global Medical Expert, GlaxoSmithKline, UK, 2Allergy and Respiratory Medicine, University of Southampton, UK

Conflict of interest: Yes

Mepolizumab add on therapy was assessed in the treatment of EGPA in a randomized, placebo-controlled, double-blind, parallel-group, multicenter study in patients with a history of relapsing or refractory disease on stable therapy with prednisolone/prednisone ≥7.5-≤50mg/day with or without additional immunosuppressive therapy for ≥4 weeks (Wechsler et al NEJM 2017;376:1921-1932). Mepolizumab 300mg subcutaneously or matching placebo was given every 4 weeks, in a 52 week study. Co-primary endpoints were, accured duration of remission (Birmingham Vasculitis Activity Score [BVAS]=0, prednisolone/prednisone dose ≤4mg/day) over 52 weeks and the proportion of patients in remission at both Weeks 36 and 48. Secondary endpoints included average glucocorticoid dose during weeks 48-52 and time to first EGPA relapse. Safety was also assessed. There were 136 randomized patients (mepolizumab n=68, placebo n=68). Duration of remission accured over 52 weeks was significantly prolonged with mepolizumab vs placebo (odds ratio: 5.91 [95% confidence interval [CI]: 2.68,13.02]; p<0.001); a significantly higher proportion of patients were in remission at Weeks 36 and 48 (32% vs 3%, respectively, odds ratio: 16.74 [95% CI: 3.61,77.56]; p<0.001). Significant reductions in average daily glucocorticoid dose during Weeks 48-52 were seen with mepolizumab vs placebo (odds ratio: 0.20 [95% CI: 0.09,0.41]; p<0.001). Time to first EGPA relapse was significantly longer with mepolizumab vs placebo (hazard ratio: 0.32 [95% CI: 0.21,0.50]; p<0.001). Rates of adverse events (AEs) and serious AEs were similar for mepolizumab and placebo. This study thus demonstrates consistent and meaningful clinical benefits of mepolizumab in patients with EGPA.

LS3  Utilization of Biomarkers targeting Remission in RA Treatment - Making use of Autoantibody and MMP-3 Assays -
Eiichi Tanaka
Institute of Rheumatology, Tokyo Women’s Medical University Hospital, Tokyo, Japan

Conflict of interest: None

In recent years, the treatment of Rheumatoid Arthritis (RA) has been significant advances with the introduction of biologics. The treatment goal is shifting from “Reduce disease activity” to “Prevent bone and joint destruction”, and remission is now a realistic treatment target. The Institute of Rheumatology Rheumatoid Arthritis (IORRA) study has demon-
strated clear improvement in patient outcome. In order to assure better patient outcomes, early diagnosis and intervention based on Treat to Target recommendations, as well as Tight Control through careful monitoring are necessary. When planning such an RA treatment strategy, biomarkers provide invaluable objective information. Biomarkers used in the treatment of RA can largely be divided into two categories, auto-immune antibody tests and tests for markers of inflammation. Auto-immune antibody tests include rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA). These are given significant weight in the ACR/EULAR new classification criteria for early diagnosis, as they may be positive even prior to the onset of joint inflammation. On the other hand, markers of inflammation include serum CRP and ESR for the evaluation of disease activity, and Matrix Metalloproteinase-3 (MMP-3) as an indicator of the degree of synovitis. As these reflect the effectiveness of treatment, they are important in the Tight Control of disease activity. These biomarkers are also noted as “Guidance of medical care” for the treatment of Juvenile idiopathic arthritis (JIA), a pediatric rheumatoid disease. This seminar will cover the basics of biomarkers which are reimbursable under the Japanese national health insurance system and are currently being utilized in Japan, along with presenting some of the evidences that has been published in recent years. In addition, the MDMA scoring system which shows high correlation with RA disease activity and has been used in the United States will also be covered.

**LS4**

Nurse education for total care of rheumatoid arthritis
Mie Fusama
Nursing Department, NTT West Osaka Hospital

Conflict of interest: None

Rheumatoid arthritis (RA) therapy has made dramatic progress with the spread of MTX and biologics, and the need for total care by nurses has increased. Total care is indispensable in order to improve QOL so that patients can receive optimal treatment and live their own lives while aiming to achieve remission. Total care for RA that nurse think about is as follows: · As a medical staff, aiming to maximize the treatment effect while considering the physical, psychological and social aspects of the patient · Stay closer to the patient who lives everyday while suffering from diseases, improve the quality of medical care while sharing goals with the patient · We need to provide information (about diseases, treatment, side effects, etc.) that patients can understand their illnesses and can make “ Shared decision making” with medical staff. Self-management guidance is also important. In order to alleviate the patient’s anxiety and to make better communication, we should acquire the basic attitude (such as listening comprehension and empathic understanding) necessary for psychological support. However, in reality, nurses themselves often find it difficult to master and practice these diverse tasks. Therefore, comprehensive nurse education from patient assessment to treatment / self-management, monitoring and follow-up is necessary. In this seminar, we will consider current situation, issues and perspectives, including the activities of Asia-Pacific Initiative for Rheumatology Nurse Education (ASPIRE), which we are collaborating with Asian countries on nursing education to support total care of RA.

**LS5**

Early diagnosis and evaluation of the disease activity for systemic sclerosis -Where are we and where are we going? -
Hidekata Yasuoka
Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine

Conflict of interest: None

Hidetaka Yasuoka Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine Systemic sclerosis (SSc) is a systemic fibrotic disease characterized by microvascular injury and autoantibody production. In usual wound healing, the process proceeds as follows; 1) injury as a trigger, 2) succeeding infiltration of immune cells to the lesions, 3) tissue damage and repair, and 4) healing or regeneration of the tissue. However, the healing step is insufficient or abnormal, it will go to 5) residual of damage and remodeling. In patients with SSc, most of the cases were diagnosed during the course to the phase 5, and the causality of SSc can be explained by the abnormality of any of these steps. Thus, it is easy to understand that less patients are detected at the phase 2, inflammatory phase. And also, evaluation of disease activity is difficult, since the process of damage and repair is mixed in phase 4. Moreover, since SSc is a systemic disease with multiple organ involvements, remodeling process of each organ is different, which makes complicate to evaluate the “systemic” activity of the disease. There is no available treatment to halt the process of fibrosis or remodeling and prognosis of SSc is still poor. Therefore, the trial for the development of novel treatment approach is an urgent and important issue in SSc. Thus, I would like to discuss the approach for early detection of SSc to improve the prognosis, and evaluation methods for the disease activity to establish better outcomes for clinical trials. For now, it is important for us to recognize that there are 2 disease types, limited-cutanous and diffuse-cutanous SSc, which of these have different natural courses. And then, we should be aware of the early signs for SSc, referring the 2013 new classification criteria for SSc, which might be clues to reach the early diagnosis of SSc. For evaluation of disease activity of SSc, modified Rodnan skin score is still useful. Including the information presented, these points will be discussed in this session.

**LS6**

IGRA practice in rheumatoid arthritis
Shigeto Tohma
Department of Rheumatology, National Hospital Organization Tokyo National Hospital

Conflict of interest: None

Infliximab (IFX) was approved and reimbursed for Crohn’s disease (CD) in 2002 and for Rheumatoid arthritis (RA) in 2003. Since then, a variety of Biologics has been clinically developed for inflammatory diseases such as inflammatory bowel disease (IBD) and psoriasis with better outcome. At the same time these drugs usage has increased the opportunistic infection risk such as tuberculosis due to their immunosuppressive nature. This risk has been strongly informed via “Biologics practice guideline” and “Biologics and Respiratory disease, practice guideline”, insisting the importance of thorough evaluation by quaternary, chest X-ray, IGRA/TST. Thanks to these efforts TB SIR has been decreasing in RA with slight increase at the early phase. In IBD and psoriasis TB development has also been well controlled. The newly diagnosed TB case number has been decreasing down to 13.9 in 100,000 in 2016. The characteristic feature of TB case is increasing number of TB development from latent TB infection (LITBI) among elderly people those were TB infected at their younger age. These people are likely to develop active TB due to age associated weak immune status and immunosuppressive treatment for their underlying disease. It is necessary to design TB treatment plan for these patients considering the following points; 1. Extrapulmonary tuberculosis is more often, difficult and tend to delay the TB diagnosis. 2. The underlying disease is likely re-activated during prior TB treatment. 3. IRIS likely occurs when stop Biologics treatment. Therefore, it is critical to fully screen LTBI by X-ray and IGRA and perform prophylaxis TB treatment if necessary. Also important is to closely monitor an early symptom of TB development during the course of Biologics by distinguishing inflammation by underlying disease progression from TB infection/reactivation. To access the risk/likeliness of TB development from LTBI some predictive markers has been investigated such as neutrophil, CD8 count, lymphocyte subset analysis, and Monocyte/Leukocyte ratio. The clinical utility of these predictive marker has to be investigated if it works well under immunosuppressive therapy.

**LS7-1**

Baricitinib overturn the treatment concept of RA! ~Musculoskeletal ultrasound depicts the novel utility of BAR in clinical practice~
Kenta Misaki
Department of Rheumatology, Kita-Harima Medical Center

Conflict of interest: Yes

The clinical indication of Biologics (Bio) for Rheumatoid arthritis (RA) has caused the paradigm shift, and it had also approved under the
medical insurance in Japan since 2003. Bio make it possible to improve the RA prognosis as a clinical remission, however we often encounter the cases unfortunately led to drastic radiographic destruction after achieving clinical remission, and those refractory to multiple Bio. It is easily suggested that good outcome is only brought to the RA patients triggered by particular cytokine as we expected because the target of Bio is just for one-focused cytokine. As it is still difficult to apply the tailored medicine for RA in clinical setting, the treatment of Bio sometimes produce a poor cost-effect result and unexpected bone destruction during the Bio switching. JAK inhibitor (JAKi) induced the efficacy for RA patients under the mechanism of working in upper RA inflammatory pathway, inhibiting the multiple cytokine signaling. JAKi has been also available in Japan since 2013, it is noteworthy JAKi was approved all the same time in all over the world. Now, 2 kinds of JAKi including Baricitinib (BAR) are focused as one of the novel therapeutic items. RA treatment strategy is not only the administration of Bio/JAKi, but also the achievement of sustained radiographic remission. One of the useful procedures for monitoring the RA disease activity is musculoskeletal ultrasound (MSKUS). Recently MSKUS is shared the spotlight as a pivotal non-invasive examination tool for Rheumatologist as well as Bio/JAKi. The collaboration between MSKUS and Bio/JAKi will enable to early diagnosis, early treatment induction, early achievement of remission and finally reduce/withdraw various DMARDs. I am going to introduce the utility of BAR and MSKUS in dairy clinical setting with current topics and evidence in this session.

LS7-2 Expectation of Baricitinib in the treatment of rheumatoid arthritis
Kensuke Oryoji
Center for Rheumatic Diseases, Matsuyama Red Cross Hospital
Conflict of interest: Yes

Baricitinib is the second JAK inhibitor approved in Japan. The mechanism of action is inhibition of JAK 1/2 and is different from Tofacitinib previously approved with or without JAK 3 inhibitory action. IL-6, IFNγ and GM-CSF are representative of cytokines that are particularly well inhibited by JAK 1/2 inhibition. The importance of IL-6 in rheumatoid arthritis is obvious. Because the disease activity of rheumatoid arthritis correlates with the amount of macrophages in joints, we believe that it is attractive to be able to selectively inhibit IFNγ and GM-CSF, cytokines that are on-demand group. JAK inhibition seems to be well balanced to moderately suppress cytokines such as type 1 IFN, which is thought to be difficult to suppress in existing biological preparations. In this presentation, we outlined the pathological condition of rheumatoid arthritis, autoantibody and temporal phase and clinical trials of Baricitinib (RA-BEAM; noninferiority to adalimumab, RA-BEACON; efficacy on bio failure, RA-BEGIN; efficacy on almost sero-positive early RA) and the expectation for the future will be described.

LS8 Selectivity and Specificity in the treatment of RA
John D Isaacs
Institute of Cellular Medicine, Newcastle University Faculty of Medical Sciences
Conflict of interest: Yes

Following recent advances in the understanding of downstream signaling pathways, janus kinase (JAK) inhibitors have been developed as a novel approach for treating rheumatoid arthritis (RA). JAK inhibition constitutes the first major breakthrough since the advent of biologic DMARDs. As with tumor necrosis factor inhibitors, we must appreciate that JAK inhibitors have unique pharmacokinetic, pharmacodynamic, and clinical characteristics that have important implications for efficacy and safety. We will explore the JAK isoforms and their functional roles in inflammation, define JAK selectivity, and consider the potential advantages and disadvantages of inhibiting one JAK over another.

LS9-1 Recent progress in the treatment of ANCA-associated vasculitis
Masayoshi Harigai
Department of Rheumatology, Tokyo Women’s Medical University
Conflict of interest: Yes

Primary goal of treating patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis is optimizing health-related quality of life through abrogating disease activity and minimizing accrual of disease-related and treatment and complications-related damage. The treatment is consisted of remission-induction and remission-maintenance therapies. According to the 2017 Clinical Practice Guidelines for ANCA-associated Vasculitis published in February 2017, the standard remission-induction therapy for microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) is glucocorticoid (GC) plus cyclophosphamide. Rituximab (RTX) can be an alternative treatment if an attending physician is an expert with enough knowledge and experience for treating vasculitis. Efficacy of RTX for MPA and GPA has been established by RAVE study and RITUXVAS study, but evidence is still limited and a prospective observational study is in progress by JVVAS. Almost all of patients achieve remission by remission-induction therapy, but majority of them relapse unless they receive remission-maintenance therapy. Standard remission-maintenance therapy is low-dose GC and azathioprine (AZA), but a better regimen has been investigated by various clinical trials. In MAINRITSAN2 trial where GC plus RTX was compared with GC plus AZA in patients with MPA and GPA, relapse rate of RTX by Month 28 was significantly lower than that of AZA, and serious adverse events were similar. MAINRITSAN2 trial compared fixed and on-demand treatment with RTX in patients with MPA and GPA; no difference was observed in relapse rate by Month 28 between the two treatment arms, and the on-demand group received significantly less RTX than the fixed treatment group. I would like to take the advantage of this opportunity to organize most recent evidence of treatment for MPA and GPA to consider future treatment strategy.

LS9-2 Recent advances in the management of Takayasu arteritis
Mitsuaki Isobe
Sakakibara Heart Institute
Conflict of interest: Yes

The clinical guideline for management of vasculitis syndrome had been revised and published in 2018. The diagnostic accuracy of Takayasu arteritis has been greatly improved based on the development of imaging modalities including CTA and MRA. 18F-FDG-PET is useful for diagnosing the extent and degree of inflammation. As for treatment corticosteroid is the first line immunosuppressive agent and effective to subside inflammation. However, more than 60% of patients show recurrence during the tapering of corticosteroid. Various agents have been used for the second line immunosuppression. Regarding the utility of tocilizumab, Steroid dose reduction can be achieved in about 80% of patients under tocilizumab coverage. One problem is the diagnosis of recurrence during tocilizumab treatment since CRP does not show elevation even in the presence of inflammation. Precise clinical and physical assessment is required for detection of recurrence during tocilizumab treatment.

LS10 Update on Therapeutic Approaches for Myositis Associated with Interstitial Lung Disease
Takahisa Gono
Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine
Conflict of interest: None

Polymyositis/dermatomyositis (PM/DM) is a autoimmune disease, characterized by inflammation and progressive weakening of the skeletal muscles. Skin rash, arthritis, interstitial lung disease (ILD), and dermatomyopathy are also accompanied as extumuscular manifestations in patients with PM/DM. ILD is one of the leading causes for mortality in pa-
tients with PM/DM. Thus, physicians need to manage patients with PM/DM-assoicated ILD (myositis-ILD) appropriately in clinical practice. Clinical courses and response to treatment are highly variable in patients with myositis-ILD. The most useful and reliable predictor for treatment response and prognosis is the myositis-specific autoantibodies (MSAs).

Anti-MDA5 and anti-ARS antibodies are strongly related to development of myositis-ILD. Patients with anti-MDA5 usually present with clinically amyopathic DM (CADM). They frequently develop rapidly progressive ILD (RP-ILD). Thirty percent of them die due to respiratory failure related to RP-ILD in despite of intensive immunosuppressive therapy. On the other hand, patients with anti-ARS present with PM, DM, or CADM. They develop ILD gradually, from several months to six months. Although initial response to treatment with corticosteroid is good for myositis-ILD, eventually, supplement of oxygen therapy is required and/or acute exacerbation of ILD develops during long-term observation in some of patients with anti-ARS. Physicians should plan a treatment strategy in each patient with myositis-ILD, based on comprehensive evaluation of predictive prognostic factors such as age, progressive speed and extent of ILD, partial pressure of oxygen in arterial blood, forced vital capacity, serum biomarkers including CRP, ferritin and KL-6, and MSAs. I would like to give a lecture regarding update on therapeutic approaches for myositis-ILD, showing the results of postmarketing surveillance of the safety and effectiveness of tacrolimus in Japanese patients with myositis-ILD.

LS11
Early diagnosis and treatment of ssc-associated pah
Masato Okada
Immuono-Rheumatology Center, St. Luke's International Hospital

Conflict of interest: None

Connective Tissue Disease associated Pulmonary Arterial Hypertension (CTD-PAH) is a major manifestation of Anti-Nuclear Antibody associated Syndromes, such as systemic sclerosis, mixed connective tissue disease, systemic lupus erythematosus, dermatomyositis/polymyositis, Sjogren's syndrome. Early diagnosis and treatment is crucial to improve the outcome and prompt upfront combination or rapid sequential introductions of PAH specific medications including Sildenafil has become standard. Systematic screening method of CTD-PAH and treatment with immunosuppressant and pulmonary arterial dilators are discussed based on cases on Sildenafil and other regimens.

LS12-1
Strategy of pregnancy in patients with rheumatoid arthritis
Atsuko Murashima
National Center for Child Health and Development

Conflict of interest: Yes

“A sound baby in a sound maternity” is a creed of obstetric medicine. The importance of pre-conception care is becoming important as age of pregnancy is becoming high. It is important that women with chronic diseases are required further premedication care to maintain their remission status with drugs that are not harmful to both mothers. However, considering the risk of pregnancy complications such as pregnancy deterioration and pregnancy hypertension syndrome, it is important to take medical treatment with a policy that “treatment of primary disease should be given priority, but not pregnant. In pregnancy of patients with rheumatoid arthritis, it is most important to keep them for pregnancy while suppressing disease activity for fertility, maintaining remission during pregnancy, and good results of pregnancy. So, the usage strategy of disease modifying anti-rheumatic drugs is essential. Most of the labeling of medicine drugs for the pregnant women / lactating women are written with reference to reproductive experience results, but there are limits to applying the results of animal experiments to humans. It is appropriate to judge whether or not it is safe to use it in human experience, but epidemiological research outcome in Japan is hard to be reflected in the labeling. FDA classification has been used in Japan, but in 2015 this classification method was shifted to the description formula. In Japan as well, the description method of the labeling was changed for the first time in 20 years. Under such circumstances, I believe that the obstetrics and gynecologic clinical practice guideline will be a reliable tool. I will explain the method of safety evaluation during pregnancy / breast feeding and the concept of medication treatment based on it.

LS12-2
Treatment strategy of Rheumatoid Arthritis in WoCBA (Women of Child-Bearing Age) patients
Hiroaki Dobashi
Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University

Conflict of interest: None

The treatment strategy of Rheumatoid Arthritis (RA) had greatly advanced with the development of many therapeutic drugs including csDMARDs, bDMARDs, and tsDMARDs. A lot of efficacy and safety evidence for such drugs has been established, which also contributed to this advancement. However, the RA treatment strategy should be decided for individual patients based on not only his/her disease activity, but also other factors such as comorbidities, as stated in the overarching principles of 2016 EULAR Recommendation for RA Treatment: “Treatment of decisions are based on disease activity and other patient factors, such as progression of structural damage, comorbidities and safety issues.” This is also very important for WoCBA (Women of Child-Bearing Age) patients. It is necessary to pay much attention when deciding a treatment strategy for a WoCBA patient because of various characteristics they are associated with. A treatment strategy for a WoCBA patient should be decided individually for each of the three pregnancy phases (preconception, during pregnancy, after pregnancy). This talk will present typical characteristics and necessary considerations in WoCBA patients and a proposal for the treatment strategy in such patients. As a result, this talk aims to discuss about “how to support RA patients who hope to become a mother.” A patient wish is written down in the ACR draft guideline of reproductive health of ACR as “My rheumatologist knows me better than gynecologist.” I hope this seminar will be helpful for the audience to meet this wish of WoCBA patients.

LS13-1
Significance of Treatment Continuation Rate in Drug Therapy for Rheumatoid Arthritis: Review of Etanercept
Yuji Hirano
Department of Rheumatology, Toyohashi Municipal Hospital

Conflict of interest: Yes

In Japan, Etanercept (ETN) was approved for RA in 2005. Some studies have provided answers to a wide range of clinical questions regarding ETN. The TEMPO trial showed suppression of disease activity and prevention of joint destruction in patients with long-standing RA. The COMET trial showed suppression of disease activity and prevention of joint destruction in patients with disease duration less than 2 years after onset. The PRESERVE trial showed the effects in achieving bio-free remission and tapering BIO. Although some anti-TNF antibody drugs are associated with reduced effect due to production of neutralizing antibodies and development of adverse events, ETN has less immunogenic potential and is not associated with such concerns. ETN is effective even after anti-TNF antibody drugs are switched to ETN. Data on the incidence of adverse events indicate that ETN is associated with lower risks of serious infection and recurrent tuberculosis than other anti-TNF antibody drugs. In actual clinical practice, ETN may be characterized by its favorable long-term continuation rate. Studies using data from the European registries, such as DAMBIO, DREAM, RABBIT and SCQM-RA, it have demonstrated that ETN is associated with a better long-term continuation rate than anti-TNF antibody drugs. In 209 patients who initiated ETN therapy at least 10 years earlier at facilities affiliated with the Nagoya University, the long-term continuation rate was 40.5% at 10 years. In the other countries, registry studies following patients for 10 years or more have revealed favorable continuation rates for ETN therapy. The treatment continuation rate appears to reflect a combined measure of efficacy and safety. In this seminar, the clinical studies and actual clinical data on ETN are reviewed, and the significance of the continuation rate of BIO therapy is discussed.
LS15-2
Biosimilar will bring about new treatment option
Hiroaki Matsuno
Matsumo Clinic for Rheumatic Diseases, Toyama, Japan

Conflict of interest: Yes

The therapeutic effect of biologics in rheumatoid arthritis (RA) is excellent, but the cost is prohibitive, with biosimilar versions costing much less. We conducted a phase 3 study of etanercept biosimilar (ETN-BS) in Japan and the Republic of Korea (ROK). When ETN-BS was compared with etanercept-reference product (ETN-RP) in a phase 1 study, the total area under the curve (AUC: 90% confidence interval [CI], 0.87 to 1.06) and maximum drug concentration (Cmax: 0.92 to 1.13) were within the acceptable range of equivalence (0.80 to 1.25). To unify study conditions between the two countries, the maximum dose of methotrexate (MTX) was set at 16 mg/week; however, in the ROK, as only 2.5 mg MTX tablets were available, the maximum dose was set at 15 mg/week. The primary endpoint was change in Disease Activity Score 28-Erythrocyte Sedimentation Rate (DAS-ESR) at week 24 after start of treatment. We determined the acceptable range of comparability with ETN-RP as >0.6 to 0.6, because the European League against Rheumatism criteria state that a change > 0.6 in DAS28-ESR is clinically relevant. The target sample size was calculated backward from this acceptable range, using a simulation. Thus, the success rate of the study would be 90% or higher when the two-sided 95% CI of the between-group difference and the point estimate of the difference between the Japanese and Korean groups was within the acceptable range of equivalence. A comparative study of 296 patients (148 in each group) would be needed to confirm comparability using DAS28-ESR. Based on a predicted drop rate of 20%, a double-blind study protocol with 372 patients was submitted to the PMDA and eventually approved. The numbers of patients in the primary efficacy analysis set at week 24 were 164 in the ETN-BS group and 165 in the ETN-RP group. The changes in DAS28-ESR were -3.009 (95% CI, -3.198 to -2.820) for ETN-BS and -2.859 (-3.05 to -2.667) for ETN-RP, and the between-group difference was -0.150 (+0.377 to 0.078). As this was within the acceptable range of equivalence, the comparability of the 2 biologics was demonstrated. In addition, the incidence of all adverse reactions during the study period was 51.3% in the ETN-BS group and 62.0% in the ETN-RP group. Furthermore, the frequency of anti-drug antibody generation in the ETN-BS group did not exceed that in the ETN-RP group. Thus, we believe that ETN-BS can be used for RA therapy.

LS15-1
Medical economic issues of biological DMARDs in rheumatoid arthritis and future prospects
Eiichi Tanaka
Institute of Rheumatology, Tokyo Women’s Medical University Hospital, Tokyo, Japan

Conflict of interest: None

The introduction of biologics has resulted in significant advances in treatment strategies for rheumatoid arthritis (RA). On the other hand, rising healthcare costs have caused concern, placing a heavy burden on society as well as RA patients. The IORRA study has shown that RA patients’ financial burden is increasing and that direct and indirect costs associated with progression of functional impairment or decline in quality of life (QOL). This suggests that inhibiting the progression of functional impairment through aggressive control of RA may help reduce lifetime healthcare costs. Pharmacoeconomics is the scientific discipline that evaluates both the clinical benefits and economic efficiency of a drug to determine whether it is worth the cost. We have analyzed the cost-effectiveness of biologics in the treatment of RA and found that the use of biologics in Japanese RA patients is justified in the long term from a health economic perspective. These results suggest that, although biologics are expensive, their proper use in eligible RA patients may also be socially beneficial by helping maintain QOL for a long period of time and allowing patients to have a social life including workforce participation without difficulty. Under these circumstances, biosimilars for anti-TNF inhibitors have been developed with the expectation of further reducing economic burden. Biosimilars have biosimilarity (equivalence and homogeneity) to reference biological products. Approved biosimilars can be used in the same methods as reference product. Shares of biosimilars are expanding rapidly, especially in the European countries. In Japan, infliximab and etanercept biosimilars are available. Since their drug prices are approximately 60 to 70% of reference product, economic impact is expected to be large. In this Luncheon Seminar, I would like to share the medical economic issues in RA as well as the importance of pharmacoeconomics, and also discuss the future prospects for biosimilars.

LS15-2
Optimization of Biologic Treatment for Rheumatoid Arthritis
Kazuhisa Nakano
The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan

Conflict of interest: Yes

Treatment of rheumatoid arthritis (RA) has recently reached a major turning point due to the introduction of biologics targeting specific molecular aberrations, which has redefined the major treatment goals to (1) induce remission, (2) control the progression of joint destruction and functional disorders, (3) maintain remission, and (4) improve life prognosis. In Japan, 10 drugs for RA are covered by the National Health Insurance including 8 drugs with 3 different modes of action, i.e., TNF inhibitors, IL-6 receptor inhibition, and T-cell co-stimulation inhibition, and 2 biosimilars which may be regarded as generic versions of biologics. When a biologic is to be administered at our institution, a clinical pathway is utilized, thereby the patient is required to be hospitalized, a screening test including CT scan is conducted, and a fecal occult blood test and a sputum test are additionally conducted depending on the case to control adverse reactions. Thereafter, the final decision on administration is made, and the First registry is created to monitor effectiveness and safety. Meanwhile, to select a biologic, various considerations are necessary in terms of efficacy as well as safety, cost, convenience in the route and intervals of administration, etc. Based on the data from the First registry, we have studied: 1. how to quickly determine the effectiveness of the biologics, 2. possibility of dose reduction or discontinuation, 3. optimization of biologics switching, etc. I would like to present a summary of these studies and prospects for biosimilars increasingly used to offer some ideas for optimization in RA treatment.
LS16
From basic of JAKs to the JAKinibs in the clinic
Kunihiro Yamaoka
Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine

Conflict of interest: Yes

Janus kinase (JAK) is an intracellular protein that is activated immediately after the cytokine binds to the cognate receptor expressed on the cell surface. More than one JAK inhibitors have demonstrated similar efficacy to biologics, highly specific to the extracellular inflammatory cytokines. Interestingly, these two drugs belonging to two different class possess totally different mechanism of action. Biologics are highly specific to a single molecule with a long half-life and on the other hand JAK inhibitors are selective to certain JAKs, not necessarily specific with a short half-life. Thus, off-target effect should be kept in mind for JAK inhibitors. In this seminar, I will briefly introduce the basics of JAKs and how and why JAKs were targeted. In addition, I would like to discuss on what has been observed with in vitro experiments and analysis of patient specimens treated with JAK inhibitors to elucidate the mechanism of action.

LS17
Bridging the gap between patients and health care providers in Rheumatoid Arthritis with Motivational Interviewing - Making recommendations asked for by patients, and no more pushy sales
Hiroaki Harai
Harai Clinic Harai Consulting&Training Inc. Japan Association of Motivational Interviewing

Conflict of interest: None

Motivational Interviewing (hereinafter referred to as MI) is effective when proposing a new treatment method to patients in the field where new drugs are developed one after another within a relatively short period of time. Even though an effective drug is launched, it is meaningless unless patients actually try it. Healthcare professionals (HCPs) tend to simply show only the facts to their patients, or explain by saying “this works extremely well” or “the evidence is so and so “based on the viewpoint of experts. When a patient makes a decision to change the familiar treatment method to something else, it is desirable to provide information from the patient’s standpoint. Now, MI is a useful technique that strategically and intentionally brings out the feeling of the patients themselves to change. The more HCPs are the cutting edge, the more they are experts, the more they want to use new and the best treatment methods and they think it is natural for patients to follow the best treatment. If a patient does not follow the treatment, they think the patient will do so if they explain in further detail. However, the method that a HCPs teaches what they want to teach is not always useful for anyone. Offering more information to a patient who resisted when the information was given the first time would be counterproductive. If information is provided and is not appropriate for the patient’s desire to “know”, it strengthens the patient’s feeling, i.e., “I don’t want to know”. Ultimately, if a HCPs comes to feel that “this patient is stubborn and bigoted”, there is a huge gap that cannot be overcome between a HCPs and patient. What can we do to avoid creating such a gap? How can patients themselves be guided to change their behavior without using forcible guidance? I would like to talk about an overview of MI and actual clinical examples to show you that with MI you can lead the conversation with patients in constructive direction without going around and around.

LS18
Management of pain and osteoporosis of patients with rheumatoid arthritis
Isao Matsushita, Hiraku Motomura, Tomoatsu Kimura
Department of Orthopaedic Surgery, University of Toyama

Conflict of interest: Yes

In recent year, the treatment for rheumatoid arthritis (RA) has improved drastically. According to this change, disease activities of RA have been steadily decreasing. National Database of Rheumatic Disease in Japan (NinJa) showed rates of patients with DAS28 remission were 18.2% and 57.2% in 2002 and 2016, respectively. The mean of patient’s pain VAS of 2002 and 2016 were 3.6 and 2.4, respectively. Pain VAS is also gradually improved, but the tendency of the improvement slows down. Though objective indexes are improved, pain VAS, which is subjective index, is not improved enough. There are several reasons why the pain continues to exist. Subclinical inflammation and/or residual joint damage might induce pain. Many elderly RA patients who are complicated with osteoarthritis might show arthralgia. Rheumatologists identify the cause of the pain and must cure. Osteoporosis is serious complication for patients with RA. It was reported that the RA patient with the past of the vertebral fracture showed significantly higher HAQ-DI than the patient without the past history. Subanalysis of BeSt study indicated that use of bisphosphonate was independent factor of the maintenance of bone mineral density. And it was reported that frequency of fracture did not decrease though disease activity was improved. Rheumatologists have to practice dual T2T aiming at suppression of disease activity and inhibition of bone mineral density loss in order to maintain ADL and QOL of RA patients during long-term period.

LS19-1
Tremfya’s usefulness on PsA
Shigeyoshi Tsuji
National Hospital Organization Osaka Minami Medical Center

Conflict of interest: Yes

Psoriasis is the typical disease of inflammatory keratosis, and its incidence rate in Japan reach 0.34%. Psoriatic arthritis, characterized by inflammation of a joint, spondylitis, inflammation of digit, enthesitis appear in patients with RA. It was reported that the RA patient with the past of psoriasis arthritis, the RA patient with the past of ulcerative colitis, the RA patient with the past of uveitis, the RA patient with the past of vasculitis, the RA patient with the past of ankylosing spondylitis, the RA patient with the past of Behcet disease, the RA patient with the past of dermatomyositis, the RA patient with the past of CREST syndrome has higher risk of disease activity. If you can avoid exacerbation, the RA patient with the past of psoriasis arthritis, the RA patient with the past of ulcerative colitis, the RA patient with the past of enthesitis should be managed in a good way. From this point of view, we should consider that psoriasis arthritis can be managed in the same way as RA. Furthermore, psoriasis arthritis have high ratio of cardiac infarction especially in younger generation. Also, since approx. 30% of psoriatic arthritis come with spondylitis, without proceeding an appropriate therapeutic intervention at the earliest timing, it causes bony ankylosis and disturb patients’ QOL badly, therefore Rheumatologists need to consider psoriatic arthritis as one of diagnostic criteria for patients who claim chronic lower back pain or arthritis without specific cause/reason. What is the best treatment method for patients with psoriatic arthritis to obtain better QOL? Firstly, by giving patients a basic guidance of better living, exercise therapy, nutritional guidance, etc. it can improve their comorbidity related to metabolic syndrome, and this improvement will maximize an efficacy of pharmacotherapy to contribute to increase persistency rate. I consider that this is one of the key. The other treatment method is pharmacotherapy. In 2010, biological products against psoriasis/psoriatic arthritis became applicable to insurance in Japan and this fact changed the treatment method for psoriasis/PsA drastically and contributed to improve patient’s QOL. And, in 2018 Tremfya, anti-human IL-12p19 monoclonal antibody product became applicable to insurance against psoriasis/PSP as well. This addition can broaden option of pharmacotherapy. In this lecture I would like to introduce the latest knowledge of psoriatic arthritis, and positioning/possibility of Tremfya.

LS19-2
Medical care for PPP, from the view of dermatologist
Tadashi Terui
Division of Dermatological Science, Department of Dermatology, Nihon University School of Medicine

Conflict of interest: Yes

Psoriasis is the typical disease of inflammatory keratosis, and its incidence rate in Japan reach 0.34%. Psoriatic arthritis, characterized by inflammation of a joint, spondylitis, inflammation of digit, enthesitis appear in patients with RA. It was reported that the RA patient with the past of psoriasis arthritis, the RA patient with the past of ulcerative colitis, the RA patient with the past of enthesitis should be managed in a good way. From this point of view, we should consider that psoriasis arthritis can be managed in the same way as RA. Furthermore, psoriasis arthritis have high ratio of cardiac infarction especially in younger generation. Also, since approx. 30% of psoriatic arthritis come with spondylitis, without proceeding an appropriate therapeutic intervention at the earliest timing, it causes bony ankylosis and disturb patients’ QOL badly, therefore Rheumatologists need to consider psoriatic arthritis as one of diagnostic criteria for patients who claim chronic lower back pain or arthritis without specific cause/reason. What is the best treatment method for patients with psoriatic arthritis to obtain better QOL? Firstly, by giving patients a basic guidance of better living, exercise therapy, nutritional guidance, etc. it can improve their comorbidity related to metabolic syndrome, and this improvement will maximize an efficacy of pharmacotherapy to contribute to increase persistency rate. I consider that this is one of the key. The other treatment method is pharmacotherapy. In 2010, biological products against psoriasis/psoriatic arthritis became applicable to insurance in Japan and this fact changed the treatment method for psoriasis/PsA drastically and contributed to improve patient’s QOL. And, in 2018 Tremfya, anti-human IL-12p19 monoclonal antibody product became applicable to insurance against psoriasis/PSP as well. This addition can broaden option of pharmacotherapy. In this lecture I would like to introduce the latest knowledge of psoriatic arthritis, and positioning/possibility of Tremfya.
thenar, and anti thenar on the hand and the arc towards to edge, heel on the sole. Pustules eventually became crust and desquamate, sometimes it cause crack by forming inflammatory keratosis after repeating inflammatory reaction. In PPP, there are patients who have osteoarticular symptoms which is called as Palmoplantar pustulotic Arthro-Osteitis. Osteoarticular symptoms often is observed in chest rib joint, but sometimes appears in sacroiliac articulation, peripheral joint. Symptoms of PPP appears on the hand where is seen always by the others, and patients feel pain by soaking their hands with water while taking bath, doing dishes, feel pain in their sole while they walk, or feel pain in their joint if patients have osteoarthritis. This is a disease which can easily destroy QOL. Up to present, basic medical care of PPP are causal therapy such as focal infection treatment, symptomatic treatment by using external medicine, oral agent, phototherapy, or giving guidance of better living ex. quit smoking. There are only a few suitable medicine for symptomatic treatment, and it cause difficulty sometimes for medical care. November last year, Guselkumab which is IL-23p19 inhibitor approved as biologic medicine for PPP for the first time. In this lecture session, we will explain clinical pathophysiology, characteristics along with introduction of clinical test result of Guselkumab and would like to study positioning of treatment of PPP.

**LS20-1**
**Surgery for rheumatoid arthritis in the era of biological DMARDs and targeted synthetic DMARDs**
Katsunori Ikari
Department of Orthopedic Surgery, Tokyo Women’s Medical University

Conflict of interest: None

Rheumatoid arthritis is the most common autoimmune disease characterized by progressive joint damage. Clinical outcomes have improved dramatically and remission is possible for many patients because of advances in medical treatment in these 20 years. There were many reports that showed a decrease in RA-related surgical procedures. However, certain number of patients still need RA-related surgeries. Combination therapy consisting of medical treatment and surgical intervention is thought to be effective in improving the quality of life for RA patients who have joint destruction. I will show you recent trends in RA-related orthopedic surgery in Japan.

**LS20-2**
**Effectiveness of bDMARDs by analyzing big claimed data**
Katsuhiko Takabayashi 1,2
1Sanwa Hospital, 2Department of Medical Informatics, Chiba University Hospital

Conflict of interest: None

Rheumatoid arthritis is a systemic autoimmune disease with arthritis as the main symptom. The joint destruction with the synovitis progresses from the early stage. Since the irreversible physical dysfunction is caused by the joint destruction, the precise diagnosis and treatment from the early stage are necessary. Recently, in addition to the development of biologicals (bDMARDs) targeting cytokines that influence in pathogenesis and low molecular medicine targeting JAK as an intracellular tyrosine kinase, the treatment to target and maintain remissions with the conception of Treat to Target (T2T) contributed to the control for the destruction of joint structures and the functional disorders. Any drug is expected to be effective in 1st Line treatment, however it is necessary to treat with considering the difference between real world data as clinical practices used in various patients and clinical trials conducted in limited patients. CISA (Clinical Information Statistical Analysis) is the medical statistics data accumulated from the claimed data by the cooperation of 13 national university hospitals. CISA is widely utilized for clinical pharmacological research, efficacy investigation of the drug, medical needs investigation, and so on. The result is helpful for the Japanese medical treatment. and CISA as a database is useful for the people. The National Database (NDB) is stored and constructed from Japanese health insurance claims Data and specific Health checkups data and Specific health Guidance data. It is going to be used as a big database for epidemiology and clinical research as investigation for preparation, implementation and evaluation of medical cost optimization plans. In this seminar, I would like to focus on the efficacy and safety of RA treatment by analyzing these databases.

**LS21**
**Managing Remission in RA**
Paul Emery 1,2
1University of Leeds, Leeds Institute of Rheumatic & Musculoskeletal Medicine, Leeds, UK, 2Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, UK

Conflict of interest: Yes

Remission is the target of all guidelines for the management of RA. It is now more frequently achieved due to more aggressive treatment approaches and the early use of very effective drugs: a treatment strategy is now required for these large numbers of patients reaching remission. An initial trial of methotrexate with steroids is probably not optimal for all. Guidelines suggest that patients should be tapered, but there is a lack of objective evidence of which ones are appropriate. Initial studies suggested that with early use of biologics and methotrexate it was possible to stop the biologic. This will be discussed, although there is little evidence that biologics can be stopped in late disease except in specific cases. Tapering of the biologic, however, has been successful in many randomized controlled trials. One problem with remission is the lack of agreement on a definition of either remission or flare. All composite scores suffer from the disadvantage that joint counts are inaccurate when patients are close to remission. Therefore, attempts have been made to use more objective measures; these include imaging and immunological measures (in particular T-cell sub-sets). A recent study has shown that for csDMARDs seropositivity, HAQ, quality of life and presence of power Doppler are all predictive of flare on tapering, whereas for bDMARDs only low T-reggs and quality of life were predictive. Other studies have shown that sustained deep remission was an effective predictor of successful stopping of etanercept. Thus there is increasing evidence that one can predict the likelihood of individual’s flaring on tapering and stopping. These should now be tested in randomized controlled studies.

**LS22-1**
**Disease burden of psoriatic arthritis and its overcome by anti-TNF therapy**
Hideto Kameda
Faculty of Medicine, Toho University, Tokyo, Japan

Conflict of interest: Yes

Psoriatic arthritis (PsA) is the most common disease among predominantly peripheral spondyloarthritides. Patients with severe PsA experience impaired quality of life (QOL) due to mutilans joint deformity or axial joint ankylosis mimicking ankylosing spondylitis. The primary pathophysiology of PsA includes enthesis, which is believed to develop secondary synovitis, dactylitis and nail changes. And the repairing process to the micro-injury at enthesis leads to osteoproliferative changes, while osteoclast activation by the adjacent synovitis leads to bone erosion: A complicated joint structural change in PsA is likely to thus develop. Tumor necrosis factor (TNF) is one of the critical cytokines involved in the joint disease of PsA, and its neutralization by biological agents such as adalimumab (ADA) enables PsA patients to achieve the treatment goal such as remission or minimal disease activity (MDA). In ADEPT trial, patients receiving ADA showed significantly better improvement in skin and joint diseases as well as QOL examined by SF-36 than those receiving placebo. Further, patients receiving ADA showed significantly less radiographic progression defined by modified total Sharp score than those receiving placebo, and MDA was achieved in 33.3% of the ADA group, which was significantly higher than 3.2% in the placebo group. In addition, a work productivity and activity impairment (WPAI) study in the postmarketing surveillance of PsA patients in Japan demonstrated significant decrease of the overall work impairment score by ADA treatment for 24 weeks, providing an evidence supporting the benefit of ADA therapy for WPAI.
LS22-2
TNF alpha inhibitor in the treatment of ankylosing spondylitis
Yuho Kadono
Orthopaedic Surgery, Saitama Medical University

Conflict of interest: Yes

Recently, it becomes well known that spondyloarthriteps (SpA) is a kind of umbrella inflammatory disease concept including ankylosing spondylitis (AS) and psoriatic arthritis. AS involves not only sacroiliitis or spondylitis but also coxitis or enthesitis. AS exhibits inflammatory back pain which is one of the major clinical aspects, uveitis, psoriasis, or inflammatory bowel disease. Since TNFa is a major cytokine in the pathogenesis, TNF alpha inhibitor shows effectiveness in treatment of AS. We sometimes have difficulties to diagnose AS. We should distinguish it from mechanical pain or fibromyalgia. When we find out spinal involvement in images, we should distinguish it from diffuse idiopathic skeletal hyperostosis or osteitis condensans illi. If the inflammation was not well controlled, spinal fusion would progress. Spinal fusion leads to impairment of activity of daily living, ADL. The goal of AS treatment is to control disease activity monitoring BASDAI or ASDAS, to inhibit the progression of bone change, and to protect from AS-related impairements. NSAIDs is the first choice, and TNFa inhibitor would be considered when NSAIDs were insufficient.

LS23
Treatment of rheumatoid arthritis in the new era
Tsutomu Takeuchi
Division of Rheumatology, Keio University School of Medicine

Conflict of interest: Yes

The treatment of rheumatoid arthritis (RA) has made an innovative progress in the last decade. In 2010, new RA classification criteria developed by the American College of Rheumatology/European League Against Rheumatic Diseases (ACR/EULAR) were introduced which allowed for early diagnosis with higher sensitivity. In 2011, the ACR/EULAR new remission criteria for RA were proposed to establish more stringent clinical remission criteria that directly related to improvement in the outcome, prevention of joint destruction. In addition, the “Treat-to-Target” strategy has been recognized globally and, the treatment recommendations were updated in 2014, and also in Japan. Furthermore, the EULAR recommendations were updated in 2016. These changes that occurred after 2010 are the most drastic in the history of RA treatment. These changes are the results of the review of the overall treatment flow, “diagnosis-treat to target-clinical remission-improvement in outcome”, in order to preserve long term quality of life of the patients. Denosumab is a fully human IgG2 monoclonal anti-RANKL antibody that inhibits the binding of RANKL to RANK. It suppresses bone resorption by inhibiting the generation, function and survival of osteoclasts. In Japan, denosumab has been applied in clinical practice as an anti-osteoporotic agent since 2013. Furthermore, in 2017, denosumab was approved for the inhibition of the progression of bone erosion associated with RA, thereby a new treatment option targeting joint destruction has become available in addition to csDMARDS, bDMARDs and tsDMARDs. This session will review the role and action of denosumab as the new treatment option in RA treatment, including the results of a long-term observational study in Japanese patients.

LS25
Reconsidering remission induction and maintenance of therapy in patients with rheumatoid arthritis
Isao Matsumoto
Division of Rheumatology, Department of Internal Medicine, University of Tsukuba

Conflict of interest: Yes

Recent therapies for rheumatoid arthritis (RA) were dramatically progressed continuously, we need to diagnose earlier, and intensive therapy aimed to clinical remission and its maintenance are strongly recommended especially in active RA. A lot of biologics targeting inflammatory cytokines (TNFα and IL-6), T cells-co stimulator and JAK are available in Japan. From the view of the effective therapy with new molecular, immunological and genetic studies, the etiology of RA has been reconsidered. But we have faced primary and secondly disabled to these drugs, and comorbidities in patients with RA limits the choice of effective drugs due to conceivable side effects. Eight kinds of biologics (plus two bio similars) are approved in Japan, and five out of eight are TNF inhibitors. In this seminar, we discuss remission induction and maintenance regulated by TNF inhibitors which have history of more than 15 years, and up-dated mechanisms by TNFα regulation in arthritis. In addition, we also discuss about new biomarker of RA such as citrullinated proteins in serum, recently identified by us, for monitoring disease activity, diagnosis and pathogenesis.

LS26-1
Adult hypophosphatasia: a disguised adult bone metabolic disease in rheumatic outpatients
Nobuaki Ito
Division of Nephrology and Endocrinology, The University of Tokyo Hospital

Conflict of interest: None

Hypophosphatasia: HPP is a bone metabolic disease with impaired bone calcification due to ALPL mutation. While neonatal severe type of HPP shows devastating bone malformation, adult HPP develops chronic bone/muscle pain, recurrent and prolonged pseudofracture/fracture, muscle weakness and fatigue. The most prevalent pathogenic mutation of ALPL: c.1559delT is recognized at one in 480 in Japanese. Heterozygotes of pathogenic mutations are seen at one in 100–200. In Europe, the prevalence of symptomatic adult HPP is reported to be one in 6370. The screening method for osteomalacia including HPP simply consists of serum ALP, Pi, Ca, Alb. When serum ALP is under low-normal range in

reactive lymphocytes. Infliximab, the first anti-TNFα antibody approved in Japan for RA, and other biological agents have contribute to high clinical efficacy and caused paradigm shift in RA treatment. These drugs are highly efficacy, but they often cause infection diseases and respiratory complications, resulting in the difficulty to continue RA treatment. Therefore, infection management in RA is critical to improve patient outcomes. Tuberculosis patients were increased rapidly in the initial administration of anti-TNF treatment, for whom latent tuberculosis (LTBI) reactivation were strongly suspected. Therefore, LTBI screening and a primary prevention with INH before administration of anti-TNF inhibitor became the urgent needs, after that prophylactic treatment with INH is effective for LTBI suspected patients. Interferon-γ release assay is very useful in LTBI screening, but needs comprehensive judgment, including that of image findings and interview, are required for interpretation of the result (negative/positive/indeterminate/invalid) under immunosuppressive treatment. As per a PMS on actual use of biologic drugs, infections, including bacterial pneumonia, Pneumocystis pneumonia, and herpes zoster, along with tuberculosis, occurred at a certain rate. The Department of First Internal Medicine, University of Occupational and Environmental Health, Japan (UOEH), has planned and implemented criteria for primary prevention based on screening conducted at introduction of registry (FIRST registry) of RA patients who introduced biological drugs and actual condition survey of infections, and has increased effects on onset inhibition. Better treatment outcomes will be obtained through proper management of them.

LS24
Management of Infections and Respiratory Complications That Rheumatologists Should Know - Practical side of Diagnosis, Treatment, and Prevention -
Kazuyoshi Saito1,2
1Center for Rheumatic Disease, Tobata General Hospital, 2The First Department of Internal Medicine, University of Occupational & Environmental Health

Conflict of interest: None

Autoimmune diseases such as rheumatoid arthritis (RA) are treated with anti-inflammatory and immunosuppressive drugs to normalize self-
symptomatic patients or in normal range in existence with overt pseudo-
fracture/fracture, the genetic test for ALPL should be considered. When
the adequate diagnosis of adult HPP is made, Asfotase Alpha is useful to
improve the symptoms in qualified patients. However, most adult HPP
patients who visited rheumatologists or orthopedists complaining above
mentioned symptoms were misdiagnosed as having rheumatoid arthritis,
fibromyalgia, polymyositis, ankylosing spondylitis, primary osteoporosis,
plantar fasciitis and so on, because recognition rate of this disease among
rheumatologists or orthopedists is still very low and pseudo-fracture is of-
ten elusive in X-ray imaging. After all, most of these adult HPP patients
lose opportunities to be correctly diagnosed and adequately treated.
Meanwhile, in adult HPP patients like other osteomalacia patients, the use
of bisphosphonates and the other bone antiresorptive drugs is practically
contraindicated as this could develop more atypical fractures in these pa-
tients. Furthermore, intensive physical therapy itself could also cause
pseudo-fractions. Therefore, patients presenting chronic bone/muscle
pain, pseudo-fracture/fracture and osteoporosis should be screened for HPP
and hypophosphatemic osteomalacia in order to avoid misguided medical
and physical therapy.

LS26-2
Consideration of adult type hypophosphatasia from the viewpoint of
a rheumatologist
Kenji Yoshida
Immu-no-Rheumatology Center, Matsuyama Red Cross Hospital
Conflict of interest: None

Have you ever heard of a disease called hypophosphatasia (HPP)? While awareness of this disease has been increased among obstetricians and
pediatricians, HPP is unknown by physicians in specialties for adult
patients. HPP is an inherited metabolic bone disorder caused by de-
creased alkaline-phosphatase (ALP) activity due to mutations of the
ALP gene that encodes ALP involving bone mineralization and as a re-
sult, skeletal, muscular, and dental manifestations are developed. Addi-
tionally metabolic disorders of calcium pyrophosphate cause ectopic cal-
cification which can lead to pseudogout. On the one hand the majority of
patients with HPP in Japan have been detected in newborns and juveniles,
on the other hand patients who onset HPP in adulthood, called adult form
of HPP, have rarely been diagnosed. This is possibly related to low
awareness of the disease among physicians who may encounter adult
HPP patients. HPP in adult population may get overlooked because symp-
toms and severity vary among patients. It is also known that adult
patients with HPP suffer from unexplained systemic pain, joint pain,
musculoskeletal pain, muscular weakness, chondrocalcinosis and stress
fractures, which impairs their ADL and quality of life. Therefore rheuma-
tologists and orthopedists would have opportunities to see HPP patients.
Once HPP is aware, it can be relatively easily suspected from medical
history and low ALP activity and diagnosis is confirmed by gene muta-
tion analysis. We present a case of 69 years old male diagnosed as HPP,
particularly the process of diagnosis from the perspective of a rheumatol-
ogist.

LS27
Evolution of IL-6 Inhibition therapies in rheumatoid arthritis-Sari-
lumab, a fully human monoclonal antibody against IL-6 receptor-
Motomu Hashimoto
Department of Advanced Medicine for Rheumatic Diseases, Kyoto Uni-
versity
Conflict of interest: Yes

IL-6 is one of the key cytokines involved in both autoimmunity and
inflammation of rheumatoid arthritis (RA) pathology. IL-6 inhibitors not
only inhibit bone destruction but also improves the subjective symptoms
of RA patients, so it shows excellent efficacy and continuity rate in clini-
cal practice. There are various methods for inhibiting IL-6 signaling, such
as IL-6 inhibition and IL-6 receptor inhibition, classical IL-6 signaling
inhibition and IL-6 trans-signaling inhibition, or gp130 and Jak-Stat path-
way inhibition. Inhibition of the IL-6 receptor is one of the most effective
methods among them. In order to “evolve” the bDMARDs by obtaining
the antibody with higher affinity and lower immunogenicity, various at-
tempts have been made including the phage-display method or immuniz-
ing transgenic containing human immunoglobulin genes. Sarilumab is a
“fully human” monoclonal antibody that targets the IL-6 receptor. Sari-
lumab is a so-called “hybrid” bDMARDs that inherited functional char-
acteristics of IL-6 receptor inhibition from tocilizumab with manufactur-
ing method inherited from Golimumab. It is welcome that now we have a
second option to inhibit IL-6 signaling by bDMARDs in RA. In this pre-
sentation, the role of IL-6 in RA pathology and the history of “evolution”
of therapeutic methods to inhibit IL-6 signaling will be reviewed, with
the introduction of therapeutic strategy using Sarilumab in clinical prac-
tice.

LS28-1
Considering the positioning of Iguratimod from its pharmacological
action
Kosuke Ebina
Graduate School of Medicine, Department of Orthopaedic Surgery, Osak-
ka University
Conflict of interest: Yes

It has been confirmed that Iguratimod (IGU) exhibits unique pharmaco-
logical actions as follows. In vitro. 1. IGU suppressed TNF-α produc-
tion from mouse and rat macrophages when stimulated with zymosan or
lipopolysaccharide (LPS), and inhibited inflammatory cytokines produc-
tion such as TNF-α, IL-1β, IL-6, IL-8 and MCP-1 upon stimulation of
human macrophages with LPS. 2. In the clinical blood concentration at
human administration, IGU suppressed IgG production from B cells as
well as methotrexate (MTX). 3. IGU suppressed the production of IL-6,
IL-8, IL-17, RANKL, MMP-3 upon stimulation of human RA synovial
with TNF-α, IL-1 and IL-6. 4. IGU suppressed RANKL-induced
differentiation of RAW264.7 cells into osteoclasts, and promoted differ-
etiation of osteoblasts in cooperation with Runx-BMP-2. Based on these evi-
dences, IGU may be effective not only in suppressing inflammation of
arthritis but also in suppressing bone and joint destruction. In vivo 1. IGU
in corporation with MTX suppressed arthritis and bone-joint destruction
in collagen-induced arthritis of rats. 2. IGU reduced the combined dose
of glucocorticoid by suppressing macrophage migration inhibitor factor
(MIF) in autoimmune disease model mice. 3. IGU inhibited osteoclast
differentiation and bone loss in postmenopausal osteoporosis model mice.
4. IGU improved the pain threshold of the sciatic nerve entrapment model
rat. Based on these evidences, IGU is expected not only to protect bone
joints from destruction, but also to reduce concomitant glucocorticoid
dosing and to improve pain of RA. Taken together, IGU can be adapted to
patients who have difficulty in using sufficient amount of MTX, diffi-
culty in controlling pain, high RF value, high risk of joint destruction
progression, and difficulty in reducing glucocorticoid dosing. Further de-
velopment of clinical evidence and application is expected in the future.

LS28-2
New development of RA treatment with csDMARDs ~ Iguratimod~
Masato Okada
Immu-no-Rheumatology Center, St. Luke’s International Hospital
Conflict of interest: Yes

In recent years, there is no doubt that biologic disease modifying an-
ti-rheumatic drugs (bDMARDs) have reached their peak in rheumatoid
arthritis (RA) treatment. Although bDMARDs are very useful agents,
their usefulness is supported by an appropriate combination with conven-
tional synthetic disease modifying anti-rheumatic drugs (csDMARDs).
Iguratimod (IGU) is one of the csDMARDs with anti-inflammatory and
immunomodulatory actions. It suppresses production of cytokines such as
IL-β, TNF-α, IL-6, IL-8, and also immunoglobulin. In Japan, it has
been used for patients with RA especially in early stage, its importance in
clinical practice is increasing. In past randomized control studies, the ef-
cicacy of IGU has been demonstrated, but its tolerability is not clearly
known. Therefore, we conducted a retrospective study on 456 patients
who received IGU. In this study we examined the tolerability of IGU in
clinical practice and the relationship between IGU retention rate and
complications such as malignancy, tuberculosis infection and interstitial
lung disease. We examined the reasons for termination for patients who

discontinued IGU, the main reasons for discontinuation due to adverse events were renal damage 22.8% (26/114), liver dysfunction 22.8% (26/114), gastrointestinal disturbance 18.4% (21/114), etc. However, the extent of these adverse events was mild and quickly recovered after discontinuation of IGU administration. In addition, when examining whether or not there is a difference in retention rate of IGU depending on the presence or absence of complications such as malignancy, tuberculosis, and interstitial lung disease, no significant difference was observed. In conclusion, IGU shows adequate considerable retention rate and good tolerability in clinical practice.

LS29-1
Importance of quantitative evaluation of quality of life in patients with systemic lupus erythematosus and usefulness of Japanese LupusPRO as a disease-specific instrument for measuring quality of life
Mitsuyuki Inoue
Department of Nursing, Hyogo University of Health Sciences

Conflict of interest: None

Symptoms of systemic lupus erythematosus (SLE) may present in various way and are difficult to predict. These not only have negative impacts by restricting daily life functions and interpersonal relationships with others, but can also interfere with life events such as school attendance, employment, pregnancy, and childbirth. SLE patients experience continually declining health even when they proactively protect themselves against ultraviolet rays and avoid fatigue. It is also difficult for others to understand the effects of SLE patients. The sum of these issues decreases SLE patients’ quality of life (QOL). A previous study found QOL of SLE patients was difficult to measure with conventional QOL-related instruments. However, the Japanese LupusPRO (Inoue et al., Lupus, 2017), a specific QOL questionnaire for SLE, was developed. This enables measurement of QOL in SLE patients. The original English LupusPRO (Jolly et al., Smin Arthritis Rheum., 2012) is a patient-reported outcome questionnaire for measuring 12 aspects of QOL of SLE patients. That original has been translated into many languages and international comparisons are possible. In this seminar, we will examine the importance of quantitative evaluation of QOL in SLE patients and the usefulness and specific tasks of the Japanese LupusPRO, based on clinical trial data and interviews with SLE patients.

LS29-2
Long-term management of SLE patients to improve the quality of life
Nobuyuki Yajima
Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

Conflict of interest: Yes

The prognosis for systemic lupus erythematosus (SLE) is improved, and the patient’s quality of life (QOL) is garnering attention. The goal of the treatment is to be able to be conscious of the QOL of patients twenty to thirty years ahead. Not only organ failure of SLE, but the side effects of drugs, anxiety about diseases, and deviations from women’s lifestyles are all related to the patient’s QOL. Organ failure of SLE is affected by the severity of the organ failure and the number and degree of relapse; it is essential how can prevent the flare. While there is too much treatment to be aware of the relapse prevention, the risk of the occurrence of side effects of the drug rises, the Treat to Target recommendation, which was published in 2014, mentions corticosteroid tapering and adjustment of immunosuppressive agents. In the quality indicator that created in 2009, modification of corticosteroids and immunosuppressive agents when more than PSL10 mg was described. Also, the criteria for remission, such as LLDAS definition and DORIS definition, are being discussed, and while long-term management is being paid attention, it is still up to each physician where to set the goal goals in real clinical. In this lecture, I will talk about the Treat to Target recommendation with SLE, particularly appropriate corticosteroid dose, steroid tapering, and long-term management to prevent flare. In addition, I will introduce our pregnant women management in our department for maternity outpatient, and I would be more than happy if my speech could be of some reference to you all. The PLEASURE-J Study, which is a registry of SLE, is also introduced. It is the first disease Registry of ICR, and it collects the information of SLE patients at 6-40 years old and plans to expand to facilities nationwide from April 2019. Features of this registry are that patient-reported outcome (PRO), such as Lupus Pro, SF12, sleep, exercise is included abundantly. It will be a good opportunity to pay attention to the importance of the QOL of SLE.

LS30
The management of connective tissue disease associated pulmonary arterial hypertension - How will it have changed after WSPH2018? -
Masaru Kato
Department of Medicine II, Hokkaido University Hospital

Conflict of interest: Yes

The poor prognosis of connective tissue disease associated pulmonary arterial hypertension (CTD-PAH), particularly that of systemic sclerosis associated PAH (SSc-PAH), is one of the issues to be solved in the management of rheumatic diseases. Early diagnosis and treatment using a detection program have been shown to be the most effective way to improve the prognosis of SSc-PAH. In World Symposium on Pulmonary Hypertension 2018 which was held in Nice, pulmonary hypertension was suggested to be redifined from mean pulmonary arterial pressure (mPAP) of ≥25 mmHg to that of >20 mmHg. Moreover, SSc patients with mPAP of >20 mmHg, pulmonary arterial wedge pressure of <15 mmHg, and pulmonary vascular resistance of >3 WU are supported by recent data to be potentially treated with pulmonary vasodilators. Since current programs, such as the DETECT algorithm, are for mPAP≥25 mmHg detection, new programs to predict mPAP of >20 mmHg are desired. Although PAH patients are usually treated with upfront combination therapy with two or more pulmonary vasodilators, initial monotherapy has a potential role in some specific PAH subsets, including elderly patients, patients with cardiopulmonary comorbidities, patients with suspicion of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis, and patients with very mild disease. SSc-PAH is frequently complicated with left heart disease, interstitial lung disease, and/or pulmonary veno-occlusive disease and may therefore benefit from initial monotherapy more than other forms of PAH. SSc patients with 20≤mPAP<25 mmHg may also be treated with initial monotherapy. In this seminar, we introduce our recent study on the detection of “very early SSc-PAH”, our treatment regimen for SSc-PAH, and finally the latest evidence on immunosuppressive therapy for CTD-PAH.

LS31
The current strategy of ANCA-ASSOCIATED VASCULITIS management
Hiroaki Dobashi
Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University

Conflict of interest: Yes

The primary systemic vasculitides (PSV) are characterized by inflammation of many vessels. PSV often could cause multiple organ damage which is strongly associated with prognosis. Chapel Hill nomenclature is widely used to define different forms of vasculitis according to the size of the predominantly affected vessels. Recently among small vessel vasculitis, Vasculitis associated with the presence of anti-neutrophil cytoplasm antibody (ANCA), termed AAV, advances have been made in understanding it’s pathogenesis and evidence for treatment. However in AAV, morbidity and mortality are still very high, in the induction phase because of high disease activity and infections, in maintenance phase due to major flares of AAV, cardiovascular disease and complications of malignancies. AAV is classified into three major forms: granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatoses (EGPA). In diagnosis of AAV, ANCA is a major diagnostic biomarker. However not all AAV patients are positive for ANCA. Additionally, the frequency of positivity of ANCA (c-ANCA or p-ANCA) in Japanese AAV patients is different from those of other countries such as Europe or USA. We should pay much attention about ANCA positivity at the diagnosis of AAV. In treatment of AAV at the induction...
Osteoarthritis is a disease that causes pain and dysfunction of the knee joint with degeneration of the articular cartilage but the disease state is not the same in all patients and it is necessary to construct a treatment strategy according to the individual disease condition. One of the most important exercise therapies is muscle training, but muscular strength training is less effective for the patients with sufficient muscle strength. Attempts to change exercise therapy by the presence or absence of muscle weakness, lateral thrust, obesity, etc. also proceed. For orthotic therapy, foot insole and unloader knee brace are used. Although it has been reported that the adduction moment and the clinical symptoms are also reduced, from now on, it is necessary to investigate to which patient the effectiveness of the orthotic therapy is high. Articular cartilage, synovial membrane, and subchondral bone are conceivable as targets of drug therapy. Inflammation of the synovial membrane is an exacerbating factor of pathological condition also in osteoarthritis of the knee, oral administration of nonsteroidal anti-inflammatory drugs, topical drugs for external use, intraarticular injection of steroid, etc. are used. However, patients with osteoarthritis are not always strongly inflamed, and the results of studies so far revealed that patients with injections of steroid joints are effective. It is thought that anti-inflammatory treatment should be limited at the time of strong inflammation. Not only articular cartilage and synovium but also subchondral bone status are known to affect the pathology of osteoarthritis. On the other hand, various results have been obtained on the method of managing pain. Although weak opioids have also come to be used frequently, there are many unclear points about side effects and dependency in long-term use, and easy prescription should be avoided. Serotonin/noradrenaline reuptake inhibitor (SNRI) and acetaminophen can also be used. Our options have been increasing, but establishing an appropriate method of administration is a future task.

Conflict of interest: Yes

Osteoarthritis is a disease that causes pain and dysfunction of the knee joint with degeneration of the articular cartilage but the disease state is not the same in all patients and it is necessary to construct a treatment strategy according to the individual disease condition. One of the most important exercise therapies is muscle training, but muscular strength training is less effective for the patients with sufficient muscle strength.

Attempts to change exercise therapy by the presence or absence of muscle weakness, lateral thrust, obesity, etc. also proceed. For orthotic therapy, foot insole and unloader knee brace are used. Although it has been reported that the adduction moment and the clinical symptoms are also reduced, from now on, it is necessary to investigate to which patient the effectiveness of the orthotic therapy is high. Articular cartilage, synovial membrane, and subchondral bone are conceivable as targets of drug therapy. Inflammation of the synovial membrane is an exacerbating factor of pathological condition also in osteoarthritis of the knee, oral administration of nonsteroidal anti-inflammatory drugs, topical drugs for external use, intraarticular injection of steroid, etc. are used. However, patients with osteoarthritis are not always strongly inflamed, and the results of studies so far revealed that patients with injections of steroid joints are effective. It is thought that anti-inflammatory treatment should be limited at the time of strong inflammation. Not only articular cartilage and synovium but also subchondral bone status are known to affect the pathology of osteoarthritis. On the other hand, various results have been obtained on the method of managing pain. Although weak opioids have also come to be used frequently, there are many unclear points about side effects and dependency in long-term use, and easy prescription should be avoided. Serotonin/noradrenaline reuptake inhibitor (SNRI) and acetaminophen can also be used. Our options have been increasing, but establishing an appropriate method of administration is a future task.

Conflict of interest: Yes

LS32
A Review and Update to the Comprehensive Treatment of Rheumatoid Arthritis [RA] - from the Past to the Future
Kunihiro Yamaoka
Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine

Conflict of interest: Yes

Since the successful introduction of the biological disease-modifying anti-rheumatic drug class [bDMARD] that first launched in 2001, RA treatment outcomes have made both significant and remarkable progress. It is widely believed that patient treatment starts with the conventional synthetic disease-modifying anti-rheumatic drug class [sDMARD]. From here, many patients transition to combination therapy involving bDMARD or targeted synthetic DMARD [tsDMARD], especially if or when the disease activity does not achieve the targeted remission. Remission evaluation is focused on the Treat to Target (T2T) strategy. While this is a realistic and achievable goal for RA patients, approximately 50% do not achieve goal and therefore require further treatment strategy modification. Several unique targets are under development in order to bridge the T2T gap, with the hope of further progress for positive treatment outcomes. For this presentation, I would like to offer a review and summary of the key landscape assets, and discuss the future patient treatment optimization with RA.

LS33-1
Pathophysiology and treatment strategy of knee osteoarthritis
Shuichi Matsuda
Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Conflict of interest: Yes

Osteoarthritis is a disease that causes pain and dysfunction of the knee joint with degeneration of the articular cartilage but the disease state is not the same in all patients and it is necessary to construct a treatment strategy according to the individual disease condition. One of the most important exercise therapies is muscle training, but muscular strength training is less effective for the patients with sufficient muscle strength.

Attempts to change exercise therapy by the presence or absence of muscle weakness, lateral thrust, obesity, etc. also proceed. For orthotic therapy, foot insole and unloader knee brace are used. Although it has been reported that the adduction moment and the clinical symptoms are also reduced, from now on, it is necessary to investigate to which patient the effectiveness of the orthotic therapy is high. Articular cartilage, synovial membrane, and subchondral bone are conceivable as targets of drug therapy. Inflammation of the synovial membrane is an exacerbating factor of pathological condition also in osteoarthritis of the knee, oral administration of nonsteroidal anti-inflammatory drugs, topical drugs for external use, intraarticular injection of steroid, etc. are used. However, patients with osteoarthritis are not always strongly inflamed, and the results of studies so far revealed that patients with injections of steroid joints are effective. It is thought that anti-inflammatory treatment should be limited at the time of strong inflammation. Not only articular cartilage and synovium but also subchondral bone status are known to affect the pathology of osteoarthritis. On the other hand, various results have been obtained on the method of managing pain. Although weak opioids have also come to be used frequently, there are many unclear points about side effects and dependency in long-term use, and easy prescription should be avoided. Serotonin/noradrenaline reuptake inhibitor (SNRI) and acetaminophen can also be used. Our options have been increasing, but establishing an appropriate method of administration is a future task.

Conflict of interest: Yes

LS33-2
Mechanism and treatment of chronic musculoskeletal pain from perspectives of pain clinic
Masako Iseki
Department of Anesthesiology and Pain Management, Juntendo University School of Medicine, Japan

Conflict of interest: Yes

Pain is defined as ‘An unpleasant sensory and emotional experience’ by International Association for the Study of Pain. Chronic pain is defined as ‘pain that extends beyond the expected period of healing or progressive pain due to non-cancer diseases.’ Pain is necessary for people as an alarm signal of the body, however its protraction can lead to lower quality of life. Comprehensive Survey of Living Conditions by Ministry of Health, Labour and Welfare in Japan reported that, of top five health-related subjective symptoms, three are painful symptoms in men (low back pain, shoulder pain, and joint pain), and four in women (low back pain, shoulder pain, joint pain, and headache). Protraction of pain, which reduces the productivity of young and middle-aged people, and prevents the independence of the elderly, is increasingly becoming a major problem in Japan where the population is rapidly aging and birthrate is declining. There are many patients suffering chronic musculoskeletal pain, and they are longing for appropriate alleviation of pain to secure quality of life. With regard to preservation treatment in general, pharmacotherapy is usually the first choice. Drugs are selected based on the type of pain; non-nerve, neuropathic, or mixed pain. However, when the pain exacerbates with movement or hold of body, it is sometimes difficult to alleviate with drugs only. Moreover, environmental factors around each patient can affect the pain. Thus, there are many factors and issues to be considered in the clinical practice. This talk will cover standard treatment of musculoskeletal pain, particularly focusing on pharmacotherapy.

Conflict of interest: None

Statements of treat to target for systemic lupus erythematosus (SLE) recommend that the treatment target of SLE should be remission of systemic symptoms and organ manifestations, and that prevention of flares is a realistic target in SLE and should be a therapeutic goal (van Vollenhoven RF et al. Ann Rheum Dis 2014;73: 958-967. doi:10.1136/annrheumdis-2013-205139). The introduction of corticosteroids in the 1950s improved survival rate of lupus patients remarkably; however, a new issue arose about corticosteroid-related organ damage, such as atherosclerosis and osteoporosis in long-term. Therefore, the best way to prevent damage accrual at this moment is treating patients with minimum, necessary, and sufficient amount of steroids so as not to cause a flare-up. Belimumab (trade name Benlysta), anti B lymphocyte stimulator (BLYS) antibody, is a novel therapeutic agent for SLE. This molecular targeted therapy suppresses B lymphocyte activation and decreases autoimmune antibodies including anti-DNA antibody. Clinical trials revealed disease activity significantly subsided in Belimumab group compared to placebo (Zhang F, et al. Ann Rheum Dis 2018;77:355-363. doi:10.1136/annrheumdis-2017-205139) and long-term prevention of flares over seven years in lupus patients with Belimumab treatment (Furie RA, et al. Arthritis Rheum 2018;70:868-877. doi:10.1002/art.40439). Belimumab is indicated for the treatment of active, autoantibody-positive adult patients with SLE who are receiving standard therapy. In order to draw out its full potential, use the drug as early as possible before organ damage appears
The development of treatment for women with systemic lupus erythematosus (SLE) leads to be able to wish for pregnancy. Taking remission with medicines that can be used during pregnancy, evaluating severe organ lesions, anti-SS-A antibody · anti-phospholipid antibody, blood pressure and glucose tolerance, osteoporosis and taking measures are important as a pre-conception care in SLE. Pregnancy in remission is a prerequisite for obtaining good pregnancy outcome. The treatment with steroids has been standard in SLE patients during pregnancy, but steroids should be decreased as they increase the risk of gestational diabetes, pregnancy hypertension, infections and premature rupture. In that case, combined use of an immunosuppressive agent and hydroxychloroquine is also useful. Azathioprine, cyclosporine, tacrolimus were contraindicated for pregnant women on the basis of animal tests, but teratogenicity was considered negative from the experience of transplant patients and it became capable to be used during pregnancy in 2018. Mycophenolate mofetil, one of the immunosuppressants, is teratogenic and it is necessary to instruct contraception during use. It is estimated that the anti-SS-A antibody retains about 1%, and it is frequent as a specific antinuclear antibody. Congenital cardiac block related to this antibody is about 1%, but it is a serious disease condition and it is a troublesome task to be done on countermeasures. On the other hand, there are cases where good results can not be obtained with the policy of prevention of thrombus formation in pregnancy of anti-phospholipid antibody carriers. On the pregnancy management method of these antibody holders, based on the results of the research group so far, we will present the best possible countermeasures. Sometimes evidence is poor as a major reason for pregnancy to be difficult. As a foundation for creating evidence from Japan to the world at the same time as improving such a situation, the Japanese Rheumatology Association says, “A prospective cohort study on long-term and short-term prognosis including young SLE patients in Japan, and outcomes of pregnancy: PLEASURE-J study “started. We have already cooperated from many facilities, but we would like to ask for your continued support and cooperation.

**LS34-2**
SLE and pregnancy
Atsuko Murashima
National Center for Child Health and Development, Tokyo, Japan
Conflict of interest: Yes

The development of treatment for women with systemic lupus erythematosus (SLE) leads to be able to wish for pregnancy. Taking remission with medicines that can be used during pregnancy, evaluating severe organ lesions, anti-SS-A antibody · anti-phospholipid antibody, blood pressure and glucose tolerance, osteoporosis and taking measures are important as a pre-conception care in SLE. Pregnancy in remission is a prerequisite for obtaining good pregnancy outcome. The treatment with steroids has been standard in SLE patients during pregnancy, but steroids should be decreased as they increase the risk of gestational diabetes, pregnancy hypertension, infections and premature rupture. In that case, combined use of an immunosuppressive agent and hydroxychloroquine is also useful. Azathioprine, cyclosporine, tacrolimus were contraindicated for pregnant women on the basis of animal tests, but teratogenicity was considered negative from the experience of transplant patients and it became capable to be used during pregnancy in 2018. Mycophenolate mofetil, one of the immunosuppressants, is teratogenic and it is necessary to instruct contraception during use. It is estimated that the anti-SS-A antibody retains about 1%, and it is frequent as a specific antinuclear antibody. Congenital cardiac block related to this antibody is about 1%, but it is a serious disease condition and it is a troublesome task to be done on countermeasures. On the other hand, there are cases where good results can not be obtained with the policy of prevention of thrombus formation in pregnancy of anti-phospholipid antibody carriers. On the pregnancy management method of these antibody holders, based on the results of the research group so far, we will present the best possible countermeasures. Sometimes evidence is poor as a major reason for pregnancy to be difficult. As a foundation for creating evidence from Japan to the world at the same time as improving such a situation, the Japanese Rheumatology Association says, “A prospective cohort study on long-term and short-term prognosis including young SLE patients in Japan, and outcomes of pregnancy: PLEASURE-J study “started. We have already cooperated from many facilities, but we would like to ask for your continued support and cooperation.

**LS35-2**
Positioning and practice use of biologics in systemic juvenile idiopathic arthritis
Masaaki Mori
Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University
Conflict of interest: Yes

Canakinumab (CAN) is a recombinant human IgG1 monoclonal anti-interleukin-1β (IL-1β) antibody, and it binds to IL-1β then suppresses inflammation by neutralizing its activity. In Japan, CAN was approved for systemic Juvenile Idiopathic Arthritis (sJIA) in 2018 July as additional indication. It was 5 years behind US approval in 2013 May and EU approval in 2013 August. CAN is administered subcutaneously with 4 mg/kg (maximum dose is 300 mg) every 4 weeks. CAN achieved improvement in sJIA clinical symptoms and tapering of glucocorticoid (GC) in clinical studies, but serious adverse event may occur in the administration. Pediatric Rheumatology Association of Japan developed a guidance for post-marketing surveillance of CAN upon the approval for sJIA to ensure appropriate use and sufficient safety. The guidance was created based on the results of clinical studies to date. CAN administration is considered for the following sJIA patients: 1) patients don’t show improvement in clinical symptoms such as fever, rash, arthritis, and inflammation, 2) patients cannot achieve tapering of GC, or have concern of side effects with long-term of GC, 3) patients have no or insufficient efficacy to, or not tolerant to anti-IL-6R antibody, tocilizumab. When macrophage-activation syndrome occurs, methylprednisolone pulse and dexamethasone therapy (off-label use), and continuous infusion of cyclosporine (off-label use) should be used, then CAN shouldn’t be administered until the condition is stable. Besides, MHLW Insurance Bureau issued an important notification upon the approval of CAN in sJIA, indicating 1) basically CAN administration should be considered for patients who have insufficient efficacy to other biologics, 2) the followings need to be specified in the notes of medical remuneration claims (1) Name and duration of used other biologics, (2) reason (s) to consider CAN administration is necessary. In short, CAN cannot be used essentially as first biologics from health insurance aspect in Japan. This session will overview positioning and evidence of CAN in sJIA outside of Japan also approach for appropriate use of CAN in Japan.

**LS35-1**
Diagnosis and Treatment of autoinflammatory syndrome in adult
Koichiro Ohmura
Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine
Conflict of interest: None

Since autoinflammatory syndrome is a hereditary disease, many of the patients show their symptoms in childhood. However, some develop the disease after they become adults. We physicians have to know the characteristics of the popular autoinflammatory diseases such as Familial Mediterranean Fever (FMF), TNF receptor-associated periodic syndrome (TRAPS), and Cryopyrin-associated periodic syndrome (CAPS). CAPS consists of 3 different diseases depending on their severity, FCAS, Muckle-Wells Syndrome (MWS), and CINCA. MWS is most often found in adults. Typical clinical symptoms of FMF is the short duration of fever (0.5-3 days) and serositis presenting severe abdominal pain. Usually colchicine is effective. TRAPS shows long duration of fever (> 7 days) and serositis (abdominal pain) and rash with muscle ache are the typical symptoms. Conjunctivitis and periocular edema are also found frequently in TRAPS patients. CAPS (MWS) shows urticarial eruptions and arthralgia typically. Progressive sensorineural hearing loss and chronic aseptic meningitis are also important complications. Colchicine is usually ineffective to TRAPS and CAPS, but moderate to high dose corticosteroid is effective. Recently canakinumab was admitted to use for CAPS, TRAPS and treatment-resistant FMF and it is very effective for such diseases who are resistant to the conventional therapy or hard to decrease the corticosteroid dose. I will overview the differential diagnosis points of autoinflammatory diseases in adults with some of case records.

**LS36-1**
Diagnosis and pathogenesis of Sjögren’s syndrome - From the viewpoint of a dermatologist -
Yoshinao Muro
Department of Dermatology, Nagoya University Graduate School of Medicine
Conflict of interest: None

Sjögren’s syndrome (SS) is a systemic autoimmune inflammatory disease characterized by secretory gland dysfunction leading to oral and ocular dryness and by various kinds of autoantibodies. SS can be primary or secondary to other systemic autoimmune diseases, i.e., rheumatoid arthritis, systemic lupus erythematosus (SLE), and systemic sclerosis. Japan has been promoting research of intractable diseases and financially supporting patients with these diseases. The number of designated intractable diseases (DID) was expanded from 56 to 306 by July 2015 where SS has also been included. We should increase social recognition of SS more than ever. A recent Japanese survey with questionnaires for patients with SS clarified that dry mouth contributes to painful experiences and quality of life impairment in many patients. They often meet difficulties in conversation, eating, and sleep. Early detection and early effective treatment should be provided to the disease. In Japan, the revised criteria for the diagnosis of SS proposed by the Japanese Ministry of Health have been used commonly in daily clinical practice and clinical studies, and also used as certification criteria for the national registry of DID. New ACR-EULAR classification criteria for primary SS (pSS) were published in 2016, and a recent Japanese study showed that this criteria had significantly higher sensitivity in diagnosis of pSS than the Japanese criteria. In
LS36-2
Sjögren’s syndrome: evidence review
Atsushi Kawakami
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Japan

Conflict of interest: Yes

Sjögren’s syndrome (SS) is an autoimmune disease the prominent symptoms being dry eye and dry mouth. It preferentially occurs in female subjects older than middle age. SS is categorized into primary SS (pSS) which is not associated with other well defined connective tissue diseases (CTDs), and secondary SS (sSS), which is associated with other well defined CTDs such as rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE). Moreover, pSS is further subdivided into the glandular form, with involvement of the exocrine glands only, and the extra-glandular form, with the involvement of organs other than exocrine glands including lung, kidney, joint, muscle and nervous systems. The Research Program for Intractable Disease of the Ministry of Health, Labor and Welfare (MHLW) has conducted epidemiological study for SS and revealed that the ratio of primary to secondary is 6:4, glandular form to extra-glandular form in pSS 7:3, 60% of underlying diseases of sSS RA and SLE, respectively. Thus, the requirement of measure of dryness, organ damages, underlying diseases and complications including malignant lymphoma is necessary in clinical practice of SS. SS includes varying pathological conditions and Research Team for Autoimmune Diseases, the Research Program for Intractable Disease of MHLW, has developed clinical practice guideline (CPG) for SS 2017. This consists of 38 clinical questions (CQ) documented by integrating the body of evidence for each outcome, based on the systematic review report and evidence evaluation sheets produced by the systematic review team members including diagnosis, complications, treatment of glandular form and extra-glandular form, management of pregnancy and delivery. Regarding to treatment, CPG states about dry mouth (CQ24), salivary gland swelling (CQ25), eyelids (CQ26), punctal plug (CQ27), corticosteroid (CQ28, CQ29), immunosuppressants (CQ30, CQ31), biologics (CQ32, CQ33), pediatric patients (CQ34, CQ35, CQ36). Investigations of SS has been developing and Japanese society of SS has also published and revised the manual sheets produced by the systematic review team members including diagnosis, complications, treatment of glandular form and extra-glandular form, management of pregnancy and delivery. Regarding to treatment, CPG states about dry mouth (CQ24), salivary gland swelling (CQ25), eyelids (CQ26), punctal plug (CQ27), corticosteroid (CQ28, CQ29), immunosuppressants (CQ30, CQ31), biologics (CQ32, CQ33), pediatric patients (CQ34, CQ35, CQ36). Investigations of SS has been developing and Japanese society of SS has also published and revised the manual textbook regarding SS. SS is certified as a designated intractable disease by the MHLW in January 2015 and become to be popular in clinical field. However, EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) does not include glandular symptoms (dryness) and no biologics are yet approved though several clinical trials has progressed. The evidence of SS will be reviewed in this seminar.

LS37-1
This is my strategy how to use Abatacept!—The clinical position of Biologies focus on T cell interaction—
Kenta Misaki
Department of Rheumatology, Kita-Harima Medical Center

Conflict of interest: Yes

Biologies (Bio) have been approved under the medical insurance in clinical setting since 2003 in Japan. It would not be exaggeration to say that the clinical adaptation of Bio brought a distinct paradigm shift concerned with drastic improvement of Rheumatoid arthritis (RA) disease activity. Initially one after another anti-TNF inhibitor (TNFi) were approved, and additionally non-TNF agents were come to the fore in 2008 in our country. Abatacept (ABT): CTLA4-Ig interacted between innate and adaptive immunity was adapted in clinical setting in 2010. At the same time, the first EULAR recommendation was published with the treatment strategy that TNFi were confirmed as first Bio, revised version of the recommendation in 2013 were mentioned the ABT was advocated as part of the first Bio for RA. Rheumatologist is capable to obtain the treatment options of First Bio. Moreover JAK inhibitor was added as our clinical option for RA treatment in 2013 and the theory of Treat to Target made it possible to indicate the RA treatment goal. Based on the above, it is possible for us to achieve the radiographic remission besides the reduction or withdraw of therapeutic agents. As it is pity to miss the best treatment opportunity by means of excellent Bio, early diagnosis of RA and appropriate First Bio combined with DMARDs are now required for Rheumatologist. RA pathogenesis is diverse, however musculoskeletal ultrasound (MSKUS) is one of the most useful clinical procedures to detect the subclinical synovitis and subtle bone erosion not depicted in X-ray film without harm. MSKUS is gradually applied to dairy clinical practice. It is suggested the Duet dance performance between Bio and MSKUS make it possible of achievement of radiographic remission and drug withdraw. In this session, I am going to introduce the efficacy of ABT as first Bio to RA patients in our institution and the clinical adaptation of MSKUS.

LS37-2
Importance of clinical data in RA treatment
Naoki Ishiguro
Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine & Faculty of Medicine

Conflict of interest: Yes

Clinical studies are roughly divided into two types, interventional studies and observational studies. Interventional research is a study to obtain results from artificially determining treatments according to certain conditions. Observational research is a research method to observe practical clinical practice. A typical example of intervention studies is a development trial of drugs performed by drug company. What is formed by observational research based on actual clinical practice becomes knowledge called real world data. Clinical studies are divided into two types, prospective and retrospective studies. For prospective studies, data is gathered according to purpose, which is considered to be more reliable. Clinical trials are prospective studies, in most cases taking the form of intervention studies in which a control group is established. By doing random assignment, we are conducting research work with elimination of artificial bias in enrolled cases. It is well accepted as a situation of high fairness, and it is regarded as an indispensable research for drug development. On the other hand, by manipulating inclusion standards, it is common for research to be conducted on a group of patients whose medicinal effect is likely to differ. Most of clinical trials that is said to be EBM-like high quality from blindness and the presence of control treatment is this kind of studies. Real world data is generally originated from the observational research work after marketing, so it is natural that the bias to be referred to as doctor’s preference is given to the case of administration. It may be possible to reduce the preference bias of doctors rather than single facility research by multicenter collaborative research. The primary advantage of clinical observational studies is the observation period. Therefore, in actual clinical studies it is required to observe the enrolled cases as long as possible over the long term, and it is important that the target cases are followed up as precisely as possible. It is not preferable that there are many dropout cases that are not subject to analysis. Meanwhile, in a clinical trial such as being blind and placing a placebo control group, there is always a problem of loss of treatment opportunities for participants, and a long research term causes human rights problems. Here is the reason why the blinded period of clinical trials with control group stays in the short term within 6 months. High quality observational research that require long-term observation is important for resolving some clinical questions.
Interstitial lung disease (ILD) causes major morbidity and mortality in patients with systemic sclerosis (SSc). A number of observational studies have revealed that only <30% of SSc-ILD at diagnosis progress to end-stage lung disease and result from poor mortality. The remaining patients show stable lung function throughout the disease course without treatment. Since tissue distortion caused by excessive fibrosis is irreversible, it is difficult to achieve normalization of lung function by delayed intervention. Extensive stage based on global lung involvement attributable to SSc-ILD on high-resolution computed tomography (HRCT) and/or present predicted forced vital capacity % ≤ 70% is used to identify patients who are likely to develop end-stage lung disease in clinical practice, but patients in the extensive stage are obviously those with progressive ILD who already have irreversible lung damage. Therefore, it is critical to identify patients at greater risk of progression at early phase when lung function is normal without irreversible damage. To identify patients with progressive SSc-ILD early in the disease course, fibrotic score on HRCT, early diffuse cutaneous SSc with rapidly progressive skin thickening, and circulating biomarkers, such as KL-6 and CCL18, are shown to be useful. Before the dawn of SSc-treat ment era, this lecture features basic knowledge required for management of SSc-ILD, highlighting how to identify patients with progressive disease, who are eligible for treatment.

**Evening Seminar**

**ES1-1**

Safety and Effectiveness of Abatacept for Rheumatoid Arthritis-Safety First-
Mitsumasa Kishimoto
Immuno-Rheumatology Center, St Luke’s International Hospital

Conflict of interest: Yes

For rheumatoid arthritis (RA), availability of various DMARDs including MTX and biological DMARDs and targeted small molecules, has increased treatment options, improving both short-term and long-term outcomes and QOL. Appropriately-tailored treatment of individuals with RA in daily practice, however, depends on an accurate differential diagnosis and evaluation of patient’s co-morbidities before starting these effective treatment, but is still often based on experientially-derived clinical judgement. One of the common co-morbidity in RA is an interstitial lung disease (ILD) which is associated with poor prognosis in RA patients. Treatments such as methotrexate or anti-TNF agents, have been implicated in the exacerbation of an ILD. Abatacept is a biological DMARDs that has demonstrated a lower risk for infection in comparison with other bDMARDs among RA patients. At first, I introduce the data presented in EULAR 2018; the potential cost differences associated with the reduced risk of infection among RA patients treated with abatacept vs. other tDMARDs is discussed here. Secondly, I would show a new clinical data regarding RA patients complicated with ILD treating with abatacept or tocilizumab, and its basic study in chronic graft-versus-host disease (cGVHD) mouse model. In daily clinical practice, these data re-assured our knowledge on safety profile in treatment of RA with abatacept.

**ES1-2**

Optimization of Rheumatoid Arthritis therapy: current issues and outlook for the future
Tsutomu Takeuchi
Division of Rheumatology, Keio University School of Medicine

Conflict of interest: Yes

There have been many advances and innovations in the diagnoses and treatment of Rheumatoid Arthritis (RA) in the past few years. There has been numerous amendments to treatment recommendations and guidelines, such as ACR, EULAR and Treat to Target (T2T). It goes without saying that one of the factors is the development of biological disease-modifying ant-rheumatic drugs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs). With the development of these drugs, Clinical remission is the primary goal in the treatment of the disease and both structural and functional remission have become possible. It greatly contributes to the improvement in the patient’s Quality of Life (QOL). On the other hand, there are many kinds of issues, such as how to treat patients appropriately and monitor the patients, and how to predict the reduction in dose until medication is no longer necessary. We need to understand the characteristics of each bDMARD and tsDMARD as well as the patient’s background so as to maximize the effectiveness and minimize any adverse events with medical therapy. There are 15 bDMARDs and tsDMARDs for RA in Japan, divided into 4 class clusters, TNF inhibitors, IL6 inhibitors, T-cell co-stimulate and Jak inhibitors. Based on clinical evidence, the effectiveness of each drug is nearly equivalent. However, some patients have not yet reached the ideal therapeutic goal. In recent years, the population of the world has been aging. This is especially true for Japan, which has the highest rate of aging. This trend is expected to continue. It shows that we require more care regarding the prevention of adverse events when using bDMARDs and tsDMARDs on patients over 65 and have lung complications in our RA study group (cohort). For our treatment strategy, understanding the background of each patient as well as the characteristics of each drug is of the utmost importance. This seminar will outline the current issues with RA and the latest evidence regarding ABT in Japan and consider the optimization of RA therapy.
ES2-1
Treatment standardization of systemic lupus erythematosus
Tatsuya Atsumi
Department of Rheumatology, Endocrinology and Nephrology Faculty of Medicine and Graduate School of Medicine Hokkaido University, Hokkaido, Japan

Conflict of interest: Yes

Systemic lupus erythematosus (SLE) affects multiple organs and tissues in a different way, and such heterogeneity of clinical aspect is making difficult to standardize the management of lupus patients in clinical practice. In the history, corticosteroids (CS) dramatically improved the mortality of lupus patients; on the other hand, major or minor adverse events of CS would significantly affect to their morbidity. Recently, the potent immunosuppressants are efficiently used for the remission induction in patients with SLE. Amongst the lupus organ involvements, lupus nephritis (LN) is one of the most common and important manifestation, and the better use of immunosuppressants are described in two major guidelines for lupus nephritis. JCR and MHLW have collaborated to established SLE guideline according to the GRADE method. In this guideline, recommendation statement was classified into 3 categories; recommended, suggested and proposed. Referring another SLE guideline for British National Health System, established by BSR, we discuss the significance of the Japanese SLE guideline for our daily clinical practice.

ES2-2
The problem of glucocorticoids in SLE, and pathways to a solution
Eric Morand
Monash University, Melbourne, Australia

Conflict of interest: None

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Uncontrolled disease activity, observed in 60% of patients despite standard of care therapy, leads to the accrual of irreversible organ damage, which in the case of renal, central nervous system (CNS), and cardiovascular systems can have fatal consequences. Thus patients with SLE, the majority of whom are young women, face chronic illness, loss of health, reduced work participation, and a very significant risk of premature death. Because of a lack of significant advances in therapy, the majority of patients still receive was classified into 3 categories: recommended, suggested, and proposed. Referring another SLE guideline for British National Health System, established by BSR, we discuss the significance of the Japanese SLE guideline for our daily clinical practice.

ES3-1
Immunopathology and recent epidemiology in Behçet’s disease
Mitsuhito Takeno
Department of Allergy and Rheumatology, Nippon Medical School

Conflict of interest: Yes

This seminar summarizes current understanding of the immunopathology of Behçet’s disease and reviews recent epidemiology in Japan. Behçet’s disease has a unique epidemiology feature that the patient distribution form the Mediterranean area to the Middle East Asia and East Asia, where coincide with high frequent areas of HLA-B51 positive individuals. A couple of epidemiological analyses in immigrants from the prevalent areas to other areas suggest that both the genetic and environmental factor are involved in the etiology. Before 2000, one of favorable hypotheses is that microbial agents trigger autoimmune responses in hosts having genetic predispositions, resulting in the development of the disease. However, lack of the disease-specific autoantibodies, abnormal innate immune functions, clinical manifestations with attacks and remissions, rather suggest features as an autoinflammatory disease. GWAS and subsequent detail genetic analysis have identified the disease susceptible genes in both innate and acquired immune systems, suggesting the mixed features of autoimmunity and autoinflammation. Furthermore, epistasis between HLA-B51 and ERAP-1 suggests that the disease belongs to recently proposed MHC-I-opathy along with ankylosing spondylitis and psoriasis. Epidemiological data showed that patients receiving medical support as the specific intractable disease had been rising from 1972 to 2000, thereafter reached the plateau. Recent chronological changes were summarized aging, decreasing frequency of ocular lesion and HLA-B51 positive patients, and increasing female patients and intestinal type. Early diagnosis and early treatment due to the spread of the revised diagnostic criteria might partly contribute to the chronological changes. Rather, our studies suggest that patients with Behçet’s disease are classified into several clinical subgroups and that the proportions of individual subgroups have been changing presumably through the gene-environment interaction.

ES3-2
Diagnosis of special type of Behçet’s disease and the latest treatment
Hirofumi Kikuchi
Department of Internal Medicine, Teikyo University School of Medicine

Conflict of interest: None

Intestinal, vascular, and central nervous system (CNS) lesions are present in special types of Behçet’s disease (BD). Intestinal lesions may develop anywhere from the esophagus to rectum, but typically, round-oval deep ulcer is formed in the ileocecum and induces symptoms such as abdominal pain, diarrhea, and bloody feces. Medium-to-large dose steroid administration is the main treatment for remission induction, and mesalazine and salazosulfapyridine are often used concomitantly. The effect of TNF inhibitor alone is insufficient in many cases of intestinal BD, and combination with an immunosuppressor is necessary. Vascular lesions develop in various blood vessels from the aorta to veins, with a frequency of about 5-10% in patients with BD. Colchicine and nonsteroidal anti-inflammatory drugs do not inhibit inflammation sufficiently in many cases, and steroids, cyclophosphamide, azathioprine, methotrexate (MTX), and infliximab are required. In Japan, complication by deep vein thrombosis-associated pulmonary thromboembolism is often encountered, for which antithrombotic drugs are concomitantly administered, in addition to immunosuppressors. CNS lesions are divided into acute type and chronic progressive type. Headache, fever, and local nerve symptoms develop in the acute type neuro BD (ANB), and an increase in the number of cells in cerebrospinal fluid (CSF) is useful, if CNS infections are excluded. In the chronic progressive type neuro BD (CPNB), cognitive impairment, character change, truncal ataxia, and dysarthria progress, and a persistently high level of CSF IL-6 and brain stem atrophy are the characteristic findings. ANB is dealt with separately for acute phase and prevention of recurrence. Acute phase is treated with steroids that are rapidly administered at a medium or high dose when cerebral local signs progress. Response to steroids is favorable, but symptoms may recur even in ANB. Colchicine is recommended for prevention. Acute phase in CPNB is also treated with high-dose steroids. CSF IL-6 transiently decreases after administration, but increases again with steroid dose reduction. MTX has been shown to decrease CSF IL-6 and inhibit progression of mental and neurologic manifestations. In a study of long-term outcomes of the CPNB in Japan, the mortality and rate of patients who became bedridden were significantly lower in the MTX treatment group. For intractable cases in which the effect of MTX is insufficient and cases in which use of MTX is difficult, administration of infliximab should be considered.
Recent medical advancements have expanded treatment options and due to this, it is becoming increasingly important for doctors to communicate sufficiently with patients and their families to reflect their values in treatment decisions. Informed consent (IC) is widely known as the basis of consensus building between doctors and patients. In IC, patients are provided with information to make an autonomous decision to either select, agree to or reject treatment based on their understanding. However, lately in the clinical practice, doctors tend to provide information in order to gain consensus, rather than providing information to empower the patient to make a treatment decision. This is a deviation from the initial purpose of IC, and is becoming a growing concern. Now, shared decision making (SDM) is emerging as the new approach to decision making and consensus building. What is the difference between SDM and IC? SDM focuses on sharing the treatment decision process of all potential treatments, enabling both parties to make a decision and form a consensus simultaneously. The dramatic advances in RA treatment has enabled many patients to reach and sustain remission. Having multiple treatment options are favorable for patients, while it puts pressure on HCPs to identify the right option for patients. Furthermore, HCPs are expected to practice evidence-based medicine (EBM), which cannot be achieved in isolation from SDM. EBM defines that evidence is a critical factor for decision making, however to make a comprehensive decision, all other factors cannot be neglected. The aim of this seminar is to explore SDM and its true values. For a deeper understanding of SDM, we shall start by looking at the association between EBM and SDM, and how to connect SDM with practice guidelines. After introductions of specific case studies, a panel discussion will be held to explore how SDM should be implemented to the field and the important key points that must be followed in practice.

ES5-1
Benefit of Interleukin-6 inhibition in rheumatoid arthritis
Kunihiro Yamaoka
Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine
Conflict of interest: Yes
Health, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 3 Nursing Division, Saiseikai Yokohama City Tobu Hospital

ES6
Diagnosis and treatment of CTD-PAH with lung involvement – Challenges for the future –
Masaru Kato
Medicine II, Hokkaido University Hospital, Japan
Conflict of interest: Yes

Considerable experience has proven the usefulness of biological DMARDs (bDMARDs) not only in rheumatoid arthritis (RA) but also a wide range of inflammatory diseases. However, it has also become clear that there are few diseases like RA in which similar efficacy can be observed with tumor necrosis factor (TNF) and interleukin-6 (IL-6) inhibition contributing to understand the RA pathology. During the recent years, tocilizumab (TCZ) has revealed the efficacy in Takayasu’s arteritis and giant cell arteritis and an additional new IL-6 receptor antibody has been approved for RA. Janus kinase inhibitor (Jakinib) an orally available DMARD that has demonstrated similar efficacy with bDMARD is approved for RA. Janus kinase inhibitor (Jakinib) an orally available DMARD that has demonstrated similar efficacy with bDMARD is known to suppress both IL-6 production and IL-6 signaling with variety of other mechanism of action. According to the latest ACR/EULAR recommendations, IL-6 inhibitors and Jakinibs have some advantages in monotherapy that make one believe that these drugs have different feature compared to TNF inhibitors. Recently, tapering and/or cessation of concomitant csDMARDs or bDMARDs have been conducted in patients in remission. The results of these studies (ACT-TAPER, COMP-ACT, SURPRISE) have suggested that tapering or cessation of MTX in TCZ combo therapy would be the feasible strategy in clinical practice. Although Jakinibs and bDMARDs possess evident difference in mechanism of action, the anti-rheumatic effect is similar. Elucidating the changes by these drugs in whole body and local joint inflammation could lead toward precision medicine. In this lecture, we will focus on the effectiveness of IL-6 inhibition and future positioning.

ES5-2
Treatment optimization in RA - For Patients -
Andrew Östör
Department of Medicine, Monash University
Conflict of interest: None

Rheumatoid arthritis (RA) is autoimmune disease that is associated with a reduced quality of life (QOL) by systemic inflammation, disability by progressive bone destruction, early death by poor management of comorbidities, and socioeconomic costs by loss of work. The primary objective for RA treatment is to maximize QOL through early diagnosis and intervention with optimal therapies. As a consequence medication adherence is essential for RA patients. However, medication adherence rates may be as low as 30% in patients with RA thus increasing the cost of care and leading to poor patient outcomes. Currently, rheumatologists usually prescribe conventional synthetic DMARDs (csDMARD) for RA, progressing to biologic DMARDs (bDMARD) to improve the short- and long-term outcomes. Currently, bDMARD added to MTX is gold standard therapy for patients with moderate to severe RA and an inadequate response to csDMARDs. Meanwhile, approximately one-third of patients discontinue or are non-compliant with MTX because of preference or toxicity. Taking these facts into consideration, strategies for the appropriate use of biologics as monotherapy is needed to adequately manage RA. Tocilizumab (TCZ), which is anti-interleukin 6 receptor antibody, can reduce the signs and symptoms of RA in combination with a csDMARD and as monotherapy in MTX-intolerant patients or patients for whom MTX is ineffective or inappropriate. Furthermore, we investigated whether TCZ plus a tapering MTX dose had comparable efficacy and tolerability compared with TCZ plus a stable MTX dose in patients with severe RA and an inadequate response to MTX who had achieved an EULAR response after TCZ combination therapy. The results of this clinical study increases the treatment strategies available to patients with active severe RA and allows for individualized, tailored therapy. I will focus on the optimization of current RA treatment for patients in this symposium.
Rheumatoid arthritis (RA) is an autoimmune disease characterized by synovitis, which eventually causes joint damage. Various cytokines play a critical role in the synovitis and anti-cytokine therapies have been developed for the clinical use. Monoclonal antibodies against TNFα and IL-6R have proved the importance of these cytokines in the pathogenesis of RA and lead to new therapeutic concepts and strategies in the treatment of RA. Tofacitinib (TOFA) is the first JAK inhibitor (JAKi) which comes 5 years old as another anti-cytokine drug for rheumatoid arthritis. JAKs are tyrosine kinases within cells. When a cytokine binds with its receptors, JAKs are activated to in turn activate STAT molecules. JAKi is an oral drug with low molecular weight and inhibits the kinase activity of JAKs. Thus JAKi inhibits signaling of cytokines that utilize JAKs. Because JAKi inhibits signaling of multiple cytokines which belongs to type I and II cytokine families, the mechanisms of immunosuppression should be different from biologics which blocks a specific cytokine. Today, 2 JAKi are used in clinical settings. The two JAKi possess different selectivity on JAKs, which may lead to different clinical effects. Various clinical trials have proved the clinical efficacy of TOFA. ORAL STEP has shown that TOFA is as effective as adalimumab when used in combination with MTX. ORAL SOLO has shown clinical usefulness of TOFA as a monotherapy. A clinical advantage of TOFA is that it is an orally available drug, because some patients prefer oral agents to injections. Another advantage of TOFA is that it reduces patient pain score quickly. These features of TOFA has made the drug widely used in the world.
Conflict of interest: None

Palmpoplantar pustulosis is relatively frequent in Japanese population. Among the extra-cutaneous manifestations associated PPP, arthralgia is the most common comorbidity, termed as palmpoplantar arthro-ostitis (PAO). Chest wall is the most frequently involved, and the ratio of PAO in PPP is observed in nearly 30% in the university hospitals. By contrast, SAPHO syndrome (synovitis, acne, pustulosis, hyperostosis, osteitis) is extremely rare in Japanese population. Skin eruption of SAPHO syndrome is not limited to PPP, but acne inversa (hidradenitis suppurativa) is also rarely observed. In addition, acne of SAPHO syndrome is not usual acne but severe acne (acne conglobata, cystic acne, etc.). Looking at the papers outside Japan, cases of PPP and arthralgia are diagnosed as SAPHO syndrome. If we diagnose such cases as SAPHO syndrome, we have many Japanese cases of SAPHO syndrome. PPP, as well as PAO, is closely related to focal infection, and treatment aiming at focal infection, such as tonsilllectomy or dental caries treatment, dramatically improves skin and joint manifestation. By contrast, SAPHO syndrome, and also CRMO syndrome, are suggested to belong to autoinflammatory syndrome. In this talk, the concept of PAO, and difference between PAO and SAPHO syndrome, will be presented from dermatological perspective.

ES9-2
Differential diagnosis of non-radiographic axial spondyloarthritis
Yuho Kadono
Orthopaedic Surgery, Saitama Medical University
Conflict of interest: Yes

Recently, it becomes well known that spondyloarthritis (SpA) is a kind of umbrella inflammatory disease concept including ankylosing spondylitis (AS) and psoriatic arthritis. SpA exhibits not only arthritis or spondylitis but also enthesitis. SpA which shows sacroiliac joint or spine involvement like AS, is roughly classified into axial SpA (axSpA). We use ASAS criteria to classify axSpA, and call it a ‘non-radiographic axSpA’ when we can detect just a small radiographic change. Although there is the classification criteria, we sometimes have a difficulty to diagnose. We should distinguish inflammatory back pain from mechanical pain or fibromyalgic pain. When we find spinal fusion or hyper ossification, we should distinguish axSpA from degeneration, diffuse idiopathic skeletal hyperostosis or osteitis condensans illi. When we find STIR high lesions, we should distinguish axSpA from overuse, injury or infection. We should be careful and judge by not only cross-sectional but also longitudinal points of view.

ES9-3
Diagnosis and management of functional pain syndrome which is mistaken for SpA
Kenji Miki1,2,3, Masao Yukioka4
1Faculty of Health Science, Osaka Yukioka College of Health Science, 2Center for Pain Management, Orthopaedic Surgery, Hayashi Hospital, 3Pain Medicine & Research Information Center (NPO-PMRIC), 4Department of Rheumatology, Yukioka Hospital
Conflict of interest: Yes

Functional pain syndrome falls under the concept of “Functional Somatic Syndrome” proposed by Simon Wessely, and has become recognized as “central dysfunctional pain.” The definition of pain is “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage.” Also, “Many people report pain in the absence of tissue damage or any likely pathophysiological cause; usually this happens for psychological reasons... Activity of nociceptive pathways is not pain, which is always a psychological state.” A total of 175 outpatients with a chief complaint of chronic pain were classified as fulfilling the diagnostic criteria of fibromyalgia (FM), spondyloarthritis (SpA), or neither. There were 83, 14 and 82 patients in the FM, SpA and chronic widespread pain group, respectively. Approximately 30 percent of patients with SpA met the diagnostic criteria of FM, a functional pain. (Chronic pain disease: difference in the treatment response between FM and rheumatic SpA. The Journal of Japan Spondyloarthritides Society 2 (1): 79-87 2010). Although it is most important to eliminate organic diseases from functional pain, organic diseases which appear as pain, numbness, trembling, etc. are often difficult to diagnose. Patients with chronic pain are said to become chronic due to how they are supported by health professionals. Communication skills, etc. of health professionals are important also from the standpoint of medical ethics. A paradigm shift of healthcare from “giving” to “supporting” in the management of patients with chronic pain is important. In workshops for healthcare professionals at Pain Medicine & Research Information Center (NPO-PMRIC), communication skills, cognitive behavioral therapy, and overall chronic pain knowledge can be learned. Multi-disciplinary medical care becomes possible if all health professionals including nurses, PTs and others acquire the skills to act on behalf of busy physicians.

ES10-1
Prevention and measures for frailty and sarcopenia
Hidenori Arai
National Center for Geriatrics and Gerontology
Conflict of interest: Yes

Aging is a global issue and patients with rheumatoid arthritis (RA) are getting older because of the improvement of medical management. Therefore, we need to deal with various problems associated with aging. Among them, geriatric syndromes such as sarcopenia and frailty are often found in RA patients and are associated with various outcomes such as falls, bone fractures, decreased quality of life and declines in daily living activities (ADL). Sarcopenia is a disease associated with outcomes such as falls and fractures due to a decrease in skeletal muscle mass and muscle strength associated with aging, and the proportion of sarcopenia in RA patients is extremely high. Meanwhile, frailty is considered to be a condition which is liable to cause dysfunction in daily life functions in response to acute stresses. Although it is a syndrome that can occur to anyone with aging, its evaluation is important because frailty is a determinant of prognosis in older RA patients. Regarding diagnosis, grip strength, walking speed, limb skeletal muscle mass are used for sarcopenia, while Cardiovascular Health Study’s criteria are often used for evaluation of frailty, but measurement of grip strength and walking speed is common. On the other hand, the kihon checklist developed in Japan is 25 self-answered questionnaires, and if there are more than 8 items, the risk of needing long-term care insurance certification significantly increases. Therefore, it is considered to be an effective index for evaluating the presence or absence of frailty. What is important for the intervention of sarcopenia and frailty is the intake of protein and vitamin D with sufficient energy intake; additionally, combination of resistance training and aerobic exercise is recommended. For RA patients, due to the presence of arthritis, adequate consideration is required for resistance training. In this symposium, I would like to discuss about the concepts, implications, diagnosis and interventions for frailty and sarcopenia, which are an important problem in older rheumatoid arthritis patients.

ES10-2
Treatment strategy for elderly RA patients accompanied with sarcopenia
Motomu Hashimoto
Department of Advanced Medicine for Rheumatic Diseases, Kyoto University
Conflict of interest: Yes

Patients with rheumatoid arthritis (RA) exhibit a characteristic body composition abnormality called “Rheumatoid Cachexia”, in which the muscle mass decreases and fat mass increases due to the influence of inflammatory conditions and physical dysfunction. Therefore, RA patients have increased prevalence of sarcopenia compared to the general elderly, leading to high risk of falls and fractures. Furthermore, some RA patients exhibit “sarcopenic obesity”, who accumulate visceral fat mass even in normal body weight and have high risk of arteriosclerosis. Since inflammatory cytokines such as TNF-α and IL-6 are deeply involved in such characteristic body composition abnormalities in RA, the use of biological DMARDs which directly inhibit these cytokines could decrease sarcopenia in RA patients. On the other hand, the use of steroids acts to re-
duce inflammation and decrease sarcopenia if short-term and small amount, but if used at long term / high dose, it could promote sarcopenia by inducing steroid myopathy. Therefore, if we could achieve clinical remission using biological DMARDs reducing steroid use, it could decrease sarcopenia, improve the metabolic abnormalities, and greatly improve ADL / QOL of RA patients. Elderly RA patients not only have sarcopenia but also have various problems such as deterioration of cognitive function and medical complications. In this presentation, the treatment strategy for elderly RA patients accompanied with sarcopenia will be discussed.

**ES11-1**

**Treat-to-target (T2T): strategic effectiveness and challenges in the new decade**

Josef S Smolen  
Department of Internal Medicine 3, Medical University of Vienna, Austria

Conflict of interest: Yes

T2T is part of RA/PsA management recommendations. Stringent clinical remission conveys best outcomes (damage, function). Imaging remission is not better than clinical remission, except higher costs, drug use and adverse events. Thus, clinical remission is gold standard for T2T. ACR and EULAR have provided stringent remission definitions not affected by types of therapy, particularly CDAI (no acute phase reactant). Remission defined by DAS28 shows damage progression and erroneously high responses when IL-6 or Jak-inhibitors are used (many patients “in remission” have high activity). Changing cutpoints for DAS28 remission does not help. ACR-EULAR Boolean definition is often missed due to PtGA-1/2cm. One can develop remission definitions excluding patient input; modifications of SDAI were similar to traditional SDAI. But excluding patient perspectives in remission definition has to be evaluated against consequences of ignoring patient perspectives. Rather a slightly higher threshold for PtGA when defining remission may suffice. Just like classification criteria for one disease should not be used for another disease (e.g. RA classification for patients with SLE), clinical scores should not be used for patients with another disease (e.g. CDAI for patients with fibromyalgia). T2T recommendations account for patient factors when defining treatment target or using scores. With CDAI remission, PtGA is counterbalanced by lack of joint swelling and tenderness. Low disease activity by CDAI and SDAI is a good alternative, especially in patients with long-standing disease. DAS28-LDA is not ideal, because upon IL-6 or Jak-inhibition erratic results are seen (especially DAS28-CRP vs DAS28-ESR). The biggest challenge for T2T is implementation in practice. Given that targeting a good clinical outcome is as good as targeting imaging outcome, the implementation of assessing joints and indices in practice is not only timely but also urgently needed.

**ES11-2**

**Significance of T2T treatment strategy reconsidered from new evidence**

Tsutomu Takeuchi  
Division of Rheumatology, Keio University School of Medicine

Conflict of interest: Yes

“Treat to Target: T2T”, an approach that sets a treatment target and optimizes treatment in the pursuit of that target has brought a major advancement in the treatment of rheumatoid arthritis (RA). The treatment strategy was widely recognized, including Japan, through global dissemination activities and based on this new approach, treatment recommendations were revamped by EULAR and ACR, and additionally the treatment guidelines in Japan were also revised. However, during dissemination and educational activities of T2T in Japan, there was not enough evidence to suggest that patient outcome was improved in daily clinical practice. Therefore, in cooperation with over 100 facilities in Japan to which rheumatologists affiliate, targeting early stage RA patients scheduled to begin treatment with methotrexate (MTX) and MTX without the use of biologic preparation, we examined the influence of T2T in daily clinical practice on outcome of RA patients, using HAQ as an indicator (HAQ study). Also, especially at an early stage of 2 to 3 years since the onset of RA, joint destruction progresses quickly, and when bone erosion is recognized, deformation occurs in a few years, so a treatment strategy for preventing joint destruction progression in this phase is essential. Therefore, in early RA, more powerful tight controls aiming for clinical remission are desired. However, in daily clinical practice these goals are not easy to achieve. In order to achieve early clinical remission, it is critical that MTX, which is considered as the first-line treatment for RA, and biologics that have powerful clinical and radiographic efficacy, are introduced at an appropriate timing according to the patients’ background. In this seminar, we will reconsider the realities of RA treatment in Japan and the significance of T2T treatment strategy based on the HAQ study results, and also deepen our consideration of the treatment strategy to maximize the outcome for RA patients.

**ES12**

**Respiratory infection risk in rheumatic disease patients with the topic of pneumococcal vaccine**

Sadatomo Tasaka  
Department of Respiratory Medicine, Hirosaki University Graduate School of Medicine

Conflict of interest: None

The introduction of biologics is changing rheumatoid arthritis (RA) therapy. However, infectious complications are related to immunosuppressant therapy. Early diagnosis, appropriate treatment, and prevention are important. Pneumonia commonly causes hospitalization of RA patients, and respiratory infections are frequent and often severe. Complications such as interstitial pneumonia and alveolar hemorrhage make it difficult to diagnose respiratory infections in patients with rheumatic disease. Respiratory disease can occur regardless of RA activity such as joint symptoms. Drug-induced pneumonia is related to MTX or biologics. Differentiating non-infectious respiratory disease is a challenge. RA and SLE are risk factors for infections themselves, as well as drugs and complications. Prednisolone, MTX, and TNF inhibitors with anti-inflammatory and immunosuppressant actions may re-activate occult infections to induce opportunistic infections. Pneumonia is the most frequent infection in RA patients as said earlier. Pneumococcus is the most frequently isolated pathogen in community-acquired pneumonia. Pneumococcal vaccination can prevent pneumococcal pneumonia. It is recommended along with influenza vaccination in immunosuppressed adult patients, such as RA patients, by the American College of Rheumatology (ACR) and the European Congress of Rheumatology (EULAR). In Japan, pneumococcal vaccination is recommended in the guideline for the treatment with MTX and the guidelines for the use of TNF inhibitor, tocilizumab, and abatacept for RA of the Japan College of Rheumatology. Two types of pneumococcal vaccines, 23-valent pneumococcal polysaccharide vaccine (PPSV23) and 13-valent pneumococcal conjugate vaccine (PCV13), are currently available for use in adults (≥65 years) in Japan. I will present the mechanism of onset, characteristics, epidemiology, prevention, and diagnosis of respiratory infections in rheumatic diseases such as RA and discuss preventive vaccination.

**ES13-1**

**A strategy to treat Psoriatic arthritis: Rheumatologist’s point of view**

Mitsumasa Kishimoto  
Immuo-Rheumatology Center, St Luke’s International Hospital

Conflict of interest: Yes

The prevalence of psoriatic arthritis (PsA) among Japanese psoriasis patients is thought to be less than those in Western countries. However, in keeping with our clinical experience that the prevalence of PsA among Japanese patients may actually be higher, we reported prevalence rates of up to 20.4% among Japanese psoriasis patients. Further improvements in awareness of this disease entity is necessary to allow patients to receive early and appropriate care. Awareness of clinical characteristics of PsA, including both articular and extra-articular manifestations, is essential for this process, especially because clinical characteristics of PsA are highly variable across patients. In this session, at first, we aim to characterize the distinguishing clinical features of PsA in patients, which will allow us to improve both under-diagnosis and misdiagnosis of the increasingly treat-
able disease, and emphasize the need for early diagnosis and appropriate differential diagnosis. Secondly, the treatment guideline and recommendation for PsA is changing constantly with the advent of new therapies in the EULAR, ACR, and GRAPPA internationally, and I would introduce a current treatment strategy “T2T” and its limitation. Furthermore, therapeutic strategies of how to set the treatment target should be determined through a shared decisions between physicians and patients in consideration of the disease activity and the characteristics (presence or absence of complications) of each patient. I will present a clear exposition of significance to choose oral DMARDs in treatment of PsA including the new oral DMARDs. Apremilast is a new oral DMARDs, and Phosphodiesterase 4 (PDE4) inhibitor which inhibit proinflammatory enzyme/cytokine including IL-12, TNFα, and IL-1 via degradation of cAMP. Finally, I would introduce its mechanism of action and the long-term efficacy and safety data in PsA programs.

ES13-2 Therapeutic strategy using apremilast for psoriasis and psoriatic arthritis
Yukie Yamaguchi
Yokohama City University Graduate School of Medicine

Conflict of interest: Yes

Psoriasis is a chronic auto-inflammatory disease in which IL-23/IL-17 plays a pivotal role. Nowadays, different biologics against TNFα (infliximab, adalimumab), IL-12/23p40 (ustekinumab), IL-23p19 (guselkumab), IL-17A (secukinumab, ixekizumab), and IL-17RA (brodalumab) became therapeutic options for psoriasis in Japan. Moreover, an oral PDE4 inhibitor, apremilast, was also approved for psoriasis in 2017. Apremilast is effective for psoriasis, especially cases accompanied by pruritus, scalp psoriasis, and nail psoriasis, which remarkably improves patient’s QOL. In addition, apremilast may be considered at first for active PsA patients with enthesis if patients prefer an oral therapy. In this seminar, we will discuss best cases for apremilast therapy in psoriasis and PsA treatment.

ES14 Switching from reference product to biosimilar is not inherently dangerous
Hiroaki Matsuno
Matsuno Clinic for Rheumatic Diseases, Toyama, Japan

Conflict of interest: Yes

While tumor necrosis factor-α (TNF-α) inhibitors including reference product (RP) comprise a major strategy for the treatment of rheumatoid arthritis (RA) and other intractable autoimmune diseases, their high cost creates an economic burden in various countries and regions, including Japan. Thus, there is an increasing demand for the development of bio-similar drugs to decrease cost-effectiveness. NI-071 has been developed as a biosimilar to RP by Nichi-Iko Pharmaceutical Co., Ltd. in Japan. We conducted a phase III study in Japanese RA patients to compare the efficacy and safety of BS with those of RP in a double-blind manner using DAS28-ESR (disease activity score in 28-joint count based on erythrocyte sedimentation rate as a primary efficacy parameter). Following the double-blind period, the BS administration was continued for another 24 weeks to evaluate the drug’s long-term safety. Here, we present the data obtained in this phase III study taking into account certain factors of infliximab biosimilar. The disease activity score in 28-joint count based on erythrocyte sedimentation rate or C-reactive protein and the American College of Rheumatology 20/50/70-based efficacy profiles of BS were similar to those of RP during Period I (30 weeks) including evaluations at Week 14, a critical time point. BS efficacy was maintained throughout the 54-week study period. BS efficacy profile matched the RP profile until Week 54 after the drug switch from RP to BS at Week 30. The safety profiles of BS and RP were comparable and the long-term safety of BS was confirmed. BS demonstrated equivalent efficacy and safety to RP at treatment weeks 14 and 30, and long-term safety until Week 54 in Japanese RA patients.

ES15-1 Clinical impact of recent advances of molecular biology on rheumatoid arthritis: from bench to bedside
Keishi Fujio
Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo

Conflict of interest: Yes

In the treatment of rheumatoid arthritis (RA), treatment results are dramatically improved by the use of biological products, and clinical remission can be achieved in about half of patients. However, in about half of the remaining cases, the therapeutic effect is insufficient, and we often experience patients who are refractory to multiple biologic preparations and show rapid progress of bone destruction. Therefore, for better medical care, it is necessary to advance the elucidation of further pathological conditions of RA and select appropriate treatment. The heterogeneity of the therapeutic reactivity of RA makes it possible to speculate that various immunocompetent cells and immunological pathways are involved in the disease state. Various analytical methods have become applicable to human specimens in recent years. Mass cytometry, single cell analysis, and functional genome analysis are being applied to analysis of RA. As a result, evidence of the involvement of various immunocompetent cells in RA has been accumulated based on the peripheral blood immunocompetent cells, the local histology of inflammation and genetic risk. Epigenetic control of lymphocytes and synovial fibroblasts, which has not been previously clarified, is also becoming apparent at a deeper level. Classification of the pathological condition of RA will enable us to stratify the treatment and prognosis. Questions to be addressed are what kind of pathways are related to therapeutic reactivity and, how immune cells are modified in relation to the disease duration. With multi-subset transcriptome analyses, we have found that certain innate immunity pathways are related to therapeutic response of RA. We also address the nature of epigenetic modification unique to RA synovial fibroblasts. Further research is necessary until stratification that can be clinically applied. In this seminar, based on the latest knowledge of integrated analysis in RA, I would like to discuss the pathogenesis and treatment of RA.

ES15-2 The future of rheumatoid arthritis therapies: from life-changing to life-saving
Gurkirpal Singh
Division of Gastroenterology and Hepatology, Stanford University, USA

Conflict of interest: Yes

Recent advances in therapy of rheumatoid arthritis have led to major improvements in clinical and quality-of-life outcomes. Early aggressive treatments with “treat to target” strategies have resulted in considerably better disease control and less joint destruction. Indeed, therapies with biologic agents have been shown to reverse joint destruction, an outcome unheard of just a few years ago. We have changed lives of patients. I believe the future of rheumatoid arthritis therapies is to save lives. It is well-known that patients with RA have considerable excess mortality compared to age and gender-matched cohorts, with coronary heart disease (CHD) accounting for the largest excess. At the same time, recent studies in pathogenesis of CHD in the general population have emphasized the role of inflammation. It is now believed that the major effects of statins in reducing morbidity and mortality relate to their effects on inflammation rather than just cholesterol reduction. It is possible that the excess coronary CHD incidence in RA is likely because of high levels of circulating cytokines that enhance inflammation in the vulnerable plaque. Indeed, our work and that of others have identified RA as a CHD-equivalent risk factor, similar to diabetes. Essentially, this means that patients with RA need to be assessed as having CHD even if there are no other risk factors, just as is the practice with diabetes. However, these issues are still not widely recognized, unlike in diabetes care. Our work has shown that while CHD mortality in diabetes has declines dramatically in the US, there has been a similar significant change in RA. In my lecture, I will further explore the factors leading to premature death in RA and how we can change assessment, monitoring and treatment of our patients in order to reduce this risk. Time has come for us to move to the next step of “saving lives” from just “changing lives”.

S64
ES16  
Biotechnology-based drugs and molecularly targeted drugs in treatment of rheumatoid arthritis  
Atsushi Kawakami  
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan  
Conflict of interest: Yes  

Establishment of 2010 American College of Rheumatology (ACR)/European League Against Rheumatism (EULAR) rheumatoid arthritis (RA) criteria, development of disease-modifying antirheumatic drugs (DMARDs), that of clinical practice guideline (CPG) and recommendation, spread of magnetic resonance imaging and ultrasonography have resulted in significant progress regarding to diagnosis as well as therapy of RA. Molecularily targeted drugs markedly contribute to anti-rheumatic therapy development of RA and divided into biological DMARDs (bDMARDs) and targeted synthetic DMARDs (tsDMARDs). bDMARDs significantly suppress inflammation as well as joint destruction and are recommended to introduce in clinical practice in Phase II in case conventional synthetic DMARDs (csDMARDs) such as MTX and sulfasalazine (Phase I) does not achieve improvement at 3 months and target at 6 months or Phase III bDMARDs or Jak-inhibitor does not achieve the goal at 3/6 months stated in Japan College of Rheumatology (JCR) RA CPG 2014 as well as EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. bDMARDs of RA include TNF-inhibitors, abatacept, IL-6 receptor blocker and rituximab (not approved in Japan) and their efficacy is approved by clinical trials and studies toward csDMARDs-incomplete responder (IR) and TNF-inhibitors-IR (except TNF-inhibitors), Jak-inhibitors, tofacitinib and baricitinib, are classified as tsDMARDs and the clinical trial data has been piled up towards MTX-naive subjects, csDMARDs-IR and TNF-inhibitors-IR. Jak-inhibitors are recommended to introduce in Phase II or Phase III in EULAR recommendations 2016 update whereas Phase III in JCR RA CPG 2014. Efficacy of bDMARDs and Jak-inhibitors is excellent whereas molecularly targeted drugs are in some cases difficult to be introduced by high cost. Recently, efficacy as well as safety of biosimilars have been proved in clinical trials and the use of biosimilars is stated in the literatures including EULAR recommendations. The introduction of biosimilars into clinical practice will significantly improve the financial cost of RA treatment. The evidence of molecularily targeted drugs, including biosimilars, in RA treatment, will be discussed in this seminar.

ES17-1  
Usefulness of baricitinib in RA treatment  
Hideto Kameda  
Faculty of Medicine, Toho University, Tokyo, Japan  
Conflict of interest: None

The development and maintenance of rheumatoid arthritis are achieved through the network of various immune-related cells via the secretion of cytokines and cell-cell interaction. There are several ways to inhibit cytokine activity; the use of biologics which bind to the cytokine itself or its receptors and inhibit their activity on the surface or outside of immune-related cells; or the use of small-molecule kinase inhibitors which inhibit the intercellular cytokine signaling. For the former, due to its high “specificity”, it is important to administer the sufficient dose of biologics to completely inhibit the function of the targeted single cytokine. Therefore, it is difficult to identify the optimal dose for the amount of cytokine expression level of every patients. The latter, on the other hand, as the word “selectivity” indicates, partially inhibits the function of several cytokines with the limited dosing options to avoid off-target cellular toxicity. Baricitinib is a Janus kinase (JAK) inhibitor characterized by its high selectivity for JAK 1 and JAK 2 over JAK 3. Although the primary dosage has been set to 4mg daily administration because of its excellent potential for remission induction, 2mg daily administration is also possible according to the patient conditions. The usefulness of baricitinib will be explored in this symposium by both basic and clinical data of it.

ES17-2  
The JAK Era has Come  
Gerd R Burmester  
Department of Rheumatology and Clinical Immunology, Charite University Hospital, Berlin  
Conflict of interest: Yes

In 2016 EULAR Recommendation update, JAK inhibitors were recommended to be used in phase 2 of the treatment algorithm after csDMARD, however, with a note that biologics may still have advantage due to robust real-world experience. Since then, we have gathered enough real-world experience with JAK inhibitors for us to be able to see what benefits JAK inhibitors can bring to RA treatment, which may exceed the outcome with past treatment. In this presentation, I will discuss when JAK inhibitors might be used in 1st line therapy after csDMARDs, and also the characteristics of patients who would benefit most with JAK treatment.

ES18-1  
Potential pathogenicity of autoantibodies in rheumatoid arthritis  
Masataka Kuwana  
Department of Allergy and Rheumatology, Nippon Medical School  
Conflict of interest: Yes

A variety of autoantibodies are detected in patients with connective tissue diseases, and are utilized in clinical practice in making diagnosis and clinical subssetting. However, there has long been believed that those autoantibodies are produced as an “epi-phenomenon” reflecting ongoing pathogenic process, and lack pathogenicity by themselves, unlike autoantibodies detected in organ-specific autoimmune diseases. Autoantibodies related to RA include anti-citrullinated protein antibody (ACPA) and rheumatoid factor (RF), which are useful for making diagnosis and are thus included in the classification criteria. Recently, it has been shown that production of ACPA/RF precedes many years before onset of synovitis, and a new term “pre-RA” has been proposed as a condition of positive RA autoantibodies without any joint symptom or inflammation. RA autoantibodies are produced in genetically susceptible individuals by accumulation of environmental factors, such as smoking and periodontitis, leading to onset of synovitis through increase in antibody titters and epitope-spreading. On the other hand, high levels of RA autoantibodies are known as prognostic factor, which predict rapid joint destruction, as well as efficacy of some molecular-targeting anti-rheumatic drugs such as abatacept. Recently, a number of basic researches have revealed that ACPA is indeed involved in pathogenic process and contributes to joint destruction, through promoting differentiation of precursors into osteoclasts and triggering production of inflammatory cytokines such as TNFα, IL-6, and IL-8 by formation of immune complexes. Immunological remission is now proposed as a concept of disappearance of RA autoantibodies beyond clinical, functional, and imaging remission as the most challenging treatment goal. This lecture features recent insights into pathogenicity of RA autoantibodies and their clinical significance.

ES18-2  
Biomarker of Rheumatoid Arthritis and Its Application to Treatment Selection  
Yoshiya Tanaka  
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan  
Conflict of interest: Yes

The introduction of biological products resulted in a paradigm shift in the treatment of rheumatoid arthritis (RA), which is closely linked to the presence of standard measurements as a background factor, enabling precise and objective evaluation of disease activity and treatment response. Such measurements must be excellent in terms of versatility, economy, and reproducibility. In this manner, the disease activity index including DAS28 and SDAI satisfies these conditions. Biomarkers such as MMP-3 and multi-component markers such as MBDA are also applicable based on the state of the disease. Widely accepted imaging evalu-
tion, such as modified Total Sharp Score by joint X-ray and magnetic resonance (MR) imaging scoring, aimed for strict structural assessment, also resulted in great achievement in setting therapeutic goals. Meanwhile, no disease-specific marker, such as HbA1c for diabetes mellitus, has been identified for rheumatoid arthritis. However, in TNF inhibitor treatment, it is believed that the serum level of its ligand TNF is useful for determining drug selection and/or treatment response. In the TSUBAME Study, the association between the level of serum TNF and IL-6 was analyzed before and at 24 hours after treatment, and DAS 28 (ESR) at 12 weeks after treatment when certolizumab pegol (CZP) was additionally administered to 85 patients with RA who had sufficient response to MTX had not been obtained. At 24 hours after treatment, the blood level of CZP varied widely, and the median value was 9.4 (0.2-31.8) μg/mL, while the serum TNF and IL-6 levels had significantly decreased. In addition, the serum CZP level had a strong negative correlation with the serum TNF level at 24 hours later. DAS28 (ESR) was significantly improved from 5.5 ± 1.3 to 3.4 ± 1.5 at 12 weeks after treatment. Remission at 12 weeks later was not associated with the serum TNF or IL-6 level before treatment, but with lower serum TNF level, lower IL-6 level, and higher CZP level at 24 hours after treatment according to univariate analysis, whereas it was associated only with lower serum TNF level at 24 hours later according to multivariate analysis. These findings suggested that the blood level of CZP was negatively correlated with the serum level of the ligand, TNF at 24 hours after treatment, and that the lower serum TNF level at only 24 hours after treatment predicted the treatment response at 12 weeks later. At present, biological products have been applied for various collagen and rheumatic diseases, resulting in therapeutic breakthroughs in each area. The introduced biological products targeting TNF, IL-17, and IL-12/IL-23 result in innovative efficacy in psoriatic arthritis, associated with progressive spinal joint damage, as is the case with rheumatoid arthritis. It is found that using different biological antirheumatic drugs targeting either IL-12, IL-17, or TNF leads to a high treatment response in patients with psoriatic arthritis classified into four immunological phenotypes according to the expression pattern of peripheral lymphocyte chemokine receptor. This suggested the potential of precision medicine, optimized target therapy using lymphocyte immunological phenotype as a biomarker. The achievements mentioned above are expected to contribute to the establishment of a novel therapeutic system and strategy.

ES19-1
RA hand surgery in T2T era~ from the basics to difficult cases~
Natsuko Nakagawa
Department of Orthopaedic Surgery, Rheumatology & Collagen Disease Center, Hyogo Prefectural Kakogawa Medical Center

Conflict of interest: None

The treatment of rheumatoid arthritis (RA) has remarkably progressed. Tight control of RA disease activity makes it possible to inhibit the progression of the joint destruction. For this reason, small joint surgeries are assumed to increase in number, and RA hand surgery to be more important. On the other hand, because of this era, unsolved problems of RA hand could accumulate significantly in the near future. This study group seminar, which has been held annually since 1999, celebrates the 21st seminar this year. We are planning to have two sessions, which are audience-participating case study using Answer Pad and a special lecture with the theme of “RA hand surgery in T2T era~from the basics to difficult cases~. In case study, we will present some cases, and we would like to discuss with participants how to treat with them applying the basic concepts. For the special lecture, Dr. Keiichiro Nishida will give a lecture on surgical reconstruction of rheumatoid wrist-basic procedures and management of difficult cases-. In this seminar, we would like to make this workshop useful for clinical practice of all participants with all our effort.

ES19-2
Surgical reconstruction of rheumatoid wrist- basic procedures and management of difficult cases-
Keiichiro Nishida
Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Methotrexate (MTX) is globally considered as the anchor drug for the treatment of RA even in the biologic era. Therefore, MTX is used in more than 80% of RA patients by monotherapy or combination therapy. High-dose MTX up to 16 mg/week was approved in 2011. The PMS results showed the percentage of patients who achieved remission nearly tripled in cases of MTX more than 8 mg/week. The MTX guideline 2016 update recommends that a target of dose response is 10 to 12 mg/week based on the recent evidences and referred rapid dose escalation for the patients who have poor prognostic factors. On the other hand, 730 fatal cases possibly associated with MTX were reported by December 2017 after the marketing approval for MTX and among them, 175 patients died after 2011. Deaths associated with infections or neoplasms (lymphoproliferative disorder, LPD) are increasing, specifically, infections in 25.1% and LPD in 21.7%. The demographic analysis of patients who died of infections showed 75% of patients were aged 70 years or above, 35% of patients were treated with MTX 10 mg/week or above, and about a half of the patients were treated for 2 years or longer. Since 2014, more than 60% of patients with serious infections, were treated with concomitant biologics or JAK inhibitors, and 36.7% were treated with oral MTX 10 mg/week or above. Common serious infections included pneumonia and pneumocystis pneumonia. Chronic opportunistic infections such as TB, fungal infection, herpes infection, and nontuberculous mycobacterium infection are also increasing. Patients who died of neoplasms (LPD) since 2011 were also mostly elderly: 87.1% were aged 60 years or above. Patients treated with MTX 10 mg/week or above were only 15.3% while those treated for 2 years or longer were 54.4%. Of 457 patients with LPD, 88.0% were treated with MTX for 2 years or longer. Attention is required for elderly patients treated with oral MTX for a long time. Outcomes of the latest RA treatment have been dramatically improved because of the use of high-dose MTX as the anchor drug and the proactive concomitant use of molecular-targeted drugs in patients inadequately responsive to MTX. Considering the recent trends of adverse reactions and the aging of RA patients, however, immunosuppression relief after long-term remission should be required.
Conflict of interest: None

[W1-4] Successful rituximab therapy for refractory rapidly progressive interstitial lung disease in a patient with anti-MDA5 antibody-positive dermatomyositis
Shogo Kodama, Takashi Ozaki, Tatsuhito Umeki, Yuichi Omura, Masataka Torigoe, Chiharu Imada, Keisuke Maeshima, Koji Ishii, Hirotaka Shibata
Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Faculty of Medicine, Oita University, Oita, Japan

Conflict of interest: None

[Object] It is well known that patients with anti-MDA5 antibody (MDA5-Ab)-positive dermatomyositis (DM) could follow a lethal course despite intensive immunosuppressive therapy with steroids, calcineurin inhibitors, and intravenous pulse cyclophosphamide (IVCY). Herein, we report a case with MDA5-Ab-positive DM who developed refractory RP-ILD that was markedly relieved after rituximab (RTX) treatment.

Case report: A 54-year-old man with several months’ history of skin rash and muscle pain was admitted in another hospital and diagnosed with MDA5-Ab-positive DM complicated with ILD. He was immediately given pulse methylprednisolone, followed by oral prednisolone (1mg/kg/day) combined with tacrolimus (TAC) and IVCY. Nevertheless, his CT showed ILD progression. Moreover, he developed deep neck abscess and he was transferred to our institution on 24th day. Therapeutic plasma exchange was added to combination therapy with steroids, TAC and IVCY, which was ineffective for progressive ILD. Consequently, RTX therapy (375mg/m²/W for 4 weeks) was initiated on 39th day. A follow-up CT after RTX administration demonstrated marked improvement and he was discharged on the 165th day.

Conclusions: RTX treatment might be potential therapeutic option for refractory RP-ILD in MDA5-Ab-positive DM.

W1-5 Efficacy of plasma exchange for patients with anti-melanoma differentiation antigen 5 antibody-positive dermatomyositis at our hospital
Yukiko Iwasaki1, Aya Nishihara1, Haruka Takahashi1, Akti Kawamura1, Risa Yoshihara1, Haruka Tsuchiya1, Toshikiho Komai1, Norio Hanata1, Bunki Natsumoto1, Yusuke Sugimoto2, Akihiko Matsumoto2, Rei Ishikiri2, Yumi Tsuchida2, Yasuo Nagafuchi2, Oh Sasaki2, Hiroaki Harada1, Shuji Sumitomo1, Hirofumi Shoda1, Kanae Kubo1, Masao Nangaku2, Keishi Fujiyoshi1
1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 2Department of Internal Medicine IV, Osaka Medical College Hospital

Conflict of interest: None

[Object] Anti-aminoacyl-tRNA synthetase (anti-ARS) antibodies related interstitial lung disease (ILD) often recurred. Our objective was to clarify the efficacy of initial treatment with corticosteroids (CS) and calcineurin inhibitor (CNI), significant of recurrence, and predictive factors for recurrence in patients with ARS-ILD. [Methods] We retrospectively identified consecutive ARS-ILD patients treated with CS and CNI from 2006 to 2017. [Results] Fifty-seven patients were included and 53 improved by one year initial treatment. KL-6 changed with disease behavior. Thirty-two recurred in maintenance therapy. No significant difference was obtained between baseline patients’ characteristics with or without recurrence. KL-6 at recurrence increased from remission in all patients. In the recurrence group, respiratory function declined over the course of analysis, KL-6 increase rate from remission and CNI discontinued were independent predictive factors for recurrence. No relationship was observed between CNI continued period and recurrence. No relationship was observed between CNI continued period and recurrence. [Conclusions] In ARS-ILD, CS and CNI were well re-administered for recurrence in patients with ARS-ILD. No significant difference was observed between baseline patients’ characteristics with or without recurrence.

W1-6 Therapeutic apheresis therapy for rapid progressive interstitial pneumonia of clinically amyopathic dermatomyositis with anti-MDA5 antibody
Maki Kajitani1, Hidehiko Makino2, Shogo Matsuda2, Takaaki Ishida1, Youhei Fujiki1, Kenichiro Hata1, Tohru Takeuchi1, Shigeaki Makino1, Shigeaki Arawaka1
1Blood Purification Center, Osaka Medical College Hospital, 2Department of Internal Medicine IV, Osaka Medical College, Division of Immunology and Rheumatology, Osaka Medical College, Mishima Minimai Hospital

Conflict of interest: None

[Object] Interstitial pneumonia (IP) of clinically amyopathic dermatomyositis (CADM) with anti MDA-5 antibody typically shows rapid progress and high mortality in spite of several immunosuppression agents. [Methods] About seven cases who were performed therapeutic apheresis therapy, we assess the efficacy by some clinical functions, and outcomes. [Results] Seven cases who were given therapeutic apheresis therapy; PE/PMX 1, SePE/PMX1, PMX 2, PE/SePE 1, PE1, SePE 1. At 1year after apheresis therapy, 4 cases are alive, 2 are dead by reactivation and one is dead by laryngeal cancer. The anti-MDA5 Ab titer was decrease in three cases whose titer was detected. A-aDO2 and F/P ratio were also resolved. All cases were recovered from critical situation. [Conclusions] Therapeutic apheresis therapy is effective in controlling CADM-IP with anti MDA-5 antibody.

W2-1 Prognosis and causes of deaths of polymyositis and dermatomyositis patients with interstitial pneumonia
Shigeki Makino1, Takuya Kotani1, Takeshi Shoda2, Hidehiko Makino1, Youhei Fujiki1, Tohru Takeuchi1, Shigeaki Arawaka1
1Division of Internal Medicine, Osaka Medical College Mishima-Minami Hospital, 2Department of Internal Medicine IV, Osaka Medical College, Takatsuki, Osaka, Japan

Conflict of interest: Yes

[Background] We aim to know the influence of interstitial pneumonia (IP) involvement on prognosis of polymyositis and dermatomyositis (PM/DM). [Methods] We reviewed clinical data concerning about prognosis and causes of deaths of PM/DM-IP patients of our institute from August 2008 to July 2018. [Results] Total PM/DM-IP patients are 197 (57 males, average 64.1 years). Comparing PM/DM patients without IP (69cases, 23 males, average 58.9 years), PM/DM-IP patients were older and female dominant. Total dead cases were 39 (18males). 5-year survival rate of PM/DM-IP patients was 73.9%, 10-year survival rate was 51.9%. Deaths within 1 year were 23 (59%). Concerning about the causes of deaths of PM/DM-IP patients, early IP deaths were 21 cases, chronic progression of IP were 4, acute exacerbation of IP were 3, lung cancer were 1, other malignancy were 4, infection were 5. Total death due to IP were 28 (72%). [Conclusions] PM/DM-IP patients of our institute were older and female dominant compared to PM/DM patients without IP. 5-year survival rate of RA-IP patients was 73.9%, 10-year survival rate was 51.9%.
Deaths within 1 year were 23 (59%). Total death due to IP were 28 (72%). So IP of PM/DM profoundly influence on prognosis of PM/DM-IP patients.

**W2-2**
Clinical features and prognosis of interstitial pneumonia associated with anti-MDA5 antibody positive dermatomyositis
Ai Umeda, Takako Hashimoto, Natsuko Watanabe, Masashi Suzuki, Tatsuki Naganawa, Konomi Ashihara, Megumi Kurumizawa, Daisuke Hirano, Jo Nishino, Shusaku Fukaya, Shunji Yoshida, Hidekata Yatsuoka
Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine

Conflict of interest: None

[Object] To examine clinical features and prognosis for anti-MDA5 antibody positive dermatomyositis associated interstitial pneumonia (DM-IP) patients. [Methods] We investigated clinical features and prognosis retrospectively for anti-MDA5 antibody positive DM-IP patients hospitalized in our hospital between January 2010 and October 2018. [Results] In 19 cases (7 males), the average age at diagnosis was 54.9 years. There were 8 deaths. Male mortality rate was high (85.7%). In all death cases, triple combination therapy (steroid, calcineurin inhibitor and IVCY) was performed. In two death cases, other immunosuppressants were added to triple therapy. On the other hand, no additional immunosuppressants other than triple therapy was required in the surviving cases. Serum ferritin levels before treatment were significantly higher in the death group. In long-term survival cases, 2 of 10 cases required reintroduction with IVCY due to IP relapse. [Conclusions] Although the ferritin levels before treatment is useful for the prognosis prediction, the case of poor prognosis in the initial treatment was difficult to rescue even with a strong immunosuppressive combination therapy. In long-term survival cases there may be recurrence, but re-induction can be introduced by resuming IVCY.

**W2-3**
Change in serum ferritin levels during therapy is related to disease activity in patients with anti-MDA5 Antibody-positive dermatomyositis
Satoko Arai, Kazuhiro Kurasawa, Yuta Takamura, Tomoyoshi Miyao, Junya Nagasawa, Ryutaro Yamazaki, Takayoshi Owada, Reika Maezawa, Masafumi Arima
Department of Rheumatology, Dokkyo Medical University

Conflict of interest: None

[Object] To determine whether serum ferritin levels during the therapy are related to disease activity and predicts prognosis in patients with anti-MDA5 Ab + dermatomyositis (DM). [Methods] Subjects were consecutive 20 anti-MDA5 Ab + DM patients who admitted Dokkyo Medical University hospital from 2009 to 2015. The relation between serum ferritin levels during treatment for DM and prognosis of patients was analyzed. [Results] Of 20 subjects, 19 developed ILD, 17 of which was rapidly progressive ILD, 9 survived and 11 died. Time of death was 16 to 64 days (median: 41 days). Within 2 weeks starting therapy, serum ferritin levels were increased in all patients with poor prognosis, while 4 out 7 survivors showed the increase. After 2 week-therapy, none of the survivors did not show the increase of serum ferritin levels. In contrast, the continuous rise of ferritin levels were found in 6 of 7 patients with poor prognosis. The peak of serum ferritin levels was in 0-3 weeks (median: 0 week) in the survivor, but at 2-5 week (4 week) in dead patients. [Conclusions] Patients were poor in prognosis, when ferritin levels continuously increase, the decrease of ferritin levels was slow, or ferritin levels show re-elevation.

**W2-4**
Increased serum leucine-rich alpha2-glycoprotein (LRG) levels are correlated with the disease activity, progression, and prognosis of interstitial pneumonia in patients with dermatomyositis
Takaaki Ishida1, Takuya Kotani2, Minoru Fujimoto3, Tohru Takeuchi4, Shigeki Makino5, Shigeki Arakawa6, Tetsuji Naka7
1Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan, 2Center for Intractable Immune Disease, Kochi Medical School, Kochi University, Kochi, Japan, 3Internal Medicine, Osaka Medical College Mishima-Minami Hospital, Osaka, Japan

Conflict of interest: None

[Objective] To investigate whether leucine-rich α2-glycoprotein (LRG) can be a biomarker for interstitial pneumonia (IP) in patients with dermatomyositis (DM). [Methods] Correlations between the clinical findings and serum LRG levels were investigated in 46 patients with DM-IP. [Results] The median levels of serum LRG at baseline, and 2 and 4 weeks after the initiation of treatment in patients who died were significantly higher than those in surviving patients (P = 0.026, 0.029, 0.008). The median level of serum LRG in the DM-IP patients was significantly higher than that in the DM-CIP patients (P = 0.0004), and that in the anti-MDA5-Ab-positive group was slightly higher than that in the anti-ARS-Ab-positive group. The serum LRG levels were significantly correlated with the serum levels of LDH, CRP, ferritin, AaDO2, %D Lex, and the total GGO score. The survival rate after 24 weeks in patient with an initial LRG level of ≥17.6 pg/mL was significantly lower than that in patients with an initial LRG level of <17.6 pg/mL (P = 0.0009). [Conclusions] The serum LRG level may be a promising marker of the disease activity, progression, and prognosis in patients with DM-IP.

**W2-5**
Retrospective analysis on the relapse of polymyositis / dermatomyositis after achieving remission
Akiko Shibata, Yusuke Okada, Kentaro Chino, Takahiko Kurasawa, Hirofumi Takei, Tsuneo Kondo, Koichi Amano
Division of Rheumatology/Clinical Immunology, Department of Internal Medicine, Saitama Medical Center, Saitama Medical University

Conflict of interest: None

[Object] To elucidate the current situation of polymyositis (PM) / dermatomyositis (DM) after achieving remission in our department. [Methods] 71 PM/DM patients who have visited our department from October 2017 to October 2018 and had been diagnosed and initiated treatment in our department after April 2005, were enrolled and clinical information were analysed retrospectively from medical records. [Results] 15 cases experienced relapse (relapse rate 21%). There was no significant difference in the background features of 56 patients who were maintenance group and relapse group between 2 groups. The mean initial daily PSL dose for remission induction therapy in both groups was 47 mg and 52 mg, and immunosuppressant was used in 66% and 100% respectively and the difference was not significant. In the relapse group, 6 cases had recurrence of myositis after achieving remission (average period was 45 months), and 9 cases had worsening of interstitial pneumonia after remission (average 72 months). [Conclusions] Relapse was seen in 21% of PM/DM patients who achieved remission. Relapse rate of interstitial pneumonia was higher than that of myositis. There was no significant difference in clinical features or initial treatment between remission maintenance group and relapse group.

**W2-6**
An analysis for detecting a poor prognostic factor in polymyositis and dermatomyositis in the modern period -The result of a single-center cohort study-
Hiroshi Otwa1, Kei Araki2, Yohei Hosokawa3, Masamoto Funaki4
1Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, 2Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, 3Medical Cooperation JR Hiroshima Hospital

Conflict of interest: None

[Objective] To detect a poor prognostic factor in polymyositis and dermatomyositis (PM/DM) in the modern period. [Method] All the newly-diagnosed myositis cases, seen between April 2014 and June 2018, were included. Probable or definite cases based on the Bohan & Peter cri-
W3-1 Vascular ultrasound findings in assessing disease activity of Takayasu Arteritis (TAK)
Kasumi Takagi1, Yuichiro Shirai1, Takashi Nawata1,2, Shunsuke Uchiyama1, Seiji Kobayashi1, Takahisa Gono1, Mitsuhito Takeno1, Ikuyo Takagi1, Masataka Kuvana1
1Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan
2Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan
Conflict of interest: None

[Background] Regarding a need for a method of monitoring disease activity under treatment, we report two cases of TAK in which ultrasound (US) findings have changed over time. [Case1] A 18-year-old Japanese male with fever and fatigue showed bilateral carotid artery thickening and hyperemia of blood flow. Computed tomography (CT) revealed wall thickening of ascending aorta and its branches. He was diagnosed as having TAK. Treatment with prednisone (PSL) (30 mg/day) and tocilizumab was started. One month later, he had a relapse when tapered PSL to 15 mg/day, with carotid dilatation, CRP elevation (<0.03 to 0.12 mg/dL), and increased intima-media thickness (IMT) of left carotid artery (2.44 to 2.61 mm) by US. After PSL was increased, symptoms improved. [Case2] A 18-year-old Japanese male with fever and weight loss showed upper abdominal wall thickening. CT revealed wall thickening of thoracic and abdominal aorta, and superior mesenteric artery (SMA). He was diagnosed as having TAK. Treatment with PSL (50 mg/day) and azathioprine was started. One month later, upper abdominal wall thickening was inaudible and US revealed reduced IMT of SMA (1.7 to 1.3 mm). [Discussion] US can detect the lesion of large vessel vasculitis noninvasively and repeatedly. It could be a useful tool for assessing disease activity.

Conflict of interest: None

W3-2 Carotid ultrasonography was useful in evaluating the activity of Takayasu arteritis treated with Tocilizumab (TCZ)
Ryutaro Yamanaka, Kazuya Matsumoto, Shiochi Nawachi, Reika Hayashi, Hidetoshi Kagawa
Department of Internal Medicine, Japanese Red Cross Himieji Hospital
Conflict of interest: None

A 27-year-old woman admitted to our hospital because of high grade fever and neck pain. We diagnosed Takayasu arteritis with MRI, carotid ultrasonography showed common carotid artery wall thickening. We started treatment with PSL 50 mg/day. When we reduced PSL to 20 mg/day, the CRP value elevated. Therefore, PSL was increased to 30 mg/day, and MTX was started in combination. The CRP value again elevated, when we increased MTX to 12 mg/w and reduced PSL to 20 mg/day. We considered relapse and started using TCZ. After we used TCZ, we gradually decreased PSL, because the CRP value remained negative. After decreasing PSL to 7.5 mg/day, exacerbation of wall thickness of the common carotid artery was observed by carotid ultrasonography, so we increased to PSL 20 mg/day again. While TCZ is in use, there is a possibility that the activity still remains even though the CRP is normal. There is a risk that the finding of relapse may be delayed if activity is evaluated only by blood test. When TCZ was used, it was considered that it is necessary to periodically evaluate the activity in the imaging test. As in this case, if the active lesion is confined to the neck, it seems that evaluation by ultrasonography is useful even from the viewpoint of radiation exposure and cost.

W3-3 Usefulness of the detection of carotid artery wall blood flow signal by Super Micro-vascular Imaging (SMI) for the assessment of silent vasculitic disease activity of Takayasu arteritis
Yusuke Okada, Akiko Shibata, Kentaro Chino, Takahiko Kurasawa, Hirofumi Takei, Tsuneo Kondo, Koichi Amano
Department of Rheumatology and Clinical Immunology, Saitama Medical Center
Conflict of interest: Yes

Objectives: To investigate the usefulness of the detection of carotid artery (CA) wall blood flow signal by SMI for the assessment of vasculitic activity of Takayasu Arteritis (TAK). Methods: Four patients who had been newly diagnosed in our department from May 2015 to October 2018 and had received SMI to detect CA wall blood flow signal were retrospectively analyzed. Results: All patients were female, mean 26 years old, mean CRP 8.13 mg/dL. CA wall thickening had been confirmed by ultrasonotomography and contrast CT and the SMI signal was detected. After treatment with Steroid, CRP returned to negative and no exacerbations in CT and MRI findings in all 4 cases. In cases 1 and 2 had been treated with 1 mg/kg/day of PSL, the SMI signal remained detected after 2 weeks of treatment. Two weeks after the addition of tocilizumab, the SMI signal decreased in case 1, and disappeared in case 2. In case 3 had been treated similarly with 1 mg/kg/day of PSL, the SMI signal became undetected after 2 weeks, and continued to be undetected every several months until month 30. In the fourth patient with aortic regurgitation who underwent steroid pulse therapy, the SMI signal disappeared at week 2. Conclusions: SMI is useful as a method of evaluating latent vasculitic activity of TA with CA lesion.

W3-4 Myocardial FDG-PET/CT findings in children with Takayasu arteritis
Kenichi Nishimura, Seira Hattori, Ai Ohnishi, Ryoki Hara, Shuichi Ito
Department of Pediatrics, Yokohama City University Graduate School of Medicine
Conflict of interest: Yes

[Object] To analysis the FDG-PET/CT (PET/CT) findings in children with Takayasu arteritis (TA) except for vascular lesions. [Methods] This is a single-center retrospective observational study. We evaluated 9 children with TA and compared them with 10 children with other rheumatic disease (systemic juvenile idiopathic arthritis; 5, polyarticular juvenile idiopathic arthritis; 1, juvenile dermatomyositis; 2, Crohn’s disease; 2, Kikuchi’s disease; 1) (control group). All children were underwent PET/CT before treatment from April 2015 to March 2018. [Results] Median age of performed PET/CT was 13.9 (range; 11.1-14.9) years old in TA children and 5.4 (1.4-12.4) years old in control group. Both group included 6 females. FDG accumulation in left ventricular myocardium was observed in 8 TA patients (89%) but in 3 (30%) of control group (p=0.02). Six TA children received follow-up PET/CT. Myocardium FDG accumulation was continued in 3 children, but resolved in 2. TA children with persistent accumulation in myocardium had ascending aorta dilation later. [Conclusions] FDG accumulation in left ventricular myocardium would be a characteristic findings in children with TA, and possibly related to later ascending aorta dilation.

W3-5 The availability of temporal artery ultrasound and temporal artery biopsy in giant cell arteritis
Yasuhiro Nohda, Saori Hatachi, Saki Mukohara, Norihiko Amano, Katsuhiko Yoneda, Soshi Takahashi, Miwa Nishida, Shunichi Kumagai
Department of Rheumatic Disease, Shinko Kinen Hospital

Conflict of interest: None

[Object] Temporal artery biopsy (TAB) has long been the gold standard for the diagnosis of giant cell arteritis (GCA), but we need more accessible and less invasive tools. Recently, the availability of temporal artery ultrasound (TAU) is widespread. We examined the classification between TAU and TAB. [Methods] We examined the results of TAU and TAB in 16 patients who fulfilled the 1990 ACR classification criteria for GCA between April 2010 and October 2018. [Results] Five patents had already received immunosuppressant therapy. All patients presented with new headache, temporal artery abnormality and elevation of erythrocyte sedimentation rate. In TAU, 15 patients had wall thickening, and 8 of whom had also hypo-echoic halo. In TAB, 13 patients had a positive biopsy. All 8 patients who had hypo-echoic halo in TAU demonstrated multinucleated giant cells and fragmentation of lamina in TAB. On the other hand, in 7 patients who had nonspecific wall thickening in TAU, 5 patients had a positive biopsy. [Conclusions] TAB may not be necessary if hypo-echoic halo is observed in TAU. On the other hand, TAB is useful in case who had only nonspecific wall thickening in TAU.

W3-6 Consideration of picture images and establishment of foundation knowledge for eradicate blindness about Giant cell arteritis

Toshio Kawamoto1, Michihiro Ogasaawa1, Souichiro Nakano2, Yuko Matsuki-Muramoto1, Masakazu Matsuhashita1, Kenjiro Yamanaka3, Ken Yamaji1, Naoto Tamura1
1 Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Internal Medicine and Rheumatology, Juntendo University Koshigaya Hospital, 3 Department of Allergy and Clinical Immunology, Yamanashi Prefectural Central Hospital

Conflict of interest: None

[Object] In the 2018 EULAR recommendations, IVUS and MRI are the first-choice diagnostic methods, while CTA, MRI, and PET/CT are considered alternative methods. Since IVUSs and CTAs may be as useful as biopsies or PET/CTs in the diagnosis of GCA, we evaluated multiple cases. [Methods] The clinical and serological characteristics, imaging findings, and biopsy findings from 14 cases of GCA from our hospital, within the past 5 years were compared and evaluated. [Results] With respect to the aggregated results of the findings obtained from our hospital over the past 5 years, CTA sensitivity for GCA diagnoses was 84%, and CTAs were considered to have favorable clinical utility. Four out of 6 cases had positive biopsy results and positive CTA findings, and cases with negative CTA findings also had negative findings as a result of other imaging tests, indicating that biopsy is indispensable in cases involving negative imaging findings. [Conclusions] We believe that the use of CTA, in conjunction with noninvasive IVUS, is useful as a diagnostic imaging method for GCA. We propose a GCA diagnostic approach that considers the usage of a temporal artery biopsy. We are going to establish foundation knowledge for eradicate blindness by constructing GCA hotline with neurology and ophthalmology.

W4-1 Change in immune phenotype by the treatment of large vessel vasculitis

Shingo Nakayamada, Yusuke Miyazaki, Hiroko Yoshinari, Akio Kawabe, Ippei Miyagawa, Satoshi Kubo, Shunsuke Furuta, Shigeru Iwata, Kazuhiro Nakano, Yoshiya Tanaka
The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan

Conflict of interest: Yes

[Object] The pathogenesis of large vessel vasculitis (LVV) such as Takayasu arteritis (TAK) and giant cell arteritis (GCA) consists of an immune abnormality; however, little is known about pathological immune cell subsets in LVV. [Methods] PBMC were obtained from 18 LVV patients (TAK 6, GCA 12) and 14 healthy donors (HD). Phenotype of immune cells was defined by flow cytometric analysis. [Results] The proportion of activated Th17 cells, Th1 cells in TAK and that of activated Th17 cells and Th1 cells in GCA were higher compared with HD. The immunosuppressive therapy improved the disease activity in all patients. The frequency of Th17 cells in TAK and that of Th1 cells in GCA was reduced by 24-week treatment with high dose glucocorticoid (GC). However, the frequency of Th17 cells was not changed by high dose GC. Of note, tocilizumab decreased the proportion of activated Th17 cells and increased the proportion of Treg cells in both TAK and GCA. [Conclusions] These results imply that IL-6 blockade may alter the balance of Th17/Treg cells by reducing Th17 but increasing Treg cell in LVV patients.

W4-2 Clinical features of large vessel vasculitis

Yui Kosumi, Hiroyuki Nakamura, Hiroshi Iesaka, Toshiyuki Watanabe, Tetsuya Horita
Tomakomai City Hospital, Tomakomai, Japan

Conflict of interest: None

[Object] To clarify clinical features of large vessel vasculitis (LVV). [Methods] Consecutive patients who were diagnosed with giant cell arteritis (GCA) or Takayasu arteritis (TA) from 2010 to 2018 were enrolled in this retrospective study. We clarified clinical characteristics and evaluated efficacy of radiographical and pathological examination for the diagnosis of LVV. [Results] A total of 32 patients were diagnosed with LVV (GCA; 26, TA; 6). Median age was 69 and 26 years old, respectively. Nineteen (73%) patients with GCA and all with TA were female. Fever was the most frequent symptom, which was found in 16 (62%) patients with GCA and 5 (83%) with TA, followed by headache in 12 (46%) with GCA and malaise in 3 (50%) with TA. Out of 21 patients who were performed with temporal artery biopsy, 11 were diagnosed with biopsy-proven GCA. Seven out of 11 biopsy-proven GCA patients had neither headache nor under jaw claudication. All patients with GCA and TA were treated with glucocorticoids. Due to the lack of treatment efficacy, immunosuppressive agents were added to 9 and 4 patients with GCA and TA, respectively. [Conclusions] Temporal artery biopsy might be recommended for patients with suspicion of GCA regardless of head symptoms.

W4-3 Validation of a score for assessment of radiologic damage in large-vessel vasculitis (Combined Arteritis Damage Score, CARDS)

Daiki Nakagomi1,2, Kei Kobayashi2, Shunsuke Furuta1, Kimie Harama1, Shinichiro Hanai1,2, Takeyuki Kanzaki1, Takao Sugiyama1, Hiroshi Nakajima1, Kenichiro Kitamura1,2
1Third Department of Internal Medicine, University of Yamanashi Hospital, 2Center for Clinical Immunology and Rheumatology, University of Yamanashi Hospital, 3Department of Allergy and Clinical Immunology, Chiba University Hospital, 4Department of Rheumatology, Shimoshiizu Hospital, National Hospital Organization, 5Department of Internal Medicine, Yamanashi Prefectural Central Hospital

Conflict of interest: None

Objective This study aimed to validate a radiologic damage score in large-vessel vasculitis (LVV) which was proposed to determine the optimized weight of imaging findings. Methods We identified 59 TAK and 62 GCA patients from four Hospitals in Japan. We evaluated stenosis, occlusion and aneurysm in 25 arterial regions from carotid artery to iliac artery with enhanced CT or MRI / MRA. We calculated the “Combined Arteritis Damage Score (CARDS)”. That was number of mild stenosis, <50% × 0.6 + number of moderate to severe stenosis, 50-99% × 1.2 + number of occlusions × 1.6 + number of aneurysms × 0.8. We compared CARDS to patient background. Results Mean age at onset in TAK was 29 years and GCA was 70 years. Female was 83% in TAK, 74% in GCA. The median of delay from symptom onset to diagnosis was 7 months in TAK, and 3 months in GCA. Median CRP and ESR level at diagnosis was 7.6mg/dl and 70mm/h in TAK, and 8.5mg/dl and 80mm/h in GCA. Frequency of arterial lesion including stenosis, occlusion and aneurism were higher in TAK than GCA. As a result, median CARDS was higher in TAK than GCA. Conclusion TAK was severer than GCA in radiologic damage in Japanese cohort. This results supports that TAK and GCA in...
W4-4
Study on the relationship between serum ALP and giant cell arteritis
Shogo Furukawa, Kumiko Shimoyama, Daisuke Suzuki, Noriyoshi Ogawa
Division of Immunology and Rheumatology, Hamamatsu University School of Medicine

Conflict of interest: None

[Object] Vascularitis has few biomarkers (e.g. CRP, ESR), and there are cases in which diagnosis and treatment are difficult. It is reported that serum ALP is elevated at the time of diagnosis of large-vessel vasculitis and normalized in response to treatment. Therefore, we examined the relationship between vasculitis and ALP in Japanese patients with large-vessel vasculitis. [Methods] We studied 19 cases of giant cell arteritis diagnosed from 2000 to 2019. We examined these cases retrospectively by dividing two groups, ALP elevated group (ALP group) and the control group. [Results] There were 4 cases (21%) in the ALP group. The CRP level was higher (14.3 vs 8.39 mg/dL) as compared with the control group. ESR (120.7 vs 103 mm/h) and the platelet count (50.2 vs 36.6 x10^9 / μL) were also higher. AST (38.7 vs 25 U/mL) and ALT (61.2 vs 24.0 U/mL) were slightly higher in the ALP group. There was only one case in both groups that showed loss of visual acuity. Serum ALP decreased promptly in response to the treatment in all 4 cases of ALP group. [Conclusions] The mechanism of ALP elevation and the pathological significance in large-vessel vasculitis are not clear. ALP could be a novel biomarker for large-vessel vasculitis, further accumulation of cases is necessary.

W4-5
The risk of cranial ischemic complications due to giant cell arteritis is related to the period of clinical manifestations
Yusuke Yoshida, Kei Araki, Hiroki Kohno, Tomohiro Sugimoto, Kazutoshi Yukawa, Tatsuomi Kuranobu, Tadahiro Tokunaga, Katsuhiro Oh, Sho Mokuda, Keisuke Oda, Takaki Nojima, Shintaro Hirata, Eiji Sugiyama
Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan

Conflict of interest: None

[Object] To clarify the risk factors of cranial ischemic complications (CICs) such as ischemic optic neuropathy or stroke in patients with giant cell arteritis (GCA) [Methods] Patients diagnosed with GCA at our hospital were consecutively registered from January 2009 to September 2018. The diagnosis of GCA was made by 1990 ACR criteria for GCA. [Results] A total of 19 patients were diagnosed with GCA. The mean age was 75.8 years old and 10 were males. Temporary artery (TA) abnormality on examination, positive for TA ultrasound, positive for TA biopsy and the complication of polymyalgia rheumatica (PMR) and CICs were observed in 73.7%, 70%, 87.5%, 42.1% and 26.3%, respectively. The mean period from the onset of PMR symptoms, such as arthralgia or myalgia, or general symptoms to the diagnosis of GCA was 6.4 months. And that of GCA symptoms, such as new onset of headache, awareness of TA abnormality or jaw claudication, was 1.9 months. All of the patients who were within 2 weeks from GCA symptom onset to GCA diagnosis didn’t develop CICs, but the patients over 10 months from the onset of PMR or general symptom to GCA diagnosis developed CICs more frequently. [Conclusions] The long period from the onset of symptoms to the diagnosis can be a risk factor of CICs in patients with GCA.

W4-6
Outcome of 115 patients with polymyalgia Rheumatica (PMR)
Akiko Ueno, Kei Hirose, Manami Hirata, Yu里o Yamamura, Noriya Momoki, Masahiro Yamamura
Department of Rheumatology, Okayama Saiseikai General Hospital

Conflict of interest: None

[Object] To invest the outcome of PMR patients diagnosed with 2012 EULAR / ACR PMR classification criteria [Methods] We have followed up 115 patients diagnosed with 2012 EULAR/ACR criteria of PMR. [Results] Male / female ratio: 1 : 1.26, age of onset 73.9±9.9 years old, observation period 44.5± 26.1 months, 6 out of 115 patients diagnosed as cancer within 2 years, 7 of whom died did. Three patients had spondyloarthitis, three had rheumatoid arthritis, one had ANCA-associated vasculitis, and one had unexplained arthritis and diagnosis changed. There was no change in PMR diagnosis for 101 other people. 41 out of 101 people recalled, 30 additional MTXs, 8 additional TCZs, outcome on the left: 47 healing cases. Maximum amount of steroids and platelet was high, and cases with low IgA were highly flareshed. [Conclusions] These results indicate that other diseases were merged or diagnosed during the course of 12.1%, and reexamination of the diagnosis / condition at the time of relapse was important.

W5-1
Risk factors for clinical fracture in RA patients
Shukou Tsumoto1, Kentaro Inui1, Yuko Sugio2, Tadashi Okano1, Masahiro Tada1, Tatsuya Koike1, Hitoshi Yoshimura1, Hiroaki Nakamura1, Saiseikai Nakatsu Hospital, Osaka, Japan, 1Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka Japan, 2Department of Orthopedic Surgery, Osaka City General Hospital, Osaka, Japan

Conflict of interest: None

[Object] We examined how bone quality would influence the rate of clinical fracture with 8 year cohort study. [Methods] Using the date of cohort study (TOMORROW, UMIN000003876), we examined risk factors for clinical fracture using multiple regression analysis. We measured BMD and also pentosidine/non-carboxyl osteocalcin/homocysteine as the marker of bone quality. [Results] Comparing RA patients (RA) and volunteers (Vo), the level of bone quality marker was higher in RA, but number of fractures showed no difference. Comparing fracture group (Fx), and non-fracture group (nFx), age (average age Fx:58.2 years, nFx:62.9 years) and urine pentosidine (average Fx:60.2ug/mg/Cre, nFx:75.6ug/mg/Cre) was significantly higher, BMD was significantly lower in Fx. Age (OR:1.05, 95%CI 1.02-1.09, p<0.001) was 95% was a significant risk marker for fracture. Fracture incidence was higher in RA and was 3.4% in RA and 1.8% in Vo. Bone quality marker and BMD rate of change were not the predictive factors for clinical fracture. [Conclusion] The rate of clinical fracture of RA was same as the Vo. It is also revealed that bone quality marker are not the predictive factor and BMD rate was the wuppessor factor for clinical fracture.

W5-2
Influence on disease activity and inflammatory biomarkers provided by orthopedic reconstruction surgery in patients with rheumatoid arthritis
Junji Hayashi, Sachiko Araki, Satoshi Nakamura, Yukiko Sato
Joint Reconstruction & Rheumatic Center, Niihashiki Central General Hospital

Conflict of interest: None

[Object] To examine the effect of orthopedic reconstruction surgery on disease activity and inflammatory biomarkers in patients with rheumatoid arthritis. [Methods] 87 patients who were passed 2years after surgery and did not undergo other orthopedic surgery in the past 2years were investigated. We investigated the transition of DAS28, CRP, MMP-3, mHAQ before and 2years after surgery. In addition, we classified it into two groups, a treatment strengthening group which started, increased and switched bDMARDs after surgery, and another treatment maintenance group, and examined the transition in the same way. Logistic regression analysis was also performed for each parameter between the two groups. [Results] DAS28, CRP, MMP-3, and mHAQ were significantly lower after surgery than before surgery. In both DAS28 and MMP-3, both groups were significantly decreased after surgery. Significant differences were found between the two groups in terms of age, MTX use, DAS28, CRP
and MMP-3 at the time of surgery, and knee joint surgery. [Conclusions] Orthopedic reconstruction surgery alone can improve disease activity, inflammatory biomarkers. However, when knee joint surgery is performed for younger patients with high disease activity and inflammatory biomarkers, there is a high possibility that treatment will be strengthened.

W5-3
Relation between radiographic findings before total joint arthroplasty and backgrounds in rheumatoid arthritis patients
Nobuyuki Asai1,2, Shuji Asai1,2, Yoshihisa Kojima2, Nobunori Takahashi2, Takuya Matsumoto2, Yasumori Sobue2, Tsuyoshi Nishiuine2, Mochihito Suzuki2, Naoki Ishiguro2
1Department of Orthopaedic Surgery and Rheumatology, NHO Nagoya Center, Nagoya, Japan
2Department of Orthopedic Surgery, Nagoya University School of Medicine, Nagoya, Japan
Conflict of interest: None

[Object] The present study was undertaken to investigate relation between radiographic findings before total joint arthroplasty and backgrounds in RA patients. [Methods] This study included 317 RA patients who underwent primary total joint arthroplasty (knee, hip, elbow, and ankle) in Nagoya University Hospital from 2007 to 2017. We conducted multivariate analysis for patient characteristics between osteophyte group (n = 229) and non-osteophyte group (n = 88). [Results] Disease duration (17 vs 13 years), rate of TEA (14% vs 6%), and rate of CRP negative (48% vs 28%) were significantly higher, and prednisone use (45% vs 63%) was significantly lower in osteophyte group than non-osteophyte group. Multivariate analysis showed disease duration (OR: 1.04, 95% CI: 1.01-1.07), prednisone use (OR: 0.49, 95% CI: 0.29-0.83), and CRP negative (OR: 0.53-0.75) contributed to osteophyte formation. [Conclusions] In RA patients without use of prednisone and CRP negative, radiographic findings show osteophyte formation before total joint arthroplasty.

W5-4
Are clinical symptoms related with hindfoot alignment after hindfoot fusion in rheumatoid arthritis?
Hiromu Ito, Ryo Sugita, Takuya Tomizawa, Koichi Murata, Shuichi Suzuki
Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine
Conflict of interest: Yes

[Object] Hindfoot arthrodesis is the major operative treatment for deformed joints and disability of the hindfoot in patients with rheumatoid arthritis (RA). However, the relationship between clinical outcome and postoperative alignment remains unverified. [Methods] We conducted a prospective comparative study in a hindfoot operation cohort. A total of 57 hindfoot arthrodesis conducted for RA patients out of 80 total operations were followed for at least one year with a complete data set and were eligible for further analyses. Clinical outcome was compared between OA and RA patients using JSSF ankle/hindfoot scale, and the association between the sale and postoperative alignment was analyzed. [Results] Clinical outcome significantly improved from 40.8 to 56.4 postoperatively. However, the outcome was better in non-RA patients with the score of 70.1, postoperatively. The postoperative alignments were significantly worse in Calcaneal pitch in RA than in OA. Patients with flatfoot deformity showed worse outcome than non-flatfoot patients both in RA and non-RA patients, and RA group had more flatfoot patients than non-RA group. [Conclusions] Flatfoot deformity could be a contributing factor for worse clinical outcome in RA patients who underwent hindfoot arthrodesis.

W5-5
Surgical outcome of lumbar spinal instrumented and fusion in patients of lumbar spinal disorders with rheumatoid arthritis
Hiroshi Takahashi, Arata Nakajima, Masato Sonobe, Manabu Yamada, Shiko Nakano, Koichi Nakagawa
Department of Orthopaedic Surgery, Toho University Sakura Medical Center
Conflict of interest: None

[Object] To evaluate the surgical outcome of lumbar spinal instrumented and fusion in patients of lumbar spinal disorders with rheumatoid arthritis (RA). Methods: 10 patients of RA who underwent lumbar instrumented and fusion surgery from 2011 to 2017 (RA group) and 31 consecutive patients of non-RA patients who underwent TLIF from 2016 to 2017 (C group) were included. We evaluated the rate of screw loosening (RA group: 90, C group: 138 screws), fusion rate using X-ray and CT at the final follow-up, and clinical outcome usingVAS and ODI. Results: The rate of screw loosening was 23.3% (21/90) in RA group whereas 5.8% (8/138) in C group that indicated a significant increase of screw loosening was observed in RA group compared with that in C group (p<0.01). Especially in the RA group, the rate of screw loosening of 6 patients using steroid is 27.3% (24/88). On the other hands, the fusion rate was 70% (7/10) in RA group whereas 83.8% (26/31) in C group that did not show significant difference. VAS and ODI showed significant improvement in RA group as well as C group. Conclusion: In the lumbar spinal instrumented fusion of patients with RA, screw loosening occurred at a high rate. However, the fusion rate and clinical improvement in RA group was favorable compared with non-RA group.

W5-6
Perioperative management in RA treated with Tofacitinib
Tomomitsu Hashiguchi, Seiichi Kawamura, Kenichi Seo
The Department of Orthopedic Surgery, Japanese Red Cross Oita Hospital
Conflict of interest: None

[Object] Tofacitinib (TOF) inhibits the multiple cytokines involved in the inflammatory cascade, hence there is concern over the side effect of infection. The perioperative management of RA treated with TOF is a major concern among orthopaedic surgeons. On the other hand, it is unknown about delayed wound healing (DWH) and surgical site infection (SSI), flare up of rheumatic symptoms in RA treated with TOF during the perioperative period. The purpose of this study is to investigate DWH/SSI and flare up of the disease in patients with RA to make an useful perioperative guideline. [Methods] Between January 2015 and October 2018, we experienced 23 operations in RA patients treated with TOF. The average pre-operative TOF discontinuation period was 2.3 days. Oral administration of TOF was restarted after removal of stitches and the total perioperative discontinuation of TOF was 18.7 days on an average. [Results] In this study, 2 of 23 cases had DWH, and Flare up of RA occurred in 9 of 23 cases on average 13.3 days after discontinuation of TOF. [Conclusions] We require further investigation about DWH/SSI and flare up of rheumatic symptoms during perioperative period in RA treated with TOF.

W6-1
Bone mineral density in postmenopausal women correlates with body mass index for lumbar spine, while it correlates with muscular volume for proximal femur
Ichiro Yoshii1, Tatsumi Chijiwa2, Naoya Sawada3
1Rheumatology and Musculoskeletal Medicine, Yoshii Hospital, 2Department of Rheumatology, Kochi Memorial Hospital, 3Department of Rheumatology, Dohgo Spa Hospital
Conflict of interest: None

[Object] Factors that influence on bone mineral density (BMD) for postmenopausal women in each part of lumbar spine and proximal femur were analyzed statistically. [Methods] BMD was measured for 426 postmenopausal women from May to August 2018. Their BMD were re-calculated for the correction of age, and each of these values in lumbar spine (LS), femoral neck (FN), greater trochanter (GT), and whole femur (WF) was set as dependent variable, while creatinine creatatin-C ratio (Cr/CysC), rheumatoid arthritis suffered (RA), body mass index (BMI), history of spinal compression fracture or severe deformity due to osteoarthritis (DS), glucocorticoid steroid administration for more than three months
(GCS), were set as independent variant. Then statistical evaluations were performed with multivariate linear regression analysis. Significant level was set within 5%. [Results] LS correlated with RA and BMI, while FN, GT, and WF correlated with Cr/CysC and RA, significantly. [Conclusions] There is different mechanism influencing on BMD between LS and femur. In LS, BMI, namely gravity has influence on BMD, while muscular volume had influence in proximal femur. Common factor was RA.

W6-2
Factors that affect bone mineral density in rheumatoid arthritis patient
Different factors works separately on each of lumbar spine and femur
Ichiro Yoshii¹, Tatsumi Chijiwa²
¹Rheumatology and Musculoskeletal Medicine, Yoshii Hospital, ²Department of Rheumatology, Kochi Memorial Hospital, ³Department of Rheumatology, Doho Spa Hospital

Conflict of interest: None

[Object] Factors that influence on bone mineral density (BMD) for rheumatoid arthritis (RA) patient in each part of the lumbar spine and proximal femur were analyzed statistically. [Methods] BMD was measured for 197 postmenopausal women from May to August 2018. Each BMD in lumbar spine (LS) and femoral neck (FN) was set as dependent variant, while age, sex, glucocorticoid administration for more than 3 months (GCS), creatinine cystatin-C ratio (Cr/CysC), 28-joints disease activity score (DAS28), modified Health Assessment Questionnaire (mHAQ), each component of EuroQol 5-dimensions (EQ-5D) were set as independent variant. Then statistical evaluations were performed with single and multivariate linear regression analysis (SLR and MLR). Significant level was set within 5%. [Results] Significant factors in LS were age, sex, GCS, DAS28, mHAQ, and gait, prepare and activity of EQ-5D with SLR, and sex, age, sex, GCS, Cr/CysC, mHAQ, and pain of EQ-5D with SLR, and age and sex with MLR. [Conclusions] There is different mechanism influencing BMD between LS and femur in RA patient. In treating osteoporosis for RA patients, attention to their age, sex, and BMI in each bone area must be paid.

W6-3
Risk factors for lumbar and femoral bone loss in patients with rheumatoid arthritis (RA)
Noriko Sasaki, Takayuki Wakabayashi, Yasuo Suzuki
Division of Rheumatology, Tokai University Hachioji Hospital, Tokyo, Japan

Conflict of interest: None

[Object] To clarify the risk factors for lumbar and femoral bone loss, we measured bone mineral density (BMD) of lumbar spine (L2-4) and femoral neck and investigate the following factors: age/ gender, BMI, duration of RA, stage/class, disease activity (DAS), RA therapy in 263 patients with RA (male 34, female 229, mean age 68.7). Among them, 139 patients were taking glucocorticoid (GC). Influence of RA activity and therapy for osteoporosis was investigated in 145 patients whose BMD was measured at more than 2 points. [Results] The patients who showed lower lumbar BMD (<80% YAM) also had lower BMD of femoral neck and distal radius. However, lower femoral BMD was not associated with lower lumbar and radial BMD. Old age, female, and BMI were identified as risk factors for both lumbar and femoral bone loss. In contrast, loss of femoral BMD was associated with high disease activity with elevated ESR and CRP, the duration of RA, and advanced stage. About a half of patients who were not taking medicine for osteoporosis showed reduction of BMD at both sites. About 80% and 60% of the patients who were treated with denosumab and bisphosphonates respectively, showed an increase in femoral BMD. Femoral BMD in RA patients.

W6-4
Early efficacy of bisphosphonate and denosumab on bone microstructure in rheumatoid arthritis
Ikuko Tanaka¹, Takashi Kato², Motokazu Kai², Kunikazu Ogawa³, Hiroaki Mizuno¹, Hisaji Oshima¹, Shigenori Tamaki¹
¹Nagoya Rheumatology Clinic. Nagoya, Japan, ²Department of Radiology, National Center for Geriatrics and Gerontology, Obu, Japan, ³Mie Rheumatology Clinic. Suzuki, Japan, ⁴Department of Connective Tissue Disease. Tokyo, Japan, Tokyo Medical Center

Conflict of interest: None

[Object] In this study, the early effect on bone microstructure by osteoporosis treatments was examined in RA patients using HR-pQCT. [Methods] 16 subjects treated with Bisphosphonate (group B) and 6 patients treated with Denosumab (group D) who examined with HR-pQCT within 3 to 6 months after starting administration were included. [Results] Total volumetric Bone Mineral Density (Tvt.vBMD) was significantly higher in Group D compared to Group B (P < 0.05) in the pre-treatment measurements. In the comparison before and after treatment, there was a significant increase in cortical vBMD (Ct.vBMD) in Group B (P < 0.01), while in Group D, Tvt.vBMD (P < 0.01), Ct.vBMD (P < 0.05), inner trabecular vBMD was significantly increased (P < 0.05). In the comparison of the changes before and after the administration, Tvt.vBMD (P < 0.01), the cortical area (P < 0.05), trabecular BMD (P < 0.05), the metal trabecular vBMD (P < 0.05) of D group increased significantly. [Conclusions] In RA patient using HRpQCT, both Bisphosphonate and Denosumab showed an increase in Ct.vBMD in the early stage of administration, and Denosumab showed effects in trabecular bone.

W6-5
Study on early effect of daily teriparatide with HR-pQCT in rheumatoid arthritis patients with marked reduction in cancellous bone
Ikuko Tanaka¹, Takashi Kato², Motokazu Kai², Kunikazu Ogawa³, Hiroaki Mizuno¹, Hisaji Oshima¹, Shigenori Tamaki³
¹Nagoya Rheumatology Clinic. Nagoya, Japan, ²Department of Radiology, National Center for Geriatrics and Gerontology, Obu, Japan, ³Mie Rheumatology Clinic. Suzuki, Japan, ⁴Department of Connective Tissue Disease. Tokyo Medical Center, Tokyo, Japan

Conflict of interest: None

[Object] In this study, we examined the change in bone microstructure 3 month after administration of daily teriparatide (dPTH) to RA patients with markedly decreased cancellous bone. [Methods] 4 patients (group P) treated with dPTH and 12 patients (group B) treated with bisphosphonate were analyzed. [Result] There was no significant difference in total bone mineral density (BMD) and cortical BMD, and the cancellous BMD showed effects in trabecular bone.

W6-6
Relation between varus alignment and posterior slope of the tibial articular surface in knees with medial osteoarthritis
Ryuji Nagamine¹, Wajia Chen¹, Toru Suguro²
¹Center of Artificial Joint and Rheumatism, Fukuoka Tokushukai Medical Center, ²Research Institute of Rheumatology Medical Treatment

Conflict of interest: None

[Object] Relation between varus angle (VTA) and posterior slope angle (PSA) of the tibial articular surface (TAS) was assessed in 100 case with medial OA and 21 cases with RA. [Methods] In each case, the VTA between the anatomical axis of the tibia and the TAS on the AP view ra
diograph of the tibia and the PTS between the line along the anterior cortex of the tibial shaft and the TAS on the lateral view radiograph of the knee were measured. The angle AWC between the line along the anterior cortex and the anterior wall of the tibial condyle was also measured. [Results] The mean ± SD of VTA and PTS was 6.5° ± 2.5° and 9.2° ± 3.8°, respectively in OA and was 4.7° ± 4.0° and 10.2° ± 3.9°, respectively in RA. The mean ± SD of AWC in OA was 15.6° ± 6.7°. AWC had a significant correlation with PTS. No correlation was found between VTA and PTS. VTA in OA was significantly larger than that in RA. No significant difference was found between PTS in OA and that in RA. The posterior slope of the TAS was created by the posterior rotation of the tibial condyle. We propose a concept of “constitutional posterior rotation”. [Conclusions] There was no correlation between the varus angle and the posterior slope angle of the tibial articular surface even in knees with medial osteoarthritis.

**W7-1**

MMP-3 and bone mineral density in Japanese patients with juvenile idiopathic arthritis from nationwide survey for the core facilities specialized in pediatric rheumatism

Kosuke Shabana1, Nami Okamoto1, Hiroaki Umebayashi2, Naomi Iwata2, Yuka Okura1, Tomohiro Kubota1, Masaki Shimizu1, Yasuo Nakagishi3, Kenichi Nishimura4, Mao Mizuta1, Masato Yashiro1, Takahiro Yasumi12, Junko Yasumura12, Hiroyuki Wakiguchi12, Masaaki Mori13

1Department of Pediatrics, Osaka Medical College, 2Department of General Pediatrics, Miyagi Children’s Hospital, 3Department of Immunology and Infectious Diseases, Aichi Children’s Health and Medical Center, 4Department of Pediatrics, KKR Sapporo Medical Center, 5Department of Pediatrics, Kagoshima University Graduate School of Medicine, 6Department of Pediatrics, Graduate School of Medical Sciences, 7Department of Pediatric Rheumatology, Hyogo Prefectural Kobe Children’s Hospital, 8Department of Pediatrics, Yokohama City University Graduate School of Medicine, 9Department of Pediatrics, Okayama University Hospital, 10Department of Pediatrics, Kyoto University Graduate School of Medicine, 11Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences, 12Department of Pediatrics, Yamaguchi University Graduate School of Medicine, 13Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences

Conflict of interest: None

[Object] We conducted a large-scale survey of MMP-3 and bone mineral density (BMD) for juvenile idiopathic arthritis (JIA) in Japan. [Methods] This first nationwide epidemiological research on JIA was organised by the study group of Ministry of Health, Labour and Welfare at January 2017. We analyzed MMP-3, BMD (DEXA, L2-L4) and administration of treatment. [Results] The data of 726 JIA patients from 15 core facilities were evaluated. MMP-3 was not correlated with JIA disease type but with age. In the cases of non-glucocorticoid (GCs) administration under 12 years old, 76% sensitivity and 64% specificity were indicative of clinical remission if MMP-3 was <10ng/mL. BMD was low in cases with long cumulative GCs dosing period. Pathological fractures (Median 13 months, 157 months, p < 0.01). [Conclusions] The BMD and MMP-3 in JIA in Japan were clarified. It was considered that the risk of pathological fracture was high in JIA with long administration period of GCs.

**W7-2**

Long term illness activity, functional outcomes, and work productivity in juvenile idiopathic arthritis patients

Takayuki Kishi1,2, Yumi Tani1,2, Eiichi Tanaka1, Katsunori Ikari4, Tomoyuki Igarashi5, Tsuyoshi Matsuyama6

1Department of Pediatrics, Tokyo Women’s Medical University, 2Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, 3Department of Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, 4Department of Orthopaedics, Tokyo Women’s Medical University, 5Department of Pediatrics, Nihon Medical University, 6Matsuyama Clinic

[Background] Biologic agents in Japan for polyarticular juvenile idiopathic arthritis (JIA) are four of tocilizumab, etanercept, adalimumab and abatacept as of October 2018. [Object] We studied whether Certolizumab Pegol (CZP) can be administered effectively and safely to the intractable JIA patients in transition phase. [Methods] The subjects were 8 JIA patients (16-26 years old, median 20.5 years) in a phase of transition of 16 years old or who were ineffective in multiple biologic agents. In all cases, the loading dose was administered and the number of tender and swollen joints, patient VAS, doctor VAS, laboratory findings (CRP, MMP-3, etc.), concomitant medications (prednisolone, methotrexate, other DMARDs) were monitored. [Results] In all cases, the symptoms and laboratory findings were improved by 12 weeks after the administration, and concomitant medications could be reduced by a certain amount. Also, no serious adverse events occurred. In 2 cases, it was tracked from the administration until 202 weeks, but the adverse effect of long-term administration was not observed. [Conclusion] CZP is no application for pediatric use and can not be used for JIA cases under 16 years of age, but it was suggested that it is an effective and safe drug for intractable transitional cases.

**W7-3**

Experience of using Certolizumab Pegol for patients with intractable juvenile idiopathic arthritis in transition phase

Yuko Akutsu1, Mariko Moroi2, Tomohiro Morio3, Masaaki Mori4, Asami Oohara1

1Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan, 2Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University, Tokyo, Japan, 3Department of Pediatrics, Tokushima University Graduate School of Medicine, 4Department of Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, 5Department of Pediatrics, Saitama Medical Center, 6Matsuyama Clinic, 7Division of Infectious Disease and Immunology, Saitama Children’s Medical Center, 8Department of Pediatrics, Kagoshima University Graduate School of Medicine, 9Department of Pediatrics, Gunma University School of Medicine, 10Department of Pediatrics, Saitama Medical University, 11Department of Pediatrics, Yokohama City University School of Medicine, 12Department of Pediatrics, Nihon University School of Medicine, 13Department of Pediatrics, Kagoshima University Hospital, 14Department of Pediatrics, Hokkaido University Hospital, 15Division of Infectious Disease and Immunology, Saitama Children’s Medical Center, 16Department of Pediatrics, Shinshu University Department of Pediatrics, Nihon Medical University, 17Matsuyama Clinic, 18Fukujinna Clinic, 19Division of Medical Informatics, St. Marianna University

[Object] We examined juvenile idiopathic arthritis (JIA) patients for long-term illness activity, functional outcomes and work productivity using the Japanese Health Assessment Questionnaire (HAQ), Disease Activity Score (DAS) 28, Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI) and Work Productivity and Activity Impairment (WPAI). [Methods] A retrospective review of these outcomes was performed in 39 patients (Female: 95% with JIA who were diagnosed before the age of 16. The median follow-up duration was 21 years. [Results] The median age at onset of illness in patients was 14 years, and at evaluation was 34 years. The median JHAQ, DAS28, SDAI, and CDAI scores were 0.1, 2.4, 5.3, and 4.8, respectively. Fifty-four percent of patients received NSAIDs at last follow up and 38% received biologic agents. Eighty-seven percent of patients had a job at time of evaluation and had worked 40 hours in one week. The illness condition was affected work productivity in 47% of patients. Work productivity was significantly associated with JHAQ and CDAI. [Conclusions] The majority of patients were maintained with low disease activity and achieved functional remission during long time follow up. The work productivity was associated with functional outcomes.

**W7-4**

Chest computed tomography (CT) findings in patients with anti-MDA5 antibody-positive juvenile dermatomyositis (JDM) complicat-ed by interstitial pneumonia (IP)

Asami Oohara1, Haruna Nakaseko1, Kazuko Yamazaki1, Kenichi Nishimura1, Yutaka Nishida1, Yuichi Yamasaki1, Shunichiro Takegaki1, Satoshi Sato1, Norimoto Kobayashi2, Takayuki Kishi12, Motomo Hashimoto1, Ichiro Kobayashi1, Shinji Akko1, Masaaki Moroi13

1Department of Infection and Immunology, Aichi Children’s Health and Medical Center, 2Department of Pediatrics, Saitama Medical University, 3Department of Pediatrics, Yokohama City University School of Medicine, 4Department of Pediatrics, Saitama Medical Center, 5Department of Pediatrics, Tokyo Medical University, 6Matsuyama Clinic, 7Division of Infectious Disease and Immunology, Saitama Children’s Medical Center, 8Department of Pediatrics, Nihon Medical University School of Medicine, 9Department of Pediatrics, Gunma University School of Medicine, 10Department of Pediatrics, Saitama Medical University, 11Department of Pediatrics, Tokyo Medical and Dental University, Tokyo, Japan, 12Department of Lifetime Clinical Immunology, Tokyo Medical and Dental University, Tokyo, Japan, 13Department of Pediatrics, Tokushima University Graduate School of Medicine, 14Department of Pediatrics, Kagoshima University Hospital, 15Department of Pediatrics, Hokkaido University Hospital, 16Division of Infectious Disease and Immunology, Saitama Children’s Medical Center, 17Department of Pediatrics, Shinshu University Department of Pediatrics, Nihon Medical University, 18Matsuyama Clinic, 19Fukujinna Clinic, 20Division of Medical Informatics, St. Marianna University

Conflict of interest: None

[Background] Biologic agents in Japan for polyarticular juvenile idiopathic arthritis (JIA) are four of tocilizumab, etanercept, adalimumab and abatacept as of October 2018. [Object] We studied whether Certolizumab Pegol (CZP) can be administered effectively and safely to the intractable JIA patients in transition phase. [Methods] The subjects were 8 JIA patients (16-26 years old, median 20.5 years) in a phase of transition of 16 years old or who were ineffective in multiple biologic agents. In all cases, the loading dose was administered and the number of tender and swollen joints, patient VAS, doctor VAS, laboratory findings (CRP, MMP-3, etc.), concomitant medications (prednisolone, methotrexate, other DMARDs) were monitored. [Results] In all cases, the symptoms and laboratory findings were improved by 12 weeks after the administration, and concomitant medications could be reduced by a certain amount. Also, no serious adverse events occurred. In 2 cases, it was tracked from the administration until 202 weeks, but the adverse effect of long-term administration was not observed. [Conclusion] CZP is no application for pediatric use and can not be used for JIA cases under 16 years of age, but it was suggested that it is an effective and safe drug for intractable transitional cases.
ment of Medicine, 1Department of Pediatrics, Tokyo Women’s Medical University, 2Department of Advanced Medicine for Rheumatic Diseases, Kyoto University, 3Center for Pediatric Allergy and Rheumatology, KKR Sapporo Medical Center, 4Department of Pediatrics, Kyoto Prefectural University of Medicine, 5Lifetime Clinical Immunology, Tokyo Medical and Dental University

Conflict of interest: None

[Object] To investigate the chest CT findings related to treatment resistance in patients with anti-MDA5 antibody-positive JDM with IP. [Methods] A multicenter collateral retrospective study. The pattern of CT findings before and after corticosteroid + cyclosporine and/or cyclophosphamide (ground-glass opacity [G], consolidation [C], reticulation [R], or nodule [N]) and the changes were investigated. [Results] Eleven CT images from 10 patients at the time of initial onset and relapse were obtained. The outcomes included 2 mortalities and 8 surviving cases. Before treatment, [G] was observed in all cases, [C] in 7 cases, [R] in 10 and [N] in 3. In the mortality cases, diffuse [G] (central lobular distribution (c): 1 case, c+ panicular lobular distribution (p): 1 case) were observed before treatment. In both cases, [G] did not improve even after treatment. In the surviving cases, diffuse p [G]: 2 cases, random c+ [G]: 1 case, upper lobular p [G]: 1 case, lower lobular c [G]: 1 case/p [G]: 4 cases. After treatment, [G] improved/disappeared promptly in 7 cases. Finally, [C][N] [R] remained, but [G] disappeared. [Conclusions] Special attention may be needed in patients with diffuse [c] including [G] before treatment as well as in cases where [G] does not improve even after treatment.

W7-5 Nephrotoxicity after long-term use of calcineurin inhibitors in patients with juvenile lupus nephritis Masao Ogura1, Kentaro Nishi1, Shuichi Ito1,2 1pediatric Nephrology and Rheumatology, National Center for Child Health and Development, 2Department of Pediatrics, Yokohama City University

Conflict of interest: None

[Object] Efficacy of calcineurin inhibitors (CNI) for lupus nephritis (LN) has been established, but irreversible nephrotoxicity may occur as long-term use. However, there has been few report focusing on CNI nephrotoxicity in patients with LN. [Methods] Among CNI patients with juvenile LN who were treated in our institute between April 2008 and April 2018. We performed renal biopsy after more than two years from initiation of CNI. [Results] Renal biopsy was performed in 6 patients (male 4, female 2). Tacrolimus (Tac) was used in 5 and cyclosporine (CsA) in one. The median age of CNI initiation was 11.1 years old, the median time from CNI initiation to renal biopsy was 2.3 years (2.2-4.8 years). The eGFR at CNI initiation and at renal biopsy was 111.8 and 100.8 ml/min/1.73 m², respectively (p=0.06). The vascular toxicity of CNI was confirmed in 2 cases; arteriovenous meandering (3.9 years Tac use) and arteriolar sclerosis (4.8 years Tac use). No patient developed glomerular sclerosis or interstitial fibrosis. [Conclusions] As our patients were treated with relatively low dose of CNI, CNI nephrotoxicity might be mild and could be reversible. However, our study suggests that renal biopsy for evaluation of CNI nephrotoxicity should be considered if patient use CNI more than 3 years.

W7-6 Cytokine profile of macrophage activation syndrome associated with Kawasaki disease Naoto Sakumura, Hitoshi Irbu, Maiko Takakuwa, Natsumi Inoue, Mao Mizuta, Masaki Shimizu Department of Pediatrics, School of Medicine, Institute of Medical, Pharmacutical and Health Sciences, Kanazawa University

Conflict of interest: None

[Object] To clarify the kinetics of cytokine release and to compare the accuracy of serum biomarkers for the diagnosis of macrophage activation syndrome (MAS) complicating kawasaki disease (KD). [Methods] We analysed serum IL-18, neopterin, IL-6, STNFR-II and II levels in 78 patients with KD including 5 MAS by enzyme-linked immunosorbent assay. Results were compared with the clinical features of KD and MAS. [Results] Serum IL-18, neopterin, sTNFR-II levels and sTNFR-II/I ratio were significantly elevated in KD patients with MAS compared with those in patients with acute-phase of KD before the administration of intravenous immunoglobulin. Receiver operating characteristic curve analysis revealed area under the curve values and cut off values of IL-18, neopterin, sTNFR-II levels and sTNFR-II/I ratio were 0.9813/1165 ng/ml, 0.9750/30.0 nmol/l, 0.9969/16600 pg/ml, and 0.9875/4.475, respectively. Serum sTNFR-II levels correlated positively with disease activity including serum AST, LDH and fibrinogen levels. [Conclusions] IFN-γ and TNF-α are closely associated with the pathogenesis of MAS associated with KD as well as MAS associated with other diseases such as systemic juvenile idiopathic arthropitis. Serum sTNFR-II might be a useful marker to diagnose the transition to MAS from active-phase KD.

W8-1 Identification of disease related T cell pathways in rheumatoid arthritis Masaru Takeshita1, Katsuya Suzuki1, Yasushi Kondo1, Yuumi Okuzono1, Keiko Koga1, Yoshiaki Kassai1, Kanae Gamo1,2, Maiko Takiguchi1, Rina Kurisu1,Hideyuki Mototani1, Yukihiko Ebusino1, Tsutomu Takeuchi1 1Keio University, 2Takeda Pharmaceutical Company Limited, Research, Immunology Unit, 3FIMECS Inc.

Conflict of interest: Yes

[Object] T cells are considered to be important for the pathogenesis of rheumatoid arthritis (RA). This study aims to identify the features of RA T cells that are most relevant to disease. [Methods] We recruited 10 untreated RA patients, 10 patients receiving MTX, 10 patients receiving MTX and IFX, 10 patients receiving TCZ monotherapy, and 10 age- and gender-matched healthy controls. We freshly sorted CD4-Tn, Tem, and CD8-Tn, Tem, and Temra from their peripheral blood. CD4 and CD8 T cells from 4 synovial fluid of RA were also sorted. In total, 358 samples were prepared and underwent transcriptome analysis. [Results] Samples from peripheral blood clustered according to developmental stage rather than according to the presence of RA or treatment status, whereas synovial fluid T cells seemed to be the most developed. We identified several pathways, such as mTORC1, IL-2-stat5, cell cycle, and interferon-related genes, that were significantly enriched in RA samples, particularly in peripheral blood of RA patients, and interestingly, these features reverted after treatment. [Conclusions] We identified several T cell pathways that were enriched in the synovial fluid and were also observed in the peripheral blood associated with disease status.

W8-2 Abatacept modulates phenotype of circulating monocytes in patients with rheumatoid arthritis (RA) Ryoosuke Fukue, Yuka Okazaki, Masataka Kuwana Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine

Conflict of interest: None

[Object] Abatacept (ABT) inhibits T-cell activation, but recent evidence has indicated that it exerts direct effects on circulating monocytes through CD80/CD86. We investigated effects of ABT on phenotype of circulating monocytes in RA patients. [Methods] We enrolled RA patients with moderate or high disease activity, who were started on ABT or other disease-modifying anti-rheumatic drugs (DMARDs), and whole blood was obtained before, and at 3 months and 6 months after treatment introduction. Whole blood were also obtained from the patients under stable treatment with ABT or other DMARDs for at least 6 months. Multi-color flow cytometry was employed to measure mean fluorescence intensity of CD16, CD32, CD40, CD54, CD62L, CD64, CD80, CD86, CD181, CD182, CD184, CD191, CD192, CD273, CD274, CD275, HLA-DR, and CX3CR1 expressed on CD14+ monocytes. [Results] During ABT treatment, expression levels of CD184, HLA-DR, and CX3CR1 were increased, and those of CD64 and CD273 were decreased. Whereas, patients treated with non-ABT DMARDs exhibited increased expression of
Conflict of interest: None

[W8-4]

Central Sensitization in patients with rheumatoid arthritis using the central sensitization inventory

Moe Saitou, Kentaro Noda, Taro Ukichi, Yohsuke Oto, Kazuhiro Otani, Masayuki Yoshiga, Haruyasu Ito, Ken Yoshida, Daitaro Kurosaka, Moe Saitou, Kentaro Noda, Taro Ukichi, Yohsuke Oto, Kazuhiro Otani, Masayuki Yoshiga, Haruyasu Ito, Ken Yoshida, Daitaro Kurosaka

The Jikei University School of Medicine

Conflict of interest: None

Purpose: The pain of rheumatoid arthritis (RA) is thought to be nociceptive. However, recent studies indicate that RA pain also includes the mechanism of central sensitization (CS). We therefore examined the prevalence of CS among RA patients and the clinical characteristics of these patients. [Methods] The central sensitization inventory (CSI) was used to evaluate 235 outpatients with RA. The disease activity, depression and anxiety, Neuropathic-like pain, Fibromyalgia and health-related quality of life (HRQOL) were evaluated. We compared the clinical parameters between the patients with (CSI≧40) and without (CSI<39) CS. [Results] Eighteen (8.30%) of the RA patients had CS according to the CSI. A multivariate analysis of the clinical parameters associated with CS showed significant differences in EGA (OR 0.597), pain VAS (OR 1.14), FAS-31 (the fibromyalgia activity score 31) (OR 1.89), physical (OR 0.515), mental (OR 0.437), and role-social (OR 0.658) component summary scores on the Short-Form 36-item Health Survey. [Conclusion] Among RA patients with CS, there was a dissociation between EGA and the pain VAS. The proper treatment of CS in RA patients may improve their HRQOL.

Conflict of interest: None

[W8-5]

Research of risk factors related to progression of upper cervical lesion in patients with rheumatoid arthritis under biologics

Hideo Sakane1, Yukio Yonemoto1, Takahito Suto2, Koichi Okamura1, Tetsuya Kaneko1,2, Masahiro Tachibana1, Chisa Okura1, Hirota Chikuda1

1Department of Orthopaedic Surgery, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan, 2Department of Orthopaedic Surgery, Gunma National Hospital, Maebashi, Gunma, Japan

Conflict of interest: None

Purpose: Rheumatoid arthritis (RA) increases in incidence and prevalence with age until about 50 years old in Japanese. As the one of causes of difference in the number of onset of RA among generations, it seems that genetic factors affect the difference. In this study, we searched for genes associated with the onset age of RA. [Methods] We studied 21 patients (male: 3, female: 18) with RA that we could evaluate plain X-ray of the cervical spine and joint (shoulder, elbow, hip, knee, ankle) at the baseline and at 3 years. Patients with RA were 67 years old on average and had mean disease duration of 18 years. Eighty six percent of patients used MTX concomitantly, 5.9mg/week on average, 33% of patients used predonisolone. All patients treated with biologics (infiximab; 2, adalimumab; 8, etanercept; 3, tocilizumab; 8). Evaluation of the cervical spine was X-ray lateral image and atalantodental interval (ADI) and Ranawat values were measured, and the joint destruction of the limb was evaluated by ARASHI score. Serum marker (CRP, ESR, MMP-3), disease activity score (DAS28-ESR) at baseline and 6 months were evaluated. [Results] The increase in ADI was 52.4%, the decrease in Ranawat value was 47.6% at 3 years. There was correlation between the change in ADI and DAS28-ESR at 6 months and its change. But there was no correlation between the change in ADI and the progress of joint destruction in ARASHI score. The correlation between the change in Ranawat value and each parameter was not clear. [Conclusions] Early improvement of the disease activity may delay the progression of the cervical spine lesion in RA.
W9-1
Finger joint cartilage evaluated by ultrasound in patients with rheumatoid arthritis
Takehisa Ogura, Ayako Hirata, Norihide Hayashi, Sayaka Takenaka, Hideki Ito, Yuki Inoue, Chihiro Imaizumi, Kennesuke Mizushima, Takaharu Katagiri, Yuto Takakura, Hitoko Kamedo
Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center
Conflict of interest: None

[Object] Joint destruction in RA includes both bone and cartilage lesions. Since joint space narrowing (JSN) by X-ray is not a direct evaluation of cartilage, we aimed to examine the validity of ultrasound (US) cartilage evaluation in patients with RA. [Methods] We enrolled 103 RA patients in remission or low disease activity and 42 healthy subjects in this study. The cartilage thickness of bilateral MCP and PIP joints of 2nd to 5th fingers was measured by US, followed by the semiquantitative scoring of the recorded images on a scale of 0-2. In addition, JSN of corresponding joints was scored with a hand X-ray. The relationships among the three methods were assessed by Spearman’s rank correlation coefficient. [Results] The total cartilage thickness was significantly thinner in RA patients than those in healthy subjects, and the subsequent semiquantitative sum of 16 joints was significantly greater in RA patients than those in healthy subjects. In RA patients, JSN score showed a significant correlation with cartilage thickness and semiquantitative score (rho=0.57; p<0.001, rho=0.66; p<0.001, respectively). Furthermore, those scores showed a significant correlation with RA disease duration. [Conclusions] Finger joint cartilage damage by US is valid and useful in patients with RA.

W9-2
Prediction of the recurrence after adalimumab discontinuation by using ultrasound assessment -PROUD study-
Tadashi Okano1, Kenji Mamoto1, Tatsuya Koike2,3, Yuko Sugioka4, Masahiro Tada2, Makoto Wada2, Ryota Hara2, Takanori Fujimura2, Sho Sendo2, Takaichi Okano2, Yoshihide Ichise4, Ikuko Naka2, Heiseki Yu4, Akihiko Nakabayashi5, Yoshinobu Matsuura2, Takahiro Yoshikawa2, Masao Tamura6, Masayasu Kitano1, Yasuhide Kanayama7
1Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Center for Semile Degenerative Disease (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan, 3Department of Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan, 4Division of Rheumatology and Clinical Immunology, Sakai City Medical Center, Osaka, Japan, 5Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan, 6Department of Orthopaedic Surgery, Department of Rheumatology, Toyota Kosei Hospital, Toyota, Japan
Conflict of interest: Yes

[Object] We investigated the usefulness of ultrasonography (US) to predict relapse in remission patients with RA after discontinuation of biologic DMARDs. [Methods] The patients using adalimumab (ADA) and in remission (DAS28-CRP<2.6) for more than 24 weeks were included in this multicenter prospective study. ADA was stopped and followed up until week 52 and predictive factor for relapse at 24 and 52 weeks was analyzed from baseline clinical data including US examination. ADA was restarted at the time in relapse (DAS28-CRP≥3.2). US assessment was performed at 0, 12, 24, 36 and 52 weeks and the time of relapse and modified Total Sharp Score (mTSS) was evaluated at 0, 24, and 52 weeks by conventional X-ray. [Results] Fifty-three cases were included and 10 cases (18.9%) were relapse up to week 24 and 20 cases (37.7%) were up to week 52. The relapse patients tended to have long disease duration, but baseline US findings could not predict relapse. Increases in PD score were seen during follow-up in some relapsed patients. Disease activity control was good after restarted ADA in relapsed group, and there was no difference in the progression of mTSS in both relapsed and non-relapsed groups. [Conclusions] It was difficult to predict relapse by US after discontinuation of ADA in remission.

W9-3
Ultrasound-guided synovial biopsy is both safe and tolerable technique with enough quality synovial tissue for clinical assessment
Yasushi Kondo1,2, Katsuya Suzuki3, Shinji Satō3, Tsutomu Takeuchi4
1Division of Rheumatology, Tokai University School of Medicine, 2Division of Rheumatology, Keio University School of Medicine
Conflict of interest: None

[Object] To clarify the safety, tolerability and clinically usefulness of ultrasound (US)-guided synovial biopsy technique. [Methods] Undifferentiated arthritis patients who needed histopathological assessment to determine the cause of arthritis were recruited. All patients were undergone US-guided synovial biopsy and completed a tolerability questionnaire prior to and following biopsy procedures. Synovial tissue was harvested for histopathological analysis and bacterial culture. [Results] Nine patients were included in this analysis and 5 patients were biopsied from wrist and 4 were from knee joint. The mean frequencies of biopsies were 8.1 times per procedure. No significant complications include hematoma, infections and nerve injury were reported following the procedure. We found no significant changes in pain, swelling and stiffness of biopsy sites from before and after procedures. Synovial tissue samples were almost enough quality to assess histopathological analysis and useful for diagnosis of infection or amyloidosis associated arthritis. [Conclusions] US-guided synovial biopsy is a safe and well-tolerated technique for obtaining enough quality of synovial tissue for clinical assessment.

W9-4
Significance of power Doppler ultrasonography for the assessment of response to therapy in peripheral Spondyloarthritis
Keita Fujikawa1, Tomohisa Uchida1, Yushiro Endo2, Akinari Mizokami3, Masanobu Mine1, Atsushi Kawakami4
1Department of Rheumatology, Japan Community Healthcare Organization, Ishahaya General Hospital, 2Department of Immunology and Rheumatology, Unit of Advanced Medical Sciences, Division of Advanced Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 3Department of Rheumatology, Suga Orthopedic Hospital
Conflict of interest: None

[Object] This study investigated the response to therapy of peripheral Spondyloarthritis (pSpA) by power Doppler ultrasonography (PDUS). [Methods] A total 26 patients with active pSpA (24 of uSpA and 2 of PsA) who were treated with csDMARDs or bDMARDs and followed up for more than 6 months were recruited. We assessed the articular synovia, tendons and tendon sheaths, and entheses by PDUS at baseline and follow-up. We evaluated the synovitis score (0-28), tenosynovitis score (0-10), and enthesitis score (0-16) by PDUS and disease activity. [Results] The disease activity decreased from baseline to follow-up; DAPSA from 19.9 to 9.4, ASDAS-CRP from 2.0 to 1.3. 19 patients (73%) fulfilled DAPSA remission criteria. The number of patients with PDUS synovitis decreased from 19 (81%) to 3 (19%), PDUS tenosynovitis 21 (81%) to 5 (19%), and PDUS enthesitis from 26 (100%) to 18 (69%). The synovitis score improved from 1.9 to 0.2, tenosynovitis score from 3.0 to 0.2, enthesitis score from 4.4 to 1.7 (p<0.001, respectively). There was no correlation between each PDUS score and DAPSA or ASDAS-CRP at baseline and follow-up. [Conclusions] This study indicated that synovitis, tenosynovitis and enthesitis by PDUS reflected active inflammation of pSpA and were useful for monitoring the disease activity.

W9-5
The high prevalence of sonographic psoriatic arthritis findings in psoriasis patients without musculoskeletal pain and its clinical significance
Yuya Tabuchi1, Motomu Hashimoto2, Shuji Akizuki3, Ran Nakashima1
1Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, 2Department of Rheumatology and Clinical Immunology, Sakai City Medical Center, Osaka, Japan, 3Division of Rheumatology, Department of Internal Medicine, Takanohara Central Hospital, Osaka, Japan, 4Department of Rheumatology, Toyota Kosei Hospital, Toyota, Japan
Conflict of interest: None

[Object] Joint destruction in RA includes both bone and cartilage lesions. Since joint space narrowing (JSN) by X-ray is not a direct evaluation of cartilage, we aimed to examine the validity of ultrasound (US) cartilage evaluation in patients with RA. [Methods] We enrolled 103 RA patients in remission or low disease activity and 42 healthy subjects in this study. The cartilage thickness of bilateral MCP and PIP joints of 2nd to 5th fingers was measured by US, followed by the semiquantitative scoring of the recorded images on a scale of 0-2. In addition, JSN of corresponding joints was scored with a hand X-ray. The relationships among the three methods were assessed by Spearman’s rank correlation coefficient. [Results] The total cartilage thickness was significantly thinner in RA patients than those in healthy subjects, and the subsequent semiquantitative sum of 16 joints was significantly greater in RA patients than those in healthy subjects. In RA patients, JSN score showed a significant correlation with cartilage thickness and semiquantitative score (rho=0.57; p<0.001, rho=0.66; p<0.001, respectively). Furthermore, those scores showed a significant correlation with RA disease duration. [Conclusions] Finger joint cartilage damage by US is valid and useful in patients with RA.
Kosaku Murakami, Hajime Yoshifuji, Masao Tanaka, Koichiro Ohmura, Kohei Nishitani, Koichi Murata, Hiromu Ito, Tsuneyo Mimori
1Department of Rheumatology and Clinical Immunology, The Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Department of Advanced Medicine of Rheumatic Diseases, The Graduate School of Medicine, Kyoto University, Kyoto, Japan, 3Department of Orthopedics, The Graduate School of Medicine, Kyoto University, Kyoto, Japan

Conflict of interest: None

[Object] To examine the prevalence of sonographic psoriatic arthritis (PsA) in psoriasis patients without musculoskeletal (MSK) pain, and its significance. [Methods] We evaluated 38 consecutive psoriasis outpatients January 2017 to March 2018, using power Doppler (PD) and color superluminal microvascular imaging (cSMI). The dorsal side of the hand (fingers and joints of the digits and wrist) and the Leeds Enthesitis Index (LEI) points on the dominant side were scanned. [Results] In the hand, 82% with MSK pain (n=14 of 17), whose patient’s pain was evaluated or evaluator’s pain was not zero, were PD positive and 88% were cSMI positive, while 71% without MSK pain (n=15 of 21) were PD positive and 95% were cSMI positive. At the LEI points, 29% with MSK pain were PD positive and 29% were cSMI positive, while 24% without MSK pain were PD positive and 33% were cSMI positive. The most frequent Doppler positive sites were the extensor tendons around the PIP joints. The cSMI positivity on any LEI point in patients without MSK pain was positively correlated with ESR, not but CRP. [Conclusions] There was a high prevalence of sonographic PsA findings even in patients without MSK pain, and the cSMI positivity at the LEI points positively correlated with ESR in those patients.

W9-6
Indicators for active musculoskeletal ultrasound findings of psoriatic arthritis vary on each body part
Shuji Sumitomo1, Shoko Tateshii1,2, Harumi Shirai1, Kumiko Ono1, Jun Hirose1, Ayumi Yoshizaki1, Yoshhide Asano1, Shinichi Sato1, Sakae Tanaka1, Keishi Fuji1, Kazuhiko Yamamoto1, Hiroko Kanda1
1Department of Allergy and Rheumatology, The University of Tokyo, Graduate School of Medicine, 2Department of Clinical Laboratory Medicine, The University of Tokyo, Graduate School of Medicine, 3Department of Dermatology, The University of Tokyo, Graduate School of Medicine, 4Department of Orthopaedic Surgery, The University of Tokyo, Faculty of Medicine

Conflict of interest: None

[Object] In this study, the musculoskeletal ultrasound (MSUS) findings were divided into seven body parts (fingers, wrist joints, elbows, shoulders, knees, ankle joints, toes), and the relationship between the clinical index of psoriatic arthritis (PsA) and the MSUS findings of each part was examined. [Methods] Total 98 PsA consecutive cases who fulfilled CASPAR criteria were evaluated. PASDAS, DAPSA, PASLI, DAS28-CRP, DAS28-ESR, BASDAI, SDAI, CDAI, CPDAI were calculated. MSUS evaluated 60 joints, 16 entheses and 24 tendons. The relationship between the clinica scores and the MSUS findings of 7 body parts was analyzed using the Random forest and the Receiver Operating Characteristic (ROC) curve analysis. [Results] DAS 28 in the fingers, wrist, and ankle, BASDAI in the elbow, shoulder and knee is most predictive of active MSUS findings (PD >= 1 in joints or tendons or positive for inflammation scores of adhesion inflammation). [Conclusions] Composite measures predicting active MSUS findings were different according to body parts. BASDAI is important when considering elbow, shoulder and knee, which is presumably related to the importance of the element of enthesitis in these parts. Careful evaluation according to each part is considered important for prediction of MSUS.

W10-1
Retrospective Analysis of clinical features of Methotrexate related Lymphoproliferative Diseases (MTX-LPD) patients with Rheumatoid Arthritis (RA) diagnosed at our hospital
Ryotaro Nagata1, Hiroshi Takei2, Sho Ishigaki2, Yoshiro Kanayama2, Yuto Takakura1, Mayu Nagata1, Satoshi Kawai1, Megumi Iwasaki1, Ryo Hazue1, Hiroaki Taguchi1, Yasuo Ohsone1, Yutaka Okano2
1Department of General Internal Medicine, Kawasaki Municipal Kawasaki Hospital, 2Center for Arthritis and Rheumatic Diseases, Kawasaki Municipal Kawasaki Hospital

Conflict of interest: None

[Object] To clarify the clinical features of poor prognosis MTX-LPD of RA patients in our hospital. [Methods] 26 (22 women, 4 men) of MTX-LPD diagnosed cases from April 2010 to June, 2018 were retrospectively studied by medical record about poor prognosis defined with death or relapse after chemotherapy. [Results] 2 high RA-disease activity and 7 cases with complication of grade 3 or more related to LPD were included. Of 21 biopsies cases,16 came to malignant lymphoma (ML) diagnosis. There were 10 spontaneous regressions, including a relapse after regression,15 chemotherapy cases,2 relapses after chemotherapy and 6 deaths. To compare poor prognosis cases with not, no difference was found about age and MTX dose/duration. B symptoms (85.7 and 22.2%), mean CRP (9.42 and 2.39 mg/dL), LDH (628 and 326 U/mL), and sIL-2R (7667 and 2200 U/mL) were significantly higher in poor prognosis (P <0.05). About Performance Status (PS) decline (PS >3), difference was not found in the comparison (P=0.07), but the correlation of PS decline with B symptom, CRP and sIL-2R was found (P <0.05). The diagnosis of ML was not correlated with prognosis. [Conclusions] Clinical findings related to the severity of LPD which lowers PS, rather than diagnosis of ML, is suggested to be significant prognostic factor for MTX-LPD.

W10-2
Clinicopathological analysis of methotrexate-associated lymphoproliferative disorders in rheumatoid arthritis
Takahiro Okai, Eigo Kikuchi, Naoe Aoki, Taro Yoshioka
Center for Rheumatology and Joint Surgery, Wakawaka General Hospital, Tokyo, Japan

Conflict of interest: None

[Object] To analyze of methotrexate-associated lymphoproliferative disorders (MTX-LPD) in rheumatoid arthritis (RA). [Methods] We performed a retrospective analysis of the RA patient characteristics, clinical features and treatment outcomes of cases with MTX-LPD who were treated from 2008 to 2017 in our center. MTX-LPD was diagnosed based on the histological examination and/or the radiographic findings. [Results] There were 21 RA patients with MTX-LPD (mean age: 77.6 years, mean disease duration of RA: 14.3 years). There were elderly and long RA duration compared with non MTX-LPD RA patients. 14 patients performed histological examination (diffuse large B-cell lymphoma (n=5), immunoblastic T-cell lymphoma (n=2), non-neoplastic tissue (n=4)). Spontaneous regression occurred in 62% (13/21) after MTX discontinuation. 33% (7/21) required additional chemotherapy and/or radiotherapy. Regression was associated with low clinical stage of LPD, low LDH and low soluble IL-2 receptor at the diagnosis of LPD. [Conclusions] The early detection of LPDs and the early cessation of MTX are important for the management of RA patients especially elderly and longstanding history of RA.

W10-3
Clinical features of rheumatoid arthritis complicated by MTX-LPD
Masaru Yoshimura, Hideki Kasahara, Miyuki Bohgaki
NTT-East Sapporo Hospital

Conflict of interest: None

[Objectives] We aim to analyze clinical features of MTX-LPD in our department. [Methods] We examined the clinical pictures of 17 MTX-LPD cases (LPD group), and retrospectively compared LPD group with 326 non MTX-LPD cases (non-LPD group) in 481 RA patients who had visited us as of October, 2018. [Result] In the LPD group, 8 patients had visited us before they developed MTX-LPD. They accounted for about 2.4% of the total patients who had taken MTX in our department. The mean age at onset of MTX-LPD was 67.3±10.8 years, 12 patients were females and 5 were male. The mean disease duration of RA was 15.3±11.9 years, MTX dose was 9.1±2.6 mg/week, mean period of MTX

S79
administration was 6.1±3.6 years, and total cumulative dose was 2359±1750 mg. Pathological findings included 2 follicular lymphoma, 4 DLBCL, 2 Hodgkin lymphoma, 1 lymphomatoid granulomatosis, and 2 polymorphic LPD. Five of 9 cases were EBER positive. The spontaneous regression after stopping MTX was detected 10 cases (58.8 %). The duration of RA in LPD group vs non-LPD group was 15.4±11.9 years vs 8.3±8.5 years (p<0.003). The Steinhocker stage 3 or 4 were 58.8 % vs 20.2 % (p=0.0008). [Conclusion] This study has suggested that duration of RA and Stage 3 and 4 might be associated with development of MTX-LPD.

W10-4
Analysis of the predictive factor and mechanism about spontaneous regression of MTX-LPD
Tomohiro Kameda1, Hiromi Shimada1, Shusaku Nakashima1, Yumi Nomura1, Risa Wakiya1, Mikiya Kato1, Taichi Miyagi1, Hiroaki Dobashi2
1Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan, 2Department of Orthopaedic Surgery, Kagawa University, Kagawa, Japan

Conflict of interest: None

[Object] Recently, there are some reports that the Epstein-Barr virus infection or change of peripheral lymphocyte counts (PLC) after MTX discontinuation is related to spontaneous regression of LPD. We investigate the predictive factor for spontaneous regression and the mechanism of MTX-LPD. [Methods] We enrolled RA patients who developed MTX-LPD, and divided into patients who were followed-up after the discontinuation of MTX alone (SR group) and patients who were receivedchemotherapy (CTx group). The following differences between the two groups were examined: 1) change of PLC after MTX discontinuation, 2) CD8 positive lymphocyte and expression of Granzyme B (GZB) that is the marker of activated T cell of lymphoid cell specimen using immunohistochemistry (IHC). [Results] We enrolled 50 MTX-LPD patients, and divided into 34 patients in SR group and 16 patients in CTx group. In SR group, the PLC significantly elevatedafter MTX discontinuation. In addition, we investigated 12 cases (7 in SR group and 5 in CTx group) that were performed IHC of specimen. CD8 positive lymphocyte counts and the expression of GZB was lower in SR group than CTx group. [Conclusions] We consider that the PLC and the analysis of lymphocyte in biopsy specimen are predictive marker of the spontaneous regression of LPD.

W10-5
Clinicopathological analysis of the influence of calcineurin inhibitors on Lymphoproliferative disorders in patients with Rheumatoid arthritis
Yoshishiko Hoshida1, Shiro Ohshima2, Yukihiko Saeki2, Atsushi Kaneko3, Masao Katayama1, Atsushi Hashimoto1, Kuniko Akiya1, Shigeru Yoshizawa4, Akira Okamoto5, Norie Yoshikawa6, Noriyuki Chiba7, Kenji Ichikawa8, Takao Sugiyaama9, Tomoya Miyamura10, Akiko Mitus11, Atsushi Iha11, Koichiro Takahi12, Yasuo Suenaga13, Hiroshi Tsutani17, Fumonori Hirano14, Shunsuke Mori15, Shigeto Tohma16
1Department of Pathology, NHO Osaka Minami Medical Center, 2Department of Rheumatology, NHO Osaka Minami Medical Center, 3Department of Rheumatology, NHO Nagoya Medical Center, 4Department of Rheumatology, NHO Sagamihara National Hospital, 5Department of Rheumatology, NHO Tokyo Medical Center, 6Department of Rheumatology, NHO Fukuoka Hospital, 7Department of Rheumatology, NHO Himeji Medical Center, 8Department of Rheumatology, NHO Miyakonojo Medical Center, 9Department of Rheumatology, NHO Morokoa Hospital, 10Department of Rheumatology, NHO Hokkaido Medical Center, 11Department of Rheumatology, NHO Shimizou Hospital, 12Department of Rheumatology, NHO Kysyu Medical Center, 13Department of Rheumatology, NHO Disaster Medical Center, 14Department of Rheumatology, NHO Yokohama Medical Center, 15Department of Rheumatology, NHO Toneyama Hospital, 16Department of Rheumatology, NHO Beppu Medical Center, 17Department of Rheumatology, NHO Awara Hospital, 18Department of Rheumatology, NHO Asahikawa Medical Center, 19Department of Rheumatology, NHO Kumamoto Saishunso Hospital, 20Department of Rheumatology, Seirei Hamamatsu General Hospital, 21Infectious Disease Clinic, Seirei Hamamatsu General Hospital

[Object] Since 1999, TAC has been approved for the medical insurance adapted for patients with RA. Currently, approximately 10% of patients with RA received TAC. TAC administration is regarded as a risk factor of the onset of PT-LPD, especially in pediatric liver transplantation. However, whether TAC is related to LPD development like MTX-LPD among the patients with RA remains unclear. [Methods] Sixty-three patients with RA who had been receiving TAC treatment were enrolled for the study at 33 hospitals belonged to the National Hospital Organization. [Results] TAC-LPD and MTX-LPD showed similar clinicopathological characteristics. About 27% of TAC-LPD had developed LPD within 1 year after initiating TAC. In TAC-LPD, one case showed spontaneous regression with withdrawal of TAC only. The 5-year survival rate in TAC-LPD was significantly worse than that in MTX-LPD. Multivariate analysis revealed that TAC was an independent unfavorable prognostic factor. Among the regression cases that were withdrawn from MTX and/or TAC medication after LPD onset, the frequency of recurrence is higher in the cases of newly TAC administration than that in those of continuous TAC administration. [Conclusion] The RA patients taking calcineurin inhibitors should be taken care for the developing LPD.

W10-6
Clinical characteristics of the rheumatoid arthritis patients who developed lymphoproliferative disorder
Daisuke Kobayashi1,2, Yoko Wada1, Satoshi Ito2, Akira Murasawa2, Koji Nakazono2, Hajime Ishikawa2, Ichie Narita1
1Division of Clinical Nephrology and Rheumatology, Niigata University, Niigata, Japan, 2Niigata Rheumatic Center, Niigata, Japan

Conflict of interest: None

[Object] To survey the clinical characteristics of patients with rheumatoid arthritis (RA) who developed Lymphoproliferative disorder (LPD). [Methods] Patient data were obtained retrospectively from medical records. Thirty-two patients (15 men, 17 women) developed a LPD (LPD group). We compared them with 96 patients without LPD (control group), who were matched for age, sex, and RA duration among 2,628 patients with RA who attended our outpatient department in 2017. [Results] The median patient age was 71.0 years, and the duration of RA was 15.5 years. Twelve patients were diagnosed with diffuse large B cell lymphoma, 6 with Hodgkin lymphoma, and 5 with T cell lymphoma; 9 patients had other diagnosis. Many patients in LPD group were Stage IV, and Class 3 or 4 (75.0% vs 42.7 %, p<0.01, 71.8% vs 53.1%, p<0.05, respectively). 75 % of patients were treated with MTX in LPD group, and 42.7 % in control (p=0.0879). Although ESR, CRP, DAS28-ESR, CDAI were not different significantly in both group, MMP-3 is low in LPDs group (80.1 ng/mL vs 102 ng/mL, p<0.05). [Conclusions] Many patients in LPD group were Stage IV, and Class 3/4 compared to the patients without LPD. This might indicate cumulative disease activity were background for the development of LPD but not current disease activity.
corticoid therapy (EGT group) and 7 patients did not receive EGT (no EGT group). EGT groups was significantly lower prevalence of 30-day mortality, admission to the ICU, mechanical ventilations than those of no EGT group. Conclusions: The addition of EGT within 48 hour in patients with PCP with systemic rheumatoid disease with moderate to severe hypoxemia were associated with improved respiratory outcomes.

W11-2
Prognosis factors associated with Pneumocystis pneumonia in systemic rheumatic disease
Shin-ichiro Omura1, Toshiaki Miyamoto2, Daisuke Shichii3, Taio Naniwa1
1Department of Rheumatology, Nagoya City University, 2Department of Rheumatology, Seirei Hamamatsu General Hospital, 3Infectious Disease and Rheumatology, Seirei Mikatahara General Hospital

Conflict of interest: None

Objective: To determine the prognostic factors associated with Pneumocystis pneumonia (PCP) in systemic rheumatic disease. Methods: We reviewed medical records of patients with systemic rheumatoid disease who developed Pneumocystis pneumonia. The diagnosis of PCP was based on following the three points, clinical symptoms, GGO on CT scan, and elevated B-D glucan or positive PCR test. The severity of hypoxemia was classified the CDC guideline. The primary outcomes was respiratory failure, including 30 day death, ICU admission, and ventilator support. Results: Of the 93 patients with PCP, 3 patients (3.2%) died of PCP. Nine patients developed respiratory failure and there were significantly differences regarding the proportion of severe hypoxemia, A-aDO2≧45mmHg, in the diagnosis. A-aDO2≧45mmHg in the diagnosis of PCP was independently associated with respiratory failure. Conclusions: We must administer anti-PCP drug and prednisolone if A-aDO2 was ≧45mmHg.

W11-3
Long-term prognosis of rheumatoid arthritis patients who survive pneumocystis jirovecii pneumonia: comparison of the recent and old era
Harunobu Iida1, Hironori Hanaoka2, Yukiko Takakuwa1, Yoshioki Yamashita1, Kimito Kawahata1
1Division of Rheumatology and Allergology, St. Marianna University School of Medicine, 2Division of Rheumatology, Keio University School of Medicine

Conflict of interest: None

[Object] To evaluate the long-term survival of patients with rheumatoid arthritis (RA) who survived Pneumocystis jirovecii pneumonia (PCP), focusing on the era in which it was diagnosed. [Methods] Patients with RA who were diagnosed with PCP at our hospital from 2001 to 2017 were retrospectively evaluated. The patients were divided into 2 groups according to the era in which they were diagnosed: 2001-2008 and 2009-2017. We compared clinical characteristics when PCP was diagnosed and the last visit between groups. We also compared their cumulative survival rates. [Results] Eleven-patients were diagnosed with PCP in 2001-2008 and 19 in 2009-2017. Patients diagnosed with PCP in 2001-2008 were significantly younger than those diagnosed in 2009-2017 (p=0.01). On analysis of the last visit, patients diagnosed in 2001-2008 had a higher percentage of glucocorticoid (GC) use, higher dose of GC, and lower percentage of biologics use than those diagnosed in 2009-2017 (p<0.01, p<0.04, and p=0.02, respectively). Cumulative survival rate was significantly higher in 2001-2008 than 2009-2017 (p<0.01). The main cause of death was severe infection. [Conclusions] Survival of RA patients who experienced PCP may be improving. Alternative use of biologics for GC may contribute to this better outcome.

W11-4
Examination of availability and adverse events related to the dose of sulfamethoxazole-trimethoprim in rheumatic diseases
Tomoya Harada, Yuriro Sueda, Yoshahiru Funaki, Miki Takata, Ryota Okazaki, Akira Yamasaki
Department of Respiratory Medicine and Rheumatology, Tottori University Hospital, Yonago, Tottori, Japan

Conflict of interest: None

Objectives: Pneumocystis jirovecii pneumonia (PCP) is not an uncommon opportunistic infection in systemic rheumatic disease in Japan. However, there have been no evidence of restarting immunosuppressive drugs after developing PCP. In this study, we investigate the recurrence of PCP after starting immunosuppressive drugs with anti-pneumocystis drugs. Method; Sixty patients was admitted to the hospital and 37 patients who restarted immunosuppressive drugs with anti-PCP drugs included in this study. Results: Twenty three patients received both metho-
trexate (MTX) and biologics (Bio), and 14 patients received MTX. All patients received anti PCP drugs, SMX/TMP;21, pentamidine;11, atovaquone;5. The observation period was 125 weeks. No patients developed PCP recurrence. However 1 patients developed PCP recurrence after the termination of anti-PCP drugs. Conclusion: It is possible that patients may have received immunosuppressive drugs with anti-PCP drugs after the development of PCP.

W11-7 Efficacy and Safety of Weekly One Tablet Sulfamethoxazole-trimethoprim for Chemoprophylaxis of Pneumocystis Pneumonia

Shinji Fukaya1, Makoto Onobori1,2
1Department of Rheumatology, Tsukuba Gakuen Hospital, 2Onobori Clinic

Conflict of interest: None

[Object] Sulfamethoxazole-trimethoprim (ST-mix) is effective for prophylaxis of pneumocystis pneumonia (PCP). The decision of prophylaxis varies among rheumatologists due to side effect of ST-mix. In our hospital, chemoprophylaxis is adopted to RA patients who use methotrexate (MTX) with weekly one tablet ST-mix. This study aimed to evaluate the efficacy and safety of this method for chemoprophylaxis of PCP. [Methods] Subjects are RA patients who used MTX from January 2008 to December 2017. Exposure to RA treatments, persistence and side effects of ST-mix, and incidence of PCP were retrospectively analyzed. [Results] Mean age was 71±12 y.o. Overall observation was 3234PY, MTX-use and ST-mix with MTX accounted 2930PY and 2171PY (74.1%), respectively. Mean dosages of corticosteroid and MTX were 1646PY (74.1%), respectively. Among 511 patients who may have received immunosuppressive drugs with anti-PCP drugs after the development of PCP, there were 14 lymph node swelling, 14 parenchymal lung lesions (14 thick bronchial vascular thickening, 9 cysts, -3 ground - glass opacities, 9 nodular shadows (6 small, 3 large) Respiratory function test showed a FEV1.0% reduction in 3 out of 8 patients. 10 cases are treated with TCZ, and 1 case with steroid therapy. There are no cases to supply supplemental oxygen. [Conclusions] When diagnosing CD, it is desirable to perform chest CT to evaluate lung involvement and start the appropriate treatment.

W12-1 Clinical features of 8 cases with familial Mediterranean fever as a fever of unknown origin

Rina Watanabe1, Hirotaka Sakuraba1, Yasuhisa Mura1, Naboko Tanaka1, Keisuke Hasui1, Hiroto Hiraga1,2, Dai Kishida3, Yosh I Ishiguro4
1Department of Gastroenterology and Hematology, Hiroshi University School of Medicine, 2Department of Community Healthcare Development in Odate and North Akita, Hiroshi University Graduate School of Medicine, 3Division of Nurology and Rheumatology, Department of Internal Medicine, Shinshu University School of Medicine, 4Division of Clinical Research, Hiroshi National Hospital Organization

Conflict of interest: None

Introduction: Familial Mediterranean fever (FMF) is an autoinflammatory disease characterized by periodic fever and serositis. Method: Medical records were reviewed during period between January 2008 and December 2017. Clinical features of the patients with Familial Mediterranean fever (FMF), who had first visits to our department due to unidentified fever were assessed. Results: Total 149 cases of unidentified fever were enrolled, and 110 patients fulfilled the criteria of classical fever of unknown origin (FUO). Of 8 cases with FMF diagnosed based on modified Tel Hashomer criteria met the criteria of classical FUO. The mean age of onset was 44.8 years. The mean duration of attacks were 10.1 days. Five patients had atypical disease forms. MEVF gene mutations were observed in 6 patients, exon 2 mutation (n=5) and exon 1 mutation (n=1). Colchicine was effective in 7 patients. Discussion: In our study, the clinical features were late onset, moderate or mild disease activity and longer period of fever attack. These characteristics might be related to MEVF mutations except exon 10. FMF is a major disease characterized by periodic fever, and hard to unite criteria of classical FUO. Periodic fever is important in diagnosis of FUO and we should assume FMF as a cause of FUO.

W12-2 A retrospective observational analysis of idiopathic multicentric Castleman disease-associated lung disease

Shinichiro Tsunoda, Ruriko Kuratani, Satoshi Baba, Rina Okita, Rumiko Miyagi, Kaori Seki, Satoko Nozato
Division of Immunology & Rheumatology, Department of Internal Medicine, Sumitomo Hospital

Conflict of interest: None

[Object] Castleman disease (CD) is a lymphoproliferative disease that causes various clinical symptoms due to overproduction of IL-6. Pulmonary lesions were easily damaged, which was contained in the clinical stratification of CD both overseas and in Japan. Therefore we examined the lung lesions of idiopathic multicentric CD (iMCD). [Methods] We examined lung lesions and clinical data and treatment details of 14 patients (9 men, 5 females, and median age 54 years) confirmed as iMCD retrospectively. [Results] Histological subtype is plasma cell type in all cases. The blood test at the first visit was as follows: CRP 5.42±3.22 mg/dl, Hb 11.3±2.1 g/dl, Alb 3.1±0.8 g/dl, IgG 4222±1367 mg/dl, Elevated KL-6 level was found in 1 case. The CHAP score was 3.5 ± 3.1. In CT image findings, there were 14 lymph node swelling, 14 parenchymal lung lesions (14 thick bronchial vascular thickening, 9 cysts, 9 ground - glass opacities, 9 nodular shadows (6 small, 3 large) Respiratory function test showed a FEV1.0% reduction in 3 out of 8 patients. 10 cases are treated with TCZ, and 1 case with steroid therapy. There are no cases to supply supplemental oxygen. [Conclusions] When diagnosing CD, it is desirable to perform chest CT to evaluate lung involvement and start the appropriate treatment.

W12-3 A 64-year-old woman with multicentric reticulohistiocytosis successfully treated with Etanercept

Masako Utsunomiya1,2, Ayaka Maeda1, Akito Takamura2
1Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, 2Department of Rheumatology, Musashino Red Cross Hospital

Conflict of interest: None

Case: A 64-year-old woman with a history of hypertension and Grave’s disease presented with a ten-months history of multiple skin eruptions that had evolved over several months into reddish-brown papules, together with a progressive inflammatory polyarthritis. Physical examination showed tenderness and swelling in the distal interphalangeal (DIP) joints, the proximal interphalangeal (PIP) joints, the metacarpophalangeal (MCP) joints and the bilateral knee joints. Multiple papules around 2mm in diameters were also observed on the dorsal and lateral aspects of fingers, and the forehead, paranasal face and auricle. Rheumatoid factor, anti-nuclear antibody and anti-SSA / Ro antibody were negative, and anti-CCP antibody was weakly positive. Knee synovial fluid analysis showed cell counts of 2380 / μL, negative crystals and increased histiocytes on cytology. Joint X-ray of hands revealed erosion in DIPs, and MRI of hand showed synovitis in all DIP, PIP and MCP joints. A skin biopsy was performed, and the lesions were diagnosed as multicentric reticulohistiocytosis (MRH). With methotrexate and etanercept her arthritis is in remission. Clinical implication: Because it is uncommon to encounter MRH in Japan, we report this case with literature review.

W12-4 Effect of the biological drug on refractory relapsing polychondritis

Seido Ooka, Kumiko Tonooka, Kanako Suzuki, Hisae Fujimoto, Hiromi Matsushita, Yukiko Takakura, Kana Ishimori, Kimito Kawahata
Division of Rheumatology and Allergy, Department of Internal Medicine, St. Marianna University School of Medicine

Conflict of interest: None

[Object] Relapsing polychondritis (RP) is rare disease to result in inflammation to a systemic cartilage tissue, but the cause is unknown. A steroid or an immunosuppressive drug is used for the treatment, but the cases that cannot control condition appear. We examined an effect about a biological drug for refractory RP. [Methods] From January, 2010 to Octo-
ber, 2018, we investigated patients with RP of 56 cases that met classification criteria of Damiani and Michet or MacAdams. We introduced a biological drug for refractory RP14 case and examined effect of treatment backward. [Results] infliximab (INF) was used for nine cases, and tocilizumab (TCZ) was used for five cases. It was necessary until an effect of INF for three months from one week. There were two canceled cases in the TCZ group. There was not INF effect, and the case changed to TCZ was one case. In a case lack in the improvement of RPDAI, there was the decrease in Visual Analogue Scale (VAS) and steroid dose. [Conclusions] It was suggested that there was a constant effect in the biological drug for refractory RP.

W12-5
Clinical manifestations of Adult-onset Still's disease patients
Takahiro Sugiyama1, Nozomi Nishimura1, Shunsuke Furuta1, Kei Ikeda1, Takao Sugiyama2, Hiroshi Nakajima1
1Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, 2Department of Rheumatology, National Shimoshizu Hospital, Chiba, Japan

Conflict of interest: None

[Background] Adult-onset Still's disease (AOSD) is a systemic inflammatory disease, but actually it is considered as a heterogeneous disease. Regarding the prognosis, some patients with AOSD experience multiple relapses but others do not. However it is difficult to predict the relapse. [Object] We aimed to reveal the clinical manifestations of AOSD patients. [Methods] A total of 64 AOSD patients (15 men and 48 women) diagnosed between 2000 and 2018 were identified from medical records. Baseline characteristics, treatments, and relapses were evaluated by retrospective chart review. [Results] The median age of disease onset was 38 years old. At the disease onset, 100% of the patients had fever, 88.1% had arthralgia, and 90.1% had erythema. Macrophage activation syndrome was occurred in 20.7%. Corticosteroids were administered in all but one case, and the median starting dose of prednisolone was 50mg/day. During the follow-up period, only one case died of infectious disease. Twenty cases experienced relapse, and the cumulative 5-year relapse-free survival rate was 65.0%. [Conclusions] Although the prognosis of AOSD is relatively good, patients with AOSD often experienced relapses. We discuss the risk factors for the relapse of AOSD with some literature review.

W12-6
Progressive factors associated with achievement of drug-free remission in patients with adult onset still disease
Masashi Suzuki, Shusaku Fukaya, Natsuko Watanabe, Tatsuki Naganawa, Ai Umeda, Konomi Ashihara, Megumi Kurumizawa, Daisuke Hirano, Takako Hashimoto, Jo Nishino, Shunji Yoshida, Hidekata Yasuoka
Division of Rheumatology, Department of Medicine, Fujita Health University School of Medicine

Conflict of interest: None

[Object] To identify the progressive factors associated with achievement of drug (PSL, immunosuppressant) free remission in patients with adult onset still disease (AOSD) [Methods] 23 patients, who admitted to our department from April 2005 to August 2018 were enrolled. Patients who achieved drug-free remission (group A) and compared with patients without drug-free remission (group B), whose observation periods were matched. Clinical parameters including labo data, physical findings and treatment were compared. [Results] 6 group A patients and 4 group B patients were extracted. No patients were deceased during follow up period. The number of Pts was higher in group A compared with group B. Initial amount of PSL (group A 26.6±11.7mg/day vs group B 48.8±22.5mg/day, p=0.07), and frequency of additional use of immunosuppressant were lower in group A compared with group B (group A 2cases vs group B 4 cases, p=0.07). for the other items including Hb, LDH, CRP, Ferritin, there were no difference between 2 groups. [Conclusions] Interestingly, the number of the Pts was higher in patients with AOSD who achieved drug-free remission. Underlying disease process including possible hemophagocytosis feature may associate with the Pts count. Pts might be a novel biomarker for AOSD.

W13-1
Risk factors of pregnancy outcome in patients with Systemic Lupus Erythematosus
Chie Kohnoshi1, Kayoko Kaneko1, Chinatsu Takai2, Shuko Mishima1, Misato Kawakami2, Mikako Goto2, Michiru Kina1, Satoshi Watanuki1, Yuri Hiramatsu1, Yoko Miura1, Sakiko Isojima1, Mari Yamamoto8, Atsushi Iiha1, Yoshio Fujita1, Shoji Sugita1, Atsuko Murashima1,2
1Division of Maternal Medicine, Center of Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, 2Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, 3Department of Rheumatology, Showa University Hospital, 4Department of Rheumatology, Chubu Rosai Hospital, 5Department of Rheumatology, National Hospital Organization Yokohama Medical Center

Conflict of interest: None

[Object] To identify predictors of pregnancy outcome for preconcept care (PCC) of SLE (systemic lupus erythematosus) patients. [Methods] Data were collected about organ lesion, complication, treatment, laboratory data and pregnancy outcome of SLE patients delivered at our and participating hospital between 2002-2017. Cases in which occurred preterm birth or stillbirth or LFD (Light For Date) were defined as APO (Adverse Pregnancy Outcome) group. We statistically compared with APO and non-APO group. [Results] Of 128 pregnancies in 106 patients, preterm birth occurred in 44 cases, stillbirth in 2 cases, LFD in 35 cases. Antiphospholipid antibody syndrome (APS), hypertension, chronic kidney disease (CKD), thrombocytopenia in 2nd trimester, and daily dose of steroid during pregnancy are associated with APO. Lupus nephritis (LN), low complement level and positive anti-DNA antibody were not related to APO. [Conclusions] This study suggests that APS, hypertension, CKD and steroid dose are risk factors for APO as previous reports. LN and serological activity that have been thought to be the risk are not associated in this analysis. Pregnant women with these factors could obtain well outcome. We expect that these findings lead to better PCC for SLE patients.

W13-2
Risk factors associated with adverse events during pregnancy and delivery in women with systemic lupus erythematosus –LOOPS registry–
Hiroko Yoshihar1, Kazuhisa Nakano1, Kazuyoshi Saito2, Kei Suske Nakatsuka1, Shingo Nakamayada1, Masao Nawata2, Shigeru Iwata2, Kentaro Hanami1, Shunsuke Fukuyo1, Satoshi Kubo1, Ippei Miyagawa1, Ayako Yamaguchi1, Akio Kawabe1, Yusuke Miyazaki1, Naohki Oikubo1, Ryuichiro Kanda2, Yoshiya Tanaka2
1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 2Department of Rheumatology, Tobata General Hospital, 3Department of Rheumatology, Fukuoka Yutaka Central Hospital

Conflict of interest: None

[Object] To identify pregnancy outcome for APO of SLE (systemic lupus erythematosus) patients. [Methods] Data were collected about organ lesion, complication, treatment, laboratory data and pregnancy outcome of SLE patients delivered at our and participating hospital between 2002-2017. Cases in which occurred preterm birth or stillbirth or LFD (Light For Date) were defined as APO (Adverse Pregnancy Outcome) group. We statistically compared with APO and non-APO group. [Results] Of 128 pregnancies in 106 patients, preterm birth occurred in 44 cases, stillbirth in 2 cases, LFD in 35 cases. Antiphospholipid antibody syndrome (APS), hypertension, chronic kidney disease (CKD), thrombocytopenia in 2nd trimester, and daily dose of steroid during pregnancy are associated with APO. Lupus nephritis (LN), low complement level and positive anti-DNA antibody were not related to APO. [Conclusions] This study suggests that APS, hypertension, CKD and steroid dose are risk factors for APO as previous reports. LN and serological activity that have been thought to be the risk are not associated in this analysis. Pregnant women with these factors could obtain well outcome. We expect that these findings lead to better PCC for SLE patients.
SLE should be quiescent before the conception with use them.

**W13-3**

Risk factors for adverse pregnancy outcomes and Apgar score of newborns in pregnancy and delivery complicated with SLE

Hiromi Shimada, Tomohiro Kameda, Shusaku Nakashima, Risa Wakiya, Mikiya Kato, Taichi Miyagi, Hiroaki Dobashi
Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University, Kagawa, Japan

Conflict of interest: None

[Object] We investigate the risk factors for adverse pregnancy outcomes (APOs) complicated with SLE and Apgar score of newborns from SLE mothers. [Methods] We extracted 49 SLE patients who were managed from preconception counseling to pregnancy and delivery in our institution. We analyzed the risk factors for APOs and Apgar score of newborns. [Results] In preterm birth, SLEDAI at the first trimester, anti ds-DNA antibody was significantly high. The average dose of corticosteroid during pregnancy and the rate of intensification of treatment was high. In LFD newborns, the serum complement levels were low, and SLEDAI at the third trimester was high. Apgar score at 1 minute was correlated significantly with SLEDAI at 3rd trimester and anti ds-DNA antibody, and at 5 minutes was correlated with anti ds-DNA antibody. Multivariate analysis showed that there was a significant difference between Apgar score and anti ds-DNA antibody. [Conclusions] We revealed that immunological abnormalities, high disease activities, and corticosteroid treatments were demonstrated as the risk factors for preterm birth and LFD. Apgar score of newborns was associated with anti ds-DNA antibody significantly, therefore, we suggest that Apgar score might become a risk factor for neurological development.

**W13-4**

Is there a difference in pregnancy course and pregnancy outcome among childhood onset systemic lupus erythematosus (SLE) and adult-onset SLE patients?

Yuri Hiramatsu1, Eri Nakamura1, Takao Kiboshi2, Takaaki Ishida1, Youhei Fujiki1, Nami Okamoto2, Kosuke Shabanai2, Takuya Kotani1, Shigeki Makino1, Tohru Takeuchi1, Shigeki Arawaka1

1Department of Internal Medicine IV, Osaka Medical College, Takatsuki, Osaka, Japan, 2Department of Pediatrics, Osaka Medical College, Takatsuki, Osaka, Japan

Conflict of interest: None

[Object] The onset of SLE is common in young women, and about 20% of the onset develops in less than 18 years of age. Childhood SLE exhibits the same symptoms as adult SLE, but it is reported that there are many cases of nephritis complications compared with adult cases and there are many cases of severe cases. In recent years SLE patient’s pregnancy has increased, among them cases where childhood SLE women become pregnant, but differences in pregnancy management with adult SLE are not clear. We examine differences in pregnancy course and pregnancy outcome between both. [Methods] Comparison of pregnancy course and outcome for 23 women with childhood SLE (onset below 18 years of age) and 63 adult SLE women who underwent pregnancy control at our hospital during the period from 2003 to 2018. SLEDAI was used for disease activity assessment. [Results] The median value is shown below. A comparison between childhood SLE and adult SLE is described. SLEDAI values during the pregnancy period, pregnancy period, and postpartum period were significantly lower in childhood SLE during the disease period of 15.7 vs 6.1 years. For pregnancy outcomes, there was no significant difference. [Conclusions] Disease activity during pregnancy was significantly lower in childhood SLE than in adult SLE.

**W13-5**

Current condition of clinical practice and childbirth of female patients with rheumatoid arthritis who wish to have children in 2017

Toshibo Matsui1, Takao Sugiyama2, Shigeto Toma3

1Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, 2Department of Rheumatology, National Hospital Organization Shimoshizu National Hospital, 3National Hospital Organization Tokyo National Hospital

Conflict of interest: Yes

[Object] To clarify the current condition of clinical practice and childbirth of female patients with rheumatoid arthritis (RA) who wish to have children. [Methods] Among 15,185 patients registered in NinJa (National Database of Rheumatic Diseases in Japan) 2017, we extracted female patients under 50 years of age (1,599 cases) and collected information on the presence or absence of childbirth, pregnancy, lactation, and wish to have children. Patients whose information could be collected (916 cases) were classified into group A (under 30 yrs, 76 cases), group B (30-34 yrs, 77 cases), group C (35-39 yrs, 168 cases), and group D (over 40 yrs, 640 cases) and their data were analyzed. [Results] There were 20 births which represent 80.5% [95% CI: 45.2 - 115.8] of the expected number of births calculated from the demographic change survey for the same year. There was no significant difference in CDAI and PSL usage rates between patients with or without wish to have children in all groups, however, usage rate of biologics (54.4% vs 35.4%, p<0.05), and the selection rate of etanercept (94.7% vs 30.7%, p<0.001) were significantly more in patients with wish to have children in group D. [Conclusions] Female RA patients over 40 yrs who wish to have children need more strong treatment for RA.

**W13-6**

Clinical courses of pregnant women with rheumatoid arthritis who received Etanercept during pregnancy

Chintatsu Takai1, Mikako Goto1, Misato Kawakami1, Chie Kohnoe2, Shuko Mishima2, Kayoko Kaneko2, Aruoko Murashima1,2

1The Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development, 2Division of Maternal Medicine, Center for Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development

Conflict of interest: None

[Object] To clarify the clinical courses of pregnant women with rheumatoid arthritis (RA) who received Etanercept (ETN) during pregnancy. [Methods] We detected 195 pregnancies with live birth in patients with RA who had received Etanercept (ETN) at 0th week of pregnancy at our hospital from 2003 to 2017. The disease activity and medication before, during and postpartum were investigated retrospectively. [Results] ETN was discontinued after diagnosis of pregnancy in 16 cases of 25 cases. Of the 16 cases discontinued ETN, 8 cases experienced disease flare during pregnancy and restarted ETN in 7 cases. Of the other 8 cases without disease flare, 7 cases remained discontinued through pregnancy. No significant difference was detected in the disease activity at 3 months before pregnancy among continued group (9 cases), re-started group (8 cases), and discontinued group (8 cases). The disease flare after delivery within 1 month was detected 2 cases in continued group, 4 cases in re-started group and 1 case in discontinued group. No major anomaly was detected in all the 25 cases. [Conclusion] Around half of the cases discontinued ETN during pregnancy experienced disease flare and re-started ETN. It is necessary to clarify which patient can discontinue ETN or not.

**W14-1**

The Toe Lesion of Patient with Rheumatoid arthritis

Satoke Yokoyama1, Mami Nakahara2, Harako Ito2, Yoko Nemoto4, Mitsuhiko Kawagoe1, Kazutoshi Aoki1

1Aoki Medical Clinic Saitama Japan, 2Juntendo University Koshigaya Hospital, 3Ina Hospital, 4Kaneko Clinic

Conflict of interest: None

[Object] Deformity of toe is common in rheumatoid arthritis (RA) patient, and it causes pain and infection. It is important to find and care the toe lesion of RA early. Therefore, we investigated frequency of the tolesion. [Methods] The subject were 572 RA patients who visited 4 RA clinics from June to July 2018. The questions consists of sex, age, disease
period, sort of toes lesion and treatment. [Results] 572 patients answered the question. M/F ratio was 1:5. 349 patients (61%) had toe lesion, which were callus-calvarus 48%, hallux valgus 42%, incurrednail, deformity 19%, cornification 15%, flat feet 13%, nail hyperplasia 12%, trichophytia 11%, tailor’s bunion 6%. Of these, it was 245 non-treatment (70%). [Conclusions] Because foot is weight bearing joint, its destruction and deformity occurs frequently. Foot joint is not included in DAS28 and there is few opportunity to examine it This study showed joint destruction and deformity were overlooked frequently (70%). ADL of RA patient was improved drastically with evolution RA treatment. Consequently, load to foot became bigger. Nurse must accumulate knowledge for foot care and cooperate with physician in order to find the foot lesion. We will accumulate more data about how foot lesion affect HAQ.

W14-2
Usability of Cimzia AutoClicks correlated with hand functions in patients with rheumatoid arthritis
Kaoru Nagari1, Yasumori Sobe2, Tsuyoshi Nishiumi1, Mochihito Suzuki1, Nobunori Takahashi3, Takuya Matsumoto4, Nobuyuki Asai5, Shuji Asai6, Toshisika Kojima7, Naoki Ishiguro8
1Nursing Department, Nagoya University Hospital, 2Department of Orthopedic Surgery, Nagoya University Hospital

[Conclusions] Because foot is weight bearing joint, its destruction and deformity occurs frequently. Foot joint is not included in DAS28 and there is few opportunity to examine it This study showed joint destruction and deformity were overlooked frequently (70%). ADL of RA patient was improved drastically with evolution RA treatment. Consequently, load to foot became bigger. Nurse must accumulate knowledge for foot care and cooperate with physician in order to find the foot lesion. We will accumulate more data about how foot lesion affect HAQ.

W14-3
Daily living guidance to rheumatism patients using Web videos and their effect on self-efficacy
Yuki Tanaka1, Naomi Takahashi1, Akio Ohnishi1, Noriyoshi Shimahara2, Shinji Sato3, Makoto Onishi4, Yasuaki Okuda5, Naoya Sawada6
1Department of Nursing, Center for Rheumatic Diseases, Dohgo Spa Hospital, Ehime, Japan, 2Department of Rehabilitation, Center for Rheumatic Diseases, Dohgo Spa Hospital, Ehime, Japan, 3Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Ehime, Japan

Conflict of interest: None

[Object] Using Web videos, conduct activities of daily living and guidance on joint protection, examine the satisfaction of daily living behavior and the influence on self-efficacy. [Methods] Make movies with doctors / therapists about living behavior, domestic action, bathing behavior. Disease activity - Pain of each joint VAS · PSEQ · Analysis of daily life satisfaction. [Results] There was no significant difference between HAQ-DL, SDAI, and pain VAS before and after video observation. However, the VAS values of wrist and knee joints were improved. Patients who preferred PSEQ after observation had significantly higher age (p<0.05). Cutoff value with “not usable” as the end point was a grip power of 13 kg and a pinch force of 1.2 kg. Disease duration and the score of DAS28 did not affect the usability of Cimzia AutoClicks. Fifty percent of patients preferred buttonless. [Conclusions] Hand functions of patients that used it and those who could not use it were necessary for the use of this instrument. Grip power (18.5 kg vs 7 kg), pinch force (3.3 kg vs 0.4 kg), and the score of HAND20 (23 points vs 63 points) were significant factors between patients who could use it and those who could not use it (p<0.05). The average age of the patients was 61.8 years with the average age for each drug was 131 cases for DMARD, 44 cases for GC and 61 cases for NSAID. The number of patients accurately grasping the classification of drugs and drug names were 158 cases (85.9%) for BIO, 89 cases (67.9%) for DMARD, 20 cases (45.5%) for GC, 44 cases (72.1%) for NSAID. The average age (years) of drug content graspers and non-graspers was 59.0, 69.5 in BIO, 60.7, 64.2 in DMARD, 59.9, 66.7 in GC, 58.1, 65.0 in NSAID, respectively. [Discussion] As a result of investigating the degree of recognition of prescribed drugs in RA patients using BIO, it became clear that patients who did not grasp the type of medicine or drug name increased with age.

W14-4
How well do rheumatoid arthritis patients recognize the prescribed medications?
Noriko Iwata1, Masato Sato2, Tomohisa Tani3, Yoshiro Ohashi4
1Nursing Department, Juntendo Koshigaya Hospital, 2Department of Rheumatology and Internal Medicine, Juntendo Koshigaya Hospital

Conflict of interest: None

[Objectives] Drug therapy for rheumatoid arthritis (RA) is classified into 4 types: non-steroidal anti-inflammatory drug (NSAID), disease modifying antirheumatic drug (DMARD), biological drug (BIO), glucocorticoid (GC). We investigated to what extent the RA patients recognize the medicine being used. [Methods] We listened to the types of medicines (NSAID, DMARD, BIO, GC) currently prescribed for RA patient in outpatient clinic and their drug name. Of 267 people examined, 184 subjects using BIO were analyzed. [Results] There were 31 males, 153 females, ages from 14 to 84 years old, average 61.0 years old. The number of usage for each drug was 131 cases for DMARD, 44 cases for GC and 61 cases for NSAID. The number of patients accurately grasping the classification of drugs and drug names were 158 cases (85.9%) for BIO, 89 cases (67.9%) for DMARD, 20 cases (45.5%) for GC, 44 cases (72.1%) for NSAID. The average age (years) of drug content graspers and non-graspers was 59.0, 69.5 in BIO, 60.7, 64.2 in DMARD, 59.9, 66.7 in GC, 58.1, 65.0 in NSAID, respectively. [Discussion] As a result of investigating the degree of recognition of prescribed drugs in RA patients using BIO, it became clear that patients who did not grasp the type of medicine or drug name increased with age.

W14-5
Biologic DMARD monotherapy for the treatment of elderly onset rheumatoid arthritis
Megumi Kobayashi1, Ryoko Koyanagi1, Yoshioki Yamashita2, Hidehiro Yamaida1 1Department of Rheumatology, Yokohama General Hospital, 2Center for Rheumatic Diseases, Seirii Yokohama Hospital, 3Rheumatology and Allergology, St. Marianna University School of Medicine

Conflict of interest: None

[Object] To investigate whether our intensive commitment by medical team to patients with elderly-onset rheumatoid arthritis (EORA) treated with biologics contributed to the safety management. [Methods] Patients with EORA >65 year-old, visited to our clinic from 2015, and treated with biologic (B-) DMARDs alone were retrospectively investigated. [Results] Twenty-three patients were included. The mean age was 78-year-old. The mean follow-up period was 21 months. They had average of 10 swollen joints. HAQ and RAPID3 was 0.9 and 13, respectively. Seven patients had cerebrovascular diseases, each 6 HBV infection / lung diseases, and 5 diabetes mellitus. The patients were treated with subcutaneous abatacept (n=17), etanercept (n=3), tocilizumab (n=2). All except 2 patients received B-DMARDs at the clinic at every 1 or 2 weeks by RA care nurses with careful assessment of the patients. The continuation rate was 80% at 2 year with improvement such as RAPID3 4.9, and HAQ 0.6 (P<0.05). Serious adverse events were included lung cancer (n=1), renal cancer (n=1). No patients experienced serious infections. [Conclusions] No serious infections were seen in our EORA patients. B-DMARDs monotherapy seemed to be safe in this patient population with aggressive commitment of medical staff.

W14-6
Research on the symptoms of depression of elderly patients with rheumatoid arthritis
Mami Nakahara1, Shigeto Kobayashi2, Issei Kida3, Kyoko Kubono1
1Nursing Department, Juntendo Koshigaya Hospital, 2Department of Rheumatology and Internal Medicine, Juntendo Koshigaya Hospital

Conflict of interest: None

[Object] To investigate whether our intensive commitment by medical team to patients with elderly-onset rheumatoid arthritis (EORA) treated with biologics contributed to the safety management. [Methods] Patients with EORA >65 year-old, visited to our clinic from 2015, and treated with biologic (B-) DMARDs alone were retrospectively investigated. [Results] Twenty-three patients were included. The mean age was 78-year-old. The mean follow-up period was 21 months. They had average of 10 swollen joints. HAQ and RAPID3 was 0.9 and 13, respectively. Seven patients had cerebrovascular diseases, each 6 HBV infection / lung diseases, and 5 diabetes mellitus. The patients were treated with subcutaneous abatacept (n=17), etanercept (n=3), tocilizumab (n=2). All except 2 patients received B-DMARDs at the clinic at every 1 or 2 weeks by RA care nurses with careful assessment of the patients. The continuation rate was 80% at 2 year with improvement such as RAPID3 4.9, and HAQ 0.6 (P<0.05). Serious adverse events were included lung cancer (n=1), renal cancer (n=1). No patients experienced serious infections. [Conclusions] No serious infections were seen in our EORA patients. B-DMARDs monotherapy seemed to be safe in this patient population with aggressive commitment of medical staff.
A study of music therapy for patients with rheumatoid arthritis on emotional relaxation by using Emotional Relaxation Scale

Yasushi Miura1, Ikuo Yamazaki1, Kenya Oga1, Koji Fukuda2, Ryosuke Kuroda3
1Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, 2Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 3Department of Healthcare and Welfare, International University of Health and Welfare, 4Ibaragi Prefectural University of Health Sciences Hospital

Conflict of interest: None

[Objectives] We previously reported that music therapy improves general health condition, positive emotion and self-efficacy of patients with rheumatoid arthritis (RA) and decreases pain, anxiety and negative emotion. In this study, we investigated the effects of music therapy on relaxation by using Emotional Relaxation Scale (ERS). [Methods] Music therapy was conducted by a music therapist, a pianist, hospital staffs, and students. Eight Japanese songs were sung with a piano accompaniment and 2 were played with chime bars by the participants. General health condition, pain, emotions and emotional relaxation were surveyed by self-rating questionnaire including 10cm general health visual analogue score (VAS), face pain rating scale, TMS, PMS and ERS. [Results] Fourteen female patients were participated. mHAQ was 0.56±0.67 (0-2.50). GH-VAS was significantly improved from 3.4 to 2.4 and FS from 5.7 to 4.3 respectively. The negative emotions evaluated by TMS were decreased and the positive emotions by TMS and PMS were increased. Meanwhile, all four subscales of ERS showed the median score of 4 among 5 indicating positive emotional relaxation effects. [Conclusions] Music therapy increase positive emotions and decrease negative emotions resulting emotional relaxation on patients with RA.

Pain accrused by RA patients - Relationship between pain intensity, dysfunction, psycho-psychological problems, comparison with disease activity -

Noriyoshi Shimahara1, Shinji Sato1, Yuki Tanaka1, Naoya Sawada2, Yasuaki Okuda1, Makoto Onishi2
1Department of Rehabilitation, Center for Rheumatic Diseases, Dohgo Spa Hospital, 2Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, 3Department of Nursing, Center for Rheumatic Diseases, Dohgo Spa Hospital

Conflict of interest: None

[Introduction] In This Study, we report the relationship between pain intensity, functional impairment and psycho-psychological problems due to disease activity status. [Materials] Of the female RA patients in our hospital visit, 64 subjects agreed to participate in this study were taken.

[Methods] Study was conducted in a prospective study. The evaluation items were SDAI as disease activity, P-VAS as pain intensity, PDAS and HAQ as evaluation of functional impairment, PCS and HADS as psychophysiological states, and the state of SDAI, And analyzed these relationship. [Results] In group comparison, pain intensity and dysfunction did not differ over low disease activity. Patients who showed a catastrophic trend existed outside the remission group. PCS and HADS showed a significant difference depending on the status of disease activity, but helplessness showed a high trend regardless of disease activity. VAS showed moderate correlation with SDAI, PDAS, HAQ, PCS, HADS, and showed a causal relationship with PCS and HADS. [Discussion] Other than the remission group, there was a catastrophic trend, and pain and dysfunction were affected by disease activity. It was suggested that psychological problem was more influential to symptoms of RA patients.
W15-5
Adaptation of shoulder joint rehabilitation in rheumatoid arthritis patients -Examination with ultrasonography- 
Akira Inoue1, Takuro Okari1, Keio Ayabe2
1Department of Rehabilitation, Keiyu Orthopedic Hospital, 2Department of Orthopedic Surgery, Keiyu Orthopedic Hospital
Conflict of interest: None

[Object] We compare ultrasound findings due to differences in disease activity, clarify the relationship with local inflammation, and help setting rehabilitation strength. [Methods] The subjects were 21 patients with RA patients 21 shoulder (low, middle and high disease activity 7 each), frozen shoulder 20 cases (20 affected side, 20 healthy side), ultrasonography evaluated inflammation area. The examination site was taken as the total Doppler area in bispe groove, rotator interval, subacromial bursa, subdeltoid bursa. Disease activity was DAS 28-ESR. Statistics were tested using multiple comparison tests, and group comparisons were performed in 5 groups. [Results] The Doppler area in each group (high / middle / low disease activity / frozen shoulder affected side / healthy side) is 35.8 / 31.7 / 13.3 / 12.9 / 4.5 mm² and frozen shoulder affected side and low disease activity, high disease activity and There was no significant difference in medium disease activity, but there was a significant difference in comparison between other groups (p <.05). [Conclusions] The same long supplied as frozen shoulder and low disease activity are the same disease activity. The necessity of proceeding wisely with medium / high disease activity was considered.

W15-6
New RA patient education using Web video 
Naoya Sawada1, Shinji Sato2, Noriyoshi Shimahara2, Ako Ohnishi2, Makoto Onishi1, Kiyoshi Takasugi1
1Department of Internal Medicine, Dohgo Spa Hospital, 2Department of Rehabilitation, Dohgo Spa Hospital, 3Nursing Department, Dohgo Spa Hospital
Conflict of interest: None

[Object] To improve access to self-care and daily guidance of patients with RA by using Web video. [Methods] We selected the theme based on the needs heard from RA patients, 1. correspond to morning stiffness 2. exercise for deformation prevention (finger / toe) 3. joint protection method in daily life 4. foot care 5. guide of brace, And so on. As a “rehabilitation / self-care of RA” using Web video site, it was released sequentially from September 2017 and urgent viewing. (https://www.youtube.com/channel/UCBemown4OXIAmRUIe 9hepA) [Results] Approximately 17 thousand views were viewed in one year. The preventive exercise for joint deformation was the most frequently viewed and the evaluation was high. It was thought that it reflects the need for fear of deformation progress and countermeasure method. There was also a report of improving deformity of the fingers from the patients used. Sharing skills and knowledge of doctors, nurses and therapists led to medical care smoothing. Although there were no reports of adverse events, there were cases where viewing was difficult for the elderly. [Conclusions] The use of Web video was useful for expanding opportunities for RA patient education.

W16-1
Analysis of the association between aging and circulating follicular T helper (Tfh) cells in patients with rheumatoid arthritis 
Yoko Yabe, Shin-ichiro Kagami
Research Center for Allergy and Clinical Immunology, Asahi General Hospital, Chiba, Japan
Conflict of interest: None

[Object] The aim of this study is to analyze the association between aging and circulating Tfh cells in RA. [Methods] We retrospectively reviewed the medical records of 53 patients who were diagnosed as RA and analyzed for peripheral Tfh (CD3+CD4+CD45RA-CXCR5+) cells from July 2014 to May 2018 in our hospital. The Tfh cells were divided into three subsets: Th1 (CXCR3+CCL4-), Th2 (CXCR3-CCL4+) and Th17 (CXCR3-CCL4+). [Results] The median age at diagnosis was 64 years (IQR:50-70 years) and 38 cases were female. The median titers of ACPA and RF at diagnosis were 66.1 U/ml (IQR:3.1-413.8 U/ml) and 57.1 IU/ml (IQR:10.75-191.9 U/ml), respectively. As age increased, the titers of ACPA and RF tended to decrease. The ratio of Th2/Tfh cells had a significant positive correlation with age (p=0.01, R=0.33), and the ratio of CD28+ Tfh2/Tfh cells had a significant negative correlation with age (p=0.01, R=-0.31). Neither the ratio of Th1/Tfh cells or Th17/Tfh cells were significant correlation with age. Expression of CD28 on Tfh1 cells and Tfh17 cells were not decreased. [Discussion] Aging was involved in expression of CD28 on Tfh2 cells in RA patients. In elderly RA patients, CD28 negative Th2 cells were increased, hence the production of autoimmune antibodies might be impaired.

W16-2
Factors associated with the muscle mass change of patients with rheumatoid arthritis in 7 years 
Shinichi Nogi1, Akito Tominaga1, Koichiro Horie1, Takuya Katakuni1, Kako Kodama1, Kanako Ikawa1, Hirota Tsuno1, Takahiro Nunokawa1, Hideki Ogihara1, Akiko Komiya2, Atsushi Hashimoto1, Toshihiro Matsui1, Shigeto Tohma1
1Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, 2Department of Clinical Laboratory, National Hospital Organization Sagamihara National Hospital, 3National Hospital Organization Tokyo National Hospital
Conflict of interest: None

[Objectives] There are few reports about measurement of muscle mass in rheumatoid arthritis (RA) patients. We measured muscle mass of RA patients in 7 year intervals to investigate the relationship between their muscle mass change and backgrounds. [Methods] Muscle mass of 86 RA patients were measured using MC180 Body Composition Analyz- er in 2010 and 2017 at our hospital. Patients’ backgrounds from NinJa database were associated with muscle mass change (balance (2017-2010) or ratio (2017/2010)). [Results] Their mean age in 2017 was 62.4±9.1 years old. Muscle mass in 2010 showed significant negative correlation with their age or physical function evaluations (mHAQ). Muscle mass change (balance or ratio) showed significant negative correlation with mean DAS28-ESR or -CRP during 7 years and no correlation with initial RA disease activity, clarify the relationship with local inflammation, and help setting rehabilitation strength. [Methods] The subjects were 21 patients with RA patients 21 shoulder (low, middle and high disease activity 7 each), frozen shoulder 20 cases (20 affected side, 20 healthy side), ultrasonography evaluated inflammation area. The examination site was taken as the total Doppler area in bispe groove, rotator interval, subacromial bursa, subdeltoid bursa. Disease activity was DAS 28-ESR. Statistics were tested using multiple comparison tests, and group comparisons were performed in 5 groups. [Results] The Doppler area in each group (high / middle / low disease activity / frozen shoulder affected side / healthy side) is 35.8 / 31.7 / 13.3 / 12.9 / 4.5 mm² and frozen shoulder affected side and low disease activity, high disease activity and There was no significant difference in medium disease activity, but there was a significant difference in comparison between other groups (p <.05). [Conclusions] The same long supplied as frozen shoulder and low disease activity are the same disease activity. The necessity of proceeding wisely with medium / high disease activity was considered.

W16-3
Serum myostatin in patients with rheumatoid arthritis and its correlation with body composition 
Yoko Wada1, Masanori Sudo1, Shunsuke Sakai1, Sayuri Takamura1, Ayako Wakamatsu1, Yukiko Nozawa1, Hiroe Sato1, Daisuke Kobayashi1, Takeshi Nakatsue1, Takeshi Kuroda1, Masaaki Nakano2, Ichiei Narita1
1Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Health Administration Center, Niigata University, Niigata, Japan, 3Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata, Japan
Conflict of interest: None

[Object] To investigate the possible role of myostatin in body composition in patients with rheumatoid arthritis (RA). [Methods] Ninety-eight RA patients who visited Niigata University Hospital between April to June 2017, were recruited in this study. Body composition was measured by bioelectrical impedance analysis with a tetrapolar impedance meter. Serum myostatin level was measured by ELISA. Patients’ laboratory findings and disease activities were also measured, and the correlations between the titer of serum myostatin and these factors were analyzed.
[Results] In Spearman’s correlation coefficient analysis, serum myostatin level was positively correlated with skeletal muscle mass index and fat-free mass index (FFMI), and negatively correlated with percent body fat (%BF), fat mass index (FMI), swollen joint counts, ESR, and DAS28-ESR (4). In 72 female patients in this study, %BF and FMI/FFMI ratio was significantly higher in patients with low FFMI group (FMMI=13.82, n=22), compared to those with normal FFMI group (n=50). [Conclusions] Serum myostatin level was significantly correlated with body composition and disease activity in RA patients. Patients with lower level of myostatin showed a trend of decreased skeletal muscle and increased body fat, so-called rheumatoid cachexia.

W16-6 Rheumatoid arthritis is high risk factor of death from TOMORROW study Koji Mandai1, Tatsuya Koike2, Tatsuya Sugioka2, Kentaro Inui2, Tadashi Okano1, Yutaro Yamada2, Shohei Anno4, Masahiro Tada1, Hiroaki Nakamura1 1Department of Orthopaedics, Osaka Social Medical Center, 2Center for Senile Degenerative Disorders, Osaka City University Graduate School of Medicine, 3Department of Orthopaedic, Search Institute for Bone and Arthritis Disease, 4Department of Orthopedics, Osaka City University Graduate School of Medicine, 5Department of Orthopaedic, Yodogawa Christian Hospital, 6Department of Orthopaedic, Osaka City General Hospital Conflict of interest: None

[Object] We investigated the risk factor of death in patients with rheumatoid arthritis (RA) from TOMORROW study. [Methods] This study included 413 participants, comprising 208 patients with RA and 205 age- and sex- matched healthy volunteers (Vo) from the prospective “TOMORROW” cohort study that has been ongoing since 2010 were included in this study (women, 84%; mean age, 58 years old). Median disease duration was 10.3 years. [Results] The rate of accomplishment for 8 years was 83.2% in the RA group and 92.7% in the Vo group. There were 14 deaths in the RA group (8.41/1000 person-years) and 2 in the Vo group (0.1/1000 person-years) (p=0.0035) for 8 years. Infection was the most common cause of death in the RA group (43%). Cox hazard analysis showed that RA was a significant factor of death (hazard ratio [HR], 7.74; P=0.007). In the RA group, steroid use (HR:5.06, P=0.007), low platelets (HR:12.9, P=0.002) were independent factors of death. Disease activity, duration of disease, use of biological products, use of methotrexate, presence of fall over 8 years was not a significant factor. [Conclusions] RA was significant high risk factor of death. Steroid use and low platelets were independent factors of death in RA patients.

W17-1 Runx2+ Sox9+ positive synovial cells differentiate into hyperplastic chondrocytes; its results in bony ankylosis Yoko Miura, Satoshi Kanazawa Department of Molecular and Cellular Biology, Nagoya City University Graduate School of Medical Sciences Conflict of interest: None

[Object] Rheumatoid arthritis (RA) is a type of chronic inflammation with bone destruction, which leads to bony ankylosis. To confirm ectopic differentiation of synovial fibroblasts (SFs) into osteo-chondrocytes in RA, we studied the fate of SFs with histopathological analyses in mouse model. [Methods] D1BC mice were induced with a low-dose of bovine COL10a1 transgene. In situ differentiation markers for SFs and osteochondrogenic lineage. B7.1 transgene was used as a lineage tracing marker. [Results] D1BC mice shared common features of patients in RA such as chronic inflammation and bony ankylosis. S100A4 and vimentin were expressed in SFs, which expressed Col2a1 and Col10a1. Pannus is composed of three types of SFs, Runx2+, Sox9+ positive, Runx2+ single positive and double negative cells. Ectopic Colagen X positive hypertrophic chondrocytes (HCs) were observed adjacent to pannus. These HCs expressed Runx2+, Sox9+ and underwent differentiation into osteoelastic cells, leading to bony ankylosis. [Conclusions] Runx2+, Sox9+ positive SFs have a feature of osteo-chondrogenic lineage and differentiate into osteocytes via HCs.
**W17-2**

**IL-17 is expressed on rheumatoid arthritis and Psoriatic arthritis and mediates angiogenesis**

Shinichiro Nishimi, Takeo Isozaki, Masahiro Hosonuma, Airi Nishimi, Sho Ishii, Takahiro Tokunaga, Yuyo Ikar, Hidekazu Furuya, Kuninobu Wakabayashi, Tsuyoshi Kasama

Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

Conflict of interest: None

[Object] IL-17 expression is reported on rheumatoid arthritis (RA) and psoriatic arthritis (PsA). However, the role of IL-17 in angiogenesis is unclear. We have shown the expression of IL-17 in arthritis. [Methods] We measured IL-17 in RA, PsA and osteoarthritis (OA) serum using ELISA. To determine IL-17 expression in synovial tissues, immunohistochemistry was performed. Finally, to determine the regulation of proangiogenic mediators in IL-17 stimulated fibroblasts, ELISA was used. [Results] IL-17 in PsA serum was significantly higher compared with RA and OA. IL-17 is expressed in synovial tissues. VEGF, MCP-1/CCL2 and ENA-78/CXCL5 in IL-17 stimulated fibroblast conditioned medium was significantly higher compared with that in nonstimulated fibroblast conditioned medium. [Conclusions] These data show IL-17 upregulates the production of angiogenic growth factors in synovial fibroblasts.

**W17-3**

**Analysis of the role of RORgammat+Foxp3+ regulatory T cells in the regulation of autoimmune arthritis**

Kotona Furuyama, Yuya Kondo, Masahiro Yokosawa, Masaru Shimizu, Hiroto Tsuboi, Isao Matsumoto, Takayuki Sumida

Department of Internal Medicine, Faculty of Medicine, University of Tsukuba

Conflict of interest: None

[Object] To clarify the role of RORγt Foxp3+ regulatory T (Tr17) cells in the development autoimmunity arthritis. [Methods] 1) Lymph node cells were harvested from C57BL/6 mice on 10 days after CII immunization. Cytokine production was analyzed from Tr17 cells by FCM. 2) Lymph node cells were harvested from C57BL/6 mice on 10 days after first CII immunization. Expression of RORγt in Foxp3+ regulatory T (Tr17) cells were analyzed by FCM. 3) Collagen induced arthritis (CIA) was induced in C57BL/6 mice and RORγtCre (control) mice by CII immunization. Incidence and severity of CIA were evaluated. 4) Lymph node cells were harvested from C57BL/6 mice and control mice on 10 days after CIA immunization, and cultured with CIA in vitro. IL-17 and IFNγ in culture supernatant were measured by ELISA. [Results] 1) IL-10 production was significantly increased in Tr17 cells compared with RORγtTreg cells (p<0.001). 2) Frequency of RORγtFoxp3+Tr17 cell was decreased in C57BL/6 mice compared with control mice (p=0.001). 3) CIA tended to be exacerbated in C57BL/6 mice compared with control mice. 4) Production of CIA reactive IL-17 production tended to be decreased in C57BL/6 mice compared with control mice. [Conclusions] Tr17 cells might regulate the pathogenesis of CIA.

**W17-4**

**The role of IL-34 in pathogenesis of rheumatoid arthritis**

Hiroto Tsuboi, Isao Matsumoto, Takayuki Sumida

Department of Internal Medicine, Faculty of Medicine, University of Tsukuba

Conflict of interest: None

[Object] To treat rheumatoid arthritis (RA), controls of inflammation and bone destruction are important. Interleukin (IL) - 34 is a novel cytokine involved in chronic inflammation and bone resorption, which discovered as a second ligand of colony-stimulating factor-1 receptor (CSF-1 R). There is no data on Japanese patients for IL-34 in RA pathology. The aim of this study is to clarify the role of IL-34 in the pathogenesis of Japanese RA. [Methods] RA and osteoarthritis (OA) patient sera and RA synoviocytes were used. IL-6 and IL-34 were measured by ELISA. [Results] Serum IL-34 was significantly increased in RA compared to OA (p<0.05). Serum IL-34 was increased in some RA patients with negative inflammatory findings and active synoviots with MRI or echo. IL-34 production was spontaneously observed in the culture supernatant from RA primary synoviocytes. RA fibroblast-like synovial cells (FLS) produced IL-34 upon stimulation with IL-1 and TNFα. IL-6 produced from RA FLS stimulated with IL-1 was suppressed by anti-IL-34 antibody and anti-CSF-1-R antibody. [Conclusions] IL-34 production is elevated in Japanese RA patients, and IL-34 is produced in synovium and revealed that they are involved in the pathogenesis. It was suggested that IL-34 could be a new therapeutic target for RA.

**W17-5**

**Murine Osteoblasts Secrete High Concentration of Osteoprotegerin and Suppress Osteoclastogenesis by Inhibiting Soluble RANKL**

Hiroaki Yazawa, Maiko Yanagisawa, Yoshimi Aizaki, Kojiro Sato, Toshihide Mimura

Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University

Conflict of interest: None

Purpose: We once reported that although human M-CSF and human RANKL can induce murine osteoclastogenesis in vitro, human synoviocytes can’t induce osteoclasts (OCs) when it was co-cultured with mouse OC precursor cells. Thus, synoviocytes have a character different from osteoblasts. Human synoviocytes stimulated by Vitamin D3(1,25(OD)3) and prostaglandinE2(PGE2) did not produce RANKL but secreted a high concentration of osteoprotegerin (OPG), a decoy receptor for RANKL. Interestingly, mouse osteoblasts secreted much more OPG than RANKL. Our purpose is to further investigate the results. [Methods] We obtained osteoblast from neonatal mouse calvaria. They were co-cultured or cultured separately with mouse bone marrow cells (BMCs). We detected OCs by using tartrare-resistant acid phosphatase staining. [Results]: When osteoblasts and BMCs are cultured separately with 1,25 (OD)3, and PGE2, OCs were not induced. In the presence of M-CSF and a high dose of RANKL (>10ng/ml), BMCs transformed into OCs. [Conclusion]: We propose that membrane-bound RANKL plays a more important role than soluble RANKL in osteoclastogenesis. This may work as a mechanism that prevents ectopic osteoclastogenesis. We also speculate that M-CSF secreted from osteoblasts is insufficient for OC precursor cells to survive.

**W17-6**

**Chronotherapy with Baricitinib attenuates CIA mice arthritis**

Arisa Yaekura1, Ikumi Okumura1, Kenta Kaneshiro1, Koto Uchida1, Yuto Oketani1, Kanta Morii1, Kohsuke Yoshida1, Yoshiko Kawasaki1, Nao Shibanuma1, Yoshitada Sakai2, Akira Hashiramoto1

1Department of Biophysics, Division of Clinical of Immunology, Kobe University Graduate School of Health Sciences, Kobe, Japan, 2Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan, 3Department of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, 4Department of Rehabilitation Science, Kobe University Graduate School of Medicine, Kobe, Japan

Conflict of interest: None

[Object] Diurnal variations are observed in symptoms of rheumatoid arthritis (RA), and serum cytokine concentrations of collagen-induced arthritis (CIA) mice is reported to increase from morning to evening. JAK inhibitor baricitinib (BAR), a wide-ranged cytokine blocker, is oral administered once a day. In this study, the effect of timing of BAR administration, targeting peaks of cytokine secretion, was examined in CIA mice. [Methods] CIA mice were administered a dose of 3 mg/kg of BAR once a day at zeitgeber time (ZT) 0 or ZT12 for 18 days. On day18, splenic lymphocytes were isolated to measure expressions of IL-1β, IL-6, IL-17A, TNF and IFNγ by Real-time PCR. [Results] Arthritis score of ZT0 group decreased from day9 as compared to untreated group, and those of ZT12 group was significantly higher than those of ZT0 group from day15. Expressions of IL-6, IL-17A, IFNγ in lymphocytes were significantly decreased by BAR treatment as compared with untreated group. Expressions of IL-1β in ZT0 treated group were significantly decreased as compared with untreated mice, whereas those in ZT12 group were significantly increased as compared to untreated mice.
were not. Expressions of TNF in ZT0 group were lower as compared with ZT12 group. [Conclusions] Effectiveness of chronotherapy targeting cytokine secretions is suggested.

W18-1
HLA-DR sequence variants in idiopathic membranous nephropathy and bucillamine-induced membranous nephropathy
Atsushi Komatsuda, Hideki Wakui
Akiota University Graduate School of Medicine

Conflict of interest: None

[Object] Several recent studies in patients with idiopathic membranous nephropathy (i-MN) showed that HLA-DR-B15 genes are significantly associated with i-MN. On the other hand, bucillamine, one of DMARDs, is known to induce MN (bi-MN). However, there is only 1 report on analysis of HLA regions in Japanese patients with bi-MN, which showed HLA-DR-B8 is associated with bi-MN. [Methods] A total of 31 patients with i-MN and 22 patients with bi-MN were enrolled. All patients were Japanese. We analyzed HLA-DR using genomic DNA prepared from peripheral mononuclear cells from each patient. We then studied differences in HLA-DR among the 2 groups. [Results] Allelic frequency distributions for HLA-DR8 were not different between the i-MN and the bi-MN groups (14.75% and 27.3%, p=0.18). Allelic frequency distributions for HLA-DR15 were significantly different between the i-MN and the bi-MN groups (34.4% and 2.27%, p=0.002). There are no differences in other HLA-DR. [Conclusions] HLA-DR15 may become a new biomarker indicating the protective factor of bi-MN.

W18-2
Efficacy and safety of biologic agents in elderly patients with rheumatoid arthritis
Akiko Kasahara, Takashi Kida, Takuya Inoue, Shunya Kaneshita, Tomoya Sagawa, Risa Sagawa, Kazuki Fujioka, Hidetake Nagahara, Makoto Wada, Masatake Kohno, Yutaka Kawahito
Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine

Conflict of interest: None

[Object] To evaluate the efficacy and safety of biologic agents in elderly patients with rheumatoid arthritis (RA). [Methods] Retrospective study in a total of 152 elderly patients with rheumatoid arthritis, from April 2008 to March 2017. The study population was divided into two age groups (young-old (109 patients): 65 to 74 years and old-old (43 patients): ≥75 years), and the efficacy and safety of biologic agent therapy were assessed. [Results] Overall, 68 (young-old:old-old: 40:28) patients were treated with abatacept; 34 (27/7) with etanercept; 22 (20/2) with tocilizumab; 14 (10/4) with golimumab; 9 (7/2) with certolizumab; 3 (3/0) with adalimumab and 2 (0/2) with infliximab. One-year adherence rates were 77 % in young-old patients and 74 % in old-old patients. Adverse Events were 16.7/100 person-year in young-old patients, and 26.4/100 in old-old patients. Serious infections requiring hospitalization were 1.6/100 person-year in young-old patients, and 6.8/100 person-year in old-old patients. [Conclusions] Abatacept was most used in old-old patients. The rate of serious infection was higher in old-old patients. This study suggests that we have to use biologic agent more carefully in old-old patients.

W18-3
Placental transfer of tocilizumab in a patient with rheumatoid arthritis
Yoshifumi Tada, Mariko Sakai, Yoshinobu Nakao, Akihito Maruyama, Yuri Sadanaga, Nobuyuki Ono, Syuichi Koarada
Department of Rheumatology, Saga University, Faculty of Medicine, Saga, Japan

Conflict of interest: None

Tocilizumab (TCZ) use during pregnancy in patients with rheumatoid arthritis (RA) has not been evaluated in detail. We investigated the placental transfer of TCZ. A 39-year-old Japanese woman with RA has been treated with TCZ and prednisolone. When she became pregnant after an embryo transfer, we stopped TCZ and increased prednisolone. However, the RA exacerbated and the fetus died. An attempt to control her RA with certolizumab pegol failed, so TCZ was resumed. The patient again became pregnant after the next frozen embryo transfer. We continued TCZ throughout an uneventful pregnancy. She gave birth at 38 weeks of gestation by Caesarean section to a girl weighing 3,276 g with no congenital abnormalities. Although the infant was hypoglycemic at birth, she grew normally and continued to thrive. The TCZ concentration of maternal serum at birth was 6.17 mg/mL, and the transfer rate in umbilical cord blood and neonatal sera were 89% and 78%, respectively. We also measured total IgG and IgG1 subclass concentrations. The transfer rates of IgG and IgG1 in cord blood were 152% and 145%, and those in neonatal blood were 159% and 153%, respectively. These results showed that TCZ was transferred to fetus, but its transfer rate seemed to be lower than those of natural IgG and IgG1 antibodies.

W18-4
An attitude survey on RA treatment of clinicians in northeastern Osaka (3rd report)
Yoshio Ozaki1,2,3, Saki Tsujimoto1,2, Akihiro Tanaka1,2,5, Keiko Shimamoto1,2,3, Tohru Nishizawa1,2, Hideki Amuro1,2,3, Yosun Son1,2,3, Hideo Kagawa1,2,3, Yasuo Kunugiza1,8, Tetsuyoshi Teranishi1,2,3, Shigeo Miyashita1,6, Shinobu Morishita1,6, Tomoki Ito2, Shosaku Nomura2
1Department of Rheumatology and Clinical Immunology, Kansai Medical University Hospital, 2First Department of Internal Medicine, Kansai Medical University, 3Kagawa-Clinic, Orthopaedic Surgery, JCHO Hoshigaoka Medical Center, 4Teranishi Naika, 5Miyashita RA & Orthopaedic Clinic, 6Morishita Orthopaedic and RA Clinic, 7Kita-kawachi Rheumatism Network

Conflict of interest: None

[Object/Methods] Katikawachi region in northeastern Osaka has a population of 1.2 million people. In this region, the majority of examinations and medical treatments for rheumatoid arthritis (RA) are performed in clinics. We conducted 3rd sentiment survey to build a collaborative system for continuous and effective RA medical examination. Objectives/Method: The survey was distributed to 180 facilities, including internal medicine and orthopedic surgery departments of hospitals and clinics which follow RA patients. [Results/Conclusions] Answers were obtained from 103 facilities (41.2%). 50% of facilities specialized in RA (RA clinic) and 23% of non-specialized facilities (non-RA clinic) diagnosed RA using ACR/EULAR criteria. Doctors in RA clinics made much of physi-cal assessment of joint (TJC: RA clinics 64% vs non-RA clinics 15%, SJC 74% vs 31%). Furthermore, 59% of doctors in non-RA clinics did not use MTX for RA treatment.

W18-5
Circulated cooperation of the hospital and polyclinic for rheumatoid arthritis treatment in Yamagata area (Yamagata Area Rheumatoid Arthritis Neo Noticeable Associated Network; YARANNA network)
-For the introduction of two physicians in charge-Yuya Takakubo1,2,4,5, Suran Yang1,3,5,6, Akiko Sasaki2,3,4, Yuta Suzuki1,6, Yoshioka Hospital, 2Department of Rehabilitation & Orthopaedic Surgery, Yamagata Prefectural Central Hospital, 3Department of Orthopaedic Surgery, Yamagata Prefectural Hospital, 4Department of Orthopaedic Surgery, Yamagata Prefectural Hospital, 5Department of Orthopaedic Surgery, Okita-shi Medical Center, 6Department of Orthopaedic Surgery, Okita-shi Medical Center

Conflict of interest: None

[Object/Methods] Kitakawachi region in northeastern Osaka has a population of 1.2 million people. In this region, the majority of examinations and medical treatments for rheumatoid arthritis (RA) are performed in clinics. We conducted 3rd sentiment survey to build a collaborative system for continuous and effective RA medical examination. Objectives/Method: The survey was distributed to 180 facilities, including internal medicine and orthopedic surgery departments of hospitals and clinics which follow RA patients. [Results/Conclusions] Answers were obtained from 103 facilities (41.2%). 50% of facilities specialized in RA (RA clinic) and 23% of non-specialized facilities (non-RA clinic) diagnosed RA using ACR/EULAR criteria. Doctors in RA clinics made much of physical assessment of joint (TJC: RA clinics 64% vs non-RA clinics 15%, SJC 74% vs 31%). Furthermore, 59% of doctors in non-RA clinics did not use MTX for RA treatment.
five years. [Methods] We investigate numbers of the patients and polyclinics which has agreed the circulated cooperation as YARANNA network and the drug using for them. [Results] We have one hundred seventy-seven patients (11% in all our patients) with RA which has agreed the YARANNA network. They included fifty-three patients receiving biologicals, one hundred three non-biologics, nine for the treatment of osteoarthritis, seven for rehabilitation and two for osteoporosis. [Conclusion] The patients with RA which prefer regular visit with our university hospital may continue to increase, because of the unique right of free-access to any hospital for Japanese patients and increasing elderly people with many complications. It is important to spread this circulated cooperation system of YARANNA network in our area.

W18-6
Factors for delayed treatment intervention in patients with newly diagnosed rheumatoid arthritis
Shohei Nakamura1,2, Yohei Seto2, Isao Matsuura1, Hisashi Yamanaka2 1Department of Rheumatology, Tokyo Women’s Medical University Yachiyo Medical Center, 2Department of Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University

Conflict of interest: None

[Object] To study the proportion and factors which the delayed treatment intervention in patients with newly diagnosed rheumatoid arthritis (RA). [Methods] Patients (clinically suspect arthritis; CSA, undifferentiated arthritis; UA and rheumatoid arthritis; RA fulfilled the ACR/EULAR 2010 classification criteria) were included retrospectively in this study who had newly referred to the clinic from September 2013 to September 2018, and naïve to anti-rheumatic drugs. Patients’ background, and the factors for delayed intervention were evaluated. [Results] Total of 4 CSA (Age 59, female 2), 23 UA (Age 68, female 19), 71 RA (Age 56, female 42) were included. Duration from the first visit to treatment intervention was 0, 14 and 0 day, respectively. The reason for delayed intervention were assessment for comorbidity, family planning, differential diagnosis for other rheumatic diseases and/or connective tissue diseases, and planned elective surgeries. [Conclusions] Early treatment intervention is one of the fundamentals for newly diagnosed RA, and management of factors for the intervention delay shall be important.

W19-1
Extending tocilizumab infusion intervals from 4 to 6 weeks in rheumatoid arthritis patients
Osamu Saiki, Hiroshi Uda Department of Rheumatology, Higashiosaka City Medical Center

Conflict of interest: None

[Object] We showed that the interval between successive IV TCZ can be extended from 4w to 6w in 60% of patients with low diseases activity (LDA) at 4w intervals (Clin Exp Rheum, 2017). We investigated the efficacy and safety of extending the interval from 4w to 6w. [Methods] A retrospective observational study was conducted by enrolling patients in whom the intervals of TCZ infusions could be extended from 4w to 6w with an LDA for more than 2 years. We compared the efficacy and safety of TCZ infusions at 4w and 6w in a cohort of patients. We also examined serum lipid, platelet, IL-6 and trough TCZ levels. [Results] A total of 125 patients with an LDA at 4w intervals were enrolled, of which 78 patients maintained LDA at 6w intervals. After extending the intervals, the efficacy was maintained, and the side effects decreased significantly. In addition, the levels of total cholesterol and triglyceride were returned to normal, and the serum trough levels of TCZ became undetectable at 6w intervals. [Conclusions] We proved that intervals between TCZ infusions can be extended from 4w to 6w in more than 60% of RA patients along with a decrease in the side effects, thus suggesting the need to change the infusion intervals in suitable patients.

W19-2
Comparative effectiveness of switching to TNF inhibitors, abatacept or JAK inhibitors after inadequate response to tocilizumab in patients with rheumatoid arthritis
Hiroshi Kanazawa, Hiromitsu Takemori Department of Rheumatology, Aomori Prefectural Central Hospital

Conflict of interest: None

Objective: In EULAR recommendation for management of RA (2016 update) a bDMARD or tDMARD failed, treatment with another bDMARD or a tsDMARD should be considered. The aim of study is to compare the effectiveness of TNF inhibitors (TNFi), abatacept (ABT) or JAK inhibitors (JAKi) after inadequate response to tocilizumab (TCZ-IR) in patients with RA. Method: In this retrospective study, we evaluated 27 RA patients (85.2% of women, average age 59.8 years old, and average disease duration 8.2 years), switched to TNFi (9, IFX (1), ETN (3), GLM (2) and CDP (3)), ABT (11), or JAKi (7, tofacitinib (6), baricitinib (1)) after TCZ discontinuation by the clinical effectiveness and background at week 24. Result: The drug retention rate at week 24 was 55.6% (TNFi), 63.6% (ABT) and 57.1% (JAKi). The proportion rate of patients achieving CDAI < 2.8 (remission) was 22.2% (TNFi), 36.3% (ABT) and 14.3% (JAKi). The mean value of CDAI at week 24 was 8.38 (TNFi), 6.16 (ABT) and 7.93 (JAKi). In this analysis, significant difference was not provided statistically. Serious adverse event was not observed in any groups. Conclusion: Our findings showed no significant difference of switching to TNFi, ABT or JAKi after TCZ-IR. Further clinical trial is expected for RA patients with TCZ-IR.

W19-3
Switching to Abatacept from Other Biological Agents due to Adverse Event in Patients with Rheumatoid Arthritis
Yuji Hirano, Daisuke Kihira Department of Rheumatology, Toyohashi Municipal Hospital

Conflict of interest: Yes

[Object] Main reasons for stopping biological agents (BIO) in RA patients are lack of efficacy (LOE) and adverse event (AE). Information on next choice after stopping BIO due to AE are lacking. We have chosen abatacept (ABT) after BIO which is stopped due to AE and investigated concomitant with MTX. 66.7% was concomitant with PSL. If all reasons for stopping drugs were asigned as outcome, mean drug retention periods was 1037 days and 808 days in ABT and former BIO, respectively and there were no significant difference (p=0.198). If only AE was assigned as outcome, there was significant differences (ABT: 1428 days, former BIO: 808 days, p=0.023). Reasons for stopping ABT were LOE in 5 cases and AE in 4 cases. DAS28-CRP and SDAI were significantly improved after ABT initiation. [Conclusions] It was suggested that ABT after BIO failed due to AE was acceptable.

W19-4
Stopping methotrexate in combination with abatacept for rheumatoid arthritis-multicenter analysis using FIT-RA registry
Hiraku Motomura1,2,3, Shinichi Kato2,3, Hiroshi Fujinaga4,5, Tetsuo Watanabe5, Haruki Takagi1, Toshiyuki Kitaori4, Hirofumi Taki6, Koichiro Shinoda7, Tomoatsu Kimura1 1Department of Orthopedic Surgery, University of Toyama, 2Department of Rheumatology, Jouhoku Hospital, 3Department of Rheumatology, Kamaraya Hospital, 4Japanese Oriental Medicine and Rheumatology, Toyama Prefectural Central Hospital, 5Department of Orthopedic Surgery, Fukui Red Cross Hospital, 6Department of First Medicine, University of Toyama

Conflict of interest: None

Objective: In EULAR recommendation for management of RA (2016 update) if a bDMARD or a tDMARD failed, treatment with another bDMARD or a tsDMARD should be considered. The aim of study is to compare the effectiveness of TNF inhibitors (TNFi), abatacept (ABT) or JAK inhibitors (JAKi) after inadequate response to tocilizumab (TCZ-IR) in patients with RA. Method: In this retrospective study, we evaluated 27 RA patients (85.2% of women, average age 59.8 years old, and average disease duration 8.2 years), switched to TNFi (9, IFX (1), ETN (3), GLM (2) and CDP (3)), ABT (11), or JAKi (7, tofacitinib (6), baricitinib (1)) after TCZ discontinuation by the clinical effectiveness and background at week 24. Result: The drug retention rate at week 24 was 55.6% (TNFi), 63.6% (ABT) and 57.1% (JAKi). The proportion rate of patients achieving CDAI < 2.8 (remission) was 22.2% (TNFi), 36.3% (ABT) and 14.3% (JAKi). The mean value of CDAI at week 24 was 8.38 (TNFi), 6.16 (ABT) and 7.93 (JAKi). In this analysis, significant difference was not provided statistically. Serious adverse event was not observed in any groups. Conclusion: Our findings showed no significant difference of switching to TNFi, ABT or JAKi after TCZ-IR. Further clinical trial is expected for RA patients with TCZ-IR.
Does the dose reduction strategy of MTX following remission with biologics in rheumatoid arthritis maintain the remission status?

Miki Nakajima, Tsuyoshi Jotoku, Norio Morimoto
Katsuragi Hospital

Conflict of interest: None

[Object] The aim of this study was to assess whether the dose reduction of MTX after sustained remission combined with biologics is useful for rheumatoid arthritis patients.

[Methods] Disease activity score (DAS28-ESR) and biological naïve were 6 patients (33.3%). The mean time to stopping of concomitant MTX with ABT was 1.8 years. No patient resumed MTX to final follow up. The mean DAS28-ESR was 4.65 at baseline, decreased to 2.67 at the time of stopping MTX and furthermore decreased to 2.40 at final follow-up. [Conclusions] MTX in combination with ABT was stopped in one-third of patients. The clinical efficacy after stopping MTX maintained during ABT therapy.

W20-1
The efficacy and safety of remission induction therapy in patients with giant cell arteritis (GCA)

Masa Taniguchi, Kenichiro Tokunaga, Hideko Oshikawa
Department of Rheumatology, Japanese Red Cross Kumamoto Hospital

Conflict of interest: None

[Object] To assess the efficacy and safety of remission induction therapy in patients with giant cell arteritis (GCA). [Methods] We reviewed clinical data of patients with GCA diagnosed between Nov 2014 and Aug 2018. [Results] Fourteen patients with GCA (average age 73.5 years (y) (60-86), disease duration 30 months (mts) (3-90),4 women (28.6%) participated and were observed for 21.3 mts (2-48.5). Twelve patients underwent temporal artery biopsy, which confirmed arteritis in 57.1%. Initial treatment was prednisolone (PSL; 1 mg/kg/d); the initial remission induction rate was 92.9%, and time to remission was 0.6 mts (0.25-4). Seven patients were observed for more than 12 mts. At 12 mts, the average PSL dose was 6.0 mg/d, cumulative PSL dose was 6068.4 mg, and remission rate was 87.5%. No patients received tocilizumab, and 14.3% received methotrexate and PSL. The relapse rate was 35.7%, and mean time to relapse was 13.2 (2-48.5) mts. Adverse events were diabetes mellitus (21.4%), infection (14.3%), and others. [Conclusions] Almost all patients achieved initial remission, which was maintained for 12 mts. Meanwhile, high infection and diabetes incidences were observed. The relapse rate after 12 mts was relatively high despite sufficient steroids. Further research will help determine appropriate PSL doses.

W20-2
Tocilizumab as remission induction and steroid-sparing therapy for giant cell arteritis

Hiroshi Ito, Hideo Yamada, Hironori Hanaoka
Medical Center for Rheumatic Diseases, Seirei Yokohama Hospital

Conflict of interest: None

[Objective] The clinical question on the treatment of giant cell arteritis (GCA) with tocilizumab (TCZ) is how to reduce the cumulative dose of steroids because of multiple comorbidity. Here we describe 5 GCA cases in whom we attempted a rapid tapering of steroid after methylprednisolone (mPSL) pulse plus TCZ therapy. [Cases] Five patients (mean age 74.8) with GCA were treated with mPSL pulse and TCZ without other immunosuppressants. The clinical manifestations included headache, jaw claudication, double vision in 2 cranial-GCA, and fever, abdominal pain in 3 large vessel-GCA. Two patients had polymyalgia rheumatica (PMR). Mean initial dose of PSL was 22.5 mg. The median observation periods was 11 months. All patients responded well to the induction therapy, resulting in remission. PSL was tapered down to the mean 6 mg/day after 3 months. Three patients discontinued PSL within 10 months. One patient showed a flare of PMR after 10 months, which was treated with increasing dose of PSL, because the patient experienced leukocytopenia which improved after extending the interval of TCZ. There was no other serious adverse events. [Conclusion] Induction therapy with mPSL pulse and TCZ may facilitate the tapering and cessation of steroid without adding serious adverse events in GCA.

W20-3
Usefulness of tocilizumab for patients with Takayasu’s arteritis

Shota Okamoto, Hiroto Tsuibo, Taihei Nishiyama, Hirofumi Toko, Masaru Shimizu, Fumika Honda, Mizuki Yagishita, Ayako Ohyma, Izumi Kurata, Saori Abe, Hiroiuki Takahashi, Atsuzu Osada, Masahiro Yokosawa, Yuya Kondo, Isao Matsumoto, Takayuki Sumida
Department of Internal Medicine, Faculty of Medicine, University of Tsukuba

Conflict of interest: None

[Object] To investigate usefulness of tocilizumab (TCZ) for patients with Takayasu’s arteritis (TKA). [Methods] We examined 1) background, 2) concomitant drugs, 3) CRP, 4) prednisolone (PSL) dose, 5) relapse and adverse events, in patients with TKA who started TCZ between Aug 2017 and Sep 2018 in our hospital, retrospectively. [Results] 1) 6 patients (all...
female, 25.0±8.1 years old, 5.2±4.8 years of disease duration, 3 cases of type II a and 3 of type V) were investigated. TCZ was used for the first induction therapy (Tx) in 2 cases and the maintenance Tx in 4 cases. All 6 cases received TCZ subcutaneously. 2) In 2 cases of induction Tx, 45 and 30 mg/d of PSL was concomitantly used. In 4 cases of maintenance Tx, 9.0±4.3 mg/d of PSL was used, and all 4 cases received concomitant immunosuppressants (MTX in 2 cases, azathioprine 2, CsA 1, and MMF 1). 3) CRP significantly decreased from 1.9±2.6 (0W) to 0.03±0.0 (8W) mg/dl (P=0.05). 4) In 2 cases of induction Tx, PSL doses were tapered from 1.1 and 0.3 mg/kg/d (0W) to 0.5 and 0.3 mg/kg/d (8W), respectively. In 4 cases of maintenance Tx, PSL doses (0.2±0.1 mg/kg/d) did not change for 8W. 5) No relapse and adverse events occurred for 32.0±19.4W of observational period. [Conclusions] TCZ might serve as both induction and maintenance Tx for TKA.

W20-4
Efficacy and safety of tocilizumab in patients with recurred Takayasu arteritis in our hospital
Mikiya Kato, Taichi Miyagi, Risa Wakiya, Shusaku Nakashima, Hiromi Shimada, Tomohiro Kameda, Hiroaki Dobashi
Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Kagawa University School of Medicine

Conflict of interest: None

[Object] To investigate the efficacy and safety of TCZ for the treatment of TAK patients who recurred during tapering GC. [Methods] Six subjects of TAK treated with TCZ were analyzed. Baseline characteristics, remission rate, adverse events, GC dose, were examined retrospectively. The structural changes of LV were evaluated using enhanced-CT, MRI, and FDG-PET. [Results] All 6 cases (one male and 5 females) were initiated by TCZ treatment. The average age was 38.0 ± 14.2 years old. The disease duration at the administration of TCZ was 157 ± 131 months. The mean dosage of PSL was 7.42 ± 4.09 mg/day, and the immunosuppressants combined with GC were prescribed in 3 cases. The dose escalation of GC was conducted in only one patient at TCZ administration. Within 6 months after initiating TCZ treatment all patients achieved remission, and the PSL dose was reduced to 4.33 ± 2.49 mg/day. Immunosuppressants could be discontinued in 2 out of 3 cases. No serious adverse events were observed. [Conclusions] TCZ was a safe and effective option of treatment for TAK. In addition, the treatment strategy for the recurred TAK patients without dose escalation of GC could be conducted using TCZ. Furthermore, we will discuss the structural changes of LV treated with TCZ using imaging findings.

W20-5
Consideration on the persistence rate and therapeutic effect of tocilizumab for large vasculitis
Atsushi Yamamoto, Kaori Ishimura, Hiroki Akazawa, Chisato Ashida, Shinkai Ri, Asuka Inoue, Toshihiko Shiga, Kazuya Kishimoto, Yasuaki Hirooka, Yuji Nozaki, Koji Kinoshita, Masanori Funachi, Itaru Matsumura
Kinki University School of Medicine Affiliated Hospital College of Cologen Disease

Conflict of interest: None

Objective: Tocilizumab (TCZ) efficacy has been reported as a treatment for Takayasu arteritis and giant cell arteritis. In this study, we investigated continuation rate, inflammatory marker and relapse rate of TCZ treatment group (P+T group) combined with steroid and steroid monotherapy group (P group) in large vasculitis. METHODS: As of October, 2018, the baseline of P group (11 cases), P+T group (9 cases), continuation rate after 6 months for inflammatory large-scale vasculitis in 20 cases at our hospital, inflammation Markers, and whether or not relapse was present were examined. Results: the six-month continuation rate in the P+T group was 1 case but 100% was found in the diverticulitis. Baseline and AWBC and ΔCRP after 6 months were significantly lower in the P+T group than in the P group. There was no significant difference in PIt and blood sediment. in relapse within 6months of treatment, 3 of 11 patients showed back pain, general malaise and CRP elevation, but no relapse wa observed in groups. TCZ therapy for large-scale vasculitis has good continuation rate, good inflammatory response reduction and no recurrence, so it was shown to be useful for Large vessel vasculitis.

W20-6
The use of biologics in large vessel vasculitis
Tsuyoshi Shirai, Tomoyuki Mutoh, Yoko Fujita, Hiroshi Fujii, Tomonori Ishii, Yasuhiro Hibayashi, Hideo Harigae
1Hematology & Rheumatology, Tohoku University Graduate School of Medicine, 2Department of Rheumatology, Hikarigaoka Spellman Hospital

Conflict of interest: None

[Object] Large vessel vasculitis (LVV) contains Takayasu arteritis (TAK) and giant cell arteritis (GCA). Although biologics are approved for LVV, little information exist. This study analyzed LVV patients treated with biologics. [Methods] 101 LVV patients (GCA, 6) who visited our hospital in 2018 were retrospectively evaluated. Details of biologics, dosing of prednisolone (PSL) and immunosuppressants, efficacy, and adverse events were evaluated. [Results] 26 patients (TAK, 25) were treated with biologics including tocilizumab (TCZ, n=20), infliximab (n=2), adalimumab (n=2), golimumab (GLM, n=2), abatacept (n=2), and rituximab (n=1). Mean-follow up duration was 27 months. In TAK, 23 cases received biologics upon relapse, and two cases for extravascular manifestations. The mean dose of PSL was reduced from 10.6 to 6.4 mg/day (P=0.001). PSL was stopped in one patient under TCZ. Immunosuppressants were used in 12 cases, and stopped in 6 cases. Biologics were switched in 3 cases. Two patients receiving TCZ experienced relapse, and they were treated with GLM or high dose of PSL. [Conclusions] The use of biologics showed significant steroid-sparing effect in TAK. Meanwhile, some cases relapsed without the elevation of inflammatory markers, indicating needs to monitor symptoms and imaging.

W21-1
Current state of the health care costs of patients with ANCA-associated vasculitis in Japan using a large insurance database
Hirokazu Nishina, Eiichi Tanaka, Ryoko Sakai, Masayoshi Harigai, Hisashi Yamanaka
Department of Rheumatology, Tokyo Women’s Medical University Hospital

Conflict of interest: None

[Objective] The aim of this study is to investigate the current medical cost by treatment in Japanese ANCA associated vasculitis (AAV) patients. We use a large insurance database. [METHODS] We selected 8,402 cases from 24,673 cases of hospitalized AAV (microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA) patients from April 2008 to April 2017. Prednisolone (PSL) over 30 mg or steroid pulse therapy or immunosuppressive drugs (rituximab, cyclophosphamide, methotrexate, mycophenolate mofetil and hospitalization days over 7 days) were defined as induction therapy group and we analyzed these (2,299 cases). [Results] AAV (821 cases), MPA (1,055 cases), GPA (261 cases), EGPA (404 cases). Median of hospitalization cost was 1,382,524 yen, 1,413,041 yen, 1,359,152 yen, 1,454,047 yen. In the case of IVCY, they were slightly increased (1,762,436 yen, 1,839,252 yen, 1,486,644 yen, and 1,938,735 yen). In the case of rituximab, It were doubled (2,699,665 yen, 2,778,315 yen, 2,770,317 yen, 3,104,470 yen). In the case of plasma exchange, they were tripled (3,978,383 yen, 3,663,162 yen, 4,404,019 yen, 4,032,512 yen). [Conclusion] In Japanese AAV patients, medical costs become expensive due to rituximab and plasma exchange.

W21-2
QOL of elderly ANCA-associated vasculitis
Yoko Miura, Ryo Yanai, Nobuyuki Yajima
Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

Conflict of interest: None
As advances in the treatment of ANCA-associated vasculitis, acute phase deaths have decreased. So, it is important to treat with keeping quality of life. In this study, we determined the factors related to re-hospitalization of elderly ANCA-associated vasculitis people. [Methods] 68 ANCA-associated vasculitis patients who diagnoses at Showa university hospital department of Rheumatology were targeted. They were hospitalized among January 2006 and July 2017. The main outcome is re-hospitalization which was unexpected. The type of vasculitis, damaged organ, age, underlying disease, BMI, steroid pulse, the use of immunosuppressant, and infection during first hospitalization, rehabilitation and ABD were considered as risk factors. [Results] 68 patients with anca-associated vasculitis were examined. Of the 68 people, 50 MPA, 10 GPA, 8 EGPA, age 77.7 ± 7, female 73.4%. The prevalence of the unscheduled hospitalization within one year was 31.8%. Infections were the most common reasons for hospitalization. There are no remarkable factors of the unscheduled hospitalization within one year. [Conclusions] The prevalence of the unscheduled hospitalization within one year was 31.8%. Infections were the most associated vasculitis were examined. Of the 68 people, 50 MPA, 10 GPA, 8 EGPA, age 77.7 ± 7, female 73.4%. The prevalence of the unscheduled hospitalization within one year was 31.8%. Infections were the most common reasons for hospitalization. There are no remarkable factors of the unscheduled hospitalization within one year. [Conclusions] The prevalence of the unscheduled hospitalization within one year was 31.8%. Infections were the most

W21-3
The clinical features of otitis media with ANCA-associated vasculitis in Ehime university hospital
Koichi Suemori1, Jun Ishizaki1, Takuya Matsumoto1, Eiji Sada2, Katsumi Takenaka2, Hitoshi Hasegawa1
1Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, 2Ehime Prefectural University of Health Sciences

Conflict of interest: None

[Object] To investigate clinical characteristics, efficacy, and safety of treatment in patients with otitis media with ANCA-associated vasculitis (OMAAV) in our hospital. [Methods] 30 patients (8 males, 13 females) who were diagnosed with OMAAV between March 2010 and February 2018 were retrospectively evaluated. [Results] Mean age was 67.8-year-old. The durations from the onset to the diagnosis were 3 months (median value). The clinical symptoms were impaired hearing, congested feeling, tinnitus, headache and fever. MPO- and PR3-ANCA were positive in 23 and 4 cases, respectively. Hypertrophic pachymeningitis, facial palsy, pulmonary disorders and renal lesions were observed in 4, 5, 14 and 8 cases, respectively. Otitis media was involved in bilateral ears in 19 cases. All patients were treated with prednisolone (mean 0.71mg/kg/day), 22 with methyldprednisolone pulse therapy, 21 with azathioprine, 9 with intravenous cyclophosphamide, and 8 with rituximab. In 29 of 49 ears, audibility test was improved one month after initial treatments. Overall, 24 patients survived, 10 re-exacerbated and 6 (4 with infection and 2 with other disease) died. [Conclusions] Although immunosuppressive therapy was effective against OMAAV, infection should be remarkable as treatment-related-death.

W21-4
Predictor for otitis media in patients with ANCA associated vasculitis
Seiji Kobayashi, Hiroko Kadota, Shinji Watanabe, Yuichiro Shirai, Takahisa Gono, Mitsuhito Takeno, Masataka Kuwana
Nippon Medical School Graduate School of Medicine

Conflict of interest: None

[Objective] Diagnosis and treatment at the early stage in OMAAV is important in view of prognosis of hearing in patients with AAV. In addition, it is necessary to choose effective immunosuppressive therapy in terms of organ disorders associated with systemic vasculitis. Therefore, we examined predictors for OMAAV complications in patients with AAV. [Methods] This is a single-center, retrospective study involving 22 patients with AAV between January 2016 and September 2018. All patients underwent otolaryngologic evaluation of otitis media. Demographic and clinical information was obtained by review of medical charts. [Results] Eight patients (36.4%) were diagnosed with OMAAV. Of all ears, one ear was sensorineural hearing loss, four ears were conductive hearing loss, and seven ears were mixed hearing loss. All AAV patients complicated with OMAAV had mastoiditis, compared with those without OMAAV (100% vs 21.4%, P<0.001). In OMAAV patients, responsiveness to induction therapy with steroid or immunosuppressive agents was poor, and recovery of hearing was poor. [Conclusions] Mastoiditis is one of the predictors for otitis media in patients with ANCA associated vasculitis.

W21-5
Association of Otitis Media with ANCA Associated Vasculitis and Hypertrophic Pachymeningitis
Takeshi Nakatsu1, Shunusuke Sakai1, Sayuri Takamura1, Ayako Wakamatsu1, Hiroe Sato2, Daisuke Kobayashi1, Yoko Wada1, Takeshi Kuroda3, Masaki Nakano1, Ichiee Narita1
1Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Health Administration Center, Niigata University, Niigata, Japan, 3Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University, Niigata, Japan

Conflict of interest: None

[Object] We clarify an association of otitis media with ANCA associated vasculitis (AAV) and hypertrophic pachymeningitis (HP). [Methods] Two hundred and eight patients with ANCA associated vasculitis (107 microscopic polyangiitis, 71 granulomatosis with polyangiitis and 30 eosinophilic granulomatosis with polyangiitis were admitted to Niigata University Hospital from 1989 through 2018. An association of AAV and HP was analyzed in 36 patients with otitis media and 172 patients without otitis media. [Results] 10 cases (28 %) of HP were observed in otitis media group and five cases (2.9 %) of HP in non-otitis media group (P<0.01). Three cases (8 %) of facial palsy were seen in otitis media group and no cases were observed in non-otitis media group (P=0.01). In all 15 cases of HP, 10 cases of otitis media or mastoiditis, six cases of sinusitis, two cases of orbital or cavernous inflammation, and one case of nasopharyngeal inflammation were seen. No eye, ear, nose, or throat manifestations were observed in one case. [Conclusion] Since HP is often complicated with otitis media with AAV, brain MRI should be considered to search HP in otitis media with AAV.

W21-6
Incidence and risk factors of new-onset hypertrophic pachymeningitis in patients with anti-neutrophil antibody-associated vasculitis
Aya Inamafu, Naoki Sawa, Akanori Sekine, Masahiro Kawada, Eiko Hasegawa, Junichi Hoshino, Yoshifumi Ubara, Kenmei Takaichi Nephrology Center, Toranomon Hospital

Conflict of interest: None

[Object] Hypertrophic pachymeningitis (HP) is a rare complication in patients with anti-neutrophil antibody-associated vasculitis (AAV). The incidence and risk factors associated with new-onset HP remains unknown. [Methods] We retrospectively studied 93 AAV patients, comparing HP incidence between patients with granulomatosis with polyangiitis (GPA) and to those with microscopic polyangiitis (MPA). We further analyzed the risk factors for HP. [Results] Among 93 patients (MPA; 76, GPA; 17), 6 developed HP (MPA; 1, GPA; 5) over an average observation period of 4 years. All patients who developed HP were positive for MPO-ANCA. HP incidence was significantly higher in patients with GPA than in those with MPA (60.2 vs 3.3 persons per 1000 person-years, P=0.002). Univariate classification and regression tree (CART) analysis grouped the patients into HP patients with GPA who have otitis media (33%) and patients with HP who have sinusitis (21%), and both conditions were associated with new-onset HP (P<0.001 and P=0.014, respectively). Adjusted odds ratio for otitis media was 38.1 (P=0.004). [Conclusions] HP incidence was higher in patients with GPA than in those with MPA. Otitis media was the most discriminating factor to predict new-onset HP in patients with AAV.

W22-1
Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis and Previous Inadequate Response to TNF Inhibitors: SPIRIT-P2 (2-years data from Phase 3 Study)
Masato Okada1, Akimichi Morita2, Ko Nakajo3, Hitoe Torisu-Iataka1, Amanda M Gellett1, Lisa Kerr4

Conflict of interest: None

[Object] SPIRIT-P2 (2-years data from Phase 3 Study)
Conflict of interest: Yes

[Object] Evaluate efficacy and safety of ixekizumab (IXE) in patients (pts) with active psoriatic arthritis (PsA) who have had an inadequate response (IR) or intolerance to 1 or 2 TNF inhibitors (TNFi). [Methods] Pts were randomized to placebo (PBO) or, after a 160 mg initial dose, to IXE 80 mg every 4 weeks (Q4W) or 2 weeks (Q2W). Pts in PBO were re-randomised to IXE Q4W or Q2W at Week (Wk) 16 if IRs or Wk 24. From Wk 32, pts were discontinued if TJC and SJC improvement <20%. ACR20/50/70, PASI17, LEI, LDI-B, MDA, DAS28-CRP, HAQ-DI were evaluated. Ad-hoc analysis for Wk0-108 included pts randomized to IXE at Wk 0. [Results] 186 of 363 pts continued Wk 108. Wk 108 efficacy was 59.6/46.6/23.2%/23.2%/24.3%/28.6%; PASI17: Q4W=65.1%, Q2W=48.3%; LEI=0%; Q4W=4/5.5%, Q2W=3.7%); LDI-B=0%; Q4W=63.0%, Q2W=60.0%; MDA: Q4W=30.7%, Q2W=25.9%; DAS28- CRP change from baseline (CBF): Q4W=-2.1, Q2W=-1.8; HAQ-DI CBF: Q4W=-0.39, Q2W=-0.35). Most Adverse Event (AE) were mild/moderate in severity. 3 deaths occurred, and incidence of Serious AE in Q4W and Q2W were 5.8 and 7.7/100 pt-yr. [Conclusions] 2-years IXE treatment showed clinically meaningful and sustained improvement in PsA signs and symptoms among pts who have IR or intolerance to TNFi. No unexpected safety outcomes were reported.

W22-2 Efficacy and Safety of Risankizumab in Japanese Patients with Active Psoriatic Arthritis: Results From a Phase 2 Trial
Masato Okada1, Graham Heap2, Ann Eldred2, Andrew Topp2, Susumu Kitamura3, Akimichi Morita1
1St. Luke’s International Hospital, Tokyo, Japan, 2AbbVie Inc., North Chicago, IL, USA, 3AbbVie GK, Tokyo, Japan, 4Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan

Conflict of interest: Yes

[Object] Risankizumab (RZB), a humanized IgG1 mAb, binds to the p19 subunit of interleukin-23, a key cytokine in the pathogenesis of psoriatic arthritis (PsA). We report results from a Japanese subset from a RZB study in patients (pts) with PsA. [Methods] In this double-blind, dose-ranging phase 2 study, pts with active PsA were randomized 2:2:2:1:2 (stratified by prior TNF inhibitor and concurrent methotrexate use) to RZB (150 mg at Wk 0, 4, 8, 12, and 16 [Arm 1]), 150 mg at Wk 0, 4, and 16 [Arm 2]), 150 mg at Wk 0 and 12 [Arm 3]), 75 mg at Wk 0 [Arm 4]) or matching placebo (PBO, Arm 5). The primary efficacy endpoint was ACR20 response at Wk 16. [Results] Of 185 pts enrolled, 14 were from Japan. At Wk 16, 100% of Japanese pts in RZB arms 1, 2, and 4 and 33% in arm 3 achieved ACR20 responses (82% all RZB vs 0% PBO, P=0.05); global Wk 16 ACR20 responses were 57%-65% across all RZB arms (36% PBO). Wk 24 RZB ACR20 responses were 73% (0% PBO, Japan) and 48% (31% PBO, global). RZB was well tolerated in Japanese RZB-treated pts; there were no serious adverse events (AE), deaths, or tuberculosis cases; infection was the most common AE (36% all RZB vs 33% PBO). [Conclusions] In Japanese pts with PsA, ACR20 responses were significantly greater in pts receiving RZB, and RZB was well tolerated.

W22-3 SPIRIT-P1, a phase 3 study of ixekizumab (IXE): 3-year efficacy and safety results in patients (pts) with active psoriatic arthritis (PsA)
Hideto Kameda1, Suchitrita Rathmann2, Kohei Hagimori3, Ryuji Nagamine1, Weijia Chen1, Toru Suguro2
1Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan, 2Department of Geriatric and Environmental Dermatology, Nagoya City University Graduate School of Medicine, Nagoya, Japan, 3Eli Lilly and Company, Indianapolis, IN, USA, 4Eli Lilly Japan K.K., Kobe, Japan

Conflict of interest: Yes

[Object] To assess efficacy and safety of IXE up to 3 years in PsA pts. [Methods] Biologic DMARD-naive PsA pts (N=417 [ITT], 12 Jp) were randomized to placebo (N=106), adalimumab (N=101) 40 mg once every 2 wks (Q2W), or IXE 80 mg (starting dose 160 mg) Q2W (N=103) or Q4W (N=107) in the Double-Blind Treatment Period (Wk 0-24). Pts who completed the period entered the Extension Period (Wk 24-52) and the Long-term Extension Period (LTEP: Wk 52-156), and were given 80 mg IXEQ4W or IXEQ2W. [Results] Of 210 pts (IXE-ITT, 6 Jp) randomized at Wk 0, 125 (60%) pts completed LTEP. ACR20/50/70 response rates (mNRI) at Wk 52 for IXEQ2W (62/56/44%) and IXEQ4W (70/52/33%) were consistent with those at Wk 52 (mNRI) for IXEQ2W (76/61/45%) and IXEQ4W (76/60/40%). In IXE-ITT Jp pts, 2 out of 4 (IXEQ2W) and 1 out of 2 (IXEQ4W) completed LTEP and were ACR20/50/70 responders. In the majority of pts, radiographic progression was not found or minimal through Wk 156. Frequencies of TEAEs were similar between IXEQ2W and IXEQ4W. The majority of TEAEs were mild or moderate in severity. [Conclusion] In IXE-treated pts, improvements in PsA symptoms persisted up to 3 years. No unexpected safety signals were observed, and the safety profile was consistent with previous IXE studies.

W22-4 Early diagnosis of psoriatic arthritis: How to diagnose arthritis preceding-psoriatic arthritis earlier
Syuichi Koarada1, Mariko Sakai1, Yoshinobu Nakao1, Yuri Sadanaga1, Akihito Maruyama1, Nobuyuki Ono1, Mitsunori Komine2, Yoshifumi Tada1
1Division of Rheumatology, Saga University, 2Department of Orthopaedics, Tsutsumi Rehabilitation Clinic

Conflict of interest: None

[Object] In psoriatic arthritis (PsA), joint destruction is progressive and early diagnosis is required. However, early diagnosis of arthritis preceding-PsA (AP-PsA) is difficult. Clinical features of AP-PsA are analyzed and extract factors contributing to early diagnosis. [Methods] Of 107 patients with PsA, we examined clinical features and images. In early PsA, sensitivity of CASPER and Fournie classification were analyzed. [Results] Among PsA, AP-PsA is 21%, skin preceding-PsA (AP-PsA) is difficult. Clinical features of AP-PsA are analyzed and early diagnosis is required. However, early diagnosis of arthritis preceding-psoriatic arthritis earlier is difficult before appearance of rash. A novel classification with comprehensive and including a new modality is required.

W22-5 Is there any tissue that exists in all organs involved in spondyloarthritis?
RyujI Nagamine1, Weijia Chen2, Toru Suguro3
1Center of Artificial Joint and Rheumatism, Fukuoka Tokushukai Medical Center, 2Research Institute of Rheumatology Medical Treatment

Conflict of interest: None

[Object] Spondyloarthritis (SpA) is a type of arthritis that attacks the spine and the joints. SpA can also involve the skin, intestines, eyes and genital organs. Diagnosis of SpA is based mainly on the results of a medical history and physical exam. It has not been reported why so many different organs are involved. Our hypothesis was that there is any tissue that exists in all organs involved in SpA. Literature review was performed to detect such tissue in SpA. [Methods] The lesion locates in every organ in SpA. Literature review was performed to detect such tissue in SpA. [Results] The tissue that locates in all lesion was the lymph tissue. Mucosa associated lymph tissue (MALT) is located in lung
(BALT), colon (GALT), skin (SALT) and eye. The MALT is the immune system that produces IgA. CD8 positive T cell exists in the MALT. The dendritic cell main works as the antigen presenting cell. Bursa and lymph tissue exist in the enthesis. Therefore, the lymph tissue exists in all lesions of SpA. Further study is necessary to clarify the pathology of SpA in each lesion. However, the lymph tissue can connect all organs involved in SpA. [Conclusions] The lymph tissue exists in all lesions in SpA.

W23-2 Effect of biologics on pulmonary events in rheumatoid arthritis patients with existing lung disease
Shinji Watanabe, Takahisa Gono, Yuichiro Shirai, Seiji Kobayashi, Mitsuhiro Takeno, Masataka Kuwana
Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan
Conflict of interest: None

[Object] To investigate whether administration of biologics newly cause pulmonary events in rheumatoid arthritis (RA) patients with existing lung disease. [Methods] 90 RA patients with existing lung disease, including interstitial lung disease [ILD] in 37 patients, airway disease [AD] in 52, and emphysema in 21, were enrolled in this study. The patients were divided into biologics group (n=38: TNF inhibitors in 16, abatacept in 19, tocilizumab in 10) and non-biologics group (n=52) to compare pulmonary events, including pulmonary infection, exacerbation of ILD or AD, and development of organized pneumonia, by using the Propensity score (PS) matching method. [Results] The pulmonary events occurred in 31 cases. The levels of KL-6 and steroid use were identified as factors significantly related to administration of biologics by multiple logistic regression analysis. We adjust these two factors to match clinical background between the two groups by using the PS matching. There was no significant difference in the pulmonary events between the two groups (P = 0.37). [Conclusions] In RA patients with existing pulmonary disease, the administration of biologics was not significantly associated with the development of pulmonary events.
subjects examined treatment, images, and prognosis using the clinical data. [Results] RA-ILD was 95 cases (36 males, 59 females, average age of 69 ± 9.9 years). The using MTX was 37 cases (38%), the amount of MTX was 6.9 ± 2.4 mg, the using PSL 35 cases (36%), the amount 5.6 ± 3.1mg, the using TAC 36 cases (37%), the amount 2.1 ± 0.8 mg, the using IGU 2 patients (0.02%), the using SASP 33 cases (34%), and the using BUC 6 cases (0.06%). The total of Bio + TOF use was 61 cases (64%), INF 3 cases (3%), ETN 6 cases (6%), ADA 5 cases (5%), GLM 5 cases (5%), CTZ 0 cases (0%), ABT 29 cases (30%), TCZ 5 cases (5%), TOF 3 cases (3%), and many cases of using ABT. [Conclusions] In the treatment of RA-ILD, bio was used at a high frequency of 64%, and treatment was relatively safe.

W23-5 Poor prognostic factors in RA patients with acute lung injury Tomoyuki Miyao, Kazuhiro Kurasawa, Yuta Takamura, Ayae Tanaka, Ryutaro Yamazaki, Satoko Arai, Takayoshi Owada, Reika Maezawa, Masafumi Arima
Department of Rheumatology, Dokkyo Medical University

Conflict of interest: None

[Object] To identify poor prognostic factors in RA patients with acute lung injury, a critical situation in RA-ILD. [Methods] We retrospectively reviewed 26 consecutive RA patients (8 male, 18 female) with acute lung injury that was diagnosed by respiratory failure and CT findings. To find prognostic factors, we compared clinical features of dead patients with survivors. [Results] No differences were found in backgrounds (gender, age, disease duration, and treatment for RA) between dead patients and survivors. Preexisting ILD and UIP were not identified as poor prognostic factors. Fever and respiratory symptoms were similarly found in both groups. Respiratory condition on admission was a factor to distinguish the dead and the live. GGO/consolidation was equally found in both groups, however, newly developing traction ectasia was frequently found in dead patients. Serum LDH and KL-6 levels were significantly high in dead group, but not CRP levels. Positivity of b-D glucan test was similar in both groups. Treatment for lung injury was similar in both groups. [Conclusions] Only severity of lung injury on the admission, which was suggested by respiratory condition, traction ectasia and elevated KL-6 and LH levels, was a poor prognostic factor in RA patients with acute lung injury.

W23-6 We evaluated the risk factor of clinical fractures in patients with rheumatoid arthritis -TOMORROW study- Shohei Anno1, Kentaro Inui2, Yuku Sugioka3, Kenji Mamoto3, Tadashi Okano3, Masahiro Tada4, Tatsuya Koike5,6, Ayako Kubota7,1, Masayuki Sekiguchi7, Arata Nakajima7, Masato Sonobe8, Toru Suguro9, Hiroshi Takahashi7,10
1Toho University Omori Medicine Center, Tokyo, Japan, 2Departments of Orthopaedics and Rheumatology, Toho University Sakura Medical Center, Chiba, Japan

Conflict of interest: None

[Object] We investigated the clinical and radiological results of the SK procedure in RA wrists. [Methods] 43 joints were subjected to a follow-up for one year or more after operation. The average age of the patients was 60.3 years old at surgery, and the average disease duration was 15.7 years. Biologics were used in 36 joints at surgery and in 37 joints at the operation. The evaluation item was the excursion of the wrist and the forearm at surgery and at the time of the study. Radiographic evaluation was CHR and CTI. The presence or absence of joint surface remodeling between the radio carpal joint in lateral views was also examined. [Results] A significant difference was observed in pronation, but no significant difference was observed in supination and wrist excursion. No significant difference was observed in CHR and CTI. In the lateral views, remodeling was observed for 11 joints (25.6%) at surgery and 24 (53.5%) joints at follow-up. It increased significantly. [Conclusions] The S-K procedure maintained excursion, and no carpal collapse or progression of ulnar deviation was observed. Remodeling in radio carpal joint was observed with a significant difference. The effectiveness of the SK procedure was suggested in cases of progressed bone destruction.
carpal bone collapse change, improvement of forearm rotation range was obtained, and the SK method is considered to be an effective method. There is a tendency to suppress radial carp joint destruction under the combined use, there is a possibility of expansion of the SK appendaged case in the future.

**W24-3**

**Long Term Results of Unlinked type Total Elbow Arthroplasty for Rheumatoid Arthritis**

Yoshio Uchida1, Takuki Nishikawa, Kenichi Shimane, Kenta Makabe
1Department of Rheumatology, Bokutoh Metropolitan Hospital, Tokyo, Japan, 2Department of Rheumatology, Uchida Clinic

Conflict of interest: None

[Object] To evaluate a long-term outcome of unlinked type total elbow arthroplasty (TEA) in rheumatoid arthritis. [Methods] Primary TEAs from January 2007 to December 2008 were reviewed. Radiographic images, clinical results and complications were evaluated. Survival rate was calculated using TEA revision as the endpoint. [Results] We evaluated 35 elbows. Revision TEA was four elbows. In all revision TEA cases there was no cement filling avoble the proximal edge of the humeral component. Two elbows perforated to extra cortically ulnar component. Two elbows ulnar neuropathy, One elbow posterior interosseous nerve paralysis. One elbow delay of wound healing and two elbows intraoperative fracture. The loosening of compartments were 3 elbows on the humerus side and 4 elbows on the ulnar side. One elbow of ulnar neuropathy did not improve. The range of motion, MEPS was significantly improved at the time of the last observation than before the operation. The survival rate was 84.1% at 100 months postoperatively. [Conclusions] The results of the unlinked TEA were as good as the past reports.

**W24-4**

**The relationship between the joint line and postoperative range of motion after K-elbow total elbow arthroplasty**

Kota Shimomura1,2, Mitsuyasu Iwasawa1, Takeomi Nakamura1, Satoru Ohashi1
1Department of Orthopedic Surgery, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan, 2Department of Orthopaedic Surgery, Sapporo Medical University, Sapporo, Japan

Conflict of interest: None

[Object] To investigate the correlation between the joint line after implantation, osteotomy and postoperative range of motion (ROM) following the use of K-elbow. [Methods] 12 elbows were operated on - 8 cases of Painful Instability (PI), and 4 of Painful Stiffness (PS). The joint line of humeral implant setting was measured at the base of the olecranon fossa, and the ulnar joint line at the olecranon dorsum cortex. [Results] For PI, preoperative mean ROM was Extension-27°, Flexion134°and postoperative was -32°, 132°. Preoperative mean ROM was -31°, 80°and postoperative was -41°, 120°for PS. The Mayo Elbow Performance Scores were PI: 93, PS: 90, improved significantly. The mean displacement on the humeral side were PI: 3.2mm, PS: 1.1mm (p=0.05), and in the ulnar side were PI: 1.7mm, PS: 3.1mm (p=0.01). No correlation was apparent between displacement and postoperative ROM. Postoperative ROM is greater in PI cases, so more bone was left intact to promote stability. PS cases tend to be more stable, so more bone was cut to achieve greater postoperative ROM. Postoperative ROM was limited in PS cases, but showed significant improvement. [Conclusions] Good postoperative outcomes were obtained, although the course of action required is different for PI and PS.

**W24-5**

**Complication after Total Elbow Arthroplasty for Rheumatoid Arthritis**

Kenji Kishimoto, Toshihisa Kojima, Nobunori Takahashi, Shuji Asai, Nobuyuki Asai, Takuya Matsumoto, Yasumori Sobe, Tsuyoshi Nishiume, Mochihito Suzuki, Yutaka Yokota, Kyosuke Hattori, Naoki Ishiguro
Orthopaedic Surgery and Rheumatology, Nagoya University Hospital

Conflict of interest: None

Object Total elbow arthroplasty (TEA) which relieves elbow pain and improves range of motion is accepted as the treatment for severely destroyed elbow joints in patients with rheumatoid arthritis (RA). But the rate of infection after TEA is higher than THA and TKA, and TEA has various complications such as fracture and nerve injury. This study attempted to examine complication after TEA. Methods We performed primary TEA for 39 elbows in 36 patients with RA between 2004 and 2018. We examine the complication after TEA. Results Mean age of patients was 64 years. There were 6 males and 30 females. Mean disease duration of RA was 22 years. 25 elbows were treated with unlinked TEA and 14 elbows were treated with semiconstrained TEA. We identified complications in 14 elbows. There were infection in 2 cases, fracture in 7 cases, nerve injury in 3 cases, wound trouble in 1 case and aseptic loosening in 2 cases. 3 patients required reoperation and 2 patients required revision. Mutilating changes of elbow joints and semiconstrained type are relatively high risk of fracture (P<0.05). Conclusions The rate of fracture and nerve injury after TEA is relatively high. We must particularly take care of cases with mutilating changes of RA.

**W25-1**

**10-year longitudinal changes of rheumatoid thumb deformity**

Ryo Oda1,2, Shogo Toyama1,2, Masato Ohara1, Daigo Taniguchi1, Daisaku Tokunaga1,2, Hiroyoshi Fujiwara1, Makoto Wada1, Masataka Kohno1, Yutaka Kawahito1, Toshikazu Kubo1,4
1Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 2Department of Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 3Center for Rheumatology, University Hospital Kyoto Prefectural University of Medicine

Conflict of interest: None

[Object] Rheumatoid thumb deformity that is functionally important occurs frequently, and it interferes with the pinchand grip. In this study, we investigated the time course of the new occurrence and progression of rheumatoid thumb deformity in the long term. [Methods] 37 cases 63 fingers who completed follow-up investigation in 5 years and 10 years were targeted. The thumb deformities were classified into Nalebuff classification and type CM and type MP with only thumb CM joint or MP joint destruction. The thumb deformities at each evaluation point were recorded and the change with time were investigated. [Results] The thumbs without deformations at each evaluation time point were 10/53 thumbs at the time of start / 5 years / 10 years respectively. Type I were the most frequent through the course, 35/34/34 thumbs. type CM for 6/6/1 thumbs, type MP for 3/3/1 thumbs, and these many cases advanced to type III. In 4 type I thumbs advanced to type IV. [Conclusions] In this study, it became clear that the rheumatoid thumb deformities increased and progressed over time. In addition to appropriate medication therapy, it is important to intervention such as orthosis and surgery at appropriate timing according to the progress of deformation, in order to maintain daily living activities.

**W25-2**

**Swan-neck and Boutonniere deformity in rheumatoid hand - 10-year cohort of rheumatoid hand -**

Masato Ohara1, Shogo Toyama1,2, Ryo Oda1,2, Daigo Taniguchi1, Daisaku Tokunaga1,2, Hiroyoshi Fujiwara1, Makoto Wada1, Masataka Kohno1, Yutaka Kawahito1, Toshikazu Kubo1
1Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 2Department of Development of Multidisciplinary Promote for Physical Activity, Graduate School of Medical Science, Kyoto Prefectural University of Medicine

Conflict of interest: None

[Object] In rheumatoid arthritis, fingers are hindered and daily activity disorders are caused. Even now medication has advanced, some cases
show the progression of deformation and new incidence. In this study, we investigated long-term changes in the occurrence and progression of Swan-neck and boutonniere deformities. [Methods] 37 cases 63 fingers completed follow-up in 5 years and 10 years were targeted. Swan-neck and boutonniere deformities were classified into Nalebuff classification, functions were assessed with MKI, and ADL with DASH. [Results] 9 deformities newly occurred in 14 hands no deformation initially. Swan-neck deformities increased from 65.1% to 81.0%, boutonniere deformities from 19.0% to 33.3%, finally the deformities are mixed in 14 hands. MKI worsened from 32.1 to 29.1 and DASH from 51.3 to 53.4. In swan-neck deformities, MKI and DASH were poor even in mild cases, boutonniere deformities progressed and MKI and DASH worsened. [Conclusions] In this study, dysfunction has also progressed with increase of finger deformity. Although appropriate medication is important to prevent new deformation, it is also important to apply treatment such as orthosis and surgery at appropriate timing in accordance with the progress of deformation for maintaining daily living activities.

W25-3
Deformity progression pattern analysis from a cumulative evaluation of each finger deformity in rheumatoid hand
Shogo Toyama1,2,3, Ryo Oda1,4, Daisaku Tokunaga2,3, Yutaka Kawaaho4,5, Yasuo Mikami2, Masataka Kohno4, Makoto Wada6,7
1Department of Development of Multidisciplinary Promote for Physical Activity, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 2Department of Rehabilitation Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 3Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 4Department of Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 5Center of Rheumatic Diseases, University Hospital, Kyoto Prefectural University of Medicine

Conflict of interest: None

[Introduction] Rheumatoid hands are highly complexed and involved some typical deformities, then require us rheumatologist well-experienced. Additionally, there is almost no evidence showing a natural history from a long-term viewpoint, so it is difficult for us to show a clear treatment strategy. We have performed an original hand cohort and shown some trials for comprehensive evaluation. [Methods] We assessed overall 156 cases 297 hands cross-sectionally at the three endpoints (2004, 2009 and 2015). A cluster analysis was done using each parameter of each deformity, and classified subjects into 7 groups. We interested in the cases with any changes in groups between endpoints and analyzed them mainly. [Results] The most typical transient pattern was following; starts from thumb typel deformity, next observe a worsening of ulnar drift or swan-neck deformity. In these cases, if thumb joints affection continued, a severe functional impairment developed irrespective of the status of the other fingers. [Conclusions] It is more desirable that rheumatologists could intervene before disability develops than after disability become apparent. We believe all rheumatologist should keep in mind of the natural history of deformity progression to avoid any irreversible functional impairments.

W25-4
Patient’s satisfaction of Swanson metacarpophalangeal arthroplasty for the rheumatoid hand
Shinji Taniguchi1,2, Hajime Ishikawa1, Asami Abe1, Tomonori Sakamoto1, Hiroshi Otani1, Kiyoshi Nakazawa1, Yoichi Kuroawa1, Eiko Hasegawa1, Satoshi Ito1, Koichi Nakagawa2, Akira Murasawa1,2,3
1Department of Rheumatology, Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan, 2Department of Orthopaedic Surgery, Toho University Sakura Medical Center, Sakura, Japan

Conflict of interest: None

[Objective] To clarify the patient’s satisfaction level of Swanson metacarpophalangeal Joint Arthroplasty (SMPA) for the rheumatoid hand and to investigate the factors, which associate with its level. [Methods] A prospective study was performed on 145 metacarpophalangeal joints in 49 hands of rheumatoid arthritis patients, who underwent SMPA at our hospital from March 2013 to March 2015. A follow up period was three years. Subjective measurements included visual analogue scale (VAS) of Pain, Appearance, Motion, Power, Usability and Overall satisfaction (0:dissatisfied,100:highly satisfied). Objective measurements included arc of motion, grip power and prehensile pattern. For the hand in which SMPA was performed in the thumb or the index finger, tip and side pinch power were also measured. [Results] The average VAS of each satisfaction level at three years after surgery were Pain:78.0, Appearance:68.7, Motion:59.4, Power:53.1, Usability:62.8, Overall:71.0. The factor which affected Overall satisfaction was Usability (P<0.01). There was a positive correlation between Usability and change in prehensile pattern (r=0.297) and between Usability and change in side pinch power (r=0.350). [Conclusions] Usability of the hand was associated with prehensile pattern and side pinch power.

W25-5
Investigation of reoperative cases with fracture of hand finger silicone implant in RA patients
Toshiharu Okuda
Okuda Orthopedic Clinic

Conflict of interest: None

Objective: Silicon implants are often used mainly for MP joints for the reconstruction of deformed fingers of RA patients, but, there are problems such as sinking and breakage as a change. The use of silicone implant in RA finger reconstructive surgery at our hospital was 326 joints. We report cases where recursive surgery has been performed due to the patient’s wishes. The damaged implants were Swan 5 joints for MP joints, 2 Avanta joints for PIP joints, and 1 Swan joints. Results: There were no postoperative complications such as infection. Although the elapsed time is as short as 1.8 years on average, there is no pain/ deformation, instability and range of motion are improved, patient satisfaction is high, no ADL disorder is present at present. Conclusion: Finger joint arthroplasty using silicone implant is relatively easy to replace when the implant is broken, and it seems to be useful as a method for reconstructing deformed RA fingers.

W26-1
Transcription factors regulating pathogenic mechanisms of Tph cells
Hiroyuki Yoshitomi1,2,3, Aya Miyagawa-Hayashino4, Akinori Okahata1, Kohei Doi1, Kohei Nishitani1, Koichi Murata1, Hiromu Ito1, Tatsuaki Tsuruyma2, Hironori Hagi3, Shuichi Matsuda3, Junya Toguchida1,2,3
1Institute for Frontier Life and Medical Sciences, Kyoto University, 2Center for iPS Cell Research and Application, Kyoto University, 3Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, 4Department of Diagnostic Pathology, Kyoto University Hospital, 5Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, 6Department of Drug Discovery Medicine, Kyoto University Graduate School of Medicine

Conflict of interest: Yes

[Objective] PD-1 (high) CXCR5 (-) helper T (Tph) cells are a distinct CD4+ subset that is involved in the pathogenesis of rheumatoid arthritis (RA). However, transcription factors that regulate Tph cells have been unclear. [Methods] We comprehensively analyzed gene expression in human CD4+ T cells under conditions above followed by identification of upregulated transcription factors. Additionally, we analyzed function of Maf and Blimp1 reportedly regulated transcription factors in Tph cells. [Results] Sox4 was identified as the transcription factor upregulated under inflammatory conditions above. Lentinival overexpression into human naïve CD4+ T cells showed the involvement of Sox4 in upregulation of PD-1 and CXCL13, and in downregulation of CXCR5. On the other hand, Maf was involved in the upregulation of genes related to B-help activities; transcription repressor Blimp1 generally downregulated genes above. Interestingly, while TGF-β upregulated both Sox4 and Maf, IL-2 downregulated Sox4 but upregulated Maf. [Conclusions] Collectively,
The effect of ribavirin on improving IFN signature of SLE patients is obtained by correcting multiple histone modification abnormalities

Yojiro Arinobu1, Koichi Akashi1, Hiroaki Niino2, Takahiko Horiuchi3
1Department of Internal Medicine, Kyushu University Beppu Hospital, 2Department of Clinical Immunology, Rheumatology and Infectious Diseases, Kyushu University Hospital, 3Faculty of Medical Sciences Medical Education, Kyushu University School of Medicine

Conflict of interest: None

[Object] Interferon stimulated gene (ISG) is involved in the pathogenesis of SLE. We have reported the antiviral drug, ribavirin, can increase the H3K9me2 level in the ISG region and decrease expression of ISG in CD4 naïve T cells of SLE patients. In order to elucidate the more detailed mechanism of action of ribavirin, we performed the analysis of multiple histone modifications and histone modifying enzyme. [Methods] Expression of ISG in CD4 naïve and memory T cells obtained from SLE patients and healthy subjects was compared by qPCR and microarray analysis. Histone modification levels in the ISG region were compared by ChIP-qPCR. Furthermore, histone modification levels in the ISG region were compared in those cells under ribavirin treatment. [Results] In SLE, high expression of ISG was observed compared to healthy individuals, and multiple histone modification abnormally levels were observed in these findings imply that pathogenic functions of Tph cells are regulated finely by several transcription factors depending on surrounding inflamatory environments.

W26-2
Functions and TCR repertoire of PD-1-high CD4 T cells in rheumatoid arthritis
Takahide Sakuragi1, Hisakata Yamada1-2, Akihisa Haraguchi1, Junichi Fukushi1, Satosho Ikemura1, Yukio Akasaka1, Toshifumi Fujiwara1, Tomoko Tsutui2, Masakazu Kondo1, Yasunari Nakashima1
1Department of Orthopaedic Surgery, Kyushu University, 2Kondo Clinic of Rheumatology and Orthopaedic Surgery

Conflict of interest: None

W26-3
MAIT cells as a new therapeutic target of systemic lupus erythematosus
Go Murayama1,2, Asako Chiba2, Hirofumi Amano1, Ken Yamaji1, Naoto Tamura1, Sachiko Miyake1
1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan

Conflict of interest: None

W26-4
The effect of ribavirin on improving IFN signature of SLE patients is obtained by correcting multiple histone modification abnormalities
Qiaoeli Wang1, Daisuke Oryoji1, Yasutaka Kimoto1, Tetsushin Murakami1, Masahiro Ayano1, Hiroki Mitoma1, Mitsuteru Akahoshi1, Yojiro Arinobu2, Koichi Akashi3, Hiroaki Niino4, Takahiko Horiuchi5
1Department of Internal Medicine, Kyushu University Beppu Hospital, 2Department of Clinical Immunology, Rheumatology and Infectious Diseases, Kyushu University Hospital, 3Faculty of Medical Sciences Medical Education, Kyushu University School of Medicine

Conflict of interest: None

W26-5
The expression and pathogenesis of citrullinated Inter alpha trypsin inhibitor heavy chain 4 (ITIH4) in inflamed joints
Atsama Osada, Isao Matsumoto, Izumi Kurata, Ayako Ohyama, Yuya Kondo, Hiroto Tsuiboi, Takayuki Sumida
Department of Internal Medicine, Faculty of Medicine, University of Tsukuba

Conflict of interest: None

Background/Purpose: ITIH4 is one of the citrullinated proteins in blood, which is associated with disease activity in pGIA and RA. The aim of this study was to clarify the expression of native or citrullinated ITIH4 in inflamed joints and to investigate the involvement of PAD enzymes. [Methods] 1) Immunohistochemistry (IHC) of ITIH4 was performed in pGIA joints. 2) Citrullinated ITIH4 in pGIA joints was assessed by immunoprecipitation and Western blot. 3) PADI4 mRNA and protein increased in pGIA joints of Day14. 4) ITIH4 concentration in SF was significantly higher in RA patients. 5) Citrullinated ITIH4 was detected in SF from untreated RA and osteoarthritis (OA) patients were examined by ELISA. 5) Citrullinated ITIH4 in SF from untreated RA and OA patients were assessed by immunoprecipitation and Western blot. [Results]: 1) and 2) The increased amount of ITIH4 and its citrullination was observed in pGIA joints of Day14. 3) PADI4 mRNA and protein increased in pGIA joints of Day14. 4) ITIH4 concentration in SF was significantly higher in RA patients. 5) Citrullinated ITIH4 was detected in SF from RA. The intensity of citrullinated ITIH4 was higher in SF than plasma in each RA patients. [Conclusion] The citrullinated ITIH4 was generated in inflamed joints via PADI4.
[Object] To elucidate factors involved in joint pain, we semi-comprehensively investigated pain-related miRNAs of synovial fluid-derived exosomes in the patients with OA and RA. [Methods] Exosomes were isolated from synovial fluid samples obtained from 8 patients (4 with OA and 4 with RA). From these 4 patients with OA, synovial fluid was obtained two times, at painful period (Painful OA:P-OA group) and at pain-free period (Non-painful OA:NP-OA group). The miRNAs extracted from the exosomes were subjected to miScript miRNA PCR Array™ (Qiagen). The miRNAs whose expression levels were significantly different between the NP-OA and the P-OA groups were considered to be the candidates involved in knee OA related pain. Furthermore, we compared the expressions of these exosomal miRNAs between the OA and the RA groups. [Results] MicroRNAs which showed significantly different expression levels between the NP-OA and the P-OA groups were miR-21-5p, miR-25-3p, miR-204-3p, miR-199a-3p, miR-199b-3p, miR-30d-5p, miR-495-3p, miR-92a-3p, and miR-146b-5p (paired-T test, p<0.05). Out of these miRNAs, the expression level of miR-92a-3p was significantly lower in the RA group, compared to the P-OA group. [Conclusions] Exosomal miRNAs involved in joint pain could be different between OA and RA.

W27-1
Clinical result of IVCY therapy in patients with interstitial pulmonary fibrosis associated with connective tissue disease

Rumiko Miyagi, Satoshi Baba, Rina Okita, Kuriko Kuratani, Shinnichiro Tsunoda
Division of Immunology and Rheumatology, Sumitomo Hospital

Conflict of interest: None

[Object] To evaluate the efficacy and side effect rate of IVCY in patients with interstitial pneumonia associated with connective tissue disease in our hospital. [Methods] We investigated the medical records of 11 patients with interstitial pneumonia who had admitted to our hospital from March 2017 until October 2018. [Results] 11 patients (5 rheumatoid arthritis, 1 scleroderma with anti-centromere antibody-positive, 1 scleroderma with anti-RNA polymerase III antibody-positive, 1 scleroderma with anti-RNP antibody-positive, 1 polymyositis and 2 dermatomyositis) were treated with IVCY therapy. The age median was 76 years old. Observation mean period was 13 months. IVCY therapy of 500mg/2-4week was administered from 3 to 8 times. Before and after IVCY therapy, PSL dose was 16.8±12.3mg→7.5±4.4mg, KL-6 levels was 1684±1955U/ml→1580±1505U/ml and respiratory function (%VC) was 62.8±12.2%→66.9±11.3%. [Conclusions] Although there was not the clear improvement of KL-6 levels and respiratory function (%VC) before and after IVCY therapy, we were able to reduce a dose of PSL and no fatal cases were observed. IVCY therapy could be effective in elderly patients with interstitial pneumonia.

W27-2
Association between Autoantibodies and Long-term Clinical Outcomes in Pulmonary Arterial Hypertension (PAH) related with Connective Tissue Diseases

Yuko Shirota1,2, Tsuyoshi Shirai2, Hiroshi Fujii2, Takao Kodera1, Junichi Kameoka1, Tomonori Ishii1, Hideo Harigae2
1Department of Hematology and Rheumatology, Tokushima Medical and Pharmaceutical University Hospital, 2Department of Hematology and Rheumatology, Tokohu University Hospital

Conflict of interest: Yes

[Object] We assessed the detailed autoantibodies and discriminative long-term clinical symptoms and followed up their outcomes. [Methods] This retrospective study included 50 CTD-PAH associated with SSc (n=17), SLE (n=18), primary SS (n=8), and MCTD (n=7) referred to our hospital between 2000 and 2018. We obtained their serum and determined autoantibodies against centromere, Scl-70, RNA-polymerase III, centriole, NuMA1, RNP, Sm, SSA/Ro, SSA/Ro52, SSB, PM-Scl, fibrillarin, Thy/To, Ku, dsDNA, nucleosomes, histones, ribosomal P. We treated all patients with pulmonary vasodilators, and additionally treated with immunosuppressants, including IVCY and steroid for the patients with inflammatory symptoms. [Results] In terms of SSc, we divided into three groups, which were (1) overlapping SS (n=7), (2) with centriole antibodies (n=3), or (3) others (n=7). We treated some SSc-PAH with SS and centriole- by immunosuppressants. there was a trend towards a better survival rate in centriole or SS-SSc-PAH than in other SSc. One of anti-Th/To Ab positive SSc-PAH relapsed. Ribosomal P antibody existed in 5 patients and 3 were severe PAH. [Conclusions] We suggested that detailed auto-antibody investigation are useful to estimate long-term clinical outcome, and expect the effect of immunosuppressants.

W27-3
Three cases of exacerbated rheumatoid arthritis-associated interstitial lung disease treated with two immunosuppressive drugs

Kayoko Hase1, Kyoko Kojima1, Jun Kishi1, Ryosuke Sato2, Shinji Yoshioka2
1Department of Medicine, Division of Rheumatology, Tokushima Municipal Hospital, Tokushima, Japan, 2Orthopedic Surgery, Tokushima Municipal Hospital, Tokushima, Japan

Conflict of interest: None

[Background] Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is poor prognosis; however, there is no established evidence to cure disease in acute exacerbation. [Case] Three all men in the RA-ILD had RA treatment. Case1 was 71-year-old, appeared cough, fever and dyspnea, was admitted. From the sputum MRCNS was detected, we tried VCM drip with no improvement. As exacerbated RA-ILD, he was treated with mPSL0.5g pulse at the 2nd day and mPSL1.0g pulse at the 10th day. On PSL30mg/day, his condition became more exacerbated so he was treated with cyclosporine (CSA) 200mg/day at the 15th day and cyclophosphamide (CY) intravenous infusion at the 17th day; however died at the 30th day. Case2 was 74-year-old, and Case3 was 69-year-old, after the PSL dosage was reduced to 5or 4mg/day, and RA-ILD were exacerbated. These patients were treated with mPSL1.0g pulse at 1st day, CsA200mg/day + CY100mg/day by oral were started early until the 6th day. Case2, mPSL1.0g pulse was added at the 8th day and both patients on PSL60mg/day after pulse therapy. PSL are gradually reduced and CsA200mg/day + CY50mg/day are continued. [Discussion] RA-ILD should be considered also in addition to the steroids from an early stage with multiple immunosuppressive drugs for acute exacerbation.

W27-4
Comparison of prognosis and causes of deaths of 4 rheumatic diseases (RA, SSc, PM/DM, MPA) with interstitial pneumonia

Shigeki Makino1, Takuya Kotani1, Takeshi Shoda2, Hidehiko Makino2, Koji Nagai3, Tohru Takeuchi3, Shigeki Arawaka3
1Division of Internal Medicine, Osaka Medical College Mishima-Minami Hospital, Takatsuki, Osaka, Japan, 2Department of Internal Medicine IV, Osaka Medical College, Takatsuki, Osaka, Japan, 3Division of Rheumatology, Yodogawa Christian Hospital, Osaka, Japan

Conflict of interest: Yes

[Background] We aim to compare the differences between the interstitial pneumonia (IP) involvement on prognosis of 4 connective tissue diseases (RA, SSc, PM/DM, MPA). [Methods] We reviewed clinical data concerning about prognosis and causes of deaths of each connective tissue diseases with IP patients of our institute from August 2008 to July 2018. [Results] RA-IP patients are 255 (114 males, average 74 years). Dead cases were 40 (22 males). 5-year survival rate was 84%, 10-year survival rate was 60%. IP related death were 14 (35%), lung cancer related death were 7. SSc-IP patients are 212 (34 males, average 70 years). Dead cases were 25 (7males). 5-year survival rate was 91%, 10-year survival rate was 80%. IP related death were 7 (28%). PM/DM-IP patients are 197 (57 males, average 64 years). Dead cases were 39 (18males). 5-year survival rate was 74%, 10-year survival rate was 52%. IP related death were 28 (72%). MPA-IP patients are 70 (31 males, average 76 years). Dead cases were 20 (8males). 5-year survival rate was 81%, 10-year survival rate was 50%. IP related death were 6 (30%). [Conclusions] Between 4 diseases-IP patients, SSc-IP patients had better prognosis. In 4 diseases-IP patients, many IP related deaths were observed. So IP of 4 diseases influence on prognosis.
W27-5
The efficacy of OP treatment for BMD and lean mass in patients with rheumatoid arthritis
Tsuyoshi Watanabe
Department of Orthopedics, National Center for Geriatrics and Gerontology

Conflict of interest: None

[Background] Rheumatoid arthritis (RA) causes secondary Osteoporosis (OP) and low lean mass (LM). OP pharmacological treatment should improve bone mineral density (BMD) and LM. [Objective] To assess the efficacy of OP treatment in RA patients during the prospective observational study for 1 year. [Methods] 72 patients (53 female and 19 males; mean age 74.6) with RA were enrolled in the study in 2016-2017. They completed risk factors questionnaire, Health Assessment Questionnaire (HAQ). Disease activity were assessed with SDAI, BMD, SMI, total body composition, LM and fat mass, and fat free mass index were measured by dual energy X-ray absorptiometry (Hologic Discovery). Patients were followed up in 12 months. [Results] Average SDAI was decreased from 8.13 to 5.3. OP and low LM patients were found out in 34% and 52%. Osteo-Sarcopenia patients are 39%. Average change rate of BMD and LM was +5.1% in Lumbar Spine (LS), +1.6% in Femoral neck and -1.2% in SMI. OP group was treated by some medicine. In OP group BMD and LM were +5.1% in Lumbar Spine (LS), +1.6% in Femoral neck and -1.2% in SMI. OP; LS +10.2%: +3.2%, Femoral neck +6.5%: +0.3%, SMI +5.8%: -3.6%. No statistical difference was found with using bDMARDs, Glu non-OP; LS +10.2%: +3.2%, Femoral neck +6.5%: +0.3%, SMI +5.8%: -3.6%. No statistical difference was found with using bDMARDs, Glucocorticoid use and SDAI.) [Conclusions] OP treatment may maintain not only BMD but also LM.

W27-6
The analysis of 16 cases of osteonecrosis of the femoral head in autoimmune disease
Aki Sakashita1, Aiko Hirano1, Yu Isoda1, Kazuki Fujioka1,3, Hitadeke Nagahara1, Shogo Toyama2,3, Iyo Oda2,3, Toshikazu Kubo2,3, Makoto Wada1, Masatake Kohno1, Yutaka Kawahito1,3

Conflict of interest: None

[Objective] The use of glucocorticoid is the risk factor for osteonecrosis of the femoral head (ONFH) in autoimmune disease. We examined 16 cases of ONFH to clarify its clinical features. [Method] We retrospectively analyzed clinical data of 16 ONFH cases with autoimmune diseases treated with glucocorticoids from January 2008 to October 2018. [Results] The average age at the diagnosis of ONFH was 47.5 years and the male-to-female ratio was 4:12. Six cases were patients with SLE, 2 were MPA, 2 were dermatomyositis, and the others were MCTD, GPA, EGPA, PN, adult onset Still’s disease. Five patients took steroid pulse therapy and average of the maximum dose of prednisolone was 46mg/day. The median duration from the starting of the steroid therapy to diagnosis of ONFH was 14.6 months. Eleven patients had bilateral necrosis, but only 2 patients of them had bilateral pain, 8 had unilateral pain, and had no pain. All 16 cases underwent X-ray at diagnosis, however only 3 cases of them had abnormal findings in it, and all of them needed surgical treatment. In total 5 patients needed surgical treatment, 4 of which was total hip arthroplasty, and 1 of which was osteotomy. [Conclusion] ONFH with autoimmune disease was often asymptomatic, and one third patients needed surgical treatment.

W27-8
Methotrexate dose on the efficacy and safety of certolizumab pegol in patients with rheumatoid arthritis
Shinkai Ri, Yuji Nozaki, Hiroki Akazawa, Chisato Ashida, Fusayo Ikeda, Atsuhito Yamamoto, Tetsu Itami, Kenji Sakai, Asuka Inoue, Toshihiko Shiga, Kazuya Kishimoto, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura

Department of Rheumatology and Rheumatology, Kindai University Facult of Medicine

Conflict of interest: None

[Object] With the aging of rheumatoid arthritis (RA) patients, there are cases in which methotrexate (MTX) increase and selection of TNF inhibitors therapy are difficult. Currently, there are few reports comparing therapeutic effects by certolizumab pegol (CZP) against MTX dose, and we examined the therapeutic effect by MTX dose in CZP therapy. [Methods] From August 2013, RA cases treated with CZP (N=28) were retrospectively studied. The continuation rate, the clinical treatment effect (DAS28-CRP), the disease activity and EULAR treatment response by DAS28- CRP, the disease activity and EULAR treatment response by DAS28-CRP in high (~8mg/week) and medium to low (~8mg/week) MTX dose were the main outcome measure. They were compared for RA cases treated with adalimumab (ADA) (N=40) as control group. [Results] With respect to the continuation rate one year after CZP and ADA treatment, ADA group significantly higher in the H group, and there was no significant difference in the L group. DAS remission rate, one year after treatment DAS 28-CRP did not show any significant difference in both groups, but the group with good therapeutic response (Good + Moderate response) significantly increased with L group’s CZP treatment. [Conclusions] They was showed that ADA treatment is higher effect in high MTX dose, CZP in medium to low MTX dose.
Conflicts of interest: None

[Objective] Biologic agents used in patients with rheumatoid arthritis (RA) have increased in recent years. We investigated the efficacy, safety, and continuation rate of abatacept (ABT) or tocilizumab (TCZ) in our RA patients. [Methods] 155 patients treated with ABT or TCZ retrospectively were observed for one year. We compared the baseline characteristics, disease activity, physical disability, continuation rate, and safety. [Results] In ABT group (n=76) compared with TCZ group (n=79), we found older at initiation (ABT vs. TCZ: 63 vs. 57 years), higher HAQ-DI (1.4 vs. 1.0), and fewer MTX-users (46.1 vs. 65.8%). Age of onset, disease duration, rate of female, naïve rate of biologics, body weight, DAS28-ESR4, MMP-3, ACPE positive rate, dose of MTX, and dose of PSL were similar. CDAI and HAQ-DI significantly decreased in one year in both groups. There were fewer patients who achieved remission or low disease activity in ABT group than in TCZ group (63.3 vs. 84.4%). There was no significant difference in the continuation rate (81.6 vs. 84.8%), adverse events (10.5 vs. 10.1%), and inefficacy rate (7.9 vs. 3.8%). [Conclusions] Smaller efficacy was obtained in ABT group, who had disadvantageous conditions, compared to TCZ group, but continuation rate and safety were equivalent between two groups.

W28-4
In adalimumab treatment, Remission induction and treatment continuation at 208 weeks in 186 patients
Toshiaki Miyamoto, Kenji Yamazaki, Ryuhei Ishihara
Internal Medicine and Rheumatology, Seirei Hamamatsu General Hospital

Conflict of interest: Yes

Objective Clinical usefulness and treatment continuation following 256 weeks of adalimumab (ADA) in rheumatoid arthritis (RA) patients were investigated. [Methods] Subjects were 186 analyzable patients introduced to ADA at the author's institution from May 2009 to Oct. 2014. Mean age was 54 years, mean duration of illness 6.8 years. 151 received MTX (10 mg/week (≥10 group) and 29 MTX<10 mg/week (<10 group). The course of DAS28 (ESR), HAQ and remission rate were analyzed. [Results] Overall DAS28 (ESR) remission rate showed clinical remission in 48% of patients from 12 weeks, and achieved 66% from 52 weeks, after that this condition continued. Changes in DAS 28 (ESR) remission rates of 4, 12, 24, 52, 80, 152, 208, 256 weeks for the <2 and ≥2 groups were similar to those seen in the N and S groups. Overall HAQ remission rate at 256 weeks was 82%; treatment continuation rate was 63.3%, and those of ≥10 group was 65.2%. Conclusion Remission was induced early with ADA in about 48% of patients, and achieved 66% of patients at 256 weeks. ADA plus an adequate dose of MTX with early escalation in early-stage RA and Bio Naive patients is the best approach to maximally exploit the ADA potential.

W28-5
Long-term efficacy and safety of treatment with tocilizumab (TCZ) in elderly rheumatoid arthritis patients (RA)
Shiro Ohshima1, Kentaro Isoda1, Yuji Yoshida1, Maiko Yoshimura1, Yoshinori Harada1, Satoru Teshigawara1, Hidetoshi Matsuoka1, Kentaro Kuzuya2, Yasutaka Okita1, Eri Oguro2, Takaaki Noguchi2, Shosuke Akita1, Shigeo Sumida1, Jun Hashimoto1, Yoshihiro Okaki1,2
1Department of Rheumatology, Seigaiha Internal Medicine Rheumatology, 2Department of Rheumatology, Osaka University Medical School

Conflict of interest: None

[Objective] We compared the impact of poor prognostic factors of radiographic damage between untreated early rheumatoid arthritis (RA) and early RA after 12, 24, and 36 months of treatment. [Methods] This study included 130 outpatients with a disease duration of <1 year (median, 3 months; 74% women). The outcome was assessed on the basis of the presence or absence of radiological progression of RA in the hand, wrist, and foot. [Results] At baseline, 30% of the patients already had a bone erosion, and the following were the associated risk factors: presence of anti-cyclic citrullinated peptide (CCP) antibody (odds ratio [OR], 6.6), high disease activity (OR, 1.66), and delayed treatment initiation (OR, 1.36). By contrast, only high disease activity at 12 months (OR, 2.03; 95% confidence interval [CI], 1.11-3.73) was associated with new bone lesion at 12 months. Furthermore, a new bone lesion at the following months was associated with the most recently developed bone lesion (OR, 20.5 for 24 months and 10.9 for 36 months). The cutoff SDAI score for preventing new bone lesion at 12 months was estimated to be 2.25 (sensitivity, 72%; specificity, 55%; area under the curve [AUC], 0.72). [Conclusions] To prevent structural damage, induction to deep remission in 12 months is most important.

W28-6
Patient Reported Outcome survey on syringe formulation and auto-injector formulation of adalimumab
Tomohiko Yoshida1,2, Naoko Katsuyama1,2, Yoichiro Akiyama1,2, Yasuhiro Otaki1,3
1Department of Rheumatology, Setagaya Rheumatology Clinic, 2Department of Rheumatology, Toshin Yoshida Internal Medicine Rheumatology, 3General Medical Education and Research Center, Teikyo University

Conflict of interest: None

[Objective] Adalimumab (ADA) auto injector formulation (AI) was additionally released in June 2018. Changes from syringe formulation (SY) to AI were expected to cause changes in patient’s self-injection operability, storage and management, psychological state such as tension, psychiatric pain, and the like. We conducted questionnaires on RA patients and investigated Patient Reported Outcome in adding AI. [Methods] We targeted 30 RA patients administering SY of ADA visiting our hospital from August to October 2018. 1 Procedure 2 Device 3 Storage and management 4 Feeling 5 pain upon injection We conducted a questionnaire usingVAS. [Results] [Pain upon Injection] There was no difference between SY and AI VAS 12:12. [Management] VAS 26:32 of SY and AI. [Technique] SY and AI were VAS 27:6. [Device] VAS 27:9 with SY and AI. [Feeling] SY and AI were VAS 40:12. [Conclusions] ADA has SY and AI forms. AI was easier in injection procedure and the feeling of tension and anxiety to injection were alleviated. AI, which is easy to grasp for RA patients and invisible injection needles, was supported.
W29-2

Examination of the factor to give residual symptoms among patients with rheumatoid arthritis in SDAI-remission or low disease activity—Analysis of joint ultrasonography, PRO, patient background and the serologic characteristics—
Masao Nawata1,2, Yuuya Fujita1,2, Kazuki Someya1,2, Kazuyoshi Saito1,2, Yoshiya Tanaka2
1Tobata General Hospital, 2University of Occupational and Environmental Health, Japan

Conflict of interest: None

[Objectives] We identified factors contributing residual symptoms of RA patients in SDAI-remission. [Methods] 127 patients were enrolled. The symptoms were measured by visual analog scale (VAS) and power doppler (PD) with 26 both hands joints. I evaluated age, sex, the number of tender and swelling joints (TJ and SJ), the serologic characteristics (CRP, ESR, CCP, RF, MMP-3), PRO (morning stiffness, pain-VAS, fatigue-VAS). [Results] The 127 patients background the sex 17.3%/82.7% (M/F), TJ 2.7±4.6, SJ 1.4±3.2, CRP 1.0±2.0, RF 111.2±187.6, CCP 270.3±491.1, MMP-3 153.6±296.2, DAS28 10.5±12.4, morning stiffness 199.2±7229, pain-VAS 3.4±3.0, fatigue-VAS 3.7±3.1, GS 1.3±1.0, PD 0.8±0.9 (mean±SD). I made a stratified analysis in SDAI-remission group and SDAl-low disease activity group. As a result of single variable analysis, TJ, SJ, CRP, pain-VAS, fatigue-VAS, GS≧2, PD1 and PD2 were extracted for significant difference. For the multivariate analysis by the step Wise method, TJ, fatique-VAS and GS≧2 were extracted with a dominant difference. After performing a stratified analysis more fatique-VAS, TJ and GS≧2 were extracted for significant difference. [Conclusions] Association was shown in the residual symptoms (fatigue-VAS) with the residual inflammation (TJ and GS≧2) and significant difference.

W29-3

The optimal timing of administration of TNF inhibitors to lead to drug-free remission in early RA is the “time corresponding to phase 1 of the EULAR recommendation”
Eiji Matsui
Medical Corporation Matsui Orthopedic Clinic, Uji, Kyoto, Japan

Conflict of interest: None

In 2014, the presenter developed the “Matsui method” of drug-free remission in early RA patients. The purpose of the study was to demonstrate the mechanism that drug-free remission is achieved when the Matsui method is performed. (Theory of the Matsui method) Drug-free remission is achieved when all of the activated TNF-producing cells are lead to apoptosis. Among TNF-producing cells, membranous TNF-producing cells can be killed by administration of IFX, ADA, and GLM. By contrast, non-membranous TNF-producing cells cannot be killed. To kill non-membranous cells, wait until they change to membranous cells and administ bio. After TNF-producing cells finish producing TNF-α, they enter a resting phase. The resting cells subsequently divide and exponentially increase in number. It takes approximately six months for each cell group to be activated again and change to membranous cells. “Deep remission” is “a state in which TNF-α is not present in the blood and only unused bio that has been administered is present in the body”. When membranous cells appear in this environment, a large amount of unused bio will immediately kill the membranous cells. That is, if deep remission can be achieved quickly and maintained for nine months, it is possible to kill all TNF-producing cells.

W29-4

Trends in methotrexate dose and disease activity in patients with rheumatoid arthritis who had achieved remission by adalimumab plus methotrexate treatment
Toshihiko Hidaka, Kazuyoshi Kubo, Yayoi Hashiba, Hiroshi Kuroda
Insititutition of Rheumatology, Zenjinkai Shinmin-no-Mori Hospital, Miyazaki, Japan

Conflict of interest: Yes

[Objectives] We assessed the trends in methotrexate (MTX) dose in patients with rheumatoid arthritis (RA) who achieved remission by adalimumab (ADA) plus MTX treatment. [Methods] In 77 RA patients who had been treated with ADA, 31 RA patients who had achieved within one year and maintained remission more than 3 months by ADA plus MTX treatment were evaluated. These patients were divided into 3 groups; group R (G-R, n=8): patients who reduced MTX dosage, group M (G-M, n=19): maintained MTX dosage, group I (G-I, n=4): increased MTX dosage. We assessed DAS28ESR, SDAI and the trends in MTX dose in 3 groups at the point of 0, 3, 6, 9 and 12 months after remission. [Results] Mean age, mean disease duration (months), DAS28ESR, SDAI, MTX dosage at the start of ADA were as follows; G-R: 56.3, 56.6, 4.72, 20.14, 10.5mg/W, D-M: 54.1, 14.9, 3.80, 13.48, 10.4mg/W and G-I: 55.0, 10.0, 3.78, 11.16, 9.0mg/W, respectively. DAS28, SDAI and MTX dosage at the point of remission/12 months after remission were as follows; G-R: 2.12/1.88, 3.38/1.14, 10.5/6.9, G-M:2.01/1.77, 3.29/1.74, 10.5/10.5, and G-I: 2.05/1.88, 1.92/1.80, 9.0/11.3, respectively. [Conclusions] Regardless of MTX dosage, patients with RA who had achieved remission by ADA plus MTX treatment in early phase can maintain remission.

W29-5

Predictors of sustained remission in rheumatoid arthritis patients using gradual de-escalation of abatacept
Masaoami Yamasaki
Shin-Yokohama Rheumatology Clinic, Yokohama, Japan

Conflict of interest: None

[Objectives] To study prognostic factors for achievement of sustained remission in rheumatoid arthritis patients receiving gradual de-escalation of abatacept. [Methods] Efficacy was evaluated by CDAI and Boolean remission criteria. Abatacept were gradual de-escalation with patient who had sustained remission (susREM) for 3 months. [Results] 237 of RA patients were treated with abatacept and enrolled in this study. Overall susREM rate was 38.0% (90 cases). 88 out of 90 cases were achieved drug reduced remission (DRR) and 6 out of 88 patients were achieved drug free remission (DFR). Although there were no significant differences in duration of RA, age and initial CDAI, ACA positive, combination of csDMARDs and reduction of CDAI at first 3 months of treatment were predictors for susREM. DFR patients showed lower number of swelling joints compared with DRR patients. All patient achieved to DFR fulfill Boolean remission criteria. [Conclusions] ANCA positivity, combination of csDMARDs and more rapid initial response are the predictor of successful tapering and maintaining remission. Using gradual de-escalation of abatacept also useful for susREM.

W29-6

Comparative Analysis of bDMARDs retention rates from National Database in Japan
Katsuhiko Takabayashi1,2, Fumihiko Ando2, Takahiro Suzuki2,4, Kei Ikeda1, Hiroshi Nakajima1, Hideki Hanaoka1,4
1Sanwa Hospital, 2Department of Management and Medical Informatics, Chiba University Hospital, 3Department of Clinical Research, Chiba University Hospital, 4Department of Allergy and Collagen Diseases, Chiba University School of Medicine

Conflict of interest: None

[Objectives] To analyze the effectiveness of bDMARDs from NDB data. [Method] By using NDB (National Database which includes all Japanese claims data) the retention rates of 166,987 patients who were treated by bDMARDs and Jak inhibitor at least once in 7 years were analyzed by Caplan Meier Method. [Result] Tofacitinib has the longest retention months (median 34 months) and highest retention rate (0.56 at 2 years), following by TCZ, ABT, GLM, ETN, IFX, CPZ and ADA. [Conclusion] The retention rate is the highest in Jak inhibitor followed by non TNF inhibitor and TNF inhibitors.
W30-1
Factors Affecting Differences between Responders and Non-responders on Work Productivity in RA Patients Treated with Tocilizumab-SC: A 104-week-Results in the FIRST ACT-SC Study
Yoshiya Tanaka1, Hitode Kameda2, Kazuyoshi Saito3, Yoko Kaneko4, Eiichi Tanaka5, Shinsume Yasuda6, Naoto Tamura7, Keishi Fuji8, Takao Fuji9, Toshihisa Kojima10,11, Hitoshi Kohsaka11
1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 2Tobata General Hospital, 3Division of Rheumatology Department of Internal Medicine, Keio University School of Medicine, 4Institute of Rheumatology, Tokyo Women’s Medical University, 5Department of Rheumatology, Endocrinology and Nephrology, Hokkaido University Faculty of Medicine and Graduate School of Medicine, 6Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, 7Department of Allergy and Rheumatology, The University of Tokyo, 8Department of Rheumatology and Clinical Immunology, Wakayama Medical University, 9Department of Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 10Department of Rheumatology, Tokyo Medical and Dental University

Conflict of interest: Yes

[Object] In a study conducted on patients with rheumatoid arthritis (RA) receiving subcutaneous injections of tocilizumab (TCZ-SC), the effect on labor productivity was evaluated, and the factors contributing to improvement were determined. [Methods] FIRST ACT-SC Study (UMIN000012306) was a cohort study assessing the 2-year treatment outcome of TCZ-SC in biologics-naive Japanese patients with RA. Logistic regression was performed to determine the factors that contributed to responses in terms of activity impairment (AI) of WPAI. In addition, the association of these responses with the withdrawal rate and the quality of life (QOL) was also evaluated. [Results] Of the 295 patients were included in the analysis. The results showed an association between the results of subjective assessments, such as the utility value of EQ-5D (p<0.001) and HAQ-DI (p=0.02). Findings also suggested that subjects in a better condition were more likely to be AI responders. A significant difference in withdrawal rate was found between responders and non-responders (27.0% vs. 46.9%; p<0.001). [Conclusions] Starting TCZ-SC treatment at an early stage may contribute to an improvement in labor productivity, a long-term continuation of treatment, and an improvement of the QOL.

W30-2
Onset of action of sarilumab plus methotrexate (MTX) in patients (pts) with active rheumatoid arthritis (RA) and inadequate response to MTX in 2 phase 3 studies (KAKEHASI and MOBILITY)
Yoshiya Tanaka1, Kazuteru Wada2, Yoshihito Takahashi3, Owen Hagino4, Hubert Van Hoogstraten5, Neil Graham1, Hitode Kameda4
1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 2Sanofi, 3Sanofi, 4Sanofi Genzyme, 5Regeneron Pharmaceuticals, Inc., 6Division of Rheumatology, Department of Internal Medicine, School of Medicine, Toho University

Conflict of interest: Yes

[Object] In a study conducted on patients with rheumatoid arthritis (RA) receiving subcutaneous injections of tocilizumab (TCZ-SC), the effect on labor productivity was evaluated, and the factors contributing to improvement were determined. [Methods] FIRST ACT-SC Study (UMIN000012306) was a cohort study assessing the 2-year treatment outcome of TCZ-SC in biologics-naive Japanese patients with RA. Logistic regression was performed to determine the factors that contributed to responses in terms of activity impairment (AI) of WPAI. In addition, the association of these responses with the withdrawal rate and the quality of life (QOL) was also evaluated. [Results] Of the 295 patients were included in the analysis. The results showed an association between the results of subjective assessments, such as the utility value of EQ-5D (p<0.001) and HAQ-DI (p=0.02). Findings also suggested that subjects in a better condition were more likely to be AI responders. A significant difference in withdrawal rate was found between responders and non-responders (27.0% vs. 46.9%; p<0.001). [Conclusions] Starting TCZ-SC treatment at an early stage may contribute to an improvement in labor productivity, a long-term continuation of treatment, and an improvement of the QOL.

W30-3
Long-Term Effect of Sarilumab Plus Methotrexate on Disease Activity, Physical Function and Radiographic Progression: A 5-Year Analysis
Yoshiya Tanaka1, Gerd R Burmester2, Yong Lin3, Gregory St John4, Sheldon Wang5, Juan José Gómez-reino Carnota6, José Antonio Maldonado-cocco7, Juan Carlos Salazar-buitrago8, Désirée Van Der Heijde9, Mark C Genovese10, Hitode Kameda11
1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, 2Charité - University Medicine Berlin, 3Sanofi Genzyme, 4Regeneron Pharmaceuticals, Inc., 5Complejo Hospitalario Universitario de Santiago de Compostela, 6School of Medicine, Buenos Aires University, 7Riesgo de Fractura S.A.-CAYRE, 8Leiden University Medical Centre, Leiden, The Netherlands, 9Stanford University Medical Center, 10Division of Rheumatology, Department of Internal Medicine, School of Medicine, Toho University

Conflict of interest: Yes

[Object] To examine 5-year safety, efficacy and radiographic outcomes of sarilumab in adults with RA and inadequate response to methotrexate (MTX-IR). [Methods] In MOBILITY (NCT01061736) Part B Cohort 2 1197 patients with moderately to severely active RA and MTX-IR were randomized to placebo, sarilumab 150 or 200mg SC q2w+MTX for 52 weeks. 897/901 completers received sarilumab 200mg q2w+MTX in the open-label extension EXTEND (NCT01146652). [Results] Initial treatment with sarilumab 200mg+MTX was associated with reduced radiographic progression at Year 5 vs sarilumab 150mg+MTX or placebo+MTX (no progression in mTSS: 52% vs 47% and 40%, respectively). Efficacy (DAS28-CRP, CDAI and HAQ-DI) was sustained. The safety profile was stable over 5-year follow-up and consistent with IL-6R blockade. Absolute neutrophil count <1000/mm3 was observed but not associated with increased rate of infection. [Conclusions] Clinical efficacy, including reduction in disease activity, improvement in physical function, and inhibition of radiographic progression with sarilumab+MTX was sustained over 5-years. No new safety signals emerged. [Acknowledgments] Study funding and editorial support (Natalie Roberts, Adelphi Communications Ltd) was provided by Sanofi Genzyme and Regeneron Pharmaceuticals, Inc.

W30-4
Sustained Clinical Remission after Discontinuation of Infliximab with a Raising Dose Strategy or a Standard Dose Treatment in Patients with Rheumatoid Arthritis (RRRR study): A Randomized Controlled Trial
Yoshiya Tanaka1, Takao Koike1,2, Nobuyuki Miyasaka3, Tsuneyo Mimori4, Tutomu Takeuchi5, Shintaro Hirata6, Hidekata Yassouka7, Yoko Kano8, Kosaku Murakami6, Tomohiro Koga7, Kazuhisa Nakano8, Koichi Amano9, Kazuyasu Ushio10, Tatsuya Atsumi11, Masayuki Inoo12, Kazuhiro Hatta13, Shinichi Mizuki14, Shohei Nagaoka15, Shinichiro Tsunoda16, Hiroaki Dobashi17
1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 2Hokkaido Medical Center for Rheumatic Diseases, 3Department of Medicine II, Hokkaido University Graduate School of Medicine, 4Department of Rheumatology, Tokyo Medical and Dental University, 5Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 6Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 7Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, 8Department of Rheumatology, School of Medicine, Tokyo Women’s Medical University, 9Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 10Department of Rheumatology & Clinical Immunology, Saitama Medical Center, 11Ushio Clinic, 12Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, 13Utats Hospital, 14Department of General Medicine, Tenri Hospital

Conflict of interest: Yes

[Object] This post-hoc analysis assessed the time to onset of clinical efficacy and durability of response of sarilumab at Weeks (wks) 2, 4, 8, 12 and 24 in the phase 3 MOBILITY and KAKEHASI studies. [Methods] In MOBILITY (global centres) and KAKEHASI (Japan), pts with a prior inadequate response to MTX (MTX-IR), received subcutaneous sarilumab 150 mg q2w + MTX (S150), 200 mg q2w + MTX (S200), or placebo + MTX (P) for up to 52wks. [Results] Baseline characteristics were well balanced in both studies. Sarilumab showed improvements (vs P) in efficiency at all timepoints. Improvements in ACR20 response were seen as early as 2wks in both studies: MOBILITY (20.5% S150; 20.8% S200; both nominal p<0.01 vs P); KAKEHASI (18.5% S150; 15.0% S200; nominal p<0.05 vs P); and, from around wk4 for ACR50/70. In both studies, greater reductions in DAS28-CRP from baseline were observed with both doses of sarilumab vs P at wk2 (nominal p<0.0001 vs P). Numerical improvements of both doses in CDAI (nominal p<0.05 vs P) and HAQ-DI were observed from wk2. TEAEs were consistent with the class. Infection was the most common TEAE (≧10% of patients) in all groups at wk12 TEAEs. [Conclusions] Sarilumab rapidly improved signs and symptoms and physical function in MTX-RA pts both in Japan and overseas.
ment of Rheumatology, Matsuyama Red Cross Hospital. 1Department of Rheumatology, Yokohama Minami Kyosai Hospital, 1Division of Rheumatology Department of Internal Medicine, Hyogo College of Medicine, 1Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University

Conflict of interest: Yes

Object: The Remission induction by raising the dose of Remicade in RA study (RRRR Study) (UMIN000005113) was designed to evaluate the clinical remission after 54 weeks of “programmed” treatment, whose dose of IFX for each patient was determined by the baseline serum TNF-α. Methods: RRRR study was a randomized, active controlled, multicenter phase4 study. IFX-naïve RA patients who showed MTX-IR were randomized to the programmed treatment group, a dose of IFX was kept or raised based on baseline levels of serum TNF the standard treatment group, 3mg/kg of IFX was kept. If patients showed a SDAI≤3.3 at week 54, they discontinued IFX. Results: 405 patients were enrolled in the study. At week 54, 39.4% in the programmed group and 32.3% in the standard group could attain the remission defined by SDAI and withdrew IFX treatment. At week 106, the 1-year sustained discontinuation rate, the primary endpoint, of the programmed group and standard group was 23.5% and 21.6%, respectively. Conclusions: Programmed treatment strategy using different dose of IFX based on the baseline levels of serum TNF-α tended to increase the remission rate at week 54, but did not increase the sustained remission rate after 1-year discontinuation of IFX treatment at week 106.

W31-1-1 Frequency and related factors of pancytopenia in patients with systemic lupus erythematosus (SLE) Daijirou Soda1,2, Susumu Nishiyama1, Tetsushi Aita1, Yasuhiro Yoshinaga1, Shoji Miyawaki1, Akio Morinobu2 1Rheumatic Disease Center, Kurashiki Medical Center, 2Division of Rheumatology, Kobe University Hospital

Conflict of interest: None

[Object] To examine the frequency and related factors of pancytopenia in SLE patients. [Methods] Of 224 patients with SLE (visited our hospital 2005-2017), 25 (24 females) developed pancytopenia. Age at the SLE onset was 20.0±14.6 and the disease duration was 20.2±13.3 years. [Results] Pancytopenia occurred 37 times. Age at the first occurrence of pancytopenia was 49.4±13.5. Median duration (IQR) of the 37 times pancytopenia was 7 (3-16.5) days. Patients were classified as A) 11 patients due to SLE, B) 5 due to SLE and drugs, C) 5 due to SLE and other diseases, D) 1 due to drugs, and E) 3 due to other diseases. Patients with SLE-related pancytopenia (A+B+C) had significant high SLEDAI and short period from the SLE onset to the pancytopenia occurrence compared to others (D+E). Abnormal findings except for hypocoelullarity of bone marrow or reticulocyte index were 0/6 in SLE-related pancytopenia and 3/3 in SLE-unrelated. The cumulative survival rates of 10, 20, and 30 years in patients with pancytopenia were 95.5, 68.4, and 35.9%, respectively. [Conclusions] High disease activity and short duration until the pancytopenia occurrence was observed in patients with SLE-related pancytopenia. Prognosis of SLE patients accompanied by pancytopenia was poor.

W31-1-2 Effectiveness of hydroxychloroquine (HCQ) on thrombocytopenia associated with systemic lupus erythematosus (SLE) Sayaka Takatori, Kensaku Okamoto, Yuta Ikechi, Tomomi Kawahata, Kitaru Tanaka, Kyohoe Takatori, Ryoja Yoshimoto, Kouhei Eguchi, Daisuke Fujishiro, Satoru Kodama, Atsushi Kobayashi, Yuichi Makino, Tsuguhito Ota Division of Metabolism and Biosystemic Science, Department of Medicine, Asahikawa Medical University, Asahikawa, Japan

Conflict of interest: None

[Object] To analyze an effect of HCQ on thrombocytopenia associated with SLE [Methods] Among the 58 SLE patients administered with HCQ at our hospital, 4 cases showed an increase in platelet (Plt) count from thrombocytopenia of less than 100,000 (μL) at the time of diagnosis or during their clinical course. We reviewed the clinical course of the 4 cases. [Results] <Case 1> A 57-year-old female. Prednisolone (PSL) was administered against immune thrombocytopenic purpura (ITP), but low Plt counts persisted. Then she was diagnosed as SLE and HCQ was introduced. Plt count was increased from 19,000 to 90,000. <Case 2> A 16-year-old female. Diagnosis of SLE was made and treated with PSL and HCQ. Plt increased from 73,000 to 227,000. <Case 3> A 37-year-old female. She was diagnosed as SLE and lupus nephritis class IV +V (WHO). Since decrease in Plt count was persistent, splenectomy was performed. Plt increased to 70,000 temporarily, but her Plt decreased to 15,000. After introduction of HCQ, Plt increased to 56,000. <Case 4> A 38-year-old female. She was diagnosed as SLE and treated with PSL. Her Plt count was decreased to 80,000 but after introduction of HCQ it was increased to 110,000. [Conclusions] Treatment with HCQ may potentially therapeutic for thrombocytopenia in SLE.

W31-1-3 Investigation of the Risk for Clinical Macrophage Activation Syndromes in Patients with Systemic Lupus Erythematosus Yasuhiro Hasegawa, Yoshiyuki Arinuma, Kazuma Ino, Junichi Kondo, Takumi Muramatsu, Yu Matsuveda, Takayuki Hoshiyama, Toshihiro Tono, Tatsuhiko Wada, Tatsuo Nagai, Sumiaki Tanaka, Kunihiro Yamaoka Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine

Conflict of interest: None

[Object] Macrophage activation syndromes (MAS) clinically involved in SLE patients (CMSA) is prevalent but refractory complication in patients with SLE. The aim of this study is to investigate the risk for MAS. [Methods] SLE patients who had admitted for induction therapy in Kitasato University hospital since January in 2010 to September in 2018 were enrolled. Patients having CMSA were defined as those who fulfilled ACR/EULAR 2016 classification criteria for MAS in sJIA. Risk factors for CMSA were investigated based on medical histories. [Results] 71 patients were enrolled. Of 71 patients, 13 patients (17.6%) were complicated with CMSA. CRP level was not a risk for CMSA. Among immunological tests, higher C1q was a risk for CMSA (odds ratio (OR), 7.36, p=0.21), unlike higher IgG or lower complement. Among antibodies, positive for anti-Sm antibody independently increased a risk for CMSA (OR 4.31, p=0.02) in multivariate analysis. Steroid pulse therapy and calcineurin inhibitors were used for treatment. There was no fatal patient during observation period. [Conclusions] CMSA is one of the complications by high disease activity of SLE. An appropriate clinical diagnosis of MAS and use of calcineurin inhibitor could improve prognosis.

W31-1-4 Retrospective study of combination therapy including continuous hemodiafiltration with a cytokine-adsorbing hemofilter (AN69ST) for hemophagocytic lymphohistiocytosis complicated with systemic lupus erythematosus Koto Hattori1, Yuichi Ishikawa1, Yasuhiro Koizumi2, Orie Chinone1, Michio Fujiwara1, Yasuhiro Kita1 1Department of Rheumatology, Yokohama Rosai Hospital, 2Immuno-Rheumatology Center, Yokohama Rosai Hospital, 1Department of Nursing, Yokohama Rosai Hospital

Conflict of interest: None

[Object] To examine the clinical course and safety of continuous hemodiafiltration with a cytokine-adsorbing hemofilter (AN69ST-CHDF) for hemophagocytic lymphohistiocytosis complicated with systemic lupus erythematosus Koto Hattori1, Yuichi Ishikawa1, Yasuhiro Koizumi2, Orie Chinone1, Michio Fujiwara1, Yasuhiro Kita1 1Department of Rheumatology, Yokohama Rosai Hospital, 2Immuno-Rheumatology Center, Yokohama Rosai Hospital, 1Department of Nursing, Yokohama Rosai Hospital

Conflict of interest: None

[Object] To examine the clinical course and safety of continuous hemodiafiltration with a cytokine-adsorbing hemofilter (AN69ST-CHDF) for hemophagocytic lymphohistiocytosis complicated with systemic lupus erythematosus (SLE-HPS). [Methods] We retrospectively examined four SLE-HPS patients who received combination therapy including AN69ST-CHDF at our department from 2016 to 2018. [Results] The study subjects were four SLE-HPS patients. The median age was 42. Three patients had neuropsychiatric SLE, and one had HPS from onset of SLE. When AN69ST-CHDF was initiated, glucocorticoid pulse therapy and plasma exchange were given in all patients. The median duration of the stay in the ICU and oxygen therapy were 17 days and 15 days, respec-
W31-1-5
Analysis of pulmonary manifestations in systemic lupus erythematosus
Kaoru Mizukawa, Keisuke Nishimura, Keichiro Kadoba, Hiroki Mukoyama, Tomohiro Yosida, Daisuke Waki, Toshikiyo Yokota
Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan
Conflict of interest: None

[Object] Pulmonary involvement in systemic lupus erythematosus (SLE) are rarely reported. We analyzed the clinical features of patients with pulmonary involvement in SLE. [Methods] To analyze the clinical features of 138 patients with SLE who were treated in our hospital from January 2006 to July 2018. And to analyze 23 patients with mixed connective tissue disease (MCTD) involving lung treated in the same period. [Results] Patients with SLE were diagnosed with ACR or SLICC criteria. Of 138 patients, 21 patients had pulmonary manifestation. Sixteen patients had interstitial lung disease (ILD), two had diffuse alveolar hemorrhage (DAH), two had pulmonary hypertension (PH) and one had both DAH and PH. Pulmonary involvements were found to be significantly more frequent in older (p=0.0011), men (p=0.0098), and negative of anti-Ro/SSA antibody (p=0.0002). In MCTD patients, 14 patients had ILD, four had PH, three had both ILD and PH, one had lipid pneumonia, and one had hilar lymphadenopathy. Two-year survival rate of SLE patients with pulmonary involvement is 85.2%, equivalent to MCTD patients. [Conclusions] Pulmonary involvements in SLE are more common than conventional reports.

W31-1-6
Comorbidity of malignancies in systemic lupus erythematosus patients in the cohort of LUNA registry
Kunihiro Ichinose1, Takashi Iga2, Momoko Okamoto1, Nobuyuki Yajima2, Ken-ji Sada2, Ryusuke Yoshimi3, Shigeru Ohno3, Mizuna Ototu4, Yoshiro Endo5, Sosuke Tsuji5, Ayuko Takatani5, Yoshimasa Shimizu6, Remi Sunimiyoshi7, Tomohiro Koga7, Shin-ya Kawashiri7, Naoki Iwamoto8, Mami Tamai8, Hideki Nakamura8, Tomoki Origiuchi8, Atsushi Kawakami8
1Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 2Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 3Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 4Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, 5Center for Rheumatic Disease, Yokohama City University Medical Center, 6School of Health Sciences, Division of Physical Therapy, Nagasaki University
Conflict of interest: None

[Object] It is known that the incidence of malignancies is higher in systemic lupus erythematosus (SLE) patients compared to healthy subjects. We examined the malignancy complication of patients with SLE in the cohort of LUNA registry. [Methods] We evaluated 234 cases diagnosed as SLE and could detect the presence or absence of malignancy. The life history such as drinking and smoking, treatment including steroid pulse, intravenous cyclophosphamide pulse therapy (IVCY) and hydroxychloroquine (HCQ), vaccination history, and comorbid complications were retrospectively analyzed. [Results] Comorbidity of malignancy was observed in 23 cases (9.8%). No association was found between age, the treatment history of steroid pulse, IVCY, HCQ and malignancy. Fourteen of 23 (60.9%) cases had gynecological malignancies such as uterus and ovarian cancer. Comorbidity of malignancy associated with higher SDI (SLICC Damage index) (p=0.0229), history of osteoporosis (p=0.0049), non-inoculation of pneumococcal vaccination (p=0.0169), history of pyelonephritis (p=0.0095) and ovarian insufficiency (p=0.0032). [Conclusions] Further large scales of cohort and longitudinal studies are needed to examine the relationship between SLE complications and the incidence of malignancy.

W31-1-7
Baricitinib (Bari) in Systemic Lupus Erythematosus (SLE): Results from a Global Phase 2, Double-Blind, Placebo-Controlled Study
Yoshiya Tanaka1, Daniel Wallace2, Richard Furie3, Kenneth Kalunian4, Marta Mosca5, Michelle Petri6, Thomas Dörner7, Mario Cardiel8, Ian Bruce9, Ayako Konomidou10, Taeko Ishii10, Yasushi Takita10, Elisa Gomez10, Maria Silk11, Robert Hoffman11
1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2David Geffen School of Medicine, University of California, Los Angeles, USA, 3Zucker School of Medicine at Hofstra/Northwell, New York, USA, 4Univ of California at San Diego School of Medicine, La Jolla, USA, 5Univ of Pisa, Pisa, Italy, 6Johns Hopkins Univ School of Medicine, Baltimore, USA, 7Charite Universitätsmedizin Berlin, Berlin, Germany, 8Centro de Investigación Clinica de Morelia SC, Morelia, Mexico, 9The Univ of Manchester, Manchester, UK, 10Eli Lilly Japan K.K., Kobe, Japan, 11Eli Lilly and Company, Indianapolis, USA
Conflict of interest: Yes

[Object] To report results from a Global Phase 2, double-blind, placebo (PBO)-controlled study of Bari in SLE patients (pts). [Methods] Of 314 SLE pts (positive ANA or anti-dsDNA, clinical SLEDAI-2K≥4 with arthritis and/or rash and background therapy required), 57 were Asian and 33 were Japanese (JP). Randomization was 1:1:1 to PBO, Bari 2 or 4mg groups. The primary endpoint was resolution of SLEDAI-2K arthritis and/or rash at wk 24. [Results] At wk 24, a significantly greater proportion of pts receiving 4mg compared to PBO achieved resolution of SLEDAI-2K arthritis and/or rash (67% vs 53%; p<0.05); and SRI-4 response (64% vs 48%; p<0.05). Fewer flares (SELENA-SLEDAI Flare Index) occurred in 4mg than PBO. Greater proportion of pts achieved LL-DAS, and reductions in tender joint count from baseline with 4mg compared to PBO. Rates of adverse events (AEs) led to discontinuation (PBO: 3.8%; 2mg: 9.5%; 4mg: 10.6%) and serious AEs (PBO: 4.8%; 2mg: 10.5%; 4mg: 9.6%) were higher for Bari compared to PBO. There were no deaths, malignancies, major adverse cardiovascular events, tuberculosis, or serious herpes zoster infections. Consistent results were observed in pts from Asia/JP. [Conclusions] Bari 4mg was associated with clinical improvements compared to PBO and an acceptable benefit/risk profile.

W31-2-1
The analysis of Lupus Low Disease Activity State after induction treatments in patients with SLE
Jun Kikuchi, Hironori Hanaoka, Shuntaro Saito, Naoshi Nishina, Kotaro Otomo, Yuko Kaneko, Katsuya Suzuki, Tsutomu Takeuchi
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Conflict of interest: None

[Object] Lupus Low Disease Activity State (LLDAS) defined by Franklyn et al has been reported to be associated with the organ damage and relapse in SLE. The purpose of this study is to clarify the factors related to the attainment of LLDAS after induction therapy. [Methods] Active SLE patients with BILAG 1A or 2B or more who started induction therapy from April 2015 to October 2018 in our hospital and were followed for more than 12 months were selected. [Results] We enrolled 63 patients with a mean age of 42 years, a disease duration of 86 months, the first-onset 37%, average SLEDAI 16 and nephritis 68%. Eighty-six percent experienced LLDAS during the average observation period of 28 months. The median percentage to attainment of LLDAS was 53% at 12 months. LLDAS attainment within 12 months was significantly greater in
patients with first-onset, exhibited fever at baseline, low SLEDAI and low urinary protein creatinine ratio in patients with lupus nephritis after treatment for 3 months. [Conclusions] LLDAS attainment in 12 months after the induction therapy remained about half in SLE patients. First-onset, presenting fever, low SLEDAI and urinary protein after treatment for 3 months were advantageous to LLDAS attainment.

W31-2-2
The predictive factors for LLDAS attainment in systemic lupus erythematosus: A cross-sectional study of LUNA registry
Daiga Kishimoto1, Ryoysuke Yoshimi1, Yosuke Kunishita1, Chiharu Hidekawa1, Natsuki Sakurai1, Masaki Mitsushashi1, Yumiko Sugiyama1, Yuki Iizuka1, Takaaki Komiya1, Hitredo Nagai1, Naoki Hamada1, Naomi Tsuchida1, Yutarou Soejima1, ReiKou Kaniyama1, Kouji Kobayashi1, Yukiko Asami1, Yohei Kirino1, Nobuyuki Yajima1, Ken-ei Sada1, Kunihiro Ichinose1, Shigeru Ohno1, Hideaki Nakajima1
1Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, 2Center for Rheumatic Disease, Yokohama City University Medical Center, 3Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 4Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 5Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences

Conflict of interest: None

[Object] To search for factors which affect the achievement of lupus low disease activity state (LLDAS) using a multicenter SLE registry: [Methods] We cross-sectionally analyzed the relationship between the LLDAS achievement and various parameters related to the patients’ background by using the data of SLE patients registered in the LUNA registry. [Results] Among 165 cases, 60 (36%) achieved LLDAS. Fever and anti-SS-A antibody seropositivity at onset were observed more frequently in the non-LLDAS achievement group as compared with the achievement group (52% vs 33%, p = 0.034, and 67% vs 48%, p = 0.019, respectively). Although proliferative nephritis was observed less frequently in the non-LLDAS (87% vs 51%, p = 0.017), there was no difference in the frequency of membranous nephropathy. In the non-achievement group, tacrolimus (28% vs 13%, p = 0.034), hydroxychloroquine (49% vs 25%, p = 0.002), bisphosphonate (64% vs 47%, p = 0.036), and sulfamethoxazole-trimethoprim (13% vs 1.7%, p = 0.017) were administered more frequently, and azathioprine were administered less frequently (8.6% vs 23%, p = 0.008) than in the achievement group [Conclusions] Fever at onset and serum anti-SS-A antibody seropositivity may be risk factors for not achieving LLDAS.

W31-2-3
Serologically Active Clinically Quiescent Disease in Systemic Lupus Erythematosus: a 5-year Follow-up Study
Naoko Konda, Yasuhiro Katsumata, Yuko Okamoto, Rina Mouriya, Sayumi Baba, Mari Tochihara, Shin ya Hirahara, Akira Nishino, Yasushi Naoko Konda, Yasuhiro Katsumata, Yuko Okamoto, Rina Moriya, Sayumi Baba, Mari Tochihara, Shin ya Hirahara, Akira Nishino, Yasushi

Conflict of interest: None

[Object] We studied the clinical features of serologically active clinically quiescent (SACQ) SLE in prospectively followed Japanese SLE patients. [Methods] Japanese patients with SLE were enrolled and assessed using SLEDAI-2K and SDI. SACQ was defined as the state without clinical activity (clinical SLEDAI-2K ≦ 0), with persistent serologic activity (increased anti-ds DNA and/or hypocomplementemia), and PSL ≦ 7.5 mg. The Clinical features of SACQ and 5-year outcome of the patients with SACQ were analyzed. In addition, patients with SACQ were compared with those who were both clinically and serologically quiescent (CQSQ;SLEDAI-2K ≦ 0). [Results] Ultimately, 148 patients enrolled (at baseline, mean age 45.0, 134 female, mean disease duration 12 years, mean SDI 1.1), 16 patients satisfied SACQ (mean age 13.0, 16 female, mean disease duration 12 years, mean SDI 1.2), 22 patients satisfied SQQC. Among the original SACQ group, 7 patients remained SACQ, 2 patients became SQQC, and 7 patients were in clinical flare in 2016. There were no significant differences between the SACQ and SQQC groups in the ratio of SACQ or SQQC, SDI, score or rate increase of SDI, dosages of PSL, decrease dosage or rate of PSL. [Conclusions] This study showed some clinical features of SACQ in Japanese patients with SLE.

W31-2-4
Remission and flare in patients with systemic lupus erythematosus (SLE) according to the definition “DORIS” -Durable remission off steroid is rare-
Shoji Miyawaki, Susumu Nishiyama, Tetsumi Aita, Yasuhiro Yoshinaga

Conflict of interest: None

[Object] Retrospective assessment of remission and flare in 83 SLE patients according to DORIS (Definitions Of Remission In SLE, 2015). [Methods] 83 SLE patients were divided into 1) clinical remission (ClinR), 2) clinical remission on treatment (ClinROT), 3) complete remission (CompR), 4) complete remission on treatment (CompROT), and non-remission (NonR). [Results] Disease duration of SLE was 24.7±8.6 years. One hundred-eleven ClinR, 35 ClinROT, 65 NonR and 2 off steroid ClinR were observed; no CompR. Seventy-nine (69.9%) flares occurred in ClinR +ClinROT were significantly higher than 16 (45.7%) flares in CompROT. Thirty-one patients with cumulative remission of more than 50% of disease duration were significantly older, had shorter duration until first remission, more ClinROT or CompROT, lower nephropathy, lower maximum SLEDAI and SLICC damage index (SDI) than 52 patients with remission of less than 50% of duration. Twenty-one patients with prednisolone (PSL) 2.5 mg daily had significantly longer cumulative remission, more CompROT, and less flares and increase of SDI than patients maintaining more than PSL 5 mg daily. [Conclusions] Prolonged remission off steroid is rare in Japanese SLE compared to Caucasian SLE. Maintenance of PSL 2.5 mg daily might be useful to prolong remission.

W31-2-5
A Prospective cohort study on the short and long-term prognosis, including pregnancy outcomes, of young patients with systemic lupus erythematosus in Japan. (Pleasure-J study): progress report
Kayoko Kaneko1, Nobuyuki Yajima2, Yoko Miura2, Yasunori Iwata3, Kae Onishi4, Naoshi Nishina5, Takuya Nemoto6, Toru HIRONO7, Nobuya Abe8, Takako Miyamae9, Hideyuki Iwai10, Kenji Oku11, Tsutomu Takeuchi1, Naoto Tamura12, Masaaki Mori13, Takashi Wada14, Atsuko Murashima12

Conflict of interest: None

[Object] A Prospective cohort study on the short and long-term prognosis, including pregnancy outcomes, of young patients with systemic lupus erythematosus in Japan. (Pleasure-J study): progress report

[Objective] Systemic lupus erythematosus (SLE) is more prevalent in young people. While the life prognosis has got to be improved, the accumulated physical and mental damage and the decline in QOL due to long-term morbidity are remained to be unsolved problem. We started multi-center prospective cohort study from November 2017 to clarify the
physical and mental prognosis of young SLE patients in Japan. [Method] Six to 40 years old SLE patients diagnosed within one year were registered. Disease activity (SLEDAI-2K), physical function disorder (SLICC/ACR Damage Index) and comprehensive/disease specific quality of life (SF12v2, Lupus PRO) were evaluated. [RESULTS] Thirty-three patients were enrolled. 4 males, 29 females, median age at the time of registration was 24 (19.5, 28.5) years old. SLEDAI-2K at diagnosis is 16 (10, 21). In QOL evaluation, the disease-specific health related and non-health related score were 60.4 (44.2, 81.7) and 57.7 (50, 69.7). The comprehensive QOL summary score in the physical, mental and role/social aspect were 50.0 (39.1, 60.8), 48.2 (42.0, 55.8) and 39.72 (26.8, 48.1), respectively. [Conclusion] The prospective cohort study of the young SLE has been started. It is expected that we could report high-quality evidence on the prognosis of Japanese young SLE.

W32-1
Comprehensive analysis of correlation between each clinical symptom, laboratory finding, and organ involvement in systemic lupus erythematosus patients

Takeshi Iwasaki1, Hiroshi Doi1, Yuya Tabuchi1, Mototsuro Ohshige1, Kazuoto Hiramoto, Yuko Kaneko, Tsutomu Takeuchi1

Division of Rheumatology, Keio University School of Medicine

Conflict of interest: None

[Object] To clarify the pathological mechanisms of systemic lupus erythematosus (SLE) by analyzing correlation between each clinical symptom, laboratory finding, and organ involvement. [Methods] 362 SLE patients in Kyoto University Hospital were surveyed for 15 organ involvements, each item of new ACR/EULAR classification criteria, sex, anti-U1RNP, and anti-SS-A/Ro antibodies. We conducted comprehensive univariate (Fisher’s exact test) and multivariate (lasso regression) correlation analysis. [Results] By univariate analysis, correlation between fever and arthritis as well as low complement and Class III/IV lupus nephritis, etc. were identified. By multivariate analysis, correlations between pleural/pericardial effusion and fever; lupus colitis and low complement / anti-SS-A/Ro; alopecia or acute cutaneous lupus and anti-U1RNP; pulmonary hypertension and anti-U1RNP/anti-dsDNA; etc. were identified. [Discussion] By comprehensive analysis, novel correlations between organ involvement and serological tests were identified. These results may facilitate prediction of future organ involvement and patient education as well as understanding pathological mechanisms. [Conclusion] Comprehensive correlation analysis was useful to identify new biomarkers to predict certain organ involvements.

W32-2
Evaluation of relapse rate and life prognosis after therapy induction in proliferative and membranous lupus nephritis

Momoko Okamoto1, Kunihito Ichinose1, Keita Fujikawa2, Yoshiro Horai1, Naoki Matsuoka1, Masahiko Tsuboi3, Fumiaki Nonaka1, Yukitaka Ueki1, Yushiro Endo1, Souke Tsujii1, Ayuko Takatani1, Toshimasa Shimizu1, Remi Sumiyoshi1, Tomohiro Koga1, Shin-yaw Kawashiri1, Naoki Iwamoto1, Mami Tama1, Tomoki Ogurichi1, Atsushi Kawakami1

1Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 2Department of Rheumatology, JCHO Ishahaya General Hospital, 3Department of Rheumatology, NHO Nagasaki Medical Center, 4Nagasaki Medical Hospital of Rheumatology, 5Department of Island and Rural Medical Research, Nagasaki University Graduate School of Biomedical Sciences, 6Shiboh Chiho Hospital, 7Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences

Conflict of interest: None

[Object] To evaluate the relapse rate and life prognosis after therapy induction in proliferative and membranous lupus nephritis (LN). [Methods]: One hundred fifty one cases who underwent renal biopsy at our hospital and community hospitals from 1993 to 2016 were enrolled in this study. We retrospectively analyzed the complete response (CR) rate at 12 months after therapy induction and evaluated the predictive factors for CR, relapse rate and life prognosis. [Results]: In 140 cases, we were able to examine the therapeutic response, relapse rate and life prognosis at 12 months after therapy was introduced. Multivariate analysis showed that lower index of chronicity as assessed by the NIH histological scoring system in proliferative LN, and neutrophil infiltration and CH50 in membranous LN were predictive factors for achieving CR at 12 months. Kaplan-Meier analysis showed that relapse rate and life prognosis were not different in proliferative and membranous LN. [Conclusions]: In general, proliferative LN is more immunologically active than membrane LN, however there were no influence on the achieving CR at 6 months and 12 months after therapy induction, the relapse free period and life prognosis.

W32-3
Influence of prior treatment on pathology and prognosis in 54 patients with lupus nephritis

Kazuya Matsumoto, Shoichi Nawachi, Reika Hayashi, Ryutaro Yamanaka, Hitotsubi Kagawa

Japanese Red Cross Society Himeji Hospital

Conflict of interest: None

[Object] ISN / RPS classification type IV is the most common in many lupus nephritis reports, but we experience relatively large number of type III patients. We examined the effect of treatment preceding renal biopsy on histology and remission rate. [Methods] We include 54 lupus nephritis patients underwent initial renal biopsy from October 2007 to March 2018. We treated them for more than 6 months. We divided them into two groups, pre-biopsy treatment group that was treated prior to renal biopsy and post-biopsy treatment group that started treatment after renal biopsy. We conducted cross-sectional study. [Results] In our pre-biopsy treatment group and 19 patients were in post-biopsy treatment group. The numbers of patients in each category were as follows: class II, 4; class III, 17; class IV, 29; class V, 4. The proportion of type III in the proliferative type tended to be high in the former. In addition, the longer the preceding treatment period, the more the proportion of type III tended to increase. The complete remission rate at 6 months was significantly higher in the former group than the latter (71% vs. 42%, p=0.04). [Conclusions] Present study suggest that early treatment may improve the histology and prognosis in lupus nephritis patients.
W32-4
Analysis of 21 cases of lupus nephritis who underwent both the first and second biopsy at our department
Yoshinori Takei, Hidekazu Ikeuchi, Masato Kinoshita, Junya Suwa, Shunsuke Takahashi, Yuko Oishi, Mithuharu Watanabe, Hiroko Hamatani, Masao Nakasatomi, Toru Sakairi, Yoriaki Kaneko, Keiju Hiromura
Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine
Conflict of interest: None

[Object] In the present study, we sought to determine the histological changes of LN in the repeat biopsy. [Methods] We retrospectively analyzed LN patients who underwent a repeat renal biopsy, among 165 biopsy-proven Japanese LN patients (14 males and 151 females) at our department between 1976 and 2017. Renal histology was categorized by ISN/RPS 2003 classification. Class III+V and IV+V were classified as mixed type. Data were expressed as median (IQR). [Results] Twenty-one patients (3 males and 18 females) received a repeat renal biopsy. Median age at the 1st biopsy was 30 years old (23.3, 36.2). The interval between the 1st and the repeat biopsy was 15.7 years (12.4, 19.4). All patients received renal biopsy due to flare. Histological analysis was observed in 7 pts. Chronic lesions (A/C or C) were increased from 5 pts to 17 pts at the repeat biopsy (p=0.001). [Conclusions] Repeat biopsy was performed a long time after the first biopsy due to flare. More than 30% patients showed class transformation and chronic lesions were increased in the repeat biopsy.

W32-5
Risk of thrombosis in patients with lupus nephritis with steroid pulse therapy
Suguru Honda1, Ryoko Sakai1, Sho Suzuki1,2, Masayoshi Harigai1, Hisashi Yamanaka1
1Department of Rheumatology, School of Medicine, Tokyo Women’s Medical University, 2Department of Public Health, School of Medicine, Tokyo Women’s Medical University
Conflict of interest: None

[Objective] To compare risk of thrombosis between patients with and without steroid pulse (SP) in lupus nephritis (LN). [Methods] Using claims data provided by Medical Data Vision Co., Ltd (Tokyo, Japan), we defined individuals as LN cases if they had at least one LN diagnostic code, started daily prednisolone ≥ 30mg, and were 16 years old or over between April 2009 and January 2018 (n=1217). LN cases were divided into 2 groups; receiving SP (SP group: n=692) or not receiving SP (non-SP group: n=525). After propensity-score matching (n=434), incidence of thrombosis at Month 1, 2, 3, 4, and 12, and mortality at Month 3 were calculated. [Results] The mean age was 47 years old and proportion of female was 76%. There were no statistically significant differences in baseline variables between the two groups. The incidences of thrombosis were not significantly different (SP vs non-SP at Month 1, 2, 3, 4, and 12 months; 3.0% vs 4.4% (p=0.28), 3.5% vs 5.1% (p=0.24), 3.9% vs 5.3% (p=0.331), 4.6% vs 5.5% (p=0.536), and 4.6% vs 6.0% (p=0.536), respectively). However, mortality of the SP group at Month 3 were significantly elevated (SP vs non-SP; 4.6% vs 0.7% (p<0.0001)). [Conclusion] This study revealed that SP did not increase the risk of thrombosis in patients with LN.

W32-6
Identification of Predictive factors of cardiovascular events in patients with systemic lupus erythematosus from the LUNA registry : A cross-sectional study
Takashi Iwaga1, Kunihiro Ichinose1, Momoko Okamoto1, Nobuyuki Yazima2, Ken-ei Sada1, Ryusuke Yoshimi1, Shigeru Ohno2, Mizuna Otsuka1, Yushiro Endo2, Susuke Tsuj1, Ayuko Takatani1, Toshikazu Shimizu2, Remi Sumiyoshi2, Tomohiro Koga4, Shin-ya Kawashiri1, Naoki Iwamoto1, Mami Tama1, Hideki Nakamura5, Tomoki Origuchi6, Atsushi Kawakami1
1Department of Immuno- and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 3Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 4Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, Japan, 5Department of Internal Medicine, Kumamoto University School of Medicine, Kumamoto, Japan, 6Department of Public Health and Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Conflict of interest: None

[Objective] The risk of developing cardiovascular events (CVD) in systemic lupus erythematosus (SLE) was evaluated using a multicenter registration study [Lupus registry of nationwide institution (LUNA)] in Japan. [Methods] We analyzed the presence or absence of CVD about 532 SLE patients. The relationship between cardiovascular events, blood test data, life history, medications and complications was retrospectively evaluated. [Results] We found 93 cases (17.5%) accompanied with CVD. Among the disease-related features the group of patients who had CVD showed significantly higher maximum dose of prednisolone in past (p<0.0095), lower hemoglobin level (p=0.0267), higher CRP value (p=0.0194), lower estimated glomerular filtration amount (eGFR) (p=0.0002), comorbidity of idiopathic necrosis of femoral head (p=0.0040), ovarian dysfunction (p=0.0175), comorbidity of diabetes (p<0.0001), fewer event of new skin rash (p=0.0087) and fewer event of hair loss (p=0.0074) compared to the group that had not CVD. The multi-variate analysis revealed that the predictive factors for CVD was eGFR (OR: 0.985, 95% CI: 0.974-0.997, p=0.0120), diabetes (OR: 2.453, 95% CI: 1.112-5.409, p=0.0319). [Conclusions] The risk of developing CVD in SLE of LUNA registry was consistent with the results reported in other countries.

W33-1
The flare and damage of patient with systemic lupus erythematosus in long term maintenance therapy
Ryutarou Matsunura, Kazuyuki Ishijima, Keiko Umemiya, Yoshihiro Oya, Hidekazu Futami, Takuya Nakazawa
Center of Rheumatology, Allergy and Clinical Immunology, National Hospital Organization Chiba East National Hospital
Conflict of interest: Yes

[Object] Results of long term conventional maintenance therapy in patients with SLE are not clear. [Methods] The flare and damage of 22 patients with SLE who had history of maintenance treatment more than 20 years were examined retrospectively. [Results] The onset of SLE was an average of 28.7 years old and a duration of treatment period was 21-46 years, an average of 27 years. At the time of onset strong activity including lupus nephritis, alveolar hemorrhage and CNS lupus was seen. Large dose steroid treatment, steroid pulse therapy and cyclophosphamid IV therapy were carried in more than 80 percent. Less than 5 mg of steroid was done in the majority an average of 27 years later. At the onset of SLE, the DNA antibody was positive and became negative by 80 percent, and positiveness of a ANF and anti SS-A antibody continued. Flare was observed in a case of 3/4, and there was serious flare in a case of 1/4, and significant correlation was observed in accumulation of damage and the number of times of flare. 2 patients of more than 7 damage score were dead by cardiovascular disease. [Conclusions] For the more improving of vital prognosis and QOL, the restrain accumulation of damage by preventive medical care should be need in long term treatment of a SLE patient.

W33-2
Corticosteroid-sparing effect of hydroxychloroquine versus tacrolimus in patients with systemic lupus erythematosus
Masahiro Ayano1,2, Mitsuteru Akahoshi1, Yasutaka Kimoto1, Hiroki Mitoma1, Yojiro Arinobu1, Koichi Akashi1, Takahiko Horii1, Hiroaki Niio1
1Department of Medicine and Biosystemic Science, Kyushu University, 2Department of Immuno- and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Conflict of interest: None

[Object] The risk of developing cardiovascular events (CVD) in systemic lupus erythematosus (SLE) was evaluated using a multicenter registration study [Lupus registry of nationwide institution (LUNA)] in Japan. [Methods] We analyzed the presence or absence of CVD about 532 SLE patients. The relationship between cardiovascular event, blood test data, life history, medications and complications was retrospectively evaluated. [Results] We found 93 cases (17.5%) accompanied with CVD. Among the disease-related features the group of patients who had CVD showed significantly higher maximum dose of prednisolone in past (p<0.0095), lower hemoglobin level (p=0.0267), higher CRP value (p=0.0194), lower estimated glomerular filtration amount (eGFR) (p=0.0002), comorbidity of idiopathic necrosis of femoral head (p=0.0040), ovarian dysfunction (p=0.0175), comorbidity of diabetes (p<0.0001), fewer event of new skin rash (p=0.0087) and fewer event of hair loss (p=0.0074) compared to the group that had not CVD. The multi-variate analysis revealed that the predictive factors for CVD was eGFR (OR: 0.985, 95% CI: 0.974-0.997, p=0.0120) and diabetes (OR: 2.453, 95% CI: 1.112-5.409, p=0.0319). [Conclusions] The risk of developing CVD in SLE of LUNA registry was consistent with the results reported in other countries.
Graduate School of Medical Sciences, Fukuoka, Japan, 1Department of Stem Cell Biology and Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 2Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 3Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

Conflict of interest: None

[Object] This study aimed to compare the corticosteroid-sparing effect of hydroxychloroquine (HCQ) with tacrolimus (TAC) in patients with systemic lupus erythematosus (SLE). [Methods] The subjects of this study were 66 SLE patients who received HCQ or TAC from September 2015 to March 2018. We assessed changes in doses of prednisolone, SLEDAI score and serum C3 and anti-dsDNA levels, and examined continuation rates and adverse effects. [Results] 42 and 23 SLE patients received HCQ and TAC, respectively. At baseline, SLEDAI score and use of other immunosuppressive agents in HCQ groups were significantly higher than in the TAC groups. The median daily dose of prednisolone was reduced from 9 mg at baseline to 8.25 mg at 6 months and 8 mg at 12 months in HCQ group (p<0.001), whereas the dose was reduced from 10 mg at baseline to 9 mg at 6 months and 9 mg at 12 months in TAC group (p=0.10). The SLEDAI score and serological markers improved remarkably similarly in both the groups. The continuation rate at 12 months was 82.3 and 78.6%, respectively. Adverse events with discontinuation of treatment were almost the same between the groups. [Conclusions] The both HCQ and TAC showed high efficacy in mild active SLE patients. Corticosteroid-sparing effect of HCQ might be superior to TAC.

W33-4
Efficacy of hydroxychloroquine (HCQ) and experience of HCQ monotherapy in our hospital

Masanobu Horikoshi1, Akari Kato1, Teppei Kamikawa1, Yuichi Handa1, Teruchika Yamada2, Akinari Mizokami2, Toshiyuki Aramaki1, Yukitaka Ueki1, Mizuna Otsuka1, Momoko Okamoto1, Yushiro Endo1, Sosuke Tsuji1, Ayuko Takatani1, Yoshimasa Shimizu1, Remi Sumiyoshi1, Tomohiro Koga1, Shin-ya Kawashiri1, Naoki Iwamoto1, Takashi Igawa1, Mami Tama1, Hideki Nakamura1, Tomoki Origuchi1, Atsushi Kawakami1

1Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Preventive Medicine, Nagasaki University Graduate School of Biomedical Sciences, 2Department of Rheumatology, JCHO Isahaya General Hospital, 3Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, 4Division of Physical Therapy, Nagasaki University School of Health Sciences

Conflict of interest: None

[Object] To examine the details of cases in which hydroxychloroquine (HCQ) was administered to systemic lupus erythematosus (SLE). [Methods] Among the patients diagnosed as SLE in 1997 ACR classification criteria, 71 patients who received HCQ were analyzed. They were added during maintenance therapy for SLE. [Results] The average dose of prednisolone in the maintenance therapy was reduced (-1.25±4.56mg at 54 week (48 cases), and 7.5mg ±12.6mg at 104 week (21 cases). The serum complement C3 and C4 were increased (C3: 25.4 ± 18.1 mg/dL at 54 week, 8.95 ±32.3 mg/dL at 104 week, C4: 8.0 ±5.0 mg/dL at 54 week, 7.75 ±7.37 mg/dL at 104 week). Seven cases withdrew HCQ for drug rash, 1 case withdrew for general malaise, and 1 case withdrew for patient’s decision. [Conclusions] Additional administration of hydroxychloroquine is expected to reduce prednisolone without flare of the disease activity of SLE. Conflict of interest: No
day and 37 days observation. We collected patients reported safety outcome including eruption, itching sensation, fever, vomiting, nausea, diarrhea, cough every 2 weeks. [Results] Two patients (1 female and 1 male) were enrolled. Average age was 37.0 ± 21.2 years. At baseline, prednisolone dose was 2.5 ± 3.5 mg/day, 1 patient was additionally treated with mycophenolate mofetil 2000 mg/day and systemic lupus disease activity index was 1.0 ± 1.4. Over 75.5 ± 57.3 days observation, recurrence of skin eruption was not reported in all the patients. [Conclusions] Desensitization of HCV might be safe and future work should be performed to further verify our results.

W34-1 Reactivation of hepatitis B virus (HBV) in patients with HBV carrier-rheumatoid arthritis
Atsushi Hashimoto1, Toshihiro Matsui1, Fuminori Hirano2, Kenji Ichikawa1, Noriyuki Chiba3, Takao Sugiyama1, Ryutaro Matsumura1, Hiroshi Tsutani4, Atsushi Kaneko2, Masao Katayama5, Yukiko Sacki6, Akira Okamoto7, Eiichi Suzumura8, Shigeru Yoshizawa9, Yasuo Suenaga10, Koichiro Saida11, Yukitomo Urata12, Shigeto Tohma13
1Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, Sagamihara, Japan; 2National Hospital Organization Asahikawa Medical Center, Asahikawa, Japan; 3National Hospital Organization Hokkaido Medical Center, Sapporo, Japan; 4National Hospital Organization Morioka National Hospital, Morioka, Japan; 5National Hospital Organization Shimoshizu National Hospital, Yotsukaido, Japan; 6National Hospital Organization Chiba Higashi National Hospital, Chiba, Japan; 7National Hospital Organization Awaranational Hospital, Awaran, Japan; 8National Hospital Organization Nagoya Medical Center, Nagoya, Japan; 9National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan; 10National Hospital Organization Himeji National Hospital, Himeji, Japan; 11National Hospital Organization Kyushu Medical Center, Fukuoka, Japan; 12National Hospital Organization Fukusuka National Hospital, Fukuoka, Japan; 13National Hospital Organization Beppu Medical Center, Beppu, Japan; 14National Hospital Organization Miyakonojo Medical Center, Miyakonojo, Japan; 15Tusgaru General Hospital, Goshogawara, Japan; 16National Hospital Organization Tokyo National Hospital, Tokyo, Japan

Conflict of interest: Yes

[Object] Rheumatoid arthritis (RA) patients with hepatitis B virus (HBV) infection have higher risk for HBV reactivation. We investigated frequency of HBV reactivation in HBV carrier-RA patients and their usage of nucleoside analogues (NA). [Methods] We retrospectively analyzed HBV carrier (HBs antigen positive)-RA patients in 14 hospitals in Japan and so on. A patient with biologic therapy and a patient with salazosulfapyridine and iguratimod involved in reactivation. No patients died of HBV reactivation on the setting.

W34-2 Clinical features and human T-cell leukemia virus type 1 (HTLV-1) markers in HTLV-1-positive patients with rheumatoid arthritis during anti-rheumatic therapies; a retrospective cohort study
Kunihiro Umekita1, Yaoi Hashiba2, Yumi Kariya3, Ayako Aizawa4, Chihiro Iwao5, Kosho Iwao6, Mao Rikitake7, Takeshi Kawaguchi8, Motohiro Matsu9a, Kazuyoshi Kubo10, Shunichi Miyayama11, Katoko Takajo12, Ichiro Takajo13, Toshihiko Hidaka14, Akihiko Okayama15
1Institute of Rheumatology, Infectious Diseases and Laboratory Medicine, Internal Medicine, University of Miyazaki; 2Zenjinkai Shinmin-no-Mori Hospital

Conflict of interest: None

[Object] HTLV-1 proviral load (VL) was quantified in HTLV-1-seropositive RA patients. [Methods] HTLV-1 infection was screened and confirmed in 365 RA patients. Twenty-three HTLV-1-positive RA patients were included in the study cohort. Blood samples were obtained from these patients at each observation time point. The values of HTLV-1 proviral load (PVL) and serum soluble IL-2 receptor (sIL-2-R) were measured. [Results] The median value of HTLV-1-positive patients was 3.3 fold higher than those of HTLV-1-negative patients with RA (P = 0.02). Three HTLV-1-positive RA patients showed a high PVL value which is known as one of risk factors of ATL development. No remarkable changes were observed in the PVL and sIL-2R values during the observation period. The PVL values in two patients who had a high PVLs were more likely to decrease after withdrawal from MTX. [Conclusions] Although it remains unclear whether anti-rheumatic therapies affect HTLV-1 infection, a through clinical assessment of developing ATL may be necessary in daily clinical practice for RA patients in HTLV-1-endemic areas in Japan.

W34-3 The time-sequence changes of human T-cell leukemia virus type 1 (HTLV-1) markers in HTLV-1-positive patients with rheumatoid arthritis
Katsumi Eguchi1, Toshihiro Matsui1, Kaoru Terada1, Toshiyuki Aramaki1, Yoshika Tsuji1, Atsushi Kawakami2, Kazuhiko Inokuma3, Yuichi Handa9, Hiroyuki Hagiyama10, Yoshinobu Koyama11, Kaoru Arii12, Yoshinori Urushitani13, Yukihiko Ikeno14, Takeshi Suzuki15, Masatoshi Kodaya1, Atsushi Omoto1, Shigekyo Inokuma16,17, Daigo Taniguchi18
1Center for Rheumatic Disease, Japanese Red Cross Kyoto Daichi Hospital; 2Department of Rheumatology, Nagaoka Red Cross Hospital; 3Department of Rheumatology, Osaka Red Cross Hospital; 4Department of Orthopedics, Fuku Red Cross Hospital; 5Department of Rheumatology, Matsuyama Red Cross Hospital; 6Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital; 7Department of Orthopedics, Nagano Red Cross Hospital; 8Department of Internal Medicine, Fukuoka

Conflict of interest: None

[Object] To investigate the time-sequence changes of human T-cell leukemia virus type 1 (HTLV-1) markers, which are risk factors for ATL development, in HTLV-1-positive rheumatoid arthritis (RA) patients. [Methods] HTLV-1 infection was screened and confirmed in 365 RA patients. Forty patients (33.6%) had received no NA. HBV reactivation was found in 10 patients who all had taken no NA. Their RA therapies before reactivation were methotrexate (n=7), corticosteroids (n=5), tacrolimus (n=3) and so on. A patient with biologic therapy and a patient with salazosulfapyridine and iguratimod involved in reactivation. No patients died of HBV reactivation on the setting.

W34-4 Effectiveness of prophylactic administration of nucleic acid analogs for hepatitis B virus reactivation under immunosuppressive treatment in rheumatoid arthritis patients with persistent infection
Wataru Fukuda1, Tadamasa Hanyu2, Masaki Katayama3, Shinichi Mizuki4, Toshiyuki Kitaori5, Akitomo Okada6, Masatoshi Hayashi7, Masayuki Miyata8, Yuichi Handa9, Hiroyuki Hagiyama10, Yoshinobu Koyama11, Kaoru Arii12, Yoshinori Urushitani13, Yukihiko Ikeno14, Takeshi Suzuki15, Masatoshi Kodaya1, Atsushi Omoto1, Shigekyo Inokuma16,17, Daigo Taniguchi18
1Department of Rheumatology, Nagaoka Red Cross Hospital; 2Department of Rheumatology, Osaka Red Cross Hospital; 3Department of Rheumatology, Matsuyama Red Cross Hospital; 4Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital; 5Department of Orthopedics, Nagano Red Cross Hospital; 6Department of Rheumatology, Nagano Red Cross Hospital; 7Department of Orthopedics, Nagano Red Cross Hospital; 8Department of Internal Medicine, Fukuoka

Conflict of interest: None

[Object] HTLV-1 proviral load (VL) was quantified in HTLV-1-seropositive RA patients. [Methods] HTLV-1 VL in 83 patients were measured by real-time PCR. [Results] The median VL was 8.6 copies/1000PBMCs (range, 0-256.6). The median VL were significantly correlated with the titers of anti-HTLV-1 antibodies and counts of circulating lymphocytes. As compared with the group in th absence of comorbidities, the median VL were significantly higher in RA groups with bronchiectasis, malignancies, autoimmune diseases, and opportunistic infections. 

There were no differences in the VL among the kinds of biological DMARDs. Median VL in the patients treated with JAK inhibitor were preferentially distributed in the highest quartile. [Conclusions] These results indicated that seropositive RA patients comorbid for pulmonary diseases, autoimmune diseases, malignancies and opportunistic infections might have a higher HTLV-1 proviral loads. It seems likely that these comorbidities, and elevated anti-HTLV-1 antibody titer and circulating lymphocyte count might be clinically useful surrogate markers of HTLV-1 VL, resulting in a significantly high risk for ATL.
Red Cross Hospital, 1Department of Rheumatology, Saitama Red Cross Hospital, 2Department of Rheumatology, Yokohama-City Bay Red Cross Hospital, 3Department of Internal Medicine, Japanese Red Cross Kochi Hospital, 4Department of Rheumatology, Matsue Red Cross Hospital, 5Department of Orthopedics, Japanese Red Cross Kyoto Daini Hospital, 6Department of Rheumatism, Musae Red Cross Hospital, 7Department of Allergy and Rheumatic Diseases, Japanese Red Cross Medical Center, 8Department of Allergy and Rheumatology, Chiba Central Medical Center, 9Department of Rheumatology, Okayama Red Cross Hospital

Conflict of interest: None

[Object] Immunosuppressive therapy (IST) should be avoided in hepatitis B virus (HBV) persistently infected patients with RA, and prophylactic nucleic acid analogue (NA) administration is recommended when the therapy is inevitable. We investigated the effectiveness of NA by phylactic nucleic acid analogue (NA) administration is recommended for hepatitis B virus (HBV) persistently infected patients with RA, and prophylactic nucleic acid analogue (NA) administration is recommended when the therapy is inevitable. We investigated the effectiveness of NA by 1Department of Clinical Immunology and Rheumatology/Infectious Diseases, Kyushu University, 2Department of Internal Medicine, Kyushu University, 3Department of Epidemiology, Kyushu University, 4Department of Medical Education, Faculty of Medical Sciences, Kyushu University

Conflict of interest: None

W34-5
A case of intracranial varicella zoster virus vasculopathy difficult to distinguish from neuropsychiatric systemic lupus erythematosus
Tomofumi Tatsutani1, Shoichiro Inokuchi1, Yojiro Arinobu1, Koji Mishima1, Masahiro Ayano1, Yasutaka Kimoto2, Hiroki Mitoma2, Mitsuteru Akahoshi3, Koichi Akashi3, Takahiko Horiiuchi3, Hiroaki Nito2
1Department of Clinical Immunology and Rheumatology/Infectious Disease, Kyushu University, 2Department of Internal Medicine, Kyushu University, 3Department of Medical Education, Faculty of Medical Sciences, Kyushu University

Conflict of interest: None

[Case] The patient was an 18-year-old female diagnosed with SLE at 6-year-old and has been treated with combination of immunosuppressive drugs. Two months before she visited our hospital, she presented headache, vomiting and symptoms of cranial nervous disorder. Head MRI showed multiple white matter hyperintensities on T2WI/FLAIR and inter leukin-6 levels in cerebrospinal fluid (CSF) were elevated. She was diagnosed as neuropsychiatric SLE, and treated with corticosteroid pulse therapy and intravenous cyclophosphamide pulse therapy. However, she developed hydrocephalus and disturbance of consciousness. She was transferred to our hospital. The next day, she presented generalized tonic-clonic seizure. Intraventricular hemorrhage and exac terruption in the hydrocephalus was identified in head CT. Angiography showed multiple cerebral aneurysms. As VZV-DNA was detected in the CSF, she was diagnosed as VZV vasculopathy and treated with anti-herpes virus agents for seven weeks. [Discussion] Intracranial VZV vasculopathy is caused by reactivation of latent VZV within cranial nerves and characterized by vessel wall damage and aneurysm. As the clinical manifestations of intracranial VZV vasculopathy may be resemble with that of NPSLE, careful diagnosis should be warranted.

W34-6
A case of Mycoplasma haemohominis infection, which is the second case in the world that exhibits the pathology of SLE and has been diagnosed with the next generation sequencer
Takahiro Tokunaga, Sho Ishii, Ryo Ynai, Yoko Miura, Tsuyoshi Kasama
Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

Conflict of interest: None

A 56-year-old woman. Spotted or patchy erythema appeared one week after traveling to Australia, and it extinguished in 5 days. After that, intermittent fever lasted for 2 months. Physical findings were cheek erythema, lymph node, hepatosplenomegaly. Progressive pancytopenia, liver injury, ANA40 times (SPECKLED, cytoplasmic) Anti-dsDNA antibody 93.4U/ml Anti-Sm antibody24.3U/ml Anti-cardiolipin antibody 22U/ml Anti mitochondrial M2 antibody19.2U/ml SMA80 times, urinray showed 0.62g/Cr granular cylinder. Five were met in SLE (1997 ACR) and seven in SLICC (2012). Bone marrow revealed HPS and plasma cell, and liver biopsy showed AHI. We started steroid therapy for HPS by SLE, but it was poor. Despite having no hemorrhagic diathesis, it became a hemorrhagic shock after liver biopsy and died. Fever and skin rash were observed in a needle sticking at the time of liver biopsy, infection was suspected and metagenon analysis of urine revealed 16S rRNA of Mycoplasma haemohominis in both patients. It is an infectious cause hemolytic anemia in cats, but the patholo gy in humans is unclear. There has been one report from the UK, this example is the second report in the world. We report a case of Mycoplasma haemohominis infection with pathology of SLE.

W35-1
Prevention of osteoporosis in patients with rheumatic diseases using steroids
Hideshi Yamazaki, Tetsuo Takanashi
Center for Rheumatic Disease, Marunouchi Hospital

Conflict of interest: None

[Object] We examined osteoporosis status in steroid-treated patients to investigate preventive effects of steroids on osteoporosis and their effects in rheumatic disease patients. [Methods] Patients with rheumatic diseases using steroids in 2017 were investigated with regard to steroid dosage, osteoporosis treatment, treatment contents, bone mineral density (BMD), fracture occurrence, and preventive effect on osteoporosis. [Results] In total, 391 steroid-treated patients, 27-94 years old (mean 71 years), 309 with rheumatoid arthritis, 43 with polymyalgia rheumatica, and 29 other cases. Steroid dosage was 1-30 mg (average 4.9 mg) in terms of prednisolone. There were 262 cases of osteoporosis treatment, 47 with steroid withdrawal, and 82 untreated cases. Osteoporosis treatment consisted of bisphosphonate in 169 cases, active vitamin D3 in 47, denosumab in 23, and other drugs in 33. Average BMD was 92.6% for lumbar YAM and 74.9% for the femur. Bone fractures occurred in 91 cases (23.2%). [Conclusions] Preventive measures against osteoporosis for rheumatic diseases during steroid therapy in daily clinical practice are insufficient. It is necessary to reduce steroids and review osteoporosis drugs for interventional patients.

W35-2
Protective efficacy for glucocorticoid induced osteoporosis of bisphosphonate
Takao Sugiyama, Toyohiko Sugimoto, Chisaki Ajima, Yusuke Yokoyama, Mieko Yamagata, Ayako Norimoto, Yoshie Sanayama, Masaaki Furukawa
Department of Rheumatology, National Hospital Organization Shimoshi zu National Hospital

Conflict of interest: None

[Object] The glucocorticoid induced osteoporosis (GIO) cause vertebral fracture (VF) and is a serious problem on glucocorticoid (GC) therapy. Lately, aggressive prophylaxis of the bisphosphonate (BP) is recommended. We confirm effect of BP on GIO and adverse reaction of BP in a long term. [Methods] We observed 127 patients who started GC therapy (≧PSL20mg/day) and BP at the same time, and whose bone density (BD) was inspected before and during therapy. 19 patients were men, and 108 women. The age of them was 58.1 y.o. and, they started PSL 34.3mg and was observed for 83.1 months after treatment, in average. We examined a change of YAM (BMD), fracture occurrence, and preventive effect on osteoporosis. [Results] The study population consisted of 391 steroid-treated patients, 27-94 years old (mean 71 years), 309 with rheumatoid arthritis, 43 with polymyalgia rheumatica, and 29 other cases. Steroid dosage was 1-30 mg (average 4.9 mg) in terms of prednisolone. There were 262 cases of osteoporosis treatment, 47 with steroid withdrawal, and 82 untreated cases. Osteoporosis treatment consisted of bisphosphonate in 169 cases, active vitamin D3 in 47, denosumab in 23, and other drugs in 33. Average BMD was 92.6% for lumbar YAM and 74.9% for the femur. Bone fractures occurred in 91 cases (23.2%). [Conclusions] Preventive measures against osteoporosis for rheumatic diseases during steroid therapy in daily clinical practice are insufficient. It is necessary to reduce steroids and review osteoporosis drugs for interventional patients.
W35-3
Efficacy and safety of sodium RISedronate for glucocorticoid-induced osteoporosis with rheumatoid arthritis (RISOTTO study): a multicenter, double-blind, randomized, placebo-controlled trial
Yuichiro Fujieda1, Tetsuya Horita2, Kazuhide Taninuma3, Yoshihito Amasaki4, Hideki Kasahara5, Shin Furukawa6, Tsuyoshi Takeda7, Shinji Fukaya8, Kazuo Matsui9, Akira Sagawa10, Kou Katayama11, Koaru Takeuchi12, Kazuaki Katsumata13, Takashi Kurita14, Masaru Kato15, Kenji Oku16, Shinshuke Yasuda17, Norimasa Iwasaki18, Tatsuya Amumi19
1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University, 2Internal Medicine, Tomakomai City Hospital, 3Hokkaido Medical Center for Rheumatology, 4Teine Keijinkai Hospital, 5Department of Rheumatology, NTT Sapporo Medical Center, 6Internal Medicine, Kushiro Red Cross Hospital, 7Internal Medicine, Hokkaido Spinal Cord Injury Center, 83rd Department of Internal Medicine, Obihiro Kosei Hospital, 9Internal Medicine, Takikawa City Hospital, 10Sagawa Akira Rheumatology Clinic, 11Katayama Orthopedic Rheumatology Clinic, 12Aozora Takeuchi Internal Medicine Clinic, 13Department of Rheumatology, Teine Keijinkai Hospital, 14Internal Medicine, Kitami Red Cross Hospital, 15Department of Orthopaedic Surgery, Graduate School of Medicine and Faculty of Medicine, Hokkaido University
Conflict of interest: Yes
Object: Sodium Risedronate (RIS) is effective in the treatment of glucocorticoid-induced osteoporosis (GIO). However, the efficacy and safety of RIS for GIO with rheumatoid arthritis (RA) remains unclear. Methods: This 6 months randomized study of 19 centers tested the efficacy and safety of 75mg once-monthly oral RIS for treatment of GIO with RA patients. Ninety-nine patients were randomized to 2:1 and the results of 95 patients (RIS n=61), placebo-control (PB) n=34) were analyzed. The primary endpoint was the change from baseline in lumbar spine bone mineral density (L-BMD). The secondary endpoint was the change from baseline in femoral neck bone mineral density (F-BMD) and the occurrence of vertebral fractures. The incidence of adverse events was evaluated. Results: The change of L-BMD in RIS group was significantly higher compared with PB group (RIS: 3.49% (95% CI: 1.92-5.05) vs PB: 0.12% (95% CI: -0.27-2.30), p <0.0001). There was no significant difference in F-BMD. Adverse events were observed in 28 patients (RIS: 19 (30.2%), PB: 9 (26.5%) without serious adverse events. In addition, non-traumatic vertebral fractures were identified in 10 patients (RIS: 6, PB: 4). Conclusion: RIS is effective for bone mineral augmentation and acceptable to patients for treatment of GIO with RA.

W35-4
A prospective, single-center, open-label, randomized-controlled study on drug therapy for the prevention of glucocorticoid-induced osteoporosis following teriparatide therapy in patients with collagen vascular diseases. Denosumab or Bisphosphonates?
Hirofumi Takei1, Yusuke Okada2, Akiko Shihata3, Kentaro Chino4, Takahiko Kurasawa5, Ayumi Okuyama6, Tsuneo Kondo7, Koichi Amano8
1Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Kawagoe, Japan
Conflict of interest: None
Object: Although bisphosphonates (BP) have been used for steroid-induced osteoporosis, there are some cases with insufficient response. Denosumab (DMAB) or teriparatide (TRPD) can be alternatives to BP. We prospectively compared the effects of DMAB and TPTD on bone mineral density (BMD) in patients who had been resistant to BP. Methods: Thirty six patients taking BP for steroid-induced osteoporosis whose YAM in lumbar spine or femoral neck less than 70% were examined. BP participants received alfacalcidol. The primary endpoint was Percent change in bone mineral density (BMD) of the lumbar spine and femoral neck and incident vertebral fracture and non-vertebral fracture at 12 months of treatment. Results: New vertebral fracture and non-vertebral fracture did not have both groups. Both groups decreased BMD of the lumbar spine and femoral neck from 12 months to baseline. Alendronate and denosumab treatment decreased serum level of TRACP-5b and BAP at 12 months. Conclusions: In patients treated with high-dose prednisolone, alendronate and denosumab suppressed bone turnover. But both treatment decreased BMD.
W36-1
Trajectories of EQ-5D in RA patients treated with biologics using the IORRA cohort
Kumiko Saka1, Eiichi Tanaka2, Eisuke Inoue3,2, Mai Abe4, Mika Kawano5, Eri Sugano6, Naohiro Sugitani7, Yoko Higuchi8, Moeko Ochiai9, Rei Yamaguchi10, Naoki Sugimoto11, Katsunori Ikari1, Ayako Nakajima12, Atsuo Taniguchi13, Hisashi Yamanaka1
1Department of Rheumatology, School of Medicine, Tokyo Women’s Medical University, 2St Marianna University, 3Mie University

Conflict of interest: None

[Objective] To identify subclasses with distinct trajectories of EQ-5D in RA patients who initiated biologics (BIO) and examine clinical features whose QOL improved after initiation of BIO use in daily practice. [Methods] The subjects were 785 RA patients who initiated BIO. We estimated the latent classes for the time trend of EQ-5D score for 3 years after initiation of BIO use. We estimated each patients’ latent class based on posterior probability. We compared clinical characteristics of each latent class. [Result] Clustering the 785 patients based on the time trend of the EQ-5D score, they were classified into four classes; Class1 (N=160): patients with persistent low EQ-5D score (EQ-5D stayed under 0.6), Class2 (N=314): patients with persistent moderate EQ-5D score (EQ-5D around 0.7), Class3 (N=229): patients whose EQ-5D score improved after BIO use (EQ-5D improved from 0.7 to 0.9), and Class4 (N=82): patients with persistent high EQ-5D score (EQ-5D stayed around 0.9). The patients in Class3 were younger (p=0.001), shorter disease duration (p=0.001), higher DAS28 (p=0.01), lower J-HAQ (p=0.038), and more frequent in non-steroid use (p=0.002) than those in Class2. [Conclusion] We elucidated clinical features of RA patients whose QOL improved after BIO use in daily practice.

W36-2
Using treat-to-target strategy by determining physical disability and glucocorticoid reduction strongly influence functional remission in rheumatoid arthritis
Takafumi Hagiwara, Kazuya Kamada, Noriyuki Namura
Department of Rheumatology, Takarazuka City Hospital

Conflict of interest: None

[Object] We aimed to determine the factors that inhibit the achievement of functional remission (FcR) in terms of HRQoL. [Methods] A total of 277 patients with RA who had undergone first treatment between October 2014 and December 2017 and had not changed/added another DMARDs for 12 weeks before the observation day were examined. We evaluated the HAQDI and EQ5DSL. FeR was defined in this study as HAQDI ≤ 0.5 and EQ5D ≥ 0.867. We investigated some factors at the first interview and the last observational day. The odds ratio for FeR was examined. [Results] Odds ratios were 1.034 (p=0.202) for disease duration (per 1 year), 1.576 (p=0.001) for HAQ-DI at first interview (per 0.5), 0.615 (p=0.232) and 4.943 (p=0.01) for GCs state, and 1.164 (p=0.05) for age at last observational day. [Conclusions] Our results indicated the importance of functional assessment at first interview and demonstrated how to use GCs for the treatment of RA. To achieve FeR, functional assessment should be performed during the first interview and short-term use of GC is useful for prompt functional recovery, in consideration of aging.

W36-3
Elderly in patients with rheumatoid arthritis affects aging of modified health assessment questionnaire independently of disease activity: TOMORROW study
Kazuki Orita1, Kentaro Inui2, Tadashi Okano2, Tatsuya Koike3, Masahiro Tada4, Yuko Sugioka5, Hiroaki Nakamura6
1Department of Orthopedics, Daito Chuo Hospital, 2Department of Orthopedics, Osaka City University, 3Department of Orthopedics, Osaka City General Hospital, 4Search Institute for Bone and Arthritis Disease (SINBAD), 5Center for Senile Degenerative Disorders (CSDD), Osaka City University Medical School

Conflict of interest: None

[Object] We investigated the change of mHAQ in RA patients and examined the relationship with disease activity. [Methods] We used RA patient data from 2010 (BL) to 2017 for TOMORROW study (a prospective cohort study of 208 patients with RA and 202 volunteers matching age and sex). DAS-CRP in BL was divided into three groups of low (<2.7), middle (2.7-4.1), high (4.1 ≤) and related to the change of mHAQ. Changes in mHAQ after 7 years (ΔmHAQ), correlation between Δ mHAQ and each BL factor and multivariate analysis with Δ mHAQ as the objective factor and each BL factor and variations as an explanatory factor were performed. [Results] mHAQ tended to increase over time. There was no significant correlation between Δ mHAQ and each BL factor. In the three group comparison, the mHAQ was significantly higher in the high group than in the other groups (p<0.001). In multivariate analysis using Δ mHAQ as a objective factor, age and BL-DAS using each BL factor as an explanatory factor were extracted and the change of BMI and DAS-CRP using each variation as an explanatory factor were extracted as independent factors. [Conclusions] The aging of mHAQ in patients with RA was independently associated with the aging as the disease activity fluctuated.

W36-4
Influence of the age of patients with rheumatoid arthritis on clinical joint assessments
Ayako Hirata, Takehisa Ogura, Norihide Hayashi, Takaharu Katagiri, Chiihiro Imaizumi, Yuki Inoue, Kenneso Usuizhina, Munetsugu Imamura, Sayaka Takenaka, Hideki Ito, Rie Kujime, Hideko Kameda
Toho University Ohashi Medical Center, Tokyo, Japan

Conflict of interest: None

[Object] To validate the clinical assessments of rheumatoid arthritis (RA) by using ultrasonography (US) as the gold standard in the current super-aged society. [Methods] Fifty RA patients (68 y/o in average) who underwent US examination for IP/PIP, MCP, hand, elbow, shoulder, knee and foot joints in addition to the questionnaire for the presence of subjective joint symptoms (spontaneous pain or stiffness) and the joint examination for the presence of tenderness and swelling were enrolled in this study. Each clinical assessment was evaluated for its sensitivity and specificity referring to the presence of US synovitis. [Results] The number of patients was as follows: 15 for the age <65, 20 for 65-75 and 15 for ≥75, respectively. Among a total of 1492 joints, the sensitivity and specificity were 49% and 90% for subjective symptoms, 32% and 93% for tenderness, and 44% and 93% for swelling, respectively. Joint swelling showed the best accuracy without the influence of patient age. By contrast, the specificity of subjective symptoms decreased to 82% in the age ≥75 group, and the sensitivity of tenderness was <30% except for the age ≥75 group (40%). [Conclusion] RA clinical assessments other than joint swelling were affected by the age of patients.

W36-5
Prediction for individual prognosis using big data in patients with rheumatoid arthritis
Susumu Nishiyama1, Tetsuji Sawada2, Tetsushi Aita2, Yasuhiyo Yoshinaga3, Shigeto Tohma4
1Rheumatic Disease Center, Kurashiki Medical Center, 2Department of Rheumatology, Tokyo Medical University Hospital, 3Department of Rheumatology, National Hospital Organization Tokyo National Hospital

Conflict of interest: None

[Object] To predict individual prognosis of patients with rheumatoid arthritis (RA) using big data. [Methods] Joint index vector V (x, y, z): x (upper limb index), y (lower limb index), z (large or small dominance) was calculated in each patients with RA registered in the National Data-base of Rheumatic Diseases in Japan (NinJa). Large joint dominant (LAR) group was defined as square root of (x2+y2) ≤ 0.1 & z > 0.2. Transformation matrix was computed from mean vector and its translation vector. [Results] Patients in the LAR group had high disease activity and poor physical function. (Positive Predictive Value, Negative Predictive Value, Likelihood Ratio) in predicting LAR group with estimated vector were (0.59, 0.85, 5.9) for all subjects, (0.61, 0.86, 7.2) for MTX users, (0.68, 0.82, 7.4) for bDMARDs users, and (0.68, 0.84, 8.6) for
both users. Of female patients with disease duration ≤ 10 years who were predicted in the LAR group with MTX therapy but in the non-LAR group with MTX and bDMARDs, 75% were actually entered in the non-LAR group with MTX and bDMARDs, while 53% with MTX therapy. [Conclusions] Joint index vector was useful tool for precision medicine using big data.

**W36-6**
Significance of body mass index as a prediction factor for treatment effect of biological disease modifying anti-rheumatic drugs in rheumatoid arthritis - Results from Kansai Consortium for Well-Being of Rheumatic Disease Patients
Kosaku Murakami1, Motomu Hashimoto2, Takashi Matsuo1, Koichi Murata1, Wataru Yamamoto1,2, Ryota Haro1, Masaki Katayama1, Akira Onishi1, Sadao Jinnouchi1, Tohru Takeuchi1, Yuko Sugioka2, Tatsuya Koike2, Hideki Arimura2, Toru Hirano1, Kosuke Ebina1, Kohei Nishitani1, Masao Tanaka2, Hiroto Ito2, Koichi Ohmura2, Tsuneo Mimori1
1Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, 2Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, 3Department of Health Information Management, Kurashiki Social Care Center, 4Center for Rheumatic Diseases, Nara Medical University, 5Department of Rheumatology, Osaka Red Cross Hospital, 6Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 7Department of Internal Medicine IV, Osaka Medical College, 8First Department of Internal Medicine, Kansai Medical University, 9Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine, 10Department of Orthopedic Surgery, Osaka University Graduate School of Medicine, 11Department of Orthopedic Surgery, Kyoto University Graduate School of Medicine

Conflict of interest: None

[Objective] To assess whether body mass index (BMI) affects clinical outcomes in rheumatoid arthritis (RA) patients starting a molecular-targeted agent. [Methods] From Kansai consortium for well-being of rheumatic disease patients (ANSWER) cohort, we analyzed RA patients who continued a bDMARD more than 6 months. Dividing these patients between BMI more than 24 (high BMI) or not (low BMI), we compared the achievement rate of Simplified Disease Activity Index Remission (SDAI-REM) defined as lower than 3.3. [Results] In each drug, patients number and SDAI-REM rate (low BMI, high BMI, p-value by Chi-square test) after 6 months was as follows; Infliximab (IFX, 73): 46%, 19%, p=0.0311; Etanercept (ETN, 93): 45%, 55%, not significant (NS); Adalimumab (ADA, 51): 33%, 47%, NS; Golimumab (GLM, 99): 36%, 35%, NS, Certolizumab pegol (CZP, 34): 17%, 60%, p=0.0115; Tocilizumab (TCZ, 147): 32%, 15%, p=0.042; Abatacept (ABT, 125): 26%, 21%, NS. [Conclusions] A contribution of BMI for therapeutic outcome seems to vary with each bDMARD in real world observation.

**W37-1**
Can the leucine-rich alpha-2-glycoprotein (LRG) detect ultrasound subclinical synovitis in patients with rheumatoid arthritis?
Yutaro Yamada1,2, Kentaro Inui1, Tadasu Okano1, Koji Mandai1,2, Kenji Mamoto1, Yuki Sugiooka1, Tatsuya Koike1, Hiroaki Nakamura2
1Department of Orthopedics, Osaka City University Graduate School of Medicine, 2Department of Orthopedics, Nara Medical University, 3Department of Orthopedics, Tohoku Medical and Pharmaceutical University Hospital, Sendai, 4Department of Rheumatology, Kurume University Graduate School of Medicine, 5Department of Rheumatology, Kurume, Japan, 6Department of Rheumatology, Tohoku University Graduate School of Medicine, 7Department of Rheumatology, Tohoku Medical and Pharmaceutical University Hospital, Sendai, 8Department of Rheumatology, Kurume University Medical Center, Kurume, Japan, 9Department of Rheumatology, Kurume University Medical Center, Kurume, Japan, 10Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 11Institution of Rheumatology, Zenjinkai Shimin-no-Mori Hospital, Myazaki, Japan, 12Department of Community Medicine, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 13Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 14Department of Rheumatology, Tenjinkai Koga Hospital 21, Kurume, Japan, 15Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 16Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan, 17Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, 18Community Medicine, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 19Department of Rheumatology, Nagasaki Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 20Department of Rheumatology, Tenjinkai Koga Hospital 21, Kurume, Japan

Conflict of interest: None

[Background] The subclinical synovitis (SS) can be detected by ultrasound (US) in CRP-negative patients with rheumatoid arthritis (RA). The new biomarker 'leucine-rich alpha-2-glycoprotein' (LRG) is known to be more sensitive to inflammation. [Objective] We investigated the utility of LRG in detecting SS. [Methods] We examined laboratory data in 34 patients with RA (27 female, average age 65.0). Their LRG level was also measured by ELISA method. They had US at bilateral MCP,PIP, wrist and MTP joints and are semi-quantitatively assessed by Grey Scale and Power Doppler score (GSUS, PDUS). We investigated the relationships between LRG and conventional inflammatory marker, disease activity, GSUS and PDUS. [Results] LRG was significantly correlated with CRP (r=0.69, p<0.001) and ESR (r=0.54, p=0.001), but not with DAS28-ESR (r=0.15, p=0.38) and PDUS (r=0.06, p=0.73). 12 patients had SS. Among those with or without SS, CRP was 0.21±0.22, 0.53±1.04mg/dl (p=0.29), ESR was 21.9±25.8, 17.3±12.7mm/h (p=0.49), LRG was 64.7±17.6, 68.4±19.4ng/ml (p=0.58), respectively. The cut-off value of LRG for predicting SS, defined as PDUS-1, was 63.5ng/ml (AUC 0.564) by ROC analysis, however kappa value of this was -0.15. [Conclusion] LRG cannot detect SS. This indicates the importance of US.

**W37-2**
Prognostic factors toward Health Assessment Questionnaire disabili-

ty progression in rheumatoid arthritis patients in clinical practice: A post hoc analysis of a nationwide longitudinal cohort in Japan
Remi Sumiyoshi1, Yoshihiko Hidaka2, Tomohiro Koga3, Akitomo Okada1, Takaaki Fukuda1, Tomonori Ishii1, Yukitaka Ueki1, Takao Kodera2, Munetoshi Nakashima1, Yuichi Takashashi1, Yoshiro Horai4, Ryu Watanebe1, Hiroshi Okuno1, Toshiyuki Aramaki1, Tomomasu Izu1,1, Oiwa Takeki4, Tatsutani4, Miyashita4,1, Shin-ya Kawashiri1,11, Naoki Iwamoto1, Kunihiro Ichinose1, Mami Tamai1, Hideki Nakamura1, Tonomi Oriuchi17,1, Kiyoshi Aoyagi11, Katsumi Eguchi13,1, Atsushi Kawakami1
1Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Institution of Rheumatology, Zenjinkai Shimin-no-Mori Hospital, Myazaki, Japan, 3Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, Nagasaki, Japan, 5Department of Rheumatology, Tenjinkai Koga Hospital 21, Kurume, Japan, 6Department of Hematology and Rheumatology, Tohoku University Hospital, Sendai, Japan, 7Rheumatic and Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Japan, 8Department of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University Hospital, Sendai, Japan, 9Department of Rheumatology, Kurume University Medical Center, Kurume, Japan, 10Yu Family Clinic, Miyagi, Japan, 11Department of General and Internal Medicine, Rheumatology, Clinical Research Center, National Hospital Organization, Nagasaki Medical Center, Omura, Japan, 12Department of Orthopaedic Surgery, Tohoku Rosai Hospital, Sendai, Japan, 13Department of Orthopaedic Surgery, Tohoku University Medical School, Sendai, Japan, 14Department of Rheumatology, Kurume University Medical Center, Kurume, Japan, 15Department of Rheumatology, Kurume, Japan, 16Department of Rheumatology, Tsukuba University Medical Center, Tsukuba, Japan, 17MiyaShita Rheumatology Clinic, Omura, Japan, 18Department of Community Medicine, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 19Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 20Department of Public Health, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 21Sasebo City General Hospital, Sasebo, Japan

Conflict of interest: None

[Object] To determine prognostic factors of progression of the Health Assessment Questionnaire (HAQ) scores in patients with rheumatoid arthritis (RA) in clinical practice. [Methods] Using data from a nationwide, multicenter, prospective study in Japan, we evaluated 408 RA patients with moderate to high disease activity at study entry after being treated with conventional synthetic DMARDs. These patients were treated according to a treat-to-target (T2T) strategy for 1 year. We performed a multiple logistic regression analysis to explore the factors to predict the progression of HAQ score at 1 year. [Results] During the observation, although the DAS28-ESR improved from 4.27 to 3.16, the progression of HAQ score was observed in 24.7% of the patients. The multiple logistic regression analysis revealed the independent variables to predict the HAQ progression were: time-integrated DAS28-ESR during the 1 year baseline >0.5 (OR=13.9, 95%CI 7.88-24.4). [Conclusions] Our data suggests that maintaining clinical improvement according to T2T and initiating the treatment at the early stage before ADL impairment are important for functional improvement after 1 year.
Estimation of the IFX conc to a certain extent was thought to be possible estimated by the time required for the colored line to appear. [Conclusion] 20 µg/mL and 20 s, indicating that the approximate IFX conc could be pear were 3 μg/mL and 100 s, 5 µg/mL and 70 s, 10 µg/mL and 30 s, and 268 s for 16.7-fold dilution. Subsequently, for the 19 patients, a graph was prepared with the actual measured IFX conc on the Y-axis and of 19.89 µg/mL. Next, the IFX concs of 19 patients and the time required dilution by a factor of 2, 4, 5, 6.7, and 16.7 of a patient with an IFX conc kit could be used to estimate IFX conc. [Methods] As a preliminary test, the time for the colored line to appear was measured for serum samples diluted by a factor of 2, 4, 5, 6.7, and 16.7 of a patient with an IFX conc of 19.89 µg/mL. Next, the IFX concs of 19 patients and the time required for the colored line to appear in the kit were measured to determine. [Results] The time required for the colored line to appear for patients in the preliminary test was 16 s for 1-fold dilution, 36 s for 2-fold dilution, 61 s for 4-fold dilution, 82 s for 5-fold dilution, 109 s for 6.7-fold dilution, and 268 s for 16.7-fold dilution. Subsequently, for the 19 patients, a graph was prepared with the actual measured IFX conc on the Y-axis and the time required for the colored line to appear on the X-axis. The graph showed that the IFX conc and the time required for the colored line to appear were 3 µg/mL and 100 s, 5 µg/mL and 70 s, 10 µg/mL and 30 s, and 20 µg/mL and 20 s, indicating that the approximate IFX conc could be estimated by the time required for the colored line to appear. [Conclusion] Estimation of the IFX conc to a certain extent was thought to be possible using the qualitative kit.

Discrepancy between the efficacy of biological RCT and the effectiveness in daily practice based on the IORRA cohort

Object: To investigate discrepancy between the efficacy of biological RCT and the effectiveness in RA patients in routine clinical practice based on the IORRA. [Method] The effectiveness of biologics (etanercept (n=33), golimumab (n=20), certolizumab (n=17), abatacept (n=14), and tocilizumab (TCZ, n=24)) in RA patients who initiated in 2016 was compared with the efficacy based on each RCT (total 8 trials). The effectiveness was evaluated by ACR achievement rates and remission rate at half a year after initiation of biologics. [Results] According to the MATSURI study (TCZ) whose inclusion criteria were not strict, eligible patients (n=13) indicated better effectiveness than those in non-eligible patients (n=11). In other 7 RCTs, there were almost no patients who fulfilled inclusion criteria in the IORRA. When compared under that condition, ACR achievement rate was higher in patients with RCTs, while remission rate was higher in patients in the IORRA. Average DAS28 at baseline in the RCTs group was significantly higher than that in the IORRA. [Conclusion] Although RA patients in RCT indicated better ACR achievement rate than those in routine practice, clinical remission was difficult to achieve. This might be due to the difference in disease activity at baseline.

The clinical significance of patient reported outcomes (PROs) in patients with rheumatoid arthritis (RA) under a treat-to-target (T2T) strategy

The clinical significance of patient reported outcomes (PROs) in patients with rheumatoid arthritis (RA) under a treat-to-target (T2T) strategy

Object: Patients with RA demonstrate circadian variations of symptom such as morning stiffness or increased cytokine’s production around mid-night, and we have reported influences of clock genes on the pathogenesis of RA. In this study, we compared the variation of clock genes’ expressions in leukocytes by treatments with biological DMARDs (bDMARDS), and evaluated the relationship with the disease activity. Methods: Total RNA was extracted from leukocytes to examine expressions of clock genes (Bmal1, Clock, Per1,2, Cry1,2) and clock controlled genes (Dbp, Hif, Tef, E4bp4, Rora, Rorγ, Rev-erba) by Real-time PCR. Blood samples was collected before and after the study end-point; DAS28-ESR<3.2. 15 RA patients treated with bDMARDS were enrolled in this study; TNF inhibitor (TNFi: 5), Tocilizumab (TCZ: 5), Abatacept (ABT: 5). Results: At the end points, expressions of Clock were increased (TNFi; p=0.064, TCZ; p=0.076, ABT; p=0.01), expressions of Per2 were increased (TNFi; p=0.055, TCZ; p=0.05, ABT; p=0.01), and expressions of Rora were increased (TNFi; p=0.075, TCZ; p=0.098, ABT; p=0.05), as compared with those before treatments. Conclusions: Results indicated that Clock, Per2 and Rora could be useful as a biomarker to represent the therapeutic response for bDMARDS or the disease activity in RA.

Long term Efficacy and Safety Results from the Phase 2b/3 Randomized, Placebo-controlled, Double-blind trial of Upadacitinib, a JAK-1 Selective inhibitor in Japanese Patients with Active Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic DMARDs

In this study, we compared the variation of clock genes’ expressions in leukocytes by treatments with biological DMARDs (bDMARDS), and evaluated the relationship with the disease activity. Methods: Total RNA was extracted from leukocytes to examine expressions of clock genes (Bmal1, Clock, Per1,2, Cry1,2) and clock controlled genes (Dbp, Hif, Tef, E4bp4, Rora, Rorγ, Rev-erba) by Real-time PCR. Blood samples was collected before and after the study end-point; DAS28-ESR<3.2. 15 RA patients treated with bDMARDS were enrolled in this study; TNF inhibitor (TNFi: 5), Tocilizumab (TCZ: 5), Abatacept (ABT: 5). Results: At the end points, expressions of Clock were increased (TNFi; p=0.064, TCZ; p=0.076, ABT; p=0.01), expressions of Per2 were increased (TNFi; p=0.055, TCZ; p=0.05, ABT; p=0.01), and expressions of Rora were increased (TNFi; p=0.075, TCZ; p=0.098, ABT; p=0.05), as compared with those before treatments. Conclusions: Results indicated that Clock, Per2 and Rora could be useful as a biomarker to represent the therapeutic response for bDMARDS or the disease activity in RA.
bVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 1The First Department of Internal Medicine, University of Occupational and Environmental Health

Conflict of interest: Yes

[Object] Long-term efficacy and safety of upadacitinib (UPA) in Japanese patients (pts) with active RA and inadequate response to conventional synthetic DMARDs (csDMARDs-IR). [Methods] Pts on stable cs-DMARDs were randomized to receive UPA 7.5, 15 or 30 mg once daily or placebo (PBO) (upto Wk12, PBO thereafter) in a blinded manner. Reported here are safety and efficacy outcomes (ACR, DAS28 [CRP] responses) at Wk60 (as observed analysis). [Results] Of 197 pts treated, 156 (79.2%) completed Wk60. Proportion of pts (15mg, Wk60, as observed) - ACR20 and DAS28-CRP≤3.2, both 88%; ACR50: 67%; ACR70: 51%; DAS28-CRP<2.6: 72%. Responses with all doses were improved or maintained through Wk60. Frequencies of TEAEs, serious/opportunistic infections, herpes zoster, lymphopenia, neutropenia and CPK elevation were highest in the 30mg arm. Upto Wk60, 2 deaths (30mg, 1 TEAE respiratory failure), 2 malignancies (15 mg, ALL; 30mg, Hodgkins disease: 1 each), 2 MACE events (7.5mg, cerebral infarction; 30mg, respiratory failure: 1 each), 1 DVT event (30mg) and no cases of tuberculosis were recorded. [Conclusions] Through Wk60, all 3 doses of UPA were effective in treating signs and symptoms of RA. The overall safety was consistent with global UPA trials in RA.

W38-4
RAJ3: Efficacy and safety of peficitinib (ASP015K), a novel oral JAK inhibitor, in patients with RA who had an inadequate response to DMARDs
Yoshiya Tanaka1, Tsutomu Takeuchi1, Sakae Tanaka2, Atsushi Kawakami3, Yeong-Wook Song4, Yi-Hsing Chen5, Hiroyuki Izutsu6, Yuichiro Kaneko7
1University of Occupational and Environmental Health, 2Keio University School of Medicine, 3University of Tokyo, 4Nagasaki University, 5Seoul National University, Korea, 6Taichung Veterans General Hospital, Taiwan, 7Astellas Pharma, Inc.

Conflict of interest: Yes

[Object] To assess efficacy and safety of switching to UPA monotherapy vs continuing methotrexate (MTX) as a blinded study drug in MTX intolerant responders. [Methods] Pts received (1:1:1) once-daily UPA 15 or 30mg monotherapy or continued MTX (cMTX) at prior stable dose. Primary endpoints at Wk 14 were pts achieving ACR20 or DAS28-CRP<3.2. [Results] All 648 randomized pts, including 65 Japanese pts, were treated; 92.3% completed 14 wks. Primary and key secondary endpoints were met (p<0.001). At Wk 14, significantly more pts on UPA 15 and 30 vs cMTX achieved ACR20 (67.7% and 71.2% vs 41.2%), and DAS28-CRP<3.2 (44.7% and 53.0% vs 19.4%). AEs were reported at similar rates across arms; serious AEs were higher on UPA15 but similar between cMTX and UPA 30. More infections were reported in cMTX and UPA30 vs UPA15. Herpes zoster was highest on UPA 30. 3 malignancies (cMTX:1; UPA15: 2), 3 adjudicated MACE (UPA15: 1; UPA 30: 2), 1 adjudicated PE (UPA 15), 1 death (UPA15: stroke due to ruptured aneurysm) were reported. Lab abnormalities were consistent with prior UPA studies. [Conclusions] In MTX-IR pts, switching to UPA monotherapy showed significant improvements vs continuing MTX. Safety was similar to prior UPA studies.

W38-3
Upadacitinib as Monotherapy: A Phase 3 Randomized Controlled Double-Blind Study in Patients with Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Yoshiya Tanaka1, Josef S Smolen2, Stanley Cohen3, Paul Emery4, William Rigby5, Ying Zhang6, Alan Friedman7, Ahmed A Othman8, Heidi S Camp9, Aileen L Pangan9
1The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, 2Medical University of Vienna, Austria, 3Metroplex Clinical Research Center, TX, USA, 4Leeds Inst of Rheumatic & Musculoskeletal Medicine, Leeds NIHR BRC, UK, 5Dartmouth College, NH, USA, 6AbbVie Inc., North Chicago, IL, USA

Conflict of interest: Yes

[Object] Compare safety/efficacy and inhibition of structural damage with upadacitinib (UPA) monotherapy vs methotrexate (MTX) in MTX-naïve patients (pts). [Methods] Pts received (1:1:1) once-daily UPA 15mg, 30mg monotherapy, or weekly MTX. Primary endpoints were ACR20 at Wk12, or DAS28CRP≤2.6 at Wk24. [Results] 945/947 pts, in 15mg, 30mg monotherapy, or weekly MTX. Primary endpoints were met. ACR20 rates at Wk12 or earlier were 48.3% and 50.0% vs 18.5%. At Wk24, ΔmTSS were 0.14-0.28 vs 0.67 and more pts had no radiographic progression on 28CRP<2.6 (48.3% and 50.0% vs 18.5%). More pts on UPA vs MTX achieved LDA and remission. Rate of AEs and serious AEs were similar on UPA15 and 30mg vs MTX. More pts on UPA vs MTX achieved LDA or PBO (upto Wk12, UPA thereafter) in a blinded manner. Reported here are safety and efficacy outcomes (ACR, DAS28 [CRP] responses) at Wk60 (as observed analysis). [Results] Of 197 pts treated, 156 (79.2%) completed Wk60. Proportion of pts (15mg, Wk60, as observed) - ACR20 and DAS28-CRP≤3.2, both 88%; ACR50: 67%; ACR70: 51%; DAS28-CRP<2.6: 72%. Responses with all doses were improved or maintained through Wk60. Frequencies of TEAEs, serious/opportunistic infections, herpes zoster, lymphopenia, neutropenia and CPK elevation were highest in the 30mg arm. Upto Wk60, 2 deaths (30mg, 1 TEAE respiratory failure), 2 malignancies (15 mg, ALL; 30mg, Hodgkins disease: 1 each), 2 MACE events (7.5mg, cerebral infarction; 30mg, respiratory failure: 1 each), 1 DVT event (30mg) and no cases of tuberculosis were recorded. [Conclusions] Through Wk60, all 3 doses of UPA were effective in treating signs and symptoms of RA. The overall safety was consistent with global UPA trials in RA.

W38-5
RAJ4: Efficacy and safety of peficitinib (ASP015K), a novel oral JAK inhibitor, in patients with RA who had an inadequate response to methotrexate (MTX)
Tsunomo Takeuchi1, Yoshiya Tanaka2, Sakae Tanaka2, Atsushi Kawakami3, Hiroyuki Izutsu4, Yuichiro Kaneko5
1Keio University School of Medicine, 2University of Occupational and Environmental Health, 3University of Tokyo, 4Nagasaki University, 5Astellas Pharma, Inc.

Conflict of interest: Yes

[Object] To evaluate the efficacy and safety of peficitinib (PEF) when used alone or in combination with DMARDs for RA in patients who had an inadequate response (IR) to DMARDs. [Methods] This was a multicenter, randomized, placebo (PBO)-controlled, double-blinded study conducted in Japan, Korea and Taiwan. Patients with RA and an IR to DMARDs were randomized to either PBO (n=102), PEF 100 mg/day (PEF 100, n=104), PEF 150 mg/day (PEF 150, n=102), or etanercept 50 mg/wk (Open-label, n=201). At wk12, patients in the PBO were switched to PEF 100 or 150 under blinded condition. A stable dose of DMARDs throughout the 52-wk study were permitted to be taken for patients with DMARDs concomitantly. [Results] ACR20 response rate at wk12 or early termination was higher in the PEF 100 and 150 than in the PBO (p<0.001). The 12-wk safety outcome was similar among all groups, but serious adverse events were more common in the PBO. The incidence of serious infection and herpes zoster were higher in the PEF groups, with no clear dose-dependency. No deaths were reported during the study. [Conclusions] In patients with RA who had an IR to DMARDs, PEF 100 and 150 are effective in reducing symptoms. Compared with safety profile of PEF in previous studies, no additional safety concerns were identified.
Conflict of interest: Yes

[Object] To evaluate the efficacy and safety of peficitinib (PEF) when used in combination with MTX for RA in patients who had an inadequate response to MTX. [Methods] Patients with RA in Japan who had an inadequate response to MTX were randomized to either PBO (n=170), PEF 100 mg/day (PEF 100, n=175) or PEF 150 mg/day (PEF 150, n=174) concurrently with MTX at a stable dose (≤16 mg/week) during the 52-wk study. At wk12, patients who showed an inadequate response in the PBO group were switched to PEF 100 or 150, and those remaining were switched to PEF 100 or 150 at wk28 under blinded condition. [Results] ACR20 response rate at wk12/early termination (ET) was higher in the PEF 100 and 150 groups than in the PBO group (p<0.001). At wk28/ET, the mean change in modified Total Sharp Score was smaller in the PEF groups than in the PBO group (p<0.001). The incidence of serious infection and herpes zoster were higher in the PEF groups during the study, with no clear dose-dependency. [Conclusions] In patients with RA who had an inadequate response to MTX, PEF 100 or 150 taken concurrently with MTX reduced RA symptoms and prevented joint destruction. Compared with safety profile of PEF in previous studies, no additional safety concerns were identified.

W38-6 Characterization and changes of lymphocyte subsets in Baricitinib-treated patients with rheumatoid arthritis: an integrated analysis

Yoshiya Tanaka1, Tsutomu Takeuchi2, Iain McNenes1, Masaru Tanaka2, Yasushi Takita3, Nicole Byres4, Lei Chen5, Stephanie Bono6, Maher Issa7, William Macias8, Veronica Rogai9, Terence Rooney10, Douglas Schlitching11, Masayoshi Hara12, Paul Emery13
1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3University of Glasgow, Glasgow, UK, 4Eli Lilly K.K., Kobe, Japan, 5Eli Lilly and Company, Indianapolis, USA, 6Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 7Leeds MSK Biomed / Chapel Allerton Hospital, Leeds, UK

Conflict of interest: Yes

[Object] To evaluate changes in lymphocyte subsets during Baricitinib (Bari) treatment and association with infections. [Methods] An analysis was conducted by pooling data from 3 completed Phase 3 trials comparing placebo and Bari and 1 ongoing long-term extension study in 2186 patients (including 227 Japanese) with RA. [Results] Bari was associated with an early transient increase in total lymphocyte count at week 4, which returned to baseline by week 12. Up to week 104, transient changes were within normal reference ranges in T cell subsets were observed. B cells and subsets increased after 4 weeks with no further increases noted through 104 weeks. Natural killer (NK) cells transiently increased after 4 weeks, before decreasing below baseline levels and then stabilizing over time. A modest potential association was observed for Bari 4-mg between low NK cells and treatment emergent infections but not for serious infections or herpes zoster. No notable difference was observed for Japanese and overall. [Conclusions] Changes in lymphocyte subsets were largely within normal reference ranges, and were not associated with serious infections.

W39-1 Long-term Safety (up to 6 years) of Baricitinib (Bari) in Patients (pts) including Japanese (JP) with Moderate to Severe Active Rheumatoid Arthritis (RA): an Integrated Analysis

Masayoshi Harigai1, Tsutomu Takeuchi2, Josef S Smolen3, Kevin Winthrop4, Mark C Genovese5, Taeko Ishii6, Minako Sato7, Atsushi Nishikawa8, Yasushi Takita9, Terence Rooney10, Chris Dickson11, Yoshiya Tanaka12
1Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3Medical University of Vienna, Vienna, Austria, 4Oregon Health Sciences University, Portland, USA, 5Stanford University Medical Center, Palo Alto, USA, 6Eli Lilly Japan K.K., Kobe, Japan, 7Eli Lilly and Company, Indianapolis, USA, *The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

Conflict of interest: Yes

[Object] To evaluate long-term safety of Bari in pts with moderate to severe active RA including JP. [Methods] Incidence rates (IR per 100 patient-year [PY]) of adverse events (AEs) were calculated using data in the ALL BARI RA analysis set which included pts exposed to any Bari dose, and from completed phase 1-3 studies and an ongoing long-term extension study. [Results] 3492 pts (514 JP) were exposed to Bari for 7860 total PY (maximum exposure: 6 years) as of Apr 2017. Compared with previously reported (cut off Sep 2016), similar trend was observed in IRs of deaths (0.35), AEs leading to discontinuation (5.4), malignancies excluding non-melanoma skin cancer (0.8), major adverse cardiovascular events (0.5), serious infections (3.0), Herpes zoster (HZ) (3.3), lymphoma (0.08), GL perforation (0.04), tuberculosis (0.14), and pulmonary embolism and deep vein thrombosis (0.53). In JP, HZ (6.9) were more frequent than overall, but the HZ IR was similar to previously reported and stable with longer exposure and events were considered manageable. IRs of AEs except for HZ were not notably different from those in the previous report. [Conclusions] With longer exposure, Bari had an acceptable safety profile in pts with active RA as described in the previous report.

W39-2 Dose reduction of baricitinib for rheumatoid arthritis patients who achieved remission or low disease activity in real world data

Eiji Torikai, DaiSuke Suzuki
Department of Rheumatology, Iwata City Hospital

Conflict of interest: None

[Object] To investigate the effects of baricitinib (Bari) dose step down in patients who achieved remission (RMS) or low disease activity (LDA) with 4mg/day of Bari treatment. [Methods] We included 12 RA patients in RMS or LDA who received 4mg/day of Bari dose for >3months. They stepped down to 2mg/day and could rescue to 4mg/day if in flare-up. We evaluated the changes of disease activity and HAQ. [Results] At the start of Bari treatment, mean ages, disease duration, MTX dose, PSL dose, CDAI and HAQ were 62.0years, 3.03years, 7.64mg/week (91.7%) and 3.70mg/day (41.7%), 26.5 and 0.74 respectively. At the step-down of Bari, mean score of CDAI and HAQ were 4.63 and 0.21. Nine of 12 patients sustained RMS or LDA after the step down. Three patients who flared up could re-capture RMS or LDA after rescue. Although HAQ of them also deteriorate at flare-up (mean score: 0.50), they were improved after rescue (mean score: 0.29). No patient discontinued Bari due to adverse events. Three patients discontinued Bari because of sustained RMS. [Conclusions] Most patients could sustain RMS or LDA with step down therapy to Bari dose of 2mg/day in real world clinic. All patients who flared up could captured their previous status of the disease activity and HAQ.

W39-3 The Efficacy of baricitinib for patients with rheumatoid arthritis resistant to several other biologic agents

Tomofumi Kiyokawa, Yukiko Takakwa, Yoshihki Yamasaki, Takayasu Ando, Harunobu Iida, Yutaka Goto, Kanako Suzuki, Yusa Asari, Marina Uchida, Hisae Fujimoto, Kana Ishimori, Keiichi Sakurai, Hiromi Matsushita, Kumiko Tonooka, Mitsuru Imamura, Takeshi Suzuki, Hiroko Nagafuchi, Seido Ooka, Kimito Kawahata
Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kanagawa, Japan

Conflict of interest: None

[Object] To investigate the efficacy of baricitinib (BAR) for patients with rheumatoid arthritis (RA) resistant to several other biologic anti-rheumatic drugs (bDMARDs). [Methods] We retrospectively analyzed 6 patients with RA who were previously treated with several bDMARDs and showed resistance to those drugs and then switched to BAR from January to September 2018. Efficacy of BAR was evaluated at 12 weeks.
from the initiation of BAR. [Results] All 6 patients were female. Anti-CCP antibodies and rheumatoid factor were positive in all patients. The mean age of the patients was 64.7 year-old with mean disease duration of 13.9 years. The DAS28-ESR at the baseline was 4.83. Methotrexate (average dose of 6 mg/week) was used in 2 patients and prednisolone (average dose 2.7 mg/day) in 3. All six patients had previously treated with one or more tumor necrosis factor (TNF) and interleukin-6 (IL-6) inhibitors and therefore received three or more bDMARDs. DAS28-ESR at 12 weeks was 3.20, which was significantly lower than the baseline with a change of -1.63 (P = 0.046). [Conclusions] The significant improvement of DAS28-ESR was seen by BAR. BAR can be the candidate for RA patients who showed resistance to several other bDMARDs such as IL-6-IR and TNF-IR.

W39-4
Does the Efficacy of Tofacitinib depend on previous DMARDs?
Tsunoe Kondo, Yusuke Okada, Akiko Shibata, Kentaro Chino, Takahiko Kurasawa, Hiromi Otake, Koichi Amano
Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University

Conflict of interest: None

[Object] To elucidate whether the efficacy of tofacitinib (Tofa) is different among previous DMARDs in RA patients. [Methods] The medical records of 91 RA patients who had received Tofa and been followed up for more than 24 weeks were retrospectively evaluated. [Results] Female records of 91 RA patients who had received Tofa and been followed up for more than 24 weeks were retrospectively evaluated. [Results] Female

W39-5
7 RA patients passed more than one year after discontinuation of concomitant MTX by the treatment with tofacitinib (TOF)
Keio Ayabe, Akira Inoue, Takuro Okari
Keiyu Orthopedic Hospital Gunma Japan

Conflict of interest: None

[Objectives] We performed reducing and discontinuation of MTX for RA patients good in progress out of the concern such as decline in age of the renal function, pulmonary obstacles, other many complications or lymphoproliferative disorders in Keiyu Orthopedic hospital from several years ago. We reduced and discontinued concomitant MTX for the patients under treatment with biologics and JAK inhibitor equally in progress if good. This study aims to evaluate the effect of tofacitinib (following TOF) for RA patients after discontinuation of concomitant MTX. [Methods] Seven of 34 RA patients passed more than three years after the initiation of the treatment with TOF by August, 2015 from December, 2013 apply in Keiyu Orthopedic Hospital. The seven patients (5 males 4 females; mean age:68.7 years old) passed more than one year after discontinuation of concomitant MTX by the treatment with TOF. We examined the progress such as changes of the disease activity and laboratory data for them. [Results] Mean DAS28CRP was improved (baseline/3 years after dosage: 3.3/2.1) inspite of discontinuation concomitant MTX. [Conclusions] Tofacitinib is the drug which can reduce and discontinues concomitant MTX.

W40-1
Chronic damage in elderly-onset ANCA-associated vasculitis
Keiji Ohashi, Ken-ei Sada, Yosuke Asano, Keigo Hayashi, Yuriko Yamamura, Sumie Asano Hiramatsu, Michiko Morishita, Haruki Watanabe, Mariko Narazaki, Yoshinori Matsumoto, Tomoko Kawabata, Jun Wada
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Conflict of interest: None

Background: Characteristics of chronic damage in patients with elderly onset antineutrophil cytoplasmic antibody-associated vasculitis (AAV) are not fully elucidated. Method: Thirty-two patients with microscopic polyangiitis or granulomatosis with polyangiitis, diagnosed and treated at Okayama University Hospital from 2009 to 2013, were enrolled. The patients were divided into two groups based on age of onset: elderly onset group, onset ≥70 years; control group, onset <70 years. We compared the Vasculitis Damage Index (VDI) at 18-24 months after the initiation of treatment between two groups. Result: Mean age of elderly onset and control group were 77 and 61 years, respectively. There was no significant difference in sex, type of vasculitis, disease activity at baseline and total VDI. As for each organ damage, elderly onset group had significantly higher score in musculoskeletal (0.35 vs 0, p = 0.013) and neuropsychiatric involvement (0.65 vs 0.20, p = 0.05) than control group. Significant muscle atrophy or weakness in musculoskeletal and ‘peripheral neuropathy’ in neuropsychiatric damage were the most frequent items. Conclusion: More rapid tapering of glucocorticoids and earlier initiation of rehabilitation might be required for patients with elderly onset AAV highly.

W40-2
Clinical significance of podocyte foot process effacement in ANCA-associated vasculitis
Yoshinobu Fuke1, Yusuke Murata1, Seiichiro Hemmi1, Takamasa Nozaki2, Noboru Kitamura2, Takayuki Fujita1, Masami Takei1, Masanori Abe1
1Division of Nephrology, Hypertension and Endocrinology, Niho University, School of Medicine, Tokyo, Japan, 2Division of Hematology and Collagen Disease, Niho University, School of Medicine, Tokyo, Japan, 3Department of Nephrology and Blood Purification, Yokohama Chuo Hospital

Conflict of interest: None

[Object] ANCA-associated vasculitis (AAV) is characterized by necrotizing lesions and crescent formations in kidney, frequently leading to rapidly progressive glomerulonephritis. Podocyte injury is well known to involve in the pathogenesis of urinary protein (UP) and glomerulosclerosis in various glomerular diseases, however few studies have been assessed in AAV. This study aims to provide clinical significance of podocyte foot process effacement (FPE) in AAV. [Methods] 27 adults with AAV were studied. FPE rates were calculated by FPE length/GBM length×100 (%) on electron micrograph. We analysed relationships between FPE rate and, laboratory and renal pathological findings. [Results] Mean FPE rate was 42.2±13.4%. FPE rate was correlated with UP (r=0.615, p<0.001), and negatively with Ccr (r=−0.496, p<0.005). There was strong correlation between FPE rate and global sclerotic glomeruli+crescentic glomeruli/all glomeruli rate (r=0.750, p<0.001). In Histopathologic classification of ANCA-associated glomerulonephritis, FPE rate of focal class (n=12: 33.8±10.8) was significantly lower than, crescentic class (n=4: 53.4±11.1) and mixed class (n=10:45.2±10.0) (p<0.05). [Conclusions] Expanded FPE suggesting podocyte injury might involve progression of the renal injury and the prognosis in AAV.

W40-3
Evaluation of clinical and pathohistological features of renal biopsy proven ANCA associated vasculitits: single center study
Taro Horino, Satoshi Inotani, Tatsuki Matsumoto, Yoshiko Shimamura, Kosuke Inoue, Yoshio Terada
Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University

Conflict of interest: None

[Object] ANCA-associated vasculitis (AAV) is characterized by necrotizing lesions and crescent formations in kidney, frequently leading to rapidly progressive glomerulonephritis. Podocyte injury is well known to involve in the pathogenesis of urinary protein (UP) and glomerulosclerosis in various glomerular diseases, however few studies have been assessed in AAV. This study aims to provide clinical significance of podocyte foot process effacement (FPE) in AAV. [Methods] 27 adults with AAV were studied. FPE rates were calculated by FPE length/GBM length×100 (%) on electron micrograph. We analysed relationships between FPE rate and, laboratory and renal pathological findings. [Results] Mean FPE rate was 42.2±13.4%. FPE rate was correlated with UP (r=0.615, p<0.001), and negatively with Ccr (r=−0.496, p<0.005). There was strong correlation between FPE rate and global sclerotic glomeruli+crescentic glomeruli/all glomeruli rate (r=0.750, p<0.001). In Histopathologic classification of ANCA-associated glomerulonephritis, FPE rate of focal class (n=12: 33.8±10.8) was significantly lower than, crescentic class (n=4: 53.4±11.1) and mixed class (n=10:45.2±10.0) (p<0.05). [Conclusions] Expanded FPE suggesting podocyte injury might involve progression of the renal injury and the prognosis in AAV.
Conflict of interest: None

[W40-4] Urinary inflammatory cell analysis reflects the renal histopathology in ANCA-associated vasculitis
Masanori Sudo, Yoko Wada, Ayako Wakamatsu, Yukiko Nozawa, Hiroe Satō, Daisuke Kobayashi, Takeshi Nakatsuie, Takeshi Kuroda, Masaaki Nakano, Ichiei Narita
Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, Niigata University Health Administration Center, Niigata, Japan, School of Health Science, Faculty of Medicine, Niigata University Division of Medical Technology, Niigata, Japan
Conflict of interest: None

Objective: To investigate the utility of urinary inflammatory cell analysis for assessing renal pathological injury in ANCA-associated vasculitis (AAV). Methods: Thirty-six AAV patients who had been referred to Niigata University Hospital between 2002 and 2018, and performed percutaneous kidney biopsy and urinary inflammatory cell analysis, were participated in this study. The pathological findings were classified into Berden’s classification (a method to categorize glomerular lesions into four classes) and Neumann’s classification (a method to evaluate glomerular septal thickening, consolidation in 21. For airway and pleural responsiveness and treatment. Results: For interstitial lung lesions were identified 76 MPA patients whose chest CT images before and within 3 months after treatment were available. We determined the presence and the responsiveness to treatment (improved/unchanged/worsened) of a total of 22 CT imaging components. We examined the relevance between responsiveness and treatment. Results: For interstitial lung lesions were responsive, grand glass opacity (GGO) improved in 22 patients, interlobular septal thickening in 21, consolidation in 21. For airway and pleural lesions, bronchiolitis improved in 32, bronchial wall thickening in 21, pleural thickening in 10. We treated by prednisolone 40mg/day (median dosage). The 50 patients received intravenous cyclophosphamide pulse therapy (IVCY), and 16 methylprednisolone pulse therapy. Most of the them whose GGO was improved were received IVCY: (improved: 20 of 22, unchanged/worsened: 30 of 54, P = 0.0061) Conclusions: The improvement of GGO was relevant to use of IVCY.

W40-5 Clinical study of rituximab maintenance therapy according to demand for patients with refractory granulomatosis with polyangiitis with renal dysfunction
Miho Karube, Yoko Ozawa, Noriko Ikegaya, Soko Kawashima, Takahisa Kawakami, Kazuhiro Fukuoka, Yoshinori Komagata, Shinya Kaname
First Department of Internal Medicine, Nephrology and Rheumatology, Kyorin University School of Medicine
Conflict of interest: None

Objective: RTX treatment of refractory GPA patients compared B cell suppression and onset of vasculitis in On Demand and periodic treatment. Methods: The subjects were 2 patients who underwent RTX treatment irregularly in response to elevated B cells due to impaired renal function. Six patients on routine treatment had normal renal function and infused with RTX approximately every 6 months. Both groups were observed for 24 weeks to 36 weeks. Results: Renal function of on-demand patients was less than eGFR 45 ml/min/1.73 m². Both RTX doses were 375 mg/m² once. Serum IgG decreased from 799.5 mg/dl to 458.5 mg/dl after 6 months. CD19 positive change averages 8.5 months. One patient had relapse of vasculitis. The patient’s interval of administration was 20 months. On the other hand, 6 patients who had normal renal function and regularly administered RTX did not show decrease in serum IgG or B cell positivity and did not show recurrence of vasculitis. Conclusions: Refractory GPA with impaired renal function sustains low serum IgG values even on-demand treatment. However, there is fear of relapse of vasculitis due to prolonged administration interval, prompt RTX treatment is desired after elevation at least CD 19 while paying attention to infectious diseases.

W40-6 Responsiveness to immunosuppressive treatment of lung abnormalities on chest computed tomography and the relevance of initial therapy for remission induction in patients with microscopic polyangiitis
Mieko Yamagata, Kei Ikeda, Takashi Ishii, Hiroshi Kawashima, Daisuke Kashiwakuma, Shin-ichiro Kagami, Isso Watanabe, Daiki Nakagomi, Takao Sugiyama, Shunsuke Furuta, David Jayne, Hiroshi Nakajima
1Department of Rheumatology, National Hospital Organization Shimoshihuzo Hospital, Yotsukaido, Chiba, Japan, 2Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan, 3Research Center for Allergy and Clinical Immunology, Asahi General Hospital, Asahi, Chiba, Japan, 4Department of Internal Medicine 3 Faculty of Medicine, University of Yamanashi, Chuo, Yamashita, Japan, 5Department of Rheumatology and Allergy, Japanese Red Cross Narita Hospital, Narita, Chiba, Japan, 6Lupus and Vasculitis Clinic, Addenbrooke’s Hospital, Cambridge University Hospitals, Cambridge, UK
Conflict of interest: None

Objective: A wide variety of lung abnormalities on the chest computed tomography (CT) can be identified in patients with microscopic polyangiitis (MPA). We aimed to determine the responsiveness of lung lesions to immunosuppressive therapy and investigated the responsiveness to treatment and what kind of treatment. Methods: We retrospectively identified 76 MPA patients whose chest CT images before and within 3 months after treatment were available. We determined the presence and the responsiveness to treatment (improved/unchanged/worsened) of a total of 22 CT imaging components. We examined the relevance between responsiveness and treatment. Results: For interstitial lung lesions were responsive, grand glass opacity (GGO) improved in 22 patients, interlobular septal thickening in 21, consolidation in 21. For airway and pleural lesions, bronchiolitis improved in 32, bronchial wall thickening in 21, pleural thickening in 10. We treated by prednisolone 40mg/day (median dosage). The 50 patients received intravenous cyclophosphamide pulse therapy (IVCY), and 16 methylprednisolone pulse therapy. Most of the them whose GGO was improved were received IVCY: (improved: 20 of 22, unchanged/worsened: 30 of 54, P = 0.0061) Conclusions: The improvement of GGO was relevant to use of IVCY.
cells. [Results] LDG frequencies were higher in AAV patients. AAV-LDG showed higher ability of NETs formation relative to NDG. We identified two subsets of AAV-LDG, CD10 positive LDG showing mature neutrophil characteristics and CD10 negative LDG showing immature granulocyte characteristics. Although the frequency of CD10 positive LDG decreased along with disease activity, the frequency of CD10 negative LDG increased. Comparative proteomic analysis revealed common protein were upregulated in both populations of LGDs. The expression of protein in granules of CD10 negative LDGs revealed they are immature granulocytes. [Conclusions] CD10 positive LDG and CD10 negative LDG were distinct subset each other and they may have different roles in AAV.

W41-2
Serum TIMP1 level as a disease activity marker in ANCA-associated vasculitis patients during induction and maintenance therapy
Jun Ishizaki1, Takuya Matsumoto1, Koichiro Suemori1, Eiji Sada2, Katsumo Takenaka3, Hitoshi Hasegawa1 1Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan, 2Department of Medical Technology, Ehime Prefectural University of Health Sciences

Conflict of interest: None

[Object] We have reported that TIMP1 was the best-performing biomarker of disease activity before treatment and at 6 months after treatment in ANCA-associated vasculitis (AAV). We examine whether the levels of serum TIMP1 are useful as a disease activity marker during induction and maintenance therapy. [Methods] The subjects were 24 AAV patients. Serum TIMP1 levels were measured by ELISA using serum samples collected serially from December 2017 to October 2018. Remission was defined as BVAS (ver.3) of 0, and relapse was defined as the newly present or worse of one or more symptoms of BVAS. [Results] Of the 5 new-onset patients, the TIMP1 levels in 3 remission patients rapidly decreased to 2 to 3 months after induction therapy, but those in 2 non-remission patients remained high. The TIMP1 levels of 16 patients who kept in remission had a median value of 138 ng/mL, which is almost same to healthy subjects. In the 3 relapsed cases, TIMP1 levels were elevated and were significantly higher than the remission group. Moreover, TIMP1 levels at 3 or 6 months before relapse were high. [Conclusions] Serum TIMP1 level was suggested to be a useful marker for judgment of the remission and prediction of relapse in AAV.

W41-3
the research of circulating cell free DNA in anca associated vasculitis as a bio-marker
Teppei Hashimoto1, Yuichi Yokoyama1, Mai Morimoto2, Naoto Azuma3, Kohsuke Yoshida1, Akira Hashiramoto1, Kiyoshi Matsui1 1Department of Rheumatology, Hyogo College of Medicine, 2Department of Rheumatology, Hyogo Prefectural Nishinomiya Hospital, 3Department of Biophysics, Kobe University Graduate School of Health Sciences

Conflict of interest: None

[Objective] ANCA associated vasculitis (AAV) patients may be fatal course at a few weeks and required the bio-markers or prognostic factors. Fragmented cell-free DNA (ccf-DNA) is released into blood circulation as results of damage or death of cells, and it is significantly increased in those of cancer patients and inflammatory disease to be used in monitoring disease activities. In AAV, it is not clear whether the concentration of ccf-DNA is useful bio-marker, however it is possible to be increased associated with vascular endothelial cells injury and neutrophil extracellular traps. [Method] The study group includes 8 patients with EGPA, 7 MPA and 8 GPA. The concentration of ccf-DNA in serum was measured by quantitative real-time PCR before and after therapy, and 10 healthy individuals. We also evaluated the correlation between ccfDNA and the clinical activity. [Result] The concentration of ccf-DNA before therapy in EGPA patients was higher than healthy individuals (p=0.001) MPA (p=0.001) and GPA (p=0.001). After therapy, it was decreased in EGPA patients, not changed in MPA and GPA. It was also correlated with BVAS in EGPA patients. [Conclusion] Considering to the result, ccf-DNA may be associated with eosinophils released. Cef DNA is useful biomarkers in EGPA patients.

W41-4
Low serum complement C3 is a risk factor for relapse of antineutrophil cytoplasmic antibody-associated vasculitis
Sotaro Nakajima1, Naoto Azuma1, Ken-etsu Sada1, Masayoshi Harigai2, Hirofumi Makino1 1Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2Department of Rheumatology, School of Medicine, Tokyo Women’s Medical University, Tokyo, Japan

Conflict of interest: None

[Object] This study aimed to reveal the value of low serum complement C3 in predicting the risk of relapse in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). [Methods] We conducted a retrospective analysis of 83 consecutive patients who were diagnosed with AAV at our hospital from 1999 to 2018. The association between C3 level and relapse-free time was analyzed. [Results] Ten cases (13%) had a low C3 level (<90 mg/dL), and there were no significant differences in onset age, sex, disease type, and ANCA subtype. A low C3 level was significantly associated with the percentage of patients who achieved remission (70% vs. 94%; p=0.03). Among them, the median relapse-free time was significantly shorter in the low C3 group [8 months; 95% confidence interval (CI) 3-NA] than the control group (64 months; 95%CI 46-123, p=0.008). The data were corrected by multiple logistic regression analysis with age, sex, disease type, ANCA subtype, Five Factor Score, lung involvement, and cardiac involvement reported as risks of relapse in the past. Low complement was still related to relapse (p=0.02, hazard ratio 5.26, 95%CI 1.37-20.28). [Conclusion] We found that a low C3 level at diagnosis was significantly associated with the relapse ratio in AAV patients.

W41-5
Effectiveness and safety of concomitant cyclophosphamide as remission induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis; a propensity score-matched analysis of RemIT-JAV and RemIT-JAV-RPGN
Haruki Watanabe1, Ken-etsu Sada1, Masayoshi Harigai2, Hirofumi Makino1 1Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 2Department of Rheumatology, School of Medicine, Tokyo Women’s Medical University, Tokyo, Japan

Conflict of interest: Yes

[Object] To evaluate effectiveness and safety of concomitant cyclophosphamide (CY) for patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). [Methods] Newly diagnosed MPA and GPA patients were enrolled from two prospective cohort studies. A propensity score (PS) for the use of CY was calculated using age, types of vasculitis, renal function, disease activity, disease severity and glucocorticoids (GC) dosage. After PS-matching, outcomes were compared between 94 patients with CY (CY group) and 94 without CY (non-CY group). [Results] Baseline characteristics were balanced except for MPO-ANCA positivity (87% in CY vs. 97% in non-CY, p=0.028). Six-month-remission rates were comparable while the proportion of the remission with prednisolone dose of ≤10 mg/day tended to be more frequent in CY group than non-CY group (47% vs. 32%, p=0.052). Overall, relapse-free, and end-stage renal disease-free survival rates, Vasculitis Damage Index, and serious infections were comparable between the two groups. GC doses at each time points were lower in CY group than non-CY group (0.19 vs. 0.27 mg/kg/day at 6 month, p=0.0001; 0.14 vs. 0.18 at Month 12, p=0.0047; and 0.09 vs. 0.14 at Month 24, p=0.0024). [Conclusions] GC sparing effect of concomitant CY was demonstrated.

W41-6
Association study of MUC5B and TERT polymorphisms with interstitial lung disease in ANCA-associated vasculitis
Aya Kawasaki1, Ken-etsu Sada1, Fumio Hirano1,4, Shigeto Kobayashi1, Hidehiro Yamada1, Hiroshi Furukawa1,2, Kenji Nagasaka3, Takahiko Sugihara2, Aika Suzuki1,4, Kunihiro Yamagata1, Takayuki Sumida1, Shigeto Tohma1,2, Sakaeh Honma3, Shoichi Ozaki1,4, Hiroshi Hashimoto1,4

Conflict of interest: None
Predictors of Deterioration of IgG4-Related Disease in Untreated Patients with IgG4-Related Disease

Ichiro Mizushima1, Masahiro Konishi2, Hajime Sanada3, Kazuyuki Suzuki4, Akari Takeji5, Satoshi Hamada6, Kiyoko Ito7, Takashi Kawane8, Hiroshi Fujii9, Kazunori Yamada10, Mitsuhiro Kawano11
1Department of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, 2Department of Nephrology, Rheumatology, and Infectious Diseases, Toyama Red Cross Hospital

Conflict of interest: None

[Object] This study aimed to clarify the outcomes of untreated patients (Pts) with IgG4-RD and the factors related to the outcomes. [Methods] We retrospectively evaluated clinical features including laboratory data and involved organs at diagnosis in 107 Pts with IgG4-RD. Among them, 27 Pts were followed up without treatment after the initial diagnosis. Age- and sex-adjusted logistic regression analysis was performed to assess factors related to deterioration of IgG4-RD. [Results] The Pts comprised 73 men and 34 women (mean age 65.7 years). The 27 untreated Pts had significantly lower IgG4-RD responder index (10.8 vs 13.8, P=0.048) and fewer affected organs (1.9 vs 3.0, P=0.001) than did the 80 Pts who underwent treatment. Of these 27 Pts, 5 experienced deterioration of IgG4-RD. In logistic regression analysis, serum IgG4 elevation (per 100 mg/dL, odds ratio 1.194, 95% confidence interval 1.017-1.402) was the only significant factor related to deterioration in Pts who underwent treatment. [Conclusions] The present study suggests that serum IgG4 levels may be useful to predict the outcomes of untreated Pts with IgG4-RD, who tend to have fewer affected organs and lower IgG4-RD responder index.

Conflict of interest: None

Validation of the diagnostic criteria for IgG4-related kidney disease 2011: a single center experience

Takako Saeki1, Tomoyuki Ito2, Maasa Tamura2, Hajime Yamazaki1, Ichiei Narita3
1Department of Internal Medicine, Nagaoka Red Cross Hospital, 2Department of General Medicine, Nagaoka Red Cross Hospital, 3Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences

Conflict of interest: None

[Object] To validate the diagnostic criteria for IgG4-related kidney disease (IgG4-RKD) 2011. [Methods] Seventeenth patients with renal abnormalities, in whom the serum levels of IgG4 and/or IgG4-positive plasma cells were evaluated histopathologically between 2012 and 2018 at Nagaoka Red Cross Hospital, were classified according to the diagnostic criteria for IgG4-RKD 2011. The final clinical diagnosis for each patient was based on the attending physician’s opinion. [Results] Among 17 patients, the final diagnosis was IgG4-RKD in 8 and non-IgG4-RKD in 9. Of the 8 patients with IgG4-RKD, 7 were classified as definite IgG4-RKD. However, one patient who had tubulointerstitial nephritis with abundant IgG4-plasma cell infiltration with fibrosis, but without storiform fibrosis in the renal pathology was classified as possible IgG4-RKD. Of the 9 non-IgG4-RKD patients, 6 were classified as possible IgG4-RKD and 3 as unlikely IgG4-RKD. [Conclusions] The IgG4-RKD criteria 2011 are useful for diagnosis of IgG4-RKD and their specificity is high. However, “storiform fibrosis” as a requirement for diagnosis of definite or probable IgG4-RKD might decrease the sensitivity.
**W42-4**  
**Consideration concerning similarities and differences between ANCA-associated vasculitis and IgG-4 related diseases: case series and review of literature**  
Junichi Ishikawa, Shunjiro Kurihara, Kazuma Iida, Norihiro Mimura, Hirotoshi Kawashima, Takao Yanagisawa, Masaki Hiraguri  
Internal Medicine (Rheumatology, Allergy), Japnese Red Cross Narita Hospital  

Conflict of interest: None

[Introduction] Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) and immunoglobulin G4-related diseases (IgG4-RD) are regarded as entirely different disease types with different etiological mechanisms. However, we experienced two cases that had clinical features of both AAV and IgG4-RD. [Case presentations] The first case is an 81-year-old woman who showed periaortitis and retroperitoneal fibrosis with elevation of myeloperoxidase-ANCA and IgG4 levels. The second case is a 63-year-old woman who had dura mater, ear, nose, lung, and kidney involvement with serum negative for ANCA and elevated IgG4. Renal biopsy revealed tubulointerstitial nephritis involving IgG4+ plasma cells. On the other hand, lung biopsy showed features of AAV. These two cases suggested that AAV and IgG4-RD might overlap. To investigate the similarities and differences between AAV and IgG4-RD, we retrospectively analyzed 13 cases of AAV, and 13 cases of IgG4-RD at our hospital, and found some differences that can be useful in the differential diagnosis. [Conclusions] Although AAV and IgG4-RD are distinguishable based on characteristic findings in many cases, the diagnosis can be unclear in rare cases, in which clinicians should consider possible coexistence of AAV and IgG4-RD.

**W42-5**  
**A case of IgG4-related disease with pancytopenia due to hypophysitis and bone marrow involvement**  
Masahiro Sekiguchi, Yuichi Yokoyama  
Division of Rheumatology, Department of Internal Medicine, Hyogo Prefectural Nishinomiya Hospital, Hishinomiya, Japan  

Conflict of interest: None

[Case] An 82-year-old woman with malaise was referred because of anemia. Workup showed pancytopenia (white blood cells: 2,000/μl, hemoglobin: 8.5 g/dl, platelets: 14.7×10^4/μl), hyponatremia, hyperkalemia, hypocomplementemia, and β2-microglobulin in urine, and markedly elevated IgG (6,538 mg/dl) and IgG4 (2,410 mg/dl) levels. Renal biopsy revealed tubulointerstitial nephritis involving IgG4-positive plasma cells. On the other hand, lung biopsy showed features of AAV. These two cases suggested that AAV and IgG4-RD might overlap. To investigate the similarities and differences between AAV and IgG4-RD, we retrospectively analyzed 13 cases of AAV, and 13 cases of IgG4-RD at our hospital, and found some differences that can be useful in the differential diagnosis. [Conclusions] Although AAV and IgG4-RD are distinguishable based on characteristic findings in many cases, the diagnosis can be unclear in rare cases, in which clinicians should consider possible coexistence of AAV and IgG4-RD.

**W42-6**  
**Is dyslipidemia a complication of IgG4RD?**  
Kazuhiro Hatta, Hiroyuki Akebo, Hirofumi Miyake, Ryuichi Sada, Hiroyasu Ishimaru  
Department of General Internal Medicine, Tenri Hospital  

Conflict of interest: None

A 79-year-old female came to hematological department of our hospital, because of further exam of systemic lympho-adenopathy. Because FDG-PET scan showed pancreatic mass and aortic wall uptake. Laboratory data revealed ANA and RF positivity, she transferred to our depart-ment. From pancreatic lesion and elevation of IgG4 value (900), she was diagnosed to have IgG4RD. In addition, high triglyceride value (900) and low HDL-cholesterol (20) were noted, and triglyceride increased to maximum to 2631mg/dl, which went down to 1200 mg/dl with anti-TG drug. Soon after corticosteroid started both values reached to within normal range. [Conclusions] This clinical course showed us that dyslipidemia might be a complication of IgG4RD.

**W43-1**  
**A case of IgG4 related disease diagnosed by pathological findings of ruptured subclavian aneurysm**  
Hyeryong Lee, Soko Kawashima, Hickaru Kukimoto, Takayuki Takahashi, Yoshinori Komagata, Shinya Kaname  
First Department of Internal Medicine, Nephrology and Rheumatology, Kyorin University School of Medicine  

Conflict of interest: None

Background: IgG4-related disease (IgG4-RD) is a disease of unknown showing swelling and nodular lesions of whole body organs by infiltration of IgG4-positive plasma cells. Arterial lesions arising from IgG4-RD are often reported in abdominal aorta. However, it is rare that the branch of aorta is involved and there are not any other involved organs than the artery. Case: A 70-year-old male who had a history of endovascular repair for abdominal aortic aneurysm 5 years ago was admitted into our emergency department because of hemoptysis. CT scanning showed a ruptured right subclavian artery aneurysm, and it perforated the trachea. The pathological findings of ruptured aneurysm from the cardiovascular operation revealed significant infiltration of IgG4 positive plasma cells into the vessel wall. We confirmed the diagnosis of IgG4-RD, in spite of no other organ involvements. He responded well to steroid therapy and the remission have been maintained after the dose reduction of steroid. Discussion: In our case, ruptured subclavian aneurysm was associated with IgG4-related aortitis. IgG4-related vascular lesions were observed in the subclavian artery without multiple organs phenomenon. To our knowledge, this is the first report of a patient with ruptured subclavian aneurysm.

**W43-2**  
**Antibodies to IgG4 may participate the complement activation in patients with IgG4-related disease**  
Hiroshi Watanabe, Junpei Temmoku, Yuya Fujita, Naoki Matsuoka, Makiko Furuya Yashiro, Tomoyuki Asano, Shuzo Sato, Hiroko Kobayashi, Kiyoshi Migita  
Department of Rheumatology, Fukushima Medical University  

Conflict of interest: None

[Object] To investigate the possibility that antibodies to IgG4 contribute to the activation of the complement pathway in IgG4-related disease (IgG4RD) with hypocomplementemia. [Methods] To determine which complement pathway was activated in patients with IgG4RD, we measured the ability of the complement capacity of all three pathways using Wielisa method. Then, we measured the titer of antibodies to IgG4 in sera of IgG4RD patients. Complement-activating ability of antibodies to IgG4 in sera was determined with C4 deposition assay. [Results] We observed reduced complement activity in all complement pathways of sera of IgG4RD with hypocomplementemia. We also observed elevated levels of antibodies to IgG4 as well as C4 deposition in sera of IgG4RD patients with hypocomplementemia. [Conclusions] Antibodies to IgG4 may participate the complement activation in patients with IgG4RD by forming immune complex.

**W43-3**  
**The pathogenic roles of CCL18-CCR8 axis in patients with IgG4-related disease**  
Hirotoshi Kawashima, Takao Yanagisawa, Masaki Hiraguri  
First Department of Internal Medicine, Nephrology and Rheumatology, Kyorin University School of Medicine  

Conflict of interest: None

A case of IgG4-related disease diagnosed by pathological findings of ruptured subclavian aneurysm.
Conflict of interest: Yes

[Object] To clarify the protein expression and expressing cells, and the pathogenic roles of CCL18 and its receptor CCR8 in patients with IgG4-related disease (IgG4-RD). [Methods] 1) The protein expression and expressing cells of CCL18 in labial salivary glands (LSGs) were compared between IgG4-RD (N=3), Sjögren’s syndrome (SS) (N=4), and healthy controls (HC) (N=5) by immunofluorescence (IF) staining. 2) The expression and expressing cells of CCR8 in LSGs were compared between 3 groups by IF. 3) The effects of the CCL18-CCR8 axis on total IgG, IgG2, and IgG4 production by PBMCs of HC stimulated with CD40L, IL-4, IL-10, and IL-21 were examined by in vitro assays. [Results] 1) In LSGs of IgG4-RD, CCL18 macrophages, DCs, and plasmaocytes significantly increased in SS and HC, and CCL18 was significantly increased in HC (P<0.05). 2) CCR8 was similarly expressed in LSGs of IgG4-RD and SS, and CCR8 was up-regulated in LSGs of IgG4-RD and enhanced IgG4 production, suggesting the pathogenic roles of this axis in IgG4-RD.

W43-4
Usefulness of PET/CT in IgG4 related diseases
Sosuke Tsuji1, Yuya Fujita2, Ayuko Takatani1, Takashi Igawa1, Yoshimasa Shimizu1, Rumi Sumiyoshi2, Tomohiro Koga1, Shin-ya Kawashiri1, Naoki Iwamoto1, Kunhiro Ichinose1, Hideki Nakamura1, Tomoki Origuchi2, Atsushi Kawakami2
1Department of Immunology and Rheumatology, University of Advanced Preven-tive Medicine, Tokyo, Japan, 2Department of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan
Conflict of interest: None

[Object] We analyzed cases of IgG4 related disease (IgG4-RD) who underwent PET/CT in our hospital and examined the usefulness of PET/CT in IgG4-RD. [Methods] This study included 20 IgG4-RD patients. We compared the findings of PET/CT with those of plain CT which was diagnosed as IgG4-RD from July 2005 to August 2017. [Results] The median age of the case was 58.4 ± 13.4 years. There were 13 males and 7 females. The median IgG4 was 690.2 ± 597.3 mg/dl. The median of initial dose of PSL was 30 mg. In the pathological tissues, 16 cases had IgG4 / IgG ≥ 40%. There were 16 cases in which PET/CT was performed before treatment and 4 cases were after treatment. The organs in which abnormal findings was pointed out by PET-CT, but not pointed out by CT fore treatment and 4 cases were after treatment. The organs in which abnormal findings was pointed out by PET-CT, but not pointed out by CT were significantly increased than in SS and HC, and CCL18 was significantly increased in HC (P<0.05). 2) CCR8 was similarly expressed in LSGs of IgG4-RD and SS, and CCR8 was up-regulated in LSGs of IgG4-RD and enhanced IgG4 production, suggesting the pathogenic roles of this axis in IgG4-RD.

W43-5
Diffuse large B cell lymphoma of the prostatic gland arising from a patient with clinically and laboratory Castleman disease and pathologically IgG4 related disease
Keigo Setoguchi, Fangyi Chin, Hideyuki Takahashi, Sayaka Tsuchu Department of Systemic Immunological Diseases, Tokyo Metropolitan Komagome Hospital
Conflict of interest: None

A 66 year-old man presented with urinary retention due to prostatic gland swelling. Though, he had had lymphenophathy (neck, axilla, inguinal, mediastimum and pelvic) and lymph node biopsy consisted with IgG4 related disease, his laboratory data showed anemia, hypergamma-globulinemia and serum high level of CRP. He had been clinically ob-served as a Castleman disease without specific treatment. His serum level of PAS was within normal range. His prostatic hypertrophy was suspect-ed of IgG4 related disease. His prostatic biopsy showed diffuse large B cell lymphoma. He was treated with chemotherapy (R-CHOP) and his urinary retention was improved. His laboratory findings suggesting Castleman disease were also improved.

W43-6
A case of IgG4-related disease (IgG4-RD) with ureteropelvic junction mass and tubulointerstitial nephritis (TIN) without imaging abnormality of the renal parenchyma
Tatsuhito Miyana1,2, Ichiro Mizushima1, Masahiro Konishi2, Hajime Sanada1, Kazuyuki Suzuki1, Ryoko Hamano1, Susumu Kitajima1, Hiroaki Muramoto1, Akari Takeji1, Satoshi Haru1, Kiyoko Ito1, Takashi Kawane1, Hiroshi Fujii1, Kazunori Yamada2, Mitsuhiro Kawanod
1Internal Medicine, JCHO Kanazawa Hospital, Kanazawa, Japan, 2Department of Rheumatology, Kanazawa University Hospital, Kanazawa, Japan, 3Department of Nephrology, Rheumatology, and Infectious Diseases, Toyama Red Cross Hospital
Conflict of interest: None

A 72 years-old man was admitted to our hospital because of progressive renal failure. He had been followed up for 18 years after surgical re-moval of bladder tumor. Six months before the present admission, periodic computed tomography (CT) revealed his right ureteropelvic junction mass. He was clinically diagnosed as right ureter cancer and received neoadjuvant therapy and right nephroureterectomy. Pathological study revealed IgG4-positive cell infiltration, obliterate phebitis and storiform fibrosis in the removed mass, leading to the diagnosis of IgG4-RD. Moreover, there was IgG4-positive plasma cell infiltration in the right kidney although no imaging abnormality was detected by preoperative CT. Because renal function gradually worsened and IgG4-related tubulo-intestinall nesphritis (IgG4-TIN) in the left kidney was suspected, he was admitted. Close examinations suggested no IgG4-related extra-renal organ involvement neither imaging abnormality of the left kidney. However, glucocorticoid trial to treat suspected microscopic TIN resulted in an improvement of his renal function, suggesting that he had IgG4-TIN. The possibility of IgG4-TIN should be considered in IgG4-RD patients with renal dysfunction even if no imaging abnormality is observed.

W44-1
Efficacy and safety of secukinumab in Japanese patients with active anklyosing spondylitis: Results from an open-label, phase 3 study (MEASURE 2-J)
Mitsumasa Kishimoto1, Atsu Taniguchi2, Brian Porter1, Sibylle Haemmerle2, Shigeto Kobayashi3
1St. Luke’s International University and St Luke’s International Hospital, 2Tokyo Women’s Medical University, 3Novartis Pharmaceuticals Corpora-tion, 4Novartis Pharma AG, 5Juntendo Koshigaya Hospital
Conflict of interest: Yes

[Object] To assess the clinical efficacy, safety and tolerability of secukinumab (SEC) subcutaneous injections up to 52 weeks in Japanese patients with active AS [Methods] Thirty Japanese patients with active AS fulfilling modified NY criteria, with a score ≥ 4 on BASDAI and ≥4 cm spine pain score on a V AS despite current or previous treatment with NSAIDs and/or anti-TNFα (TNFi) agents, were included. Patients received open-label SEC150mg at W0, 1, 2, 3, and 4, followed by treatment every 4 weeks. The primary outcome was ASAS20 response rate at W16. Overall safety and tolerability were also assessed [Results] Twenty-five subjects completed treatment up to W52. Response for the primary endpoint ASAS20 (70.0%) improved relative to baseline at W16. SEC was efficacious in both TNFi naïve patients and patients who failed prior TNFi therapy. These improvements were maintained throughout W52. ASAS20 response rate of HLA-B27 positive patients was 64.3% versus negative 75.0% at W16. AE rate was 86.7%, and 3 SAEs were reported. The most frequent AE was nasopharyngitis (50%). [Conclusions] SEC treatment improved the signs and symptoms of active AS in Japanese pa-tients, with a similar safety profile as seen in past global SEC studies, demonstrating that SEC is a beneficial treatment option in AS
Efficacy and safety of ixekizumab (IXE) in patients (pts) with active ankylosing spondylitis (AS)/radiographic axial spondyloarthritis (16-week results): COAST-V, a phase-3 randomized, active and placebo (PBO)-controlled study
Tetsuya Tomita1, Ayako Konomi2, Ko Nakajo3, Fangyi Zhao1, Hilde Cartier4
1Department of Orthopedic Biomaterial Science, Osaka University Graduate School of Medicine, Osaka, Japan, 2Eli Lilly Japan K.K., Kobe, Japan, 3Eli Lilly and Company, Indianapolis, IN, USA

Conflict of interest: Yes

[Object] To report efficacy and safety at Wk16 from the first 52 Wk phase-3 study to treat active AS pts with IXE. [Methods] Biologic DMARD-naive pts with established diagnosis of AS with sacroiliitis defined radiographically via modified New York criteria were included. Pts were randomized to PBO, 80mg IXE Q2W or Q4W, or 40mg Q2W adalimumab (ADA). Primary endpoint was ASAS40 response at Wk16 and major secondary endpoint (mSASSS) included ASAS20, BASDAI50, etc. [Results] Of 341 randomized pts, 97% completed Wk16. Baseline demographics and disease characteristics were comparable among study arms (age: 41.7yr, disease duration: 16.0yr, BASDAI 6.7 [mean]). Significantly more pts achieved ASAS40 at Wk16 with IXEQ2W (52%) and IXEQ4W (48%) than with PBO (18%, p < 0.001). ASAS40 at Wk16 in ADA (36%) was also higher than PBO. Both IXE arms showed significantly greater improvements for all mSASSS at Wk16 vs PBO. Among 7 pts enrolled in Jp, 1 pt enrolled in IXEQ4W arm achieved ASAS40, ASAS20 and BASDAI50 at Wk16, whereas 3 pts in PBO arm failed to respond. TEAE/SAE frequency was comparable among all arms. Majority of TEAEs reported were mild or moderate. [Conclusion] Via 16 Wk IXE treatment, significant improvements in the signs and symptoms of AS were observed with no unexpected safety signals.

Analysis of factors involved in radiographic changes in patients with ankylosing spondylitis
Kurisu Tada1, Shigeto Kobayashi2, Eri Hayashi2, Hitoshi Inoue2, Ken Yamaji1, Naoto Tamura1
1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, 2Department of Orthopaedic Surgery, Juntendo University School of Medicine, 3Department of Internal Medicine, Juntendo Koshigaya Hospital

Conflict of interest: None

[Object] The objective is to evaluate the radiographic change of ankylosing spondylitis patient with mSASSS (modified Stoke Ankylosing Spondylitis Spine Score) and to analyze factors involved in the radiographic progression. [Methods] We examined 46 patients who fulfilled the modified New York criteria and taking X-ray and MRI. [Results] In X-ray, the average mSASSS score was 8.9 in patients with ankylosing spondylitis. The prevalence or severity of clinical and radiographic axial spondyloarthritis in patients with inflammatory bowel disease

Conflict of interest: None

Clinical features of Spondyloarthritis associated with inflammatory bowel disease in our institution
Masatoshi Kadoya, Takuya Yanagida, Satoshi Omura, Atsushi Omo, Wataru Fukuda
Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daichii Hospital, Kyoto, Japan

Conflict of interest: None

[Object] Spondyloarthritis (SpA) is a common extraintestinal complication in patients with inflammatory bowel disease (IBD). We examined the clinical features of IBD-related arthritis. [Methods] 11 patients with IBD-related arthritis visiting our institution were enrolled in the study. We investigated their clinical characteristics, clinical courses and treatments. [Results] The average age of patients was 49.8±16 years, and 3 were male. Among 11 cases, 9 cases were ulcerative colitis. 10 patients were peripheral SpA. Only one case was positive for ACPA (Anti-Citrullinated Protein Antibodies). 6 cases out of 11 were positive for ANA (anti nuclearolar antibody). Their ANA patterns were homogenous and/or speckled. As for clinical courses, those who were positive for ANA, arthritis tend to occur later than those who were not. Concerning about treatments for IBD-related arthritis, 2 patients were observed without any medicaments. MTX was used in two cases, and Tacrolimus was administered in one case. By using these treatments, patients with IBD-related arthritis, their clinical courses may differ according to their ANA positivity.

The prevalence or severity of clinical and radiographic axial spondyloarthritis in patients with inflammatory bowel disease
Tadashi Okano1, Kentaro Inui1, Koji Mandai1, Yutaro Yamada1, Yuko Sugioika, Tatsuya Koike1,2, Hiroaki Nakamura1
1Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, Osaka, Japan, 3Shirahama Foundation for Health and Welfare, Wakayama, Japan

Conflict of interest: None

[Object] The prevalence or severity of clinical and radiographic axial spondyloarthritis in patients with inflammatory bowel disease (IBD) such as ulcerative colitis (UC) and Crohn’s disease (CD), was assessed by X-ray and MRI. [Methods] A total of 56 subjects, including 39 UC patients (19 males, 20 females) and 17 patients of CD (10 males, 7 females) were included. Imaging evaluation was performed blindly by two readers in X-ray and MRI. [Results] In X-ray, the average mSASSS score was 8.9 in patients with inflammatory back pain (IBP), and 6.5 (p = 0.257) in patients without IBP. There were 11 patients on bilaterally Grade 2 or uni-
W45-1
A subgroup analysis in the basis of the presence or absence of airway and ear involvement may be important for classification and treatment of relapsing polychondritis
Jun Shinizu1, Yoshihisa Yamano2, Kimito Kawahata3
1Department of Immunology and Medicine, St. Marianna University School of Medicine, 2Institute of Medical Science, St. Marianna University School of Medicine, 3Division of Rheumatology and Allergology, St. Marianna University School of Medicine
Conflict of interest: None

[Objective] We conducted an epidemiological survey of 239 patients with RP and obtained clinical information in 2014. Based on these data, we addressed how organized involvement in RP patients related to one another. [Methods] We assigned the numbers 1 and 0 to describe the presence and absence, respectively, of organ involvement and obtained a correlation matrix. [Results] From the correlation matrix, we found a significant inverse relationship between airway involvement and ear involvement. We then applied a subgroup analysis in the basis of airway involvement (A subgroup) and ear involvement (E subgroup). A and E subgroups included 19.7% and 49.4% patients, respectively. The remaining 29.3% patients formed third subgroup (O subgroup) with both A and E involvement. In the clinical data, progressive disease course were frequently observed in A and O subgroup compared with E subgroup. Two major poor prognostic factors, cardiovascular and CNS involvement, were frequently observed in E plus O subgroups compared with A subgroup. A subgroup patients did not develop cardiovascular involvement. [Conclusions] Subgroup analyses of patients with RP may provide new insights into the classification and treatment of RP.

W45-2
Clinical features of elderly onset Still's disease
Sayaka Takenaka, Takehisa Ogura, Chihiro Imaizumi, Yuto Takakura, Yuki Inoue, Hideki Ito, Norihide Hayashi, Ayako Hirata, Hideto Kameda Ohashi Hospital
Conflict of interest: None

[Objective] It is said that the age of onset of adult onset Still's disease (AOSD) is often distributed between 16 and 35 years old. However, there are cases of onset in the elderly, therefore its clinical features are examined. [Methods] From May 2011 to October 2018, we extracted 20 cases of AOSD. In 6 cases of aged onset over 65 years old (age of onset is Age 65 to 84 years old, median 70.5 years old, 5 women) and 14 cases of under 65 years of age (age of onset is 26 to 53 years old, median 38 years old, 12 women). [Results] Typical eruption was 50% (80% under 65 years old) and lymph node swelling 50% (79% same) tended to be less in elderly onset cases. Therefore, comparing the number of applicable items of Yamaguchi et al.'s classification criteria, the median value of 5 items (7 items) was significantly lower in older onset (p = 0.0056). With regard to treatment, steroids were administered in all cases except for one case initiated at other hospitals, and pulse therapy was 20% (42.9% of the patients) with an aging episode, and the initial dose of steroids was 50 mg median prednisolone / day, And tocilizumab use was 20% (35% same). [Conclusions] The elderly onset AOSD tended to be less prone to typical rash or lymph node swelling.

W45-3
Steroid-sparing Effect of Tocilizumab on the Treatment of Adult Onset Still's Disease
Hiroshi Kataoka, Tomoko Tomita, Makoto Kondo, Masaya Mukai Rheumatology and Clinical Immunology, Sapporo City General Hospital
Conflict of interest: None

[Objective] To assess the efficacy and safety of Tocilizumab (TCZ) on the treatment of adult onset Still’s disease. [Methods] Fifty-two patients who were registered as adult-onset Still’s disease (AOSD) in the electric record in our hospital were listed for this study and in 24 patients of them, who had received treatment for over 3 months with complete data to evaluate treatment efficacy, we retrospectively analyzed CRP, ferritin in each of corticosteroid (CS) monotherapy group, CS+metrotrexate (MTX) group and TCZ group. This study was certified by the ethical committee in our hospital. [Results] Seven patients of CS monotherapy (4 females; mean age 47, 3 males; mean age 33), 8 patients of CS+MTX (all females; 57 y.o.) and 9 patients of TCZ (5 females; average age 48, 4 males; 37 y.o.) were analyzed in this study. There were no difference in initial CRF, ferritin and CS dose among three groups. In any of treatment group, CRP and ferritin were decreased by 3-month therapy. TCZ showed an advantage in lowering effect of CRP and tapering CS dose compared with MTX without serious health issue (p=0.0092 for CRP, p=0.064 for CS reduction). [Conclusion] In real world experience, TCZ was found to have promising CS sparing effect.

W45-4
Recovery period for prolonged thrombocytopenia in TAFRO syndrome: five encountered cases and literature review
Yuta Yamaguchi, Yuichi Maeda, Yumiko Mizuno, Maya Yagita, Yusuke Manabe, Takayoshi Morita, Masayuki Nishide, Hyota Takamatsu, Toru Hirano, Masashi Narazaki, Atsushi Kumanogoh
Department of Respiratory Medicine and Clinical Immunology, Osaka University Medical Hospital, Osaka, Japan
Conflict of interest: None

[Objective] TAFRO syndrome is a newly proposed disease that is different from Castleman’s disease. Generally, high-dose corticosteroids are used for treatment; however, other immunosuppressive therapies are administered in refractory cases. We aimed to determine the required to recover from prolonged thrombocytopenia in TAFRO syndrome. [Methods] We included five encountered cases in this study; furthermore, we also evaluated 60 peer-reviewed reports that were obtained from PubMed. Recovery from thrombocytopenia was defined as a platelet count of more than 50,000/μL. Mortality and the cause of death were also monitored. [Results] Thrombocytopenia tended to last longer than other symptoms. In our four cases, the median period for the recovery was 43 days. In 41 cases of literature review, recovery from thrombocytopenia required 40 days. In our two cases, it suggested that D-dimer titers and platelet counts might be inversely correlated. Seven out of 60 cases were fetal, and 4 cases were due to infection. [Conclusions] It takes approximately 40 days to recover from thrombocytopenia associated with TAFRO syndrome. Therefore, when other symptoms are improving, physicians should not easily administer another immunosuppressant only for treatment of persistent thrombocytopenia.

W45-5
A case of autoimmune pancreatitis and autoimmune salivary glanditis by administration of nihormarb
Yuki Shimada1, Yuji Akiyama2
1Department of Supportive Oncology and Palliative Medicine, Saitama Medical University International Medical Center, Hidaka, Japan, 2Division of Rheumatology, Department of Internal Medicine, Ogawa Red Cross Hospital, Ogawa Town, Japan
Conflict of interest: None

[Case] A 75-year-old man. Nephrectomy was performed on renal cell carcinoma and treated with chemotherapy, but it was ineffective and changed to nihormarb. He was aware of dry mouth and epigastralgia. In
blood test, Amylase 656U/l. Anti nuclear antibody and anti SS-A antibody, anti SS-B antibody were negative. IgG4 was 13.9 mg/dl. MRI revealed pancreatic head enlargement and a stenotic image in the main pancreatic duct. IgG4 was normal but diagnosed as AIP. Salivary gland scintigraphy showed a decrease in accumulation in salivary glands. Lip biopsy could not be done. Dry eye was diagnosed. He was diagnosed with autoimmune salivary glanditis. Administration of prednisolone (PSL) 1mg/kg/day to AIP was started. Symptoms improved, pancreatic enzymes decreased on the 2nd day of administration. Imaging findings also improved. Dry mouth improved, and salivary gland function improved. Pancreatic symptoms and dry mouth improved with PSL, but dry eye did not change. [Clinical significance] Adverse events of nimbomab are versatile, adverse events due to immune reactions are often negative for autoantibodies. In this case an autoimmune mechanism may be considered. Since it may improve with PSL, we should be careful of dry mouth after administration of nimbomab.

W45-6
The ratio of serum MMP-3 to CRP is useful for distinguishing PMR-mimicking EORA from true PMR at the onset
Takeshi Suzuki1, Yu Seri1, Akitake Suzuki2
1Division of Allergy and Rheumatology, Japanese Red Cross Medical Center, 2Department of Rheumatology, Mitsui Memorial Hospital
Conflict of interest: None

[Object] To determine the usefulness of serum MMP-3/CRP ratio, which may represent the proportion of synovial inflammation to whole (synovial and extra-synovial) inflammation, in distinguishing PMR-mimicking EORA from true PMR. [Methods] The medical records of patients who visited our hospitals for examination of PMR-like symptoms were retrospectively reviewed to identify patients who fulfilled the requirements: (i) 2012 PMR classification criteria were met; (ii) 2010 RA classification criteria were not met (Score <6); (iii) serum MMP-3 and CRP -factors were not met (Score <6); (iii) serum MMP-3 and CRP were measured on the same day before starting treatment with corticosteroids or DMARDs; (iv) the final diagnosis was confirmed as PMR or RA by the agreement between two certified rheumatologists who reviewed the clinical data during the one-year follow-up. [Results] Eight PMR-mimicking EORA patients and 29 PMR patients were found and analyzed. MMP-3/CRP ratio was significantly higher in PMR-mimicking EORA than in PMR (126x10^-4 [127x10^-4] vs 29.2x10^-4 [33.7x10^-4], median [interquartile range]). MMP-3 and CRP ratio demonstrated an AUC of 0.845 (95% CI: 0.641-1). [Conclusions] MMP-3/CRP ratio may be useful for distinguishing PMR-mimicking EORA from true PMR even when the classification criteria are not met.

W46-1
Clinical characteristics of late-onset patients having adult-onset Still’s disease
Dai Kishida, Takearon Ichikawa, Satoru Uchiyama, Noriko Sagaguchi, Kenichi Ueno, Yasahito Shinjohama, Yoshihisa Sekijima
Department of Neurology and Rheumatology, Shinshu University School of Medicine, Matsumoto, Japan

Conflict of interest: None

[Object] Adult-onset Still’s disease (AOSD) usually occurs in young adult. But we sometimes encounter patients of advanced age. Our aim was to evaluate the clinical characteristics about late-onset AOSD patients. [Methods] We retrospectively analyzed clinical features about 32 patients with AOSD between April 2008 and September 2018. Patients were divided into two groups based on the age of disease onset (65 years and older or not). [Results] Eleven patients (34.4%) experienced their first symptom at age ≥65 years. High fever (100%), arthritis (90.9%), and rash (90.9%) were common symptoms among them. The percentage of serositis (36.4%), hemophagocytic syndrome (36.4%), high ratio of neutrophils (72.7%), and elevated serum ferritin level (more than 3,000 ng/ml) (72.7%) were higher than early-onset patients. However, they indicated higher frequency in more than 3 cycles of methylprednisolone pulse therapy than early-onset patients despite lower that in administering immunosuppressant (54.3%) such as tocilizumab (18.2%). Infections required hospital treatment (54.5%) was more frequent in the late-onset group. [Conclusions] Late-onset patients with AOSD tend to be more severe condition. They were treated mainly with glucocorticoids and we need to manage to decrease infections.

W46-2
Clinical significance of serum interleukin-18 level in the differential diagnosis of adult Still’s disease and hemophagocytic syndrome
Toshihiro Shiga, Kazuya Kishimoto, Yuji Nozaki, Koji Kinoshita, Masanori Funacchi, Itaru Matsumura
Kindai University Hospital, Faculty of Medicine, Osaka, Japan

Conflict of interest: None

[Object] Adult Still’s disease (ASD) is a systemic inflammatory disease that is associated with activation of macrophage. It has been suggested that IL-18 is associated with the pathogenesis of ASD. ASD shares several clinical and laboratory variables with hemophagocytic syndrome (HPS). So, It is difficult to differentiate these diseases. We evaluate the clinical significance of serum IL-18 level to differentiate ASD and HPS. [Methods] Thirty-six patients with ASD and Twenty-one patients with HPS, who were admitted to our hospital between January 2012 and October 2019, were enrolled. ASD patients were diagnosed according to Yamaguchi criteria. Serum concentration of CRP, LDH, GOT, GPT, ferritin, sIL-2R, IL-6 and IL-18 was determined in both ASD and HPS. [Results] The serum IL-18 level in ASD patients was significantly higher than that in HPS patients (p<0.0001), and that of sIL-2R was lower (p=0.0001). Between ASD and HPS, serum concentrations of CRP, LDH, GOT, GPT, ferritin, and IL-6 were not significantly different. IL-18 serum levels in ASD patients positively correlated with serum ferritin levels (r=0.6, p<0.0001). [Conclusions] We argue that IL-18 can be a biomarker for differential diagnosis between ASD and LAHS and be associated with activation of macrophage.

W46-3
The utility of serum IL-18 as a disease activity marker in adult onset Still’s disease -IL-18 reflects remaining fever and rash in inactive patients-
Nanami Mino1, Hiroaki Hatano2, Hiroyuki Yamashita1, Shinji Izuka1, Toshiaki Kobayashi1, Satoko Nakajima1, Kyoko Motomura1, Shunta Kaneko1, Yoko Takahashi1, Hiroshi Kamei1, Takashi Hosokawa2, Takeshi Kaneko2, Tomomi Tada1, Kenji Funakoshi2, Shinta Nakagawa2, Shinichiro Nameki1, Jun Fukui1, Koji Nomura2, Hiroshi Fujimura2

Conflict of interest: None

[Object] Monitoring of disease activity is crucial for preventing flares of adult-onset Still’s disease (AOSD). This study aimed to reveal the utility of serum interleukin (IL)-18. [Methods] Twenty-seven patients treated at our hospital from 2014-2018 were enrolled. Serum markers [ferritin, C-reactive protein (CRP), and IL-18] and disease activity were analyzed. Patients were classified by Pouchot’s score: ≥3, active; <3, inactive. Inactive patients with fever or evanscent rash were defined as “smoldering”, and those without as “remission”. [Results] The mean age was 38.2 years and there were seven males. IL-18 showed a moderate correlation with ferritin and CRP (r=0.497, 0.379, respectively; both p<0.001) by Spearman’s correlation test. IL-18 and ferritin showed a significant difference between active and inactive patients (p=0.004) by Mann-Whitney U-test. However, a significant difference between “smoldering” and “remission” patients was observed only in IL-18 (p=0.004), with a sensitivity of 70.4% and a specificity of 82.3% (IL-18 cutoff: 10807 pg/mL). [Conclusions] IL-18 was correlated with ferritin and CRP and was useful for evaluating AOSD activity. Moreover, IL-18 remained high in inactive cases with fever and rash; thus, IL-18 might be involved in their pathogenesis.

W46-4
Clinical features of 5 cases of immune checkpoint inhibitor-induced inflammatory arthritis
Takashi Hosokawa1, Takeshi Kaneko2, Tomomi Tada1, Kenji Funakoshi2, Shinichiro Nameki1, Jun Fukui1, Koji Nomura2, Hiroshi Fujimura2

Conflict of interest: None
Conflict of interest: Yes

[Objectives] We aimed to determine the clinical features of immune checkpoint inhibitor-induced inflammatory arthritis. [Method] We analyzed the records of patients who were administered anti-PD-1 (programmed cell death-1) antibodies (nivolumab, pembrolizumab) and admitted to our hospital between September 2014 and October 2018. We examined patients showing an exacerbation of RA/polymyalgia rheumatica (PMR), as well as patients with new-onset arthritis resembling RA and PMR. [Results] We identified 4 patients with lung cancer and 1 with esophagogastric junction cancer. Two patients presented with exacerbation of pre-existing RA/PMR, 2 with new-onset arthritis similar to RA, and 1 with new-onset arthritis similar to PMR. Patients with new-onset arthritis demonstrated rapid improvement following the administration of 10-20 mg of prednisolone (PSL). However, patients presenting with exacerbation of pre-existing RA/PMR did not show noticeable improvement despite the administration of increased PSL doses. [Conclusion] New-onset arthritis and exacerbation of pre-existing arthritis after the administration of anti-PD-1 antibodies respond differently to low-dose PSL therapy. Further examination of patients is necessary in this regard.

W47-1
Comparison of clinical characteristics between RS3PE syndrome and elderly-onset rheumatoid arthritis
Tomoki Oriuchi1, Masataka Umeda1, Tomohiro Koga1, Shin-ya Kawashiri2, Naoki Iwamoto3, Kunihiro Ichinose4, Kazuhiko Arima5, Mami Tamai1, Hideki Nakamura1, Toshiaki Tsukada6, Taichiro Miyashita1, Toshiyuki Arakami7, Yukiitaka Ueki2, Munetoshi Nakashima2, Masako Furuyama1, Akinari Mizokami6, Nozomi Iwana2, Fumiko Shomura7, Atsushi Kawakami1
1Nagasaki University, Nagasaki, Japan, 2Aino Memorial Hospital, Unzen, Japan, 3Miyashita Rheumatology Clinic, Omura, Japan, 4Sasebo Central Hospital, Sasebo, Japan, 5Kurume University Medical Center, Kurume, Japan, 6Nagasaki Medical Center, Omura, Japan, 7Ureshino Medical Center, Ureshino, Japan
Conflict of interest: None

[Object] To evaluate the efficacy and safety of tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment
Yuko Kaneko1, Hideto Kameda2, Kei Ikeda3, Tomonori Ishii4, Kosaku Murakami5, Hyota Takamatsu6, Yoshiya Tanaka7, Tsutomu Takeuchi8
1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 2Department of Internal Medicine, Toho University Ohashi Medical Center, 3Department of Allergy and Clinical Immunology, Chiba University Hospital, 4Clinical Research, Innovation and Education Center, Tohoku University Hospital, 5Department of Rheumatology and Clinical Immunology, Kyoto University, 6Department of Respiratory Medicine and Clinical Immunology, Osaka University, 7The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
Conflict of interest: Yes

[Object] To evaluate the efficacy and safety of tocilizumab in patients with adult-onset Still’s disease (AOSD). [Methods] Patients with AOSD refractory to glucocorticoids were randomised to intravenous tocilizumab at a dose of 8mg/kg or placebo every 2 weeks during the 12-week, double-blind phase. Patients received open-label tocilizumab for 40 weeks

W47-2
A randomised, double-blind, placebo-controlled phase III trial of tocilizumab in patients with adult-onset Still’s disease refractory to glucocorticoid treatment
Yuko Kaneko1, Hideto Kameda2, Kei Ikeda3, Tomonori Ishii4, Kosaku Murakami5, Hyota Takamatsu6, Yoshiya Tanaka7, Tsutomu Takeuchi8
1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, 2Department of Internal Medicine, Toho University Ohashi Medical Center, 3Department of Allergy and Clinical Immunology, Chiba University Hospital, 4Clinical Research, Innovation and Education Center, Tohoku University Hospital, 5Department of Rheumatology and Clinical Immunology, Kyoto University, 6Department of Respiratory Medicine and Clinical Immunology, Osaka University, 7The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health
Conflict of interest: Yes

...other medical services...
subsequently. Primary outcome was ACR50 response at week 4. Secondary outcomes included ACR20/50/70, systemic feature score, glucocorticoid dose, and adverse events at each point. [Results] Twenty six patients in each group were included in the efficacy analysis. ACR50 at week 4 was achieved in 61.5% in the tocilizumab group and 30.8% in the placebo group (p=0.24). The mean changes in systemic feature score at week 12 were -4.1 in the tocilizumab group and -2.3 in the placebo group (p=0.003). The dose of glucocorticoids at week 12 decreased by 46.2% in the tocilizumab group and 21.0% in the placebo group (p=0.017). At week 52, the rates of ACR20, ACR50 and ACR70 were 84.6%, 84.6%, and 61.5%, respectively, in both groups. Serious adverse events were infections, asptic necrosis in the hips, exacerbation of AOSD, drug eruption, and anaphylactic shock. [Conclusions] The study suggests that tocilizumab is effective in AOSD.

**W47-3**
Clinical features of 22 patients with Parvovirus B19-associated arthritis
Kenji Funakoshi1, Takashi Hosokawa1, Takeshi Kaneko1, Tomomi Tada1, Shinichiro Nameki1, Jun Fukui1, Koji Nomura1, Hiroshi Fujisawa1, Division of Rheumatology, Osaka General Medical Center, 2Department of Orthopedic Surgery, Osaka General Medical Center

Conflict of interest: None

**Objectives:** We analyzed the clinical features of Parvovirus B19 (PVB19)-associated arthritis (PVB19 arthritis) in 22 patients. **Methods:** We retrospectively reviewed patients aged ≥ 16 years who visited our hospital between April 2008 and March 2018 with arthralgia and showed a positive PVB19 immunoglobulin M antibody test. **Results:** The study included 28 patients and 22 were diagnosed with PVB19 arthritis. Most patients (91%) presented with associated symptoms including fever (59.1%), edematous extremities (50%), rash (45.5%), posterior cervical pain (18.2%), cervical lymphadenitis (13.6%), and pharyngalgia (9.1%). Of these patients, approximately 31.8% reported a history of contact with an infected individual. The anti-cyclic citrullinated peptide (CCP) antibody (14 patients) was negative. The rheumatoid factor test was positive only in 13.6% of patients. Other laboratory tests showed no leukopenia, anemia in 27.3%, hypocomplementemia in 68.8% (11/16), and a positive antinuclear antibody test in 71.4% (15/21) patients. **Conclusions:** History taking and physical examination play a key role in diagnosing PVB19 arthritis. A negative anti-CCP antibody test or hypocomplementemia may help to distinguish PVB19 arthritis from other similar conditions.

**W47-4**
Calcineurin Inhibitors for Adult-onset Still’s Disease: A Multi-center Epidemiological (CHANCE) Study
Yuichiro Fujieda1, Hiroyuki Nakamura1, Masato Tamuri1, Shin Furukawa1, Ryo Hisada1, Yuka Shimizu1, Ikuma Nakagawa1, Akito Tsutsumi1, Takashi Kurita1, Hiroshi Kataoka1, Masaya Muka1, Hideki Kasahara1, Atsushi Noguchi1, Yoshiharu Amasaki1, Tatsuya Atsumi1, 1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine Hokkaido University, 2Internal Medicine, Tomakomai City Hospital, 3Internal Medicine, Kushiro Red Cross Hospital, 4Department of Internal Medicine, Oihiko Kosei Hospital, 5Internal Medicine, Takakawa City Hospital, 6Internal Medicine, Kitami Red Cross Hospital, 7Division of Rheumatology and Clinical Immunology, Sapporo City General Hospital, 8NTT Sapporo Medical Center, Department of Rheumatology, 9Department of Rheumatology, Toyon Hospital

Conflict of interest: None

[Object] To elucidate the efficacy and safety of calcineurin Inhibitors for patients with adult-onset Still’s disease (AOSD). [Methods] This is a multi-center historical cohort study comprised of the consecutive patients with AOSD from 2000 diagnosed according to Yamaguchi classification criteria. The endpoints were set as the time from the initiation of treatment to recurrence and safety. These endpoints were evaluated for each recurrent event. [Results] 151 patients with 212 events were enrolled in the study. Median age was 42 years old, female ratio was 70%, and median follow-up period was about 3 years. Calcineurin inhibitors were used in 67 events (tacrolimus: 54, cyclosporine: 13) with recurrent history, serious leukocytosis, high ferritin level and/or disseminated intravascular coagulation. Calcineurin inhibitors led to significantly longer recurrence-free survival (78% versus 65% at 3rd year. log-rank test, p = 0.01). Adverse events occurred in 21% of patients treated with calcineurin inhibitors and 10% without ones (chi-square test, p = 0.04). [Conclusions] Calcineurin inhibitors would be an additional option for AOSD, but might increase adverse events.

**W47-5**
HLA phenotype of 30 patients with SAPHO syndrome
Masao Tamura, Takahiro Yoshikawa, Tepppei Hashimoto, Mai Morimoto, Naoto Azuma, Masayasu Kitano, Kiyoshi Matsu Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan

Conflict of interest: None

[Objectives] To assess the clinical and laboratory features, HLA phenotype in Japanese patients with SAPHO syndrome. [Methods] Thirty patients (female/male: 20/10, mean age at diagnosis: 51.8years) were diagnosed with SAPHO syndrome from September 2014 to October 2018 at our hospital. We examined the HLA phenotype and assessed the clinical and laboratory features. [Results] Among the 30 patients, 23 had cutaneous involvement, 22 had palmoplantar pustulosis, 1 had acne, and 7 had no cutaneous involvement. Bone symptoms involved mainly the anterior chest wall (n=27.90%), spine (n=9.30%), and sacroiliac joints (n=3.10%). 11 had peripheral arthritis.4 patients had comorbid disease (Crohn’s disease, ulcerative colitis, relapsing polychondritis, Behcet’s disease. We treated 5 patients with biologics (2 with Adalimumab, 1 with Secukinumab, 2 with Guselkumab) for intractable cases. HLA-A26 was present in 13patients (43%); B61 in 10 (33%); B62 in 7 (23%). [Discussion] HLA-A26, B61, B62 were frequently detected, these may be disease-sensitive genes. Also, refractory cases were associated with HLA-B51, B61, B62. We conduct much accumulation and want to examine a tendency of HLA in the SAPHO syndrome of this country in future.

**W47-6**
Clinical features and treatment results of the patients with SAPHO syndrome in Ehime university hospital
Tsukuya Matsumoto1, Jun Ishizaki1, Koiehiro Suemori1, Eiji Sada1, Katsuo Takenaka1, Hitoshi Hasegawa1, 1Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan, 2Department of Medical Technology, Ehime Prefectural University of Health Sciences

Conflict of interest: None

[Object] [Methods] Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome was proposed by Chamot et al. in 1987. This disease is characterized by pustular skin lesions and osteoarticular lesions. We analyzed 19 patients with SAPHO syndrome in our hospital. [Results] Nineteen patients (12 females, 7 males) were between 21- and 76-year-old (mean 54). Osteoarthrits symptoms occurred in the anterior chest in 14 patients (73%), spine in 8 (42%), and extremities in 8 (42%). The frequency of these symptoms was almost same with the other reports. All patients had received multiple NSAIDs and the following DMARDS: 4 patients with corticosteroids; 9 with methotrexate; and 8 with sulfasalazine. Some patients were effective with these treatments, but others had continued the pain of osteoarthrits. In the refractory cases, six patients were treated with TNF inhibitors (3 with infliximab, 2 with adalimumab, and 1 with etanercept). TNF inhibitors were effective for all patients. [Conclusions] Since patients having SAPHO syndrome may be accompanied with strong pain and bone fracture, early diagnosis and therapy are important to prevent the pain, joint deformities, and other complications. We report clinical features and treatment results in our hospital with a review of the literature.
Conflict of interest: None

W48-1
Nailfold videocapillaroscopy in our institution
Yuji Yoshioka, Yuji Uzawa, Daisuke Kanai, Akiko Suda, Shohei Nagaoka
Yokohama Minami Kyosai Hospital

Conflict of interest: None

[Object] Various nailfold capillary abnormalities are pointed out in connective tissue diseases. We investigated Nailfold videocapillaroscopy (NVC) in our institution. [Methods] 79 cases examined NVC from April 2015 to September 2018 were included. We examined for nailfold capillaries of both sides 2-5 fingers, enlarged (>20µm), giant capillaries (>50µm), hemorrhages, capillary loss (<9), ramified capillaries. [Results] The average age was 62.9 years old (±15.7), women were 65 cases (82.9%). 27 systemic sclerosis, 15 systemic lupus erythematosus, 12 Sjogren’s syndrome, 8 rheumatoid arthritis, 6 polymyositis/dermatomyositis, 6 microscopic polyangiitis were included, 17 cases were not diagnosed any connective tissue diseases. Enlarged capillary was observed in 43 cases (54.4%), giant capillary in 21 cases (26.6%), hemorrhages in 36 (45.6%), capillary loss in 20 cases (25.3%), ramified capillaries in 39 cases (49.4%). 11 cases (13.9%) had no capillary abnormality. In systemic sclerosis, the capillary and capillary loss had significant odds ratio; 6.94 (95%CI:2.31-20.8, p=0.001), 3.29 (95%CI:1.15-9.43, p=0.027) respectively. Ramified capillaries were related significant odds ratio 3.53 (95%CI:1.02-12.3, p=0.047) in systemic lupus erythematosus. [Conclusions] We reported NVC in our institution.

W48-2
Symmetrical MCP joints tenosynovitis determined by MRI is a predictor of RA development in patients with undifferentiated arthritis
Mami Tamai1, Masataka Oki1, Nozomi Oki1, Kunikazu Ogawa1, Haisaj Oshima1, Ikuko Tanaka1
1Nagoya Rheumatology Clinic, 2Department of Radiology, National Center for Radiographics and Gerontology, Obu, Japan, 3Mie Rheumatology Clinic, Suzuka, Japan, 4Department of Connective Tissue Disease, Tokyo, Japan, Tokyo Medical Center

Conflict of interest: None

[Objectives] We used HR-pQCT (Xtreme CT II, Scanco Medical) to image all joints from the wrist joint to the DIP joint. Those images were reconstructed using a 3D workstation. We present 3 arthritis cases and report the usefulness of this imaging technique. [Case 1] 41-year-old female, finger pain appeared 3 months ago, ACPA 11.9 U/mL, RF 10 IU/mL. Three bone erosion were recognized by horizontal section and coronal section in wrist, but it could not be found by simple X-ray. [Case 2] 50-year-old female, about 10 years ago, the deformation of the DIP joint has occurred and pain has appeared recently in the PIP joint. Osteophyte formation and bone erosion of the DIP · PIP joint were confirmed by corona nary section. Pencil in Cup deformity was observed in the sagittal section, and it was diagnosed as peripheral spondyloarthritis. [Case 3] 52-year-old female, visited by fever and wrist arthritis. Calcification was found in the triangular fibrous ligament and around the carpal bones in HR-pQCT, which was diagnosed as pseudogout. [CONCLUSIONS] 1. Development of peripheral joint imaging technique using HR-pQCT. 2. HR-pQCT is helpful for the diagnosis of arthritis and the understanding of the pathology by examining all the joints from the wrist joint to the DIP joint in detail.
tively. [Results] BMD of femoral neck was correlated with trabecular volumetric densities (Th.vBMD) (r=0.84, p<0.01). The patients with US-proven active synovitis (PD≤2) showed less Th.vBMD, trabecular number (Th.N) and trabecular thickness (Th. Th) as compared with the patients with US-PD<2 synovitis (Th.vBMD:121.5 mg/cm³ vs 145.3 mg/cm³). These tendencies were also shown in bone destruction measured by x-ray. The longitudinal analysis of 10 patients revealed that Th.vBMD and Th.N were improved along with improvement of disease activity, but Th. Th was not improved. [Conclusions] This study revealed that bone destruction and synovitis were associated with bone micro-architecture, and the different of treatment response by parameter of bone micro-architecture. However, this study was mainly transverse analysis and small samples, we need longitudinal analysis using larger samples.

W48-6 Quantitative analysis of juxta-articular osteoporosis by HR-pQCT in patients with rheumatoid arthritis
Kounosuke Watanabe1, Ko Chiba1, Naoki Iwamoto2, Nozomi Okiz1, Masataka Uetani1, Atsushi Kawakami2, Makoto Osaki1
1Department of Orthopedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Japan
Conflict of interest: None

W49-1 Clinical results and radiographic changes after malleolar osteotomy/ fracture at total ankle arthroplasty in rheumatoid arthritis cases
Makoto Hirao1, Jun Hashimoto1, KoSuKe Ebina1, Hideki Tsuboi1, Koichi Takahashi1, Hisamoto Fromm1, Takaaki Noguchi2, Yasuo Kunugiza1, Shigeo Yoshii1, Hideki Yoshikawa1
1Department of Orthopedics, Osaka University Graduate School of Medicine, 2Orthopaedics, Rheumatology, National Hospital Organization, Osaka Minami Medical Center, 3Orthopaedics, Rheumatology, Osaka Rosai Hospital, 4Orthopaedics, Rheumatology, National Hospital Organization, Toneyama Hospital, 5Department of Orthopaedics, JCHO Hoshigaoka Medical Center
Conflict of interest: None

W49-2 Correction loss of toe arthroplasty for rheumatoid arthritis forefoot deformity
Kota Shimomura1,3, Mitsuyasu Iwasawa1, Takeomi Nakamura1, Satoru Ohashi1, Tetsuro Yasui2
1Department of Orthopedic Surgery, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan, 2Department of Orthopaedic Surgery, Teikyo University Hospital, Mizonokuchi, Japan, 3Department of Orthopaedic Surgery, Sapporo Medical University, Sapporo, Japan
Conflict of interest: None

W49-3 Risk factors contributing to the deterioration of the hallux valgus angle after the metatarsal osteotomy with temporary fixation for hallux valgus
Takuya Tomizawa1, Hiromu Ito1,2, Koichi Murata1,2, Masayuki Azukizawa1, Shuichi Matsuda1,2
1Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2The Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan
Conflict of interest: None

[Object] To examine the loss of correction following toe arthroplasty for rheumatoid forefoot deformities. [Methods] 56 patients (72 toes) underwent surgery between 2014-2017. They were examined pre-operation, post-operation, and at 1, 3, 6, and 12 months. The loss of correction, and the correlation in all groups were measured. [Results] The loss of correction in the 1/3/6/12 month period was: RA group: 8/10/11, Non-RA group: 7/10/11/12, Conservative group: 8/10/11/10, Resection group: 16/19/20/21 degrees. A significant loss of correction was seen in the 1-month postoperative surgery in all groups. It was also significant in the Resection group throughout. A correlation was present between loss of correction and both the preoperative HVA value and the postoperative length of the gap between the 1st-2nd metatarsals. Results showed no significant difference between the RA and the Non-RA toes, plus a tendency for resection to cause loss of correction. The differences in the patients’ backgrounds may affect the results. [Conclusions] Equivalent results can be expected when using conservative toe arthroplasty on both RA and Non-RA patients. Care should be taken during surgery planning and aftercare in cases where loss of correction may easily occur.

W49-4 Risk factors contributing to the deterioration of the hallux valgus angle after the metatarsal osteotomy with temporary fixation for hallux valgus
Takuya Tomizawa1, Hiromu Ito1,2, Koichi Murata1,2, Masayuki Azukizawa1, Shuichi Matsuda1,2
1Department of Orthopaedic Surgery, Kyoto University Graduate School of Medicine, Kyoto, Japan, 2The Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Graduate School of Medicine, Kyoto, Japan
Conflict of interest: None

[Object] Collagen diseases such as rheumatoid arthritis (RA) often causes a hallux valgus (HV). After metatarsal osteotomy with temporary fixation (MOWTF), some patients relapse hallux valgus. But there are few reports on the risk factor of recurrence. [Methods] From January 2011 to August 2018, 54 feet performed MOWTF at Kyoto University Hospital were examined. We recorded the age, gender, collagen disease including RA, methotrexate (MTX) dose, steroid-use, and biologic-use. On X-rays, we evaluated the hallux valgus angle. Then, we collected the correction angle (CA), correction-loss angle (CLA), length of distal metatarsal bone after osteotomy (LDMB), permanent placement of implants (PI). On univariate analysis and multivariate analysis, CA was applied as a target variable. On multivariate analysis, we adjusted for age, gender and collagen disease. [Results] On univariate analysis, LDMB, CA, and PI were significant factors. On multivariate analysis, LDMB, and CA were extracted as significant risk factors. [Conclusion] Regardless of collagen disease or fixed implants, after MOWTF for HV, we should be careful with the patients performed osteotomy at more proximal sites and the person corrected larger hallux valgus angle. Because
they might be easy to relapse HV.

**W49-4**
The gap between theoretical and actual shortening of the first metatarsal in rotational closing-wedge osteotomy
Haruki Tobimatsu, Katsunori Ikari, Koichiro Yano, Ken Okazaki
Department of Orthopedic Surgery, Tokyo Women’s Medical University

Conflict of interest: None

[Object] Since 2010 we have had favorable results at our hospital with rotational closing-wedge osteotomy of the first metatarsal accompanied by distal oblique osteotomies of the second to fifth metatarsals. In this study, we examined the discrepancy between theoretical and actual degrees of shortening that resulted from rotational closing-wedge osteotomy of the first metatarsal. [Methods] We studied 37 foot of 37 patients that underwent rotational closing-wedge osteotomy of the first metatarsal. If 0 is IMA and a is the width of the distal cut, the shortening b should theoretically be b = (a/2) sin θ. We measured actual shortening and assessed that against the theoretical shortening, using a paired t-test. [Results] Mean theoretical shortening was 1.82 ± 0.47 mm, mean actual shortening was 3.19 ± 0.93 mm, and the mean difference was a significant increase of 1.37 ± 1.1 mm (P < 0.01). [Conclusions] Rotational closing-wedge osteotomy of the first metatarsal is an excellent procedure, providing a way to correct varus deformity of the first metatarsal in a pre-planned way. Shortening of the metatarsal is unavoidable and shortening of the second metatarsal is not to be included, realizing the potential error of the theoretically calculated degree of shortening.

**W49-5**
The effect of forefoot arthroplasty for the balance and gait function in patients with rheumatoid arthritis
Motohiro Suzuki, Tetsuya Ichikawa, Tetsuyuki Nagafusa, Eiji Torikai, Shigeyuki Miyamoto, Ryu Okabayashi, Yukihiro Matsuyama
1Department of Orthopaedics, Hamamatsu University School of Medicine, 2Department of Rehabilitation, Hamamatsu University School of Medicine, 3Department of Orthopedics, Narita Memorial Hospital, 4Department of Rheumatology, Iwata City General Hospital, 5Department of Orthopaedics, Kikugawa City General Hospital

Conflict of interest: None

[Object] We assessed the effect of forefoot arthroplasty for the balance and gait function in patients with rheumatoid arthritis (RA) by gravicorder and foot print gait analyser. [Methods] We measured 16 RA patients (20 feet) performed forefoot arthroplasty by gravicorder (gravicorder GP6600; ANIMA) and foot print gait analyser (ZenoWalkwayZ-212; ProtoKinetics). We measured following indices in the pre- and post-operative course. We assessed differences of the balance and barycentric orbit in standing position by gravicorder and walking cycle, walking speed, and rate of both single and bilateral leg support by gait analyser. [Results] The primary load of pre-operative course were 5 feet (25%) on the bilateral side equally. The improvement of primary load was observed in 18 feet (90%) after forefoot arthroplasty. The movement of balance was improved after operation. On the other hand, walking cycle, walking speed, and rate of both single and bilateral leg support showed no differences statistically between pre- and post-operative course. [Conclusions] The forefoot arthroplasty in RA affected the improvement of balance movement in standing position. On the other hand, it did not affect the gait function.

**W49-6**
Setting target of JSSF RA foot ankle score for foot surgery in patients with rheumatoid arthritis based on patient-reported physical function
1Department of Orthopaedic Surgery and Rheumatology, Nagoya University Graduate School of Medicine, 2Orthopedic Surgery, Niigata Rheumatic Center, 3Orthopaedic Surgery and Spinal Surgery, The University of Tokyo Hospital, 4Rehabilitation Medicine, The University of Tokyo Hospital, 5Orthopedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 6Orthopedic Surgery, Yukioka Hospital, 7Department of Rheumatology, National Hospital Organization Osaka Minami Medical Centre, 8Orthopedic Surgery, National Hospital Organization Kyushu Medical Centre, 9Orthopedic Surgery, Keio University, School of Medicine, 10Orthopedic Surgery, University of Toyama, Faculty of Medicine, 11Orthopaedic Surgery, Saitama Medical University, 12Orthopedic Surgery, Kariya Yoyota General Hospital, 13Medical Education, Nagoya City University Graduate School of Medical Sciences

Conflict of interest: None

[Object] The aim of this study is to set the target value of JSSF RA foot ankle score (JSSF-RA) based on patient subjective physical function. [Methods] This research is a multicenter prospective, observational study conducted as a research by the Japanese Ministry of Health, Labor and Welfare. As a preoperative evaluation of foot surgery for RA patients, JSSF-RA, Timed Up & Go test (TUG), pain, global patient evaluation, physical function (HAQ), QOL (EQ-5D), and depression (BDI-II) were collected. Correlation of each parameter was examined. The relationship between HAQ remission (HAQ≦0.5) and JSSF-RA was examined with UNIANOVA adjusted for age and gender. [Results] Analysis was conducted on 417 RA patients. Mean values of age, disease duration, and DAS 28 were 64.1 years, 16.9 years and 3.01, respectively. JSSF-RA showed significant correlation with age, disease duration, HAQ, EQ-5D, and TUG. In patients with HAQ remission, mean JSSF-RA adjusted age and gender was 77.6 (95% CI: 74.3-80.9). EQ-5D (0.68 vs 0.59) and TUG (90.0 s vs 13.1 s) were significantly better in patients with JSSF-RA: CA=74 (95% CI lower limit) in HAQ remission was considered to be at least 74. It could be an important value as the target of the RA foot surgery.

**W50-1**
Distance from femoral nerve to acetabular margin -cadaveric anatomical study-
Kensuke Yoshino, Junichi Nakamura, Shigee Hagiwara, Yuya Kawarai, Masahiko Sugano, Kento Nawata, Masahiko Suzuki, Seiji Ohtori
Department of Orthopaedic Surgery, Graduate School of Medicine, Chiba University

Conflict of interest: None

[Object] To demonstrate safer areas in the anterior acetabulum by measuring the distance between the femoral nerve and the acetabular margin. [Methods] Eighty-four cadaveric hips from 44 formalin embalmed human specimens were dissected. The iliopectos muscle and the femoral nerve were exposed. The tensor fascia latae and rectus femoris muscles were detached, the anterolateral joint capsule was resected to see the bony acetabular rim and the femoral head. The measurement points were determined along the acetabular rim every 30 degrees drawing a reference line from the anterior superior iliac spine through the center of the acetabulum, describing the intersection as 0 degrees. The minimum distance to the femoral nerve margin was measured by a divider at each measurement point. [Results] The mean minimum distances were 33.2±5.1 mm (0 degrees), 24.4±5.0 mm (30 degrees), 18.4±4.2 mm (60 degrees), 16.6±3.6 mm (90 degrees), 17.9±4.0 mm (120 degrees) and 23.2±5.0 mm (150 degrees). It was significantly shorter at 90 degrees point than at the others (Linear mixed effects model, Tukey’s test, p<0.05). [Conclusions] Considering the anatomical distance, it is relatively safe for the femoral nerve to avoid the anterior acetabulum from 90 degrees area in insertion and placement of reTRACTORS.

**W50-2**
Change of lumbar and femoral bone mineral density after total hip arthroplasty in patients with rheumatoid arthritis and osteoarthritis
Hyomin Choe, Ken Kumagai, Shunsuke Yamada, Akira Morita, Arata Usui, Akiko Nagao, Yutaka Inaba
Department of Orthopaedic Surgery, Yokohama City University
Conflict of interest: None

[Object] We evaluated the change of lumbar and femoral bone mineral density (BMD) after total hip arthroplasty (THA) in patients with rheumatoid arthritis (RA) and osteoarthritis (OA). [Methods] 80 hips (26 with RA and 54 with OA) were enrolled in this study. Lumbar and femoral BMD was measured before and 1 year after THA. From the treatment for osteoporosis, patients were divided into no treatment, vitamin, and bisphosphonate group. Changes of lumbar and femoral BMD after THA were compared between RA patients and OA patients in each group. [Results] Femoral BMD were significantly decreased after THA in no treatment group or vitamin group, whereas femoral BMD in bisphosphonate group were not decreased after THA. The reduction of BMD in no treatment group was significantly higher in OA patients than that in RA, although BMD in bisphosphonate group had no difference between RA and OA patients. [Conclusions] Without treatment for osteoporosis, femoral BMD in RA and OA patients were significantly decreased after THA. Medication for osteoporosis is necessary in both RA and OA patients after THA so that they can prevent the bone fragility fractures that may severely disable daily activity of patients.

**W50-3**
The rotational alignment of femoral component of total knee arthroplasty decided with 3D-MRI
Yoshikazu Tsuneizumi
Chiba Rehabilitation Center
Conflict of interest: None

[Object] Objects: 101 primary TKAs. Diagnoses were 90 knees of OA and 11 knees of RA. [Methods] The angle between posterior condylar axis (PCA) and SEA, CEA were measured with preoperative 3D-MRI. The external angle of the femoral component was set to be between SEA and CEA. The preoperative plan for TKA was made with 3D-CT software ZedKnee, and the alignment of component was examined with ZedKnee postoperative mode. The rotation angle with respect to the preoperative SEA was examined. The difference between the theoretical angle of femoral component rotation from SEA in preoperative MRI and the postoperative rotational angle by CT was examined. [Results] The mean rotation alignment of the femoral component was 1.2° (SD 1.9) external rotation from SEA. The error from the theoretical angle of the rotation was 0.3° (2.0) internal rotation and the absolute error value was 1.5°. Eighty-nine % of knees showed that the rotational alignment of femoral component was between CEA and 2° inner rotation from SEA. There was the significant weak correlation between the flexion alignment of the femoral component and the error of the rotation. [Conclusions] Accuracy of rotational alignment of femoral component decided with 3D-MRI was comparable with conventional methods.

**W50-4**
Perioperative complications of joint replacement surgery for haemophilic arthropathy
Takuya Matsumoto, Nobunori Takahashi, Shuji Asai, Nobuyuki Asai, Yasumori Sobue, Tsuyoshi Nishiume, Mochihito Suzuki, Naoki Ishiguro, Toshihisa Kojima
Department of Orthopaedic Surgery and Rheumatology, Nagoya University Hospital
Conflict of interest: None

[Object] The aim of this study was to investigate the incidence of postoperative complications following large joint replacement for haemophilic arthropathy. [Methods] Thirty patients who underwent total knee replacement surgery (TKA) or total hip replacement surgery (THA) for haemophilic arthropathy from 1995 to 2017 and were enrolled and postoperative complications was investigated. [Results] The subjected joints were 32 TKA and 12 THA. Average age was 44.2 years, gender was all male, and average observation period was 11.4 years. All 31 cases were positive for HCV antibody and 7 cases (22.6%) were positive for HIV antibody. As postoperative complications, superficial infection were found in 8 joints (17.8%), deep infection in 3 joints (6.7%), intra-articular bleeding which requires interruption of rehabilitation or additional ad-ministration of coagulation factors in 8 joints (18.2%), aseptic loosening in 7 joints (15.5%), removal of the implant in 2 joints, revision in 1 joint, and periprosthetic fracture in 1 joint. No case developed venous thromboembolism. [Conclusions] The incident rate of complications such as postoperative infection and intra-articular bleeding is remarkably high in large joint replacement for haemophilic arthropathy. Careful postoperative observation is needed.

**W50-5**
Comparison of clinical outcomes of total knee arthroplasty between the patients of osteoarthritis and rheumatoid arthritis using new Knee Society Score
Kohei Nishitani1,2, Hiromu Ito3, Shinichiro Nakamura1, Koichi Murata1,2, Motomu Hashimoto1,3, Masao Tanaka1,3, Tsuneyo Mimori1, Shuichi Matsuda2
1Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, 2Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, 3Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University
Conflict of interest: None

[Object] The purpose was to evaluate clinical outcomes between total knee arthroplasty (TKA) for osteoarthritis (OA) and rheumatoid arthritis (RA) using New Knee Society Score (NKSS). [Methods] This study included 245 OA (age: 74±7, 199 females, BMI: 26.8) and 56 RA (age: 66±11, 49 females, BMI: 23.8) cases, who underwent primary TKA between 2012 to 2016, and whose pre-operative and 1-year post-operative NKSS were available. Among 245 OA cases, age, gender, and BMI matched 56 cases (age: 69±7, 49 females, BMI: 24.8) were extracted, and compared with RA cases. [Results] Preoperative NKSS showed no difference in symptom (OA 10.1±5.9, RA 9.1±5.2 (p = 0.35), satisfaction (OA 15.0±6.7, RA 13.2±6.47 (p = 0.18), but function was higher in OA (OA 48.1±18.8) than RA (RA 40.8±17.5) (p = 0.04). At 1-year, NKSS showed no difference in symptom (OA 20.8±4.6, RA 19.8±5.2 (p = 0.53)), satisfaction (OA 27.4±8.5, RA 26.3±8.6 (p = 0.44)) and in function (OA 71.2±16.5, RA 65.3±19.3 (p = 0.10)). One-year improvements of symptom (OA 10.7±6.6, RA 10.7±7.3 (p = 0.99)), satisfaction (OA 12.4±8.0, RA 13.1±10.0 (p = 0.70)), and function (OA 23.1±17.6, RA 24.5±19.6 (p = 0.70)) were comparable. [Conclusions] TKA for OA and RA was evaluated using NKSS. Comparable improvement in symptom, satisfaction and function is expected in RA.

**W50-6**
Examination of secondary sarcopenia preventive effect by branched chain amino acid (BCAA) nutritional intervention in the perioperative period of rheumatoid arthritis foot patients
Shigeyoshi Tsuji, Jun Hashimoto, Kentaro Isoda, Takaaki Naguchi, Shouake Akita, Koji Yachi, Shiro Ohshima, Yukihiko Saeki
NHO Osaka Minami Medical Center
Conflict of interest: None

[Object] To investigate the preventive effect by supplementation with BCAA for muscle mass reduction and muscle weakness risk associated with inflammatory stress by foot surgery in RA. [Methods] The subject was 20 patients with rheumatoid arthritis undergoing foot surgery. This research is a randomized control study. It is divided into both BCAA administered group (10cases) and BCAA nothing group (10cases). In the BCAA administration method, BCAA 4000mg (20g/day) is taken orally for a total of 5 times before meal, bedtime and immediately after rehabilitation for a total of 16days from the day before surgery to 2 weeks after surgery. Muscle mass measurement method DXA. Muscle mass measurement by body composition meter is performed before and 2 weeks after surgery. Muscular strength measurement methods are as follows: (1) average hand grip strength, (2) average knee extension strength (kg). [Results] For SMI, in the BCAA+ group, preop 5.02 / postop 4.92, P= 0.06, in the BCAA -group, preop 5.09 / postop 4.73, P= 0.01. [Conclusions] It was suggested that administration of BCAA for prevention of secondary sarcopenia in the RA foot surgery period may be useful.
Erythrocyte methotrexate (MTX)-polyglutamates levels in patients with rheumatoid arthritis are related to polymorphisms in genes associated with MTX-metabolism

Miwa Nishida1,2, Satori Hatachi3, Soshi Takahashi1, Yasuhiro Nohda1, Katsuhiko Yoneda1, Sakii Mukohara1, Norihiko Amano1, Akira Onishi1, Shunichi Kumagai1,2
1Center for Rheumatic Diseases, Shinko Hospital, 2Shinko Institute for Medical Research, 3Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine

Conflict of interest: None

[Object] To clarify the factors that affected the concentration of erythrocyte MTX-PGn and associated with MTX-hepatotoxicity. [Methods] Concentrations of erythrocyte MTX-PGn were detected by LC-MS/MS. MTX-PGn levels were measured in 189 RA patients with stable dosage of MTX which included 42 patients with elevated transaminases (>40 U/L), and the 9 SNPs including 5 SNPs in MTX-PG related genes were identified by RT-PCR. [Results] Total concentrations of MTX-PGn were 84±37.3 mmol/L (mean±SD) in 147 RA patients. In univariate analysis the concentration of MTX-PGn were correlated with dosage of MTX, BMI, RBC, Cr and SLC19A1 c.80G>A (p=0.029). In multivariate analysis the concentration of MTX-PGn were correlated with dosage of MTX, BMI, RBC and CrGh c.452C>T or FPGS c.*192T>C (p<0.05). In the hepatotoxicity group, the concentration of MTX-PGn were higher than in the group of normal range transaminase and were correlated with dosage of MTX, Cr and GGH c.452C>T (p<0.035). [Conclusion] We revealed that erythrocyte MTX-PG concentration were also related to polymorphism of MTX-PG related genes, not just clinical characteristics such as dosage of MTX, BMI, RBC and Cr.

W51-2 Predictive factors for the adequate second-choice of bDMARD or JAK-inhibitor in the first bDMARD-IR patients with RA –From First registry–

Kazuhisa Nakano1, Shingo Nakayamada1, Shigeru Iwata1, Kentaro Hanami1, Shunsuke Fukuyo1, Satoshi Kubo1, Ippei Miyagawa1, Akio Kabawe1, Yusuke Miyazaki1, Ayako Yamaguchi1, Kazuyoshi Saito1, Shinya Tanaka1,2
1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 2Internal Medicine, Tobata General Hospital

Conflict of interest: Yes

[Object] To find the predictors of the effectiveness of the second-line bDMARD or JAK-i in RA treatment. [Methods] The subjects were 513 RA pts (from 2011 to 2018) who switched to other bDMARDs or JAK-i because of failure or lack of efficacy and/or toxicity of the first bDMARD. The 1st EP is the retention rate and the REM or LDA achievement rate for each formulation at 6 months. As a 2nd EP, patient characteristics involved in achieving CDAI-REM or LDA at 6 months were analyzed. [Results] The overall age/disease duration was 62 (y)/116 (m), 80% of the first bDMARD was TNFi. Number of pts/age (y) / half-year retention rate (%) / CDAI-REM or LDA achievement rate (%) were ETN 52/68/81/79, ADA 80/57/85/81, GLM 47/64/77/74, CZP 51/56/80/69, ABT 125/67/85/72, TCZ 123/60/90/69, Tofa 27/59/89/70. Main factors that contribute to achieving CDAI-REM or LDA at 6 months are as follows: ETN: low pain (p)-V AS, low HAQ, low HAQ, low HAQ, high ACPA, low p-V AS, low p-V AS, high ACPA, low p-V AS, high HAQ, low HAQ, high ACPA. In Tofa, p-VAS was not a factor to determine effectiveness. [Conclusions] The effectiveness of all bDMARDs except for Tofa was influenced by the degree of pain. In CZP and ABT, TCZ, the high levels of ACPA was an indicator of good response.

W51-3 What affects joint destruction of the hip joints in rheumatoid arthritis - a 4-year longitudinal study from KURAMA cohort -

Kohei Doi1, Hiromu Ito1, Takuya Tomizawa1, Matayuki Azukizawa1, Koichi Murata2, Kohei Nishitani2, Motomo Hashimoto1, Masao Tanaka1, Shinichiro Ishie1, Tsuneo Mimori1, Shuichi Matsuda1
1Department of Orthopaedic Surgery, Graduate School of Medicine, Kyoto University, 2Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University

Conflict of interest: None

[Object] To find the predictors of joint destruction of hip joints in patients with RA. [Methods] Among 179 RA patients in the study who switched to a second-line bDMARD, SNPs strongly correlated with the therapeutic effect of TCZ were detected. [Results] At 6 months, 71 patients in whom SNPs analysis was performed were included. Judged by CDAI at 6 months after initiation of TCZ, 41 patients with remission or low disease activity were classified into responder group. Among them, 7 patients whose agent was switched due to deterioration over 1 year after initiation of TCZ were classified into secondary non-responder group, and 19 patients who had continued to use TCZ for over 3 years were classified into long-term user group. Using genome-wide SNP analysis, SNPs strongly associated with the therapeutic effect of TCZ was determined. [Conclusions] Associated with long-term use of TCZ, SNPs located on the genes of SEMA4A and MAGI2 were extracted. SEMA4A is involved in angiogenesis and activation of T cells. MAGI2 is involved in apoptosis via Fas/FasL signal pathway. [Conclusions] These results suggested that the detected SNPs were potential candidate for predicting the therapeutic effect of TCZ in RA patients before the treatment.

W51-5 Association between distribution of affected joints and disease activity score in rheumatoid arthritis patients-Answer cohort study-

Yuichi Maeda1, Toru Hirano1, Motomo Hashimoto1, Wataru Yamamoto1, Kosuke Ebina1, Kosaku Murakami1, Tohru Takeuchi1, Kenichiro Hata1, Yousu Son1, Hideki Amuro7, Akira Onishi1, Sadao Jinno4, Masaki Katayama5, Yusuke Manabe1, Yuta Yamaguchi1, Yumiko Mizuno1, Tatsuya Yagita1, Ryota Harta1, Atsushi Kumanogoh1
1Department of Respiratory Medicine and Clinical Immunology, Osaka University, Graduate School of Medicine, 2Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University

Conflict of interest: None

[Object] To find the predictors of joint destruction of hip joints in patients with RA. [Methods] Among 179 RA patients in the study who switched to a second-line bDMARD, SNPs strongly correlated with the therapeutic effect of TCZ were detected. [Results] At 6 months, 71 patients in whom SNPs analysis was performed were included. Judged by CDAI at 6 months after initiation of TCZ, 41 patients with remission or low disease activity were classified into responder group. Among them, 7 patients whose agent was switched due to deterioration over 1 year after initiation of TCZ were classified into secondary non-responder group, and 19 patients who had continued to use TCZ for over 3 years were classified into long-term user group. Using genome-wide SNP analysis, SNPs strongly associated with the therapeutic effect of TCZ was determined. [Conclusions] Associated with long-term use of TCZ, SNPs located on the genes of SEMA4A and MAGI2 were extracted. SEMA4A is involved in angiogenesis and activation of T cells. MAGI2 is involved in apoptosis via Fas/FasL signal pathway. [Conclusions] These results suggested that the detected SNPs were potential candidate for predicting the therapeutic effect of TCZ in RA patients before the treatment.
Conflict of interest: None

[Object] It is unknown which part of the joints strongly contributes to increased levels of ESR and CRP in rheumatoid arthritis (RA) patients.

[Methods] We analyzed retrospectively 56976 clinical data (5002 RA patients) who visited our hospitals in 2011 to 2018. We divided the joints into 6 sites (shoulders, knees, wrists, elbows, MCPs, PIPs) for further analysis. We investigated the correlation between swollen, tender joints and the disease activity-related score such as ESR, CRP, PtVAS (patient visual analogue scale) and DrVAS. We also analyzed relationship between affected joints and autoantibodies such as rheumatoid factor and anti-citrullinated peptide antibody. [Results] Interestingly, among the 6 sites, knees are the strongest factors which induce increased levels of ESR and CRP. By contrast, PIPs are the weakest factors which contribute to elevated levels of ESR and CRP. PtVAS and DrVAS strongly correlated with increased affected joints of hands and knees. Intriguingly, we also found that the levels of rheumatoid factor and anti-citrullinated antibody are correlated with the score of wrists. [Conclusions] Thus, these findings suggest that different joint distribution in RA patients leads to different results of disease activity score or autoantibody production.

W51-6
Systemic immune-inflammation index in rheumatoid arthritis patients: Relation to disease activity
Takahiro Yoshikawa, Maki Shibamoto, Kazuteru Noguchi, Rei Tedokoro, Kazuyuki Hatano
Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine

Conflict of interest: None

[Object] To assess systemic immune-inflammation index (SII) in rheumatoid arthritis (RA) patients and compare between active cases and those in remission.

[Methods] In 734 RA patients registered in the database of our department from 2015 to 2016, a total of 437 eligible RA patients were included in this study, excluding 296 patients whose neither the RA disease activity or laboratory data were available. Correlations of SII with the disease activity of RA were evaluated. SII was calculated by the following calculation formula; SII = Netrophils (%) / Lymphocyte (%) * Platelets (G/L).

[Results] The median age of patients was 65.0 (54.0-73.0) years and the median of disease duration was 9 (6-14) years.

The DAS28-ESR was median 2.69 (1.94 - 3.49). SII was 618.3 (420.8 - 962.1). There was a significant correlation between SII and DAS28-ESR (r=0.335, P<0.0001), and SII was significantly elevated as disease activity increased (median 532.2 in remission, 579.9 LDA, 796.9 in MDA and 962.1). There was a significant correlation between SII and DAS28-ESR (r=0.335, P<0.0001), and SII was significantly elevated as disease activity increased.

Conflict of interest: None

W52-2
Pathogenic role of fractalkine in interstitial pneumonia
Soichi Yamada1, Natsuko Kusunok1, Hiroshi Sato1, Sei Muraoaka1, Tosho Imai2, Shinichi Kawai2, Toshihiro Nanki3
1Division of Rheumatology, Department of Internal Medicine, School of Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, 2KAN Research Institute, Inc, Kobe, Japan, 3Department of Inflammation & Pain Control Research, School of Medicine, Toho University, Tokyo, Japan

Conflict of interest: None

[Object] Treatment for interstitial pneumonia (IP) associated with collagen diseases has not been established yet. It is expected to elucidate the pathogenesis of IP and development of novel therapy. We aimed to clarify the role of fractalkine (FKN) in IP. [Methods] Bleomycin (BLM) was intratracheally administered to C57BL/6 mice. Expression of FKN and the receptor CX3CR1 was analyzed immunohistochemistry. The mice were treated with anti-FKN mAb or control Ab intraperitoneally for 2 weeks. The lung was stained with hematoxylin-eosin, and collagen eluted from the lung was quantified. In vitro, mouse lung fibroblasts (MLFs) were stimulated with FKN. Production of collagen and the cell movement was examined. [Results] Expression of FKN and CX3CR1 was upregulated in BLM-induced IP. Treatment with anti-FKN mAb did not significantly alter inflammatory cell infiltration. However, collagen in the lung decreased. Stimulation with FKN did not alter the production of collagen from MLFs, but enhanced the cell movement significantly.

[Conclusion] FKN might be involved in increasing collagen in the IP and cell movement of MLFs. It is suggested that FKN may contribute fibrosis of IP.

W52-3
Autoantibody-inducing CD4 T (α/CD4 T) cells which induce SLE contain follicular helper T cell in addition to IL-21-producing CX-CR5/ICOShiPD-1hi population
Ken Tsuniyama, Shunichi Shiozawa
Institute for Rheumatic Diseases

Conflict of interest: None

[Object] Autoantibody-inducing CD4 T (α/CD4 T) cell is indispensable for our ‘self-organized criticality’ theory that induces SLE. We previously showed that the α/CD4 T cell belongs to CD45RB<sup>122</sup> subpopulation. Here we further dissected the phenotype of α/CD4 T cell. [Methods] BALB/c mice were repeatedly immunized with OVA, and
SLE was induced. Cell surface marker and cytokine production of CD45RB+ CD4 T cell were examined using flow cytometry and ELISA. These CD4 T cells were adoptively transferred into recipient mice, and anti-ds DNA antibody and urine albumin were detected. [Results] After repeated immunization with OVA, not only CXCR5+ICOS+PD-1+ follicular helper T (Tfh) cell but also CXCR5+ICOS+PD-1- cell was increased in CD45RB+ CD4 T cell. CXCR5+ICOS+PD-1- CD4 T cell highly produced IL-21 rather than Tfh cell. Both CD4 T cells were induced anti-ds-DNA antibody in the recipient mice. Further, CXCR5+ICOS+PD-1- CD4 T cell strongly induced kidney injury as compared to Tfh cell. [Conclusions] In addition to Tfh cell, IL-21-producing CXCR5-ICOShiPD-1hi CD4 T cell was increased in line with induction of SLE. This novel CXCR5+ICOS+PD-1hi CD4 T cell appears to be responsible for helping B cell to induce autoimmune and driving CD8 T cell to cause lupus tissue injury.

W52-4
The regulation of skin fibrosis in systemic sclerosis by extracellular ATP via P2Y2 purinergic receptor
Sei-ichiro Motegi, Osamu Ishikawa
Department of Dermatology, Gunma University Graduate School of Medicine

Conflict of interest: None

[Object] Objective was to elucidate the role of extracellular ATP, which can act as a damage-associated molecular pattern molecules (DAMPs), in skin fibrosis in systemic sclerosis (SSc). [Methods] Production of IL-6 and collagen in SSc or normal fibroblasts treated by ATP was analyzed. [Results] We identified that hypoxia enhanced ATP release, and extracellular ATP enhanced IL-6 production more significantly in SSc fibroblasts than in normal fibroblasts. Non-selective P2 receptor antagonist and selective-P2Y2; receptor antagonists, kaempferol and AR-C, significantly inhibited ATP-induced IL-6 production and phosphorylation of p38 in SSc fibroblasts. Collagen type I production in SSc fibroblasts by ATP-induced IL-6/IL-6 receptor trans-signaling was inhibited by kaempferol and p38 inhibitor, SB203580. Amount of ATP in bleomycin-treated skin was increased, and administration of AR-C significantly inhibited bleomycin-induced dermal fibrosis in mice. [Conclusions] These results suggest that vasculopathy-induced hypoxia and oxidative stress might enhance ATP release in the dermis in SSc, and extracellular ATP-induced phosphorylation of p38 via P2Y2 receptor might enhance IL-6 and collagen type I production in SSc fibroblasts.

W52-5
Elevated Serum Concentration of Amphiregulin in Patients with Idiopathic Inflammatory Myopathy and Systemic Sclerosis
Akito Kawamura, Norio Hanata, Yasuo Nagafuchi, Yusuke Sugimori, Satomi Kobayashi, Yukiko Iwasaki, Hirofumi Shoda, Keishi Fujio
Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Conflict of interest: None

[Object] Amphiregulin (AREG) belongs to the epidermal growth factor that seems to be involved in the pathophysiology of autoimmune diseases such as rheumatoid arthritis (RA), while there is a paucity of research to show the association of AREG in idiopathic inflammatory myopathy (IM) and systemic sclerosis (SSc). In this study, we measured the serum concentration of AREG in patients with IM and SSc. [Methods] Serum concentration of AREG in patients with 18 IM, 6 SSc and 7 RA was measured by ELISA and compared to that of 6 healthy controls (HC). The relationship between the serum concentration of AREG and the clinical parameters such as autoantibody profiles, presence of interstitial lung disease (ILD), and serum creatine kinase (CK) value were analyzed. [Results] The serum concentration of AREG was significantly elevated in patients with IM (33.2±16.5 pg/ml, p=0.0066), SSc (25.4±10.9 pg/ml, p=0.025) and RA (20.5±7.95 pg/ml, p=0.044) compared to that in HC (11.9±3.47 pg/ml). In particular, there was a tendency that the serum concentration of AREG was elevated in IM with ILD compared to that in IM without ILD (37.3±5.06 vs 24.9±4.14, p=0.096). [Conclusions] The serum concentration of AREG was significantly elevated in patients with IIM and SSc compared to that in HC.

W52-6
Intravenous low-molecular-weight heparin PLGA micro-particles inhibit lung fibrosis of bleomycin-induced interstitial pneumonia
Takuya Kotani, Takayasu Suzuki, Shogo Matsuda, Takao Kiboshi, Koji Nagai, Kenichiro Hata, Tohru Takeuchi, Shigeki Arakawa
Department of Internal Medicine IV, Osaka Medical College

Conflict of interest: None

[Object] Interstitial pneumonia (IP) is a life-threatening pathological condition that causes respiratory failure when it progresses. The development of new treatments is thus required for IP from the viewpoint of the poor effect and adverse effects of the currently available treatments. Heparin promotes the production of hepatocyte growth factor (HGF) in various cells and is useful for not only promoting cell proliferation but also immune response modulating action and anti-fibrotic effect. We investigated the therapeutic effect of intravenous low-molecular-weightheparin PLGA micro-particles (LMWH/PLGA) in a mouse model of bleomycin-induced IP. [Results] Heparin increased HGF production in the culture supernatant of type 2 alveolar epithelial cells. LMWH/PLGA inhibited fibrosis in the lung. The levels of TNF-α, IL-6, IL-1β, COL1α1, and TIMP mRNA expression at 28 days after BLM administration were significantly lower in LMWH/PLGA treated group compared with those in non-treated group. [Conclusions] Intravenous LMWH/PLGA showed anti-fibrotic effect on IP model mice.

W53-1
Intrapleural methylprednisolone injection in pleuritis associated with connective tissue diseases: report of three cases
Saki Minoda, Yoichi Nakayama, Hirofumi Miyake, Hiroyuki Akebo, Ryuichi Sada, Hiroyasu Ishimaru, Kazuhiro Hatta
General Internal Medicine, Tenri Hospital

Conflict of interest: None

[Case] (Case 1) A 79-year-old woman with rheumatoid arthritis (RA) presented with bilateral exudative pleural effusion. Although 0.8mg/kg of prednisolone (PSL) were not effective, bilateral intrapleural methylprednisolone injection (ip-mPSL-i, 125mg in each side) could reduce her pleural effusion. (Case 2) An 83-year-old woman with Sjogren’s syndrome presented with right exudative pleural effusion. She did not have an indication of high dose PSL or pleurodesis because of her background. We performed 120mg of ip-mPSL-i, which reduced her pleural effusion and turned her exudative pleural effusion into transudate. (Case 3) A 70-year-old woman with SLE and stage 3 pharyngeal cancer presented with cytology-negative left exudative pleural effusion. Either 1mg/kg of PSL and 120mg of ip-mPSL-i were not effective, and, she died due to Klebsiella bacteremia and invasive aspergillosis after 4 weeks. [Discussion] Effectiveness of ip-mPSL-i for pleural effusion due to connective tissue diseases (CTDs) other than RA is still unclear. We performed the injection for 3 cases of CTDs-related pleurisy. 2 cases without advanced cancer achieved a therapeutic effect. [Clinical Significance] ip-mPSL-i is one of the useful options for pleural effusion caused by CTDs.

W53-2
Systemic AL Amyloidosis Mimicking Seronegative Rheumatoid Arthritis
Mikiko Iguchi
National Hospital Organization Kyoto Medical Center

Conflict of interest: None

Systemic AL amyloidosis mimicking seronegative rheumatoid arthritis A-51-year-old women suffered from symmetrical multiple joint swelling simulating rheumatoid arthritis. Treatment with prednisolone, methotrexate and tocilizumab was not sufficiently improved her arthritis. Further examination revealed Bence Jones Protein in urine without monoclonal protein on immunoelectrophoresis in serum. Bone marrow biopsy didn’t show typical plasma cell infiltration and a synovial biopsy revealed amyloid deposition composed AL kappa-amyloid. From these
WS5-3
Six cases with Chlamydia-associated rheumatoid arthritis, who could stop disease-modifying antirheumatic drug

Naruhiko Takasawa1,2, Junichi Kamooza1, Yukio Sekiguchi1, Takeshi Sasaki1,2
1Department of Internal Medicine, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital, 2Department of Rheumatology, Tohoku Medical and Pharmaceutical University Wababayashi Hospital, Division of Hematology and Rheumatology, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Department of Internal Medicine, Tohoku Medical and Pharmaceutical University Natori Hospital

Conflict of interest: None

Chlamydia infection often causes acute onset of polyarthritis. We have demonstrated that rheumatoid arthritis (RA) may occur in association with Chlamydia infection in some cases. We here report six cases with RA, who were all positive for anti-Chlamydia pneumoniae IgM antibodies at onset. The therapy using minocycline (MINO) and methotrexate (MTX) could bring them termed as Chlamydia-associated RA, into remission without any disease-modifying antirheumatic drug (DMARD) including MTX. Six cases were in their forties to seventies. They fell to the acute-onset RA, got swollen joints and met the diagnostic criteria for RA. Vascular signals of joint echo were recognized and matrix metalloproteinase 3 (MMP-3) was elevated in all six cases. Anti-cyclic citrullinated peptide (CCP) antibodies were negative in half of six cases. They were treated with MTX and MINO. The treatment was effective for all the cases and the administration with biological DMARD was unnecessary in any cases. Six to ten mg of MTX per week were administered to them and induced remission. The amount of MTX was reduced gradually and treatment with DMARD including MTX was ceased finally. These indicate that Chlamydia-associated RA may be a subtype of RA, which has good prognosis.

WS5-4
Endotheliopathy Induces Renal Dysfunction Of TAFRO Syndrome: Clinicopathological Analysis Of 7 cases Of TAFRO syndrome

Hiroki Mizuno, Daisuke Ikuma, Shunsuke Yamada, Norikazu Toi, Shinsuke Yamada, Norikazu Toi, Yutaka Furumitsu, Kenichirou Fumbei, Yoshifumi Ubara
Department of Rheumatology, Toranomon Hospital

Conflict of interest: None

[TAFRO syndrome is subtype of multicentric Castleman disease, characterized by thrombocytopenia, anasarca, fever, reticulin fibrosis, organomegaly. Renal dysfunction is known as a manifestation of TAFRO syndrome, sometimes requiring hemodialysis, but pathophysiology has not been elucidated yet. [Methods] Design; case series. Subject; 7 cases of TAFRO syndrome treated in our hospital between April in 2014 and October in 2018. [Results] Median age was 53 y.o. (min 34, max 84), 3 cases were female. Body weight gain was 17.6 (8.3, 26.4) kg and platelet count was 4.1 (2.8, 11.5)*10^4/μL. Serum creatinine was 1.17 (0.77, 5.71) mg/dL and maximum level was 2.67 (1.43, 6.28) mg/dL. Hemodialysis was required in 5 cases. Severe endothelial injury with tuft occlusion was observed in all cases. All cases were treated by glucocorticoid and 6 cases by tocilizumab. Thrombocytopenia was treated by thrombopoietin receptor agonist in 5 cases. 1 case was died by aspiration pneumonia and hemodialysis was not required after the treatment in all cases. Critical hemorrhage was occurred in 4 cases and PRES was occurred in 1 case during the treatment. [Conclusions] Severe endothelial injury was commonly seen in all patients with TAFRO syndrome and renal dysfunction. This change is specific in TAFRO syndrome.

WS5-5
Clinical significance of myositis-specific autoantibodies in idiopathic interstitial pneumonia

Yasu Matsuzawa, Kotaro Kumano
Department of Internal Medicine, Toho University Sakura Medical Center, Sakura, Japan

Conflict of interest: None

[Object] To clarify clinical significance of myositis-specific autoantibodies in idiopathic interstitial pneumonia (IIP). [Methods] All IIP patients who visited our department between December, 2015 and July, 2018 were subjected to measurement of myositis-specific autoantibodies using EUROLINE test. [Results] 240 patients of IIP were subjected. The HRCT patterns (number of the patients) of the patients were UIP (65), possible UIP (48), inconsistent with UIP (80), OP (40), DAD (7). Myositis-specific autoantibodies: OJ, EJ, PL12, PL7, SRP, Jo-1, Mi2 were positive in 5, 3, 9, 14, 9, 1, 7 patients. 7 patients were positive for multiple autoantibodies. The HRCT patterns of the 40 patients were UIP (7), possible UIP (9), inconsistent with UIP (20), OP (3), DAD (1). Acute exacerbation was observed in 7 patients, and 9 patients have died. The risk factor for acute exacerbation were anti PL12 antibodies (OR 1.99, p=0.006) and anti PL7 antibodies (OR1.5, p=0.04), and the risk factors for death was anti PL12 antibodies (OR 1.7, p=0.03) in multivariate analysis. [Conclusions] Myositis-specific autoantibodies was positive for 40 of 240 patients of IIP. Anti PL12 antibodies and anti PL7 antibodies were risk factors of acute exacerbation, and anti PL12 antibodies was poor prognostic factor.

WS5-6
Sleep status in RA patients receiving steroid medication

Noriyuki Hayashi1, Shinmuke Yamada1, Norikazu Toi1, Yutaka Furumitsu1, Shinichirou Iamauchi1, Masaaki Inaba1
1Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, Osaka, Japan, 2Department of Internal Medicine, Ohno Memorial Hospital, Osaka, Japan, 3Department of Orthopedic Surgery, Ohno Memorial Hospital, Osaka, Japan

Conflict of interest: None

[Background] There are not so many reports that examine the association between prednisolone (PSL) use and sleep status in RA patients, though it is known that sleep disorder is one of the important side effects of PSL. [Object] We investigated the influence that steroid medication gave in sleep status in RA patients. [Methods] We examined 28 RA patients (PSL user/non-user number:13/15, 64.9/61.3 years of age, DAS28 (CRP):3.2/3.5). In all patients, subjective and objective sleep status were assessed by Pittsburgh Sleep Quality Index (PSQI) and single-channel EEG, respectively. [Results] PSQI levels was 6.6 ± 3.2 in 28 RA patients. Approximately 71% of them had a diagnosis of sleep disorder (PSQI ≥ 5.5). Although there was no significant difference in age and DAS28 between PSL user and non-user, nocturnal awakening tended to be longer in PSL user than in PSL non-user, and slow wave sleep (SWS) and δ-power as sleep quality parameter were higher significantly in PSL non-user than in PSL user, and nocturnal awakening tended to be longer in PSL user than in PSL non-user, and slow wave sleep (SWS) and δ-power as sleep quality parameter were higher significantly in PSL non-user than in PSL user. In multiple regression analysis including age, DAS28, and PSL use or not, only PSL use was associated significantly in a negative manner with δ-power. [Conclusions] Steroid medication has a negative effect on sleep status in RA patients.

WS5-4
Involvement of mast cells in the development of tissue fibrosis of Sjögren’s syndrome via fibroblast immune function

Shinjiro Kaieda, Kyoko Fujimoto, Yumi Yoshida, Makiko Hayashi, Takuma Koga, Hiroaki Ida
Department of Medicine, Division of Respiratory, Neurology and Rheumatology, Kureme University School of Medicine

Conflict of interest: None

[Object] We examined whether mast cells (MCs) play a critical role in sialadenitis in patients with Sjögren’s syndrome (SS). [Methods] Labial salivary glands (LSG) samples were collected from 22 individuals with
primary SS and 10 with sicca syndrome. The degree of fibrosis in LSG was graded on a quantitative scale as previously reported. Human mast cell line 1 (HMC-1) were stimulated with or without recombinant IL-33/SCF for 24 hours and HMC-1 conditioned medium was collected. Pro-fibrotic factors and collagen synthesis in fibroblasts was evaluated. [Results] The number of MCs in LSGs of patients with SS was significantly increased. There was a significant negative correlation between the Sax-on’s test results and the MC density (r=0.6742, P=0.006). whereas there was no correlation between the focus score and the MC density (r=0.01545, P=0.58), a significant correlation between the MC density and the degree of fibrosis was observed (r= 0.5911, P=0.0038). MCs were usually present in close proximity to EVG-stained fibrous tissue. Significant up-regulation of profibrotic factors and Col Iα mRNA was observed in fibroblast cultured in HMC-1-conditioned medium. [Conclusions] MCs contribute to sialadenitis in patients with SS by induction of tissue fibrosis via fibroblast immune function.

W54-2
Studies on anti-carbamylated protein antibody and the joint destruc-tion in Sjögren’s syndrome patients
Kazuko Shimazawa1, Yassyhi Tanaka1, Ryosuke Yoshihara1, Miki Murata2, Natsuko Nakagawa1, Atsuo Ueji1, Toshiyuki Ota2, Ken Tsuniyama2, Shunichi Shiozawa1
1Rheumatology & Collagen Disease Center, Hyogo Prefectural Kakogawa Medical Center, 2Collagen & Rheumatic Disease Center, Iizuka Hospital, 3Institute for Rheumatic Diseases
Conflict of interest: None

INTRODUCTION Anti-carbamylated protein antibody (aCaPAb) re-acts against homocitrulline an amino acid harbouring additional CH2 res-idue on citrulline scaffold. aCaPAb has previously been detected in 20% of Japanese patients with primary Sjögren’s syndrome (pSS). We here evaluated 20 aCaPAb-positive pSS patients in comparison with 78 aCa-PAb-negative pSS patients to clarify the contribution of aCaPAb to the clinical features. METHODS The presence of IgG antibody reactive against carbamylated fibrinogen was measured by using ELISA. RESULTS Among aCaPAb-positive pSS, the positive ratios for rheumatoid factor, anti-SS-A Ab and ACPA were higher as compared with those neg-ative for aCaPAb-negative pSS patients. The number of tender joints were; zero was 40% and 53.8%, 1~2 was 30% and 30.8%, >3 was 30% and 30.2% in the aCaPAb-positive and aCaPAb-negative patients, respec-tively. The modified Sharp score 0 was 50% and 72.4%, score 1 was 70% and 63.9%. Apart from the severity of the disease, there were a significant difference in the number of tender joints (p=0.0038), the degree of fibrosis (p=0.0008), the extent of joint destruction (p=0.0038) and carpal tunnel syndrome (p=0.0038). CONCLUSION Both aCaPAb and OA are associated with joint destruction in pSS.

W54-3
Assessment of submandibular glands using shear wave elastography in patients with early-stage Sjögren’s syndrome
Naoaki Hashimoto1, Masayasu Kitano2, Takashi Nakazawa3, Tsuyoshi Iwasaki1, Takenori Hashimoto1
1Hashimoto Rheumatology Clinic, 2Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, 3Department of Rheumatology, Osaka Saiseikai Nakatsu Hospital, 4Department of Pharmacy, Hyogo University of Health Sciences
Conflict of interest: None

Object: The submandibular gland (SG) ultrasonography is useful for the diagnosis of Sjögren’s syndrome (SS) patients, but it is difficult to di-aognose early-stage SS patients with normal saliva flow (JCR2016). We assess oral health-related quality of life (OHRQoL) and evaluate changes in OHRQoL within three years in patients with Sjögren’s syndrome (SS). [Methods] 35 SS patients and 23 controls (non-SS) were enrolled. OHRQoL was evaluated using a short version of the Oral Health Impact Profile (OHIP-14), which is a self-administered questionnaire. Higher scores indicate poorer OHRQoL. 22 patients and 14 controls was followed up for three years. In the SS group, the OHIP-14 score was significantly higher compared with the non-SS group (11.3 ± 7.1, p= 0.027). Salivary flow rate in the severe group (score ≥14) was significantly higher than that in the mild group (≤13). Scores of “trouble pronouncing words”, “uncomfortable to eat”, “self-con-scious”, “diet unsatisfactory” in the SS group were significantly higher than those in the non-SS group. The OHIP-14 score significantly increased after three years in the SS group (10.2 ± 12.6, p=0.040). This change was not observed in the non-SS group. Scores of “irritable with others”, “difficulty doing jobs”, “life unsatisfying”, “unable to function” significantly increased in the SS group. [Conclusions] OHRQoL is im-paired in SS patients. Sustained xerostomia can cause poorer OHRQoL associated with social disability and handicap.

W54-5
Effectiveness of abatacept for patients with secondary Sjögren’s syn-drome (SS) associated with rheumatoid arthritis (RA). An open label, multicenter, prospective study: ROSE (Rheumatoid Arthritis trial to-ward Sjögren’s syndrome Endocrinopathy) trial
Fumika Honda1, Hiroto Tsutub1, Kazuhisa Nakano2, Yoshihi Tanaka2, Hideki Nakamura1, Atsushi Kawakami1, Yuichiro Fujieda2, Tatsuya Atsumi3, Yasunori Suzuki2, Mitsuhiro Kawano4, Yuko Kaneko5, Tsutomu Takeuchi1, Hitomi Harahaka1, Masami Takei1, Naoto Tsumura1, Yoshiharu Takasaki1, Kazuhiro Yokota1, Yoshitoh Miura1, Kosaku Murakami1, Tsuneyo Mimori1, Shiro Ohshima1, Naoto Azuma1, Hajime Sano2,1, Susumu Matsui1, Isao Matsumoto3, Takayuki Sumida1
1Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan, 2The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3Unit of Translational Medicine, School of Medicine, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 4Internal Medicine II, Hokkaido University, Sapporo, Hokkaido, Japan, 5Division of Rheumatology, Department of Internal Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, Japan, 6Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 7Division of Hematology and Rheumatology, Department of Medicine, Nihon University Itabashi Hos-pital, Tokyo, Japan, 8Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 9Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 10Department of Rheumatology and Clinical Immunolo-
Conflict of interest: Yes

[Objectives] To clarify the effectiveness of abatacept (ABT) for patients with secondary SS (sSS) associated with RA. [Methods] Patients with sSS with RA were enrolled in ROSE I trial designed as an open-labeled, multi center, prospective study. 1) The primary endpoint was the achievement of SDAI remission at 52 weeks (W) after treatment with ABT. 2) Secondary endpoint included Saxon’s and Schirmer’s test. 3) In ROSE II, ESSDAI and ESSPRI were also included in secondary endpoint. [Results] 61 patients (all female) were enrolled (36 in ROSE I and 25 in ROSE II). Among them, 43 patients (36 in ROSE I and 7 in ROSE II) who had completed the evaluation at 52 W were analyzed in this study. 1) SDAI significantly decreased from 20.8±11.5 (W0) to 10.2±10.1 (52W), and patients who achieved SDAI remission significantly increased from 0 (W0) to 12 cases (27.9%) (52W) (N=43, p<0.05). 2) Saxon’s and Schirmer’s test significantly improved from 2034±1789 (0W) to 2405±1852 mg/min (24W) (N=41, p<0.05) and 4.7±5.8 (W0) to 6.0±7.4 (24W) mm/min (N=34, p<0.05, respectively). 3) ESSDAI significantly decreased from 9.6±5.4 (W0) to 3.6±2.3 (24W) (p<0.05), while ESSPRI did not significantly change (4.5±2.0 to 3.9±2.0) (N=7). [Conclusion] ABT was effective for both RA and SS manifestations of sSS with RA.

Conflict of interest: Yes

**W54-6**

Clinical characteristics of Sjögren’s syndrome induced by immune checkpoint inhibitors

Mikito Suzuki, Takahisa Gono, Shiniro Watanabe, Yuichiro Shirai, Seiji Kobayashi, Mitsuhiro Takeno, Masataka Kuwana

Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan

Conflicts of interest: Yes

**Objectives:** We experienced two cases who developed Sjögren’s syndrome (SS) after administration of ICI. The aim of this study is to identify clinical characteristics of ICI-induced SS by literature review.

**Methods:** We reviewed clinical information of our cases and published literature reporting ICI-induced SS. We conducted a PubMed search on the following keywords: “Sjögren”, “immune checkpoint inhibitor”, “Ipilimumab”, “Nivolumab”, “Pembroliuzumab”, “Atezolizumab”, “Avelumab”, “Durvalumab”. Results: A total of 16 cases including our 2 cases developed SS at 14 weeks of the median period after initiation of ICI. The mean age was 62 years and 50% were female. The most common malignancy was melanoma in 8 cases. Five cases received combination therapy with CTLA-4 inhibitors and PD-1 inhibitors. CTLA-4 inhibitor or PD-1 inhibitor was received in 7 and 4, respectively. Regarding the treatment for SS, ICI was ceased in 2 cases. 10 cases received corticosteroid (CS). Pilocarpine and cevimeline were administered in 3 and 1 case, respectively. Sicca symptoms improved in 13 of 16 cases.

**Conclusions:** Sicca symptoms developed more acutely and the response to the treatment with CS for SS was better in ICI-induced SS, different from clinical characteristics in classic primary SS.

**W55-1**

Comparison of effectiveness of biologic DMARDs stratified by disease activities using propensity score matching

Kazuyoshi Saito1,2, Kazuhide Nakano1, Shingo Nakayamada2, Shigeru Iwata2, Satoshi Kubo1, Ippei Miyagawa2, Shunshuie Fukuyo2, Yusuke Miyazaki2, Kentaro Hanami3, Ayako Yamaguchi3, Akio Kawabe3, Masao Nawata1, Yuya Fujita4, Yoshiha Tanaka4

1Center for Rheumatic Disease, Tobata General Hospital Kitakyushu Japan, 2The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu Japan, 3Department of Rheumatology, Wakamatsu Hospital of the University of Occupational and Environmental Health, Kitakyushu Japan, 4Department of Emergency Medicine, University Hospital of Occupational and Environmental Health, Kitakyushu Japan

Conflict of interest: None

[Object] This study aimed to evaluate the effectiveness of biologics stratified by disease activities at induction in RA from our university cohort (FIRST registry). [Methods] We retrospectively examined patients treated with TNF inhibitors (TNFi; IFX 345, ETN 348, ADA 517, GLM 106, CZP 161), TCZ 490, ABT 49. After stratification with disease activities (H group; high disease activity DAS28ESR≥5.1, ML group; 2.6−5.1) at induction, we compared the patients’ background, CDAI at 2 and 52 wks after treatment using PS matching. [Results] Patients were divided to two groups as TNFi (H:913, ML:256), TCZ (H:355, ML:135), ABT (H:309, ML:188). Shorter disease duration, higher ratio of bio-naïve and concomitant treatment with MTX in TNFi, higher titers of CRP, MMP in TCZ, higher age in ABT were observed in both H and ML group. After PS matching, however CDAI at both 2 and 52 wks were comparable in both H and ML group, effectiveness was TNF=TCZ, ABT at 2 wks and TNF, TCZ=ABT at 52 wks in H group. [Conclusions] Disease activity at initiation of biologics might be one of important factor for selection of biologics. Although, there was slight differences among biologics, we have to decide biologics after comprehensive consideration including adverse effects that we did not discussed in this study.

**W55-2**

Comparison of drug tolerability and discontinuation reasons between 7 biologics in elderly patients with rheumatoid arthritis -Data from Kansai consortium for well-being of rheumatic disease patients (AN-SWER cohort)-

Kosuke Ebina1, Motomo Hashimoto1, Wataru Yamamoto1,4, Toru Hirano3, Yuichi Maeda4, Koichi Murata2, Ryota Har4, Akira Onishi4, Sadao Jinn3, Yonsu Son2, Hideki Amuro4, Masaki Katayama3, Tohru Takeuchi4, Koji Nagai1, Hideki Yoshikawa1

1Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, 2Department of Respiratory Medicine and Clinical Immunology, Osaka University, Graduate School of Medicine, Osaka, Japan, 3Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, 4Department of Health Information Management, Kurashiki Sweet Hospital, 5The Center for Rheumatic Diseases, Nara Medical University, 6Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 7First Department of Internal Medicine, Kansai Medical University, 8Department of Internal Medicine IV, Osaka Medical College, 9Department of Rheumatology, Osaka Red Cross Hospital

Conflict of interest: Yes

[Object] To compare the tolerability and discontinuation reasons between 7 biologics in elderly (65 years of age or older) RA. [Methods] 1098 biologics treatment courses from 2009 to 2017 (female 80.8%, age 71.7y, RF positivity 81.1%, Bio naïve 62.0%, number of each agent; ABT 272, TCZ 234, ETN 184, GLM 159, IFX 101, ADA 97, and CZP 51) were included in this multi-center, retrospective study. Drug tolerability and discontinuation reasons were adjusted by potent confounding factors (age, sex, and switched biologics number) with an Cox proportional hazards model and evaluated at 36 months. [Results] Adjusted cumulative incidence rates of each discontinuous reason were as follows. Drug inefficacy (ABT 18.1%, TCZ 22.5%, GLM 23.4%, IFX 28.9%, ADA 33.0%, CZP 40.5%, ETN 42.6%; Cox P < 0.001), toxic adverse events (ABT 4.6%, CZP 6.5%, ETN 14.3%, TCZ 15.2%, GLM 15.5%, ADA 15.8%, IFX 21.5%; Cox P = 0.03), remission (IFX 8.4%, TCZ 7.0%, ETN 6.4%, BMT 5.7%, GLM 3.2%, CZP 0.0%; Cox P = 0.46). Overall adjusted retention rates excluding non-toxic events and remission were ABT 78.1%, TCZ 65.8%, GLM 64.9%, ADA 56.3%, IFX 55.8%, CZP 55.0%, ETN 47.1% (Cox P < 0.001). [Conclusions] ABT showed lowest inefficacy and toxic events, and highest retention rate in adjusted model.

**W55-3**

The efficacy, safety and adherence of biologic disease-modifying anti-rheumatic drugs, infliximab, tocolizumab and abatacept, in elderly patients with rheumatoid arthritis

Takuma Wada1, Yu Funakubo1, Mayumi Matsuda1, Hiroaki Yazawa1, Yoshinobu Nakao2, Noritsune Kozu1, Keita Okamoto1, Takashi
Maruyama1, Yoshihiro Yoshida1, Kazuhiro Yokota1, Yasuto Araki1, Hiroshi Kajiyama1, Kojiro Sato1, Yuii Akiyama1, Yoshitohide Minamura1 1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, Saitama, Japan, 2Department of Rheumatology, Saga University Hospital, Saga, Japan, 3Kouzu Orthopedic Clinic, Chiba, Japan, 4Department of Rheumatology, Ogawa Red Cross Hospital

Conflict of interest: None

W55-4 Reduced renal function in patients with rheumatoid arthritis treated with biologic agents
Eigo Kikuchi, Naoko Aoki, Taro Yoshioka, Takahiro Okai Center for Rheumatology and Joint Surgery, Kawakita General Hospital, Tokyo, Japan

Conflict of interest: None

[Objective] We aimed to examine the reduction of renal function and its risk factors in patients with rheumatoid arthritis (RA) treated by biologic agents. [Methods] We used biologic agents to treat patients with RA who had visited our hospital between 2011 and 2016. All patients had exhibited eGFR values of ≥70 (mL/min/1.73 m²) prior to use of biologic agents. The end point was decline in eGFR by ≥20% for ≥3 months; moreover, the patients were analyzed according to their age (≥65 years old vs <65 years old) and the presence or absence of NSAID use. [Results] Overall, 180 patients (153 females, 85.0%, average age 57.6 ± 16.1 years, ABT 23 cases, ADA 19 cases, CZP 19 cases, ETN 54 cases, GLM 16 cases, IFX 18 cases, TCZ 31 cases) were enrolled in this study. The longest cumulative incidence of reduced renal function in the 60-month period was 45.4%. The cumulative incidence was 68.1%, among patients aged ≥65 years (n = 66) and 33.4% in those <65 (n = 114) [p < 0.001 (log-rank test)]. The cumulative incidence in NSAID users (n = 70) was 61.6%, whereas in non-NSAID users (n = 110), it was 36.9% (p = 0.016). [Conclusions] It is recommended that renal function should be closely monitored in elderly patients who are undergoing treatment for RA with biologic agents and are taking NSAIDs.

Conflict of interest: Yes

W55-5 Current situation and secular change of biosimilars in NinJa
Toshihiro Matsui1, Atsushi Hashimoto1, Atsushi Kaneko2, Shigeto Tohma3 1Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, 2Department of Orthopedic Surgery, National Hospital Organization Nagoya Medical Center, 3National Hospital Organization Tokyo National Hospital

Conflict of interest: Yes

[Objective] To investigate the current situation and secular change of biosimilars in patients with rheumatoid arthritis (RA) in Japan. [Methods] Using the data of NinJa (National Database of Rheumatic Disease in Japan) from 2014 to 2017, we compared the actual use and users’ background of between infliximab (IFX) and infliximab BS (IFX-BS). [Results] The number of patients registered in each fiscal year of NinJa was 15023 (2014) → 15100 (2015) → 15341 (2016) → 15185 (2017), respectively. Total number and percentage of IFX or IFX-BS users gradually decreased from 490 [3.3%] → 449 [3.0%] → 406 [2.6%] → 324 [2.1%]. IFX users decreased from 400 [3.8%] → 362 [3.0%] → 278, but IFX-BS users showed an increasing trend from 0 → 21 → 36 → 64, and the rate of biosimilar users (IFX-BS/IFX + IFX-BS) also increased from 0 → 2.7% → 10.8% → 14.2%. Comparison of IFX users and IFX-BS users in NinJa 2017 revealed that there were significant differences in age, disease duration, disease activity (DAS28-ESR), patient global assessment, body weight, dose per body weight, and the number of vials used. Meanwhile, for IFX-BS users, the usage rate of steroid was lower (10.9% vs 25.9%, p < 0.05) and physical function (mean mHAQ) was better (0.172 vs 0.339, p < 0.05). [Conclusions] The use of biosimilars showed an increasing trend gradually.

Conflict of interest: None

W55-6 Drug tolerability of secondary biologies in patients with rheumatoid arthritis who were primarily treated by non-TNF inhibitors biologics-[Data from Kansai consortium for well-being of rheumatic disease patients (ANSWER cohort)]
Kosuke Ebina1, Motomo Hashimoto2, Wataru Yamamoto3, Toru Hiroano4, Yuiichi Maeda, Koichi Murata2, Ryota Hara4, Akira Onishi4, Sadao Jinno1, Yonsu Sor1, Hideki Amuro1, Masaki Katayama1, Tohru Takeuchi1, Koji Nagai1, Makoto Hiro1, Hideki Yoshikawa1 1Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, 2Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, 3Department of Rheumatology and Clinical Immunology, Osaka University, Graduate School of Medicine, 4The Center for Rheumatic Diseases, Nara Medical University, 5Department of Clinical Immunology, Kobe University Graduate School of Medicine, 6First Department of Internal Medicine, Kansai Medical University, 7Department of Health Information Management, Kurashiki Sweet Hospital, 8Department of Internal Medicine IV, Osaka Medical College, 9Department of Rheumatology, Osaka Red Cross Hospital

Conflict of interest: Yes

[Objective] To compare the tolerability of secondary biologics in patients with rheumatoid arthritis (RA) who were primarily treated by non-TNF inhibitors. [Methods] 146 biologics treatment courses who were primarily treated by non-TNF inhibitors (TNFi) (ABT 57 cases, TCZ 89 cases) from 2009 to 2017 (female 82.6%, age 59.5y, RF positivity 73.9%, MTX 29.5%, PSL 21.9%) were included in this multi-center, retrospective study. Biologics were classified as TNFi, ABT, or TCZ, and tolerability was estimated using a Kaplan-Meier method at 36 months. [Results] ABT was switched to TNFi (33 cases) or TCZ (24 cases), and TCZ was switched to TNFi (61 cases) or ABT (28 cases). Main cause of discontinuation was inefficacy (89.0%) for 1st biologics, whereas inefficacy (49.5%), non-toxic reasons (25.8%), and toxic reasons (20.6%) for 2nd biologics. Overall retention rates excluding non-toxic reasons at 36 months were ABT to TNFi (57.1%) vs. ABT to TCZ (70.9%) (Log-rank P = 0.40), and TCZ to TNFi (35.8%) vs. TCZ to ABT (63.0%) (Log-rank P = 0.17). [Conclusions] Although ABT→TCZ and TCZ→ABT tended to show higher persistency compared to switching to TNFi, no significant differences were observed in drug tolerability of secondary biologics who were primarily treated by non-TNF inhibitors in RA.
[Object] We examined the inflammation of synovium before and after biologic agents in the patients with rheumatoid arthritis (RA) and to investigate the association between synovial histopathology and disease activity. [Methods] Synovial tissues were collected from 34 RA joints before and after biologics. The average age and disease duration of the study subjects were 64 and 22.5 respectively. Histopathological changes in the synovial tissues were compared based on Rooney’s score. We examined correlation between pathological findings in RA synovium and disease activity under biologics. [Results] Rooney score before between and after biologic agents improved from 28.4 to 12.0 showing significant difference. Significant improvement in Rooney score was observed in all items. After the use of biologic agents, MDA group had significantly higher in scores of focal aggregates of lymphocytes, diffuse infiltrates of lymphocytes, and Rooney total scores than Remission and Low disease activity groups. [Conclusions] The study results demonstrated that biologics agents significantly decreased inflammatory changes in the synovial lining layers and sublining layers. In addition, the results suggested that histopathological findings in the subsynovial tissue reflected disease activity.

W56-2 Serum levels of ROM, an oxidative stress marker at 12 weeks during treatment with tocilizumab is a useful biomarker to predict the clinical remission at 52 weeks
Arata Nakajima, Masato Sonobe, Hiroshi Takahashi, Shinji Taniguchi, Manabu Yamada, Shijo Nakano, Koichi Nakagawa Department of Orthopaedic Surgery, Toho University Sakura Medical Center
Conflict of interest: None

[Object] Tocilizumab (TCZ) strongly suppresses inflammatory reaction; however, clinicians sometimes see discrepancy between the improved laboratory data and actual symptoms of patients. Therefore, it is necessary to develop a novel biomarker other than CRP to predict the future clinical remission during early treatment. [Methods] A total of 46 RA patients (mean age: 60.1 y.o., disease duration: 8.1 y) during treatment with TCZ including 32 naïve and 14 switched from other biologics were enrolled in this study. Associations between serum levels of ROM, CRP, and MMP-3 at 4 and 12 weeks and the remission by DAS28-ESR, CDAI, SDAI and Boolean at 52 weeks were investigated. [Results] There were no significant differences in CRP, MMP-3, and ROM between remission and non-remission groups at 4 weeks. ROM levels at 12 weeks in the DAS-, SDAI-, and Boolean-remission groups were significantly lower than those in their non-remission groups. ROC curves demonstrated the AUC of ROM was 0.735 (p = 0.024) and its cut-off value was 305.5 (sensitivity: 70%, specificity: 72.2%). Neither CRP nor MMP-3 was able to predict clinical remission at 52 weeks. [Conclusions] ROM at 12 weeks during treatment with TCZ was a useful biomarker to predict the DAS-remission at 52 weeks.

W56-3 Increase of serum bone alkaline phosphatase level after tocilizumab treatment; from comparison study of serum biomarkers between infliximab and tocilizumab
Naoshi Nishina, Keiko Yoshimoto, Tsutomu Takeuchi Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Conflict of interest: None

[Object] To elucidate the differences of the mechanism of action between infliximab (IFX) and tocilizumab (TCZ) by comparing time course of serum biomarkers. [Methods] Patients with rheumatoid arthritis who started IFX or TCZ as the first biological agent from 2010 to 2013 at our institution were included. Serum samples were collected at week 0, 6, 22, and 54 for IFX and at week 0, 4, 24, and 52 for TCZ, respectively. Serum biomarkers (interleukin [IL]-6, tumor necrosis factor α, soluble IL-6 receptor, vascular endothelial growth factor [VEGF], Bone alkaline phosphatase [BAP], and osteocalcin) were measured by electrochemiluminescence assay. [Results] The rate of methotrexate use was significantly higher in IFX group (n=57) than in TCZ group (n=70) (96% vs 76%). Median IL-6 level decreased in IFX group (8.9 pg/ml at week 0 to 1.2 pg/ml at week 54), but increased in TCZ group (from 5.2 to 15.3 pg/ml). VEGF level decreased in both group. Median BAP level remained at the same level in IFX group (from 17.9 to 15.6 ng/ml) although significant increase was observed in TCZ group (from 7.9 to 86.6 ng/ml) (p<0.01). [Conclusions] Serum BAP level increased after TCZ treatment in contrast to IFX treatment. These two agents may have different effect on bone in spite of same clinical benefit.

W56-4 Improvement of matrix metalloproteinase-3 at 12 weeks is an independent predictive factor for achievement of low disease activity at 52 weeks after starting abatacept treatment in rheumatoid arthritis
Nobunori Takahashi Nagoya University Graduate School of Medicine
Conflict of interest: Yes

[Object] Japanese PMS reported that effectiveness of abatacept in bio-switch RA patients was significantly lower than that in bio-naive patients. We investigated predictive factors for good clinical effectiveness of abatacept in the bio-switch RA patients. [Methods] Participants were consecutive 423 RA patients treated with abatacept and observed for longer than 52 weeks, in the TBC Registry system. Multivariate logistic regression analysis was used to study predictive factors for achievement of low disease activity at 52 weeks, separately in bio-naive and bio-switch group. [Results] ROC analysis revealed that MMP-3 improvement rate at 12 weeks had highest AUC and cut-off value of 20.0%. In bio-naive group, DAS28-ESR score at baseline was the only predictive factor, while 20% improvement of MMP-3 at 12 weeks was an independent predictive factor (adjusted OR: 3.550, p=0.005) in addition to DAS28-ESR in the bio-switch group. [Conclusions] In bio-switch patients, we sometimes have difficulty to obtain good clinical response of abatacept and it would be even more important to judge whether to continue abatacept as early as possible. Our results suggested that the improvement of MMP-3 at 12 weeks would be a key to predict good clinical effectiveness of abatacept at 1 year.

W56-5 The efficacy and safety of abatacept in patients with rheumatoid arthritis and interstitial lung disease
Sho Sasaki, Yasushi Kondo, Takayoshi Kurabayashi, Yasushi Koyama, Chihio Yamada, Shini Sato Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine
Conflict of interest: None

[Object] To assess the efficacy and safety of abatacept in patients with rheumatoid arthritis (RA) and interstitial lung disease (ILD) associated to RA. [Methods] We enrolled 24 patients with RA who were treated with abatacept between 2011 and 2017 at Tokai University Hospital. We compared the efficacy and safety between RA patients with ILD and without ILD. We retrospectively evaluated the disease activity using the change in DAS28-ESR and PSL dose at ABT initiation 0 month and after 12 months (12M). The safety was assessed using continuing rate of ABT. [Results] There were no statistically significant differences in gender, age, duration of disease, DAS28-ESR score, MTX and PSL dose between the two groups. At the 12 months after ABT initiation, there was a significant improvement in DAS28-ESR score (5.0±1.0 vs. 3.5±1.4, P=0.006). There was a significant reduction in the mean dose of PSL (8.5±5.2 vs. 5.4±4.1, P=0.007). There was no significant difference in reduction rate of DAS28-ESR between RA patients with and without ILD groups (-1.6±1.4 vs. -1.3±0.5, P=0.3). No significant difference in continuing rate between both groups at the 12 months was observed (11 [69%] vs. 4 [50%]). [Conclusions] ABT showed the equivalent efficacy and safety for RA with ILD as well as RA without ILD.

W56-6 Abatacept in rheumatoid arthritis patients with collagen disease
Kazunori Yamada, Kiyoaki Ito, Yasunori Suzuki, Fae Suzuki, Satoshi Iwai
Conflict of interest: None

[Object] To elucidate the differences of the mechanism of action between infliximab (IFX) and tocilizumab (TCZ) by comparing time course of serum biomarkers. [Methods] Patients with rheumatoid arthritis who started IFX or TCZ as the first biological agent from 2010 to 2013 at our institution were included. Serum samples were collected at week 0, 6, 22, and 54 for IFX and at week 0, 4, 24, and 52 for TCZ, respectively. Serum biomarkers (interleukin [IL]-6, tumor necrosis factor α, soluble IL-6 receptor, vascular endothelial growth factor [VEGF], Bone alkaline phosphatase [BAP], and osteocalcin) were measured by electrochemiluminescence assay. [Results] The rate of methotrexate use was significantly higher in IFX group (n=57) than in TCZ group (n=70) (96% vs 76%). Median IL-6 level decreased in IFX group (8.9 pg/ml at week 0 to 1.2 pg/ml at week 54), but increased in TCZ group (from 5.2 to 15.3 pg/ml). VEGF level decreased in both group. Median BAP level remained at the same level in IFX group (from 17.9 to 15.6 ng/ml) although significant increase was observed in TCZ group (from 7.9 to 86.6 ng/ml) (p<0.01). [Conclusions] Serum BAP level increased after TCZ treatment in contrast to IFX treatment. These two agents may have different effect on bone in spite of same clinical benefit.
Hara1, Ichiro Mizushima2, Hiroshi Fujii2, Takashi Kawane1, Kazuaki Mizutomi1, Mitsuhito Kawano2
1Department of Advanced Research in Community Medicine, Kanazawa University Graduate School of Medical Sciences, 2Department of Rheumatology, Kanazawa University Hospital, 1Kaga Medical Center, 2Kim Clinic, 3Toyama Red Cross Hospital

Conflict of interest: None

[Object] To retrospectively evaluate the efficacy of abatacept (ABT) in rheumatoid arthritis (RA) patients (pts) with other collagen diseases (CDs). [Methods] Forty-five RA pts who were treated with ABT were enrolled in this study; of these, 23 had other CDs (CD group, methotrexate [MTX] 43.5%) and 22 did not (non-CD group, MTX 50.0%). We evaluated disease activity at 0, 24, 52, and 104 weeks (wks) after ABT therapy and the persistence rate. [Results] The mean ages were 55.9 and 63.3 years in the CD and non-CD groups, respectively. The mean DAS 28 (%28) was 5.7 and 5.1 in the CD and non-CD groups, respectively. The changes in DAS at 24 and 52 wks in the CD group showed no significant differences from those in the non-CD group. Changes in DAS were also significantly different between the pts who received and those who did not receive MTX. Persistence rates at 104 wks were 100% and 77.3% in the CD and non-CD groups, respectively. [Conclusions] ABT was effective in RA pts with other CDs regardless of MTX use.

W57-1 Actual dosage and adverse effect of methotrexate in patients with juvenile idiopathic arthritis: single center experience
Ai Ohnishi, Seira Hattori, Kenichi Nishimura, Ryoki Hara, Shuichi Itô
Department of Pediatrics, Yokohama City University

Conflict of interest: None

[Object] We examined actual status of Methotrexate (MTX) treatment among juvenile idiopathic arthritis (JIA) patients in our institute and analyzed the background why patients decreased or discontinued MTX. [Methods] We retrospectively reviewed the electric medical chart of JIA patients, having significant MTX from April 2011 to March 2018 and collected the data. The target dose of MTX defined as 10 mg/m²/week, max 16mg/week. [Results] 53 JIA patients (male 20, female 33) were classified into; systemic (n=9), polyarticular (n=21), oligoarticular (n=15) and psoriatic/ enthesitis-related (n=8). Median age starting MTX was 8.5 years old (range 1.5-18.8). Median dose of maximum MTX was 8.9mg/m²/week. Adverse effects were observed in 36 (68%). 15 patients (28%) were forced to reduce or discontinue MTX due to adverse effect and 16 patients (30%) consequently needed biologics. Half of patients who started folic acid when MTX started, had nausea/vomiting. At the last observation, targeted dose was achieved only in 9 (9%), but 29 (55%) maintained remission using MTX below the target dose. [Conclusions] Many patients failed to achieve the target dose, resulted in adding biologics. Optimal dose varies widely by patient's background, disease activity and concomitant therapy.

W57-2 Adverse event reports of oral Methotrexate (MTX) using the database of the Pharmaceuticals and Medical Devices Agency (PMDA)
Naonori Tsuda1, Shigeko Inokuma2, Kenichi Hiragi1, Yoshinori Masui1, Toshihazu Kano1
1Department of Rheumatology, Kohnodai Hospital, National Center for Global Health and Medicine, 2Department of Allergic Disease and Rheumatology, Chiba Central Medical Center

Conflict of interest: None

[Object] The Japanese Adverse Event Report database (JADER) in the Pharmaceuticals and Medical Devices Agency (PMDA) collects information on drug adverse events throughout Japan. We analyzed the various adverse events of oral Methotrexate (MTX), which is the important drug in rheumatoid arthritis treatment, according to its clinical contents. [Methods] From the list of adverse event reports of oral MTX published at JADER on PMDA, the number and the clinical contents of adverse events were analyzed within 2004 to 2008 (5 years), 2009 to 2013 (5 years), and 2014 to 2017 (4 years). We reorganized the categories partly to suit the clinically appropriate classification. [Results] The median of adverse events of oral MTX was 436 within 2004 to 2008, 668 in 2009 to 2013 and 1471 in 2014 to 2017. The details were in the order of blood / lymphatic system disorder 25% (blood cytopenia 24%), infection 25%, and respiratory disorder 24% (interstitial lung disease 20%) in 2004 to 2008, whereas neoplastic diseases were 40% (lymphoproliferative disorder (LPD) 34%), infectious diseases 17% and blood / lymphatic system disorders 13% (cytopenia 12%) in 2013 to 2017. [Conclusions] Reported adverse events of oral MTX were changing over time. LPD is increasing recently and caution is required.

W57-3 Diagnosis for chronic hepatic disorder induced by methotrexate (MTX)
Masayuki Miyata
Fukushima Red-Cross Hospital

Conflict of interest: None

[Object] Hepatic disorder is most frequent side effect in MTX Tx. Acute hepatic disorder can be noticed and dissolved by addition of folic acid, on the other hand, chronic hepatic disorder is hard to be noticed. Histopathology of this closely resembles that of non-alcoholic steatohepatitis (NASH). Fibrosis marker, Fibrosis-4 index (FIB-4) could be applied for diagnosis of chronic hepatic disorder. [Methods] FIB-4 was screened in non-alcoholic RA patients and the average was calculated. Fourteen patients, who have high FIB-4 and agreed to take liver biopsy, were enrolled. All patients quit taking MTX after liver biopsy. Three of them underwent 2nd biopsy in 2 years. [Results] Thirteen of 14 patients showed NASH-like hepatic disorder. The one showed simple steatosis. Almost of all patients decreased FIB-4 values after discontinuation of MTX. Second biopsies showed improved NASH, suggesting that FIB-4 seems valuable marker. Multivariate linear regression analysis identified the following factors as being significantly associated with FIB-4: Age, Class and CRE. [Conclusions] In order to monitor the degree of fibrosis of MTX-induced chronic hepatic disorder, FIB-4 was valuable. Combination with other fibrotic markers and diagnostic imaging may improve the safety in the MTX treatment.

W57-4 2-year real-world observation of disease control with optimizing dose of methotrexate (MTX) while reducing or discontinuing prednisolone (PSL) in patients with rheumatoid arthritis (RA)
Shintaro Hirata1, Kei Araki2, Hiroki Kohno3, Kazutoshi Yukawa1, Tadahiro Tokunaga4, Tsatsumi Kuranobu5, Katsuhiro Oh1, Yusuke Yoshida1, Tomohiro Sugimoto1, Sho Mukuda1, Keisuke Oda1,2, Takaki Nojima3, Eiji Sugiyama1
1Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 2Department of Internal Medicine, Hiroshima Clinic, Hiroshima, Japan, 3Nojima Internal Medicine Clinic, Hiroshima, Japan

Conflict of interest: Yes

[Object] At JCR2018 we reported that PSL could be reduced without deterioration of RA with optimized MTX at 1-yr. Herein we investigated 2-yrs results of disease control and medication. [Methods] RA patients who had regularly visited our clinic for ≥1yr were consecutively registered during Sep-Oct 2016. Clinical demographics as well as disease status and medication at baseline (BL), yr-1 and -2 were collected. Basic therapeutic strategy was to increase MTX while reducing PSL based on patient’s consent. bDMARDs/JAKi were allowed if required. [Results] 70 patients were enrolled. Age (median [IQR]) 62 [51, 68] yrs; female 69%; disease duration 6.8 [3.4, 13.7] yrs. MTX users at BL, 1 and 2 yrs were 57, 67 and 59%, whereas doses (mean±SD) were 9.8±3.2, 11.6±3.7 and 10.5±3.8 mg/w, respectively. PSL users were 56, 26 and 10%, whereas doses were 3.6±3.4, 2.9±2.6 and 3.6±2.8mg/d. bDMARDs/JAKi users
were 16, 18 and 26, newly initiated in 2 and 8 during BL-1-2yrs. CDAI / SDAI / DAS28-REM at BL, 1- and 2- yrs were; 24, 39, 49% / 27, 41, 52% / 35, 41, 48%, respectively. MTX was withdrawn due to renal dysfunction or neoplasms. [Conclusions] Optimizing MTX with bDMARDs/ JAKi if required resulted in discontinuation of PSL in 90% of the patients, whereas PSL might delay clinical decision-making.

**W57-5**

Iguratimod (IGU) add-on therapy for RA patients inadequately controlled with bDMARDs

Ken Hasegawa
Department of Orthopaedic Surgery, Meinan Hospital, Nagoya, Japan

Conflict of interest: None

[Object] If the treatment target is not achieved with the bDMARD therapy, another bDMARD should be considered by the treatment guideline for RA. A csDMARD add-on is also a treatment option in daily clinical practice. Efficacy and sustainability of IGU add-on therapy were evaluated in RA patients treated by bDMARDs. [Methods] IGU was added on bDMARD in 6 patients (3 male, 3 female; 54.7±15.8 years old, disease duration 13.1±7.1 years, bDMARD therapy duration 21.0±20.4 months). Disease activity score (SDAI), RF value and MMP-3 value were compared between before and after the IGU therapy. Drug persistency rate were estimated by Kaplan-Meier method (Start point was defined as the introduction of IGU, end-point was defined as the discontinuation of IGU or bDMARD). [Results] At the start of IGU at 6 month later, SDAI were 14.0±14.0±4.7±0.5±1 (P=0.35), RF were 389.7±562.1 U/mL/160.3±231.0 U/mL (P=0.27), MMP-3 were 238.1±172.5ng/ml/103.4±79.2ng/ml (P=0.09). SDAI 50/70/85 achievement rate were 67/33/0% at 6 months (LOCF method). Persistency rate were 67%/67%/103.4±79.2ng/ml (P=0.09). SDAI 50/70/85 achievement rate were 67% at 6 months. IGU combination with bDMARD was effective and sustainable in most cases. [Conclusions] IGU add-on therapy could be one of valuable treatment options in daily clinical practice when the previous bDMARD therapy was failed.

**W57-6**

Experiences of Iguratimod (IGU) therapy in elderly patients aged 75 and over with rheumatoid arthritis

Toshihiko Hidaka, Yaoi Hashiba, Kazuyoshi Kubo, Hiroshi Kuroda
Institution of Rheumatology, Zenjinkai Shimin-no-Mori Hospital, Miyazaki, Japan

Conflict of interest: Yes

[Objectives] We assessed the efficacy of Iguratimod (IGU) in patients with elderly rheumatoid arthritis (ERA) aged 75 or over. [Methods] One hundred and nine RA patients who had been treated with IGU were evaluated. These patients were divided into two groups; group U (G-U, n=76): patients aged under 75, group G (G-G, n=33): aged 75 and over. We compared the SDAI, ACR response, EULAR response and adverse effects (AEs) of G-G with G-U until 1-year treatment. [Results] G-G was significantly longer in disease duration, higher in Class, DAS28-ESR and combination rate of steroid, and lower combination rate of MTX than G-U. G-G was significantly lower in SDAI remission rate than G-G (G: 50%, G: 21%, P<0.05). There were no significant difference in SDAI low disease activity rate, ASDAI, EULAR good and moderate response rate and ACR 20/50/70 response rate between G-G and G-U. There was no significant difference in AEAs rate between G-G and G-U (G: 29%, G: 22%, ns). There was no significant difference in AEs rate between G-G and G-U (G: 73%, G: 80%, NS). [Conclusion] IGU therapy is safe and clinically effective for even older RA patients aged 75 and over.

**W58-1**

A multicenter, prospective study of clinical features of Japanese systemic sclerosis with progressive disease activity in the early clinical stage

Akira Utsunomiya1, Minoru Hasegawa1, Yoshihide Asano2, Osamu Ishikawa3, Hirahito Endo4, Yasushi Kawaguchi5, Masatake Kuwana6, Daisuke Goto6, Shinichi Sato2, Hiroki Takahashi7, Kazuhiko Takehara8, Sumiaki Tanaka9, Manabu Fujimoto10, Hiro Nobu Ino11
1Department of Dermatology, School of Medicine, Faculty of Medical Sciences, University of Fukui, Fukui, Japan, 2Department of Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, 3Department of Dermatology, Gunma University Graduate School of Medicine, Gunma, Japan, 4Department of Rheumatology, Jusendo General Hospital, Fukushima, Japan, 5Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 6Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 7Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan, 8Department of Rheumatology, Sapporo Medical University School of Medicine, Hokkaido, Japan, 9Department of Molecular Pathology of Skin, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan, 10Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan, 11Department of Dermatology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan, 12Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

Conflict of interest: None

Object: Racial differences may perturb the overall clinical course and physical disability of systemic sclerosis, particularly in cases with early progressive disease. Methods: We enrolled 248 patients with aggressive clinical states in the early disease stage, and monitored their symptoms and laboratory states each year for 7 years in 10 facilities. Results: 193 (78%) were female with the mean age at the study registration of 49.3 years. Anti-topoisomerase I antibody and anticientromere antibody were detectable in 145 (58%) and 22 (9%), respectively. 171 (69%) had interstitial lung disease. Comparing between registration and final assessment points, subjects receiving monotherapy with corticosteroid were 57% and those having a combined therapy with corticosteroid and immunosuppressants were 11%, although the latter increased to 29%. MRSS decreased from 18.5 to 12.8 by 1-year, and became constant at around 10. Serum KL-6 level was stable, whereas %VC, digital ulcer, and HAQ-DI were gradually exacerbated. Conclusion: Japanese systemic sclerosis with early progressive disease activity tended to resolve their skin sclerosis during 7-year follow up. However, the physical disability was aggrivated by respiratory dysfunction and digital ulceration.

**W58-2**

Characteristics of CRP positive systemic sclerosis

Kae Takagi1, Yasushi Kawaguchi2, Manabu Kawamoto3, Yuki Ichimura2, Akiko Tochimoto2, Chikako Fukasawa4, Hisashi Yamanaka2
1Internal Medicine, Tokyo Women’s Medical University Medical Center East, 2Rheumatology and Clinical Immunology, Tokyo Women’s Medical University Hospital

Conflict of interest: None

[Object] Some of the patients with systemic SSc exhibit elevated levels of CRP. However, roles of CRP in the clinical features of SSc remains controversial. The purpose of this study is to clarify the characteristics of CRP-positive SSc patients. [Methods] Four hundred and twenty-five SSc patients were involved in this study. The cases accompanied by infection were excluded. Clinical features were compared between CRP-positive 100 cases and CRP-negative 318 cases. [Results] The frequency of arthritis (p=0.00658, OR 2.109), interstitial pneumonia (IP) (p=0.00163, OR 2.837), pulmonary hypertension (PH) (p=0.01289, OR 2.525) and lower gastrointestinal tract failure (p=0.02999, OR 2.166) was significantly higher in the CRP-positive group. The patients with rheumatoid arthritis (p=0.00658, OR 2.109), systemic lupus erythematosus (p=0.00771, OR 4.153) and anti-DNA antibody positivity (p=0.04365, OR 2.536) was also significantly higher in the CRP-positive group. The frequency of TBX21 rs11650354 CC genotype was not significantly different between these groups. [Conclusions] SSc patients with an elevated level of CRP positively was associated with IP or PH that determine poor prognosis. This therefore suggests CRP is a useful marker to predict for the prognosis or disease activity of SSc.
W58-3
Evaluation of renal dysfunction in patients with anti-centromere anti-
body positive limited cutaneous systemic scleroderma
Taro Horino, Satoshi Inotani, Tatsuki Matsumoto, Yoshio Shimamura, Kosuke Inoue, Yoshiho Terada
Department of Endocrinology, Metabolism and Nephrology, Kochi Medical
School, Kochi University

Conflict of interest: None

[Object] Anti-centromere antibody positive limited cutaneous sys-
temic scleroderma (lcSSc) tends to be neglected because of the mild
range and degree of skin symptoms compared to diffuse cutaneous type.
Clinical features of renal dysfunction in patients with centromere anti-
body positive lcSSc (ACA-lcSSc) are examined. [Methods] 80 patients
who had hospitalized in our outpatient clinic from 2012 to 2018 were en-
rolled. All patients met the American College of Rheumatology classifi-
cation criteria for lcSSc. We assess their clinical characteristics and data.
[Results] Female were 74 (92.5%). Mean age was 67.6 years old. Clinical
characteristics; Incidence of Raynaud phenomenon and sclerodactyly
were 76 and 89.3%. Organ damages; interstitial pneumonia, pulmonary
hypertension, PBC, Sjogren syndrome, Hashimoto’s disease, CKD were
30.0%, 33.3%, 46.2%, 55.6%, 36.2% and 46.2%, respectively. Incidence
of overt proteinuria was 31.2%. Renal biopsy was performed in 7 cases,
in which 6 cases had lupus nephritis and one had non-IgA mesangial pro-
liferative glomerulonephritis. [Conclusions] To our knowledge, there is
no report that studies case series of ACA-lcSSc with LN. Our data sug-
gested that in ACA-LcSSc, SLE was thought to merge at a relatively high
rate.

W58-4
Prognosis and causes of deaths of Systemic sclerosis patients with in-
terstitial pneumonia
Shigeki Makino1, Hidehiko Makino2, Takeshi Shoda1, Takaaki Ishida3, Takuya Kotani1, Tohru Takeuchi4, Shigeki Arawaka5
1Division of Internal Medicine, Osaka Medical College Mishima-Minami
Hospital, Takatsuki, Osaka, Japan, 2Department of Internal Medicine IV,
Osaka Medical College, Takatsuki, Osaka, Japan, 3Division of Rheuma-
tology, Yodogawa Christian Hospital, Osaka, Japan

Conflict of interest: Yes

[Background] We aim to know the influence of interstitial pneumonia
(IP) involvement on prognosis of Systemic sclerosis (SSc). [Methods]
We reviewed clinical data concerning about prognosis and causes of
deaths of SSc-IP patients of our institute from August 2008 to July 2018.
[Results] Total SSc-IP patients are 212 (34 males, average 69.7 years).
Comparing SSc patients without IP (479cases, 41 males, average 63.6
years), SSc-IP patients were older and male dominant. Total dead cases
were 25 (7males). 5-year survival rate of SSc-IP patients was 91.4%, 10-
year survival rate was 80.2%. Concerning about the causes of deaths of
SSc-IP patients, chronic progression of IP were 6 cases, acute exacerbation
of IP were 1, pulmonary hypertension were 1, lung cancer were 2, other
malignancy were 3, infection were 1, cardiac disease were 2. [Conclu-
sions] SSc-IP patients of our institute were older and male dominant com-
pared to SSc patients without IP. 5-year survival rate of SSc-IP patients
in our institute were older and male dominant compared to SSc patients
without IP. 5-year survival rate of SSc-IP patients was 91.4%, 10-year survival rate was 80.2%. Leading cause of deaths of
SSc-IP patients were chronic progression of IP 6 cases. Total death due
to pulmonary lesion were 10 (40%). So pulmonary involvement of SSc in-
fluence on prognosis of SSc-IP patients.

W58-5
Efficacy and Safety of Tocilizumab for the Treatment of Systemic
Sclerosis (SSc) in Japanese Patients: Results from a Phase 3 Ran-
donized Controlled Trial
Masataka Kuwana1, Yoshihito Shima2, Yoshiya Tanaka1, Kazuhioko Takehara1, Norihiro Okada1, Hiroko Igarashi2
1Department of Allergy and Rheumatology, Nippon Medical School,
2Thermo-therapeutics for Vascular Dysfunction, Osaka University Graduate
School of Medicine, 3The First Department of Internal Medicine, University of Occupational and Environmental Health, 4Department of
Dermatology, Kanazawa University, 5Clinical Information & Intelligence
Department, Chugai Pharmaceutical Co., Ltd, 6Clinical Science & Strate-
gy Department, Chugai Pharmaceutical Co., Ltd

Conflict of interest: Yes

[Object] To investigate the efficacy and safety of tocilizumab (TCZ)
for Japanese patients (JP) with diffuse cutaneous SSc (dCSSc). [Methods]
Patients with disease duration of ≤5 years were randomly assigned 1:1
to receive weekly double-blind injections of subcutaneous TCZ 162 mg
or placebo (PBO) for 48 wks. [Results] 210 patients (ITT) were treated
with TCZ (n=104, JP: n=12) and PBO (n=106, JP: n=8). Mean baseline
values were: disease duration, 22.64 months; modified Rodnan skin score
(mRSS), 20.35; and percent predicted forced vital capacity (ppFVC),
82.12%. Mean change in mRSS from baseline to wk 48 (primary end-
point) was -6.14 with TCZ (JP: -7.89) and -4.41 with PBO (JP: -4.63);
the difference in mean change between TCZ and PBO was -1.73, \( p = 0.098 \) (JP: -3.26). Mean change in ppFVC from baseline to wk 48 (sec-
ondary endpoint) was -0.38% with TCZ (JP: 3.76%) and -4.58% with
PBO (JP: -0.83%); the difference in mean change for the ITT population
was 4.2% (95%CI: 2.0, 6.4). No new safety signal with TCZ treatment
was observed. [Conclusions] The primary endpoint was not met, but the
results favor TCZ over PBO for improvement in mRSS, and clinically
meaningful differences in FVC were shown with no safety concern. Re-
sults of the JP were consistent with the ITT population.

W58-6
Efficacy and safety of combination therapy with prednisolone and
oral tacrolimus or azathioprine for progressive interstitial pneumo-
ia with systemic sclerosis
Takao Kiboshi1, Takuya Kotani1, Junichi Konna2, Reiko Wakura1, Takeshi Shoda1, Tomohiko Kuboyama1, Hidehiko Makino1, Shogo Matsuda1, Takayasu Suzukai1, Takaaki Ishida1, Koji Naga1, Kenichiro Hata1, Shigeki Makino1, Tohru Takeuchi1, Shigeki Arawaka1
1Department of Internal Medicine IV, Osaka Medical College, Takatsuki,
Osaka, Japan, 2Department of Internal Medicine, Osaka Medical College
Mishima-Minami Hospital, 3Department of Rheumatology, Yodogawa
Christian Hospital

Conflict of interest: None

Objectives: We retrospectively investigated efficacy and safety of
combination therapy with prednisolone (PSL) and tacrolimus (TAC) or
azathioprine (AZA) for progressive interstitial pneumonitis with systemic
sclerosis (SSc-PIP). Methods: Eighteen patients were TAC and 19 were
AZA treated groups. Results: In TAC treated group, 17 patients were
women with the median age being 65 (range 38-81) years. Ten patients
had diffuse type of SSc. The median period from the appearance of respi-
atory symptoms to the start of treatments (disease duration) was 31
(range 8-373) weeks. In response to treatment 1 year after, IP improved
in 6 patients, stable in 12 patients. Presently, 12 patients who could be
followed up. IP improved in 6, stable in 5 patients, and deteriorated in 1
patient. In AZA treated group, 13 patients were women with the median
age being 69 (range 56-77) years. Eleven patients had diffuse type of
SSc. The median disease duration was 28 (range 1-141) weeks. In re-
spose to treatment 1 year after, IP improved in 5 patients, stable in 11
patients. Presently, 16 patients who could be followed up. IP improved in
5, stable in 11 patients. Conclusions: Combination therapy with PSL and
TAC or AZA appeared to be well tolerated and effective in suppressing
the disease activity of SSc-PIP.

W59-1
Follow up study of 30 patients with eosinophilic granulomatosis with
polyangitis
Hiroki Mukoyama, Keisuke Nishimura, Kaoru Mizukawa, Keiichiro
Kadoba, Tomohiro Yoshida, Daisuke Waki, Toshihiko Yokota
Department of Endocrinology and Rheumatology, Kurashiki Central
Hospital, Kurashiki, Okayama, Japan

Conflict of interest: None

[Objectives] We analyzed the long-term prognosis of eosinophilic
granulomatosis with polyangiitis (EGPA). [Methods] To analyze the clinical features of 30 patients with EGPA treated in our hospital from 2000 to 2018 retrospectively. [Results] Average age was 65.6 ±13.2 years old. Male/female were 6/24. Time after starting treatment was 65 ± 56 months. ACR criteria was used for diagnosis. Twenty-seven patients had asthma, 27 had peripheral nerve involvement, 24 had motor neuropathy, nine had lung involvement, four had cardiac involvement and four had gastrointestinal involvement. Fifteen patients had a positive test for MPO-ANCA. On Baseline, five factor scores 2009 (FFS) were 0 (n=7), one (n=11), two (n=13), and three (n=1). BVAS version 3 was 18.0 ± 5.4. Glucocorticoids were administered in all the patients, and intravenous methylprednisolone in 13 patients. Immunosuppressants for remission induction therapy were administered in 16 and intravenous immunoglobulin was administered in nine. Relapses occurred in 13 patients. Remission induction treatment with immunosuppressants was associated with significantly less frequent relapses (p=0.03). [Conclusions] Remission induction treatment with immunosuppressants was associated with significantly less frequent relapses in EGPA patients.

W59-2

Prognosis of organ involvement due to eosinophilic granulomatosis with polyangiitis (EGPA)

Hironobu Nobata, Asako Kachi, Masako Koshino, Naoya Matsuoka, Hirokazu Sugiyama, Mayumi Ito, Makoto Yamaguchi, Shiko Iwagaitsu, Takayuki Katsuno, Shogo Banno, Yasuhiko Ito

Nephrology and Rheumatology, Aichi Medical University

Conflict of interest: None

[Object] EGPA is a disease characterized by multiple organs involvement, which lung, sinus, heart, kidney and GI involvement, also polyneuropathy. We decided therapeutic target for mainly polyneuropathies, but sensory disorder highly remain. [Methods] For the patients with EGPA treated at our hospital, we investigated retrospectively about clinical symptoms, examinations, organ damage, treatment and prognosis. [Results] Twenty cases (M/F 8/12). Data are expressed as median. Age 61yro. Preceding asthma 19 cases and 7 of them were exacerbated one year before onset. Lung involvement were 16, sinus 15, heart 4, kidney 2, GI 2, sensory peripheral nerve disorder 17 (with motor nerve 12) cases. Laboratory data: eosinophil count 8588/μL, CRP 5.92mg/dl, IgE 1230mg/dl, ANCA positive 11 cases, RF positive all cases. Treatment: steroid pulse 17 cases, cyclophosphamide and rituximab 13 cases (days to first time are day 9), mepolizumab only one case. Results: Lung, cardiac, kidney, GI involvement improved in all cases, exacerbation of asthma was none within 1 year, but 6 cases exacerbated after that. IVlg could improve subjective symptoms in all cases, but 13 cases remained numbness. All cases could recover to walk. [Conclusions] Prognosis of organ involvement except sensory disorder is satisfied in most cases.

W59-3

The analysis of 3 cases which improved the neurologic symptoms by mepolizumab to eosinophilic granulomatosis with polyangiitis which recurred by conventional therapy


Division of Hematology and Rheumatology, Department of Medicine, Niho University

Conflict of interest: Yes

[Object] Mepolizumab acquired approval of additional adaptation to eosinophilic granulomatosis with polyangiitis (EGPA) in 2018. But clinical evidence of each complication of EGPA was unknown. We considered improvement of clinical manifestation, laboratory findings and complication treated with mepolizumab by which 3 case of EGPA recurred during tapering prednisolone. [Methods] We analyzed CRP, c eosinophil count, serum IgE, Exhaled NO, FEV1.0% and improvement of complication of EGPA between pre and post 24 weeks treatment of mepolizumab. [Results] Although CRP, count of eosinophil, serum IgE, Exhaled NO were improved, FEV1.0% was not improvement. Skin eruption was improve by 2 of 3 cases. Subjective symptom of the neurologic symptoms estimated in global scale was improved. [Conclusion] Although it was existed to the evidence of restraint recurrence and maintenance of remission, evidence of each laboratory findings and complication of EGPA was unknown. Especially, it’s important to estimate improvement of neurologic disorder which is the most important complication of EGPA. In this report, we are checking it only by a subjective symptom used global scale. In future, I’d like to estimate using peripheral nerve communication speed and skin perfusion pressure measurement.

W59-4

Low-dose mepolizumab as maintenance therapy with eosinophilic granulomatosis with polyangiitis

Yutaka Goto, Yukiko Takakuwa, Takeshi Suzuki, Kanako Suzuki, Takayasu Ando, Harunobu Iida, Marina Uchida, Yusa Asari, Hisaie Fujimoto, Kana Ishimori, Keichi Sakurai, Hiromi Matsushita, Tomomichi Kiyokawa, Kumiko Tonooka, Mitsuhiro Imamura, Yoshioki Yamasaki, Seido Ooka, Hiroko Nagauchi, Kimito Kawahata

Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine

Conflict of interest: None

[Objectives] Mepolizumab is an anti-IL-5 monoclonal antibody targeting eosinophilic inflammation, which was shown to be an effective maintenance therapy of EGPA in the phase 3 clinical trial. However, the dose of mepolizumab used in this trial was 3-fold higher than 100mg dose approved for severe asthma. Here, we investigated the efficacy and safety issue of low-dose mepolizumab for patients with EGPA. [Methods] We retrospectively examined EGPA patients who met the 2012 Chapel Hill classification and treated with mepolizumab 100mg/4 weeks for severe asthma from 2017 to 2018. We evaluated efficacy and safety for 6 months. [Results] Nine patients (3 female, 59±13 years old) with EGPA (33% ANCA-positive) requiring maintenance PSL or immunosuppressive drug were included in this analysis. All patients had neurological involvement. The dose of PSL at initiation of mepolizumab was 9±1 mg, which by 6 months had fallen to 6±2 mg. Two patients were able to discontinue an immunosuppressive drug. Blood eosinophil counts reduced from 1089±949 ×10^6/μl at initiation of mepolizumab to 45±39 ×10^6/μl at 6 months. No episodes of vasculitis or disease exacerbations and severe adverse events occurred for 6 months. [Conclusions] Low-dose mepolizumab might be effective in maintenance therapy for EGPA.

W59-5

Efficacy and safety of Cyclophosphamide and Rituximab in the initial remission induction therapy for ANCA-associated vasculitis (AAV)

Yuri Sadanaga1, Nobuyuki Ono1, Yukiko Takeyama1,11, Yasushi Inoue1, Tomoya Miyamura1, Kinesuke Oyori1,11, Naoyasu Ueda1, Shuji Nagano1, Hisako Inoue1, Mariko Sakai1, Yoshihito Narita1, Akihito Maruyama1, Suyichi Koorada1, Yutaka Chifu1, Takanoy Sawabe1, Shun-Ichi Ohta1, Seiji Yoshizawa1, Kyoko Orsuka1, Yasutaka Kimoto1, Katsuhisa Miyake1, Takahiko Horiiuch1, Hitoshi Nakashima1, Hiroaki Niirou1, Yoshifumi Tada1

1Department of Rheumatology, Faculty of Medicine, Saga University, Saga, Japan, 2Division of Connective Tissue Disease, Fukuoka Red Cross Hospital, Fukuoka, Japan, 3Department of Internal Medicine and Rheumatology, National Hospital Organization Kyusyu Medical Center, Fukuoka, Japan, 4Division of Rheumatology, Matsuyama Red Cross Hospital, Matsuyama, Japan, 5Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan, 6Center for Rheumatology, Iizuka Hospital, Iizuka, Japan, 7Department of Rheumatology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan, 8Department of Rheumatology, Shimonoseki City Hospital, Shimonoseki, Japan, 9Department of Rheumatology, Hamanomati Hospital, Fukuoka, Japan, 10Division of Rheumatology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan, 11Department of Internal Medicine, Saiseikai Karatsu General Hospital, Saga, Japan, 12Department of Medicine and Biosystemic Sciences, Kyusyu University Graduate School of Medical Sciences, Fukuoka, Japan, 13Department of Internal Medicine and Immunology, Kyusyu University Beppu Hospital, Beppu, Japan, 14Division of Nephrology and Rheumatology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
Conflict of interest: None

[Object] To evaluate the efficacy and safety of Cyclophosphamide (CY) and Rituximab (RTX) in the initial remission induction therapy for ANCA associated vasculitis (AAV). [Methods] Using a multicenter cohort database of AAV (KVAS cohort) mainly conducted in our hospital, we retrospectively extracted patients who used CY or RTX as initial induction therapy from May 2010 to May 2018, classified into CY or RTX groups, and evaluated clinical features, remission rates, adverse events. [Results] CY was used in 47 patients and RTX in 20 patients. The average age was 67.6 (26-86) years old in CY group, and 71.5 (54-88) years old in RTX group, male was 49% in CY group and 50% in RTX group. CY group had 36 (63%) MPA, 15 (26%) GPA and 6 (11%) UCAAV. RTX group had 11 (55%) MPA and 9 (45%) GPA. The average of BVAS was 17.1 (4-49) in CY group and 17.7 (8-32) in RTX group. Remission rate at 6 months was 66.7% in CY group and 80% in RTX group, and the average PSL dose at 6 months was 11.6 (4-50) mg/day in CY group and 8.8 (4-18) mg/day in RTX group. The adverse events were 36 in 23 patients in CY group, male was 49% in CY group and 50% in RTX group.

W60-1 Analysis of clinical features in ANCA-associated vasculitis treated with rituximab: single center experience
Soko Kawashima, Kazuhiro Fukuoka, Yoshinori Komagata, Shinya Kaname
First Department of Internal Medicine, Kyorin University School of Medicine

Conflict of interest: None

[Object] Rituximab therapy (RTX) in ANCA-associated vasculitis (AAV) has increased, and the scenes to consider how to use it are increasing. Thus, we analyzed our patients treated by RTX. [Methods] We retrospectively analyzed the clinical database of the 28 patients with AAV who were treated by RTX to our hospital after 2014 were followed up. At the onset, all patients fulfilled the Chapel Hill Consensus Conference (CHCC) classification criteria for MPA and GPA. And also, compared the clinical features between RTX group and non-RTX group. [Results] RTX induction age was 70 years old. RTX was used in 10.8% for the initial AAV. The average of total RTX dose for initial induction was 2g. For maintenance therapy, regular dosing every 6 months or irregular dosing at intervals of 6 months or more were done. Some relapses at irregular administration were seen. Though main reasons for RTX discontinuing was infection, many cases had remission and decreasing steroid dosage. In comparison between RTX usage example and RTX unused example, death: 10.7% vs 14.0%, dialysis withdrawal: 60% vs 0%, relapse: 10.7% vs 16.3%. [Conclusions] These results showed that AAV treated by RTX is good trend. But, we should evaluate the efficacy and safety of treatment and consider the better ways to use RTX.

W60-2 A Single Center, Retrospective Analysis of RTX Treatment for Japanese Patients with ANCA-associated vasculitis
Kei Hirose1, Manami Hirata1, Kazuyuki Fujita2, Noriya Momoki2, Akiko Ueno2, Masahiro Yamamura1
1Department of Internal Medicine, Okayama Saiseikai General Hospital, 2Fujita Clinic

Conflict of interest: None

[Object] To determine the real world practice of RTX treatment for Japanese patients with AAV. [Methods] This study included 30 MPA and 4 GPA patients (17 males and 17 females; 33 MPO-ANCA positive), with the median age of 77 years. [Results] For the initial RTX cycle, only one infusion in 8, 2 in 17, 3 in 2, and 4 in 7. At 6 months, 71.4% (15/21) reached remission, and PSL was 4.5mg/day. At RTX start, 3, 6, 12, 18, and 24 months, PSL levels were 40.0mg/day, 6.0mg/day, 1.75mg/day, 2.5mg/day, and 0mg/day. 3 relapsed (1 within 6 months, 2 within 18months). 14 patients discontinued RTX by 6 months, due to 9 AEs, 1 death by MPA, 2 for other hospitals, 1 remission and 1 unknown, 4 with-
W61-1
Analysis of sequential development of pulmonary lesions in patients with rheumatoid arthritis
Ayae Tanaka, Yuta Takanaka, Tomoyuki Miyao, Ryutaro Yamazaki, Satoke Arai, Takayoshi Owada, Reika Maczawa, Masafumi Arima, Kazuhiro Kurasawa
Department of Rheumatology, Dokkyo Medical University
Conflict of interest: None

[Object] To clarify the sequential developmental pathway of pulmonary abnormalities in RA. [Methods] Subjects were consecutive 208 RA patients treated with biological DMARDs (Bio) and received HRCT scan before and during the therapy. Pulmonary abnormalities were classified into 20 lesions. Cluster analyses were conducted according to pre-existing and newly developing of pulmonary lesions. A checkerboard analysis was conducted to examine the relationship between pre-existing and newly developing lesions. [Results] Subjects were 64 male and females with age of 59.2 ± 10.3 years. Bronchiolitis and curved linear opacity were developed in patients without pre-existing pulmonary lesions. In patients with pre-existing diseases, various lesions were developed, which had relation to the pre-existing ones. [Conclusions] Pre-existing pulmonary lesions induced new pulmonary lesions. Airway diseases, particularly bronchiolitis, might be an important initial lesion that induces ILD.

W61-2
The Impact of Immunosuppressants and Biologics on the Prognosis of Interstitial Lung Disease Associated with Rheumatoid Arthritis
Keisichiro Kadoha, Keisuke Nishimura, Kaoru Mizukawa, Hiroki Mukoyama, Tomohiro Yoshida, Daiku Waki, Yoshitaka Yokota
Department of Endocrinology and Rheumatology, Kurashiki Central Hospital
Conflict of interest: None

[Object] To assess the prognosis of interstitial lung disease (ILD) associated with rheumatoid arthritis (RA). [Methods] We reviewed the medical records of RA patients who visited our department from January 2008 to July 2018. Among the patients diagnosed as RA for the first time at our department, 41 patients had ILD at the initial presentation. We retrospectively reviewed the clinical features of 40 ILD patients with non-specific interstitial pneumonia (NSIP) or organizing pneumonia (OP) pattern on chest CT scan. [Results] Fifteen patients had ILD requiring hospitalization. Among them, 14 patients received increased doses of glucocorticoid, 12 patients received calcineurin inhibitors (CNIs), and 4 patients received other immunosuppressants. Two patients suffered severe relapse requiring hospitalization during follow-up (they had received CNI and cyclophosphamide, respectively). Thirteen patients required biologics to control their arthritis (TNF inhibitors 7, abatacept 7, tocilizumab 5). Among them, only two patients under treatment with TNF inhibitors suffered relapse requiring hospitalization. [Conclusions] Most patients with RA-ILD received CNIs, with fair prognosis and few relapses. The use of TNF inhibitors for RA patients with ILD is a potential risk for relapse.

W61-3
The assessment of the influence of biologics to the pre-existing interstitial pneumonia in rheumatoid arthritis
Kentaro Kuzuya, Eri Oguro, Yasutaka Okita, Hidetoshi Matsuoka, Satoru Teshigawara, Maiko Yoshimura, Yui Yoshida, Kentaro Isoda, Yoshinori Tada
Department of Rheumatology, Fukuoka University, Fukuoka, Japan
Conflict of interest: None

[Object] To investigate the efficacy and safety of RTX maintenance therapy for ANCA-associated vasculitis (AAV). [Methods] We used a multicenter cohort database of AAV (KVAS cohort) and retrospectively extracted patients who used RTX as maintenance therapy. The doses of PSL, relapses, and adverse events (AE) were examined. [Results] Among 141 patients who achieved remission, RTX was used in 16 cases (12 GPA, 3 MPA, 1 unclassified AAV) as maintenance therapy. Average age was 71.2 (62-83) years old (female 69%). 11 were positive for MPO-ANCA, and 5 for PR3-ANCA. 14 had been treated with RTX remission induction therapy. The average PSL dose before maintenance therapy was 7.1 (2.5-12.5) mg/day, MTX in 5 cases and TAC in 1 case were used. The average PSL dose after 6 months was 2.9 (0.8-5) mg/day, 5 cases withdrew corticosteroids and there were no recurrence within 6 months. At the final observation, the average PSL dose was 3.3 (0-7.5) mg/day. Six cases with PSL dose above 5 mg/day showed 3 relapses. The occurrence of severe AE was 4 incidents in 4 cases in 6 months and 7 incidents in 6 cases in total. [Conclusions] We proved that RTX maintenance therapy was useful and safe in Japanese AAV patients. But it is considered that corticosteroid withdrawal will be a subject for further study.

W60-6
Study on administration status of rituximab in ANCA-associated vasculitis
Kazuaki Fujioka, Tomoya Sagawa, Akiko Kasahara, Shunya Kaneshita, Takuya Inoue, Takashi Kida, Hidetake Nagahara, Makoto Wada, Masataka Kohno, Yutaka Kawahito
Inflammation and Immunology, Graduate School of Medical Science, Kyushu University
Conflict of interest: None

[Object] Rituximab (RTX) can be used as a therapeutic option for ANCA-associated vasculitis (AAV), and the cases treated with it are increasing in recent years. However, the optimal administration protocol for Japanese is not clear. [Methods] We investigated the clinical profiles of AAV patients who were treated with RTX in our hospital. [Results] The traceable AAV cases treated with RTX were 6 cases (MPA 2, GPA 3, OMAAV 1; Average Age is 72.3). 3 cases had RTX as initial induction therapy; the others were used as re-induction because of relapse. In all cases, improvement of disease activity (mean BVAS 18.5 point to 7.7 point) was observed in 1 month after the initial treatment of RTX. As maintenance therapy, 3 cases had only PSL, and in the other cases RTX was administered again. Immunosuppressive agents were not added in all cases. In 4 out of 6 cases, the timing and frequency of RTX therapy was adjusted from CD19 (+) cells percentage and clinical course. Adverse events were 3 infection cases and 1 leukopenia. Throughout the study period, there were no case of relapse or who require PSL increase. [Conclusions] RTX therapy for AAV is useful for both induction and maintenance therapy. Adjustment of administration pattern based on clinical course and laboratory data can be possible.

W60-7
The assessment of the influence of biologics to the pre-existing interstitial pneumonia in rheumatoid arthritis
Kentaro Kuzuya, Eri Oguro, Yasutaka Okita, Hidetoshi Matsuoka, Satoru Teshigawara, Maiko Yoshimura, Yui Yoshida, Kentaro Isoda, Yoshinori Tada
Department of Rheumatology, Fukuoka University, Fukuoka, Japan
Conflict of interest: None

[Object] To investigate the efficacy and safety of RTX maintenance therapy for ANCA-associated vasculitis (AAV). [Methods] We used a multicenter cohort database of AAV (KVAS cohort) and retrospectively extracted patients who used RTX as maintenance therapy. The doses of PSL, relapses, and adverse events (AE) were examined. [Results] Among 141 patients who achieved remission, RTX was used in 16 cases (12 GPA, 3 MPA, 1 unclassified AAV) as maintenance therapy. Average age was 71.2 (62-83) years old (female 69%). 11 were positive for MPO-ANCA, and 5 for PR3-ANCA. 14 had been treated with RTX remission induction therapy. The average PSL dose before maintenance therapy was 7.1 (2.5-12.5) mg/day, MTX in 5 cases and TAC in 1 case were used. The average PSL dose after 6 months was 2.9 (0.8-5) mg/day, 5 cases withdrew corticosteroids and there were no recurrence within 6 months. At the final observation, the average PSL dose was 3.3 (0-7.5) mg/day. Six cases with PSL dose above 5 mg/day showed 3 relapses. The occurrence of severe AE was 4 incidents in 4 cases in 6 months and 7 incidents in 6 cases in total. [Conclusions] We proved that RTX maintenance therapy was useful and safe in Japanese AAV patients. But it is considered that corticosteroid withdrawal will be a subject for further study.
Conflict of interest: None

Objective: To assess the influence of biologics (Bio) to the pre-existing interstitial pneumonia (IP) in rheumatoid arthritis (RA). [Methods] We retrospectively examined the relationship between the disease activity score (DAS) and incidence of microalbuminuria in 304 RA patients. Patients were divided into two groups: group 1, including patients that their average disease activity score 28-erythrocyte sedimentation (DAS28-ESR) was <3.2 and group 2, the patients that their average DAS28-ESR was >3.2. The outcome of interest was incidence of microalbuminuria. We evaluated incidence of CKD using Kaplan-Meier curves, and calculated hazard ration using Cox proportional hazards models. [Results] The incidence of microalbuminuria in group 1 was higher than that in group 2 (p=0.041). High average DAS28-ESR was an independent predictor of the incidence of CKD (hazard ratio, 2.96; 95% confidence interval 1.24-5.89, p=0.035). [Conclusions] High disease activity was a significant risk factor for incidence of microalbuminuria.

Conflict of interest: None

Objective: To clarify the incidence of malignant tumors that can be indicated for immune checkpoint inhibitors (IC) in rheumatoid arthritis (RA) patients. [Methods] In RA patients, the development of malignant tumors that can be indicated for IC was investigated at every year from September 2014, (September 2014 - August 2015: 2014 group; September 2015 - August 2016: Group 2015; September 2016 - August 2017: 2016 Group; September 2017 - August 2018: 2017 group). Patients with a history of malignant tumor treatment within 10 years were excluded at registration. IC adaptation was judged by the presence or absence of IC adaptation approval at diagnosis of malignant tumor. [Results] The number of RA patients, age (year), malignant tumor incidence (%), IC-adaptive malignant tumor incidence (%) of each group are shown; [n=479, 68 (61-77), 9 (1.9%), 0 (0%)], [n=504, 68 (61-77), 12 (2.4%), 0 (0%)], [n=514, 68 (61-77), 7 (1.4%), 1 (0.2%)], [n=526, 67 (60-76), 37 (7.0%), 9 (1.7%)]. [Conclusions] The incidence of IC-adapted malignancy has increased in RA due to an increase in malignant tumor incidence, development of a new IC (methods), combined use of IC and other cancer treatment methods, and expansion of IC indication diseases.

Conflict of interest: None

Objective: To evaluate the profile and frequency of malignancy among patients with systemic sclerosis (SSc), and the association between disease-specific autoantibodies and malignancies. [Methods] We conducted a single-center retrospective study of SSc patients who visited our institution between 2008 and 2017. [Results] The total observation period was 1,344 person-years. Among 166 patients with SSc, 58% were positive for anticentromere antibodies, 16% were positive for anti-Scl-70 antibodies and 5% were positive for anti-RNA polymerase III antibodies. Of the 166 patients, 25 malignancies (15.1%) were observed. Breast cancer (n=9) was the most frequent, followed by lung cancer (n=5) or gastric cancer (n=4). As for the prevalence of malignancy, there were no statistical differences among the types of autoantibodies. Cancer developed after the diagnosis of SSc in 60% of patients and 40% had occurred before the diagnosis of SSc. About intervals between the diagnosis of SSc and malignancy, 56% of cancer developed within 50 months of SSc diagnosis. [Conclusions] SSc is associated with the increased incidence of cancer, particularly of the breast and lung. Investigations for underlying malignancy should be considered in medical care for SSc.
W62-2
Association of Anti-RNA Polymerase III Antibody and Malignancy in Patients with Systemic Sclerosis
Yoshihito Tanaka, Masanari Kodera
Department of Dermatology, JCHO Chukyo Hospital
Conflict of interest: None

[Object] Systemic Sclerosis (SSc) patients with anti-RNA polymerase III (RNAP) antibody have been reported to have an increased risk of malignancy. The aim of this study was to investigate the relationship between disease-specific autoantibodies and malignancy, and to examine the expression of RNAP in tumor tissues in SSc patients. [Methods] Among 156 Japanese SSc patients in our hospital, 13 were positive for RNAP antibody, 35 were positive for anti-topoisomerase I (Topo I) antibody and 108 were positive for anticentromere antibody (ACA). We examined the incidence of malignancy in these patients. Malignant tumor tissues were stained using an anti-POLR3A antibody (Atlas antibodies, Sweden). [Results] The prevalence of malignancy was significantly higher in patients with RNAP antibody (6/13, 46.2%) than in those with Topo I antibody (2/35, 5.7%) and in those with ACA (7/108, 6.5%). Importantly, the ratio of patients with RNAP antibody and malignancy developed malignancy from 2 years before to 1 year after SSc onset. Expression of POLR3A protein was observed in the tumor tissue. [Conclusions] SSc patients with RNAP have an increased risk of malignancy. POLR3A protein was expressed frequently in tumor tissues. We thought that RNAP antibody could be a tumor maker in SSc patients.

W62-3
Exploring the prominent genes for pathogenesis of pulmonary arterial hypertension in systemic sclerosis. ~ Shedding on the “exercise induced pulmonary hypertension”
Yoshinobu Koyama, Toshie Higuchi
Rheumatology, Center for Autoimmune Diseases, Japan Red Cross Okayama Hospital
Conflict of interest: None

[Object] To detect candidate genes involved in the pathogenesis of exercise-induced pulmonary hypertension (exPAH) at the early stage of SSc. [Methods] Total of 88 patients who had not met PAH criteria with Raynaud phenomenon, skin sclerosis or SSc-related autoantibody was enrolled. Exercise Doppler echocardiography was carried out to segregate exPAH from normal response group (exN) with 33.5% reduced tube length (31.2±2.0 mm vs 47.0±1.3 mm, p<0.01, n=3). [Conclusions] We detected the impaired vasculogenesis of EC in SSc-PAH using disease-specific iPSc, which might be involved in the pathogenesis of SSc-PAH.

W62-4
Impaired vasculogenesis of endothelial cells derived from iPSc in a patient with systemic sclerosis associated pulmonary artery hypertension
Yuki Kudo, Masaru Kato, Yuhei Shibata, Masatoshi Kanda, Wen Shi Lee, Michihiro Kono, Eri Sugawara, Michihito Kono, Yuichiro Fujieda, Yuki Kudo, Masaru Kato, Yuhei Shibata, Masatoshi Kanda, Wen Shi Lee, Michihiro Kono, Eri Sugawara, Michihito Kono, Yuichiro Fujieda, Yuki Kudo, Masaru Kato, Yuhei Shibata, Masatoshi Kanda, Wen Shi Lee, Michihiro Kono, Eri Sugawara, Michihito Kono, Yuichiro Fujieda, Yuki Kudo, Masaru Kato, Yuhei Shibata, Masatoshi Kanda, Wen Shi Lee, Michihiro Kono, Eri Sugawara, Michihito Kono, Yuichiro Fujieda
Department of Immunology and Rheumatology, Division of Advanced Preventative Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 1Department of Immunology and Rheumatology, Division of Advanced Preventative Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Conflict of interest: None

[Object] Systemic sclerosis associated pulmonary arterial hypertension (SSc-PAH) is associated with less favorable outcome, compared to other PAH, and with comorbidities including venous, cardiac and lung involvement. We aimed to clarify the pathogenesis of SSc-PAH using disease-specific induced pluripotent stem cells (iPSc). [Methods] Peripheral blood mononuclear cells obtained from a 76 y.o. female SSc-PAH patient with venous, cardiac and lung comorbidities and a healthy donor were transfected with sendai virus vector containing Oct3/4, Sox2, Klf4 and L-Myc to establish iPSc. Endothelial cells (EC) were differentiated with the culture system of BMP-4, Activin, bFGF, CHIR99021, SB431542. The vasculogenesis of EC was evaluated by tube formation assay in vitro. The tube length was measured by image processing software. [Results] EC differentiated from the SSc-PAH patient and those from the healthy donor were morphologically similar. However, the vasculogenesis was significantly impaired in the SSc-PAH patient compared to the healthy donor with 33.5% reduced tube length (31.2±2.0 mm vs 47.0±1.3 mm, p<0.01, n=3). [Conclusions] We detected the impaired vasculogenesis of EC in SSc-PAH using disease-specific iPSc, which might be involved in the pathogenesis of SSc-PAH.

W62-5
A new concept of M1 and M2 monocytes in systemic sclerosis
Naoki Iwamoto1, Mizuna Otsuka1, Momoko Okamoto1, Yushiro Endo1, Susuke Tsujii1, Ayuko Takatani1, Toshimasa Shimizu2, Remi Sumiyoshi1, Tomohiro Koga1, Shin-ya Kawashiri1, Takashi Iwaga1, Kunihiro Ichinose1, Mami Tamai1, Hideki Nakamura1, Tomoki Origuchi1, Atsushi Kawakami1
1Department of Immunology and Rheumatology, Division of Advanced Preventative Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Physical Therapy, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Conflict of interest: None

[Object] Recently, the relation with M1 macrophage and fibrosis have been reported in several diseases. Similar with macrophages, monocytes can be classified into M1 and M2 subset. We attempted to investigate the relationship among M1 or M2 in systemic sclerosis (SSc). [Methods] This study included 23 RA patients and 20 healthy donors. Using fluorescence-activated cell sorting, we defined CD14+, CD68+ and CCR2+ positive cells as M1 monocytes and CD14+, CX3CR1+ and CD163+ positive cells as M2 monocytes. We also examined the ability of cytokines, chemokines and TGF-β secretion of CD14+ positive cells from SSc and M2 monocytes from healthy donors by multiplex bead array assay. [Results] SSc patients had higher M2/M1 ratio as compared with healthy control (7.00 vs 1.63, P<0.05). And, there was tendency that M2/M1 ratio was higher in SSc patients complicated with interstitial pneumonia. Furthermore, the ability of TGF-β secretion of M2 monocytes was higher than that of M1-dominant monocytes. [Conclusions] Our present study suggested that the imbalance of M1/M2 monocytes might contribute to pathogenesis of SSc.

W62-6
Cyclin-dependent kinase 4/6 inhibitor ameliorates dermal fibrosis in murine models of systemic sclerosis
Akio Yamamoto, Fumitaka Mizoguchi, Kimito Kawahata, Tetsuya Saito, Hitoshi Koshaka
Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU)
Conflict of interest: None

[Object] In the skin lesions of early systemic sclerosis (SSc), increased proliferation of fibroblasts is observed. The objective of this study was to examine the effects of cyclin-dependent kinase 4/6 inhibitor (CDKI) on SSc dermal fibroblasts and the therapeutic effect in murine models of SSc. [Methods] Effects of palbociclib, a CDKI, on fibroblasts were examined in the presence or absence of TGF-β in vitro. Hypochlorous acid-induced (HOCI) model and bleomycin-induced model were used to study the effect of palbociclib as monotherapy or in combination with galninsertib, a TGF-β inhibitor, on skin fibrosis in vivo. [Results] Treatment with palbociclib significantly suppressed the proliferation of fibroblasts in vitro. Palbociclib treatment also attenuated collagen deposition in the skin of SSc and bleomycin-induced mice. [Conclusions] Palbociclib may be a potential therapeutic option for treating SSc.
sults] Palbociclib suppressed the proliferation of fibroblasts. TGF-β-induced increase of ACTA2 expression was suppressed in the presence of palbociclib, while phosphorylation of Smad2/3 was not. Palbociclib decreased dermal thickness and collagen contents, and suppressed fibroblast proliferation in murine models of SSc. The combination therapy with galunisertib was more effective than either monotherapy in HOCl model. [Conclusions] CDKI suppressed the proliferation of fibroblasts and the differentiation to myofibroblasts in vitro. CDKI ameliorated the skin fibrosis in vivo. These results should encourage the use of CDKI to treat human SSc.

W63-1
Quantitative evaluation of mRNA expression of MEFV gene product pyrin in human tissues
Naoko Nakano1,2, Kazunaga Agematsu3, Akihiro Yachie1, Kiyoshi Migita1, Takeshi Urano4, Tomohiro Koga5, Atsushi Kawakami2, Junya Masumoto2
1Department of Pediatrics, Ehime University Graduate School of Medicine Shitsukawa Toon Ehime Japan, 2Department of Pathology, Ehime University Graduate School of Medicine Toon-Ehime Japan, 3Department of Infectious Immunology, Shinshu University-Graduate School of Medicine Matsumoto-Nagano Japan, 4Department of Pediatrics, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University School of Medicine, Kanazawa, Ishikawa, Japan, 5Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan

[Object] To clarify the association between various clinical symptoms and mutation of MEFV. [Methods] Genomic DNA were purified from white blood cells in FMF patients, and MEFV has been explored. [Results] We have analyzed MEFV in 6 patients with FMF. Case1; female 17 yo, she had recurrent fever (RF) with chest pain at 11 yo. MEFV showed compound heterozygote mutations (L110P+E148Q/M694I) from each father/mother. Case 2; female 29 yo, she had chest pain, arthralgia, RF and positive rheumatoid factor. Because of severe diarrhea she needed canakinumab injection. MEFV indicated compound heterozygous mutations (E148Q/M694I) from father/mother. Case 3; male 16 yo, he had RF with headache. MEFV was heterozygous mutations (E148Q+P369S+R408Q) from only father. Case 4; female 36 yo, she had RF from 10 yo 2-3 times/year. MEFV showed E148Q+S503C from only father. Case 5; male 31 yo, he had RF per month one year before. MEFV could not show abnormality. Case 6; female 15 yo, she had RF with headache and chest pain every 3-6 months. MEFV showed homozygote of E148Q. [Conclusions] These results showed improvement of symptoms by the treatment of colchicine except for case 2. Two cases of FMF indicated positive rheumatoid factors with arthralgia, showing compound heterozygote of E148Q/M694I in MEFV.

W63-2
Specific cytokine secretion patterns for detecting pathogenic MEFV variants
Takayuki Tanaka1, Takeshi Shibata2, Ryuta Nishikomori2, Hiroaki Ida2, Hirofumi Shibata1, Kazushi Izawa1, Takahiro Yasumi1
1Department of Pediatrics, Kyoto University Graduate School of Medicine, 2Department of Respiratory, Neurology, and Rheumatology, Kumamoto University Faculty of Medicine

Conflict of interest: None

[Background] FMF is an autoinflammatory disorder caused by MEFV mutation. As many as 340 sequence variants have been reported regarding MEFV, but only a few mutations, such as M694I, are relevant to FMF, and the significance of most variants are unclear. [Object] To clarify the characteristics of FMF-patients derived hematopoietic cells, and then recapitulate the phenotype with MEFV-mutant iPSC cell-derived macrophages (iPS-MPs) [Methods] We obtained monocytes and monocyte-derived macrophages from FMF patients. We also established iPS-MPs with MEFV mutations. [Results] The IL-1beta secretion was comparable between FMF and control monocytes, and colchicine failed to suppress the secretion from FMF monocytes. IL-1beta secretion from monocyte-derived macrophages were higher in FMF patients, and that was inhibited by colchicine. This phenotype was reproduced with patient-derived iPS-MPs. iPS-MPs with exogenous M694I MEFV expression also secreted more IL-1beta than iPS-MPs with transgene WT MEFV expression. [Conclusions] We revealed the characteristics of primary cells from FMF patients, and the phenotype of macrophages matches the clinical phenotypes. We recapitulated this cytokine response with iPS-MPs, and established a platform to evaluate various MEFV variants.

W63-3
The study of clinical feature and gene analysis in patients with Familial Mediterranean Fever (FMF)
Tatsuo Ishizuka1, Kei Fujioka1, Ichiro Mori1, Tomofumi Takeda1, Saori Inui1, Koichiro Taguchi1, Takahide Ikeda2, Hiroyuki Morita2, Tomoko Toma3, Akihiro Yachie1
1Gifu Municipal Hospital, 2Department of General Internal Medicine, Gifu Graduate School of Medicine, 3Department of Pediatrics, Kanazawa Graduate School of Medicine

Conflict of interest: None

[Object] To clarify the association between various clinical symptoms and mutation of MEFV. [Methods] Genomic DNA were purified from white blood cells in FMF patients, and MEFV has been explored. [Results] We have analyzed MEFV in 6 patients with FMF. Case1; female 17 yo, she had recurrent fever (RF) with chest pain at 11 yo. MEFV showed compound heterozygote mutations (L110P+E148Q/M694I) from each father/mother. Case 2; female 29 yo, she had chest pain, arthralgia, RF and positive rheumatoid factor. Because of severe diarrhea she needed canakinumab injection. MEFV showed compound heterozygous mutations (E148Q/M694I) from father/mother. Case 3; male 16 yo, he had RF with headache. MEFV was heterozygous mutations (E148Q+P369S+R408Q) from only father. Case 4; female 36 yo, she had RF from 10 yo 2-3 times/year. MEFV showed E148Q+S503C from only father. Case 5; male 31 yo, he had RF per month one year before. MEFV could not show abnormality. Case 6; female 15 yo, she had RF with headache and chest pain every 3-6 months. MEFV showed homozygote of E148Q. [Conclusions] These results showed improvement of symptoms with colchicine and showed compound heterozygote of E148Q/M694I in MEFV.

W63-4
The interim analysis of post-marketing all-patient surveillance of canakinumab in Japanese patients with cryopyrin-associated periodic syndrome
Kazako Matsumoto
Medical Devisio, Novartis Pharma K.K.

Conflict of interest: None

[Objectives] A post-marketing all-patient (pt) surveillance of canakinumab (CAN), a human Anti-interleukin-1β monoclonal antibody is ongoing to assess its safety and efficacy in Japanese pts with cryopyrin-associated periodic syndrome. This is an interim report of 6 years post-launch in daily medical practice. [Methods] A total of 90 pts (55 sites) were registered with 83 (50 sites) included in a database lock in June 2018. 80 pts were assessed as safety population and 77 were for efficacy assessment. [Results] Of 80 pts for safety, the mean age of pts at dosing initiation was 24.2 years. The number of pts with Familial cold autoinflammatory syndrome/Muckle-Wells syndrome/Neonatal onset multi-system inflammatory disease were 10/46/24, respectively. 3 were discontinued and 8 were cessation of CAN. Adverse drug reactions (ADR) were seen in 22 pts (27.5%). Severe ADRs were 3.75% in 3 newly enrolled pts with pneumonia, RS virus Bronchiolitis, Rhabdomyosarcoma, Neutropenia and Fever. The death was seen in one NOMID 0-year boy with no causality, having circulatory collapse and sepsis. Of 77 pts for efficacy, at 24-104 weeks, 75-82% of new pts and 83-94% of pts from clinical study remained flare free after achieving remission. [Conclusions] The further assessment is required until the final report.
The functional analysis of peripheral blood mononuclear cells in a patient with A20 haploinsufficiency (HA20) with a new mutation (Cys200AlafsX16)

Yuya Fujita1, Kazunaga Agematsumi, Jumpei Temmokui, Makiko Furuya Yashiro1, Naoki Matsuoka1, Tomoyuki Asano1, Shuzo Sato1, Hiroko Kobayashi1, Hiroshi Watanabe1, Tomohiro Koga1, Atsushi Kawakami1, Kiyoshi Mitiga1
1Department of Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan, 2Department of Infectious Immunology, Shinshu University Graduate School of Medicine, Matsumoto, Japan, 3Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Conflict of interest: None

Objective: Heterozygous germ line mutations in the TNFAIP3 gene cause HA20, which presents as early onset autoinflammatory disease resembling Behcet’s disease. The aim of this study was to identify the mechanism of inflammation in HA20 using mononuclear cells (PBMCs) of a patient with a new mutation. Case: A 17-year-old Japanese boy had a 3-year history of recurrent painful oral ulcer and periodic fever. His mother and sister had exhibited similar symptoms. He was diagnosed as HA20 with a new mutation (Cys200AlafsX16), which result in premature stop codon in the OUT domain of A20.

Method: We isolated PBMCs from the patient and healthy subjects. PBMCs were stimulated with TNF-α (10 ng/ml) for 24 hr. Cellular supernatants were assayed for IL-1β by ELISA and cellular lysates were subjected to immunoblot using anti-A20 or anti-IκB-α antibodies. Result: A20 expression was reduced in PBMCs from the patient with HA20 compared to those from control PBMCs. TNF-α induces degradation of IκB-α was accelerated in PBMCs for HA20, which is associated with the increased IL-1β production. Conclusion: TNFAIP3 mutation lead to impaired A20 expression, which could be responsible for the TNF-α-induced NF-κB activation process due to the increased degradation of IκB-α.

Efficacy of the urinary N-telopeptide/urinary creatinine ratio in assessing disease activity in pediatric chronic recurrent multifocal osteomyelitis

Yoji Uejima, Satoshi Sato, Eisuke Suganuma, Yutaka Kawano
Division of Infectious Disease, Immunology, and Allergy, Saitama Children’s Medical Center

Conflict of interest: None

Objective: Chronic recurrent multifocal osteomyelitis (CRMO) is characterized by aseptic and non-tumor disease of the bone. Although CRMO has been established as an autoinflammatory disease, the markers of disease activity are unknown. We investigated the efficacy of the urinary N-telopeptide/urinary creatinine ratio (uNTX/uCr), a bone resorption marker for osteoporosis and bone metastasis, in assessing the disease activity of CRMO. [Method] We enrolled 6 patients (3F, 3M) diagnosed with CRMO between February 2014 and September 2018. [Results] The median age of disease onset and mean duration of symptoms before diagnosis were 10.2 years (3-13 years) and 9.8 months, respectively. The most common symptom was local pain (5/6). The mean value of uNTX/uCr at the time of diagnosis (494.5 mmol/mmol/Cr) decreased in 4 patients who showed remission. Among these, 2 showed improvement after additional therapy with alendronate and 2, after remission of the biology. Among the remaining 2 patients, uNTX/uCr decreased in the patient whose symptoms improved, whereas it increased in the patient with no improvement. [Conclusion] uNTX/uCr increased during symptomatic exacerbation of CRMO and decreased at the time of remission. Thus, uNTX/uCr may be an indicator of the disease activity of CRMO.

Magnetic resonance imaging of skeletal muscles in patients with dermatomyositis: characteristic findings and diagnostic performance

Taro Ukichii, Ken Yoshida, Kentaro Noda, Kazuhiro Furuya, Daitaro Kurosaka
Department of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine

Conflict of interest: None

Objective: To define characteristic findings on MRI of skeletal muscles in patients with dermatomyositis (DM) relative to those in patients with other idiopathic inflammatory myopathies (IIMs) and to assess their diagnostic performance. [Methods] Differences in the frequency of various findings on MRI of proximal limb skeletal muscles between 36 DM, 17 amyopathic DM, 19 polymyositis (PM), and 16 non-IIM patients were analyzed. [Results] Characteristic MRI findings in DM patients were subcutaneous high signal intensity (HSI), fascial HSI, peripheral distribution of HSI in muscle, and heterogeneous pattern of HSI in muscle. Homogeneous HSI pattern in muscle was less frequently observed in DM patients compared with PM or non-IM patients. Interobserver agreement in the interpretation of MRI findings ranged from substantial to almost perfect (kappa 0.67 to 0.98). The likelihood of DM score ≥ 3 (assessed by counting the number of characteristic MRI findings in DM patients) showed good diagnostic performance in DM (short-tau inversion recovery: sensitivity 72.2%, specificity 88.5%, AUC 84.9%; gadolinium-enhanced fat-suppressed T1-weighted: sensitivity 81.2%, specificity 91.5%, AUC 89.9%). [Conclusions] Muscle MRI could be a useful tool for distinguishing DM from other IIMs.
find common and different point of myositis-specific autoantibodies, we performed RNA-Seq of immune cell subsets in peripheral blood from IIM patients. [Methods] 45 IIM patients and 58 healthy controls (HCs) were picked up. 7 had anti-MDA5 antibody (MDA5-Ab) and 14/53 had anti-ARS/Mi-2/TIF1 antibodies. Among 7 MDA5-Ab positive patients, all had interstitial pneumonia and 4 were before treatment. RNA-Seq of each immune cell subset was performed with HiSeq2500. [Results] The percentage of plasmablast (PB) significantly increased in IIM, especially in MDA5-Ab positive patients. Weighted gene co-expression network analysis showed positive correlation between MDA5-Ab positivity and the module (groups of genes) comprised of type 1 IFN signature in almost all subsets. Machine learning showed type 1 IFN signature module of PB can distinguish MDA5-Ab from other autoantibodies most accurately among all modules from all subsets. [Conclusions] The characteristics of MDA5-Ab positive IIM was enhanced type 1 IFN signature in wide range of immune cell subsets. This approach would reveal the characteristics of other autoantibodies-positive IIM patients.

**W64-4**

Autoantibodies and cytokine profiles in dermatomyositis/polymyositis

Kazuhito Kurasawa, Satoko Arai, Yuta Takamura, Tomoyuki Miyao, Ryutaro Yamazaki, Ayae Tanaka, Takayoshi Owada, Reika Maezawa, Masafumi Arima

Department of Rheumatology, Dokkyo Medical University

Conflict of interest: None

[Object] By autoantibodies, mastitis was classified into subgroups with characteristic clinical features. It is unknown whether subgroups have characteristic cytokine profiles. The purpose of this study was to answer the question and if so to determine the profile. [Methods] Cytokine levels in sera from mastitis (anti-MDA5: 22, -ARS: 18, -TIF1-g: 5) and 8 controls were measured using multiplex-array. [Results] IP-10 levels were increased in myositis patients, but not in controls. In anti-MDA5 Ab + myositis, IL-6, IL-10, IL-15, TNF-a, IFN-a and MCP-1 level was increased. In anti-ARS Ab+ cases, IFN-a levels were elevated as well as TNF-a and MCP-1. Using the correlation coefficient between cytokines, cytokine groups were identified. In anti-MDA5 Ab+ cases, 2 cytokine groups were identified; one includes IFN-a, IL-15, TNF-a and IL-10, and the other involved IL-6, MCP-1. Both groups related to IP-10. In in anti-ARS Ab+ cases, 2 groups were found; one included NF-a, MCP-1 and IP-10 and the other had IFN-b as sole component. [Conclusions] Cytokine profiles differ among subgroups in myositis. In anti-DDA+ myositis, IL-15 and IFN-a with strong correlation and IL-6 were characteristic cytokines, while IFN-b was an unique one in anti-ARS+ one.

**W64-5**

Branched chain amino acids in the treatment of polymyositis and dermatomyositis: results from BTOUGH study

Naoki Kimura, Hitoshi Kohsaka

Department of Rheumatology, Tokyo Medical and Dental University, Tokyo, Japan

Conflict of interest: None

[Object] To assess the efficacy and safety of branched chain amino acids (TK-98) in the treatment of polymyositis and dermatomyositis (PM/DM). [Methods] Untreated adults with PM/DM were enrolled in a randomized, double-blind trial to receive either TK-98 or placebo in addition to the conventional therapy. After 12 weeks, patients whose average MMT score was under 9.5 were enrolled in an open label extension study for 12 weeks. The primary end point was the change of manual muscle test (MMT) score at 12 weeks. The secondary end point was the disease activity and the change of functional index (FI) that evaluates dynamic muscle function. [Results] Twenty-four patients and 23 patients were randomized to receive TK-98 and placebo, respectively. The change of MMT scores at 12 weeks was equivalent (0.70±0.19 and 0.69±0.18, respectively). The MMT scores in both groups improved similarly throughout the extension study. The improvement of FI in shoulder flexion at 12 weeks was significantly better in the TK-98 group. The differential change of average FI per time was larger in the TK-98 group. No difference was found in the disease activity and the adverse events. [Conclusions] BCAA was effective on the improvement of dynamic repetitive muscle function in patients with PM/DM.

**W64-6**

The predictive factor of effectiveness of intravenous immunoglobulin therapy in dermatomyositis and polymyositis

Keiichi Sakurai, Seido Ooka, Yutaka Goto, Harunobu Iida, Takeyasu Ando, Kanako Suzuki, Yusa Asari, Marina Uchida, Shoshi Shingawara, Tomofumi Kiyokawa, Hiromi Matsuhashi, Kana Ishimori, Hisae Fujimoto, Yukiko Takakaya, Kumiko Tonoooka, Machiko Mizushima, Mitsuru Imamura, Takeshi Suzuki, Yoshioki Yamashita, Hiroko Nagafuchi, Kimito Kawahata

St. Marianna University

Conflict of interest: None

[Object] For the treatment of dermatomyositis (DM) and polymyositis (PM), high-dose intravenous immunoglobulin therapy (IVIG) is often performed, and sometimes repeated. But immunoglobulin is the formula from human blood, so the social cost of IVIG is serious problem. [Methods] DM and PM patient who were diagnosed in our department and were performed IVIG therapy was analyzed. The clinical data of these patients, such as creatinine kinase (CK), aldolase, and myocardial departure enzymes, before and after IVIG. The primary invalid was defined as the case whose CK did not decrease after IVIG. The secondary invalid was defined as the case whose CK increased within 6months after IVIG. [Results] 23 case were analyzed. Average CK was 1014U/l before IVIG. The primary invalid cases were 3. Secondary invalid cases were 5. The average serum concentration of myosin light chain before IVIG in the primary invalid cases was 7.4ng/ml, that in the secondary invalid cases was 13.84ng/ml, and that in successful cases was 132.97ng/ml. The higher concentration of myosin light chain cause higher therapeutic efect. (P< 0.0017, Kruskal-Wallis test) [Conclusions] We found that the serum concentration of myosin light chain would be a predictive factor of the primary and secondary invalid of IVIG therapy.

**W65-1**

Usage of biological DMARDs by renal function for rheumatoid arthritis patients

Yasumasa Kimoto1, Tetsushin Murakami1, Daisuke Oyoyo1, Masahiro Ayano2, Hiroki Mitoma1, Mitsutaru Akahoshi2, Yojiro Arinobu1, Hiroaki Niiro3, Koichi Akashi1, Takahiko Horuiichi1

1Internal Medicine, Kyushu University Beppu Hospital, 2Department of Medicine and Biosystemic Science, Kyushu University Hospital, 3Department of Medical Education, Kyushu University Graduate School of Medical Sciences

Conflict of interest: None

[Background] It is known that renal function decreases with age. In Japan of super aged society, it is inferred that decline in renal function affects the treatment of rheumatoid arthritis (RA). [Objective] To examine the use of biological anti-rheumatic drugs (bDMARDs) by renal function of RA patients in our hospital. [METHODS] We examined the use of bDMARDs by age / eGFR for 203 cases of receiving bDMARDs as of September, 2018. [Results] Many of anti-TNF antibody preparations, which are considered to require MTX combination in terms of therapeutic effect, have been used for cases with poor renal function reduction. In addition, non - TNF preparations that are expected to be effective in monotherapy were also frequently used in cases with decreased renal function.

**W65-2**

Evaluation of factors of patient characteristics associated with renal dysfunction in patients with rheumatoid arthritis

Yosuke Hattori, Daihei Kida, Tomotaro Sato, Kenya Terabe, Koichi Mori, Shotaro Mori, Atsushi Kaneko

Orthopaedic Surgery and Rheumatology, National Hospital Organization Nagoya Medical Center

Conflict of interest: None
[Object] This study aimed to assess renal dysfunction in patients with rheumatoid arthritis (RA). [Methods] Our subject population comprised 1316 RA patients, for whom we assessed factors that could potentially affect the estimated glomerular filtration rate (eGFR), as follows: age, gender, disease duration, stage, class, RF, body mass index (BMI), MTX dosage, PSL dosage, Biologics use, HAQ, EQ-5D tender joint count, swollen joint count, patient global assessment, CRP, and DAS28-CRP. Stepwise multiple regression analysis was performed using eGFR as the dependent variable and all other variables as independent variables. [Results] We obtained the following values: age: 63.4±12.7 years, disease duration: 13.9±11.2 years, BMI: 21.5±3.4 kg/m², MTX dosage: 4.4±4.2mg/week, eGFR: 75.4±24.6 ml/min, DAS28-CRP: 2.8±1.1, and eGFR: 71.3±20.1 ml/min/1.73 m². The adjusted coefficient of determination was 0.26. Standardized partial regression coefficients were as follows: age, -0.48; BMI, -0.11; MTX dosage, 0.10 (all significant at the 1% level). [Conclusions] Our findings suggest that factors of patient characteristics that impact renal dysfunction in patients with RA are age, BMI, and MTX dosage.

W65-3 The effectiveness of eopcin beta pegol (continuous erythropoietin receptor activator, CERA) in patients with rheumatic diseases complicated with chronic kidney disease (CKD)
Satoshi Ito1, Yoichi Kurosawa2, Eriko Hasegawa2, Daisuke Kobayashi3, Shintarou Taniguchi1, Asami Abe2, Hiroshi Otani2, Kiyosyo Nakazono1, Akira Murasawa1, Ichiei Narita1, Hajime Ishikawa1
1Department of Rheumatology, Niigata Rheumatic Center, 2Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences

Conflict of interest: Yes

[Object] To analyze efficacy of CERA in patients with rheumatic diseases complicated with CKD. [Methods] Among 43 patients with rheumatic diseases (M3, F40) who received CERA, 11 patients died or transferred within 12M. Thirty two patients were followed up more than 12 M. There were 26 RA, 1 MPA with RA, 1 OA, 1 M, and 1 PMP patients. Their clinical data were analyzed. [Results] Patients were 78.0±1.2 YO and disease duration was 17.9±2.8 years. Mean BUN was 30.2±2.5 mg/dl, Cr was 1.4±0.1 mg/dl, and eGFR was 39.5±3.6 ml/min. Serum iron and ferritin were not low (51.0±6.7 μg/dl, 220.0±52.8 ng/ml) and UIBC was not raised (173.6±16.4 μg/dl). MCV was not decreased (90.4±2.3) and serum erythropoietin (EPO) was not raised (20.2±2.0 μIU/ml; n=19). There was no patient whose EPO was over 50 μIU/ml. By usage of CERA (41.9±5.1 μg/M), Hb was raised from 8.7±0.2 to 10.1±0.2 (p<0.0001). Hb in patients without iron preparation (n=27) was also raised from 8.7±0.2 to 10.0±0.2 (p<0.0001). [Conclusions] CERA was effective in rheumatic patients complicated with CKD. Even with low Cr, we should suspect CKD and start CERA in the early stage. In RA patients, it might be possible to discontinue CERA with the intensification of the treatment of RA.

W65-4 Usefulness of assessment of the GERD symptom with the use of GerdQ interview sheet in rheumatic disease
Kazuya Kishimoto, Yuji Nozaki, Tetsu Imani, Kenji Sakai, Shinoki Ri, Asuka Inoue, Toshihiko Shiga, Koji Kinoshita, Masanori Funahuchi, Itaru Matsumura
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Sayama, Osaka, Japan

Conflict of interest: None

Objectives: We have a lot of opportunities to prescribe NSAIDs or DMARDs in rheumatic clinic, but it's difficult to ask a patient about his upper gastrointestinal symptom since a consultation hour is limited. There is a previous study that GERD scores of systemic scleroderma (SSc) and Behcet disease (BD) were increased in rheumatic diseases. Methods: We investigated the frequency of heartburn, regurgitation, epigastric pain, nausea, sleep disturbance, additional use of commercial drug by GerdQ in 350 rheumatic patients. Patients were asked to recall symptoms during the last 7 days. The definition of treatment-resistant GERD is that total score is more than 8, and any of heartburn, regurgitation, sleep disturbance, use of commercial drug is more than 2 days. Results: 40 of 350 patients has a treatment-resistant GERD. Patients were diagnosed as RA (n=11), SSc (n=7), SLE (n=6), BD/MCTD/PM/PM/DM (n=6), and other rheumatic disease (n=6). The Mean age was 59 years and the mean disease duration was 114 months. The administration rate of PPI was 65%. Conclusion: Even though an administration of PPI, a treatment-resistant GERD was recognized with GerdQ interview sheet in rheumatic diseases. Usefulness to evaluate symptoms and reconsider treatment content was suggested.

W65-5 Examination of 10 cases of intestinal emphysema secondary to autoimmune diseases
Kana Ishimori, Seido Ooka, Kanako Suzuki, Harunobu Iida, Takayasu Ando, Yutaka Goto, Maruna Uchida, Yusa Asari, Hisae Fujimoto, Keichi Sakurai, Hiromi Matsushita, Tomofumi Kiyokawa, Yukiko Takekawa, Kumiko Tonooka, Mitsuru Imamura, Takeshi Suzuki, Yoshioki Yamasaki, Hiroko Nagafuchi, Kimito Kawahata
Rheumatology and Allergology, St. Marianna University School of Medicine

Conflict of interest: None

[Object] The intestinal emphysema is a state with the gas in intestinal wall and classified in idiopathy and a secondary. It is unknown what the outcome intestinal emphysema with collagen diseases is. We examined intestinal emphysema of this hospital. [Method] From January, 2010 to October, 2018, we investigated clinical data referring the patients with intestinal emphysema diagnosed by CT at St. Marianna university school of medicine. [Results] Ten intestinal emphysema was detected, but there was no stomachache in 8 cases. Two cases with stomachache die with sepis. Five scleroderma, four systemic lupus erythematous, one derma-tomysitis were included. The case that showed increase of the activity at an intestinal emphysematous diagnosis was one case, and most were found accidentally. And they are improved by rest. Four of five cases of scleroderma caused intestinal pseudo-obstruction. [Conclusions] As for the intestinal emphysema associated with collagen disease, most had a good prognosis. The possibility that stomachache, portal vein emphysema, sepsis had a poor prognosis was suggested.

W65-6 Relationship between serum oxytocin levels, disease activity, activity of daily life, quality of life and depression in patients with rheumatoid arthritis
Yusuke Miwa1, Nobuyuki Yamajima2, Ryoko Takahashi1, Ryoko Yanai1, Sakiko Isojima1, Masayuu Uemura1, Nao Oguro1, Yoko Miura1, Mayu Saito1, Mika Hatano1, Tomoki Hayashi1, Kosuke Sakurai1, Tsuyoshi Kasama1, Michio Hosaka1
1Division of Rheumatology, Department of Medicine, Showa University, School of Medicine, 2Psychosomatic Medicine, Katsuyama Clinic

Conflict of interest: Yes

[Object] Oxytocin (OXT) also referred to as a happy hormone. However, the relationship between depression and RA has not yet been clarified. The objective of this study was to investigate the relationship between serum OXT levels and disease activity, depression, ADL, and QOL in RA. [Methods] This study included 119 RA patients. We measured the following variables: baseline characteristics including age, sex, disease duration, smoking history, BMI, prednisolone dose, MTX dose, and serum levels of RF, MMP-3, CRP and ESR. The disease activity of RA was assessed using the SDAI; depression was assessed using the Hamilton Depression Rating Scale; ADL were assessed using the HAQ-DI; and QOL was assessed using the SF-36. Serum OXT levels were determined by ELISA. The subjects were divided into two groups according to the higher or lower of the serum OXT levels, and a retrospective study was performed. [Results] The serum OXT levels were correlated with age (r=0.043). Weak correlations of MTX dose (r=0.028), swollen joint count (r=0.306), ESR (r=-0.245) and CRP (r=-0.283) were noted.
W66-1
The regulation of AMP-activated protein kinase by uric acid in mice
Yoshitaka Kimura, Daisuke Tsukui, Tamiko Yanagida, Hajime Kono
Department of Rheumatic Disease, Jujo Takeda Rehabilitation Hospital, 1Center for Rheumatic Diseases, Jujo Takeda Rehabilitation Hospital, 2Department of Rheumatology and Clinical Immunology, Kyoto University
Conflict of interest: None

[Object] It’s reported that AMPK activation protected against the development of atherosclerosis. Hyperuricemia is regarded as one of the risk factors of atherosclerosis. In this study, we clarified the association of uric acid with AMPK. [Methods] Secretable uricase (suUOX) or intracellular uricase (intUOX) transgenic mice express extracellular or intracellular uricase that lead to reducing levels of the uric acid of outside or inside of the cells, respectively. The uricase transgenic mice and control mice were administered with 30% fructose solution for 5 days. In another experiment, Apoe−/− mice were fed with high fat diet for 16 weeks with or without administration of 60 µg/ml allopurinol in the drinking water. In both experiments the activities of AMPK of the leukocytes were evaluated by western blot. [Results] In fructose experiment, activities of AMPK were significantly increased in both types of uricase transgenic mice. In high fat diet experiment, activities of AMPK were increased in mice with allopurinol. [Conclusions] Decreasing uric acid levels by expressing uricase or inhibition of xanthine oxidase inhibitor both activated AMPK of leukocytes in mice. It suggests that uric acid has a role in development of atherosclerosis via regulation of AMPK activity.

W66-2
A pilot survey about the method of synovial fluid crystal examination in Japan
Takayasu Kise1, Naoto Yokogawa1, Naoki Tanomogi1, Masahiro Iida1, Shuhei San1, Yusuuke Nakamichi1, Tatsuo Mori1, Nanase Honda1, Michiru Kina1, Eiisuke Takamatsu1, Kae Onishi1, Yuji Miyoshi1, Satoshi Watanuki1, Masako Utsunomiya1, Yoshiki Nagai1, Kota Shimada1, Ikuko Masuda1, Shoji Sugii1
1Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, 2Department of Rheumatic Diseases, Tokyo Metropolitan Health and Medical Treatment Corporation, Tama-Hokubu Medical Center, 3Division of Emergency and General Medicine, Tokyo Metropolitan Tama Medical Center, 4Center for Rheumatic Diseases, Jujo Takeda Rehabilitation Hospital
Conflict of interest: None

[Objective] We performed a pilot survey about the crystal examination method in Japan. [Method] We sent a questionnaire about the identification of crystals in synovial fluid to 173 institutions in Japan. The questionnaires are following; 1) Which department is seeing crystal-induced arthritis?, 2) Is microscopic examination used for the diagnosis of crystal induced arthritis?, 3) Who is examining the synovial fluid?, 4) Is a compensated polarized microscope available in own institution?. [Results] We received the replies from 80/173 institutions (46.2%). The results were following; 1) orthopedic surgery 64, rheumatology (internal medicine 43, surgery 9), internal medicine or general internal medicine 10; 2) 6 did not use microscopic examination because of non-availability; 3) laboratory 49, outsourcing 27. physician 6; 2) 6 did not use microscopic examination because of non-availability; 3) laboratory 49, outsourcing 27. physician 6; 4) laboratory 43, not available 26, own department 3, unknown 8. Contacting the laboratories, we found almost all institutions including outsourcing companies did not have compensated polarized microscope and are using a light microscopy with polarized plates. Examination is often performed after centrifuging. [Conclusion] A standard crystal identification method is not used in Japan. The standardization of microscopic examination is urgent subject in Japan.

W66-3
Validation of the protocol for detecting monosodium crystal deposition in dual-energy computed tomography (DECT) and pitfalls in interpretation
Yohei Seto1, Atsuo Taniguchi1, Naomi Ichikawa1, Hisashi Yamanaka1
1Institute of Rheumatology, Tokyo Women’s Medical University, 2Tokyo Women’s Medical University Yachiyo Medical Center
Conflict of interest: None

[Object] DECT has currently been recognized as a non-invasive imaging modality which enables detection of monosodium urate (MSU) crystal deposition. We report a validation study for a single-source DECT (Discovery CT 750HD, General Electric) using a sample extracted from a patient with tophaceous gout. [Methods] a 77 year-old man attended the clinic with subcutaneous mass in the right lateral malleolus, suspected of gouty tophus. Aspiration and microscopic examination revealed the presence of MSU crystal and confirmed the diagnosis. The supernatant and precipitation acquired by settled separation were scanned by DECT and compared with the reference standard derived from the chemical formula and mass attenuation coefficient of urate. [Results] The change in the Hounsfield Unit was similar between the reference standard and the precipitation, and the effective atomic number of the precipitation was more approximate to the reference than that of the tophus detected in vivo. Whereas, applying the sample including supematant as a reference resulted in increased sensitivity and also detection of artefact. [Conclusions] Density of MSU crystal deposition in vivo should be considered for interpretation of DECT image despite our confirmation of the validation for the reference standard.

W66-4
Usefulness of musculoskeletal ultrasonography to evaluate chondrocalcinosis in acute calcium pyrophosphate crystal arthritis (pseudogout)
Yukiko Komano1, Sayaka Uno1, Kaori Yanagawa1, Aiko Kishida1, Keiichiro Ohmura2, Toshihiro Mata1, Ikuko Masuda1
1Center for Rheumatic Diseases, Jujo Takeda Rehabilitation Hospital, 2Department of Rheumatology and Clinical Immunology, Kyoto University
Conflict of interest: None

[Background] Demonstration of calcium pyrophosphate (CPP) crystals in synovial fluid and/or radiographic chondrocalcinosis (CC) has been the gold standard for the diagnosis of calcium pyrophosphate deposition (CPPD). Recently, potential utility of ultrasonography (US) in diagnosis of CPPD including pseudogout has been reported. [Object] To investigate the usefulness of US in diagnosis of pseudogout. [Methods] Retrospective study. 24 consecutive patients (July/2015–July/2018) diagnosed with pseudogout in our rheumatology clinic. Clinical records were reviewed. [Results] 18 patients (17 females) who underwent radiographic and US assessment were analyzed. Mean age was 86 y.o. The main sites where CPP deposition was detected by US are hands (11/21), knees (9/16), shoulders (3/4). Three patients fulfilled the above gold standard. In others, the diagnosis was based on symptoms and CC of affected joints (6 cases), CC of asymptomatic joints (2 cases), US identification of CPP deposition and CC of asymptomatic joints (4 cases), US identification of CPP deposition without CC (2 cases), solely in clinical symptoms (1 case). Detection rate of CPP deposition in affected joints by US is relatively high compared to that by radiography. [Conclusions] US is a useful diagnostic tool for pseudogout.

W66-5
Ultrasound-guided aspiration for diagnosis in Pseudogout of the hip: two case reports
Ryozo Harada1, Keiichiro Nishida1, Ryuichi Nakahara1, Yoshihisa Nasu2, Koji Takasugi1, Misuzu Fujimori1, Kazuhiko Ezawa1, Shinichiro Fujita1, Kie Inoue1, Wataru Yamamoto1
1Department of Rheumatic Disease Center, Orthopaedics, Kurashiki Sweet Hospital, 2Department of Orthopaedics, Okayama University Hospital, 3Department of Rheumatic Disease Center, Internal Medicine, Kurashiki Sweet Hospital, 4Department of Rehabilitation, Kurashiki Sweet Hospital
Conflict of interest: None

[Object] Demonstration of calcium pyrophosphate (CPP) crystals in synovial fluid and/or radiographic chondrocalcinosis (CC) has been the gold standard for the diagnosis of calcium pyrophosphate deposition (CPPD). Recently, potential utility of ultrasonography (US) in diagnosis of CPPD including pseudogout has been reported. [Object] To investigate the usefulness of US in diagnosis of pseudogout. [Methods] Retrospective study. 24 consecutive patients (July/2015–July/2018) diagnosed with pseudogout in our rheumatology clinic. Clinical records were reviewed. [Results] 18 patients (17 females) who underwent radiographic and US assessment were analyzed. Mean age was 86 y.o. The main sites where CPP deposition was detected by US are hands (11/21), knees (9/16), shoulders (3/4). Three patients fulfilled the above gold standard. In others, the diagnosis was based on symptoms and CC of affected joints (6 cases), CC of asymptomatic joints (2 cases), US identification of CPP deposition and CC of asymptomatic joints (4 cases), US identification of CPP deposition without CC (2 cases), solely in clinical symptoms (1 case). Detection rate of CPP deposition in affected joints by US is relatively high compared to that by radiography. [Conclusions] US is a useful diagnostic tool for pseudogout.
Yasuhiro Morutani1, Hiroshi Horuchii2, Tsuyoshi Toyota1, Yoshiyuki Kotoda1, Yoshiyuki Nakamura1, Tsutomu Takizawa1
1Department of Orthopedic Surgery, Nagano Matsushiro General Hospital, Nagano, Japan, 2Department of Rehabilitation, Shinshu University Hospital

Conflict of interest: None

[Introduction] Atraumatic acute inflammatory hip joint pain requires differential diagnosis of rheumatoid arthritis, crystal induced arthritis and infectious arthritis, and it may be difficult to diagnose. [Objective] We report two cases in which ultrasound-guided aspiration of the hip joint was useful for diagnosis and treatment. [Case 1] 92-year-old female couldn’t moved with right hip joint pain. X ray and CT showed no fracture, but fluid accompanied by calcification was observed in the anterior direction in hip joint. [Case 2] 81-year-old female with pelvic fractures in resting hospitalization, suddenly had right hip joint pain and couldn’t moved. we found a fluid accumulation around the hip joint. [Results] Ultrasonography-guided aspiration of the hip joint may be performed easily and safely, and useful for diagnosis and treatment of hip joint pseudogout.

[W67-1] The study of liver fibrosis in rheumatoid arthritis (RA) patients with methotrexate (MTX) treatment using Combi-Elasto and liver fibrosis score
Motokazu Kai1, Shigenori Tamaki1, Kunikazu Ogawa1, Takashi Kato4, Ikuko Tanaka1
1Motokazu Kai1, Hiroshi Horuchii2, Tsuyoshi Toyota1, Yoshiyuki Kotoda1, Yoshiyuki Nakamura1, Tsutomu Takizawa1
1Department of Orthopedic Surgery, Nagano Matsushiro General Hospital, Nagano, Japan, 2Department of Rehabilitation, Shinshu University Hospital

Conflict of interest: None

[Introduction] Atraumatic acute inflammatory hip joint pain requires differential diagnosis of rheumatoid arthritis, crystal induced arthritis and infectious arthritis, and it may be difficult to diagnose. [Objective] We report two cases in which ultrasound-guided aspiration of the hip joint was useful for diagnosis and treatment. [Case 1] 92-year-old female couldn’t moved with right hip joint pain. X ray and CT showed no fracture, but fluid accompanied by calcification was observed in the anterior direction in hip joint. [Case 2] 81-year-old female with pelvic fractures in resting hospitalization, suddenly had right hip joint pain and couldn’t moved. we found a fluid accumulation around the hip joint. [Results] Ultrasonography-guided aspiration of the hip joint may be performed easily and safely, and useful for diagnosis and treatment of hip joint pseudogout.
W67-4
Examination of LPS binding protein and CD57 expressing NK cells in ACPA antibody negative RA patients
Masao Takemura1, Masao Sato2, Tomohiro Sasakid, Tsuneo Watanabe4, Kuniaki Saito1
1Advanced Diagnostic System Research Laboratory, Fujita Health University Graduate School of Health Sciences, Toyoake, Aichi, Japan, 2Ohashi-Tani Orthopedics, Gifu, Japan, 3Ota Orthopedics Clinico, Gifu, Japan, 4Gifu University School of Clinical Laboratory, Gifu, Japan, 2Department of Disease Control and Prevention, Fujita Health University Graduate School of Health Sciences, Toyoake, Aichi, Japan
Conflict of interest: None

[Object] There are reports that patients with rheumatoid arthritis (RA) have less onset of dementia. Accumulation of amyloid β (Aβ) is thought to be one of physiological phenomena accompanying aging and its relation to dementia has been studied. In this study, anti-Aβ autoantibody was measured and the relationship between NK cell and LPS binding protein (LBP) was examined. [Methods] The subjects were 127 patients with rheumatic outpatient clinical visits. Seventy two patients (age 55.6 ± 16.9 years) diagnosed with RA, 55 cases of unknown arthritis (UA) (60.5 ± 13.4 years). Routine clinical examination was conducted on the relationship with ACPA antibody, CRP, RF, IgG, IgA, IgM. [Results] The anti-Aβ-40 antibody concentration (Mean ± SE) was 16.3 ± 1.9 u in the RA group and was significantly higher compared with UA group; 12.8 ± 1.9 u (p <0.01). On the other hand, LBP was significantly (p <0.05) high in the RA group 4.9 ± 0.4 μg/mL than in the UA group 3.6 ± 0.2 μg/mL. There was no significant difference between the RA group and the UA group for CD57+/CD8+ cells (%). [Conclusions] These results imply that autoantibodies and cellular origin are involved in their pathogenesis complicatedly.

W67-5
The relationship between the onset of rheumatoid arthritis and the balance of blood monocyte subsets
Eriko Tanaka1,2, Shiro Ohshima1,2, Yukihiko Saeki1,2,3,4
1Department of Rheumatology, Ginnankai Clinic, 2Department of Clinical Research, NHO Osaka-Minami Medical Center, 3Department of Rheumatology and Allergology, NHO Osaka-Minami Medical Center
Conflict of interest: None

[Object] In humans, monocytes are composed of three distinct subsets based on their expression of CD14 and CD16; inflammatory (I), patrolling (P), phagocytic monocytes. To evaluate the correlation between blood monocyte subsets and the onset or the disease activity of RA in patients with new-onset arthritis. [Methods] The patients were diagnosed within one month from initial visit and divided into three groups which were RA (n=73), OA (n=47), and UA (n=47) groups. In fresh peripheral blood of all patients, the membrane molecules of monocytes were analyzed immediately using flow cytometry using the antibodies anti-CD14 and anti-CD16. [Results] The percentages of I monocytes in RA and UA group were significantly higher and than that in OA group (p=0.001, p=0.036). While that of P monocytes in UA group was significantly higher than that in RA group (p=0.0004). The ratio of I/P in RA group was significantly higher than that in UA group (p=0.0003). Moreover the ratio of I/P was correlated with DAS28CRP (r=0.43, p=0.0001). [Conclusions] This study suggests that in human blood monocyte subsets the I-biased monocyte is possible to correlate with the onset of RA and disease activity of arthritis and P monocytes possibly prevent the development of RA from UA.

Conflict of interest: None

W67-6
Comparison between the usefulness of temporal artery biopsy and imaging tests for the detection of temporal artery lesion in giant cell arteritis
Ko Takamatsu, Hideyuki Horikoshi, Rika Suzuki, Yasuyoshi Kusanagi, Fumihiko Kimura, Kenji Itoh
Division of Hematology and Rheumatology, Department of Internal Medicine, National Defense Medical College
Conflict of interest: None

[Object] Temporal artery biopsy (TAB) and imaging tests are used for detecting temporal artery (TA) lesion in giant cell arteritis (GCA); however, the concordance rate remains unclear. We compared the efficacy of TAB and imaging tests in detecting TA lesion in GCA. [Methods] We retrospectively reviewed patient characteristics, clinical symptoms, imaging test results, and TAB for 6 patients diagnosed with GCA. [Results] Three men and 3 women, with a median age of 74.5 (25th-75th percentile, 70-79.8) were analyzed. Clinical symptoms included fever in 1 patient, malaise in 2, weight loss in 4, jaw claudication in 2, visual loss in 1, and complication with polymyalgia rheumatica in 5. Laboratory tests showed that the CRP level was 7.5 (3.50-12.23) mg/dL, ESR was 109.5 (92.75-117.25) mm/h, WBC was 7000 (6375-8525)/µL, Hb level was 10.7 (9.88-10.88) g/dL, and Plt level was 37.8 (30.83-39.50) × 104 /µL. Imaging tests showed 1/5 (17%) of TA abnormality on MRT and 3/6 (50%) of TA wall thickening on ultrasonography (US); moreover, 5/6 (83%) patients demonstrated arteritis on TAB. Three patients without cranial symptoms were all TAB-positive, and 2/3 in lack of TA lesion on US were TAB-positive. [Conclusions] TAB is more useful than US for detecting TA lesion in GCA.

W68-1
The relationship between Anti-citrullinated peptide antibody and osteoporosis
Hiroyuki Nagata1, Kentaro Inui2, Tsutsuya Kikobe1,2, Yuko Sugioka1, Tadashi Okano1,2, Kenji Mamoto1, Yutaro Yamada2, Koji Mandai1, Masahiro Tada1, Hiroaki Nakamura1
1Orthopedic Surgery, Osaka General Hospital of West Japan Railway Company, 2Orthopedic Surgery, Osaka City University Hospital, 3Orthopedic Surgery, Hamayuu Hospital, 4Orthopedic Surgery, Osaka City Society Hospital, 5Orthopedic Surgery, Osaka City General Hospital
Conflict of interest: None

[Object] The factor of osteoporosis of rheumatoid arthritis (RA) is various, but there are reports that a disease itself is risk of osteoporosis. This time, the relation between the bone density and Anti-citrullinated peptide antibody (ACPA) was investigated. [Methods] We use the data from TOMORROW (the positive cohort study which consists of 202 RA patients and 202 controls whose age and sex were matched: UMIN000003876). We divided into three groups by the titer of ACPA at base line (BL). We have performed a multiple regression analysis of the objective variable DXA value, as an explanatory variable clinical data of BL. We also have performed a multiple regression analysis as explanato- ry variables clinical data of BL and objective variable amount of change in seven years lower limb bone density (BMD). [Results] In the context of the BMD in the BL there is no correlation between 3 group (p=0.90.9). In the analysis of change in seven years, we also find the correlation between 3 group (p=0.30.5). [Conclusions] ACPA is not associ- ated with osteoporosis, also involved in the bone loss of seven years was not observed.

W68-2
Clinical factors affecting the change of anti-CCP antibody in rheumatoid arthritis patients
Ichiro Nakamura1,2, Katsumi Ito1, Takuo Juji4, Naohiro Izawa1, Akhiro Uchido1, Takumi Matsumoto5, Jinju Nishino1, Sakae Tanaka2
1Faculty of Medical Science, Teikyo-Hissey University, 2Department of Rheumatology, Heisei Yokohama Hospital, 3Department of Orthopedic Surgery, University of Tokyo, 4Department of Rheumatology, JCHO Yugawara Hospital
Conflict of interest: None

[Object] Anti-CCP antibody (ACPA) is widely used for diagnosis of rheumatoid arthritis (RA). There are few reports that ACPA values fluctuate due to RA treatment, whereas, in the clinical course, the values sometimes change dramatically. The purpose of this study is to clarify the clinical factors affecting the change of ACPA values in RA patients. [Methods] 234 patients (195 women, 39 men) with RA, in whom ACPA values were measured twice with an interval of more than five years,
were analyzed. The mean age of patients was 67.6 years old, and the mean duration of RA was 17.4 years. Five clinical factors including smoking history, periodontal disease, Brinkman index, family history of RA and usage of biologic agents were evaluated for the change of ACPA values. [Results] Among these factors, usage of biologic agents significantly reduced ACPA values. Smoking history and periodontal disease have a tendency to increase ACPA values. In 56 patients, ACPA increased more than twice, while, in 50 patients, it decreased to less than half. Between two groups, multiple logistic analysis was performed with above factors as explanatory variables, revealing that biologic agents significantly reduced ACPA to less than half. [Conclusions] Biologic agents have the potential to decrease ACPA values.

**W68-3**  
**Risk factors for CMV infection in autoimmune disorder**  
Sayuri Takamura1, Daisuke Kobayashi1, Shunsuke Sakai1, Ayako Wakamatsu1, Yukiko Ozawa1, Hiroe Sato1, Takeshi Nakatsue1, Yoko Wada1, Takeshi Kuroda1, Masaaki Nakano1, Ichieti Narita1  
1Division of Clinical Nephrology and Rheumatology, Niigata University Medical and Dental Hospital, 2School of Health Sciences, Niigata University, 3Niigata University Health Administration Center

Conflict of interest: None

[Purpose] To identify the risk for CMV infection in patients with autoimmune disorders on steroid therapy. [Method] Forty-nine (Male: 19, Female: 30) patients with autoimmune disease who started taking prednisone (≧20mg/day) in our hospital were enrolled. Weekly CMV pp65 antigen evaluation were performed. If summation of positive cells in 2 slides was ≧5, they were diagnosed as positive in this study (CMV positive group). [Results] Patients with SLE: 11, ANCA-associated vasculitis (AAV): 8, MCTD: 6, interstitial pneumonia with anti-ARS-Ab; 5, rheumatoid arthritis: 4, IgG4 related disease; 3, clinically amyopathic dermatomyositis (CADM); 2, adult onset still’s disease (AOSD); 2, and others; 8 were started taking prednisolone, and 8 patients (SLE:2, AAV:2, CADM:2, AOSD:1, and MCTD:1) became positive CMV antigenemia. Total lymphocyte count and serum albumin level were low (710/μl vs 1210/μl; p=0.002, 2.80 g/dl vs 3.55 g/dl; p=0.030, respectively), and HbAlc was high (6.4 % vs 5.8 %; p=0.007) in CMV positive group. All patients in CMV positive group received steroid pulse therapy (p=0.001). [Conclusion] Lymphoctopenia, hypoalbuminemia, high HbAlc, and receiving steroid pulse therapy were associated with the risk of CMV pp65 antigen positivity.

**W68-4**  
**Evaluation of human non-mercaptoalbumin in patients with rheumatoid arthritis and systemic lupus erthematosus**  
Hideto Takada, Suguru Honda, Masako Majima, Naoko Konda, Yasuhiro Katsumata, Michi Tsutsumino, Masayoshi Harigai, Hisashi Yamanaka Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Conflict of interest: None

[Background] Patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) are at high risk of atherosclerosis and have high mortalities due to cardiovascular disease and stroke. Oxidative stress is involved in the progression of atherosclerosis and the percentage of high mortalities due to cardiovascular disease and stroke. Oxidative stress is involved in the progression of atherosclerosis and the percentage of high mortalities due to cardiovascular disease and stroke. Oxidative stress is involved in the progression of atherosclerosis and the percentage of high mortalities due to cardiovascular disease and stroke.

[Methods] We measured HNA% in healthy controls and patients with RA and SLE by using high-performance liquid chromatography. We used multivariate analysis to identify factors associated with HNA%. [Results] SLE patients had significantly higher HNA% than age-matched healthy controls, while RA patients did not. HNA% was significantly higher in SLE compared to RA. In SLE patients, HNA% was associated with dyslipidemia after adjusting for age and sex. [Conclusions] This study revealed the redox state of serum albumin in patients with RA and SLE, and its association with dyslipidemia.

**W68-5**  
**Is alpha-defensin useful for differential diagnosis of arthritis exacerbation and suppurative arthritis in RA patients?**  
Tomohiro Ojima, Seigaku Hayashi Department of Rheumatology, Fukui General Hospital

Conflict of interest: None

[Object] We investigated whether alpha-defensin, which is useful for the diagnosis of periarticular joint infection (PJII), can distinguish between arthritis exacerbation and suppurative arthritis in RA patients. [Methods] Thirty joints who developed acute and chronic arthritis in RA patients were included. Peripheral blood data, synovial fluid culture, presence/absence of crystals, white blood cell count, neutrophil fraction, alpha-defensin (lateral flow kit, Zimmer) of all cases were examined. Synovial biopsy and surgery were performed, and histopathological examination was added. The presence or absence of infection was performed according to the MSIS criteria (2013), and the diagnostic accuracy of alpha-defensin was evaluated. [Results] Despite multiple culture of synovial fluid, bacterial culture was negative except for one case of CNS positive. Alpha-defensin positivity was 67% (20/30) and infection was 40% (12/30) on MSIS criteria. The diagnostic accuracy of pyogenic arthritis of alpha-defensin was 60% sensitivity and 100% specificity. [Conclusions] The diagnosis of pyogenic arthritis occurring in patients with RA is problematic and there is no choice but to respond to case-by-case basis at present.

**W68-6**  
**Clinical significance of anti-DFS70 antibodies in connective tissue diseases and healthy individuals**  
Kenichi Uto1, Nobuhide Hayashi2, Yuji Nakamachi1, Akio Morinobu1, Jun Saegusa1,2  
1Department of Clinical Laboratory, Kobe University Hospital, 2Department of Medical Technology, Faculty of Health Sciences, Kobe Tokiwa University, 3Division of Rheumatology and Clinical Immunology, Department of Internal Medicine, Kobe University Graduate School of Medicine

Conflict of interest: None

[Object] The antinuclear antibody (ANA) test is clinically important for the diagnosis of connective tissue diseases (CTD). However, anti-DFS70 antibodies have been reported have the higher prevalence in healthy individuals with high titers of indirect immunofluorescent test (FANA). In this study, we evaluated the clinical significance of anti-DFS70 antibodies in CTD patients and healthy individuals. [Methods] We studied 252 healthy individuals and 281 CTD patients. Anti-DFS70 antibodies and eight disease-specific antibodies were tested by ELISA. ANA screening and determination of dense fine speckled (DFS) pattern was tested by FANA. [Results] The positivity rate of anti-DFS70 antibodies was comparable in healthy individuals (16.7%) and CTD patients (16.7%). There was a significant correlation between anti-DFS70 ELISA titters and FANA titters only in healthy individuals. The prevalence of monospecific anti-DFS70 antibodies (anti-DFS70 ELISA positive/eight disease-specific antibodies negative) or DFS pattern was significantly higher in healthy individuals than CTD patients. [Conclusions] Anti-DFS70 antibodies are responsible for ANA positivity in healthy individuals. It is necessary to suspect the presence of anti-DFS70 antibodies in cases of DFS pattern in CTD screening by FANA.

**W69-1**  
**Predictors for complete clinical response of skin and muscle disease in patients with cancer-associated myositis (CAM)**  
Hiroyo Kadota1, Takahisa Gono1,2, Yukie Yamaguchi2, Eri Watanabe2, Yuko Okazaki1, Yuichiro Shirai1, Seiji Kobayashi1, Mitsuhiro Takeno1, Chiihiro Terai2, Masataka Kuwana1  
1Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan, 2Department of Rheumatology, Saitama Medical Center, Jichi Medical University, 3Department of Environmental Immuno-Dermatolo-
Clinical characteristics of cancer-associated myositis in patients with synchronous multiple primary malignancies

Mita Sakuraba, Hiroko Kadota, Takahisa Gono, Yukie Yamaguchi, Eri Watanabe, Yuka Okazaki, Shinji Watanabe, Yuichi Shirai, Seiji Kobayashi, Mitsubishi Takeno, Chiihiro Terai, Masatasa Kuwana

1Department of Allergy and Rheumatology, Nippon Medical School, Tokyo, Japan; 2Department of Rheumatology, Saitama Medical Center, Jichi Medical University, Saitama, Japan; 3Department of Environmental Immunology, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Conflict of interest: None

[Object] To elucidate the clinical characteristics of cancer-associated myositis (CAM) in patients with synchronous multiple primary malignancies (MPM). [Methods] A retrospective study of CAM patients admitted to our hospital between January 1992 and October 2018. [Results] Of 141 patients, 14 (six men, eight women) had synchronous MPM. Among these, five had MPM and none had CAM [four had clinically amyopathic DM (CADM)]. The median interval between the diagnosis of myositis and the occurrence of synchronous MPM was 70.5 (25-3,009) days. During follow-up, eight patients had pneumonia and three had pneumothorax. Nine patients improved with conservative treatment. On univariate analysis, interstitial lung disease (p = 0.001), CADM (p = 0.006), steroid pulse (p = 0.002), high C4 (p < 0.04), low CK (p = 0.04), low serum albumin (p = 0.01), and low peripheral blood lymphocytes (p = 0.02) were associated with increased pneumomediastinum. Survival was significantly (p = 0.01) lower in patients with pneumomediastinum than in those without. [Conclusions] This study is the first to associate a high C4 level, low serum albumin, and low peripheral blood lymphocytes with pneumomediastinum.

Clinical characteristics of patients with clinically amyopathic dermatomyositis (CADM) positive for anti-TIF-1r antibody

Miswa Kanaoka, Yukie Yamaguchi, Asami Akita, Yasushi Ototake, Nobuaki Ikeda, Michiko Aihara

Department of Allergy and Rheumatology, National Center for Global Health and Medicine;
National Institutes of Health, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of Neurological Disorders and Stroke, and National Institute of Environmental Health Sciences, Bethesda, Maryland, United States

Conflict of interest: None

[Object] To analyze the clinical features of patients with anti-TIF-1r antibody (Ab)-positive dermatomyositis (DM), especially in cases of CADM. [Methods] CADM cases were extracted from anti-TIF-1r Ab-positive DM and their clinical features were evaluated. [Results] Within 31 cases of DM patients positive for anti-TIF-1r Ab in our department, there were 7 CADM cases (22.6%). In these cases, Gottron’s papule, heliotrope rash, and periangual erythema tended to be highly observed compared to that in patients with non-CADM patients with this Ab. The prevalence of malignancy within 2 years before and after the onset of DM was 58.3% (14/24) in anti-TIF-1r Ab-positive non-CADM patients, while that was 14.3% (1/7) in anti-TIF-1r Ab-positive CADM patients, which was significantly lower (P = 0.04). Meanwhile, interstitial lung disease was observed in 4 out of 7 patients with CADM (57.1%), which was significantly higher than that in anti-TIF-1r Ab-positive non-CADM patients (3/24, 12.5%, P = 0.01). Finally, serum anti-TIF-1r antibody lev-
el was significantly lower in CADM patients than that in non-CADM cases (64.0 ± 47.0, 104.1 ± 36.8 respectively, P = 0.03). [Conclusions] Anti-TIF-1r Ab-positive CADM cases may have different clinical features from the normally recognized antibody profile.

**W69-6**
Clinical characteristics of anti-Ro 52 antibody in dermatomyositis/ polymyositis
Mariko Momohara, Yoshinao Muro
Department of Dermatology, Nagoya University Graduate School of Medicine

Conflict of interest: None

[Object] Anti-Ro 52 antibody is one of the most common antibodies in inflammatory myositis and known as associating with interstitial lung disease (ILD) and coexisting with anti-Jo-1. We tried to clarify the clinical significance of anti-Ro52 in different inflammatory myositis specific autoantibodies (MSA)-positive groups. [Methods] Of all 229 dermatomyositis (DM) and polymyositis (PM) patients, 167 cases (DM 152, PM 10, juvenile DM 5) fulfilled the criterion of Bohan and Peter, and 62 clinical amyopathic DM patients fulfilled the criterion of Sontheimer. Anti-Ro52 was detected by ELISA. [Results] 46 patients were anti-Ro 52 positive (20%). ILD was frequently complicated with anti-Ro 52 positive patients (35 of 46: 78%) (P<0.0001), and anti-Ro 52 was highly positive in anti-ARNA polymerase 1 RNA synthetase (ARS) antibodies positive group (19 of 32) (P<0.0001). But ILD frequencies of anti-Ro 52 -positive and -negative groups were not statistically different in each coexisting MSA-positive patients. Anti-Ro 52 positive rates were similar in anti-Jo1 (61%) and other anti-ARSs (52%) (P=0.7). [Conclusions] Although anti-Ro 52 was highly positive with anti-ARS antibodies, it was simultaneously present with other MSA.s. Anti-Ro 52 did not contribute as the risk of ILD in each MSA-positive group.

**W70-1**
Analysis of chronological changes in J-HAQ and factors associated with achieving J-HAQ remission 5 years after disease onset in patients with rheumatoid arthritis using the IORRA cohort
Mai Abe1, Eiichi Tanaka1, Eisuke Inoue1, Mika Kawano1, Eri Sugano1, Naohiro Sugitani1, Kumiko Sakai1, Yoko Higuchi1, Moeo Ochiai1, Rei Yasuhide1, Naoko Sugimoto1, Katsunori Ikari1, Ayako Nakajima1, Atsue Taniguchi1, Hisashi Yamanaka1
1Institute of Rheumatology, Tokyo Women’s Medical University Hospital, Tokyo, Japan, 2Division of Medical Informatics, St. Marianna University School of Medicine, Kanagawa, Japan, 3Center for Rheumatic Disease, Mie University Hospital, Mie, Japan

Conflict of interest: None

[Object] To evaluate chronological changes in J-HAQ score and J-HAQ remission rates 5 years after rheumatoid arthritis (RA) onset using the IORRA cohort. [Methods] RA patients who first visited at our hospital in the year of RA onset were divided into two groups, 1) RA onset between 2000 and 2005 (former onset group: n=357) and 2) RA onset between 2006 to 2010 (recent onset group: n=291). J-HAQ and J-HAQ remission rate at baseline and 5 years after onset in each group were investigated, and factors associated with J-HAQ remission after 5 years were assessed. [Results] Average J-HAQ/J-HAQ remission rate at baseline and 5 years after onset were 0.659/52.2% and 0.316/78.4%, respectively, in the former onset group. J-HAQ/J-HAQ remission rate at baseline and 5 years after onset were 0.705/52.2% and 0.430/71.4%, respectively, in the recent onset group. Significant factors associated with achieving J-HAQ remission after 5 years were patients in the recent onset group, male, younger, lower J-HAQ at baseline, and non-steroid user. [Conclusions] J-HAQ score improved with improvement of RA treatment strategy in recent years. In order to achieve J-HAQ remission after 5 years RA onset, treatment from early stage to prevent deterioration of J-HAQ and treatment without steroid seems to be important.

**W70-2**
Transitions of clinical characteristics, incidence and prognosis of 447 cases of AA amyloidosis complicating RA in Dohgo Spa Hospital
Yasuki Okuda, Kenichiro Matoba, Kazuo Jouyama, Akihiro Yamada, Yosuke Murata, Naoya Sawada, Ayuko Sagabe, Atsushi Kondo, Makoto Onishi, Kiyoshi Takasugi
Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama, Ehime, Japan

Conflict of interest: None

[Objective] To investigate transitions of the clinical features, incidence and the prognosis of AA amyloidosis complicating RA (AA) in our hospital. [Methods] We divided the 447 AA patients into 4-decade interval group (1980,1990,2000,2010) by the year of the AA diagnosis and compared the clinical features, incidence and prognosis of each group. [Results] 1. RA onset age of AA was not different significantly in each decade group. 2. Interval from onset of RA to AA diagnosis was prolonged in recent onset groups. 3. Incidence of AA was significantly decreased in recent onset groups. 4. CRP values were decreased significantly by the lapse of time. 5. Prognosis (5-year survival rate) improved significantly in recent decade group. [Conclusions] Decreased incidence and improved prognosis of AA were demonstrated due to progress of treatment of RA in our epidemiologic study.

**W70-3**
Epidemiology of rheumatoid arthritis in Japan
Masayo Kojima
Department of Medical Education, Nagoya City University Graduate School of Medical Sciences

Conflict of interest: None

[Object] To identify the epidemiological characteristics of rheumatoid arthritis (RA) patients in Japan by using the data of the National Life Insurance Survey. [Methods] Of the 224,208 households including 565,133 subjects, total of 272,558 men and 295,196 women excluding 672 age-missing people were selected. “RA patients” were defined as those who had any mental stress with daily life was higher in RA patients than in non-RA. [Conclusions] The present results were almost consistent with recent reports from Europe and the United States. The necessity to consider RA medical care in the framework of regional inclusive care system in the future.

**W70-4**
The risk of hospitalized infection in patients with systemic lupus erythematosus with hydroxychloroquine
Ryoko Sakai1, Suguru Honda1, Sho Suzuki1,2, Masayoshi Harigai1, Hisashi Yamanaka1
1Department of Rheumatology, Tokyo Women’s Medical University, 2Tokyo Women’s Medical University, Department of Public Health

Conflict of interest: Yes

[Object] To compare risk of hospitalized infection (HI) between users and non-users of hydroxychloroquine (HCQ) in systemic lupus erythematosus (SLE). [Methods] Using claims data provided by Medical Data Vision Co., Ltd (Tokyo, Japan), we defined individuals as SLE cases if they had at least one SLE diagnostic code and one prescription of predefined drugs for SLE and were 16 years old or over between September 2015 and July 2017 (n=17,483). SLE cases who had at least one prescription of HCQ were defined as HCQ group (n=1,431), and others were defined as non-HCQ group (n=16,052). Among these SLE cases, propensity-score-matched cases were observed for 1 year in this study (n=1,331 in each group). We compared the proportion of cases with HI between the two groups using chi square test, and calculated the odds ratio (OR) of the
W70-5
Analysis for clinical characteristics and social productivity of patients with malignant rheumatoid arthritis, based on the clinical personal record database

Yoshiyuki Abe1, Hiroaki Dobashi2, Tamihiro Kawakami3, Taichi Hayashi4, Shinya Kaname1, Masayoshi Harigai4, Naoto Tamura1
1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Division of Hematology, Rheumatology, and Respiratory Medicine, Department of Internal Medicine, Kagawa University, Kagawa, Japan, 3Division of Dermatology, Tohoku Medical and Pharmaceutical University, Miyagi, Japan, 4Department of Internal Medicine, University of Tsukuba, Ibaraki, Japan, 4First Department of Internal Medicine, Kyorin University School of Medicine, Tokyo, Japan, 4Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan

Conflict of interest: None

Object: To evaluate the clinical data and social activity of patients with malignant rheumatoid arthritis (MRA) in Japan, including the changes over time. Methods: Using the clinical personal record database stored in the Ministry of Health, Labor and Welfare from 2003 to 2014, we evaluated retrospectively and cross-sectionally about the patient background, treatment, and social activity. Results: The average age gradually increased from 62.0 years old in 2003 to 65.1 years old in 2014, and female rates were about 70 to 73%. The fulfilling rate of each component in MRA classification criteria almost did not change over time. As for the treatment, use of DMARDs and immunosuppressants were increased. In contrast, proportion of patients with surgery, doses of corticosteroid, use of NSAIDs, and use of plasma exchange were decreased. In social activities, “recuperation” and “hospitalization” were decreased, while “household worker” “worker” were increased. Conclusion: Evaluation of the time course of patients with MRA in Japan revealed that the increase in use of DMARDs and immunosuppressants. As for social activities, the results suggest that social productivity of MRA patients improved over time.

W70-6
The habits of smoking, drinking alcohol and caffeinated coffee consumption in rheumatoid arthritis (Comparison with healthy control) - TOMORO study -

Hitoshi Yoshimura1, Kentaro Inui2, Tatsuya Koike4,5, Yuko Sugikoa3, Tadashi Okano, Kenji Mamoto1, Masahiro Tada1, Hiroki Nakamura3
1Department of Orthopaedic Surgery, Osaka Saiseikai Nakatsu Hospital, 2Department of Orthopaedic Surgery, Osaka City University Graduate School of Medicine, 3Department of Orthopaedic Surgery, Osaka City General Hospital, Osaka, Japan, 4Department of Orthopaedic Surgery, Search Institute for Bone and Arthritis Disease, Wakayama, Japan, 5Department of Orthopaedic Surgery, Center for Senile Degenerative Disorders, Osaka City University Medical School, Osaka, Japan

Conflict of interest: None

Purpose: The association between smoking and rheumatoid arthritis (RA) patients is well known, however there is few reports on lifestyle habits. In this study we analyze the consumption of smoking, coffee and alcohol in RA patients in relation to healthy control. Methods: We analyzed baseline data from the TOMORO study (UMIN000003876), which is a 10-years prospective cohort for age and sex matched RA (n=208) and volunteers (Vo) (n=205). Data on smoking history and alcohol (Alc), caffeinated coffee, decaffeinated coffee and Japanese tea intake were self-reported on the questionnaires. Alc intake was categorized into 3 groups by calculating the amount per day using Alc unit (1 unit is pure Alc 20 mg). We categorized frequency of Alc intake per week into 3 groups, number of cups of coffee and Japanese tea intake per week into 4 groups each. We performed multivariate analysis. Results: We analyzed 191 Vo and 208 RA with complete data about luxury items. In multivariate analysis, smoking history (OR 5.03, p=0.04), 26 unit of Alc intake per day (OR 0.20, p=0.04) and 1-7 cup of caffeinated coffee intake per week (OR 0.26, p=0.04) were significantly different between RA and Vo. Conclusions: In RA patients smoking seems to be high and moderate intake of Alc and caffeine seems to be low.

W70-7
Longitudinal study of the effects of biological DMARDs on work productivity in rheumatoid arthritis patients in daily practice using the Institute of Rheumatology Rheumatoid Arthritis (IORRA) Cohort

Eiichii Tanaka1, Isuake Inoue1, Mai Abe1, Mika Kawano1, Eri Sugano1, Naohiro Sugitani2,3, Kumiko Saka1, Yoko Higuchi1, Moeko Ochiai1, Rei Yamaguchi1, Naoki Sugimoto1, Katsunori Ikari1, Ayako Nakajima1,2, Atsuo Taniguchi1, Hisashii Yamakaka1
1Institute of Rheumatology, Tokyo Women’s Medical University Hospital, Tokyo, Japan, 2Division of Medical Informatics, St. Marianna University School of Medicine, Kanagawa, Japan, 3Center for Rheumatic Diseases, Mie University Hospital, Mie, Japan

Conflict of interest: None

[Object] To conduct a longitudinal study of the effects of biologics on work productivity in Japanese RA patients in daily practice. [Methods] RA patients who participated in the IORRA and initiated biologics between 2012 and 2016 as well as who were paid workers were selected for the Bio group. For a control group, matching by age, sex, and DAS28 score at baseline was used from RA patients who had never used biologics before. Changes from baseline at mean 15 months in the scores of absenteeism (AB), and presenteeism (PR) in both groups were calculated using the WPAI. The effects of biologics on these scores were analyzed. [Results] Among RA patients in the IORRA, 157 patients were selected each for the Bio and the control group. The changes in AB/PR scores were from 1.4%/20.1% at baseline to 2.0%/12.3% at mean 15 months in the Bio group and from 2.1%/20.1% at baseline to 2.7%/20.1% at mean 15 months in the control group. The introduction of biologics resulted in improvement in PR (p=0.003) score. [Conclusions] The introduction of biologics improved the work productivity, especially presenteeism, in RA patients based on data from an observational cohort representing daily practice in Japan.

W71-1
Incidence of malignant lymphoma and other malignancies in patients with rheumatoid arthritis

Atsushi Hashimoto1, Toshihiro Matsui2, Shigeto Toma2
1Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, 2National Hospital Organization Tokyo National Hospital

Conflict of interest: Yes

[Object] Patients with rheumatoid arthritis (RA) have higher incidence of malignant lymphoma (ML) than the general population. We assessed the incidence of malignancies including ML in RA patients over time. [Methods] Using the data from a nationwide multicenter Japanese RA cohort database ‘NinJa’ from 2003 to 2017, we estimated standardized incidence ratio (SIR) of malignancies. Incidence of malignancies in the general population was obtained from Cancer Registry and Statistics (Cancer Information Service, National Cancer Center, Japan.). [Results] In 2017, 177 patients developed malignancies (including 27 ML) in a total of 15185 patients. Lung cancer (n=29, 16.4%) was most frequent followed by ML (15.3%), colon (n=26), breast (n=18) and gastric cancer (n=16, 9.0%). SIR of entire malignancies was 0.98 (95% confidence interval (CI) 0.84-1.13), which was approximately 1 as before. SIR of ML was 4.44 (95% CI 2.77-6.12), which was significantly higher than the general population as before. SIR of ML rose to 5 to 6 in 2014-15 and thereafter declined as in the past. SIR of colon cancer was 1.31 (95% CI 0.81-1.82). [Conclusions] RA patients have incidence of ML about 4 times as high as the general population constantly during the past 15 years.
**W71-2**

Association between activity of arthritis at onset of disease and titters of autoantibodies for elderly-onset rheumatoid arthritis

Kenji Yamazaki, Ryuehi Ishihara, Toshiaki Miyamoto

Seirei Hamamatsu General Hospital

Conflict of interest: None

---

[Object] We elucidate the association between activity of arthritis at onset of disease and titters of their autoantibodies in Elderly-onset rheumatoid arthritis (YORA). [Methods] We enrolled 315 patients who were affected arthritis first visited in our institution from September 2013 until August 2018. We set semi-quantitative results of musculoskeletal ultrasounds (Gray Scale: GS, Power Doppler: PD) as surrogate marker of activity of arthritis at onset of disease based on the evidence that results of ultrasounds is an independent predictor of structural damage in early RA. [Results] In YORA group, there is an association between RF titer and GS/PD score (GS; p=0.17, p=0.029/PD; p=0.22, p=0.01). On the other hand, in EORA group, There is no association between RF titer and GS/PD score statistically (GS; p=0.14, p=0.10/PD, p=0.11, p=0.18). When we analyzed sensitivity by changing cut-off age from 60 years to 65 years and 70 years, the correlation coefficients tended to decline. With respect to ACPA, GS/ PD score are associated with ACPA titer. [Conclusions] EORA has weaker association between activity of arthritis at onset of disease and RF titer than YORA. In EORA, RF titer may be useless for prognostic factor.

---

**W71-3**

Analysis of the oral microbiome in general population: focused on rheumatoid arthritis and anti-CCP Ab positivity

Mami Tamai, Shin-ya Kawashiri, Mako Nagayoshi, Atsushi Kawakami Nagasaki University, Nagasaki, Japan

Conflict of interest: None

Objectives: To evaluate the oral microbiome in the subjects with rheumatoid arthritis and anti-CCP Ab (ACPA) positive from the general population. Methods: Salivary samples were obtained from 1219 subjects in general population, and 165 rRNA OTU analysis were carried out. There were 26 subjects with ACPA-positive, and 32 patients with RA (out of 10 ACPA-positive), then, age and gender adjusted subjects with ACPA-negative and -positive were selected (n=52). PERMANOVA analysis of the weighted UniFrac distance developed (p-value<0.05). microbial community composition Results: Median age 70y.o., %Female 63%, 11 current smokers, 27 subjects with dry mouth symptoms, 13 anti-HTLV-I Ab positive subjects. Multivariate analysis showed the association of microbial community composition between RA and non-RA (p=0.04), especially ACPA positive RA. Cardiobacterium increased in RA group. Conclusions: Our analysis suggest that there was difference of the oral microbiome between patients with RA and non-RA subjects, especially remarkable for anti-CCP positive RA.

---

**W71-4**

Left Ventricular Diastolic Dysfunction in Japanese Rheumatoid Arthritis

Manami Hirata1, Kei Hirose1, Yu rico Yamamura1, Nortiya Momoki1, Akiko Ueno1, Masahiro Yamamura1

1Department of Rheumatology, Okayama Saiseikai General Hospital, Department of Nephrology, Okayama Saiseikai General Hospital

Conflict of interest: None

[Background] It has been reported from the other country that patients with rheumatoid arthritis (RA) are more likely to have left ventricular diastolic dysfunction (LVDD). We investigated LVDD in Japanese RA patients, without a history of HF. [Methods] We analyzed RA patients who underwent echocardiography examinations from April 2016 to March 2018, in a retrospective way. We evaluated LVDD by 2015 ASE/EACVI echocardiography guideline. [Ejection fraction (EF) exceeded 50%, a ratio of early diastolic transmitial velocity to early diastolic mitral annular velocity (E/e'ratio) >14 and e'<7.] [Result] The study included 39 RA subjects (29 female). Mean age was 76.8 ± 16.3 years old. RF positive in 30, ACPA positive in 24. Mean disease duration was 6 years (Median 1-58years), tender 1.2±2.0/28 joints, swelling 1.0±1.8/28 joints. Hypertension 26, diabetes mellitus10, hyperlipidemia 9, smoking history 11. No HF was included. Assessment of E/Aratio with pulse doppler, the former evaluation, LVDD 34subjects (94%) included. Compared with ASE/EACVI2015 evaluation, LVDD 14subjects (36%) included. [Conclusion] LVDD is known as one of the predictor of heart failure with preserved EF. We reported that the prevalence of LVDD in Japanese RA is approximately the same frequency with previous reports.

---

**W71-5**

The causes of death in deceased patients with RA by NinJa 2017 cohort

Atsushi Kaneko1, Toshihiro Matsui2, Shotaro Morii3, Yosuke Hattori1, Tomotaro Sato1, Masao Katayama4, Shigeto Tohma4

1Department of Orthopaedic Surgery and Rheumatism, Nagoya Medical Center, 2Department of Rheumatology, Nagamihara National Hospital, 3Department of Collagen Disease and Rheumatology, Nagoya Medical Center, 4Department of Rheumatology, Tokyo Medical Center

Conflict of interest: None

[Objectives] The purpose of the present study is to evaluate the age at death and the cause of death in patients with rheumatoid arthritis (RA) in NinJa2017 [Methods] 135 Japanese deceased patients with RA, who were registered in the large cohort database (NinJa: National Database of Rheumatic Diseases by i-net in Japan). We investigated the age at death, the causes of death of all patients. [Results] The mean age at death was 77.6year old. The major cause of death in deceased patients was infection in 39 patients involving in pneumonia in 30 patients. Next was malignancy in 31 patients, respiratory dysfunction involving intestinal pneumonia in 15 patients, cardiovascular disease in 18 patients, unknown sudden death in 5 patients. [Conclusion] The life expectancy of Japanese patients with RA was getting better. But the average of RA onset is recently older, the duration from RA onset to death is shorter. The major causes of death were infection, especially pneumonia.

---

**W71-6**

Background of patients with rheumatoid arthritis undergoing joint arthroplasties -Analysis using the National Database of Rheumatic Diseases in Japan (NinJa)

Tetsuro Yasu1, Atsuhisa Yamada1, Shigeru Nakamura1, Mitsuuyasu Iwasawa1, Sakae Tanaka1, Toshihiro Matsui2, Shigeto Tohma3

1Department of Orthopaedic Surgery, Teikyo University Mizonokuchi Hospital, Kanagawa, Japan, 2Department of Orthopaedic Surgery, NHO Sagamihara National Hospital, Kanagawa, Japan, 3Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, 4Department of Rheumatology, NHO Sagamihara National Hospital, Kanagawa, Japan, 5NHO Tokyo National Hospital, Tokyo, Japan

Conflict of interest: None

Object Number of arthroplasties for rheumatoid arthritis (RA) has been reducing. The purpose of this study was to clarify the difference in patient background and its secular change at each surgical site. Methods The background data of patients who underwent arthroplasty of knee (TKA), hip (THA), and elbow (TEA) from 2003 to 2017 were extracted from NinJa. Results 1,816 TKAs, 727 THAs, and 383 TEAs were performed. The background data of patients who underwent arthroplasty of knee (TKA), hip (THA), and elbow (TEA) from 2003 to 2017 were extracted from NinJa. Results 1,816 TKAs, 727 THAs, and 383 TEAs were performed. The average value of mHQA was 0.86, 1.11, and 1.13 in TKA, THA, and TEA group, respectively. There was a significant declining trend in each group. The difference among groups tended to shrink recently. The average value of DAS28CRP was 3.4, 3.2, and 3.2 in TKA, THA, and TEA group, respectively. There was a significant declining trend in each group. The difference among groups tended to shrink recently. The average value of mHQA was 0.86, 1.11, and 1.13 in TKA, THA, and TEA group, respectively. There was a significant declining trend in each group. The difference among groups tended to shrink recently. The average value of DAS28CRP was 3.4, 3.2, and 3.2 in TKA, THA, and TEA group, respectively. There was a significant declining trend in each group. The difference among groups tended to shrink recently. The average value of DAS28CRP was 3.4, 3.2, and 3.2 in TKA, THA, and TEA group, respectively. There was a significant declining trend in each group. The difference among groups tended to shrink recently. The average value of DAS28CRP was 3.4, 3.2, and 3.2 in TKA, THA, and TEA group, respectively. There was a significant declining trend in each group. The difference among groups tended to shrink recently. The average value of DAS28CRP was 3.4, 3.2, and 3.2 in TKA, THA, and TEA group, respectively. There was a significant declining trend in each group. The difference among groups tended to shrink recently.
W71-7
Discontinuation of concomitant methotrexate in patients with rheumatoid arthritis treated with tocilizumab: a prospective intervention study (T-ReX study)

Shuji Asai1, Toshihisa Kojima1, Masatoshi Hayashi2, Masahiro Hanabayashi1, Yashuhide Kanayama4, Toki Takekoto1, Yuichiro Yabe1, Tomoe Shionoura3, Hisato Ishikawa1, Yutaka Yoshioka1, Takefumi Kato1, Yuji Hiranoi5, Takayoshi Fujibayashi1, Yosuke Hattori1, Tomonori Kobayakawa1, Nobunori Takahashi4, Takuya Matsumoto1, Nobuyuki Asai1, Yasumori Sobue3, Tsuyoshi Nishiume4, Mochihito Suzuki1, Naoki Ishiguro1

1Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan, 2Department of Rheumatology, Nagano Red Cross Hospital, Nagano, Japan, 3Department of Rheumatology, Ichinomiya Municipal Hospital, Ichinomiya, Japan, 4Department of Rheumatology, Kosei Hospital, Toyota, Japan, 5Department of Orthopedic Surgery, Anjo Kosei Hospital, Anjo, Japan, 6Department of Rheumatology, Toyota Shinjuku Medical Centre, Tokyo, Japan, 7Department of Rheumatology, Shimizu Kosei Hospital, Shimizu, Japan, 8Department of Rheumatology, Japanese Red Cross Nagoya Daichi Hospital, Nagoya, Japan, 9Department of Rheumatology, Handa Municipal Hospital, Handa, Japan, 10Department of Orthopedic Surgery, Konan Kosei Hospital, Konan, Japan, 11Department of Orthopedic Surgery, Nagoya Medical Center, Nagoya, Japan, 12Department of Rheumatology, Chutouen General Medical Centre, Kakegawa, Japan

Conflict of interest: Yes

[Object] To evaluate the efficacy of discontinuation of concomitant methotrexate in patients with rheumatoid arthritis (RA) treated with tocilizumab (CT). [Methods] T-ReX study, a multicenter, open label, uncontrolled, prospective study, included the RA patients who maintained low disease activity (CDAI ≤ 10) for ≥ 12 weeks with combination therapy with tocilizumab plus methotrexate. Methotrexate was stopped following biweekly dosing for 12 weeks. The primary endpoint was the proportion of patients maintaining low disease activity at week 36 (24 weeks after stopping methotrexate). Secondary endpoints included physical function outcomes, quality of life, and gastrointestinal symptoms. [Results] A total of 49 patients completed 36 weeks. The proportion of patients maintaining low disease activity at week 36 was 75.5% with a lower 95% confidence limit exceeding the assumed threshold response rate of 60%. There were no significant changes in HAQ-DI and EQ-5D score from week 0 to week 36. The prevalence of GERD defined as FSSG score ≥ 8 was significantly decreased from week 0 to week 12 (27.1% to 18.4%; P = 0.025). [Conclusions] Discontinuation of concomitant methotrexate is feasible in the RA patients with stable low disease activity on tocilizumab.

W72-1
Investigation of immune cell subsets involved in Behçet’s syndrome by comprehensive gene expression analysis

Mai Okubo1, Shuji Sumitomo1, Mineo Ota1, Yusuke Takeshima1, Haruyuki Yanoaka2, Harumi Shirai1, Satomi Kobayashi1, Yusuke Sugimori1, Junko Maeda1, Hiroaki Hatano1, Yasuo Nagafuchi1, Yukiko Iwasaki1, Hirofumi Shoda1, Tomohisa Okamura4, Kazuhiro Yamamoto1, Keishi Fujio3

1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Japan, 2Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Japan, 3RIKEN Center for Integrative Medical Sciences, Japan

Conflict of interest: Yes

[Object] The functions of immune cell subsets that participate in pathologic conditions of Behçet’s syndrome (BS) are unknown in detail. We aimed to elucidate immune cell subsets involved in BS by flow cytometry (FCM) analysis and exhaustive gene expression analysis by RNA sequence (RNA-seq). [Methods] FCM analysis and cell sorting of 19 PBMC subsets were performed in BS patients (n=23, including 11 HLA-B51 positive patients) and healthy controls (HC; n=28). Neutrophils were obtained by magnetic cell separation. Comprehensive gene expression analysis with RNA-seq for a total of 20 subsets was performed. The relationship between gene expression and clinical parameter was analyzed. [Results] Th17 cells were significantly increased in BS compared to HC. From the network analysis based on the gene expression, gene modules that characterized BS were found in antigen presenting cell (APC) subsets such as dendritic cells, rather than Th17 cells. A module of genes correlated with HLA-B51 positivity was found in CD8 positive T cells. [Conclusions] The results of current analysis indicated the importance of Th17 cells and APCs in BS pathology. We aim to elucidate their functions, interactions and their relationship with genetic factors through further analysis.

W72-2
Mitochondrial DNA in membrane vesicles plays critical roles in pathogenesis for Behçet’s disease

Hachirou Konaka1,2, Jeong Hoon Park1,2, Yasuhiro Kato1,3, Hyota Takamatsu1,2, Atsushi Kumanogoh1,2

1Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University Japan, 2World Premier International Research Center, Immunology Frontier Research Center, ‘NTT West Osaka Hospital

Conflict of interest: None

Mitochondrial DNA (mtDNA) is known to induce inflammation via activating inflamasome and DNA sensors, leading to exacerbate various diseases. However, pathological significance of mtDNA in autoimmune diseases (ADs) has not been elucidulated. In order to clarify the involvement of mtDNA in BD pathogenesis, we measured the amount of mtDNA in serum of ADs by quantitative PCR. We found that serum mtDNA level is high in BD compared to other ADs. We also found that mtDNA was detected in ex vivo cellular membrane vesicles (EMVs) purified by ultracentrifugation. Since EMVs are known to be important for the cell-cell communication, we stimulated THP1 monocytic cells, with BD-derived EMVs. We found that BD-derived EMVs could induce IL-1β production, which was diminished in NLRP3-deficient THP1 cells. Then, we assessed the releasing mechanism of mtDNA in EMVs. The release of mtDNA from BD monocytes increased by ATP stimulation, which diminished by treatment with caspase1 inhibitor, suggesting that inflamasome activation causes the increased release of mtDNA in EMVs in BD. Collectively, we revealed a novel etiology of BD, namely, inflamasome activation increases the release of mtDNA in EMVs, which causes additional inflammation via activating NLRP3-inflamasome.

W72-3
Cluster analysis of Behçet’s disease: 2218 cases from a Japanese clinical database of patients receiving financial aid

Mitsuto Takeno1, Michiko Kurosawa2, Yutaro Soejima3, Yohei Kirino1

1Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, 2Department of Epidemiology and Environmental Health, Juntendo University, 3Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine

Conflict of interest: Yes

[Object] To determine subgroups of Behçet’s disease (BD) by clinical manifestations. [Methods] We investigated the data of BD patients who were newly registered to the Japanese Ministry of Health, Labour and Welfare, from 2003 to 2014. Cluster analysis was performed for clinical manifestations, pathology test, and HLA-B51 by Hayashi’s quantification third methods using HALBAU version 7. [Results] After screening 9045 cases, 2218 eligible cases (male 945, female 1273, mean age 39.9 ± 8) were included. We identified 3 distinct clusters: group A (male, ocular inflammation, HLA-B51-positive, neurologic involvement), group B (female, genital ulcers, onset age: <30 years, ocular inflammation-negative, HLA-B51-negative, neurologic involvement-negative), and group C (onset age: 30-39 years, skin lesions, arthritis). [Conclusions] Because of short disease duration, clinical manifestations were little modified by therapies, while additional symptoms cloud appear later in this study population. Similar clustering patterns were observed in a Yokohama cohort. It is important to determine prognosis and genetic susceptibility for individual clusters,
leading to the establishment of precision medicine in future.

**W72-4**

Patients with intestinal involvement compose a distinct subset in Behcet’s disease in Japan

Yutaro Soejima¹, Yohei Kirino², Mitsushi Takeno², Michiko Kurosawa³, Yuki Izuka¹, Takeaki Uehara¹, Ryusuke Yoshimi¹, Yukiko Asami¹, Akiko Sekiguchi¹, Atsushi Itaha¹, Shigeru Ohno¹, Toshihisa Igashira¹, Shohei Nagaoka⁴, Yoshiaki Ishigutubo¹, Hideaki Nakajima¹
¹Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, ²Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, ³Department of Epidemiology and Environmental Health, Juntendo University Graduate School of Medicine, ⁴Department of Rheumatology, Chigasaki Municipal Hospital, ⁵Yokosuka Rheumatology Center, Yokosuka City Hospital, ⁶Department of Rheumatology, Fujisawa City Hospital, ⁷Department of Rheumatology, National Hospital Organization Yokohama Medical Center, ⁸Rheumatology Center, Yokohama City University Medical Center, ⁹Department of Rheumatology, Yamato Municipal Hospital, ¹⁰Department of Rheumatology, Yokohama Minami Kyoisai Hospital, ¹¹Yokohama City University Conflict of interest: None

Clinical feature and treatment of vascular Behcet’s disease in Japan

Patients with intestinal involvement compose a distinct subset in Behcet’s disease in Japan. Half the cases occurred within less than a year from onset of Behcet’s disease in more than half the cases. We looked the deep venous thrombosis (n=9), inferior vena cava thrombosis (n=1), cerebral venous sinus thrombosis (n=1), aneurysm (n=10), arteriab obstruction (n=6) and dissection (n=2), organ infarction (n=3). Duration between the first vascular event and onset of Behcet’s disease was within less than a year in 13 cases. 23 cases used immunosuppressive agents. [Conclusions] In this study, arterial disease were more present than venous disease. Also, the first vasculart events occurred within less than a year from onset of Behcet’s disease in more than half the cases.

**W72-6**

Efficacy of Apremilast for Oral Ulcers Associated With Active Behcet’s Syndrome Over 28 Weeks in a Japanese Subgroup: Results From a Phase III Study

Hiroki Dobashi¹, Yoshia Tanaka², Hajime Kono³, Shoji Sugiu⁴, Mitsumasa Kishimoto⁵, Sue Cheng⁶, Maria Paris⁷, Mitsushi Takeno⁸
¹Kagawa University, ²University of Occupational and Environmental Health, ³Teikyo University School of Medicine, ⁴Tokyo Metropolitan Tama Medical Center, ⁵Immuno-Rheumatology Center, St. Luke’s International Hospital, ⁶Celgene Corporation, ⁷Nippon Medical School Conflict of interest: None

[Objective] Apremilast 30 mg BID (APR) was assessed over 28wks in a Japanese subgroup with Behcets syndrome and oral ulcers (OU). [Methods] Adults were stratified by region (Japan/other) and received APR or PBO for 12wks, followed by active treatment (tx). The primary endpoint was AUCWk0-12. Wk12 variables were prespecified without multiplicity adjustment. Nominal P values are given. Wk28 data are as observed. [Results] Included were 19 APR and 20 PBO patients (pts). Mean baseline OU count was 3.8 (APR) and 3.7 (PBO); mean pain VAS was 54.3 (APR) vs 61.7 (PBO). AUCWk0-12 was significantly lower for APR vs PBO (115.9 vs 253.3; P=0.0168). Significantly more APR pts had OU complete response at Wk12; between-group difference in OU pain was not significant. Efficacy was sustained with continued tx through 28wks. At Wk28, 65% (APR) and 53% (PBO) of pts had complete OU response; 64% and 30% had reduced OU pain. At 12wks, adverse event (AE) rates were similar (APR: 74%; PBO: 75%). Common AEs were diarrea, upper respiratory tract infection, nausea, and headache. No new safety concerns were identified up to 28wks. [Conclusions] APR showed efficacy for OU in Japanese pts with Behcet’s syndrome. Benefits were sustained up to 28wks with continued tx. Safety was consistent with APR’s AE profile.

**W73-1**

The influence of malnutrition on serious infectious complications in patients with rheumatoid arthritis

Kentaro Isoda¹, Shiro Ohshima¹, Shigeoshi Tsugi¹, Yui Yoshida², Eri Oguro¹, Kentaro Kuzuya³, Yasutaka Okita³, Hitodoshi Matsuoka³, Satoru Teshigawara⁴, Maiko Yoshimura⁵, Yoshinori Harada⁶, Takaaki Noguchi⁷, Shosuke Akita⁸, Jun Hashimoto⁸, Yukihiro Saeki⁸
¹Department of Rheumatology and Allergology, National Hospital Organization Osaka Minami Medical Center, ²Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, ³Department of Rheumatology, National Hospital Organization Osaka Minami Medical Center Conflict of interest: None

[Objective] To investigate the influence of nutritional status on serious infectious complications in patients with rheumatoid arthritis (RA). [Methods] This retrospective cohort study comprised 1315 patients (≥ 65 years old) with RA treated at our hospital at April 2016. Observation period is for 2 years. All patients were divided into infectious group complicated with severe infections requiring hospitalisation and non-infectious group without severe infectious events. Clinical findings and prognostic nutritional index (PNI) were compared in the 2 groups. Patients backgrounds were adjusted by propensity score (PS) matching. [Results] Infectious group included 66 patients, and non-infectious group 1466. Thirty-five patients of each group were chosen by PS matching. From the results of comparison in the adjusted groups, PNI of infectious group (median: 41.3, IQR: 38.9 - 45.2) was significantly decreased than that of non-infectious group (median: 46.3, IQR: 43.7 - 50.1) (p < 0.001). Infectious complication in patients with PNI < 45.0, cut-off value by ROC analysis, was higher than PNI ≥ 45.0 (HR: 1.835, 95%CI: 1.136 - 2.972, P = 0.013). [Conclusion] Malnutrition is a risk factor for severe infectious complication in RA.

**W73-2**

Helicobacter cinaedi bacteremia associated with painful erythema in rheumatoid arthritis with malignant lymphoma

Shunichi Fujita¹, Hiroaki Hayashi¹, Shoko Tsugi², Mayuko Fukushima³, Takehiko Akagi¹, Hiroshi Sawachikai³, Nami Kurosaki³, Hiroyasu Hirano³, Tomoyuki Muka³, Yoshitaka Morita³ Conflict of interest: None

[Objective] Vascular involvement is the causes of mortality and morbidity in Behcet’s disease. The aim of this study is to investigate clinical characteristics and treatments of patients with vascular Behcet’s disease. [Methods] 225 patients with Behcet’s disease in Tohoku University hospital during January 2007 to December 2017 were enrolled to this study. Clinical characteristics, the subtypes of vascular involvement, treatments were retrospectively evaluated of vascular Behcet’s disease. [Results] Among 225 patients, 24 patients had vascular involvements. 10 patients (41.7%) had venous disease and 17 patients (70.8%) had arterial disease. We looked the deep venous thrombosis (n=9), inferior vena cava thrombosis (n=1), cerebral venous sinus thrombosis (n=1), aneurysm (n=10), arteriab obstruction (n=6) and dissection (n=2), organ infarction (n=3). Duration between the first vascular event and onset of Behcet’s disease was within less than a year in 13 cases. 23 cases used immunosuppressive agents. [Conclusions] In this study, arterial disease were more present than venous disease. Also, the first vasculart events occurred within less than a year from onset of Behcet’s disease in more than half the cases.

**W73-1**

The influence of malnutrition on serious infectious complications in patients with rheumatoid arthritis

Kentaro Isoda¹, Shiro Ohshima¹, Shigeoshi Tsugi¹, Yui Yoshida², Eri Oguro¹, Kentaro Kuzuya³, Yasutaka Okita³, Hitodoshi Matsuoka³, Satoru Teshigawara⁴, Maiko Yoshimura⁵, Yoshinori Harada⁶, Takaaki Noguchi⁷, Shosuke Akita⁸, Jun Hashimoto⁸, Yukihiro Saeki⁸
¹Department of Rheumatology and Allergology, National Hospital Organization Osaka Minami Medical Center, ²Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center Conflict of interest: None

[Objective] To investigate the influence of nutritional status on serious infectious complications in patients with rheumatoid arthritis (RA). [Methods] This retrospective cohort study comprised 1315 patients (≥ 65 years old) with RA treated at our hospital at April 2016. Observation period is for 2 years. All patients were divided into infectious group complicated with severe infections requiring hospitalisation and non-infectious group without severe infectious events. Clinical findings and prognostic nutritional index (PNI) were compared in the 2 groups. Patients backgrounds were adjusted by propensity score (PS) matching. [Results] Infectious group included 66 patients, and non-infectious group 1466. Thirty-five patients of each group were chosen by PS matching. From the results of comparison in the adjusted groups, PNI of infectious group (median: 41.3, IQR: 38.9 - 45.2) was significantly decreased than that of non-infectious group (median: 46.3, IQR: 43.7 - 50.1) (p < 0.001). Infectious complication in patients with PNI < 45.0, cut-off value by ROC analysis, was higher than PNI ≥ 45.0 (HR: 1.835, 95%CI: 1.136 - 2.972, P = 0.013). [Conclusion] Malnutrition is a risk factor for severe infectious complication in RA.
Conflict of interest: None

W73-3  Necrotizing fasciitis in three patients with rheumatoid arthritis treated with tocilizumab
Atsushi Omoto, Satoshi Omura, Takuya Yanagida, Masatoshi Kadoya, Wataru Fukuda
The Center for Rheumatic Disease, Japanese Red Cross Kyoto Daichi Hospital

Conflict of interest: None

[Case 1] A 74-year-old woman with rheumatoid arthritis (RA) treated with tocilizumab (TCZ) was admitted as an emergency because of pain in the right leg with erythema. She was diagnosed with necrotizing cellulitis and started on intravenous antibiotics and debridement. Skin swabs grew haemolytic group G streptococcus. [Case 2] A 68-year-old woman with RA treated with TCZ and end-stage renal damage was admitted as an emergency because of pain in abdomen with purpura. She was diagnosed with necrotizing cellulitis and started on intravenous antibiotics and debridement. Skin swabs grew Staphylococcus aureus. [Case 3] A 71-year-old woman with RA and systemic sclerosis treated with TCZ was admitted as an emergency because of pain in the right leg with erythema and purpura. She was diagnosed with necrotizing cellulitis and started on intravenous antibiotics and debridement. Skin swabs grew Staphylococcus aureus. (discussion) We report 3 cases of NF with RA treated with TCZ. 41 RA cases with NF were reported and 17 patients were used biologic DMARDs including TCZ. TCZ might lead to NF get worse.

W73-4  The risk for urinary tract infection among rheumatic disease patients with asymptomatic bacteriuria
Tomohiro Yoshida, Keisuke Nishimura, Kaoru Mizukawa, Keiichiro Kadoba, Hiroki Mukoyama, Daisuke Waki, Toshihiko Yokota
Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan

Conflict of interest: None

[Object] Our aim is to clarify whether asymptomatic bacteriuria (AB) is the risk for urinary tract infection (UTI) among those who have rheumatic diseases (RD) and is receiving immunosuppressive therapy. [Methods] Inpatients with RD, who administered medium or high dose prednisolone (≧0.5mg/kg) from April 2015 to March 2018, were recruited. We divided them into 2 groups (AB in urinalysis before treatment or not) and examined retrospectively whether they developed UTI. [Results] Ninety-one RD patients were recruited (52 were AB positive, 59 were AB negative). ANCA-associated vasculitis (33.0%) and systemic lupus erythematosus (14.3%) were the most common. When started treatment, patients with AB administered significantly more prednisolone. And their lymphocyte and serum albumin were significantly few. In both group some patients administered immunosuppressant (cyclophosphamide, methotrexate, etc). Patients with AB developed significantly more UTI than patients without AB (8/32 (25%) vs 5/59 (8.5%), p=0.0165). Within thirteen UTI patients, ten were female. Six had acute pyelonephritis, six had acute cystitis, and one had emphysematous cystitis. [Conclusions] Patients with AB may develop UTI significantly after immunosuppressive therapy, but there may be a possibility of overestimation.

W74-1  A therapeutic intervention of osteoporosis for patients with rheumatoid arthritis
Ayano Hayashi1, Hidenori Tanigawa2, So Nomoto2
1Department of Nursing, Saiseikai Yokoamashi Tobu Hospital, 2Department of Orthopedic Surgery, Saiseikai Yokoamashi Tobu Hospital

Conflict of interest: None

[Object] To evaluate the characteristics of the newly developed tuberculosis (TB) in the registered patients in NinJa cohort study for rheumatoid arthritis (RA). [Methods] We calculated the standardized incidence ratio (SIR) of TB from the clinical data on National Database of Rheumatic Disease by iR-net in Japan [NinJa] prospectively from 48 facilities for 15 years. [Results] Among 141,047 patients registered from 2003 to 2017, 74 patients developed TB and the SIR of TB was 2.13 (95%CI:1.65-2.62). 8 patients (10.8%) were treated with biologic agents, and 26 patients (35.1%) were treated with MTX. The mean age of them was 71.4 years old and the mean duration of RA before the onset of TB was 10.3 years. Among 849 patients who have been administered JAK inhibitors (Tofacitinib 767, Baricitinib 82) since 2012, nobody has developed newly tuberculosis until 2017. [Conclusions] Similarly our last reports, the incidence of TB in RA patients was in the downward trend. By this study, in elderly, in patients with RA of long-term morbidity is the high risk of the newly developed TB.

Conflict of interest: None
W74-2
A status report on medical treatment for osteoporosis in rheumatic patients
Hiroshi Fujimaki1, Akihiro Nakazawa1, Motoharu Hirano2, Yoshihiro Kusayama1, Yutaka Inaba3
1Department of Orthopaedic Surgery, Yokohama Municipal Citizen’s Hospital, Yokohama, Japan, 2Department of Rheumatology, Yokohama Municipal Citizen’s Hospital, Yokohama, Japan, 3Department of Orthopaedic Surgery, Yokohama City University, Yokohama, Japan

Conflict of interest: None

[Object] The aim of this study was to investigate the status of medical treatment for osteoporosis in rheumatoid arthritis (RA) patients. [Methods] A total of 119 RA patients over 40 years old (83 females and 36 males, average 69.3 years old) were enrolled. Fracture risk of each patient was evaluated using FRAX, and bone mineral density data of femoral neck was also available in 105 patients. The indication of treatment for osteoporosis was defined as follows; 1) patients with 15% or higher fracture risk estimated by FRAX, 2) patients who met diagnostic criteria for osteoporosis, regardless of the fracture risk level. We assumed that history of past fracture and corticosteroid (CS) use affect the osteoporosis treatment rate in RA patient cohort. [Results] We specified 71 patients who met the indication for osteoporosis treatment. However, 31 patients of those were without any anti-osteoporotic drug. The treatment rate for patients with a history of CS use (58.3%) was significantly higher than patients without CS (p=0.02). The presence of past fracture history did not affect the treatment rate. [Conclusions] The number of potential subjects for osteoporosis treatment was underestimated. We should consider osteoporotic treatment more seriously in RA patients with a high risk of fracture.

W74-3
The sufficiency level of vitamin D for collagen disease in our faculty
Daisuke Nozawa1,2, Shigeru Hioki2
1Department of Orthopedic Surgery, University of Tsukuba, Faculty of Medicine, 2Department of Orthopedic Surgery, Tsukuba Central Hospital

Conflict of interest: None

[Object] We report on the sufficiency level of vitamin Din patients with collagen disease among patients who could measure serum 25-hydroxyvitamin D (25 (OH) D) concentration at our facility. [Methods] We investigated 106 patients who measured 25 (OH) D between Female 89 cases, male 17 cases. There were 14 patients with collagen disease. The disease was 6 cases of rheumatoid arthritis, 1 case of Sjögren’s syndrome, scleroderma, systemic sclerosis, dermatomyositis, IgA nephropathy, polymyalgia rheumatica, adult still disease, psoriasis respectively. Average 69.1 years old. Based on the judgment criteria for vitamin D deficiency / deficiency using serum 25 (OH) D concentration, 30 ng/ml or more is satisfied, less than 30 ng/ml is not satisfied, 20 ng/ml or more and 30 ng / ml was determined as vitamin D insufficiency, and less than 20 ng/ml was determined as vitamin D deficiency, and the proportion of each group was determined. [Results] The average concentration of 25 (OH) D was 15.8 ng/ml. Satisfied was only one person (7%), insufficiency 21% and deficiency 72%. In non-collagen disease group, there were 22% of insufficiency and 78% of deficiency. [Conclusions] It was thought that vitamin D sufficiency level was low in all patients, not only patients with collagen disease.

W74-4
Efficacy of denosumab in patients with rheumatic diseases for 36 months
Kotaro Shikano, Kaichi Kaneko, Mai Kawazoe, Keiko Koshiba, Shotaro Masuoka, Satoshi Mizutani, Soichi Yamada, Hiroshi Sato, Sei Muraoka, Toshihiro Nanki
Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine

Conflict of interest: None

[Object] We previously reported the efficacy of 12-month treatment of denosumab, anti-RANKL mAb, for rheumatic diseases. We continued denosumab for 36 months, and analyzed the efficacy of the treatment. [Methods] One hundred patients with rheumatic diseases (52 RA, 14 SLE, 11 PMR, 5 PM/DM, 4 SS, 3 MCTD, 3 SSc, 2 vasculitis syndrome and 6 other diseases) extended denosumab therapy to 36 months. Serum levels of bone turnover markers and lumber BMD in 33 patients were examined at 36 months. [Result] Serum levels of NTX, TRACP-5b, and BAP significantly decreased after 12 and 36 months. BMD significantly increased from baseline. Two patients developed compression fracture, and BMD was decreased in one patient. By multi regression analysis, the dosage of prednisolone was extracted as the inhibiting factor for increase of BMD. [Conclusions] Denosumab is effective for rheumatic diseases in 36 months. Higher dose of prednisolone may suppress increase of BMD by treatment with denosumab.

W74-5
The Report of the Treatment for Glucocorticoid-induced Osteoporosis in Our Hospital and the Interference in Insufficient Medication by the Pharmacist
Miho Manabe1, Akiko Yoshida1,2
1Pharmaceutical Division, Medical Technology Department, Keishinkai Kyoto Kizugawa Hospital, 2Department of Rheumatology, Keishinkai Kyoto Kizugawa Hospital, 3Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University

Conflict of interest: None

[Object] Glucocorticoid (GC)-induced osteoporosis (GIO) is the important side effect of GC therapy. I investigated the treatment for GIO in our hospital. [Methods] Outpatients were resistered who had visited the department of rheumatology in our hospital from June to August in 2018, and who had taken Predonine (PSL) for more than 3 months. This was retrospective study using medical records and the risk factor score of GIO was quoted from Guidelines for GIO of the Japanese Society (2014). [Results] 48 patients; RA (21), PM (15), RS3PE syndrome (6), SLE, MCTD, PsA, Behcet’s disease, IgG4-RD, and IgA vasculitis (each for 1 patient) were enrolled. The average age was 73.4 y.o. and man/woman ratio was 16/32. The average PSL dose was 4.3 ± 2.81mg/day,8 patients didn’t took any drug for GIO, though they had more than 3 risk factors of GIO score. 20 patients took only bisphosphonates (BP),5 patients took the combination of BP and vitamin D tablets (Vit.D) and 13 patients took Bisphosphonates, 6 cases were measured their bone density. Medications were suitable for patients with renal failure. After hearing from the patients and the physician, treatments for GIO were adjusted properly. [Conclusions] The treatment for GIO in our hospital was insufficient, but pharmacists could try to change GIO treatment better.

W74-6
Anti-resorptive agents-related Osteonecrosis of the jaw (ARONJ) in RA patients
Megumi Ibuki1, Hideaki Oyabu1, Tatsuya Hojo1, Kazuha Kizaki1, Noboru Funakoshi1, Fumiharu Yamashita1
1Department of Orthopedic Surgery, Meiji University of Integrated Medicine, Kyoto, Japan, 2Department of Dentistry, Meiji University of Integrated Medicine, Kyoto, Japan, 3Department of Health and Sports Science, Doshisha University, 4Department of Orthopedic Surgery, Kyoto Shimogamo Hospital, 5Department of Rheumatology, Kyoto Shimogamo Hospital

Conflict of interest: None

[Object] Osteonecrosis of the jaw (ONJ) is caused by various factors including inflammation and osteomyelitis. In recent years, it has been suspected that therapeutic targets for bone resorption by osteoclasts, bisphosphonates (BP) and denosumab are associated with anti-resorptive agents-related osteonecrosis of the jaw (ARONJ). We analyzed the incidence of ONJ in our hospital and introduced two ONJ cases with RA. [Results] We identified 7 cases of ONJs out of 10670 patients (average 1255 patients per year) who visited the department of dentistry in our hospital from 2010 to 2018. The incidence rate was increased after 2016, 1 case in 2013, 3 cases in 2016, 1 case in 2017, 2 cases in 2018. The underlying disease was 4 cases of prostate cancer (denosumab), 2 cases of
RA (1 case denosumab, 1 case minodronate) and 1 breast cancer (zole-
dronate). Case1 RA 85 y.o. female ARONJ stage3 with fistula Case2 RA 69 y.o. female ARONJ stage2 [Clinical significance] In RA patients, ste-
roids and immunosuppressive agents are frequently used for suppressing
inflammation and it potentially increases the risk of ONJ. We believe that
physicians and dentists should share patients’ information provision, co-
operating with each other. When ONJ occurs, it is necessary to examine
withdrawal of anti-rheumatic drug.

W75-1
Investigation of the effects of Igarutimod in combination therapy for RA patients experiencing insufficient results with biologics
Daisuke Tomita1, Tetsu Itami2, Satoshi Tsutsumi1, Kosuke Okuda1, Yuji Nozaki1, Masanori Funaiuchi1, Itaru Matsumura2, Tsukasa Matsubara1
1Matsubara Mayflower Hospital, Hyogo, Japan, 2Department of Hemat-
ology and Rheumatology, Kinki University Faculty of Medicine, Osaka, Japan

Conflict of interest: None

Purpose: We investigated of Igarutimod (IGU) combination treatment for RA patients already using biologics (Bio), who were unable to
achieve low disease activity and we compared the effectiveness of each of
the biologics. Methods: We added IGU to the treatment of RA patients
already being treated with Bio more than 3 months, and retrospectively
analyzed its effects on the 42 patients who were able to continue for 12
week. Baseline we use age, morbidity history, stage, class, MTX usage,
MTX dosage, PSL usage, PSL dosage, DAS28-ESR, we evaluated using
LDA rates and change in CDAI at 12 and 24 weeks after combined. Re-
results: Background: Age 64.9, disease duration 16.7, MTX had used 56%
and dosage was 7.5mg. PSL had used 42% and dosage was 3.4mg. Stage
2.63, Class 1.73. Bio type: 17 TNF inhibitors (IFX6, ETN 8, GLM 1, CZP
2), 15 ABT, 7 TCZ, 1 TOF are used. CDAI before IGU was
14.6±8.39, at 12 weeks 10.0±9.97, at 24 weeks 8.64±9.29. Before admin-
istration of IGU LDA was 30.77%, at 12 weeks 64.71%, and at 24 weeks
75.76%. It was suggested that TCZ is more effective in IGU combination
therapy than ABT and TNF inhibitor. Conclusion: In cases in which bi-
ologics are not sufficient effective, IGU can improve disease activity, and
TCZ is suggested as being more effective than ABT and TNF inhibi-
tor.

W75-2
Add-on Iguratimod to patients with rheumatoid arthritis inadequate-
ly responding to biological DMARDs
Ayaka Yoshikawa1, Koji Nagai1, Kenichiro Hata1, Takuya Kotani1, Yoko Matsumura2, Tohru Takeuchi1, Motomu Hashimoto1, Wataru
Yamamoto3,11, Kosaku Murakami4, Toru Hirano5, Kosuke Ebina6, Yonsu
Sato1, Hideki Amuro1, Akira Onishi1, Kengo Akashi1, Ryota Hara1, Masaki
Katayama1, Shigeki Arawaka7
1Department of Internal Medicine IV, Osaka Medical College, 2Department of Central, Osaka Medical College, 3Department of Advanced Medicine
for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, 4Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, 5Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, 6Department of Orthopaedic Surgery, Graduate School of Medicine, Osaka University, 7First Department of Internal Medicine, Kansai Medical University, 9Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 10The Center for Rheumatic Diseases, Nara Medical University, 11Department of Rheu-
matology, Osaka Red Cross Hospital, 12Department of Health Information Management, Kurashiki Sweet Hospital

Conflict of interest: None

[Object] To examine whether the effectiveness of rheumatoid arthritis (RA) patients treated with iguratimod (IGU) during the use of biological
DMARDs (bDMARDs) differ between bDMARDs. [Methods] 87 RA patients who used bDMARDs for more than 12 weeks and then added
IGU for 24 weeks were included. We retrospectively analyzed the disease activity between bDMARDs from the ANSWER cohort. [Results] The
mean age was 64.3 ± 12.8 years, a female of 76.2%, mean disease dura-
tion was 9.6 ± 8.6 years, mean duration of bDMARD treatment was 1.4 ±
1.6 years. bDMARDs were (1) TNF-a inhibitor 43 cases, (2) TCZ 16
cases, (3) ABT 28 cases. The mean ADAS 28-ESR (0w-24w) was
1.12±0.8 ((1):1.02±0.7, (2):1.13±0.9, (3):1.26±0.89). The ADAS 28-ESR
remission rate was improved from 8.5% at baseline to 45.5% at 24
weeks’ administration of IGU ((1):2.4±47.4, (2):25.0±53.9, (3):7.7–38.5),
and the CDAI remission rate was significantly improved from 0.0% at baseline to 27.7% at 24 weeks’ administration of IGU
((1):0–24.4, (2):0–28.6, (3):0–32.1), respectively (P<0.001). The pa-
tient background factor was not different except for the MTX amount,
and the effectiveness was equivalent among the bDMARDs. [Conclu-
sions] Add-on IGU to bDMARDs can be expected to can expect equiva-
 lent effects regardless of the type of bDMARDs.

W75-3
Biologic agent therapy of rheumatoid arthritis in the elderly with lung disease
Tatsuo Watanabe1, Toshihisa Kojima1, Nobunori Takahashi2, Shuji Asai1, Yasumori Sobue1, Naoki Ishiguro4
1Department of Orthopedic Surgery, Daido Hospital, 2Department of Orth-
opedic Surgery, Nagoya University Graduate School of Medicine

Conflict of interest: None

[Object] Of the treatment of rheumatoid arthritis (RA), biologic agent
therapies are chosen, if disease activity remains moderate or high despite
cDMARDs therapy. Elderly and lung disease are the major risk factor
for infection in biologic agent therapy. We investigate biologic agent
therapy of rheumatoid arthritis in the elderly with lung disease. [Methods]
Records of relevant patients with RA were collected from the Tsurumai
Biologic Communication Registry, wherein the department of Nagoya
University and 20 affiliated hospitals in Japan are enrolled. A total of 873
biologics-naive and age 75 and older patients were recruited from Janu-
ary 2004 to December 2014. We studied the choice of the biologic agent
year by, and baseline disease activity drug continuation rates. [Results]
From 2005 to 2010, etanercept was used the most. After the advent of
abatacept (ABT), ABT was used the most. Drug continuation rates in the
group with lung disease were: 70.6% (2004-2007), 93.5% (2008-2010),
94.1% (2011-). [Conclusions] Increasing of drug continuation rates
seemed for accumulation of experience.

W75-4
Ten-year retention rate and outcome of etanercept in patients with rheumatoid arthritis in clinical practice
Toki Takemoto1, Takeshi Oguchi1, Atsushi Kaneko1, Yuji Hirano1, Yutaka
Yokota1, Nobunori Takahashi1, Toshihisa Kojima1, Naoki Ishiguro4
1Department of Orthopedic, Anjo Kosei Hospital, Anjo, Japan, 2Department
of Orthopedic, National Hospital Organization Nagoya Medical Center,
3Department of Rheumatology, Toyohashi Municipal Hospital,
4Department of Orthopedic Surgery, Nagoya University Graduate School of
Medicine

Conflict of interest: None

[Object] Biologic agents (bDMARD) are regarded as a major ad-
vantage in the treatment of rheumatoid arthritis (RA), but data on the long-
term effects of bDMARD remain relatively scarce. So, the aim of this
study is to evaluate the ten-year outcome of etanercept (ETN) in patients
with RA. [Methods] RA patients who started ETN between 2005 and
2007 were investigated and 205 patients were enrolled. [Results] At base-
line, average age 57.6 years old, DAS28-CRP was 5.4 and rate of con-
comitant MTX was 51%. Ten-year retention rate of ETN was 41% and
75 patients actually continue ETN at 10 year. There was higher retention
rate in patient concomitant with MTX. After 10 years, there were 68% of
RA patients who continue to visit our hospitals for treatment, and 10%
patients who died. [Conclusions] In this study, the overall 10-year drug
retention rate for RA patients treated by ETN results comparatively good
and follow up rate at 10 year also results comparatively good.
W75-5

Short-term clinical effectiveness of biosimilar product of etanercept on rheumatoid arthritis patients

Akihiro Uchio, Takuo Juji, Katsumi Ito, Naohiro Izawa, Takumi Matsumoto, Jinju Nishino, Ichiro Nakamura, Sakae Tanaka
1JCHO Yugawara Hospital, 2Heisei Yokohama Hospital, 3The University of Tokyo Hospital, 4Teikyo Heisei University

Conflict of interest: None

[Object] In drug therapy of rheumatoid arthritis (RA), economical efficiency is an important factor as well as efficacy and safety. Biological agents are widely introduced in RA patients. However, due to its expensive medical expense, the usage of biology is sometimes limited or even given up. In this study, we investigated the effectiveness and safety of its bio-similar (BS) product of etanercept. [Method] We targeted 39 patients who were using ETN at JCHO Yugawara Hospital, Heisei Yokohama Hospital, changed to BS and were able to follow the course of 3 months after change. We measured and compared CRP, RF, MMP-3, HAQ, DAS28CRP, SDAI, CDAI before BS and 3 months after change. The reason for changing to BS, the presence or absence of side effects and the feeling after the change were also investigated. [Result] There was no difference in CRP, RF, HAQ and DAS28CRP, but there was significant difference in SDAI, CDAI and MMP-3. There were no cases in which arthritis exacerbated after BS change, which was consistent with international joint Phase III clinical trial. 30 people changed to BS for reasonable price. 11 patients had relieved injection pain and no new adverse events occurred. [Conclusion] BS was comparable with ETN.

W75-6

Differences of clinical performance between 50mg and 100mg of golimumab in patients with rheumatoid arthritis

Kengo Harigane, Yuichi Mochida, Kagayaki Sahara, Naoto Mitsugi, Ken Kagumai, Hyomin Choe, Akiko Nagaoka, Yutaka Inaba
1Center for Rheumatic Diseases, Yokohama City University Medical Center, 2Department of Orthopaedic Surgery, Yokohama City University Medical Center, 3Department of Orthopaedic Surgery, Yokohama City University

Conflict of interest: Yes

[Object] This study evaluated the differences of clinical performance between 50mg and 100mg of golimumab in patients with rheumatoid arthritis [Methods] The clinical background and the changes of disease activity score (DAS28-ESR) were analyzed for fifty-nine patients (50mg group; 37 cases, 100mg group; 32 cases) who were treated with golimumab at least three months. [Results] The rates of concomitant use of methotrexate (MTX) were 83.8% in 50mg group and 43.8% in 100mg group. The mean doses of MTX were 8.2 and 6.8 mg/week respectively. Also, the rates of concomitant use of prednisolone (PSL) were 56.8% in 50mg group and 53.1% in 100mg group. The mean doses of PSL were 4.4 and 4.0 mg/week respectively. The DAS28-ESR at baseline were 3.86 in 50mg group and 3.95 in 100mg group (n.s.). The rates of remission at 12 and 24 weeks were 42.4%, 45.8% in 50mg group and 50.0%, 54.1% in 100mg group. The averaged differences of DAS28-ESR from baseline at 12 and 24 weeks were -0.82, -1.18 in 50mg group and -1.30, -1.52 in 100mg group (n.s.). [Conclusions] Although there were no statistically significant results from our data, the administration 100mg of GLM tended to show better clinical efficacy in early period of treatment.

W76-1

Characteristics of the patients with Systemic lupus erythematosus (SLE) in our division and the efficacy of Belimumab

Hitoshi Kodera, Yoshifumi Matsumoto
Kuwana City Medical Center

Conflict of interest: None

[Object/Methods] To analysis the treatment of SLE patients who have consultations in our division for more than one year. Also to verify the effectiveness and safety of BEL. [Results] There were 32 subjects (female 29). Average age 47.6 years old, age at diagnosis 36.6 years old. Lupus nephritis diagnosed by renal biopsy was 40.6% of them. In initial symptoms, skin rash tended to be more frequent in juvenile onset, and serositis tended to be higher in elderly ones. Hydroxychloroquine (HCQ) was used at 65.6 %, and its average age was 42 years old, which is younger than the non-use cases (58.5 years old). The steroid free was 40.6 % of the total, and there was a tendency of frequent use of combination of immunosuppressants. BEL was used for four cases (the average age was 29.8 years old), mainly because of the experience of side effects for immunosuppressive drugs or of planning ofchildbearing. One of the cases was the one with the difficulty of steroid tapering, but after 6 months, the case succeeded in decreasing prednisolone 5 mg/day. [Conclusions] There is a tendency to reduce the dose of steroid with the use of HCQ and immunosuppressant in our division. And it was confirmed that BEL is useful for some case with difficulty of steroid tapering.

W76-2

Clinical features and the efficacy in patients with systemic lupus erythematosus treated with belimumab

Taihei Nishiyama, Yuya Kondo, Shota Okamoto, Hirofumi Toko, Masaru Shimizu, Fumika Honda, Ayako Ohyama, Izumi Kurata, Mizuki Yagishita, Saori Abe, Masahiro Kosawa, Atsumu Osada, Hiroto Subo, Isao Matsumoto, Takayuki Sumidita
Department of Internal Medicine, Faculty of Medicine, University of Tsukuba Hospital, Tsukuba, Ibaraki, Japan

Conflict of interest: None

<Objective> To clarify the clinical features and the efficacy in systemic lupus erythematosus (SLE) patients treated with belimumab (BLM) <METHODS> This study included six cases with SLE treated with BLM in University of Tsukuba hospital. We retrospectively evaluat ed 1) baseline characteristics, 2) purpose of BLM therapy, 3) clinical course in two cases treated with BLM for 12 weeks, and 4) adverse events. <RESULTS> 1) The mean age was 34.2±12.8 years old. The mean of SLE disease activity index (SLEDAI) and of anti-DNA antibody titer were 4.83±3.58 and 43.8±50.9 IU/mL, respectively. The mean prednisolone (PSL) dose was 14.5±3.6mg/day. 2) BLM was used to treat arthritis flare-up in one case, nephritis in one case, thrombocytopenia in one case, and to reduce PSL dose in three cases. 3) In case 1 with arthritis flare-up, both SLEDAI and anti-DNA antibody titer were decreased. PSL could be reduced from 17.5 to 13 mg/day. In case 2 treated with BLM to reduce PSL dose, PSL could be reduced from 12.5 to 8 mg/day. 4) Three cases experienced cough, infusion reaction and lassitude, respectively. BLM was discontinued in case with lassitude. <CONCLUSION> Our observations suggested that BLM might be effective for the improvement of disease activity and the reduction of PSL dose in patients with SLE.

W76-3

Safety and Efficacy of Belumimab in Pediatric Patients with SLE: The BEL114055 Phase II, Randomized, Placebo-controlled and multinational Study of Belimumab in Pediatric patients with SLE including the Japanese Children

Suyui Takei, Masaaki Morii, Naomi Iwata, Hiroaki Umebayashi, Ken Clark1, Antonio Nino2, Anne Hammer, Beulah Ji, David Roth3
1Pediatric Department of Kagoshima University Hospital, Japan, 2Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Japan, 3Department of Infection and Immunology Aichi Children’s Health and Medical Center, Japan, 4Department of Rheumatology - Infectious Disease, Miyagi Children’s Hospital, Japan, 5GSK Stevenage UK, 6GSK Upper Providence USA, 7GSK, Stockley Park UK

Conflict of interest: None

[Object] This study evaluated the efficacy and safety of belimumab (BEL) when added to standard of care therapy compared to placebo (PBO) over 52 weeks in pediatric SLE subj. incl. 6 Japanese (J) children (NCT0169765). [Methods] SLE subj. aged 5-17 years with a SELENA SLEDAI score of ≥ 6, were to be dosed with BEL 10 mg/kg intravenously (IV) every 28 days through W48, with a final evaluation at W52. The primary endpoint was the SLE responder index (SRI) response rate at W52. Due to the rarity of the disease in children, the study was not
powered to detect statistical significance. [Results] 93 subj. were randomized to BEL [53 (J: 2)] and PBO [40 (J: 4)]. The SRI response rate at W52 was numerically higher for BEL [52.8%, 28/53] compared with PBO [43.6%, 17/40] (OR:1.49, 95%CI:1.04-3.46). The outcome using PRINTO measures, a composite assessment specific to pediatric SLE, also showed positive effect in favour of BEL. The overall incidence of adverse events was similar between groups. The safety profile of subj. in BEL incl. the J children was generally favorable. [Conclusions] The efficacy and safety results in the study were consistent with those of in BEL IV adult studies. No new safety issues were identified in pediatric SLE subj. incl. J children. GSK funded this study.

**W76-4**

**Study on the effect of mycophenolate mofetil (MMF) for neuropsychiatric SLE (NPSLE)**

Tamao Nakashita, Akira Yoshida, Akira Jibatake, Shinji Motojima

*Rheumatology and Allergy, Kameda Medical Center, Kamogawa, Japan*

**Conflict of interest:** None

[Object] MMF is a standard regimen for the treatment of lupus nephritis. However, its effect on NPSLE has not been extensively studied. We studied the effect of MMF on NPSLE. [Methods] Patients with SLE who were enrolled who used MMF for the treatment of LN for more than 6 months complicated with NPSLE. [Results] Subjects were 16 patients (male 2, female 14), with the mean age of 47.3 years. The purposes of MMF introduction were induction of CR in 2, maintenance of CR in 12, and treatment for relapse in 2. Episodes of NPSLE were classified as neurological symptoms in 8, diffuse neuropsychiatric symptoms in 12, and peripheral neuropathy in 1 according to the ACR criteria. The mean dose of PSL at the introduction of MMF was 16.8mg/day and 10 patients were on HCQ. The concentration of IL-6 in CSF was more than normal range in 6 with the mean of 162.3 pg/ml. Anti-ribosomal P antibody and anti-NR2 antibody were positive in 5/6 and 3/7, respectively. Abnormal EEG and MRI findings were seen in 9 and 4, respectively. The mean dose of MMF was 142mg/day and the mean duration of administration was 691 days. The mean dose of PSL was significantly reduced to 6.84mg/day. SLEDAI score and patients’ VAS were also improved significantly. [Conclusions] The usefulness of MMF on NPSLE was suggested.

**W76-5**

**A comparative analysis between mycophenolate mofetil and intravenous cyclophosphamide in induction therapy for the patients with lupus nephritis**

Mizuki Yagishita, Yuya Kondo, Taihei Nishiyama, Shota Okamoto, Hirofumi Yokoyama, Masaru Shimizu, Fusuki Honda, Akako Ohyama, Saori Abe, Hiroyuki Takahashi, Masahiro Yokusawa, Atsumu Osada, Hiroto Tsuboi, Isao Matsumoto, Takayuki Sumida

*Department of Internal Medicine, Faculty of Medicine, University of Tsukuba*

**Conflict of interest:** None

[Objective] To compare efficacy and treatment continuation rate between mycophenolate mofetil (MMF) and intravenous cyclophosphamide (IVCY) in induction therapy for lupus nephritis. [Methods] We examined patients with lupus nephritis received induction therapy with MMF or IVCY between January 2010 and April 2018. We retrospectively investigated 1) patient characteristics, 2) treatment efficacy and 3) treatment continuation rate for 6 months. [Results] 1) Twenty six cases (MMF:13/IVCY:13) were included. Initial prednisolone dose was significantly lower in MMF group (39.1±16.9 vs 54.6±9.1 mg/day, p=0.02). In MMF group (100% vs 53%, p<0.01) [Conclusion] At 6 months after the treatment, there were no significant differences in efficacy between MMF and IVCY, and continuation rate was significantly higher in MMF.

**W77-1**

**The utility of red cell distribution width in the patients with systemic sclerosis related interstitial lung disease**

Tomoya Sagawa, Takashi Kida, Risa Sagawa, Akiko Kasahara, Shunyu Kaneshita, Takuya Inoue, Kazuki Fujioka, Hitdepate Nagahara, Makoto Wada, Masataka Kohno, Yutaka Kawahito

*Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine*

**Conflict of interest:** None

[Object] In the patients with systemic sclerosis (SSc) related interstitial lung disease (ILD), serum KL-6 may not reflect their severity in some cases. Recently, the utility of red cell distribution width (RDW) has been reported as the diagnostic marker of pulmonary hypertension in SSc patients. The aim of this study is to investigate the relationship between RDW and pulmonary function in the patients with SSc related ILD. [Methods] SSc patients with ILD who performed pulmonary function test at our hospital from April 2008 to September 2017 were enrolled. The medical records of 45 consecutive patients were reviewed retrospectively. Baseline demographic data, laboratory findings including RDW and %VC were obtained from medical records at the time of first pulmonary function test. [Results] With the exclusion of 28 patients for some reasons, 17 patients were reviewed. The median age was 54 (46-63) years and 15 patients were female. The median value of RDW, KL-6, and %VC was 13.3 (12.6-14.1), 460 (264-577) U/ml, and 84.5 (80.2-92) %, respectively. While there was no significant correlation between KL-6 and %VC, RDW and %VC had significant negative correlation (r = -0.54, p = 0.027). [Conclusions] RDW may correlate with the reduction of %VC in the patients with SSc related ILD.

**W77-2**

**Change in breast muscle volume in patients with scleroderma associated with interstitial lung disease assessed using computed tomography**

Takashi Nawata1,2, Yuichiro Shirai3, Masataka Kuswana1

1Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 2Department of Medicine and Clinical Science, Yamaguchi University Graduate School of Medicine, Yamaguchi, Japan

**Conflict of interest:** None

[Object] We investigated the association between change in breast muscle volume and pulmonary function in systemic sclerosis (SSc) patients with interstitial lung disease (ILD). [Methods] Twenty five patients with SSc-ILD, who were underwent chest computed tomography (CT) and pulmonary function test, were assessed. Maximum diameter of diaphragm (MDD) and pectoralis major muscle area (PMMA) and skeletal muscle area (SMA) at the level of 12th thoracic vertebra were obtained using CT. [Results] In patients with SSc-ILD, MDD and PMMA decreased (p<0.01, p=0.016, p=0.031). The area of ILD also increased (p=0.016). The change of MDD and PMMA showed correlations with the change of both ILD area (p=0.01, p=0.045) and serum level of KL-6 (p=0.023, p=0.022). On the other hand, the change of SMA showed correlations with the initial ILD area (p<0.01) and the change of tidal volume (p=0.01). The patients whose initial ILD area were more than 10 % showed reduction of SMA (p=0.019). With regard to complications, gastrointestinal tract disorders decreased MDD (p=0.024). Myocardial disorders also decreased SMA (p=0.023). [Conclusions] Our study suggests the possibility that volume loss of breast muscle in SSc-ILD patients cause the decline in pulmonary function.

**W77-3**

**Prognosis of Borderline Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis**

Sumiaki Tanaka, Yu Matsueda, Tatsuo Nagai, Kunihiro Yamaoka

*Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine*

**Conflict of interest:** Yes

[Object] In patients with systemic sclerosis (SSc) related interstitial lung disease (ILD), serum KL-6 may not reflect their severity in some cases. Recently, the utility of red cell distribution width (RDW) has been reported as the diagnostic marker of pulmonary hypertension in SSc patients. The aim of this study is to investigate the relationship between RDW and pulmonary function in the patients with SSc related ILD. [Methods] SSc patients with ILD who performed pulmonary function test at our hospital from April 2008 to September 2017 were enrolled. The medical records of 45 consecutive patients were reviewed retrospectively. Baseline demographic data, laboratory findings including RDW and %VC were obtained from medical records at the time of first pulmonary function test. [Results] With the exclusion of 28 patients for some reasons, 17 patients were reviewed. The median age was 54 (46-63) years and 15 patients were female. The median value of RDW, KL-6, and %VC was 13.3 (12.6-14.1), 460 (264-577) U/ml, and 84.5 (80.2-92) %, respectively. While there was no significant correlation between KL-6 and %VC, RDW and %VC had significant negative correlation (r = -0.54, p = 0.027). [Conclusions] RDW may correlate with the reduction of %VC in the patients with SSc related ILD.
W77-4

Identifying the factors to predict borderline pulmonary hypertension and evaluating clinical outcomes during a 5-years period in patients with systemic sclerosis

Katsushiko Yoneda, Soshi Takahashi, Saki Mukohara, Norihiko Amano, Yasuhiro Ohida, Miwa Nishida, Saori Hatachi, Shunichi Kumagai
Department of Rheumatological Disease, Shinko Hospital, Hyogo, Japan

Conflict of interest: None

[Objective] To identify the factors for predicting pulmonary hypertension (PH) and borderline PH with mPAP more than 21mmHg (overt and borderline PH), and to evaluate clinical outcomes for 5 years in patients with SSc. [Method] Among 113 patients with SSc visiting our hospital between January 2011 and May 2014, we performed right heart catheterization (RHC) in 47 cases with consent. 3 patients with PCWP more than 15mmHg were excluded. In 44 cases, relevant multivariate was carried out for identifying the factors for predicting overt and borderline PH. The clinical outcomes were tracked from medical records to investigate whether the predicting factors were effective. [Results] Among 44 patients, RHC demonstrated mPAP more than 21mmHg. Relevant multivariate revealed that %DLCo, estimated systolic PAP (esPAP) and BNP were correlated with mPAP. Though one patient developed PH by left heart disease and one patient developed borderline PH in 17 patients with "less than 35mmHg of esPAP" and "more than 80% of %DLCo", there were no deaths in the original disease for 5 years. [Conclusion] Though it is important to detect the borderline PH with RHC, echocardiography and pulmonary function test may have predicting ability for the necessity of RHC and that for clinical outcomes.

W77-5

Clinical characteristics associated with esophageal dysfunction in systemic sclerosis (SSc)

Yuichiro Shirai, Masatake Kuwana
Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan

Conflict of interest: None

[Objective] To clarify clinical characteristics associated with esophageal function in SSc. [Methods] Among 227 SSc cases who visited our clinic between 2014 and 2018, we enrolled 39 consecutive cases in the study who underwent high resolution manometry. We analyzed associations between esophageal motility assessed by Chicago classification, upper and lower esophageal sphincter (UES and LES) pressure and clinical characteristics. [Results] Among 39 cases, 34 were women, 20 were diffuse cutaneous SSc (dcSSc), and 22 had interstitial lung disease (ILD). When we classified patients into normal (n = 12), ineffective esophageal motility (n = 6), and absent contractility (n = 21), 3 groups were correlated with dcSSc, maximal esophageal diameter in CT scan, presence of ILD (P<0.026, 0.007, 0.029), and inversely with pulmonary function (%TLC, %FVC, %DLCO) (P=0.014, 0.028, 0.004). Reduced UES pressure was correlated with age at onset and presence of ILD (P=0.043, 0.047) and inversely with proton pump inhibitors use (P=0.03). Reduced LES pressure was correlated with smoking (P=0.03). [Conclusions] In SSc, esophageal dysmotility was correlated with presence of ILD and reduced pulmonary function and it was prominent in dcSSc. Further studies are required to clarify causal relationship.

W77-6

Survey on Dysphagia Using Simple Questionnaire EAT-10 in Patient with Systemic Sclerosis

Tatsuaki Naganawa, Shunji Yoshida, Natsuko Watanabe, Masashi Suzuki, Ai Umeda, Konomi Ashihara, Megumi Kurumizawa, Daikise Hirano, Takako Hashimoto, Jo Nishino, Shusaku Fukaya, Hidetaka Yasuoka
Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine

Conflict of interest: None

[Objective] In Systemic Sclerosis (SSc), symptom of upper gastrointestinal tract is thought to be due to gastroesophageal reflex or motion dysfunction. However, swallowing function is not well evaluated. Our aim is to investigate the actual condition of dysphagia in patient with SSc. [Methods] 10 with SSc who randomly selected from patient visited during from November to December 2016. Polymyositis/Dermatomyositis (PM/DM) patients were selected as controls. The feature of dysphagia were evaluated by Self-assessment of feeling with difficulty at swallowing and the simple swallowing evaluation form, EAT-10. [Results] Based on self-assessment, 50% of patients with SSc felt difficulty of swallowing and 40% did not, whereas 28.6% of patients with PM/DM did and 50% did not in PM/DM. By EAT-10, there were 3 in SSc (30%) and 2 in PM/DM (14%) who were suspected to have dysphagia, which is a same trend with self-assessment. As for the contents of swallowing, there was no difference in difficulty with liquids or solids between SSc and PM/DM. However, swallowing difficulty of tablets was confirmed with 5 in SSc (50%), and 2 in PM/DM (14%). [Conclusion] Swallowing difficulty of patients with SSc comes from not only esophageal dysfunction but also oropharyngeal disorder, which may be different from PM/DM.

W78-1

Analysis of the optimal blood concentration of tacrolimus in systemic lupus erythematosus

Koichiro Taguchi, Hideki Tani, Takahide Ikeda, Hiroyuki Morita, Motochika Asano, Yoshiko Kitada
Department of General Internal Medicine, Gifu University Hospital

Conflict of interest: None

[Objective] We evaluated the optimal blood concentration of tacrolimus (TAC) in systemic lupus erythematosus (SLE). [Methods] SLE treated with TAC was 18 cases from April 2013 to May 2018. 6 cases discontinued TAC. 12 cases continued for 6 months, and divided into two groups, the TAC trough level < 5 ng/mL (A, 4 cases) and ≥ 5 ng/mL (B, 8 cases). [Results] 3 cases discontinued by the suspicion of the side effect. But those were not measured the trough level. The mean age of the groups was 36±12, all of the cases were women. Baseline characteristics were balanced between the groups. The mean dose of TAC at month 6 was 2.8 mg in the group A and 2.3mg in the group B. The amount of urine protein, SLEDAI and an average daily dose of prednisolone were significantly reduced in the group B at both month 3 and month 6. Otherwise, there was no significant difference between groups in the laboratory data and the rates of side effect. [Conclusions] These data suggested the trough level ≥ 5 ng/mL was the useful marker for the treatment of SLE. The side effect did not occur both groups. We assumed this was because the trough level was < 8 ng/mL except for 1 case. Two thirds of the cases treated with TAC 2 mg/day were the trough level ≥ 5 ng/mL. Therefore, we recommend TAC was started with 2 mg/day.

W78-2

Hydroxychloroquine modulates elevated expression of S100 proteins in systemic lupus erythematosus with lupus nephritis

Risa Wakiya, Tomohiro Kameda, Shusaku Nakashima, Kiyo Ueda, Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan

Conflict of interest: None

[Objective] To evaluate the therapeutic strategy for borderline pulmonary arterial hypertension (PAH) associated with Systemic Sclerosis (SSc), we evaluated the long-term prognosis of borderline PAH (borderline-PAH) in SSc patients. [Methods] We selected 11 SSc patients who fulfilled the criteria for border-PAH by right heart catheterization in our hospital from 2011 to 2018. We performed survival analysis under retrospective cohort study design. [Results] Eligible patients were all females, and included 6 diffuse cutaneous and 5 limited cutaneous SSc patients. The age at diagnosis of border-PAH was 63±16 years old. All patients had no symptoms and had been treated with beraprost sodium. Mean pulmonary arterial pressure, pulmonary capillary wedge pressure, cardiac output and pulmonary vascular resistance levels were 22.4±4.2, 7.5±4.2, 5.0±1.1 L/min and 2.1 WU, respectively. In the observation period, no patient had been treated with PAH-specific drugs. Two patients had died of lung cancer and liver cancer. No patient had additional echocardiographic findings indicating PAH. [Conclusions] Our results show that no SSc patient developed of PAH from border-PAH, resulting in deliberate consideration for the indication for treatment of border-PAH in SSc patients.
Hiromi Shimada, Mikiya Kato, Taichi Miyagi, Hiroki Dobashi
Department of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University

Conflict of interest: None

[Object] To clarify the effect of HCQ treatment on serum levels of S100A8 and S100A9 proteins in SLE patients with sustained remission of lupus nephritis (LN). [Methods] All patients enrolled in this study started HCQ treatment and had been receiving oral HCQ sulfate continuously for at least 3 months. There was no need for additional immunosuppressive treatments, including glucocorticoids, to any patient during the 3 months prior to starting HCQ because of sustained low disease activity in these patients. Immunological biomarkers, SELENA-SLEDAI and CLASI score were investigated in this study. Serum levels of S100A8 and S100A9 were measured at the time of HCQ administration as well as 3 or 6 months later using ELISA (CircuLex ELISA Kit, MBL). In addition, we investigate interferon-α. [Results] We enrolled 79 patients. 26 cases were sustained remission of LN patients. HCQ significantly lowered levels of S100A8 and S100A9. Elevated levels of S100A8 and S100A9 were seen in patients with LN and significantly lowered in LN patients regardless of sustained remission of LN. [Conclusions] HCQ lowered serum levels of S100 protein and might suppress disease activity in sustained remission of LN patients. We could define LN as complete remission of belimumab.

S100 was also positively correlated with SLEDAI scores (Spearman’s correlation coefficient 0.46, p < 0.001). The five patients’ total score for 1997 ACR and 2012 SLICC criteria was 98%, 100% and 98%, respectively. In the five patients who did not meet the new criteria, 3 were male, and ANA was <1:40 for 1 and 1:40 for 3 patients, whereas 1 patient showed ANA 1:160 but total score was only 9.

Conflict of interest: None

W78-3
Research of each marker and free blys before and after administration of belimumab
Seiji Tanaka
Department of Pediatrics, Kurume University

Conflict of interest: None

[Object] We compare free blys and other marker in the acute period and revial and the maintenance period. [Methods] SLE patients from 16 years old to 21 years old. observation period 3 six months. We examine combination blys which soluble blys and sledai score and free fusibility blys which are not connected, the change in the stage of a disease and serum c3, c4, anti-ds-dna antibody, b-cell number, the change of the memory b cells number. We perform sandwich elisa using blys and commercial antiblys antibody, and the measurement of free blys divides into free blys and combination type blys and compares it. [Results] As for the sledai score, two points accepted a point zero, asent of c3 (p=0.29), asent of c4 (p=0.03), an ascent of ds-dna (p=0.53) wbc (p=0.71) to two people in approximately blimmub use. We switch to belimumab solid-phase assay and enforce it again without being made solid-phase in the system of measurement using commercial blys. [Conclusions] We accepted improvement of c4 after belimumab use, but there was not the significant difference in c3. It is thought to be allowed to examine the dosage to the condition of a patient by the condition of a patient such as the drops of the complement at the time of the revival.

W78-4
The analysis of anti ds-DNA antibody evaluation between CLEIA and ELISA
Taichi Miyagi, Mikiya Kato, Risa Wakiya, Hiromi Shimada, Syusaku Nakashima, Tomohiro Kameda, Hiroaki Dobashi
Kagawa University Hospital

Conflict of interest: None

[Object] ELISA system was used to evaluate serum anti-double stranded DNA antibody (ds-DNA ab) until 2017, and then it had changed into CLEIA system in our institution. After that changing, we experienced some cases which titer of ds-DNA ab had varied substantially. Therefore, we investigated the difference between CLEIA and ELISA. [Methods] We examined the SLE patients who had the same treatment within 6 months. We classified them into 3 groups according to the changes of ds-DNA ab titer between ELISA and CLEIA. Group A was increasing, B was decreasing, C was unchanged cases. We assessed disease activity of SLE by SELENA-SLEDAI (SLEDAI) and SLEDAI (+) which defined as exclude ds-DNA ab factor from SLEDAI. [Results] We could analyze 115 cases. Group A was 4, B was 27, and C was 84 cases. In group A, mean SLEDAI of 2 cases which had changed into positive was 20.50, and mean SLEDAI (-) was 18.50. In group B, mean SLEDAI of 18 cases which had changed into negative was 2.33, and mean SLEDAI (+) was 2.33. There exist 2 in latter 18 cases, who had high disease activity. They had the history of NPSLE. [Conclusions] The CLEIA was better than ELISA as for reflecting disease activity. However, it is necessary to pay much attention to the cases which ds-DNA ab dissociates from SLEDAI.

W78-5
Importance of serum phosphatidylserine-specific phospholipase A1 (PS-PLA1) as a novel biomarker of systemic lupus erythematosus (SLE)
Tetsuji Sawada1, Harumi Shirai2, Yukiko Iwasaki2, Koichiro Tahara1, Haeru Hayashi1, Keishi Fuji1
1Department of Rheumatology, Tokyo Medical University Hospital, 2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo

Conflict of interest: None

[Object] To assess the utility of serum PS-PLA1 in SLE diagnosis and disease activity monitoring. [Methods] We measured PS-PLA1 using AIA-21 (Tosho) in 146 patients (pts) with SLE (including 43 untreated pts), 80 disease control (35 active RA, 22 SSc, and 23 SS), and 237 healthy controls. [Results] PS-PLA1 was significantly higher in SLE than in healthy controls and RA. Although PS-PLA1 was significantly elevated in SSc and SS compared with healthy controls, PS-PLA1 was significantly higher in untreated SLE than in healthy controls, treated SLE, and disease control. ROC analysis revealed that a cut-off value of 17.9 ng/mL distinguished untreated SLE from disease control (sensitivity 88% specificity 57%). SLEDAI was positively correlated with PS-PLA1, anti-dsDNA Ab, and IgG, and inversely correlated with C3. PS-PLA1 was significantly higher in SLE patients with high disease activity than in those with low disease activity. PS-PLA1 decreased significantly in parallel with improvement of SLEDAI in 25 SLE pts whose paired serum samples were available pre- and post-treatment. [Conclusions] PS-PLA1 is elevated in SLE in parallel with disease activity, suggesting that PS-PLA1 may be a novel biological marker for SLE disease activity monitoring.

W78-6
Comparison of proposed ACR/EULAR new classification criteria for SLE with 1997 ACR and 2012 SLICC criteria
Hiroshi Doi1, Takashi Iwasaki1, Yuya Tabuch1, Shuji Akizuki1, Kosaku Murakami1, Ran Nakashima1, Motomu Hashimoto2, Hajime Yoshifuji3, Masao Tanaka1, Wataru Yamamoto1, Koichiro Ohmura1, Tsumeyo Mimori1
1Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 3Kurashiki Sweet Hospital

Conflict of interest: None

[Object] We aimed to examine the sensitivity of newly proposed ACR/EULAR criteria in Japanese patients and clarify the characteristics of patients who did not meet the new criteria. [Methods] We examined 319 SLE patients in Kyoto University Hospital whose clinical history and examination results were clearly described in charts. [Results] 313, 319, and 314 out of the 319 SLE patients met the 1997 ACR, 2012 SLICC, and new ACR/EULAR criteria, respectively, and their sensitivity was 98%, 100% and 98%, respectively. In the five patients who did not meet the new criteria, 3 were male, and ANA was <1:40 for 1 and 1:40 for 3 patients, whereas 1 patient showed ANA 1:160 but total score was only 9. The five patients’ total score for 1997 ACR and 2012 SLICC criteria ranged from 4 to 8 (average 5) and from 6 to 8 (average 7.25), respectively. [Conclusions] Sensitivity of new classification criteria was reported to be 98% in Derivation cohort and 96% in Validation cohort, which was similar in our patients. 4 patients who did not meet new criteria due...
to shortage of ANA titer satisfied both 1997 ACR and 2012 SLICC criteria and were clinically considered to be SLE. When new classification criteria were applied to diagnosis, careful consideration should be taken for patients with low ANA titer.

W79-1
Antiphospholipid antibody cross-reactive with DNA activates the TLR9 pathway leading to a thrombophilic state, which is suppressed by chloroquine
Tetsuo Kubota
Department of Immunopathology, Tokyo Medical and Dental University Graduate School of Medical and Dental Sciences, Tokyo, Japan

Conflict of interest: None

[Object] In the pathogenesis of antiphospholipid syndrome (APS), antiphospholipid antibodies (APAs) play a significant role by stimulating monocytes and vascular endothelial cells. This study aims to clarify how APAs activate the cells. [Methods] IgG monoclonal anti-CLβ2-GPI antibody WB-6 was prepared from an (NZWxBXSB)F1 mouse, and the specificity was tested by ELISA. PBMCs from healthy volunteers, monocytic leukemia cells THP-1, or vascular endothelial cells HUVECs were incubated with WB-6, and the effect of the antibody was estimated by fluorescence microscopy, flow cytometry, and measurement of cytokine expression. [Results] WB-6 was cross-reactive with DNA. Highly purified WB-6 without DNA contamination still bound to DNA. WB-6 entered monocytes, THP-1, and HUVECs, and the internalization was diminished by pretreatment of the cells with DNase I. WB-6 induced tissue factor expression in monocytes and THP-1, and this effect was suppressed by chloroquine. Culture supernatant of THP-1 incubated with WB-6 contained TNF-α, and this conditioned medium stimulated HUVECs to express ICAM-1 and VCAM-1. [Conclusions] APAs cross-reactive with DNA bind to cell surface DNA, enter living cells, and activate VECs to express ICAM-1 and VCAM-1. [Conclusions] APAs activate the cells. [Methods] IgG monoclonal anti-CLβ2-GPI antibody WB-6 was prepared from an (NZWxBXSB)F1 mouse, and the specificity was tested by ELISA. PBMCs from healthy volunteers, monocytic leukemia cells THP-1, or vascular endothelial cells HUVECs were incubated with WB-6, and the effect of the antibody was estimated by fluorescence microscopy, flow cytometry, and measurement of cytokine expression. [Results] WB-6 was cross-reactive with DNA. Highly purified WB-6 without DNA contamination still bound to DNA. WB-6 entered monocytes, THP-1, and HUVECs, and the internalization was diminished by pretreatment of the cells with DNase I. WB-6 induced tissue factor expression in monocytes and THP-1, and this effect was suppressed by chloroquine. Culture supernatant of THP-1 incubated with WB-6 contained TNF-α, and this conditioned medium stimulated HUVECs to express ICAM-1 and VCAM-1. [Conclusions] APAs cross-reactive with DNA bind to cell surface DNA, enter living cells, and activate the TLR9 pathway, which may contribute to the thrombophilic state of APS.

W79-2
The Direct Effect of Anti-Sm Antibody on MMP-2 Up-regulation and Claudin-5 Degradation in Brain Endothelial Cells
Yoshiyuki Arinuma, Kunihiro Yamaoka
Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine

Conflict of interest: Yes

[Object] Breakdown of the blood-brain barrier (BBB) integrity is required for development of psychiatric manifestations in SLE. The aim of this study is to investigate the direct effect of anti-Sm antibody (Ab) on brain endothelium cells and the role in breakdown of BBB integrity. [Methods] A human brain hemangiosarcoma cell line was stimulated with monoclonal anti-Sm or anti-RNP Ab. Tight junction (TJ) composing protein, claudin-5 expression was measured by western blot. MMP-2 that is known to degrade TJ protein and claudin-5 mRNA were evaluated by q-PCR. [Results] Compared to control Ab, expression of claudin-5 protein was significantly reduced by anti-Sm Ab, and increased by anti-RNP Ab. Meanwhile, combinatory stimulation with anti-Sm Ab and anti-RNP Ab significantly reduced claudin-5 protein expression. Claudin-5 mRNA expression was increased by anti-RNP Ab, while anti-Sm Ab made no change. Interestingly, MMP-2 mRNA expression was significantly increased by anti-Sm Ab but not by anti-RNP Ab. [Conclusions] Depending on the notion of MMP2 on degradation of TJ protein and claudin-5 mRNA, anti-Sm Ab could directly affect brain endothelium cell through up-regulation of MMP-2 expression could cause degradation of claudin-5. On the other hand anti-RNP Ab could have a protective effect.

W79-3
Neuroinflammation as a potential target of neuropsychiatric systemic lupus erythematosus
Atsushi Nomura, Go Murayama, Asako Chiba, Sachiko Miyake
Department of Immunology, Juntendo University School of Medicine

Conflict of interest: None

Objective SLE causes disabling neuropsychiatric symptoms even in the quiescent phase. Innate immune-mediated inflammation has attracted attention as a pathogenic mechanism in neuropsychiatric diseases; therefore, we investigated the CNS of lupus-prone mice. Methods FcrRIIB+ Yaa, NZB/NZW, and MRL/lpr were used to analyze immunopathology in the CNS. The composition and activation status of immune cells in the CNS were analyzed by flow cytometry. Immunohistochemistry of brain sections and RNA-seq analysis of microglia were performed using FcrRIIB+ Yaa mice. Results Upregulation of MHC class I and PDCA1 were observed in microglia and CD11b+ myeloid cells, indicating they were activated in response to interferons (IFN). Microglial gene expression analysis revealed the upregulation of inflammation-related genes including Aporo, Axl, Clec7a, and Il1g as well as IFN responsive genes. Upregulated chemokine gene expressions including Ccl5 and Cxcl10 were concurrent with increased T cells and Ly6C+ monocytes. Concluding Microglia in lupus exhibit a unique phenotype characterized by upregulated expressions of neurodegeneration-related genes and IFN responsive genes. Interaction with peripheral cells and brain resident cells was presumed to orchestrate neuroinflammation.

W79-4
Association of Soluble Programmed Death-ligand 1/2 and Interleukin 21 with Systemic Lupus Erythematosus
Shinya Hirahara, Yasuhiro Katsunuma, Hidenaga Kawasumi, Akira Nishino, Masanori Hanaoka, Hirokazu Nishina, Yasushi Kagawuchi, Hisashi Yamanaka
Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan

Conflict of interest: None

[Object] Programmed cell death protein 1 (PD-1) and PD-1 related molecules, which are expressed on T follicular helper cells, play a key role in pathology of systemic lupus erythematosus (SLE). We have reported that the serum levels of sPD-1 are higher in SLE patients and they are moderately correlated with the SLEDAI-2K scores and the anti-dsDNA antibody titers. We aimed to retrospectively evaluate the usefulness of soluble programmed death-ligand 1/2 (sPD-L1/L2) and IL-21 in SLE patients. [Methods] We measured the levels of sPD-L1/L2 and IL-21 by ELISA in sera of patients with SLE (n = 73) and systemic sclerosis (SSc), and healthy controls (HC), and compared them. We also analyzed the association of the levels of sPD-L1/L2, and IL-21 with clinical information and the serum sPD-1 levels in SLE patients. [Results] The levels of sPD-L1 in SLE patients with SLEDAI-2K ≥ 6 were significantly higher than those in SLE patients with SLEDAI-2K <6, SSc patients, and HC (p < 0.05). The levels of sPD-L2 were moderately correlated with the anti-dsDNA antibody titers, levels of C3 and C4, SLEDAI-2K, and serum sPD-1 levels. [Conclusions] The present study suggested an association of serum sPD-L2 with SLE and its disease activity and its usefulness as a diagnostic and activity biomarker for SLE.

W79-5
Expansion of Peripheral Helper T cells Associated with Disease Activity in Systemic Lupus Erythematosus
Ayako Makiyama1,2, Asako Chiba1, Go Murayama1,2, Ken Yamaji2, Naoto Tamura2, Sachiko Miyake1
1Department of Immunology, Juntendo University School of Medicine, 2Department of Rheumatology, Juntendo University School of Medicine

Conflict of interest: None

[Object] To assess whether recently identified “peripheral helper” T (Tph) cells are involved in the pathogenesis of systemic lupus erythematosus (SLE). [Methods] Peripheral blood mononuclear cells were obtained from patients with SLE and healthy subjects, and were analyzed by flow cytometry. We defined Tph cells as memory CD4+ T cells expressing PD-1hi and lacking CXCR5. The frequency and activated status of Tph cells were compared with B cell subsets and the disease activity. The cytokine production of Tph cells was analyzed with intracellular staining. [Results] The frequency of Tph cells was increased in SLE patients than...
DOCK8-Expressing CD4 T cell as Autoantibody-Inducing CD4 T (aiCD4 T) Cell That Causes Systemic Lupus Erythematosus (SLE): Proof of Concept of Self-Organized Criticality Theory as a Cause of SLE

Shunichi Shiozawa1,2, Ken Tsuniyama1, Keiichi Sakurai1, Hideyuki Kagawa1, Takashi Yamane1, Motohiro Oribe1, Koji Ishii1, Takahiko Horiiuchi2, Ryosuke Yoshihara1, Miki Murata1, Kazuko Shiozawa1
1Institute for Rheumatic Diseases, 2Kyushu University Beppu Hospital, 3Himeji Red-Cross Hospital, 4Department of Rheumatology, Kakogawa City Central Hospital, 5Rheumatology & Collagen Disease Center, Hyogo Prefectural Kakogawa Medical Center, 6Oribe Rheumatology Clinic, 7Nephrology & Rheumatology, Oita University School of Medicine

Conflict of interest: None

[Object] To prove Self-Organized Criticality Theory where SLE develops as a natural consequence of routine but exaggerated immune response against antigen when stimulated maximally beyond immune system’s self-organized criticality, we characterized the aiCD4 T cell.
[Methods] DOCK8+ cell was identified by mass spectrometry of cell membrane and the in vivo transfer study. [Results] Transfer of DOCK8+ CD4 T cells into naive mice induced autoantibodies including anti-dsDNA and anti-Sm antibodies and organ diseases such as WHO IV/V lupus nephritis, skin lichenification degeneration, pericholangitis, pneumonitis, thyroiditis, perineuritis, panniculitis and splenic periarteriolar fibrosis with amyloid-like deposits, a classical Onion-skin lesion of SLE. Such manifestations subsided after anti-DOCK8 Ab therapy. The DOCK8+ CD4 T cell is a large lymphocyte with abundant ER and mitochondria, expressing ICOS, PD1, Ly6C and LFA1 but not CCR5. The cell produced increased IFNg, IL-4, IL-6, IL-17, IL-21 and IL-22, and its TCR repertoire was highly deviated. [Conclusions] The DOCK8-expressing CD4 T cell that emerges as a natural consequence of exaggerated immune response against antigen when stimulated maximally beyond immune system’s self-organized criticality, and causes SLE.

International Concurrent Workshop

ICW1-1
The genetic and clinical prediction models for efficacy and hepatotoxicity of methotrexate in patients with rheumatoid arthritis: a multicenter cohort study

Akira Onishi1, Miwa Nishida1, Keisuke Nishimura1, Kenta Misaki1, Yumiko Nobuhara1, Saori Hatachi2, Takashi Nakazawa2, Goh Tsujii3, Akio Morinobu1, Shunichi Kumagai2
1Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 2Center for Rheumatic Diseases, Shinko Hospital, 3Department of Endocrinology and Rheumatology, Kurashiki Central Hospital, 4Department of Rheumatology, Kita-Harima Medical Center, 5Department of Rheumatology, Osaka Saiseikai Nakatsu Hospital, 6Tsuji Rheumatology Clinic, 7Shinko Institute for Medical Research

Conflict of interest: None

[Object] To develop combined genetic and clinical models to predict the efficacy and hepatotoxicity of MTX. [Methods] Patients with RA under the treatment of MTX according to Japanese guideline for the management of RA with MTX were enrolled. To predict the efficacy and hepatotoxicity, 1,971 polymorphisms of 246 enzymes/transporters potentially relevant to pharmacokinetics and pharmacodynamics of MTX were measured by the DMET microarray (Affymetrix Inc.) and direct-sequencing method and clinical variables at baseline were collected. The EU-LAR-CRP response criteria was used to classify patients with RA as responders (good response) and non-responders (moderate or no response). Hepatotoxicity was defined as either serum AST or ALT levels higher than 1.5 times the upper limit of the normal range. [Results] A total of 86 patients with RA was included from 4 institutes. The median age was 61.5 years with 81.3% of women. For efficacy, genetic prediction model using 7 SNPs showed area under the curve of ROC (AUC) was 0.822 with sensitivity of 74.3% and specificity of 76.8%, while combined clinical and genetic model indicated AUC = 0.844 with sensitivity of 81.5% and specificity of 76.9%. By incorporating clinical variables into the genetic model, overall category-free net reclassification improvement (NRI) was 0.700 (P < 0.0001) and overall integrated discrimination improvement (IDI) was 0.089 (P < 0.0001). For hepatotoxicity, genetic prediction model using 7 SNPs showed AUC = 0.783 with sensitivity of 70.0% and specificity of 80.0%, while combined clinical and genetic model indicated AUC = 0.906 with sensitivity of 85.1% and specificity of 78.8%. Overall category-free NRI was 1.122 (P < 0.0001) and overall IDI was 0.279 (P < 0.001). [Conclusion] Genetic and clinical models showed higher predictive accuracy for both efficacy and hepatotoxicity of MTX. These models should be validated with a larger scale of prospective study.

ICW1-2
A comprehensive study of analyzing quantitative trait loci (qQTL) effects in various immune cell subsets in peripheral blood mononuclear cells (PBMCs) of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) patients

Hiroaki Hatano1, Mineto Ota1,2, Yusuke Takeshima1,2, Yukiko Iwasaki1, Yasuo Nagafuchi1, Yuta Kachi1,2, Hirofumi Shoda1, Tomohisa Okamura1,2, Keishi Fujio1, Kazuhiko Yamamoto3
1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 3Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Kanagawa, Japan

Conflict of interest: None

[Object] Recently, genome-wide association studies (GWAS) have identified many loci associated with autoimmune diseases, such as SLE and RA. However, the effects of GWAS single nucleotide polymorphism (SNPs) on splicing isoforms in various subsets of immune cells in PBMCs have not been fully investigated. [Methods] We previously conducted sorting and RNA sequencing of 21 immune cell subsets in PBMC from 49 SLE and 30 RA patients and 36 healthy volunteers and also got their genotyping data from whole blood. Here, we analyzed cis-acting
sQTL effects of RA and SLE GWAS SNPs in this dataset. [Results] Many transcript-SNP-subset pairs were detected after FDR multiple testing adjustment. We confirmed some sQTL effects on the transcripts of the genes (e.g. NADSYN1, UBASH3A, SNRPC...) were shared in most cell subsets expressing the genes. On the other hand, several sQTL effects were observed only in parts of cell subsets. [Conclusions] Our results suggest some GWAS SNPs are associated with diseases through alternative splicing and such sQTL effects work in parts of immune cell subsets of PBMC.

ICW1-3
A phenoeme-wide association study of the MHC region in 166,190 Japanese using NGS-based classical and non-classical HLA imputation
Yukinori Okada1,2, Saori Sakaue1,3
1Department of Statistical Genetics, Osaka University Graduate School of Medicine, 2Department of Statistical Immunology, IFReC, Osaka University, 3Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo

Conflict of interest: None

[Object] The major histocompatibility complex (MHC) region at chromosome 6 confers genetic risk on a variety of human complex traits, while detailed fine-mapping of the causal genetic variants and genes has yet to be elucidated. In this study, [Methods] We conducted NGS-based genotyping of the 33 human leukocyte antigen (HLA) genes of the Japanese population (n = 1,120), providing high resolution allele catalogue up to 6-digit HLA alleles of both classical and non-classical HLA genes. Together with population-specific deep whole-genome sequencing (WGS) data of Japanese (n = 1,276), we conducted NGS-based HLA, SNV, and Indel imputation of the large-scale genome-wide association (GWAS) genotype data of Japanese from BioBank Japan Project, a nation-wide hospital-based cohort of Japan (n = 166,190). Using imputed genotype data, we conducted a phenome-wide association study (PheWAS) assessing 106 clinical phenotypes including human complex diseases (e.g., rheumatoid arthritis, Graves' disease, type 1 diabetes, asthma, atopic dermatitis, and others), as well as anthropometric, biochemical, and hematological quantitative traits. [Results] The PheWAS identified significant genotype-phenotype associations across 52 phenotypes. Fine-mapping within the MHC region revealed multiple association patterns conferring independent risks from the classical HLA genes including those represented as non-classical HLA gene variants, non-HLA variants within MHC, and long-range haplotype spanning the entire MHC region. Novel MHC associations of the traits were also identified (pollinosis, hyperlipidemia, myocardial infarction, stable angina, type 2 diabetes, liver cancer, liver cirrhosis, and nephrotic syndrome). MHC region-wide heritability estimates and genetic correlation network analysis elucidated polygenic architecture shared across the phenotypes. [Conclusions] This study should contribute to our understanding of genetic and phenotypic landscape of MHC.

ICW1-4
Immune cell profiling of rheumatoid arthritis identified disease activity and treatment resistance related gene networks
Saeko Yamada1, Yasuo Nagafuchi1, Mineto Ota1, Yusuke Takeshima1, Hiroaki Hatano1, Yukiko Iwasaki1, Shuji Sumitomo1, Tomohisa Okamura1, Hirofumi Shoda1, Kazuhiko Yamamoto2, Keishi Fujio1
1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 2Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN

Conflict of interest: Yes

[Object] Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammatory synovitis and destruction of joint cartilage. In this study, we performed transcriptome analyses of cell subsets of peripheral blood taken from RA patients and tried to identify gene module networks closely associated with disease activity and treatment resistance. [Methods] Peripheral blood mononuclear cells were obtained from 37 healthy donors and 28 RA patients, who were just before the induction of bDMARDs or tsDMARDs. We isolated 16 cell subsets by fluorescence-activated cell sorting (FACS), and RNA sequencing was performed. 16 out of 28 RA patients were reanalyzed 6 months after the induction of treatment. A network analysis WGCNA and differential expression analysis were performed for each subset. The expression of most highly connected "hub genes" was compared between before and after the treatment. [Results] WGCNA of the pre-treated patients revealed that a gene module including STAT5B and CTBP1 in neutrophils correlated most to the DAS28-ESR disease activity (Spearman’s rho (r) = 0.78, p = 5e-04). bDMARDs or tsDMARDs treatment decreased the expression of 32% (12/37) of the hub genes (FDR < 0.20). It is also revealed that the treatment resistance (low decrease of DAS28-ESR) was correlated most to a module containing NFkB signaling genes in plasmacytoid dendritic cells (pDCs) and plasmablast subset (r = -0.61 and -0.54, p < 0.05). Almost none of the hub genes in this module changed the expression after treatment (0% or 2% FDR < 0.20). [Conclusions] In this study, we identified candidate subset-gene networks that are independently related to disease activity or treatment resistance. Enhanced NFkB signaling in pDCs and plasmablast could be a biomarker for treatment resistance and a novel therapeutic target for treatment-resistant RA.

ICW1-5
Upregulation of LINC00487 in Peripheral B cell Subsets Associated with Disease Activity among Patients with Primary Sjögren’s Syndrome
Jun Inamo1, Katsuya Suzuki1, Masaru Takeshita1, Yoshiaki Kassai1, Maiko Takiguchi1, Rina Kurisu1, Yuumi Okuzono1, Tsutomu Takeuchi1
1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 2Immunology Unit, Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited

Conflict of interest: Yes

[Object] Although B cells are considered to play an important role in the pathogenesis of primary Sjögren’s syndrome (pSS), the mechanism is still unclear. Here, we investigated the differential gene expression of peripheral B cell subsets in pSS patients. [Methods] We enrolled pSS patients (n=6) and healthy controls (HC) (n=6). Peripheral B cells were separated into 4 subsets: CD38+IgD−, CD38−IgD−, CD38−IgD+ and CD38+IgD+. Total RNA was extracted and gene expression was measured using the Human Genome U133 Plus 2.0 Array (Affymetrix). [Results] After excluding HLA and interferon signature genes, LINC00487 was the most upregulated gene in all B cell subsets, namely CD38+IgD− (r=0.96, p=0.002), CD38−IgD− (r=0.90, p=0.015), CD38−IgD+ (r=0.81, p=0.049) and CD38+IgD+ (r=0.96, p=0.003). [Conclusions] LINC00487 was upregulated in all pSS B cell subsets and correlated with disease activity. These results may suggest that long non-coding RNA contributes to B cell dysregulation in patients with pSS.

ICW1-6
SH3BP2 gain-of-function mutation ameliorates lupus in B6.MRL-Faslpr mice
Akiko Nagasu1, Tomoyuki Muki1, Masanori Iseki2, Hajime Nagasu1, Kyoko Kawahara1, Shoko Tsuji3, Shunichi Fujita1, Naoki Kashihara1, Katsuhiko Ishihara4, Yoshitaka Morita1
1Department of Rheumatology, Kawasaki Medical School, Kurashiki, Japan, 2Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Japan, 3Department of Nephrology and Hypertension, Kawasaki Medical School, Kurashiki, Japan

Conflict of interest: Yes

[Object] SH3BP2 (Src homology domain 3 binding protein 2) is an adaptor protein, which is dominantly expressed in immune cells, and regulates intracellular signaling pathways. We have previously reported that SH3BP2 regulates macrophage activation, TNF production, and autoantibody production in a murine arthritis model. To further investigate the role of SH3BP2 in other autoimmune diseases, we here tested a murine lupus model using SH3BP2 mutant mice. [Methods] SH3BP2 gain-of-
function mutant (P416R knockin; Shi3bp2+/+) mice and lupus-prone; B6.MRL-Fas<sup>−/−</sup> mice were crossed to yield the double mutant (KJ+/Fas<sup>+</sup>) mice. Serum anti-dsDNA antibody levels and a histopathological index of glomerulosclerosis were assessed at 48 weeks of age. B and T cell subsets in the lymph nodes were analyzed by flow cytometry. Spleenic B cell proliferation was determined by CFSE assay. TNF mRNA expression in lymph nodes was analyzed by real-time PCR. [Results] SH3BP2 gain-of-function mutation alleviates lupus phenotypes, as shown by an increased survival rate, reduced proteinuria, and improved glomerulosclerosis. Serum anti-dsDNA antibody levels were significantly reduced in the KI+/Fas<sup>+</sup> mice (90.5% decrease compared to those in Fas<sup>−/−</sup> mice). B220<sup>−</sup>CD4<sup>−</sup>CD8<sup>−</sup> double-negative T (DNT) cell population, which is known as characteristic cells in the Fas<sup>−/−</sup> mice, were decreased in the lymph nodes of the KI+/Fas<sup>−/−</sup> mice. Proliferation capacities of spleenic B cells were comparable between Fas<sup>−/−</sup> and KI+/Fas<sup>−/−</sup> cells. TNF mRNA expression in lymph nodes tended to increase in the KI+/Fas<sup>−/−</sup> mice compared to that in the Fas<sup>−/−</sup> mice. [Conclusions] SH3BP2 gain-of-function mutation ameliorated clinical and immunological phenotypes of the lupus-prone mice. Elevated TNF production might compensate the impaired apoptosis of the DNT cells in the KI+/Fas<sup>−/−</sup> mice. Further analyses are required to reveal the immunoregulatory roles of SH3BP2.

**ICW2-1 Impact of switching oral bisphosphonates to denosumab or daily teriparatide on the progression of radiographic joint destruction in patients with biologic-naïve rheumatoid arthritis**

Kosuke Ebina, Makoto Hirao, Yuki Etani, Akira Miyama, Kenji Takami, Hideki Yoshikawa

Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan

**Conflict of interest:** Yes

**Object** The aim of this study was to clarify the effects of switching oral bisphosphonates (BPs) to daily teriparatide (TPTD) or denosumab (DMAb) on the radiographic joint destruction in female, biologic-naïve, RA patients. [Methods] 155 patients were allocated depending on each physician’s decision, to (1) BP-continue group (n=63), (2) switch-to-TPTD group (n=31), or (3) switch-to-DMAb group (n=61). Ninety patients (n=30 for each group; mean age 68.2 years, 96.7% postmenopausal, DAS28-CRP 2.4, methotrexate treatment 81.1%, prednisolone treatment 69.9%, lumbar T-score -2.0, prior BP treatment 44.8 months, TRACP-5b 286.4 (mU/dl), and modified total Sharp score (mTSS) 87.0) were retrospectively selected using propensity score to match the baseline clinical backgrounds. The primary endpoint was to clarify the change of the mTSS from baseline to 12 months (Δ12M mTSS). After 12 months, the mean changes of the modified Sharp erosion score were significantly lower in the switch-to-DMAb group (0.2 ± 0.1; mean ± standard error) than in the switch-to-TPTD group (1.3 ± 0.5; P < 0.05), and mTSS was significantly lower in the switch-to-DMAb group (0.2 ± 0.2) than in the BP-continue group (1.0 ± 0.3; P < 0.05) and the switch-to-TPTD group (1.7 ± 0.6; P < 0.05). Patients with Δ12M mTSS ≥ 3 (Clinically relevant radiological progression) (%) were BP (10.0%, TPTD (20.0%), and DMAb (3.3%), respectively (TPTD vs. DMAb; P = 0.05). The percent change of TRACP-5b after 6 months (%) (Δ6M TRACP-5b) were BP (-4.6), TPTD (-64.9), and DMAb (-29.0), respectively. Among the factors which significantly correlated with Δ12M mTSS (baseline DAS28-CRP, ACPA positivity, and Δ6M TRACP-5b), logistic regression analysis revealed that Δ6M TRACP-5b was a remaining significant factor associated with Δ12M mTSS (β = 0.30, 95% CI: 0.002-0.016; P < 0.01). [Conclusions] The change of systemic bone turnover induced by osteoporosis agents may affect local joint destruction besides of inflammatory state.

**ICW2-2 A prospective observational study on the incidence of beaking, a sign of atypical femoral fractures, in patients with rheumatoid arthritis**

Chinatsu Takai<sup>1</sup>, Hiroe Sato<sup>2</sup>, Naoki Kondo<sup>2</sup>, Yoichi Kurosawa<sup>2</sup>, Eriko Hasegawa<sup>1</sup>, Shinji Taniguchi<sup>1</sup>, Daisuke Kobayashi<sup>1, 4</sup>, Asami Abe<sup>1</sup>, Satoshi Ito<sup>1</sup>, Kiyoshi Nakazono<sup>2</sup>, Akira Murasawa<sup>2</sup>, Naoto Endo<sup>2</sup>, Ichiei Narita<sup>2</sup>, Hajime Ishikawa<sup>1</sup>

<sup>1</sup>Niigata Rheumatic Center, Shibata, Niigata, Japan; <sup>2</sup>Niigata University Health Administration Center, Niigata, Japan; <sup>3</sup>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan; <sup>4</sup>Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

**Conflict of interest:** None

**Object** The incidence of thickening of the lateral cortex of femora termed “beaking” is known to precede atypical femoral fracture (AFF). It is reported that beaking was detected in 8-10% of patients with autoimmune diseases taking bisphosphonates and glucocorticoid (GC), and bone absorption inhibitor and GC are generally considered as risk factors of AFF. However, the incidence of beaking in patients with rheumatoid arthritis (RA) is unknown. [Methods] A total of 209 patients with RA (female 78.9%, median age 67 years old, median disease duration 11 years, GC use 74.6% and bone resorption inhibitor use 67.5%) who were underwent anterior-posterior X-rays and dual-energy X-ray absorptiometry (DXA) at recruitment and at 1 year were enrolled. Focal lateral cortical thickening in femoral X-rays was defined as beaking. Statistical analyses were performed using Fisher’s exact test and Mann-Whitney U test. [Results] Beaking was detected in 3 patients (1.4%) at recruitment and its incidence was increased to 6 patients (2.9%) at 1 year. Five of them were using bone absorption inhibitor (alendronate, 3; minodronate, 1; denosumab, 1) and 4 were taking GC. The significant higher incidence of beaking was found in patients taking more than 5 mg daily dose of prednisolone both at recruitment and at 1 year (4/47 patients vs. 2/162 patients, p=0.024, 4/50 patients vs. 2/159 patients, p=0.031), in patients who had received GC continuously more than 7 years (5/85 patients vs 1/124 patients, p=0.042), and in patients who received alendronate at recruitment (3/27 patients vs 3/182 patients, p=0.030). No significant difference was detected in the past history of bone resorption inhibitor use, duration of bone resorption inhibitor treatment or T-score of femoral neck measured by DXA. [Conclusions] This is the first report of prospective study about the incidence of beaking in patients with RA. Long-term or higher-dose use of GC could be risk factors in patients with RA.

**ICW2-3 Five-year follow-up of beaking and osteoporosis in patients with autoimmune diseases treated with prednisolone and bisphosphonates**

Hiroe Sato<sup>1</sup>, Naoki Kondo<sup>2</sup>, Naoto Endo<sup>2</sup>, Shunsuke Sakai<sup>4</sup>, Sayuri Takamura<sup>1</sup>, Ayako Wakamatsu<sup>1</sup>, Daisuke Kobayashi<sup>1</sup>, Takeshi Nakatsue<sup>2</sup>, Takeshi Kuroda<sup>2</sup>, Masaki Nakajima<sup>2</sup>, Ichiei Narita<sup>2</sup>, Hajime Ishikawa<sup>1</sup>, Ichiei Narita<sup>4</sup>, Takeshi Nakatsue<sup>2</sup>, Takeshi Kuroda<sup>2</sup>, Masaki Nakajima<sup>2</sup>, Ichiei Narita<sup>2</sup>, Hideo Yoshikawa<sup>2</sup>

<sup>1</sup>Health Administration Center, Niigata University; <sup>2</sup>Division of Orthopedic Surgery, Niigata University Graduate School of Medical and Dental Sciences; <sup>3</sup>Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences; <sup>4</sup>School of Health Sciences, Faculty of Medicine, Niigata University

**Conflict of interest:** None

**Object** Beaking is a localized femoral reaction that can lead to an atypical femoral fracture (AFF). Previously, we reported a high frequency of beaking in patients with autoimmune diseases treated with prednisolone (PSL) and bisphosphonates (BP). Here, we report 5-year follow-up data and retrospectively analyze the influence of the discontinuation of anti-resorption drugs on osteoporosis. [Methods] The study initially enrolled 125 patients with autoimmune diseases taking BP and PSL and 100 patients were re-examined 5 years later. The incidence of beaking was examined by femoral X-rays. Bone metabolic markers and bone mineral density (BMD) were compared between the groups in which anti-resorption drugs were discontinued and continued. Statistical analyses were performed using the t-test. [Results] Beaking was observed in 10 of 125 patients at recruitment and in 18 of 100 patients at 5 years. Complete AFF occurred in one patient. The BP was discontinued in 31 patients and the most frequent reason was beaking. Four were changed to denosumab and five were given teriparatide. At the 5-year follow-up, 27 patients were not taking anti-resorption drugs (discontinued group) and no clinically obvious osteoporotic fractures were seen after discontinuation. The annual change in BMD did not differ between the discontinued and continued groups. The serum NTx concentration was elevated at follow-up in both groups (discontinued vs. continued: from 9.6±1.7 to 12.5±2.9, p<0.001 vs. from 11.0±4.3 to 13.6±9.0 nmolBCE/L, p=0.037). Urine NTx was elevated only in the discontinued group (from 109.5±87.8 to 114.2±98.3 nmolBCE/L, p<0.001).
165.6±121.3, p=0.03 vs. from 141.7±140.8 to 164.2±125.0 nmolBCE/ mmol-Cr, p=0.332). The bone specific alkaline phosphatase concentration did not change significantly in either group. [Conclusions] The incidence of beaking was increased at 5 years in patients taking PSL and BP. Discontinuation of the anti-resorption drugs did not worsen the BMD and bone metabolic markers obviously.

ICW2-4
E3-Ubiquitin Ligase RNF146 links Bone to Energy Metabolism through regulation of the RUNX2 Transcriptional Activity controlled by the Wnt-FGF18-TAZ Axis
Yoshinori Matsumoto1,2, Ken-eki Sada1, Jun Wada1
1Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2Princess Margaret Cancer Center, University of Toronto, Canada

Conflict of interest: None

[Object] Bone undergoes continuous remodeling equally regulated by osteoblast-mediated bone formation and osteoclast-mediated bone resorption. RUNX2, the osteoblastogenic master transcription factor, forms the critical complex with the transcriptional coactivator TAZ for osteoblast differentiation and skeletal formation. Here we uncover a genetic evidence showing that the E3-ubiquitin ligase RNF146 links bone to energy metabolism through regulation of the RUNX2-TAZ transcriptional activity. [Methods] We generated Rnf146 conditional knockout mice (Rnf146fl/fl Osterix-Cre) to examine the in vivo bone metabolism in the absence of RNF146 in osteoblasts. Micro-CT, histomorphometric analysis, ISH, IHC, Co-IP, ChIP, promoter assay, BrdU assay, ubiquitin/proliferation/differentiation assay, glucose tolerance test and ELISA were performed to investigate the molecular mechanisms in this study. [Results] We found that Rnf146fl/fl Osterix-Cre shows phenotypic similarities to Cleidocranial Dysplasia, an autosomal dominant human disorder characterized by abnormal bone development due to defective osteoblastogenesis. Loss of RNF146 stabilized its substrate AXIN1, leading to impaired CLEIDOCRANIAL DYSPLASIA, an autosomal dominant human disorder characterized by rheumatic diseases treated by glucocorticoids. Our observation that RNF146 links bone loss to abnormal glucose tolerance through regulation of the RUNX2-TAZ transcriptional activity could expand the concept that RUNX2-TAZ regulates bone and energy metabolism/differentiation and subsequent impaired osteocalcin production. [Conclusions] Our observation that RNF146 links bone loss to abnormal glucose tolerance through reduced osteocalcin production by osteoblasts in patients with rheumatic diseases treated by glucocorticoids.

ICW2-5
Functional differences between osteoclasts and osteoclast-like cells from peripheral blood mononuclear cells in patients with rheumatoid arthritis
Kazuhiro Yokota1, Shinya Tanaka2, Kojiro Sato1, Yoshimi Aizaki1, Noritsune Kozu1, Hiromi Oda2, Toshihide Mimura1
1Department of Rheumatology and Applied Immunology, Faculty of Medicine, Saitama Medical University, 2Department of Orthopaedic Surgery, Saitama Medical University, 1Kozu Orthopaedic Clinic

Conflict of interest: None

[Object] Osteoclasts (OCs) are giant multinucleated cells formed from precursors of the monocyte/macrophage lineage, which play an important role of bone destruction in rheumatoid arthritis (RA). Previously, we reported that osteoclast-like cells (OLCs) are differentiated from mouse bone marrow macrophages stimulated with TNFα and IL-6, which have a bone resorption activity both in vitro and in vivo. The present study investigates functional differences between OCs and OLCs in peripheral blood mononuclear cells (PBMCs) from patients with RA and healthy controls (HCs). [Methods] PBMCs and CD14+ monocytes from 9 RA patients and/or HCs were stimulated with RANKL or TNFα and IL-6. The number of tartrate-resistant acid phosphatase-positive multinucleated cells (OCs/OLCs) and bone resorption were assessed. The relationship between the number of OCs/OLCs and the modified total Sharp score or systemic bone mineral density (BMD) was also examined. [Results] The number of OCs and OLCs from PBMCs in RA patients was significantly increased compared with that in HCs (RA OCs 53.2±16.4 vs. HCs OCs 7.9±3.4, p<0.01; RA OLCs 19.6±4.2 vs. HCs OLCs 1.8±0.9, p<0.01). These cells showed bone resorption activity on dentin slices. Moreover, they showed significantly increased expression of cathepsin K mRNA compared with osteoclast precursors (OCPs) (OCs 9.4±3.5-fold, OLCs 2.3±0.5-fold vs. OCPs 1.0±0.0-fold, p<0.01, respectively). The number of OCs significantly negatively correlated with systemic BMD in RA patients (r=−0.67, p<0.05), while the number of OLCs significantly positively correlated with the modified total Sharp erosion score (r=0.79, p<0.05). [Conclusions] Our results demonstrated that PBMCs of patients with RA showed higher OC/OLC differentiation potential than that of HCs. Further, PBMCs-derived OLC bone resorption activity could likely play a potential role in the bone destruction in RA patients. OLCs could form a subpopulation of OCs, possibly different from conventional OCs.

ICW2-6
WW domain-containing protein 2 (Wwp2) maintains cartilage homeostasis in coordination with miR-140
Sho Mokuda1,2, Merissa Olmer1, Martin K Lotz2, Eiji Sugiyama1, Hiroshi Ashara1,3
1Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, 2Department of Molecular Medicine, The Scripps Research Institute, La Jolla, CA, USA, 3Department of Systems BioMedicine, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan

Conflict of interest: None

[Object] The Wwp2 gene encoding WW domain-containing protein 2 (Wwp2), which belongs to the HECT-type E3 ubiquitin ligase family, also encodes miR-140 generated from intron of its pre-mRNAs. Wwp2 is abundantly expressed in articular cartilage; however, its function remains unclear. We investigated the function of Wwp2 for cartilage homeostasis and the therapeutic potential of Wwp2 replacement against cartilage defects caused by arthritis. [Methods] We detected the expression of human Wwp2 and mouse Wwp2 in damaged articular cartilage and investigated its contribution in cartilage homeostasis using Wwp2 knockout mouse and Wwp2-C838A enzyme dead mouse models generated with CRISPR/Cas9 system. We also examined the effect of in vitro-transcribed (IVT) Wwp2 mRNA in experimental osteoarthritis (OA) mouse model. The targets of Wwp2 and its cooperative function with miR-140 were elucidated using dual treatment with IVT Wwp2 mRNA/miR-140 mimic and integrated ChIP-seq/TargetScan database search. [Results] Human Wwp2 mutation and mouse Wwp2 protein expression levels were decreased in OA cartilage compared to healthy controls. Both Wwp2 knockout mouse and Wwp2-C838A enzyme-inactivated mouse exhibited aggravated cartilage damage. IVT Wwp2 mRNA injection into mouse joints reduced the severity of experimental OA. We also identified Runx2 as a Wwp2 sub-strate via Runx2 poly-ubiquitination and degradation. Dual treatment with IVT Wwp2 mRNA/miR-140 mimic and integrated ChIP-seq/TargetScan database analysis revealed that Wwp2 and miR-140 cooperatively regulate several genes such as Adamts5, Glis3, Bmp2k. [Conclusions] We propose that Wwp2 has a role in protecting cartilage from arthritis by suppressing Runx2-induced genes, especially Adamts5, via Runx2 poly-ubiquitination and degradation. The overlapping targets of the newly identified Wwp2-Runx2 pathway and miR-140 suggest that products from the Wwp2 locus cooperatively regulate several cartilage-related genes at pre- and post-transcriptional stages.

ICW3-1
Risk assessment and long-term prognosis of patients with SLE-associated pulmonary arterial hypertension: A multi-center cohort study in China
Junyan Qian1, Mengtao Li1, Qian Wang1, Zhuang Tian2, Jiuliang Zhao1, Xiaoxia Zuo3, Miaojia Zhang6, Ping Zhu7, Yi Zheng9, Wufang Qi10, Yang Li11, Zhuoli Zhang8, Feng Ding12, Jieruo Gu13, Yi Liu14, Xiaofeng Zeng15

[Object] SLE-associated pulmonary arterial hypertension: A multi-center cohort study in China

Jyunan Qian1, Mengtao Li1, Qian Wang1, Zhuang Tian2, Jiuliang Zhao1, Zhuang Tian2, Jiuliang Zhao1, Xiaoxia Zuo3, Mi...
Objective: This study aimed to investigate the prognostic value of a multidimensional risk assessment in SLE-associated pulmonary arterial hypertension (PAH). Methods: This study involved fourteen high ranked rheumatology centers in China. All SLE patients were fulfilled the 1997 revised American Rheumatism Association criteria. PAH was diagnosed based on the ERS guidelines. Baseline characteristics were collected. Patients underwent regular follow-up visits. The outcome was all-cause mortality. Two different methods of risk categorization, including low-risk criteria number of none to 4 and mean risk score of 1 (low-risk), 2 (intermediate-risk) or 3 (high-risk) based on the PAH risk categorization, were applied based on baseline data. According to first follow-up data, patients were further divided into increased risk, remained risk and decreased risk group. Kaplan-Meier survival curves and Cox analysis were conducted based on baseline risk categorizations and follow-up risk changes. Results: 282 patients were enrolled. The 5-year survival of patients categorized into none, 1, 2, 3 and 4 low risk criteria group were 42.7%, 64.8%, 86.1%, 90.2% and 91.7%, respectively (HR=0.59, 95% CI 0.44-0.78, p<0.001). When categorized according to the mean risk score at baseline, the 5-year survival of patients in low, intermediate and high-risk group were 92.3%, 60.4% and 50.0%, respectively (Log-rank, p=0.001). At first follow-up visit, 51 patients remained in the same risk group, 77 patients improved to lower risk group and 19 patients worsened to higher risk group. The 5-year survival of these three groups of patients were 65.4%, 88.1% and 23.8% respectively (log-rank, p<0.001). Conclusion: Our study, for the first time, validated the prognostic value of risk stratification strategy at baseline and follow-up visit in patients with SLE-associated PAH. Improving to low-risk group can be a future treatment target for SLE-associated PAH patients in clinical practice.

Conflict of interest: None

LUNA registry study

Over one hundred patients who were enrolled, 98 and 461 belonged to LO and EO group respectively. There was no significant difference in male to female ratio and glucocorticoid usage between LO and EO groups (0.20 vs 0.13, p = 0.17, and prednisolone 6.6 ± 8.8 vs 7.0 ± 6.7 mg/day, p = 0.59, respectively). Immunosuppressants had been less used in LO group as compared to EO group (71.4% vs 80.6%, p = 0.042). Although the usage rates of cyclophosphamide and azathioprine showed no differences between the groups, methotrexate was used (8.2% vs 18.7%, p = 0.011), tacrolimus (30.6% vs 43.6%, p = 0.018), rituximab (1.0% vs 6.1%, p = 0.043) were less used in LO group as compared to EO group. There was no significant differences in skin rash, serositis, vasculitis, anti-SS-A and anti-dsDNA antibody seropositivities. [Conclusions] Immunosuppressants were less used in late onset SLE. There were no significant differences in clinical features which have been pointed out as being related to age of onset in the previous studies.

ICW3-3 A Retrospective Analysis of Treatment Efficacy in Different types of Cutaneous lupus

Navjeet Gill1, Stephanie Keeling2

1University of Alberta, Edmonton, Canada, 2Division of Rheumatology, Faculty of Medicine, University of Alberta, Edmonton, Canada

Conflict of interest: None

Object] Cutaneous lupus (CLE) has various presentations and treatment options. The purpose of this study is to determine the ideal treatment for different types of CLE and specific cutaneous features. [Method] A retrospective electronic medical record review (EMR) was performed on all patients with active CLE seen at the University of Alberta’s rheumatology-dermatology clinic between 2012 to 2018. Data evaluated the achievement of one of three endpoints: improved cutaneous features, remission (or stability; no new disease features), or no effect at last consult. Variables collected included: patient demographics (age and gender), type of CLE, cutaneous features at presentation, histopathology, lupus serology results, previous agents tried, treatment regimen at endpoint, and number of flares after endpoint. [Results] A total of 41 patients (80% female; mean age 43 (SD 17)) were categorized as follows: 46% (n=19) chronic cutaneous lupus (CCLE), 22% (n=9) undefined CLE, 20% (n=8) subacute cutaneous lupus (SCLE), 10% (n=4) mixed discoid and SCLE, and 2% (n=1) acute cutaneous lupus. The most commonly used medications included hydroxychloroquine (HC; average end dose 329 mg for 327 days), topical steroids (class 3.3, 352), and prednison (average start dose 33, 175) which achieved remission in 46%, 24%, and 22% respectively. Thirty-four percent (n=14) were on a single agent at endpoint, most commonly HC (n=6). Half of these patients achieved remission on a single agent. HC was the most successful agent in achieving remission in all three major categories of lupus represented in this study (CCLE, SCLE, undefined CLE) and specific manifestations including discoid lesions, alopecia, malar rash, and CLE with normal C-reactive protein (CRP). [Conclusions] The agents, dose, and duration of treatment is similar across different categories and features of CLE. HC is a mainstay in CLE treatment and has increased efficacy when combined with another agent - ideally prednison.
ICW3-4
Crescent formation in active lupus nephritis is a poor prognostic factor of renal outcomes

Aya Nawata1,2, Kazuhisa Nakano1, Hiroko Yoshinari1, Yoshino Inoue1, Naoaki Okubo1, Yurie Sato1, Hiraoki Tanaka1, Yasuyuki Todoroki2, Hiroko Miyata1, Masanobu Ueno1, Atsushi Nagayasu1, Takafumi Aritomi1, Ryuichiro Kanda1, Yuya Fujita1, Masashi Funada1, Ayako Yamaguchi1, Taeko Azuma1, Keisuke Nakatsuka2, Masao Nawata1, Shingo Nakayama1, Yoshiya Tanaka1
1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 2Department of Pathology, University of Occupational and Environmental Health, Japan, 3Department of Internal Medicine, Kyushu Rosai Hospital, Moji Medical Center, 4Department of Internal Medicine, JCHO Fukuoka Yutaka Central Hospital, 5Department of Rheumatology, Tohoku University Hospital

Objective: To explore the predictors of neuropsychiatric lupus (NPSLE) at diagnosis among patients with systemic lupus erythematosus (SLE) using Cox regression model.

Methods: A retrospective study comprising 150 patients with SLE who visited our hospital between 2006 and 2017. Overall event-free survival was estimated by Kaplan-Meier analysis. The event was defined as death or neuropsychiatric flare. The neuropsychiatric flare was defined using current INS/RPS classification, further investigation is required. The primary endpoint was RR achieving rate, and the secondary endpoint was baseline histological and clinical factors related to NR. [Results] Baseline data: mean age 39,135 females, histological class III:n=53, IV=n=58, pure IV:n=30. At 52 w, SLEDAI (16→2), BLAG (17→2) score was significantly decreased. PSL dose was reduced (48→9mg). At 52w, all cases were classified as NR (n=125,82%) and RR (n=27,18%). All of pure V reached remission. Histologically, III or IV (RR n=114;91% vs NR n=27;100%, p=0.01) and cellular/fibrocellular crescent (RR n=51;40% vs NR=18;66%, p=0.01) were more frequent in NR. Clinically, coexisting hypertension (RR n=7;6% vs NR n=9;33%, p=0.01) and higher urine protein level (RR 1.5g vs NR 2.2g, p<0.01) were detected in NR. IVCY improved remission rate (RR n=84;68% vs NR n=9;41%, p=0.03). After long-term, eGFR level were lower in NR (RR 81 vs NR 50, p<0.01, median:138 months). 3 cases developed ESRD showing crescent formation. [Conclusions] Histological factors contributing to NR were III or IV LN and crescent. This result suggested therapeutic response was better in cases with IC deposition than those with inflammatory lesions. The problems is it could not be pointed out crescent formation in current INS/RPS classification, further investigation is required.

Conclusions: The ten-year event-free survival was 84.2%. Hypocomplementemia and NPSLE at diagnosis were independent poor predictors for neuropsychiatric flare.

Conflict of interest: None

ICW3-6
Macrophage activation syndrome as the initial manifestation of juvenile systemic lupus erythematosus: from a single center study

Satoshi Sato, Yoiti Uejima, Eisuke Sugasuna, Yutaka Kawano
Division of Infectious Diseases and Immunology, Saitama Children’s Medical Center

Objective: Lupus nephritis (LN) exhibits various histological findings including inflammatory lesions such as crescent formation and immune complex (IC) deposition lesions. In INS/RPS 2003 classification, both lesions are classified as class III, IV and V. In this study, we examine the association between the histological factors and renal remission at 52 weeks. [Methods] This is a retrospective study. 152 cases of LN class III, IV, and V out of 274 SLE perfomed renal biopsy in our department between 1995 to 2017 were registered. 52 weeks after biopsy, they were classified as renal remission (RR) and non-remission (NR) according to ACR and LUNAR remission criteria by eGFR or scCr and proteinuria. The five- and ten-year event-free survival was 86.0% (95% CI 85.7%, 86.2%) and 80.0% (95% CI 79.4%, 80.6%), respectively. The five- and ten-year event-free survival during the observation period. The median period to neuropsychiatric flare was 2.0 years (lower and upper quartile: 0.9 and 4.9, respectively). The five- and ten-year event-free survival was 86.0% (95% CI 85.7%, 86.2%) and 80.0% (95% CI 79.4%, 80.6%), respectively. Hypocomplementemia (p<0.01) and NPSLE (p=0.01) at diagnosis were independent poor predictors for event-free survival. [Conclusions]: The ten-year event-free survival was 84.2%. Hypocomplementemia and NPSLE at diagnosis were independent poor predictors for neuropsychiatric flare.

Conflict of interest: None

ICW3-5
Predictors of neuropsychiatric flare in patients with systemic lupus erythematosus

Kunyuki Asato, Michihito Kono, Michihiro Kono, Keita Ninagawa, Taiki Sato, Toshiyuki Watanabe, Yuka Shimizu, Yuichiro Fujiyada, Masaru Kato, Kenji Oku, Toshiyuki Bohgaki, Oga Amegual, Shinseku Yasuda, Tatsuya Atsumi
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University

Objective: To explore the predictors of neuropsychiatric flare in Japanese patients with systemic lupus erythematosus (SLE). [Methods] This retrospective study comprised 160 patients with adult-onset SLE who visited our hospital between 2006 and 2017. Overall event-free survival was estimated by Kaplan-Meier analysis. The event was defined as death or neuropsychiatric flare. The neuropsychiatric flare was defined using American College of Rheumatology case definitions and ACR criteria. Predictors of neuropsychiatric flare at diagnosis were analyzed by Cox regression model. [Results]: One hundred and forty-seven patients (91.9%) were female and mean age at diagnosis was 34.5±12.3 years old. The median observation period was 8.4 years (lower and upper quartile: 5.0 and 12.1, respectively). Their mean SLEDAI at diagnosis was 13.0±7.5. Main clinical manifestations at diagnosis were lupus nephritis (25.6%), serositis (20.0%), neuropsychiatric SLE (NPSLE) (10.0%), anti-phospholipid antibody syndrome (9.3%). Simultaneously with diagnosis, 26 patients were treated with intravenous cyclophosphamide and glucocorticoid (GC) for induction, 11 patients with calcineurin inhibitors and GC, 6 patients with mycophenolate mofetil and GC, and 103 patients with GC monotherapy. Twenty-three patients (14.3%) experienced at least one neuropsychiatric flare during the observation period. The median period to neuropsychiatric flare was 2.0 years (lower and upper quartile: 0.9 and 4.9, respectively). The five- and ten-year event-free survival was 86.0% (95% CI 85.7%, 86.2%) and 80.0% (95% CI 79.4%, 80.6%), respectively. Hypocomplementemia (p<0.01) and NPSLE (p=0.01) at diagnosis were independent poor predictors for event-free survival. [Conclusions]: The ten-year event-free survival was 84.2%. Hypocomplementemia and NPSLE at diagnosis were independent poor predictors for neuropsychiatric flare.

Conflict of interest: None

ICW4-1
Clinical Features and Risk Factors of Pulmonary Embolism in Patients with Systemic Lupus Erythematosus

Hanxiao You, Juliujin Zhao, Qian Wang, Xiaofeng Zeng, Mengtao Li
Department of Rheumatology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Objective: To explore the clinical features and risk factors of pulmonary embolism (PE) in patients with systemic lupus erythematosus (SLE). [Methods] A case-control study was conducted in patients complicated with PE among SLE patients admitted to Peking Union Medical College Hospital from 2012 to 2017. Clinical and laboratory data of case group (SLE-PE) and age, sex, and entry-time-matched control group (SLE-non-PE) were analyzed by the single factor analysis and multivariate analysis to explore the risk factors of PE among SLE patients. A p value of 0.05
or less was considered to be statistically significant. [Results] 77 patients were eligible for enrollment into the case group and 231 contemporaneous SLE patients without PE as the control group. Among the SLE-PE group, the majority were female (63; 81.8%), with a mean SLE course of 29.04±6.61 months before PE events and a high mortality rate of 9.1% after PE. Multivariate analysis revealed that duration of SLE < 1.5 years (odds ratio (OR) 5.129, p < 0.001), lupus nephritis (OR 3.225, p 0.001), thrombocytopenia (OR 3.121, p < 0.005), high hypersensitive c-reactive protein (hsCRP) (OR 6.937, p < 0.001), anti-SSA positive (OR 2.989, p 0.003) and aPL positive (OR 9.15, p < 0.001) were independent significant risk factors of PE in SLE patients. [Conclusions] PE is a serious complication among SLE patients with a high mortality rate. The risk is higher during the first year immediately after the diagnosis of SLE. Shorter SLE course less than 1.5 years, positive antiphospholipid antibodies, lupus nephritis and elevated inflammatory markers are independent risk factors of PE among SLE patients.

ICW4-2
Effects of antiphospholipid antibodies and hematological abnormalities on short- and long-term mortality in blood-stream infections associated with commensal Streptoccocal infection
Yu-min Kuo1,2, Song-chou Hsieh 2, Jen-hao Chen 3, Yen-chun Lin2, Jean
Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan, 2Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan, 3Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan, Department of Microbiology and Immunology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan, 4Graduate Institute of Immunology, College of Medicine, National Taiwan University, Taipei, Taiwan

Conflict of interest: Yes
[Object] Antiphospholipid (aPL) antibodies have been proposed to activate platelets and contribute to vegetation growth and embolization in infective endocarditis (IE). The presence of anticardiolipin (aCL) and anti-β2-glycoprotein I (β2GPI) antibodies have been reported to be associated with embolic events in IE. Besides, production of aPLs and anti-dsDNA were observed in the rats with bacteremia caused by S. mutans in our previous study. Therefore, we hypothesized that aPLs and anti-dsDNA as well as anti-dsDNA were predictors of short- and long-term outcome of blood-stream infections with/without IE have not been evaluated. [Methods] We studied 51 patients with commensal streptococcal bacteremia with/without definite IE (Duke-Li criteria) from our prospective cohort (2002-2009). Serum aCL IgG and IgM and anti-β2GPI IgG antibodies were detected by ELISA (Thermo Fisher). The relationship between antibodies as well as other clinical parameters and short- and long-term mortality were studied with Kaplan-Meier and Cox multivariate analyses. [Results] The mean follow-up periods were 296±314 weeks. At least one aPL antibody was found in 11 patients (21%). The 30- and 90-days mortality rates were 15.7% and 27.4% respectively. Risk factors predictive of 90-day mortality were leukopenia (Hazard ratio 3.0, 95% CI 0.8 to 15.2, p= 0.09), both presence of anti-β2GPI IgG and leukopenia (Hazard ratio (HR) 4.6, 95% CI 0.9 to 23.1, p= 0.06), and presence of either leukopenia or thrombocytopenia but positive anti-β2GPI IgG (HR 7.0, 95% CI 2.2 to 25.7, p= 0.001). Clinical parameters predictive of 10-year mortality were leukopenia (Hazard ratio 3.5, 95% CI 1.5 to 8.1, p= 0.004) and presence of thrombocytopenia (HR 2.4, 95% CI 0.9 to 6.2, p= 0.07), but not any of proportions of autoantibodies. [Conclusions] The presence of anti-β2GPI IgG (not other aPLs and anti-dsDNA) and hematological abnormalities (either leukopenia or thrombocytopenia) could significantly predict 90-days mortality rate among patients with commensal Streptococcal infection.

ICW4-3
Factor Xa inhibitors for preventing recurrent thrombosis in patients with antiphospholipid syndrome: A longitudinal cohort study with propensity score-based analysis
Taiki Sato, Yuichiro Fujieda, Hiroyuki Nakamura, Naoki Ohnishi, Keita Ninagawa, Kumiuki Aso, Nobuya Abe, Michihito Kono, Masaru Kato, Kenji Oku, Toshiyuki Bochkagi, Olga Amengual, Shinshue Yasuda, Tatsuya Atsumi
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Conflict of interest: None
[Object] The clinical indications of factor Xa inhibitors for the patients with antiphospholipid syndrome (APS) are not fully established. The aim of this study was to clarify the efficacy and safety of factor Xa inhibitors for APS patients in real world. [Methods] This is a retrospective cohort study comprised of consecutive patients with APS between April 1990 and June 2018 in our Rheumatology department. Patients treated with factor Xa inhibitors were extracted from the cohort. As a control group, patients treated with warfarin were selected from the same cohort with matched age, gender, coexistence of SLE and having anti-platelet therapy. We used propensity score adjustment for each of the confounding factors for multivariate Cox proportional hazard model. Primary endpoint was set as thrombotic and haemorrhagic event-free survival for 5 years. [Results] Among 206 patients with APS, 10 had a history of anti-Xa therapy (4 rivaroxaban, 6 edoxaban). In all the 10 patients, factor Xa inhibitors were switched from warfarin. Event-free survival was significantly shorter on anti-Xa therapy than that on warfarin therapy in these 10 patients (Hazard ratio: 11.4, 95% CI: 1.6-233.2). Similarly, event-free survival in patients treated with factor Xa inhibitors was significantly shorter compared with controls (Hazard ratio: 6.8, 95% CI: 1.6-30.7). After adjustment, event-free survival in patients with anti-Xa therapy remained significantly shorter (Hazard ratio: 21.9, 95% CI: 2.2-264.7). [Conclusions] This study provided an unfavourable evidence on the efficacy and safety of factor Xa inhibitors for APS patients. From our findings, factor Xa inhibitors for APS may not be recommended and warfarin remains the mainstay treatment for APS.

ICW4-4
Prothrombin/MHC class II complexes expressed on procoagulant cells are one of the targets of pathogenic antiphospholipid antibodies
Naoki Ohnishi, Yuichiro Fujieda, Michihito Kono, Masaru Kato, Kenji Oku, Toshiyuki Bochkagi, Olga Amengual, Shinshue Yasuda, Tatsuya Atsumi
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Conflict of interest: None
[Objectives] Antiphospholipid syndrome (APS) is characterized by thrombosis or pregnancy morbidity and the presence of antiphospholipid antibodies (aPL). Phosphatidylserine-dependent antiprothrombin antibodies (aPS/PT) recognize the phosphatidylserine/prothrombin (PS/PT) complex, and are strongly correlated with APS. Recently, misfolded β2-glycoprotein I (β2-GPI) molecules transported to the cell surface with major histocompatibility complex class II (MHC II) were reported as targets of autoantibodies in patients with APS. APS patients with anti-β2-GPI are highly likely to share the thrombophilic pathophysiology with those with aPS/PT, therefore we hypothesized that misfolded prothrombin (PT), likewiseβ2-GPI, are transported to the cell surface by MHC II in procoagulant cells, consequently being targeted by aPS/PT. [Methods] 1) The interaction between PT and MHC II was analyzed by flow cytometry (FCM) and immunoprecipitation, using co-expression of PT and several alleles of MHC II in HEK293T cells. 2) Synthesis of PT in monocytes was investigated in phorbol-12-myristate-13-acetate (PMA) treated THP-1 cells by western blotting and FCM. 3) Cell surface transportation of synthesized PT was evaluated by FCM on THP-1 cells co-stimulated with PMA and interferon gamma. [Results] 1) Overexpressed PT/MHC II complexes were detected on THP-1 cell surface by a mouse monoclonal aPS/PT. The dependency of MHC II allele effects on aPS/PT binding was confirmed. 2) PMA-treated THP-1 cells synthesized PT with stronger binding to aPS/PT than to non-pathogenic monoclonal anti-PT antibody. 3) aPS/PT binding to PT/MHC II complexes were confirmed in co-stimulated THP-1 cells. No binding was observed between non-pathogenic monoclonal anti-PT antibody and PT/MHC II complexes. [Conclusion] PT proteins synthesized by monocytes were presented on the cell surface by MHC II. The expression of PT/MHC complexes on stimulated mono-
Conflict of interest: Yes

[Object] Although elevated incidence and mortality for cardiovascular diseases are reported in patients with rheumatoid arthritis, the mechanisms by which chronic inflammation induces thrombosis have not been fully elucidated. Recently, in vivo imaging technique was reported for the thrombus formation by using a two-photon excitation microscope. In the model, intravascular administration of hematoxylin and subsequent laser irradiation to the peripheral artery induce the local thrombus formation. To evaluate the effect of chronic inflammation on pro-thrombotic condition, we visualized and quantified the thrombus formation in vivo in TNF-transgenic arthritis mice. [Methods] Blood flow, platelets, and neovascularized vessels were visualized by rhodamine-labeled dextran, DyLight488-labeled anti-GPlbβ antibody, and Hoechst, respectively. After the hematoxylin administration, the testicular arteries were exteriorized and irradiated by the laser, and then the thrombus formation was quantified by the microscope. 16 week-old TNF-transgenic mice (n=4) and the wild-type mice (n=6) were used. One to four areas per each mouse were analyzed. [Results] Platelets adhesion to the vessel wall, thrombus formation, and subsequent obstruction of the vessels were observed within approx. 10 seconds. Initial platelet attachment times were 4.61 ± 3.53 sec in arthritis mice and 5.53 ± 3.74 sec in control mice (P = 0.50); vascular obstruction times were 37.60 ± 15.41 sec in arthritis mice and 28.23 ± 12.78 sec in controls (P = 0.09); speed of thrombus formation were 224.3 ± 113.6 um2/sec in arthritis mice and 235.8 ± 169.1 um2/sec in controls (P = 0.15). [Conclusions] The arterial thrombus formation in mice was visualized by the in vivo imaging technique. The presence of chronic arthritis did not significantly affect the severity of thrombus formation. This result might be caused by too strong induction of thrombosis, which could mask the pro-thrombotic status of arthritic condition.

ICW6-4
Cutaneous Collagenous Vasculopathy in Patients with Connective Tissue Disease: A diagnostic challenge
Noreen Walsh, Phillip Moss, Thai Yen Ly, Sylvia Pasternak, Peter J Green, Kerri Purdy, Christopher Gallant, Ariel Burns, Mary Lou Baxter, Colleen Kelly, Elana Murphy, John G Hanly Dalhousie University, Halifax, Nova Scotia, Canada

Conflict of interest: None

Objectives: Cutaneous collagenous vasculopathy (CCV), a recently described, rare, superficial dermal microangiopathy of unknown etiology, shares clinical and histopathological features in common with cutaneous lupus erythematosus and dermatomyositis. Fewer than 50 cases have been reported in the literature. Concurrence of CCV and connective tissue diseases (CTD) may present a diagnostic quandary. Our objectives were to determine whether CCV cases at our center were associated with CTD and to identify distinguishing features between CCV and cutaneous manifestations of CTD. [Methods] The laboratory information system at a single academic health care center (2000-2018) was searched to identify cases with a diagnosis of CCV. All pathological material and clinical charts were reviewed. The demographic, clinical and pathological data were documented. [Results] We identified 6 cases of CCV (4 female, 2 male; median age 57 years). Clinically, a telangiectatic eruption was present in all patients, affecting the lower limbs and other sites (N=5) and the abdomen and arms (N=1). All patients had been seen by a dermatologist and 3 by a rheumatologist. A concurrent CTD was present in 2 cases; Sjogren’s syndrome (N=1) and undifferentiated connective tissue disease (N=1). In both, the clinical differential diagnosis included CCV and cutaneous involvement by the CTD. In all 6 cases, histopathological examination revealed a non-inflammatory vasculopathy, with PAS-positive, diastase resistant, hyaline thickening of ectatic superficial capillary walls, and loss of pericytes. These hallmarks of CCV excluded skin disease attributable to CTD in the two relevant cases. [Conclusion] Concurrency of CCV and CTD, though uncommon, presents a diagnostic challenge. The clinical distribution of the CCV eruption, favoring the lower limbs, and its non-inflammatory character histopathologically distinguish it from cutaneous involvement by a CTD.
that the levels of palmitoleyl ethanolamide (PEA), an endogeneous N-acyl-ethanolamide, in both serum and spleen were reduced in MRL/lpr mice. PEA suppressed pro-inflammatory cytokine (IL-6, IL-12, and IL-23) production induced by TLR9 stimulation (CpG-ODN) in bone marrow derived dendritic cells (BMDC) in vitro. Moreover, upregulation of MHC class II, CD86 and CD40 induced by CpG-ODN in BMDC were significantly attenuated by PEA. In splenic B cells, in addition to inhibition of IL-6 production and surface marker upregulation, cell proliferation and IgM production were suppressed by PEA. To examine whether PEA reduces TLR9-mediated inflammation in vivo, we assessed serum IL-6 levels in mice injected with CpG-ODN and D-galactosamine, resulting in reduction of IL-6 levels by intraperitoneal administration of PEA. [Conclusions] In MRL/lpr mice, PEA levels are decreased in the serum and spleen compared to MRL/MpJ mice. PEA reduces TLR9-mediated pro-inflammatory cytokine production both in vitro and vivo, suggesting that PEA might be a novel therapeutic candidate to modulate inflammation related to SLE.

ICW5-3 Glutaminase 1 is a target for Th17-related autoimmune diseases
Michihito Kono1, Nobuya Yoshida1, Kayaho Maeda1, Abel Suárez-Faeys1, Vasileios C Kyttaris1, George C Tsokos1
1Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Japan, 2Division of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, Sapporo, Japan
Conflict of interest: None

[Object] Glutaminase 1 (Gls1) is the first enzyme in glutaminolysis. We previously showed that the selective Gls1 inhibitor Bis-2-(5-phenylaminediazo-2-yl)ethyli sulphone (BPTES) suppresses Th17 cell development and suppresses experimental autoimmune encephalomyelitis (EAE). However, the involved mechanisms and whether inhibition of glutaminolysis can be useful in the treatment of systemic lupus erythematosus (SLE) remain unknown. [Methods] MRL/lpr mice were treated by BPTES or vehicle control and disease activity was examined. Then naïve CD4+ T cells from patients with SLE were cultured under Th17 conditions with BPTES or the vehicle. Furthermore, using newly generated Gls1 conditional knockout mice in IL-17 producing cells, in vitro Th17 differentiation and EAE disease were investigated. The expression of hypoxia-inducible factor 1α (HIF1α) and the von Hippel-Lindau tumor suppressor protein (VHL) which degrades HIF1α were examined. [Results] MRL/lpr mice with BPTES improved autoimmune pathology in a Th17-dependent fashion. T cells from patients with SLE treated with BPTES displayed decreased Th17 differentiation. Using the conditional knockout mice we demonstrated that both the in vitro Th17 differentiation and the development of EAE depend on Gls1. Gls1 inhibition reduced the expression of HIF1α protein, while the expression levels of VHL were found to be increased suggesting excessive degradation of HIF1α. [Conclusions] We have provided evidence that inhibition of glutaminolysis can be used to treat patients with SLE and Th17-related autoimmune diseases. Mechanistically we showed that glutaminolysis inhibition suppresses HIF1α expression in Th17 cells by increasing VHL.

ICW5-4 Atypical complement receptor C5aR2 transports C5a to initiate neutrophil adhesion and inflammation
Yoshishige Miyabe
Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School
Conflict of interest: None

[Object] “Atypical” chemoattractant receptors (ACKRs) act as nonsignaling chemokine sinks helping to maintain chemoattractant gradients. In addition, ACKR1 on endothelial cells (ECs) has been shown to transport chemokines produced in tissue across ECs and regulate neutrophil recruitment. Recently, we found that ACKR1 and “atypical” complement C5a receptor 2 (C5aR2) were highly expressed in the joint ECs of immune complex (IC)-induced arthritis. However, their roles in an inflammatory arthritis remain unclear. [Methods] We induced arthritis in wild-type (WT), C5aR2- or Ackr1-deficient (KO) mice to study their roles in IC-induced arthritis. To determine their roles on hematopoietic vs. non-hematopoietic cells, we generated bone marrow chimeric mice and induced arthritis. How they collaborate to control neutrophil recruitment into the joint were defined using multi-photon intravital microscopy (MP-IVM). To directly study if C5aR2 transports C5a and ACKR1 transports CXCR2 ligands into the vessel lumen to initiate neutrophil recruitment, we used a superfusion assay and MP-IVM. Finally, we visualized the requirement for C5aR2 for the transport of C5a from the extracellular space into the lumen of vessels overlying the joint. [Results] Abrogation of C5aR2 and Ackr1 ameliorate IC-induced arthritis. C5aR2 and ACKR1 expressed on non-hematopoietic cells are required for IC-induced arthritis. C5aR2 is required for transporting tissue-derived C5a into the vessel lumen to induce C5aR1-mediated neutrophil arrest. In addition, Ackr1 transports CXCR2 ligands across the joint ECs to induce CXCR2-dependent neutrophil extravasation in the joints. C5a was visualized on the luminal surface of the joint ECs in the joints of WT and Ackr1-KO mice, but not in C5aR2-KO mice. [Conclusion] These findings provide new insights into how “atypical” chemoattractant receptors collaborate with “classical” signaling chemoattractant receptors to control the recruitment of neutrophils into inflamed joints.

ICW5-5 PI3K-Akt pathway plays a crucial role in production of collagen in Fli1 deficient condition and its inhibitor has the therapeutic potential in treating fibrosis
Yuko Ota, Warren Strober, Atsushi Kitani
Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, Bethesda MD, USA
Conflict of interest: None

[Object] Systemic sclerosis (SSc) is a connective tissue disease characterized by fibrosis of the skin and internal organs. Previous studies have shown that dermal fibroblast in patients with SSc frequently shows decreased levels of Fli1 due to hypermethylation. We aimed to clarify the mechanisms underlying the regulation of Fli1 gene of fibrosis using Fli1 deficient cells and mice generated by the CRISPR/Cas9-mediated gene edition. [Methods] Fli1-deficient fibroblast cell line and mice were generated by CRISPR/Cas9 system using paired guide RNAs specific for Fli1 and a nicksense Cas9. NIH3T3 cells were transfected with a LenticRISPR v2 vector and then selected by puromycin. We evaluated collagen and profibrotic cytokine production in the absence of Fli1 by mRNA level. To reveal the mechanism for induction of collagen in Fli1 KO cells, we treated the cells with various antibodies and inhibitors and performed RNA-seq analysis. We evaluated the candidate drug using bleomycin-induced lung fibrosis model and collagen production in skin fibroblasts from patients with SSc. [Results] qPCR studies revealed that Col1A1, Col1A2, Fibronectin, TGF-β1 and IL-6 mRNA levels were increased in Fli1 KO 3T3 fibroblasts. Antibody neutralization of TGF-β1, IL-6/IL6R, each alone or in combination failed to suppress the increased collagen production. Surprisingly, Col1A2 mRNA was dramatically inhibited by a PI3K inhibitor but not MAPK inhibitors, suggesting a PI3K-Akt pathway was regulating collagen synthesis in KO cells. Furthermore, RNA-seq reveals several molecules to induce collagen via PI3K-Akt pathway. PI3K inhibitor attenuated bleomycin-induced lung fibrosis in Fli1 KO mice and also inhibited collagen production in skin fibroblasts from patients with SSc. [Conclusions] Lack of Fli1 expression activates the molecule that induces collagen accumulation through PI3K-Akt pathway. PI3K inhibitor showed the therapeutic potential in treating fibrosis.

ICW5-6 14-3-3 eta protein, a promising step forward in predicting response to Infliximab and its biosimilar? Results from two groups of patients diagnosed with rheumatoid arthritis in Romania
Bogdan I Gavrila, Crișoș Călaudia, Liviu Macovei, Victor Stoica, Ioan Ancuta, Mihai Bojinca
Department of Internal Medicine and Rheumatology Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
Conflict of interest: None
[Object] testing predictive value of 14-3-3eta protein regarding response to Infliximab (IFX) and its' biosimilar (Remsima) on 2 groups of patients diagnosed with rheumatoid arthritis (RA). [Methods] prospective and observational study, including 2 groups of patients with active RA, uncontrolled by csDMARDs, followed 12 months, 16 treated with IFX and 17 with Remsima. Clinical assessment was performed at 0.6,12 months according to ACR criteria and evaluation of treatment response according to EULAR criteria (good/moderate/nonresponder). [Results] 30 patients (90.91%) were women and 3 (9.09%) men. Following baseline 14-3-3eta titres and the response at 6 months, tests for identifying differences between groups showed that lower 14-3-3eta protein titres, in both groups of patients, had predictive value on achieving a good EULAR response at 6 months. For IFX, patients with good EULAR response had lower baseline titres (0.11±0.245 ng/ml) than patients with moderate response (0.70±0.705 ng/ml, p=0.049). For Remsima group, good responders had lower baseline titres (0.25±0.380 ng/ml) than nonresponders (1.67±0.615 ng/ml, p=0.004) or those with moderate response (0.25±0.401 ng/ml) Grouping patients in 2 categories (responders/nonresponders) only for IFX group, 14-3-3eta maintained value predicting a 6 months response (0.25±0.378 ng/ml), than nonresponders (1.67±0.615 ng/ml, p=0.0005). For 12 months, we didn’t find significant differences between groups regarding baseline 14-3-3 eta titres and response obtained (IFX p=0.1483, Remsima p=0.2470) The status pretreatment (positive/negative) influenced the good response for IFX group at 6 months (p=0.005). Regarding the evolution of serum titres, we noticed a reduction, statistically close to significance for IFX (baseline 0.51±0.703 ng/ml, 12 months 0.13±0.439, p=0.064), but not for Remsima (p=0.153). [Conclusions] 14-3-3 eta, a new diagnostic biomarker, could be a major candidate to distinguish pretreatment patients who will or not respond to anti-TNF α therapy.

ICW6-1 Are there differences in efficacy and safety of biological disease-modifying antirheumatic drugs between elderly-onset and young-onset rheumatoid arthritis?
Sadao Jinno1, Akira Onishi1, Kengo Akashi2, Motomo Hashimoto3, Wataru Yamamoto4, Koichi Murata1, Toru Takeuchi5, Takuya Kotani5, Yuichi Maeda6, Kosuke Ebina7, Yonsu Son8, Hideki Amuro9, Ryota Hara10, Masaki Katayama11, Jun Saegusa12, Akio Morinobu13
1Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 2Department of Advanced Medical Sciences, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 3Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan, 4Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan, 5Department of Orthopaedic Surgery, Osaka University Graduate School of Medicine, Osaka, Japan, 6First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, 7The Center for Rheumatic Diseases, Nara Medical University, Nara, Japan, 8Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan, 9Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan

Conflict of interest: None

[Object] To compare efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) between elderly-onset rheumatoid arthritis (EORA) and young-onset rheumatoid arthritis (YORA) patients. [Methods] Patients with rheumatoid arthritis (RA) aged ≥18 years enrolled in a Japanese multicenter observational registry between Sep 2009 and December 2017 who had ≥3.2 disease activity score in 28 joints-erythrocyte sedimentation rate (DAS28-ESR) when initiating bDMARDs were included. EORA was defined as RA with onset at 60 or over. A multivariate logistic regression model was performed to assess the relationship between age onset and clinical remission at 48 weeks. Clinical remission was calculated using DAS28-ESR, Simplified Disease Activity Index (SDAI), and Clinical Disease Activity Index (CDAI) scores. Biologic retention at 48 weeks was estimated using the Kaplan-Meier method. [Results] Of the 989 bDMARDs initiators, 364 patients (36.8%) were identified as EORA. Patients in the EORA group were older (73 vs 55, p=0.001) and more likely to have higher value of DAS28-ESR (5.1 vs 4.8, p < 0.001), SDAI score (22.6 vs 20.9, p=0.06), modified Health Assessment Questionnaire (mHAQ) score (1.0 vs 0.8, p < 0.001), and lower rate of positive rheumatoid factor (74% vs 82%, p < 0.001). CDAI score was similar (19.8 vs 18.9, p=0.19). Multivariate analysis demonstrated that EORA (OR 0.65, CI 0.45-0.97) was a negative predictor of the DAS28 remission, but not of the SDAI or CDAI remission. Drug maintenance rates (63% vs 61%) and adverse events discontinuation rates (2.7% vs 5.2%) were similar between the two age groups. [Conclusions] In RA patients initiating bDMARDs, there was no difference between EORA and YORA in achieving the SDAI or CDAI remission. The result that EORA was a negative predictor of the DAS28 remission could be attributed to the high weight of ESR in the DAS28. Drug maintenance and adverse events discontinuation rates were similar between the two age groups.

ICW6-2 Safety and Efficacy of Filgotinib in Japanese Patients Enrolled in a Global Phase 3 Trial of Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biologic DMARDs
Tatsunori Takeuchi1, Tsukasa Matsubara2, Tatsuya Atsumi3, Koichi Amano4, Naoki Ishiguro5, Eiji Sugiyama6, Kunhiro Yamaoka7, Mark C Genovese8, Kenneth Kalunian9, David Walker9, Jacques-eric Gottenberg10, Kurt De Vlam11, Nencha Morozaric12, Beatrice Baroni13, Franziska Matzkies14, Jie Gao15, Ying Guo16, Chantal Tasse17, John S Sundy18, Yoshiya Tanaka19
1Keio University School of Medicine, Tokyo, Japan, 2Matsubara Mayflower Hospital, Kato, Japan, 3Hokkaido University, Sapporo, Japan, 4Saitama Medical Center, Kawagoe, Japan, 5Nagoya University, Nagoya, Japan, 6Hiroshima University, Hiroshima, Japan, 7Kitasato University School of Medicine, Sagamihara, Japan, 8Stanford University, Stanford, CA, USA, 9University of California, San Diego, La Jolla, CA, USA, 10Northumbria Healthcare, UK, 11Strasbourg University Hospital, Strasbourg, France, 12Université Libre de Bruxelles, Brussels, Belgium, 13Gilead Sciences, Inc, Foster City, CA, USA, 14Galapagos NV, Mechelen, Belgium, 15University of Occupational and Environmental Health, Kitakyushu, Japan

Conflict of interest: None

[Object] We report results of Japanese patients enrolled in the FINCH 2 study (ClinicalTrials.gov Identifier: NCT02873936) of filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor in patients with RA and an inadequate response or intolerance to ≥1 biologic DMARDs. [Methods] Patients (pts) with RA were randomized globally, including at 5+ sites in Japan, 1:1 to FIL 200 mg, FIL 100 mg, or placebo (PBO) once daily for 24 weeks; pts continued background conventional synthetic csDMARDs. The primary endpoint was the proportion of subjects who achieved an ACR20 response at Week (Wk) 12. [Results] Primary and all key secondary endpoints were met for both global (N=448) and Japanese patient populations (n=40; FIL200, n=12; FIL100, n=15; and PBO, n=13). ACR20 response rates (%), p-value vs PBO in Japanese pts at Wk12 and 24 were: FIL200 83% (p=0.015), 92% (p<0.001); FIL100 53% (p=0.28), 60% (p=0.024); PBO 31%, 15%, respectively. At Wk 12, HAQ-DI LS mean changes from baseline were -0.55 (95% CI: -0.81, -0.29) and -0.30 (-0.53, -0.07) in the FIL200 and FIL100 groups, vs 0.09 (-0.16, 0.35) in PBO. At Wk 12, the percentage of Japanese pts with DAS28 (CRP) ≤3.2 was 67% FIL200 (p<0.001) and 47% FIL100 (p=0.007) vs PBO (0%). In Japanese patients, adverse event (AE) rates were similar for FIL200, FIL100 and PBO (75%, 60% and 77%, respectively) and there were no serious AEs; there was 1 case of uncomplicated herpes zoster (FIL200); and no venous thrombotic events, opportunistic infection/active TB, malignancy, GI perforation or death. [Conclusions] In this phase 3 study of pts with active RA and prior inadequate response/ intolerance to DMARDs, treatment with FIL over a 24-week period was associated with significant improvements in signs and symptoms of RA, with a safety and efficacy profile in Japanese pts consistent with that in the global population. Thus, FIL may provide a novel treatment option for pts who continue to have active RA despite prior biologic therapy.

ICW6-3 Filgotinib Week 132 Safety Data from a Phase 2b Open-Label Extension Study in Rheumatoid Arthritis
Yoshio Tanaka, Arthur Kavanagh, Mark C Genovese, Kevin Winthrop, Maria Greenwald, Lucia Ponce, Enriquez-sossa Favio,
Mykola Stanislavchuk1, Minodora Mazur6, Alberto Spindler16, Regina Cseuz11, Natalya Nikulenchuk12, Maria Glowacka-Kulesza13, Istvan Szombati14, Anna Dudek15, Neely Mozaffarian16, Joy Greer16, Rebecca Kunder16, Di An16, Luc Meuleners17, Robin Besuyen17, Rieke Alten17, René Westhovens16

1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, 2University of California, San Diego, La Jolla, USA, 3Stanford University School of Medicine, Palo Alto, USA, 4Oregon Health and Science University, Portland, USA, 5Desert Medical Advances, Palm Springs, USA, 6Cons. Priv., Temuco, Chile, 7Clinistile SA de CV, Col.Roma, Mexico, 8National Pirogov Memorial Medical University, Vinnytsya, Ukraine, 9IMSP Inst. de Cardiologie, Chisinau, Moldova, 10Centro Méd. Priv. Reum., Tucumán, Argentina, 11Revita Reumatologíai Kft, Budapest, Hungary, 12Vladimir Reg Clin Hosp, Shosse, Russian, Federation, 13Silesian Centrum Medyczne, Wroclaw, Poland, 14Qualiclinic Kft, Budapest, Hungary, 15AMED Medical Center, Warsaw, Poland, 16Gilead Sciences, Inc, Foster City, USA, 17Galapagos NV, Mchelen, Belgium, 18Schlosspark Klinik, Berlin, Germany, 19University Hospitals, Leuven, Belgium

Conflict of interest: None

[Object] Long-term safety and efficacy of the oral, selective Janus Kinase 1 (JAK1) inhibitor filgotinib (FIL) in patients (pts) with moderately to severely active RA is being evaluated in the DARWIN 3 (Phase 2b) open-label extension (OLE) study. [Methods] Eligible pts from the 24-week Phase 2b DARWIN 1 and 2 studies could enroll in DARWIN 3, where they received FIL 200 mg daily (100 mg for US males) as monotherapy or as add-on to methotrexate. We present cumulative safety data (from the patient’s first dose of FIL in the DARWIN program through 20 Feb 2018) and efficacy data (from Day 1 to Week 132 of DARWIN 3). [Results] Of 877 pts from DARWIN 1 and 2, 790 (90%) completed the OLE study and 739 (84%) enrolled in DARWIN 3; 603 (82%) were female, mean age was 53 years. At analysis, 469 (64%) remained in the OLE. Cumulative patient-years of exposure (PYE) was 2081, median time on study drug was 1197 days. Overall treatment-emergent adverse event (TEAE) and serious TEAE rates/100PYE were 146 and 5.6, respectively. [Conclusions] Filgotinib continues to demonstrate a favorable safety and tolerability profile in pts with RA over a 2.5-year period, with no new safety signals identified. Efficacy data revealed 89%, 70%, and 49% of pts had ACR20/50/70 responses, respectively, and 69% achieved DAS28 (CRP) ≤3.2 (observed case analysis). [Conclusions] Filgotinib continues to demonstrate a favorable safety and tolerability profile in pts with RA over a 2.5-year period, with maintenance of therapeutic response in the long term.

ICW6-4

Evaluation of response criteria in rheumatoid arthritis treated with biological disease-modifying antirheumatic drugs

Mariko Inoue12, Hiroko Kanda12, Shoko Tateishi12, Keishi Fujio1
1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 2Department of Immunotherapy Management, Graduate School of Medicine, The University of Tokyo

Conflict of interest: Yes

[Object] There are several mechanisms of action in biologic disease-modifying anti-rheumatic drugs (bDMARDs) used for rheumatoid arthritis (RA) treatment. Interleukin-6 inhibitor (IL-6i) blocks the production of acute-phase reactant (APR) proteins, which are part of the composite measures of disease activity of RA. In this study, we examined agreement between the European League Against Rheumatism (EULAR) response based on ESR or CRP, the Simplified Disease Activity Index 50% (SDAI50), and the Clinical Disease Activity Index 50% (CDAI50) response measures in patients treated with IL-6i and other bDMARDs. [Methods] We enrolled 306 RA patients who started or switched bDMARDs. Treatment response at 6 months was analyzed. Kappa statistics were used to evaluate the agreement between different response measures. The contribution of the APRs to improvement in disease activity scores was compared between different response measures. Change of Health Assessment Questionnaire (HAQ) scores was analyzed in patients treated with IL-6i. [Results] There was good agreement between each response measure, with κ above 0.6 in patients treated with tumor necrosis factor inhibitors (TNFi) or cytokotic T-lymphocyte-associated antigen 4 immunoglobulin fusion protein (CTLA4lg). In patients treated with IL-6i, the agreement was low between the EULAR response (ESR) and the SDAI50 or the CDAI50 (<0.43 and 0.37, respectively). Under IL-6i treatment, APR improvement accounted for 56.0% of total improvement of the DAS28-ESR. When discordance was found between the CDAI50 and EULAR response in IL-6i-treated patients, all patients were classified as EULAR-only responders. And there was no HAQ improvement in IL-6i-treated patients who only showed EULAR response and no CDAI50 response. [Conclusions] EULAR response criteria overestimate the response under IL-6i treatment because the APR improvement largely contributes to the DAS28 improvement.

ICW6-5

15-year changes in clinical outcome of bDMARDs in patients with rheumatoid arthritis –from FIRST registry–

Shunsuke Fukuyo1, Kazuhisa Nakano1, Shingo Nakayama4, Shigeru Iwata1, Kentaro Hanami2, Satoshi Kubo1, Ipeii Miyagawa1, Ayako Yamaguchi1, Yusuke Miyazaki1, Akio Kawabe1, Kazuyoshi Saito1, Yoshiya Tanaka1
1Department of First Internal Medicine, University of Occupational and Environmental Health, Japan, 2Institute of Rheumatology, Tokbata General Hospital

Conflict of interest: Yes

Objective: The aim of this study was to explore changes in clinical outcome in RA patients treated with bDMARDs over a 15-year period. [Methods] We used clinical data from FIRST registry which included all patients with RA who initiated bDMARDs therapy during 2003-2017 in our hospital. We divided 15 years into 5 terms every 3 years (2003-2005/2006-2008/2009-2011/2012-2014/2015-2017). The primary endpoint was the proportion of patients with CDAI remission at month 12 in each term. [Results]: In total 3067 patients were included. The mean age was increased over time (55.0→57.5→59.7→61.5→64.0 years). The mean CDAI score at baseline (BL) was approximately 30. 90 % of patients had moderate to high disease activity at baseline. The retention rates of bDMARDs at month 12 were almost 80 %. The proportion of patients with remission at month 12 increased over time (16.9→22.6→32.5→33.7→32.0 %). In logistic regression analysis, the factors that associated with CDAI remission were low BL-CDAI, HAQ, oral GC use and high bio-naïve rate. CDAI, oral GC use and bio-naïve rate were decreased and HAQ was increased over time. The incidence of adverse event (1000 person-years) was decreased over time (57.2→48.0→48.0→37.3→15.8). The incidence of pneumonia (1000 person-years) was decreased over time (25.2→13.5→7.9→9.5→2.4). [Conclusions]: Elderly patients treated with bDMARDs have gradually increased for 15 years in the FIRST registry. The retention rate and effectiveness of bDMARDs sustained, whereas incidence of adverse events rather decreased. Increase in option of bDMARDs could lead to such 15-year improvement.

ICW6-6

Predictive factors for remission achievement by tocilizumab monotherapy in patients with rheumatoid arthritis after inadequate response to methotrexate: a post hoc analysis of the SURPRISE study

Masaaru Kato1, Yuko Kaneko2, Yoshia Tanaka3, Masayuki Inoo4, Hitomi Haraoaka1, Koichi Amano5, Masayuki Miyata5, Yohko Murakawa5, Hidekata Yasuoka6, Shintaro Hirata5, Hayato Nagasawa6, Eiichi Tanaka6, Nobuyuki Miyasaki7, Hisashi Yamanaka8, Kazuhiko Yamamoto9, Tatsuya Atsumi1, Tsutomu Takeuchi2
1Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan, 2Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 3The First Department of Internal Medicine, University of Occupational and Envi-
Long-term retention rates of biologic disease-modifying antirheumatic drugs in elderly and very elderly patients with rheumatoid arthritis from the FIRST registry

Akiro Kawabe, Satoshi Kubo, Kazuhiro Nakano, Shingo Nakayamada, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Ippei Miyagawa, Ayako Yamaguchi, Yusuke Miyazaki, Yoshiya Tanaka

The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu

Conflict of interest: None

[Object] To identify predictive factors for clinical and structural remission by tocilizumab without methotrexate in patients with rheumatoid arthritis (RA). [Methods] This is a post hoc analysis of the SURPRISE study, a 2-year randomized, controlled study comparing the efficacy of tocilizumab with (ADD-ON) and without methotrexate (SWITCH) in active RA patients despite methotrexate therapy. The primary endpoint was the DAS28 remission (< 2.6) at week 24. The change in modified total Sharp score from baseline to week 52 (ΔmTSS/year) was also assessed as an endpoint. Patient characteristics and clinical parameters, including serum levels of CRP, IL-6, SAA, MMP-3, RF and IgG, were compared between patients who achieved DAS28 remission at week 24 and those who did not. [Results] In SWITCH (n = 96), SAA levels and DAS28 at baseline were significantly higher in patients who did not achieve DAS28 remission at week 24 than those who did (85.0 mg/mL vs 15.3 mg/mL, p = 0.006; 5.7 vs 5.0, p = 0.01; respectively). Structural remission (ΔmTSS/year <= 0.5) rate at week 52 was significantly higher in patients with SAA of <= 85.0 mg/mL than those with SAA of >= 85.0 mg/mL (71% vs 50%, p = 0.046). In contrast, in ADD-ON (n = 98), whereas DAS28 at baseline was also higher in patients who did not achieve DAS28 remission (5.6 vs 4.9, p = 0.005), SAA levels were not relevant (25.6 mg/mL vs 24.7 mg/mL, p = 0.99). In patients with SAA < 85.0 mg/mL and DAS28 <= 5.1 at baseline, both DAS28 remission (85% vs 81%, p = 0.77) and structural remission (77% vs 76%, p = 1.00) rate were comparable between ADD-ON and SWITCH. [Conclusions] SAA levels and disease activity at baseline can predict the necessity of concomitant methotrexate in tocilizumab initiation in patients with RA. Patients with both low levels of SAA and moderate disease activity at baseline may benefit similarly from tocilizumab therapy with and without methotrexate in terms of achieving clinical and structural remission.

ICW7-2
Discontinuation of oral glucocorticoid after initiation of biological DMARD due to a higher dose of methotrexate: a retrospective observational study based on data from a Japanese multicenter registry study

Mochihito Suzuki, Toshihisa Kojima, Nobunori Takahashi, Shuji Asai, Nobuyuki Asai, Takuya Matsumoto, Yasumori Sobue, Tsuyoshi Nishiue, Naoki Ishiguro

Department of Orthopedic Surgery, Nagoya University Hospital

Conflict of interest: Yes

[Object] In the treatment of rheumatoid arthritis (RA), glucocorticoid (GC) that provide anti-inflammatory effects in the early stage of treatment can be an important drug. We recommend discontinuing of GC as much as possible within 6 months, but many patients have taken oral GC in the long term in daily clinical practice. The aim of this study is to examine association of methotrexate (MTX) dose with discontinuation of GC after one year since initiation of biological DMARD (bDMARD) as 1st bDMARD. [Methods] We established the large observational cohort, the Nagoya University orthopedic facility multicenter study (TBCR). 564 patients who used GC and MTX when bDMARD was initiated as 1st bDMARD were included. In the first study, we examined predictive factors of discontinuation of GC after one year since initiation of bDMARD by using multivariate analysis in the two groups, 406 patients continued to use GC and 164 patients discontinued to use GC. In the second study, we adjusted the background at the time of initiation of bDMARD by using propensity score matching (PS) in the two groups, MTX =8mg (L group) and MTX =8mg (H group). [Results] In the multivariate analysis, age (Odds ratio (OR)0.98), MTX dose (OR1.09) and GC dose (OR0.88) were independently predictive factors of discontinuation of GC. When we adjusted age, disease duration, sex, disease activity, RF/ACPA, GC dose by using PS matching, 105 pairs were extracted. There were obvious significant differences between 24 patients (22.9%) in the L group and 43 cases (41.0%) in the H group (P = 0.007), where GC were discontinued at one year after the initiation of bDMARD. [Conclusions] In the clinical practice, MTX dose at the time of initiation of bDMARD was predictive factor of discontinuation of GC. A higher dose of MTX associated with discontinuation of GC in the patients treated with bDMARD.

ICW7-3
De-escalation of treatments after sustained remission in patients with RA - The FREE-J study, a real world prospective observational cohort study

Ayako Yamaguchi 1, Shintaro Hirata 2, Toshiaki Miyamoto 3, Kazuhide Tanigawa 4, Hideyuki Iwai 5, Yuko Kaneko 6, Tsutomu Takeuchi 7, Koichi Amano 8, Naoki Iwamoto 9, Atsushi Kawakami 9, Miho Murakami 10, Norihiro Nishimoto 10, Tatsuya Atsumi 11, Masahiro Yokosawa 11, Takayuki Sumida 11, Tsuneyo Mimori 12, Hisashi Yamanaka 12, Keishi Fujiy 14, Kazuhiwa Nakano, Yoshiya Tanaka 1

1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu
2Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Japan, 3Department of Internal Medicine and Rheumatology, Seirei Hamamatsu General Hospital, Japan, 4Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, Sapporo, 5Division of Hematology and Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, 6Department of Rheumatology, Kitasato University School of Medicine, 7Department of Rheumatology, Kobe University Graduate School of Medicine, 8Department of Rheumatology, Nagoya University orthopedic facility multicenter study (TBCR), 9Department of Rheumatology, Hokkaido Medical Center for Rheumatic Diseases, 10Department of Internal Medicine and Rheumatology, Saitama Medical University, Tokyo, 11Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, 12Department of Allergy and Rheumatology, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

Conflict of interest: Yes

[Object] Japan is facing a “super-aged” society, the wide use of bDMARDs for elderly RA patients despite methotrexate therapy. The primary endpoint was the DAS28 remission (< 2.6) at week 24. The change in modified total Sharp score from baseline to week 52 (ΔmTSS/year) was also assessed as an endpoint. Patient characteristics and clinical parameters, including serum levels of CRP, IL-6, SAA, MMP-3, RF and IgG, were compared between patients who achieved DAS28 remission at week 24 and those who did not. [Results] In SWITCH (n = 96), SAA levels and DAS28 at baseline were significantly higher in patients who did not achieve DAS28 remission at week 24 than those who did (85.0 mg/mL vs 15.3 mg/mL, p = 0.006; 5.7 vs 5.0, p = 0.01; respectively). Structural remission (ΔmTSS/year <= 0.5) rate at week 52 was significantly higher in patients with SAA of <= 85.0 mg/mL than those with SAA of >= 85.0 mg/mL (71% vs 50%, p = 0.046). In contrast, in ADD-ON (n = 98), whereas DAS28 at baseline was also higher in patients who did not achieve DAS28 remission (5.6 vs 4.9, p = 0.005), SAA levels were not relevant (25.6 mg/mL vs 24.7 mg/mL, p = 0.99). In patients with SAA < 85.0 mg/mL and DAS28 <= 5.1 at baseline, both DAS28 remission (85% vs 81%, p = 0.77) and structural remission (77% vs 76%, p = 1.00) rate were comparable between ADD-ON and SWITCH. [Conclusions] SAA levels and disease activity at baseline can predict the necessity of concomitant methotrexate in tocilizumab initiation in patients with RA. Patients with both low levels of SAA and moderate disease activity at baseline may benefit similarly from tocilizumab therapy with and without methotrexate in terms of achieving clinical and structural remission.
The effects of erythrocytes and platelets on disease activity in patients with rheumatoid arthritis - ANSWER longitudinal cohort study

Akira Onishi1, Kengo Akashi1, Sadao Jinno1, Yonsu Son2, Hideki Amuro2, Akira Nakamura3, Yoshikazu Fujikawa1, Takumi Nagamoto3, Ikuko Naka1, Takaichi S185

First Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 1Department of Medicine and Rheumatology, Keio University, 2Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 3First Department of Internal Medicine, Kansai Medical University, 1Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, 2Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, 3Department of Health Information Management, Kurashiki Sweet Hospital, 1Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, The Center for Rheumatic Diseases, Nara Medical University, 1Department of Rheumatology, Osaka Red Cross Hospital, 2Department of Internal Medicine IV, Osaka Medical College

Conclusions:
We recruited 436 patients with mean age 57.5 years, mean disease duration 105.3 months and mean DAS28-ESR score was 1.74 ±0.57. The number of patients for each strategy; 1) 80 continued all DMARDs, 2) 184 reduced dose of MTX, 3) 24 discontinued MTX, 4) 68 reduced bDMARDs, 5) 71 discontinued bDMARDs. The remission rate 1 year after the study entry was 1) 86%, 2) 82%, 3) 83%, 4) 75%, 5) 56%, respectively, in which only group 5), discontinuation of bDMARDs was significantly different from group 1), continuation of all DMARDs (OR:0.2, 95%CI:0.09-0.5, p<0.001). By the multivariate analysis, the presence of bDMARDs, lower score of DAS28-ESR and lower value of anti-CCP at the study entry were significantly correlated with the maintained remission for 1 year after the de-escalation of DMARDs. There were no significant differences in the maintained remission among different bDMARDs. Conclusions: After sustained remission in RA patients treated with MTX and bDMARDs, the remission rate 1 year after dose-reduction of MTX or bDMARDs and withdrawal of MTX was statistically comparable to that of continuation of treatments and the use of bDMARDs significantly affected with the maintained remission for 1 year after the de-escalation of DMARDs.

ICW7-5
Difference in health care utilization in RA patients according to seropositivity
Hyo-young Kim1, Soo-kyung Choi1, Seongmi Choi1, Seul Gi Im1, Sun-young Jung2, Eun Jin Jung3, Yoon-kyoung Sung4
1Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, 2Department of Statistics, Kyungpook National University, Daegu, Korea, 3Department of Information Statistics, Andong National University, Andong, Korea, 4College of Pharmacy, Chung-Ang University, Seoul, Korea

Conflict of interest: None

[Object] We aimed to compare health care utilization between patients with seropositive (SP) and seronegative (SN) rheumatoid arthritis (RA). [Methods] Using the Korean nationwide healthcare claims database between 2012 and 2016, we selected patients with SPRA and SNRA. We compared the three indices of healthcare utilization: current medications, clinic visits and hospitalization, and direct medical cost of the year. Changes of the indices from 2012 to 2016 in each SPRA and SNRA group were also analyzed. [Results] A number of 103,815 SPRA patients and 75,809 SNRA patients in 2016 were included. In current medications, methotrexate (MTX) and biologic agents were commonly used SPRA patients (73.2% and 7.9%, respectively) than SNRA patients (30.3% and 2.9%, respectively). However, the prevalence of glucocorticoids use was high in both groups; 81.9% of SPRA and 73.6% of SNRA patients. Patients with SPRA visited outpatient clinic more frequently than SNRA patients (6.0 ± 3.7 and 4.4 ± 4.0 times/year, respectively), while the number of hospitalization per person was similar in both groups (1.5 ± 1.1/year of SPRA, 1.4 ± 1.2 of SNRA, respectively). Annual direct medical cost of 2016 for each SPRA patient was higher than that of SNRA patient (1,026.7 USD and 449.8 USD, respectively) and its increase between 2012 and 2016 was prominent in SPRA patients than SNRA patients (820.6 to 1026.7 USD) than SNRA patients (327.5 to 449.8 USD). Another change in health care utilization between 2012 and 2016 was an increase in the number of patients with biologic agents use and it was prominent in SPRA patients (4,466 to 8,177 in SPRA and 1,291 to 2,209 of SNRA). [Conclusions] The seropositivity could lead to the differences in the healthcare utilization in RA patients. Patients with SPRA showed higher rates of MTX use, biologic agents use, and outpatient clinic visits than SNRA patients. Total direct medical cost for each patient was also higher.

Conflict of interest: None
in SPRA patients than SNRA patients.

ICW7-6  
Treatment Patterns in DMARD Naïve Rheumatoid Arthritis Patients: A Retrospective Analysis of US Claims Data  
Robin K Dore1, Jenya Antonova1  
1Division of Rheumatology, David Geffen School of Medicine, University of California, Los Angeles, California, USA, 2Health Economics and Outcomes Research Division, Gilead Sciences, Foster City, California, USA

Conflict of interest: None

[Object] To better understand recent advances in pharmacologic therapy for rheumatoid arthritis (RA), this study evaluated recent treatment patterns in RA patients (pts) who newly initiated a DMARD. [Methods] Adult pts with more than 2 claims for RA initiating their first DMARD between 1/2012-9/2016, with 12-months continuous enrollment pre- and post-ID and without DMARD claims 12 months pre-ID were extracted from a commercial database including medical and pharmacy health insurance claims covering about 40 million people annually. Use of conventional synthetic DMARDs (csDMARDs), TNF inhibitors (TNFi), anti-IL6 pathway antibodies, other biologic DMARDs (bDMARDs), and JAK inhibitors (JAKi), as mono- and combination with csDMARDs, was described, with median therapy duration assessed via Kaplan-Meier curves. Drug discontinuation, switching, or addition of another DMARD marked end-of-treatment. [Results] Of 26,808 pts (74.2% female; mean age 51.9), most (97.7%) initiated mono-therapy, with csDMARD (91.3%) and TNFi (6.6%) being the most frequently prescribed monotherapies. For combination therapy with csDMARDs, TNFi (88.0%) and other bDMARDs (7.3%) were most common. Median duration of index therapy did not significantly differ for monotherapy vs. combination therapy (p = 0.110). Therapy discontinuation was high: by day 90, only 71% (monotherapy) and 70% (combination) of patients remained on index therapy, and by day 360, fewer than 40% of patients remained on index therapy. Median treatment duration was 230 days (csDMARD monotherapy), 225 vs. 206 days (TNFi combination vs. monotherapy, respectively), 227 vs. 203 days (anti-IL6), 198 vs. 182 days (other bDMARDs), and 347 vs. 301 days (JAKi). [Conclusions] In a retrospective health claims study, RA pts initiating DMARDs had median duration of therapy of less than a year, suggesting a need for improved durability among treatments. However, compared to other therapies, JAKi demonstrated the longest median duration.

ICW8-1  
Peripheral immunophenotyping in idiopathic inflammatory myopathies differs between myositis-specific antibodies  
Yasuuki Todoroki1, Satoshi Kubo1, Shingo Nakayamada1, Yusuke Miyazaki2, Ipppei Miyagawa1, Hiroko Yoshinari1, Yoshino Inoue1, Naoki Okubo1, Shigeru Iwata2, Shunsuke Fukushima1, Kentaro Hanami1, Akio Kawabe3, Shin Tanaka4, Kazuhisa Nakano1, Minoru Sato1,2, Kazuyoshi Saito1,5, Yoshiya Tanaka1  
1First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 2Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Japan, 3Department of Rheumatology, Tobata General Hospital, 4Department of Clinical Pathophysiology, School of Health Sciences, University of Occupational and Environmental Health, Japan

Conflict of interest: None

[Objective] Idiopathic inflammatory myopathies (IIMs) can be classified into subgroups according to myositis-specific antibodies (MSAs) and the pathological findings of muscles. The purpose of this study was to clarify the peripheral immune cell phenotype differences among these subgroups. [Methods] Peripheral blood mononuclear cells obtained from 82 patients with untreated IIMs were used for comprehensive flow cytometric analysis based on the Human Immunology Project Consortium. MSAs were detected by immunoprecipitation and ELISA. [Results] Overall, the proportion of activated CD4+ (especially, Th1, Th17 and Treg) and activated CD8+ T cells were higher in IIMs than in healthy controls. Similarly, the proportion of IgD-CD27+B cells and plasmablasts were increased. However, the immune cell phenotypes of subgroups classified by MSAs (Anti-ARS: n=30, Anti-MDA5: n=22, Anti-TIF1γ: n=12, Others; n=18) were different. The most remarkable immune dysregulation was observed in anti-TIF1γ+ patients. In these patients, the proportions of activated T cells of CD4+/CD8+ T cells and plasmablasts were significantly higher than other cases. Next, if we compared anti-ARS+ and anti-MDA5+ patients who had intestinal lupus disease, the proportions of IgD-CD27+B cells and plasmablasts were significantly higher in anti-MDA5+ patients than in anti-ARS+ patients. In sharp contrast, effector memory CD8+ cells were increased in anti-ARS+ patients. In terms of the comparison of clinical features, the strong immune dysregulations of both T and B cell were observed in cases accompanied with malignancy among anti-TIF1γ+ patients. Meanwhile, the proportion of plasmablasts was correlated with serum level of ferritin which is one of the poor prognostic factors in anti-MDA5+ patients. [Conclusions] Immunophenotyping in IIMs revealed the differences among subgroups according to MSAs. These findings clearly showed the heterogeneity of IIMs and indicate different treatment target molecules for these subgroups.

ICW8-2  
Serum Fatty Acid Binding Protein 3 (FABP3) levels differentiate active from inactive myositis and correlate with response to therapy  
Latika Gupta, Sanjukta Majumder, Amita Aggarwal, Raminth Misra, Abl Lawrence  
Sanjay Gandhi PostGraduate Institute of Medical Sciences, Lucknow, India

Conflict of interest: None

[Object] Idiopathic Inflammatory Myositis (IIM) results in significant morbidity, and often mortality. While delayed diagnosis leads to wasted muscles, conventional markers fail to differentiate the reversible component of subclinical inflammation amongst prevalent damage. Fatty Acid Binding Protein 3 (FABP3) is a small cytosolic protein involved in fatty acid transport that is preferentially expressed in slow twitch skeletal muscle fibers. Its selective expression makes it a suitable candidate biomarker to differentiate leaky damaged muscles from those with damage. [Methods] Patients with inflammatory myositis seen between December 2017 to August 2018 were recruited. Those with active infection, pregnancy, renal dysfunction or chronic kidney disease were excluded. Apart from patient and disease variables, activity and damage were assessed using standard IMACS core set measures. Sera were collected at first visit and in those with active disease follow up samples were collected at six months. Those with MDAAT activity score greater than or equal to one were scored as active disease. FABP3 was estimated in sera using ELISA. Non-parametric tests were used for paired and unpaired analysis. [Results] 132 myositis (12 JDM, 55 DM, 19 PM, 21 Overlap and 24 ASS) patients (33 men and 99 women) with median age 38 (24.5-46.0) years and disease duration 0.9 (2.3-5.1) years were included. Mean FABP3 values were higher in those with active (5.73 ng/ml) as compared with inactive (2.92 ng/ml, p=0.0351) disease. Of the nine cases followed up for 6 months, levels (Figure) fell with treatment in treatment responders (n=7, 14.5 to 7.5 ng/ml, p=0.03). FABP3 did not differ between those with different types of myositis or history of polycyclic versus monocyclic course. [Conclusions] Serum FABP3 may be a useful marker of disease activity and response to therapy in inflammatory myositis.

ICW8-3  
Inhibition of necroptosis ameliorates in vitro and in vivo models of polymyositis  
Mari Kamiya, Fumitaka Mizoguchi, Kimito Kawahata, Hitoshi Kohsaka  
Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

Conflict of interest: None

[Object] In polymyositis (PM), CD8+ cytotoxic T lymphocytes (CTLs) play assumingly a crucial role in muscle injury. Inhibition of muscle cell death could be a novel therapeutic strategy in PM. The aims of this study are to clarify the mechanisms of CTL-mediated muscle injury and the pattern of cell death of muscle cells. [Methods] OT-I CTLs,
and their mutants lacking perforin 1 or granzyme B were cocultured with myotubes that were retrovirally transduced with the genes encoding MHC class I (H2K^b) and SIINFEKL peptide derived from ovalbumin (H2K^OVA). To discern how muscle cell death is mediated in vitro by CTL, protein-induced-myositis (CIM) was used to study the effect of necrostatin-1 (nec1) on the severity of myositis in vivo. Muscle biopsy specimens of PM patients were examined with terminal deoxynucleotidyl transferase nick-end labeling (TUNEL) assay, and histologically for the expression of necroptosis associated proteins. [Results] OT-I CTLs lacking perforin 1 or granzyme B were as cytotoxic to H2K^OVA-myotubes as wild type OT-I CTLs. Inhibition of Fas ligand by the Fas-Fe chimera protein reduced cytoxicity of CTLs against the myotubes. The TUNEL assay and time-lapse imaging of cell death visualized by Annexin V and PI revealed that the cell death of the myotubes was non-apoptotic. The CTL-mediated cell death of myotubes was inhibited by nec1, a necroptosis inhibitor but not by benzylxoycarbonyl-Val-Ala-Asp-fluoromethylketone, an apoptosis inhibitor. Therapeutic administration of nec1 significantlyameliorated CIM. Immunohistochemical staining of muscle tissue of PM patients revealed the expression of Fas and necroptosis associated proteins including phosphorylated mixed lineage kinase domain like pseudokinase on injured muscle cells. [Conclusions] Necroptosis is involved in muscle cell death of PM. Inhibition of necroptosis should be a novel therapeutic strategy in PM.

ICW8-4

Anti-MDA5 Autoantibody (Ab) Associated Juvenile Dermatomyositis (JDM) constitute a distinct phenotype in North America

Gulnara Mamyrova1, Takayuki Kishi2
1Division of Rheumatology, Department of Medicine, George Washington University School of Medicine and Health Sciences, Washington DC, USA, 2Veterans Environmental Health Sciences, National Institutes of Health, 3Veteran’s Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation

Conflict of interest: None

ICW8-5

Myofas-dominant inflammation is a novel risk factor for rapidly progressive interstitial lung disease in dermatomyositis: a study using whole body MRI

Kohei Karino, Michihiro Kono, Michihito Kono, Nobuya Abe, Yuichiro Fujiyeda, Masaru Kato, Toshiyuki Bohgaki, Olga Amengual, Kenji Oku, Shinikuse Yasuda, Tatsuya Atsumi
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Conflict of interest: None

ICW8-6

Clinical features and outcomes of anti-MDA5 antibody positive patients with idiopathic inflammatory myositis

Huizhong Qiu, Guosheng Wang, Xiaomei Li, Xiangpei Li, Zhu Chen
The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, P.R. China

Conflict of interest: None
vival rates in our patients with anti-MDA5 antibody positive were 71.4% and 52.4% at 6 and 12 months, which are significantly lower than the negative group (P<0.001). Conclusions: Anti-MDA5 antibody not only is useful for the diagnosis of ADM/HDM, but also may serve as a serum marker for acute/subacute ILD, mainly NSIP and UIP. Early monitoring of anti-MDA5 antibody in the course of the disease is helpful in predicting the progression of ILD disease, and prognosis.

ICW9-1 Prognosis of Severe Infection Recurrence Based on the Readministration of Biologic Disease Modifying Antirheumatic Drugs Post Treatment of Severe Infection in Rheumatoid Arthritis

Eri Oguro1, Yui Yoshida1, Kentaro Kuzuya1, Yasutaka Okita1, Hitotoshi Matsuoka1, Satoru Teshigawara1, Maiko Yoshimura1, Kentaro Isoda1, Yoshihisa Harada1, Shiro Ohshima1, Jun Hashimoto1, Yukihiko Sacki2
1Department of Rheumatology and Allergology, NHO Osaka Minami Medical Center, 2Department of Clinical Research, NHO Osaka Minami Medical Center

Conflict of interest: None

[Object] There is no consensus regarding the readministration of biologic disease modifying antirheumatic drugs (bDMARDs) following treatment for infection. We investigated whether the readministration of bDMARDs following treatment for infection in patients with rheumatoid arthritis (RA) affects infection recurrence. [Methods] The study sample comprised patients with RA who were examined at the Osaka Minami Medical Center between January 2010 and December 2017 and were prescribed bDMARDs. We confirmed whether bDMARDs were re-administered to patients who developed severe infection requiring hospitalization while undergoing treatment with bDMARDs. We divided subjects into a bDMARDs readministration group and discontinuation group. We followed-up with patients over the following 12 months and used logistic regression analysis to investigate the odds ratios for severe infection recurrence owing to the readministration of bDMARDs. [Results] During the study period, bDMARDs were administered to 1,176 patients. Severe infection was observed in 164 times in these patients. The severe infection onset rate was 5.73/100 person-years. There were 130 subjects (79.3%) in the bDMARDs readministration group following treatment for severe infection and 34 subjects (20.7%) in the bDMARDs discontinuation group. The severe infection recurrence rate after 12 months was 18.9%, with severe infection recurrence noted in 20 cases (15.4%) in the bDMARDs readministration group, and in 11 cases (32.4%) in the discontinuation group. The adjusted odds ratio for severe infection recurrence within 12 months in the bDMARDs readministration group was 0.46 (95% CI 0.16-1.33, p=0.15). [Conclusions] Although high rate of severe infection recurrence was observed within 12 months in patients who developed a severe infection while being treated with bDMARDs, there was no significant difference in the incidence of severe infection recurrence between the bDMARDs readministration and discontinuation group.

ICW9-2 The disease activity and the use of corticosteroid but not use of biologics are associated with serious infection in rheumatoid arthritis patients -the data from MIrAI cohort-

Yui Yoshida1, Shiro Ohshima1, Eri Oguro1, Kentaro Kuzuya1, Yasutaka Okita1, Hitotoshi Matsuoka1, Satoru Teshigawara1, Maiko Yoshimura1, Kentaro Isoda1, Yoshihisa Harada1, Shigeo Tsuji1, Jun Hashimoto1, Yukihiko Sacki2
1Department of Rheumatology and Allergology, National Hospital Organization Osaka Minami Medical Center, 2Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center

Conflict of interest: None

[Object] Anti-rheumatic drugs were reported as an risk factors of infections. However, the association between infection and the disease activity and rheumatoid arthritis (RA) progression were controversial. Our aim was to describe serious infection events (SIEs), and investigate the relation between serious infectious risk and RA disease control and anti-rheumatic drugs in real world patients with RA. [Patients] In total, 8206 patients/year RA outpatients were examined at the Osaka Minami Medical Center in the period from January 2012 to October 2017. The severity of infection was graded according to international criteria. [Results] The cohort contributed to 8206 patient-years of follow-up. There were 251 SIEs in 220 patients, at an average follow-up of 3.7 years. Incidence rate of SIE was 3.0 infections per 100 patient-years. The high disease activity (DAS28 p<0.001, mHAQ p<0.01), joint destruction (Stage p=0.02), sex (p<0.01), age (p=0.02) and the use of corticosteroid (p<0.0001) was associated with SIE. However, the use of biologics (TNF inhibitors, CTLA-4-Ig, IL-6 inhibitor) were not significantly associated with SIE. [Conclusions] From the data obtained from our cohort, good disease control of RA without the use of corticosteroid were considered very important to reduce serious infections.

ICW9-3 The use of biologic disease-modifying anti-rheumatic drugs does not increase surgical site infection and delayed wound healing among orthopaedic surgery patients

Yohei Kiso1, Keiichiro Nishida1, Masahito Watanabe1, Minami Matsuhashi1, Shunji Okita1, Hideki Ohashi1, Ryuichi Nakahara1, Yoshishita Nau1, Toshiyumi Ozaki1
1Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2Department of Intelligent Orthopaedic System, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 3Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences

Conflict of interest: None

[Objective] The aim of the study was to examine whether the use of biologic DMARDs (bDMARDs) is a risk factor of surgical site infection (SSI) and delayed wound healing (DWH) after orthopaedic procedures for rheumatoid arthritis (RA). [Patients and Methods] We investigated incidence of SSI and DWH from medical records of 515 orthopaedic procedures for RA between 2013 and 2017 in our institution. The bDMARDs were stopped pre-operatively based on the half-life of each drug and restarted after removal of stitches according to the 2014 JCR guideline. Risk factors for SSI and DWH were assessed by univariate logistic regression analysis between age, sex, disease duration, pre-operative CRP and DAS28-28-CRP, BMI, DM, glucocorticoid use, smoke, MTX use, bDMARDs use and surgical procedure. Then, the demographic data of bDMARDs user group and non-user group are matched by Propensity Score (PS) to compare the incidence of SSI and DWH between two groups. [Results] In all cases, SSI and DWH occurred in 7 cases (1.4%) and 17 cases (3.3%), respectively. Two (1.1%) cases of SSI and 9 cases (4.9%) of DWH were recorded among 183 procedures for bDMARDs users. Univariate logistic regression analyses demonstrated that age and foot surgery were associated risk factors for SSI, and age, foot surgery and smoke for DWH. 157 cases were PS-matched for each group of bDMARDs user and non-users. It was confirmed that there was no significant differences in the incidence of SSI and DWH between bDMARDs users and non-users. [Conclusion] In our institution, average 36% of patients who underwent elective orthopaedic surgeries have been treated with bDMARDs at the time of the surgery after 2013. With adequate perioperative discontinuation, the bDMARDs use was not associated with an increased risk of SSI or DWH.

ICW9-4 Safety and efficacy of bDMARDs therapy in RA patients with nontuberculous mycobacteria lung disease (NTM-LD): FIRST registry

Hiroaki Tanaka1, Kazuhisa Nakano1, Akio Kawabe1, Yusuke Miyazaki1, Satoshi Kubo1, Shunsuke Fukuyu1, Shigeru Iwata1, Shingo Nakayama1, Kazuyoshi Saito1, Yoshiya Tanaka1
1The Department of First Internal Medicine, University of Environmental and Occupational Health, Japan, 2The Department of Rheumatology, Tohoku University General Hospital

Conflict of interest: None

[Object] The aims of our study were to assess the safety and efficacy of bDMARDs therapy in RA patients with nontuberculous mycobacteria lung disease (NTM-LD): FIRST registry.
of bDMARDs in RA patients with NTM-LD. [Methods] 2076 RA patients were screened using CT-scan before starting their 1st bDMARDs treatment in our hospital from Apr 2005 to Apr 2018. NTM-LD were diagnosed by culture isolation and when PCR was positive but culture negative, NTM pulmonary colonization were diagnosed. After diagnosis, we consulted the department of respiratory medicine about management of NTM and started bDMARDs for NTM patients with high RA activity despite conventional therapy following IC. The primary endpoint was the proportion of NTM patients achieved LDA (DAS28-ESR<3.2). The secondary endpoint was continuation of bDMARD and the outcome of NTM-LD. [Results] We diagnosed 16 NTM-LD patients and 6 NTM pulmonary colonization patients during screening. Standard regimen (RFP, EB, CAM) was started for 12 patients, macrolides monotherapy for 2 patients and follow-up for 8 patients before starting bDMARDs (ABT 15, ETN 6, TCZ 1). NTM patients were significantly aged (67 vs 60 year old, p=0.027) and had long disease duration (141 vs 86 months, p=0.026), advanced Steinbrocker stage (p=0.020), while DAS28-ESR was equal between 2 groups (5.66 vs 5.68, p=0.96). 68% of NTM patients achieved LDA and 77% continued bDMARDs at 1 yr after starting bDMARDs. In 3 NTM patients bDMARDs were discontinued due to adverse event (AE) (LPD, scabies, death unrelated to NTM). Only in one patient who discontinued ETN due to AE, NTM-LD worsened and MFLX was added continuing ABT. [Conclusion] CT-Screening before starting bDMARDs was useful to detect NTM-LD. Adequate diagnosis and management for NTM-LD could enable disease control of RA with bDMARDs.

ICW9-5 Cytomegalovirus reactivation during immunosuppressive therapy for rheumatic disease
Kensuke Suga, Aya Nishiwaki, Yosuke Toda, Yoko Yabe, Takayuki Nakamura, Daisuke Kashiwakuma, Shin-ichiro Kagami
Research Center for Allergy and Clinical Immunology, Asahi General Hospital, Chiba, Japan

Conflict of interest: None

[Object] Cytomegalovirus (CMV) reactivation is a life-threatening complication in immunosuppressive therapy. However, risk factors and treatment strategy for CMV reactivation among rheumatic disease are largely unknown. The aim of this study is to investigate risk factors for CMV reactivation and to propose a strategy for managing CMV reactivation in patients receiving immunosuppressive therapy. The primary endpoint was the incidence of CMV reactivation disease. [Methods] We retrospectively analyzed 281 patients treated with immunosuppressive therapy in our department from January 2012 to April 2018. CMV reactivation was defined as positive > 1 CMV-positive cell per two slides (CMV pp65 antigenemia C10/C11). Patients with CMV reactivation were divided into two groups based on the presence of antiviral treatment for clinical symptoms. We determined a cut-off value of CMV-positive cells for the diagnosis of clinical CMV disease. [Results] The mean age was 61.0 ± 16.2 years and 194 (67%) were female. CMV reactivation was observed in 150 cases (53%), and thrombocytopenia was the most common clinical symptom (34 cases, 23%). In a multivariate analysis, CMV reactivation was associated with 4 following factors: lymphocyte counts <1000/μL (OR 3.56 [2.10-6.12], p=0.01); total dose of prednisolone (PSL) >2000mg (OR 1.89 [1.07-3.38], p=0.03); complication of interstitial pneumonia (OR 2.87 [1.68-4.98], p=0.01); combined use of immunosuppressants (OR 1.88 [1.10-3.22], p=0.02). The cut-off level of CMV pp65 antigenemia indicating clinical CMV reactivation was 10 positive cells per two slides by using receiver operating characteristic curve analysis (AUC 0.96, sensitivity 0.90, specificity 0.88). [Conclusions] Lymphocytopenia, total dose of PSL, complication of interstitial pneumonia and combined use of immunosuppressants are risk factors of CMV reactivation. We recommend that CMV pp65 antigenemia of >10 cells per two slides (C10/C11) in patients with rheumatic disease should be treated with antiviral drugs.

ICW9-6 The epidemiology and risk factors of severe herpes simplex virus infection in SLE patients: a nationwide study
Li Tzu-hao1,2, Lai Chien-chih1, Chang Yu-sheng1
1Division of Allergy, Immunology, and Rheumatology, Department of Medicine, Chiayi Branch, Taichung Veterans General Hospital, Taiwan, 2Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, Taiwan, 3Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan

Conflict of interest: None

[Object] Systemic lupus erythematosus (SLE) patients are susceptible to herpes simplex virus (HSV) infection, which is occasional but often leading to overwhelming disease such as encephalitis and keratitis. However, only few attempts have been made at the associated incidence and risk factors. [Methods] We enrolled SLE patients from the Taiwanese National Health Insurance research database between 1997 and 2012. We compared the incidence rate (IR) of severe HSV infection, including viral septicemia, meningoencephalitis, ocular infection, visceral infection and those with complications after infection, with those of non-SLE cohort. We also evaluated the risk factors of severe HSV infection by means of Cox multivariable proportional hazards model. [Results] A total of 122,520 subjects (24,504 SLE patients and 98,016 age- and gender-matched subjects as control group) were analyzed and revealed a significantly higher IR of severe HSV infection in SLE (Incidence rate ratio =3.52, p <0.001). Previous skin infection (HR=2.17, p=0.047), intravenous steroid pulse therapy (HR=4.48, p<0.001), oral daily steroid dose over 7.5mg prednisolone or equivalent (HR=1.60, p=0.010) were independent risk factors for severe HSV infection in SLE patients, while age under 18 (HR=0.47, p=0.021) was a protective factor. [Conclusions] A higher risk of severe HSV infection was observed in SLE patients. The risk factors for severe HSV infection were age over 18, previous skin infection, intravenous steroid pulse therapy and an oral daily steroid dose over 7.5mg.

ICW10-1 Automatic detection of hand joint region, ankylosis and subluxation in radiographic images using deep learning: development of artificial intelligence-based radiographic evaluation system for bone destruction
Keisuke Izumi1,2, Masahiro Hashimoto3,4, Kanata Suzuki1,2, Toshiro Endo3,5, Kentaro Doi3,5, Yuki Iwai5, Jun Inamo1, Yuichiro Ota1, Nobuhiko Kajo1, Jun Kikuchi1, Komei Sakata1, Satoshi Takashani1, Chihiro Takahashi1, Hiroshi Takei1, Hiroya Tama1, Kazuoto Hiramoto1, Yuko Kaneko1, Tetsuomi Takeuchi1
1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 2Division of Connective Tissue Diseases, National Hospital Organization Tokyo Medical Center, 3Medical AI Center, Keio University School of Medicine, 4Department of Radiology, Keio University School of Medicine, 5Fujitsu Laboratories Ltd., 6Fujitsu Ltd.

Conflict of interest: Yes

[Object] Artificial intelligence (AI) techniques including deep learning have been rapidly evolving and have yielded appreciable benefits in many fields in recent years. In rheumatology field, however, these techniques have not been used often. In an early phase of development of an AI-based automatic radiographic evaluating system for bone destruction, we aimed to develop learning-based models to automatically detect hand joint region, ankylosis and subluxation in radiographic images. [Methods] A total of 130 radiographic image sets of both hands were randomly obtained from rheumatoid arthritis patients who had visited our division at Keio University Hospital in 2015. Well-trained rheumatologists determined the boundaries of regions of MP and PIP/IP joints and evaluated the presence of ankylosis and subluxation of each joint in radiographs. These evaluations of hand joints were performed using our developed annotation software tool. In learning phase, joint images were randomly divided into five sets for 5-fold cross validation. As deep learning models, we utilized Single Shot Multibox Detector (SSD) method with ensemble learning for detecting ankylosis and subluxation of MP and PIP/IP joint regions. [Results] Our model showed 100% detection rate of MP and PIP/IP joint regions. As a performance of detecting hand joint ankylosis and subluxation, our model presented precision values of 0.85 and 0.73, recall values of 0.94 and 0.79, and F-measure values of 0.90 and 0.76, respectively. [Conclusions] Deep learning-based models to automatically detect hand joint region, ankylosis and subluxation in radiographic images were developed with relatively small samples, which suggests that the
predictive performance may increase by collecting more training dataset. Next, we are elaborating a plan for a deep learning-based evaluating system for erosion and joint space narrowing.

ICW10-2
Enhanced resting-state functional connectivity of pain processing regions associated with insufficient response to biologics in inflammatory arthritis
Nobuya Abe, Yuichiro Fujieda, Kohei Karino, Michihito Kono, Masaru Kato, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Shinsuke Yasuda, Tatsuya Atsumi
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Conflict of interest: None

[Object] Resting-state functional magnetic resonance imaging (rs-fMRI) studies previously demonstrated abnormal functional connectivity of brain related to chronic pain. However, the association between therapeutic response and abnormal functional connectivity in patients with inflammatory arthritis is still unknown. This study aimed to investigate whether the abnormal functional connectivity could predict poor response to biologics therapy in patients with rheumatoid arthritis (RA) or axial spondyloarthritis (axSpA) using rs-fMRI. [Methods] RA/axSpA patients requiring biologics treatment, underwent rs-fMRI and a clinical evaluation at baseline and 3 months. Disease activity was assessed by simplified disease activity index (SDAI) for RA and the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axSpA. Therapeutic insufficiency was defined as non-fulfillment of SDAI/ASDAS response criteria at 3 months. The network-to-whole brain connectivity were analyzed to evaluate the correlation between the functional connectivity of each network and clinical remission at 3 months. Results were significant on the cluster level with a false discovery rate corrected p-value (p-FDR) less than 0.05. [Results] Sixteen patients (11 RA, 5 axSpA, median age 60 years, 77.8% women, biologics naïve 77.2%) were analyzed. SDAI for RA and ASDAS for axSpA at baseline were 15.0 [6.15-21.8] and 2.31 [1.27-3.16], respectively. 18 biologic treatments included tumor necrosis factor α inhibitors (44%), and 11 patients (68.8%) achieved remission at 3 months. The rs-fMRI analyses revealed that the therapeutic insufficiency correlated with the left post-central gyrus connectivity to the left temporal pole (r = 0.49, p-FDR = 0.012). [Conclusion] RA/axSpA patients with persistent disease activity despite biologics therapy would share neurobiologic features of the enhanced association between left post-central gyrus and temporal pole, being potential biomarkers for therapeutic response.

ICW10-3
Lung consolidation and mediastinal lymphadenopathy in patients with early anti-citrullinated protein antibody-positive rheumatoid arthritis
Yushiro Endo, Tomohiro Koga, Shin-ya Kawashiri, Naoki Iwamoto, Kunihito Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Origuchi, Atsushi Oku
Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Conflict of interest: None

[Object] Because pulmonary disorder may influence a patient’s choice of treatments, it is important for clinicians to determine factors related to pulmonary involvement in rheumatoid arthritis (RA) patients. A previous report showed that patients with early anti-citrullinated protein antibody (ACPA) positive RA have a higher frequency of lung abnormalities than patients with early RA who are ACPA-negative; however, few reports show associations between lung lesions and ACPA-positive RA. We aimed to determine lung field characteristics associated with patients with early RA and ACPA-posivity. [Methods] We enrolled early RA 74 patients between 2014 and 2017 at our institution. All patients underwent power Doppler joint ultrasound and chest computed tomography (CT) within a few months of their first visits to our department. CT findings were blindly reviewed by two experienced thoracic radiologists who achieved good consensus. We compared clinical profiles, including CT findings, between patients with early RA who were ACPA-negative and ACPA-positive. [Results] CT showed no significant differences in airway lesions. The ACPA-positive group had more findings of consolidation and mediastinal lymphadenopathy than the ACPA-negative group. Mutivariate analyses showed that ACPA-posivity was an independent factor predicting consolidation and mediastinal lymphadenopathy in early RA patients. Interestingly, percent consolidation and mediastinal lymphadenopathy were associated with high RA disease activity and smoking history for the ACPA-positive, but not -negative, RA group. [Conclusions] Lung consolidation and mediastinal lymphadenopathy were associated with ACPA production in early RA patients. Lung consolidation detected via CT may be associated with high disease activity in ACPA-positive patients with early RA.

ICW10-4
Impact of Biological Treatment on Left Ventricular Regional Dysfunction in Rheumatoid Arthritis Patients Determined with Global Circumferential and Longitudinal Strain Values using Cardiac Magnetic Resonance Imaging
Isamu Yokose1,2, Hitomi Haroaka2, Atsuma Nishiwaki1,2, Yosuke Nagasawa2, Kaita Sugiyama2, Yutaka Tanikawa2, Masashi Oshima2, Marina Hamaguchi2, Hiroshi Tsuzuki2, Natsumi Ikumi3, Takamasa Nozaki2, Hiromi Karasawa3, Takako Shimizu4, Mitsuhiro Iwata5, Nozomi Kitamura5, Masami Takei6
1Department of Rheumatology and Internal Medicine, Kyoudo Hospital, Saseki Institute, Tokyo, Japan, 2Division of Hematology and Rheumatology, Ninoh University School of Medicine, Tokyo, Japan

Conflict of interest: None

[Object] Congestive heart failure (CHF) is a major contributor to morbidity and mortality in patients with rheumatoid arthritis (RA). However, myocardial disease is typically clinically silent. Feature-tracking (FT) cardiac magnetic resonance (CMR) imaging can be used to assess early left ventricular (LV) dysfunction. This study aimed to assess LV regional function in RA patients and to determine the impact of biological treatment using global circumferential and longitudinal strain values, assessed by FT-CMR. [Methods] RA patients and controls without cardiac symptoms were enrolled, and those with no history and/or clinical findings of cardiovascular disease underwent non-contrast CMR. Patients with RA were administered synthetic disease-modifying antirheumatic drugs (sDMARDs) or biologic DMARDs (bDMARDs). All subjects underwent evaluation of LV regional function, as measured by CMR. LV global longitudinal peak systolic strain (GLS) and global circumferential peak systolic strain (GCS) were calculated in the 16 LV segments. [Results] We compared 100 RA patients with 30 healthy controls. No statistically significant differences in cardiovascular risk (CV) factors were observed in the characteristics. GCS was significantly lower by 17% in the sDMARD group than in the bDMARD group (p<0.001). GCS in the RA group was associated with the Disease Activity Score (DAS28). GLS in the RA group was significantly reduced by 15% compared to the control group (p<0.05). GLS was lower by 16% in the sDMARD group than in the bDMARD group. [Conclusions] This prospective study assessed LV regional dysfunction in RA, using global circumferential and longitudinal strain values on CMR. Subclinical LV regional dysfunction of GCS and GLS was prominent in RA patients without cardiac symptoms. Biologic treatment may normalize LV regional dysfunction, associated with a reduction in disease activity.

ICW10-5
Detection of left ventricular regional function in primary Sjögren’s syndrome patients without cardiac symptoms, as assessed by feature tracking cardiac magnetic resonance imaging
Division of Hematology and Rheumatology, Ninoh University School of Medicine, Tokyo, Japan

Conflict of interest: None

[Object] Early left ventricular (LV) dysfunction is a major contributor to morbidity and mortality in primary Sjögren’s syndrome (pSS) patients. However, there is no consensus on the optimal CMR imaging modality for the diagnosis of LV systolic dysfunction (LVD) in pSS. This study aimed to investigate the utility of feature-tracking (FT) cardiac magnetic resonance (CMR) imaging in the assessment of LV regional function in pSS patients. [Methods] Fifty pSS patients without cardiac symptoms, as assessed by feature tracking CMR, underwent non-contrast CMR. Patients were blindly reviewed by two experienced thoracic radiologists who achieved good consensus. We compared clinical profiles, including CT findings, between patients with pSS and without pSS. CT findings were blindly reviewed by two experienced thoracic radiologists who achieved good consensus. We compared clinical profiles, including CT findings, between patients with pSS and without pSS.

Results
We compared 100 RA patients with 30 healthy controls. No statistically significant differences in cardiovascular risk (CV) factors were observed in the characteristics. GCS was significantly lower by 17% in the sDMARD group than in the bDMARD group (p<0.001). GCS in the RA group was associated with the Disease Activity Score (DAS28). GLS in the RA group was significantly reduced by 15% compared to the control group (p<0.05). GLS was lower by 16% in the sDMARD group than in the bDMARD group. [Conclusions] This prospective study assessed LV regional dysfunction in RA, using global circumferential and longitudinal strain values on CMR. Subclinical LV regional dysfunction of GCS and GLS was prominent in RA patients without cardiac symptoms. Biologic treatment may normalize LV regional dysfunction, associated with a reduction in disease activity.
[Object] The risk of major cardiovascular (CV) events and the long-term CV outcome in patients with primary Sjögren’s syndrome (pSS) remain unclear. Feature-tracking (FT) cardiac magnetic resonance (CMR) imaging can reliably be used to assess myocardial function in patients with early dysfunction. Left ventricular (LV) global longitudinal peak systolic strain (GLS) is a diagnostic of adverse cardiovascular outcomes. Global circumferential peak systolic strain (GCS) is a predictor of congestive heart failure. We sought to measure GLS and GCS using FT-CMR in pSS patients without cardiac symptoms. [Methods] PSS patients and controls without cardiac symptoms were enrolled. Patients and controls with no history and/or clinical findings of cardiovascular disease, hypertension, diabetes mellitus, or dyslipidemia underwent non-contrast CMR. The Sjögren’s syndrome disease activity index (ESSDAI) was determined. [Results] We compared 50 patients with pSS (100% women; age, 53±10 years) with 20 healthy controls (100% women; age, 54±9 years). GCS was significantly reduced in the pSS group compared with that in controls (p=0.008). A total of 11 patients (22%) had Raynaud’s phenomenon (RP). The mean ESSDAI total score was 5.46±6.21. The GCS in the RP positive group and the ESSDAI total score≧8 group decreased more than that in the RP negative group and the ESSDAI total score<8 group (p<0.009, p=0.026, respectively). Receiver operating characteristic curve analysis showed that GCS reliably detected RP and ESSDAI total score≧8 (area under the curve, 0.75 and 0.71, respectively). GLS was significantly reduced in the pSS group compared with that in controls (p=0.015). GLS in the pSS group was not associated with CV risk factors or pSS status such as RP or ESSDAI. [Conclusions] To our knowledge, this is the first prospective study of LV regional dysfunction in pSS and the only study to explore the associations of pSS characteristics with CMR-assessed GCS and GLS.

ICW10-6

The relationship between the hallux valgus angle and the dorsal dislocation of the second metatarsus analyzed through CT scans in Rheumatoid Arthritis patients

Takeomi Nakamura1, Mitsuyasu Iwasawa1, Kota Shimomura1,2, Satoru Ohashi1, Hiroki Takamure1, Tetsuro Yasui2, Takumi Matsumoto4

1Department of Orthopedics and Rheumatology, Sagamihara National Hospital, 2Department of Orthopedics, Sapporo Medical University, 4Department of Orthopedics, Teikyo University Mizonokuchi Hospital, 3Department of Orthopedics, The University of Tokyo

Conflict of interest: None

[Objective] There is still some uncertainty regarding the relationship between the hallux valgus (HV) and the dorsal dislocation of the 2nd metatarsus in patients with Rheumatoid Arthritis (RA). Our objective was to elucidate whether there is a significant difference in the pattern of deformity in patients with spread foot as opposed to those without. [Methods] Evaluation included 98 feet of 78 patients - 4 male and 74 female with HV and dislocation of the 2nd metatarsus, averaging 65 years of age. The mean duration of their RA symptoms was 22 years. The Hallux valgus angle (HVA), the 1st-2nd intermetatarsal angle (M1M2), and the 1st-5th intermetatarsal angle (M1M5) were measured on X-rays. The distance between the distal head of the metatarsus and the proximal joint line perpendicular to the axis of the metatarsus were also measured using CT scans in the sagittal plane. It was hypothesized that feet with plasticity had a higher instance of becoming spread foot. The patients were divided into two groups; the 1st where M1M5 was <30° (23 feet), and the 2nd where M1M5 was≧30° (73 feet). The groups were compared using the Pearson Correlation Coefficient (r) of the HVA and the M1M2, and of the HVA and the severity of the dislocation. [Results] Non-spread foot group averages: HVA = 41°, M1M2 = 11°, M1M5 = 25°, Dislocation = 13.5mm. Spread foot group averages: HVA = 48°, M1M2 = 15°, M1M5 = 37°, Dislocation = 14.4mm. The non-spread foot group presented a clear correlation between HVA and M1M2, and HVA and dislocation. (r = 0.564 and 0.627 respectively). For the spread foot group, r = 0.232 for HVA and M1M2, and 0.284 for HVA and dislocation. [Conclusions] Our study suggested that HV-deformity might influence the dislocation of the 2nd metatarsus in non-spread foot RA patients, perhaps relating to the lack of plasticity of soft tissue. The procedures to correct footwear deformities in RA patients with lack of plasticity might be challenging due to a possible increase in dislocations.

ICW11-1

Dysfunction of Trim21 promotes aberrant B cell differentiation in systemic lupus erythematosus

Yosuke Kunishita1, Ryusuke Yoshimi1, Reikou Kamiyama1, Daiga Kishimoto1, Takaaki Komiya1, Yumiko Sugiyama1, Yohei Kirino1, Hideaki Nakajima1

1Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 2Rheumatic Diseases Center, Yokohama City University Medical Center

Conflict of interest: None

[Background/Purpose] TRIM21 is a member of the tripartite motif family proteins and is one of the autoantigens which react with anti-SS-A antibody (Ab) seen in sera of patients with systemic lupus erythematosus (SLE) and Sjögren’s syndrome. TRIM21 has been shown to be involved in cell proliferation and apoptosis in a B-cell line. Here we examined the pathological role of TRIM21 in SLE using Trim21-deficient lupus model mice and B cells from SLE patients. [Methods] Trim21-deficient MRL/lpr mice were generated by backcrossing Trim21-deficient C57BL/6 mice to MRL/lpr mice. Urine albumin/creatinine ratio was measured as the urine protein level. Anti-dsDNA and anti-TRIM21 Abs were measured by enzyme-linked immunosorbent assay. CD43-negative resting B cells were isolated from mouse spleens or peripheral blood of SLE patients by magnetic-activated cell sorting and stimulated with several Toll-like receptor (TLR) ligands. The abilities to differentiate into plasmablasts and to produce Ab were examined by flow cytometry and cytomter head array, respectively. [Results] The levels of urine protein and serum anti-dsDNA Ab at 28 weeks of age were significantly higher in Trim21-deficient MRL/lpr mice as compared to wild-type MRL/lpr mice. When we stimulated resting B cells from these mice with TLR ligands for 24 hours, B cells from Trim21-deficient MRL/lpr mice showed significantly higher abilities to differentiate into plasmablasts and to produce Ab as compared to wild-type MRL/lpr mice. B cells from SLE patients with seropositivity of anti-TRIM21 Ab also indicated significantly higher ability to differentiate into plasmablasts and to produce Ab as compared with SLE patients with seronegativity of anti-TRIM21 Ab or healthy controls. [Conclusion] TRIM21 dysfunction promotes aberrant B cell differentiation and Ab production in SLE. Anti-TRIM21 Ab may be related to the TRIM21 dysfunction.

ICW11-2

Imbalance between Th1 and Th1-Treg-like cells depends on differential regulation of cell metabolism in patients with SLE

Shigeru Iwata, Mingling Zhang, Maiko Hajime, Naoaki Ohkubo, Hiroki Miyata, Yasuyuki Todoroki, Shingo Nakayamada, Yoshia Tanaka

The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan

Conflict of interest: None

[Objective] Th1 cells play an important role in SLE. Recently, “immunometabolism” attract much attention. In this study, we examined the involvement of immunometabolism in Th1 cells and its relevance to SLE. [Methods] PBMCs were obtained from healthy controls (HCs) and patients with SLE and analyzed by FACS. In addition, the importance of metabolic change in Th1 cells were assessed in vitro. [Results] Activated effector memory CD4 T-bet+ cells in patients with SLE were higher than HCs. The CD4 T-bet+ cells showed strong IFN-γ production. mTORC1 is well known as an inducer of aerobic glycolysis. The CD4 T-bet+ cells highly expressed p-mTORC1 and was closely related to treatment-resistance in SLE. Therefore, we would examine the effect of mTORC1 inhibitor Rapamycin (Rapa) or glycolysis inhibitor 2DG to such memory mTORC1 T-bet+ IFNy+ CD4+ cells in vitro. When CD45RA-CD4+ T cells were isolated from peripheral blood of HCs and stimulated with anti-CD3/CD28 Abs, T-bet expression and IFN-γ production as well as p-mTOC1 expression and aerobic glycolysis were induced. Interestingly, 2DG, but not Rapa, suppressed IFN-γ production and enhanced IL-2 production. Therefore, we hypothesized that 2DG induce Th1-Treg cells as one of Treg cell subsets. As predicted, 2DG induced FoxP3+T-bet IFN-γ
The University of Tokyo, Tokyo, Japan

CD45RA-CD27- double negative an important role in the differentiation from IgD-CD27- memory B cell from patients with SLE

First Department of Internal Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, 2Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Oita University, Oita, 3Mitsubishi Tanabe Pharma, Yokohama, Japan

ICW11-4

Activation of caspase-1 in CD16-positive monocyte and correlation with disease activity in systemic lupus erythematosus

Shoiacho Inokuchi1, Hiroki Mitoma1, Shioto Kawano2, Masahiro Ayano1, Yasutaka Kimoto1, Mitsuteru Akahoshi1, Yojiro Arinobu1, Koichi Akashi1, Takahiko Horii1, Hiroaki Niiro1

1Department of Clinical Immunology and Rheumatology/Infectious Disease, Kyushu University, Fukuoka, Japan, 2Department of Occupational & Environmental Health, Japan, Kitakyushu, 3Department of Internal Medicine, Kyushu University, Kitakyushu, Japan

Conflict of interest: None

[Object] Inflammatory processes such as activation of caspase-1 (Casp1) and myeloid cells like macrophages are important for the development of lupus nephritis. This study aimed to clarify activated Casp1 in each cell subset in peripheral blood cells at single-cell level and to identify the relation between inflammasome activation and clinical features.

Methods Active Casp1 in peripheral monocytes and neutrophils at steady state from SLE, the other autoimmune disease and healthy controls were evaluated by multicolor flow cytometry. The relation between clinical feature and activated Casp1 was analyzed. Results In vitro SLE, activated casp1 was upregulated in monocytes and significantly negatively correlated with serum complement C3 and CH50. A trend of positive correlation between activated Casp1 in monocytes and anti-dsDNA antibody levels was also identified. Activated Casp1 was preferentially expressed in CD16-positive (CD16+) monocytes. While activated Casp1 in neutrophils was downregulated in each disease, any correlation between activated Casp1 in neutrophils and clinical features weren’t detected. Successful treatment of SLE normalized activated Casp1 in monocytes. [Conclusions] In SLE, CD16+ monocytes express higher activated casp1 compared to healthy controls, and correlation between activated casp1 and disease activity was identified. Targeting inflammasome may be one of the therapeutic strategies of SLE.

ICW11-5

The involvement of mitochondrial activation via glutaminolysis in human B cell differentiation and its relevance to the pathogenesis of SLE

Maiko Hajime1, Shigeru Iwata1, Hiroko Miyata1, Mingzeng Zhang1, Masataka Torigoe2, Shingo Nakayama1, Kei Sakata1, Yoshiya Tanaka1

1First Department of Internal Medicine, University of Occupational & Environmental Health, Japan, Kitakyushu, 2Department of Endocrinology, Metabolism, Rheumatology and Nephrology, Oita University, Oita

Conflict of interest: None

[Object] B cells play a crucial role in SLE. Recently, “Immunometabolism” attract much attention. In this study, we examined the role of mitochondrial function and glutaminolysis in B cell differentiation and its relevance to SLE. Methods Peripheral blood mononuclear cells were obtained from healthy controls (HCs) and patients with SLE and assessed by FACS. In addition, CD19+ cells were isolated from HCs and change of mitochondrial function and glutaminolysis were assessed in the absence of glucose or glutamine, by metformin in vitro. Results) Initially, mitochondrial function in B cells from patients with SLE was assessed using DiO6 which is a marker of depolarization-activated mitochondrial membrane. CD24+DiO6- cells in IgD+CD27- memory B cell from patients with SLE were significantly higher than those of HCs. Next, we assessed the role of mitochondrial function and glutaminolysis in human B cell differentiation in vitro. Stimulation with CpG (TLR9 ligand) and IFN-α, 1 increased the area of cytoplasm including many expanded mitochondrial cristae with slightly wider and loosely organized intermembrane space in electric microscopy, accompanied with ROS production and DiO6 up-regulation, 2 induced CD27+CD38+ plasmablasts differentiation and immunoglobulin production. Interestingly, ROS production and DiO6 expression were significantly decreased in the absence of glucose, leading to inhibition of plasmablasts differentiation and immunoglobulin production. This tendency was not shown in the absence of glucose. Metformin, which is known as AMPK activator, abrogated glutamine uptake, resulting in suppression of ROS production, DiO6 expression, plasmablast differentiation and immunoglobulin production. Conclusion) These results suggest that mitochondrial activation via glutaminolysis may play an important role in the differentiation from IgD+CD27+ double negative B cells to plasmablasts and production of immunoglobulins in patients with SLE.
B cells play an important role in SLE. Recently, “Immunometabolism” attract much attention. In this study, we examined the involvement of essential amino acids in human B cell differentiation and its relevance to the pathogenesis of SLE. We examined the role of essential amino acids for human B cell differentiation in vitro. PBMCs were obtained from healthy controls (HCs) and SLE, and analyzed by FACScan. Combined stimulation with BCR, CpG (TLR9 ligand) and IFN-α induced uptake of essential amino acids and plasmablast differentiation, which were more strongly abrogated in the absence of methionine than leucine. Next, we examined the mechanism by which essential amino acids regulate intracellular signaling pathway in B cells. Combined stimulation-induced activation of BCR signal and Akt-mTORC1 pathway. As predicted, Akt-mTORC1 pathway was inhibited in the absence of both methionine or leucine. Meanwhile, BCR signal was abrogated in the absence of methionine, but not leucine. Combined stimulation suppressed BACH2 expression, whereas induced PRDM1 and XBP1 expression. EZH2 is well known as a transcriptional factor regulating histone modification. We found that EZH2 bind to the promoter region of BACH2 and induced H3K27me3, resulting in inhibition of BACH expression. EZH2 expression were abrogated in the absence of methionine. EZH2 inhibitors recovered BACH2 expression and abrogated plasmablast differentiation. Finally, we assessed the expression amino acid transporter CD98/LAT1 and EZH2 in B cells from patient sample. CD98 and EZH2, but not LAT1, in B cells from patients with SLE were highly expressed than those of HCs. EZH2 expression were correlated with CD98 expression in B cells from patients with SLE. These results indicate that essential amino acids methionine play an important role in human B cell differentiation via CD98/BCR/mTORC1-EZH2-BACH2 pathway. Methionine and their signaling pathway might be a potential therapeutic target for SLE.

ICW12-1
The relevance of B cell phenotypic changes to clinical efficacy in patients with SLE-LOOPS registry
Hiroko Yoshinari, Satoshi Kubo, Shingo Nakayamada, Kazuhisa Nakano, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Ippei Miyagawa, Yusuke Yoneda, Yusuke Inoue, Yoshiya Tanaka, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan

Conflict of interest: None

[Object] Belimumab (BLM), a human monoclonal antibody neutralizing BAFF, has been approved for SLE treatment. We investigated the clinical efficacy and changes of peripheral immunophenotype by BLM.
[Methods] 11 of inactive SLE patients treated with BEL in order to reduce glucocorticoid (GC) dose were enrolled. Primary outcome was dose of GC (PSL equivalents) at 6 months (6M) after treatment with BLM. Peripheral immunophenotypes were evaluated by multicolour flow cytometry. [Results] At baseline, mean age was 37.0 years old, SLEDAI was 4.2, and dose of PSL was 7.4 mg, respectively. Compared to healthy donor, proportion of class switched memory and IgD-CD27- B cell were increased in spite of inactive SLE. After 6M, SLE activity (SLEDAI 1.8) and dose of GC (PSL 4.6 mg) were significantly decreased and there was no incidence of flare. Regarding immune cell phenotypes, proportions of other immune cell subsets didn’t change. However, proportion of Naïve B cell (50.6–24.2%) was notably decreased and that of class switched memory (26.8–44.1%) and DN B cell (10.5–12.1%) were relatively increased compared to baseline. Actual peripheral number of naïve B cell was remarkably decreased by 72%, while that of class switched and DN B cell were not change. This change wasn’t observed in SLE patients treated without BLM (adjusted age, sex, SLEDAI and dose of PSL). Moreover, the baseline proportion of naïve B cell was negatively correlated with dose of PSL at 6M after treatment with BLM. [Conclusion] BLM could further reduce dose of GC without flare. Apoptosis of auto-reactive B cells and inhibition of Ig-class switch and Plasmablast (PB) differentiation is considered as the mechanism of BLM. We also suggested that BAFF signal itself was important for naïve B cell survival in vivo. Although it’s not clear whether this action regulates the pathogenesis of SLE, memory B cell and PB differentiation might be suppressed by decrease of its source as a long term effect.

ICW12-2
Study on the safety and effectiveness of hydroxychloroquine in patients with systemic lupus erythematosus
Ippei Miyagawa, Kazuhisa Nakano, Shingo Nakayamada, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Yusuke Miyazaki, Akio Kawabe, Yusho Inoue, Masanobu Ueno, Yoshiya Tanaka, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan

Conflict of interest: None

[Object] The effectiveness and safety of hydroxychloroquine (HCQ) have not fully been validated in Japanese patients with SLE. [Methods] The primary endpoint was the retention rate up to 1 year in 136 patients with SLE. The secondary endpoints were the changes of SLEDAI, BILAG index and concomitant corticosteroid (CS) dose (mg/day. PSL equivalent) in the remission induction therapy (n=36). CS based maintenance therapy (n=52) and HCQ monotherapy (n=48). [Results] The retention rate as primary endpoint was 80.9%. In the remission induction therapy, SLEDAI, BILAG index and concomitant CS dose were significantly decreased from 12.9±9.2 to 4.67±6.83, 14.8±10.5 to 4.78±8.39 and 55.8±14.4 to 16.0±20.3, respectively. In the maintenance therapy, SLEDAI and BILAG index were significantly decreased from 4.65±4.6 to 2.94±4.52 and 2.52±5.99 to 1.79±4.94. In the HCQ monotherapy, SLEDAI and BILAG index were significantly decreased from 4.63±3.64 to 2.81±3.60 and 3.15±3.52 to 2.09±3.08. Moreover, exacerbation rate based on the SLEDAI and BILAG was compared between the 1 year before and after induction of HCQ in 76 patients whose clinical course in both 1 year before and after induction of HCQ can be evaluated. Although the reduction rate of concomitant CS was significantly higher during 1 year after induction of HCQ, the disease exacerbation rate based on the SLEDAI and BILAG were significantly lower during 1 year after induction of HCQ. [Conclusions] HCQ, which makes it possible to reduce the concomitant CS and to suppress the exacerbation, can be the mainstream in Japanese patients with SLE.

ICW12-3
Is it important to maintain the high serum trough level in the treatment with tacrolimus for systemic lupus erythematosus?
Takaaki Komiya1, Yosuke Kunishita1, Ryusuke Yoshimi1, Yuki Iizuka1, Chiharu Hidekawa1, Masaki Mitsushashi1, Natsuki Sakurai1, Hitodo Nagai1, Naoki Hamada2, Yutaro Soejima1, Naomi Tsuchida1, Daiga Kishimoto1, Reikou Kamiyama1, Yohei Kirino1, Shigeru Ohno2, Hideaki Nakajima1
1Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 2Center for Rheumatic Diseases, Yokohama City University Medical Center

Conflict of interest: None

[Object] We have previously reported the relationship between the efficacy and serum trough level of tacrolimus (TAC) in patients with systemic lupus erythematosus (SLE) by the retrospective study. Here we prospectively measured the trough level after a year from the entry of the previous study and examined the disease activity to evaluate the significance of maintaining the trough level of TAC. [Methods] SLE patients who visited our hospital from April 2016 to September 2018 were included in the study. We collected the demographic and clinical parameters at baseline (October, 2017) and at one year (October 2018). We compare the change of SLE disease activity index (SLEDAI) and dose reduction of prednisolone between the patients who maintained high trough levels (≥ 5 ng/ml) and those who kept low trough levels (≤ 5 ng/ml). [Results] Among forty-nine patients who received TAC, 13 patients maintained the high trough level throughout the year (HT group) and 14 kept the low trough level (LT group). HT group maintained the low disease activity throughout the year, and there was no significant difference between SLEDAI at baseline and at one year (3.2 ± 2.7 vs 2.5 ± 4.3, p = 0.60). Interestingly, SLEDAI in LT group showed the tendency of decrease during
HCQ was 72% at one year. [Conclusions] HCQ was effective for skin involvement and arthritis were improved in eight cases (42%) and five nephritis in 12 cases (28%) during their whole SLE course. Anti-Ro/SSA cases (65%), hematological abnormalities in 28 cases (65%), and lupus years. Skin involvement was developed in 30 cases (70%), arthritis in 28 cases of SLE were treated with HCQ. Thirty-seven cases (86%) were female with a mean age of 39.4 years. The mean disease duration was 10.7 years. Skin involvement was developed in 30 cases (70%), arthritis in 28 cases (65%), hematological abnormalities in 28 cases (65%), and lupus nephritis in 12 cases (28%) during their whole SLE course. Anti-Ro/SSA antibody was positive in 18 cases. 2) HCQ was used to treat skin involvement in 19 cases (44%), arthritis in 14 cases (33%), hematologic abnormalities in nine cases (21%), lupus nephritis in four cases (9%). 3) Skin involvement and arthritis were improved in eight cases (42%) and five cases (36%) respectively at one year. Titers of anti-DNA antibodies were significantly decreased from 27.6±10.3 to 11.0±2.0. 4) Fourteen cases (33%) experienced adverse events and of these six cases (43%) were drug-induced cutaneous adverse reactions, three cases (21%) diarrhea. Retinal toxicity was not observed. The cumulative continuation rate of HCQ was 72% at one year. [Conclusions] HCQ was effective for skin involvement and arthritis in SLE. The most common adverse event was cutaneous adverse reaction and it was likely that anti-Ro/SSA antibody was a risk factor of HCQ-induced cutaneous skin reaction.

**ICW12-6** Do HCQ and MMF improve treatment outcome in patients with SLE? –from LOOPS registry–

Naoaki Ohkubo, Kazuhisa Nakano, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Ippei Miyagawa, Akio Yamaguchi, Akio Kawabe, Yasuke Miyaizaki, Shingo Nakayama, Yoshiya Tanaka

**Object** To clarify efficacy and safety of HCQ used for SLE patients in clinical practice. [Methods] Cases of SLE treated with HCQ in University of Tsukuba hospital between September 2015 and September 2017 were identified from electrical medical charts. We retrospectively analyzed their 1) baseline characteristics, 2) target lesions, 3) efficacy of drug-induced cutaneous adverse reactions. [Results] 1) Forty-three cases of SLE were treated with HCQ. Thirty-seven cases (86%) were female with a mean age of 39.4 years. The mean disease duration was 10.7 years. Skin involvement was developed in 30 cases (70%), arthritis in 28 cases (65%), hematological abnormalities in 28 cases (65%), and lupus nephritis in 12 cases (28%) during their whole SLE course. Anti-Ro/SSA antibody was positive in 18 cases. 2) HCQ was used to treat skin involvement in 19 cases (44%), arthritis in 14 cases (33%), hematologic abnormalities in nine cases (21%), lupus nephritis in four cases (9%). 3) Skin involvement and arthritis were improved in eight cases (42%) and five cases (36%) respectively at one year. Titers of anti-DNA antibodies were significantly decreased from 27.6±10.3 to 11.0±2.0. 4) Fourteen cases (33%) experienced adverse events and of these six cases (43%) were drug-induced cutaneous adverse reactions, three cases (21%) diarrhea. Retinal toxicity was not observed. The cumulative continuation rate of HCQ was 72% at one year. [Conclusions] HCQ was effective for skin involvement and arthritis in SLE. The most common adverse event was cutaneous adverse reaction and it was likely that anti-Ro/SSA antibody was a risk factor of HCQ-induced cutaneous skin reaction.

**ICW13-1** Complement C9 is highly expressed in synovial fluid of patients with ankylosing spondylitis

Ji-hyun Lee1, Chang-nam Son2, Sang-hyon Kim1, Hye-jin Jeong1, Jinnyeong Chae1, Jin-min Kim1, Min-soo Sul2, Seong-il Sul2, Won-ki Back2, Jin-seol Rhe3, Tae-hwan Kim3, Jae-hun Jung3, Jong-seo Kim4

1Division of Rheumatology, Department of Internal Medicine, School of Medicine, Keimyung University, Daegu, Korea, 2Department of Microbiology, School of Medicine, Keimyung University, Daegu, Korea, 3Department of Research Affairs, Keimyung University Dongsan Medical Center, Daegu, Korea, 4Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, 5Department of Applied Chemistry, Institute of Natural Science, Global Center for Pharmaceutical Ingredient Materials, Kyung Hee University, Yongin, Korea, 4Center for RNA Research, Institute of Basic Science (IBS), Seoul, Korea

Conflict of interest: None

[Object] Our aim was to identify differentially expressed protein mediators in synovial fluid (SF) of ankylosing spondylitis (AS). [Methods] A Total of 40 SF samples from 10 AS and each 10 controls [Osteoarthritis (OA), Rheumatoid Arthritis (RA), gouty arthritis (Gout)] were collected. Liquid chromatography and tandem mass spectrometry (LC-MS/MS), to identify differentially expressed proteins based on the ratios of the extracted ion current of each protein between the four groups. Among the 9 proteins showing 1.5 fold change, 8 were verified with the exception of the abundant protein Haptoglobin (HP). Matrix metalloproteinase-1 (MMP1) and Matrix metalloproteinase-3 (MMP3) were used as a positive control, and the remaining 6 proteins were subjected to western blot analysis. [Results] We identified 9 proteins that were found to be more than 1.5-fold differentially expressed in SF of AS patients compared to control groups. Proteins such as HP, MMP1, MMP3, Serum amyloid P-component (APCS), Complement factor H-related protein 5 (CFHR5), Fumarylacetatase (FAH), Mannose-binding lectin2 (MBL2), Complement component C9 (C9) and Complement C4-A (C4A) were found to be upregulated in the SF of AS patients. CFHR5 and C9 were reported in previous studies with AS serum. APCS was reported in SF as well as serum. However, FAH, C4A and MBL2 were newly discovered through this analysis. We were able to verify the unique expression level of C9 in AS sample using western blot analysis compared to the other three diseases. [Conclusions] We performed quantitatively proteomic profiling of the respective SF sample from 4 diseases, i.e., AS, OA, RA, and GOUT, by LC-MS/MS. The systematic comparative proteomic analysis of the four groups together was carried out for the first time, leading to several differentially expressed proteins in AS. Among them, we expect C9, which expression level was confirmed by western blot analysis and will be further validated by ELISA, can be a potential biomarker for AS.

**ICW13-2** Sec16A abnormalities impair antigen presentation and HLA-B27 mediated CDS T cell immune responses in axial spondyloarthritis

Fanning Zeng, Nakamura Akihiro, Haroon Nigil

University Health Network

Conflict of interest: None

[Object] HLA-B27 is the strongest genetic risk factor in axial spondyloarthritis (axSpA). A rare mutation of Sec16A was recently identified to be strongly associated HLA-B27 in the development of axSpA in a multiplex family. Sec16A plays an important role in intracellular transport and the assembly of cargo carrier vesicles. In this study, we explore
the functional impact of Sec16A abnormalities on ER-to-Golgi trafficking, HLA-B27 folding and transport, and CD8+ T cell mediated immune response. [Methods] B cell lines were generated from the multiplex family members by EBV transformation. For validation, Sec16A in B cell line (CIR-B27) and Hela cells was knocked out using CRISPR-Cas9. ER-to-Golgi transport efficiency and the assembly of intracellular transport vesicle (COPII) were evaluated. YFP-tagged HLA-B27 was used to investigate the effect of Sec16A abnormalities on HLA-B27 intracellular transport and surface expression. HLA-B27 mediated immune response was assessed by cytotoxic T-lymphocyte assay using HLA-B27 restricted peptide (NP383-391) specific CTL clones. In addition, Biold was carried out to investigate the protein-protein interaction (PPI) of Sec16A variants. [Results] Sec16A abnormalities hindered the assembly of COPII vesicles budding from the ER leading to abnormal intracellular trafficking. Using YFP-tagged HLA-B27, we found that Sec16A abnormalities delayed the intracellular transport of HLA-B27, accumulated HLA-B27 in intracellular vesicles, and impaired HLA-B27 antigen presentation. CTL cytotoxicity was significantly lower in cells with wild type Sec16A. In the PPI study, we found that Sec16A reduction decreased the affinity of Sec16A to its interactors involved in intracellular trafficking and antigen presentation. [Conclusions] Abnormalities of Sec16A may contribute to the pathogenesis of axSpA through an imbalance in HLA-B27 transport, folding, peptide binding, antigen presentation and abnormal T cell recognition.

ICW13-3
Incidence of malignancy in patients with ankylosing spondylitis with and without anti-TNF-alpha therapy: a cohort study in North Taiwan
Ming-han Chen1,2, Chang-youth Tsai1,2
1Division of Allergy-Immunology-Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan, 2Faculty of Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan

Conflict of interest: Yes

Objectives: The treatment with tumor necrosis factor-α inhibitors (TNFi) has been authorized for patients with ankylosing spondylitis (AS) for years. However, whether blockade of TNF-α enhances the risk of malignancy in AS patients is unknown. The object of this study is to determine the incidence of malignancy in AS patients with and without anti-TNF-α therapy. Methods: AS patients who visited our clinic with greater than 1-year follow-up from 2007 to 2017 were retrospectively reviewed. TNFi were prescribed in AS patients refractory to conventional therapies, defined as treatment with at least two different nonsteroidal anti-inflammatory drugs (NSAIDs) for at least 2 months. We compared rates of incident malignancy in AS patients with and without TNFi. Results: We identified 3019 cases and 2174 (72.0%) of them were male. Their mean age at the diagnosis of AS was 27.0 years old. Among them, 389 (12.9%) received TNFi treatment. Fifteen cancers were reported in 46,191 patient-years follow-up. The rates of incident malignancy were 0.62 events/1,000 person-years in the TNFi cohort and 0.28/1,000 person-years in the non-TNFi cohort. After adjustment for age and sex, there was no difference in the risk of malignancy in AS patients with TNFi compared to those without TNFi (Hazards ratio 1.071, 95% CI 0.318 to 3.599, p = 0.912). Conclusions: The incidence of cancer was not elevated during TNFi therapy compared to alternative therapy in this study, indicating that treatment with TNFi does not increase the risk of malignancy in AS patients.

ICW13-4
The clinical characteristics and treatment conditions of SAPHO syndrome: a single center study of a cohort of 50 cases
Naoki Kondo, Junichi Fujisawa, Naoto Endo
Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Conflict of interest: None

[Objective] SAPHO syndrome manifests as bone-joint involvement associated with palmoplantar pustulosis (PPP), pustulous psoriasis, and severe acne. The aims of this study were to clarify the clinical characteristics including diagnosis and to the treatment status for SAPHO syndrome. [Methods] Fifty consecutive patients (36 females and 14 males) who met the criteria for SAPHO syndrome proposed by Kahn were recruited from January 2015 to December 2017. The mean age was 58 years. The onset pattern, the interval between skin involvement and osteoarticular lesions, the distribution of osteoarticular lesions, and treatment status were examined. [Results] Fifty consecutive patients (36 females and 14 males) who met the criteria for SAPHO syndrome proposed by Kahn were recruited from January 2015 to December 2017. The mean age was 58 years. Sixty-five patients had osteoarticular symptoms without skin involvement. Sixty % of the patients had PPP and only 2 % of the patients had psoriasis vulgaris. The interval between skin involvement and osteoarticular lesions was 5.5 years on average (range: 5 to 29 years). The patients in which skin symptoms preceded was 42 % and the patients who had both symptoms simultaneously was 14 %. Sixty-six % of the patients suffered from pain in the anterior chest wall, followed by peripheral joints (22 %) and sacroiliac joint (18%). Rheumatoid factor was elevated 5 patients (10 %). Related to the treatment status, tonsillectomy was performed in 9 patients. Biopast was treated in 15 patients. Non-steroidal anti-inflammatory drugs was treated in 40 (80 %) patients. Conventionally synthetic disease modifying anti-rheumatic drugs (DMARDs) was treated in 11 (22 %) patients, followed by biological DMARDs (3 patients, 6 %). [Conclusion] The interval between skin and manifestation of osteoarticular lesions is generally long. Most cases were preceded by skin involvement. However, the attention must be paid for patients who osteoarticular lesions precede.

ICW13-5
Precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in patients with psoriatic arthritis
Ippei Miyagawa, Shingo Nakayamada, Satoshi Kubo, Kazuhiwa Nakano, Shigeru Iwata, Yusuke Miyazaki, Hiroko Yoshinari, Kentaro Hanami, Shunsuke Fukuyo, Akio Kawabe, Yoshiya Tanaka
The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan

Conflict of interest: None

[Objective] We previously presented the potential of the precision medicine using different biological DMARDs based on characteristic phenotypes of peripheral T helper cells in patients with psoriatic arthritis (PsA). Herein, we validated the usefulness of this strategy for a longer time period, with a greater number of patients. [Methods] Thirty-three patients with PsA underwent bDMARDs therapy selected based on phenotypic differences of peripheral helper T cells. The efficacies of this strategic bDMARDs treatment and the standard bDMARDs treatment administered to the other 38 patients were compared at month 12. [Results] The patients with PsA in the strategic treatment group were classified into the following 4 types based on the peripheral blood analysis: a CXCR3+CCR6+CD38+HLA-DR+ activatedTh1 cell-predominant type, CXCR3CCR6+CD38+HLA-DR+ activatedTh17 cell-predominant type, Th1/Th17-high type, and Th1/Th17-low type. In addition, SDAI was positively correlated with the proportion of activated Th17 cells and activated CD8+cells among activated Th17 cell-increased type. Accordingly, ustekinumab was administered to the activatedTh1 cell-predominant patients, secukinumab to the activatedTh17 cell-predominant patients, secukinumab or TNF inhibitor to the Th1/Th17-high patients, and TNF inhibitor to the Th1/Th17-low patients. At 12 months of treatment, PASI was significantly decreased in both group (standard: 9.2±12.7→3.6±6.9, strategic treatment: 6.6±8.7→1.3±2.7). SDAI were also significantly decreased at month 12 in both group (standard: 9.2±12.7→9.1±11.0, strategic: 17.7±10.2→3.9±4.0). The rate of low disease activity achievement according to SDAI at 12 months was significantly higher in the strategic bDMARDs treatment group compared with that of the standard bDMARDs treatment group (standard: 65.8 %, strategic: 96.9 %). [Conclusions] The data reported here indicate the potential of precision medicine based on the phenotypic differences in peripheral T helper cells.
**ICW14-1**

**Demonstration of Tissue Resident Memory T Cells in salivary gland in Patients with primary Sjögren’s Syndrome**

Hui Chi1, Xiang Yuan1, Zhen Tan1, Xu Zheng1, Xiangpei Li1, Guosheng Wang1, Yiping Wang2, Xiaomei Li2

1Rheumatology and Immunology, The First Affiliated Hospital of University of Science and Technology of China, Hefei, China, 2Westmead Institute for Medical Research, The University of Sydney, Westmead 2145 NSW, Australia.

Conflict of interest: Yes

[Object] Tissue resident memory T cell (Trm) is a novel group of memory T cells with a non-recirculating phenotype characterized by expression of CD69 and CD103 and plays a critical role in first-line defense. Effector memory T cell (Tem) and effector T cell (Teff) could be recruited into inflammatory site and transformed into Trm under microenvironment. Our aim is to explore the role of Trm in salivary gland (SG) of patients with primary Sjögren’s Syndrome (pSS) in the development of disease. [Methods] 20 pSS patients as the study group and 10 age-matched healthy volunteers as the control group were included in this study. The pSS diagnosis was done according to the International Classification Criteria (2002). The percentage of Tem, Teff and B cells in PBMCs and Trm in SG were detected by flow cytometry. Compare the difference of the percentages of Tem and Teff in patients and controls. Locate Trm and its positional relationship with B cells by Immunohistochemistry and Confocal Laser Scanning Microscopy. Analyze the correlation between B cells in the SG with CD4+Tm, CD8+Tm and serum IgG level respectively. [Results] Compared with the controls, the proportion of Tem (P=0.001) and Teff (P=0.008) in CD4+Tm cell subsets and the proportion of Tem (P=0.001) and Teff (P=0.001) in CD8+Tm cell subsets in patients were both significantly increased. Immunohistochemistry showed Trm were present in SG foci and expressed CD69, and Confocal Microscopy showed the CD4+Tm and CD8+Tm respectively and B cells were in close contact with Trm in SG foci. We detected a certain proportion of CD4+Tm and CD8+Tm in patients and the percentage of B cells in SG of patients were both positively correlated with CD4+Tm (r=0.6852; p=0.0031), CD8+Tm (r=0.4603; p=0.0310) and serum IgG level (r=0.4288; p=0.0399). [Conclusions] A small amount of Trm can against infections. As the number increasing, their functional changes contribute to the formation of foci, tissue destruction and disease progression.

**ICW14-2**

**Elevated EPSTI1 promote B cells hyperactivation through NF-κB signaling in patients with Sjögren’s syndrome**

Jinlei Sun, Haoze Zhang, Chaofeng Lian, Zhilei Chen, Tihong Shao, Suying Liu, Fengchun Zhang, Hua Chen

Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Beijing, China

Conflict of interest: None

[Object] Sjögren’s syndrome (SS) is a common systemic autoimmune disease characterized with aberrant B cells activation, which is partially understood. [Methods] We performed whole transcriptome sequencing of B cells from 3 SS patients and 3 Healthy controls (HC). We then confirmed the differential gene expressions in 40 SS patients and 40 HC by quantitative PCR and Western-blot. We further transfected with siRNA targeting candidate genes into B cells and measured the proliferation potential and immunoglobulins secretion. We examined TLR9 signaling to explore the potential molecular mechanism of B cell hyperactivation in SS. [Results] We identified 51 up-regulated and 22 down-regulated differentially expression genes in B cells from SS patients. We confirmed the RNA and protein level of EPSTI1 (Epithelial Stromal Interaction 1) in B cells from 40 SS patients was significantly higher than those from 40 HCs. Comparing with control B cells, EPSTI1-silencing B cells stimulated with CpG (but not anti-IgM) were proliferated less and produced lower level of IgG. We observed the level of p-p65, but not pJNK and (p38MAPK), were decreased in EPSTI1-silencing B cells stimulated with CpG. Consistently, we also found the level of p-p65 was significantly higher in B cells from SS patients than those from HC. Finally, the level of IkBa, a key regulator of p65, was significantly up-regulated in EPSTI1-silencing B cells and B cells from HC. [Conclusions] Elevated EPSTI1 expression in B cells from SS patients promoted TLR9 signaling activation and contributed to the abnormal B cells activation. Mechanistically, EPSTI1 stimulated the phosphorylation of p65, which was likely through the interaction and degradation of IkBa.

**ICW14-3**

**Injection of CD40 DNA vaccine ameliorates the autoimmune pathology of Non-obese Diabetic Mice with Sjögren’s Syndrome**

Zhou Yingbo1, Yuan Xiang1, Qi-ki Wang1, Guo-sheng Wang1, Xiang-pei Li1, Wang Yi-ping2, Harris David2, Xiao-mei Li1

1Department of Rheumatology and Immunology, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei, Anhui, China, 2Westmead Institute for Medical Research, University of Sydney, Westmead 2145 NSW, Australia.

Conflict of interest: None

Objective: To investigate whether CD40 DNA vaccine could inhibit the immune response and slow the disease progression of Sjögren’s syndrome (SS) in non-obese diabetic (NOD) mice. Methods: Female NOD mice were treated with CD40 DNA vaccine, empty vector and normal saline. Serum anti-CD40 antibody was measured by ELISA. Lymphocytes infiltration in the salivary glands was examined by FS calculation. Expression of CD40 and B220 in salivary were also examined with immunohistochemistry. Splenic lymphocyte phenotypes were analyzed by flow cytometry. CD40, IL-1β, TNF-α and IL-6 levels in the salivary glands were detected by PCR. Serum ANA was monitored by immunofluorescence. Results: 1) Compared with the controls, NOD mice treated with CD40 DNA vaccine showed higher levels of anti-CD40 antibody at week 6 and week 10 (P<0.05 and P<0.01, respectively). 2) The expression of CD40 in the salivary glands of NOD mice in CD40 DNA vaccine group was decreased (P<0.05). 3) Infiltration of lymphocytes was inhibited in the salivary glands of mice in the treatment group at week 10. Average weight of wet salivary gland and the ratio of average salivary gland weight to body weight of NOD mice in vaccine group were significantly lower than that in control groups. 4) The expression level of TNF-α and IL-6 in salivary glands were declined (P<0.05 and P<0.05, respectively). 5) The splenic DC and plasma cell populations were reduced and the level of ANA was decreased in the NOD mice with CD40 DNA vaccine treatment. Conclusion: CD40 DNA vaccine ameliorate the pathologic change of NOD mice with SS by downregulation of the proinflammatory cytokines of TNF-α and IL-6, decrease of the percentage of DCs and plasma cells, and suppression of autoimmune inflammation.

**ICW14-4**

**Detection of circulating M3 muscarinic acetylcholine receptor reactive Th17 cells in patients with primary Sjögren’s syndrome**

Saori Abe, Hirotu Tsuboi, Hanae Kudo, Yoko Ono, Fumika Honda, Izumi Kurata, Mizuki Yagishita, Hiroyuki Takahashi, Masahiro Yokosawa, Yuya Kondo, Isao Matsumoto, Takayuki Sumida

Department of Internal Medicine, Faculty of Medicine, University of Tsukuba

Conflict of interest: None

[Object] Sjögren’s syndrome (SS) is an autoimmune disease which is characterized by lymphocytic infiltration including CD4+IL-17 producing helper T (Th17) cells to the lacrimal and salivary glands. We previously detected anti-M3 muscarinic acetylcholine receptor (M3R) antibodies and M3R reactive CD4+IFNγ producing helper T (Th1) cells in patients with SS. Moreover, we clarified that M3R reactive Th1 and Th17 cells had pathogenic roles in the development of auto-immune sialadenitis in SS mice model. The purpose of this study was to identify circulating M3R reactive Th17 cells, and to examine the relationship between M3R reactive Th17 cells and clinical features in patients with primary SS (pSS). [Methods] 1) Peripheral blood mononuclear cells (PBMCs) were isolated from whole blood of 9 pSS patients and age gender matched 5 healthy controls (HC). According to their HLA-DRB1 typing, the 20 mer peptides from the full length of M3R, which were highly predicted to bind to HLA molecules, were identified using the immune epitope data-

S196
base website. PBMCs were stimulated with these selected M3R peptides for 39 hours, and IL-17 secretion was detected by IL-17 enzyme-linked immunospot assay (ELISPOT). 2) Clinical features were compared between M3R reactive Th17 cells positive and negative patients with pSS. [Results] 1) 5 of 9 (55.5%) pSS patients, while none of 5 (0%) HC, showed significantly increased IL-17 producing spots against M3R peptides stimulation compared with non-stimulation in ELISPOT. 2) Interestingly, 5 pSS patients positive for M3R reactive IL-17 producing spots were significantly older (71.6±8.4 vs. 40.0±18.0 years old, P=0.027) and had significantly higher ESSDAI score (8.4±4.8 vs. 2.0±0.0, P=0.031) than +4 negative patients. [Conclusions] We detected circulating M3R reactive Th17 cells in pSS patients using ELISPOT for the first time. M3R reactive Th17 cells might associate with advanced age and high ESSDAI score in pSS patients.

ICW14-5
Comparison of clinical and pathological characteristics in patients with Eosinophilic granulomatosis with polyangiitis (EGPA) and IgG4-related disease (IgG4-RD)
The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan
Conflict of interest: None

[Object] There are several similarities between EGPA and IgG4-RD such as high serum IgE levels and allergic background. In this study, we examined clinical and pathological characteristics of both EGPA and IgG4-RD in order to differentiate [IgG4-RD mimickers]. [Methods] Untreated consecutive patients who were diagnosed with EGPA and IgG4-RD in our department from 2007 to 2018 were enrolled. Immunohistochemistry including IgG4 staining was evaluated in both IgG4-RD and EGPA patients. [Results] 22 EGPA patients and 19 IgG4-RD patients were enrolled. Although the mean age was comparable (EGPA vs IgG4-RD: 59 vs 64 years old), the proportion of female was higher in EGPA (77.3% vs 42.1%). For laboratory tests, the levels of eosinophils (1817.1 ± 378.8/ml), CRP (6.5 ± 0.6 mg/dl), sIL-2R (2635.6 ± 1331.4 U/ml), C3 (118.3 ± 80.4 mg/dl), and C4 (24.4 ± 16.2 mg/dl) were significant higher in patients with EGPA. On the other hand, the elevated serum IgG4 levels were seen in all patients of IgG4-RD (mean 1110.5 ± 270.5 mg/dl) and was seen in 95% of EGPA (480.4 ± 304.2 mg/dl). In the pathological findings of the skin, panarinal sinus, temporal artery and kidney, lymphoplasmacytic infiltration with infiltrating IgG4-positive plasma cells were seen in 83% of EGPA patients. Especially, in the kidney pathology, two of four patients with EGPA had fibrosis surrounding nest (Bird’s eye pattern) and fulfilled the criteria of IgG4-related kidney disease. Namely, most of the EGPA patients met two of three items of IgG4-RD diagnostic criteria. However, EGPA cases have neither mass lesion nor hyperlastic lesion, and could not fulfill IgG4-RD diagnostic criteria completely. [Conclusions] The elevated serum IgG4 and the infiltration of IgG4-positive plasma cells were not specific for IgG4-RD. Therefore, the mass forming in tissue was one of the important clinical manifestations of IgG4-RD. Meanwhile, EGPA were able to have diagnosis of IgG4-related kidney disease which don’t have mass lesion.

ICW14-6
Pathologic role of activated SLAMF7+Th1 cells in facilitating IgG4 production by B cells in IgG4-related disease
Kazuhiko Higashioka1, Masahiro Ayano1, Yasutaka Kimoto2, Hiroki Mitoma1, Mitsuteru Akahoshi1, Yojiro Arinobu1, Koichi Akashi1, Tomohiro Koga1,2, Kiyoshi Migita3, Yushiro Endo2, Remi Sumiyoshi2, Fumiaki Nonaka4, Shin-ya Kawashiri2, Naoki Iwamoto3, Kunihiro Ichinose2, Mami Tama1, Hideki Nakamura3, Tomoki Origuchi2, Kazunaga Agematsu4, Junya Masumoto4, Akihiro Yachie4, Katsumi Eguchi4, Atsushi Kawakami2
1Center for Bioinformatics and Molecular Medicine, Nagasaki University Graduate School of Biomedical Sciences, 2Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, 3Nagasaki University Graduate School of Biomedical Sciences, 4Department of Pathology, Sasebo City General Hospital, 5Center for Rheumatic Disease, Sasebo Chuo Hospital, 6Department of Infectious Immunology, Shinshu University Graduate School of Medicine, 7Department of Pathology, Ehime University Graduate School of Medicine and Proteo-Science Center, 8Department of Pediatrics, School of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University
Conflict of interest: None

[Object] We aimed to identify the whole nucleotide sequence of the Mediterranean Fever (MEVF) gene in familial Mediterranean fever (FMF) and reveal novel single nucleotide polymorphisms (SNPs) associated with the onset of FMF. [Methods] Two hundred SNPs in the whole region of MEVF, including promoter regions and intron regions, were genotyped using next-generation sequencing in 266 Japanese patients with FMF and 288 ethnically matched controls. We performed an association analysis using these SNPs to identify genetic variants that predispose to FMF. [Results] We identified the two most significant SNPs rs28940578; E148Q in exon 2, p = 2.47 × 10−27 and rs3743930; E148Q in exon 2, OR = 1.65, p < 0.0005. Stratified analysis identified rs28940578 as a risk allele in typical FMF. Haplotype AG, defined by rs401298 and rs28940578, was the most significant and prevalent among patients with typical FMF compared with controls (22.4% vs. 0%, respectively; OR = 137, p = 1.44 × 10−17). Haplotype TGT, defined by rs11466018, rs224231, and rs401877, was the most significant among patients with typical FMF without the rs28940578 mutation compared with controls (15.9% vs. 6%, respectively; OR = 12.4, p = 0.004). [Conclusions] rs28940578 is associated with the highest risk in typical FMF cases. This is consistent with results from previous studies in Japan. We found novel disease-related SNPs that confer susceptibility to FMF.
to the onset of FMF among typical FMF without the rs28940578 mutation. There were no relevant SNPs identified in MEFV among the atypical FMF group.

ICW15-2
The study of the novel G58V mutation in the TNFRSF1A gene identified in a family with TNF Receptor-Associated Periodic Syndrome (TRAPS)
Shoko Tsuji1, Tomoyuki Mukai1, Akiko Nagasu1, Hiroyasu Hirano1, Masanori Iseki2, Takahiko Horiiuchi1, Ryuta Nishikomori1, Yoshitaka Morita1
1Department of Rheumatology, Kawasaki Medical School, Kurashiki, Japan, 2Department of Immunology and Molecular Genetics, Kawasaki Medical School, Kurashiki, Japan, 3Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan
Conflict of interest: Yes

[Object] TNF Receptor-Associated Periodic Syndrome (TRAPS) is one of the autoinflammatory diseases. TRAPS is caused by heterozygous mutations in TNFRSF1A gene. Although more than 100 TNFRSF1A mutations have been reported, only a few mutations such as T50M have been shown as TRAPS mutations. Based on the finding that T50M mutant TNFR1 is accumulated in endoplasmic reticulum (ER), it has been hypothesized that excessive ER stress causes inflammatory responses. Reflecting the mechanism, the cell surface expression of T50M TNFR1 has been shown to be decreased. Recently, we have identified two TRAPS patients with a novel G58V mutation. In this study, we examined the effects of the novel G58V mutation using a cell model by comparing with the T50M mutation and low-penetrant mutations (R92Q, T61I). [Methods] Wild-type (WT) or mutant TNFRSF1A (G58V, T50M, R92Q, T61I) constructs were transfected into HEK-293 cells. TNFR1 protein levels were examined by western blotting. The cell surface and intracellular expression levels were determined by flow cytometry. To examine the effect of G58V mutation in the patients, we measured the mitochondrial reactive oxygen species (ROS) in the peripheral blood mononuclear cell (PBMC) of the patients and healthy donors. [Results] Expression levels of the WT and mutant TNFR1 protein were comparable in the whole cell lysates of HEK-293 cells. The cell surface expression of TNFR1 was decreased in the G58V and T50M mutant cells compared to WT TNFR1-transfected cells. In contrast, the R92Q and T61I mutations did not suppress the cell surface expression of TNFR1. PBMCs from TRAPS patients carrying G58V mutation exhibited significantly higher mitochondrial ROS level than that from healthy donors. [Conclusions] The G58V TNFR1 was not expressed on the cell surface, same as the pathogenic T50M mutation. These findings suggest that G58V mutation causes pro-inflammatory status, presumably through the similar mechanisms to the T50M mutation.

ICW15-3
Characteristic features of macrophage activation syndrome in patients with adult Still's disease
Hiroya Tamai, Yuko Kaneko, Tsutomu Takeuchi
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
Conflict of interest: None

[Background] Adult Still’s Disease (ASD) sometimes develops severe complications such as macrophage activation syndrome (MAS). Although MAS can be fatal, little is known about its clinical courses and relation to initial symptoms, diagnosis and treatment. [Objectives] To clarify characteristic features of MAS in patients with ASD and identify useful factors for optimal strategy to prevent MAS. [Methods] Consecutive ASD patients diagnosed with Yamaguchi’s criteria were reviewed retrospectively in our hospital from April 2012 to September 2017. Clinical symptoms, laboratory data and treatment information were collected from their charts and analyzed. [Results] We identified 98 patients with ASD, but 33 patients were excluded from the analyses because of insufficient information at onset, resulting in 65 patients enrolled. The mean age at onset was 45.7 years old and female was 81.5%. Among them, 10 patients (15.4%) were diagnosed with MAS, with three patients developing MAS before the diagnosis of ASD, five patients after the initiation of glucocorticoid treatment, and two patients at relapse. All patients with MAS were female, and high fever as the first symptom of ASD was more frequent in patients with MAS than those without (70.0% vs 45.5%). MAS after treatment initiation occurred 24.2 days after the initiation of glucocorticoid treatment. The initial dose of prednisolone was 50mg/day in two patients and 30mg/day in three. The development of MAS was rapid with 10-fold increase in transaminase and 14 times increase in ferritin compared to their values at diagnosis. [Conclusions] The incidence of MAS was 15.4% in clinical course of ASD. More than half of MAS occurred after initiation of treatment with a rapid progression.

ICW15-4
Autoinflammation and autoimmunity in Adult-onset Still’s disease (AOSD): The relationship between HLA-Class II and MEFV genes in AOSD
Yuya Fujita1, Hiroshi Furukawa1, Jumpei Temmoku1, Makiko Furuya Yashiro1, Naoki Matsuoka1, Tomoyuki Asano1, Shuzo Sato1, Hiroko Kobayashi1, Hiroshi Watanabe1, Eiji Suzuki1, Tomohiro Koga1, Toshinasa Shinizu1, Yuki Takuma2, Akiko Nagasu1, Hiroyasu Hirano1, Ryuta Nishikomori1, Kiyoshi Migita1, Naoyuki Tsujiya1, Atsushi Kawakami2, Koriyama, Japan
Conflict of interest: None

[Objective] Adult-onset Still’s disease (AOSD) is a genetically-complex inflammatory disease, in which both innate and adaptive mechanisms contribute to the pathogenesis. Recent study revealed an unequivocal genetic association between systemic juvenile idiopathic arthritis and the major histocompatibility region, in particular with the class II allele HLA-DRB1*11. In this study, we investigated HLA-Class II and MEFV genes, which predispose to either autoimmunity and autoinflammation in Japanese patients with AOSD. [Methods] HLA-DRB1, DQB1 and DPB1 genes were analyzed in 87 Japanese patients with AOSD and 413 Japanese healthy subjects. Genomic DNA samples from the AOSD patients were also genotyped for MEFV exons 1, 2, 3, and 10 by direct sequencing. [Results] We found significant association of HLA-DRB1*15:01 (Pc=0.0002, OR=3.04, 95% CI=1.91-4.84), DR5 serological group (Pc=0.0006, OR=2.39, 95% CI=1.49-3.83) and DQB1*06:02 (Pc=0.01, OR: 2.54, 95% CI=1.51-4.28) with AOSD, whereas a protective association of DRB1*09:01 (Pc=0.0110, OR=0.34, 95% CI=0.18-0.66). The frequency of MEFV mutation was high (56.3%). The predisposing effect of DR5 was confirmed only in patients with AOSD who had MEFV variants and not in those without MEFV variants. Additionally, DR5 in patients with AOSD were associated with macrophage activation syndrome (MAS) and steroid pulse therapy. [Conclusions] Polymorphism that alter inflammation pathway such as MEFV can trigger the autoinflammation. Conversely, recent studies demonstrated that genes including HLA affect unfolding protein. Unfolded protein response (UPR) can contribute to inflammation as well as autoimmunity. We demonstrated that HLA-DRB1*15:01, DR5 and HLA-DQB1*06:02 were significantly associated with AOSD susceptibility. MEFV gene, a regulator of inflammasome, also contribute to the development of AOSD. Our data suggests the combined innate and adaptive immune dysfunction lead to Pathogenesis of AOSD.

ICW15-5
Expression of Siglec-10 was decreased on synovial fluid mononuclear cells although increased on peripheral blood mononuclear cells in juvenile idiopathic arthritis patients
Qianzi Zhao, Yang Liu, Pan Zheng, Lawrence Jung
Children’s National Medical Center, Washington, DC, USA
Conflict of interest: None

[Background] Adult-onset Still’s Disease (AOSD) is a genetically-complex inflammatory disease, in which both innate and adaptive mechanisms contribute to the pathogenesis. Recent study revealed an unequivocal genetic association between systemic juvenile idiopathic arthritis and the major histocompatibility region, in particular with the class II allele HLA-DRB1*11. In this study, we investigated HLA-Class II and MEFV genes, which predispose to either autoimmunity and autoinflammation in Japanese patients with AOSD. [Methods] HLA-DRB1, DQB1 and DPB1 genes were analyzed in 87 Japanese patients with AOSD and 413 Japanese healthy subjects. Genomic DNA samples from the AOSD patients were also genotyped for MEFV exons 1, 2, 3, and 10 by direct sequencing. [Results] We found significant association of HLA-DRB1*15:01 (Pc=0.0002, OR=3.04, 95% CI=1.91-4.84), DR5 serological group (Pc=0.0006, OR=2.39, 95% CI=1.49-3.83) and DQB1*06:02 (Pc=0.01, OR: 2.54, 95% CI=1.51-4.28) with AOSD, whereas a protective association of DRB1*09:01 (Pc=0.0110, OR=0.34, 95% CI=0.18-0.66). The frequency of MEFV mutation was high (56.3%). The predisposing effect of DR5 was confirmed only in patients with AOSD who had MEFV variants and not in those without MEFV variants. Additionally, DR5 in patients with AOSD were associated with macrophage activation syndrome (MAS) and steroid pulse therapy. [Conclusions] Polymorphism that alter inflammasome pathway such as MEFV can trigger the autoinflammation. Conversely, recent studies demonstrated that genes including HLA affect unfolding protein. Unfolded protein response (UPR) can contribute to inflammation as well as autoimmunity. We demonstrated that HLA-DRB1*15:01, DR5 and HLA-DQB1*06:02 were significantly associated with AOSD susceptibility. MEFV gene, a regulator of inflammasome, also contribute to the development of AOSD. Our data suggests the combined innate and adaptive immune dysfunction lead to Pathogenesis of AOSD.
Background/Purpose: Siglec-G (human Siglec-10 homolog) knock-out mice developed increased clinical disease in mouse arthritis model suggesting a role of Siglec-G/10 in pathogenesis of arthritis. Siglec-10 functions as an inhibitory receptor through the interaction between Siglec-10 and CD24. IL-29 has immune-regulation function. In this study, we investigated the expression of IL-29 on mononuclear cells (MCs) from synovial fluid (SF) and peripheral blood (PB) of JIA patients and assessed IL-29 as a candidate cytokine produced from the Siglec10-CD24 interaction. Methods: The expression of Siglec-10 on PB and SF monocytes was measured by flow cytometry. Flow cytometry sorting was used to isolate monocytes expressing high level of Siglec-10 for culture. Function test of IL-29 mRNA expression was assessed by quantitative real-time reverse transcriptase-polymerase chain reaction. Results: The Siglec-10+ PBMCs percentage in JIA patients was significantly higher than that in controls. In contrast, Siglec-10+ mononuclear cells percentage in synovial fluid was significantly lower than that in PB of JIA patients. One group of CD14+CD144hi monocytes in PB expresses high level of Siglec-10 (Mean fluorescent intensity, MFI). Function test showed that those Siglec-10+CD144+ monocytes from PB of healthy donor had higher IL-29 mRNA transcript after cultured with CD24 fusion protein in vitro compared to controls cultured without CD24 fusion protein. Interestingly, the percentage of this group of Siglec-10+CD144+ monocytes in PB was higher in JIA patients than in controls, however, the Siglec-10 expression level on those CD14+ monocytes in SF was significantly decreased compared to that in PB of JIA patients. Conclusion: Interaction between Siglec-10 on CD14+ monocytes and CD24 may trigger the production of IL-29 which may mediate immunoregulatory function. The reduction of SFMC Siglec10 expression in JIA patients may have contributed to the pathogenesis of JIA.

ICW16-1 Cigarette Smoking at the Time of the Onset of RA Highly Impacts on RF and ACPA Levels in Japanese RA patients; the Study from IOR-RA and KURAMA Cohorts

Yuki Ishikawa1, Katsunori Ikari2, Motomu Hashimoto1, Koichiro Ohmura2, Masao Tanaka1, Hiromu Ito1, Atsuo Taniguchi2, Hisashi Yamakana2, Tetsune Mimori2, Chikashi Terao3,4 1Joslin Diabetes Center, Harvard Medical School, 2Institute of Rheumatology, Tokyo, Japan, 3Tokyo Women’s Medical University, 4Department of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, 5Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 6Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 7Department of Investigative Medical Sciences, Yokohama, Japan, RIKEN, 8Clinical Research Center, Shizuoka General Hospital, Shizuoka, Japan, 9Department of Applied Genetics, Shizuoka, Japan, The School of Pharmaceutical Sciences, University of Shizuoka

Conflict of interest: Yes

[Object] We conducted this study to elucidate the impact of cigarette smoking on RF and ACPA levels, which has yet been unclear. [Methods] Totals of 5,694 subjects from IORRA and 545 subjects from KURAMA were enrolled. Their precise smoking status data both before and after the onset of RA were withdrawn from the database. Associations between smoking status and ACPA or RF levels were validated by multiple logistic regression models. The effect of HLA-DRB1 status on the relation above was also explored. [Results] Smoking at the time of onset was an independent risk of high levels of both antibodies, especially RF (≥300 IU/mL; OR = 2.61, p = 3.2×10-19), ACPA ≥ 100 AU/mL; OR = 1.47, p=5.5×10-9) while smoking cessation before onset significantly lowered the risks in comparison with subjects with smoking at onset (RF: OR = 0.43, p = 5.2×10-9, ACPA: OR = 0.76, p = 0.010), suggesting that RF is more sensitive to smoking status than ACPA. The effect sizes of these smoking variables were larger and significant in males than in females. The effect of smoking on high ACPA levels was only observed in the presence of shared epitope (SE, OR = 2.09). Also, the effect of smoking on high RF levels was more apparent in the presence of SE than without SE (OR = 2.93). Stratifying RA subjects by smoking status did not affect the risks of high levels of autoantibodies in the presence of HLA-DRB1*0901, frequently observed in Japanese and strongly associated with lowering ACPA levels. [Conclusions] Cigarette smoking at the time of RA onset affects both ACPA and RF levels especially in males, and RF is more sensitive to smoking status than ACPA. The effect is apparent in the presence of SE, indicating an interaction between cigarette smoking and SE in terms of ACPA and RF levels. These data collectively imply a novel potential mechanism of RA pathogenesis.

ICW16-2 Neutrophil Extracellular Trap formation with citrullinated Histone H3 and diminished macrophage effecrortosis play key roles in local anti-citrullinated peptide antibody generation in the lung

Yuko Okamoto1, Ashley Visser2, Nickie Seto3, Mariana J Kaplan3, Nickie Seto1, Mariana J Kaplan3, Mariana J Kaplan3, Hiromi Ito5, Atsuo Taniguchi2, Hisashi Yamakana2, Tetsune Mimori2, Chikashi Terao3,4 1Joslin Diabetes Center, Harvard Medical School, 2Institute of Rheumatology, Tokyo, Japan, 3National Institute of Arthritis and Musculoskeletal and Skin Diseases, Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, USA, 4Division of Pulmonary Critical Care Medicine, National Jewish Health, Denver, CO, USA, 5Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan, 6National Institute of Arthritis and Musculoskeletal and Skin Diseases, Systemic Autoimmunity Branch, National Institutes of Health, Bethesda, MD, USA, 7Department of Epidemiology, Tokyo School of Public Health, Aurora, CO, USA

Conflict of interest: None

[Object] We previously reported that anti-citrullinated (cit) peptide antibodies (ACPAs) in the lung associated with Neutrophil Extracellular Trap (NET) remnants in subjects who are At-Risk of developing future RA. Herein, we further characterized neutrophil NET formation and the role of macrophage function in association with ACPA in the lung of these subjects. [Methods] We included 49 subjects At-Risk for RA defined as being without synovitis but At-Risk for RA as first-degree relatives (FDR) of RA patients (N=30) and serum ACPA (+) subjects. Classified RA (N=11), and healthy controls (HC) (N=18) were also included. Serum and induced sputum ACPA were measured using anti-cyclic citrullinated peptide antibody (CCP) ELISA (CCP3.1, Inova). Dissociated sputum cells without stimulation were stained with Hoechst, anti-myeloperoxidase, and anti-cit-H3. Neutrophils that had formed NETs ex vivo were quantitated and characterized by microscopy. Sputum macrophages were incubated with apoptotic Jurkat cells for evaluation of effectorcrosis. Separately, in sputum cell-free supernatant, the level of cit-H3-DNA NET remnants, IL-1β, IL-6, IL-8, TNFα, MCP1, MIP1α, and MIP1β were measured. [Results] The % of sputum neutrophils forming cit-H3+ NETs ex vivo was significantly higher in At-Risk and RA compared to HC (both p<0.01). In At-Risk subjects, sputum anti-CCP levels significantly correlated with % ex vivo cit-H3+ NETs (r=0.48, p<0.01) and the level of cit-H3-DNA NET remnants (r=0.80, p<0.001). All sputum cytokeratin/chemokine levels also significantly correlated with sputum anti-CCP level. Sputum macrophage effecrortosis was decreased in At-Risk and RA compared to HC (both p<0.01). [Conclusions] Airway inflammation generating cit-H3 expressing NETs and diminished macrophage effecrortosis may play a role in the development of ACPA in the lung in subjects At-Risk for RA. Additional studies are needed to determine associations with transitions to systemic ACPA and classified RA.

ICW16-3 Follicular Helper T 17 Cell Regulates Autoantibody Hyposialylation via OX40-OX40 Ligand Axis in Experimental Arthritis

Izumi Kurata, Isao Matsumoto, Ayako Ohyama, Atsumu Osada, Yuya Kondo, Hiroto Tsuibo, Takayuki Sumida

Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, University of Tsukuba

Conflict of interest: None

[Object] Recently, IL-23-Th17 cells axis and hyposialylation of antibodies (Abs) were proved to be linked to the experimental and rheumatoid arthritis. However it remains uncertain how Tfh, including IL-17 producing Tfh (Tfh17), is associated to arthritis and whether it behaves as regulator of Ab hyposialylation. The aim of this study is to explore the relation of Tfh17 and autoantibody hyposialylation in glucose-6-phosphate isomerase (GPI) induced arthritis (GIA). [Methods] 1) Fluctuation of Tfh in draining lymph nodes were analyzed during the arthritis course.
2) Based on a result of above experiment, DCs were stimulated with purified anti-GPI Abs obtained at the arthritis onset (day 7) and resolving phase (day 28). Sialic acid in anti-GPI Abs was quantified by mass spectrometry. Artificial sialic acid removal/supplement was performed in vitro and vivo.
3) Expression of st6gal1, the responsible enzyme for sialylation, in plasmablasts (PBs) co-cultured with Th17 was measured. OX40-OX40 ligand (OX40L) pathway was blocked with monoclonal Abs. 4) Fluctuation of Th17 and its OX40 expression were analyzed.

[Results] 1) Th17 was increased and peaked at day 7. 2) DCs produced more proinflammatory cytokines when stimulated with day 7 Abs than with those of day 28. Mass spectrometric analysis revealed significant hyposialylation of day 7 Abs. Sialic-acid-reduced Abs became stronger stimulants for DCs and GIA was ameliorated when sialic acid was supplied to mice. 3) Decreased expression of st6gal1 was observed in differentiated PBs co-cultured with Th17. OX40-OX40L pathway blocking rescued this decrease. 4) Th17 was significantly increased at day 7 and the highest expression of OX40 was observed compared to other Th17 subsets.

[Conclusions] Our findings suggested Th17, especially Th17 could have a crucial role in the development of arthritis not only via PB activation, but also via regulation of autobody hyposialylation through OX40-OX40L axis in the experimental arthritis.

ICW16-4

Massive in silico studies specified UBASH3A (a suppressor of T cell receptor signaling) as a candidate pathogenic factor that is down-regulated in CD4+ T cells of patients with rheumatoid arthritis (RA). Kaoru Yamagata, Shingo Nakayama, Ippei Miyagawa, Shigeru Iwata, Yoshiya Tanaka

The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan

Conflict of interest: None

[Objective] A variety of in silico studies enable us to extract key molecules associated with a pathological condition. Using three databases to study the expression and function of extracted genes based on dys-regulated transcription, we screened a gene susceptible for RA. We next studied a molecular basis to confirm whether a specified molecule is proper as a novel therapeutic target for RA. [Methods] We focus on a gene that overlapped via meta-analysis using GWAS, dbSUPER (database of super enhancer (SE) that forms clustered enhancers related to powerful transcription), and BioGPS. CD4+ T cells and CD44 cells were separated from PBMC of age-matched healthy donor (HD; n=10) and RA (n=11), and then subjected to qPCR and WB to compare expression level of extracted gene. Effect of alleles at rs1893592 on the expression level was further studied. Immunohistochemistry (IHC) was performed to detect the protein in lymph nodes (LNs) of RA and controls. [Results] 1) In silico studies narrowed enormous ranges of genes down to UBASH3A gene, encoding a suppressor of T cell receptor (TCR) signaling, whose expression was aberrantly higher in CD4+ T cells compared with CD4+ cells among HD. Further, pathology-associated SNP in UBASH3A gene is located within SE. 2) The mRNA and protein expression of UBASH3A significantly decreased in CD4+ T cells of RA compared with those of HD. RA patients with AC and CC genotypes at rs1893592, but not AA, showed low level of UBASH3A mRNA in CD4+ T cells. 3) Clear staining for UBASH3A was detected in CD4+ T cells of LNs from patients with dermatomyositis, but not with RA. [Conclusions] Integrative analyses find overlapped UBASH3A gene specific for cell-type, SE, and RA pathology. Primary expression of UBASH3A may be impaired in CD4+ T cells of patients with RA. Minor allele C at rs1893592 suppresses expression of UBASH3A in CD4+ T cells. Down-regulation of UBASH3A may lead to aberrant activation of the TCR signaling crucial for RA pathogenesis.

ICW16-5

Prevotella copri from rheumatoid arthritis patients exacerbates collagen-induced arthritis in mice

Takuro Nii1, Yuichi Maeda1, Masashi Narazaki1, Atsushi Kumanogoh1
1Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, 2Laboratory of Immune Regulation, Graduate School of Medicine, Osaka University

[Object] In rheumatoid arthritis (RA), environmental factors such as smoking and periodontal diseases are involved in the disease onset. Among these environmental factors, altered composition of microbiota has been observed in the intestine of early RA patients. We have previously reported that some of RA patients harbored high abundance of Prevotella copri (P. copri) in the intestine. However, in tropical Asia and Africa, healthy individuals also contained high abundance of P. copri in the intestine. Therefore, we tried to analyze whether P. copri from RA patients has the ability to induce arthritis. [Methods] Firstly, by using anaerobic culture technique, we isolated P. copri from fecal samples of RA patients (RA-P. copri) and healthy controls (HC-P. copri). We investigated whole genome sequence of RA- and HC-P. copri to investigate their genome difference. Second, DBA1 mice in SPF (specific pathogen-free) condition were treated with antibiotics and inoculated RA or HC-P. copri for 5 days. After the inoculation, these mice were induced autoimmune arthritis by injection of bovine type II collagen. We evaluated clinical, pathological score in the joints and serum titers of anti-type II collagen antibody. We also analyzed immune cell populations in regional lymph nodes by flow cytometry. [Result] Interestingly, whole genome sequence revealed that RA and HC-P. copri were different. RA-P. copri has specific region on the genome. We also found the morphological difference between RA- and HC-P. copri. RA-P. copri inoculated mice had significantly higher arthritis score compared to HC-P. copri inoculated mice. In addition, increased serum anti-type II collagen antibody levels were observed in RA-P. copri inoculated mice. Moreover, increased Th1 and Th17 cell numbers in popliteal lymph nodes were also observed in RA-P. copri inoculated mice. [Conclusion] P. copri isolated from RA patients had the strong arthritis-inducing ability via disruption of gut homeostasis.

ICW16-6

Autophagy Promotes Citrullination of Vimentin and Its Interaction with Major Histocompatibility Complex class II in Synovial Fibroblasts

Eri Sugawara, Masaru Kato, Yuki Kudo, Wenshi Lee, Michihito Kono, Yuichiro Fujieda, Toshiyuki Bohgaki, Olga Amengual, Kenji Oku, Shinusuke Yasuda, Tatsuya Asumi

Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Conflict of interest: None

[Objectives] To investigate the role of autophagy in autoimmunity in rheumatoid arthritis (RA) through citrullination of vimentin and its interaction with MHC class II in synovial fibroblasts (SFs). [Methods] The cell surface expression of MHC class II and B7 costimulatory molecules on SFs was analyzed by flow cytometry after treatment with interferon gamma (IFN-γ). Intracellular citrullinated autotagogenins in SFs were analyzed by immunoblotting using serum from anti-citrullinated peptide antibodies (ACPA) positive patient as a primary antibody. SFs were incubated in serum-free medium or treated with proteasome inhibitor MG132 to induce autophagy. An autophagy inhibitor 3-methyladenin (3-MA) was used. Intracellular citrullinated vimentin (eVIM) was evaluated by immunoblotting and immunocytochemistry. The interaction between MHC class II and eVIM was evaluated with co-immunoprecipitation and proximity ligation assay. [Results] MHC class II, B7-H1, and B7-DC were expressed on SF following treatment with IFN-γ, while B7-H3 was expressed on SF regardless of the presence of IFN-γ. Anti-eVIM positive RA patients' sera recognized 54 kDa protein in SF. By co-immunoprecipitation using anti-vimentin and -citrulline antibodies, the 54 kDa protein recognized by RA sera was revealed to be citrullinated vimentin. Follow-
ICW17-1
mTORC1 phosphorylation in CX3CR1+ memory B cells and its potential as a new mode of action of TNF inhibitors in RA
Shigeru Iwata, Maiko Hajime, Mingling Zhang, Naoki Ohkubo, Kazuhisa Nakano, Shingo Nakayamada, Yoshiya Tanaka
The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
Conflict of interest: None

[Object] B cells play a crucial role in RA. Recently "Immunometabolism" attract much attention, and mTORC1 is well known as a key player of metabolic reprogramming. However, it remained elusive by which mTORC1 involved in the pathogenesis of RA. [Methods] PBMCs were obtained from 32 healthy controls (HCs) and 86 patients with bio-naive active RA and analyzed by FACS. In addition, we examined the role of mTORC1 for induction of CXCR3 on B cells in vitro. [Results] The ratio of CD19+CD27+ memory B cells, especially CD19+CD27+CXCR3+ cells were decreased in patients with RA compared to HCs. T-bet is well known as an inducer for CXCR3 in CD4+ T cells. However, the level of T-bet expression in CD19+ cells was not different between HCs and patients with RA. Meanwhile, the expression of p-mTORC1 in CD19+ cells from patients with RA was higher than that of HCs. p-mTORC1 was higher in CD19+CD27+CXCR3+ B cells than in CD19+CD27+CXCR3+ B cells. p-mTORC1 expression in CD19+CD27+CXCR3+ cells were correlated with tender joints, swollen joints, disease activity such as DAS28 (CRP), CDAI and SDAI, but not RF and anti-CCP antibodies. We examined the change of the ratio of CD19+CD27+CXCR3+ cells and p-mTORC1 expression before and at 1 year after treatment with biologics (33 patients, TNF inhibitors (TNFi) (n=19), abatacept (ABT) (n=12), tocilizumab (TCZ) (n=2)). The ratio of CD19+CD27+CXCR3+ B cells were recovered and p-mTORC1 expression were decreased in TNFi treatment group, but not in ABT treatment group at 1 year. Finally, we examined the role of mTORC1 for induction of CXCR3 expression on B cells in vitro. Combined stimulation of BCR, CD40L and IFN-γ induced CXCR3 expression on B cells, which were abrogated by mTORC1 inhibitor, Rapamycin. [Conclusions] Taken together, activation of mTORC1 is involved in the accumulation of CXCR3-positive B cells in RA synovium and TNF inhibitors possibly target at this in patients with RA.

ICW17-2
Characteristic increase in fractalkine receptor (CX3CR1)-positive helper T cells in IgG4-related disease (IgG4-RD)
Yoshino Inoue, Satoshi Kubo, Shingo Nakayamada, Kazuhisa Nakano, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Ippei Miyagawa, Yusuke Miyazaki, Akio Kawabe, Yoshiya Tanaka
The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan
Conflict of interest: None

[Object] Fractalkine is a chemokine which mediates both cell adhesion and cell migration, and enable inflammatory cells to infiltrate into peripheral tissues effectively. Since the main pathological changes of IgG4-RD include infiltration of lymphocyte and fibrotic changes in affected lesions, we investigated the significance of fractalkine in IgG4-RD. [Methods] Human CD4+CX3CR1+ T cells were induced from naive CD4+T cells under various stimulation, and the characteristics of CX3CR1 expressing cells were analyzed in vitro. The proportion of CX3CR1+ mononuclear cells in peripheral blood from healthy donor and IgG4-RD patients were analyzed by flow cytometry [Results] Expression of CX3CR1 on CD4+ T cells was induced by stimulation with TCR and IFN-γ for 5 days and around half of CD4+ T cells expressed CX3CR1. Compared with CX3CR1+ T cells, CX3CR1+ T cells highly expressed both CXCR5 and CXCR3. In addition, CX3CR1+ T cells expressed Bcl-6 and T-bet, which is a master transcriptional factor of Th1 and Th1 respectively. After stimulation by PMA and ionomycin, CD4+CX3CR1+ T cells produced both IL-21 and IFN-γ. In terms of the proportion of CX3CR1+ expression on mononuclear cells in healthy subjects, almost all CD4+ T cells expressed CX3CR1, while 5% of CD4+ T cells did. In contrast, B cells did not express CX3CR1. Similarly, in IgG4-RD patients (n=10), CX3CR1 were expressed on CD8+ T cells, but not on B cells. However, the proportion of CD4+ CX3CR1+ T cells in IgG4-RD patients were 12.3%, which was higher than in healthy subjects (p = 0.01). Furthermore, CD4+CX3CR1+ T cells expressed both CXCR5 and CXCR3 in patients with IgG4-RD. [Conclusions] Our findings suggest that CX3CR1+ helper T cells have the features of both Th1 and Th2 cells, inducing tissue injury and B cell activation. Moreover, the increased proportion of CD4+CX3CR1+Th1-Th2 like T cells indicated the possible involvement of this new subset in the pathogenesis and thus fractalkine could be a new therapeutic target for IgG4-RD.

ICW17-3
The CCL22/17-CCR4 axis in macrophage and Treg suppress disease activity in experimental crescentic glomerulonephritis treated with anti-IL-6 receptor antibody
Ryota Sakai1,2, Keiko Yoshimoto1, Katsuya Suzuki1, Tsuneo Kondo1, Takahiko Kurasawa2, Tsutomu Takeuchi2, Koichi Amano2
1Department of Microbiology and Immunology, Keio University School of Medicine, 2Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine
Conflict of interest: Yes

[Object] We recently reported that the level of CCL2/17, which is a specific ligand of CCR4, is increased in remission patients with ANCA associated vasculitis (AAV) after monotherapy with anti-IL-6 receptor (IL-6R) antibody. To determine the significance of the CCL22/17-CCR4 axis in the experimental model of crescentic glomerulonephritis (GN), which is the main symptom of AAV. [Methods] The GN model was induced by administering rabbit anti-mouse glomerular basement membrane antibodies. The outcome was evaluated by histological assessment and renal function. T cells and macrophages were analyzed by flow cytometry analysis of mononuclear cells that were isolated from the kidney. Disease activity was measured in CCR4-knock out (KO) mice and Dereg (depletion of Tregs by diphtheria toxin) mice, and in mice which received adoptive transfer of wild type (WT)- or CCR4KO-Tregs. CCL22 was dissolved in Medigel and transplanted under the kidney capsule. [Results] Disease activity peaked on day 10 in this model, accompanied by infiltration of Th1/Th17 cells. The proportion of Tregs among CD4+ T cells increased to 30%-40% on day 21 and was maintained thereafter. Treg-depletion using Dereg mice aggrandized GN symptoms, suggesting that Tregs play an important role in the control and/or tolerance of GN. CCR4-KO mice developed more severe GN compared to WT mice, and the proportion of FoxP3+/CD4+ cells was significantly decreased in CCR4-KO mice compared to WT mice. Adoptive transfer of WT-Tregs into DEREG mice ameliorated the disease, whereas CCR4-deficient Tregs failed to control GN. Local administration of CCL22 facilitated Treg migration to glomeruli and reduced GN symptoms. Anti-IL-6R antibody treatment ameliorated the disease, upregulated CCL22/17 mRNA in CD11b+ CD11c+ macrophages and enhanced the accumulation of WT-Tregs, but not of CCR4-deficient Tregs. [Conclusions] Our results suggest that the CCL22/17-CCR4 axis in macrophage and Treg plays a crucial role in the regulation of GN.

ICW17-4
Serum High Type I Interferon is Associated with Active Proliferative Lupus Nephritis in Lupus Patients Accompanied with High Interferon Signature Gene Expression and Psammocytoid Dendritic Cell Infiltration in Lupus Nephritis Kidney and Leads to Podocyte Damage
Taro Iwamoto1,2, Jessica M Dorschner 3, Mark A Jensen2, Shanmugapriya Selvaraj 4, Danielle Vsetecka 3, Shreyasee Amin1, Ashima Makol1, Florianne C Ernsste1, Thomas Osborn1, Kevin Moder2, Vaidehi R Chowdhary1, Valeria Mezzanno2, Peter Izmirl2, Michael Belmont2, Robert M Clancy2, Jill P Buyon3, Ming Wu4, Cynthia A Loomis4, Hiroaki Nakajima1, Timothy B Niewold2
1Department of Allergy and Clinical Immunology, Chiba University Hospital, 2Colton Center for Autoimmunity, New York University, New York, NY, USA, 3College of Medicine, Mayo Clinic, Rochester, MN, USA, 4Division of Rheumatology, New York University, New York, NY, USA
Conflict of interest: None

[Object] Lupus Nephritis Kidney and Leads to Podocyte Damage
[Object] Lupus nephritis (LN) remains one of the most severe organ manifestations in systemic lupus erythematosus (SLE), despite recent advancements in immunosuppressive therapies. High type I interferon (IFN) is a heritable risk for developing SLE, and previous studies have suggested a link between high IFN and lupus nephritis. However, little is known about the relationships between high levels of IFN and the subtypes of LN, and whether IFN plays a critical role in the pathogenesis of LN. [Methods] We studied 221 European-American SLE patients and measured IFN in sera by performing WISH IFN bioassay as described previously. Subtypes of LN were confirmed by renal biopsy review. Serological parameters were measured in the clinical laboratory, mRNA in situ hybridization was performed to detect IFN induced gene (IIG) expression and plasmacytoid dendritic cells in LN kidney biopsies. Real-time PCR was performed to measure gene expressions in human podocyte cell lines. [Results] Proliferative LN was significantly more common among patients with high serum type I IFN compared to patients with low levels of IFN (p<0.001, OR=3.0). Notably, IFN level was significantly higher in active proliferative LN compared to inactive proliferative LN (p<0.001), and these findings were independent of complements and anti-dsDNA antibody levels. mRNA in situ hybridization showed increased expression of IIG accompanying plasmacytoid dendritic cell infiltration in active proliferative LN kidneys. In vitro experiments demonstrated that type I IFN induced gene expressions that are related to apoptosis, cytotoxic proliferative LN kidneys. [Results] WISH IFN bioassay showed increased IFN in sera by performing WISH IFN bioassay as described previously. Subtypes of LN were confirmed by renal biopsy review. Serological parameters were measured in the clinical laboratory, mRNA in situ hybridization was performed to detect IFN induced gene (IIG) expression and plasmacytoid dendritic cells in LN kidney biopsies. Results] Our data support an association between type I IFN and active proliferative lupus nephritis, suggesting that IFN is involved in renal pathogenesis. These data also suggest that IFN could predict renal disease activity or the future risk of developing LN, especially proliferative LN in SLE patients.

ICW17-5
The role of skin tissue in type I interferon regulation and initiation of Systemic Lupus Erythematosus
Antonios Psarras1,2, Adewonuola A Alase1,2, Md Yuzaiful Md Yusof1,2, Miriam Wittmann1,2, Paul Emery1,2, Edward M Vital1,2
1Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, 2NHRI Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK

Conflict of interest: None

Object Prior to a diagnosis of SLE, there is an At-Risk stage, with ANA and elevated type I IFN (IFN-I) activity with only mild suggestive symptoms not meeting diagnostic criteria. Skin is the most commonly affected organ in SLE. It can be infiltrated by T cells, but keratinocytes and fibroblasts can also produce inflammatory mediators including IFNs. We evaluated skin of At-Risk individuals for IFN-I production compared to healthy controls (HC) and SLE patients. Methods Skin biopsies from leional and non-leional skin of SLE patients, non-leional skin of At-Risk individuals and HC were evaluated using skin hybridisation. IFN-stimulated genes (IFN Score) were measured in skin biopsies and blood using Taqman. Human keratinocytes were cultured and stimulated in vitro; IFN-I expression was measured by qPCR. Results IFN Score was increased in At-Risk individuals compared to HC but the fold difference in skin (FD 29.5; 1.3-635.0) was markedly greater than in blood (FD 2.2; 2.0-2.3) suggesting local IFN-I production. Blood IFN Score correlated with active skin but not joint involvement in SLE. Skin biopsies from HC showed no expression of IFN-I. In contrast, active skin lesions from SLE showed diffuse expression of IFN-I in the epidermis but not in leucoeyte-infiltrating areas. The epidermis of At-Risk individuals also showed diffuse expression of IFN-I, but no clinical/histopathological features of inflammation. UV provocation notably enhanced IFN-I expression. Keratinocytes from HC (n=3), At-Risk individuals (n=5) and SLE patients (n=5) were cultured and treated with TLR3 or RIG-I stimuli for 24 hours. Keratinocytes from At-Risk and SLE patients showed higher expression of IFN-I at baseline; after stimulation the expression of IFN-I and IFNB was significantly increased compared to HC. Conclusions IFN-I production, a key pathogenic process at the early stage of SLE, is mediated by keratinocytes suggesting that organs such as the skin play an active role in initiating disease.

ICW17-6
Serum levels of TNF-a at 24 hours after the first administration of certolizumab pegol predicts the efficacy of certolizumab pegol at week 12 in TSUBAME study (UMIN00002381) from FIRST registry Yusuke Miyazaki, Kazuhisa Nakano, Satoshi Kubo, Shingo Nakayamada, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Ippei Miyagawa, Akio Kawabe, Yoshihi Tanaka
The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

Conflict of interest: Yes

[Object] To increase the remission rate of rheumatoid arthritis (RA), it is necessary to determine the efficacy of the tumor necrosis factor (TNF) inhibitor as early as possible. Moreover, the response to certolizumab pegol (CZP) at 12 weeks has been reported to predict its long-term efficacy. In this study, we assessed the efficacy of CZP and the relationship between serum TNF-a and IL-6 levels and serum CZP levels and clinical response. [Methods] Eighty-five patients with RA and inadequate response to MTX who received CZP were enrolled. The primary endpoint was changed in DAS28 (ESR) at 12 weeks, and secondary endpoints were changes in serum TNF-a, IL-6 and CZP levels at 24 hours after first administration of CZP and the correlation between serum biomarkers and clinical response. [Results] CZP significantly improved DAS28 (ESR) at 12 weeks (baseline and 12w =5.45±1.25 and 3.35±1.46, respectively, p<0.01). Serum TNF-a and IL-6 levels were significantly decreased at 24 hours. Serum CZP levels at 24 hours were widely distributed (median 9.4μg/ml, range 0.2-31.8μg/ml). No correlation was found between TNF-a and IL-6 levels at baseline and clinical response. In univariate analysis, low serum TNF-a and IL-6 levels and high CZP levels at 24 hours after were associated with DAS28 (ESR) remission at 12 weeks. In multivariate analysis, only low serum TNF-a levels at 24 hours were significantly associated with DAS28 (ESR) remission at 12 weeks (OR 0.017, 95%CI 0.003, 0.752). Body mass index and rheumatoid factor did not correlate with serum CZP levels at 24 hours. However, serum TNF-a levels at 24hours inversely correlated with serum CZP levels at 24 hours (r=-0.601, p<0.01) [Conclusions] CZP was effective in cases in which serum TNF-a levels were rapidly increased and serum TNF-a was strongly neutralized in only one day. These results suggest that low serum TNF-a levels at 24 hours after first administration of CZP may predict the efficacy of CZP.

ICW18-1
The role of Jazf1 in the production of IL-10 in Tr1 cells
Masanori Kono1, Tomohisa Okamura1,2, Mariko Inoue1, Toshihiko Komai1, Yukiko Iwasaki1, Yusuke Takeshima1,2, Shuji Sumitomo1, Hirofumi Shoda1, Kazuhiko Yamamoto1, Keishi Fujio1
1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 3Max Planck-The University of Tokyo Center for Integrative Inflammology, The University of Tokyo, Tokyo, Japan, 4Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Kanagawa, Japan

Conflict of interest: None

[Object] Juxtaposed with another zinc finger gene 1 (JAZF1) gene has been identified as a susceptibility locus for Systemic Lupus Erythematosus (SLE) in GWAS. A recent study revealed that JAZF1 exhibits cis-expression quantitative trait locus (eQTL) effect specifically in CD4+ T cells in SLE patients, indicating that JAZF1 expression in CD4+ T cells may play an important role in the pathogenesis of SLE. However, the precise role of JAZF1 in autoimmunity diseases remains elusive. In this study, we aimed at clarifying the role of JAZF1 in the immune system. [Methods] To evaluate the function of Jazf1-expressing cells, we generated Jazf1-GFP reporter mice. Quantitative RT-PCR was performed on FACSSorted various types of immune cells from C57BL/6 or Jazf1-GFP mice. Mouse Jazf1 gene was cloned into the pMIG vector and then transduced into MACS-sorted splenic CD4+ T cells. IL-10 detection in culture supernatants was performed by ELISA. [Results] Among various immune cells, Jazf1 was preferentially expressed in CD4+ CD25+LAG3 regulatory T cells (LAG3 Tregs) which are equivalent to Tr1 cells characterized by...
high levels of interleukin (IL)-10 production. Jazf1-GFP CD4 T cells showed elevated expression levels of Lag3 and Egr2, the characteristic genes of Lag3 Tregs. Intriguingly, Jazf1 expression was inversely correlated with IL-10 expression at both mRNA and protein levels in Lag3 Tregs. As expected, ectopic expression of Jazf1 decreased IL-10 production in CD4 T cells under Tr1 differentiation condition. [Conclusions] We previously reported that Egr2-expressing Lag3 Tregs ameliorate pathology of lupus-prone mice, and Egr2 is a susceptible gene for SLE. In this study, we revealed that Jazf1 plays a pivotal role in IL-10 production from Lag3 Tregs. These findings suggest that Jazf1 is a novel therapeutic target for treating autoimmune diseases, such as SLE. Further studies are needed to evaluate the role of Jazf1 in human Lag3 Tregs.

**ICW18-2**

Antigen-specific Foxp3+ Tregs suppress cognate antigen response but not suppress non-cognate antigen response

Yoshiihro Oya1, Hidekazu Futami1, Takuya Nakazawa2, Ryutaro Matsumura1, Hiroshi Nakajima1, Ethan Shevach1 1Department of Rheumatology, Allergy & Clinical Immunology, National Hospital Organization Chiba-East National Hospital, 2Department of Allergy and Clinical Immunology, Graduate School of Medicine, Chiba University, 1Laboratory of Immunology, Cellular Immunology Section, National Institutes of Health, NIAID

Conflict of interest: None

[Background/Purpose] Suppressive function of Foxp3+ T regulatory cells (Tregs) has been established in autoimmune diseases and in allergy. However, how they mediate their suppressive function remains unresolved. To develop Treg therapy, it is needed to understand the biochemical nature and its specificity of suppressor mechanisms in more detail. [Methods] (1): Two antigen-specific naïve effectors (Teff) cells from TCR transgenic Rag2-/- mice (OTII Tg mice and SM Tg mice) were transferred to syngenic recipient mice together with APCs pulsed with two antigens and antigen-specific Tregs. Two antigen peptides were pulsed either on distinct APCs or on the same APCs. Splenocytes from the recipient mice were analyzed to determine the Treg suppression on each Teff. (2): APCs pulsed with both peptides were co-cultured with antigen-specific Tregs, and Tregs were depleted out at 18 hours by cell sorting to obtain the suppressed APCs. The stimulatory function of the sorted APCs was determined by co-culture with two TCR Tg Teffs. [Results] (1): In the co-transfer with distinct APCs, Tregs suppressed the cognate antigen specific Tcells, but not the non-cognate antigen specific Teffs. Treg suppressed only the cognate antigen-specific Teffs even when both antigen peptides were pulsed on the same APCs. (2): Teffs were suppressed by the suppressed APCs in the absence of Tregs. Antigen-specificity of the suppression was also maintained by the suppressed APCs. [Conclusions] Under the suppression of Tregs, both the suppressed Teffs and the non-suppressed proliferating Teffs were able to co-exist in the same environment, indicating that APCs are capable of stimulating the non-cognate Teffs even though they suppress the cognate Teffs. These findings suggest that Tregs can mediate antigen-specific suppression through APCs and might shed light on the unresolved issues caused by the unwanted non-specific suppression by the conventional immune-suppressive therapies.

**ICW18-3**

Distribution of immune-suppressive cells and Toll-like receptors in synovial tissues in the patients with rheumatoid arthritis which were treated by anti-TNF agents

Yuya Takakubo1, Suran Yang1, Yuta Suzuki1, Hiroharu Okui1, Yasusho Naganuma2, Akiko Sasaki2, Kan Sasaki2, Hiroshi Orui1, Michiaki Takagi1 1Department of Rehabilitation & Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan, 2Department of Orthopaedic Surgery, Yamagata Saisei Hospital, 1Department of Orthopaedic Surgery, Yamagata Central Hospital

Conflict of interest: None

[Objectives] The aim of this study was to investigate the immune-inflammatory cells, including Toll-like receptors (TLRs)-equipped cells, in synovial tissue samples from the patients with rheumatoid arthritis (RA) on anti-TNF agents compared to patients with treatment of conventional synthetic disease-modifying antirheumatic drug (csDMARD). [Methods] Immune-inflammatory cells were evaluated in RA synovitis in patients with anti-TNF group (n=22 (etanercept 16, infliximab 6)) or csDMARD group (n=21) by immunohistochemical and immunofluorescence study. Mean duration of affection by RA of anti-TNF group and csDMARD group was 8.4 years and 11.4 years, respectively. Period of anti-TNF group was14 months. Mean CRP level of anti-TNF group and csDMARD group was 1.4 mg/dl and 2.1 mg/dl and that of DAS28-CRP score (4) of anti-TNF group and csDMARD group was 4.1 and 4.5 at enrolling their samples, respectively. CD3 (T cells), CD20 (B cells), CD68 (macrophages), S-100 (dendritic cells: DC) and TLR1 to 9 immunoreactive cells were counted in at least five x 200 light microscope fields in larger lymphoid infiltrates. The intensity of the inflammation was estimated using the Krenn histopathological grading system (grade 0-3). [Results] The grading scores of synovitis was both 1.6 in each group and correlated best with the T and B cells in the both groups (p=0.05). Interestingly, both T and B cell counts were lower in the anti-TNF than in the csDMARD group (p=0.05). In contrast, the C-reactive protein (CRP) and disease activity score DAS28-CRP did not show clear-cut correlations with the inflammatory grade of the synovitis. Similar numbers of cells immunoreactive for TLR-1 to TLR-9 were found in synovitis in both groups. [Conclusion] Patients clinically responding to anti-TNF agents might still have the potential of moderate/severe local joint inflammation, composed in particular of and possibly driven by the autoinflammatory TLR+ cells.

**ICW18-4**

Inhibitory cytokine synergy of IL-10 and TGF-β3 contributes to humoral immune tolerance mediated by metabolic reprogramming

Toshihiko Komai1, Tomohisa Okamura1,2, Mariko Inoue1, Kaoru Morita1, Yukiko Iwasaki1, Shuji Sumitomo1, Hirofumi Shoda1, Kazuhiko Yamamoto1,3,4, Keishi Fujio1 1Department of Allergy and Clinical Immunology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 2Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, 3Max Planck, Center for Integrative Inflammology, The University of Tokyo, Tokyo, Japan, 4Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Kanagawa, Japan

Conflict of interest: Yes

[Object] There is growing evidence that modulation of immunometabolism could be a therapeutic target in systemic lupus erythematosus (SLE). In this study, we assessed the effect of inhibitory cytokine synergy (ICS) of IL-10 and TGF-β3 on B cell metabolic reprogramming and lupus pathologies. [Methods] LPS-stimulated B cells in the presence or absence of IL-10 and/or TGF-β3 were analyzed by RNA sequencing (RNA-seq) and immunoblotting. Oxygen consumption rates (OCR) and extracellular acidification rates (ECAR), as a measure of oxidative phosphorylation and glycogenesis respectively, were evaluated by extracellular flux analyser. In vivo, the therapeutic effects of pCAGGS-Ill10, and/or pCAGGS-Tgfb3 plasmid vectors in NP-LPS immunized C57BL/6 mice and imiquimod (IMQ)-treated lupus model mice were assessed. In addition, metabolic signals from NP-LPS-immunized mice treated with anti-IL-10 and anti-TGF-β blocking antibody were evaluated by flow cytometry. [Results] RNA-seq and immunoblotting revealed that mammalian target of rapamycin (mTOR) signaling and metabolism pathway were preferentially suppressed in the IL-10/TGF-β3 condition. Intriguingly, both OCR and ECAR were reduced in IL-10/TGF-β3 condition, and enhancement of mTOR signals by MHY1485 counteracted the ICS effects. Simultaneous administration of pCAGGS-Ill10 and pCAGGS-Tgfb3 inhibited NP-specific and anti-dsDNA antibody production in NP-LPS immunized and IMQ-treated mice, respectively. Further, a combination of anti-IL-10 and anti-TGF-β antibody enhanced NP-specific antibody production with enforced phosphorylation of S6RP and mitochondrial membrane potentials in B cells. [Conclusions] Our findings indicate that ICS contributes to regulate systemic humoral immune responses and lupus pathologies via down-regulation of mTOR signaling and metabolic state in B cells. Fine tuning of immunometabolism mediated by ICS effect might provide novel therapeutic approaches for SLE.
ICW18-5
Modulation of arthritis by type 2 innate lymphoid cells
Yasunori Omata1,2, Georg Schett3, Mario Zais3
1Department of Orthopaedic Surgery, The University of Tokyo, 2Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and Universitätsklinikum Erlangen, Germany
Conflict of interest: None

[Object] Besides many well-characterized cellular and molecular components of innate and adaptive immune system that influence inflammatory processes, recent characterization of innate lymphoid cells (ILC) has revealed an essential role for these populations in the initiation, regulation and resolution of inflammation. ILC2 depend on the transcription factors GATA3 and RORα and produce the type 2 cytokines IL-4/13 upon the activation by IL-25/33. We investigate the role of ILC2 during inflammatory arthritis. [Methods] Human peripheral blood samples collected from patients with rheumatoid arthritis (RA) and healthy controls were analyzed by FACS. Tissue samples (spleen, blood and mesenchymal lymph nodes) from K/BxN serum induced arthritis model (SIA) and collagen induced arthritis (CIA) model were investigated at different time points. Gain (IL-25/33 mini-circle treatment, IL-2/IL-2 antibody complex treatment and adoptive transfer of wild-type or IL-4/13-/- ILC2) and loss (RORα -/-/GATA33/3 mice and Tie2cre/RORαfl/fl mice) of ILC2 function were investigated during arthritis were performed to unravel the role of ILC2. [Results] We detected significantly increased ILC2 in blood of RA patients compared to healthy controls. In both SIA and CIA, we detected insults during arthritis were performed to unravel the role of ILC2. [Conclusions] Our data suggests that ILC2 are protective to arthritis.

ICW19-1
Rheumatoid Meningitis: Meningeal Biopsy Is Not Essential for Diagnosis
Fawad Aslam1, Angela Parsons2, Marie Grill3, Brent P Goodman1
1Department of Rheumatology, Mayo Clinic, Scottsdale, Arizona, USA., 2Department of Neurology, Mayo Clinic, Scottsdale, Arizona, USA
Conflict of interest: None

[Objectives] Rheumatoid meningitis (RM) is a rare complication of RA. Current clinical practice relies on a meningeal biopsy for diagnosis. Previous reports have emphasized the importance of a biopsy to diagnose RM. Our study aimed to review the clinical history of RM and assess the role of meningeal biopsy in RM patients. [Methods] An administrative database search was done within the Mayo network from 1990-2017 to identify RM patients for this retrospective study. Patients were included if RA was diagnosed by a rheumatologist and RM was diagnosed both by a rheumatologist and neuroradiologist. [Results] Fourteen RM patients were identified. Mean age was 67 years and 57% were males. RA duration was from 0-40 years. None had seronegative disease. RA was controlled in 10/11 (91%) at RM diagnosis. Skin nodules were present in 4/13 (31%) and erosions in 3/10 (30%) patients. Headache, seizure and hemiparesis were the commonest presentations of RM. None had cranial neuropathies. Cerebrospinal fluid cell count and protein levels were abnormal in 11/14 (79%) cases. On MRI, all patients showed enhancement of the pachymeninges, leptomeninges or both: 12/14 (86%) had a frontoparietal pattern. Of the 10 biopsied patients, 90% had nonspecific inflammation. None showed vasculitis or rheumatoid nodules. Infections and IgG4 changes were absent. Corticosteroids, rituximab and methotrexate were used for treatment. 10/12 (83%) patients who underwent repeat MRI showed resolution. The 4 RM patients treated without a biopsy did similarly well. [Conclusion] RM can present at any time in RA and occurs in well controlled RA. MRI shows frontoparietal meningeval enhancement. Biopsy is negative for pathognomonic RM features. Those with suspected RM without biopsy do equally well. In contrast to the previous literature, our study shows that clinical evaluation, testing and imaging in RA patients with meningitis, in the absence of atypical features, is sufficient to diagnose RM without a biopsy.

ICW19-2
Screening by CT at the administration of bDMARDs has detected 25 patients with malignancy among 3015 patients with RA, from FIRST registry
Hiroko Miyata1, Kazuhisa Nakano1, Shingo Nakayama1, Shigeru Iwata1, Ayako Yamaguchi1, Shunshuke Fukuyo1, Satoshi Kubo1, Ippei Miyagawa1, Kazuoyoshi Saito2, Yoshiya Tanaka1
1The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2The Internal Department of Tobata General Hospital, Ikikai, Japan
Conflict of interest: None

[Objectives] To clarify the outcome of RA patients complicated with malignancy. [Methods] 3015 RA patients were screened using CT-scan before starting bDMARDs in our hospital between January 2005 to September 2017. csDMARD-IR RA patients after curative resection of malignancy were considered to start bDMARDs under adequate IC. The primary endpoint was the achievement rate of LDA (DAS28-ESR <3.2) at one year after discovery of malignancy. The secondary endpoints were taken as the patients’ background factors at the time of diagnosis of each malignancy. [Results] In the wake of CT scan, malignancy was diagnosed in 25 patients (lung cancer; 12, malignant lymphoma (ML), 4, breast can-
cer; 1, uterine cancer; 1, gallbladder cancer; 1, thyroid cancer; 1, bladder cancer; 1, liposarcoma; 1, kidney cancer; 1, GIST; 1. Four patients with advanced cancer (lung cancer, uterine body cancer, liposarcoma, malignant lymphoma each) received palliative care and the other 21 patients underwent surgery or chemotherapy. The 2-year survival rate was 78.6% (mean observation period: 31.9 months). DAS28-ESR was 5.57 at the time of malignancy diagnosis. 9 cases (36%) achieved LDA after one year. In 9 patients with bDMARD in 11 early cancers, 6 achieved LDA. 2 without bDMARD did not achieve LDA. In 4 cases with advanced malignancy, 2 with ML could maintain LDA with R-CHOP, and a case with thymic cancer/ breast cancer underwent surgery + chemotherapy, treated with low-dose GC + SASP, and shifted with LDA / HDA, respectively. The mean age of RA patients complicated with malignancy was significantly older than those without malignancy (67.9 vs. 61.2, p = 0.018). [Conclusion] Screening CT before starting biologics is very important and was useful for detection of early lung cancer in particular. Adequate diagnosis and management for malignancy could enable disease control of RA with bDMARDs.

ICW19-3
Clinical and prognostic characteristics of systemic lupus erythematosus related pseudo-intestinal obstruction in a multi-center cohort study
Liying Peng, Mengtao Li, Dong Xu, Qian Wang, Jiliang Zhao, Ziqian Wang, Xiaofeng Zeng
Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China

Conflict of interest: None

Object This study aimed to explore the clinical features and outcomes of systemic lupus erythematosus related pseudo-intestinal obstruction (SLE-IPO) in a multi-center cohort from China. Methods Patients were enrolled from 14 centers to establish a multi-center cohort of SLE-IPO and related data were collected retrospectively. SLE patients with clinical manifestations and image evidence of IPO were included. SLE patients without any gastrointestinal (GI) involvement were recruited as a control group. All-cause death and SLE flare as well as SLE-IPO flare were primary and secondary endpoints. Results 220 SLE-IPO patients and 440 SLE patients without GI involvement were included. The time from onset to SLE diagnosis were 4.1 months for SLE-IPO group and 2.0 months for control group. SLE-IPO patients were commonly complicated with smooth muscle dysfunction, including pyloureterectasis (38.6%), bladder contracture (12.7%), thick gallbladder wall (20.3%) and cholangiectasis (5.3%). SLEDAI score was higher in SLE-IPO group (9.5±6.2 vs. 5.9±6.6, p<0.001). SLE-IPO patients also had a larger proportion of specific organ involvement, including nephritis (56.8% vs. 33.2%), hematological involvement (58.2% vs. 47.5%), neuropyschiatric involvement (11.4% vs. 4.3%) and serositis (33.2% vs. 11.4%). SLE-IPO was associated with anti-SSA antibody (OR=2.005, p<0.001) and anti-RNP antibody (OR=2.776, p=0.001). We recorded 18 deaths and 66 flares in SLE-IPO group. Elevation of serum alkaline phosphatase (ALP) or γ-glutamyl transpeptidase (GGT) was the independent risk factor for death (HR=4.163, p=0.020). Independent risk factor for flare was anti-nucleosome antibody (HR=2.031, p<0.032). No independent risk factor was found for IPO flare. Conclusions SLE-IPO often presents with higher activity and specific organ involvements. Anti-SSA and anti-RNP antibodies were associated with SLE-IPO. Serum ALP or GGT elevation and anti-nucleosome antibody are potential predictors for death and SLE flare respectively.

ICW19-4
Risk Analysis of Pregnancy Complications in Patients with Connective Tissue Diseases: A Single-center Retrospective Study on Maternal and Fetal Outcomes
Eri Sugawara, Masaru Kato, Yuki Kudo, Wenshi Lee, Michihito Kono, Yuichiro Fujieda, Toshiyuki Bohgaki, Olga Amengual, Kenji Oku, Shinshuke Yasuda, Tatsuya Asumi
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan

Conflict of interest: None

Objectives: We aimed to evaluate the obstetric complications and the risk factors for these events in pregnant women with connective tissue diseases (CTDs). Methods: A single-center retrospective study of women with CTDs at Hokkaido University Hospital between 2007 to 2016 was conducted. Clinical features including general background, autoantibodies, therapies, disease flare, pregnancy complications as well as fetal outcomes were retrospectively collected. The rate of pregnancy complications was compared with the general obstetric population in Japan (GOP) provided by Japan society of obstetrics and gynecology. Results: Overall 133 pregnancies in 95 women with CTDs were recorded. Underlying CTDs were systemic erythematosus (SLE) (n=57), primary antiphospholipid syndrome (APS) (n=35), rheumatoid arthritis (n=10) and Other CTDs (n=31). Anti-phospholipid antibodies (aPL) in 43 pregnancies (32%), glucocorticoid use in 62 pregnancies (62%), tacrolimus use in 20 pregnancies (15%). There were 24 disease-flare (18%), but no CTD-related death. We recorded 113 live births, 7 abortions, 8 miscarriages and 6 stillbirths. In CTDs, emergency cesarean sections and pre-term deliveries appeared significantly more frequent than in GOP (30% vs 12%, p=0.001, 21% vs 5%, p=0.001). APS had the highest frequency of preterm deliveries (37%). Birth weight in SLE and APS were significantly lower than GOP (2417±790 g and 2207±1030 g vs 2853±569 g, p<0.001). In pregnancies with SLE, anti-DNA antibody positivity was significantly correlated with the risk of fetal complications (odds ratio 3.475, CI 1.081-11.168, p=0.036) and low complement level represented the risk of maternal complications (odds ratio 3.909, 1.026-14.884, p=0.046). Conclusion: Pregnancies with CTDs were at increased risk of having both maternal complications and adverse neonatal outcomes, suggesting that their pregnancies should be closely monitored.

ICW19-5
Mortality and complication of patients with rheumatoid arthritis admitted to intensive care unit in Kyushu University Hospital
Toshifumi Fujiwara1,2, Yukio Akasaki1, Satoshi Ikemura1, Junichi Fukushi1, Yasuharu Nakashima1
1Department of Orthopaedic Surgery, Kyushu University Hospital, 2Emergency and Critical Care Center, Kyushu University Hospital

Conflict of interest: None

Object] The patients with rheumatoid arthritis (RA) are associated with high mortality caused by comorbidity and complication, and are often required the intensive treatment. Severe infections are among the most common causes of their mortality in intensive care unit (ICU). To determine prognostic factors and mortality in patients with RA, including juvenile idiopathic arthritis (JIA), admitted to the ICU in Kyushu University Hospital, we examined the treatments of RA and JIA, comorbidities, complications, the reasons admitted to the ICU, intensive treatments, mortalities within 30 days and 1 year, retrospectively. [Methods] Between January 2010 and March 2018, 53 patients (17 males, 36 females) with RA or JIA staying at the ICU of our institution over 48 hours were included in this study. The admission to the ICU were performed total 59 times because 5 patients were admitted over twice. The average of age and RA duration at the admission was 66.4±17.7 years (5-96) and 13.5±14.1 years (0-61), respectively, and the average of follow-up duration was 724.4±893.3 days (3-3153). [Results] The reasons for ICU admission included cardiovascular complications (27.1%), infection (28.8%), neurological complications (3.4%), respiratory problem (11.7%), gastrointestinal problems (3.4%), endocrinological cause (3.4%), liver problems (8.5%), kidney problems (6.8%), and others (6.8%). The average of ICU length of stay was 7.0±6.3 days (2-24). The mortality within 30 days was 26.4% (14/53), and 18 of 47 patients (38.3%), excluded 6 patients from 53 patients due to the change of hospital within 30 days (7 patients:50%) and 1 year (9 patients:50%) were mainly caused by infection. [Conclusions] Our study has shown the high mortality of RA patients admitted to the ICU.
ICW19-6

The risk factors and prognosis of primary Sjögren’s syndrome-associated interstitial lung disease: a multi-center cohort study

Ziwei Liu, Qian Wang, Dong Xu, Mengtao Li, Xiaofeng Zeng
Peking Union Medical College Hospital

Conflict of interest: None

University Graduate School of Medicine
Department of Respiratory Medicine and Clinical Immunology, Osaka
Masayuki Nishide, Atsushi Kumanogoh

Peking Union Medical College Hospital

The risk factors and prognosis of primary Sjögren’s syndrome-associated interstitial lung disease (pSS-ILD). [Methods] Baseline clinical manifestations, lab tests, autoantibody, pulmonary function tests (PFT), chest high resolution CT (HRCT), and treatment were retrospectively collected from Peking Union Medical College Hospital and 27 CTD-ILD centers in China. Chest HRCT and PFT were performed to confirm and evaluate ILD. Patients with pSS but without ILD were enrolled as controls. The primary end point was all-cause death, and secondary end point was ILD deterioration, defined as FVC declining ≥10% and/or DLCO declining ≥15%. [Results] This cohort enrolled 258 patients with pSS-ILD, and 88% were female. Mean age was 58.0±10.6 years. In 44.2% of patients, ILD was the initial manifestation of pSS. Most common HRCT pattern was NSIP. FVC was 80.4±19.8%. 1243 pSS patients without ILD were enrolled as controls. Male (OR 2.494, 95%CI 1.166-5.333, p=0.018), age of pSS onset (OR 1.066, 95%CI 1.047-1.085, p<0.001), and anti-Ro52 antibody (OR 2.797, 95%CI 1.585-4.936, p=0.001) were identified as independent risk factors for ILD. In 230 patients with complete survival data, 18 patients died. The 1-, 3-, and 5-year cumulative survival rates were 96.6%, 86.3%, and 79.6%, respectively. Male (HR 4.810, 95%CI 1.271-18.205, p=0.021), age (HR 1.079, 95%CI 1.008-1.156, p=0.033), and DLCO<50 (HR 5.762, 95%CI 1.149-28.891, p=0.028) were identified as independent prognostic factors. A total of 50 patients entered the ILD deterioration analysis, and 14 deteriorated. Age of ILD onset (OR 1.072, 95%CI 1.012-1.155, p=0.018) was identified as predictive factor for ILD deterioration. [Conclusions] This study indicates that pSS patients with male gender, late pSS onset, and anti-Ro52 positivity are recommended to perform chest HRCT and PFT as early screening of ILD. DLCO, as a predictor of survival, should be evaluated at every follow-up visit in patients with pSS-ILD.

ICW20-1

Semaphorins and their involvement in the pathogenesis of autoimmune vasculitis

Masayuki Nishide, Atsushi Kumanogoh
Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine

Conflict of interest: None

[Object] Semaphorins are intimately associated with the pathogenesis of autoimmune diseases (Nishide and Kumanogoh, Nat Rev Rheumatol. 2018). Recently, we reported an inhibitory function of semaphorin 4D (SEMA4D) in neutrophil activation (Nishide et al. Ann Rheum Dis. 2017). Based on these findings, we aim to clarify how Semaphorin-mediated signaling is involved in the pathogenesis of ANCA-associated vasculitis (AAV). [Methods] In vivo study, we are developing a passive transfer model of acute AAV, using purified antibody or splenocytes taken from MPO-deficient mice immunized with recombinant mouse MPO. The model is evaluated by histological score of kidneys, laboratory findings, and flow cytometry analysis detecting neutrophil extracellular trap (NET) formation. In vitro study, cell transfectants are established by introducing a construct expressing SEMA4D. These transfectants were subjected to proteomics study, immunopresipitation assay, and reporter cell assay. [Results] In our model, mice exhibit glomeruli vasculitis andduced during KD’s acute inflammatory phase. [Object] This study aimed to investigate the risk factors and prognosis of primary Sjögren’s syndrome-associated interstitial lung disease (pSS-ILD). [Methods] Baseline clinical manifestations, lab tests, autoantibody, pulmonary function tests (PFT), chest high resolution CT (HRCT), and treatment were retrospectively collected from Peking Union Medical College Hospital and 27 CTD-ILD centers in China. Chest HRCT and PFT were performed to confirm and evaluate ILD. Patients with pSS but without ILD were enrolled as controls. The primary end point was all-cause death, and secondary end point was ILD deterioration, defined as FVC declining ≥10% and/or DLCO declining ≥15%. [Results] This cohort enrolled 258 patients with pSS-ILD, and 88% were female. Mean age was 58.0±10.6 years. In 44.2% of patients, ILD was the initial manifestation of pSS. Most common HRCT pattern was NSIP. FVC was 80.4±19.8%. 1243 pSS patients without ILD were enrolled as controls. Male (OR 2.494, 95%CI 1.166-5.333, p=0.018), age of pSS onset (OR 1.066, 95%CI 1.047-1.085, p<0.001), and anti-Ro52 antibody (OR 2.797, 95%CI 1.585-4.936, p=0.001) were identified as independent risk factors for ILD. In 230 patients with complete survival data, 18 patients died. The 1-, 3-, and 5-year cumulative survival rates were 96.6%, 86.3%, and 79.6%, respectively. Male (HR 4.810, 95%CI 1.271-18.205, p=0.021), age (HR 1.079, 95%CI 1.008-1.156, p=0.033), and DLCO<50 (HR 5.762, 95%CI 1.149-28.891, p=0.028) were identified as independent prognostic factors. A total of 50 patients entered the ILD deterioration analysis, and 14 deteriorated. Age of ILD onset (OR 1.072, 95%CI 1.012-1.155, p=0.018) was identified as predictive factor for ILD deterioration. [Conclusions] This study indicates that pSS patients with male gender, late pSS onset, and anti-Ro52 positivity are recommended to perform chest HRCT and PFT as early screening of ILD. DLCO, as a predictor of survival, should be evaluated at every follow-up visit in patients with pSS-ILD.

ICW20-2

Transcriptomic analysis can identify decreased DNA methyltransferases expression and is associated with coronary artery lesion formation in Kawasaki disease

Huang Ying-hsiens, Kuo Ho-changs
1Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, 2Kawasaki Disease Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Conflict of interest: None

[Object] Kawasaki disease (KD) is the most common acute coronary vasculitis disease to occur in children. Although we have uncovered global DNA hypomethylation in KD, its underlying cause remains uncertain. In this study, we performed a survey of transcript levels of DNA methyltransferases and demethylases in KD patients. [Methods] We recruited 145 participants for this study. The chip studies consisted of 18 KD patients that were analyzed before undergoing intravenous immunoglobulin (IVIG) treatment and at least 3 weeks after IVIG treatment, as well as 36 control subjects, using Affymetrix GenChip Human Transcriptome Array 2.0. An additional study of 91 subjects was performed in order to validate real-time quantitative PCR. [Results] In our microarray study, the mRNA levels of DNMT1 and DNMT3A were significantly lower while TET2 was higher in acute-stage KD patients compared to the healthy controls. Through PCR validation, we observed that the expression of DNMT1 and TET2 are consistent with the Transcriptome Array 2.0 results. Furthermore, we observed significantly lower DNMT1 mRNA levels following IVIG treatment between those who developed CAL and those who did not. [Conclusion] Our findings provide an epigenetic study of DNA methyltransferases and demethylases changes and are among the first evidence that transient DNA hypomethylation is induced during KD’s acute inflammatory phase.

ICW20-3

Rheumatoid Factor Relates to Characteristic Manifestations in Patients with Eosinophilic Granulomatosis with Polyangiitis

Jun Inamo, Yuko Kaneko, Yuichiro Ota, Tsutomu Takeuchi
Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine

Conflict of interest: None

[Object] To investigate the role of rheumatoid factor (RF) in patients with eosinophilic granulomatosis with polyangiitis (EGPA). [Methods] Consecutive patients who were newly diagnosed with EGPA from August 1998 to January 2018 in Keio University Hospital with RF titre at diagnosis available were enrolled. We divided patients according to the median level of RF titre (75 IU/mL) and compared clinical features between two groups. [Results] Fifteen patients were enrolled in the study. The mean age was 54.5 years old, and 73% were female. Among them, 7 patients were in the RF high titre group (RF=75 IU/mL) and 8 patients were in the RF low titre group (RF<75 IU/mL). While the Birmingham Vasculitis Activity Score was comparable between the two groups (22.4 vs 19.0, p=0.451), the count of eosinophil at diagnosis was significantly higher in RF high titre group than RF low titre group (20207/µl vs 5144/µl, p=0.013). All patients with positive MPO-ANCA were in the RF low titre group, Gastrointestinal and skin lesions were more frequent in the RF high titre group, and parenchymal organ lesions, such as heart and renal organ involvement, were frequent in the RF low titre group. MPO-ANCA titre was significantly correlated with RF titre in the low RF titre group (r=0.675, p=0.027). [Conclusions] EGPA patients can be classified to two subgroups according to RF titre. Those two subgroups showed different clinical and serological features, suggesting EGPA might be caused by two distinct pathogenesis.

ICW20-4

Endothelial protein C receptor and scavenger receptor class B type 1 are major autoantigens in Takayasu arteritis

Tomoyuki Mutoh, Tsuyoshi Shirai, Hiroshi Fuji, Tomonori Ishitani, Hideo Harigae
Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine
[Object] Takayasu arteritis (TAK) predominantly affects females in Asia. Although the presence of anti-endothelial cell antibodies (AECA)s have been reported in TAK, it has been difficult to identify autoantigens. We used a serological identification system for autoantigens using a retroviral vector and flow cytometry (SARF), and tried to identify autoantigens in TAK. [Methods] AECA activity against human umbilical vein endothelial cells (HUVEC) was measured and selected as prototype AECA for SARF. Rat myeloma cells expressing HUVEC cDNA library were generated, and stained with prototype AECA.s. Then, cells with strong fluorescence were sorted by flow cytometry, and cDNA inserted was analyzed. The frequency and specificity of autoantibodies, and the clinical characteristics were evaluated. [Results] SARF was performed by using nine TAK sera with AECA activities. Four clones which bound to prototype AECA were successfully established by limiting dilution methods. HUVEC cDNA inserted into each clone was cloned and confirmed that endothelial protein C receptor (EPCR) and scavenger receptor class B type 1 (SR-BI) were novel autoantigens in TAK. Among 51 TAK patients, 15 (33.3%) or 17 (34.7%) showed AECA activity against EPCR or SR-BI, respectively. The overlap was observed in 2 patients (3.9%). TAK was classified into 3 subtypes based on the profile of autoantibodies. Anti-EPCR group showed high prevalence of stroke, ulcerative colitis, and type II artery lesion. Anti-SR-BI group presented higher levels of inflammatory markers, type V artery lesion, and older age at onset. Aortic regurgitation (AR) was rare in anti-SR-BI group. Double-negative group presented higher rates of surgery for AR. [Conclusions] EPCR and SR-BI were identified as major autoantigens in TAK. AECA.s against EPCR or SR-BI were observed in 66.7% of patients. Autoantibodies against these membrane proteins could be used for classification and management of TAK in clinical practice.

ICW20-5 Tocilizumab Monotherapy for Large Vessel Vasculitis, Results of 104-week Treatment of a Prospective, Single-Center, Open Study Shuntaro Saito 1,2, Ayumi Okuyama 2, Yusuke Okada 2, Akiko Shibata 2, Ryota Sakai 3, Kentaro Chino 2, Takahiko Kurasawa 2, Tsuneo Kondo 2, Hirofumi Takei 4, Koichi Amano 2

1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, 2Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University, 3Department of Microbiology and Immunology, Keio University School of Medicine

Conflict of interest: None

[Object] To evaluate the efficacy and safety of tocilizumab (TCZ) monotherapy for Large Vessel Vasculitis (LVV), including Takayasu arteritis (TAK) and Giant cell arteritis (GCA). [Methods] Eleven LVV patients (3 TAK patients and 8 GCA patients) who had been newly diagnosed at our hospital from January 2013 to May 2016 were studied. TCZ (8mg/kg) was administered intravenously every 2 weeks for the first 2 months and every 4 weeks for the next 10 months (total 15 times) without any corticosteroid (CS) or immunosuppressants (IS). Patients were followed for another 1 year after last TCZ administration without any treatment. The efficacy was assessed by clinical symptoms (fever, headache, etc.) and CRP level. Complete and partial response (CR and PR) was defined as disappearance or improvement of all clinical symptoms due to vasculitis and normalization of CRP. Poor clinical response was defined as patients who did not satisfy the criteria of CR/PR/relapse. Relapse of the disease was defined as the worsening or recurrence of clinical symptoms, increase of CRP attributable to activity of vasculitis. [Results] The mean age was 58.9 y/o, the mean disease duration was 3.4 months, mean CRP was 6.0 mg/dl at the diagnosis of the LVV. Efficacy of the TCZ monotherapy in active LVV was assessed in 11 patients. Although 1 GCA patient had TCZ withdrawal due to heart failure at week 24, there were no other serious adverse events. Relapse after TCZ cessation was assessed in 10 patients who completed week 52. CR and PR rate were 73%/18% at week 24, and were maintained at week 52. Relapse occurred in 40%, although 60% completed week 104 after TCZ cessation. [Conclusions] This is the first study to show the effectiveness of TCZ monotherapy in LVV patients, which could suggest the crucial role of IL-6 in the pathogenesis of LVV. TCZ monotherapy showed high response rate as an induction therapy, and some of the patients did not require maintenance therapy after TCZ cessation.

ICW20-6 Poor obstetric outcomes in North Indian women with Takayasu’s arteritis Latika Gupta, Durga Misra, Sakir Ahmed, Avinash Jain, Abhishek Zanwar, Amita Aggarwal, Vikas Agarwal, Able Lawrence, Ramnath Misra Sanjay Gandhi PostGraduate Institute of Medical Sciences, Lucknow, India

Conflict of interest: None

[Body] Takayasu’s arteritis (TA) affects young women in the childbearing age group. We studied obstetric outcomes in these patients before and after disease onset. [Methods] Women aged more than 18 years with Takayasu’s arteritis (ACR 1990 criteria) were included. Demographic data, clinical features, menstrual status, history of conception and maternal and fetal outcomes were recorded from hospital records and telephonic interview. Results are in median and IQR. [Results] In 64 women with TA of age 29 (24-38) years and disease duration 5 (4-10) years, 74 pregnancies had occurred before disease onset in 29 women, while 20 had a total 38 pregnancies after onset of disease. In eight, diagnosis was made during pregnancy. Age at disease onset was 22 (18-30) years. Type 5 disease was the most common (n=32, 59.3%), and equal number of patients had Ishikawa’s class 1 and II disease (n=26, 40.6%). Median ITAS (n=44) was 13 (7-16), DeTak 12.5 (9-16.75) and TADS 8 (6.5-10). 16 were unmarried of whom 6 did not marry due to disease. 25 patients wanted to get pregnant, of which 8 (30%) did not do so because of her disease. Obstetric outcomes were poorer in pregnancies that occurred after the onset of disease as compared with those prior to it (RR=1.5, p=0.01). Pregnancies after onset of TA carried very high risk of maternal (RR3.9, P<0.001) as well as fetal complications (RR= 2.0, p=0.001). Hypertension was the most common maternal complication (Table 1), and it occurred most often in the last trimester. The baby weight at birth was lower in births after disease (2.3 vs. 3.0, p=0.01). Wong’s score greater than or equal to 4 predicted lower birth weight (p=0.04). ITAS scores exhibited moderate correlation with DeTak (r=0.78) and TADS (r=0.58). ITAS, ITAS-A, DeTak and TADS could not predict obstetric outcomes. [Conclusions] Women with TA suffer from poor maternal as well as fetal outcomes.

ICW21-1 Integrated bulk and single-cell RNA-sequencing identified disease relevant monocyte subset and key driver inflammatory gene module of systemic sclerosis Satomi Kobayashi 1, Yasuo Nagafuchi 1, Hirofumi Shoda 1, Mai Okubo 1, Yusuke Sugimori 1, Mineto Ota 1,2, Yusuke Takeshima 1,2, Shuji Sumitomo 1, Tomohisa Okamura 1,2, Kazuhiko Yamamoto 1,2, Keishi Fujio 1

1Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 2Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, 3Center for Integrative Medical Sciences, RIKEN

Conflict of interest: Yes

[Object] This study aimed to elucidate the characteristic transcriptional patterns of peripheral blood immune cells in systemic sclerosis (SSc) and to identify responsible single cells and driver genes of SSc. [Methods] We sorted peripheral blood immune cells from SSc patients and healthy controls (HCs) into 20 cell subsets using flow cytometer, and performed RNA-sequencing (RNA-seq). We performed differentially expressed genes (DEGs) analysis and weighted correlation network analysis (WGCNA) using RNA-seq data of all subsets and found modules of strongly correlated genes. Knowledge-based pathway analysis was performed with Ingenuity Pathway Analysis (IPA). Single-cell RNA-seq of 878 monocytes from SSc patients were performed with ICELL8 system. We defined each cluster signature scores, using marker genes of each single-cell cluster. Bayesian network analysis, not relying on any biological knowledge, was performed to validate key driver genes in SSc. [Results] All subsets showed enhanced inflammatory cytokine signaling. WGCNA data indicated that monocytes had the strongest correlation with DEGs in SSc patients. A total of 35 DEGs were identified, including several key driver genes. [Conclusions] This study identified candidate drivers of systemic sclerosis and suggested the involvement of monocytes in the disease pathogenesis.
showed that monocyte inflammatory gene module, including JUNB, NFκB1A, and CXCL8, was one of the most characteristic modules in SSc. Single-cell RNA-seq of monocytes from SSc patients revealed that monocytes were divided into 7 clusters. The monocytes in one “inflammation cluster” characterizedly expressed inflammatory module genes. This inflammatory single-cell signature was elevated in bulk monocytes in SSc. Bayesian network analysis validated inflammatory gene module as key upstream driver genes in SSc and identified candidate marker genes. [Conclusions] Monocytes play a crucial role in the pathogenesis of SSc for producing inflammatory cytokines. Disease-relevant monocytes, characterized by high expression of inflammatory module genes might be a novel therapeutic target in SSc.

ICW21-2
Efficacy and safety of botulinum toxin B injection for Raynaud’s phenomenon and digital ulcers in patients with systemic sclerosis: single-blind, randomized trial
Sei-ichiro Motegi, Osamu Ishikawa
Department of Dermatology, Gunma University Graduate School of Medicine

Conflict of interest: None

[Object] Patients with systemic scleroderma (SSc) typically develop Raynaud’s phenomenon (RP) and persistent digital ischemia and often develop digital ulcers (DUs). Currently, there is no satisfactory treatment for RP and DUs in SSc. We previously reported that botulinum toxin A (BTX-A) injection was effective for the treatment of RP and DUs in SSc patients. However, the efficacy of BTX-B injection has never been examined. The objective was to assess the efficacy and safety of BTX-B for treatment of RP and DUs in SSc patients. [Methods] In the prospective, single-blind, randomized trial, total 45 SSc patients with RP were blinded and randomly divided into 4 groups; no treatment control group, and 3 treatment groups, using 250, 1,000 or 2,000 U of BTX-B injections in the hand with more severe symptoms (UMIN000019985). [Results] Four weeks after injection, the pain/numbness VAS and Raynaud’s score (indicating the severity of RP in SSc patients) in the 1,000- and 2,000-U-treated groups were significantly lower than in the control group and 250-U-treated group. These beneficial effects were sustained until 16 weeks after the single injection. At 4 weeks after injection, skin temperature recovery in the 2000-U-treated group was significantly improved. The numbers of DUs in the 1,000- and 2,000-U-treated groups were significantly lower than in the control group. Furthermore, no new DUs developed in the groups treated with 1,000 and 2,000 U for 16 weeks after injection. No systemic or local adverse events were observed in any patients. [Conclusion] We conclude that 1,000 and 2,000 U BTX-B injection significantly suppressed the activity of RP and DUs in SSc patients without any serious adverse events, suggesting that BTX-B might have potential as a long-term preventive and therapeutic agent for RP and DUs in SSc patients. Based on this clinical research result, we are currently doing investigator-initiated clinical trial (A double-blind, randomized, placebo-controlled trial).

ICW21-3
Endothelial ephrin B2 signaling drives protection against pulmonary fibrosis
Brian Wu1, Sayaka Nakamura1,2, David Lagares1, Evgeny Rossomacha2, Akhiro Nakamura1,2, Pouliami Datta1, Arsfatuzzaman Raza1, Philippe P Monnier2, Jianping Wu2, Boris Hinz2, Mohit Kapoor1,2
1Departments of Surgery and of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada, 2Division of Genetics and Development, Krembil Research Institute and University Health Network, Toronto, Ontario, Canada, 3Division of Pulmonary and Critical Care Medicine, Fibrosis Research Center and Center for Immunology and Inflammatory Disease, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA, 4Vision Division, Krembil Research Institute, Toronto, Canada, 5Department of Medicine, University of Montreal Hospital Research Centre (CRCHUM), Montreal, Québec, Canada, 6Laboratory of Tissue Repair and Regeneration, Matrix Dynamics Group, Faculty of Dentistry, University of Toronto, Toronto, Canada

Conflict of interest: None

[Object] Ephrin B2 is a signaling ligand prominently expressed in endothelial cells and has been implicated in driving vasculogenesis and the wound healing response. We have previously shown that ephrin B2 expression in fibroblasts promote myofibroblast activation and migration, which strongly influences the development of fibrosis. Indeed, knockout of ephrin B2 in fibroblasts was shown to provide partial protection against induced pulmonary fibrosis. We seek to understand the role of endothelial-expressed ephrin B2 in pulmonary fibrosis. [Methods] We have generated endothelial-specific knockouts for ephrin B2 and the eB4 receptor for the Cre recombinase system. Genetic knockouts were induced through tamoxifen treatment (1 mg/day in 100 µl corn oil; 5 days) and bleomycin (1.2 U/kg in 50 µL PBS), intratracheally instilled to promote the development of pulmonary fibrosis. Mice were sacrificed at 14-days post bleomycin and fibrosis is assessed through histological staining (Masson’s Trichrome). [Results] Our conditional ephrin B2 knockout mice were confirmed through biochemical assessment and genotyping. Our endothelial knockout of ephrin B2 provides notable protection against the development of bleomycin-induced pulmonary fibrosis in mice compared to corn oil/PBS treated controls. Image quantification of Masson’s Trichrome staining indicated substantial protection against the development of pulmonary fibrosis. [Conclusions] Ephrin B2 in endothelial cell may drive pro-fibrotic processes and the cell-specific knockout appears to drive protection against the development or progression of fibrosis in mouse lungs. Our ongoing studies are assessing whether ephrin B2 is mediated through its receptor ephB4 in fibroblasts and endothelial cells. We anticipate pro-fibrotic character of ephrin B2 may be mediat ed through eB4 receptor.

ICW21-4
Aryl hydrocarbon receptor signals attenuate lung fibrosis in bleomycin induced mice model for pulmonary fibrosis through increase of regulatory T cells in the lung
Hiroshi Takei1,2, Hidekata Yasuoka1,3, Keiko Yoshimoto1,4, Tsutomu Takeuchi1
1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Center for Arthritis and Rheumatic Diseases, Kawasaki Municipal Kawasaki Hospital, Kawasaki, Japan, 3Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine, Nagoya, Japan, 4Clinical and Translational Research Center, Keio University Hospital, Tokyo, Japan

Conflict of interest: None

[Object] Systemic sclerosis (SSc) is characterized by autoimmunity and systemic fibrosis. Recent reports suggest that aryl hydrocarbon receptor (AhR) signals by various ligands such as tryptophan derivatives can induce immune responses including autoimmunity. The aim of this study is to investigate the effect of immunological changes induced by AhR signals can affect the process of fibrosis using the animal model. [Methods] Bleomycin (BLM) was intratracheally administered to C57BL/6 mice at a dose of 0.06 units/body. Either 1 µg of 5,11-Dihydroindolo [3,2-b] carbazole-6-carboxaldehyde (FICZ), a natural AhR ligand, or vehicle was i.p. administered at week 3 by histopathology score (Ashcroft score) and the deposition of lung fibrosis at week 3 evaluated by histological staining. The Ashcroft score was revealed to be lower in FICZ group compared to corn oil/PBS treated controls. Image quantification of Lung fibrosis led to better survival during 21 days in FICZ group (p < 0.05). Other subsets such as B cells, NK cells, neutrophils, IL-17A+CD4+ T cells and IL-17A+γδ+ T cells were reduced (4.8x104 ± 0.6 vs 2.5x104 ± 1.4, p < 0.05) Other subsets such as B cells, NK cells, neutrophils, IL-17A+CD4+ T cells and IL-22+CD4+ T cells were comparable between two groups. Semi-quantification of lung fibrosis using flow cytometry. Pulmonary fibrosis was evaluated at week 3 by histopathology score (Ashcroft score) and the deposition of collagen detected by colorimetric assay. [Results] Flow cytometry analyses revealed more CD4+Fox3+ Treg infiltration in the lung of FICZ group at week 1 (4.1x104 ± 1.0 vs 2.5x104 ± 0.6, p < 0.05) whereas IFNγ+CD4+ T cells and IL-17A+γδ+ T cells were reduced (4.8x104 ± 1.4 vs 10.3x104 ± 1.9 and 1.2x104 ± 0.6 vs 2.7x104 ± 0.5 respectively, p < 0.05). Other subsets such as B cells, NK cells, neutrophils, IL-17A+CD4+ T cells and IL-22+CD4+ T cells were comparable between two groups. Semi-quantification of lung fibrosis at week 3 evaluated by histopathology score (Ashcroft score) was revealed to be lower in FICZ group compared to vehicle group (2.7 ± 0.8 vs 4.6 ± 0.6, p < 0.01), which was further confirmed by lower lung soluble collagen at week 3 in FICZ group (2042 ± 277 µg vs 4423 ± 1296 µg, p < 0.01). Furthermore, improvement of lung fibrosis led to better survival during 21 days in FICZ group (p < 0.05). [Conclusions] Stimulation of AhR signals attenuated pulmonary fibrosis induced by BLM. Immunological changes induced by AhR stimulations may contribute to ameliorate succeeding fibrotic processes in vivo.
ICW21-5
Estimation by nailfold videocapillaroscopy (NVC) is valuable to predict interstitial pneumonitis in patients with SSC
Yurie Sato1, Satoshi Kubo1, Kazuhisa Nakano1, Shingo Nakayamada1, Yasuyuki Todoroki2, Shigeru Iwata1, Kentaro Hanami2, Shunsuke Fukuyo1, Akio Kawabe1, Yusuke Miyazaki1, Minoru Satoh2, Yoshiha Tanaka1
11st Department of Internal Medicine, University of Occupational and Environmental Health, Japan, 2Department of Clinical Nursing, School of Health Sciences, University of Occupational and Environmental Health, Japan
Conflict of interest: None

[Objective] Detection of microvascular abnormalities by NVC enables early diagnosis of SSC. However, how these microvascular abnormalities contribute to fibrogenesis is not well known. We investigated the relationship between nailfold capillary changes and interstitial lung disease (ILD) which represents tissue fibrosis in SSC. [Methods] 247 SSC patients were enrolled. Nailfold capillary was evaluated and classified into 4 types of NVC pattern by using NVC (N: Normal, E: Early, A: Active, L: Late). We evaluated ILD quantitatively with using CT scoring method. [Results] The mean age was 64.8 years and the mean disease duration was 7.6 years. The prevalence of ILD was 32.8% and NVC abnormalities was 66.8%. As NVC pattern progress, complication of ILD was increased (Incidence rates of ILD: N: 29.1%, E: 27.6%, A: 33.3%, L: 51.4%). There were around 30% of patients who had ILD without NVC abnormalities. Regarding the changes of NVC abnormalities, 62.1% of patients remained unchanged and 22.4% worsened at 1 year. As for ILD, 34.0% improved, 34.0% unchanged and 32.0% worsened in 47 patients who could follow up with CT after 1 year. The changes of ILD were correlated with baseline NVC pattern, 7 patients (58%) who had Active pattern at baseline showed improvement of ILD. Moreover, 43.8% of those cases showed improvement of NVC abnormalities. While, improvement of ILD was only found in 10% of Late pattern. In contrast, improvement of ILD remained in 33.3% of Normal pattern. Consistently, progression of nailfold abnormality was not observed in Normal pattern even ILD worsened. [Conclusions] Most of the cases with advanced capillary abnormality had a higher incidence and the degree of capillary abnormality correlated with treatment response to ILDs. However, ILD and NVC abnormality progressed independently in some cases. These results suggest that the association between fibrosis and microvascular abnormalities is not uniform and NVC may be beneficial to detect such heterogeneity of SSC.

ICW21-6
Incidence And Prognostic Factors For Exacerbation In Patients With Interstitial Pneumonia With Autoimmune Features
Okinori Murata
Division of Pulmonary Medicine, Allergy, and Rheumatology, Department of Internal Medicine, Iwate Medical University School of Medicine
Conflict of interest: None

[Objective] Patients with idiopathic interstitial pneumonia (IIP) may have features of connective tissue diseases (CTDs). The term interstitial pneumonia with autoimmune features (IPAF) has been recently proposed for such patients. A few studies have been reported in prevalence of IPAF which was varied from 7.3% to 34.1%. Factors reported to indicate a poor prognosis in IPAF include age, smoking history, decline in %DLCO and presence of a multi-compartment feature within the morphological domain. To date, however, no study has comprehensively described prevalence of IPAF and factors of exacerbation. The aim of study was to identify of prevalence of IPAF in patients with interstitial lung disease (ILD), prognostic factors for exacerbation. [Methods] Of 672 patients who had visited our department between April 2009 and March 2018, 68 patients who diagnosed as IPAF were enrolled. They were divided into two groups, which presented exacerbation and non-exacerbation. Clinical, laboratory and imaging data were collected from medical records and statistically analyzed. [Results] Prevalence of IPAF was 10.1%. Of 68 patients with IPAF, 53% were women and mean age at diagnosis was 64.2 ± 13.8 years old. Mean observation period was 28.8 ± 30.4 months. Exacerbation rate was 25% (n=17). Overall death rate was 5.9% (n=4) and respiratory death rate was 2.9% (n=2). Comparison of characteristics at diagnosis between the exacerbation group and non-exacerbation group showed that the exacerbation group had a significantly elevated rate of smoking, KL-6, and SP-D (P=0.012, 0.0064, and 0.029, respectively). [Conclusions] Our large-scale cross-sectional cohort study revealed prevention of IPAF in patients with ILD and identified three baseline factors associated with exacerbation in the patients with IPAF.

ICW22-1
Functional recovery of Hip Fracture Patients with Rheumatoid Arthritis: Retrospective Analysis using a National Database in Japan
Hiroyuki Okada, Takumi Matsumoto, Yasunori Omata, Jun Hirose, Sakae Tanaka
Department of Orthopaedic Surgery, The University of Tokyo
Conflict of interest: None

[Objective] The object of this study was to clarify the prognosis of hip fracture with Rheumatoid Arthritis (RA) with a national database separately divided into femoral neck and trochanteric fractures. [Methods] A total of 71,687 femoral neck fracture patients and 70,196 femoral trochanteric patients without psychiatric disorder including dementia were enrolled. They were admitted with ambulance between April 2010 and March 2015. They were dichotomized into two groups: with RA or without RA (non-RA). Baseline demographic information included age, sex, smoking, obesity, and comorbidities. The primary outcome was mortality during hospitalization. The secondary outcome was in-hospital change of Barthel index. Univariable analysis compared outcomes between RA or non-RA group using two-tailed unpaired t-test for continuous variable and chi-square test for discontinuous variable. Multivariable analysis extracted risk factors of mortality and improving factors of Barthel index. [Results] The numbers of RA patients were 1,444 in femoral neck and 1,086 in femoral trochanteric fracture. More femoral neck fracture occurred in RA patients [2.01% vs 1.55%; chi-square test p < 0.001]. Patients in RA group were younger [neck 76.0 years vs 79.1 years; p < 0.001; trochanteric 79.5 years vs 83.1 years; p < 0.001]. In univariable analysis, mortality rate was lower in RA group [neck 2.08% vs 3.26%; p = 0.012; trochanteric 1.84% vs 2.86%; p = 0.045]. Multivariable analysis showed no significant difference in mortality. Barthel index in RA group was better both at admission and at discharge, besides, the improvement was also better. Multivariable linear regression analysis revealed that RA was ADL improving factor in neck fracture with [Coefficient 2.29 [95% CI 0.30 to 4.28]]. [Conclusions] Our large-scale cross-sectional cohort study revealed prevention of hip fracture in RA group was not inferior to non-RA patients. Besides, ADL recovery of neck fracture was better in RA groups. One of the reasons might be loss of ADL with injury was limited in RA group.

ICW22-2
The clinical outcome of MSK unconstrained total elbow arthroplasty in patients with rheumatoid arthritis
Naoki Kondo1, Katsumitsu Ara2, Junichi Fujisawa1, Naoto Endo1, Tadamañ Hanyu1
1Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Division of Orthopaedic Surgery, Niigata Prefectural Chuo Hospital, Joetsu, Japan
Conflict of interest: None

[Objective] Total elbow arthroplasty (TEA) is a treatment option for destructive and painful unstable elbows in patients with rheumatoid arthritis (RA). We evaluated the clinical outcome of unconstrained total elbow arthroplasty (MNSK system). [Methods] 75 unconstrained TEAs were performed in patients with RA (mean age, 64 years; range, 41-79 years). Total follow up rate was 97 %. Outcome measures included the Japanese Orthopaedic Association functional evaluation score for the elbow joint (JOA score), range of motion, and arc. Bone ingrowth of the humeral component, the incidence of stress shielding around the humeral stem, and incidence of loosening of the ulnar component, complications, and survival rate were investigated. [Results] Mean follow-up was 5.2 (range, 2-11.3) years. The JOA elbow score improved from 42 points preoperatively to 87 points postoperatively (p=0.0001). Each subitem improved...
(p<0.0001). Flexion improved from 109° to 134°; the flexion plus extension arc improved from 70° to 108° (p<0.0001). Bone ingrowth of the humeral implant were achieved in all elbows. Stress shielding of the humeral component was detected in 11 elbows (14%); it was significantly higher in 10-mm-diameter and 9-mm-diameter humeral stems than in 8-mm-diameter ones (p=0.008). The ulnar component showed no loosening, except 1 elbow due to infection. Complications were detected in 9 patients (9 elbows, 12 %): periprosthetic infection (3), fracture (4), and dislocation (2). Survival rates were 97% at 5 years and 93% at 10 years postoperatively. [Conclusions] The unconstrained MNSK system for patients with RA showed good outcome in the JOA score and range of motion with a good survival rate. Stress shielding can be avoided by using an 8-mm-diameter humeral stem.

ICW22-3
Proof-of-concept data showing differential effects of ex vivo polarized monocyte/macrophages in a novel human osteoarthritis explant model
Mable Wing Yan Chan 1,2, Alejandro Gomez-aristizabal 1, Rajiv Gandhi 1, Wayne Marshall 1, Nizar Mahomed 1, Sownmya Viswanathan 1,2,4
1Arthritis Research Program, University Health Network, Toronto, Canada, 2Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Canada, 3Cell Therapy Program, University Health Network, Toronto, Canada, 4Division of Hematology, Department of Medicine, University of Toronto, Toronto, Canada
Conflict of interest: None

[Object] Monocytes/macrophages (MΦs, as a heterogenous population) are innate immune cells that mediate inflammation and homeostatic tissue repair. We have identified pro-inflammatory MΦs as the major immune infiltrators of osteoarthritic (OA) joints. We aim to understand the role of pro-inflammatory (M1) versus homeostatic (M2) MΦs within OA and propose that modulation of the MΦ populations via ex vivo polarized MΦ-based cell therapy will serve as a multimodal treatment that reduces both inflammation and matrix degradation. [Methods] We developed a human explant model using OA cartilage and synovium from total knee replacements that can measure changes in gene expression (qRT-PCR) and extracellular matrix (ECM) catabolism (Safranin-O cartilage histology, cytokeratin and protease inhibitor levels in medium by immunobeaosay). CD14+ MΦs were isolated from peripheral blood and ex vivo polarized into pro-inflammatory (M1, IFN-γ+LPS) and homeostatic (M2, IL-10+TGF-β) MΦs by previously optimized 48 h cytokine protocols. Ex vivo polarized MΦs were then co-cultured with explants and samples were harvested at 2- and 7-day. [Results] Principal component analysis of our OA cartilage gene panel demonstrates differential effects of pro-inflammatory M1 MΦs versus homeostatic M2 MΦs (N=6). Addition of M1 MΦs upregulates catabolic ECM and pro-inflammatory genes and downregulates anabolic genes in OA cartilage. M2 MΦ treatment upregulates anabolic ECM gene expression. Changes in protein levels of soluble TIMP1 mirror gene expression, with 1.5-fold increase in the M1 group and 1.4-fold decrease in the M2 group (N=6). Synovium gene expression was variable (N=4), although addition of M1 MΦs trends upregulation of pro-inflammatory and chemotactic genes. [Conclusions] Polarized MΦs play a significant role in the modulation of the OA inflammatory and degradative microenvironment. Our findings provide proof-of-concept towards using MΦ-based therapy as a novel method for treating OA.

ICW22-4
Knee osteoarthritis and menopausal hormone therapy in postmenopausal women: a nationwide study
Jae Hyun Jung1,2, Gwan Gyu Song1,2, Sung Jae Choi1,2, Bang Cho Hee3,4
1Korea University College of Medicine, Seoul, Korea, 2Division of Rheumatology, Department of Internal Medicine, Korea University Guro Hospital, Seoul, Korea, 3Division of Rheumatology, Department of Internal Medicine, Korea University Ansan Hospital, Ansan, Gyeonggi, Korea, 4Korea University College of Nursing, Seoul, Korea
Conflict of interest: None

[Object] The incidence of osteoarthritis (OA) increases after menopause, and this is related to hormonal changes in women. Estrogen deficiency is known to affect the development of OA, and menopausal hormone therapy (MHT) is suggested to be related to the development of OA. However, the relationship between knee OA and MHT remains controversial. The association between knee OA prevalence and MHT was investigated using large-scale national data. [Methods] Data were collected from 4766 postmenopausal women from the Korea National Health and Nutrition Examination Survey (2009-2012). We included. MHT was defined as regular hormone medication for ≥1 year, and demographic and lifestyle variables were compared between the MHT and non-MHT groups. Knee OA was defined according to symptoms and radiographic findings. [Results] In the multiple logistic regression models (adjustment for MHT duration, age, BMI, menarche and menopause age, HTN, DM, alcohol consumption, smoking status, and socioeconomic status), the OA odds ratio was 0.70 for the MHT group (95% confidence interval, 0.50-0.99), compared to the non-MHT group. [Conclusions] The prevalence of knee OA was lower in participants with MHT than in those without MHT.

ICW22-5
Annihilation of Surgically-induced Osteoarthritis (OA) by Inhibition of Acutaxin
Poullami Datta1, Sayaka Nakamura1, Evgeny Rossomacha1, Helal Endisha1, Carolen Younan1, Kaushik H Borada1, Kim Perry1, Nizar N Mahomed2,3, Rajiv Gandhi1,2,4, Jason S Rockel1, Mohit Kapoor2,3
1Krembil Research Institute, UHN, 2Toronto Western Hospital, 3LMP Department, University of Toronto, 4Department of Surgery, University of Toronto
Conflict of interest: None

Objective: Osteoarthritis (OA) is a chronic, progressive joint disease leading to a poor quality of life. Previously, we reported that select Lyso-phosphatidylcholines (lysoPCs) are increased in animal models of OA. We also identified that these particular metabolites may promote OA pathogenesis in an autotaxin (ATX) - dependent manner. ATX is an enzyme responsible for the conversion of lysoPC to the inflammatory mediator lysophosphaticacid (LPA). Previous studies have also shown that ATX levels in plasma and synovial fluid correlate with the severity of knee osteoarthritis. Thus, we sought to identify if local pharmacological inhibition of ATX can attenuate surgically-induced OA in vivo and its mechanism of action in vitro. [Methods] 9 week-old mice were subjected to surgically-induced OA. ATX antagonist (PF -8380, Pfizer) was injected intra-articularly in the knee joints at 2nd, 4th, 6th and 8th week of post surgery and subsequent knee joint pathology was evaluated. Primary human chondrocytes were treated with IL-1β/ATX antagonist, and the expression of catabolic markers was determined. [Results] Local injection of ATX antagonist reduced the degree of cartilage degeneration in surgically induced OA models compared to saline injected controls. ATX antagonist also reduced the amount of synovitis as compared to controls. Immunohistochemical analysis of mouse knee joints showed decreased expression of catabolic markers (C1-2C and MMP 13) in ATX treated mice compared to control mice. In vitro, ATX antagonist attenuated IL-1β-induced increases in the expression of MMP13. Conclusion: Inhibition of ATX attenuates surgically-induced OA. We are currently investigating the mechanism of action of ATX in attenuating OA. Our data, to date, suggests pre-clinical efficacy of ATX to limit OA progression.

ICW22-6
Analysis of walking functions in patients with rheumatoid arthritis using a wearable device
Masahiro Tada1,2, Noriaki Hidaka1,2
1Department of Orthopaedic Surgery, Osaka City General Hospital, 2Department of Orthopaedic Surgery, Osaka City University Graduate School of Medicine, 3Department of Orthopaedic Surgery, Yodogawa Christian Hospital, 4Department of Orthopaedic Surgery, Osaka Social Medical Center Hospital
Conflict of interest: None

[Object] It is unknown how walking is related to disease activity and body composition. The factors related to walking and their relationships with locomotive syndrome were investigated in RA patients using a
was recommended that they exceed 3333 steps per day.

steps and walking EX. To prevent locomotive syndrome in RA patients, it syndrome and muscle power were independently related to the number of EX. Number of steps and walking EX were negatively correlated with MMP3, DAS28ESR, HAQ, locomotive syndrome, and frailty, and positively correlated with leg muscle score, muscle power, muscle speed, grip strength, and walking speed on univariate analysis. In addition, calorie consumption was positively correlated with muscle mass and bone mass. Locomotive syndrome and muscle power were identified as independently associated with the number of steps and walking EX on multivariate analysis. With respect to calorie consumption, only muscle power was identified as an independent factor. When the number of steps was under 3333 on ROC curve analysis, the odds ratio of locomotive syndrome increased 14.4-fold (95%CI: 5.0-41.6) compared with over 3333 (p<0.001). [Conclusions] Locomotive syndrome and muscle power were identified as independently associated with the number of steps and walking EX. To prevent locomotive syndrome in RA patients, it was recommended that they exceed 3333 steps per day.

Poster Session

P1-001
A study of information collection concerning rheumatoid arthritis in patients with rheumatoid arthritis -based on the IORRA cohort
Rei Yamaguchi1, Eiichi Tanaka1, Esuke Inoue2,3, Mai Abe1, Mika Kawano1, Eri Sugano1, Naohiro Sugitani1,4,5, Kumiko Saka1, Yoko Higuchi1, Moeko Ochiai1, Naoki Sugimoto1, Katsunori Ikari1, Ayako Nakajima1, Atsuo Taniguchi1, Hitoshi Yamanaka1
1Institute of Rheumatology, Tokyo Women’s Medical University Hospital, 2Department of Medical Informatics, St. Marianna University School of Medicine, Kanagawa, Japan, 3Department of Rheumatology, Mie University Graduate School of Medicine, Mie, Japan

Conflict of interest: None

[Object] To examine how rheumatoid arthritis (RA) patients are collecting information and their usefulness. [Methods] The subjects were RA patients who participated in the IORRA in 2017. Based on patient self-reported, the difference in the background of information on RA and the usefulness of information using VAS scale were cross-sectionally evaluated. [Results] A total of 8,026 answers were obtained from 3,470 RA patients (multiple choices allowed). The patient background was 86.8% for women, average age 62.3 years, DAS28 2.55, J-HAQ 0.58, and biologics user 27.2%. The most frequent information sources were medical institutions (doctors, nurses, pharmacists, etc.) (28.9%), television (15.5%), pamphlets distributed at hospital and pharmacy (8.80%), the Internet (8.77%), and newspapers (6.90%). Internet was the most frequent (46.4%) under the age of 40. The average VAS of usefulness was the highest in medical institutions (74.1), followed by television (62.0), pamphlets (59.8), books on RA (53.5), newspapers (49.7), and the Internet (48.2). [Conclusion] RA patients obtained information widely from medical institution and mass media. Especially the reliability of information from medical institutions was high. The information sources were different by patient’s age group.

P1-002
Evaluation of factors associated with sarcopenia in patients with rheumatoid arthritis
Takeshi Mochizuki1, Koichiro Yano2, Ryo Hiroshima1, Katsumori Ikari2, Ken Okazaki2
1Department of Orthopaedic Surgery, Kamagaya General Hospital, 2Department of Orthopaedic Surgery, Tokyo Women’s Medical University

Conflict of interest: Yes

[Objective] Rheumatoid arthritis (RA) is a chronic, systemic, and inflammatory disease. This study aimed to identify the prevalence of sarcopenia and factors associated with sarcopenia in RA. [Methods] Overall, 127 patients aged over 65 years with RA were enrolled in the study. Muscle mass was assessed using bioelectrical impedance analysis. Sarcopenia was defined as low muscle mass and low muscle strength in accord with the consensus report of the Asian Working Group for Sarcopenia. Statistical analysis was performed to examine relationship between patient characteristics [age, gender, disease duration, body mass index, disease activity, calf circumference, grip strength, gait speed, HAQ-DI, Mini nutritional assessment (MNA) score, serum albumin, skeletal muscle mass index (SMMI), and bone mass] and sarcopenia. [Results] The prevalence of sarcopenia was 24.4%. The significant related factors by multivariate logistic regression analysis were grip strength (p=0.003), MNA score (p=0.024), and SMMI (p=0.004). [Conclusion] Grip strength, MNA score, and SMMI were associated with sarcopenia. Interventions are required for elderly patients with RA identified as having related factors of sarcopenia to prevent its adverse health consequences.

P1-003
A survey on trends of five years of patients with the elderly patients (aged 75 years or more) with rheumatoid arthritis
Moto Kobayashi1, Takeshi Kashiwagara2, Natsuo Konishi1, Masakazu Urayama1, Hiroki Ito1, Tsutomu Sakuraba1, Toshiaki Aizawa6, Hidekazu Abe1, Norio Suzuki1, Keiji Kamo1, Hiroshi Aouma1, Yusuke Suginuma1,2, Tetsuya Kawano1, Masaaki Ogino1,2, Yoichi Kataoka1,2, Hiromi Morita1,3

Conflict of interest: None

[Object] To examine trends of five years of patients with the elderly patients (aged 75 years or more) with rheumatoid arthritis.

[Methods] The data from a prospective observational study (CHIKARA study, UMIN000023744) were used. A total of 85 of the 100 RA patients entered and wore an activity meter (HJA-750C; OMRON) for 7 consecutive days. The average daily number of steps, walking exercise (EX) (Mets x Time), and calorie consumption were calculated. The relationships of disease activity, body composition, muscle function, sarcopenia, locomotive syndrome, and frailty were analyzed by uni- and multi-variate analyses. The correlation between the number of steps and locomotive syndrome was examined by receiver operating characteristic (ROC) curve analysis. [Results] The patients’ mean age was 65.2 years (women n=67, men n=18), disease duration was 7.7 years, DAS28ESR was 3.12, and the HAQ score was 0.6. Number of steps and walking EX were negatively correlated with MMP3, DAS28ESR, HAQ, locomotive syndrome, and frailty, and positively correlated with leg muscle score, muscle power, muscle speed, grip strength, and walking speed on univariate analysis. In addition, calorie consumption was positively correlated with muscle mass and bone mass. Locomotive syndrome and muscle power were identified as independently associated with the number of steps and walking EX on multivariate analysis. With respect to calorie consumption, only muscle power was identified as an independent factor. When the number of steps was under 3333 on ROC curve analysis, the odds ratio of locomotive syndrome increased 14.4-fold (95%CI: 5.0-41.6) compared with over 3333 (p<0.001). [Conclusions] Locomotive syndrome and muscle power were identified as independently associated with the number of steps and walking EX. To prevent locomotive syndrome in RA patients, it was recommended that they exceed 3333 steps per day.
Kunitaka Yang1, Wataru Watanabe1, Nobuhiro Ishizawa1, Kazuhiro Shoji2, Hitodewi Watanabe3, Yosuke Iwamoto4, Naohisa Miyakoshi5, Yoichi Shimada6
1Department of Orthopedic Surgery, Hiraka General Hospital, 2Department of Orthopedic Surgery, Akita City Hospital, 3Department of Orthopedic Surgery, Akita Kousei Medical Center, 4Department of Orthopedic Surgery, Ogachi Central Hospital, 5Department of Orthopedic Surgery, Noshiro Kousei Medical Center, 6Department of Orthopedic Surgery, Kita Akita Municipal Hospital, 7Department of Orthopedic Surgery, Ugo General Hospital, 8Department of Orthopedic Surgery, Nakadori General Hospital, 9Department of Orthopedic Surgery, Koto Kousei Hospital, 10Joto Orthopedic Clinic, 11Department of Orthopedic Surgery, Honjo Daiichi Hospital, 12Department of Orthopedic Surgery, Fujiwara Memorial Hospital, 13Shoji Orthopedic Clinic, 14Watanabe Orthopedic Clinic, 15Department of Orthopedic Surgery, Akita University Graduate School of Medicine

Conflict of interest: None

[Objective] We are active in raising treatment of rheumatoid arthritis (RA) patients and eliminating regional disparity at the Akita Orthopedic Group on Rheumatoid Arthritis (AORA) established in 2010. We extracted the data from the AORA registry, examined the trend of RA patients in the last 5 years [METHODS] From the AORA registry from 2013 to 2017, rheumatism patients over 75 years old were investigated. [RESULTS] The proportion of patients aged 75 years or older in the entire AORA registry showed a tendency to increase over the years from 26.3% to 31.0%. The usage rate of MTX was 33.9% to 40.8%, and the average usage amount was 5.1 to 5.6 mg/week, and it showed a somewhat increasing trend over time on a year-to-year basis. The usage rate of steroids was 49.2% to 56.5%, varying from year to year, the average usage amount was around 3.8 mg/day and did not change very much. Regarding bDMARDs, the frequency was 10.1 to 17.7%, which showed an increasing tendency over time. The disease activity indicators had a declining trend over the years since 2013. The HAQ-DI showed no remarkable change. [CONCLUSION] Since the disease activity of older patients with RA after AORA was founded was on a downward trend, the results of the treatment improvement listed as the goal were observed.

P1-004
Big regional differences in drug-use and expenditure in the treatment of rheumatoid arthritis extrapolated from the National Database open data released in 2016-18
Yasuyuki Kamata, Seiji Minota
Rheumatology and Clinical Immunology, Jichi Medical University

Conflict of interest: None

[Objective] To clarify whether there are prefecture-to-prefecture differences in drug-use and expenditure in the treatment of RA in Japan by analyzing the National Database open data released between 2016 and 2018 by the Ministry of Health, Labor and Welfare (MHLW). [Methods] Data on MTX and seven biologies that have indication for the treatment of RA were analyzed in this study. There is an assumption that the morbidity of RA is equal throughout Japan at 0.6% of general population. The dosage and cost of drugs for an RA patient were calculated by dividing the total amount of thereof in each prefecture released by MHLW by the estimated number of RA patients. [Results] The maximum regional differences in the prescribed dosage of MTX (mg) and the cost of biologies were 2.7-fold (highest in 445 mg and lowest in 165 mg) and 2.4-fold (highest in 366,000 yen and lowest in 154,000 yen), respectively. In five prefectures, the cost of biologics per RA patient was markedly higher than the national average whereas MTX dose was smaller than that. [Conclusions] There are big prefectural differences in the usage of MTX and biologics in Japan. In order to implement a universal practice of good RA treatment, these data need to be addressed and scrutinized.

P1-005
Survey for AI medical in the Remote medical care for patients with RA or OA
Ryuji Nagamine1, Weijia Chen1, Toru Suguro2
1Center of Artificial Joint and Rheumatism, Fukushima Tokushukai Medical Center, 2Research Institute of Rheumatology Medical Treatment

Conflict of interest: None

[Object] There are few specialists for RA or OA in remote places and islands. We have a plan of AI medical for the remote medical care in such places. In this study, survey of the patients was performed to clarify the necessity of AI medical. [Methods] The author works in Fukushima. In one hospital in Ishigaki island, a survey was performed. We provided a questionnaire to 107 patients and got a reply from 71 patients (average age 66.8 years old, 18 cases with RA, 45 cases with OA, etc). Nine patients with RA are taking bDMARD. The contents of the questionnaire were “do they have smartphone?”, “do they need AI?” etc. Number of patients who visited the hospital in Fukushima to have operation was also assessed. [Results] 23 patients (33%) have smartphones. 58 patients (82%) trust AI medical and 56 patients (79%) will pay for the AI medical. 44 operations including total knee arthroplasty were performed in the past 3 years. The result of the questionnaire revealed the lack of specialists and necessity of AI medical in Ishigaki island. AI medical is useful and convenient for the patients to get information about bDMARD and the follow up of the operations. Japan has so many islands and remote places. [Conclusions] In Ishigaki island, many patients think that AI medical is necessary.

P1-006
Ideal medical collaboration considering patients' movement in rheumatoid arthritis
Hitodewi Kagawa1, Ryutaro Yamanaka1, Masashi Tamaki2, Yasuaki Aoki2, Hideyuki Okamoto1, Hidekazu Dan1, Ken-ichi Sorachi1
1Department of Internal Medicine, Japanese Red Cross Himeji Hospital, 2Department of Orthopedic Surgery, Japanese Red Cross Himeji Hospital, 3Okamoto Internal Medicine Clinic, 4Dan Orthopedic Clinic, 5Sorachi Internal Medicine Clinic

Conflict of interest: None

[Object] We conducted a questionnaire survey to clarify modifiable factors that regulated patients’ movement in rheumatoid arthritis (RA). [Methods] Questionnaire items concerning Jan to Dec 2017 were as follows: the number of patients newly-diagnosed/continuously treated/referred/reversely introduced, and the treatment policy and specific treatment for RA patients. [Results] Among 23 institutions, 14 (hospital 2, clinic 12; internal department 9, orthopedic department 5; specialist 4, non-specialist 10) answered to the questionnaire. A total of 1028 patients were identified and their movement was as follows: 157 newly-diagnosed cases, 130 cases introduced from other institutions, 129 cases introduced to other institutions, and 4 deaths. The strongest factors influencing in every clinical decision regarding patients’ introduction for non-specialists was the number of patients experienced. Most non-specialists were concerned about safety management for MTX and lack of experience in use and safety management for biological agents. [Conclusions] Non-specialists exceeding experience of 50 cases possibly provide medical care comparable to a specialist. Close collaboration with a small number of non-specialists interested in rheumatology may improve the gap of regional medical collaboration.

P1-007
Medical care for rheumatoid arthritis at the core hospital without professional rheumatologists in a remote island of Okinawa prefecture
Masashi Momose1, Mitsuyo Kinjo2
1Department of Internal Medicine, Okinawa Miyako Hospital, 2Department of Rheumatology, Okinawa Chubu Hospital

Conflict of interest: None

[Object] Miyakojima is a remote island located 290 km far from Okinawa mainland, where 55,000 people reside. Okinawa Miyako Hospital
is the only general hospital, and internists who graduated from residency program in Okinawa Chubu Hospital serve rheumatology care under supervision of specialists. Rheumatology training is incorporated into our 4-year residency program. We aim to describe how specialized care for RA is provided in Miyakojima. [Methods] We investigated the patients prescribed DMARDs from 1/10/2015 to 1/10/2018 by using pharmacy database. [Results] Among 259 patients using DMARDs, 211 RA patients were included after reviewing medical record. The average age was 62.3 years, and gender ratio was 1:5.8:1.61 (76.3%) patients were positive for anti-CCP antibody, 139 positive for RF, and 20 positive for anti-SS-A antibody. 32 patients had RA-ILD, 15 had DM, and 14 had cancer. There are 137 (64.9%) patients using MTX, 100 using SASP, 56 using BUC, and 33 (15.6%) using bDMARDs. During the observation period, 22 patients were hospitalized due to infection. Mortality related to RA is 0%. [Conclusions] Rheumatology training during residency helps young doctors in underserved area provide care for RA patients as well as using bDMARDs in concert with specialists.

P1-008
Association of bDMARDs use with eGFR change in five years in NinJa 2012-2017 cohort
Hiroshi Kajiyama1, Hishashi Nomu2, Hirota Tsuo3, Atsushi Hashimoto4, Toshihiro Matsui4, Atsushi Kaneko4, Shinichiro Tsunoda5, Kazuhiro Yokota6, Yasuto Araki7, Kojiro Sato7, Yu Funakubo8, Kiyoishi Matsui8, Koichi Saishi8, Shigeto Tohma8, Toshihide Mimura8
1Department of Rheumatology and Applied Immunology, Saitama Medical University, 2The Institute of Statistical Mathematics, 3Department of Rheumatology, National Hospital Organization, Sagamihara National Hospital, 4Department of Orthopaedic Surgery and Rheumatology, National Hospital Organization, Nagoya Medical Center, 5Department of Rheumatology, Sumitomo Hospital, 6Department of Orthopaedic Surgery, National Hospital Organization, Miyakonojo Medical Center, 7Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, 8Department of Rheumatology, National Hospital Organization, Tokyo National Hospital

Conflict of interest: None

[Object] The purpose of this study is to test if bDMARDs use is associated with eGFR change. [Methods] Retrospective observational study. Analyzed were 1933 RA cases who were registered to NinJa annu-

P1-009
Clinical characteristics of seronegative arthritis including rheuma-
toid arthritis
Ichiro Yoshi1, Tatsumi Chijiiwa2, Naoya Sawada2
1Rheumatology and Musculoskeletal Medicine, Yoshii Hospital, 2Department of Rheumatology, Kochi Memorial Hospital

Conflict of interest: None

[Object] Characteristics of seronegative arthritis were investigated. [Methods] From August 1st, 2010 to July 31, 2018, 884 arthritis patients who were suspected rheumatoid arthritis (RA), were followed up for more than one year. In these, 96 patients were seronegative arthritis with RF nor ACPA. These 96 patients were followed up for 4.8 years. The averages of initial diagnostic observations were TJC (28) 4.8, SJC (28) 5.0, PaGA 43.5, PhGA 40.7, CRP 1.4mg/dl, ESR 36mm/h. MMP-3 143ng/ml, and RF 107U/ml. Bone erosion was present at a rate of 31.5% at initial diagnosis. We compared the groups with and without bone erosion, year of diagnosis, background at the time of diagnosis on 1185 RA patients. [Results] Duration ranged from 0-49 years and average was 6.4 years. The averages of initial diagnostic observations were TJC (28) 4.8, SJC (28) 5.0, PaGA 43.5, PhGA 40.7, CRP 1.4mg/dl, ESR 36mm/h. MMP-3 143ng/ml, and RF 107U/ml. Bone erosion was present at a rate of 31.5% at initial diagnosis. We compared the groups with and without bone erosion, and it was found that it took time to receive a diagnosis. In the group of patients with bone erosion, inflammation markers were higher. However, time of initial diagnosis and bone erosion was not relevant. [Conclusions] As has been reported previously, the cohort study also found that the inflammation makers in patients presenting with bone erosion were higher. The rate of bone erosion has not changed since 2010, the problem would seem to stem from lack of access to specialists.

P1-010
Multi center collaboration findings regarding observations at initial diagnosis of rheumatoid arthritis (RA)
Keiko Funahashi1, Tsukasa Matsubara2, Eisuke Shono1, Motohiro Orike2, Kei Suzuki Hashimoto2, Akira Sagawa2, Tamami Yoshitama2, Takeshi Mitsuka3, Tomohiko Yoshida3, Atsuko Imai3, Nobuaki Miyake4, Kazuyasu Ushio5, Tomomaro Izumi4, Tomomi Tsuru5, Yosuke Nishioka5, Shigeto Kiyokawa2, Norihiro Nishimoto2
1Clinical Research, Matsubara Mayflower Hospital, 2Japanese Clinician’s Biologies Research Group

Conflict of interest: None

[Object] There are very few based on observations at the time of initial diagnosis. We performed a retrospective study of the initial diagnoses of patients currently being treated. [Methods] A survey was undertaken at 18 facilities from September to December 2017. Survey items were hematological examination, clinical findings, presence or absence of bone erosion, year of diagnosis, background at the time of diagnosis on 1185 RA patients. [Results] Duration ranged from 0-49 years and average was 6.4 years. The averages of initial diagnostic observations were TJC (28) 4.8, SJC (28) 5.0, PaGA 43.5, PhGA 40.7, CRP 1.4mg/dl, ESR 36mm/h. MMP-3 143ng/ml, and RF 107U/ml. Bone erosion was present at a rate of 31.5% at initial diagnosis. We compared the groups with and without bone erosion, and it was found that it took time to receive a diagnosis. In the group of patients with bone erosion, inflammation markers were higher. However, time of initial diagnosis and bone erosion was not relevant. [Conclusions] As has been reported previously, the cohort study also found that the inflammation markers in patients presenting with bone erosion were higher. The rate of bone erosion has not changed since 2010, the problem would seem to stem from lack of access to specialists.

P1-011
Observations of RA at the time of diagnosis and the effect of patients’ treatment history on treatment-a multi-center study
Keiko Funahashi1, Tsukasa Matsubara2, Eisuke Shono1, Motohiro Orike2, Kei Suzuki Hashimoto2, Akira Sagawa2, Tamami Yoshitama2, Takeshi Mitsuka3, Tomohiko Yoshida3, Atsuko Imai3, Nobuaki Miyake4, Kazuyasu Ushio5, Tomomaro Izumi4, Tomomi Tsuru5, Yosuke Nishioka5, Shigeto Kiyokawa2, Norihiro Nishimoto2
1Clinical Research, Matsubara Mayflower Hospital, 2Japanese Clinician’s Biologies Research Group

Conflict of interest: None

[Object] The influence of patient history on the activity level the findings at diagnosis is unclear. It is also unclear whether they influence on treatment. We therefore we compared patient history as well as the state of patients’ present treatments and diagnostic findings. [Methods] 1185 patients at 18 facilities who were initial diagnosed with RA were included. Blood examination results, clinical findings, the presence or absence of bone erosion, as well as background factors. In addition, we compared diagnostic findings between GroupB (treated with bDMARDs or tsDMARDs) and GroupC (treated with csDMARDs) [Results] It was found that neither smoking history, gynecological ailments, surgical history, gastrointestinal disorders, periodontal disease history, nor genetic
background had an effect on disease activity at the time of diagnosis. On the other hand, the ratio of patients with erosin in Group B was significantly higher than that of Group C. In addition, the average values of diagnostic indicators was higher in Group B. [Conclusions] RA treatment guidelines take three stages. However as there is evidence of use of bDMARDS and tsDMARDS to early RA, and considering this resluts, the use of bDMARDS and tsDMARDS to serve early RA should be considered.

P1-012
A study on chronic kidney disease in patients with rheumatoid arthritis
Miki Takata, Tomoya Harada, Ryota Okazaki, Yoshihiro Funaki, Yuriko Sueda, Akira Yamashiki
Division of Medical Oncology and Molecular Respiriology Department of Multidisciplinary Internal Medicine Faculty of Medicine, Tottori University, Yonago, Japan

Conflict of interest: None

[Object] It is known that chronic kidney disease (CKD) is relatively common in patients with RA than that in general adults. To assess renal function is important for RA therapeutic strategy. [Methods] We targeted RA patients who were following for more than 3 months as of 2018. Patients with estimated glomerular filtration rate (eGFR) < 60 ml / min / 1.73 m² for more than 3 months were defined as CKD. Patient background and treatment options were examined. [Results] One hundred and three RA patients were retrospectively analyzed. Among those, 23 (22.3%) were indicated to have CKD. The mean age of patients with CKD was significantly higher than that of without CKD (without CKD: 60.36 ± 1.57 vs with CKD: 73.09 ± 1.94; p <0.01), whereas Tac was prescribed more to patients without CKD (without CKD: 22.3%) were indicated to have CKD. The mean age of patients with RA were indicated to have CKD. Especially for elderly men, the proportion of CKD was significantly higher, and it was considered to be a group to be careful about RA treatment selection.

P1-013
Characteristics of patients with rheumatoid arthritis and investigation of drug therapy
Takeshi Kuroda1, Masanori Sudo1, Sayuri Takamura1, Shunsuke Sakai1, Ayako Wakamatsu1, Hiroe Sato1, Daisuke Kobayashi1, Takeshi Nakatsue1, Yoko Wada1, Masaaki Nakano2, Ichie Narita1
1Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 2Department of Medical Technology, School of Health Sciences, Faculty of Medicine, Niigata University

Conflict of interest: None

[Object] We compared data for RA patients between 1991 and 2018 to clarify the clinical features and therapy in the elderly in 2018. [Methods] We evaluated 429 cases of RA in 1991 and 368 cases of RA in 2018 treated in our department. First, the age and sex ratios of the two groups were evaluated. Then, the clinical features of the 129 younger-onset elderly RA (YORA) patients and the 108 elderly-onset RA (EORA) patients in 2018 were assessed. [Results] In 1991 the onset of RA peaked in patients in their 50s and 60s, whereas in 2018 peak occurred in patients in their 60s and 70s. A homogeneity test of the odds ratio of gender between 1991 and 2018 revealed no significant difference. Among 368 patients treated in 2018, polymyalgia was observed in 8 patients over the age of 60 years, and its occurrence was statistically significant (P=0.02). AA amyloidosis was observed in only 5 YORA patients. With regard to MTX use, no inter-group difference was observed, but high doses of MTX were not used in the EORA group. Biological agents were used for 23% of the EORA patients and for 38% of the YORA patients, the frequency of abatacept and etanercept use being significant. [Conclusions] The use of medicine appears to be a characteristic feature of care provided for elderly patients with RA.

P1-014
The treatment of patients with elderly-onset rheumatoid arthritis at Hokkaido Medical Center for Rheumatic Diseases
Hokkaido Medical Center for Rheumatic Diseases

Conflict of interest: None

[Object] With the increase in the elderly population, opportunities to treat elderly-onset rheumatoid arthritis (EORA) cases are increasing. We investigated EORA cases at our hospital. [Methods] We compared the characteristics, disease activity, and clinical course of 83 patients of untreated RA who started treatment in September 2017 to September 2018 at our hospital, and classified it into a group under 60 years old (non-EORA group) and a group aged over 60 years (EORA group). [Results] Of the 83 non-treated RA cases (average age 59.0 years old (20 to 91 years old), male: 21; female 62) visited our hospital, 45 patients (54.2%) in the non-EORA group and 36 (45.8%), and 15 patients (18.1%) were over 75 years old. Disease activity was significantly higher in the EORA group. There was no significant difference in the duration of disease between the two groups, the Steinbrocker stage classification, the serumnegative RA occupation rate, and the MTX usage rate. The bDMARD usage rate was high in the EORA group (p=0.035). [Conclusions] EORA group accounted for less than half of cases of untreated RA at our hospital. In the EORA group, the inflammatory response, disease activity, and the use rate of bDMARDS were high. MTX was also actively used even for elderly people.

P1-015
Development of a nationwide database of JIA: CoNinJa (Children’s version of NinJa)
Toshihiro Matsui1, Kosuke Shabana2, Shigeto Tohma3, Masaaki Mori4
1Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, 2Department of Pediatrics, Osaka Medical College, 3National Hospital Organization Tokyo National Hospital, 4Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, National University Corporation Tokyo Medical and Dental University

Conflict of interest: Yes

[Object] To conduct a large-scale, continuous and long-term investigation on clinical practice and prognosis concerning patients with juvenile idiopathic arthritis (JIA), this study aims to construct a nation-wide JIA database: CoNinJa (Children’s version of NinJa), which has the same platform as a nation-wide adult RA database: NinJa (National Database of Rheumatic Diseases in Japan). [Methods/Results] In addition to all the items collected in NinJa, the items necessary for the evaluation of JIA were covered. Unlike NinJa, CoNinJa added findings and disease type at the onset, past history of medications and complications. Patients with all disease types of JIA regardless of current age were registered in CoNinJa. We made the data of CoNinJa possible to be taken over to NinJa. We decided to collect data once a year. In the first year (2006), 15 facilities were participated and 714 cases (202 systemic JIA, 223 oligoarticular JIA, 93 RF (-) polyarticular JIA, 146 RF (+) polyarticular JIA, and 36 en- thesitis-related JIA) were registered in CoNinJa. [Conclusions] CoNinJa was developed and started operation. We will collect data continuously and clarify the actual condition and problems of JIA practice in Japan; and investigate the long-term prognosis of JIA by taking over to NinJa.

P1-016
The relationship of distal interphalangeal (DIP) joint involvement with high disease activity status in rheumatoid arthritis (RA) - Analysis based on NinJa2017 database using Nishiyama’s Joint index vector
Takahiro Mizuuchi1, Tetsuji Sawada1,Susumu Nishiyama2, Mayu Tago1, Koichiro Tahara1, Eri Kato1, Hiroyuki Mori1, Haeru Hayashi1, Toshihiro Matsui1, Shigeto Tohma1
1Department of Rheumatology, Tokyo Medical University Hospital Shinjuku Japan, 2Rheumatic Disease Center, Kurashiki Medical Center, Kura-
Conflict of interest: None

[Object] To analyze the relationship of DIP joint involvement (DIP+) with disease activity and affected joint distribution in RA. [Method] We used the data of adult-onset RA patients registered in NinJa 2015-2017. [Purpose] We have previously demonstrated that PGA-PhGA discordance was significantly related to pain, functional impairment (mHAQ), upper and lower joint indices (x and y) were significantly higher in DIP+ patients than those without. Large joint predominance index (z), mHAQ, upper and lower joint indices (x and y) were significantly higher in DIP+ patients. On the other hand, in addition to TJC, SJC, DAS28-CRP, mHAQ, upper and lower joint indices (x and y) were significantly more prevalent in women. Mean age was significantly lower in DIP+ patients. On the other hand, in addition to TJC, SJC, DAS28-CRP, mHAQ, upper and lower joint indices (x and y) were significantly higher in DIP+ patients than those without. Large joint predominance index (z), was negative in DIP+ patients. The limitation of the present study includes lack of radiographic information. [Conclusion] We have clearly demonstrated that DIP involvement was significantly associated with high disease activity and joint deformity or small-joint predominance, albeit infrequently. We consider that it is necessary to pay more attention to DIP symptoms in active RA patients.

P1-017
Shift of the discordance of global assessment (GA) of rheumatoid arthritis (RA) disease activity between RA patients (PGA) and their physicians (PhGA) - Analysis based on NinJa 2015-2017 database and Nishiyama’s joint index vector

Yusuke Yamamoto1, Tetsuji Sawada1, Susumu Nishiyama2, Mayu Tago1, Koicho Tahara1, Eri Kato1, Hiroaki Mori1, Haeru Hayashi1, Toshihiro Matsui1, Shigeto Tohma1

1Department of Rheumatology, Tokyo Medical University Hospital, 2Rheumatic Disease Center, Kurashiki Medical Center, 3Department of Rheumatology, NHO Sagamihara Hospital, 4NHO Tokyo Hospital

Conflict of interest: None

[Object] We have previously demonstrated that PGA-PhGA discordance was significantly related to pain VAS, functional impairment (mHAQ), upper and lower joint indices (x and y) were significantly higher in DIP+ patients than those without. Large joint predominance index (z), was negative in DIP+ patients. The limitation of the present study includes lack of radiographic information. [Conclusion] We have clearly demonstrated that DIP involvement was significantly associated with high disease activity and joint deformity or small-joint predominance, albeit infrequently. We consider that it is necessary to pay more attention to DIP symptoms in active RA patients.

P1-018
The cause of death of rheumatoid arthritis patients who died in our hospital

Atsushi Kondo, Ayuko Sogabe, Naoya Sawada, Yosuke Murata, Akihiro Yamada, Kazuo Jouyama, Kenichiro Matoba, Yasuaki Okuda, Makoto Onishi, Kiyoshi Takasugi

Dohgo Spa Hospital, Matsuyama, Japan

Conflict of interest: None

[Object] Rheumatoid arthritis (RA) patients with joint deformity or with high disease activity has dramatically decreased because of the appearance of biological products. There are many patients in our hospital who are forced to stay in hospital or who have been examined for many years due to RA. We investigated the causes of death, age, etc. of patients who died in our hospital. [Methods] We collected all patients who died in our hospital during the 10 years from January 2008 to September 2018, and extracted RA patients among them, examined by a medical record about age, RA disease duration and cause of death. [Results] During this period, the number of patients who died at our hospital was 168, among which 112 RA patients had RA. The mean age at the time of death of RA patients was 82.2 ± 7.3 years, age of onset was 55.0 ± 16.9 years, and the mean disease duration until death was 27.2 ± 15.6 years. The most common cause of death was 35 cases (31%) of pneumonia, 12 cases (11%) of heart failure, 9 cases (8%) of septicemia, and 8 cases (7%) of senility. [Conclusions] In most cases, disease activity of rheumatoid arthritis was low, and the age of death was not different from that of healthy people regardless of age of onset and duration of disease.

P1-019
The role of SH3BP2 in rheumatoid arthritis and systemic lupus erythematosus murine models

Kyoko Kawahara, Tomoyuki Mukai, Akiko Nagasu, Shoko Tsuji, Yoshitaka Morita

Department of Rheumatology, Kawasaki Medical School

Conflict of interest: Yes

[Object] The adaptor protein SH3BP2 is widely expressed in immune cells and controls intracellular signaling pathways. In this study, we investigated the role of SH3BP2 in rheumatoid arthritis and systemic lupus erythematosus murine models. [Method] SH3BP2-deficient mice were backcrossed onto DBA/1 background. SH3BP2-deficient mice were immunized against bovine type II collagen (CII), and the development of arthritis was observed. Serum anti-CII antibody levels were determined. The response of the lymph node cells to the CII were analyzed. Next, for the lupus model, we used Fas-lpr mice, which possess impaired Fas signaling. SH3BP2-deficient Fas-lpr mice were created, and then serum anti-dsDNA antibody of the mice were determined at 32-week old. [Result] In the arthritis model, SH3BP2 deficiency suppressed the induction of arthritis, accompanying with the decreased anti-CII antibody. The response of lymph node cells to CII was not altered. In the lupus model, the development of the anti-dsDNA antibody was significantly decreased by SH3BP2 deficiency. [Conclusion] SH3BP2 deficiency suppressed the development of the disease-associated antibodies. SH3BP2 could be a potential therapeutic target for autoimmune diseases.

P1-020
Increased Interferon alpha production by monocytes associated with enhanced STING pathway in systemic lupus erythematosus

Go Murayama1,2, Asako Chiba3, Ayako Makiyama1,2, Ken Yamaji1, Naoto Tamura1, Sachiko Miyake2

1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan

Conflict of interest: None

<Background> We reported that the proportion of IFNα producing monocytes stimulated with STING agonist was significantly increased in SLE patients. In this study, we investigated STING-signaling pathway in SLE. [Methods] Peripheral blood mononuclear cells (PBMCs) from SLE patients and healthy controls (HCs) were stimulated with a STING agonist, 2′-3′-cGAMP, and the proportion of IFNα positive cells was investigated by intracellular cytokine staining and flow cytometry. After pretreatment with or without IFNα for 24 hours, IFNα production and localization of STING in monocytes from HCs were assessed. [Results] The frequency of IFNα+ monocytes in SLE was positively correlated with SLEDAI. The expression of STING was increased and co-localization of STING and TBK1 was enhanced in monocytes from SLE patients. Pretreatment with IFNα enhanced IFNα production by monocytes stimulated with 2′3′-cGAMP and co-localization of STING with TBK1. [Conclusions] IFNα is known to be playing an important role in the pathogenesis of SLE. We found enhanced IFNα production by lupus monocytes was partially due to increased expression of STING and co-localization of


**P1-021**

Tofacitinib inhibits granulocyte- macrophage colony-stimulating factor-induced NLRP3 inflammasome activation in human neutrophils

Jumpei Temmoku, Makiko Furuya Yashiro, Yuya Fujita, Naoki Matsuoka, Tomoyuki Asano, Shuzo Sato, Eiji Suzuki, Hiroko Kobayashi, Hiroshi Watanabe, Kiyoshi Migita

1Department of Rheumatology, Fukushima Medical University School of Medicine, 2Department of Rheumatology, Ohta Nishinouchi Hospital

Conflict of interest: None

[Object] GM-CSF has emerged as a crucial cytokine that activates myeloid cells to initiate tissue inflammation. The molecular actions of GM-CSF against innate immunity are poorly characterized. We investigated the in vitro effects of GM-CSF on the activation of human myeloid lineages, neutrophils. [Methods] Human neutrophils were stimulated with GM-CSF in the presence of absence of tofacitinib. The cellular supernatants were analyzed for interleukin-1 beta (IL-1β) and caspase-1 by ELISA methods. JAK2/STAT3 activation in neutrophils was assayed by Western blot using phospho-specific antibodies. [Results] Stimulation with GM-CSF alone, was shown to increase the release of IL-1β and cleaved caspase-1 (p20) from human neutrophils. Tofacitinib, which inhibits GM-CSF-induced JAK2-mediated signal transduction, completely abrogated GM-CSF-induced IL-1β secretion. GM-CSF stimulation also induced NLRP3 protein expression in neutrophils, which was abrogated by tofacitinib. [Conclusions] These results indicate that GM-CSF signal transduction, completely abrogated GM-CSF-induced IL-1β secretion, abrogates GM-CSF-induced JAK2-mediated signal transduction, completely abrogated GM-CSF-induced IL-1β secretion. GM-CSF stimulation also induced NLRP3 protein expression in neutrophils, which was abrogated by tofacitinib. [Conclusions] These results indicate that GM-CSF signaling induces NLRP3 inflammasome activation. This process can be blocked by tofacitinib, which interferes with JAK2/STAT3 signaling pathways. Our data suggest that JAK inhibitors have the potential to block the GM-CSF-mediated inflammasome activation.

**P1-022**

CDK4/6 activity stabilizes AP-1 components c-Jun and Fra1, and regulates AP-1 transcriptional activity in rheumatoid arthritis synovial fibroblasts

Tadashi Hosoya, Tetsuya Saito, Yasuhiro Tagawa, Akio Yamamoto, Kimito Kawahata, Nobuyuki Miyasaka, Hitoshi Kohsaka

Department of Rheumatology, Tokyo Medical and Dental University (TMDU), Tokyo, Japan

Conflict of interest: None

[Object] Rheumatoid arthritis (RA) synovial fibroblasts (RASFs) are the main source of matrix metalloproteinases (MMPs). This study was designed to discern the underlying mechanisms in the regulation of MMPs by the cyclin-dependent kinase (CDK) 4/6. [Methods] CDK4/6 activity was inhibited or enhanced with a small-molecule CDK4/6 inhibitor (CDKI) or gene transduction. Expression of inflammatory mediators was evaluated at the protein and transcription levels. Binding of the nuclear extracts to TRE, AP-1 targeted sequence, was assessed. Protein expression was evaluated with or without MG132 as a proteasome-inhibitor. [Results] CDKI inhibited the transcription of the MMP-1 and MMP-3 genes, which contain the TRE sequence in their promoter and decreased the amount of nuclear proteins binding to the TRE sequence. Among the AP-1 binding proteins, the c-Jun and Fra1 proteins were decreased when CDK4/6 activity was inhibited and increased when CDK4/6 activity was enhanced. CDK4/6 protected both of the proteins from proteasome-dependent degradation. [Conclusions] CDK4/6 stabilized c-Jun and Fra1 proteins and regulated the transcriptional activity of AP-1. CDK1 would provide anti-inflammatory effects in inflammatory diseases including RA by the selective down-regulation of c-Jun and Fra1.

**P1-023**

Immunohistochemical staining of the lip tissues from Sjögren syndrome patients with the monoclonal anti-Ro52 autoantibody obtained using the ISAAC system

Maiko Okamura, Hirofumi Taki, Koichiro Shinoda, Hiroyuki Hounoki, Reina Tsada, Kazuyoshi Tobe

1Department of Rheumatology, Internal Medicine, Takaoka-saiseikai Hospital, 2The First Department of Internal Medicine, University of Toyama

Conflict of interest: None

[Object] Ro52 is a protein in cytoplasm. Ro52 specific autoantibody (anti-Ro52 autoantibody) appear in the sera of connective tissue diseases (CTDs) patients. Some reported the relationship of anti-Ro52 autoantibody with the CTDs and it is suspected that Ro52 and Ro52 specific autoantibody relate to CTDs. Immunohistochemical analysis using human monoclonal anti-Ro52 autoantibodies obtained from CTD patients showed the portality of Ro52 and suggested the relationship with CTDs. [Methods] We obtained 12 human monoclonal anti-Ro52 autoantibodies from 4 CTD patients (European J Immunol. 2018;48 (10):1717-1727) using ISSAC system (Nat Med. 2009 Sep;15 (9):1088-92). We stained the lip tissues of Sjögren syndrome (SS) patients and healthy donors, using the human monoclonal anti-Ro52 autoantibody. [Results] In immunohistochemical analysis of lip tissues of 5 SS patients and 5 healthy donors, cytoplasm of acinar cell and ductal epithelium of SS lip tissues were stained by human monoclonal anti-Ro52 autoantibody. It was reported that ductal epithelium of SS lip tissues were stained by monoclonal anti-Ro52 autoantibody producing hybridoma (Clin Exp Immunol. 2014;177:244-252). [Conclusions] Immunohistochemical analysis suggested that Ro52 appear in injured tissues and seem to be related to CTDs.

**P1-024**

CCL11 is involved in cell migration in rheumatoid arthritis

Kuninobu Wakabayashi, Takeo Isozaki, Masahiro Hosonuma, Atsushi Nishimi, Shinichiro Nishimi, Sho Ishii, Yuzo Ikari, Takahiro Tokunaga, Hideaku Furuya, Katsunori Inagaki, Toshiyoshi Kasama

1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 2Department of Orthopedics, Showa University School of Medicine

Conflict of interest: None

[Object] The aim of this study is to investigate the expression and the function of CCL11 in fibroblast like synoviocyte (FLS) of rheumatoid arthritis (RA). [Methods] We measured the levels of CCL11, TNF-α, MCP-1, MIP-1α and RANTES in synovial fluids (SFs) from the patients with RA using ELISA. [Results] CCL11, MCP-1, MIP-1α and RANTES in the culture medium were measured by ELISA. To confirm the role of CCL11 in cell migration, FLS were stimulated with CCL11 and were allowed to migrate through uncoated transwell chambers. Finally, to block the expression of CCL11, FLS were transfected with siRNA against CCL11, and we demonstrated migration assay and expression analysis. [Results] The levels of CCL11 in SFs from the patients with RA were positively correlated with the levels of TNF-α, MCP-1 and MIP-1α. The secretion of MCP-1, MIP-1α and RANTES in RA FLS conditioned medium were increased by TNF-α stimulation. CCL11 stimulated cells were significantly higher efficient at migration than unstimulated cells. CCL11 siRNA treatment decreased the secretion of MCP-1 in TNF-α treated RA FLS conditioned medium and the RA FLS migration. [Conclusions] These data show that CCL11 is involved in cell migration in RA.

**P1-025**

Dissociation of arthritis symptoms and pain-related behavior in experimental arthritis

Yohsuke Oto, Takayuki Matsushita, Masayuki Yoshiga, Kazuhiro Oto, Kentaro Noda, Daitaro Kurosaka

1Division of Rheumatology, Department of Internal Medicine, The Jikei University School of Medicine, 2Center for Neuroscience of Pain, The Jikei University School of Medicine

Conflict of interest: None

[Object] Rheumatoid arthritis (RA) patients are suffering from pain, even in optimal control of inflammatory disease, as revealed with recent studies showing a low correlation between the pain intensity and objective measures of inflammation. To clarify this mechanism, we developed
novel methods to evaluate pain-related spontaneous voluntary behavior in RA model. [Methods] Collagen-induced arthritis (CIA) was induced in mice and spontaneous behavior was examined. In voluntary wheel running test, mice were single-housed in home cage with running wheels to count rotation numbers. In thermal preference test, mice were allowed to freely explore between plates with elevating (25-49°C) and fixed temperature (25°C), and the ratio of staying on elevating plate were calculated. Tofacitinib was administered subcutaneously by osmotic pump. [Results] In voluntary wheel running test, CIA decreased the rotation numbers. In thermal preference test, CIA preferred staying on median temperature region (32-43°C). These behavioral indices significantly correlated with arthritis score, which were eliminated by tofacitinib treatment despite improvement of the arthritis score. [Conclusions] By tofacitinib treatment, transient dissociation between pain-related behavior and arthritis score were observed in CIA.

P1-026
Interferon-gamma-producing ability of NK cells in adult-onset Still’s disease
Yasuhiro Shimoejima, Dai Kishida, Yoshiki Sekijima
Division of Nurology and Rheumatology, Department of Internal Medicine, Shinshu University School of Medicine

Conflict of interest: None

[Object] We investigated interferon-γ (IFN-γ)-producing ability in circulating natural killer (NK) cells from patients with adult-onset Still’s disease (AOSD). [Methods] Twenty patients in the acute phase of AOSD (acute AOSD), 7 of the 20 patients after treatment, and 11 healthy controls (HC) were employed. NK cells and their IFN-γ expression levels were analyzed by flow cytometry. The cytokine receptors of interleukin-12, interleukin-15, and interleukin-18 on NK cells were also evaluated. [Results] The frequency of NK cells was significantly lower in acute AOSD than in HC. IFN-γ expression in NK cells was significantly increased and was improved after treatment. However, IFN-γ expression in NK cells revealed an inverse correlation with serum ferritin levels. Expression of IL-12 and IL-15 receptors on NK cells was significantly increased in acute AOSD, whereas that of IL-18 receptor indicated no significant difference between three groups. [Conclusions] The ability of IFN-γ production in NK cells may be correlated with disease activity; meanwhile, upregulation of IL-12 and IL-15 receptors on NK cells may compensate for promoting IFN-γ production in acute AOSD.

P1-027
Anti-Fractalkine Monoclonal Antibody Suppresses Joint Destruction by Inhibiting Migration of Osteoclast Precursors and Inducing Synovial Cell Death in Collagen-Induced Arthritis Model Mice
Kana Negishi-Hoshino, Tomoya Nakatani, Yoshikazu Kuboi, Wataru Ikeda, Naoto Ishii, Nobuyuki Yasuda, Toshio Imai
KAN Research Institute, Inc.

Conflict of interest: None

[Object] The purpose of this study is to elucidate the roles of the fractalkine (FKN)-CX3CR1 axis in the collagen-induced arthritis (CIA) mice. [Methods] The arthritis score was monitored, and joint destruction was evaluated by histology. The mRNA levels in the affected joints were assessed by quantitative RT-PCR. Osteoclast precursors (OCPs) were transferred to CIA mice to evaluate the migration of OCPs into the synovium. Apoptosis of fibroblast-like synoviocytes (FLS) was measured by histology. [Results] Anti-mouse FKN (mFKN) mAb significantly improved synovitis and joint destruction with marked reduction of Tof and Il16 mRNA expression in the joints. Anti-mFKN mAb strongly inhibited the OCP migration into the synovium, whereas etanercept or tofacitinib had no significant effects. OCPs derived from CX3CR1 knock out mice also markedly decreased the migration to the synovium compared with OCPs derived from wild type mice. Apoptosis of FLS in the synovium was significantly induced after the single administration of anti-mFKN mAb. [Conclusions] FKN-CX3CR1 axis could directly regulate the OCP migration and the FLS survival. Inhibition of FKN-CX3CR1 axis could be an attractive new therapeutic option for the treatment of both joint destruction and synovitis in rheumatoid arthritis patients.

P1-028
The roles of JAK/STAT pathway in the pathogenesis of HTLV-1-positive rheumatoid arthritis
Yumi Kariya, Kunihiko Umekita, Takeshi Kawaguchi, Motohiro Matsuda, Shunichi Miyauchi, Ichiro Takajo, Akihiko Okayama
Department of Internal Medicine, Rheumatology, Infectious Diseases and Laboratory Medicine, Faculty of Medicine, University of Miyazaki Japan

Conflict of interest: None

[Object] We investigated the role of JAK/STAT pathway in modification mechanism of RA (Rheumatoid arthritis) condition resulting from HTLV-1 (Human T-cell leukemia virus type 1) infection. [Methods] In HTLV-1 infected cell lines (MT2B, MT2J) and HTLV-1 not infected T cell line (Jurkat), treated with Tofacitinib (Tof), cell proliferation analysis and expression mRNA of IL-6 and IFNγ were measured using real-time quantitative PCR. Phosphorylation of STAT in MT2B and MT2J was assessed by immunoblot. In RASF (RA synovial fibroblasts) cultured with each cell lines and treated with Tof, expression mRNA and protein level of IL-6 and CXCL10 were measured using real-time quantitative PCR and ELISA. [Results] Tof suppressed cell proliferation, mRNA expression and production of IL-6 and IFNγ in MT2B and MT2J dose dependent manner, but not in Jurkat. Phosphorylation of STAT was inhibited by Tof. In RASF cultured with MT2B and MT2J, Tof reduced IL-6 and CXCL10 level dose dependent manner. [Conclusions] Our findings demonstrated that activated JAK/STAT pathway is important for proliferation and production of inflammatory cytokines of HTLV-1 infected cell. Therefore Tof has potential to be effective for treatment of HTLV-1 positive RA regulating activation of HTLV-1 infected cell and RASF.

P1-029
Fas ligand influences the gene expressions of various key molecules in rheumatoid synovial fibroblasts
Koji Fukuda1, Yasushi Miura1,2, Yoshihisa Maeda1, Shinya Hayashi1, Ryosuke Kuroda1
1Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan, 2Division of Orthopedic Science, Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, Kobe, Japan

Conflict of interest: None

[Object] Fas ligand (FasL) is a member of tumor necrosis factor superfamily (TNFSF6) and reported to be involved in synovial hyperplasia of rheumatoid arthritis (RA). Apoptosis through Fas/FasL pathway of RA synovial cells was inhibited by pro-inflammatory cytokines present within the synovium. In this study, we investigated the gene expression profiles regulated by FasL in rheumatoid synovial fibroblasts (RA-FLS) to reveal the mechanism how FasL is involved in the pathogenesis of RA. [Methods] RA-FLS were incubated with FasL for 12h. Gene expressions were detected by microarray assay. [Results] The most upregulated 3 genes by FasL were dual specificity phosphatase 6 (DUSP6), epiregulin (EREG) and interleukin11 (IL-11). DUSP6 regulates CD4+ T-cell activation and differentiation. EREG associates with the development of cytokine-induced arthritis. IL-11 decreases the pro-inflammatory cytokines. The most downregulated 3 genes were angiotensin-like 7 (ANGPTL7), protein inhibitor of activated STAT2 (PIAS2) and growth differentiation factor 5 (GDF5). ANGPTL7 promotes pro-inflammatory responses. PIAS proteins inhibit the activated STAT. GDF5 is associated with joint destruction of RA. [Conclusions] FasL regulates the expression of various genes in RA-FLS and may affect the pathogenesis of RA.

P1-030
Roles of histone acetyltransferases and transcriptional factor ROR alpha/REV-ERB alpha against TNF-alpha-induced CCL2 expression in RA-FLSs
Ikumi Okumura1, Kohsuke Yoshida1, Kenta Kaneshiro1, Koto Uchida1, Arisa Yaekura1, Yuto Oketani1, Kanta Morii1, Koji Tateishi2, Yasuhiro Terashima1, Yoshihiko Kawasaki1, Nao Shibanuma1, Yoshihata Sakai1, Akira Hashimoto2
1Department of Biophysics, Division of Clinical of Immunology, Kobe University Graduate School of Health Sciences, Kobe, Japan, 2Department of Pathogenesis and Medicine, University of Miyazaki, Japan

Conflict of interest: None
ment of Orthopedic Surgery, Kohnan Kagokawa Hospital, Kagokawa, Ja-
p
1Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan, 2Department of Orthopedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, 3Department of Rehabilitation Science, Kobe University Graduate School of Medicine, Kobe, Japan

Conflict of interest: None

[Object] We have reported that TNFα induced expressions of clock gene Bmal1 through transcriptional activator Rora and repressor Rev-er-
bα in RA fibroblast-like synoviocytes (RA-FLSs) and that histone acetyl-
transferases CBP and p300 were involved in this process. In the present-
study, we focused on chemokine CCL2, regulated by RORα and REV-ERBα as well as Bmal1, to investigate the effect of histone acetyl-
transferases on TNFα-induced CCL2 expression in RA-FLSs. [Methods] RA-FLSs were pretreated with RORα antagonist SR1001 (20μM), REV-
ERBα agonist GS4112 (20μM) or CBP/p300 inhibitor C646 (25μM) for 1 h and then stimulated with TNFα (10ng/ml). Likewise, small inter-
fering RNA (siRNA) of both CBP and p300 were introduced into RA-
FLSs, and stimulated with TNFα. Thereafter, intracellular CCL2 mRNA and culture supernatant CCL2 were analyzed by qPCR and ELISA, re-
spectively. [Results] TNFα-induced CCL2 expression was further inhib-
ited by simultaneous treatment with both SR1001 and GS4112, as com-
pared with solo treatment of each agents. Further, CCL2 expressions were also suppressed by treatment with C646, and silencing of both CBP and p300 genes. [Conclusions] We newly found that TNFα induced ex-
pression of CCL2 through RORα and REV-ERBα, which was associated with CBP/p300 in RA-FLSs.

P1-031  
The nociceptive pain control in the hypothalamo-neurohypophysial/spinal pathway in the carrageenan induced arthritis rats  
Makoto Kawasaki1, Haruki Nishimura1, Yasuhiito Motojima1, Takenori Matsuura1, Hitoshi Suzuki1, Yoshiaki Yamanaka1, Hideo Oishi1, Yoichi Ueta1  
1Department of Orthopedic Surgery, University of Occupational and En-
vironmental Health, 2Department of Physiology, University of Occupa-
tional and Environmental Health

Conflict of interest: None

[Object] We evaluated the neurological reaction in the hypothalamo-
neurohypophysial and hypothalamo-spinal pathway using the knee arthri-
tis model rats. [Methods] Adult male Wistar rats were used. The right
knee arthritis was induced by intra-articular injection of 100 μL of 3 %
carrageenan. Carrageenan-treated rats were perfused at 3, 6, and 12 hours after injection for immunohistochemistry. Furthermore, Carrageenan-
treated rats were decapitated 2 and 6 hours after injection for in situ hy-
bridization and collecting blood samples. [Results] The number of the Fos-LI positive cells in lamina I-II of the dorsal spinal cord, paraventricu-
lar nucleus and supraoptic nucleus was counted. The number of them in
lamine I-II of the dorsal spinal cord, paraventricular nucleus and supraoptic nucleus was counted. The number of them in all regions were significantly increased in the arthritis rats. In addition, all of the plasma oxytocin (OXT), vasopressin (AVP) and corticosterone were significantly increased in the arthritis rats. Furthermore, all of expression levels of OXT mRNA, AVP mRNA and corticotropin-releasing hormone mRNA in the hypothalamus and proopiomelanocortin mRNA in the anterior pituitary were significantly increased in the arthritis rats. [Conclusions] The hypothalamo-neurophysiological and hypothalamo-
spinal pathway were activated by the nociceptive stress of knee arthritis.

P1-032  
A disintegrin and metalloprotease -17 is involved proliferation of rheumatoid arthritis osteoblasts  
Hidekazu Furuya, Takeo Iizakai, Shinichiro Nishimi, Airi Nishimi, Sho Ishii, Takahiro Tokunaga, Yuzo Ikari, Kuninobu Wakabayashi, Tsuyoshi Kasama  
Division of Rheumatology, Department of Medicine, Showa University School of Medicine

Conflict of interest: None

[Object] We have previously reported ADAM-17 is expressed in rheumatoid arthritis (RA) synovial fluids and synovial tissues. The pur-
pose of this study was to clarify the role of ADAM-17 in bone destruction of RA. Here, we examine the role of ADAM-17 in proliferation of RA osteoblast (HOB). [Methods] To examine the expression of ADAM-17 in RA-HOB, RA-HOB were stimulated with concentration adjusted TNF-α at 24 hours and measured using ELISA. To determine ADAM-17 expression in RA-HOB lysate, western blotting (WB) was also performed. To confirm the presence of ADAM-17 on RA osteoblasts, immunostaining was performed. Finally, in order to examine the role of ADAM-17 in os-
teoablasts growth, cell proliferation assay was performed. [Results] ADAM-17 was expressed in TNF-α stimulated RA-HOB conditioned medium, which was significantly higher compared to non-stimulated RA-
HOB conditioned medium. We also found that ADAM-17 expression in RA-HOB by using immunostaining and WB. Using siRNA assay, ADAM-17 in RA-HOB was suppressed. In the osteoblast deficient in ADAM-17, the proliferation ability of the cell was decreased by 13%. [Conclusions] In this study, we showed the role of ADAM-17 in RA-
HOB proliferation, suggesting the possibility that it plays an important role in bone destruction in RA.

P1-033  
IL-6 induces the resistance for apoptosis-induction via circadian clock gene Hif in synovial cells  
Yuto Oketani1, Koto Uchida1, Kohji Suzuki1, Kenta Kaneshiro1, Kanta Morii1, Arisa Yaekura1, Ikumi Okumura1, Kohsuke Yoshida1, Yoshiko Kawasaki1, Koji Tateishi1, Yasuhiro Terashima1,2, Nao Shibanuma1, Yoshitada Sakai1, Akira Hashimoto1  
1Department of Biophysics, Division of Clinical of Immunology, Kobe University Graduate School of Health Sciences, Kobe, Japan, 2Department of Rheumatology, Kobe Kaisei Hospital, Kobe, Japan, 3Department of Orthopedic Surgery/Rheumatology, Kohnan Kagokawa Hospital, Kagokawa, Japan, 4Department of Orthopaedic Surgery, Kobe Kaisei Hospital, Kobe, Japan, 5Department of Rehabilitation Science, Kobe University Graduate School of Medicine

Conflict of interest: None

[Object] Interleukin-6 (IL-6) is responsible for the pathogenesis of rheumatoid arthritis (RA), however, the detailed mechanism how it ef-
fects on synovial hyperplasia remains unclear. We’ve reported the rela-
tion between the growth activity of RA fibroblast-like synoviocytes (RA-
FLSs) and clock genes. In this study, we explored the effect of IL-6 on dexamethasone (DEX)-induced apoptosis of RA-FLSs. [Methods] Syno-
vial cells were treated with or without DEX (10,100,300,500 μM:24 hr) and examined cellular viabilities by WST-8. Synovial cells were treated with or without IL-6/IL-6R (100 ng/ml:48 hr) and DEX (10 μM:24 hr) to examine cellular viabilities by WST-8, expressions of PARP by western blotting and Hif/Te/f/Dhp/Bik by qPCR. [Results] DEX decreased cell viabilities dose-dependently, which was disturbed by IL-6/IL-6R pre-
treatment. IL-6/IL-6R inhibited cleavages of PARP, and suppressed the expressions of circadian transcriptional factor Hif and pro-apoptotic fac-
tor Bik. [Conclusions] Results suggested that IL-6 induces the resistance for apoptosis via clock genes in RA-FLS.

P1-034  
Analysis of inflammatory cytokine levels produced from M1/M2 macrophages in AOSD  
Hideto Nagai1, Yohei Kirino1, Hiroto Nakano1, Ryusuke Yoshimi1, Yusuke Kunishita1, Naomi Tsuchida1, Naoki Hamada1, Yutaro Soejima1, Takaaki Komiya1, Reikou Kamiyama1,2, Daiga Kishimoto1, Natsuki Sakurai2, Masaki Mitsushashi1, Yukie Iizuka1, Chiharu Hiddenaka1,2, Yuki Yoshikawa1, Yumiko Sugiyama1, Kouji Kobayashi1, Takeaki Uehara1, Shigeru Ohno1, Shohei Nagaoka1, Hideaki Nakagami1,2  
1Department of Stem Cell and Immune Regulation, Yokohama City Uni-
versity Graduate School of Medicine, Yokohama, Japan, 2Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, 3Rheumatic Diseases Center, Yokohama City University Medical Center, 4Department of Rheumatology, Yokohama Minami Kyousai Hospital, 5Department of Rheumatology, Chigasaki Municipal Hospital

Conflict of interest: None...
P1-033 Novel multiple heterozygous NUDT15 variants caused an azathioprine-induced severe alopecia, tongue ulcer and leukopenia in a systemic lupus erythematosus patient: Case report

Mizuna Otaka, Tomohiro Koga, Remi Sumiyoshi, Momoko Okamoto, Yushiro Endo,Susuke Tsuiji, Ayuko Takatani, Toshushima Shimizu, Takashi Ighawa, Shin-ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Oruguchi, Atsushi Kawakami
Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Conflict of interest: None

[P1] Histopathological changes of synovial tissue in rheumatoid arthritis patients treated with TNF inhibitors

Yoshinori Takashima, Koji Fukuda, Shinya Hayashi, Tomoyuki Kamena, Ryosuke Kuroda, Marowa Hashimoto, Kazuhisa Ouhara, Syuichi Munenaga, Shintaro Hirata, Eiji Sugiyama, Tsukasa Matsubara
1 Department of Orthopedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; 2 Matsubara Mayflower Hospital, Kato, Japan; 3 Research Institute of Joint Disease, Kobe, Japan

Conflict of interest: None

[P1-035] Histopathological changes of synovial tissue in rheumatoid arthritis patients treated with TNF inhibitors

Yoshinori Takashima, Koji Fukuda, Shinya Hayashi, Tomoyuki Kamena, Ryosuke Kuroda, Marowa Hashimoto, Kazuhisa Ouhara, Syuichi Munenaga, Shintaro Hirata, Eiji Sugiyama, Tsukasa Matsubara
1 Department of Orthopedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan; 2 Matsubara Mayflower Hospital, Kato, Japan; 3 Research Institute of Joint Disease, Kobe, Japan

Conflict of interest: None

[P1-036] The effect of ACPA derived from RA patient’s B cell in the activation of osteoclastogenesis

Kazuhiro Ouhara, Syuichi Munenaga, Shintaro Hirata, Eiji Sugiyama, Hidemi Kurihara
1 Department of Periodontal Medicine, Hiroshima University, Graduate School of Biomedical & Sciences; 2 Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital

Conflict of interest: None

[P1-037] Novel multiple heterozygous NUDT15 variants caused an azathioprine-induced severe alopecia, tongue ulcer and leukopenia in a systemic lupus erythematosus patient: Case report

Mizuna Otaka, Tomohiro Koga, Remi Sumiyoshi, Momoko Okamoto, Yushiro Endo, Susuke Tsuiji, Ayuko Takatani, Toshushima Shimizu, Takashi Ighawa, Shin-ya Kawashiri, Naoki Iwamoto, Kunihiro Ichinose, Mami Tamai, Hideki Nakamura, Tomoki Oruguchi, Atsushi Kawakami
Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Conflict of interest: None

[P1-038] Factors that correlate with creatinine cystatin-C ratio

Ichiro Yoshii, Tatsumi Chijiwa, Naoya Sawada
1 Rheumatology and Musculoskeletal Medicine, Yoshii Hospital; 2 Department of Rheumatology, Kochi Memorial Hospital; 3 Department of Rheumatology, Dohgo Spa Hospital

Conflict of interest: None

[P2] Relationships between creatinine cystatin-C ratio (C/C ratio), that is estimated reflection of muscular power, and other factors were evaluated statistically. [Methods] From May to September 2018, C/C ratio was measured from 426 subjects. Relationship between C/C ratio and age, sex, body mass index (BMI), cystatin-C (CysC), creatinine kinase (CK), red blood cells (RBC), bone mineral density in lumbar spine and femoral neck (BMD-LS and BMD-FN), suffering rheumatoid arthritis (RA), Barthe Index (BI), were evaluated statistically with single mode linear regression analysis. Statistical significance was set within 1%. [Results] Aging, being female, and CysC correlated significantly with C/C ratio negatively, while CK, RA, BI score, and BMD-FN demonstrated positive correlation. Influence of aging is more evident in female than in male. BMI and BMD-LS demonstrated no significant correlations. [Conclusions] C/C ratio is suggested that reflects muscle volume. This index is also suggested the correlation with activities of daily living. BMD demonstrated significant correlation with C/C ratio in femur, but not in lumbar spine, where is influenced by other factors predominantly. From these results, C/C ratio candidates as one index for reflection of RA treat effects.
P1-039

Attempt of optimal use of infliximab by Remicheck Q

Hidetaka Futami, Kazuyuki Ishijima, Keiko Umemiya, Yoshihiro Oya, Takuya Nakazawa, Ruyutaro Matsumura

Center of Rheumatology, Allergy and Clinical Immunology, National Hospital Organization Chiba East National Hospital

Conflict of interest: None

[Object and Methods] During the treatment of infliximab, for the case requiring reexamination of therapy due to ineffectiveness, we performed Remicheck Q, and examined the results of the examination of these cases and clarified whether it was effective for selection of therapy. [Results] For 18 patients receiving infliximab, the Remicheck Q examination was carried out. A positive result was obtained at 85% in 12 cases of rheumatoid arthritis, 3 cases of Behcet's disease, 2 cases of psoriatic arthritis, 1 case of ankylosing spondylitis disease. There were also 5 cases using biosimilars, and in cases with clinical effect, all cases were positive. Among the eight patients with insufficient clinical effect, 5 cases were positive in Remicheck Q, 3 cases required switching to other biological products. Three cases of Remicheck Q negative, 2 cases became positive for Remicheck Q by increasing infliximab. [Conclusions] Remicheck Q examination for patients receiving infliximab is thought to provide valuable information for treatment changes, especially for ineffective cases. Although it had insurance problems, it was suggested that it is a useful test for biosimilar usage cases.

P1-040

The diagnostic utility of IgG rheumatoid factor (IgG-RF) and anti-agaractosyl IgG antibody (CA-RF) in rheumatoid arthritis (RA)

Moemi Miyazaki, Kenshi Inoue, Naofumi Dobushi, Kenta Misisaki

Department of Rheumatology, Kita-Harima Medical Center

Conflict of interest: None

Object: Serum RF and anti-cyclic citrullinated peptide antibody (ACPA) are commonly applied to diagnose RA. However, there’s no established diagnostic marker for seronegative RA. Here, we investigated the utility of serum IgG-RF and CA-RF in the clinical situation of diagnosis of RA. Methods: We retrospectively analyzed 202 patients who visited our hospital department due to arthralgia. Serum IgG-RF and CA-RF were measured between April and September 2016 as their first visit examination. ROC analysis was performed to evaluate the sensitivity, specificity and cut-off value of these two markers. 2010 ACR/EULAR-RA classification criteria was adapted to diagnose RA. Results: Two-hundred two patients (M: 66; F: 136, mean age: 60.8 years old) were included in this study, and 60 patients (29.7 %) were diagnosed as RA. Sensitivity and specificity of IgG-RF and CA-RF were Sen: 70.0 %, Spe: 73.2 % (PPV: 52.5 %, NPV: 85.2 %) and Sen: 73.3 %, Spe: 81.7 % (PPV: 62.9 %, NPV: 87.9 %) respectively. AUCs and cut-off values of IgG-RF and CA-RF were AUC: 0.740, cut-off: 1.85 and AUC: 0.817, cut-off: 16.1 AU/mL respectively. Conclusions: Serum IgG-RF and CA-RF could be useful markers as an adjunct to the diagnosis of RA as mentioned above.

P1-041

Anti-citrullinated protein antibodies are low affinity and cross-reactive

Akihisa Haraguchi1, Hisakata Yamada2, Masakazu Kondo1, Toshifumi Fujiwara1, Takahide Sakaguchi1, Tomoko Tsutsui1, Yasuharu Nakashima1

‘Kyushu University, ‘Kondo Clinic of Rheumatology and Orthopaedic Surgery

Conflict of interest: None

[Object] Anti-citrullinated protein antibodies (ACPAs) are specifically produced in rheumatoid arthritis (RA). It has been reported that avidity of some ACPAs is lower than that of foreign antigen-specific antibodies, but it is unclear whether 1) low avidity is common to all ACPAs, 2) low avidity is a general feature of autoantibodies, or 3) the differences in affinity associates with cross-reactivity among ACPAs. To address these issues, we measured avidity of various antibodies including ACPAs and other autoantibodies. [Methods] Antibodies in the serum from RA patients were detected by ELISA. Binding avidity was measured by adding NaSCN to the assay. Cross-reactivity was measured by pre-incubation of the serum with the competitor peptides. [Results] All ACPAs, including anti-CCP, and anti-citrullinated fibrinogen (cFib), a-enorase (cEno), and histone H3 (cHis), were low avidity compared to antibodies against foreign antigens, whereas other autoantibodies, including anti-SS-A and TPO antibodies, were comparably high avidity. There was a cross-reactivity among ACPAs in most cases, and the binding to cEno was overwhelming. [Conclusions] Self tolerance might not be the reason for the low avidity of ACPAs. A relationship between avidity and cross-reactivity of ACPAs was suggested.

P1-042

Serum cystatin C is associated with older age, TAC use, higher ESR but not with DAS28 in RA patients with normal eGFR

Shuzo Yoshida1, Yuko Kimura1, Akito Machida2, Nobuhisa Shibahara3

1Department of Immuno-Rheumatology Center, Arisawa General Hospital, Hirakata, Osaka, Japan, 2Department of Orthopedic Surgery, Arisawa General Hospital, Hirakata, Osaka, Japan, 3Department of Urology, Arisawa General Hospital, Hirakata, Osaka, Japan

Conflict of interest: None

[Object] To evaluate the association of serum cystatin C (CyS-C) with disease activity in RA patients with normal eGFR. [Methods] We retrospectively assessed the association of CyS-C with patient background and disease activity including CRP, ESR, and DAS28 in RA patients with normal eGFR. [Results] One hundred patients with RA were evaluated. Sixty-nine patients were normal eGFR (eGFR >60 mL/min/1.73 m²). In the patients with normal eGFR, the mean age was 65.8±13.1 years, mean disease duration was 9.3±9.6 years, and mean DAS28-CRP was 2.61±1.38. Forty-one patients administered MTX, 12 patients TAC, and 20 patients PSL. Thirty-three patients were elevated CyS-C. CyS-C elevated group significantly older age, higher CRP, higher ESR. However, no differences were observed between elevated CyS-C group and normal CyS-C groups in DAS28-CRP. In multiple logistic regression analysis, older age, higher ESR, and TAC use was identified as independent predictors of factors for elevated CyS-C. [Conclusions] The results of this study indicated that older age, TAC use, and higher ESR associated with elevated serum CyS-C in RA patients with normal eGFR.

P1-043

Measurement of human high affinity immunoglobulin gamma Fc receptor I (FCGR1A) concentrations in serum and plasma and comparison with neutrophil CD64 by flow cytometry in patients with infection

Akiko Komiya1, Akito Tominaga2, Kako Kodama3, Takuya Kakutani4, Koichiro Horie2, Shinichi Nogi5, Kanako Iwata4, Hirota Tsuno1, Hideki Ogihara1, Tatsuo Ikenaka2, Takahiro Nunokawa1, Atsushi Hashimoto6, Shigeto Tohma7, Yoshihiro Matsu1

1Department of Clinical Laboratory, National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan, 2Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, 3Department of Rheumatology, Clinical Research Center for Allergy and Rheumatology, National Hospital Organization Sagamihara National Hospital, 4Department of Rehabilitation, National Hospital Organization Sagamihara National Hospital, 5Department of Emergency, National Hospital Organization Sagamihara National Hospital, 6Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, 7Department of Emergency, National Hospital Organization Sagamihara National Hospital

Conflict of interest: None

[Object] Recent studies have shown that quantifying CD64 (Fc gamma RI) on neutrophils by flow cytometry is a useful diagnostic marker of infection. On the other hand, the establishment of a serological diagnostic test is also desired for ease of sample storing. In this study, we investigated the serum and plasma levels of human high affinity immunoglobulin gamma Fc receptor I (FCGR1A) in patients with infection to determine the usefulness for detecting infectious disease. [Methods] FCGR1A were detected in the sera and plasma using ELISA kit from patients with infections before treatment with antibiotics. We also measured neutrophil...
CD64 expression quantitatively by flow cytometry. Cut-off point for CD64 positivity was 2000 molecules/cell as defined in our previous study. Correlation was evaluated by Spearman’s rank correlation coefficient testing. [Results] The expression level of neutrophils CD64 from 66 patients with infection in active phase was 5540.3 ±427.88 molecules/cell (mean ± SEM). Correlation of CD64 expression on neutrophils with serum CD64 was -0.1764 (p = 0.1565) and -0.1645 with plasma CD64 (p = 0.1869). [Conclusions] In this study, there is no statistical correlation between CD64 on neutrophils and CD64 in sera and plasma in patients with infection.

P1-044
How can patients with rheumatoid arthritis planning surgical treatment of lower limb ?
Ryo Okabayashi1, Motohiro Suzuki1, Tetsuya Ichikawa3, Tetsuyuki Nagafusa1, Eiji Torika2, Shigeyuki Miyamoto1, Yukihiro Matsuyama1
1Department of Orthopedics, Hamamatsu University School of Medicine, 2Department of Orthopedics, Iwata City Hospital, 3Department of Orthopedics, NARITA Kinen Hospital, 4Department of Rehabilitation, Hamamatsu University School of Medicine, 5Department of Orthopedics, Kikugawa City Hospital
Conflict of interest: None

[Object] Medication for rheumatoid arthritis (RA) has been changed drastically after appearance of methotrexate (MTX) and biologics (Bio). The purpose of this study is to investigate the effect of medication such as MTX and Bio for the blood examination data in RA patients especially planning surgical treatment of lower limb. [Methods] During 1990 to 2017, 63 patients underwent total knee arthroplasty or forefoot arthroplasty. We classified this period into 4 subgroups (group A: before 1990 that MTX was not permitted in Japan, group B: 1999 to 2002 that MTX was permitted and Bio was not permitted, group C: 2002 to 2010 that the first stage of Bio, group D: 2010 to 2017 that the second stage of Bio). We evaluated the preoperative datum of laboratory findings such as 1 hour-ESR, AST, ALT, BUN, creatinine, total protein, albumin, and CRP. [Results] Mean ESR (mm/h) was lower in group D than in group A and B (A: 65.8, B: 61.2, C: 40.1, D: 29.7). Mean CRP (mg/dl) was significantly lower in group B, C and D than in group A (A: 4.24, B: 1.2, C: 0.95, D: 0.4). There were no differences of other date items in these groups. [Conclusions] We can perform surgical treatment such as TKA and/or forefoot arthroplasty in well controlled inflammatory condition of RA since post-marketing of MTX.

P1-045
A temporal artery ultrasonography image of the giant cell-related arteritis and histologic examination
Yukie Saito1, Yuji Uzawa1, Yuji Yoshioka2, Daisuke Kanai2, Akiko Sada2, Shohei Nagaoka2
1Yokohamaminakkyousai Hospital, 2Yokohamaminakkyousai Hospital
Conflict of interest: None

[Object] The giant cell-related arteritis (GCA) features the permeation of the many nuclei giant cell pathologically and is the disease that inflammation happens in all layers characteristics. It enforced sonography (US) and examined US image and the biopsy result of the case that endure sonography in patients with finger symptoms (50.9±4.2 years old) who showed no RA change by X-ray were examined. All spine and sacroiliac joint Xray was further evaluated with 50 inflammatory back pain cases. [Results] Enthesitis was found in 67% of all cases and was significantly higher than 52% of synovitis (p<0.016). RF was positive in 32% of enthesitis, 37% in synovitis, ACPA was positive in 25% of enthesitis and 32% in synovitis. In 50 cases spine and sacroiliac joint X-ray was taken, paraspinal bone formation was found in 60% and sacroiliac joint findings according to the ankylosing spondylitis (AS) New York Criteria were found at 66%. [Conclusions] Enthesitis was found in 67% of all cases and was significantly higher than 52% of synovitis (p<0.016). RF was positive in 32% of enthesitis, 37% in synovitis, ACPA was positive in 25% of enthesitis and 32% in synovitis. In 50 cases spine and sacroiliac joint X-ray was taken, paraspinal bone formation was found in 60% and sacroiliac joint findings according to the ankylosing spondylitis (AS) New York Criteria were found at 66%. In cases finger stiffness and pain, enthesitis of distal phalange was observed more frequently than synovitis. There was the possibility of spondyloarthritics including AS, and it was considered that US examination including the distal phalange was necessary.

P1-046
Anti-interleukin-10 antibody in systemic lupus erythematosus
Marina Uchida, Seido Ooka, Kanako Suzuki, Yutaka Goto, Hisae Fujimoto, Kana Ishimori, Hiromi Matsushita, Kimito Kawahata
St. Marianna University School of Medicine
Conflict of interest: None

[Object] Cytokines contribute to various manifestations of systemic lupus erythematosus (SLE). Although antibodies against cytokines are known to be present in SLE, there have been few studies which have determined the presence of anti-IL-10 antibody. Therefore, we assayed anti-IL-10 antibody in SLE and examined the clinical significance. [Methods] We performed a retrospective study of 80 Japanese patients with SLE. Sixteen scleroderma patients, 19 rheumatoid arthritis (RA) patients, 23 Behcet’s disease patients, and 23 healthy subjects were selected as control groups. Clinical information was abstracted from medical records. Anti-IL-10 antibody level was determined with an enzyme-linked immunosorbent assay. [Results] Fourteen patients with SLE were found to be anti-IL-10 antibody-positive. Absorbance was significantly higher in serum from patients with SLE and RA than in healthy individuals. In SLE, patients with low complement values were significantly more common in the antibody-positive group. Serum IgG levels were significantly higher in the antibody-positive group. [Conclusions] The present study found that anti-IL-10 antibody is present in SLE and related to clinical parameters. These results suggest that anti-IL-10 antibody may be involved in part of the disease process of SLE.

P1-047
Study on synovitis and enthesitis of distal phalange using joint ultrasonography in patients with finger pain or stiffness
Shigenori Tamaki1, Takashi Kato2, Motokazu Kai1, Kunikazu Ogawa2, Hisaji Oshima3, Ikuko Tanaka1
1Nagoya Rheumatology Clinic. Nagoya, Japan, 2Department of Radiology, National Center for Geriatrics and Gerontology, Obo, Japan, 3Mie Rheumatology Clinic. Suzuki, Japan, 4Department of Connective Tissue Disease. Tokyo, Japan, Tokyo Medical Center
Conflict of interest: None

[Object] Since enthesitis of distal phalange often accompanies tendinitis and manifests symptoms such as finger stiffness and pain, it is necessary to distinguish from rheumatoid arthritis (RA). We observed all distal phalanges in joint US and prospectively studied the utility of US in differentiating between synovitis and enthesitis. [Methods] 130 patients with finger symptoms (50.9±4.2 years old) who showed no RA change by X-ray were examined. All spine and sacroiliac joint Xray was further evaluated with 50 inflammatory back pain cases. [Results] Enthesitis was found in 67% of all cases and was significantly higher than 52% of synovitis (p<0.016). RF was positive in 32% of enthesitis, 37% in synovitis, ACPA was positive in 25% of enthesitis and 32% in synovitis. In 50 cases spine and sacroiliac joint X-ray was taken, paraspinal bone formation was found in 60% and sacroiliac joint findings according to the ankylosing spondylitis (AS) New York Criteria were found at 66%. [Conclusions] In cases finger stiffness and pain, enthesitis of distal phalange was observed more frequently than synovitis. There was the possibility of spondyloarthritics including AS, and it was considered that US examination including the distal phalange was necessary.

P1-048
Study of disease assessment for rheumatoid arthritis based on joint ultrasonography
Mihoko Henmi, Akihiro Narita, Atsuko Sugimura, Fumihiko Sakamoto, Yuko Aoki, Akemi Kitano, Takeya Ito, Toshiyuki Hattori, Norifumi Sawamukai, Masato Isobe, Jun Fukae, Megumi Matsushahi, Akio Mitsuzaki, Masato Shimizu, Kazuhide Tanimura, Takao Koike
Hokkaido Medical Center for Rheumatic Diseases, Sapporo, Japan
Conflict of interest: None
P1-049
Evaluation of Direction of Probe in Ultrasound Sonography of 1st and 5th Metatarsal Phalangeal Joints in Patients with Rheumatoid Arthritis
Hiroko Minamoto1, Yuji Hirano2, Daisuke Kihira2
1Department of Clinical Laboratory, Toyohashi Municipal Hospital, 2Department of Rheumatology, Toyohashi Municipal Hospital

Conflict of interest: None

[Objective] Ultrasound sonography (US) is important in examination of rheumatoid arthritis (RA). Although detection of synovitis can save time, risk of missing pulse doppler (PD) or bone erosion (ERO) should be considered. This study evaluated direction of probe in US examination on 1st and 5th MTP joints in RA patients. [Methods] 120 RA patients in whom US were performed from Jan-Aug in 2018 were used in this study. Detection rates of PD and ERO in 1st and 5th MTO joints were compared. [Results] Patients characteristics: 88 female and 62 male. Mean age was 60.9 years old. RA duration was 7.5 years. Mean DAS28-CRP was 2.8. Mean mHAQ was 0.35. Detection rates of PD: Positive in 16.3% at 1st MTP and 15.8% at 5th MTP from the saggital view. Positive in 13.8% at 1st MTP and 11.7% at 5th MTP from the side view. Detection of ERO: Positive in 1.3% at 1st MTP and 1.3% at 5th MTP from the saggital view. Positive in 10.4% at 1st MTP and 15.4% at 5th MTP from the side view. [Conclusions] Although there were not so much differences in detection rates of PD between the saggital view and the side view, there were differences in detection rates of ERO.

P1-050
Validation of a novel automatic software for evaluating sonographic synovitis in rheumatoid arthritis
Kei Ikeda1, Yuki Matsamoto2, Takahiro Sugiyama1, Manami Kato1, Tamadichi Kasuya1, Takashi Kamagai1, Kazumasa Suzuki2, Hiroki Furuya1, Masashi Fukuda1, Aiko Saku1, Sohei Makita1, Takashi Itoh1, Mieko Yamagata1, Shunsuke Furuta1, Hiroshi Nakajima1
1Department of Allergy and Clinical Immunology, Chiba University Hospital, 2Corporate R&D Headquarters, KONICA MINOLTA, INC., 3Department of Rheumatology, National Hospital Organization Shimoshizu National Hospital

Conflict of interest: Yes

[Objective] We aimed to validate the accuracy and utility of a novel automatic software in evaluating sonographic synovitis. [Methods] We recruited 20 rheumatoid arthritis (RA) patients who underwent ultrasound for evaluating synovitis. We scanned the PIP joints, MCP joints, midcarpal joint, radiocarpal joint, and distal radioulnar joint, bilaterally, and stored the image representing the most severe synovitis in each joint region. We evaluated these stored images by semiquantitative grading (0-3) and a novel automatic software for gray-scale (GS) synovial hypertrophy and synovial power Doppler (PD) signals and analyzed their correlations. [Results] 15 patients were women with mean age 65.0 year-old, mean disease duration 6.1 years, mean SDAI 19.7, mean total GS score 39.9, and mean total PD 10.6. Correlation coefficients between GS score and software-based synovial hypertrophy area were 0.67 for the PIP joints, 0.70 for the MCP joints, and 0.76 for the wrist joints, whereas those between PD score and software-based ratio of synovial PD signal area were 0.84 for the PIP joints, 0.79 for the MCP joints, and 0.69 for the wrist joints. [Conclusions] Automatic evaluation of synovitis by a novel software correlated well with conventional semiquantitative evaluation in active RA.

P1-051
Ultrasonographic evaluation of the toe joint in patients with rheumatoid arthritis
Atsushi Nagata1, Yasuhide Kanayama1, Hitomi Nagasaka1
1Department of Clinical Technology, Toyota Kosei Hospital, Toyota Japan, 2Department of Orthopedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota Japan

Conflict of interest: None

[purpose] Examine an existence views rate of the toe joint in the joint echo in the rheumatic. [Objective] I intended for150cases that enforced an echo in a diagnosis of RA or a disease activity evaluation purpose during from April to June in 2018. [Methods] I followed=joint echo imaging law guidelines=with 36 places of 32 joints of both sides MCP, PIP, wrist, MTP and evaluated GS, PD, in grade 0-3. In 150, I examined The following items about 115 cases that enforced an echo for 35 diagnosis purposes, disease activity evaluation purpose. (1) Existence views rate of 26 GS, PD every each joint which led to a diagnosis of RA in 35 (if there are views, I define GS≧2, PD≧1) (2) 115 if there are views [Results] patient background, 37 men, woman 113, average age were 60.9 years old. (1) GS≧2 MCP11 (42.3%), PIP9 (34.6%), wrist18 (69.2%), MTP21 (80.8%), PD≧1 MCP9 (34.6%), PIP7 (26.9%), wrist17 (65.4%), MTP12 (46.2%). (2) GS≧2 MCP47 (40.9%), PIP33 (28.7%), wrist12 (53.9%), MTP105 (91.3%), PD≧1 MCP42 (36.5%), PIP24 (20.9%), wrist74 (64.3%), MTP36 (31.3%). [Conclusions] It was 26 cases that led to a diagnosis of RA in the echo of the diagnosis purpose, and it was high, and, as for the PD incidence of the toe joint, it was thought that the observation of the toe joint was useful following a wrist.

P1-052
Analysis of subclinical synovitis by re-palpation after ultrasonography in patients with rheumatoid arthritis in clinical remission
Jun Ishizaki1, Takuya Matsamoto1, Koichihiro Suemori1, Eiji Sada2, Katsuto Takenaka1, Hitoshi Hasegawa1
1Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan, 2Department of Medical Technology, Ehime Prefectural University of Health Sciences

Conflict of interest: None

[Objective] We examine whether subclinical synovitis is palpable by re-palpation after ultrasonography (US), and the differences in clinical significance of the palpable and non-palpable synovitis groups are analyzed. [Methods] In 55 patients archived in clinical remission, bilateral hand and finger joints were scanned using US, imaging the dorsal surface. Only each number of subclinical synovitis in three areas including the wrist (the radial, median and ulna side; 6 sites), the MCP and the first IP and 2-5th PIP joint was presented to the attending physician and palpation was performed. The Grey scale (GS) and power Doppler (PD) graded on a semi-quantitative scale (0-3) and the presence of spontaneous pain and joint destruction were compared in 2 groups. [Results] 18 patients (32.7%) had subclinical synovitis in 38 sites. 17 sites (44.2%, wrist 9/20, MCP 6/16, IP 2/2) were palpable by re-palpation after RA. Synovitis with high GS grade was easy to palpate (G1: 3/11, G2: 10/22, G3: 4/5), but there was no difference by PD grade. There was no significant difference in the presence of spontaneous pain and bone erosion in 2 groups. [Conclusions] Our analysis suggested that about half of the subclinical synovitis found using US in remission patients is observable with palpation.
P1-053
Power Doppler ultrasound findings in Löfgren syndrome
Tomohisa Uchida1, Keita Fujikawa1, Akinari Mizokami1, Atsushi Kawakami2
1Department of Rheumatology, Japan Community Healthcare Organization, Isahaya General Hospital, Isahaya, Japan, 2Unit of Translational Medicine, Department of Immunology and Rheumatology, Unit of Advanced Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan
Conflict of interest: None

Background: Löfgren syndrome is an acute form of sarcoidosis, which is characterized by a triad of arthritis, bilateral hilar lymphadenopathy (BHL), and erythema nodosum (EN). The prevalence of the syndrome is extremely rare in Japan. We evaluated our case by power Doppler ultrasound (PDU) and compared the findings with previous reports.

Case report: A 62 years-old female suffering from arthralgia of knee and ankle joints with EN-like rash and swelling of lower extremities was admitted to our hospital. The serum levels of ACE and lysozyme were elevated and BHL was identified on chest CT. FDG uptake in hilar lymph nodes and periaortic tissue was shown on PET-CT. In PDU, the presence of subcutaneous edema with PD signals and slightly tenosynovitis was determined, and joint effusion of knee and ankle joints without synovitis was detected. Cutaneous biopsy supported EN and lung and lymph node biopsy revealed non-necrotic granuloma. She was diagnosed with Löfgren syndrome. Her symptoms improved after NSAID treatment.

Result: PDUS findings in the present case were compatible with previous reports. Conclusion: In Löfgren syndrome, the PDUS findings of periartitis due to subcutaneous edema with hyperperfusion and tenosynovitis without synovitis will facilitate the diagnosis.

P1-054
A case of immune-mediated meningococcal arthritis with tenosynovitis confirmed by using joint ultrasoundgraphy
Department of Rheumatology, Chubu-Rosai Hospital
Conflict of interest: None

A 20-year-old woman had sore throat 2 weeks before her visit. She then developed fever and arthralgia from a day before admission. During the course, headache and dysuria, and urinary frequency did not appear. On examination, the temperature was 38.3°C. The both side of hand joints, elbow joints, and feet joints were erythematous and warm, and movement and palpation of these joints caused pain. The laboratory test showed leukocytosis of 11200 /mm3, normal serum creatinine and urinalysis, normal liver function tests, and CRP level was 7.37 mg/dl. Both blood and synovial cultures were negative. Neisseria meningitidis grew in pharyngeal culture. By using ultrasonography, we confirmed tenosynovitis of both hands and fingers joints by grayscale (GS) and power doppler (PD). We obtained date of 5 patients (male / female: 3/2) and average age is 63.6 years [54, 82]. All of them, RF and anti-CCP antibody are negative. There is no significant difference in the site of arthritis. Four patients have already treated with PSL 5 mg/day or more before the first visit. Two patients diagnosed with RA in our department and intervene therapeutically. Background disease of PRS is lung cancer in 3 cases and malignant lymphoma in 2 cases. All of them are advanced cancers of Stage III to IV. [Conclusion] It is difficult to distinguish between PRS and RA / PMR only by echocardiography.

P1-056
Comparison of hand joint / shoulder joint echo findings and clinical features of tumor associated syndrome in our hospital
Shoichi Nawachi, Kazuya Matsumoto, Reika Hayashi, Ryutaro Yamanaka, Hitodoshi Kagawa
Department of Nephrology and Rheumatology, Japanese Red Cross Society Himeji Hospital
Conflict of interest: None

[Background] Differentiation between paraneoplastic syndromes (PRS) and rheumatoid arthritis (RA) / polymyalgia rheumatica (PMR) is sometimes difficult. There are few reports mentioning PRS. We examined the joint echo findings obtained in 5 cases of PRS while comparing with the clinical features. [Methods] Between April 2015 and September 2018, we investigate and examine five patients which shows significant findings (synovitis, bursitis and biceps tendon attachment flame) with joint echo and whose malignant tumors is found later. Regarding RA, we evaluate synovial membranes of both hands and fingers joints by grayscale (GS) and power doppler (PD). [Results] We obtained date of 5 patients (male / female: 3/2) and average age is 63.6 years [54, 82]. All of them, RF and anti-CCP antibody are negative. There is no significant difference in the site of arthritis. Four patients have already treated with PSL 5 mg/day or more before the first visit. Two patients diagnose with RA in our department and intervene therapeutically. Background disease of PRS is lung cancer in 3 cases and malignant lymphoma in 2 cases. All of them are advanced cancers of Stage III to IV. [Conclusion] It is difficult to distinguish between PRS and RA / PMR only by echocardiography.

P1-057
Pathology of residual synovitis and potential of controlling their inflammation in rheumatoid arthritis (preliminary report)
Jun Fukae, Akemi Kitano, Akihiro Naria, Mihoko Henni, Fumihiko Sakamoto, Yuko Aoki, Masato Isobe, Norifumi Sawamura, Toshiyuki Hattori, Akio Mitsuaki, Takeya Ito, Masato Shimizu, Megumi Matsushashi, Tomotu Kamishima, Kazuhide Tanimura, Takao Koike
1Hokkaido Medical Center for Rheumatic Diseases, 2Faculty of Health Sciences, Hokkaido University
Conflict of interest: None

[Background] Residual synovitis (R-synovitis) still remain in rheumatoid arthritis (RA) despite clinical remission. R-synovitis have risk of joint structural destruction and lead to generalized disease relapse in near future. We used imaging technologies and studied active synovitis and reported that ostetitis strongly had relation to R-synovitis. We further observe significant change of active-synovitis with osteitis and study that whether anti-rheumatic therapy + denosumab suppress change to R-synovitis or not. [Methods] We study patients with active RA and compare patients treated with DMARDs and DMARDs + denosumab. Clinical examination, joint magnetic resonance imaging and ultrasonography are performed sequentially. Metacarpophalangeal, proximal interphalangeal and wrist joints are observational targets. [Preliminary results] 13 patients were entered the study and ongoing (age 47-75, F/M = 12/1, DAS28=median 5.4). [Discussion] In the previous report, we reported active synovitis + osteitis significantly lead to R-synovitis. Denosumab that suppress osteoclasts might control osteitis and then suppress change...
to R-synovitis. We focused on synovitis-osteitis and continue the study.

### P1-058
**Photoacoustic imaging of synovium in rheumatoid arthritis**

Koichi Murata1,2, Moritoshi Furu1,2, Hiromu Ito1, Motomu Hashimoto1,2, Masao Tanaka1, Kohei Nishitani1,2, Kosaku Murakami1, Tsuneyo Mimori1, Shuichi Matsuda2

1Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 2Department of Orthopaedic Surgery Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan

Conflict of interest: None

**[Object]** Photoacoustic imaging is an emerging imaging modality based on photoacoustic effect. Image reconstruction of a photoacoustic wave emitted by absorption of light energy by nanosecond pulsed laser enables to visualize a blood vessel with high spatial selectivity. We have developed a new photoacoustic imaging device (PAI-05) which is superior to existing ones at resolution of 0.2 mm in 3D image and will show the results of imaging of RA patients. [Methods] We used the wavelength of the laser light being 797 nm. Hands of six RA patients with finger joint pain or swelling (age: 50-83 years, 5 females, disease duration: 0.5 - 40 years, Stage: 1-4, DAS 28 (ESR): 2.1-6.4) were visualized. Results were compared with sonographic examination, disease activity, and ultrasound images. [Results] Regarding the superficial palmar artery, high resolution images was obtained. Regarding the deep part, the synovial membrane beneath the extensor tendon was poorly visualized, but a blood vessel image, which could be detected by ultrasound in a certain degree or more, was obtained in the area that was not obstructed by extensor tendons.

### P1-059
**Dynamic Contrast Enhanced Magnetic Resonance Imaging of Hand and Foot is Beneficial Diagnostic Tool in Rheumatoid Arthritis Diagnosis**

Minami Matsushahi1, Ryuichi Nakahara2, Masahito Watanabe1, Shunji Okita1, Yohei Kiso1, Yoshihisa Nasu1, Keiichiro Nishida1, Toshifumi Ozaki1

1Department of Orthopaedic Surgery Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan, 2Department of Intelligent Orthopedic System, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan

Conflict of interest: None

**[Object]** The purpose of this study is to investigate the usefulness of our new MRI protocol evaluating bilateral hands and feet with one test. [Methods] First, we took T1-weighted (T1W), T2W, and after injection of dynamic and 3D dynamic scanning of hands with the head first prone position. Then, a patient was changed position to foot first supine, 3D dynamic and T1W of feet was taken. Retrospectively, we investigated 30 cases that had undergone rheumatoid arthritis (RA) and 16 cases with undifferentiated arthritis (UA) who underwent our MRI protocol. 16 cases were diagnosed to be rheumatoid arthritis (RA), and 14 cases to be non-RA. The MRI findings including synovitis, tenosynovitis, and bone marrow edema were evaluated, and the prevalence of findings was compared between two groups. [Results] Synovitis in both hands and feet were detected in 75% patients of RA group (only in hands; 13% only in feet; 6%). In non-RA group, the proportion of them 43%, 0%, 7%. In RA group, five of seven patients who didn’t fulfill the ACR/EULAR RA classification criteria showed significant MRI findings of feet. These MRI findings helped to start rheumatic treatment at early stage. [Conclusions] In this study, 81.8% of RA patients showed positive MRI findings in both hands and feet. Our MRI protocol can be a beneficial tool for diagnostic screening of rheumatic UA.

### P1-060
**Predictors of improved MRI findings in rheumatoid arthritis patients one year after treating with TNF inhibitors**

Yasuhito Kubota

Kubota Orthopedics and Rheumatology Clinic, Toyota, Aichi, Japan

Conflict of interest: None

**[Object]** This study aimed to examine the predictors of rheumatoid arthritis patients whose MRI findings improved one year after treating with TNF inhibitors. [Subjects] Subjects were 14 patients. Mean age was 50.3 years. TNF inhibitors used were: adalimumab (n=6), golimumab (n=6), etanercept (n=1), and infliximab BS (n=1). [Methods] Hand MRI were performed before and one year after treating with TNF inhibitors. Bone erosion, joint space narrowing (JSN), bone marrow edema, synovitis, and tenosynovitis were scored by RAMRIS. Those who had total MRI scores that improved by ≥20% were assigned to the improvement group (group I), and the remaining patients were assigned to the non-improvement group (group N). Age, disease duration, stage, and baseline MRI score were assessed for both groups. [Results] The group I consisted of 7 patients with a mean disease duration of 31.4 months. The group N consisted of 7 patients with a mean disease duration of 79.6 months. Baseline MRI scores in the group I vs. the group N were as follows: mean bone erosion: 8.4 vs. 14.3, JSN: 4 vs. 31.4, bone marrow edema: 5.7 vs. 13.6, synovitis: 8.0 vs. 6.9, and tenosynovitis: 7.6 vs. 8.0. [Conclusions] The group I had low scores for baseline total MRI and JSN scores, and tended to have a shorter disease duration.

### P1-061
**Three cases which could evaluate disease activity of large vasculitis with DWIBS**

Hidetoshi Matsuoka1, Yuji Yoshida1, Eri Oguro1, Kentaro Kuzuya1, Yasutaka Okita1, Satoru Teshigawa1, Maiko Yoshimura1, Kentaro Isoda1, Yoshinori Harada1, Shiro Ohshima1, Jun Hashimoto1, Yukihiko Sack1

1Department of Rheumatology & Allergology, NHO Osaka-Minami Medical Center, 2Department of Clinical Research, NHO Osaka-Minami Medical Center

Conflict of interest: None

**[Object]** Large vasculitis is diagnosed from symptoms, blood tests, image findings. To prevent complications such as visual loss of giant cell arteritis and vasocclusion / occlusion of Takayasu arteritis, diagnosis at an early stage and image inspection for detection of vascular stenosis / occlusion / dilation and aneurysm is very important. Although contrast CT is a useful test, it has problems of radiation exposure and contrast medium. The imaging range is limited for MRI and ultrasound. DWIBS is a whole body MRI using a diffusion weighted image in the imaging method announced in 2004. It is an examination spreading in the area of malignant tumor and it is reported that finding similar to FDG - PET can be obtained in the tumor area, and whole - body screening is possible with out cheap, no exposure, no drug administration. We report three cases in which DWIBS was useful for evaluation and activity evaluation of large-scale vasculitis at our hospital and follow-up follow-up.

### P1-062
**Association between bone marrow lesion in preoperative knee MRI of patient undergoing total knee arthroplasty and symptom and function of the knee joint**

Daisuke Hamada, Tomohiro Goto, Koichi Sairyo

Department of Orthopedics, Tokushima University Graduate School

Conflict of interest: None

**[Object]** Bone marrow lesion (BML) is observed as ill-defined hypointensity area in T1 weighted images and hyperintensity area in STIR or fat suppressed T2 weighted images of the MRI. The association between BML and knee pain has been reported. However, the number of studies that examined the extent of BML and symptom and function of the knee before total knee arthroplasty is still limited. The purpose of this study is to examine the association between BML in preoperative MRI of
the patient undergoing total knee arthroplasty and the symptom and function of the knee joint. [Methods] Eighty-two knees in 64 patients who underwent TKA and performed preoperative MRI since 2014 was included. The extent of BML is scored using MRI Osteoarthritis Knee Score (MOAKS). The knee symptom and function were evaluated using 2011 Knee Society Score (KSS). The correlation between BML score and each item of the KSS was examined. [Results] BML score was correlated with the objective evaluation score that indicated preoperative alignment and range of motion. No significant correlation was found in other KSS items. [Conclusions] Unexpectedly, there was no correlation between symptom and BML score and significant correlation was found between objective evaluation and BML score.

P1-065
Evaluation of radiological changes of distal interphalangeal joint in patients with rheumatoid arthritis
Satoshi Ikemura, Junichi Fukushima, Yukio Akasahi, Toshifumi Fujiwara, Yasuharu Nakashima
Department of Orthopaedic Surgery, Graduate School of Medical Sciences, Kyushu University
Conflict of interest: Yes

[Object] The purposes of this study were to evaluate the frequency of the radiological changes of DIP joint, and to determine the factors associated with its changes. [Methods] This study reviewed 49 RA patients. The changes of metacarpophalangeal (MP), thumb interphalangeal (IP), and proximal interphalangeal (PIP) joints as well as DIP joint, were investigated with comparison between initial and final hand radiographs. Clinically, the duration of disease, disease activity (DAS28-CRP), therapeutic drugs were investigated. [Results] Radiological changes of DIP joint were observed in 4 patients (8.2%). In the radiological DIP change positive group, the rate of presence of radiological rheumatic changes of MP and PIP joints were significantly higher than those in the radiological DIP change negative group (P<0.05). The mean DAS28-CRP (3.91) in the radiological DIP change positive group was significantly higher than that (2.28) in the radiological DIP change negative group (P=0.05). [Conclusions] Radiological rheumatic changes of DIP joint were observed in 4 patients (8.2%) during the course of disease. The results of this study indicate that disease activity relates to radiological rheumatic changes of DIP joint as well as other common sites of deformity, such as MP and PIP joints.

P1-064
Two cases of atlantoaxial synovitis
Tetsushi Aita1, Mayuko Fukushima, Shunichi Fujita, Takahiko Akagi, Hiroshi Sawachika, Tomoyuki Mukai, Yoshitaka Morita
Department of Rheumatology, Kawasaki Medical School, Kurashiki, Japan
Conflict of interest: None

A 62-year-old man was referred to our clinic with lower leg edema and abdominal pain. He presented with nephrotic-range proteinuria, and a renal biopsy revealed lupus nephritis of the membranous type. Antinuclear antibody and anti-DNA antibody were positive, but antiphospholipid antibody was negative. Abdominal computed tomography also indicated mesenteric panniculitis. He started to receive prednisolone (50 mg/day) and mycophenolate mofetil (1000 mg/day). These treatments improved abdominal pain, while sudden onset of dysarthria was developed on the 10th day. Brain magnetic resonance imaging (MRI) showed acute cerebral infarction, and then he started to take anticoagulant and antiplatelet agents. Despite these treatments, he developed repeated recurrences of cerebral infarction on the 11th and 12th days. High-resolution magnetic resonance vessel wall imaging revealed intracranial arterial wall thickening with vessel wall contrast enhancement. A diagnosis of cerebral vasculitis in SLE was made. Steroid pulse therapy and intravenous cyclophosphamide therapy were performed, but he died of brainstem infarction on the 27th day. Clinical significance: The vessel wall MRI techniques may contribute to early diagnostic assessment of cerebral vasculitis in SLE, and improve patient outcomes.

P1-066
The development of the automatic measurement of joint space distance of the metacarpophalangeal joint of the rheumatoid arthritis patient by the super-resolution image processing. Second report: Edge abstraction by mask processing by GraphCut
Koji Funahashi1, Tadahiro Natsume1, Ken Ikuta1, Katsuyoshi Koyama2, Kiyomi Koike3, Junichiro Hagita3, Naoki Fukaya1
1Department of Orthopedic Surgery, Kariya Toyota General Hospital, 2Department of Nephrology and Rheumatology, Kariya Toyota General Hospital, 3Habirisu Hitoshi
Conflict of interest: None

[Background] We reported that the measurement of joint space distance (JSD) using the curve fitting method and super-resolution image processing for detecting the radiographic progression. [Object] To develop the algorithm of automatic measurement of JSD for the purpose of saving the time. [Methods] We prepared bilateral 2nd-5th metacarpophalangeal (MCP) joint X-ray images of rheumatoid arthritis patients. Edge extraction was performed by GraphCut which is a tool on MatLab, measurement JSD by the curve fitting method were performed automatically. We compared the difference between automatic measurement and manual operation. [Results] In 29 joints of 40 joints (72.5%) in both 2nd-5th MCP joint, the difference of measurement value between automation and manual operation was less than 0.1mm. In 30 joints of 40 joints, (80.0%) it was less than 0.2mm. In index and middle finger, 18 joints (90.0%) were less than 0.1mm. All joints were less than 0.2mm. In ring and little finger, 11 joints (55.0%), 12 joints (60.0%) were respectively. [Conclusions] We tried the automation of the measurement of the JSD. We developed the method that the measurement value was calculated in several seconds automatically.

P1-067
Carpal bone cysts resembling erosions are relatively common findings
Atsushi Moriya1, Hiroshi Tanaka1, Eiichii Shiigi1, Hiroki Yamagata1, Yasuhiro Tanii2
1Yamaguchi Prefectural Grand Medical Center, 2Nagato General Hospital
Conflict of interest: None

[Object] To investigate the prevalence and distributing features of
carpal bone cysts. [Methods] We analyzed 156 CTs on carpal bones of patients with distal radius fractures (a mean age of 63 years). Patients bone with carpal bone fracture or prior arthralgia were excluded from this study. Cystic alterations on CTs were evaluated separately in each carpal bone in the sagittal, coronal and transverse planes. A carpal bone cyst was defined as a sharply marginated intraosseous radiolucent lesion (usually larger than 2 mm in size). [Results] CTs showed carpal bone cysts in 72 (46%) out of 156 subjects. Altogether, 121 carpal bone cysts were found in the 1404 carpal bones evaluated (4 in the trapezium, 10 in the trapezoid, 21 in the capitate 5 in the hamate, 24 in the scaphoid, 35 in the lunate, 21 in the triquetrum, and 1 in the pisiform). Cystic alterations were found more often in the older subjects. [Conclusions] The distribution and frequency of cystic alterations as detected by CTs in carpal bones were identified. Cystic lesions were found frequently seen in the capitah, scaphoid, lunate and triquetrum, which also frequently show bone erosions in rheumatoid arthritis. These finding of the present study may be considered when distinguishing arthritic joints from normal joints.

P1-068
Mid-term efficacy and prevention of knee joint destruction of Infliximab in rheumatoid patients
Masaki Usui1, Kazuo Fujiwara1, Shinji Narazaki2, Hiroshi Wakabayashi2
1Okayama City Hospital, Okayama, Japan, 2Okayama City Hospital, Okayama, Japan

Conflict of interest: None

[Object] Mid-term efficacy and prevention for knee joint destruction of Infliximab (IFX) in rheumatoid patients for the knee joint destruction of infliximab was examined. [Methods] In the patients who introduced IFX for RA from June, 2004 to August, 2009, radiographic appearance of both knee joints standing position in 22-patients having a knee joint symptom was studied. The dosage start age was an average of 54.3 years old. Larsen Grade of 1/2/3/4/5 at the time of the dosage start was 2, 23, 8, 7, 2, 2 knees each. [Results] Larsen Grade of 1/2/3/4/5 in 2014 was 2, 20, 11, 7, 2, 2 knees each. Progress of Grade was seen in 5 knees, but the improvement such as open sizes of joint space was seen in 8 knees. Larsen Grade of 1/2/3/4/5 in 2018 was 1, 17, 11, 9, 4, 31 knees each. Progress of Grade was seen in 14 knees, and 1 knee of Grade3 became Grade4, and TKA was enforced. [Conclusions] Improvement of the radiographic appearance was seen in the short term, but a progress of Grade was not avoided in the mid-and-long term by the IFX dosage.

P1-069
Predictors of radiographic progression in patients with rheumatoid arthritis by using magnetic resonance imaging and ultrasound
Ayuko Takatani1, Mami Tamai1, Nozomi Oki1, Yoshikazu Nakashima1, Mizuna Otsuka1, Momoko Okamoto1, Yushiro Endo1, Sosuke Tsujii1, Toshimasa Shimizu1, Remi Sumiyoshi1, Tomohiro Koga1, Shin-ya Kashaw44hi1, Naoki Iwamoto1, Takashi Iwagawa1, Kunihiro Ichinose1, Kazuhiko Arima1, Hideki Nakamura1, Tomoki Orugiuch1, Masataka Uetani1, Atsushi Kawakami1
1Nagasaki University Graduate School of Biomedical Sciences, Department of Radiological Science, Nagasaki, Japan, 2Department of Rheumatology and Clinical Immunology, Kyoto University, 3Department of Radiology, Saga Medical School, Saga, Japan, 4Department of Radiology, Nagasaki University Graduate School of Medical Sciences, Department of Public Health, Nagasaki, Japan

Conflict of interest: None

[Object] To clarify the predictors of radiographic progression in patients with rheumatoid arthritis. [Methods] Forty four patients with RA were enrolled and observed for 12 months. They were evaluated by using US synovitis score, semi-quantitative exam by grey-scale and power Doppler (PD) every 3 months. MRI and radiograph were done every 6 months. Synovitis, bone marrow edema and bone erosion were assessed by the Rheumatoid Arthritis Magnetic Resonance Imaging Scoring system (RAMRIS). Radiographic progression was defined as ΔGenent-modified Sharp score (GSS) >0.5. After univariate analysis, multivariate analysis was performed to establish the predictors for radiographic progression. [Results] Median of disease duration was 8.5 months and that of DAS28-CRP was 4.18 at baseline. Radiographic progression was found in 14 patients. A univariate analysis showed radiographic joint space narrowing score and RAMRIS synovitis scores, bone marrow edema score and erosion score at baseline were associated with radiographic progression. Multivariate analysis revealed RAMRIS bone marrow edema score and CRP at baseline were predictors of radiographic progression. [Conclusions] Our findings suggest MRI bone marrow edema score and CRP at baseline were useful to predict radiographic progression.

P1-070
Accuracy assessment of metacarpophalangeal joint space and bone microstructure measurements on HR-pQCT imaging
Nozomi Oki1, Ko Chiba2, Kounosuke Watanabe2, Masataka Uetani1, Makoto Osaki1, Naoki Iwamoto1, Atsushi Kawakami1
1Department of Radiological Science, Nagasaki University Graduate School of Biomedical Sciences, 2Department of Orthopaedic Surgery, Nagasaki University Graduate School of Biomedical Sciences, 3Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences

Conflict of interest: None

[Objective] The purpose of this study is to evaluate the accuracy of metacarpophalangeal (MCP) joint space and bone microstructure measurements on HR-pQCT imaging. [Methods] A total of 30 MCP joints in 16 healthy controls were scanned by HR-pQCT repeatedly three times. A dedicated software was used for measurements of the joint space and bone microstructural parameters of the MCP joints. According to the image quality grading, HR-pQCT images were classified into two groups with or without grade 4. Reproducibility of the three measurements was evaluated by RMS%CV (Root Mean Square% Coefficient of Variance) and compared in the two groups. [Results] The RMS%CV of without grade 4 group and with grade 4 group were joint space width (JSW) mean 1.79%, 1.92%, JSW minimum 4.88%, 8.29%, JSW. maximum 1.84%, 1.04%, JSW. Asymmetry 4.6%, 10.66%, joint space volume 1.35%, 1.36%, VBDM 0.62%, 2.03%, BV/TV 0.81%, 2.28%, Tb. Th 0.51%, 0.78%, Tb. Sp 2.15%, 4.71%, SMI 2.58%, 6.88%, Conn.D 1.42%, 6.14%, respectively. [Conclusions] The accuracy of joint space and bone microstructure measurements using HR-pQCT was sufficient by obtaining images with less motion artifact. This technique is thought to be applicable to longitudinal studies of inflammatory joint diseases such as rheumatoid arthritis.

P1-071
A case of the submandibular tumor which occurred in a patient with Sjogren’s syndrome/scleroderma. The importance of follow-up study by ultrasonography
Kaori Yanagawa1, Sayaka Ueno1, Koichiro Ohmura2, Yukiko Komano1, Ikuko Masuda1
1Center for Rheumatic Diseases, Juo Takeda Rehabilitation Hospital, 2Department of Rheumatology and Clinical Immunology, Kyoto University

Conflict of interest: None

A 70 years-old woman who had been diagnosed as limited type scleroderma and Sjogren syndrome, developed left submandibular swelling. Ultrasonography showed a 4cm of left submandibular gland tumor. After continuing the swelling of area one year later, ultrasonography revealed that tumor had a tendency to increase in size. Contrast MRI and CT showed tumor was solid and lobular with gadolinium enhancement, unlike benign pleomorphic adenoma or Warthin’s tumor. For the purpose of treatment and diagnosis, surgery to remove all tumor was performed. The tumor were somewhat malignant findings which is reaching wide-spread to deep-layer of the gland with strong adhesion. The pathologic diagnosis was the MALT lymphoma secondary to sialadenitis associated with Sjogren’s syndrome, in acknowledgment of LEL (lymphoepithelial lesion) with many irregular-shaped lymphocytes colonization. Immunostaining of that lesion showed that the plasma cells of 100% of IgG4/IgG ratios lay scattered to LEL surrounding tissue, suggested IgG4-RD co-ex.
isted in that lesion. (Even though the serum IgG4 level has never been high). When it is associated with a parotid swelling for Sjogren’s syndrome, it is necessary to be closely followed-up by ultrasonography with a suspect of malignant lymphoma.

**P1-072**
A case of Budd-Chiari syndrome associated with systemic lupus erythematosus (SLE) and anti-phospholipid antibody syndrome (APS), whose clinical course was followed-up by abdominal ultrasonography (AUS)

Sayaka Ueno1, Koichiro Ohmura2, Kaori Yanagawa1, Yukiko Komano1, Ikuko Masuda1  
1Center for Rheumatic Diseases, Jujo Takeda Rehabilitation Hospital, Kyoto, Japan, 2Department of Rheumatology and Clinical Immunology, Kyoto University

Conflict of interest: None

[Case] 62 years old female was diagnosed with SLE and APS by having episodes of thorombus of deep vein in 1973 and inferior vena cava (IVC) in 1974. In 2011, abdominal CT and MRI pointed out a severe stenosis of IVC, leading to the diagnosis of Budd-Chiari syndrome. The case had been followed up by AUS thereafter. In 2013, AUS showed a hepatosplenomegaly, small amount of ascites, and localized coarsening of liver S6,7. In 2016, coarsening spread throughout liver, however, no other changes were detected. She had right hypochondriac pain in 2017, AUS showed a 90 mm of hepatocellular carcinoma (HCC) protruding out of liver S6,7. In 2016, coarsening spread throughout liver, however, no other changes were detected. She had right hypochondriac pain in 2017, AUS showed a 90 mm of hepatocellular carcinoma (HCC) protruding out of liver S6,7. Although she was referred to a specialist, she eventually died due to intraportal rupture of HCC. [Discussion] Disease activity of the primary diseases were in remission. Hepatobiliary enzyme was within the normal range, HBV and HCV were negative throughout the observation period. However, portal hypertension due to IVC obstruction lasted for a long time, and hepatic roughness localized in 2013 spread to the whole liver in 2016. Retrospectively, hepatic fibrosis had clearly progressed, and the risk of developing HCC was high. Further tests by other modalities such as MRI and the earlier referral to a specialist should have been considered.

**P1-073**
A study of appropriate biologics (Bio) for elderly rheumatoid arthritits (RA) patients

Yasuo Inoue1, Kae Takagi2, Junji Chiba1  
1Department of Orthopadic Surgery, Tokyo Women’s Medical University Medical Center East, 2Department of Internal Medicine, Tokyo Women’s Medical University Medical Center East

Conflict of interest: None

[Object] The aim of this study is to clarify which specific Bio are appropriate for elderly RA patients by comparing Bio for both groups. [Methods] Of 238 patients of RA treated with Bio were divided into two groups by age. 145 patients under 64 years old were grouped as Group Y (GY), 93 patients over 65 years old were grouped as Group O (GO). The efficacy of each Bio in the two groups was compared based on the change of 0 to 6 months in disease activity, ΔDAS (CRP), and the degree of functional improvement, ΔHAQ. The persistency and the number of consecutive days of each Bio, and complications developed after the Bio administration were compared in both groups. [Results] The top three Bio with highest persistency in GO were tocilizumab, infliximab and etanercept. Abatacept was initiated to the patients with the longest disease duration and the highest average age, and the persistency in both groups were almost equal. [Conclusions] In addition, the effectiveness of each Bio was not significantly different in both groups. However, since the persistency of each Bio recognizes the difference between the two groups, the treatment by the Bio for elderly RA is necessary to examine characteristics of each Bio.

**P1-074**
Comparison of molecular targeted therapy for rheumatoid arthritis patients - Seronegative VS Seropositive -

Satoshi Baba, Rina Okita, Ruriko Kuratani, Rumiko Miyagi, Shinichiro Tsunoda  
Division of Rheumatology, Sumitomo Hospital, Osaka, Japan

Conflict of interest: None

[Object] Seronegative rheumatoid arthritis still has many unknown points. We compare Seropositive RA (SPRA) and Seronegative RA (SNRA), and show the difference in reactivity to molecular targeted therapy. [Methods] From March 2016 to October 2018, 66 patients who initiated molecular targeting drugs newly in our hospital were classified into SPRA group and SNRA group, and clinical evaluation (DAS 28, CDAI, SDAI) were compared. [Results] There were 39 patients with SPRA (Toctilizumab <TCZ>:9, Etanercept <ETN>:3, Abatacept <ABT>:8, Certolizumab pegol <CZP>:13, Tofacitinib <TOFA>:6), 27 patients with SNRA (TCZ:6, Sarilumab <SAR1>:2, ETN:3, ABT:2, CZP:10, Infliximab <IFX>:1, TOFA:1, Baricitinib <BARI>:2). There was no significant difference in the decrease of CDAI at 6 months (p = 0.35). In addition, we compared decrease of DAS28 and SDAI score at 6 months for drugs other than IL-6 inhibitors. There was no significant difference in the reduction of the DAS28 score (p = 0.22), but the SDAI score was significantly lower in the SNRA group than in the SPRA group (SN: -23.4 VS SP: -15.5, p = 0.032). [Conclusions] The therapeutic effect of molecular targeted drugs on SNRA may be better than SPRA.

**P1-075**
A research of cases in which more than 10 years have passed since the start of biological drug treatment in rheumatoid arthritis patients

Daisuke Kihira, Yuji Hirano, Yukiyoshi Oishi  
Department of Rheumatology, Toyohashi Municipal Hospital

Conflict of interest: None

[Object] To investigate the long-term outcome of rheumatoid arthritis (RA) patients who have been in the treatment for 10 years or more from the start of Bio. [Methods] We surveyed 74 patients with RA who were treated more than 10 years as of December 2017 from start of Bio. We divided patients into two groups, 41 patients who continued Bio for 10 years or more and 33 cases who discontinued. Cases in which Bio were changed were analyzed as continuation group. The two groups were compared statistically. [Results] All patient characteristics: average age 58.3 years, mean disease duration 11.4 years, average DAS28-CRP 5.47. Total continuation rate was 83.8% at 3 years, 71.6% at 5 years, 55.4% at 10 years. The Bio continuation group was significantly better in DAS28-CRP, SDAI, mHAQ, MMP3, CRP than the Bio discontinuation group at last. Comparison of the two groups at the time of start of Bio showed that age, body weight (BW), PSL administration rate, MTX administration rate and mHAQ showed a significant difference in univariate analysis. DM cases were present only in the discontinuation group. In multivariate analysis, significant difference was observed in BW and PSL administration rate. [Conclusions] It was suggested that the long-term persistence rate of Bio was affected by BW, administration of PSL, and DM.

**P1-076**
Biologic treatment in elderly patients with rheumatoid arthritis

Hideki Takagi, Masayuki Watanabe  
Orthopedic Surgery, Nagoya Central Hospital

Conflict of interest: None

[Object] The aging of patients with rheumatoid arthritis (RA) is progressing in Japan. However, there are few reports on the use of biological products for elderly patients over 75 years old. We examined the outcome of treatment with biologic agents for elderly RA patients aged over 75 years. [Methods] We investigated the patient background at the time of introduction, introduced drugs, adverse events and outcome in 9 patients who introduced biologicals in RA patients over 75 years old. [Results] Introduced drugs were abatacept 3, infliximab 2, adalimumab 1, tocilizumab 1, certolizumab-pegol 1, golimumab 1. The age at the time of administration was 75 to 87 years old (median 76 years old), the administration period was 2 months to 11 years (median 3 years 6 months), and only 3 cases were able to continue until the investigation. The reasons for discontinuation were all 6 cases of adverse events, of which 2
cases of lung cancer, 2 cases of bacterial pneumonia, 1 case of pneumonia, and 1 case of heart failure. (Conclusions) As a result of administering biologic products to elderly patients aged over 75 years, two-thirds cases were discontinued due to adverse events, and it was confirmed again that extreme caution was required for the occurrence of side effects.

P1-077
The comparative effect of TNF inhibitors, Tocilizumab (TCZ) and Methotrexate (MTX) on diabetic control in patients with Rheumatoid arthritis (RA)
Kei Fujioka, Saori Inui, Tomofumi Takeda, Ichiro Mori, Tatsuo Ishizuka
Center of General Internal Medicine and Rheumatology, Gifu Municipal Hospital, Gifu, Japan

Conflict of interest: None

[Object] To determine the comparative effects of anti-rheumatic medications (TNFi, TCZ, and MTX) on glucose tolerance. [Methods] We identified 30 RA patients complicated with glucose intolerance (HbA1c ≥ 5.6) at our hospital from May 2013 to October 2017, and treated with as follows: TNFi + MTX group (10 cases: IFX 1 case, ETN 5 cases, GLM 4 cases), MTX alone group, and TCZ ± MTX group (10 cases) had been registered. We have compared the changes of HbA1c levels, body weight and DAS 28-ESR before and after treatments for 6 and 12 months. We analyzed these results with paired and unpaired t test using JMP12.2.0. [Results] Each group showed significant improvement of DAS 28-ESR after treatment for 6 and 12 months (P < 0.05). The mean reduction in HbA1c showed a significantly decreases in the TCZ ± MTX group after treatment for 6 (P=0.01) and 12 months (P < 0.01), and MTX alone group for 12 months (P = 0.05). There were no significant differences in body weight between each group. [Conclusions] In this study, The TCZ group showed a significant improvement in the glucose tolerance than TNFi. Although MTX has the improvement of glucose tolerance, these effects were attenuated in combination with TNF.

P1-078
Ultrasonographic evaluation of Tocilizumab and TNF antagonist therapy in patients with rheumatoid arthritis
Yasuhide Kanayama1, Atsushi Nagata2, Hitomi Nagasaka3
1Department of Orthopaedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, 2Department of Clinical Technology, Toyota Kosei Hospital, Toyota, Japan, 3Department of Orthopaedic Surgery, Chuno Kosei Hospital

Conflict of interest: None

[Object] To evaluate the clinical efficacy of Tocilizumab (TNF) and TNF antagonist (TNF) therapy in patients with rheumatoid arthritis (RA) using ultrasonography (US). [Methods] We used TCZ and TNF treated 26 and 33 RA patients more than 24 weeks. We evaluated the improvement of gray scale (GS) and power doppler (PD) score from baseline to week 24. [Results] In the patients receiving TCZ (n=26) and TNF (n = 33), the mean age was 58.6 vs 55.0 years old (p=0.216), disease duration was 7.9 vs 5.1 years (p=0.516), the mean MTX dose was 11.1 vs 10.8 mg/w (p=0.404), the rate of ACPA positive was 85% vs 85% (p=0.980), DAS28-ESR was 5.33 vs 4.78 (p=0.052), GS score was 21.2 vs 17.3 (p=0.197) and PD score was 12.6 vs 9.0 (p=0.233). The respective changes in GS and PD score after 4 weeks were as follows: GS: -2.0 vs -3.9 (p=0.612) and PD: -2.5 vs -1.3 (p=0.322). The respective changes in GS and PD score after 12 weeks were as follows: GS: -6.7 vs -5.2 (p=0.396) and PD: -5.5 vs -2.6 (p=0.150). The respective changes in PD score after 24 weeks were as follows: GS: -11.4 vs -7.9 (p=0.171) and PD: -8.4 vs -4.7 (p=0.160). [Conclusion] The present study provides evidence supporting the TCZ and TNF therapy improved not only the disease activity but also the inflammatory synovitis.

P1-079
The examination of the efficacy of biologics (Bio) after switching from TNF-inhibitors (TNF-i) in rheumatoid arthritis (RA) patients
Misuzu Fujimori1, Koji Takasugi1, Kazuhiko Ezawa1, Ryozo Harada4, Wataru Yamamoto2, Masamitsu Natsumeda1, Keiichiro Nishida1
Department of Internal Medicine, Kurashiki Sweet Hospital, Kurashiki, Japan, 2Department of Orthopedics, Kurashiki Sweet Hospital, Kurashiki, Japan, 3Department of Rheumatoid Disease Center, Kurashiki, Japan, 4Department of Orthopedics, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Conflict of interest: None

[Object] We compare the efficacy of TNF-i v.s. abatacept (ABT) v.s. tocilizumab (TCZ) with insufficient response to first TNF-i on RA treatment. [Methods] 80 RA patients were changed their treatment from TNF-i to other Bio (another TNF-i: 28 cases, ABT: 29 cases, TCZ: 23 cases) through Jan 2014 to Dec 2017 in our hospital. We compared their background, clinical response (DAS28, CDAI and SDAI) and retention rate at 6 and 12 months, between these 3 groups. [Results] No significant association was found in any backgrounds and retention rates between 3 groups. ΔDAS, ΔCDAI and ΔSDAI at 6 months were higher score in TCZ group than them in ABT group. There were 12 cases in TNF-i group, 7 cases in ABT group and 12 cases in TCZ group which showed good or moderate response in DAS28 at 6 months. In the comparison of the background among these BAS responders, ABT group were significantly older than TNF-i group, and RF-positive cases were more in TCZ group than them in TNF-i group. [Conclusions] Our study suggested that ABT may be effective in older patients and non-TNF-i may be more effective in RF-positive patients after switching of first TNF-i.

P1-080
The efficacy of bDMARDs therapy in elderly-onset rheumatoid arthritis
Kiichiro Ando, Hiroaki Sakai
Department of Orthopedic Surgery, Chuno Kosei Hospital

Conflict of interest: None

[Object] To evaluate the efficacy of biologic disease-modifying anti- rheumatic drugs (bDMARDs) therapy. [Methods] This study comprised 7 patients with EORA. Patients received tocilizumab, abatacept, golimumab and adalimumab therapy with or without methotrexate for 6 months. The outcomes were assessed with the disease activity during 6 months study period, using the 28-joint Disease Activity Score based on the erythrocyte sedimentation rate (DAS28 ESR) and Clinical Disease Activity Index (CDAI). [Results] DAS28ESR (from 3.7 to 2.4) and CDAI (from 5.5 to 3.0) decreased significantly from baseline to Week 24. DAS28ESR Remission achieved in 6 cases at Week 24. Tocilizumab mono-therapy was also effective with RA patients of in adequate response to other bDMARDs therapy. The retention rate of tocilizumab at 24 weeks was 100%. The average dose of methotrexate tapered from 6.5mg to 3.5mg. The average dose of glucocorticoid also tapered from 5.0mg to 4.0mg. [Conclusions] These results suggested that bDMARDs therapy is effective in patients with EORA.

P1-081
Consideration of Biologies for Elderly onset rheumatoid arthritis
Mio Matsuura, Yuichiro Takami
Department of Rheumatology, Kinan Hospital

Conflict of interest: None

[Object] We introduced Biologies to elderly patients with rheumatoid arthritis (RA) and examined the effectiveness and safety of them at our hospital and two related hospitals. [Methods] We targeted 100 RA patients aged 75 or older who are treated with the Biologies from April 2013 to October 2018 at the above three hospitals. [Results] The mean age was 81 ± 0.5, mean disease duration was 7.9 ± 1.0, 68 women (68%). Among them, infectious complications that required hospitalization were 3 cases. That was 2.03 cases / 100 persons-year. Of these cases, 49 cases were in which the efficacy evaluation of more than 6 months could be analyzed. We used HAQ and DAS28 ESR to an index of effectiveness. The results was HAQ 1.59 ± 0.13 (at the time of introduction) / 0.68 ± 0.16.
0.12 (after 6 months=2) and DAS 28-ESR 4.94 ± 0.16 ([1]) / 3.00 ± 0.22 ([2]). 39 cases (79.6%) had restrictions on physical function with HAQ>0.5 at the time of introduction. After 6 months, it decreased to 21 cases (43%). [Conclusions] The effectiveness and safety of biologics can be expected in elderly people.

P1-082 Clinical evaluation of abatacept and golimumab in patients with rheumatoid arthritis in our department
Yui Akifyama1, Takuma Wada2, Mayuko Takamatsu Sakamoto2, Takashi Maruyama2, Yoshihiro Yoshida2, Kazuhiro Yokota2, Noritsugu Kozu2, Hiroshi Kajiyama2, Yasuto Araki2, Kojiro Sato2, Yu Funakubo2, Toshihide Mimura2
1Division of Rheumatology, Department of Internal Medicine, Ogawa Red Cross Hospital, Saitama, Japan, 2Department of Rheumatology and Applied Immunology, Saitama Medical University, Saitama, Japan, 3Department of Orthopedics, Kouzu Clinic, Chiba, Japan

Conflict of interest: Yes

[Object] To investigate the efficacy and the adherence of abatacept (ABT) and golimumab (GLM) in RA patients. [Patients] ABT/GLM: 26 (5 males, mean 63.1 yo, mean disease duration 9.7 y) / 25 (3 males, 66.1 yo, 11.1 y), MTX; 16 (5 mg/w) / 17 (5.52 mg/w), PSL; 19 (4.73mg/day) / 13 (4.9). Bio-naïve: 6/11. [Methods] Efficacy of ABT and GLM was evaluated by DAS28-ESR4, CDAI and SDAI for 156 weeks. [Results] 1) Mean DAS28 at the baseline (ABT/GLM): 5.87/5.80, CDAI 25.47/23.42, SDAI 28.64/27.48. The disease activity was significantly decreased in both groups. As time went by, the ratio of LDA + remission increased significantly until 24 weeks and maintained until 208 weeks in both groups. No significant difference in both groups. 2) The adherence rate; more than 80% (ABT/GLM) at W52, 62.9%/50% at W104, 61.5%/40.0% at W156 and 46.2%/56.0% at W208. No significant difference in both groups. 3) HAQ-DI was significantly improved after 12 weeks in ABT. 4) Both levels of CRP and MMP-3 were significantly reduced in GLM after 12 weeks, while the only CRP level in ABT after 52 weeks. 5) Drop-out reasons (ABT/GLM); inadequate response 5/7, cancer1/1, organizing pneumonia 0/1, pneumonia 1/1, EBV reactivation 1/1, remission1/0 and so on. [Conclusions] The efficacy and the adherence of ABT and GLM were similar.

P1-083 Biological treatments in the elderly patients with rheumatoid arthritis
Seiko Yamazaki1, Nobuo Matsui2
1Yamasaki Orthopedic Rheumatology Clinic, 2Nagoya City General Rehabilitation Center Affiliated Hospital

Conflict of interest: None

[Object] The purpose of our study was to assess and compare the effects and safety of biological treatments in elderly patients with RA. [Methods] From February 20th to September 30th, subjects were 12 RA patients (4 males, 8 females) aged over 65 years who used biological agents, average age 73.9 years (66 to 81 years old), Nine elderly onset aged over 60 years, average disease duration 15.5 years, ACPA positive 9 cases, INF 1 case · TCZ 3 cases · GLM 7 cases · ABT 1 case, 5 cases switching from other bDMARDs. The evolution of disease activity by DAS 28 ESR, SDAI, MTX dosage, and extended of bDMARDs administration period were examined. [Results] As a result of comparing before and after the biological treatments, DAS 28 ESR improved from 5.28 to 3.09 and SDAI improved from 27.86 to 8.26. The dose of MTX was reduced from an average of 8.6 to 6.3 mg/w, and the administration interval was extended in two cases of GLM. Transient liver function disorder was observed in 2 patients with GLM. In 2 cases of TCZ and GLM, administration was discontinued for economic reason. MTX combination was discontinued in 2 cases of GLM. [Conclusions] An effective treatment was obtained for elderly RA patients by careful selection of adaptive cases and appropriate biological drugs.

P1-084 Safety and effectiveness of certolizumab pegol in patients with rheumatoid arthritis in real-life settings: Final 24-week results of post-marketing surveillance
Hideto Kameda1, Keiichiro Nishida2, Toshihiro Nanki3, Shigeki Momohara4,5
1Division of Rheumatology, Department of Internal Medicine, Toho University Ohashi Medical Center, 2Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 3Division of Rheumatology, Department of Internal Medicine, School of Medicine, Toho University, 4Hakkeikai Incorporated Medical Institution, 5Department of Orthopaedic Surgery, Keio University

Conflict of interest: Yes

[Object] Safety and efficacy of certolizumab pegol (CZP) was evaluated in a real-world setting in Japanese patients (pts) with rheumatoid arthritis using post-marketing surveillance data. [Methods] Adverse events (AEs) observed during the 24-week (wk) CZP treatment period were recorded. Disease activity was evaluated using DAS28-ESR at baseline, Wk12, Wk24 and withdrawal. [Results] 3727 pts were enrolled; safety/efficacy were evaluated in 3647/1807 pts. Total CZP exposure was 1679.8 pt-years. AEs were reported in 24.7% pts, adverse drug reactions (ADRs) in 14.6%. The only ADR reported in >1% pts was rash. Selected serious ADRs of interest included infections (n=111; 3.0%), tuberculosis (6; 0.2%), allergic reactions (9; 0.2%), interstitial lung disease (17; 0.5%), heart failure (2; 0.1%), malignancy (8; 0.2%), hepatic failure (7; 0.2%). No autoimmune diseases, demyelinated diseases or pan-cytopenia were reported. There were 9 deaths, 3 drug-related. From baseline to last observation DAS28-ESR reduced from 4.76±1.36 to 3.43±1.48 and response rates of EULAR Good response and Good or Moderate response were 34.9% and 66.6% respectively. [Conclusions] CZP efficacy was confirmed in the real-world. No new safety signals were identified, and the safety profile was consistent with the class.

P1-085 Effectiveness of early introduction of Certolizumab pegol in the treatment of elderly onset rheumatoid arthritis
Eriko Hasegawa1,2, Satoshi Itou1, Yoichi Kurosawa1,2, Shinji Taniguchi1, Asami Abe1, Hiroshi Otani1, Kiyoshi Nakazono1, Akira Murasawa1, Ichiei Narita2, Hajime Ishikawa2
1Department of Rheumatology, Niigata Rheumatic Center, Shibatashi Niigata, Japan, 2Division of Clinical Nephrology and Rheumatology, Niigata University Medical and Dental Hospital, Niigata, Japan

Conflict of interest: None

[Object] Elderly onset rheumatoid arthritis (EORA) often develops with high disease activity. Comorbidities are associated with intolerance to the treatment. Certolizumab pegol (CZP) for early RA patients was shown to be effective in C-OPERA study, but the evidence in elderly patients is limited. We aimed to investigate the effectiveness of early induction of CZP in EORA. [Methods] We retrospectively analyzed the data obtained from consecutive 12 EORA patients who started treatment with CZP within 3 months after the induction of conventional synthetic disease modifying anti-rheumatic drugs. [Results] Disease duration of RA at the time of induction of CZP was 3.1±1.6 months. The duration from introduction of csDMARDs was 19.1±11.8 days. Interstitial pneumonia was accompanied in 1 patient, chronic kidney disease in 5 patients and diabetes mellitus in 4 patients. After 4 weeks of treatment, DAS28-ESR (5.8±1.1 vs. 3.0±1.3, p=0.002) and HAQ-DI (1.6±0.9 vs. 0.5±0.6, p=0.002) were significantly decreased. No infection was occurred during the observational period. [Conclusions] Early introduction of CZP was effective in ameliorating disease activity and activity of daily life among elderly patients. Further investigation is needed to assess efficacy and safety.
P1-086
Clinical Feature of our RA Patients with Golimumab < What is the surrogating marker of effectiveness? How will be the failure case of GLM? >
Hiroshi Hori 1, Tsuyoshi Kobashigawa 1, Toru Yago 2, Eri Watanabe 2, Hiroki Yabe 2, Chihito Tera 2, Shigeru Katak 2
1General Medicine, Jichi Saitama Medical Center, 2Department of Rheumatology, Jichi Saitama Medical Center

Conflict of interest: None

P1-087
Clinical Feature of our RA Patients with Golimumab < What is the surrogating marker of effectiveness? How will be the failure case of GLM? >
Yusuke Sugimura 1, Takeshi Kashiwagura 1, Natsuo Konishi 2, Masakazu Urayama 2, Hiroki Ito 2, Moto Kobashigawa 2, Takayuki Tani 2, Tsutomu Sakuraba 2, Toshiaki Aizawa 2, Hidekazu Abe 2, Norio Suzuki 2, Keiji Kamo 2, Hiroshi Aonuma 2, Tetsuya Kawano 2, Yusuke Iwamoto 2, Naohisa Miyahoshi 2, Yoichi Shimada 2
1Department of Orthopedic Surgery, Nakadori General Hospital, Akita, Japan, 2Akita Orthopedic Group on Rheumatoid Arthritis, 3Department of Orthopedic Surgery, Akita University Graduate School of Medicine

Conflict of interest: None

P1-088
Effectiveness and safety of golimumab in rheumatoid arthritis patients over 75 years of age
Yoichi Kurosawa 1, Satoshi Ito 1, Eriko Hasegawa 2, Daisuke Kobashigawa 2, Shinji Taniguchi 2, Asami Abe 1, Hiroki Otani 1, Kiyoshi Nakazono 1, Akira Murasawa 1, Ichirio Narita 1, Hajime Ishikawa 1
1Department of Rheumatology, Niigata Rheumatic Center, Niigata, Japan, 2Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences

Conflict of interest: None

P1-089
Prediction of efficacy of each biologics based on serum IL-6 concentration
Mitsuhiro Iwahashi 1, Kazuyuki Yoshizaki 2, Hirofumi Watanabe 2, Shuntaro Miyoshi 1, Rie Sasaki 2, Jiro Yamana 2, Seizo Yamana 2
1Division of Rheumatology, Higashihiroshi Memorial Hospital, 2Department of Biomolecular Science and Regulation, The Institute of Scientific and Industrial Research, Osaka University

Conflict of interest: Yes

P1-090
Tocilizumab treatment is more effective for patients with rapid progression of joint erosion
Shinya Hayashi 1, Tsukasa Matsubara 2, Koji Fukuda 3, Keiko Funahashi 3, Marowa Hashimoto 3, Tomoyuki Kamenaga 1, Yoshinori Takashima 1, Ryosuke Kuroda 1
1Kobe University Graduate School of Medicine, 2Matsubara Mayflower Hospital, 3Research Institute of Joint Disease

Conflict of interest: None
Conflict of interest: None

[Object] To clarify the role of IL-6 in the continuity of joint inflammation in RA. [Methods] Tocilizumab (TCZ) was used to interfere with IL-6 signaling in inflammatory joints of RA. The efficacy was evaluated by DAS28-ESR and CRP in 296 (female 254) patients with RA who had received TCZ not less than 84 days between May 28, 2008 and August 31, 2018. [Results] Mean patient age was 58.2 years and mean disease duration 9.1 years. DAS28-ESR was 4.50 ± 1.34 (mean ± SD) initially, falling to 2.60 ± 1.19 after 1 month, to 1.72 ± 0.88 after 3 months and to 1.48 ± 0.80 after 1 year. It was less than 1.50 until 10 years later. Swollen joint count (SJC) was 4.17 ± 3.83 initially, falling to 0.45 ± 1.02 after 1 month and to 0.17 ± 0.66 after 6 months. It was less than 0.50 until 10 years later. CRP was 1.54 ± 2.10 mg/dl initially and it was less than 0.20 for 10 years thereafter. No “no response” was shown by EULAR response criteria. These indicate that arthritis was almost completely ameliorated by TCZ irrespective of baseline characteristics. [Conclusions] TCZ was effective against arthritis in all patients, indicating that IL-6 is essential for the continuity of joint inflammation in RA. Thus, perfect blockade of IL-6 signaling in inflammatory joints is key to complete remission of RA.

P1-094
Methotrexate tapering pattern over two years of adalimumab and high-dose methotrexate combo therapy (≥12 mg/week) for patients with rheumatoid arthritis: post-hoc analysis of HAWK Study 104-week data
Yoshiya Tanaka1, Tsuneo Mimori2, Hisashi Yamanaka3, Naomi Sunaga3, Kazuo Morita4, Junko Kimura4, Tsutomu Takeuchi1,2
1,2) The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, School of Medicine, Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, 3Institute of Rheumatology, Tokyo Women’s Medical University, 4AbbVie GK, Tokyo, Japan

Conflict of interest: Yes

[Object] To investigate the extent of methotrexate (MTX) dose reduction over 2 years in patients with rheumatoid arthritis (RA) who commenced treatment with MTX and adalimumab (ADA). [Methods] Using data from the HAWK study, MTX dosage patterns were analyzed in patients with early RA (≤2 years) and DAS28-CRP >3.2.12) Where both the baseline and 104-week data points were available, average DAS28-CRP values were calculated to evaluate the relationship between final MTX dose and effectiveness. [Results] Among the 130 patients in the effectiveness analysis set with DAS28-CRP data at 104 weeks, the proportion of patients receiving MTX at a dose of <8/8/10/10/12/12 mg/week at 104 weeks was 10%/20%/15%/55%, respectively. The mean DAS28-CRP score at 104 weeks was 3.11/3.54/1.62/1.62, respectively, and the mean change from baseline was 3.36/3.06/2.88/2.93, respectively. No significant differences in change from baseline were observed between groups (paired t-test: p = 0.5385). [Conclusions] At 104 weeks, around 30% of patients could reduce MTX dose below 10 mg without a negative impact on disease activity.

P1-095
Infliximab dose adjustment can improve the clinical outcomes of rheumatoid arthritis patients by RemicheckQ
Yuji Nozaki, Yasuaki Hirooka, Chisato Ashida, Daisuke Tomita, Akinori Okada, Asuka Inoue, Koji Kinoshita, Masanori Funachki, Itaru Matsumura
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine

Conflict of interest: None

[Object] We evaluated the clinical responses of 42 patients with rheumatoid arthritis (RA) undergoing continuous or dose-adjusted infliximab treatment over 12 months. [Methods] Patients have not done the RemicheckQ test and received the 3 mg/kg infliximab continuously (R-; n=30), and received the dose adjustment of infliximab (3 mg/kg and 6 mg/kg) from week 14 (R+; n=12) based on the RemicheckQ test. The retention rate and clinical response were determined at month 12. [Results] R+ and R- groups retention rates at week 54 were 91.7% and 71.7%, and the groups’ remission disease activity in the DAS28 were 80% and 31.3%, respectively. DAS28 score at 12 months was significantly decreased in the R+ group. [Conclusions] In an assessment of adequate RemicheckQ test, the RA patients who did not respond to the initial dose of infliximab showed improved clinical responses after a dose adjustment.
of infliximab.

P1-096
The Clinical Efficacy of Certolizumab Pegol (CZP) in Rheumatoid Arthritis (RA) : A Multicenter Retrospective Study (The Second Report)

Akira Furusaki1, Akira Sagawa1, Yoshiharu Amasaki1, Atsushi Noguchi1, Kazuo Matsu1, Izumi Yasuda1, Kinimori Hasegawa1, Satoko Nakamura2
1Sagawa Akira Rheumatology Clinic, 2Department of Rheumatology, Toranomon Hospital, 3Joint Medicine, Yagi Orthopaedic Hospital, 4Department of Rheumatology, Sapporo Yamanoue Hospital, 5Department of Rheumatology, Hokkaido Orthopaedic Memorial Hospital

Conflict of interest: None

[Object] We investigate efficacy and the drug survival of CZP in RA in daily clinical practice in Sapporo. [Methods] We conducted a retrospective survey of the medical records of patients who started CZP until April 2018. [Results] 62 patients (53 women) were evaluated. Baseline characteristics of the patients mean age 53.1 years, mean disease duration 11.2 years, mean CZP use 3.06 years, MTX use 85.5%, mean MTX dosage 7.8mg/week, PSL use 56.6%, mean PSL dosage 2.2mg/day, Bio-naive 27.4%, DAS28-ESR 4.63±0.18, SDAI 20.9±1.3. At Week 24, the remission rate of DAS28 and SDAI were 24.2% and 16.1% respectively. Of 37 patients who have reached moderate response (MR) at 12 weeks, 22 had sustained remission or low disease activity until last observation. However, of 9 patients who had not reached MR at 12 weeks, only one attained the target. The drug survival rate of CZP after 1 and 3 years was 86.5%, and 51.5% (log-rank test). The improvement of MMP-3 at 4 weeks attained the target. The drug survival rate of CZP after 1 and 3 years was 86.5%, and 51.5% (log-rank test). The improvement of CRP at 4 weeks was 53%. The drug survival rate of CZP after 1 and 3 years was 86.5%, and 51.5% (log-rank test). The improvement of DAS28 at 4 weeks was 86.5%. The drug survival rate of CZP after 1 and 3 years was 86.5%, and 51.5% (log-rank test)

P1-097
Safety and therapeutic effect predictive factors of golimumab for Juntendo University hospital aged rheumatoid arthritis patients

Nagachika Sugisaki1, Kurisu Tada, Yosihyuki Abe, Michihiro Ogasawara, Ran Matsudaira, Ken Yamaji, Naoto Tamura
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

Conflict of interest: None

[Object] We examined the clinical effect and safety of senior patients at Golimumab (GLM) for administered rheumatoid arthritis (RA) patients. [Methods] All of 73 patients were started to receive subcutaneous injections every 4 weeks of GLM. And we analyzed on safety, continuation rate and side effects at the less than 65 years or over 65 years group. [Results] DAS28 remission patients (score<2.3) at week 52 was 56.1%. The mean score of DAS28 at baseline, 52 were 4.03±1.38, 2.47±1.10. Remission group were disease duration until initiation of administration was short, the degree of progress of joint destruction was low, methotrexate (MTX) concomitant dose was high, and steroid combined dose was low. In comparison between young people and the elderly, there was no difference in disease duration, stage, class until initiation of administration, there was no advantage in CRP/mHAQ/DAS 28 CRP at 52 weeks. And there was significant frequency of occurrence of serious adverse events. [Conclusions] GLM administration is validity from the administration early, we showed also high continuation rate after 52 weeks, also high DAS28- CRP remission achievement rate. In addition, it was suggested that administration for elderly people is as safe as young patient.

P1-098
The analysis of effect and safety in the combination therapy of Abatacept and Tacrolimus for RA

Tomoya Nakajima1, Yoshikazu Fujikawa2, Yumiko Nobuhara1, Takashi Nakazawa1
1Osaka Saiseikai Nakatsu Hospital, 2Kobe University Hospital

Conflict of interest: None

[Background] Both Abatacept (ABT) and Tacrolimus (Tac) are DMARDs which have similar mechanism of action against T cells. Whether both drugs should be used together in RA treatment is unclear. [Object] To reveal the effect and safety in the combination therapy of ABT and Tac (‘ORE-Tacro’). [Methods] We extracted the RA patients prescribed with ‘ORE-Tacro’ from October 2017 to September 2018, and analyzed DAS28- CRP and the adverse events. [Results] In 14 patients except 2 of Tac self-discontinuation, 7 patients achieved moderate EU- LAR response. Then, six patients with Tac followed by ABT were analyzed, and the effects of Tac could not predict the therapeutic outcome of ABT. ‘ORE-Tacro’ failure due to severe adverse event was only one event in the patient with pneumonia (6.6 events/100 person-year). This incidence was equivalent to that of Japanese post-marketing surveillance of abatacept. [Conclusions] It was proved that ‘ORE-Tacro’ can be effective in spite of similar mechanism of action. There could be no increase of adverse event, so this combination therapy can be a promising treatment option. However, the patients’ predictive factors for ‘ORE-Tacro’ remain unclear in our study.

P1-099

Hideto Kameda1, Christine Xu2, Kazuteru Wada3, Owen Hagino4, Anne Paccaly5, Hubert Van Hoogstraten6, Yoshiya Tanaka7
1Division of Rheumatology, Department of Internal Medicine, School of Medicine, Toho University, 2Sanofi Genzyme, 3Sanofi K.K., 4Sanofi, 5Regeneron Pharmaceuticals, Inc., 6The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan

Conflict of interest: Yes

[Object] To evaluate sarilumab exposure-response (E-R) relationships for pharmacodynamic (PD) biomarkers, efficacy and safety endpoints in Japanese vs non-Japanese patients with RA. [Methods] The Japanese Phase 3 KAKEHASI study (NCT02293902) data were evaluated against pooled data from the global (non-Japanese) MOBILITY (NCT01061736 Part B) and TARGET (NCT01709578) studies. Patients received placebo or sarilumab (150 or 200mg SC qw2) plus conventional synthetic DMARDs. [Results] Exposure-response relationships between functional sarilumab trough concentrations and PD biomarkers (C-reactive protein, serum amyloid A), efficacy parameters (ACR20/50/70, DAS28- CRP), and safety parameter (absolute neutrophil count) were assessed at Week 24. Consistent E-R relationships supported extrapolation of efficacy and safety results from non-Japanese to Japanese patients. PD biomarkers, efficacy and safety assessments were similar between Japanese patients and non-Japanese patients with body weight <60kg, and ≥60kg to <100kg. [Conclusions] These empirical E-R analyses support the approved dosage of sarilumab (200mg qw2 SC) in Japan. [Acknowledgments] Study funding and editorial support (Vicki Cronin, Adelphi Communications Ltd) were provided by Sanofi and Regeneron Pharmaceuticals, Inc.

P1-100
Early phase biologic therapy in patients with elderly-onset rheumatoid arthritis (after the age of 80)

Ikuo Onishi, Kentaro Susaki, Yoshifumi Akashi, Satoshi Tohdo, Masayuki Inou, Noriyuki Kurata
Utazu Hospital

Conflict of interest: None

[Object] Early phase EORA patients should be treated using the treat-to-target strategy, although low disease activity is the realistic goal due to their co-morbidities, patient factors and drug-related risks. Biologics therapy could be a choice of treatment. We treated 16 early phase of EORA patients (>=80 years) with biologics and analyzed clinical, biologic, immunogenetic data. [Methods] 16 patient (man:5, woman 11, 83.9±2.9 years old), disease duration: 1.95±1.14month. No one was treated with MTX, 10 patients were treated with PSL (mean 5.9mg). 6 patients had pulmonary disease. 7 patients had diabetes. 8 patients were treated
with abatacept, 8 patients were treated with Golimumab. [Results] Baseline disease mean activity were DAS-44-CRP4.5, SDAI 24.2, HAQ1.84. After 3 months, mean activity were improved to DAS-44-CRP2.5, SDAI 6.1, HAQ1.58. 2 patients were withdrawn. One of them got Pneumocystis jirovecii. 8 of 10 patients could taper or stop of PSL. [Conclusions] Biologics treatments in early phase of EORA are useful even after the age of 80. We may prevent progression to irreversible geriatric syndromes, patients with EORA. While we must take care of the risk of serious infection.

P1-101
The comparison of time until 1st biologic introduction with elderly onset rheumatoid arthritis (ERA) and non-elderly onset rheumatoid arthritis (NRA)
Noriyuki Namura, Kazuya Kamada, Taka'fumi Hagiwara
Department of Rheumatology, Takarazuka City Hospital
Conflict of interest: None

[Object] In ERA patients, most of them develop acutely, and have high acute response from their onset. And we often experience that their function level is suddenly affected. It is important to recover their function immediately with target to strategy. We examined the difference in the time until 1st biologic introduction from ERA and NRA. [Method] We examined 229 RA patient in our hospital. We defined the onset RA 60 years or older as ERA and the others as NRA. The number of biological preparation user of them, ERA was 31 cases, and NRA was 29 cases. We analyzed both group using background factors and their time until 1st biologic introduction. [Results] We found that the period until 1st biologic introduction for ERA was statically significantly shorter than NRA. Regarding their background factors, their CRP have a statically significant difference. But we could find no difference in their gender, ESR, RF, ACPA, mHAQ, DAS28ESR, SDAI at their 1st visit. In the regression analysis, we showed negative correlation in the onset age and time until 1st biologic introduction (p<0.01). [Conclusions] In ERA who might have high acute phase response, we showed the time until 1st biologic introduction is shorter than NRA. But, there was no significant difference in clinical background both groups.

P1-102
Clinical features of our hospital with or without MTX in rheumatoid arthritis treatment
Keina Yomono1, Ken Nagahata1, Shuhei Hattori1, Kei Shimogori2, Shotaro Suzuki1, Seiji Takenouchi1, Lisa Hirahara1, Ritsuko Yokochi1, Noboru Hagino1
1Division of Hematology and Rheumatology, Teikyo Chiba Medical Center, 2Jyouban Hospital
Conflict of interest: None

[Object] We cross-sectionally investigated the characteristics of RA patients without MTX treatment, compared with the ones with MTX. [Methods] Single-center cross-sectional study was performed, and 312 RA outpatients were analyzed. Patients with or without MTX group were compared about their clinical features and current treatments. [Results] In total, 213 patients were analyzed (non-MTX group n=106; MTX group n=206). Non-MTX group patients’ median age at analysis was 73 (range 66-79) years old. Anti-CCP antibody positivity rate was 81.1%. Glucocorticoid (GC) use was 54.7%, median GC dosage was 4 (range 2.5-5) mg/day. bDMARDs were used in 34.9% of non-MTX group. The reasons for not using MTX are (1) significant adverse reaction (30.1%), (2) clinically-significant lung disease in (27.3%) and others. In the group with MTX, the median age at analysis was 64 years (range 56-72), and the anti-CCP antibody positivity rate was 71.8%. GC is used in 22.3%, median dosage was 2.5 (range 2-4) mg/day. bDMARDs were used in 33.9%. The median dose of MTX was 10 (range 8-12) mg/week. [Conclusions] In our study, MTX avoidance in RA treatment was associated with more systemic GC use. No difference was seen in the prescription rate and selection of bDMARDs.

P1-103
Understanding of methotrexate (MTX) in patients with rheumatoid arthritis (RA) treated with MTX and their health literacy (HL)
Teruhisa Azuma
Department of General Internal Medicine, Shirakawa Kosei General Hospital
Conflict of interest: None

[Object] To describe understanding of MTX in RA patients and their HL. [Methods] Cross-sectional study using original questionnaire and HLS-EU-Q16 in single institute. [Results] 50 RA patients (women 86%) were enrolled. Understanding of why and when to take MTX and folate was high, however, understanding of when to stop MTX was low. Proportion of low HLS (<33) was 60%. [Conclusions] We need to enhance understand of when to stop MTX, incorporating to education tool considering their HL.

P1-104
Overall Treatment (Tx) Satisfaction in Rheumatoid Arthritis Patients (pts) in Low Disease Activity (LDA) or Remission (REM) and Their Treating Physicians (phys): A Cross-sectional Survey
Yuko Kaneko1, Masayo Sato2, Zhihong Cai2, Minako Sato2
1Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Eli Lilly Japan K.K.
Conflict of interest: Yes

[Object] To assess if there is a discordance in overall Tx satisfaction between pts and phys. [Methods] A multi-center (Jp), non-interventional, cross-sectional observational study with phys and their pts (LDA or REM) was conducted. Using a structured survey questionnaire, anonymous data on Tx satisfaction and relevant information were collected from both subjects separately. [Results] At 15 sites, 204 pts and 38 treating phys were enrolled and 202 pairs were concordance-evaluable. Mean age of pts was 64.7 yr, proportion of female was 67.3% and mean disease duration was 12.3 yr. For 2-level (satisfied or unsatisfied) assessment of Tx satisfaction, 195 pts from self-evaluation (96.5%) and 190 pts evaluated by phys (94.1%) answered ‘satisfied’ with high level of concordance (184 pairs, 91.1%). As for communication between pts and phys, a shared Tx decision was made in more than 90% of the pairs. The most popular answer about the most important Tx goal was different between pts (‘Have a social life without worrying’) and phys (‘Prevent joint damage, deformity, and joint swelling’). [Conclusion] Tx satisfaction was high in both subjects. Some differences were observed in detailed questions of Tx outcomes and the most important goal.

P1-105
Actual conditions of drug prescription with a risk of falling for rheumatoid arthritis patients
Kosuke Sakurai1, Nobuyuki Iyai1, Masahiro Hosonuma1, Tomoki Hayashi1, Mika Hatano1, Mayu Saito2, Nao Oguro2, Yoko Miura2, Ryo Yanai1, Sakiko Isojima1, Ryo Takahashi1, Yusuke Miwa1
1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, 2Pharmacy of Showa University Hospital
Conflict of interest: None

[Object] There is a report describing a high risk of falling for rheumatoid arthritis (RA) patients. But incidents have not been evaluated by concomitant drug as a risk factor. The study aims to investigate actual conditions how often drugs with a risk of falling could be prescribed for RA patients. [Methods] The study targeted RA patients who visited Department of Rheumatology at Showa University Hospital in 2017. We selected the patients who received a prescription for drugs with a risk of falling. We set 4 categories of drugs with a risk of falling: sedatives/hypnotics, antidepressants, antipsychotics and benzodiazepines (BZDs). [Results] 116 patients received a prescription for drugs with a risk of falling. The breakdown of the prescriptions was 83 for sedatives/hypnotics, 13 for antidepressants, 4 for antipsychotics, and 38 for BZDs. For the 4 categories of drugs, there were 95 patients for the prescription of 1 drug, 14
patients for the prescription of 2 type drugs, and 7 patients for the prescription of more than 3 type drugs. 5 out of 116 patients were periodically visiting the hospital specifically for mental/nervous system disorder. [Conclusions] Drugs with a risk of falling were prescribed 12% of the RA patients. Since those drugs may possibly increase a risk of falling.

P1-106
Cost and effectiveness analysis of DMARDs therapy (annual report from Ninja 2017)-the cost of DMARDs increase again and the cost-effectiveness decreased-

Yasuo Suenaga1, Shunsuke Mori1, Toshihiro Matsui2, Shigeto Tohna1
1Department of Rheumatology, Beppu Medical Center, NHO, Oita, Japan, 2Department of Rheumatology, National Hospital Organization Sagamihara National Hospital, ‘National Hospital Organization Tokyo National Hospital

Conflict of interest: Yes

[Objectives] To evaluate the balance between the clinical effects of recent anti-rheumatic treatment and its cost [Method] The Data from RA patients registered in the large cohort database (NinJa) in 2002-2017 was analyzed. They included clinical indices and dosage of DMARDs. The annual cost-effectiveness calculated from them. [Results] All averages of clinical indices were decreasing constantly, but more slowly in 2016-2017. The annual cost of DMARDs was about 500,000 yen / patient in 2017, 20,000 yen higher than the cost in 2016. The rate of the cost of biologics was 71.4 % and decreased in 3 years. However, the usage rates of GLM and JAK inhibitors increased. Their annual costs /patient were higher than other DMARDs. ([The rate of the number of low activity patients to that of high activity patients] / cost) were increasing since 2009 and exceeded the level in 2003 (pre-bio-era in Japan), but decreased in 2017. [Conclusion] The NHI price revision leaded to the stop of increase of the DMARDs’ cost in 2014. And it continued without the price revision in 2016. We expected that the cost of DMARDs might have hit the ceiling. Contrary to our expectation, it increased again in 2017. The increase of the usage of GLM and JAK might be involved with that augmentation.

P1-107
Cessation of Adalimumab after complete remission

Sho Sendo, Yoshikazu Fujikawa, Takumi Nagamato, Yuzuru Yamamoto, Yoshihide Ichise, Hirotaka Yamada, Ikuko Naka, Yo Ueda, Takaichi Okano, Kengo Akashi, Akira Onishi, Jun Saegusa, Akio Morinobu
Rheumatology and Clinical Immunology, Kobe University Hospital

Conflict of interest: None

[Objectives] To elucidate the course after stopping adalimumab (ADA) because of achieving complete remission (CR) in rheumatoid arthritis (RA) patients. [Methods] We retrospectively analyzed the course of 11 RA patients after stopping ADA. [Results] Baseline characteristics of 11 patients were following; age:60.1±12.8,y.o, male/female:1/10, RF:62 (26-177), ACPA:47.4 (6.8-163.6), Class:1.6±0.5, stage:2.0±0.9, duration from diagnosis to starting ADA:52 (20-140) months (M), duration of using ADA:30 (16-37) M, MTX using rate:100%, MTX dose:6.2±2.3mg/wk, GC using rate:27.3%, GC dose:0 (0-0.86) mg/day and DAS28CRP:1.5±0.42. Four patients (36.4%) restarted ADA; relapsed group (RG), and the others sustained cessation of ADA; non-relapsed group (nRG). The duration of stopping ADA was 5.0±3.0M in RG and 76.2±11.2M in nRG. There was no difference between RG and nRG in RF, ACPA, Class, stage, duration from diagnosis to starting ADA, DAS-28CRP and GC dose. RG tended to be longer duration of using ADA (RG:49.8±32.3M, nRG:23.7±9.9M, p=0.071), and tended to be higher MTX dose at the point of stopping ADA (RG:8.0±2.8mg/wk, nRG:5.1±2.5mg/wk, p=0.056). [Conclusion] More than 70% patients who achieved CR could stop ADA for a long duration, while most of the RG needed to restart ADA within 6 M after stopping it.

P1-108
Significance of Measurement of Remi-check Q in RA Patients Treated with Infliximab in Extended Interval Method - Possibility of Indication to Drug Holiday -

Toshiyuki Kitaori, Haruki Takagi, Kazutaka Takatsuka, Hiroko Morise, Tomoya Kotani, Akinori Murakami
Fukui Red Cross Hospital

Conflict of interest: None

[Object] The clinical significance of REMI check-Q (RQ, LDI Medi-ence Corporation, Tokyo Japan) measurement in RA patients treated with long term administration of IFX at extended dosing interval was clarified. [Methods] The concentration of IFX was measured by RQ in 28 RA pa-tients treated with this agent for at least 2 years, and positive rate was evaluated. The patients were divide into RQ positive group and negative group and group comparison was performed. The comparison between groups divided by administration interval to 8-9w (standard) and 10-12 w (extended) groups were also performed. [Results] The RQ positive rate was 50% (14/28 cases). No significant difference was observed in back-grounds between positive and negative groups. RQ was positive in 66.7% (10/15 cases) of standard group and 30.3% (4/13 cases) of extended group, whereas DAS28-ESR was 2.82 and 2.29, respectively. [Conclu-sions] In extended group 9 patients had negative RQ results, reducing the overall positive rate. Unexpectedly, however, all of them maintained the activity status of REM or LDA. It is inferable from our experiences that drug holiday of IFX may be achieved successfully in some patients whose disease activity stay good even after RQ turn negative along with extended administration interval.

P1-109
Efficacy and clinical significance of shortening the duration of subcu-taneous injection of Tocilizumab

Tamami Yoshitama
Yoshitama Clinic for Rheumatic Diseases

Conflict of interest: None

[Objective] To shorten the administration interval of Tocilizumab (TCZ) subcutaneous injection and evaluate its effectiveness and clinical significance. [Methods] Out of 185 subjects who introduced TCZ from June 2008 to August 2018 in our hospital,29 subjects changed from intravenous drip infusion to subcutaneous injection and 83 cases started with subcutaneous injection were targeted. We shortened the administration period for 11 cases in which low disease activity could not be achieved by CDAI evaluation at 3 months after the start of TCZ subcutaneous injection and evaluated prospectively for DAS, CDAI, HAQ, joint ultrason sound examination 3 months later. Patients who failed to confirm the effic-acity were changed to other DMARDs and evaluated the effectiveness after 3 months. [Results] Six cases were able to be judged effective in the CDAI evaluation and confirm improvements by joint ultrasonography at 3 months after shortening the administration period. The medicines were changed from TCZ to Adalimumab, Golimumab, Tofacitinib, and Balic-tinib for invalid cases and the efficacy was confirmed in either case. [Conclusions] It was suggested that discrimination of effective cases for shortening TCZ administration period has significance in achieving T2T.

P1-110
A questionnaire survey for patients treated by tocilizumab at our hospital

Akinori Murakami, Haruki Takagi, Kazutaka Takatsuka, Toshiyuki Kitaori, Hiroko Morise, Tomoya Kotani
Department of Orthopaedic Surgery, Fukui Red Cross Hospital

Conflict of interest: None

[Object] We performed a questionnaire survey whether patients treated with tocilizumab (TCZ) evaluated intravenous route (IV) and whether they wanted to switch to subcutaneous route (SC). [Methods] 28 patients (6 males and 22 females) currently treated with TCZ-IV for rheumatoid arthritis in our hospital were asked. [Results] Dissatisfaction points were found in 20 patients for the prescription of 2 type drugs, and 7 patients for the medication to Drug Holiday -
to switch to SC. A reason of the choice of SC was shortening of outpatient time (57%). Reasons of the choice to keep IV were reassurance for infusion in the hospital (70%) and fear of auto-injection (35%). In patients dissatisfied with cost, there was significantly more hope of IV interval extension than SC transition. We expected that patients who had history of other medication SC had anticipated less resistance to SC, but there was no significant. [Conclusions] As in past reports, many patients didn’t want to switch to SC. It is considered that the cause is that we didn’t adequately inform patients that SC was cheaper due to body weight and that if the previous SC drug form was syringe type, patients felt familiar. We need to explain the device improvement and the reduction of cost sufficiently and suggest a treatment method suitable for patients.

P1-111
Steroids or bDMARDs? Patients’ choice
Runa Minami1,2, Naoki Nishijima2, Kazuma Sawabe1, Masato Araki1
1Misugikai Otokoyama Hospital, 2Tango Central Hospital

Conflict of interest: None

[Object] With the advent of biologic drugs and methotrexate, disease activity can be well controlled in Rheumatoid Arthritis. However, because bDMARDs are expensive, we sometimes use them under the dosage recommended in package inserts. [Methods] 219 patients who regularly visit our hospital in 2018 for RA treatment was analyzed. We collected the patients’ data of sex, age, dosage of bDMARDs, MTX, csDMARDs and steroid. [Results] Average age of the patients were 68 (30–97), 163 female and 56 male. 80 were treated with bDMARDs. 23 of 32 treated with ETN were treated with low dose. 16 of 24 treated with ABT were treated with low dose. 11 treated with GLM and 8 treated with TCZ were prescribed as indicated in package inserts. 91 were treated with prednisolone and 35 were prescribed more than 5mg/day. 19 of 35 were not treated with bDMARDs. 7 of 35 were treated with bDMARDs but low dose. [Conclusions] Steroids sometimes cause side effects such as osteoporosis and infection, and recommended to discontinue in 6 months or use lower dose than 5mg/day. However, more than 16% of patients of RA were prescribed more than 5mg/day and 74% of them were not treated with bDMARDs or with low dose. We conclude that 12% of patients of RA chose steroids rather than bDMARD by economical reason.

P1-112
Investigation of surgical treatment during treatment of rheumatoid arthritis (RA) in our hospital
Kota Azuma, Makoto Terada, Yuko Kashihara, Yuka Hyodo, Shiori Hiromi
Itami City Hospital

Conflict of interest: None

Objective: Considering the risk of perioperative infection and wound healing, it is desirable to withdraw anti-RA drugs, but exacerbation of joint symptoms due to discontinuation is also expected. Methods: We studied postoperative infections in 119 RA patients who underwent surgical treatment at our hospital. Male 19, female 100. At the perioperative period, oral DMARDs were continued, the biological preparation was discontinued. Results: There were 3 cases of infections after surgery, osteomyelitis, suppurative spondylitis, tibialis muscle abscess. Both improve with antibiotic treatment. Two cases were steroid users, in one case abatacept, three cases MTX 4 to 8 mg were used. Discussion: According to the guidelines of the Japanese Rheumatology Association, MTX is recommended not to increase the risk of complications if it is 12 mg/week or less, continuation of the perioperative period is recommended. On the other hand, a certain rest period is required for biological products before and after the perioperative period. Although we could not point out obvious infectious disease risk factors in this study, we believe the risk of infectious diseases is infinitely low according to the guidelines. We will report on literature on the study of 119 cases this time and report it.

P1-113
Rheumatoid arthritis with progression of joint destruction although C-reactive protein (CRP) negative persisted by using methotrexate (MTX) : A case report
Masashi Morishige, Manabu Yamamoto, Koji Yoshida
Department of Orthopaedic Surgery, JCHO Tokuyama Central Hospital

Conflict of interest: None

[Case report] A 62-year-old man persisting arthralgia for about 10 months had swelling and tenderness of the right index finger PIP joint, left knee joint and bilateral 2nd-5th toe MTP joints. Laboratory date revealed CRP was negative (0.02mg/dl), but RF and ACPA were high (RA:1920U/ml, ACPR:229U/ml). In X-ray, erosion was observed in the hand and foot joints, the modified total sharp score (mTSS) was 22 pts. MTX was started with the diagnosis of RA, but the joint swelling and pain persisted (despite negative CRP). Half a year later, biological disease-modifying anti-rheumatic drugs (bDMARDs) was considered, but denied due to economics. For 7 years joint destruction had progressed despite negative CRP and mTSS increased to 129 pts. [Discussion] CRP is thought to be negative for RA with no or low IL-6 production. It is reported MTX reduce IL-6 but does not affect TNF and TNF has low correlation with IL-6. Although TNF inhibitor is effective in the MTX ineffective case, but it was difficult to use bDMARDs in this case. It should be changed or added to other synthetic DMARDs (sDMARDs). [Clinical significance] There are no clear criteria for the selection of DMARDs in the MTX ineffective case. This case suggested which DMARDs should be used in the MTX ineffective case.

P1-114
Clinical effectiveness and safety of Etanercept Biosimilar
Takashi Mitsushashi1,2, Kenji Mannami1, Makoto Mannami1
1Mannami Orthopedic Surgery, 2Kyoto Ohara Memorial Hospital

Conflict of interest: None

[Object] To evaluate the clinical effectiveness and safety of Etanercept Biosimilar (ETN-BS) [Methods] Since May 2018, ETN-BS has been administered to 10 patients with RA in our clinic. The patients were 2 men and 8 women with a mean age of 64.4 years. Of the patients, 20% concomitantly used MTX. 3 were biologic-naive patients previously treated with csDMARDs, and 7 were switched from other biologics (2 from etanercept, 2 from golimumab, 2 from certolizumab, and 1 from abatacept). The effectiveness and safety of ETN-BS were evaluated using the 28-item Disease Activity Scale (DAS28) and simplified disease activity index (SDAI) over time. [Results] The mean DAS28 and SDAI scores at the initiation of ETN-BS (week 0) were 3.56 and 19.3, respectively. At week 12, the mean DAS28 and SDAI scores were 2.74 and 8.04, respectively. One patient without combination use of MTX developed an adverse reaction (eruption) to ETN-BS and discontinued its use 2 months after treatment initiation. [Conclusions] Although further follow-up was necessary, use of ETN-BS resulted in decreased disease activity and remission induction as indicated by the decrease in DAS28 and SDAI scores to 2.74 and 8.40, respectively. ETN-BS may be a promising treatment option with respect to medical economics.

P1-115
Efficacy and safety of Golimumab in the elderly patient with rheumatoid arthritis
Koes Ohi1,2, Yasuo Inoue1, Kae Takagi1, Katsunori Ikari1,2, Junji Chiba1, Hisashi Yamanaka1, Ken Okazaki2
1Institute of Rheumatology, Tokyo Women’s Medical University, 2Department of Orthopedics, Tokyo Women’s Medical University, 2Department of Orthopedics and Rheumatology, Tokyo Women’s Medical University Medical Center East, 2Department of Internal Medicine, Tokyo Women’s Medical University Medical Center East

Conflict of interest: None

[Object] The proportion of elderly RA is growing as a result of the increasing aging population. It is not well-known how their complications and comorbidities have influence on the elderly RA receiving bio-
P1-116

Efficacy of iguratimod plus TNF inhibitor in rheumatoid arthritis patients who MTX cannot be continued

Tomohiro Miyamoto1, Kenji Yamazaki, Ryuei Ishihara
Internal Medicine and Rheumatology, Seirei Hamamatsu General Hospital

Conflict of interest: Yes

Objective Iguratimod (IGU) was approved in June 2012 and recommended by guideline 2014 in the treatment of rheumatoid arthritis (RA). Although there have been efficacy of monotherapy and concomitant MTX in clinical trials, however, there have been no reports of concomitant biological DMARDs (Bio). Therefore, we investigated efficacy of IGU+Bio therapy in RA patients who had MTX intolerance. Method Subjects were 9 patients who had MTX intolerance from June 2015 to July 2018. Previous treatment Bio was ADA. Baseline characteristics were Mean age 61.3 years, mean duration of illness 94.0 months, corticosteroid use 11.1% (mean 3.0 mg/day). The course of DAS28, SDAI, CDAI and remission rates were analyzed. Results Mean DAS28-CRP, SDAI, CDAI were decreased trend from the initiation of IGU treatment at 24 weeks (3.29→2.55, 15.3→8.58, 14.5→7.74) and at 52 weeks (3.29→2.44, 15.3→8.24, 14.5→7.34). Remission rates of DAS28-CRP, SDAI, CDAI were 50%, 50% at 24 weeks and 60%, 60% at 52 weeks. Conclusion IGU+Bio might be a new RA treatment option for aiming remission in patients who had MTX intolerance.

P1-117

A case report of rheumatoid arthritis who had appeared lung tuberculosis after baricitinib administration despite negative result of interferon gamma release assay

Ichiro Yoshii
Rheumatology and Musculoskeletal Medicine, Yoshii Hospital

Conflict of interest: None

Purpose We have experienced one rheumatoid arthritis (RA) patient who appeared lung tuberculosis (TB) after baricitinib (BAR) administration despite negative pre-screening result of interferon gamma release assay (IGRA). Case Presentation Eighty-four-year-old man consulted as dermatomyositis (DM) because of her history of pulmonary TB during childhood. On January 2018, she developed RA, therefore Tocilizumab was started without LTBI treatment. In August 2018 she was admitted to our hospital for further evaluation. Her chest-X ray for screening on admission showed a fine grayish shadow, subsequent sputum showed the presence of tubercle bacillus, leading to the diagnosis of pulmonary TB. Clinical significance Since the screening methods such as IGRA as well as the treatment of LTBI was established, the clinical guideline had recommended the biologic agents should be administered concomitant with LTBI treatment for 6–9 months in case of the previous infection of TB. However we have no answers regarding to the questions such as “How long the effectiveness of initial LTBI treatment is persistent?” “In the case of bio-switch, should we perform re-treatment for LTBI?” In this context, this case clearly highlights the clinical caveat for TB, as reconsidering the necessity of LTBI re-treatment and the importance of sharing the medical information between medical facilities.

P1-118

A case of severe and prolonged agranulocytosis induced by salilumbab

Midori Kitayama1, Ayaka Inoue1, Hiroaki Nakagawa1, Takuro Maeda1, Noriaki Yo1, Chihiro Tanaka1, Takashi Yamane1, Rimi Iwamoto2, Yasuhiro Terashima1
1Department of Rheumatology, Kakogawa Central City Hospital, 2Department of Pharmacy, Kakogawa Central City Hospital

Conflict of interest: None

A 78-year-old woman was diagnosed as RF/ACPA positive RA. CsDMARDs were started but high disease activity remained. Abatacept was administered, but failed after 2 months, so she had received salilumbab (at the time WBC count 6080/μL). She came to ER a few hours after injection, complaining of shivering high fever, and was hospitalized. On the next day, a blood exam showed WBC 830/μL (Neu11%), and then she was transferred to our hospital. We started G-CSF and antibiotics followed by febrile neutropenia. On day 5, we stopped treatment since WBC count rose to 4200/μL (Neu40.9%). On day 9, WBC count decreased to 1980/μL (Neu18%), so we restarted G-CSF until day 11. We need G-CSF administration again on day 16 because of neutropenia, but after that, WBC count recovered steadily to range before salilumbab injection. IL-6 is an important mediator for RA and to inhibit IL-6 would make improvement in disease activity. The process of agranulocytosis caused by IL-6 inhibitors is not unclear. The frequency of agranulocytosis is less than 0.1% in tocilizumab and 0.6% (1/161 cases) in salilumbab. It happens the next day of tocilizumab administration and it takes 1-2 weeks to get improvement in WBC count. This case indicates we need careful intervention for neutropenia induced by salilumbab.

P1-119

A case of lung-tuberculosis (TB) in a patient of rheumatoid arthritis long after the initial treatment for the latent tuberculosis infection (LTBI)

Satoko Nakamura1, Kiminori Hasegawa2
1Department of Rheumatology, Hokkaido Orthopaedic Memorial Hospital, Sapporo, Japan, 2Department of Rheumatology, Sapporo Yamanoue Hospital, Sapporo, Japan

Conflict of interest: None

Case A 77-year-old female was diagnosed as dermatomyositis (DM) on 2015 followed by treated with steroid pulse therapy and MTX at the previous hospital. INH was co-administered for her LTBI for 6 months, because of her history of pulmonary TB during childhood. On January 2018, she developed RA, therefore Tocilizumab was started without LTBI treatment. In August 2018 she was admitted to our hospital for further evaluation. Her chest-X ray for screening on admission showed a fine grayish shadow, subsequent sputum showed the presence of tubercle bacillus, leading to the diagnosis of pulmonary TB. Clinical significance Since the screening methods such as IGRA as well as the treatment of LTBI was established, the clinical guideline had recommended the biologic agents should be administered concomitant with LTBI treatment for 6–9 months in case of the previous infection of TB. However we have no answers regarding to the questions such as “How long the effectiveness of initial LTBI treatment is persistent?” “In the case of bio-switch, should we perform re-treatment for LTBI?” In this context, this case clearly highlights the clinical caveat for TB, as reconsidering the necessity of LTBI re-treatment and the importance of sharing the medical information between medical facilities.

P1-120

When RA Patients treated with MTX admitted by infection, we should start Leucovin rescue

Akiko Muki1, Megumi Matsueda1, Mayumi Kawaguchi2
1Department of Rheumatology, Coop-Osaka Hospital, 2Internal Medicine, Mimihara General Hospital
Conflict of interest: None

[Object] Methotrexate (MTX) has been used for many years in patients with rheumatoid arthritis (RA). We experienced cases of RA patients treated with MTX who were admitted with infection and cytopenia. We investigated how severe infections are related to the cytopenia of MTX. [Methods] Among RA patients treated with MTX, admitted with infectious disease since 2014 were studied. We retrospectively investigated the diagnosis of infection and renal function, protein -albumin, blood cell count, edema, dehydration and drug therapy before and after hospitalization. [Results] 21 cases were studied. M:F 1:3. Age 73 +13 years old. 11 pneumonia, 4 pyelonephritis, 2 cholecystitis, 2 tuberculosis, 2 others. Cytopenia was confirmed in 6 cases, and pancytopenia was 4, rescued with leucovorin. Cytopenic cases were elder, lower protein albuminemia, decreased renal function. Some cases developed into cytopenia after hospitalization or MTX doses <4 mg. [Discussion] Pancytopenia caused by MTX is a risky condition. In this study, 20% (4/21) patients suffered from severe infection among RA using MTX were not rare. [Conclusions] RA patients who are using MTX are hospitalized for infection, we should not only discontinue of MTX, and also start leucovorin rescue.

P1-121 Clinical study of MTX-LPD developed during RA treatment
Masahiro Kondo1, Yohko Murakawa1, Tomoko Sugira2, Mayuko Moriyama3, Manabu Honda1
1Faculty of Medicine, Department of Rheumatology, Shimane University, Sugiura Clinic
Conflict of interest: None

Objective Occurrence of MTX-LPD in RA patients has been reported. Causative or predictive factors of it remained to be unknown. Method Clinical characteristics of 21 MTX-LPD patients treated in our hospital or Hamada medical center were analyzed retrospectively. Results Average prescription period, average maximum dosage and average total prescription dosage of MTX were 5.9 yrs (2-12.7), 11.3 mg/wk (4-16) and 2453 mg (394-4726), respectively. Six of 10 cases who were examined EBV were positive. Pathologically 6 of 12 cases showed DLBCL. DAS28-ESR score was under LDA in 10 cases. In ten, peripheral blood lymphocyte counts (PBLC) decreased at onset of LPD compared with 6 month before onset, especially in EBV positive ones. LD in 8 cases were improved with the cessation of MTX, however 2 of them recurred thereafter accompanied with decrease in PBLC. Unfortunately, 4 cases were dead. Conclusions Accumulative amounts or taking periods of MTX seem to be irrelevant to LPD onset in our cases, because LPD occurred in some of them treated with a small amount or in a relatively short period of MTX. PBLC decrease was observed at onset and relapse of LPD, particularly in EBV-positive ones. The decrease in PBLC might be involved in the onset and be useful for prediction of MTX-LPD onset.

P1-122 Analysis of 15 cases of methotrexate related lymphoproliferative disease (MTX-LPD) in our hospital
Junki Hiura1, Ayumi Uchino1, Toshiyuki Ota2, Shuji Nagano1
1Department of Rheumatology, Iizuka Hospital, Fukuoka, Japan, 2Center for Rheumatology, Iizuka Hospital, Fukuoka, Japan
Conflict of interest: None

[Object] To clarify the clinical characteristics of MTX-LPD in rheumatoid arthritis (RA) patients. [Methods] The 15 MTX-LPD patients (12 females, 3 males) who received RA treatment at our hospital between January 2012 and September 2018 were selected. We analyzed about background, clinical course and treatment of RA after development of LPD. [Results] The mean age and RA duration at LPD diagnosis were 66.3 and 11.1 years, respectively. The mean MTX dose was 6.9 mg/week, total dose was 1926 mg, and used period was 6.1 years. The pathological type was composed of 10 diffuse large b-cell lymphoma (DLBCL), 2 T cell lymphoma, 1 follicular lymphoma, 1 MALT lymphoma, 1 EBV-LPD respectively. 4 of 15 cases were improved naturally, and 1 case was being observed after MTX stopping. 9 cases were need to chemotherapy. 2 cases were relapsed and 1 case died. 1 of 15 case died before chemotherapy. 2 cases of death were both DLBCL. 6 cases were received sultosafiprydine (SASP), after development of LPD, tocilizumab (TCZ) was used in other 3 cases, 4 cases were drug free. [Conclusions] As previously reported, it was suggested that DLBCL histological type was related to poor survival. RA treatment after development of LPD was mainly performed by SASP, and TCZ was tended to be chosen as bDMARDs.

P1-123 The analysis of the treatment in 21 RA patients with methotrexate associated lymphoproliferative disorders (MTX-LPD)
Kazuya Kamada, Noriyuki Namura, Takafumi Hagiwara
Department of Rheumatology, Takarazuka City Hospital
Conflict of interest: None

[Object] Because reports and analysis of RA treatment with MTX-LPD are insufficient, as for the rheumatic treatment before and after the MTX-LPD onset, we cannot yet have conviction. [Methods] In our facility, we investigated 21 RA patients who developed MTX-LPD between 2011 and 2016. And we retrospectively examined RA disease activity from their medical record. [Results] After stopping of MTX treatment, as for 14 of 21 MTX-LPD patients, their MTX-LPD resulted in spontaneously regression. But others needed chemotherapy (cTx) for their treatment. The average time to RA treatment resumption from MTX-LPD onset of cTx (-) and cTx (+) were 30 days and 450 days respectively. The change of RA disease activity in 12 months before and after MTX-LPD onset (-12M/ 0M/+12M) were 3.6/6.6/11.9 for CDAI, 0.6/3.9/1.9 for CRP (mg/dL), 93/94/125 for MMP-3 (ng/mL) and 320/144/7 for RF (U/mL). In 14 of 21 cases, they needed biologic therapy, and the time to biologics introduction from MTX-LPD onset of cTx (-) and cTx (+) were 350 days and 1127 days respectively. [Conclusions] Our analysis suggested that RA disease activity became gradually worsen after MTX-LPD onset. Biologic agent is often required with many cases of MTX-LPD by a restriction of the csDMARDs use.

P1-124 Two cases of patients with rheumatoid arthritis who had cancers diagnosed by screening CT scan of lung before administration of biological DMARDs
Yuju Joyo1, Yohi Kawaguchi1, Yusuke Oguri1, Hiroto Mitsu1, Gen Kuroyanagi1, Yuko Nagaya1
1Department of Orthopaedic Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan, 2Department of Joint Surgery for Rheumatic Diseases, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Conflict of interest: None

[Objective] We report the two cases of patients with rheumatoid arthritis (RA) who had cancer diagnosed by screening CT scan of lung before administration of biological DMARDs (bDMARDs) in our hospital between April 2017 and May 2018. [Case 1] A 77-year-old woman developed RA at age of 75 years and had been treated with methotrexate (MTX), prednisolone (PSL) and tacrolimus, however her arthralgia had gradually worsened. The CT scan of lung revealed the breast cancer. After radical mastectomy, low diseases activity of RA is maintained without introduction of bDMARD. [Case 2] An 83-year-old woman with early stage pancreatic cancer. MTX was ceased. She died in a month after diagnosis. But others needed chemotherapy (cTx) for their treatment. RA disease activity became gradually worsen after MTX-LPD onset. Biologic agent is often required with many cases of MTX-LPD by a restriction of the csDMARDs use.

P1-125 A study on the effect of renal dysfunction in RA
Kazuhiro Fukuoka, Chinatsu Hyodo, Yoshinori Komagata, Shinya
Conflict of interest: None

[Object] Because reports and analysis of RA treatment with MTX-LPD are insufficient, as for the rheumatic treatment before and after the MTX-LPD onset, we cannot yet have conviction. [Methods] In our facility, we investigated 21 RA patients who developed MTX-LPD between 2011 and 2016. And we retrospectively examined RA disease activity from their medical record. [Results] After stopping of MTX treatment, as for 14 of 21 MTX-LPD patients, their MTX-LPD resulted in spontaneously regression. But others needed chemotherapy (cTx) for their treatment. The average time to RA treatment resumption from MTX-LPD onset of cTx (-) and cTx (+) were 30 days and 450 days respectively. The change of RA disease activity in 12 months before and after MTX-LPD onset (-12M/ 0M/+12M) were 3.6/6.6/11.9 for CDAI, 0.6/3.9/1.9 for CRP (mg/dL), 93/94/125 for MMP-3 (ng/mL) and 320/144/7 for RF (U/mL). In 14 of 21 cases, they needed biologic therapy, and the time to biologics introduction from MTX-LPD onset of cTx (-) and cTx (+) were 350 days and 1127 days respectively. [Conclusions] Our analysis suggested that RA disease activity became gradually worsen after MTX-LPD onset. Biologic agent is often required with many cases of MTX-LPD by a restriction of the csDMARDs use.
Kaname
Department of Nephrology and Collagen Disease, Kyorin University School of Medicine

Conflict of interest: None

[Object] We tried to clarify the relationship between rheumatoid arthritis (RA) treatment and renal function. [Methods] We classified each case of CKD by eGFR at the initiation of treatment in RA patients who had been treated in our hospital after 2014. In addition, retrospective studies were conducted on the relationship between the use of medications such as glucocorticoid (GC), NSAIDs, csDMARDs, bDMARDs and eGFR. We also observed the dose reduction effects of bDMARDs in MTX, tacrolimus, buccillamine treating groups. [Results] In our study, the incidence of CKD was equivalent to the general population and tended to increase with age. In the case of impaired renal function, the amount of MTX dosages was small, and there was a tendency to be used in combination with other drugs. In addition, the combined use of bDMARDs, GC usage and MTX dose reduction effects were observed (20% and 15%, respectively). [Conclusions] In some RA cases, serum creatinine level was found lower because their muscle volume is relatively low, and these made reduce the average eGFR data in a whole cases. Renal dysfunction in RA is responsible for limiting the range of use of therapeutic agents. In these cases, treatment using bDMARDs in combination was considered to be useful.

P1-126 Organizing pneumonia in rheumatoid arthritis patients treated with anti-tumor necrosis factor biology: A case series
Akira Okamoto1, Tetsugi Kawamura2, Rinko Katsuda2, Yasutaka Ohnishi2, Koheti Miyake1, Akiko Kitagawa1
1Department of Rheumatology, National Hospital Organization Himeji Medical Center, 2Respiratory Medicine, National Hospital Organization Himeji Medical Center

Conflict of interest: None

[Background] Organizing pneumonia (OP) induced by treatment with anti-TNF biologics in rheumatoid arthritis (RA) patients is rare. Herein, we report four such cases. [Case 1] A 76-year-old male. OP was treated with high-dose prednisone (PSL), showing improvement. Subsequently, he was treated with methotrexate (MTX), and certolizumab pegol (CZP) for uncontrolled arthritis. OP relapsed 56 days after initiation of CZP. [Case 2] A 58-year-old female. OP was treated with high-dose PSL, showing improvement. Subsequently, she was treated with PSL, MTX, and etanercept (ETN). OP relapsed 525 days after initiation of ETN. [Case 3] A 78-year-old male treated with PSL, MTX, and ETN. OP occurred 31 days after initiation of ETN. Treatment with ETN was discontinued and switched to ABT [A1]. Although OP improved, arthralgia continued. ABT was switched to golimumab (GLM). OP relapsed 32 days after initiation of GLM. [Case 4] A 69-year-old female reported cough and arthralgia and was diagnosed with RA complicated by OP. She received PSL and MTX. Although OP improved, arthritis continued and CZP was initiated. OP relapsed 392 days after initiation of CZP. [Conclusion] Physicians should closely monitor patients for the occurrence of OP after treatment with anti-TNF biology.

P1-127 Nivolumab-induced recurrence of rheumatoid arthritis in a patient with advanced metastasis of gastric adenocarcinoma
Masataka Nishikawa1, Atsushi Goshima2, Hajime Owaki1
1Department of Rheumatology, Japan Community Healthcare Organization Osaka Hospital, 2Department of Orthopaedic Surgery, Japan Community Healthcare Organization Osaka Hospital

Conflict of interest: None

[Case] 63 years-old male. He had developed rheumatoid arthritis (RA) at the age of 46 years. His remission had been maintained with methotrexate (MTX) at 8mg/week, and tacrolimus at 1.5mg/day. He underwent the surgery for gastric adenocarcinoma and received chemotherapy (CTx) at the age of 55 years. Although the medication for RA was discontinued, another 5 years remission maintained. Although he redeveloped RA at the age of 60 years, he achieved remission again with MTX. He discontinued MTX again because of CTx for peritoneal metastasis at the age of 61 years. Prednisolone (PSL) 5mg/day was administrated for the side effect of CTx and another 2 years RA remission was maintained. Nivolumab was administrated at the age of 63 years, because of advanced peritoneal metastasis. After 2nd administration, his RA symptoms were worsened (TJC: 3, SJC: 6, CRP 4.92mg/dL, VAS 77mm, DAS28-CRP 5.31). The increase of PSL (10mg/day) was selected, because of terminal status of his life. Although RA symptoms were improved, he was dead 3 month later. [Clinical significance] Nivolumab inhibits these interaction between PD-1 and PD-L1 thus inhibiting the cancer immune escape pathway. This case teaches the rheumatic side effects of immunotherapy in the treatment of cancer, especially in patients with RA.

P1-128 Unique seasonal change in number of bDMARDs initiation observed from NDB analyses
Fumihiko Ando1, Katsuhiko Takabayashi2, Takahiro Suzuki3, Hideki Hanakoshiba4
1Division of Medical Informatics., Chiba University Hospital, Chiba, Japan, 2Department of Internal Medicine., Sanwa Hospital, Matsudo, Japan, 3Clinical Research Center, Chiba University Hospital, Chiba, Japan

Conflict of interest: None

[Object] To analyze initiation numbers of bDMARDs to rheumatoid arthritis patients. [Method] We analyzed 51,018,706 claimed data over seven years for patients treated with biological disease-modifying anti-rheumatic drugs (bDMARDs). 205,906 patients with rheumatoid arthritis (RA) were treated with bDMARDs at least once during these seven years from big claim data. [Result] We noted an apparent seasonal change in number of bDMARDs initiation. It shows a sine curve shape, with the highest months from June to August and the lowest in December and January in every year. It was also observed from each drug, or each prefecture. [Conclusion] From NDB analysis we noted seasonal sine curve change in number of bDMARDs initiation.

P1-129 Problems of treatment with rheumatoid arthritis at cases of medical lawsuit
Kentarou Doce, Kazuhiisa Nozawa, Souichiro Nakano, Kentaro Minowa, Ken Yamaji, Naoto Tamura
Department of Rheumatology, Juntendo University School of Medicine

Conflict of interest: None

[Background and methods] Treatment of rheumatoid arthritis has progressed rapidly in these days, but there is risk of emerging medical lawsuit due to adverse effects of drugs. We examined the problems in medical lawsuit and referred them to their clinical guidelines and the attached documents with drugs. [Methods] We analyzed the problems at the cases of medical lawsuit. [Results] There are many problems about lack of informed consent about adverse effects to patients in the case of lawsuit. Doctors must get latest information about adverse effects from the attached documents and medical literatures and give the informed consent to the patients before the induction of the treatment. In addition, we must take care about onset and worsening in not only interstitial pneumonia, liver damage, kidney damage, cytopenia, HBV, HCV, tuberculosis and fungus infection, but also varicella, measles, disseminated herpes zoster, intestinal diverticulum and psoriasis. There is a lost case in medical lawsuit for doctor in the patient with disseminated herpes zoster induced by steroid therapy. [Conclusion] It is very important to give informed consent to patients about predictable adverse effects of the treatment from latest drug information in the attached documents.

P1-130 Factors related to fatigue in patients with rheumatoid arthritis
Yoshio Nagayama
Nagayama Rheumatology Orthopaedics, Sakai, Japan
Conflict of interest: None

[Object] To evaluate factors related to fatigue in patients with RA. [Methods] We examined 305 RA patients who were evaluated the fatigue using FACT-F. We divided into a low fatigue group (L) with 36 points or more and a high fatigue group (H) with 35 points or less. We examined a cross-sectional study on the relationship between each factor such as age, gender, disease duration, Steinbrocker classification, RA disease activity, medication, Hb, HADS-D, HADS-A. [Results] There were 166 cases in group L and 139 cases in group H. The age was 63.1 in group L, 68.5 in group H (P<0.01). Class was 1.64 in group L, 1.90 in group H (P<0.01), DAS28-CRP was 1.67 in group L, 2.20 in group H (P<0.01), SDAI was 3.98 in group L, 7.35 in group H (P<0.01), MTX dosage was 7.59 in group L, 5.97 in group H (P<0.01). Use of biologics was 21.6% in group L, 34.5% in group H (P=0.01). Hb was 12.7 in group L, 12.2 in group H (P<0.01), HADS-D was 3.28 in group L, 8.21 in group H (P<0.01), HADS-A was 3.96 in group L, 7.58 in group H (P<0.01), there were significant differences. In multiple logistic regression analysis, high HADS-D and high HADS-A were extracted as independent risk factors. [Conclusions] Depression and Anxiety were risk factors for fatigue in patients with rheumatoid arthritis.

P1-131
Current status of late-elderly rheumatoid arthritis patients treated by biological agents (comparing the situation of care insurance service)
Hitoshi Tada1, Yuko Fujiwara2
1Internal Medicine, Haradao Hospital, Fukuoka, Japan, 2Department of Orthopedics, Haradao Hospital, Fukuoka, Japan
Conflict of interest: None

[Object] Continuing treatment of patients with rheumatoid arthritis (RA) until the terminal stage is a problem for the future. We report the outcome of late-elderly RA patients who were introduced biological agents (Bio) because of high disease activity with or without care insurance services. [Methods] Since 2005, 28 RA patients with late-elderly who are 75 years of age or older at our hospital were treated with Bio. Of 7 patients (R patients) we received care insurance services. We compared the period of treatment and complications of 7 patients with the 21 patients (NR patients) who were not received care insurance services. [Results] Average of age at the start of Bio therapy, R patients was 78.5 (71-86), and NR patients was 75.2 (64-88), average treatment period was 72.4 months (24-159 median 49.3), and 65.0 months (5-161, median 42.0), respectively. In R patients, there were 3 deaths due to complication, in NR patients, there were 8 deaths, respectively. [Conclusions] Our data showed that late-elderly RA patients can be continued Bio therapy with care insurance service and can be receive almost same treatment as outpatients. Cooperation between medical care and nursing care is essential for the community-based integrated care systems.

P1-132
Survey of Attitude for Member of Team Medical Care for Rheumatoid Arthritis
Kanako Shimura, Miho Tachihara, Setsuko Tajima, Yukie Saio
Department of Rheumatology, Toho Hospital
Conflict of interest: None

Purpose: We set up medical care team for Rheumatoid Arthritis on September, 2017. We surveyed attitude of team members by questionnaire. Eligible person: Team member (exclude MD): 27 person, 12 types of occupation. Methods: On A: May, B: July, and C: September of 2019, we surveyed attitude of team members by questionnaire on a five point scale, and evaluated the average by 6 ranks. Results: Result of B was similar to A. But attitude of members on C was changed in comparison to A as follows. Rank up: worthwhile of job, understanding by another occupation, motivation to prepare plan, understanding to another occupation, and motivation to admit seminar. 2 ranks down: Motivation to participate in team, inform importance of team, participation and presentation at meetings. Conclusions: Although the member’s attitude to improve their skill went up, the attitude was not connected with motivation to participate and to give presentation at the meeting.

P1-133
Treatment strategy for super elderly rheumatoid arthritis patient
Ichiro Yoshi1, Tatsumi Chijiwa2, Naoya Sawada3
1Rheumatology and Musculoskeletal Medicine, Yoshii Hospital, 2Department of Rheumatology, Kochi Memorial Hospital, 3Department of Rheumatology, Dooho Spa Hospital
Conflict of interest: None

[Object] Number of aged rheumatoid arthritis (RA) patient is increasing partly due to social population ageing. We would think treatment strategy for RA patient who is older than 75-year-old in reviewing our cases, retrospectively. [Methods] We picked up 576 RA patients who were treated for more than three years, who configured 151men and 425 women, and average age at first consult was 65.1. Patients were divided according to age when disease activity recorded minimum (min-DAS), as less than 65, 65 to 74, and no less than 75. Mean values of as 28-joints disease activity score with C-reactive protein (DAS28- CRP) at first consult, when clinical remission was attained, at min-DAS, and after min-DAS, and patients’ clinical background, administration ratio and dose of methotrexate and glucocorticoid (GCS), biological agent administration (BIO) ratio were compared in the three groups statistically with ANOVA. [Results] No statistical difference demonstrated in all parameters, except of GCS administration ratio at min-DAS. That demonstrated significantly higher in the group no younger than 75 than the other two groups, while it turned the same after min-DAS. [Conclusions] It is suggested that aiming clinical remission is the right treatment strategy even for super elderly RA patient.

P1-134
Drug therapy for patients with rheumatoid arthritis at JCHO Yugasara Hospital
Takuo Juiji1, Ichiro Nakamura1, Naohiro Izawa2, Akihito Uchio3, Takumi Matsumoto1, Jinju Nishino1, Katsumi Ito4, Sakae Tanaka5
1Department of Rheumatology, Yugasara Hospital, Japan Community Health Care Organization, Kanagawa, Japan, 2Faculty of Medical Science for Health, Teikyo Heisei University, Tokyo, Japan, 3Department of Rheumatology, Heisei Yokohama Hospital, Kanagawa, Japan, 4Department of Orthopaedic Surgery, Faculty of Medicine, The University of Tokyo, Japan
Conflict of interest: None

[Object] Treatment of rheumatoid arthritis (RA) is progressing year by year. Control of disease activity has been improved by the approval of methotrexate (MTX) and the introduction of biologic agents. In this study, we investigated the drug therapy of patients with rheumatoid arthritis in our hospital. [Methods] We examined the rheumatic drugs used for RA patients treated at our hospital. [Results] There were 407 RA patients treated at our hospital, 336 women, 71 males, average 68.1 years of age. In the use of csDMARDs, 250 cases of MTX, 77 cases of salazosulfapyridine, 65 cases of bucillamine, 48 cases of iguratimod, 35 cases of gold sodium thiomalate. The combined number of csDMARDs was 0 - 4, with an average of 1.3. Dose of MTX was 1 to 11 mg/week, 5.1 mg/week on average, and combined use of folic acid was 66 cases. Use of glucocorticoids were 150 cases, 0.5 to 10mg/day in conversion of prednisolone, and an average of 3.4 mg/day. The use of biological agents was 153 out of 407 patients, 43 cases of etanercept, 31 cases of abatacept, 26 cases of tocilizumab, 16 cases of infliximab, 15 cases of golimumab and 4 cases of adalimumab. [Conclusions] We investigated the contents of drug treatment of RA patients treated in our hospital.
P1-135 Safety of abatacept under the multi-disciplinary approach for the treatment of elderly people with rheumatoid arthritis
Satomi Kashiwaya, Sanae Kawahara, Mika Ogawa, Sachiko Kojima, Yuka Tashiro, Hiroshi Ito, Hironori Hanaoka, Hidehiro Yamada
Medical Center for Rheumatic Diseases, Seirei Yokohama Hospital

Conflict of interest: None

To assess the safety of abatacept (ABT) under our multi-disciplinary approach for the treatment of elderly people with rheumatoid arthritis (RA). In 2016 we established the co-laborative medical team for rheumatoid diseases, consisting of pharmacists, care nurses and rheumatologists. We retrospectively reviewed the medical charts of the consecutive 151 RA patients who were introduced with ABT from 2016 until March 2018. Tolerability and serious adverse events of ABT was compared between elderly group (age 75 or older) and control group (age less than 75). Mean age of the elderly (n=66) and the control (n=85) was 81 and 64, with male ratio of 17% and 20%, respectively. MTX was co-administered in the elderly less commonly with less doses than the control. Concomitant prednisolone was used in about 40% of both groups with similar initial doses. The 2-years event-free survival of ABT was 54% in the elderly and 63% in the control (p=0.29). Cumulative severe adverse event rate and cumulative rate of insufficient efficacy was similar between groups (p=0.12, p=0.72). Severe infection occurred in 2 elders (2.70/100 person-year). Our multi-disciplinary approach for the treatment of elderly RA with ABT seemed working. Further work is needed to reduce treatment-related co-morbidities.

P1-136 Relevance of biologies for the long-term effects and patient satisfaction in the elderly on set rheumatoid arthritis
Kosaku Oda, Ikuyo Noguchi
Department of Orthopedic Surgery, Takatsuki Red Cross Hospital Osaka Japan

Conflict of interest: None

[Object] Treatment for EORA needs with various complications and polypharmacy. Efficacy of T2T improved by practicing safety management. On the other hand, effectiveness of the patient’s own satisfaction is left. Therefore, we examined the relationship between long-term effectiveness and patient satisfaction with Abatacept and Golimumab for EORA. (Method) We randomly extracted EORA aged 65 years older during the 3years from 2015 to 2018. Examined the background, disease activity, HAQ transition, patient satisfaction survey of the ABT and the GLM group. (Result) Group A 10 pts 75.6 ±7.0y, Group G 9 pts 73.2 ±4.0 y were the same background. cGFR, the dose of MTX, DAS-CRP showed a declining in both groups significantly. In HAQ maintained 36 months later. No liver and kidney disease exacerbations and serious infection were observed in both groups. (Conclusion) By actively intervening treatment including BIO in EORA with high disease activity, it controls HAQ and leads to prolongation of healthy life. However, long-term effectiveness and patient satisfaction do not necessarily agree with each other, and efforts to further improve patient satisfaction by communicating with patients through team including nurses are necessary.

P1-137 A practice report of the educational hospitalization program by the multidisciplinary team for patient with Rheumatoid Arthritis in our hospital and consideration from questionnaire
Ryuhei Ishihara, Kenji Yamazaki, Toshiaki Miyamoto
Seirei Hamamatsu General Hospital

Conflict of interest: None

[Object] We grasp the shortcoming of outpatient care of rheumatoid arthritis (RA) in educational hospitalization. [Methods] Our hospital perform the educational program for patients with doctors, nurses, pharmacists, occupational therapists, medical social workers. The study include 7 patients in May - September 2018. We conducted a questionnaire about the problem for each individual and evaluate understanding of each aspect of RA (disease, treatment, care, nutrition, rehabilitation, welfare system) by Visual analogue scale. Statistical analyses were performed using Kruskal-Wallis tests, Bonferonni-adjusted Wilcoxon ranks test. [Results] There is not a statistical difference between understandings each aspect of rheumatoid arthritis care at the time of admission (p=0.6). Multiple comparison showed a tendency to have a poor understanding of welfare system than disease understanding, albeit not statistically significant (p=0.015). There was a significant improvement in the understanding of each aspect at the time of discharge. There was no uniform answer for future worries, so it was considered that custom-built program was necessary for each. [Conclusions] Insufficient element has no tendency for each patient, so we need to deal with patients individually not only uniformly.

P1-138 Perioperative complications after spine surgery and joint surgery in patients with rheumatoid arthritis during biologic agent therapy
Taketoshi Kushida1, Noritomo Ichikawa1, Takarani Saito1, Yoshiho Ozaki2, Yonsu Son3
1Department of Orthopaedic Surgery, Kansai Medical University Hospital, 2Department of Rheumatology and Clinical Immunology, Kansai Medical University Hospital

Conflict of interest: None

[Object] The aim of this study was to evaluate the risk factors of biologic agents for rheumatoid arthritis (RA) during perioperative complications after spine surgery. [Methods] We analyzed the perioperative complications after spine surgery in 65 patients treated with biologic agents from January 2006 through December 2016 at our hospital. They were divided into 3 groups (22 patients treated with spine surgery, 28 patients treated with TKA and 15 patients treated with THA). [Results] In this study, there were one deep infection in TKA group and one postoperative hematoma in spine group. [Conclusions] Many patients treated with biologic agents had no complication during perioperative period. However, we always have to pay attention to serious complications.

P1-139 Effects of low intensity pulsed ultrasound on bone healing after metatarsal shortening offset osteotomy
Shoichi Kaneshiro, Hideki Tsuibo
Department of Orthopaedic Surgery, Japan Organization of Occupational Health and Safety, Osaka Rosai Hospital

Conflict of interest: None

[Object] We evaluated effects of LIPOS on bone healing after metatarsal shortening offset osteotomy (MSO). [Methods] We enrolled consecutive 122 toes of 34 female patients (Pts) who underwent MSO for RA or hallux valgus (HV). 64 toes of 17 Pts from July without LIPOS treatment (C group; RA 15, HV 2) were compared with 58 toes of 17 Pts with LIPOS treatment (L group; RA 11, HV 6). The corrected metatarsal heads were fixed with K-wires for 2 weeks (Ws). After removal of the K-wires, full weight-bearing was allowed with fitting of an arch support. At 4 days after surgery, we began LIPOS treatments and continued the application for 12 Ws postoperatively. We assessed clinically JSSF standard rating system, and radiographically the osteotomy site to determine the time to callus formation and union using x-rays. [Results] JSSF lesser toes scale significantly improved postoperatively from 43.4 to 83.9 in the C group, and from 44.2 to 87.1 in the L group. The time to callus formation was 9.6 Ws in the C group, and 8.2 Ws in the L group. There were no significant differences between groups. The time to union was 15.2 Ws in the C group, and 12.8 Ws in the L group. There was a significant difference. [Conclusions] Our results indicate that LIPOS accelerated bone healing after we performed MSO.
Fujigaoka Hospital

Conflict of interest: None

[Object] Bone quality of RA is insufficient. Recently 3D porous cementless cup has been introduced and used for RA in our institute. The aim of this study is to evaluate the short term result of 3D porous Continuum cementless cup. [Methods] The use of Continuum cup for RA started from 2014 and 11 joints of 9 patients were undergone cementless total hip arthroplasty. Among them, clinical and radiological evaluation were performed. [Results] JOA score was improved from 41 to 95 at the last follow up period. All cup was stable and no intra- and postoperative complication was occurred. Initial gap was detected on 1 joint and completely filled at the last follow up period. [Conclusions] The short term result of 3D porous Continuum cup for RA is satisfactory with adequate initial stability even porous bone. Although further investigation is essential, the cup could obtain long-term stability because of 3D porous surface structure.

P1-141
A case of using tocilizumab for rheumatoid arthritis difficult to manage pain while waiting conversion surgery
Tetsuo Watanabe1, Hiroshi Fujinaga1, Hideyuki Kitahara1, Hiroaki Hikiami1, Kozo Takahashi2
1Japanese Oriental Medicine and Rheumatology, Toyama Prefectural Central Hospital, 2Department of Clinical Laboratory, Toyama Prefectural Central Hospital, 1Department of Japanese Oriental Medicine, Faculty of Medicine, University of Toyama, 2Shikino Care Center

Conflict of interest: None

[Introduction] Recent progress of chemotherapy make conversion surgery (CS) safe and effective for initially unresectable patients. However, the report is rare about rheumatoid arthritis (RA) of uncontrollable disease activity while waiting CS. [Case] A 65 years old female with RA under remission with infliximab (IFX) was diagnosed as pancreatic hilar cancer. IFX and methotrexate were stopped, and laparoscopic gastric jejunal bypass surgery was performed. After 11 courses of GEM/nab-PTX therapy, it was regarded as an indication for CS. Polyanthralgia appeared, at her age of 67, at 3 weeks after the end of chemotherapy. Combined with preoperative radiotherapy, DAS28-ESR was reached at 6.84 since intravenous dexamethasone palmitate, loxoprofen, igramimod, salazosulfapyridine, 15mg of prednisolone (PSL) and tramadol were ineffective. After tocilizumab (TCZ) subcutaneous injection was started, pain was improved the following week, PSL were tapered, and TCZ was stopped due to remission with the second administration. There was no relapse of pain for 26 days after last TCZ and she went into pancreaticoduodenectomy. [Conclusion] This case suggested the efficacy of using TCZ for the patient of RA with difficulty of pain relief during CS preoperative term.

P1-142
Conservative treatment of broad skin necrosis after total knee arthroplasty at rheumatoid arthritis patient. A case report
Shigeru Hikoi1, Daisuke Nozawa2
1Department of Orthopedic Surgery, Tsukuba Central Hospital, 2Department of Orthopedic Surgery Faculty of Medicine, University of Tsukuba

Conflict of interest: None

[Object] Skin necrosis is serious complication after total knee arthroplasty, especially in rheumatoid arthritis patient. Usually, muscle flap is first choice for the treatment of broad skin necrosis, but conservative treatment is another option. [Methods] A 78-year-old woman, who developed rheumatoid arthritis of the mutilance type at 65 years old, achieved total knee arthroplasty on her left knee. Wound necrosis, the size was 4 by 5 centimeter, was revealed at 3 weeks after the surgery. Two consecutive skin flap surgeries were ended in failure, skin necrosis got to larger (3.5 by 9 centimeter). The patient didn’t want another operation. Afterward she received conservative treatment for 1 year until achieved epithelialization. [Results] Broad skin necrosis could achieve epithelialization with conservative treatment for 1year. [Conclusions] This case suggests that a long term conservative treatment can be an optional therapy for broad skin necrosis after total knee arthroplasty.

P1-143
Conservative treatment for patella fractures after total knee arthroplasty: two case reports
Takeshi Yoshikawa, Midori Tono
Department of Orthopaedic Surgery, Kagawa Prefectural Central Hospital

Conflict of interest: None

[Object] We report two cases of patellar fractures after total knee arthroplasty (TKA) that was treated successfully with conservative methods. (Case1) A 75-year-old woman was operated with PS-type TKA for osteoarthritis of her left knee. 2 months after operation, displaced patellar fracture (Keating classification type-2B) was detected accidently by the X-ray of the schedule. In spite of displaced fracture, we tried conservative treatment for that fracture. 10 months later, she had no pain, no extensor lag, no complications. (Case2) A 70-year-old woman was operated with PS-type TKA for rheumatoid arthritis of her right knee. 1 month after operation, she was diagnosed as a displaced patellar fracture (Keating classification type-2B). Same as case1, we treated conservatively, and we got a good result three months later. (Conclusions) Patellar fractures after TKA, even if displaced fracture, associated with an intact extensor mechanism and a stable implant were treated successfully with nonoperative means. On the other hand, operation for this fracture was reported to be associated with a high rate of complication and reoperation.

P1-144
Changes in walking ability following forefoot reconstruction for patients with rheumatoid arthritis
Hyunho Lee1,2, Hajime Ishikawa1, Asami Abe1, Shinji Taniguchi1, Tomonori Sakamoto1, Yoichi Kurosawa1, Eriko Hasegawa1, Chinatsu Takai1, Daisuke Kobayashi1, Hiroshi Otani1, Satoshi Ito1, Shu Saito2, Kiyoshi Nakazono1, Akira Murasawa1
1Department of Rheumatology, Niigata Rheumatic Center, 2Department of Orthopaedic Surgery, Nihon University School of Medicine

Conflict of interest: None

[Objectives] To clarify changes in plantar pressure and walking ability after rheumatoid forefoot reconstruction [Methods] 74 feet in 55 patients were evaluated. Patients were divided into two groups: group Sw, 59 feet treated by Swanson implant arthroplasty for the 1st MTP; group No, 15 feet treated by arthrodesis for the 1st IP or nothing at the 1st MTP. Most patients were treated by shortening oblique osteotomy at the 2nd to 5th metatarsal neck. Peak plantar pressure and TUG, gait speed, stride and cadence for walking ability were measured just before surgery and at 1 year after surgery. [Results] Peak pressure at the 1st IP, 2nd and 3rd MTP decreased, MM and LM increased in group Sw significantly. Preoperative peak pressure at the 1st IP in group Sw was significantly lower than that in group No, and it decreased more postoperatively. TUG decreased, gait speed and stride increased significantly in both groups. There was no significant differences in walking ability between two groups. Moderate positive correlation between preoperative peak pressure at the 2nd MTP and walking ability was found. [Conclusion] The patients whose walking ability was maintained highly with forefoot deformity might need early surgical intervention.

P1-145
Comparison of the First Metatarsal Shortening osteotomy and the scarf osteotomy by Short-term results for Forefoot Deformities of Rheumatoid arthritis
Kenta Makabe1, Yoshiho Uchida1, Kenichi Shimane1, Yuichi Nagase2, Takuji Nishikawa1
1Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, 2Department of Rheumatology, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan

Conflict of interest: None

[Object] We compare short-term postoperative results of the first...
metatarsal shortening osteotomy and the Scarf osteotomy, for forefoot deformities of rheumatoid arthritis (RA). In addition, in each group, we divided into two, older than 70 years and those with less. [Methods] Twenty-two feet of 18 cases are group A, underwent the first metatarsal shortening osteotomy between September 2013 and January 2018, and 26 feet of 21 cases are group B, underwent the Scarf osteotomy between April 2015 and May 2018. We checked AP view of weight-bearing radiographs at pre-operation and at final follow-up. Clinical evaluation included the JSSF RA foot ankle scale and the SAFE-Q at final follow-up. [Results] The mean follow-up period was 44 and 26 months. HV angle improved from 36.1 degrees to 10.6 degrees, and 45.0 to 17.7 degrees. SAFE-Q was generally comparable each other. Nine feet in Group A and 15 feet in Group B were over 70 years of age, but there was no significant difference in each of the outcomes compared with those under 70 years. [Conclusions] There was no statistically difference in these osteotomies. Preoperative HV angle is larger in group B, Scarf osteotomy is useful for severe Hallux valgus in RA patients. In addition, both osteotomies are useful for older people aged 70 years.

P1-146
Results of joint-preserving procedures by a modified Mann method of the first metatarsal by concomitant use of metatarsal bone shortening for the treatment of hallux valgus in rheumatoid patients
Daichi Mukunoki1, Keita Nagira1, Masako Hayashihara2, Chikako Takeda1, Hideki Nagashima1, Hiroshi Hagiino2
1Department of Orthopedics, Tottori University Hospital, Yonago, Tottori, Japan, 2Department of Health Sciences, Tottori University School of Medicine, Yonago, Tottori, Japan

Conflict of interest: None

[Object] This study aimed to evaluate joint-preserving surgery by a modified Mann method by concomitant use of metatarsal bone shortening for the treatment of hallux valgus in rheumatoid patients. [Methods] Radiographic outcome in terms of hallux valgus angle (HVA), metatarsal1-metatarsal2 angle (M1M2A), metatarsal1-metatarsal5 angle (M1M5A) were investigated after an average of 4 years postoperatively. The change in HVA at 5 degrees or more postoperatively was defined as an exacerbation. Between the improvement group and the exacerbation group, various parameters were examined. [Results] Mean age of the patients was 62.8 years (8 females) and mean disease duration of RA was 17.4 years. The mean preoperative HVA, M1M2A, and M1M5A were 42.7 degrees, 15.2 degrees, and 31.7 degrees respectively. The mean HV A, M1M2 A, and M1M5 A at the last investigation were 9.8 degrees, 5.1 degrees, 15.2 degrees, and 31.7 degrees respectively. Deviation of the seed bone showed a tendency of maladaptation in the exacerbation group. [Conclusions] Mann’s modified method with concomitant use of first metatarsal shortening osteotomy corrects HV angle well. By performing rotation correction with the first metatarsal bones, there is a possibility of preventing hallux valgus postoperative recurrence.

P1-147
Evaluation of adductor hallucis tendon transfer using a suture anchor with metatarsal osteotomy for hallux valgus deformity of rheumatoid arthritis
Taro Yoshioka1,2, Kosuke Ishizaka1, Eigo Kikuchi1, Takahiro Okai2
1Department of Orthopaedics, Kawakita General Hospital, 2Center for Rheumatology and Joint Surgery, Kawakita General Hospital

Conflict of interest: None

[Object] We evaluated the results of seven cases of adductor hallucis tendon transfer using a suture anchor with metatarsal osteotomy for hallux valgus deformity in patients with rheumatoid arthritis (RA). [Methods] From September 2017, six patients involving seven cases were treated. RA disease activity was in remission in all patients. Metatarsal osteotomy for corrective hallux valgus was performed. A distal osteotomy using modified Mitchel method was performed in six of the seven cases. Proximal osteotomy was performed by using the modified Mann method in one case. The adductor hallucis tendon was released on the lateral side of the base of the proximal phalanx of the great toe and was attached to the lateral side of the metatarsal head by using suture anchor. As a clinical outcome, the hallux valgus angle (HVA), M1M2 angle (M1M2A), and JSSF Hallux scale score were measured at preoperatively and 6 months postoperatively. [Results] The HVA, M1M2A, and JSSF hallux scale score were significantly improved postoperatively. No patient complained of residual pain. [Conclusions] Adductor hallucis tendon transfer using a suture anchor with metatarsal osteotomy for hallux valgus deformity of RA was found to be a useful surgical technique.

P1-148
Short-term results of proximal closing-wedge osteotomy of the first metatarsal in rheumatoid arthritis
Ryo Tanaka, Haruhiko Akiyama
Department of Orthopaedics, Gifu University School of Medicine

Conflict of interest: None

[Object] However there are various operative procedures for forefoot deformities, a large number of first-metatarsal osteotomies have difficulties in correcting the rotational deformities and adjusting the shortened quantity of the metatarsal bone. The aim of this study is to assess the results of proximal closing-wedge osteotomy for patients with rheumatoid arthritis (RA) in our institution. [Methods] From January 2016 through April 2018, 6 feet were treated this procedure. Subjective, functional, and radiographic outcome were assessed. [Results] The mean Japanese Society for Surgery of the Foot hallux scale improved from 42.0 to 92.5 postoperatively. The average hallux valgus and intermetatarsal angles improved from 43.6° preoperatively to 17.3° postoperatively, and 17.7° to 6.0°, respectively. To assess the repositioning of pronation deformity of the first metatarsal, the medial sesamoid was measured according to the measurement system proposed by Hardy and Clapham. All foot was classified as grade VII preoperatively and 3 of these were grade IV or lower at the latest follow-up. [Conclusions] Proximal closing-wedge osteotomy of the first metatarsal was beneficial for correcting forefoot deformities in RA over the short term.

P1-149
Tenotomy of Tibialis anterior muscle tendon caused by it being exposed after Total ankle arthroplasty in rheumatoid arthritis patients: reports of three cases
Takaki Noguchi1, Shigeyoshi Tsuji1, Makoto Hirao2, Kosuke Ebina1, Hiroshi Takasu, Hidetoshi Tsushima, Kenjiro Fujimura, Satoshi Kamura1
1Department of Orthopaedics, Osaka Minami Medical Center, 2Department of Orthopaedics, Osaka University Graduate School of Medicine, 3Department of Orthopaedics, Osaka Rosai Hospital

Conflict of interest: None

[Purpose] Exposure of TA by wound healing trouble after TAA in RA patients is one of the serious complications. We examined the postoperative process about 3 patients who resected TA immediately after exposure of TA. [Method] 3 patients underwent TAA through an anterior approach in RA. We examined ROM and muscle strength of ankle, wound healing period and walking start time after tenotomy. [Results] We operated tenotomy within 3 days after exposure of TA. Patients started to walk in 14 days and wound healing was recognized in 21 days after surgery. Drop foot was not seen and there is no difference between pre- and post-operative dorsiflexion power of ankle. In addition, the change was not seen in ROM after tenotomy. [Discussion] It has been reported that there are 10-30% of complications associated with wound healing after TAA. Especially in RA, wound healing trouble risk is increased. Not only it takes several months for healing by the conservative therapy and causes reduction of the ADL, but also is accompanied by the risk of the deep infection once when TA is exposed. Drop foot and decreasing dorsiflexion power of ankle was not seen because it was tightly inserted implant in TAA. If TA is exposed by wound healing trouble after TAA, tenotomy of TA is an effective therapeutic method.

P1-150
Medium to long-term Clinical and Radiographic Outcome of a Total Ankle Arthroplasty in Patients with Rheumatoid Arthritis
Hiroshi Takasu, Hidetoshi Tsuchima, Kenjiro Fujimura, Satoshi Kamura,
Hisaaki Miyahara
Department of Orthopedics, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

Conflict of interest: None

[Object] We report the medium to long-term outcome of a total ankle arthroplasty (TAA) in patients with rheumatoid arthritis (RA) in our hospital. [Methods] Between 2009 to 2016, we performed TAA in 11 patients with RA (1 man and 10 women, mean age was 64.7 years old), using FINE total ankle system. The mean follow-up duration was 60 (range, 18-114) months. Outcomes were evaluated with the preoperative and postoperative range of motion (ROM), the Japanese Society for Surgery of the Foot (JSSF) scale score and a postoperative self-administered foot-evaluation questionnaire (SAFE-Q), the angle of varus and valgus of ankles, the angle between of the placement of the implant and the complications. [Results] The preoperative ROM (plantar/dorsal flexion) was 16.5°±12.9°/4.0°±4.6°, and the postoperative ROM was 21.4°±7.7°/7.7°±4.1°. The angle of the placement of the implant was 0.1°±4.0°. The three patients fractured the medial malleolus. The three patients had loosening of the implant, however, they didn’t need to have re-operation, such as the re-replacement of implant, or the arthrodesis. [Conclusions] The medium to long-term clinical outcomes for the TAA in our hospital were found to be satisfactory.

P1-151
Characteristics of rheumatoid arthritis patient who underwent total knee arthroplasty-comparisons before and after appearance of biological DMARDs
Ryuta Sakurai, Kenjiro Fujimura, Takashi Komatsu, Hisaaki Miyahara
Orthopedics/Rheumatology, National Hospital Kyusyu Medical Center

Conflict of interest: None

Objectives: It is reported the number of total knee arthroplasty (TKA) in rheumatoid arthritis (RA) patients is decreasing. This change might cause by the usage of biological DMARDs. We investigated the characteristics of RA patients who will lead to TKA. Methods: We divided RA patients into two groups (group A and group B). Group A included the patients who underwent TKA from 1998 to 2002, and group B included from 2013 to 2017. We investigated disease-modified anti-rheumatic drugs (DMARDs), mean age, disease duration, C-reactive protein (CRP) and radiographic changes. Result: DMARDs usage and mean age was significantly increased and CRP was significantly decreased in after group. Disease duration was not changed. The number of patient with joint space narrowing and osteophytes were not significantly changed but bone destruction and bone cyst were significantly decreased in group B. Conclusions: After the appearance of biological DMARDs, RA is better controlled from the perspective of CRP, the existence of Larsen classification, bone destruction and bone cyst in X-ray. However, we found less prevalence of osteoporosis in RA patients with that in OA patients. Consequently, biological DMARDs usage increases the patients' ADL. A bone density examination to RA patients undergoing TKA is recommended.

P1-152
A comparison of prevalence of osteoporosis between in rheumatoid arthritis patients and osteoarthritis patients with total knee replacement
Hidenori Tanigawa1, Ayano Hayashi2, So Nomoto1
1Department of Orthopaedic Surgery, Saiseikai Yokohamashi Tobu Hospital, 2Department of Nursing, Saiseikai Yokohamashi Tobu Hospital

Conflict of interest: None

[Object] More than 80000 total knee arthroplasties (TKAs) are performed in a year for osteoarthritis (OA) patients or rheumatoid arthritis (RA) patients. A complication of osteoporosis can increase the risk of postoperative fractures or implant loosening. An OLS (Osteoporosis Liaison Service) team encourages the patients to take a bone density examination for early diagnose of osteoporosis. In this study, we compared the prevalence of osteoporosis in RA patients with that in OA patients. [Methods] The subjects are 20 RA patients undergoing TKA from January 2015 to April 2018, and 119 OA patients undergoing TKA in 2017. A bone density examination was performed before surgery. [Results] The result in RA patients was following: Osteoporosis 35%, Bone loss 60%, Normal: 5%, whereas the result in OA patients was following: Osteoporosis 19.3%, Bone loss 58%, Normal: 22.7%. The T score in RA patients (-2.24) was significantly decreased compared to that in OA patients (-1.59). [Conclusions] The prevalence of osteoporosis is higher in the RA patients compared with OA patients. It is reported that ten percent of patients would experience falls within a year after the surgery, and a fall decreases the patients’ ADL. A bone density examination to RA patients undergoing TKA is recommended.

P1-153
Factors affecting the postoperative patients’ satisfaction of total knee arthroplasty in rheumatoid arthritis
Atsuo Uefuji, Natsuko Nakagawa, Toshihiko Harada
Hyogo Prefectural Kagokawa Medical Center

Conflict of interest: Yes

[Object] Total knee arthroplasty (TKA) is considered to be a good treatment. Though, some patients continues complains. The purpose of this study was to show the preoperative factors affecting postoperative patient satisfaction of TKA in rheumatoid arthritis (RA) patients. [Methods] 17 knees of 16 patients (2 male and 14 female with mean age of 67.0±8.6 years old) with RA, undergoing primary TKA, were included in this study. Patients were assessed using patients’ expectation part of the 2011 Knee Society Score. The consideration items were age, duration of RA, functional class score of American College of Rheumatology, surgery history of hip or knee arthroplasty, image of Femoro Tibial angle in standing position Xp, image of Patella Tilt in lying position CT, and serum CRP score at the time of TKA. [Results] Younger than 70 years old patients showed better postoperative expectation scores compared to older patients. Patients with lower than 10 degree Patella Tilt, showed better scores compared to patients with higher degree. There were no significant differences in other items. [Conclusions] Patients with high age and patients with high degree Patella Tilt showed worse outcomes. We should increase clinical cases and do more considerations for those patients.

P1-154
Evaluation of the effect of Total Knee Arthroplasty to functional analysis in rheumatoid arthritis patients
Kenya Terabe, Daihei Kida, Yusuke Hattori, Shotaro Mori, Tomotaro Sato, Atsushi Kaneko
National Hospital Organization Nagoya Medical Center

Conflict of interest: None

[Object] In this study, we evaluate the efficacy of Total Knee Arthroplasty (TKA) to functional analysis in rheumatoid arthritis patients. [Methods] 70 patients (Pts) who underwent TKA were included in this study. 5 patients were man and 65 were woman. The baseline mean age and duration of RA were 66.2±11.1 years, 18.3±12.4 years respectively. Efficacy was evaluated based on mHAQ and SDAI comparing with pre and post 1 year TKA. We investigated factors that relate with improvement of mHAQ. [Results] Average of mHAQ improved 0.9±0.6 at baseline to 0.8±0.6 at 1 year after TKA. mHAQ was improved in 27 Pts, no change in 28 Pts, worsened in 15 Pts. Average of SDAI and MMP-3 significantly improved 12.2±7.3 to 9.3±8.3, 229.9±278.0 to 119.9±156.2, respectively. mHAQ was improved in 27 Pts (R group) and was not improved in 43 Pts (N group). The decrease of SDAI (△SDAI) in R group is significantly higher than that in N group (R group: -5.5±6.7, N group: -1.5±6.1 p=0.05). In addition, There was a significantly correlation with △mHAQ and △SDAI (r=0.324 p<0.01). [Conclusions] In this study, improvement of mHAQ after TKA surgery relate with that of SDAI. These results suggested that improvement of mHAQ after TKA surgery needs to that of disease activity.

P1-155
Improvement of Locomotive syndrome score 25 after total knee arthroplasty
Kensuke Koyama1,2, Yoshihiro Takayama1,2, Hirotaka Haro1,2

Conflict of interest: None

[Object] More than 80000 total knee arthroplasties (TKAs) are performed in a year for osteoarthritis (OA) patients or rheumatoid arthritis (RA) patients. A complication of osteoporosis can increase the risk of postoperative fractures or implant loosening. An OLS (Osteoporosis Liaison Service) team encourages the patients to take a bone density examination for early diagnose of osteoporosis. In this study, we compared the prevalence of osteoporosis in RA patients with that in OA patients. [Methods] The subjects are 20 RA patients undergoing TKA from January 2015 to April 2018, and 119 OA patients undergoing TKA in 2017. A bone density examination was performed before surgery. [Results] The result in RA patients was following: Osteoporosis 35%, Bone loss 60%, Normal: 5%, whereas the result in OA patients was following: Osteoporosis 19.3%, Bone loss 58%, Normal: 22.7%. The T score in RA patients (-2.24) was significantly decreased compared to that in OA patients (-1.59). [Conclusions] The prevalence of osteoporosis is higher in the RA patients compared with OA patients. It is reported that ten percent of patients would experience falls within a year after the surgery, and a fall decreases the patients’ ADL. A bone density examination to RA patients undergoing TKA is recommended.
The effect of stress steroid on the total hip and knee arthroplasty in rheumatoid arthritis

Sumito Kawamura¹, Daisuke Kawamura², Koji Suzuki³
¹Department of Orthopaedic Surgery, Kobayashi Hospital, ²Department of Orthopaedics, Kawamura Orthopaedics, ³Department of Orthopaedic Surgery, Hokkaido Orthopaedic Memorial Hospital

Conflict of interest: None

[Object] There were few reports on locomotive syndrome score 25 (LSS25) related to surgical intervention. The purpose of this study was to examine the relationship between total knee arthroplasty (TKA) and improvement of locomotive syndrome score. [Methods] Fifty four patients (OA:45, RA:9) underwent primary unilateral TKA and got consent before surgery were included. Using LSS25 before and 6 months of TKA, we examined the degree of improvement of LSS25. Furthermore, in order to find preoperative factors to satisfy locomotive syndrome degree 2 (LSS25<16 points), logistic regression analysis was performed. [Results] LSS25 was significantly improved from preoperative 46 points to 25.6 points after 6 months. Five patients satisfied the locomotive syndrome degree 2 before TKA, but increased 20 cases in 6 months after surgery. Male, preoperative LSS25 were the relative factors for satisfying the locomotive syndrome degree 2 in 6 months after TKA (p<0.05). [Conclusions] Multiple factors such as osteoporosis and spinal disease were affected to LSS25, but it was suggested that unilateral TKA improves in the short time.

Assessment of the results of total knee arthroplasties in patients with rheumatoid arthritis using the Knee Injury and Osteoarthritis Outcome Score (KOOS)

Masato Sonobe¹, Arata Nakajima¹, Takashi Nakamura², Hiroshi Takahashi¹, Shinji Taniguchi¹, Manabu Yamada¹, Keita Koyama¹, Keichiro Yamamoto¹, Shiko Nakano³, Toru Suguro³, Koichi Nakagawa¹
¹Department of Orthopaedic Surgery, Toho University Sakura Medical Center, ²Department of Orthopaedic Surgery, Toho University Omori Medical Center, ³Japan Research Institute of Artificial Joint

Conflict of interest: None

[Object] The study included 83 knees in 66 Patients who underwent primary TKA between June 2010 and March 2018 at our hospital. Patients included 6 men and 60 women, with the average onset of RA was at 53.1 years and the average duration of RA was 14.5 years. They were classified into two groups (valgus, neutral + varus) by femorotibial angle. We investigated the following as risk factors: onset of RA, gender, BMI, duration of RA, medication, disease activity, RF, ACPA, osteoporosis, mLDFA (mechanical lateral distal femoral angle), MPTA (medial proximal tibial angle). We compared these risk factors between the valgus and another groups. [Results]: A univariate analysis demonstrated that there was a significant difference in duration of RA, mLDFA, and MPTA between the two groups. A multivariate logistic regression analysis demonstrated that there was a significant difference in MPTA between the two groups. [Conclusions]: This study suggested that longer duration of RA, smaller mLDFA, and bigger MPTA were risk factors of valgus knee in patients with rheumatoid arthritis.

Motional analysis of RA wrist after Sauvé-Kapandji procedure- In association with smoothness of articulation

Yusuke Yamamoto, Hisashi Ohki, Makoto Kitade, Yuya Izubuchi, Akihiko Matsumine

Department of Orthopaedics and Rehabilitation Medicine Faculty of
Insufficiency fracture of the diaphyseal radius after Sauve-Kapandji procedure in a rheumatoid arthritis patient

Takahiro Iwata, Mitsuru Saito
Medical Science, University of Fukui

Conflict of interest: None

Object Sauvé-Kapandji procedure (SK) is one of typical surgical treatments. We performed motion analysis of wrist joint of the patients after SK procedure and evaluated the smoothness of the joint movement. Methods The subjects were 7 females, 10 hands undergone SK procedure (SK-RA). Steinbrocker ’s classification was Stag III 2 cases, Stage IV 8 cases. The control group consisted of 8 RA patients, 8 hands (RA), and 3 healthy volunteer, 6 hands (HY). A biaxial electric angle meter was used to measure the wrist joint angle. For data analysis, two channels of analog amplifier and analysis software were used. We calculated the jerk in each movement of palmar-dorsi flexion, ulnar-radial deviation and darts slow motion. In the SK-RA, X-ray measurement of the wrist joint was performed. We compared the three groups. Results In the SK-RA group, the range of motion was smaller than that of the HV group. Compared to the RA, the movable axis and the angular jerk of the SK-RA tended to approach the HV. The angular jerk in the SK-RA did not depend on the joint morphology. Conclusions The wrist stabilizes after SK procedure, and it was suggested that the function improvement could be expected regardless of the joint destruction and the joint morphology.

Insufficiency fracture of the diaphyseal radius after Sauve-Kapandji procedure in a rheumatoid arthritis patient

Takaiiro Iwata, Mitsuru Saito
Department of Orthopaedic Surgery, Takayama Red Cross Hospital

Conflict of interest: None

Case report We report a case of insufficiency fracture of the diaphyseal radius after Sauve-Kapandji (S-K) procedure in a rheumatoid arthritis (RA) patient. A 79-year-old woman had been mediated with methotrexate and etanercept. She had undergone S-K procedure of the left wrist combined with synovectomy and tendon transfer, due to extensor tendon rupture of little finger. Bone density of femoral neck was 51% of the young adult mean and administered denosumab. Although she had not experienced any recent trauma, she presented with left forearm pain 9 months postoperatively. Radiographs showed transverse fracture of the diaphyseal radius. We performed open reduction and internal fixation (ORIF) with a locking plate. We treated with low intensity pulsed ultrasound (LIPUS). The fracture healed within 7 months. This case represents the first description of presentation with diaphyseal radius fracture after the S-K procedure in a RA patient treated by ORIF and LIPUS. We considered mechanical stress resulting from the absence of ulnar support, osteoporotic bone, and high activities of daily living under biological agent as contributory factors. Orthopaedic surgeons should be aware that insufficiency fracture after the S-K procedure could occur at the diaphyseal radius in RA patients.

Conservative treatment for distal radius fractures in rheumatoid arthritis patients

Rika Kakutani1, Takahiro Nezu2, Tadamasa Hanyu2
1Department of Orthopedic Surgery, Nagaoka Red Cross Hospital, 2Department of Rheumatology, Nagaoka Red Cross Hospital

Conflict of interest: None

Object To investigate the results of revision total elbow arthroplasty (TEA) in patients with rheumatoid arthritis (RA). Methods 3 revision TEAs with 2 patients were performed due to implants loosening. We investigated the clinical course and the factors of causes of loosening (C.L.). Results 1st patient with FINE ELBOW (F-E), loosening of ulnar component was onset at 1 year 5 months after primary operation (P.O.). Revision TEA was done with using a metal sack at 1 year 7 month from P.O. The C.L were thought the insufficiency of cementing (I.C.) and of ability of fixation on all poly. component. 2nd patient with Coonrad-Morrey loosen-
P1-165  
Evaluation of complications of total elbow arthroplasty for Rheumatoid arthritis  
Satoshi Kamura, Hitodeshi Tsushima, Kenjiro Fujimura, Koji Sakuraba, Hisaaki Miyahara, Takashi Komatsu, Ryuta Sakurai, Hiroshi Takasu  
Department of Orthopaedic Surgery and Rheumatology, National Hospital Organization Kyushu Medical Center  
Conflict of interest: None  

[Object] We presented that Total elbow arthroplasty (TEA) is a reliable treatment for severe rheumatoid arthritis (RA) of the elbow previously. The study also showed a relatively high occurrence of complication in TEA. The purpose of this study was to assess the risks of those complications, especially periprosthetic fractures. [Methods] The objects were 29 RA patients (34 elbows) treated using TEA in our center between 2009 and 2018. [Results] The mean mean age and disease duration of them was 66.4 and 27.9 years respectively. The semi-constrained, cemented prosthesis was used for all case. Results: The post-operative complications occurred in 12 patients, fracture in seven patients (20.6%) and ulnar nerve disorder in five patients (14.7%). Neither surgical site infection and soft tissue disorder were observed in the serial. The mean age of patients with and without fracture was 70.1 and 65.4 respectively and the mean disease duration was 34.3 and 26.2 years respectively. [Conclusions] Our study may reveals that fracture after TEA tend to occurr in eldery people with bone fragility. It suggested that making decision of surgical indication carefully and treatment for osteoporosis were important in TEA for RA.

P1-166  
A case of rheumatoid arthritis with severe metallosis of ulnar component after K-ELBOW total elbow arthroplasty  
Takeshi Oguchi, Toki Takemoto, Sakurako Yoshino, Shiro Urata  
Department of Rheumatology and Orthopaedic Surgery, Anjo Kosei Hospital, Aichi, Japan  
Conflict of interest: None

[Introduction] K-ELBOW total elbow arthroplasty (TEA) has been used in patients with rheumatoid arthritis (RA) for relief of pain or improvement of elbow function in Japan since 2005; however we experienced a case of revision surgery due to severe metallosis of ulnar component. [Case report] A 72-year old female with a 29-year history of RA was underwent right K-ELBOW TEA eight years ago. Her preoperative right elbow range of motion (ROM) was from 45 to 125 degree, JOA score was 47, and her left elbow was almost ankylosing. Although ADL improved markedly after TEA, synovial fluid punctured from her joint showed black after 7 years. We diagnosed as metallosis and a revision surgery was performed. Intraoperative findings showed implant failure of the ulnar component with severe metallosis in the soft tissues around the prosthesis. No findings of loosening of both implants, only ulnar component was revised with long stem. At 1 year after revision, ROM of the elbow was from 45 to 140 degrees, JOA score was improved from 83 points preoperatively to 88 points postoperatively. [Conclusions] We need attention to TEA complications associated with malrotation of ulnar component. The case report emphasizes that the indications for surface replaced type TEA should be carefully considered.

P1-167  
Surgical outcome of linked total elbow arthroplasty  
Tomoya Kotani, Haruki Takagi, Kazutaka Takatsuka, Toshiyuki Kitaori, Hiroko Morise, Akinori Murakami  
Fuku Red Cross Hospital  
Conflict of interest: None

[Object] We discussed about TEA implant failure in our hospital. [Methods] Between 2003 and 2018, we performed 9 linked TEA. There were 8 rheumatoid arthritis cases and 1 osteoarthritis case. Mean follow-up time was 6.6 years. [Results] Our used implant were Connard-Morrey (n=3), Discovery (n=5) and SOLAR (n=1). Revision cases were 3 cases (Discovery only). The follow-up time of revision cases was mean 3.3 years (range:2-5 years). The complications of revision cases were radiographic loosening and bone defect. Their humeral stems were implanted for flexed position.2 patients were very high activity. [Conclusions] We experienced the low follow-up time that was 10 years over, but then follow-up time about cases of implant failure that was 2 years. There are few cases, and every cases were not any differences of medical treatment about rheumatoid arthritis. The good alignment of implantation and patient education are important.

P1-168  
Clinical outcome of the PROSNAP linked elbow prosthesis for the rheumatoid elbows  
Shunji Okita1, Keiichiro Nishida1, Minami Matsushashi1, Masahito Watanabe1, Yohei Kiso1, Hideki Ohashi1, Ryuichi Nakahara1, Yoshihisa Nasu1, Toshifumi Ozaki1  
1Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 2Department of Intelligent Orthopaedic System, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 3Department of Medical Materials for Musculokeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences  
Conflict of interest: None

[Object] We investigated the mid-term clinical results of total elbow arthroplasty (TEA) using the linked elbow prosthesis (PROSNAP) for the rheumatoid elbows. [Patients and Methods] We investigated 38 elbows of 36 rheumatoid arthritis (RA) patients The mean follow-up period was 54.0 (range:12-116) months. The clinical condition was assessed according to range of motion (ROM), Japanese Orthopaedic Association-Japan Elbow Society Elbow Function Score (JOA score), and Mayo Elbow Performance score (MEPS). [Results] The mean preoperative ROM in extension and flexion were -33.9 degrees and 105.7 degrees, respectively. The mean preoperative JOA score and MEPS were 45.4 points and 48.0 points, respectively. The mean postoperative ROM in extension and flexion were -29.6 degrees and 140.4 degrees, respectively. The mean postoperative JOA score and MEPS were 87.3 points and 95.1 points, respectively. Two elbows (5.2%) required revision surgery, due to infection and breakage of polyethylene liner of ulnar component. [Conclusions] Although the clinical results of PROSNAP for the RA elbows were satisfactory, two elbows (5.2%) required revision surgery.

P1-169  
Aiceo  
Yu Sakuma1,2, Haruki Takimoto1,2, Naoko Koenuma1,2, Koichiyo Yano1,2, Katsunori Ikarı1,2, Ken Okazaki1  
1Department of Orthopedic Surgery, Tokyo Women’s Medical University, Shinjuku, Tokyo, 2Joint Surgery, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan  
Conflict of interest: None

[Object] Swanson (Sw) and AV ANТА (Av) is silicone prosthesis which is widely used in the metacarpophalangeal (MP) joint arthroplasty of the patients of rheumatoid arthritis (RA). Here we report the postoperative fracture rates of the implants. [Method] We examined postoperative X-ray of the RA patients who underwent MP joint arthroplasty with Sw or Av from September 2012 to November 2017. [Results] Of all 105 corresponded cases, we reviewed 78 hands (68 hands of 62 female, 10 hands of 10 male, mean age of 63.9) the images of which were available. Sw were inserted in 158 fingers of 50 hands, and mean post-operated period were 2.05 (0.89-9.67) years. Av were in 132 fingers of 38 hands, and post-operated period were 2.65 (1.05-6.65) years. The cases in which at least one prosthesis was broken were 15 hands (39%) in Av group, 3 hands (7.5%) in Sw group. Only one case represented pain symptom and needed revision surgery. [Conclusion] In our study, the fracture rates were significantly high in Av group. Only one fracture case needed revision owing to symptomatic complaints, therefore implant fracture is likely not to be a problem clinically. When we select the silicon implant, we should consider not only its fracture rate, but also clinical results and characteristic features.
P1-170
Boutonniere deformity of rheumatoid thumb-108 cases of Flexible hinge toe Swanson implant arthroplasty
Tetsuya Nemoto1,2, Hajime Ishikawa2, Issaku Toyohara3, Asami Abe2, Hiroshi Otani2, Hyunho Lee2, Kiyoshi Nakazono2, Akira Murasawa2, Satoshi Ito2, Daïsuke Kobayashi2, Chinhatsu Takai2, Takeshi Kijima2, Katsumi Inagaki1
1Department of Orthopedic Surgery, Showa University, 2Department of Rheumatology, Niigata Rheumatic Center, 3Department of Rheumatology, Northern Area Medical Association Hospital

Conflict of interest: Yes

[Objective] We hypothesized flexible hinge toe implant would improve the clinical outcomes and radiological findings of Boutonniere deformity of rheumatoid thumb. [Patients and Methods] Swanson implant arthroplasty for the thumb MP joint was performed on the 108 cases (male 11, female 97) with minimum follow up of 6 months. The average age was 61 yrs. old and the average follow-up period was 4 yrs. Radiological findings and complications were assessed. [Results] In the radiological assessment, the pre- and the postoperative flexion angles at the arthroplasty for at the thumb MP joint was performed on the 108 cases, Northern Area Medical Association Hospital

P1-171
Reverse total shoulder arthroplasty for seronegative rheumatoid arthritis : A case report diagnosed at late stage
Terufumi Shibata1, Teruaki Izaki1, Akira Maeyama1, Tomonobu Hagio1, Naoko Himuro2, Katsuhisa Miyake2, Hitoshi Nakashima2, Takuaki Yamamoto1
1Department of Orthopaedic Surgery, Fukuoka University Faculty of Medicine, 2Division of Nephrology and Rheumatology, Department of Internal Medicine, Fukuoka University Faculty of Medicine

Conflict of interest: None

Report of the case A 80-year-old female complained of pain in her right shoulder after falling on his right side. Assessment at her local hospital reveals no bony injury. Despite participation in a physiotherapy and intra-articular injection for three months, she continued to complain of pain and the development of glenohumeral joint space narrowing was confirmed on radiographs. She referred to our hospital for diagnostic evaluations. She had the diabetes. The physical examination for the shoulder couldn’t reveal the signs of infection. Laboratory tests included an elevated CRP (1.06mg/dl). WBC was normal (4900/µl), and RF and a CCP antibodies weren’t identified. Imaging revealed the destruction of the humeral head and the glenoid and the large glenohumeral joint effusion. Arthroscopic debridement was performed to rule out the septic shoulder arthritis. Intra-articular cultures were negative, but the radiological progression was confirmed. More detailed clinical assessment found the left wrist pain from the past and the prominent erosive changes in bilateral wrists were seen on the radiographs. She was diagnosed with seronegative RA, and the reverse total shoulder arthroplasty was performed. DMARDs were introduced postoperatively, resulting in improvement of her condition.

P1-172
Total Joint Arthroplasty was Improved Quality of Life greater than Synovectomy in Patients with Rheumatoid Arthritis
Jiro Kato, Shusuke Ota, Takanobu Doi
Department of Orthopaedic Surgery, Shizuoka Medical Center, National Hospital Organization, Shizuoka, Japan

Conflict of interest: None

[Object] The aim of this study is to identify the quality of life (QoL) changes in patients with rheumatoid arthritis (RA) following total joint arthroplasty (TJA) or joint synovectomy. [Methods] A retrospective chart review was conducted in patients with RA. A total of 18 patients (18 females, mean age, 69.6±7.7 years; mean disease duration, 13.4±11.0 years) were identified. To explore the QoL changes, we divided the patients into two groups depend on the type of surgery (group T, TJA; group S, joint synovectomy), and tested the differences for statistical significance using t test or chi square test. [Results] Group T showed significantly lower preoperative index value of EQ-5D (group T, 0.504; group S, 0.700), higher preoperative DAS28-CRP (group T, 4.74; group S, 3.07) and better improvement of visual analogue scale (VAS) at 6&12 months after operation (group T, 26/15; group S,56/60) than group S. After the surgery of lower leg, group T showed significantly better improvement of mHAQ and EQ-5D domain of mobility than group S. [Conclusions] In RA patients with joint destruction, we should operate TJA to improve their QoL. However, we have to arrange the prospective study to clarify the efficacy of synovectomy at upper joint.

P1-173
The association of fall history with performance-based physical function and postural sway in patients with rheumatoid arthritis
Kensuke Kawabata1, Takumi Matsumoto2, Ryutaro Takeda1, Taro Kasai1, Song Ho Chang1, Jun Hirose2, Saka Tanka3
1Department of Orthopaedics, Fukuoka University Faculty of Medicine, Japan, 2Bone and Cartilage Regenerative Medicine, Division of Tissue Engineering, Faculty of Medicine, The University of Tokyo, Tokyo, Japan, 3Department of Orthopaedics, Ibaraki Prefectural Central Hospital, Ibaraki, Japan, 4Department of Orthopaedics, The University of Tokyo Hospital, Tokyo, Japan

Conflict of interest: None

[Object] Patients with rheumatoid arthritis (RA) are at increased risk of falls; therefore, its prevention and prevention are one of the critical issues to be addressed. The aim of this study was to evaluate the ability of the short physical performance battery (SPPB) and center of pressure (COP) to discriminate between patients with and without a history of falls. [Methods] Fifty patients with RA were enrolled and divided into two groups according to the presence or absence of history of falls within a year. Physical performance was assessed using SPPB. Postural sway was assessed using a force platform in below positions: (1) standing with feet together side-by-side with eyes opened or closed; (2) semitandem with right or left foot forward; (3) tandem with right or left foot forward. The backgrounds, physical function, and postural sway were compared between the two groups. [Results] Fourteen patients (28%) reported falls. There were no significant differences in baseline characteristics and SPPB between the two groups. The group with a history of fall had significantly lower postural stability only in semitandem. [Conclusions] Numerical evaluation of postural sway in the semitandem position seems to be more appropriate than SPPB for assessing the risk of falls in patients with RA.

P1-174
Pre examine interview for outpatients of rheumatoid arthritis by physiotherapist
Akira Inoue1, Takuro Okari1, Keio Ayabe2
1Department of Rehabilitation, Keiyu Orthopedic Hospital, 2Department of Orthopedic Surgery, Keiyu Orthopedic Hospital

Conflict of interest: None

[Object] Report the usefulness of interview by physiotherapist for outpatient rheumatoid arthritis (RA). [Methods] The RA outpatient at our hospital is a reservation system, and we use interviewing using waiting time. Cold symptoms, complications, presence or absence of side effects due to oral administration, residual medicine, presence / absence of other department visits, blood sampling, tender / swollen joints, HAQ survey. In addition, performed self exercise, ADL guidance, ulcer check and insole creation. [Results] The number of registered patients is 1013. 27.4% who had cold symptoms, side effects due to oral administration 10.3%, other departments visits 20.7% (internal medicine 59.7%, ophthalmology 26.2%, dentistry 21.6%). Side effects / complications were found in 49
cases of herpes zoster, interstitial pneumonia, CKD (eGFR 29 or less) and foot ulcer. Insulin took effect in 50 cases, foot VAS significantly improved. [Conclusions] As a result of achieving results with insulin creation and rehabilitation guidance, there is utility of interview before physical examination by physiotherapist.

P1-175
A pilot evaluation of physical activity by pedometer in a rheumatoid patient (RA) before and after the prescription of rheumatic shoe orthosis
Megumi Ato1, Ikuko Masuda1, Yukiko Komano1, Koichiro Ohmura2, Toshihiro Mata1, Aiko Kishida1
1Rehabilitation Center, Jujo Takeda Rehabilitation Hospital, Center for Rheumatic Diseases, 2Department of Rheumatology and Clinical Immunology, Kyoto University

Conflict of interest: None

[Object] There are few studies that evaluate a change of the quantity of the walk of RA patients. Using an electric pedometer, we tried to evaluate their physical activity. [Case and Methods] 70 years old patient who has three years history of RA, was admitted to our hospital for evaluation and education of RA. We used a pedometer to evaluate her physical activity. Since her chief complaint was painful feet while walking, she was prescribed rheumatic shoes after the discharge. The change of her physical activity before/after the hospitalization, and after the wearing rheumatic shoes was reported. m-HAQ and functional foot index was also assessed. [Results] The average steps after the discharge improved to 3254, compared to those in the hospital (2311). The average steps after the rheumatic shoe’s prescription improved furthermore to 3,535. m-HAQ did not show the major change. The foot function index was improved to 46 points in final assessment from 49 points at the initial evaluation. [Conclusion] This pilot study suggested the importance of continuous physical exercise for RA patient while taking care of the pain when walking. Also, relief of pain by wearing rheumatic shoes, contributed improvement of overall locomotor activity as well as her motivation to keep active.

P1-176
A transitional case of juvenile dermatomyositis (JDM) that has been shown to improve ADL / QOL by rehabilitation
Yusuke Yamada1,2, Yuki Asai1,2, Yoshihiro Ishihara1,2, Naoto Tamura1, Masahiko Yasuda1,2
1Internal Medicine, Nakaizu Spa Hospital, Izu, Japan, 2Internal Medicine and Rheumatology, Juntendo University, Tokyo, Japan

Conflict of interest: None

[Object] In recent years the prognosis of many pediatric chronic illnesses has improved, accompanied by those scenes which are required to seamlessly shift to adulthood are increasing. We report a case in which rehabilitation was useful for such transitional periods. [Methods] We evaluate the ADL / QOL improvement of a 22-year-old female JDM patient using the bio-psycho-social model, who was introduced to our hospital for rehabilitation purposes. She was hospitalized two times for two months with her hope. [Results] In this case, psychotherapy was successful first, from which there was an enhancement of exercise therapy, further correction of cognitive distortion, leading to an improvement not only ADL but also QOL. [Conclusions] In transitional medicine, we realized that a comprehensive approach such as team medical care and family-oriented care in rehabilitation is useful. [Clinical significance] Chronic illnesses such as collagen diseases often have problems including family members as well as their own, depending on the age of the patient and the life stage, not limited to the transition period. We could see the multifaceted expanse of rehabilitation medicine including multi - occupational collaboration system from this experience.

P1-177
The efficacy and safety of mycophenolate mofetil as a maintenance therapy for systemic lupus erythematosus
Shunsuke Sakai1, Yoko Wada1, Sayuri Takamura1, Ayako Wakamatsu1, Yukiko Nozawa1, Hiroe Sato2, Daisuke Kobayahsi1, Takeshi Nakatsu1, Takeshi Kuroda1, Masaaki Nakan1, Ichiei Narita1
1Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences, 2Internal Medicine, Niigata University Hospital for Medicne, Niigata, Japan

Conflict of interest: None

[Object] To examine the efficacy and safety of mycophenolate mofetil (MMF) as a maintenance therapy in patients with systemic lupus erythematosus (SLE). [Methods] Thirty-one SLE patients (2 males and 29 females) who visited Niigata University Hospital and treated with MMF between October 2017 to September 2018, were enrolled. We investigated the dosage of prednisolone (PSL), laboratory data, SLE disease activity index (SLEDAI) at the time of MMF initiation, and followed the changes at 12 weeks (n = 31), 24 weeks (n = 28), and 36 weeks (n = 20) after MMF initiation, respectively. Adverse events were also evaluated. [Results] The mean age at MMF initiation was 45 ± 13 years, the mean PSL dosage was 10.9 mg/day, and the mean SLEDAI was 1.52. The mean PSL dosage was decreased to 10.2 mg at 12 weeks, 9.9 mg at 24 weeks, and 9.9 mg at 36 weeks. The mean SLEDAI was 0.87 at 12 weeks, 0.78 at 24 weeks, 0.95 at 36 weeks and kept low disease activity. Although adverse events were observed in 3 patients with nausea, 1 patient with loss of appetite, and 2 patients with infections, there was no discontinuation of MMF during study period. [Conclusions] In maintenance phase of SLE patients, MMF was safe and effective to reduce the dosage of PSL and control disease activity.

P1-178
Administration of hydroxychloroquine to treat systemic lupus erythematosus: Is it appropriate for young patients?
Toshiaki Kobayahsi, Hiroyuki Yamashita, Shinni Izuka, Sotaro Nakajima, Nanami Min, Kyoko Motomura, Shunta Kaneko, Yuko Takahashi, Hiroshi Kaneko
Department of Rheumatology, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan

Conflict of interest: None

[Object] The effectiveness and safety of administration of hydroxychloroquine (HCQ) to treat systemic lupus erythematosus (SLE) was examined. [Methods] SLE patients who regularly visited our outpatient clinic were examined and compared retrospectively with HCQ-prescribed and non-prescribed cases. [Results] HCQ was prescribed in 41 cases (34 females, 83%). Improvement was found in 19 patients (90.5%) among 21 who had rash or hair loss before commencement. Side effects were observed in 7 cases, 4 at the beginning and 1 at the dose increase, while 3 cases were discontinued. In the case of cessation, there was 1 case of rash at the beginning and 2 of ocular lesions. Thirty cases continued for more than 6 months, with the longest being 72 months. HCQ was selected earlier in cases of first incidence after the approval of HCQ. Among the 226 patients given an immunosuppressive agent, 37 patients (16.4%) continued with HCQ administration. The mean age was 36.2 ± 11.2 years (HCQ), and case 52.6 ± 15.3 years (non - HCQ) (p <0.01); younger patients were prescribed HCQ. [Conclusions] HCQ is effective for the skin eruption and depilation of SLE, and sparing of steroids. It is expected that HCQ-prescribed cases will increase mainly in young people in the future.

P1-179
The real-world tacrolimus use in systemic lupus erythematosus: a cross-sectional study of the LUNA registry
Masaki Mitsushashi1, Yosuke Kunishita1, Ryusuke Yoshimi2, Chiharu Hidewaka1, Natsuki Sakurai1, Yumiko Sugiyama2, Daiga Kishimoto1, Yuki Izuka1, Takaaki Komiyama1, Hideto Nagai1, Naoki Hamada1, Naomi Tsushima1, Yutaru Soezima1, Keikou Kamiyama1, Kouji Kobayashi1, Yukiko Asami1, Yohei Kiritono1, Nobuyuki Yajima3, Ken-ei Sada4, Hideto Ichinose5, Shigeru Ohno5, Hideaki Nakajima2
1Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, 2Center for Rheumatic Diseases, Yokohama, Japan

Conflict of interest: None

[Object] The effectiveness and safety of tacrolimus (MMF) as a maintenance therapy in patients with systemic lupus erythematosus (SLE) was examined. [Methods] Thirty-one SLE patients (2 males and 29 females) who visited Niigata University Hospital and treated with MMF between October 2017 to September 2018, were enrolled. We investigated the dosage of prednisolone (PSL), laboratory data, SLE disease activity index (SLEDAI) at the time of MMF initiation, and followed the changes at 12 weeks (n = 31), 24 weeks (n = 28), and 36 weeks (n = 20) after MMF initiation, respectively. Adverse events were also evaluated. [Results] The mean age at MMF initiation was 45 ± 13 years, the mean PSL dosage was 10.9 mg/day, and the mean SLEDAI was 1.52. The mean PSL dosage was decreased to 10.2 mg at 12 weeks, 9.9 mg at 24 weeks, and 9.9 mg at 36 weeks. The mean SLEDAI was 0.87 at 12 weeks, 0.78 at 24 weeks, 0.95 at 36 weeks and kept low disease activity. Although adverse events were observed in 3 patients with nausea, 1 patient with loss of appetite, and 2 patients with infections, there was no discontinuation of MMF during study period. [Conclusions] In maintenance phase of SLE patients, MMF was safe and effective to reduce the dosage of PSL and control disease activity.
ma City University Medical Center, Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences

Conflict of interest: None

[Object] To survey the real-world situation of tacrolimus (TAC) use in the clinical practice of systemic lupus erythematosus (SLE) using a multicenter registry. [Methods] SLE patients registered in the LUNA registry were divided into two groups according to whether TAC was administered or not. The patient's demographic, clinical, and laboratory data were compared between the two groups. [Results] Among 591 patients with SLE, 189 (32%) used TAC. The mean age was significantly lower in the TAC user group than in the non-user group (44.7 ± 13.3 vs 48.5 ± 15.5 years old, p = 0.0021). Disease activity did not differ between the two groups (SLEDAI 5.6 ± 5.4 vs 4.7 ± 4.6, p = 0.057), but arthritis was significantly more frequent in the TAC user group as compared with the non-user group (16.4 vs 10.5%, p = 0.045). Furthermore, the TAC user group tended to have better renal function (eGFR 94.5 ± 31.3 vs 88.9 ± 36.0 mL/min/1.73m², p = 0.074) and higher frequency of lupus nephritis class V (34.5 vs 22.8%, p = 0.067) as compared to the non-user group. [Conclusions] TAC tended to be used frequently in younger cases and cases with arthritis or lupus nephritis class V in real-world clinical practice.

P1-180 The effectiveness in dose reduction of corticosteroids by combination use of hydroxychloroquine in maintenance phase of systemic lupus erythematosus

Takeyoshi Kurabayashi, Yasushi Kondo, Mai Sugiyama, Yuto Izumi, Yoko Nakagome, Kazuki Hirano, Sho Sasaki, Yasushi Koyama, Chihyo Yamada, Shinji Sato
Department of Rheumatology, Tokai University, Isehara, Japan

Conflict of interest: None

Purpose: To clarify the effectiveness and predictors of prednisolone (PSL) sparing effect by combination use of hydroxychloroquine (HCQ) in systemic lupus erythematosus (SLE) patients with maintenance therapy. Methods: We enrolled 63 of SLE patients who continued to use HCQ over 24 weeks with receiving PSL less than 15mg as maintenance dose at the time of HCQ initiation. We excluded the patients who added immunosuppressant after HCQ initiation. We analyzed the changes of PSL dose and clinical parameters and patients' backgrounds. Results: The mean age and disease duration were 41±11 and 13±8.7 years, respectively. Mean PSL dose were significantly reduced from the baseline to 24 and 48 weeks after initiation of HCQ. (PSL dose at HCQ initiation; 9.5 ± 3.0 mg, 24 weeks; 8.5 ± 2.9mg and 48 week; 8.0 ± 3.1mg (p < 0.01), respectively.) We found the amelioration of serological markers in patient with hypocomplementemia and/or high levels of anti-dsDNA antibody. We also identified that the SLE patients with anti-U1RNP antibody positivity is the predictive factor who was able to reduce the PSL dose within 24 week after HCQ initiation. Conclusion: Additional use of HCQ can reduce PSL dose in maintenance phase of SLE and this seemed to be more susceptible in anti-U1RNP antibody positive patients.

P1-181 Investigation of the prognosis o lupus nephritis and risk factors for achieving to complete response by EULAR/ERA-EDTA criteria in lyear

Yasuo Suzuki1, Yuki Mizutani1, Kentaro Noda1, Naohiro Sugitani1, Eiji Ishikawa2, Ayako Nakajima1
1Center for Rheumatic Diseases, Tsu, Mie, Japan, Mie University Hospital, 2Department of Nephrology, Japan, Mie University Hospital

Conflict of interest: None

[Objective] To investigate the prognosis of lupus nephritis patients who underwent renal biopsy from 2007 to 2017. [Methods] Patient's backgrounds, disease activity measured by SLEDAI, renal pathology and treatment were analyzed retrospectively. The prognosis defined by achievement of complete response rates (CR) by EULAR/ERA-EDTA criteria was evaluated in 1 year and additionally according to renal pathology type (II vs III±V vs IV±V vs V) by using Kaplan-Meier method. The factors for achieving CR was analyzed by multivariate analysis. [Results] Forty-four patients underwent renal biopsy, 77.8% were female, median [IQR] age was 35.3 [29.5, 55.2] years. Among 40 patients, 18 patients (45%) treated with steroid alone and the rest were in combination with immunosuppressants (19 with CNI and 2 with IVCY). CR was achieved in 18 cases (51.4%) in 35 patients in 1 year. There was no significant difference in cumulative CR ratio according to renal pathological types. CR was a significant risk factor for achieving to CR in 1 year with odds ratio 0.059 (95% CI:0.001-0.736, p<0.05) by multivariate analysis. [Conclusion] CR was achieved in 51.4% of patients in the cohort that immunosuppressive drugs were used in 55%.

P1-182 The prevalence and the risk factor of hypertension and dyslipidemia in systematic lupus erythematosus patients: Exploratory research

Nobuyuki Yajima1, Tomoki Hayashi1, Kosuke Sakurai1, Nao Oguro1, Yoko Miura1, Mayu Saito1, Sakiko Isojima1, Ryo Takahashi1, Kunihiro Ichinoise1, Shigeru Ohno1, Ken-i Sada2, Ryusuke Yoshimizu1, Yusuke Miwa1
1Division of Rheumatology, Department of Medicine, Showa University School of Medicine, 2Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 3Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 4Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 5Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan

Conflict of interest: Yes

[Object] There were few reports about the risk factors of hypertension (HT) and dyslipidemia (DL). The purpose of this study is to describe a prevalence of HT and DL and to evaluate the risk factor of HT and DL. [Methods] Participants were patients who satisfied ACR criteria were targeted. In SLE patients registered in LUNA database. The definition of HT was a use of anti-HT drug or >130/80. The definition of DL was a use of anti-DL drug or >130/80. The definition of DL was anti-DL drug or LDL-cho >100mg/dl or TG>175mg/dl. We performed descriptive statistics and binomial logistic regression analysis to evaluate the risk factors of HT and DL. Missing data were imputed by multiple imputation. [Results] Patients were 618. Mean age was 45.9±15.1 years old. 88% was female. Mean corticosteroids dosage was 6.9±7.0mg. Mean SLEDAI and SLICC-DI were 4.96±4.8, 0.86±1.4. A prevalence of HT and DL was 345/598 (57.4%), 385/600 (64.2%). On binominal logistic regression analysis to evaluate the risk of HT, age, sex, BMI, drinking status, current corticosteroid dose, and lupus nephritis were the independent factors. On binomial logistic regression analysis to evaluate the risk of DL, age was the independent factor. [Conclusion] The prevalence of HT and DL was over 50%. We should take care of HT and DL to prevent atherosclerosis.

P1-183 Efficacy and safety of hydroxychloroquine treatment in patients with systemic lupus erythematosus: a single center study

Naoki Matsuoka, Junpei Temnomuku, Yuya Fujita, Makiko Furuya Yashiro, Tomoyuki Asano, Shuzo Sato, Hiroko Kobayashi, Hiroshi Watanabe, Kiyoichi Migita
Department of Rheumatology, School of Medicine, Fukushima Medical University, Fukushima, Japan

Conflict of interest: None

[Object] Hydroxychloroquine (HCQ) has been used to treat lupus patients since 2015 in Japan. We aimed to show the effects of HCQ treatment in this study. [Methods] A total of 172 lupus patients treated in our hospital were analyzed retrospectively. We examined reasons of HCQ use...
and nonuse, effects of treatment with HCQ, and adverse effects. [Results] Treatment with HCQ was planned for 42 patients. The aims of HCQ treatment were decreasing corticosteroid doses (42 cases), treatment of cutaneous manifestations (11 cases), and treatment of headache/arthropathy (7 cases). All patients were examined by dermatologists before HCQ prescription, and 33 patients received HCQ. The reasons of HCQ nonuse were lupus retinopathy (5 cases), dyschromatopsia congenitai (1 case), age-related maculopathy (1 case), hemorrhage in the eye ground (1 case), and decreased disease activity (1 case). After treatment with HCQ, doses of corticosteroid were reduced in 21 patients. HCQ was discontinued in 5 patients because of adverse drug effects, but no eye toxicity was observed. [Conclusions] This study indicates physicians hesitate prescribing HCQ when patients have any retinopathy. Doses of corticosteroid were reduced in approximately two-thirds of patients after HCQ use with no severe adverse effects.

### P1-185
**Evaluation of the correlation between renal pathology and clinical course of lupus nephritis: single center study**

Taro Horino, Satoshi Inotani, Tatsuki Matsumoto, Yoshiko Shimamura, Kosuke Inoue, Yoshiho Terada

*Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University*

Conflict of interest: None

[Object] Skin hypersensitivity is important as a skin adverse events of HCQ in the early stage, and skin pigmentation is also important under long-term HCQ use. We collected the data of skin adverse events of HCQ and examined clinical outcome. [Methods] The subjects were SLE patients who started HCQ between Apr 1, 2009 and May 31, 2018 and developed skin adverse events at our hospital. [Results] Of 302 SLE patients studied, skin adverse events were seen in 9.3%. About skin hypersensitivity, 22 patients were mild to moderate and 2 patients were severe (1 patient was suspected drug-induced hypersensitivity syndrome and hospitalized). A simple dose escalation of HCQ was carried out in 14 patients with mild skin hypersensitivity, and only one patient re-experienced hypersensitivity. In addition, 3 patients developed skin pigmentation. Although, in the previous reports, the onset is usually 5 years or more after HCQ starting, each of the 3 occurred at 7, 9, and 10 months, respectively. Among them, 1 patient stopped HCQ, 1 reduced HCQ and 1 continued at the time when skin hypersensitivity is suspected. In case of mild skin hypersensitivity it may be possible to re-introduce. Skin pigmentation needs individual support.

### P1-186
**Case Series Report: ‘Multitarget Therapy’ in Japanese Patients with Lupus Nephritis**

Mari Toshihara, Yasuhiro Katsumata, Hirokazu Nishina, Masanori Hanaoka, Yasushi Kawaguchi, Hisashi Yamakawa

*Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan*

Conflict of interest: None

[Object] Although the management of lupus nephritis (LN) has progressed significantly in the last decade, evidence in Japanese patients is still lacking. We aimed to investigate the outcome of Multitarget Therapy in Japanese LN patients. [Methods] We retrospectively collected the data of LN patients treated with Multitarget Therapy (glucocorticoids, MMF and TAC) and followed for at least 48 weeks. [Results] Four women with mean age 38 years and mean disease duration 8 years were included. Renal biopsies were performed in 3, and their pathological types were IV-S (A/C)+V, IV-G (A/C), and IV-G (A/C). All cases were treated with pulses methylprednisolone followed by oral PSL 0.6 mg/kg/d and combined with MMF 1 g/d and TAC 3 mg/d. Dosage of PSL were tapered to 10 mg/d by 44 weeks in all cases. Urine protein: creatinine ratio (UPCR) decreased to less than 0.5 g/gCr by 48 weeks in all cases. eGFR was normal at baseline and remained normal in all cases. Thus, all cases achieved complete renal response (UPCR<0.56 g/gCr with normal renal function). Urine sediments normalized by 12 weeks in 2 cases. Serological activity also improved in all cases. There was no renal flare or severe adverse events. [Conclusions] This study suggested that Multitarget Therapy were useful in Japanese LN patients.

### P1-187
**The association between the dose of glucocorticoids and emotional health in patients with systemic lupus erythematosus: a cross-sectional analysis of a lupus registry of nationwide institutions (LUNA)**

Yoshia Miyawaki1, Ken-eki Sada2, Kunihiro Ichinose1, Ryusuke Yoshimi1, Shigeru Ohno1, Nobuyuki Yamai1,

1Department of Healthcare Epidemiology, School of Public Health in the Graduate School of Medicine, Kyoto University, 2Department of Neophrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan, 3Department of Immunology and Rheumatology Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences Nagasaki University Graduate School of Biomedical Sciences, 4Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 5Center for Rheumatic Diseases, Yokohama City University Medical Center, Yokohama, Japan, 6Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, Tokyo, Japan

Conflict of interest: None

[Objectives] Glucocorticoids (GC) were widely used and were generally known to cause emotional health symptoms. We assessed the association between current GC dose and emotional health among patients with systemic lupus erythematosus (SLE). [Methods] We conducted a cross-sectional study. Participants were patients with SLE aged 20 years or older from 6 institutions in Japan. The exposure was daily GC dose. The main outcome was Emotional Health domain (EH) score of Lupus Patient Reported Outcome (LupusPRO). The secondary outcome was the total score of LupusPRO. We performed a simple linear regression and multiple regression analyses. [Results] Overall, 205 patients were included; 80% were female and the median age was 44 (interquartile range (IQR) 35-55) years. The median SLEDAI was 4 (IQR 2-8) and the median GC dose was 5 (IQR 3-9) mg. The daily dose of GC negatively correlated with EH score (β=-0.60 [95%CI -1.27 to 0.07]) and the total score (β=-
0.53 [95%CI -1.01 to -0.06]). In multiple linear regression analysis, the daily dose of GC was associated with the EH score (β=-0.18 [95%CI -1.67 to -0.19]) and the total score (β=0.27 [95%CI -1.46 to -0.46]). [Conclusions] The daily GC dose was negatively associated with emotional health among SLE patients.

P1-188
Comparison of the disease control and the treatment of systemic lupus erythematosus between recent 5 years and 15 years ago
Chihiro Imaizumi, Yuki Inoue, Munetsugu Imamura, Hideki Ito, Sayaka Takonaka, Rie Kujime, Norihide Hayashi, Ayako Hirata, Takehisa Ogura, Hitoto Kameda
Division of Rheumatology, Department of Internal Medicine Faculty of Medicine, Toho University (Ohashi Medical Center)

Conflict of interest: None

[Object] The prognosis of SLE has dramatically improved, and it has been pointed out introduction of immuno-suppressants and reduction of steroid are involved. However, there were few reports comparing actual treatment. The treatment of the last 5 years and 15 years ago was compared. [Methods] SLE patients with Toho Uni. Ohashi Medical Center visit in each 5 years from 2012 to 2017 (GroupA:79) and 1999 to 2003 (group B:68), compared with PSL use, immuno-suppressant use, and relapse. [Results] The incidence of lupus nephritis (A:31%, B:38%, p=0.40) and serositis (A:29%, B:28%, p=0.87) was smilar, but the incidence of CNS was significantly higher in group B (A:7%, B:19%, p=0.04). The average number of relapsed significantly decreased in group A (A:0.26, B:0.40/year, p=0.01). The median PSL dose in initial treatment was 50mg/day (p=0.64) in both groups, and the median PSL dose at relapse was no difference (p=0.11). The dose of PSL increase for relapse was lower in group A (A:6.5, B: 14mg/day, p=0.01). The rate of introduction of immuno-suppressants in the initial treatment was higher in group A (A:43%, B:6%, p=0.01) There was no difference in the incidence of infection (p=0.58). [Conclusions] The active immuno-suppressants use in recent years resulted decrease SLE relapse and PSL dose.

P1-189
Use of hydroxychloroquine for the treatment of systemic lupus erythematosus: Experience in National Hospital Organization Himeji Medical Center
Akiko Kitagawa1, Yasutaka Ohnishi2, Rinko Katsuda2, Kohei Miyake2, Tetsuji Kawamura2, Akira Okamoto1
1rheumatism Department, National Hospital Organization Himeji Medical Center, 2pneumonology Department, National Hospital Organization Himeji Medical Center

Conflict of interest: None

[Objectives] In Japan, reimbursement of hydroxychloroquine (HCQ) was initiated in August 2015. We present our experience with the use of HCQ. [Methods] HCQ was administered to six patients with systemic lupus erythematosus (SLE) from Sep. 2015 to Sep. 2017. [Results] Treatment was cancelled in two cases due to lupus enteritis and meningesis (n=1) and cough (n=1). In those with continuous treatment (n=4), slight improvement of fever and general fatigue was observed and reduction of the glucocorticoid dosage was achieved. However, cytopenia did not improve. In one patient who discontinued treatment due to diarrhea, therapy was reinitated using lactic acid bacillus. [Clinical Importance] Our results are similar to those reported in double-blinded, randomized, clinical trials investigating the efficacy of HCQ against non-severe SLE. The ACR2015 treatment algorithm recommended the use of HCQ, along with glucocorticoids, as first-line therapy for general fatigue and polyarthritis. HCQ plays an important role in the treatment of SLE. Diarrhea was the most common side effect (5-10%) and was treatable. [Conclusion] HCQ assists the reduction of the glucocorticoid dosage in patients with SLE exhibiting clinical manifestations (i.e., arthralgia, fever, and general fatigue).

P1-190
A Review on the Continuity Rate & Termination Cause of HCQ for SLE
Shoshi Shinagawa1, Machiko Mizushima1, Tomohiko Shibata1, Naoko Katsuyama1, Toshihiko Shibata1, Tohru Yamada1, Masaomi Yamasaki1, Naoko Ohy1, Gen Ito2
1Department of Rheumatology, St. Marianna University School of Medicine, Yokohama City Seibu Hospital, 2Department of Rheumatology, St. Joseph Hospital

Conflict of interest: None

[Object] Hydroxychloroquine (HCQ) has been used for long as standard medicine for systemic lupus erythematosus (SLE). It was approved in 2015 in Japan. HCQ is relatively safe, while side effects like digestive illness and rash lead to usage termination. Now, we aimed to survey in our hospital about HCQ’s continuity rate and termination cause on SLE patients. [Methods] 40 SLE patients were studied. They have used HCQ since April 2016. The time after the treatment, patients’ background, continuity rate, and termination cause were studied. The continuity rate was analyzed by Kaplan Meier method. [Results] There were 36 female patients (90%), and HCQ starting age ranges from 19-83 (average=41.8). Median of the study is 8-month, and the 2-yr continuity rate is 71.6%. Termination include rash (4 cases.), digestive illness (3), and there are one case of eye symptom and decrease in platelet respectively. Two cases are terminated with unknown reasons. [Conclusion] The 2-yr continuity rate of HCQ on SLE patients is satisfactorily 71.6%. Majority of termination (91%) occurs within 5 months. Termination for digestive illness all occurs within 2 months. Yet, around half of the rash case occurs within a month while some continue for over 4 months. It needs our attention.

P1-191
Association between alcohol, smoking, and disease activity of systemic lupus erythematosus (the third report): cross sectional study: from LUNA registry
Mika Hatanou1, Nobuyuki Yajima1, Ken-ehi Sada2, Kunihiro Ichinose1, Ryuysuke Yoshimi3, Shigeru Ohno3
1Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 2Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 3Department of Rheumatology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, 4Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, 5Center for Rheumatic Diseases, Yokohama City University Medical Center

Conflict of interest: None

[Objectives] We aimed to examine whether alcohol and smoking are associated with the disease activity of SLE. [Methods] The research design was cross-sectional study. 618 SLE patients who satisfied ACR criteria were targeted. They were registered in databases currently being constructed at 7 hospitais. Patients divided into 4 groups; group1:smoking (-)alcohol (-), group2:smoking (+)alcohol (-), group3:smoking (-)alcohol (+), group4:smoking (+)alcohol (+). The main outcome was SLEDAI. The linear regression analysis was performed to analyze the association between smoke, alcohol and the disease activity. Confounding factors were sex, age, present corticosteroid dosage and present immuno-suppressant use. [Results] The median age was 44 years old. 89% was female. The median corticosteroids dosage was 5mg. Immuno-suppressant use was 69%. The median SLEDAI was 4. Group1 was 446/618. Group 2 was 57/618. Group 3 was 90/618. Group4 was 25/618. No significant difference was observed between the 4 groups in Kruskal Wallis test and no significant difference was observed in multiple regression analysis. [Conclusions] We did not show the association between smoking, alcohol and disease activity of SLE.

P1-192
Fragmented qrs in patients with systemic lupus erythematosus: relation to the disease activity: a cross-sectional study
Masahiro Hosonuma, Nobuyuki Yajima, Ryo Takahashi, Ryo Yanai, S251
Conflict of interest: None

[Object] Cardiovascular disease is an important contributor to mortality in Systemic Lupus Erythematosus (SLE). Fragmented QRS (fQRS) is a convenient marker of myocardial scar by ECG defined as additional spikes within the QRS complex. There is no report that examined the association of disease activity of SLE and fQRS. [Methods] The study design was a cross-sectional study. The participants were SLE patients who diagnosed at Showa University Hospital from January 2010 to December 2017. The patients with cardiac disease, other rheumatic diseases, and already treatment at the time of an ECG measurement were excluded. The outcome was Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K). A multiple regression analysis was conducted to assess the association between fQRS and SLE activity adjusted for age, sex and period from the estimated date of onset to the date of diagnosis. [Results] In total, 44 participants were enrolled. The mean age was 39.5 years, and 84.1% were female. The median SLEDAI-2K was 13.5 [IQR, 10 to 20]. 24 patients (55%) had fQRS. The regression coefficients of fQRS for SLEDAI-2K were 2.69 (p=0.008) with reference to non-fQRS. [Conclusions] Our results demonstrated that fQRS positive SLE patients have high disease activity.

P1-193
The efficacy of hydroxychloroquine (HCQ) reducing dose of steroid in patients with systemic lupus erythematosus (SLE) for 12 months (Second report)
Kenshi Inoue, Moemi Miyazaki, Naofumi Dobashi, Kenta Misaki
Department of Rheumatology, Kita-Harima Medical Center

Conflict of interest: None

[Object] We had reported in the JCR2018 that dose of steroid was significantly reduced 6 months after administration of HCQ. In this report, we evaluated the efficacy and the safety of HCQ for 12 months as co-treatment in the standard therapy of SLE. [Methods] Thirty-three patients under the maintenance therapy of SLE were enrolled in this study. Dose of prednisolone (PSL), SLE disease activity index (SLEDAI) and titers of antibodies against DNA and anti-cardiolipin antibody were examined retrospectively at 0, 3, 6 and 12 months after administration of HCQ. [Results] Dose of PSL was significantly reduced (mean±S.E) (pre-administration of HCQ:10.0±1.9 mg/day, 12 months after administration of HCQ:5.0±0.7 mg/day, p=0.001). SLEDAI was also significantly reduced. (3.0±0.6, 2.0±0.4, p=0.03). In the subgroup whose dose of PSL was less than 7.5 mg/day at the baseline, dose of PSL was remarkably reduced (3.8±0.6 mg/day, 1.9±0.3 mg/day, p<0.0001). HCQ has been continued in 91 percent of all patients for 12 months and stopped in 3 cases. The infection was clarified in 2 cases. The recurrence of SLE was revealed in only one case. [Conclusions] In the patients receiving the maintenance therapy of SLE, it is suggested that administration of HCQ on standard therapy is able to reduce dose of PSL and might be possible to withdraw PSL.

P1-194
The relevance of P-glycoprotein+CXCR4+CD27-IgD+B cells to clinical manifestation of serositis in systemic lupus erythematosus
Shizuyo Tsujimura, Yoshiya Tanaka
The First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

Conflict of interest: None

[Object] We indicated previously that P-gp+CXCR4+CD27-IgD+B cells were involved in refractory SLE with serositis and were increased in highly active RA patients with extra-articular involvement, whose P-gp+CXCR4+B cells expanded and infiltrated to inflammatory sites. We have investigated the relevance of P-gp+CXCR4+B cells and P-gp+CD27-IgD+B cells to clinical features in SLE. [Methods] Flow cytometry analyzed molecules on CD19+ cells were performed. [Results] The expression level of P-gp on peripheral B cells was high, and that of CXCR4 on peripheral B cells was varied in patients with SLE (n=39). P-gp+CXCR4+B cells ratio has no relevance to SLEDAI in whole SLE patients, NSLE, and lupus nephritis. However, P-gp+CXCR4+B cells ratio strongly correlated with SLEDAI in serositis. P-gp+CXCR4+B cells ratio correlated with P-gp+CD27-IgD+B cell ratio but not P-gp+CD27-IgD+B cells ratio. Immunosuppressive therapy resulted in reduction of P-gp+CD27-IgD+B cells ratio and P-gp+CXCR4+B cells ratio associated with improvement in clinical manifestation in highly active serositis. [Conclusion] P-gp+CD27-IgD+B cells, which is involved in disease activity and treatment resistance in serositis, seem to be co-expressed CXCR4 and infiltrate in inflammatory tissue.

P1-195
Clinical differences between macrophage activation syndrome associated with systemic lupus erythematosus and adult still disease
Daisuke Waki, Keisuke Nishimura, Kaoru Mizukawa, Keiichiro Kadoba, Hiroki Mukoyama, Tomohiro Yoshida, Toshikiko Yokota
Department of Endocrinology and Rheumatology, Kurashiki Central Hospital

Conflict of interest: None

[Object] To investigate clinical differences of macrophage activation syndrome (MAS) associated with systemic lupus erythematosus (SLE-MAS) and adult onstet still disease (ASD-MAS) [Methods] We retrospectively analyzed the secondary SLE-MAS and ASD-MAS, hospitalized at KCH between 2006-2018. [Results] fifteen patients included (SLE-MAS; n = 8, ASD-MAS; n = 7) in this study. The ASD-MAS patients were significantly older than SLE-MAS patients (68.0 vs 34.5, p=0.005). ASD-MAS patients had higher serum Alkaline Phosphatase (ALP) (419 U/L vs 132 U/L, p=0.003), neutrophil count (11424 /μl vs 1135 /μl, p=0.001), platelet count (15.6 x10^12/μl vs 6.9 x10^12/μl, p=0.021), CRP (12.79 mg/dl vs 0.28 mg/dl, p=0.001), and ferritin (18657 ng/ml vs 1522 mg/ml, p=0.037) than SLE-MAS patients. All patients finally achieved remission. Five out of 6 ASD-MAS patients needed other immunosuppressants addition to corticosteroids (CS) and calcineurin inhibitor (CI), conversely only 1 out of 7 SLE-MAS patients needed other immunosuppressants addition to CS and CI. Serum ferritin at 4 weeks after starting treatment was significantly higher in ASD-MAS groups (p=0.02). [Conclusions] Clinical profiles of MAS in ASD and SLE are quite different, and ASD-MAS patients tend to need more aggressive treatment.

P1-196
A study of 125 cases of neuro-psychiatric systemic lupus erythematosus (NPSLE) in our hospital
Tomoko Miyashita, Yoshiyuki Abe, Ken Yamaji, Naoto Tamura
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

Conflict of interest: None

[Object] We conducted retrospective observational study to investigate the baseline clinical features and prognosis of NPSLE at our hospital [Methods] From April 2008 to September 2018, NPSLE was diagnosed at our hospital and 125 patients with NPSLE who had been treated were analyzed retrospectively. Their Clinical features, treatment contents, prognosis etc. were examined. [Results] Central nervous system disorder was found in 105 cases, mental disorder in 71 cases, peripheral neuropathy in 20 cases. As for neurological symptoms, cases with multiple symptoms were also observed. Seven deaths occurred during the observation period of NPSLE, and the cause of death was 2 cases of cerebral infarction, 1 case of renal failure, 1 case of breast cancer, 1 case of suicide, and 2 cases of septic shock. There were 30 cases in which NPSLE was relapsed, and there were cases in which recurrence was observed up to seven times in some cases. [Conclusions] Because NPSLE shows various neurological symptoms by invading the central nerve, spinal cord, peripheral nerve, it is difficult to diagnose and treat NPSLE. To accumulate treatment according to each symptom of NPSLE, further accumulation of cases is necessary.
P1-197
Clinical features of patients with recurrent lupus nephritis
Eiji Suzuki1, Takashi Kanno1, Momoko Hazama1, Tomoyuki Asano1, Kiyoshi Migita1
1Department of Rheumatology, Ohta-Nishinouchi Hospital, 2Ohga Clinic, 3Department of Rheumatology, Fukushima Medical University School of Medicine

Conflict of interest: None

Objective We aimed to determine the clinical features of recurrent lupus nephritis (LN). Methods We divided 40 patients with LN who were treated between April 2005 and March 2018 at Ohta-Nishinouchi Hospital into groups with early (within one year; n = 29) and late (after one year; n = 11) remission and according to LN onset < 6 (initial n = 27) and > 6 (delayed onset: n = 13) months after being diagnosed with systemic lupus erythematosus. Renal histology, therapies to induce LN remission and recurrence after the first induction therapy were compared among the groups. Results Although immunosuppressants were more frequently prescribed, LN tended to recur more frequently among patients with late, than early remission and patients with delayed onset of LN required more time to achieve remission compared with those who had initial onset. The renal relapse-free rate was significantly higher in the group with initial, compared with delayed onset. Conclusion Patients with late remission or delayed onset of LN should be treated aggressively because LN might be difficult to treat.

P1-198
Immunohistochemical staining of lupus nephritis using anti-ribosomal P monoclonal antibody
Ayako Wakamatsu1, Hiroe Sato2, Shunsuke Sakai2, Sayuri Takamura1, Daisuke Kobayashi1, Takeshi Nakatsue1, Yoko Wada1, Takeshi Kuroda2, Masaaki Nakano1, Ichiei Narita1
1Clinical Nephrology and Rheumatology, Niigata University Medical and Dental Hospital, Niigata, Japan, 2Niigata University Health Administration Center, 3School of Health Science Faculty of Medicine, Niigata University

Conflict of interest: None

Objectives: Anti-ribosomal P antibody (Anti-P) is frequently detected in patients with systemic lupus erythematosus (SLE). We have reported that patients with anti-P and anti-dsDNA were associated with endocapillary proliferative glomerular lesions. In this study, we investigated whether the antigens of anti-P are expressed in renal biopsy tissue of lupus nephritis (LN). Methods: Thirty-four patients who were histologically diagnosed with LN in our hospital from 2005 to 2018 were evaluated. Anti-P was analyzed by an immunoblot assay using total ribosomal proteins of brine shrimp. Laboratory, histological findings and immunohistochemical (IHC) staining by anti-P monoclonal antibody were analyzed. Results: Six patients (17.6%) had anti-P anti-P, 25 (73.5%) had anti-dsDNA, 5 (14.7%) had both antibodies. One having anti-P only was ISN/RPS Class V. Five patients having both antibodies were ISN/RPS Class III/IV+V and had active lesions. IHC staining revealed that active lesions of some glomeruli were reacted by anti-P monoclonal antibody in a patient with severe LN, ISN/RPS IV+G (A), having both anti-P and anti-ds DNA (>400IU/ml). Conclusion: The antigens of anti-P were found in the glomerular lesion of LN, suggesting that anti-P might cause the aggravation of LN.

P1-199
Study of clinical significance of hydroxychloroquine in patients with systemic lupus erythematosus
Noriyoshi Ogawa, Shogo Furukawa, Kumiko Shimoyama, Daisuke Suzuki
Division of Immunology and Rheumatology, Hamamatsu University School of Medicine

Conflict of interest: None

[Objectives] To clarify the clinical significance of hydroxychloroquine (HCQ) in Japanese patients with systemic lupus erythematosus (SLE). [Methods] 21 SLE patients were subjected for the study. HCQ was administered in 4 patients (ages 35±19 year-old, 4 female, disease duration 0.1–29 years) as an induction therapy, and in 17 patients (41±12 year-old, male:female=2:15, disease duration 12±9 years) as a maintenance therapy. The effectiveness of HCQ was evaluated by SLEDAI, and adverse events were recorded. [Results] HCQ was administered in 21 out of 54 SLE patients (39%). The dosage was 200mg/day in 14 cases, and 300mg/day in 7 cases. In patients with induction therapy, the SLEDAI score was improved from 11±6 (0M) to 3.0±1.2 (6M), and to 1.3±1.2 (12M), respectively. Similarly, PSL dosage was decreased from 36±7.5mg to 12.8±2.9mg, 10.0±8.7mg. In patients with maintenance therapy, the SLEDAI score was improved from 2.8±3.0 to 1.8±1.8, 2.5±3.3. PSL dosage was decreased from 7.2±3.3mg to 6.9±3.4mg, 6.8±3.6mg. One patient of induction therapy showed mild eruption. [Conclusions] HCQ seems to be a relatively safe drug, and can be used in a maintenance therapy as well as in an induction therapy. Steroid sparing effect of HCQ in the maintenance therapy is valuable.

P1-200
Possible involvement of CD14++CD16+ monocytes expressing CX3CR1 in immunological features of patients with systemic lupus erythematosus
Keiko Yoshimoto, Katsuya Suzuki, Shuntaro Saito, Jun Kikuchi, Tsutomu Takeuchi
Keio University School of Medicine

Conflict of interest: None

[Object] Fractalkine and its receptor, CX3CR1, play an important role in chemotaxis of immune cells. In this study, we investigated the expression level of CX3CR1 in peripheral monocytes from patients with systemic lupus erythematosus (SLE) and HC to elucidate the possible involvement of CX3CR1+ monocytes in immunological features of SLE. [Methods] The expression level of CX3CR1 in peripheral monocytes (CD14+CD16+CD14+CD16+) was analyzed by FACS with whole blood samples from patients with SLE active (SLEDAI: >10, n = 22), inactive (SLEDAI: <4, n = 22) and HC (n = 34). [Results] FACS analysis revealed that the proportion of CD14+CD16+ monocytes among CD14+ cells was significantly elevated in SLE active (p = 0.0017) and SLE inactive (p = 0.0002) patients as compared to HC. Notably, the proportion of CX3CR1 positive cells in CD14+CD16+ monocytes was significantly lower in SLE inactive patients than patients with SLE active (p = 0.014) and HC (p = 0.002), whereas that proportion was not significantly different between SLE inactive and HC. [Conclusions] These results give the possibility that FKN binds its receptor, CX3CR1, expressed on CD14+CD16+ monocytes in SLE, and the cells consequently migrate into the organs through peripheral blood.

P1-201
Analysis of systemic lupus erythematosus maintaing LLDAS using RNA-seq
Yusuke Takeshima1,2, Yukiko Iwasaki2, Masahiro Nakano1, Mineto Ota1,2, Yasuo Nagauchi2, Shuji Sumitomo2, Yuta Kochi1, Tomohisa Okamura1,2, Kazuhiro Yamamoto1, Keishi Fujio1
1Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, 2Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, 3Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN

Conflict of interest: None

[Objectives] Systemic lupus erythematosus (SLE) is a systemic autoimmune disease and the association with Type I interferon (IFN) is well-known, although the detailed mechanism remains unknown. In recent years, it has been reported that maintaining the disease state at LLDAS (Lupus Low Disease Activity Score) reduces relapse. We explored the relationship between cases maintaining LLDAS and IFN signature. [Methods] Peripheral blood mononuclear cells were isolated from 49 SLE patients, and 19 subsets were collected with multicolor flow cytometer following RNA-seq. [Results] IFN signature for each immune cell subset showed broad influence beyond the cell type, and SLE patients were
grouped according to IFN signature. Antinuclear antibody, anti-dsDNA antibody, serum complement level, peripheral blood Plasmodiablast fraction ratio showed correlation with IFN signature, although correlation between IFN signature and LLDAS was not significant. Gene modules detected by network analysis suggested cell-type specific effect to maintenance of LLDAS. [Conclusion] We identified cases where IFN signature remained strongly even when LLDAS was achieved. The importance of elucidating the mechanism of IFN signal in LLDAS cases was suggested because maintenance of LLDAS alone was unable.

P1-202

Synergistic enhancement of production of proinflammatory cytokines on human peripheral blood monocytes by anti-Sm and anti-RNP antibodies

Yu Matsueda, Yoshiyuki Arinuma, Tatsuo Nagai, Sumiaki Tanaka, Shunsei Hirohata, Kunihiro Yamaoka
Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Japan

Conflict of interest: None

[Object] To elucidate the roles of serum anti-Sm antibodies in the pathogenesis of systemic lupus erythematosus. [Methods] Highly purified peripheral blood monocytes obtained from healthy donors were cultured in the presence of monoclonal anti-Sm antibody (anti-Sm mAb), monoclonal anti-U1-RNP antibody (anti-RNP mAb) or control murine IgG1 or IgG3. After various periods of incubation, levels of IL-6 and TNF-a in the culture supernatants were measured by ELISA and the expression of mRNA for various molecules in monocytes was determined using RT-PCR. [Results] Both anti-Sm mAb and anti-RNP mAb significantly increased the production of IL-6 and TNF-a of human monocytes in a dose-dependent manner, although the latter was more potent than the former. Of note, anti-Sm mAb synergetically enhanced the production and mRNA expression of IL-6 and TNF-a of human monocytes in the presence of anti-RNP mAb. Notably, anti-RNP mAb, but not anti-Sm mAb, significantly enhanced the mRNA expression of RelA in human monocytes. [Conclusions] These results demonstrate that anti-Sm and anti-RNP antibodies synergistically upregulate the expression of IL-6 and TNF-a in human monocytes. The data also suggest that the effect of anti-Sm in the synergy with anti-RNP might not involve NFkB activation.

P1-203

Serum soluble CD226 levels in patients with systemic lupus erythematosus

Miki Nakano1, Masahiro Ayan2, Kazuo Kushimoto1, Shotaro Kawano1, Yasutaka Kimoto2, Hiroki Mitoma1, Mitsuteru Akahoshi1, Yojiro Arinobu1, Koichi Akashi1, Takahiko Horiiuchi1, Hiroaki Nin1 1Department of Medicine and Bioimunological Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 2Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan

Conflict of interest: None

[Object] CD226 is a constitutary molecule expressed on T cells and NK cells, and acts as an activating receptor like CD28. Recent studies have shown serum soluble CD226 (sCD226) level is a useful biomarker in patients with cancer or GVHD. We aimed to study the relation between serum sCD226 levels and the clinical characteristics in patients with systemic lupus erythematosus (SLE). [Methods] We measured serum sCD226 levels in 66 SLE patients who were treated at our hospital and 19 healthy controls (HC) by ELISA (quantitation limit, 0.1 ng/ml). We assessed the relation between sCD226 levels and clinical manifestations, SLEDAI, laboratory data, and medications. [Results] Serum sCD226 levels in SLE patients did not differ from HC (median, 0.25 vs 0.50), but the levels in patients with active nephritis were lower than in those without (0.15 vs 0.62, p=0.009). Although sCD226 levels had no correlation with SLEDAI (p=0.01), they significantly correlated with non-renal SLEDAI (p=0.28) and renal SLEDAI (p=0.35), serum creatinine (p=0.25) and urine protein/creatinine ratio (p=0.38). [Conclusions] Serum sCD226 levels are related with nephritis and reflect disease activity, suggesting that sCD226 could be a useful biomarker and CD226 may be involved in the pathogenesis of lupus nephritis.

P1-204

Transcription factor Fli-1 impacts renal IL-17 expression, but not CXCL1 expression in MRL/lpr mouse

Shuzo Sato1, Xin Zhang2, Jumpei Temmoku1, Yuya Fujita1, Naoki Matsuoka1, Makiko Furuya Yashiro1, Tomoyuki Asano1, Hiroko Kobayashi1, Hiroshi Watanabe1, Kiyoshi Migtai1 1Department of Rheumatology, Fukushima Medical University School of Medicine, 2Division of Rheumatology and Immunology, Medical University of South Carolina, Charleston, SC, USA

Conflict of interest: None

[Object] Transcription factor Fli-1 has been reported to affect cytokine and chemokine expression, such as MCP-1, RANTES, CXCL2, G-CSF and IL-6 in the kidney of lupus model mouse. Inflammatory cytokines, IL-17 as well as CXCL1 are associated with lupus nephritis development and tissue inflammation into the kidney. To investigate whether Fli-1 impacts renal IL-17 and CXCL1 expression in lupus model mouse, we performed following experiments. [Methods] Sera of Wild-type (WT) and Fli-1 heterozygote (Fli-1+/-) MRL/lpr mice were collected, and serum IL-17 and CXCL1 concentration were measured by ELISA. Histological examination (IL-17 and CXCL1 expression) on WT and Fli-1+/- MRL/lpr mice were also performed using pathology scoring system. Real-time PCR in the kidney of these mice were analyzed and compared between the 2 groups. [Results] The expression of IL-17 in the kidney interstitium was significantly decreased in Fli-1+/- mice (p=0.012). However, expression of CXCL1 in the kidney was similar in both groups. Whereas IL-1 beta and IL-18 expression, which were associated with Th17 immune response, was significantly decreased in Fli-1+/- MRL/lpr mice compared to WT (p=0.02). [Conclusions] Fli-1 impacts renal IL-17 expression but not CXCL1 in MRL/lpr mice.

P1-205

Suppressor of cytokine signaling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis in an imiquimod-induced lupus model

Masash Fukuoka, Kotaro Suzuki, Shigeru Tanaka, Kazumasa Suzuki, Arifumi Iwata, Shunsoke Furuta, Tomohiro Tamae, Kei Ikeda, Yoko Maewawa, Akira Suto, Hiroshi Nakajima
Chiba University Hospital

Conflict of interest: None

[Background] Lupus nephritis is major organ damage in systemic lupus erythematosus. Previously, we found that suppressor of cytokine signaling 3 (SOCS3) was highly expressed in glomeruli in an imiquimod-induced lupus model and that SOCS3 expression was induced in podocytes upon IL-6 stimulation. However, the role of SOCS3 in lupus nephritis remains unknown. [Purpose] To clarify the roles of SOCS3 expressed in podocytes in glomerulonephritis in the imiquimod-induced lupus model. [Methods] Podocyte-specific SOCS3-deficient mice (Podocin-Cre x SOCS3-flox; SOCS3-cKO mice) and control mice (SOCS3-WT) were used. We examined the expression of SOCS3 in the kidney of these mice by Western blot. [Results] SOCS3-cKO mice exhibited decreased survival rate, high levels of serum creatinine and urine albumin, and severe glomerulonephritis and increased IgM deposition, as compared with SOCS3-WT mice. [Conclusion] SOCS3 expression in podocytes attenuates glomerulonephritis in the imiquimod-induced lupus model.

P1-206

A Study on the Contribution of Monocytes to the Pathogenesis of Systemic Lupus Erythematosus through the Measurements of Serum MCP-1 and Soluble VCAM-1

Masanori Hanaoka, Yasuhiko Katsumata, Hirokazu Nishina, Mari Tochihara, Shinya Hirahara, Akira Nishino, Yasushi Kawaguchi, Hisashi Yamanaka
Department of Rheumatology, Tokyo Women’s Medical University
School of Medicine, Tokyo, Japan

Conflict of interest: None

[Object] MCP-1 (monocyte chemotactic and activating factor) is a molecule involved in monocyte migration and activation. VCAM-1 (vascular cell adhesion molecule-1) is involved in monocyte adhesion. We aimed to investigate the involvement of monocytes in systemic lupus erythematosus (SLE). [Methods] 62 SLE patients who admitted to our hospital from July 2015 to May 2018 were included. 222 patients with rheumatoid arthritis, systemic sclerosis, polymyositis/dermatomyositis and systemic vasculitis who admitted at the same time were used as controls. MCP-1 and soluble VCAM-1 were measured by ELISA and statistically analyzed with clinical data. [Results] MCP-1 and soluble VCAM-1 were significantly higher in SLE patients than controls (788 pg/ml vs. 428 pg/ml in average, p = 0.001 and 1,639 ng/ml vs. 1,088 ng/ml in average, p <0.001, respectively). In the SLE group, MCP-1 and soluble VCAM-1 correlated with SLEDAI-2K, anti-dsDNA antibody titer and inversely correlated with C3 (r = 0.26, 0.43, -0.31, and r = 0.26, 0.25, -0.42, respectively). [Conclusions] Serum MCP-1 and soluble VCAM-1 were higher in SLE patients and correlated with disease activity index. It was suggested that monocytes are involved in the pathology of SLE.

P1-207

A case of systemic lupus erythematosus manifested with primary central nervous system lymphoma (PCNSL) in the course of neuro-psychiatric-SLE

Masafumi Sugiyama1,2, Akinori Okada1, Taekoo Yumoto1, Asuka Inoue1, Yasuki Hirooka1,2, Yoji Nozaki2, Koji Kinoshita3, Masanori Funachi1, Itaru Matsumura2

1Department of Rheumatology, Kindai University Nara Hospital, Nara, Japan, 2Division of Hematology and Rheumatology, Kindai University Faculty of Medicine

Conflict of interest: None

We have experienced a case of systemic lupus erythematosus (SLE) female patient, she have been diagnosed as SLE with antiphospholipid antibody syndrome. At the age of 19 years-old, she complained of hallucination which diagnosed as neuro-psychiatric-SLE, the dosage of glucocorticoid was increased. At the age of 29 years-old, she complained of right hemiplegia with paralysis, accompanied by T2-weighted high signal lesions in the mesencephalon and nucleus basalis, which was interpreted as angioedema caused by NP-SLE, intravenous cyclophosphamide (IVCY) was added. At the age of 34 years-old, her right hemiplegia deteriorated rapidly, the other multiple high signal brain lesions were confirmed. Her level of consciousness got worsened, the brain lesions surgically removed to treat cerebral herniation. Histopathological diagnosis was diffuse-large B-cell lymphoma with the immunostaining results, thought to be other iatrogenic immunodeficiency-associated lymphoproliferative disorders. She was treated with high-dose methotrexate and cytarabine arabinoside (Ara-C) regimen. Although she had a partial short response, she died after 2-months. Primary central nervous system lymphoma with SLE is quite rare, we will report our case and discuss these relationships.

P1-208

Clinical study of fourteen patients with methotrexate-associated lymphoproliferative disorders

Fusayo Ikeda, Tetsu Itami, Kaori Ishimura, Hiroki Akazawa, Chisato Ashida, Atsushi Yamamoto, Kenji Sakai, Shinkai Ri, Asuka Inoue, Toshishiko Shiga, Kazuya Kishimoto, Yuji Nozaki, Koji Kinoshita, Masanori Funachi, Itaru Matsumura

Department of Hematology and Rheumatology, Kindai University Faculty of Medicine, Osaka, Japan

Conflict of interest: None

[Object] Methotrexate-associated lymphoproliferative disorders (MTX-LPD) are defined as LPD that have developed in patients who are receiving MTX. [Methods] Because there are many clinically unclear points, we investigated 14 cases that treated with MTX for RA from 1 April 2013 to 31 March 2018. [Results] 12 women and 2 men, the age at onset was 65.4 ± 7.2 years, and the MTX administration period was 292.7 ± 204.9 weeks. In 2 cases, bDMARDs were used. In 5 cases, steroids were used, and in 3 cases, tacrolimus was used in combination. The histology of lymphoma was the 7 cases DLBCL, followed by FL 3 cases, HL 2 cases, and 2 others. There were 5 cases that resulted in remission with withdrawal of MTX, and recurrence after remission was not observed. There were 7 of 9 cases in remission after treatment, none of which showed recurrence. In RA treatment after onset of MTX-LPD, DMARDS such as SASP and IGU are often selected, in which RA activity is suppressed in prednisolone administered to lymphoma are also seen. There were 2 cases in which bDMARDs were used before the onset of lymphoma, and 3 cases were used after onset. [Conclusions] Although it was difficult to evaluate the relation with RA activity, analysis of the association with RA activity will be necessary in the future.

P1-209

A Crohn’s disease patient during infliximab treatments with the diagnosis of bone primary diffuse large B-cell lymphoma in the spine and iliac

Kenji Ikuta, Yuka Mukofujiwara

Department of Orthopedic Surgery, Kainan Hospital

Conflict of interest: None

[Object] The bone primary malignant lymphoma (BPML) onset in patients with rheumatoid arthritis and connective tissue diseases during treatments of immunosuppressive drugs and/or biologics has been rare. We experienced the Crohn’s disease patient with low back pain and lower leg pain during infliximab treatments and made the diagnosis of BPML. [Case] 28-years old man’s digestive symptom had been stable by infliximab and azathioprine combined treatments in contraction of disease six years of large intestine and small intestine type Crohn’s disease. Low back and lower leg pains had developed for three months and showed initial diagnosis, compression of the fourth lumbar vertebrae body. We performed CT guided bone biopsies and obtained the diagnosis of BPML in the spine and iliac. Hematologist start R-CHOP chemotherapies and his pains had been decreased. He had continued in remission for three years after treatments. [Discussion] BPML onset in inflammatory bowel diseases by disease activities, drug side effects or synergistic actions has been currently discussed. When we present patients with low back pain during treatments with immunosuppressive drugs and/or biologics, it should be necessary to search by multiple imaging studies and follow it up.

P1-210

Study of lymphoproliferative disorder (LPD) in patients with rheumatic diseases at our hospital

Akiyuki Nakashima1, Shigeto Horita1, Takahiro Matsunaga1, Mitsuhiro Kawano2

1Division of Nephrology and Rheumatology, Ishikawa Prefectural Central Hospital, 2Division of Rheumatology, Department of Internal Medicine, Kanazawa University Graduate School of Medicine

Conflict of interest: None

[Object] Immunosuppressants such as methotrexate (MTX) and tacrolimus (Tac) have been used for rheumatic diseases, recently LPD related to its use is reported. In order to clarify the issue, we examined LPD patients at our hospital. [Methods] LPD patients from 2012 to March 2018 were extracted from the electronic medical record and examined. [Results] LPD was found in 9 cases with rheumatoid arthritis (RA) and 1 case with scleroderma. There were 8 females and 2 men. The mean age at onset was 75.4 ± 7.0 years and the mean disease duration was 23.4 ± 21.7 years. The MTX was administered in 9 out of 10, the mean dose was 6.4 ± 6.5 mg / week, and the mean administration period was 8.2 ± 5.9 years. Three cases received biological agents. Tac was administered to 4 cases and 1 case was not administered MTX. Four cases had recovered spontaneously with only MTX discontinuation. Six cases required chemotherapy. Diffuse large cell type B cell lymphoma were 5 cases, B cell lineage 2 cases, and Hodgkin lymphoma 3 cases. Five of 10 EBV-en-
coded small RNAs (EBER) were positive. [Conclusions] The results were almost the same as previously reported. Tac was administered to 4 patients of whom one patient was not administered MTX. Thus, association between LPD and Tac solc was also suspected.

P1-211
A case of methotrexate associated lymphoproliferative disorder which was required to be differentiated from metastatic lung tumor of adrenal tumor
Yosuke Nagasawa1, Masashi Oshima1, Yutaka Tanikawa1, Marina Hamaguchi1, Shoie Yoshizawa1, Hiroshi Tsuzuki1, Kaita Sugiyama1, Atsuma Nishiwaki1, Naotomi Ikumi1, Takamasa Nozaki1, Hidetaka Shiraiwa1,2, Mitsuhiro Iwata1, Hitomi Haraoaki1, Noboru Kitamura1, Masami Taked1
1Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 2Shiraiwa Rheumatology Clinic
Conflict of interest: Yes

A 51-year-old woman was diagnosed with mixed connective tissue disease and with rheumatoid arthritis 20 and seven years ago. She had been on methotrexate (MTX) 10 mg/week, ibrutinib 50 mg/day and prednisolone 6 mg/day. She was admitted to our hospital for further examination of two weeks of dry cough. Computed tomography examination revealed existence of multiple nodules in the bilateral lungs, lymphadenopathy in axilla, hilus and mediastinum, and enlarged right adrenal gland. However, although biopsy of transbronchial tumor and bone marrow were conducted, the diagnosis was remained unknown. Peripheral blood and bone marrow fluid examination indicated elevation of Epstein-Barr virus DNA levels. Left axilla lymph node biopsy disclosed that B-cell type NATX lymphoproliferative disorder (LPD), which reach a diagnosis with MTX-LPD. Her multiple nodules, lymphadenopathy enlarged adrenal gland were improved by withdrawal of MTX. The case of MTX-LPD, which is found among patients having multiple nodules in the bilateral lungs and enlarged adrenal gland, is rarely reported in literature. We report our case with the relevant literature.

P1-212
Multiple lung nodules associated with MTX-LPD in a patient with rheumatoid arthritis
Kenji Tamagawa, Motoko Ishida, Tomoya Miyamuru, Tomoaki Iwanaga, Makiko Higuchi, Soichiro Takahama, Rumi Minami, Masahiro Yamamoto, Eiichi Suemasu
Department of Internal Medicine and Rheumatology, Clinical Research Institute, National Hospital Organization Kyushu Medical Center
Conflict of interest: None

A 66 year old female admitted to our hospital because of multiple nodules of bilateral lung and elevated level of serum CRP. She was diagnosed as rheumatoid arthritis 18 years ago and the treatment with methotrexate (MTX) was started. Her blood test revealed high titer of serum CRP and sIL-2 receptor. The significant accumulation of FDG-PET were observed in both submandibular lymph nodes, both cervical lymph nodes, both supraclavicular lymph nodes, splenic hilum, paraabdominal aortic lymph nodes and both pulmonary nodules. There were no malignant findings in bronchial alveolar lavage cytology and lung biopsy. MTX associated lymphoproliferative disorders (MTX associated EBV-positive lymphadenitis) was diagnosed from the finding of lymph node specimen. JH reconstruction was not detected. Pulmonary nodule and lymphadenopathy showed spontaneous regression after MTX withdrawal. MTX should be stopped when appearance lymphadenopathy or abnormal lung field shadow. There are not so many reports of MTX-LPD with lung lesions, but MTX withdrawal often allows improvement of lung lesions. MTX-LPD should be considered when patient’s blood test showed high level of CRP without arthritis.

P1-213
Investigation of methotrexate associated lymphoproliferative disorder (MTX - LPD) in rheumatoid arthritis patients in our hospital
Chinatsu Azuma, Tomo Oyakawa, Fuminori Kanaya
Department of Orthopedic Surgery, University of the Ryukyus
Conflict of interest: None

[Introduction] Maximum dose of MTX was approved up to 16mg/W since 2010, and MTX became an anchor drug in JCR recommendation in 2014. Recently, RA patients treated with MTX and its dose are increasing. In our hospital, 6 patients were suffered from MTX associated lymphoproliferative disorder (MTX-LPD). The purpose of this study is to investigate background of MTX-LPD patients. [Materials and Methods] We treated 170 RA patients with MTX. 6 patients were suffered from LPD, 1 man and 5 women. Age of RA onset, RA duration, BMI, MTX dose, MTX duration, disease activity (DAS28-ESR) before the onset of MTX-LPD, sIL-2R value and lymph nodes pathology were investigated. [Result] The mean age of RA onset was 43.3 ± 16.9 years, and RA duration was 20.1 years (11–47y). The mean dose of MTX was 252.2mg (343–484mg), MTX duration was 6 years (1–16y). DAS28-ESR before the onset of MTX-LPD was 3.83 (1.77–3.53), sIL-2R value 2550.8 U/ml (730–6752 U/ml). Lymph node biopsy was performed in 4 patients. MTX-LPD was spontaneously regressed after withdrawal of MTX in all patients. [Conclusions] MTX-LPD patients showed slightly higher total MTX dose and DAS28-ESR before the onset of MTX-LPD and slightly lower BMI.

P1-214
Five cases of methotrexate-associated lymphoproliferative disorders in our hospital
Shinsuke Mogi, Tomoko Matsuzaki, Mayuko Tsukida, Fumie Ohta, Yoshito Tsukada
Fujiooka General Hospital
Conflict of interest: None

We examined five cases of methotrexate-associated lymphoproliferative disorders (MTX-LPD) in our hospital since 2016 until 2018. Mean disease duration was 11.6 years, average MTX dose was 6.8mg/week. The pathological diagnosis was diffuse large B cell lymphoma in three cases, classical Hodgkin lymphoma in one case, and Hodgkin-like lymphoproliferative disease in one case. EBER-ISH test was positive in four out of five patients tested. One case gained complete remission with chemotherapy only. Four cases showed recurrence. Four cases achieved spontaneous regression only with cessation of MTX, recurrence was confirmed in one case. Exacerbation of rheumatoid arthritis was observed in one case with cessation of MTX. [Discussion] EB virus-positive MTX-LPD is reported to have high initial remission rate only with cessation of MTX. In our cases, 3 out of 4 cases soon showed partial remission, however 2 out of 3 cases relapsed within 1 year. Therefore, careful follow-up observation is necessary for MTX-LPD. In using MTX for patients with autoimmune diseases, we should consider the possibility of development of lymphoproliferative diseases. In case of MTX-LPD, EBV related protein test is mandatory, and we should continue careful monitoring under cessation of MTX.

P1-215
Clinical characteristics of lymphoproliferative disorders associated with rheumatoid arthritis: A single center study
Ryosuke Hara, Shun Nomura, Wataru Ishii
Division of Rheumatology, Nagano Red Cross Hospital
Conflict of interest: None

[Object] The aim of this study is to clarify clinical characteristics of lymphoproliferative disorders (LPD) associated with rheumatoid arthritis (RA). [Methods] Patients with RA who developed LPD in our hospital between January 2010 to September 2018 were analyzed retrospectively. [Results] Fourteen patients with RA were diagnosed with LPD. Thirteen patients were treated with MTX at the time of LPD development, and 4 of them were combined with anti-TNF-α inhibitors. The average age at the time of LPD development was 71 years. Histological diagnosis of LPD is as follows; Hodgkin’s lymphoma in 3 cases, follicular lymphoma in 3 cases, diffuse large B-cell lymphoma in 2 cases, MALT lymphoma in 2 cases, and other in 3 cases. EBER was positive with 6 patients (46.2%).
The average dose of MTX at the time of LPD development was 6.5 mg per week. LPD regressed spontaneously after discontinuation of MTX in 6 patients and the median duration from the time of MTX withdrawal to LPD regression was 4.9 weeks. LPD recurred in 3 of 6 patients, leading to chemotherapy. There were no fatal cases during the observation period. [Conclusions] LPD often regresses after discontinuation of MTX, but it is necessary to pay sufficient attention to recurrence. LPD in our hospital showed good prognosis.

**P1-216**

**Methotrexate related lymphoproliferative diseases for patients with rheumatoid arthritis**

Kei Funamura, Masataka Maeda
Nagano Red Cross Hospital

Conflict of interest: None

[Object] One side effect of MTX is LPD, and we also experienced seven cases in our hospital. [Methods] Of the patients who received MTX administration to RA, 2 males and 5 females developed MTX-LPD. [Results] The soluble IL-2 receptor is high in all cases, with an average of 1354 U / ml. LDH was high in 5 of 7 cases, with an average of 242. No cases of Sjögren’s syndrome were combined, and 4 cases of EBV positive. Four patients received chemotherapy, and three became conservative treatments. Four patients who underwent chemotherapy had remission, and the remaining three remained unresolved. [Discussion] Of the 7 cases, 4 patients who had remission had undergone chemotherapy and 3 remaining chemotherapy was not enforced. Among the three patients who did not achieve remission, 2 cases were lungs and 1 case were bones. Future diagnosis / treatment will be carried out while consulting with each department. Re-administration of MTX or TNF inhibitor has not been performed after onset. However, control of pain is poor only with steroids against poor control of RA, and BUC and SASP are used for 3 cases. Recurrence is not admitted. [Conclusions] Treatment after remission of LPD needs to avoid immunosuppressive drugs, but pain is seen in some patients, causing RA treatment difficulties.

**P1-217**

**A case of methotrexate-associated lymphoproliferative disorders (MTX-LPD) presented acute interstitial pneumonia (AIP)**

Kazuou Jouyama, Akiya Sogabe, Atsushi Kondo, Yousuke Murata, Naoya Sawada, Akihiro Yamada, Kenichiro Matoba, Makoto Onishi, Yasuaki Okuda, Kiyoshi Takasugi
Center for Rheumatic Diseases, Dolgo Spa Hospital, Ehime, Japan

Conflict of interest: None

AIP developed in an 80-year-old female with rheumatoid arthritis (RA) who has been treated with prednisolone (PSL) (5mg/day) and methotrexate (MTX) (8mg/week). Pneumocystis pneumonia (PCP) was diagnosed and MTX discontinued, treated with Trimethoprim-Sulfamethoxazole (S/T) and methyl PSL (mPSL) (500mg on 1st,125mg/day for next 3 days), PSL 10mg/day subsequently. CT on 7th day showed increasing interstitial shadows. The bolus mPSL (500-1000mg) could be commonly choice, but Steroid was reduced, because MTX-LPD was diagnosed by elevated sIL-2R (3800U/ml) and EB virus reactivation and thought exacerbated by Steroid. PSL was reduced to 7.5mg on 14th and 5mg on 19th day. PCP was denied and S/T was discontinued. The respiratory function and pulmonary shadows were improved. We guess that immunity could be inhibited by Steroid with MTX more, hence LPD and AIP exacerbated. Clinical significance is that extranodal pulmonary disease of MTX-LPD presented AIP is extremely rare and reported. Next we showed that AIP in MTX-LPD was exacerbated by Steroid and ameliorated by discontinuation of MTX, and that the bolus mPSL, standard therapy of AIP complicated with RA, was not effective. Finally elevated sIL-2R and EB virus reactivation were useful clinically enough to diagnose MTX-LPD without histology.

**P1-218**

**A case of primary breast diffuse large B-cell lymphoma associated with rheumatoid arthritis during administration of methotrexate and adalimumab**

Nobuhsa Hirashite, Hideyuki Watanabe, Minoru Takasaki
1Department of Internal Medicine, Kyushu Rosai Hospital, 2Department of Orthopaedic Surgery, Kyushu Rosai Hospital

Conflict of interest: None

A 73-year-old woman was diagnosed with RA in August 2012. She was treated with MTX from April 2014. The dosage of MTX was gradually increased to 12 mg/week in July 2014. She was additionally treated with ADA from June 2015. A tumor in her right breast was detected in May 2018, and she was diagnosed with diffuse large B cell lymphoma (DLBCL) based on a biopsy of the right breast in July 2018. Because we suspected she might have MTX or biologic-associated lymphoproliferative disorder (LPD), we stopped the administration of ADA on July 17, 2018, and that of MTX on July 27, 2018. After the withdrawal of both drugs, her LDH and sIL-2R levels decreased slightly. However, her lymphoma lesion was not ameliorated. She was started on treatment with rituximab on September 20, 2018, but her lymphoma lesion did not respond. She was therefore treated with pirarubicin, cyclophosphamide, vincristine, prednisolone (THP COP) from September 25, 2018. After being treated with rituximab and THP COP for three weeks, her lymphoma lesion showed shrinkage. When we suspected MTX or biologic-associated LPD, we stopped the administration MTX and biologics. There are few case reports of the breast primary malignant lymphoma that MTX or biologics-LPD is suspicious, and accumulation of plural cases is desirable.

**P1-219**

**A case report of methotrexate-associated lymphoproliferative disorder : MTX-LPD was suspected**

Keiji Okamoto
Department of Internal Medicine, Izumiotsu Municipal Hospital

Conflict of interest: None

[Case] A 66-year-old female. She was diagnosed with rheumatoid arthritis at 46. She took MTX 8mg/week from 48. She coincidentally got chronic bronchitis and bronchiectasis at 61. She was pointed out the left axillary lymph node increasing on chest CT at 64. sIL-2R was 2042U/mL. It was not palpable, and we couldn’t biopsy. We stop MTX. It didn’t mostly change or slightly decrease on one month later CT. sIL-2R was increased to 2723U/mL. The size change by no treatment and stopping MTX wasn’t inconsistent with MTX-LPD. She was introduced to hematologist for the treatment plan decision. sIL-2R didn’t decrease inspite of stopping MTX, and so the treatment would start as MTX-LPD by hematologist. It decreased on PET-CT performed for the biopsy lesion decison, and so the treatment plan was observation without biopsy. sIL-2R decreased later. [Clinical Significance] MTX-LPD is the lymphoproliferative disorder for taking MTX. There are patients whose tumor decrease only by stopping MTX. It is needed to treat in accordance with malignant lymphoma, if the tumor doesn’t decrease or it increase again after decreasing. The lymph node decreased only by stopping MTX, and so this case got a follow-up examination. It is needed to observe carefully for a possibility to increase again in future.

**P1-220**

**A case of diffuse large B cell lymphoma (DLBCL) in a patient treated for rheumatoid arthritis (RA) and mixed connective tissue disease (MCTD)**

Junichiro Hagita, Keisuke Kamiya, Kiyomi Koike, Katsushi Koyama
Kariya Toyota General Hospital

Conflict of interest: None

A 35-year-old woman with a 10-year history of rheumatoid arthritis (RA) and mixed connective tissue disease (MCTD) had been treated with infliximab (IFX), tacrolimus (Tac) and prednisolone (PSL). She presented with high-grade fever, cervical and intra-abdominal lymphadenopathy,
and diarrhea. One week later, she was admitted to the hospital because of a sustained fever, high inflammatory reaction, and liver dysfunction. Laboratory findings showed increased liver enzyme and atypical lymphocyte. The soluble interleukin-2 receptor level was 9,940 U/mL. EBV-VCA IgG titer level was high. The symptoms were improved with an increased dose of PSL and discontinuation of IFX and Tac. In contrast, CT revealed that cervical and intra-abdominal lymphadenopathy remained. so, Lymph node biopsy was done, she was diagnosed with diffuse large B cell lymphoma with positive EBV-NR-DNA. Fortunately, disease activity was controlled by increasing dose of PSL, she was transferred to hospitals in order to receive chemotherapy. In this case, the patient with no history of MTX was diagnosed with DLBCL. Several connective tissue diseases and using the long history of immunosuppressive drugs causes reactivation of EBV.

P1-221
Incidence of malignant tumors in the treatment of rheumatoid arthritis using biologics
Masao Sato1, Masao Takemur2, Tomohisa Tani1, Toshiro Ohashi1
1Ohashi-Tani Orthopedics, Gifu, Japan, 2Advanced Diagnostic System Laboratory, Fujita Health University

Conflict of interest: Yes

[Objective] To analyze neoplasm development in rheumatoid arthritis (RA) cases with biologics (BIO) introduced. [Methods] We examined the type of malignant neoplasms for 522 RA patients who can grasp the progress. [Results] The breakdown of cases was 110 males, 412 females, age at introduction of biological products was 11 to 86 years, average 58.2 years, disease duration was 1 to 50 years, average 8.8 years. The incidence of malignant tumors was 40 out of 521 (7.6%). Histopathological diagnosis was performed: malignant lymphoma: 11 cases, breast cancer: 6 cases, colon cancer: 5 cases, prostate cancer, stomach cancer, skin cancer: 3 cases each, lung cancer, renal cancer: 2 cases each, uterine cancer, pancreatic cancer, chondrosarcoma, malignant mesothelioma, choleodochal carcinoma: one each. The period from introduction of BIO to establishment of diagnosis of tumor was 3 months to 136 months, average 35 months. In 18 cases where BIO was discontinued at the time the diagnosis was confirmed, in other cases BIO continued or resumed after interruption. Outcome was 22 patients alive, 18 cases were dead. [Discussion] When a malignant neoplasm is confirmed, sufficient explanation and agreement such as how to treat RA after that are necessary.

P1-222
A case of multiple myeloma in an 80 year-old male patient with rheumatoid arthritis
Yuko Fujiwara1, Hitoshi Tada1, Hisaaki Miyahara1
1Department of Orthopedic Surgery, Haradai Hospital, 2Department of Internal Medicine, Haradai Hospital, 3Department of Orthopedic Surgery, Kyushu International Medical Center

Conflict of interest: None

(Case) An 80-year-old male patient with 10-year history of rheumatoid arthritis had been treated with MTX, SASP and EN. He did not have any complication these days. This patient presented with low back pain and visited a clinic and had an X-ray test, but there was no evidence of fracture. His low back pain did not improve so he visited our hospital. On MRI test L3 had an compression fracture and hospitalization for pain of fracture. His low back pain did not improve so he visited our hospital. We want to report the importance for screening for plasma cells proliferative disorders with old RA patients.

P1-223
Clinical features of connective tissue disease (CTD) patients who evaluated serum protein electrophoresis (SPE)
Takayuki Nakamura1,2, Yosuke Toda1, Yoko Yabe1, Kensuke Suga1, Daisuke Kashiwakuma1, Shin-ichiro Kagami1
1Research Center for Allergy and Clinical Immunology, Asahi General Hospital, 2Internal Medicine, Tohnosho Hospital

Conflict of interest: None

Objectives: The aim of this study to investigate the clinical features of CTD who evaluated SPE. Methods: We retrospectively analyzed 555 patients with CTD who evaluated SPE in our department from May 2012 to April 2017. M-band was detected in 73 patients, and clinical features were compared. Results: Among 73 patients, 45 patients (61.6%) were female. Mean age was 71.2 years, which was significantly older than the patients without M-band (p <0.0001). Compared to patients without M-band, the albumin-globulin ratio (p <0.0001) and hemoglobin (p <0.0001) were significantly lower in patients with M-band. The most common primary disease was Rheumatoid Arthritis (n=33, 45.2%), followed by Sjogren syndrome (n=16, 21.9%), SLE (n=7, 9.6%). Immunoelectrophoreses were performed in 45 of 73 patients; 18 patients had MG. Bone marrow examinations were performed in 15 of 18 patients, of whom 7 patients were diagnosed with monoclonal gammapathy of undetermined significance (MGUS), 6 patients with multiple myeloma (MM) (MM4, smoldering MM2) and 2 patients with malignant lymphoma (ML). Within the follow-up period, 6 of 18 patients died, 3 of them died of hematological diseases (MM2, ML1). Conclusion: Since MG is frequent in CTD and death cases exist, screening test by SPE is important.

P1-224
A sporadic case of ATTR amyloidosis involving multiple organs in non-endemic area
Manaka Goto, Eisuke Takamasa, Masahiro Iida, Nanase Honda, Yoshiki Nagai, Naoto Yokogawa, Kota Shimada, Shoji Sugii
Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center

Conflict of interest: None

Hereditary ATTR amyloidosis is caused by an autosomal-dominant mutation in transthyretin (TTR) gene, among which V30M substitution is the most common in Japan. It affects a variety of organs, including peripheral nerves and the heart. In non-endemic area it tends to develop in elderly people. Here we describe a 78-year-old female without family history who presented with 4-year history of progressively worsening weakness and became bedridden. She also reported impaired eyesight and symptoms associated with autonomic dysfunction. Echocardiography on her recent acute heart failure showed left ventricular hypertrophy and pericardial effusion. She was referred for the assessment of possible systemic amyloidosis. Nerve conduction study revealed axonal peripheral neuropathy. Further examinations were notable for vitreous opacities, proteinuria and albuminocytologic dissociation in the spinal fluid. There were no signs of malignancy or inflammatory disorders which would cause AL amyloidosis or AA amyloidosis, respectively. Abdominal wall adipose tissue biopsy demonstrated ATTR amyloid deposits and genomic DNA sequence of TTR gene revealed V30M mutation. ATTR amyloidosis was finally diagnosed. Involvement of such multiple organs is considered to be rare in non-endemic area.

P1-225
Optimal treatments for RA patients complicated by tuberculosis
Koichiro Takahi, Hiroyuki Nakaya, Kazuhiko Imoto
Orthopaedic Surgery and Rheumatology, NHO Toneyama Hospital

Conflict of interest: None

[Background/objective] According to the package insert of Japan, patients with active tuberculosis (TB) are contraindication for using PSL, MTX and biologic agents, though these medicines were often used for RA patients complicated by TB in the real world. The objective of this study is to clarify the influence of RA drugs on the TB treatment. [Pa-
A Case of Pericostal Tuberculosis in a Patient with Systemic Sclerosis
Yoshiro Fujita1,2, Naoho Takizawa1, Hiroynuki Yoshida2, Tatsuya Arai3, Yoshihiro Nakamura1, Fumiya Kitamura2, Hiroki Iki1, Yukari Murai1, Mari Yamamoto1, Tsuyoshi Watanabe1, Waka Kokuryo1, Koji Takausagi2
1Department of Rheumatology, Chubu Rosai Hospital, 2Department of Nephrology, Chubu Rosai Hospital

Conflict of interest: None

[Introduction] Autoimmune diseases including systemic sclerosis (SSc) are reported to increase risk of developing tuberculosis (Tb). We report a case of pericostal Tb in a patient with SSc without immunosuppressive agents. [Case] An 83-year old woman with a history of breast cancer and thyroid cancer was diagnosed with SSc by skin thickening of the fingers and anti-centromere antibody at age 75. She developed left pericostal mass at age 82, and received needle biopsy that showed negative result of Ziehl-Neelsen stain and malignancy. A year after, we performed needle biopsy again because of the pain flare and T-SPOT positivity. Although Ziehl-Neelsen stain was negative and granuloma was absent, both PCR and culture of Tb from the drain were positive. She was diagnosed with pericostal Tb, and treatment with antituberculous drugs was started. Pain resolved and culture of repeat biopsy returned to be negative. [Conclusion] The increased risk of developing Tb in patients with autoimmune diseases may due to immune abnormality itself or immunosuppressive therapies. It has been reported that the risk of Tb in SSc patients is 2.8-6.1 times higher than those in general population. Physicians should be aware of Tb if SSc patient follows unconventional disease course.

A Case of tuberculous hand arthritis requiring differentiation from rheumatoid arthritis
Masayuki Watanabe, Hideki Takagi
orthopedic Surgery, Nagoya Central Hospital

Conflict of interest: None

We experienced a case of tuberculous hand-arthritis requiring differentiation from rheumatoid arthritis. This case is a 73-year-old man. Patient history is epilepsy and dementia. He noticed right-hand joint swelling so he visited the hospital. He was diagnosed with rheumatoid arthritis and started taking prednisolone. However, the symptoms did not improve, he had started treatment for methotrexate. He consulted our hospital because he had continued symptoms. His right hand joint formed swelling and fistulas. Magnetic resonance imaging confirmed bone erosion and joint fluid accumulation in the right hand joint. RF, MMP-3, ACPA were all negative. Inflammatory reaction was also almost negative. We performed a joint puncture and synovectomy, TB-PCR was positive in synovial fluid. Synovial histopathology was diagnosis of mycobacteriosis. From these results, we diagnosed tuberculous hand-arthritis. This case suggested the importance of TB examination when diagnosing arthritis.

Disseminated cutaneous and subcutaneous deep infection caused by Mycobacterium chelonae in a patient with rheumatoid arthritis
Mihoko Ohshima, Makoto Sugihara, Yuji Miyoshi, Tomohiro Kozuki
Department of Rheumatic Diseases, Tama-Hokubu Medical Center, Tokyo Metropolitan Health and Medical Treatment Corporation, Tokyo, Japan

Conflict of interest: None

An 82-year-old woman with a history of methotrexate associated lymphoproliferative disorder and thyroid cancer surgery received salazosulfapyridine for rheumatoid arthritis (RA) and prednisolone (5mg) for nephrotic syndrome. She developed multiple cutaneous nodules on her left hand and lower limbs, and magnetic resonance imaging revealed deep subcutaneous abscesses near the Achilles tendon. Although several cultures were performed on specimens obtained from the nodules, only 1 new lesion showed M. chelonae on day 19. She was clinically diagnosed with disseminated cutaneous and subcutaneous deep infection caused by M. chelonae. The nodules gradually resolved. Clarithromycin and tobramycin (TOB) were initiated with further resolution of the nodules; however, TOB was changed to moxifloxacin owing to adverse effects. The deep abscesses were drained; three months later, one of them reappeared and new lesions appeared near her right Achilles tendon, tibial tuberosity and left knee, and drainage was repeated. Her anti-interferon-γ antibody test was negative. M. chelonae infection with concomitant RA is rare. Diagnosing and treating nontuberculous mycobacterial infection is difficult. Repeated acid-fast bacterial cultures are needed in patients with skin nodules of unknown origin.

A case of exacerbation of severe leg ulcers concomitant with Mycobacterium avium infection after discontinuation of adalimumab in rheumatoid arthritis
Yohei Isomura, Shinji Watanabe, Yuichiro Shirai, Seiji Kobayashi, Takahisa Gono, Mitsuhiro Takeno, Masataka Kuwana
Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo Japan

Conflict of interest: None

A 67-year-old female with a history of rheumatoid arthritis (RA) for 30 years visited her regular doctor because of high fever and swollen right ankle. She had received methotrexate, bucillamine, and adalimumab (ADA) in remission for RA. She was hospitalized under the diagnosis of bacterial cellulitis; antibiotics were administered, ADA was ceased. However, the skin lesions exacerbated. Thus she was transferred to our facility. Cutaneous histopathological findings at the small nodules on her lower legs revealed lobular panniculitis, consistent with erythema induratum of Bazin; however, no evidence of tuberculosis infection or vasculitis was found. We initiated oral predonsolone (PSL) at 30 mg/day because we speculated that the skin lesions were attributed to RA itself-associated inflammation or excessive immune response against microorganism. Thereafter Mycobacterium avium was isolated from the cultivation. We also initiated anti-mycobacterial agents along with PSL. Her leg ulcers gradually improved, followed by her hospital discharge. This is the first case demonstrating Basin-like skin manifestation as a reaction against Mycobacterium avium. We suspect discontinuation of ADA or immunological abnormality associated with RA may have contributed to the pathophysiology in this case.

A case of exacerbation of severe leg ulcers concomitant with Mycobacterium avium infection after discontinuation of adalimumab in rheumatoid arthritis
Takashi Yamane, Ayaka Inoue, Hiroaki Nakagawa, Midori Kitayama, Takuro Maeda, Noriaki Yo, Chihiro Tanaka
Rheumatic Division, Kogawara Central City Hospital

Conflict of interest: None

[Case] A 46-year-old female rheumatoid patient treated with MTX

Mycobacterium chelonae in a patient with rheumatoid arthritis
Mari Yamamoto1, Tsuyoshi Watanabe1, Waka Kokuryo1, Koji Takausagi2
1Department of Rheumatology, Chubu Rosai Hospital, 2Department of Nephrology, Chubu Rosai Hospital

Conflict of interest: None

A 67-year-old female with a history of rheumatoid arthritis (RA) for 30 years visited her regular doctor because of high fever and swollen right ankle. She had received methotrexate, bucillamine, and adalimumab (ADA) in remission for RA. She was hospitalized under the diagnosis of bacterial cellulitis; antibiotics were administered, ADA was ceased. However, the skin lesions exacerbated. Thus she was transferred to our facility. Cutaneous histopathological findings at the small nodules on her lower legs revealed lobular panniculitis, consistent with erythema induratum of Bazin; however, no evidence of tuberculosis infection or vasculitis was found. We initiated oral predonsolone (PSL) at 30 mg/day because we speculated that the skin lesions were attributed to RA itself-associated inflammation or excessive immune response against microorganism. Thereafter Mycobacterium avium was isolated from the cultivation. We also initiated anti-mycobacterial agents along with PSL. Her leg ulcers gradually improved, followed by her hospital discharge. This is the first case demonstrating Basin-like skin manifestation as a reaction against Mycobacterium avium. We suspect discontinuation of ADA or immunological abnormality associated with RA may have contributed to the pathophysiology in this case.

A case of exacerbation of severe leg ulcers concomitant with Mycobacterium avium infection after discontinuation of adalimumab in rheumatoid arthritis
Takashi Yamane, Ayaka Inoue, Hiroaki Nakagawa, Midori Kitayama, Takuro Maeda, Noriaki Yo, Chihiro Tanaka
Rheumatic Division, Kogawara Central City Hospital

Conflict of interest: None

[Case] A 46-year-old female rheumatoid patient treated with MTX
was admitted with the pulmonary abnormal shadow. Though we suspected of NTM, there were no sputum and couldn’t prove the fungus. In spite of the treatment of csDMARDs, joint destruction progressed. Then we performed the bronchoscopy before administration of bDMARDs and confirmed no fungus. Abatacept, etanercept were ineffective but the pulmonary lesions were improved and started tofacitinib. But it was ineffective for arthritis. Because deterioration of pulmonary lesions was not observed, we switched to baricitinib and achieved low disease activity. 5 months after baricitinib started, CRP elevation and the deterioration of lung lesion were observed. The bronchoscopy was carried out again, we found positive for M. avium in culture. Only by the discontinuation of baricitinib, lung lesion improved and arthritis was controlled with MTX 16 mg + SASP 1g. [Clinical Significance] Elevated risk of developing tuberculosis has been reported for JAK inhibitors as well as bDMARDs. Although there is no report on the frequency of NTM episodes caused by JAK inhibitors, in particular the difference in risk between tofacitinib and baricitinib. In this case NTM was developed after the switch of them and we report with literature review.

P1-231
Current treatment of RA patients suspected of nontuberculous mycobacterium (NTM) -the second report-
Hideki Amuro1, Yonsu Son1, Akira Onishi2, Kengo Akashi1, Motomu Hashimoto1, Takashi Matsuo1, Wataru Yamamoto1, Koji Naga1, Tohru Takeuchi3, Masaki Katayama1, Toru Hirano3, Kosuke Ebina1, Ryota Harai1, Yoshio Nomura1
1First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, 2Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, 3Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, 4Kobe University Graduate School of Medicine, 5Department of Health Information Management, Kurashiki Sweet Hospital, 6Department of Internal Medicine IV, Osaka Medical College, 7Department of Rheumatology, Osaka Red Cross Hospital, 8The Center for Rheumatic Diseases, Nara Medical University

Conflict of interest: None

[Object] To investigate current treatments of RA patients with confirmed/suspected NTM infection who have long term after onset of NTM. [Methods] We extracted NTM culture positive RA patients in ANSWER cohort, and surveyed patient profiles, current RA disease activities, and treatments in case of follow up for 3 years or more. [Results] Thirty-eight RA patients (median age 69; disease duration 113 months) were extracted. Isolated species of NTM were as follows; MAC 34 cases, abscessus 1 case. However, besides our 38 cases, there were 6 cases in which death occurred in malignancy and RA disease activity could not be tracked. [Conclusions] In this study, RA disease activity of most patients were controlled except for several cases. But our report is an analysis for a small number of cases, and accumulation of further cases is necessary.

P1-232
Extrapulmonary infections caused by nontuberculous mycobacteria complicated in patients with rheumatic diseases - report of the three cases
Ritsuko Yokochi1, Ken Nagahata1, Keina Yomono1, Shuhei Hattori1, Kei Shimogori2, Lisa Hirahara1, Shotaar Suzuki1, Seiji Takenouchi1, Noboru Hagino1
1Division of Hematology and Rheumatology, Chiba Medical Center, Japan, 2Division of Rheumatology, Jiban Hospital, Japan

Conflict of interest: None

[Background] These days, nontuberculous mycobacteria (NTM) infections are increasing worldwide. Many NTM infections are chronic lung infections, but they also case extrapulmonary infections such as disseminated infections, indolent lymphadenitis, skin, soft tissues, bones, and joints. [Methods] Retrospective chart review of extrapulmonary infections caused by nontuberculous mycobacteria complicated in patients with rheumatic diseases. [Results] The age of the onset was 66, 68 and 73 years old respectively. Two infestation bacteria were Mycobacterium chelonae, and one case was Mycobacterium intracellulare. The site of infection was bursa, skin, and joints respectively. The underlying rheumatic disease is rheumatoid arthritis, dermatomyositis, and SLE respectively. The immunosuppressants used at the onset of NTM infection were prednisolone (PSL) 6 mg / day, mizoribine 100 mg / day, tacrolimus 0.5 mg / day, tocilizumab 162 mg / 2 weeks combined, PSL 7.5 mg / day only, and PSL 10 mg / day respectively. [Conclusions] We treated three extrapulmonary infections caused by nontuberculous mycobacteria complicated in patients with rheumatic disease. Patients were all more than 65 years old, used 6mg/day and more PSL when they are diagnosed.

P1-233
Three cases of soft tissue NTM infection complicated with rheumatic disease
Takuya Nakazawa, Hidekazu Futami, Yoshihiro Oya, Kazuyuki Ishijima, Keiko Umemiya, Ryutaro Matsumura

Conflict of interest: None

No1. A 77-year-old man with microscopic polyangiitis. He was admitted to our hospital with nodules under skin. He was suspected of the exacerbation of polyangiitis. Steroid semi-pulses were done. Nodules were not improved. An open biopsy revealed M. chelonae infection. Despite of our treatment, subcutaneous nodules are repeatedly deteriorated.

No2. A 72-year-old woman with dermatomyositis. She was hospitalized with left lower thigh cellulitis. Subcutaneous nodules also appeared in the lower limbs. An open biopsy revealed M. abscesses infection. She was treated by Lzd, changed to CAM + IFM / CS. Then, CAM alone therapy was done. Exacerbation of nodule and inflammatory reaction worsen again with a a biopsy. CAM administration alone. AMK had been administered in addition to CAM, nodules were impaired. During the course, the IVIG was performed to improve dermatomyositis, but nodules also improved.

No3. A 74-year-old man with malignant RA. He had artificial joint on his right elbow. Joint edema appeared on the right elbow. M. avium isolated culture. Treatment started by CAM, RFP, EB. It is gradually becoming impaired with this treatment for several months. Currently, no diagnostic treatment for soft tissue infection by NTM has been established. We reported 3 cases of valuable cases this time.

P1-234
Clinical features of collagen vascular disease patients with Cytomegalovirus reactivation during immunosuppressive therapy
Risa Yoshihara, Hirofumi Shoda, Haruka Tsuchiya, Toshihiko Komai, Yumi Tsuchida, Yasuo Nagafuchi, Kanae Kubo, Keishi Fujio

Conflict of interest: None

[Object] To clarify the clinical characteristics of cytomegalovirus (CMV) reactivation in patients with collagen vascular diseases during immunosuppressive therapy. [Methods] We reviewed charts of patients who had reactivation of CMV antigenemia (CMV ag, C10, C11) during immunosuppressive therapy, including PSL ≥0.6 mg/kg/day from October 2017 to September 2018, and investigated the time from initiation of immunosuppressive therapy to CMV reactivation, the count of positive CMV Ag cells and organ involvements. [Results] Twenty seven cases (AAV6, DM5, SLE4, others 12) were included. The mean age was 65 years old. The mean starting dose of steroid was PSL 1.01 mg/kg/day, and 14 patients had mPSL pulses, 17 had immunosuppressive agents and 8 had biologics. The mean time from starting immunosuppressive therapy
to CMV reactivation was 31.6 days. All the 6 cases whose total number of 2 slides of CMV Ag positive cells exceeds 10 experienced severe bacterial (fungal) infection and 3 of them died. In 21 cases with less than 10 positive cells, severe bacterial (fungal) infection were caused in 2 cases, and one of them was dead. [Conclusions] The total number of 2 slides of CMV Ag positive cells exceeds 10 was a risk of severe infection and poor prognosis.

P1-235
The experiences of clinic for human T-cell leukemia virus type 1 (HTLV-1)-positive patients with rheumatic diseases
Kunihiko Umekita, Shunichi Miyauchi, Yumi Kariya, Ayako Aizawa, Takeshi Kawaguchi, Motohiro Matsuda, Ichiro Takajo, Akihiko Okayama
Department of Rheumatology, Infectious Diseases and Laboratory Medicine, University of Miyazaki

Conflict of interest: None

[Object] To investigate the significance of clinic for human T-cell leukemia virus type 1 (HTLV-1)-positive patients with rheumatoid arthritis (RA). [Methods] Six patients had visited the specialty outpatient department for HTLV-1-positive patients with rheumatic diseases (RDs) from April 2017 to September 2018. We reviewed clinical information, the first opportunity for HTLV-1 testing and reasons for visiting our department. [Result] Four of six patients were female. Median age was 69 years old. Five and one patients live in South-part of Kyushu and Shikoku region, respectively. Three, two and one patients had RA, RA with Sjoegren syndrome and polymyositis, respectively. The first opportunity of HTLV-1 testing was as follows: screening test for HTLV-1 infection during pregnancy, at the onset of RDs, at the onset of HAM before developing RDs, and at the onset of ATL in their family. The most common concern of patient was whether immunosuppressive treatment affects HTLV-1 infection and development of HTLV-1-associated disorders such as ATL. Some patients could not obtain advices until their visits and they felt better only by talk in our clinic. [Conclusion] The clinical guideline or recommendation is necessary to reduce the anxieties of HTLV-1-positive patients with RDs.

P1-236
Risk Stratification of Hepatitis B virus Reactivation in Patients with Rheumatoid Arthritis during Methotrexate Monotherapy
Wataru Fukuda1, Tadamasa Hanuy2, Masaki Katayama2, Akitomo Okada3, Shinichi Mizuki4, Masatoshi Hayashi3, Masayuki Miyata3, Yuichi Handa4, Yoshinobu Koyama5, Hiroyuki Hagiyama6, Kaoru Arii7, Toshiyuki Kitaori2, Yoshinori Urushitani2, Daigo Taniguchi8, Yoshikiko Ikemo9, Takeshi Suzuki10, Masatoshi Kadoya11, Atsushi Omoto12, Shigeko Inokuma17
1Center for Rheumatic Disease, Japanese Red Cross Kyoto Daiichi Hospital, 2Department of Rheumatology, Nagoaka Red Cross Hospital, 3Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, 4Department of Rheumatology, Matsuyama Red Cross Hospital, 5Department of Rheumatology, Osaka Red Cross Hospital, 6Department of Orthopedics, Nagano Red Cross Hospital, 7Department of Internal Medicine, Fukushima Red Cross Hospital, 8Department of Rheumatology, Saitama Red Cross Hospital, 9Department of Rheumatology, Okayama Red Cross Hospital, 10Department of Rheumatology, Yokohama-City Bay Red Cross Hospital, 11Department of Internal Medicine, Japanese Red Cross Kochi Hospital, 12Department of Orthopedics, Fukushima Red Cross Hospital, 13Department of Rheumatology, Matsue Red Cross Hospital, 14Department of Rehabilitation, Japanese Red Cross Kyoto Daini Hospital, 15Department of Rheumatology, Nusui Red Cross Hospital, 16Department of Allergy and Rheumatic Diseases, Japanese Red Cross Medical Center, 17Department of Allergy and Rheumatology, Chiba Central Medical Center

Conflict of interest: None

[Object] Reactivation of hepatitis B virus (HBV) in patients with RA receiving immunosuppressant is a serious complication, and the risk stratification may reduce patients’ burden on monitoring and prophylactic treatment. We examined risk stratification that can be clinically applicable. [Methods] RA subjects receiving methotrexate monotherapy and who were negative for HBs antigen and HBs or HBe antibody positive, were included. [Results] In 553 cases, HBV reactivation was seen in 18 cases (3.25%) for 3.55 years observation. We performed ROC analysis and set the age cutoff value at 65 year. When we calculate the score in which HBe antibody alone positivity was 1 point and the age over 65 years was 1 point, HBV reactivation at the score 0 point was 2/200 (1.0%), and the odds ratio was 3.96 (95% CI: 1.04-25.8) at one point and 7.98 (95% CI: 1.68-56.7) at two points. [Conclusions] In patient whose score with HBe antibody alone positive and old age (> 65 years old) was 0, the reactivation rate in 3.55 years was 1.0%, which was significantly lower than in patient with one or more score points. Considering that the course after reactivation is not rapidly progressive, the monitoring interval for HBV can be extended to 6 to 12 months.

P1-237
The value of CMV-IgM antibody for diagnosis of Cytomegalovirus (CMV) reactivation under immunosuppression
Ayaka Inoue, Hiroaki Nakagawa, Midori Kitayama, Takuro Maeda, Noriaki Yo, Chihiro Tanaka, Takashi Yamane
Department of Rheumatology, Kogakowa Central City Hospital

Conflict of interest: None

[Object] Early diagnosis is important because reactivation of CMV under immunosuppression by treatment of autoimmune diseases may follow fatal outcome, so we are screening with CMV pp65 antigen (C7-HRP) and CMV-IgM antibody. We have examined the value of CMV-IgM antibody for diagnosis of CMV reactivation under immunosuppression. [Methods] We examined retrospectively 56 patients that measured CMV-IgM antibody suspected of CMV reactivation between April 2017 and September 2018 in our department. We diagnosed as CMV reactivation clinically. We defined that CMV-IgM antibody titer was positive with 1.21 or higher. [Results] CMV reactivation occurred in 9 of 56 patients. CMV-IgM negative group were 43, positive group were 13. There was no difference in age, serum IgG / IgM and lymphocytes on both groups. The PSL dose tended to be higher in the positive group (15.2 mg/day) than in the negative group (8.2 mg/day) but there were no significant differences statistically. The sensitivity of CMV-IgM antibody in CMV reactivation was 55.6%, the specificity was 84.0%. And C7-HRP was 55.6%/97.9%. [Conclusions] Even under immunosuppression, the sensitivity of CMV-IgM antibody titer was equivalent to that of C7-HRP and it seemed to be useful as a screening test for reactivation of CMV.

P1-238
SLE complicated by Varicella Zoster virus myelitis from which NP-SLE should be differentiated: A case report
Kohei Nagaya1, Akimasa Asai2, Hironobu Nobata2, Shogo Banno2, Yasuhiko Ito3
1Department of Nephrology, Kizawa Memorial Hospital, 2Department of Nephrology, Rheumatology and Collagen Diseases, Aichi Medical University

Conflict of interest: None

[Case] 71-year-old man [chief complaint] constipation, fever [Present illness] A 71-year-old male referred to our department with nephrotic syndrome 3 years ago. He was diagnosed with lupus nephritis. He had been treated with PSL and MMF. Then he referred to dermatology department of our hospital with Herpes zoster 3 weeks ago. On the day of his admission, he was found in toilet and he wasn’t able to stand up. He was transported to our hospital and entered for observation. A few days later, he complained right leg paralysis and urinary retention. Because head MRI and nerve conduction velocity were almost normal, disorder of spinal cord was suspected. But lumbar cord MRI was normal. Cerebrospinal fluid test showed high level of cell count and total protein. We made additional checking of cervical and thoracic spinal cord MRI which showed high intensity area in T2 emphasized image. He was treated with aciclovir, steroid pulse therapy and plasma exchange. Then herpes zoster virus DNA was detected in cerebrospinal fluid. Cell count of fluid was decreasing and bladderrectal disorder was improved although right leg paralysis wasn’t. [Consideration] Though Herpes zoster is a major complication of SLE, myelitis is rare. Prompt discontinuation of MMF and antiviral
drugs were important.

### P1-239

**A case of rheumatoid arthritis (RA) patients with schizophrenia following rheumatic care nurse outpatient clinic**

Akihiko Hamada, Mitsuko Takiguchi, Mika Ishibashi, Megumi Inoue, Erina Shimaoka, Yuki Ueno, Minako Wakama, Katsushiro Oda, Hideyuki Shiba, Koji Nagai, Masakazu Sugino

1Department of Nurse, Koshokai Aino Hospital, Osaka, Japan
2Department of Internal Medicine, Koshokai Aino Hospital, Ibaraki, Osaka, Japan
3Department of Internal Medicine IV, Osaka Medical College, Takatsuki, Osaka, Japan

Conflict of interest: None

*<Introduction>* In our hospital, we established an outpatient by rheumatic care nurse, and in addition to teaching self injection and medication guidance, we conduct examination and joint echo examination by ‘Registered Sonographer’ of Rheumatology Association of Japan.

*<Case>* 40-year old female. On July 2014, she recognized the joint pains of both hands, both knees and the left elbow. She was diagnosed with RA. Although remission was achieved with MTX, ABT and IGU combination, she self-discontinued internal medicine and since December 2016, the disease activity of RA and has worsened. Psychiatric symptoms also appeared. In May 2016, the disease condition was defined as CRP ≧ 20 mm. We then conducted a questionnaire on the role of nurse as a coordinator, and summarized and verified it. Results: Good point of concern is “registered as a positive.” Everyone answered “nurse coordination was good” and reassured her visits. Gradually, her motivation for treatment was improved. Outpatient and joint echo by RA-expert nurses was useful. Gradually, her motivation for treatment was improved.

*<Conclusion>* The usefulness of rheumatism classes for patients involving many occupations are considered important. First, we promised his father to think about the importance of drug management and future our goals. And she was gradually in a state of mental stability. For arthritis, echo examination was performed every her visit. Gradually, her motivation for treatment was improved. Outpatient and joint echo by RA-expert nurses was useful. And team treatment is necessary for RA patients.

### P1-240

**The association of Pain Catastrophizing with residual pain in patients with rheumatoid arthritis with non-inflammatory status**

Tamami Yoshida, Motomu Hashimoto, Masao Tanaka, Hiromu Ito, Koichi Murata, Kohei Nishitani, Kosaku Murakami, Tsuyono Mimori

1Department of Internaltural University of Medicine School of Nursing, Kyoto, Japan
2Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan
3Department of Orthopedic Surgery, Graduate School of Medicine, Kyoto University, Kyoto, Japan
4Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan

Conflict of interest: None

*<Object>* Pain catastrophizing is defined as an important component contributing to a distortion in pain perception. In this study, we examined the association between residual pain and pain catastrophizing in RA patients with non-inflammatory status. *<Methods>* The non-inflammatory condition was defined as CRP ≦ 0.3mg/dL, “PCS+” was defined as 33 points or more in the Pain Catastrophizing Scale. 150 RA patients visiting Kyoto University Hospital were examined. Multivariate analysis was performed to assess pain VAS ≧20 mm as dependent variable, with age, sex, RA related variables, and PCS+ as independent variables. Furthermore, similar analysis was performed in the patient group (123 patients) with CRP ≦ 0.3 mg/dL. *<Results>* Average Age: 66±11 years, DAS28-ESR:2.52±0.98, and CRP: 0.3±0.55 mg/dL, median pain VAS: 10.5 (range1-82), 20 patients (13.3%) were PCS+. On multivariate analysis in all patients, HAQ (Odds ratio 5.6, p=0.01), stage (OR 4.8, p=0.03), CRP (OR 2.9, p=0.01) were positively associated with pain VAS ≥20 mm. In patients with CRP ≦ 0.3 mg/dL, HAQ (OR 6.1, p<0.01), PCS+ (OR 3.9, p=0.04) were positively associated with pain VAS ≥20 mm. *<Conclusions>* Pain catastrophizing is an important target to be treated in RA patient with residual pain even in non-inflammatory status.

### P1-241

**Usefulness of foot arthroalgia of patients with rheumatoid arthritis in RA-nurse outpatient practice**

Mika Ishibashi, Erina Shimaoka, Akihiko Hamada, Megumi Inoue, Mitsuko Takiguchi, Yuki Ueno, Minako Wakama, Katsushiro Oda, Hideyuki Shiba, Koji Nagai, Masakazu Sugino

1Department of Nurse, Koshokai Aino Hospital, Osaka, Japan
2Department of Internal Medicine, Koshokai Aino Hospital, Osaka, Japan
3Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan

Conflict of interest: None

*<Object>* To examine that we can select the RA patients who need actual evaluation of foot lesions with ultrasound, we compared patient’s joint pains of foot and ankle with ultrasound findings. *<Methods>* In this study 41 RA patients who are treated in our hospital and Osaka Medical College were included. After dividing the foot part into forehead, the middle foot and the back foot, we compared and examined the patient’s complaints of foot and ankle pains with ultrasound findings. *<Results>* The overall coincidence rate was 46.3%. Sensitivity, specificity, positive predictive value and negative predictive value for pain complaints and positive ultrasonography findings were 93.8%, 48.0%, 53.6%, 92.3% respectively. *<Conclusions>* There is some possibility of making more efficient daily practice, we may mainly perform ultrasound for RA patients with complaints of joint pain.

### P1-242

**The usefulness of rheumatism classes for patients involving many jobs coordinated by nurses**

Narumi Sato, Hitohu Nomura, Takao Katsuragawa, Takumi Matsumoto, Hiromi Tamura

1Nursing Department, Sapporo City Hokkaido Japan Kinikyo Central Hospital
2Internal Medicine and Rheumatology, Sapporo City Hokkaido Japan Kinikyo Central Hospital

Conflict of interest: None

*<Object>* Our hospital has been conducting rheumatism classes for early stage patients since 2003. In the “Survey of consciousness to treatment of patients using biologics” in 2014, there was a request to want to know about the latest information of treatment, side effect, ingenuity to facilitate housework, T2T and others. Thinking so far was inadequate, led by a nurse, we held new rheumatism classroom for patients with long term of disease with multiple occupations. We conduct and verify “Rheumatic Care Team Staff Questionnaire”, so we report usefulness of this coordination. *<Methods>* The target was 15 staffs consisting of 7 occupations. We conducted a questionnaire on the role of nurse as a coordinator, and summarized and verified it. Results: Good point of convening this classroom with the idea of a nurse was “we could tell the information one wishes to know” and “we could confirm of patient’s response”. Everyone answered “nurse coordination was good” and reasons are “the nearest to the patient”, “understanding the needs of the patient”, “able to bridge doctors and other occupations”. 70% said the team leader should be nurse. Conclusion: In the education to RA patients by multiple occupations, it was effective to coordinate by nurse who understood patient’s needs.

### P1-243

**The issues on the questionnaire to nurses about our monthly rheumatic care professional education workshops**

Yoshiko Takamura

Jujo Takeda Rehabilitation Hospital, Kyoto Japan

Conflict of interest: None

*<Purpose>* Current RA treatment requires complicated and sophisticated care. Our “center for rheumatic diseases” was established in 2013. Currently we have >400 RA patients (>150 are using biologics). Starting...
in 2014, the center held monthly “RA care professional workshop” for staff to study subjects for disease and treatment. We studied to see whether nurses were comprehending knowledge and showing interest in RA nursing by participating in workshops. [Method] Descriptive survey on RA nursing was conducted with 75 nurses in outpatient clinic and hospitalization unit. [Results] Questionnaire were collected from 63 nurses. 36% had attended workshops. 5% were to earn credits for RA care nursing. Understanding of underlying diseases was sound. Self-injection guidance, foot care and other aspects of RA care were of interest. However, 20% misunderstood that patients should skip MTX when they are in sickness. [Conclusion] 45% participated in workshops with sense of purpose. Through workshops, seemingly their understanding of RA nursing was deepened. We recommend participation so that nurses can provide safe and secure care for patients. Also, certified RA care nurses would be able to play a key role in patients’ education and could function with expertise with both in and outpatients.

P1-244
“Necessity of regional collaboration to come up in rheumatism and collagen disease specialized clinic” 2nd report
Yamiko Arai, Tomoko Takehisa, Ryo Sato, Takanori Azuma
Azuma Rheumatology Clinic

Conflict of interest: None

[Object] Our clinic is specialized in RA, we often ask other medical institutions for consultation, the necessity of collaboration was examined. [Methods] From 2017 / Sep to 2018 / Aug, RA patients requested consultation to other institutions were extracted and examined what kind of clinical department is referring to. [Results] There were 1154 RA patients, and the number of introduced patients was 301 (26%), the number of introductions was 335.30 kinds of field requested consultation, the top ten are: dermatology: 36, pulmonology: 35, orthopedic surgery: 33, otolaryngology: 20, dental oral surgery: 19, gastroenterology: 18, urology: 16, ophthalmology: 16, radiology: 15. [Conclusions] The reasons for consulting RA patients to other departments are mostly complications caused by RA itself or induced from RA treatment. Thus, it is difficult to support RA patients comprehensively only with RA clinic alone. Since other collagen diseases are also mixed in RA clinic, the cooperation with other departments is indispensable in the discrimination and treatment.

P1-245
Possible active roles with medical and administrative clerks to improve the quality of rheumatic practice
Keiko Kuroki, Mina Kojima, Tatsunari Fuwai, Yuka Yamashita, Koichiro Ohmura, Yukiko Komano, Itoku Masuda
Center for Rheumatic Diseases, Jujo Takeda Rehabilitation Hospital, Japan, Department of Rheumatology and Clinical Immunology, Kyoto University

Conflict of interest: None

[Background] As drug therapy for rheumatic diseases is making great strides, improvement of the quality of team medicine approach is required. We established the center for rheumatic diseases since 2013, and medical and administrative clerks have been actively involved with patient-friendly medical care and total team care. [Object] To grasp to what extent efforts to improve patient satisfaction are recognized and evaluated by outpatient with rheumatic diseases. [Methods] Patient satisfaction was measured by a survey for patients who had visited the center. The questionnaires were distributed to 100 patients who visited the center. The average score of the “Waku waku” binder was 8.5/10. The recognition rate of newsletter, opinion box, educational hospitalization was 3%, 5%, 6% respectively. There were various requests, including cutting of waiting time and implementation of outpatient rehabilitation. [Conclusions] Although the patients’ evaluation of the “Waku waku” binder was high, it was thought that introduction of utilization method was necessary. We have noticed that there are many problems to be addressed to improve the quality of care. Total team care approach would be essential to improve the rheumatic practice.

P1-246
Investigation of nursing intervention at the time of execution of leukapheresis therapy (LCAP) in rheumatoid arthritis patients
Miyouki Takemoto, Masamitsu Natsumeda
1Department of Nursery, Rheumatic Disease Center, Mabi Memorial Hospital, Kurashiki, Japan, 2Department of Internal Medicine, Rheumatic Disease Center, Mabi Memorial Hospital, Kurashiki, Japan

Conflict of interest: None

[Objectives] Leukapheresis Remedy Therapy (LCAP) is one of treatment options for such patients, but patients are concerned about pain and effectiveness associated with puncture. As a rheumatic care nurse involved in LCAP, we examined the significance of nursing intervention based on patient questionnaire as Patient Reported Outcome (PRO). [Method] A questionnaire survey was conducted on eleven subjects who underwent LCAP from August 2017 to August 2018, at the time between LCAP enforcement decision and 3 months later. [Result] Patients were with high disease activity, average DAS 28 CRP 6.2, and most of were resistant to multiple BIO and JAK inhibitors. When LCAP therapy was decided, all patients had some anxiety; but expectation for symptom improvement was also high. Regarding the attendance of nurses, 92% of patients felt a sense of security regardless of the effect of LCAP. [Conclusions] All patients has underwent LCAP safely and smoothly and accomplish with one course treatment regardless of patient background including disease activity and LCAP effectiveness. LCAP treatment requires not only precise techniques and knowledge but also nursing intervention to alleviate patient anxiety.

P1-247
A study on teaching intervention of clinical pharmacology on rheumatoid arthritis for nurses
Akiko Matsuda, Takashi Fujimoto, Ryota Harada, Takanori Fujimura, Hiroshi Aoi, Satoko Nishii, Hiroshi Hagino, Yasuhiro Tanaka
1School of Medicine, Faculty of Nursing, Nara Medical University, 2The Center for Rheumatic Diseases, Nara Medical University, 3Department of Internal Medicine, Takanoara Center Hospital, 4Department of Pharmacy, Nara Medical University Hospital, 5Department of Nursing, Nara Medical University Hospital, 6Faculty of Medicine School of Health Sciences, Tortori University, 7Department of Orthopedics, Nara Medical University

Conflict of interest: None

[Object] Biologics have led to successful therapy of RA, while adverse events have increased. Nurses are required risk-management skills based on clinical pharmacology. We investigated the effect of teaching intervention for nurses about comprehensions of clinical pharmacology on RA. We compared the effect between two groups of nurses experienced in RA therapy (group E) and those who have not (group NE). [Methods] Fifty-two nurses (39 in group E, 13 in NE) were involved. An educational program included 4 items of #1 pathophysiology, #2 therapeutic drugs, #3 risk-management and #4 use of package inserts. The program was made of 2-hours lecture. The comprehension of nurses was assessed by completing questions for each item (23 questions in total, 3 for #1, 8 for #2, 8 for #3, 4 for #4). [Results] There were no differences between two groups on the base line in the assessments. After the lecture, the assessments in E group were better (16 correct answers of 23 questions in all items were increased, 1/3, 5/8, 6/8, 4/4 in each item) than before. The assessments in NE group were better only in 2 items (2 correct answers were increased) than before. [Conclusions] We need to educate nurses more about clinical pharmacology to provide a comprehensive care for RA.

P1-248
Actual condition survey of the living guidance to a patient of the biological preparation treatment by our hospital nurse
Aya Oshimura, Shiori Tsutbuchi, Takako Takata, Takeko Koyama, Yuka Horii, Ken Takebe, Koji Tateishi, Yasuhiro Terashima
1Nursing Unit, Kohnan Kagokawa Hospital, 2Orthopedic Surgery, Kohnan Kagokawa Hospital
P1-249
How can the rheumatic clinic prevent patients with deep remission interrupting treatment? Consideration from consciousness survey on RA patients in remission 2nd report
Takaki Ura, Ryoko Okada, Yuka Seida, Yumiko Arai, Takanori Azuma
Azuma Rheumatology Clinic
Conflict of interest: None
Object In 2017, we reported that “The remission lasts more than 1 year, it can cause discontinuation of hospitalization.” We investigate the consciousness of remission cases and examine the background. Method Among 645 patients had remission in August 2017 - January 2018, maintained remission for over half a year, a questionnaire was conducted for 173 patients. The contents are A) change in ADL B) satisfaction of treatment C) intention to continue treatment D) internal condition E) intention to take medicine, Results) A) “ADL improved” 135 (80.4%) B) “Satisfied” 133 (79.2%) “dissatisfied” none C) Continue treatment “want to” 140 (83.3%) “don’t want to” 2 (1.2%) “wondering” 26 (15.5%) D) 131 (78%) “taking” medicine “2 not taking” (1.2%) E) “want to quit medicine” 20 (11.9%) “don’t want to quit” 61 (36.3%). Conclusion Even though patients satisfied with the treatment and wished to continue treatment are more than 80%, 11.9% who wanted to quit. We compared patients who wanted to “stop taking medication” and “who don’t want to”. Although there was no statistically significant difference, the tendency to stop taking medicines was recognized in patients who are using or used the b DMARDs in the past, and in patients with economic burden between the ages of 40 and 60 years.

P1-250
The association with disease activity and function and sites of hand washing residual parts in patients with rheumatoid arthritis
Yukari Suzuki1, Shuzo Yoshida2, Yuko Kimura2, Akitoshi Machida1, Nobuhisa Shibahara4
1Division of Nursing, Arisawa General Hospital, Hirakata, Osaka, Japan, 2Department of Immuno-Rheumatology Center, Arisawa General Hospital, Hirakata, Osaka, Japan, 3Department of Orthopedic Surgery, Arisawa General Hospital, Hirakata, Osaka, Japan, 4Department of Urology, Arisawa General Hospital, Hirakata, Osaka, Japan
Conflict of interest: None
[Object] We investigated the influence of disease activity and function of rheumatoid arthritis (RA) patients on hand washing residual parts. [Methods] We used hand washing checker lotion. After hand washing, we checked the site of washing residual parts using hand washing checker (Saraya Co., Ltd.). [Results] Thirty patients participated in this study. Twenty-one patients were women. The mean age was 70.6±12.3 years, mean disease duration was 9.9±10.0 years. DAS28-CRP was 2.24±0.72, HAQ was 0.71±0.90, Stage I/II was 23, and Class 1/2 was 26. The most washing residual area was interdigital space. The patients who had resid-ual parts in interdigital space were associated with higher HAQ (1.2±0.94 vs 0.9±0.2, p=0.0002) and older age (75.4±9.8 vs 62.6±11.9 years, p=0.006). There was no difference in DAS28-CRP. [Conclusions] The patients who had higher HAQ and older age had washing residual parts in interdigital space.

P1-251
The effects of surgical intervention on patient-reported outcomes in rheumatoid arthritis patients with clinical remission
Yasuko Kobashiki1, Keiehiro Nishida2, Masahiro Horita2, Yoshina Nasi3, Kenta Saiga2, Ryuchi Nakahara2, Hideki Ohashi2, Toshifumi Ozaki1
1Department of Nursing, Okayama University Hospital, 2Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 3Department of Orthopaedic Surgery, Sayo Central Hospital, 4Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 5Department of Musculoskeletal Traumatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Conflict of interest: None
[Objectives] We investigated the effects surgical treatments on patient-reported outcomes (PROs) in rheumatoid arthritis (RA) patients with clinical remission. [Patients and Methods] 132 RA patients who underwent the surgical intervention of the upper and lower limbs were divided into two groups; patients with clinical remission (R group; DAS28-CRP<2.3) and non-R group (DAS28-CRP≥2.3). Body image, depression, and function were evaluated by body image assessment tool (BIAT), Beck Depression Inventory-II (BDI-II), and HAQ-DI, respectively, at before surgery, 6 months and one year after the surgery. [Results] In R group, “Body-Depersonalization” and “Low Body-control” in BIAT, and BDI-II were significantly better than those of non-R group at one year. HAQ-DI was significantly better in R-group than in non-R group at baseline, 6 months, and one year after surgery. One year after the surgery, BIAT, BDI-II, HAQ-DI significantly improved in R group. In non-R group, “Body-esteem” in BIAT was significantly improved. However, the improvement of HAQ-DI achieved at 6 months could not be maintained at one year after the surgery. [Conclusion] Pre-operative disease control influenced the improvement of PROs such as body image, depression, as well as patients’ function after the surgery.

P2-001
Effects of SPACIA1/Saal1-deficiency on mice collagen-induced arthritis in severe or mild disease condition
Rie Komatsu1, Iwao Seki2, Tomo Sato1, Hiroyuki Aomo2, Kazuo Yudoh1, Hisateru Niki3, Kusuki Nishio4, Yoshihiro Nakajima5,6, Ryoji Fuji1
1Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan, 2AYUMI Pharmaceutical Corporation, Kyoto, Japan, 3Department of Orthopaedic Surgery, St. Marianna University School of Medicine, Kanagawa, Japan, 4Global Health Innovation Policy Program, National Graduate Institute for Policy Studies, Tokyo, Japan, 5Institute of Medical Science, Tokyo Medical University, Tokyo, Japan, 6Misato Marine Hospital, Kohchi, Japan
Conflict of interest: None
[Object] SPACIA1/Saal1 is a gene associated with the aberrant proliferation of RA synovial fibroblasts. We previously reported that collagen-induced arthritis (CIA) in SPACIA1/Saal1 transgenic mice exhibited early onset and rapid progression compared with wild-type mice; however, the mechanism of this effect remains unclear. In this study, we examined the effects of endogenous SPACIA1/Saal1 on CIA using two different production lots of bovine type II collagen which causes severe or mild arthritis. [Methods] We generated SPACIA1/Saal1-deficient mice. To assess the involvement of SPACIA1/Saal1, CIA was performed with two kinds of bovine type II collagen. Arthritis scoring, histopathological examination and the serum levels of anti-type II collagen antibody were compared between these mice and wild-type littermates. [Results] SPACIA1/Saal1-deficient mice developed CIA with delayed onset and reduced severity compared with wild-type mice in severe conditions, but not in mild conditions. [Conclusion] Consistent with our previous study,
this study also indicated that SPACIA1/Saal1 expression associates with the exacerbation of CIA, although CIA progresses slowly in the absence of SPACIA1.

[Object] Peficitinib (ASP015K) is a novel JAK inhibitor in development for the treatment of RA. We clarified the effect of peficitinib on RA FLS. [Methods] To determine whether JAK1, JAK2 and JAK3 were expressed in RA FLS, immunohistochemistry was performed. Peficitinib was added to RA FLS and stimulated with IL-6 and IL-6R. The concentration of cytokines in RA FLS cell supernatants was measured by ELISA. In addition, to determine whether peficitinib regulates JAK-STAT pathway in FLS, Western blotting analysis was performed. Next, we performed a proliferation assay of FLS and chemotaxis assay using THP-1 and PBMC to perform functional analysis by peficitinib. [Results] We found JAK1, JAK2 and JAK3 were expressed in RA ST and FLS. Expression of pSTAT1, pSTAT3 and pSTAT5 in RA FLS was suppressed by concentration dependence of peficitinib. In addition, we proved peficitinib suppress the proliferation of FLS. Suppression of chemotaxis of THP-1 and PBMC was also observed through suppression of MCP-1/CCL2 in RA FLS supernatant. [Conclusions] Peficitinib suppressed the JAK-STAT pathway of RA FLS and was involved in the suppression of RA FLS proliferation and mononuclear cell chemotaxis. It was suggested that peficitinib act on RA FLS and suppress inflammatory pathology.

Conflict of interest: None

[Object] Although a line of evidence has suggested genetic and environmental contributions to Adult-Onset Still’s Disease (AOSD), epigenetic mechanisms may play pivotal roles in the pathogenesis as well. We examined the histone modifications of peripheral white blood cells (WBCs) in AOSD. [Methods] Peripheral WBCs were obtained from 19 patients with AOSD and 16 healthy controls (HC). Peripheral WBCs were classified as follows: CD4+ T cells, CD8+ T cells, γδT cells, regulatory T cells, B cells, and monocytes. All samples were analyzed with a fluorescence-activated cell sorting (FACS). [Results] The mean fluorescence intensity (MFI) levels of H3K27me3 and H3K4me3 in AOSD were different from those in HC. Particularly, histone methylation in neutrophils, B cells, and monocytes correlated with the disease activity of

Conflict of interest: None
P2-007
The etiological significance of neutrophil extracellular traps in peptide
GPI-induced arthritis
Ayako Ohyama, Isao Matsumoto, Hoshimi Kawaguchi, Izumi Kurata,
Atsumu Osada, Yuya Kondo, Hiroto Tsuboi, Takayuki Sumida
Division of Rheumatology, Department of Internal Medicine, Faculty of
Medicine, University of Tsukuba

Conflict of interest: None

We have reported that TGFβ1 suppressed RANKL-induced osteoclast differentiation using PBMs from healthy volunteers in vitro. We had new insights from the similar experiments using PBMs and SF monocytes from RA patients. [Methods] PBMs from healthy volunteers and PBMs and SF monocytes from RA patients were isolated by the MACS magnetic beads method. Osteoclastogenesis was evaluated by TRAP staining positive multinucleated cell number and the ability to form bone resorption pits on osteo assay surface plates. mRNA expression and protein expression levels of NFATc1 and cathepsin K were examined by realtime RT-PCR and Western Blot, respectively. [Results] TGFβ1 suppressed osteoclastogenesis in a dose-dependent manner. mRNA expressions and protein expressions of NFATc1 and cathepsin K were induced by RANKL and then significantly suppressed by TGFβ1. [Conclusions] TGFβ1 suppressed osteoclastogenesis in a dose-dependent manner. mRNA expression and protein expression of NFATc1 and cathepsin K were measured by qRT-PCR and Western Blot, respectively. [Results] TGFβ1 significantly suppressed osteoclastogenesis in a dose-dependent manner. Mice were divided into three groups: 1) sham, 2) RANKL, and 3) RANKL + TGFβ1. [Conclusions] TGFβ1 significantly suppressed osteoclastogenesis in a dose-dependent manner. Mice were divided into three groups: 1) sham, 2) RANKL, and 3) RANKL + TGFβ1. Mouse bone loss was significantly prevented by TGFβ1 treatment. [Object] TGFβ1 suppressed RANKL-induced osteoclast differentiation using PBMs from healthy volunteers in vitro. We had new insights from the similar experiments using PBMs and SF monocytes from RA patients.
sity of Tsukuba, 1Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, 2Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, 3Department of Rheumatology, Sumitomo Hospital, 4Department of Orthopedics/Rheumatology, Miyakonojo Medical Center, National Hospital Organization, 5Department of Internal Medicine, Nagoya Medical Center, National Hospital Organization, 6Tochigi Rheumatology Clinic, 7Clinical Research Center, Naga- saki Medical Center, National Hospital Organization, 8Department of Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, 9Tokyo National Hospital, National Hospital Organ- ization

Conflict of interest: None

[Object] DRB1 is the most important genetic risk factors for rheuma- toid arthritis (RA). The different association pattern of DRB1 alleles with younger age onset RA (YORA) or elder age onset RA (EORA) was re- ported, but the sample sizes of these studies were modest. We investigat- ed the genotype association of DRB1 with YORA or EORA in Japanese populations. [Methods] Associations of DRB1 were analyzed in YORA or EORA patients and healthy controls. [Results] The frequencies of DRB1*04:01/DRB1*04:05 (P=0.0179, OR 23.56, 95%CI 2.12-262.47), DRB1*04:05/DRB1*09:01 (P=0.0028, OR 3.38, 95%CI 1.62-7.06), DRB1*04:05/DRB1*12:01 (P=0.0004, OR 7.21, 95%CI 2.76-18.82), and DRB1*04:05/DRB1*15:01 (P=1.09×10^-6, OR 11.68, 95%CI 4.81-28.34) were increased in YORA. The frequencies of DRB1*01:01/DRB1*04:05 (P=0.0064, OR 3.20, 95%CI 1.42-7.19), DRB1*04:01/DRB1*04:05 (P=0.0011, OR 19.04, 95%CI 2.28-158.74), DRB1*04:05/DRB1*04:05 (P=0.0047, OR 2.71, 95%CI 1.38-5.33), DRB1*04:05/DRB1*09:01 (P=0.0014, OR 2.39, 95%CI 1.43-3.99), and DRB1*04:05/DRB1*15:01 (P=0.0049, OR 3.49, 95%CI 1.53-7.99) were increased in EORA. [Conclu- sions] This is the first report for the associations of DRB1 genotype with YORA or EORA in the Japanese population and the differential dis- tribution of the genotypes was noted.

P2-012 Ablation of Shp-1 in CD11c-positive cells induces autoimmune sialadenitis: characterization of a new mouse model for Sjögren’s syn- drome

Masato Kinoshita1, Yoriaki Kaneko1, Mitsuharu Watanabe1, Shreya Shrestha1, Yuko Oishi1, Junya Suwa1, Masao Nakasatomi1, Hiroko Harada1, Toru Sakairi1, Hidekazu Ikuuchi1, Yoshio Nishima1, Keiju Hiromura1

1Department of Nephrology and Rheumatology, Gunma University Graduate School of Medicine, Maebashi, Japan, 2Department of Rheumatology and Nephrology, Japanese Red Cross Maebashi Hospital

Conflict of interest: None

[Object] Shp-1 is a negative regulator of signaling in hematopoietic cells and found that they developed tubulointerstitial nephritis (TIN). Since TIN is one of the common manifestations in Sjögren’s syndrome rapidly; however, the exact mechanism is unknown. [Objective] To investigate the ISG15 expression induced by ZOL in human γδ T cells

P2-013 Anti-rabbit podoplanin monoclonal antibody useful for evaluating engraftment of osteochondral grafts in a rabbit model

Ryuusuke Honma, Tomoto Suzuki, Yuya Takakubo, Michiaki Takagi

Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine, Yamagata, Japan

Conflict of interest: None

[Object] Podoplanin (PDPN) is a type I transmembrane O-glycopro- tein. PDPN expression has been reported in chondrocytes and osteocytes. However, there are no reports of PDPN expression in osteochondral grafts. In this study, PDPN expression in osteochondral grafts of a rabbit transplantation model was analyzed using newly established anti-rabbit PDPN monoclonal antibody, Pmb-32. [Methods] A full-thickness cylindrical osteochondral defect was created in the left knee of rabbits. An osteochondral plug from the right knee was harvested, and grafted into the distal portion of the osteochondral defect. After 3, 6 and 12-week postoperative periods, the distal part of the femur was resected. PDPN expression in resected tissues was evaluated immunohistochemically using Pmb-32. [Results] At 3, 6 and 12 weeks after surgery, PDPN was ex- pressed in osteochondral grafts, but not expressed in the non-grafted de- fault areas. Nongrafted defect was covered with noneochondrocytic tissue, where there were no chondrocytes stained with Pmb-32. [Conclusions] PDPN was expressed in osteochondral grafts of a rabbit transplantation model. Pmb-32 was able to evaluate osteochondral grafts. It may also have a potential for assessing the maturity of osteochondral grafts.

P2-014 IL-1 Inhibits the expression of DKK1, an antagonist of the Wnt signaling pathway

Satoshi Yamashiki

Kurume University Medical Center

Conflict of interest: None

[Object] Non-inflammatory articular lesion is a hallmark in neonatal-onset multisystem inflammatory disease (NOMID), also called chronic infantile neurologic cutaneous articular (CINCA), the most severe of the cryopyrin-associated periodic syndrome (CAPS), IL-1β-related mono- genic autoimmune inflammatory diseases. The pathology of joint of the disease are similar to those of fibroblast-related, a skeletal disease caused by errant activation of Wnt signal. We explored the potential role of IL-1β on Wnt signaling. [Methods] The expression of WNT and DKK1 mRNA was quantified by qPCR. The concentration of DKK1 was determined by ELISA. TCF reporter were used to evaluate the Wnt signal activity. [Results] The mRNA expression of both WNT and DKK1 was detected in fi- broblast-like synoviocytes (FLS). The supernatant of cultured FLS sup- pressed the Wnt signal, and the effect was reduced by anti-DKK1 antibody: IL-1β reduced DKK1. The supernatant of FLS cultured with IL-1β showed a reduced inhibitory effect on TCF activity. [Conclusions] FLS suppress Wnt signal via DKK1 production, and that IL-1β reduce DKK1 production from the cells and, thereby, activates Wnt signal. It is possible that the overproduction of IL-1β activates the Wnt signal and leads to articular lesion in patients with NOMID/CINCA.

P2-015 The expression of ISG15 induced by zoledronic acid (ZOL) is in- creased in human gamma-delta T cells

Toru Yagi1, Manabu Kawamoto1, Yuki Nanke1, Hisashi Yamanaka1, Tsuyoshi Kobashiguwa1, Hiroki Yabe1, Eri Watanabe1, Shigeru Kotake1

1Institute of Rheumatology, Tokyo Women’s Medical University, 2Depart- ment of Rheumatology, Jichi Medical University Saitama Medical Center

Conflict of interest: None

[Background] γδ T cells are thought to be involved in various diseases including spondyloarthritis. γδ T cells are increased by isopentenyl pyrophosphate (IPP) induced by bisphosphonate (BIS) such as ZOL (Morita et al. 2007). In addition, BIS improves clinical manifestations of SAPHO syndrome rapidly; however, the exact mechanism is unknown. [Objective] To investigate the ISG15 expression induced by ZOL in human γδ T cells prepared from the salivary glands of Shp-1 CKO in which Shp-1 gene is deleted in CD11c+ cells and found that they developed tubulointerstitial nephritis (TIN). Since TIN is one of the common manifestations in Sjögren’s syndrome, we analyzed salivary glands of Shp-1 CKO to confirm the presence of sialadenitis. [Methods] We measured the salivary flow rate and performed histological examination of salivary glands. Single cells prepared from the salivary glands were ana- lyzed by flow cytometry (FCM). [Results] Shp-1 CKO secreted less sali- va by pilocarpine stimulation. Histological study showed Shp-1 CKO ex- hibited the infiltration of CD4+ , B220+ or F4/80+ cells with periductal foci in the glands. FCM revealed that B cells increased in the glands of Shp-1 CKO. A distinct B cell subset, B-1 cells, which are an important source of autoantibodies, also increased in the glands of Shp-1 CKO. [Conclu- sions] CD11c-specific ablation of Shp-1 causes autoimmune sialadenitis characterized by the accumulation of B cells including B-1 cells. Shp-1 CKO have the potential to become a new mouse model for Sjögren’s syn- drome.
cells. [Methods] non-memory Th cells were separated by MACS. After 14 days of culture, the expression of ISG15 or CD36 was evaluated by RT-PCR in 1) unstimulated group, 2) ZOL added group (ZOL+IL-2), 3) non-ZOL added group (PHA+IL-2). [Results] The expression of CD36, an activated γδ T cell marker, was increased in group 2) compared to group 3). ISG15 expression was markedly increased in stimulated RA- and non-stimulated OA- cells, indicating that IFN signature was up-regulated. The increased γδ T cells with up-regulating IFN signature could be involved in clinical remission in BIS-treated SAPHO syndrome. ISG15 could be a useful tool for evaluating clinical response. [Conclusion] ISG15 expression was elevated in human γδ T cells increased by ZOL.

P2-016
Podoplanin is a potential biomarker of inflamed fibroblast-like synoviocytes stimulated by lipopolysaccharide
Tomoto Suzuki, Yuya Takakubo, Ryusuke Honma, Hiroharu Oki, Michiaki Takagi
Department of Orthopaedics, Yamagata University Faculty of Medicine

Conflict of interest: None

[Objective] Podoplanin is a transmembrane sialoglycoprotein, which is expressed in several normal tissues and malignant tumors. In this study, we investigated the correlations of PDVPN and synovitis using fibroblast-like synoviocytes (FLS) of rheumatoid arthritis (RA) and osteoarthritis (OA). [Methods] FLS were obtained from synovial tissues from five RA and five OA patients undergoing upper and lower limb joint surgery. FLS were stimulated with lipopolysaccharide (LPS: 1 ng/ml) for 24 hours and non-stimulated cells were used as positive and negative controls, respectively. Quantitative real-time PCR was performed to calculate the ratio of all amplified products (PDVPN, IL-6, TNF-α) to GAPDH (internal standard). Mann-Whitney U test was performed using EZR. P value of <0.05 was considered as significant difference. [Results] Stimulation with LPS increased mRNA expression levels of PDVPN, IL-6, and TNF-α compared to non-stimulated cells in RA and OA (RA: PDVPN: 3.4 ± 1.2, IL-6; 110.8 ± 86.3, TNF-α; 4.3 ± 3.6, OA: PDVPN: 5.1 ± 2.8, IL-6; 124.8 ± 78.8, TNF-α; 4.3 ± 2). There were no differences of mRNA expression levels of PDVPN, IL-6, and TNF-α between LPS stimulated RA- and OA- FLSs. [Conclusions] PDVPN may have the potential as a new biomarker and therapeutic target for RA and OA.

P2-017
Roles of layilin in human synovial fibroblasts revealed by layilin-silencing and proteome analysis
Mitsumi Arito1, Tosihyuki Sato1, Kazuki Omoteyama1, Masaaki Sato1, Maane Kurokawa2, Tomohiro Kato1
1Clinical Proteomics and Molecular Medicine, St. Marianna University Graduate School of Medicine, 2Disease Biomarker Analysis and Molecular Regulation, St. Marianna University Graduate School of Medicine

Conflict of interest: None

[Objective] To understand physiological and pathological roles of layilin in synovial fibroblasts, we investigated protein profile changes caused by layilin-silencing. [Methods] Immortalized human synovial membrane fibroblasts (HSFs) were transfected with siRNA for layilin (siL) in TNF-α-treated and -non-treated conditions. Proteins affected by siRNA were comprehensively identified by 2-dimensional fluorescence difference gel electrophoresis (2D-DIGE). Proteins of interest were identified by mass spectrometry. [Results] In the 2D-DIGE analysis, 1092 spots were detected. Proteins were identified in 25 out of 87 proteins with ±1.3-fold or greater intensity changes by siL both in the TNF-α-treated and -non-treated conditions (53 spots and 34 spots, respectively). Sixteen (64%) of the 25 protein spots were assigned to epithelial-mesenchymal transition (EMT)-related proteins. [Conclusions] Our data suggest that layilin is deeply involved in the regulation of EMT-related proteins in synovial fibroblasts. Functions of layilin in synovial fibroblasts should be investigated in the context of EMT, although synovial fibroblasts are not epithelial cells.

P2-018
Significance of auto-antibody titer categorization on disease activity in patients with rheumatoid arthritis
 Nobuo Kuramoto, Ryo Matsumiya, Misaki Yasutake, Kayoko Tabata, Katsunori Tanaka, Takao Fujii
Department of Rheumatology and Clinical Immunology, Wakahama Medical University

Conflict of interest: None

[Object] Significance of rheumatoid factor (RF) and anti-CCP antibody (Ab) categorization on diagnosis of rheumatoid arthritis (RA) was established. We examined significance of RF and anti-CCP Ab titer categorization change on the RA activity in this study. [Methods] We categorized RA patients by titers of RF and anti-CCP antibody into negative, positive, high positive in the RA cohort of our hospital. We extracted the patients who were changed to different category 1-year later and examined disease activity. [Results] 194 patients were studied. Patients’ age was 61.4, female was 80.4% and RA duration was 8.8 years. In 2017, patients with RF negative, positive, high positive were 19.6, 24.7, 55.7% respectively. Patients with anti-CCP Ab negative, positive, high positive were 19.6, 8.8, 71.6% respectively. DAS28, SDAI and HAQ were significantly improved in patients whose anti-CCP Ab was decreased. On the other hand, DAS28, but not SDAI and HAQ, was significantly improved in patients whose RF was decreased. [Conclusion] In clinical practice, more disease activity indices correlated with anti-CCP Abs than RF whereas anti-CCP Ab titer may be infrequently changed to lower category.

P2-019
Quality of life in rheumatoid arthritis patients who achieved Boolean remission
Tomonori Sakamoto1,2, Hajime Ishikawa1, Asami Abe1, Shinji Taniguchi1, Hiroshi Otani1, Kiyoshi Nakazono1, Yoichi Kurosawa1, Eriko Hasegawa1, Satoshi Ito1, Hiroshi Tsumura1, Akira Murasawa1
1Department of Rheumatology, Niigata Rheumatic Center, Niigata, Japan, 2Rheumatology Orthopedic Surgery, Oita University Hospital, Oita, Japan

Conflict of interest: None

[Object] The purpose of this study was to clarify the level of QOL and the factors that associated with QOL in RA patients who achieved Boolean remission. [Methods] This study included 73 of 180 out-patients with Boolean remission, who visited our hospital in September 2018. For each patient, age, gender, disease duration, EQ-5D, DASH, BDI-II, DAS28-ESR (4), walking speed, body composition, grip strength, Controlling Nutritional status (CONUT) were investigated. Serum MMP-3, CRP and RF were also measured. A multiple regression analysis was performed. [Results] The mean utility index score was 0.89. It was higher than the mean score of 0.76 in RA patients in the daily practice (Hoshi, D. et al. Mod Rheumatol 2016; 26 (1): 40-5). Among the 5 items of EQ-5D, the percentage of “with problems ” was 20.6% in mobility, 8.6% in self-control, 17.2% in daily activity, 17.2% in pain/discomfort, and 8.6% in anxiety/ uneasiness. There was a positive correlation between EQ-5D score and grip strength (P <0.05), but there was no correlation between the score and other items. [Conclusions] The level of QOL in the patients with Boolean remission was high, but they still had some problems. Grip strength was a factor which associated with QOL in the patients with Boolean remission.

P2-020
Relation between pain catastrophizing and non inflammatory arthralgia
Takeo Abe
Department of Rheumatology, Kobe Citizen Hospital West

Conflict of interest: None

[Background] Chronic pain exists in patients of Rheumatoid arthritis (RA) without synovitis. Past evidence of psychosocial model in chronic low back pain may support pain catastrophizing (PC) is involved in such
non-inflammatory arthralgia (NIA). [Object] To investigate relation between PC and NIA. [Method] 82 patients with RA who referred to our institution between April to October 2018, fulfilling following requirements were enrolled in this study; disease duration ≥6 months, maintaining same bDMARDs and MTX treatment at least 3 months, CRP value <0.5mg/dl, US imaging remission. We excluded patients of stage4. Pain Catastrophizing Scale (PCS) containing 3 subscales, magnification, rumination, and helplessness were used to assess PC. Patients were divided into 2 subgroups, pain VAS≥40 as NIA group and pain VAS<40 as controlled group. We retrospectively analyzed PCS score and other related clinical dates. [Result] The result showed significant positive correlations between PCS and pain VAS. Total, and 3 subscales of PCS score was significantly higher in NIA group than control group. Multivariate logistic regression analysis showed that helplessness (OR 1.21, p<0.01) was independent predictor of NIA. [Conclusion] We should take psychosocial factor as PC into consideration in NIA.

P2-021

Relationship between rheumatoid arthritis and locomotive syndrome-Longitudinal evaluation of 5 years-Yasumori Soh1,1, Yotsuba Hobo2,1, Koji Funahashi1, Nobunori Takahashi1, Shuuji Asai1, Nobuyuki Asai1, Takuya Matsumoto1, Tsuyoshi Nishiumi1, Mochihito Suzuki1, Naoki Ishiguro1
1Department of Orthopedic Surgery, Nagoya University School of Medicine, Nagoya, Japan, 2Department of Orthopedic Surgery, Kariya Toyota General Hospital

Conflict of interest: None

[Object] The aim of this study was to evaluate longitudinally the relationship between Rheumatoid arthritis (RA) and Locomotive Syndrome (LS). [Methods] 16 points or more of the 25-question Geriatric Locomotive Function Scale (GLFS-25) were defined as LS. 58 patients who examined GLFS-25 for 5 consecutive years were non-LS at the initial survey. 15 patients who became LS at the final survey (LSg) and 43 patients who remained non-LS (nLSg) were compared. [Results] The age (median) at the initial survey was 64/61 years (LSg/nLSg). DAS28-CRP was 2.1/2.2 (at the initial survey), 2.0/1.9 (1year), 2.5/1.7 (2years), 2.3/2.0 (3years), 3.1/1.8 (4years), 3.8/1.8 (5years), and that of LSg was significantly higher after 2 years. GLFS-25 was 11/6 points (at the initial survey), 10/4 points (1year), 10/4 points (2years), 11/4 points (3years), 16/3 points (4years), and that of LSg was significantly higher at any time. The cut-off point of GLFS-25 (at the initial survey) for the prediction of LS at the final survey was 11 points and that of DAS28-CRP (2 years) was 1.9. [Conclusions] It was important to practice tight control of RA disease activity in order to suppress the onset of LS. In addition, we should to focus on not only RA disease activity but also GLFS-25 score.

P2-022

Prediction of therapeutic efficacy of abatacept in rheumatoid arthritis patients-Shigeru Tanaka1, Kei Ikeda1, Mieko Yamagata1, Yoshie Sanayama1, Shinichiro Kagami2, Takeshi Umibe1, Ryutaro Matsumura1, Takao Sugiyama5, Naoki Ishiguro1
1Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan, 2Department of Allergy and Clinical Immunology, Asahi General Hospital, Chiba, Japan, 3Department of Internal Medicine, Matsudo City Hospital, Chiba, Japan, 4Allergy and Clinical Immunology, National Hospital Organization Chiba-East Hospital, Chiba, Japan, 5Department of Rheumatology, National Hospital Organization Shimoshizu Hospital, Chiba, Japan

Conflict of interest: Yes

[Object] It is difficult to predict the efficacy of DMARDs. In this study, we aimed to develop tools to predict the efficacy of abatacept in rheumatoid arthritis (RA) patients. [Methods] Thirty active RA patients who agreed with abatacept treatment were recruited in this study. Peripheral blood mononuclear cells were collected before treatment and RNAs were subjected to DNA microarray analyses. The treatment efficacy was evaluated 3 months after initial abatacept injection. Genes whose expression was associated with clinical outcome were determined by using Limma. [Results] Among 30 RA patients, 21 were classified as responders and 9 were non-responders. There were no clinical markers which could predict the efficacy of abatacept. Although we did not find any probes whose expression was significantly different between the respondents and the non-responders, there was a trend toward higher Ccerf expression in the responders (P = 0.0000738, FDR = 0.518). The variation of CDAI correlated with the expression of Ccerf (r = 0.552, P = 0.00156) but other clinical parameters did not. [Conclusions] Ccerf expression might be a possible marker to predict the efficacy of abatacept.

P2-023

Changes in homocysteine levels when biological products (BIO) are used in patients with rheumatoid arthritis-Syuji Yamada1, Kentaro Inui2, Yuko Sugioka3, Tadashi Okano2, Kenji Mamoto3, Masahiro Tada4, Tatsuya Koike3,4
1Osaka City General Hospital, 2Osaka City University Hospital, 3Center for Senile Degenerative Disorders (CSDD), Osaka City University Medical School, 4Search Institute for Bone and Arthritis Disease (SINBAD)

Conflict of interest: None

OBJECTIVE: Higher homocysteine (Hcy) is a risk factor for bone degeneration and arteriosclerosis, and it is reported that Hcy value correlates with inflammatory marker in patients with rheumatoid arthritis (RA). We investigated the relationship with markers and also examined the influence of biological products (BIO) over time. METHODS: Data from a cohort study (TOMORROW, UMIN000003876) started in 2010 consisting of 208 RA subjects and 205 volunteers (Vo) were used. To examine the influence of BIO, half of RA patients (n = 113, 54.3%) are recruited BIO group. Hcy value was measured and compared between groups with repeated measure ANOVA. RESULTS: The RA group 177 subjects (continuation rate 85.1%) and the Vo group 185 (90.2%) were able to be traced up to 2017. In the BL, the Hcy value was correlated C-reactive protein (r = 0.184, p < 0.0001). · Matrix metalloproteinase-3 (r = 0.203, p < 0.0001). In 5 times, the Hcy value was significantly higher in the RA group (P < 0.0001, repeated measure ANOVA). However, in the RA group, there was no significant difference between the BIO usage group (n = 65) and the non-use group (p = 0.889, repeated measure ANOVA). DISCUSSION: Hcy value correlated with the degree of inflammation of RA patients. Though using BIO, Hcy value couldn’t be controlled.

P2-024

Association between methotrexate dosage and renal impairment in patients with rheumatoid arthritis-Keigo Hayashi, Ken-ei Sada, Yousuke Asano, Yuriko Yamamura, Sumie Asano Hiramatsu, Keiji Ohashi, Michiko Morishita, Haruki Watanabe, Mariko Narazaki, Yoshinori Matsumoto, Tomoko Kawabata, Jun Wada
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan

Conflict of interest: None

[Object] Renal impairment is one of the major concerns in treatment with methotrexate (MTX) for malignancy, but it is still unclear whether low dose MTX in treatment for rheumatoid arthritis (RA) affect the renal function or not. [Methods] Of outpatients with RA in our registry between November 2012 and October 2017, 79 patients who had continued administration of MTX for more than 12 months were enrolled. Association between MTX dosage and annual change of estimated glomerular filtration rate (eGFR) were analyzed. [Results] Mean age was 60 years, 72% were female, and mean MTX dosage during the observation period was 8.9 mg/week. Patients treated with ≥10 mg/week of MTX (n=33) exhibited more rapid decrease in eGFR than those treated with <10 mg/week of MTX (n=46) (4.8 ± 1.2 vs. 0.2 ± 1.0 ml/min/year, p = 0.006). After adjusting confounding factors such as sex, disease activity, NSAIDs use, and biological agents use, ≥10 mg/week of MTX was still an independent factor for a decrease of eGFR (β-coefficient: 1.97, 95% confidence interval 0.160-3.786, p = 0.033). [Conclusions] Careful monitoring of renal function should be required in RA patients treated with ≥10 mg/week of MTX.
Influence of gastrointestinal symptoms on patient global assessment in patients with rheumatoid arthritis

Kaoru Nagai1, Shuuichi Sato1, Yoshitsugu Kojima1, Naoki Ishiguro1
1Nursing Department, Nagoya University Hospital, 2Department of Orthopedic Surgery, Nagoya University Hospital

Conflict of interest: None

P2-025
Factors associated with the improvement of QOL score (EQ-5D score) after 1 year in patients with early rheumatoid arthritis
Tomoyuki Miyamura, Motoko Ishida, Makiko Higuchi, Tomoaki Iwanaga, Kenji Tamagawa, Soichiro Takahama, Rumi Minami, Masahiro Yamamoto, Eiichi Suematsu
Department of Internal Medicine and Rheumatology, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan

Conflict of interest: None

[Object] The purpose of this study is to clarify the factors that affect the improvement of QOL score in patients with early RA. [Methods] We retrospectively evaluated 112 early RA patients within 2 years of onset from January 2017 to March 2017. To analyze the improvement of QOL after 1 year, we divided into two groups of QOL improvement group (EQ-5D improvement or EQ-5D=1) and non-improvement group (EQ-5D=1). [Results] Baseline disease activity was CRP 0.31mg/dL and SDAI 4.74. Cortico steroids, MTX and biologics were used in 29%, 79%, 9% of patients, respectively. The average EQ-5D scores were improved from 0.804 to 0.827 after 1 year, and 69 patients showed improvement in QOL. As for factors contributing to QOL improvement, younger age, male and lower psychological anxiety were extracted. In RA treatment, use of MTX, biologics and corticosteroids were not significant, but MTX dose was significantly higher in QOL improved group. Furthermore, in the QOL improvement group, patient's global assessment, physician's global assessment, SDAI and HAQ-DI were significantly improved after 1 year. [Conclusions] Our data indicated that patient age and administration of sufficient dose of MTX were important factors for improving QOL after 1 year in patients with early RA.

P2-026
Ultrasound evaluation after knee joint surgery in patients with rheumatoid arthritis
Ichiro Yoshii1, Tatsumi Chijiwa2, Naoya Sawada3
1Rheumatology and Musculoskeletal Medicine, Yoshii Hospital, 2Department of Rheumatology, Kochi Memorial Hospital, 3Department of Rheumatology, Center for Rheumatic Diseases, Dohgo Spa Hospital

Conflict of interest: None

[Object] Ultrasound assessment is considered useful method for detecting synovitis in RA patients due to its greater sensitivity compared with clinical joint examination. The purpose of this study was to investigate the effectiveness of systemic ultrasound assessment after knee joint surgery in RA patients. [Methods] We evaluated 8 RA patients (7 females and 1 male, average age of 56 years) who underwent total knee arthroplasty or arthroscopic knee synovectomy. Ultrasound assessment was performed at baseline and at 1, 3, and 6 months after knee joint surgery in 42 joints. DAS28-2CRP (4) was also evaluated at baseline and at 1, 3, and 6 months after surgery. [Results] In all cases, the DAS28-2CRP (4) improved from 3.72±1.16 at baseline to 2.51±0.70 at 3 months after surgery. There were also decreases from baseline to 3 months in each of the number of joints with ultrasonographic arthritics (4.9±5.2 to 0.7±0.8), total gray scale score (10.0±14.2 to 4.1±5.6), and power Doppler score (8.4±15.3 to 2.0±3.6); however, these values were slightly increased at 6 months after surgery. [Conclusions] Ultrasound assessment detected systemic arthritis improvement at 3 months and relapse at 6 months after surgery. Thus, ultrasound can accurately evaluate RA disease activity after knee joint surgery.

P2-027
Ultrasound evaluation after knee joint surgery in patients with rheumatoid arthritis
Rie Kurose1,2, Kazue Ichinoh1, Yasuyuki Ishibashi1
1Hirosaki Memorial Hospital, 2Hirosaki University Graduate School of Medicine, 3Hirosaki University Hospital

Conflict of interest: None

Purpose: HAQ of Rheumatoid Arthritis (RA) patients is one of the index to evaluate activity of RA. Due to incompleteness of HAQ, MD-HAQ is invented. In this study, we compared HAQ, MD-HAQ, and treatment goal achievement rate (TGAR) of patients with DAS28-2CRP/DAS28-2ESR. Patients and Methods: The results of 80 RA patients in Toho hospital were examined. At the first and second visits of the patients, they were examined by HAQ, MD-HAQ, and TGAR. They were also assessed by DAS28CRP/DAS28ESR by physician. The data collected above were analyzed for correlation among them. Results: DAS28CRP vs DAS28ESR: r=0.923. DAS28CRP vs HAQ: r=0.551. DAS28ESR vs HAQ: r=0.513. DAS28CRP vs MD-HAQ: r=0.518. DAS28ESR vs MD-HAQ: r=0.473. DAS28CRP vs TGAR: r=0.303. DAS28ESR vs TGAR: r=0.272. The rate of change between the 1st and 2nd visit of DAS28CRP

P2-028
The clinical significance of pain score raise in rheumatoid arthritis patient after attaining clinical remission in accordance with treat to target treatment strategy
Ichiro Yoshii1, Tatsumi Chijiwa2, Naoya Sawada3
1Rheumatology and Musculoskeletal Medicine, Yoshii Hospital, 2Department of Rheumatology, Kochi Memorial Hospital, 3Department of Rheumatology, Center for Rheumatic Diseases, Dohgo Spa Hospital

Conflict of interest: None

[Object] Pain score is important for rheumatoid arthritis (RA) patient, despite its unclear clinical significance. This study is designed to clarify the significance of pain score in correlating with other indices. [Methods] From August 2010, 473 RA patients have been treated for more than five years under treat to target treatment protocol with monitoring simplified disease activity score and its components, Health Assessment Questionnaire Disability Index, EuroQOL score with 5 dimensions (EQ5D), and pain score with visual analog scale (PS-VAS). Subjects who attained PS-VAS with no more than 10mm, were recruited. They were divided into two groups according to PS-VAS rise, i.e. whether PS-VAS rose to >10mm (G-R) or maintained (G-C). Indices between the two groups were compared statistically with Mann-Whitney U test. [Results] 22 cases in G-R and 49 in G-C were picked up. G-R demonstrated significantly younger and greater increase of tenderness joint count and patient’s global assessment, and higher score in pain/discomfort and daily living activity (ADL) in EQ5D than G-C (<0.05). Other indices demonstrated no significant differences. [Conclusions] PS-VAS rise means ADL limitation. These were more sensitive than physician’s assessment. We need to care patient’s pain more carefully.

P2-029
Correlation between DAS28CRP/DAS28ESR and HAQ/MDHAQ/treatment goal achievement rate of patients in Rheumatoid Arthritis
Yukie Saio, Miho Tachihara, Kanako Shimura, Setsuko Tajima
Department of Rheumatology, Toho Hospital

Conflict of interest: None
(RC-DAS28CRP) vs RC-DAS28ESR: r=0.974. RC-DAS28CRP vs RC-HAQ: r=0.472. RC-DAS28ESR vs RC-HAQ: r=0.450. RC-DAS28CRP vs RC-MDHQAQ: r=0.379. RC-DAS28ESR vs RC-MDHQAQ: r=0.419. RC-DAS28CRP vs RC-TGAR: r=-0.141. RC-DAS28ESR vs RC-TGAR: r=-0.134. Conclusions: MDHAQ showed intermediate correlation with activity indexes of RA as well as HAQRA. TGAR showed reverse-correlation with activity indexes of RA.

P2-030
Study of the long-term use of tocilizumab
Shunichi Imai1, Kikuko Gushiken1, Ken Hasegawa2
1Rheumatoid Arthritis Center, Minami Medical Health Cooperation, 2Department of Respiratory Medicine, Allergy and Clinical Immunology, Shinji Maeda, Shinya Tamechika, Tomoyo Maeda, Taio Naniwa

Objective: To study the long-term use of tocilizumab (TCZ). Subjects and Methods: The study followed-up 52 patients at our hospital who could continue treatment for at least 5 years after the introduction of TCZ. The number of patients in each Bio was as follows: first, n=6; second, n=26; third, n=13; fourth and subsequent, n=7. For the assessments, DAS28 (ESR), DAS28 (CRP), CDAI, SDAI, RF, MMP-3 were used. Results: 40 patients continued treatment and 12 patients had discontinued treatment. Effects similar to those at 5 years after the introduction of TCZ were maintained in 40 patients; however, nine patients experienced recurrence, and five patients discontinued treatment owing to the apparent recurrence. Discussion and Conclusion: The effects similar to those at 5 years after the introduction of TCZ were maintained in 40 patients, but nine patients subsequently experienced recurrence. Of these nine patients, seven patients did not take MTX and two patients used MTX (4mg), which suggested the tendency toward recurrence of RA in patients not using MTX and those using lower doses of MTX. Furthermore, as the levels of RF and MMP-3 increased during the course, the importance of monitoring the levels of RF and MMP-3 as predictive factors for the recurrence of RA was suggested.

P2-031
Psychological assessment of the patients with Rheumatoid Arthritis
Yasuho Kunigiza
Department of Orthopedic Surgery, JCHO Hoshigaoka Medical Center, Hirakata, Osaka, Japan

Conflict of interest: None

[Objective] Physiological status was evaluated by Self relating depression scale (SDS scale) for the outpatient of rheumatoid arthritis. [Method] SDS scale questionnaire was performed for the 75 outpatients of rheumatoid arthritis. The median age was 65.8 years and the median disease duration was 13.2 years. The correlation of SDS score and patient age, disease duration, number of operative procedure, CRP, MMP-3, DAS28, number of tender joint, the score of HAQRA was evaluated. [Results] The score of 39 and below was assessed as without depression state, the score between 40 and 49 was assessed as mild depression state, the score 50 and over was assessed as moderate or severe depression state, the score between 40 and 49 was assessed as mild depression state, 10 patients (33.3%) were assessed as without depression state. 25 patients (53.3%) were assessed as moderate or severe depression state. 9 patients (18.8%) were assessed as moderate or severe depression state. The correlation of SDS score and the score of HAQRA was confirmed. [Conclusion] The relationship between clinical activity and depression in rheumatoid arthritis patients was confirmed.

P2-032
Correlation between Extinguish-Th 17 and rheumatoid arthritis disease activity
Shinji Maeda, Shinya Tamechika, Tomoyo Maeda, Taio Naniwa
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences

Conflict of interest: None

[Object] In rheumatoid arthritis pathology, the presence of effector T cells that inflame resistentness to immunosuppression of endogenous regulatory T cells is suggested. Recent reports have shown that Extinuish-Th17 (Ex-Th17 (Th17.1)) is resistant to regulatory T cells. Therefore, in this study, we examined correlation between disease activity in active RA patients using csDMARDs and Ex-Th17 in peripheral blood. [Methods] In 40 RA patients using csDMARDs, the correlation between Ex-Th17 Ki67 positive cells (CD4+ CCR6+ CD161+ CXCRC3+ CCR4+ Foxp3+ Ki67+) and disease activity (DAS28-CRP) was analyzed ( Spearman’s rank correlation coefficient). Moreover, Ki67+ in regulatory T cells (Treg; CD4+ CD25+ Foxp3+) were analyzed, and correlation Ex-Th17-Ki67+ (Treg-Ki67+) ratios and disease activity (DAS28-CRP) were also analyzed. [Results] Disease activity (DAS28-CRP), and Ki67+ rate of peripheral blood Ex-Th17 (rho = 0.603, p = 0.0000376), the proportion of Ex-Th17-Ki67+ in CD4+ T cells (rho = 0.411, p = 0.00847), and Ex-Th17-Ki67+/Treg-Ki67+ (rho = 0.455, p = 0.00317) showed a significant positive correlation. [Conclusions] It was suggested that the relative proliferative state of Ex-Th17 may play an important role in csDMARDs treatment resistance of rheumatoid arthritis.

P2-033
Analysis of CARF following abatacept in patients with rheumatoid arthritis in the real world
Masaaki Miya1, Yutaka Motohoshi2
1Heiseihidaka Clinic, Takasaki, Gunma, Japan, 2Hidaka Hospital, Takasaki, Gunma, Japan

Conflict of interest: None

[Object] To investigate the changes in CARF following Abatacept in patients with rheumatoid arthritis. [Methods] Data of 21 patients were collected retrospectively. Abatacept was injected according to the approved method and the clinical response was evaluated following 6 months of abatacept therapy. [Results] The CARF levels at baseline correlated with ACPA. The % changes from baseline CARF correlated with the % changes from baseline CRP and DAS28-ESR, after 6 months of abatacept treatment. [Conclusions] It is possible that CARF can be used to evaluate the disease activity of rheumatoid arthritis.

P2-034
Influence on the level of ADAM-17 in serum in patients with rheumatoid arthritis by adalimumab or tocilizumab Therapy
Sho Ishii, Masahiro Hosonuma, Airi Nishimi, Shinichiro Nishimi, Takahiro Tokunaga, Yuzo Ikari, Hidekazu Furuya, Kuninobu Wakabayashi, Takeo Isozaki, Tsuyoshi Kasama
Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

Conflict of interest: None

[Object] A disintegrin and metalloproteinase (ADAM)-10 and ADAM-17 have been reported to be expressed on rheumatoid arthritis (RA) synovial fibroblasts and be involved in inflammatory of RA. Also we have reported that tocilizumab therapy decreased the level of ADAM-10 in RA serum, and might be a predictor of the effectiveness of tocilizumab in treating RA. We examined the expression of ADAM-17 in serum and disease activity in RA patients with adalimumab or tocilizumab therapy. [Method] ADAM-17 expression in serum from normal (NL) subjects and RA patients was measured. We also analyzed the correlation between ADAM-17 and disease activity score 28 (DAS28) in RA. In RA patients who newly started adalimumab (n=10) or tocilizumab (n=12), we examined the ADAM-17 level in serum and DAS28 before and after treatment. [Results] The expression of ADAM-17 in RA serum was significantly higher compared to NL serum and was correlated with DAS28. The level of ADAM-17 in RA serum after adalimumab therapy were significantly low compared with before. But there was no significant difference at the level of ADAM-17 in RA serum after tocilizumab therapy with before. [Conclusions] Adalimumab decreased the level of ADAM-17 in serum of RA patients, but tocilizumab did not it.
P2-035
The drug retention rate and the suppression rate of large joint destruction by ARASHI change score in patients medicated by Tocilizumab with rheumatoid arthritis
Atsushi Kaneko, Shotaro Mori, Yosuke Hattori
Department of Orthopaedic Surgery and Rheumatism, Nagoya Medical Center

Conflict of interest: None

[Object] The purpose of this current study is to review drug retention rate and joint destruction or remodeling in large joints with early and established rheumatoid arthritis medicated by Tocilizumab. [Methods] We investigated the drug retention rate of Tocilizumab in 117 Japanese RA patients, and the change of joint destruction or remodeling in 372 large joints of 44 RA patients. By Cumulative probability plots of ARASHI change score. [Results] The drug retention rate of Tocilizumab is 76.1% at 10 years and the suppression rate of joint destruction is 85.0% by Cumulative probability plots of ARASHI change score. [Conclusions] Tocilizumab is effective and safe in long-term results and suppressed the large joint destruction.

P2-036
Identification of the factors associated with dysfunction in rheumatoid arthritis patients
Yuji Yoshida1, Shiro Ohshima1, Eri Oguro1, Kentaro Kuzuya1, Yasutaka Okita1, Hidetoshi Matsuoka1, Satoru Teshigawara1, Maiko Yoshimura1, Kentaro Isoda1, Yoshinori Harada1, Shigerusho Tsuji1, Jun Hashimoto1, Yukihiko Sacki1
1Department of Rheumatology and Allergology, National Hospital Organization Osaka Minami Medical Center, 2Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center, 3Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center

Conflict of interest: None

[Object] To analyze the association between mHAQ and other factors in rheumatoid arthritis patients in our hospital. [Methods] We use the "Mirai" system and output the data of our hospital record. We devised them in older group (age ≥ 65) and younger (age < 65). [Results] Disease activity marker such as DAS28, CDAI, DrVAS, PiVAS, CRP were strongly correlated with mHAQ score. eGFR, Hb, LDL-Chol, lymphocyte were correlated with mHAQ only in older group. [Conclusions] For young population, mHAQ clearly reflect the activity and joint destruction of rheumatoid arthritis. However we should be careful for analyzing mHAQ score in older rheumatoid arthritis patients because it also reflect vascular damage, nutrition.

P2-037
Investigation of the scoring system predicting the efficacy of tocilizumab in patients with rheumatoid arthritis
Yukimi Otsuka1,2, Yasutaka Kimoto1, Daisuke Oryoji1, Tetsushin Murakami1, Masahiro Ayano2, Hiroki Mitoma1, Mitsuteru Akahoshi2, Yojiro Arinobu2
1Department of Internal Medicine and Clinical Immunology, Kyushu University Beppu Hospital, 2Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3Maekarta Medical Association Hospital, 4Department of Medical Education, Kyushu University Graduate School of Medical Sciences

Conflict of interest: None

[Object] To investigate the validity of the scoring system predicting the efficacy of tocilizumab (TCZ) in patients with rheumatoid arthritis (RA). [Methods] RA patients in whom treatment with TCZ was initiated from 2008 to 2015 in Kyushu University Beppu Hospital were studied retrospectively. According to the report from Nakagawa and Koyama et al. (Arthritis Res Ther 2017), the scoring system was performed as followed, platelet count ≥ 381000/mm³, Hemoglobin ≥ 11.7 g/dL (female) or ≥ 13.2 g/dL (male), AST≤ 16 IU/L, ALT≤ 15IU/L. Each item gave 1 point. We analyzed patients whose DAS28-ESR were measured both before and 24 weeks after the initiation of TCZ. DAS28-ESR response at 24 weeks was evaluated. [Results] In all 40 patients, there were 6 non-responders (15%), 12 moderate responders (30%), and 22 good responders (55%). In 17 patients predicted as good TCZ responders whose score was ≥ 2, there were 1 non-responder (6%), 7 moderate responders (41%), and 9 good responders (53%). In contrast, 23 patients whose score was ≤ 1 revealed 5 non-responders (21.7%), 5 moderate responders (21.7%), and 13 good responders (56.5%). [Conclusions] RA patients whose scores predicting the efficacy of TCZ were ≥ 2 tended to turn out to be non-responders less frequently than those whose scores were ≤ 1.

P2-038
Prospective analysis of Role/Social health QOL in SF-36 in patients with rheumatoid arthritis
Hirahito Endo1, Yoshie Kusunoki1, Aki Shoji2, Norihiko Tomozuka2
1Department of Rheumatology, Jusendo General Hospital, 2Department of Rheumatology, Akishima Hospital

Conflict of interest: None

[Object] We detected the role and social QOL component in patients with RA using patient reported outcome SF36. [Methods] In 348 RA, SF36v2™assessed at 12Months and 24 Months after therapy. We analyzed the relationship between clinical findings (disease duration, treatment), HAQ-DI, DAS28-ESR, CDAI, SDAI, CRP levels. SF-36 assessed 3 summary component summetric (physical component, mental component, role/social component) calculated according to summary standard score50 in 2007 Japanese. [Results] 348 RA patients, mean age was 62±16, 81% female, mean disease duration 6.5±15 years (early case under 1 year 47%), DAS28 5.12±2.1, HAQ-DI0.87±0.85, SF-36 Physical component summary score (PCS) 32±20, Mental component summary score (MCS) 49.8±8.5, Role/Social component summary score (RCS) 34.3±14.6, 56weeks after treatment MTX62.8%, bDMARD30%, PSL32%, reached 78% remission or low disease activity. 56 weeks SF-36 PCS39.9±10, MCS49.6±13.9, RCS 43.3±14.6. PCS and RCS significantly improved by treatment. RCS in SF-36 is significantly correlated with CRP, HAQ-DI. [Conclusions] Improvement of RCS is one of the important factor in treatment of patients with RA. Measurement of RCS in SF36 is a useful tool in confirm of QOL in patients with RA.

P2-039
Achievement of target with the first 6-months strategy for naive rheumatoid arthritis patients with contraindications to methotrexate: The result of a single-center cohort study -
Hiroshi Iwai1, Yohei Hosokawa1, Kei Araki2, Eiji Sugiyama2
1Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, 2Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital

Conflict of interest: None

[Object] To investigate achievement rate of low disease activity (LDA) and remission at initial six-months treatment in naive rheumatoid arthritis (RA) patients with contraindications to methotrexate (MTX), compared with those treated initially with MTX. [Methods] All the naive RA patients, visiting between April 2015 and April 2018, who started to take conventional synthetic DMARD (cDMARD) were included in the study. The diagnosis of RA was based on physician’s diagnosis, meeting at least five scores of the classification criteria 2010. Almost all the cases were evaluated with SDAI, every 2-6 weeks, and the therapy was adjusted according to the T2T strategy. Achievement rate of LDA and remission at Month 6, were compared between those treated initially with none-MTX cDMARD and those with MTX. Non-responder imputation was applied for any missing data (ie, withdrawal). [Result] One hundred and twenty nine patients with naïve RA were included; non-MTX (n=27) and MTX group (n=102). Achievement rate of LDA tended to be lower in non-MTX group (52% vs 73%, p=0.061), and that of remission was significantly lower in non-MTX group (11% vs 33%, p=0.030). [Conclusion] Achievement of target in naïve RA, with contraindications to MTX was not as satisfactory, as in those treated with MTX.
P2-040
Difference between patient’s global health and patient’s global assessment of disease activity, and factors influence on these scales in rheumatoid arthritis patients
Naohiro Sugitani, Yuki Mizutani, Kentaro Noda, Yasuo Suzuki, Ayako Nakajima
Center for Rheumatic Diseases, Tsu, Mie, Japan, Mie University Hospital

Conflict of interest: None

[Objective] To investigate the importance of patient’s global health (PtGH) for DAS28 and patient’s global assessment of disease activity (PtGA) for SDAI and CDAI in rheumatoid arthritis (RA) patients. [Methods] We retrospectively investigated the changes in PtGH and PtGA after treatment intensification in 12 weeks through medical records and the improving factors using logistic regression. [Results] Consecutive 37 RA patients (38 events) from October 2017 to September 2018 were enrolled. Women were 76%. The median age was 67 years, disease duration; 2.5 years. DAS28; 2.61. SDAI; 16.8 and CDAI; 15.3. Methotrexate (MTX) subset was used in 63% with median dose of 7 mg/week. Biological DMARDs and JAK inhibitor (BJ subset) were used in 21%. Other DMARDs were used in 16%. The change in PtGH in 12 weeks (ΔPtGH) was -1.68 (p<0.01), and that in PtGA (ΔPtGA) was -2.22 (p<0.01). ΔPtGH and ΔPtGA correlated significantly (r=0.61). ΔPtGH in MTX subsets was not different from that in BJ subsets in (p=0.57) and ΔPtGA was not either (p=0.50). Woman (p=0.05) and usage of steroid (p<0.01) were improving factors in ΔPtGH. There was no significant improving factor in ΔPtGA. [Conclusions] PtGH and PtGA behaved similar, however, the difference should be considered in using there patient oriented reports.

P2-041
Clinical factors associated with therapeutic response in patients with rheumatoid arthritis
Katsunori Tanaka1, Misisaki Yasutake1, Kayoko Tabata1, Ryo Matsumiya1, Nobuo Kuramoto1, Naohiro Yukawa2, Takao Fujii1
1Department of Rheumatology and Clinical Immunology, Wakayama Medical University, 2Yukawa Clinic

Conflict of interest: None

[Objective] To determine clinical factors associated with sufficient response (SR) in rheumatoid arthritis (RA) patients with moderate or high disease activity. [Methods] Among 200 patients (female = 80.0%, age = 61.3 years old, disease duration = 8.9 years) in our RA cohort, 85 patients with moderate or high disease activity (DAS28 ≥ 3.2) were divided into SR (DAS28 < 3.2) and insufficient response (IR) groups (DAS28 ≥ 3.2). We determined clinical factors associated with these therapeutic responses retrospectively. [Results] Compared with IR group, shorter disease duration, higher rate of stage I + II, more elevated Hb level (12.2 vs 11.5 g/dL) and higher HAQ score was recognized in SR group in 2017. Also, SR group had higher level of Hb (12.7 vs 11.4 g/dL) than IR group in 2018. Of note, both KL-6 (272 vs 371 U/mL) and BNP (31.6 vs 52.1 pg/mL) levels in 2018 were lower in patients with SR than in IR group. Whereas KL-6 and BNP levels were increased in both groups during a year, there are no significant differences in 2017. [Conclusions] High Hb level before and after treatment was determined as one of the associated factors with SR in RA patients. Also, after treatment, RA patients with IR group showed higher level of KL-6 and BNP than those with SR group.

P2-042
A study of a replacement for mercury hand dynamometer used for patients with rheumatoid arthritis
Yasushi Miura1,2, Koji Fukuda1, Nao Shibanuma1, Ryoouke Kuroda1
1Department of Rehabilitation Science, Kobe University Graduate School of Health Sciences, 2Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, 3Center for Rheumatic Diseases and Joint Replacement Surgery, Kobe Kaisel Hospital

Conflict of interest: None

[Objective] The grip strength of patients with RA reflects disease activity and physical function and is used in clinical practice. Because the decreased grip strength cannot be measured accurately with Smedley hand dynamometer, mercury hand dynamometer has been used. However, the Minamata convention on mercury come into effect and production, import and export of mercury containing products will be prohibited in 2021. The distribution of mercury hand dynamometer was already terminated in 2013. In this study we developed and investigated a possible replacement. [Methods] As a replacement, mercury sphygmomanometer is replaced with mercury-free one, in contrast, the grip cuff is replaced with a clip-on pediatric blood pressure cuff. The patients with RA measured grip strength with both the dynamometers and the results were statistically analyzed. [Results] A total of 130 (110 females, average 61.0 y.o.) patients with RA measured the grip strength once respectively. The average of grip strength with mercury hand dynameter was 197.89mmHg while that with the replacement was 195.98mmHg. The correlation coefficient between the both dynameters showed a strong correlation (R=0.9464, p<0.001). [Conclusions] The replacement hand dynamometer may be used to measure grip strength of patients with RA.

P2-043
The Efficacy of Infliximab Kit (Remi-Check Q) in our clinic RA patients
Akira Sagawa1, Akira Furusaki1, Iumi Yasuda2
1Sagawa Akira Rheumatology Clinic, 2Internal Medicine, Yagi Orthopaedic Hospital

Conflict of interest: None

[Objective] We investigate the efficacy of Infliximab Kit (Remi-Check Q; RQ) in our clinic RA patients. [Methods] We determined infliximab (IFX) trough level by RQ from IFX treated thirty-eight patients in our clinic. We compared the clinical manifestations with the result of RQ. [Results] Baseline characteristics of the patients mean age 66.0±2.1 years, male to female ratio 4:3, disease duration 18.1±1.3 years, stage classification (1; 3 patients, 2; 16 patients, 3; 19 patients, 4; 0 patients), mean MTX 7.8±0.4 mg/week, mean IFX use 8.8±0.6 years, mean IFX dosage 5.38±0.39 mg/kg, DAS28 2.72±0.15. 23 patients were RQ-positive, and 15 patients were RQ-negative. RQ-positive patients were more DAS remission than RQ-negative patients (56% vs 34%). 19 patients with RQ-positive were sustained IFX therapy, 4 patients were required intensified therapy. However, 8 patients with RQ-negative were required intensified therapy (Fisher’s test; P=0.033). [Conclusions] RQ is the useful device in decision of intensified IFX therapy or change in therapy. However, there are patients that clinical efficacy is poor even in RQ-positive, some patients are low disease activity in RQ-negative, and accumulation of future cases is necessary.

P2-044
Investigation of factors influencing the evaluation of PtGA in rheumatoid arthritis
Sari Takahashi1, Yoshiko Sasaki2, Masatake Komagamine1
1Komagamine Rheumatoid Orthopedic Clinic, 2Orthopedics and Rheumatology, Kojin Hospital

Conflict of interest: None

[Objective] das 28, sdaI / cdaI, boolean are used for disease activity evaluation of rheumatoid arthritis but the evaluation content of ptga is not clear. Therefore, factors influencing the evaluation of ptga were examined using a check sheet. [Methods] Using 5 troublesome questions checked in each category of stiffness, pain, and fatigue for 110. (mtx / Bio / jak). Not applicable 0 point duration · das 28 crp · haq · stiffness · Pain-VAS compared for ptga. [Results] Pain-vas (avg 38 mm / 49%) / haq remission not achieved (27 mm / 32.7%) / morning stiffness ≥ 1 minute (21.5 mm / 41.8%) / disease period over 2 years (avg 14.7 mm / 90%) The hand is stiff / painful when turning the lid or door knob / The complaints often heard in daily practice such as feeling fatigue in the evening were high scores.1, stiffness is an important symptom but not in the evaluation criteria 2, there are cases in which ptga is highly evaluated even in remission 3, ptga is mainly evaluated as fatigue but many factors were involved in this It became clear. [Conclusions] Pain-Vas influences the
evaluation of ptga and is an important item for determining clinical evaluation and thinks that it is necessary to evaluate in detail in the future. The tool used this time is a communication tool for finding the problem.

P2-045
Comparison of the persistent ratio of each biologic agent according to various clinical parameters: double center clinical study
Akitake Suzuki1, Masanobu Yoshida1, Takahiro Okai2
1Department of Rheumatology, Mitsui Memorial Hospital, 2Department of Rheumatology, Kawakita General Hospital

Conflict of interest: None

[Objective] We statistically compared the persistent ratio of anti-TNF inhibitors (TNFi), tocilizumab (TCZ), and abatacept (ABT), according to various clinical parameters. [Methods] Our study included patients with rheumatoid arthritis who had been treated with any biologic agents and collected various clinical information of them from medical charts. Subsequently, logrank analysis was conducted to compare the persistent ratio of the three biologic groups. [Results] This study included 214 patients (male 34, female 180, mean age 69.9) and 304 biologic cases were analyzed. TNFi group (mean age 61.0) included 158 cases, while TCZ group and ABT group comprised of 67 cases (mean age 59.8) and 79 cases (mean age 69.2), respectively. Overall, ABT showed significantly the highest persistence compared to TNFi and TCZ (p=0.05). TNFi showed significantly higher persistent ratio when used as first biologic agent (p=0.05). ABT showed significantly the highest persistent ratio for patients with high titer of anti-cyclic citrullinated peptide antibody (ACPA) (>100 U/ml) than with<100 and negative for ACPA (p=0.05) and in cases of positive rheumatoid factor (RF) (p=0.05). [Conclusions] These results may be useful for efficacious selection of biologics in patients with RA.

P2-046
Inefficient predictors in adalimumab treatment of ADA-naïve rheumatoid arthritis patients
Toshiaki Miyamoto, Kenji Yamazaki, Ryuei Ishihara
Internal Medicine and Rheumatology, Seirei Hamamatsu General Hospital

Conflict of interest: Yes

Objective: To construct an effective treatment policy in a clinical setting, we investigated remission predictors following ADA treatment. [Methods] 123 analyzable patients were introduced to ADA at this institution from May 2009 to December 2017. For the DAS28-ESR remission at 256W (n=77) and inefficient discontinuation (n=46) groups, background factors at baseline were extracted and inefficient discontinuation predictors and the cutoff value by ROC analysis were examined. [Results]: Mean age, duration of illness, MTX, and DAS28-ESR were 54.1 yrs, 6.1 yrs, 11.7mg, 4.6, respectively. At baseline, age, PSL concomitant use, Class, DAS28-ESR, SDAI, CDAI, HAQ, MMP-3 etc. were significantly high in the inefficient discontinuation group compared to the remission group. Also, by ROC analysis, DAS 28 - ESR ≥ 4.16 at baseline was extracted as a cut-off value. On the other hand, age, disease duration, MTX dose, RF, ACPA, body surface area etc. were not significantly different between inefficient discontinuation group and remission group. [Conclusion]: The inefficient discontinuation predictors were examined in 123 ADA that can be analyzed in our hospital. Suggesting the possibility that DAS 28-ESR, SDAI, CDAI, HAQ, MMP-3, etc. at baseline may become predictors of inefficient discontinuation.

P2-047
Usefulness of the Infliximab qualitative analysis in the patient receiving Infliximab
Naohide Takigawa, Hisako Eshiro
Department of Orthopedics, Nishinomiya Neurosurgical Hospital

Conflict of interest: None

[Objective] The purpose of this study is to clarify the usefulness of the infliximab qualitative analysis. [Methods] I intended for six cases during the infliximab dosage. At object six cases (one man, woman five, average age 63.8 years old), the MTX dose was an average of 5.7 mg. I investigated MPM-3 and DAS28CRP before the infliximab qualitative evaluation. In addition, I investigated the outcome of a half year after an evaluation. [Results] As for the infliximab qualitative positive, in MPM-3 before the inspection, an average of 106.9, DAS28-ESR were an average of 2.93 in two cases. As for the infliximab qualitative negative, in MPM-3, an average of 100.1, DAS28-ESR were an average of 3.25 in four cases. As a turning point a half year later, two cases became stable in dose escalation of 100 mg and, continued the dosage. However, two cases were dose escalation and interval reduction, but the effect was not provided and switched to a another biotherapy. [Conclusions] There were what could not calculate the trough level and the problems such as inspection being possible only to three times, but The infliximab qualitative analysis was useful at all.

P2-048
Evaluation of the pain in the biological preparation dosage for the rheumatoid arthritis using a stress sensor
Hiroshi Nakamura
Kure Medical Center/Chugoku Cancer Center, Kure, Japan

Conflict of interest: None

[Objective] It was intended to examine the clinical usefulness of the objective pain, stress index. [Method] First, we made the apparatus which could measure a heartbeat change and the breathing change using 6 axis gyro sensors by medicine mechanic cooperation at the same time. To measure the change of the pain before and after the intravenous feeding of the biological preparation in five rheumatoid arthritis patients with VAS and weighed it. For five rheumatoid arthritis patients who used biological preparation in hospitalization, we measured a breathing fluctuation index with a body leading note sensor within 30 minutes after intravenous feeding if before intravenous feeding and weighed it against other parameters. [Conclusions] the body sound sensor was able to measure a breathing fluctuation safely. Furthermore, as for the objective stress index, the related thing with the subjective pain evaluation (VAS) was suggested.

P2-049
Efficacy and safety of methotrexate for elderly-onset rheumatoid arthritis patients
Jun Fukui1, Takashi Hosokawa1, Takeshi Kaneko1, Tomomi Tada1, Kenji Funakoshi1, Shinichiro Nameki1, Koji Nomura1, Hiroshi Fujiiwa1
1Department of Rheumatology, Osaka General Medical Center, Osaka, Japan, 2Department of Orthopedic Surgery, Osaka General Medical Center, Osaka, Japan

Conflict of interest: None

[Objectives] We aimed to investigate the efficacy and safety of methotrexate (MTX) to treat patients with elderly-onset rheumatoid arthritis (EORA) within a year after diagnosis. [Methods] This retrospective study analyzed data obtained from 453 patients with RA who visited our hospital between April 2011 and July 2017. [Results] Among the 453 patients enrolled, MTX was administered to 154 patients aged 60 years or >= 60 years (EORA group) and to 122 patients aged < 60 years (YORA group). Disease activity (determined by DAS28 and SDAI) of RA at the time of diagnosis in the EORA group was higher than that in the YORA group. A year later, the disease activity was the same in both groups. The dose of MTX administered at the initiation of treatment and a year later to the EORA group was lower than that administered to the YORA group. In terms of adverse reactions, no intergroup difference was observed in the risk of infection. MTX-related toxicity occurred more commonly in the YORA group. [Conclusions] Previous reports have shown that MTX does not increase the risk of infections in patients with RA and that aging increases the risk of infections. In contrast to previous studies, this study showed that aging did not increase the risk of infections in patients using MTX.
**P2-050**
Change in serum RF titer predicts radiographic progression in RA patients treated with TNF inhibitors

Takayoshi Owada, Kazuhiro Kurasawa, Yuta Takamura, Tomoyuki Miyao, Ayae Tanaka, Ryutaro Yamazaki, Satoko Arai, Reika Maezawa, Masafumi Arima
Department of Rheumatology, Dokkyo Medical University

Conflict of interest: None

**[Object]** To determine whether continuous decrease in serum RF titer predicts radiographic remission in RA patients treated with TNF inhibitors (TNFIs).

**[Methods]** Subjects were 29 RA patients who were treated with TNFIs, had serum RF ≥451U/ml and were followed up until month 12. Serum RF was measured at month 0, 4 and 12 after starting anti-TNF therapy, and more than 10% decrease in RF titer was considered as significant reduction. Continuous RF decrease was defined as significant reductions during both month 0-4 and 4-12. RA disease activity and radiographic progression were assessed by DAS28-2CRP and modified total Sharp score (mTSS).

**[Results]** During anti-TNF therapy, 14 of 29 subjects showed continuous RF decrease (CD group), and 15 cases did not (nonCD). Between these groups, there were no differences in baseline characteristics, and DAS28-2CRP and mTSS at month 0 and 12. Median change in mTSS during month 0-12 (ΔmTSS) was 0 in CD and 1 in nonCD, and radiographic progression was smaller in CD. Additionally, ΔmTSS ≤0.5 was found in 71.4% of CD and 13.3% of nonCD, and a proportion of radiographic remission was higher in CD. In [Conclusions] Continuous RF decrease was associated with radiographic remission in TNFI-treated RA patients, and change in serum RF titer predicts radiographic progression.

**P2-051**
Examination of 104 weeks of DMARDs (tacrolimus or methotrexate) used in combination with abatacept

Takayoshi Fujiyash1, Nobunori Takahashi2, Daihei Kida1, Atsushi Kaneko1, Yuasuhide Kanayama1, Yuji Hirano1, Yuichi Yabe1, Takeshi Oguchi1, Toki Takemoto1, Masashi Kawasaki1, Toshiaki Ishiguro2, Toshihisa Kojima2
1Department of Orthopedic Surgery, Konan Kosei Hospital, 2Department of Orthopedic Surgery, Nagoya University Graduate School of Medicine, 3Department of Orthopedic Surgery and Rheumatology, Nagoya Medical Center, 4Department of Orthopedic Surgery, Toyohashi Municipal Hospital, 5Department of Rheumatology, Toyohashi Municipal Hospital, 6Department of Rheumatology, JCHO Tokyo Shinjuku Medical Center, 7Department of Orthopedic Surgery, Anjo Kosei Hospital

Conflict of interest: None

**[Object]** Examine efficacy and safety of abatacept (ABT) on rheumatoid arthritis (RA) treated with tacrolimus (TAC group), ABT plus methotrexate (MTX group), and ABT only (non-combination group) in a multicenter study by Tsurumai Biologics Communication Registry: TBCR.

**[Methods]** Of 513 patients who started treatment with ABT after marketing and received ABT for 104 weeks, 342 patients, excluding 15 patients who received TAC and MTX, were assigned to the TAC group (34 patients), the MTX group (166 patients), or the non-combination group (142 patients) to evaluate disease activity, retention rate. In [Results] The SDAI scores showed decreases in the TAC group, MTX group, and non-combination group from 30.7, 22.9, and 25.2 at baseline to 9.5, 7.9, and 8.7, respectively, at Week 104. The rates of decrease were 69.1%, 65.5%, and 65.5%, respectively, showing a larger decrease in the TAC group. The retention rate at Week 104 was 73.5%, 71.7%, and 68.3% in the TAC, MTX, and non-combination groups, respectively. No difference was found between the TAC and MTX groups. [Conclusions] A combination of ABT and TAC, which has a mechanism of action that inhibits the activation of T cells, would appear to be as effective and safe as the ABT/MTX combination.

**P2-052**
Association between functional disability and the elapsed time depending on the dose of glucocorticoids after achieving clinical remission in patients with rheumatoid arthritis

Ryota Harai1, Motomu Hashimoto2, Koichi Murata2, Wataru Yamamoto3, Tohru Takeuchi2, Koji Naga1, Yuichi Maeda1, Kosuke Ebina2, Yonshu Son1, Hideki Amuro1, Akira Onishi1, Kengo Akashi1, Masaki Katayama1, Tsutomu Kira1, Naoki Shimmyo1, Akira Kid1, Yasuhiro Akai1, Takashi Fujimoto4, Yasuhiro Tanaka1

The Center for Rheumatic Diseases, Nara Medical University, Nara, Japan, 2Department of Advanced Medicine for Rheumatic Diseases, Graduate School of Medicine, Kyoto University, Kyoto, Japan, 3Department of Health Information Management, Kurashiki Sweet Hospital, Kurashiki, Japan, 4Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan, 5Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University, Osaka, Japan, 6Department of Orthopaedic Surgery, Osaka University, Graduate School of Medicine, Osaka, Japan, 7First Department of Internal Medicine, Kansai Medical University, Osaka, Japan, 8Department of Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, 9Department of Rheumatology, Osaka Red Cross Hospital, Osaka, Japan

Conflict of interest: None

**[Object]** To investigate the relationship between the dose of glucocorticoids (GC) and HAQ-DI after achieving clinical remission in patients with rheumatoid arthritis (RA) in a time series. **[Methods]** A total of 25543 samples from 2649 RA patients who achieved clinical remission was analyzed in the ANSWER cohort. Huber-White robust sandwich estimator of a variance-covariance matrix was used. Interaction between GC dose at each visit and elapsed time was tested and adjusted by covariates at each visit in this model (Significance level 20%). A nonlinear restricted cubic-spline was contained, and missing data were imputed by the LOCF method. **[Results]** The median age was 59.8 years, female was 77.3%, median disease duration was 5.0 years, median DAS28-ESR was 2.1, HAQ-DI score was 0.125. Of all patients, 705 (26.6%) patients had been treated with oral GC at baseline. The relationship between GC dose and next HAQ-DI changed significantly (p for interaction = 0.056) depending elapsed time, and the impact of GC tended to weaken with Bio use (p for interaction = 0.316). Estimated HAQ-DI score decreased once but had increased more as the time elapsed dose-dependently. [Conclusions] Long-term use of GCs after achieving clinical remission had association with progress of functional disability.

**P2-053**
Comparison between tenderness joints that declared by the patient and that examined by medical person

Mihoko Tsujimura7, Masato Yamada1, Eiichiro Watanabe3
1Center for Rheumatic Diseases, Fuji Orthopedic Hospital, Shizuoka, Japan, 2School of Pharmacy, Nihon University, 3Department of Orthopedic Surgery, Fuji Orthopedic Hospital, Shizuoka, Japan

Conflict of interest: Yes

**[Object]** We Compare tenderness joints that declared by the patient with that examined by medical person. **[Methods]** We examined the tenderness joint in 28 joints of 218 RA patients for from September to October, 2018. PtTJ assumed it the report of the patients, and MdTJ was evaluated by a nurse. The group where all MdMJ fitted PtPJ were M, and the group where one or more differences were N. In [Results] Averge age was 65.9±13, CRP in 0.53±0.87, ESR in 27.5±19.9, DAS28 (ESR) in 2.79±1.14, MdTJ fitted PtTJ in 90.5%. M group 112 cases, N group 106 cases, PtTJ=MdTJ=0 were 101 cases, PtTJ=MdTJ=0 were 11 cases. Right fifth finger MP joint fitted it most (57.1%), the left elbow joint fit it least (7.1%). CRP in 0.35±0.55 (M), 0.72±1.08 (N), ESR in 23.1±16.2 (M), 32.2±22.3 (N), patient’s global assessment (PGA) in 28.2±16.5 (M), 31.4±22.5 (N), DAS28 (ESR) were 2.25±0.74 (M), 3.36±1.21 (N) when they compared M group and the N group. A significant difference was found all in these (p<0.01), but there were no significant differences in age between groups. [Conclusions] Inflammatory action and disease activity significantly showed high level in the patients whom PtTJ was high in. Therefore, the possibility that you should evalu-
The use of biologics. In the future, we need to consider more cases.

**Conclusion** we could not prove the significance of denosumab under evaluation. Therefore, we compared the effects of suppressing bone destruction of both groups. In addition, mTSS was used as a criterion for evaluating joint destruction. Bone destruction suppression is evaluated for joints of the hand (16 joints which are the mTSS evaluation joints.) Target patients were 8 patients without denosumab and data for 12 years were used. Denosumab combination group 8 cases, data for 17 years was used. The target joints were 144 joints and 272 joints. <Result> TNF inhibitor is used for 9 years of the combination group with denosumab and 1.25 in the group without denosumab combination, There was no significant difference between these two groups (P=0.348)

**Conclusion**: we could not prove the significance of denosumab under the use of biologics. In the future, we need to consider more cases.

**P2-055**

**Body weight and clinical efficacy to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis**

Takui Nishikawa, Toshihiro Matsu*, Sakae Tanaka*, Jinnu Nishino, Hirofumi Tsuno*, Kenichi Shimane*, Yoshio Uchida*, Shigeto Tohama* 1Department of Rheumatology, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan, 2Department of Rheumatology, NHO Sagamihara National Hospital, 3Department of Orthopaedics, The University of Tokyo 4Department of Rheumatology, NHO Tokyo National Hospital

Conflict of interest: None

**Object**: Effects of using abatacept on rheumatoid arthritis patients using biologics. **Method**: Patients using biologics at our hospital outpatient clinic were divided into two groups, namely, non-combined group with denosumab and combined group with denosumab. In addition, the effects of suppressing bone destruction of both groups were compared. mTSS was used as a criteria for evaluating joint destruction. Bone destruction suppression is evaluated for joints of the hand (16 joints which are the mTSS evaluation joints.) Target patients were 8 patients without denosumab and data for 12 years were used. Denosumab combination group 8 cases, data for 17 years was used. The target joints were 144 joints and 272 joints. <Result> TNF inhibitor is used for 9 years of the combination group with denosumab and 1.25 in the group without denosumab combination, There was no significant difference between these two groups (P=0.348).

**Conclusion**: we could not prove the significance of denosumab under the use of biologics. In the future, we need to consider more cases.

**P2-056**

**A case of latent synovitis that could be evaluated by articular echo with joint destruction progressing without inflammatory reactions, pain and swelling**

Shunsuke Sano, Tomonari Horiiuchi, Takanori Azuma Azuma Rheumatology Clinic

Conflict of interest: None

We report a case in which latent synovitis with no pain or swelling and no inflammatory response was detected by joint echo. Case 47-year-old man. Seven months ago, the patient complained of pain on both toes. Observation at first visit: TJC 17 SJC 8 CRP 0.35 MMP - 386 DASCRP 4.38 CRP 0.35 Anti - CCP antibody 466 3 RF 44 No bone erosion or stenosis on the X-ray image. Diagnosis and course: Since multiple arthritis was observed and both RF anti-CCP antibodies were positive, we diagnosed rheumatoid arthritis. MTX was prescribed to up to 10 mg / week, the findings of the joint quickly disappeared. CRP was also normalized, MMP-3 also maintained normal range, subjective symptoms and other perceptual findings were not found, but one year later X-rays were found in both limb toes, synovium thickening grade 2 Blood flow signal grade 2 was observed. Discussion: Even in the case of rheumatoid arthritis, maintaining remission and no objective findings of symptoms, we experienced progression to potential synovitis and bone destruction. Furthermore, potential active synovitis may be visualized by joint echo. We are currently studying echogenic findings and potential synovitis by performing a joint echo of fingers and toes in a patient maintaining remission.

**P2-057**

**A case of early intensification of treatment and diagnosis of secondary loss of response by using Remicade Q3 times**

Yuko Kimura, Shuzo Yoshida, Nobuhisa Shishido* 1Department of Immuno-Rheumatology Center, Arisawa General Hospital, Hirakata, Osaka, Japan. 2Department of Urology, Arisawa General Hospital, Hirakata, Osaka, Japan

Conflict of interest: None

**Case**: A 57-year-old female was diagnosed rheumatoid arthritis (RA) in X-1 year and was treated with methotrexate (MTX) 10 mg/week in other hospital. In X-2 year, she visited our hospital and increased MTX to 12 mg/week, but due to hepatic injury reduced to 10 mg/week. In June X-1 year, DAS28-ESR was elevated to 4.19, infliximab (IFX) was started. DAS28-ESR improved to 3.63 at 14 weeks after starting IFX, but IFX was increased to 6 mg/kg/6 weeks because Remi Q was negative. However, DAS28-ESR at 20 weeks was not improved, we checked Remi Q again, and it was negative. IFX was increased to 6 mg/kg/4 weeks, clinical and ultrasound remission were achieved. However, CRP was elevated in August X year and DAS 28-ESR became 2.99. We checked Remi Q again in October X year. The result was negative, we diagnosed it was secondary invalid. [Clinical significance] Remi Q at 14 weeks and 22 weeks were negative, we increased IFX dosage and intervals and subsequently maintained clinical and ultrasound remission early. Further, we noticed secondary loss of response by using Remi Q again. The activity also correlated with power doppler findings. We considered that Remi Q was a useful tool that can judge secondary loss of response at the early stage in addition to the introduction of early remission.

**P2-058**

**Experience of using golimumab in rheumatoid arthritis with interstitial lung disease in our hospital**

Hideyuki Shiho1,2, Koji Nagai1, Shogo Matsuda*, Takao Kiboshi1, Ayaka Yoshikawa1, Takaaki Ishida1, Youhei Fujiki1, Kenichiro Hata1, Takeshi Shoda1, Takuya Kotani1, Yoko Matsumura1, Tohru Tsuchuki1, Masakazu Sugino1, Shigeki Arawaka1 1Department of Internal Medicine IV, Osaka Medical College, Takatsuki, Osaka, Japan, 2Department of Rheumatology, Koshokai Aino Hospital, Ibaraki, Osaka, Japan

Conflict of interest: None

**Object**: In the rheumatoid arthritis (RA) treatment algorithm represented by EULAR recommendations in 2016, treatment with bDMARDs is recommended when csDMARDs are not effective. On the other hand, RA is known to be involved with interstitial lung disease (ILD) to about 30% to 50%. Since there is concern that ILD may be exacerbated by anti-TNFα therapy, RA with ILD often has difficulty in treatment. Therefore, we summarize cases using golimumab (GLM) against RA with ILD at our hospital and report on the clinical course. **Method**: We investigated the drug continuation rate for 11 cases in which information could be extracted among 13 RA patients with ILD who had GLM introduced since March 2015, and analyzed disease activity and adverse events. **Results**: Among 11 cases, in 1 case GLM was changed to tocilizumab due to pri-
mary invalidity, in 1 case GLM was discontinued due to pneumonias, in 2 cases GLM was discontinued due to social background, in 7 cases GLM was continued. Disease activity in 7 cases was significantly decreased at 6 months and 12 months after the start of GLM. The mean number of days of administration was 707.4 days, and all patients were still ongoing without exacerbation of ILD. [Conclusions] GLM was suggested to be an option in the treatment of RA with ILD.

**P2-059**
Relation of combined pulmonary fibrosis and emphysema (CPFE) to anti-CCP antibody (ACPA) in patients with rheumatoid arthritis
Shinji Motojima, Tamao Nakashita, Akira Yoshida, Akira Jibatake
Rheumatology and Allergy, Kameda Medical Center, Kamogawa, Japan

Conflict of interest: None

[Object] We have reported that pulmonary lesions are important not only as a prognostic factor but also as a triggering place of ACPA production. CPFE was first reported by Cottin in 2005 and is a risk factor of lung cancer and pulmonary hypertension. We studied the prevalence of CPFE in RA patients and its relation to ACPA. [Methods] Subjects are 567 RA patients who performed chest CT. Prevalence of interstitial lung diseases (ILD), classification of ILD pattern, and the presence of CPFE were studied using CT findings. [Results] ILD was found in 223 out of 567 RA patients (39.3 %), and UIP, NSIP and OP were found in 41, 167 and 14 patients, respectively. CPFE was found in 36 (6.3 % of total patients and 16.1 % of patients with ILD). Prevalence of CPFE in each ILD pattern were 53.7 %, 8.4 % and 0 % in UIP, NSIP and OP, respectively. All the patients with CPFE were smokers. ACPA titer was significantly higher in ILD group than non-ILD group (median 252 vs. 45.5, p<0.005). In ILD group, ACPA titer was significantly higher in CPFE group than non-CPFE group (median 252 vs.93, p<0.05). [Conclusions] ACPA titer was higher in ILD group, and in ILD group, CPFE group showed higher ACPA titer.

**P2-060**
A clinical investigation of the pleurisy combined with rheumatoid arthritis (RA)
Yasuhiro Yoshinaga, Tetsushi Aita, Susumu Nishiyama, Shoji Miyawaki
Rheumatic Disease Center, Kurashiki Medical Center, Kurashiki, Japan

Conflict of interest: None

[Object] To evaluate the clinical characteristics of the pleurisy combined with rheumatoid arthritis (RA). [Methods] We investigated the clinical characteristics of 20 RA patients (10 males, 10 females, mean age 64.9±8.7) admitted to our hospital with pleurisy in 2003-18. [Results] Eight out of 20 cases were RA pleurisy, 8 cases infection (4 general bacteria, 2 non-tuberculous mycobacteria (NTM), a case of tuberculosis and a case of cryptococcosis), 2 malignant pleurisy, a suspicious case of multiple pneumonia caused by MTX-LPD and a case of TNF inhibitor-induced lupus pleurisy). Looking at the causes of pleurisy by year, RA pleurisy has increased and infectious diseases are increasing. ADA and hyaluronic acid in pleural effusion may show high values even in RA pleurisy and empyema, and to distinguish from tuberculous or malignant mesothelioma, an acid bacteria test of pleural effusion, cytological diagnosis and histologic examination of pleural biopsy are necessary. [Conclusions] Recurrence of pleurisy associated with RA is diverse including RA pleurisy, malignancy, infectiousness, etc. Recently, multiple pneumonia caused by MTX-LPD, TNF inhibitor-induced lupus pleurisy is added, and it is becoming more difficult to differentiate pleurisy combined with RA.

**P2-061**
Relation of pulmonary function to anti-CCP antibody titer and RF titer
Shinji Motojima, Tamao Nakashita, Akira Yoshida, Akira Jibatake
Rheumatology and Allergy, Kameda Medical Center, Kamogawa, Japan

Conflict of interest: None

[Object] In JCR2018 we reported the relation of the presence of abnormalities in respiratory system evaluated by chest CT to anti-CCP antibody and RF titers in RA patients with short disease duration (less than 1 year). Here we studied the relationship between pulmonary function, and anti-CCP antibody and RF titers. [Methods] Subjects were 164 patients with the RA with the disease duration of less than 1 years. [Results] Pulmonary function tests were VC, FEV1, FEV1/FVC, V50 and V25. When normal values were defined as more than 80%, 80%, 70%, 70%, and 50% in %VC, %FEV1, FEV1/FVC, %V50, and %V25, respectively, percentages of patients in the normal ranges were 79%, 71%, 55%, 19%, and 16%, respectively, suggesting prevalence of small airway obstruction. There was a weak but significant inverse correlation (rs = -0.156) between anti-CCP antibody titer and %FEV1, and correlation to %V25 was tended to be significant (rs = -0.143). RF titer did not show significant correlations to any pulmonary function parameters. [Conclusions] Anti-CCP antibody titer relates to small airway obstruction in pulmonary function tests which suggests the presence of small airway inflammations.

**P2-062**
Presence of diabetes represented a risk factor for incidence of new carotid plaque in patients with rheumatoid arthritis -TOMORROW study-
Shohei Anno1, Kentaro Inui1, Yuko Sugioaka2, Kenji Mamoto2, Tadashi Okano2, Masahiro Tada4, Tatsuya Koike3,5
1Department of Orthopedic Surgery, Yodogawa Christian Hospital, 2Department of Orthopedic Surgery, Osaka City University Graduate School of Medicine, 3Center for Senile Degenerative Disorders (CSDD), Osaka University Graduate School of Medicine, 4Department of Orthopedic Surgery, Osaka City General Hospital, 5Search Institute for Bone and Arthritis Disease (SINBAD)

Conflict of interest: None

[Object] The objective of this study was to evaluate the morbidity and severity of carotid plaque in patients with RA and in age- and sex-matched controls (Co) who participated in the TOMORROW study. [Methods] This study included 360 participants (RA:175, Co:185) and carotid ultrasound was performed both at 2011 and at 2017. Atherosclerotic plaque was defined as an intima-media thickness > 1.1 mm. Severity of plaque was assessed by plaque score. [Results] Carotid plaque was observed more frequently in RA than Co at 2011 (n=82 vs n=66, p = 0.04). Incidence of new plaque were no differences between RA and Co (n=33 vs n=44, p = 0.94). Comparing RA patients with and without incidence of new plaque, age (p=0.015) and presence of diabetes (p=0.09) were higher in patients with incidence of new plaque. Plaque score became advanced both RA and Co (RA:p=0.001, Co:p=0.001). However plaque score in RA patients with plaque who had the habit of exercise did not became advanced (RA:p=0.07, Co:p<0.001). [Conclusions] There were no significant differences in incidence of new plaque, in progression rate of plaque score between RA and Co. In RA patients, presence of diabetes represented a risk factor for incidence of new plaque, and exercise can decrease the progression of the plaque.

**P2-063**
Characterization of three rheumatoid arthritis patients with recurrence of lymphoproliferative disorders
Shinya Hirata, Eiko Miyagawa, Rie Furuta, Ayako Yamamura, Mizuho Tsujihashi, Masayuki Murai, Yumiko Mizuhashi, Mikako Ikukura
Departments of Rheumatology and Clinical Immunology, Kumamoto University Hospital

Conflict of interest: None

[Objectives] Lymphoproliferative disorders (LPD) develop in some patients (pts) with rheumatoid arthritis (RA). It is hypothesized that pathogenesis of LPD are immunosuppression and reactivation of Epstein Barr virus (EBV) caused by immunosuppressant including methotrexate (MTX), chronic inflammation of RA and Sjogren’s syndrome, and so on. These mechanisms might relate to recurrence of LPD. [Methods] We analyzed 3 pts (a male and 2 females) with recurrent LPD among 21 RA pts with LPD from January 2010 to October 2018. [Results] The age was 53 to 66 years old at onset of LPD. MTX had been administered to all pts,
and the duration of MTX treatment was 15 to 149 months. A patient was treated by etanercept. They were diagnosed to have follicular lymphoma, B cell lymphoma and lymphoproliferative disorder. EBV was not detected in tumor tissues from all pts. 2 pts received chemotherapy, while one patient discontinued MTX. After treatment of LPD, 2 pts experienced relapse of RA at 3 and 13 months. They had been treated by tacrolimus, igruratimod and biological DMARDs. LPD relapsed within 21 to 56 months, and were treated by chemotherapy. [Conclusion] We experienced 3 RA pts with recurrence of LPD. The clinical histories suggested that mechanisms of LPD related to recurrence.

P2-064
The Significance of axillary lymph node enlargement as a Marker of obesity in Rheumatoid Arthritis
Masanobu Yoshida, Akitake Suzuki
Department of Rheumatology, Mitsui Memorial Hospital, Tokyo, Japan

Conflict of interest: None

[Objective] The present study was conducted to evaluate the association with axillary lymph nodes (ALN) enlargement and Rheumatoid Arthritis (RA) clinical features. [Methods] This was a retrospective observational study performed at our institute on outpatients between 2014 and 2017. All 67 untreated RA patients were performed by chest computed tomography scanning (CT), the maximum long and the maximum short diameter of left and right ALN were measured from the CT image, either the left or right ALN larger values was adopted. Exclusion criteria were malignant tumor and polyvascular disease. [Results] In multivariate analysis, the maximum and minimum short diameter of the ALN was independently associated with Body Mass Index (BMI). Both the maximum long and the maximum short diameter of ALN were significantly longer in subjects strong positive for rheumatoid factor (RF) and anti- cyclic citrullinated peptide antibody (ACPA) than in seronegative subjects. [Conclusion] ALN diameter seems to reflect RF or ACPA as markers in diagnosing and predicting the prognosis of untreated RA, and ALN diameter is associated with BMI. It is suggests that ALN diameter may be an indicator suggesting obesity, not inflammation with untreated RA patients without malignant tumor and polyvascular disease.

P2-065
Is Rheumatoid Arthritis really risk factor of osteoporosis even when T2T is widely permeated?
Ichiro Yoshii1, Tatsumi Chijiwa2, Naoya Sawada3
1Rheumatology and Musculoskeletal Medicine, Yoshii Hospital, 2Department of Rheumatology, Kochi Memorial Hospital, 3Department of Rheumatology, Center for Rheumatic Diseases, Dolgo Spa Hospital

Conflict of interest: None

[Objective] It is a long time since rheumatoid arthritis (RA) is recognized as an independent risk factor of osteoporosis (OP). However, it has already eight years since T2T protocol was advocated. It RA a real risk factor of OP? We have investigated whether it is still so. [Methods] From September 2017 to August 2018, 687 cases were examined dual energy X-ray absorptiometry, in whom 279 were RA and 408 were non-RA. In the RA cases, subjects who attained clinical remission within 1 year were picked up. From them and non-RA cases, age, sex, Barthel Index Score distribution, Creatinine/CystatinC ratio, number of comorbidities, administered drugs were matched, and then bone mineral density (BMD) of lumbar spine (LS), femoral neck (FN), whole femur (WF), and greater trochanter (GT) were compared between the two groups statistically with Mann-Whitney U test. [Results] 116 cases of RA and 108 of non-RA were recruited. Average DAS28-1CRP in RA was 1.73, while average mHAQ score was 0.47. BMD of LS, FN, WF, and GT were 93.5, 77.8, 79.9, and 83.0 (%YAM) in RA, while 77.5, 64.8, 68.3, and 73.1 in non-RA, respectively. [Conclusions] As long as RA treatment is tightly performed and attained clinical remission, RA is no longer OP risk.

P2-066
Patients with rheumatoid arthritis who complicated rapidly progressive glomerulonephritis have high disease activity and are resulted in delayed consultation to nephrologists
Shin Okuyama, Fumito Abe, Masaya Saito, Mizuho Nara, Atsushi Komatsuda
Department of Hematology, Nephrology, and Rheumatology, Akita University Graduate School of Medicine

Conflict of interest: None

[Objective] To clarify the characteristics of RPGN that merges with RA and to extract attention points in clinical practice. [Methods] We extracted cases with RPGN concurrently with RA in patients from 1998 to March 2018 at the Akita University Hospital and summarized their characteristics. [Results] Among RA 2264 cases, RPGN was merged in 5 cases (0.22%). Neither treatment history of biological products containing TNF inhibitor was present. The patient age was 53 to 91 years old (average 73.2, median 75), the ratio of male to female was 4 : 1, the initial symptom was fever and joint pain, the serum creatinine was 1.9-7.2 mg/dL (average 3.19, median 1.98), CRP was 2.89 - 20.0 mg/dL (mean value 9.32, median 4.48), ANCA was detected in 4 cases. Two patients had end-stage renal failure and three had progressed as chronic kidney disease. [Conclusions] Patients having RPGN with RA tended to have high RA disease activity and delayed consultation to kidney physician. The onset age was older as compared with AAV patients secondary to TNF inhibitors. The cause of delay is that urinalysis was not performed. Based on the above, we would like to encourage regular urinalysis for rheumatoid arthritis patients with high disease activity.

P2-067
The treatment of cutaneous ulcer due to rheumatoid vasculitis in OMMC
Maiko Yoshimura1, Eri Oguro1, Kentaro Kuzuya1, Yasutaka Okita1, Hitodetsi Matsuoka1, Satoru Teshigawara1, Yoshinori Harada1, Yuii Yoshida1, Kentaro Isoda1, Shiro Ohshima1, Ken Hashimoto1, Yukihiyo Sakci2
1Department of Rheumatology, Osaka Minami Medical Center, 2Department of Research, Osaka Minami Medical Center

Conflict of interest: None

[Objective] The skin ulcer due to the rheumatoid vasculitis (RV) is often refractory, but lacks in a well-organized report about the treatment. Steroids and cyclophamide are recommended for the RV. On the other hand, there is the report that anti-TNF agent or Abatacept is effective for a skin ulcer of RV. I would report the treatment of skin ulcer in OMMC. [Methods] I review about the treatment in these cases. [Result] We identified 11 cases of skin ulcer due to RV. One case is focal therapy only, 10 cases (almost all) use steroids. 4cases use cyclophospha- mide, 4cases use tacrolimus, 1case use anti-TNF agent, 3cases use Abatac- cept. IVIG, L-CAP therapy is also performed. Infection is most major side-effect (7cases). clinical outcome: 6cases get better or remission, 2cases died, 2cases is no change, 1case is now in the hospital. [Conclusions] Abatacept may be useful for skin ulcer of RV. Steroid monotherapy was failed. Adequate use of immnosuppressant agent or biologics is important for success of the treatment of RV.

P2-068
A case of pulmonary arterial hypertension with rheumatoid arthritis
Daiki Hayashi, Shinji Kimajima, Tadamichi Toyama, Akinori Hara, Yasunori Iwata, Norihiko Sakai, Miho Shimizu, Kengo Furuiuchi, Takashi Wada
Department of Nephrology, Kanazawa University Hospital

Conflict of interest: None

The female patient was a 35-years-old with history of rheumatoid arthritis (RA) since 27 years old. At diagnosis of RA, she presented multiple phalangeal and wrist joint pain with synovitis. However, rheumatoid factor and anti-CCP antibody were negative. She was treated with methotrexate, multiple biological drugs and immunosuppressants. She admitted
to our hospital with a dry cough. Echocardiogram indicated severe elevated right ventricular systolic pressure (RVSP) of 77 mmHg. The left ventricle was D-shape and right ventricle was enlarged in echocardiogram. Left ventricular ejection fraction was preserved. Cardiac catheterization revealed mean pulmonary artery pressure (mPAP) 44 mmHg and pulmonary capillary wedge pressure 13mmHg. Pulmonary embolism and interstitial lung disease were excluded by computed tomography of the chest and pulmonary ventilation-perfusion scintigraphy. Pulmonary arterial hypertension associated with connective tissue diseases was speculated. She was treated three courses of steroid pulse therapy (mPSL 500 mg/3 days), tacrolimus and sildenafil. Her symptoms, abnormal echocardiographic findings and RVSP improved rapidly. We report here a rare case of PH associated with RA.

P2-069
A case of rheumatoid arthritis-associated aortitis
Takahiro Tsuchida, Ko Sudo, Hiroyuki Yano, Mitsuyo Kinjo
Department of Rheumatology, Okinawa Chubu Hospital

Conflict of interest: None

Case: 65 y.o man History of present illness: After being tapered on prednisone for newly diagnosed organizing pneumonia one month earlier, the patient presented with fatigue and bilateral painful red eye. Joint pain and anaemia limited his activity and the patient became wheelchair bound. Clinical course: Physical examination revealed symmetrical polyarthritis and scleritis, and blood tests showed marked leukocytosis and thrombocytosis, elevated inflammatory markers and high rheumatoid factor and anti-cyclic citrullinated peptide antibody. Computed tomography with contrast revealed arterial wall thickening of the right external carotid artery and aortic arch. The patient was diagnosed with seropositive rheumatoid arthritis with large vessel vasculitis and scleritis. His symptoms significantly improved on high dose prednisone and intravenous tocilizumab. Discussion: Large vessel vasculitis and scleritis in a patient with newly diagnosed active rheumatoid arthritis are uncommon presentations of extra-articular manifestation. We reviewed literature on large vessel vasculitis in rheumatoid arthritis.

P2-070
In the patients with RA, vascular stiffness is related to bone mineral loss, disease activity of RA, and the degree of skeletal muscle atrophy
Yumeko Taniguchi, Ryosuke Hanaoka, Toshiko Haginoya, Sayaka Koizumi
Department of Rheumatology, Kamitsuga General Hospital

Conflict of interest: None

[Object] To clarify the relationship between increased vascular stiffness in rheumatoid arthritis (RA) patients, bone mineral loss, joint destruction and skeletal muscle atrophy. [Methods] Body component analysis was carried out by direct segmental multifrequency bioelectrical impedance analysis (DSM-BIA) for the RA patients. We measured skeletal muscle mass (SM), bone mineral content (BMC), body mass index (BMI), brachial circumference, and body fat percentage (BFP). As a simple representative of joint destruction, the activity of the carpal height ratio (CHR) of the two-hand joints was measured. Arterial velocity pulse index (AVI) was measured as a simple representative value of vascular stiffness. We used bone mass density (BMD) of the lumbar vertebrae and femoral neck by double energy X-ray absorption method as an indicator of bone mineral loss. [Results] There was a significant correlation between AVI and indicators of bone mineral loss (BMC, hip joint BMD, lumbar spine BMD), skeletal muscle atrophy (SMI, brachial circumference), and RA disease activity (CDAI, SDAI). [Conclusions] In the patients with RA, vascular stiffness is related to bone mineral loss, disease activity of RA, and the degree of skeletal muscle atrophy rather than BFP or BMI.

P2-071
A Case of Methotrexate-associated Lymphoproliferative Disease with Multiple Masses, Gastrointestinal Ulcers and Perforations
Akira Nishino, Hiteto Takada, Mari Tochihara, Shinya Hirahara, Hirokazu Nishina, Masanori Hanaoka, Yasuhiro Katsumata, Masayoshi Harigai, Hisashi Yamanaka
Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan

Conflict of interest: None

[Case] A woman in her 60s had diagnosed with rheumatoid arthritis (RA) and had been treated with methotrexate (MTX) for 16 years. She visited our hospital with one-month history of cough and dyspnea. At her visit, she presented fever and hypoxia. CT scan showed multiple masses in the lungs and pancreas. Upper endoscopy revealed multiple ulcers in the stomach and duodenum. Pathological examination of the ulcerative lesion revealed large lymphoma cells that were positive for CD20, CD79a, and LMP-1. The patient developed ileal perforation, and emergency ilectomy was performed. CD20-positive lymphoma cells were found at the perforated lesion. Therefore, we concluded that multiple masses as well as gastrointestinal ulcers and perforations were a series of manifestations of diffuse large B-cell lymphoma. Those masses did not reduce one month after withdrawal of MTX so that she was transferred to the Division of Hematology in order to receive chemotherapy. The pulmonary masses partially reduced by 2 cycles of R-CHOP. She is scheduled to receive R-CHOP for 8 cycles in total. [Clinical significance] This case suggests MTX-associated lymphoproliferative disease can cause various extranodal lesions such as multiple masses, gastrointestinal ulcers and perforations.

P2-072
Bloody pleural effusion in a case of rheumatoid arthritis; difficulty in making a differential diagnosis
Tetsushin Murakami1, Daitsuke Oryoji2, Yasutaka Kimoto1, Masahiro Ayano2, Hiroki Mitoma1, Mitsuteru Akahoshi2, Yojiro Arinobu, Koichi Akashi1, Hiroaki Niino1, Takahiko Horie1h
1Department of Internal Medicine, Kyushu University Beppu Hospital, 2Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, 3Department of Medical Education, Kyushu University Graduate School of Medical Sciences

Conflict of interest: None

[Case] 72-year old male [Chief complaint] Polyarthralgia, Right anterior chest pain, Bloody pleural effusion [Medical history] The patient developed rheumatoid arthritis in February of X-3, and right front chest pain and dyspnea appeared in July, X-3. The infiltrating shadow of the right lower lobe and right pleural effusion were observed, and pleural effusion showed yellow exudative pleural effusion. Pleural effusion gradually improved after starting PSL 30 mg / day, but a small amount of pleural effusion remained. Pleural effusion was re-exacerbated from X-2 in May, and TCZ administration was introduced in December X-2. Continued the infusion, but the right pleural effusion gradually worsened. [Course of treatment] Bloody pleural effusion was found by diagnostic thoracentesis. The result of the pathological examination indicated a granulation increase suspected of cavernous hemangioma. Malignant cells were not observed, and malignant disease was diagnosed as negative from the biopsy results. I diagnosed as malignant rheumatoid arthritis and started ABT administration. [Clinical importance] It is a case of rheumatoid arthritis combined with bloody pleural effusion and it is considered to be a highly suggestive case in distinguishing from malignant tumor.

P2-073
Clinical features of 14 patients with MTX associated lymphoproliferative disorders (MTX-LPD) in our hospital
Chisaki Ajima1,2, Takao Sugiyama1, Yusuke Yokoyama1, Mieko Yamagata1, Ayako Norimoto1, Yoshie Sanayama1, Toyohiko Sugimoto1, Masaaki Furukawa1, Daiki Nakagomi1, Kenichiro Kitamura2
1Department of Rheumatology, National Hospital Organization, Shimoshizu Hospital, Chiba Japan, 2Third Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan

Conflict of interest: None

[Case] 72-year old male [Chief complaint] Polyarthralgia, Right anterior chest pain, Bloody pleural effusion [Medical history] The patient developed rheumatoid arthritis in February of X-3, and right front chest pain and dyspnea appeared in July, X-3. The infiltrating shadow of the right lower lobe and right pleural effusion were observed, and pleural effusion showed yellow exudative pleural effusion. Pleural effusion gradually improved after starting PSL 30 mg / day, but a small amount of pleural effusion remained. Pleural effusion was re-exacerbated from X-2 in May, and TCZ administration was introduced in December X-2. Continued the infusion, but the right pleural effusion gradually worsened. [Course of treatment] Bloody pleural effusion was found by diagnostic thoracentesis. The result of the pathological examination indicated a granulation increase suspected of cavernous hemangioma. Malignant cells were not observed, and malignant disease was diagnosed as negative from the biopsy results. I diagnosed as malignant rheumatoid arthritis and started ABT administration. [Clinical importance] It is a case of rheumatoid arthritis combined with bloody pleural effusion and it is considered to be a highly suggestive case in distinguishing from malignant tumor.
[Background] Methotrexate (MTX) is the anchor drug of rheumatoid arthritis, frequently used. On the other hand, many have been reported lymphoma during treatment with MTX. [Purpose] We examined clinical pictures of 14 patients with MTX-LPD in our hospital since 2007-2018. [Result] Three of them were men, 11 were women, average age was 69 y.o. They used 3.5g of MTX for 9 years in average. Five of them used tacrolimus (TAC) together. We followed up for 34 months after MTX-LPD onset. Five patients whose onset was superficial lymphadenopathy and 3 patients discovered by subcutaneous tumor were in stage 1 or 2, and 6 patients who had the onset for an organ infiltration were in stage 4. Some symptoms appeared rapidly in the patients in stage 4, and we discovered tumors in lung or liver or abdominal cavity by image close inspection. Chemotherapy was given 3 patients as soon as discontinuing MTX, and 2 whose lesion had not reduced after MTX cancellation. All patients who used TAC together improved without stopping TAC. [Conclusion] MTX-LPD often happens in elderly patient. MTX-LPD in stage 4 remitted spontaneously only withdrawal of MTX regardless of pathologic type, including who used tacrolimus together. We recommend discontinuing MTX and observing at first when you discover MTX-LPD.

P2-076
A case of rheumatoid arthritis which aortitis and small vasculitis occurred simultaneously and died due to empyema
Ryo Yamashita, Yusuke Izumi, Takahiro Yamada
Department of General Medicine, The Jikei University Daisan Hospital, Tokyo, Japan
Conflict of interest: None

[A Case] A 74-year-old woman visited our hospital with lower leg ulcers and chest back pain. She had been diagnosed as rheumatoid arthritis when she was 30 years old and received tocilizumab and tacrolimus. Skin biopsy from leg ulcers revealed necrotizing vasculitis. Chest MRI suggested the presence of aortitis. She was treated steroid pulse therapy from day 1, prednisolone 50 mg/day from day 4, and cyclophosphamide pulse therapy from day 10. Chest MRI showed the improvement of aortitis, on the other hand lower leg ulcers did not improve. Lower leg ulcers gradually improved after the leukapheresis procedures were used from day 32. Septic shock had occurred on day 43. Antibiotics were initiated but she developed lung abcesses and died due to empyema on day 71. From the result of autopsy, the cause of death was empyema. There were no findings of aortitis. [Discussion] Although it is known that aortitis and small vasculitis are associated with rheumatoid arthritis, it is rare to develop at the same time.

P2-077
A Case of Rheumatic Meningitis with Refractory Progress due to Delayed Initial Treatment
Takuya Yangaida, Atsushi Omoto, Satoshi Oumura, Masatoshi Kadoya, Wataru Fukuda
Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan
Conflict of interest: None

An 80-year-old woman, who was diagnosed with rheumatoid arthritis 20 years ago, was admitted because of the joint pain. On the 7th day, a rapid decline in cognitive function appeared. Brain MRI revealed high signals in the brain groove and subarachnoid space of the temporal lobe and both side parietal lobes. Cerebrospinal fluid examination revealed increase in IL-6 value, increase in cells and decrease in Glucose. Malignant tumors and infectious diseases were negative, we diagnosed as rheumatic meningitis (RM). She was discharged on the 28th day because symptoms improved without treatment. However, symptoms worsened again and she was re-hospitalized. On the 56th day, Intravenous pulse steroids (methylprednisolone 500mg daily for 3 days) were administered, followed by oral corticosteroids (1.0mg/kg/day). However, symptoms worsened and intravenous cyclophosphamide (IVCY) was added but response was poor, speech became impossible at the third IVCY and IVCY was terminated. It is said that RM is often remissionable by steroid therapy in general. This case is an instructive case that showed fluctuation of symptoms at the time of onset and had a refractory course due to delayed treatment, and so we report this case with literature consideration.

P2-078
Two cases of rheumatoid meningitis with different clinical courses
Shoin Mo, Shunsuke Mori, Yasuo Suenaga
Department of Rheumatology, National Hospital Organization, Beppu Medical Center
Conflict of interest: None

Case 1, a 71-year-old male, without history of rheumatoid arthritis (RA), was admitted to our hospital because of fever, headache and gait disturbance. He was diagnosed with rheumatoid meningitis (RM) based on leptomeningeal biopsy specimens and the elevation of anti-cyclic citrullinated peptide antibody (ACPA) in serum and cerebrospinal fluid

P2-074
A case of rheumatoid arthritis (RA) with right forearm soft tissue mass
Norihiro Mayumi, Hiroki Wakabayashi, Masahiro Hasegawa, Akihiro Sudo
Department of Orthopedics, Mie University Hospital, Mie, Japan
Conflict of interest: None

[Object] We report a case of rheumatoid arthritis (RA) who became refractory after excision of right forearm soft tissue mass. [Case] A 38-year-old female with RA suffers in 19 years. A tumor appeared in the right forearm 9 months before visiting our hospital and was excised by a nearby doctor, but it relapsed and the wound became refractory, so introduced to our hospital. At the first visit, a protruding lesion was observed with leachate. Her disease activity was DAS 28-ESR 5.45. [Results] The IL-2 receptor was normal, but HTLV-1 antibody was positive. Tumor biopsy showed intense inflammatory cell infiltration with intraepithelial and interstitial neutrophils but no malignant findings. In addition, HTLV-1 antibody Western blot and virus analysis were negative and considered rheumatoid nodules. Neoplastic lesions were not observed in whole body examination by trunk CT. RA treatment was changed to iguratimod. The DAS 28 improved from 5.66 to 3.30 in 3 months and the forearm mass cured. Two years after, DAS 28 is 3.83, and recurrence of tumor mass is not admitted. [Conclusions] Although it is less frequently, rheumatic meningitis (RM) was terminated. It is said that RM is often remissionable by steroid therapy. However, symptoms worsened from leg ulcers and chest back pain. She had been diagnosed as rheumatoid arthritis when she was 30 years old and received tocilizumab and tacrolimus. Skin biopsy from leg ulcers revealed necrotizing vasculitis. Chest MRI suggested the presence of aortitis. She was treated steroid pulse therapy from day 1, prednisolone 50 mg/day from day 4, and cyclophosphamide pulse therapy from day 10. Chest MRI showed the improvement of aortitis, on the other hand lower leg ulcers did not improve. Lower leg ulcers gradually improved after the leukapheresis procedures were used from day 32. Septic shock had occurred on day 43. Antibiotics were initiated but she developed lung abcesses and died due to empyema on day 71. From the result of autopsy, the cause of death was empyema. There were no findings of aortitis. [Discussion] Although it is known that aortitis and small vasculitis are associated with rheumatoid arthritis, it is rare to develop at the same time.

P2-077
A Case of Rheumatic Meningitis with Refractory Progress due to Delayed Initial Treatment
Takuya Yangaida, Atsushi Omoto, Satoshi Oumura, Masatoshi Kadoya, Wataru Fukuda
Center for Rheumatic Disease, Japanese Red Cross Society Kyoto Daiichi Hospital, Kyoto, Japan
Conflict of interest: None

An 80-year-old woman, who was diagnosed with rheumatoid arthritis 20 years ago, was admitted because of the joint pain. On the 7th day, a rapid decline in cognitive function appeared. Brain MRI revealed high signals in the brain groove and subarachnoid space of the temporal lobe and both side parietal lobes. Cerebrospinal fluid examination revealed increase in IL-6 value, increase in cells and decrease in Glucose. Malignant tumors and infectious diseases were negative, we diagnosed as rheumatic meningitis (RM). She was discharged on the 28th day because symptoms improved without treatment. However, symptoms worsened again and she was re-hospitalized. On the 56th day, Intravenous pulse steroids (methylprednisolone 500mg daily for 3 days) were administered, followed by oral corticosteroids (1.0mg/kg/day). However, symptoms worsened and intravenous cyclophosphamide (IVCY) was added but response was poor, speech became impossible at the third IVCY and IVCY was terminated. It is said that RM is often remissionable by steroid therapy in general. This case is an instructive case that showed fluctuation of symptoms at the time of onset and had a refractory course due to delayed treatment, and so we report this case with literature consideration.

P2-078
Two cases of rheumatoid meningitis with different clinical courses
Shoin Mo, Shunsuke Mori, Yasuo Suenaga
Department of Rheumatology, National Hospital Organization, Beppu Medical Center
Conflict of interest: None

Case 1, a 71-year-old male, without history of rheumatoid arthritis (RA), was admitted to our hospital because of fever, headache and gait disturbance. He was diagnosed with rheumatoid meningitis (RM) based on leptomeningeal biopsy specimens and the elevation of anti-cyclic citrullinated peptide antibody (ACPA) in serum and cerebrospinal fluid

S280
(CSF). After treatment with high-dose prednisolone (PSL) and azathioprine, his symptoms improved. Case 2, a 78-year-old female with no prior history of RA presented with cognitive dysfunction and fever. On magnetic resonance imaging, leptomeningeal hyperintensities were observed and the leptomeningeal biopsy specimens revealed cryptococcus fungus body. Cryptococcus meningitis was considered and antifungal agent was started, however she showed consciousness disorder and polyarthritis. Because of the elevation of rheumatoid factor and ACPA in serum and CSF, she was diagnosed with RM. After the treatment with methylprednisolone pulse, she showed dramatic improvement of her consciousness and polyarthritis. Notably, the improvement was not simple reflection of RA disease activity but that their immunological dysregulation could be correlated in their pathogenesis.

P2-079
A Case of RA Patient with Multiple Pulmonary Nodules and Pneumothorax

Akiko Sasaki1,2, Yuya Takakubo1,2, Suran Yang1, Hirohuru Okii1, Yasushi Nagamune1, Yuta Suzuki1, Hiroshi Orie1, Michiaki Takagi1
1Department of Orthopaedic, Yamagata University Faculty of Medicine, 2Department of Orthopaedic, Yamagata Saisei Hospital

Conflict of interest: None

This case is 74-years old female with a 30-year history of seropositive RA with history of interstitial pneumonia. This patient was treated with tacrolimus and prednisolone. She was admitted due to the appearance of left chest pain in June 2016. Multiple pulmonary nodules accompanied with cavities were increased in CT scan of the chest. Pseudomonas aeruginosa was observed slightly in bronchial lavage fluid culture. Levofloxoxine was administered. Pulmonary biopsy was performed for definitive diagnosis of nodules. Pathologically it was a diagnosis of rheumatoid nodule without observation of vasculitis. In order to strengthen RA treatment, administration of etanercept was started. Also, the administration was discontinued because of a rapid increase in the nodule shadow and pneumothorax in February 2017. Pneumothorax relieved with rest. We switched to tocilizumab in May, but it was showed a progression of joint symptoms. We switched to abatacept as third biologics in July of the same year. Pulmonary nodules continued to decrease and increase, but joint symptoms tend to reduce and continuing administration.

P2-080
Two cases of rheumatoid meningitis diagnosed with the brain magnetic resonance imaging

Takahito Uema, Keita Uehara, Tadashi Miyara
Naha City Hospital

Conflict of interest: None

The first case is a 68-year-old woman with 3-year history of rheumatoid arthritis (RA), who presented with a 2-month history of headache and occasionally low grade fever. She developed a generalized seizure with no abnormal finding in head CT. Mononuclear cells were mildly increased in the cerebrospinal fluid (CSF). Antibiotics was ineffective, and brain magnetic resonance imaging (MRI) showed abnormal arachnoid leptomeningeal enhancement in her both frontal lobes. The second case is a 60-year-old woman with about 20-year history of RA. Five months ago, she developed subarachnoid hemorrhage, and received coil embolization treatment. She felt the numbness and weakness of her left arms after a discharge. Head CT showed no rebleeding, and brain MRI showed abnormal arachnoid leptomeningeal enhancement in her right frontal lobes. Mononuclear cells were mildly increased in the CSF, but infectious disease was negative. We suspected rheumatoid meningitis (RM) and methylprednisolone pulse therapy was started in both cases. Subsequently, their symptoms and MRI findings rapidly improved. Though RM is rare complication in RA, and its diagnosis is difficult, it must be considered in patients with longstanding RA presenting with neurological symptoms. MRI features may support the diagnosis.

P2-081
Treatement of RA in advanced elderly group

Tamao Nakashita1, Akira Yoshida1, Akira Jibatake1, Shinji Motojima1, Daisuke Kato2, Tamio Takahashi, Yoshiaki Kuga3
1Rheumatology and Allergy, Kameda Medical Center, Kamogawa, Japan, 2Kato Daisuke Clinic, Futsu, Japan, 3Tateyama Orthopedic Clinic, Tateyama, Japan

Conflict of interest: None

[Object] Percentage of elderly people is high particularly in Chiba-Boso area. Treatment of RA is done according to the guideline. However, the mean age of the patients in mega-study cited in the guideline was about 50, which is far different from that in our department (late sixties). We compared the treatment of RA in the advanced elderly group (>=75 years, group 1) with those in less than 75 years (group 2). [Methods] Subjects were 511 patients with RA, 145 in the group 1 and 366 in the group 2, respectively. [Results] The remarkable difference in the treatment was the use of MTX. The usage of MTX in the group1 and group 2 were 45 % and 75 %, respectively. The median dose of MTX in the group 1 and 2 were 0 mg and 7.75 mg, respectively. The dosage of MTX inversely correlated the age and positively correlated with eGFR. MTX was not used in patients with eGFR of less than 35. Percentage use of PSL were 50 % (median 3.75 mg) in the group 1 and 12 % (median 0 mg) in the group 2, respectively. There were no differences in the use of SASP, BUC and bDMARDS, however the use of anti-TNF antibody was less in the group 1. The percentage of LDA + remission in group 1 and 2 were 84 % and 76 %, respectively. [Conclusions] Our treatment strategy is so far working well.

P2-082
Medical treatment for rheumatoid arthritis: discontinuation of corticosteroid therapy

Suguru Ohsawa1, Masao Yukioka1, Takaaki Shibuya2
1Department of Rheumatology, Yukioka Hospital, Osaka, Japan, 2Department of Orthopaedic Surgery, Sumitomo Hospital

Conflict of interest: None

[Object] Elucidation of clinical factors for discontinuation of corticosteroid therapy with management of rheumatoid patients. [Methods] According to JCR guideline for the management of rheumatoid arthritis 2014, 161 patients with rheumatoid arthritis were clinically investigated retrospectively. We used 1987 ACR classification and 2010 ACR/EULAR new classification. [Results] Prednisolone (PSL) administration was started in 116 patients, mean age was 63 year-old, consisted 90 women and 26 men. Their mean disease period was 8 years, in which under one year was in 45 cases. All were followed for 79 months in average. At final observation, 66 cases were discontinued steroid therapy, other 50 cases were continued with mean dosage of 3mg. Mean age and disease duration were 59 year-old and 7 years in discontinued group, and 68 year-old, 9 years in continued one. Administration of methotrexate and biological DMARDs (included JAK inhibitors) were 58, and 28 in discontinued group and 30, 15 in continued one, respectively. Comorbidty of chronic renal disease was occurred in 0 case in discontinued group and 12 cases in continued one. [Conclusions] Factors for discontinuation of corticosteroid therapy for the patients with RA were small numbers of comorbidity and younger age.

P2-083
The Boolean remission rate and the annual hospitalization number for serious adverse events for high dose MTX monotherapy in Japanese patients with RA by NinJa 2017 cohort

Atsushi Kaneko1, Yoshihiro Matsu1, Shotaro Mouri1, Yoshuke Hattori1, Tomotoro Sato1, Masao Katayama1, Shigeto Tohma1
1Department of Orthopaedic Surgery and Rheumatism, Nagoya Medical Center, 2Department of Rheumatology, Sagamihara National Hospital, 3Department of Collagen Disease and Rheumatology, Nagoya Medical Center, 4Department of Rheumatology, Tokyo National Hospital

Conflict of interest: None
P2-084
Investigation of reduction and discontinuation of methotrexate in the treatment of rheumatoid arthritis patients
Toshiaki Tsukada1, Yoichi Miyazaki1, Hiroyuki Nakajima2,3, Hiromi Ishii1, Hideki Iwamuro1, Ryo Taniyama1, Kunihiro Yamamoto1, Masatoshi Sugiyama1, Naoki Itakura1, Yukihiro Sakai1, Masato Endo1, Kazumasa Nakamura1, Kiyotaka Morita1, Tomoaki Fujii1,2,3, Shirota4, Miki Takeshita5, Junichi Kameoka6

[Object] Along with aging of populations, the number of elderly patients in this group were treated with biologics.

Conflict of interest: None

P2-085
The change of renal function in elderly patients with rheumatoid arthritis receiving MTX therapy
Hiroiyuki Matsubara, Ryo Sato
Department of Orthopedic Surgery, Hekinan Municipal Hospital

[Object] Along with aging of populations, the number of elderly patients is increasing. MTX is an anchor drug for RA, but it is needed to use carefully in elderly people with renal dysfunction. Safety was examined in RA elderly patients who were receiving MTX. [Methods] Among RA patients over 75 years as of August 2018, patients receiving MTX more than 1 year were included. We investigated the change of MTX dosage in 1 year and the change of renal function using eGFR. Changes in chest x-ray and urinalysis were also examined. [Results] There were 23 patients who were receiving MTX. Disease duration was 11.5 years, the RF positive rate was 90.0%. The rate of biologies use was 40%, the rate of PSL use was 50%, and the PSL dosage was 1.0mg. There was no significant change in the dosage of MTX from 6.2mg to 7.0mg per year. Although the eGFR was not significant from 68.5 to 62.3, it showed a decreasing trend. DAS28CRP was 2.59 ± 0.93. There was no remarkable change in chest x-ray and urinalysis. There were no serious adverse events. [Conclusions] We showed that renal function tends to be lowered also in elderly patients who can receive MTX, and it was suggested that biologies were used in combination with MTX to control disease activity without increasing dosage of MTX.

Conflict of interest: None

P2-086
Safety of steroid administration in Japanese rheumatoid arthritis patients
Takao Kodera, Tomoki Takeda, Tomomi Tsutsumi, Yumiko Oka, Yuko Shiroti, Miki Takeshita, Junichi Kameoka
Division of Hematology and Rheumatology, Tohoku Medical Pharmaceutical University Hospital

Conflict of interest: None

P2-087
A retrospective study of the practice use of csDMARDs except MTX for RA
Risa Sagawa1, Takashi Kida2,3, Tomoya Sagawa4, Akiko Kasahara5, Kazuki Fujikoa6,1, Hitodake Nagahara7, Shogo Toyama8, Ryo Oda9, Toshikazu Kubo10, Makoto Wada1, Masataka Kohno2, Yutaka Kawahito3,4

1Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 2Department of Orthopaedics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan, 3Rheumatic Center, University Hospital, Kyoto Prefectural University of Medicine, Kyoto, Japan

[Object] The opinions for using steroids for treating RA is changing with the decade. Although 2016 EULAR recommendation was revised that steroid should be used at the beginning of treatment, it contains concerns that it will fall into long-term use. In this study, we investigated the risk of prolonged steroid use in our cases. [Methods] We analyzed 930 RA patients at our hospital using odds ratios for vertebral body fractures, non-vertebral fractures, etc. [Results] Analysis of 364 cases is completed and the results of the intermediate analysis are reported. The number of patients with oral steroid was 110 (30.2%). The average age of the steroid users was 68.2 years, and the non-users 66.9 years (P=0.37). In patients with steroid use, 14 cases (12.7%) of vertebral fractures were observed and 14 cases (5.5%) without use, 9 (8.2%) vs 9 cases (3.5%) of non-vertebral fractures, 23 (20.9%) vs 24 cases (9.4%) of diabetes and 7 (6.4%) vs 3 cases (1.2%) of urotone stone were observed. Odds ratio (95% CI) were 2.50 (1.72-3.27), 2.43 (1.47-3.38), 2.53 (1.91-3.16), and 5.69 (4.31-7.05), respectively. Especially, the fracture rate of steroid use over 80 years old was high rate as 41.6% at 85 to 89 years old. [Conclusions] It seems that elderly RA patients should minimize the use of steroids.

Conflict of interest: None

P2-088
Efficacy of adding iguratimod therapy in rheumatoid arthritis patients who had inadequate response to biologic DMARDs
Toshiaki Miyamoto, Kenji Yamazaki, Ryuehi Ishihara

Internal Medicine and Rheumatology, Seirei Hamamatsu General Hospital

Conflict of interest: Yes
Efficacy and safety of iguratimod in elderly patients with rheumatoid arthritis intolerant to methotrexate

Yuichi Takahashi
Yu Family Clinic

Conflict of interest: None

[Objective] To evaluate the efficacy and safety of iguratimod (IGU) in elderly patients with rheumatoid arthritis (RA) who cannot tolerate methotrexate (MTX) due to toxicity or other reasons. [Patients and methods] This study included 41 RA patients aged ≥65 years who met the 2010 ACR-EULAR classification criteria for RA. Patients were treated with IGU in the standard dose and assessed forVAS, CRP, DAS28, ESR, and HAQ-DI between weeks 0 and 52 of treatment. [Results] Patients’ mean age was 73.9 years and mean disease duration was 10.7 years. The mean baseline CRP and DAS28ESR were 2.02 mg/dL and 4.43, respectively. Patient-reported VAS, CRP, and DAS28ESR were reduced after treatment with IGU and stabilized by week 24. Remission based on DAS improvement was observed from week 12, with 50% patients showing remission or low disease activity at and after week 24. A marked decrease in patient-reported VAS was seen by week 8, suggesting high patient satisfaction level. No adverse event requiring IGU discontinuation was seen. [Discussion] The present results suggest that IGU is a viable option for elderly RA patients intolerant to MTX.

P2-093
Interstitial lung disease during iguratimod treatment

Akira Yoshida, Tamao Nakashita, Akira Jibatake, Shinji Motojima
Department of Rheumatology and Allergy, Kameda Medical Center, Chiba, Japan

Conflict of interest: None
Conflict of interest: None

[Object] Iguratimod (IGU) is a csDMARD developed in Japan. According to the post-marketing surveillance of IGU, the incidence of interstitial lung disease (ILD) is reported to be 1.16% at week 52. However, these “ILD cases” also include infection such as pneumocystis pneumonia, other drug-induced lung injury, and RA-ILD. Thus, we still do not know the exact incidence and nature of ILD induced by IGU. [Methods] We retrospectively reviewed all the 248 patients attending to our clinic who received IGU before September 2018. [Results] 4 patients developed ILD, and the incidence was 1.6%. One patient was a man, and the other 3 were women. They were 64, 63, 60, and 53 years old, respectively. 3 patients had concomitant or previous history of ILD. MTX and etanercept were used in 2 and 1 patients each. The onset of ILD were 4, 16, 46, and 34 weeks from the initiation of IGU, respectively. No patients experienced respiratory failure, and only 1 needed hospitalization. None of the cases were clearly attributable to IGU itself, since other drug-induced lung injury and exacerbation of RA-ILD were highly possible differential diagnoses. [Conclusions] Further studies are necessary to determine the exact incidence and risk factors for ILD induced by IGU.

P2-094
Effects of acetaminophen on the kidney functions of patients with non-traumatic orthopedic disease treated with long-term nonsteroidal anti-inflammatory drug therapy
Toshiaki Aizawa1, Tetsuya Kawano1, Takeshi Kashiwagura2, Naohisa Miyakoshi3, Yoichi Shimada3
1Department of Orthopedics Surgery, Kitaakita Municipal Hospital, 2Department of Orthopedic Surgery, Akita City Hospital, 3Department of Orthopedic Surgery, Akita University Graduate School of Medicine

Conflict of interest: None

[Object] To investigate the kidney functions of patients with non-traumatic orthopedic disease who had been using NSAIDs for a long time and examined the possibility of switching to acetaminophen AAP. [Methods] The subjects were 105 patients who had been using NSAIDs for at least 3 months. After checking their background characteristics, we measured their kidney functions and VAS scores, and then switched them from NSAIDs to AAP. Six months after the switch, we remeasured their kidney functions and VAS scores, and investigated whether they could continue using AAP and whether they had used NSAIDs. [Results] The patient’s mean age was 76 years, and their mean duration of NSAID use was 43 months. The mean VAS was 41 mm and mean eGFR was 67.0 mL/min/1.73 m². After the switch, 69 patients had continuously used AAP. Of these patients, 13 had used NSAIDs for rescue purposes. Overall, the mean VAS declined significantly as compared with before the switch, as did the mean eGFR. Of those who continued to use AAP, 56 patients who did not use any NSAIDs exhibited significantly lower mean VAS scores, but not a significant decline in mean eGFR. [Conclusions] Halting NSAIDs and switching to AAP could help maintain kidney functions, which could continue to decline with NSAID use.

P2-095
Investigation of an influence of body weight on DMARDs selection – a nationwide database study, NinJa2017-
Hideo Ohtsubo1, Takehisa Matsuda1, Toshihiro Matsui1, Shigeto Tohma1
1Center for Rheumatic Diseases, Japanese Red Cross Kagoshima Hospital, 2Department of Rheumatology, NHO Sagamihara National Hospital, 3NHO Tokyo National Hospital

Conflict of interest: None

[Object] Our aim is to investigate if weight influence on DMARDs selection in Japan using a nationwide database (National Database of Rheumatic Diseases by i-net in Japan, NinJa). [Methods] We examined the impact of weight in DMARDs selection in 13298 patients of NinJa2017. [Results] Age of all patients 65.9±13.2 y.o, body weight 54.2±10.7kg, adalimumab 55.5±10.6kg, certolizumab pegol 54.9±12.4kg, tocilizumab 54.8±11.2kg, abatacept 53.3±11.1kg, tofacitinib 55.7±11.8kg, denosumab 47.9±9.7kg [Conclusions] Weight mean of patients injected denosumab was light (47.9kg). Mean age of these patients was high (74.1±10.3 y.o.), but they weighed less than expected (52.6kg) from (65.2-0.17×age) their age. No patients administered other drugs had any difference in weight. As for tocilizumab, there is no dose set per body weight. So we examined the relationship between body weight and route of tocilizumab administration. There was no difference in weight between percutaneous and intravenous administration of tocilizumab.

P2-096
A case report of tuberculous subcutaneous abscess in a rheumatoid patient’s lower leg
Junpei Inoue, Kunio Yamada, Hideki Muro, Keisuke Hoshino, Kaneaki Tawada, Shinji Funahashi
Komaki City Hospital, Komaki, Japan

Conflict of interest: None

[Introduction] Methotrexate (MTX) have a risk of extrapulmonary tuberculosis, but it is rare that extrapulmonary tuberculosis occur in a lower leg. We report a rheumatoid patient suffered tuberculous subcutaneous abscess in the lower leg. [Case report] The patient was a 74-year-old woman. RA was diagnosed at the age of 50 years. MTX had been prescribed for 8 years. She was aware of gradually increasing mass in her lower leg for 3 months. Abscess was diagnosed by a plastic surgeon and was cutted open. But the mass didn’t improve and she came to our hospital. Her lower leg had a pus-like discharge from the incision. RA activity was controlled well with MTX 10 mg / week. The mass 10cm in diameter was resected. Pathological examination revealed caseating granuloma and tuberculous was cultured after 6 weeks. So she started to take anti-tuberculosis drugs. [Conclusion] Rheumatoid patients treated with immunosuppressive drug have risk of extrapulmonary tuberculosis.

P2-097
A case of Methotrexate-associated lymphoproliferative disorder (MTX-LPD) developed by short-term MTX therapy, shrinked spontaneously 1 month after MTX cessation
Hiroshi Shimagami, Taro Akira, Michiko Ohashi, Masashi Okamoto, Takehiro Hirayama, Akira Megu, Yoshinobu Matsuura, Akihiko Nakabayashi, Yoshinori Katada
Sakai City Medical Center

Conflict of interest: None

Chief complaint: fever History of Present Illness: A 87-year-old woman with rheumatoid arthritis taking 5mg/week of MTX and 5mg/day of Predonisolon presented pulmonary opacity 2 months before. Fever, sweating while sleeping, and weight loss gradually appeared. Laboratory findings included WBC1790/µL, Lymphocyte 215/µL HB7.6g/dl Cr1.1mg/dl CRP12.1mg/dl sIL-2R 3132U/ml. CT scan revealed multiple pulmonary nodules did not shrink. But it became smaller on 28th day. Discussion: In average, 1500mg of cumulative dose and 30 months of administration period were required for development of MTX-LPD. In this case, however, it was developed after short term administration. The nodules needed four weeks to start to shrink after MTX cessation, although it usually starts in two weeks. Hyporenal function might be the reason of these phenomenon.

P2-098
A case of Methotrexate-related lymphoproliferative disorder complicated by EB virus meningitis
Hiroaki Nakagawa, Ayaka Inoue, Midori Kitayama, Takuro Maeda, Noriaki Yo, Chihiro Tanaka, Takashi Yamane
Kakogawa City Hospital
Conflict of interest: None

[Case] A 70-year-old man who had diagnosed as RA at the age of 65 and treated with abatacept, MTX, iguratimod, and prednisolone, admitted with complaint of malaise and fever from 1 week ago. CT revealed systemic lymphadenopathy, and blood test revealed high LDH and sIL -2R. Since the symptoms did not improve by discontinuation of MTX and consciousness disturbance also appeared, we started GC pulse therapy. EB VCA-IgG was 640-fold, EBNA was negative, and EB virus DNA was positive, EBER positive lymphocytes were observed from lymph node biopsy and diagnosed as MTX-LPD. We also diagnosed that meningoencephalitis caused by EB virus, because mononuclear cells were increased and EB virus DNA was positive in CSF. While we tapered the prednisolone, he developed convulsion and had been impaired consciousness even after cessation. We diagnosed as nonconvulsive status epilepticus from the EEG, and his consciousness improved after initiating carbamazepine. Higher order dysfunction gradually improved and EB virus DNA changed to negative in the final examination. The CT showed lymph node reduction, it was thought that he recovered from MTX-LPD. [Clinical Significance] This is a rare case that MTX-LPD causes EB virus meningitis.

P2-099
A case of golimumab-resistant rheumatoid arthritis complicated with psoriasis who was successfully treated by addition of tacrolimus
Junichi Konma, Yumiko Wada, Takeshi Shoda
Department of Rheumatology, Yodogawa Christian Hospital, Osaka, Japan

Conflict of interest: None

A 57-year-old man had gradually complained polyarthralgia and weight loss since the beginning of 2017, he visited our hospital in August. On examination, he had bilateral joint swelling and tenderness in fingers, soulders, elbows, and knees. He also had red patches covered with scales on scalp and finger nail pitting, so we diagnosed him with psoriasis. Laboratory tests showed elevated levels of CRP, ESR, MMP-3, and RF was positive, ACPA was negative. Joint US demonstrated synovitis in joints of left MCP and both wrists. Joint X-ray did not show bone erosion or new bone formation. He was diagnosed with rheumatoid arthritis (RA) in high disease activity (DAS28-CRP 5.7), but he also could be diagnosed with psoriatic arthritis (PsA). He had interstitial pneumonia (RA) in joints of left MCP and both wrists. Joint X-ray did not show bone erosion or new bone formation. He was diagnosed with rheumatoid arthritis (RA) in high disease activity (DAS28-CRP 5.7), but he also could be diagnosed with psoriatic arthritis (PsA). He had interstitial pneumonia

P2-100
Comparison of cycling and swapping of biological agents in patients with rheumatoid arthritis
Masako Hayashihara1, Keita Nagira1, Chikako Takeda1, Daichi Mukunoki2, Hiroshi Hagino2, Hideki Nagashima1
1Department of Orthopedic Surgery, Faculty of Medicine, Tottori University, Tottori, Japan, 2Department of Life Science, Faculty of Medicine, Tottori University, Tottori, Japan

Conflict of interest: None

[Object] It is sometimes difficult to determine the second or third course of biological disease-modifying anti-rheumatic drugs (bDMARDs) when the primary bDMARDs treatment is ineffective or causes adverse events in rheumatoid arthritis (RA) patients. We assessed the reason for switching bDMARDs and subsequent outcomes in our department. [Methods] We studied 49 RA patients who had their primary bDMARDs treatment switched over six months. Five men and 44 women were included, mean age was 69.2 (range: 38-88) years and mean disease duration was 14.6 (range: 2-47) years. Patients were divided in two groups, cycling group (group C),12 patients who switched to a same class of biologic agent, and swapping group (S group). 37 patients who switched to a different class (S group). [Results] Methotrexate (MTX) was used in combination in 9 patients (75%) in group C and 15 patients (41%) in group S. The reasons for switching were an insufficient treatment response in group C and adverse events in group S. In both groups, at least 80% had low disease activity or remission following treatment. [Conclusions] Many patients switched bDMARDs due to adverse events in Group S. It is suggested that a swapping strategy is effective for patients who need to switch to bDMARDs with adverse events.

P2-101
Cost-effectiveness of biological DMARDs for rheumatoid arthritis
Masahiko Miya
Department of Rheumatology, Asama Nanroku Komoro Medical Center

Conflict of interest: None

[Object] We examined the effectiveness of biological DMARDs in rheumatoid arthritis treatment from the viewpoint of drug expenses. [Methods] For the 139 treatments of 72 patients who received the biological DMARDs at our hospital, the cost-effectiveness of each preparation was calculated. Improvement in CDAI score (ΔCDAI) per drug cost was calculated at 12 weeks and 52 weeks after dosing. The cost effectiveness was compared with ΔCDAI per 10,000 yen of drug cost for 4 weeks. [Results] Calculating the cost-effectiveness of each formulation with ΔCDAI per 10,000 yen of drug cost for 4 weeks, Tocilizumab was more cost-effective than other drugs, and golimumab and infliximab were inferior in cost-effectiveness. [Conclusions] Tocilizumab is inexpensive, and the drug cost is further reduced by decreasing dosage and prolonging the administration interval. Golimumab and infliximab were allowed to gain dose, resulting in poor cost effectiveness. In terms of drug selection, not only the effectiveness but also cost-effectiveness is necessary.

P2-102
Golimumab Treatment in Patients with Rheumatoid Arthritis -Influences of Baseline Disease Activity-
Yuji Hirano, Daisuke Kihira, Yukiyoshi Oishi
Department of Rheumatology, Toyohashi Municipal Hospital

Conflict of interest: Yes

[Object] The aim of this study is to evaluate efficacy of golimumab (GLM) in patients with RA, especially influences of baseline disease activity. [Methods] Toyohashi RA database was used. 68 RA patients treated with GLM were used 57 female and 11 male. Disease activity, drug retention rates (Kaplan-Meier) and concomitant drugs were investigated. H group in which baseline disease activity was high (DAS28-CRP 4.1) was compared with M group (2.7-4.1). [Results] Mean age was 61 years old. Mean RA duration was 12.4 years. 91.2% of cases were treated with concomitant MTX. Time-course of mean DAS28-CRP was 3.4-2.3-2.2-2.1-2.2 (0-3-6-12m-last observation). Remission rate at last observation was 65.1%. Drug retention rates were 80.8% at 1 year, 71.3% at 3 years and 62.9% at 5 years. Concomitant rates of PSL were 35% at baseline and 9% at last observation. Concomitant rates of MTX were 89% at baseline and 69% at last observation. Remission rate at last observation was 47.4% in H group and 71.4% in M group. Rates of GLM 100mg treatment at baseline and last observation were 57% and 63% in H group and 29% and 54% in M group. [Conclusions] GLM was effective in RA treatment in real-world clinical setting. In case of high disease activity, GLM100mg treatment was effectively used.

P2-103
Investigation of rheumatoid arthritis cases using infliximab BS
Masao Sato1, Masao Takemura2, Tomohisa Tani1, Toshiro Ohashi1
1Ohashi-Tani Orthopedics, Gifu, Japan, 2Advanced Diagnostic System Research laboratory, Fujita Health University

Conflict of interest: Yes

[Objectives] The use of biological drugs (BIO) for rheumatoid arthritis (RA) has significantly improved patient QOL. Biosimilars (BS) with
the same effectiveness and lower drug prices have appeared. We examined cases using infliximab BS (IFX-BS). [Methods] Ten RA cases using IFX-BS so far were examined mainly on the reasons for introduction, efficacy, adverse events, etc. [Results] The breakdown of 10 cases was 2 males and 8 females, ages 43 to 72 years, average 57.1 years. The format of IFX-BS introduction is 6 cases of changes from the original infliximab (IFX), 2 cases of BIO naïve, a switch case from other BIO and a case with history of IFX administration in the past. The total number of times IFX administration was administered at the time of changing the six cases changed from IFX was 2 times, 13 times, 20 times, 63 times, 74 times, and 109 times. The dose (mg/week) of MTX was 4 to 10, and the average was 7.33. Nine out of ten cases have good effectiveness and are under observation for 2 to 9 months, on average 4.7 months. Invalid was a drug-free and re-burned case, we switched to another BIO. There were no adverse events due to use of IFX-BS. [Discussion] The effectiveness of IFX-BS is not inferior compared to IFX and it might become one of the BIOs useful for RA patients.

P2-104 Efficacy and economic performance of infliximab BS in patient with rheumatoid arthritis in a routine care
Yutaka Yoshioka
HANDA CITY HOSPITAL
Conflict of interest: None

[Objectives] Infliximab BS (IFXBS) is a biosimilar of infliximab that has been prescribed as a first line treatment in patient with rheumatoid arthritis (RA) after inadequate response to methotrexate in our hospital. In this study, we investigated the efficacy and economic performance of IFXBS in 10 RA patients. [Methods] RA patients with an inadequate response to methotrexate (MTX) and treated with IFXBS as a first-line biologic agent for longer than 52 weeks were included in this study. We retrospectively reviewed the clinical data. [Results] Sixteen patients were included in this study. Mean age was 63 years old and mean disease duration was 11 years. Mean DAS28-CRP was 4.2 at baseline and 1.4 at 52 weeks. The number of patients who withdrew from IFXBS was six (adverse events: two patients, lack of efficacy: four patients). [Conclusion] IFXBS was effective in RA patients in a routine care. This study provides support for the possible use of IFXBS as a first line treatment in RA patients with an inadequate response to MTX.

P2-105 Assessment of sarilumab for the rheumatoid arthritis patients in real world rheumatology practice
Takeshi Suzuki, Takayasu Ando, Yutaka Gojo, Harunobu Iida, Marina Uchida, Kana Ishimori, Hisae Fujimoto, Hiromi Matsushita, Keiichi Sakurai, Tomofumi Kiyokawa, Yukiko Takakuwa, Kumiko Tonooka, Mitsuru Imamura, Yoshioki Yamasaki, Hiroko Nagafuchi, Seido Ooka, Kimito Kawahata
Division of Rheumatology and Allergology, Department of Internal Medicine, St. Marianna University School of Medicine
Conflict of interest: None

[Objective] To assess sarilumab (SAR) for rheumatoid arthritis (RA) in real world rheumatology practice. [Methods] Eligible patients had to have a diagnosis of RA and was treated with SAR after its approval. Clinical disease activity was determined using the DAS28-CRP3 (DAS). MRI's of dominant hands at baseline and follow up were obtained in some patients and scored using the RAMRIS system [Result] Fifteen patient was include in this study. The mean (+SD) age, disease duration and DAS28-CRP3 at baseline was 72.3±9.8y, 9.2±11.5y and 5.00±1.10. Only 2 patients were bio-naïve and the average number of DMARDs (biologics + JAK inhibitor) before SAR use was 3. DAS was decreased significantly at week 8. The persistence rate at week 16 was 53.3%. The reason for discontinuation was inefficacy (n=3), drug eruption (n=3) and liver enzyme elevations (n=1). RAMRIS synovitis score of a patient who had an inadequate response to tocilizumab was obviously decreased 7 to 3 and bone edema score was 2 to 1. [Conclusion] We conclude that persistence rate of SAR was comparatively acceptable for the RA patients who have long disease duration and had inadequate response to many biologics and JAK inhibitors and there might be a possibility of effectiveness of switching among different anti-IL-6 receptor antibody.

P2-106 Usefulness of shortening the administration period when the effect of tocilizumab subcutaneous injection is diminished
Masao Sato1, Masao Takemura1, Tomohisa Tani1, Toshiro Ohashi1
1Ohashi-Tani Orthopedics, Gifu, Japan, 2Advanced Diagnostic System Laboratory, Fuji Health University
Conflict of interest: Yes

[Objective] To investigate the utility of shortened period administration in Tocilizumab subcutaneous injection (TCZ) cases. [Methods] Fifteen rheumatoid arthritis (RA) cases in whom TCZ was introduced and observed for more than 24 weeks were included. [Results] The breakdown of cases was 2 men, 13 females, aged 40 to 83 years old, and the average age was 61.3 years. Seven cases were BIO naïve cases, and 6 cases from other BIOs, 2 cases of tocilizumab infusion to TCZ. From the administration interval of TCZ, there were 5 cases each with 14 days or more (no shortening group), shortening 9 to 10 days (9 to 10 days group), shortening 7 days (7 days group). Disease activity at the time of introduction of TCZ in each group tended to be higher in 7 days group. Six patients returned to the administration interval of 14 days or more within 2 months of shortening introduction. Four patients are continuing administration for 6 to 13 months at intervals of 7 to 10 days. Disease activity changes of 10 cases from the time of shortening start to at 24 weeks were 3.2±2.8 to 1.3±1.3 on DAS28-ESR (average) and 2.9±1.40 on DAS28-CRP. [Discussion] TCZ was thought to be a drug capable of enhancing the drug effect by shortening the administration interval when the effect was weakened.

P2-107 Effect of Abatacept on the level of serum TRACP-5b in Rheumatoid Arthritis
Masayasu Kitano1, Kazuyuki Tsuboi1, Mai Nakano1, Takahiro Yoshikawa1, Teppei Hashimoto1, Mai Morimoto1, Naoto Azuma1, Hajime Sano1, Kiyomi Matsu1
1Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, 2Division of Rheumatology, Kyoto Okamoto Memorial Hospital
Conflict of interest: None

[Object] To clarify the effect of abatacept (ABT) on serum tartrate resistant acid phosphatase (TRACP)-5b in rheumatoid arthritis (RA). [Methods] 28 patients with active RA (all females, mean age:56.7 years, mean disease duration:6.0 years, mean SDAI:21.7, ACPA positive:75%, oral PSL use:61%, mean PSL dose:4.9mg/day, MTX use:75%, mean MTX dose:7.1mg/week, bDMARDs naïve:100%) were started on treatment with ABT for 24 weeks. Serum levels of TRACP-5b were examined by EIA at the baseline and after 12 and 24 weeks. [Results] In the course of ABT treatment, the score of SDAI at 12 and 24 weeks decreased significantly from the baseline (21.7 vs 10.5 vs 9.5: p<0.01). The response for ABT treatment was divided into good responder, moderate responder, and no responder by EULAR criteria. In good responder, TRACP-5b levels at 24 weeks were decreased significantly from the baseline (223 vs 125mU/dl: p<0.05). Moreover, the baseline value of TRACP-5b correlated well with the rate of change value of TRACP-5b after ABT treatment for 24 weeks (R2=0.479, p=0.0267). [Conclusions] Recent study shows ABT improves osteoclastogenesis of RA via the control of inflammation and apoptosis of osteoclast precursor cells. Thus, we conclude that the suppression of TRACP-5b may be specific for ABT treatment.

P2-108 Denosumab ameliorates MRI imaging of synovitis and bone edema in rheumatoid arthritis
Keisuke Hasui, Hirotake Sakuraba, Hiroto Hira, Nahoko Tanaka, Rina Watanabe, Yasuhiisa Murai
Department of Gastroenterology and Hematology, Hiroshi University Graduate School of Medicine
Conflict of interest: None

[Object] To evaluate the effectiveness of denosumab for rheumatoid arthritis. [Methods] A total of 9 patients treated with denosumab were included in this single center, retrospective study during 2016 and 2018. We compared DAS28-ESR (4) and MRI score according to the Simplified Rheumatoid Arthritis MR Imaging Score (SAMIS) at the beginning of treatment and one year later. [Results] All patients were females. Median age was 75.0 (65-82) years old and disease duration was 10.0 (7.3-22.0) years. 6 patients had malignant diseases. Prednisolone and salazosulfapyridine were used in 5 cases and methotrexate and biologics were used in one case respectively. The mean of DAS28-ESR (4) was 4.6±1.4 at the beginning of treatment and was 3.9±0.8 at one year after treatment. There was no significant improvement. SAMIS, synovitis and bone edema were significantly improved from 22.3±14.5 to 19.6±14.9 (P=0.0196), from 6.0±3.5 to 4.8±3.3 (P=0.0384) and from 2.5±2.6 to 0.9±1.6 (P=0.0203) respectively. There was no significant change in erosion from 13.8±13.4 to 13.9±13.8. [Conclusions] Denosumab might have inhibitory effects on bone destruction.

P2-109
Study for RA therapeutics after use of IFN-free treatment; Anti-viral therapy (DAA; Direct acting antiviral), for patients with HCV RNA positive in our hospital
Yuichiro Yabe
Department of Rheumatology, JCHO Tokyo Shinjuku Medical Center, Shinjuku, Tokyo, Japan
Conflict of interest: None

[Object] Anti-viral therapy (DAA; Direct acting antiviral) can eliminate HCV. RA first selection Drug MTX refrain from use in the hepatitis virus infection sustained cases. There is no definite view for RA treatment after HCV exclusion in DAA therapy. Report on RA treatment after DAA therapy. [Object] From2008-2018, 14 RA cases were HCV antibody positive. 6 cases of HCV were RNA positive. 3 cases of DAA recipe (Ombitasvir/Paritaprevir/Ritonavir (OBV/PTVr) 2 cases, sofosbuvir + ribavirin (SOF + RBV) 1 case) were studied. [Methods] Introduction of anti-rheumatoid drugs were shown comparison of HCV RNA positive 6 cases and HCV RNA negative 8 cases, and also clarified about 3 cases of DAA recipe with complications. [Results] About HCV RNA negative, MTX5, SSZ3cases were introduced. In HCV RNA positive, MXT8mg=ABT+PSL, BUS, SSZ, TAC, GST, DMARDs-free, each one case, were introduced. Three RA cases received ADD kept HCV RNA negative. One case of ADD was added MTX to GST. One RA case with liver cancer and HCV RNA positive, was received first cancer treatment, and then ADD, moved into HCV RNA negativity. In this case, liver cancer recurrence happened was cared by surgery. [Conclusions] After the HCV RNA-negative achievement of DAA, we can use MTX, bio-DMARDs, recommend checking real liver.

P2-110
Local biologic registry for the patients with rheumatoid arthritis in our hospital -ZAO registry-
Yuta Suzuki, Yuya Takakubo, Yasushi Naganuma, Akiko Sasaki, Suran Yang, Hiroharu Oki, Hiroshi Oiu, Michiaki Takagi
Yamagata University Faculty of Medicine Department of

Conflict of interest: None

[Objectives] The aim of this study was to investigate our local biologic (BIO) registry (ZAO registry) for the patients with rheumatoid arthritis (RA) in our hospital. [Methods] 295 patients were registered with ZAO registry from 2004 to April 2018. Switching and changing BIO was decided by the judgment of each doctor. [Results] Of 295 patients, 226 subcutaneous injection, 56 intravenous fluid preparations and 13 oral agents were consisted. Kinds of BIO are TNF inhibitors (TNFi), 218 cases; IL-6i, 45 cases; abatacept (ABT), 19 cases; and tocitumab (Tofa), 13 cases. 2nd switching BIO were TNFi, 32 cases; tocilizumab (TCZ), 13 cases; ABT, 5 cases; and Tofa, 5 cases. 3rd switching BIO were TNFi, 6 cases; IL-6i, 6 cases; ABT, 3 cases; and Tofa, 2 cases. 4th switching BIO were TNFi, 2 cases; TCZ, 1 case; ABT, 1 case; and Tofa, 1 case. 5th switching BIO were TNFi, 3 cases and TCZ, 1 case. 6th switching BIO was ABT, 1 case. We had 38 withdrawn cases consisting with TNFi, 28 cases; TCZ, 6 cases; ABT, 2 cases; and Tofa, 2 cases. The reasons why to withdraw were adverse events in 28 cases. [Discussion] Subcutaneous injection preparations tended to be selected compared to intravenous preparations for the patients with RA in our hospital. The continuation rate of 1st BIO was 64% (213/333).

P2-111
Two cases with rheumatoid arthritis achieving low disease activity immediately after switching from other biologic agents to sarilumab
Masahiro Yokosawa, Hirofumi Toko, Taihei Nishiyama, Shota Okamoto, Masaru Shimizu, Fumika Honda, Akayo Ohyama, Atsumu Osada, Izumi Kurata, Mizuki Yagishita, Saori Abe, Hiroyuki Takahashi, Yuya Kondo, Hiroto Tsuboi, Isao Matsumoto, Takayuki Sumida
Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan

Conflict of interest: None

[Case 1] A 70-year-old woman, who was diagnosed with rheumatoid arthritis (RA) three years ago. Since her symptoms were not improved by prednisolone and methotrexate (MTX), she had been treated with golimumab, however, high disease activity continued. Although DAS28-CRP and CDAI were 4.4 and 19.9 respectively before switching to sarilumab (SAR), low disease activity (LDA) was achieved immediately after the initiation of SAR. After 8 weeks of administration, improvement of synovitis was confirmed by joint ultrasonography (jUS). [Case 2] A 40-year-old woman, who was diagnosed with RA more than 10 years ago. Although she had been treated with the monocotherapy of etanercept or adalimumab, or with combination abatacept, tocilizumab or certolizumab pegol and MTX, all of them resulted in primary or secondary failure. Discontinuation of MTX due to adverse effects triggered, and the disease activity rose to high (DAS28-4.18, CDAI:23.5). She was treated with SAR, and LDA was achieved immediately. After 10 weeks of administration, the improvement of synovitis was confirmed by jUS. [Conclusion] Regardless of whether MTX was used, the rapid improvement of RA was achieved with switching to SAR in cases inadequately responded to other biologic agents.

P2-112
A case of rheumatoid arthritis associated with tuberculous pleuritis with a positive conversion of T-SPOT, during anti-TNF-alpha anti-body therapy
Yohi Hosokawa, Hiroshi Oiwa
Department of Rheumatology, Hiroshima City Hiroshima Citizens Hospital, Japan

Conflict of interest: None

An 80-year-old woman with rheumatoid arthritis (RA), suffering high fever and right pleuritic pain for three weeks, was admitted to our hospital. Eight months previously, she was diagnosed with RA, and started to take methotrexate. Five months previously, treatment with anti-TNF-α antibody was added to her regimen, when the result of screening test for latent tuberculosis infection, T-SPOT, was negative. CT of the chest showed right pleural effusion and right pulmonary infiltrates. The pleural fluid analysis revealed a white blood cell count of 2094/μL with 61% of lymphocytes and an ADA level of 127U/mL. The result of the T-SPOT showed a positive conversion. The diagnosis of tuberculous pleurisy was made, and the patient improved after the antituberculous drugs. Six weeks after the diagnosis, M. tuberculosis was cultured from the bronchoalveolar fluid. Immune system against tuberculosis was achieved through formation and maintenance of the granuloma, which TNF-α and IFN-γ play a major role on. Anti-TNF-α antibody binds to TNF-α expressing macrophages, leading to apoptosis, and also suppresses production of IFN-γ. Our experience indicates that tuberculosis could be re-activated during anti-TNF-α antibody therapy, even after a negative result of T-SPOT.
P2-113
Analysis of clinical factors related to HAQ in RA patients treated with golimumab
Katsuki Kanbe
Nippori Rheumatology Clinic
Conflict of interest: None

[Object] In order to analyze clinical factors related to RA patients treated with golimumab [Methods] 57 patients was investigated in HAQ-DI treating in our clinic, mean age with 62.8 years, mean disease duration with 12.7 years, by using Pearson correlation and multiple logistic analysis. [Results] Mean DAS28 (CRP) was 2.78 and mean HAQ-DI was 0.66. Correlation to HAQ-DI were stage (p=0.007, r=0.351), class (p=0.001, r=0.510), CRP (p=0.013, r=0.327), RF (p=0.004, r=0.379), DAS28 (CRP) (p<0.001, r=0.548). In multiple logistic analysis showed stage (p=0.687), class (p=0.044), CRP (p=0.524), RF (p=0.093), DAS28 (CRP) (p=0.001). [Conclusions] HAQ-DI was related to DAS28 (CRP) significantly meaning that regulation of disease activity by tight control was most important among other clinical factors in golimumab treated patients in RA.

P2-114
The efficacy of golimumab for elderly patients with rheumatoid arthritis
Kaneaki Tawada, Kunio Yamada, Keisuke Hoshino, Shinji Funahashi, Junpei Inoue
Department of Orthopaedic Surgery, Komaki City Hospital
Conflict of interest: None

[Object] The purpose of this study was to investigate the efficacy and safety of GLM for the elderly RA patients. [Methods] Eighteen RA patients over 65 years old were treated with GLM in this study (4 males, 14 females, average age 71.4 years old, average disease duration 14.1 years). MTX was used for 15 patients, the average dose was 5.2 mg / week. There were 15 bio naïve cases and 3 switch cases. CRP, MMP-3, DAS28-CRP, CDAI and SDAI at baseline and 52 weeks were used for the estimation of the efficacy, and complications were investigated. [Results] At baseline the average CRP, MMP-3, DAS28-CRP CDAI and SDAI were 1.6, 165.1, 4.0, 16.6 and 17.8, respectively. These values were improved to 0.2, 50.4, 2.1, 5.5 and 5.6 at 52 weeks. The remission rate of DAS28-CRP was 69.2%. Intersitial pneumonia was developed in one patient as a complication. Including two cases who stopped the treatment due to decreasing of the efficacy, the continuation rate was 72.2%. [Conclusions] The incidence rate of adverse events was approximately 5% in Japanese cohort study. In this study, the incidence rate of infection was 5.5% in elderly RA patients, the rate was similar to Japanese cohort study. From this study, GLM could be a safe and effective treatment choice for elderly RA patients.

P2-115
The evaluation of Akita Orthopedic Group on Rheumatoid Arthritis registry 2018 patients who received adalimumab
Tsutomu Sakuraba1, Takeshi Kashiwagura2, Moto Kobayashi1, Yusuke Sugimura1, Masaaki Ogino1, Yoichi Kataoka1, Hiromi Morita1, Nobuhiro Ishizawa1, Kazuhiro Shoji2, Hitohoshi Watanabe1, Natsuo Konishi1, Masakazu Urayama1, Toshiaki Aizawa1, Hiroshi Aonuma1, Tetsuya Kawano1, Naohisa Miyakoshi1, Yoichi Shimada1
1Orthopedic Surgery, Hiraka General Hospital, 2Department of Orthopedic Surgery, Akita City Hospital, 3Department of Orthopedic Surgery, Nakadori General Hospital, 4Department of Orthopedic Surgery, Koto Kousei Hospital, 5Joto Orthopedic Clinic, 6Morita Orthopedic Clinic, 7Department of Orthopedic Surgery, Fujisawa Memorial Hospital, 8Shoji Orthopedic Clinic, 9Watanabe Orthopedic Clinic, 10Department of Orthopedic Surgery, Akita Kousei Medical Center, 11Department of Orthopedic Surgery, Oguchi Central Hospital, 12Department of Orthopedic Surgery, Kita Akita Municipal Hospital, 13Department of Orthopedic Surgery, Akita University Graduate School of Medicine
Conflict of interest: None

[Object] The aim of this study is investigating of the profiles of rheumatoid arthritis patients who received adalimumab (ADA). [Methods] We evaluated 92patients in the Akita Orthopedic Group on Rheumatoid Arthritis (AORA) registry (mean age, 64.2 years) who received ADA. [Results] The mean disease period was 177 months. The cases had Steinbrocker classification stages I/II/III/IV (17/24/22/28 cases), patients 1/2/3/4 (35/40/14/3 patients). Seventy-nine patients (85.9%) received methotrexate (MTX; mean dosage, 7.02 mg/week) and Twenty-nine (31.5%), prednisolone (3.06mg/day). The mean DAS28CRP (4) was 3.98 in the first ADA administration. The mean follow-up period was 103 weeks. Thirty-four patients had failure of ADA administration. Therapy was discontinued because of primary failure in 9 cases and secondary failure in 15. The mean disease activity score was 2.06, and 81 patients (88.0%) had good response in the final examination according to the criteria of the European League against Rheumatism. [Conclusions] The patients who received ADA had a high combination rate with MTX, high continuation rate, and good results, and were therefore appropriately selected and treated.

P2-116
A study on the long-term HAQ improvement effect of Adalimumab (ADA) in RA patients
Koji Nagai1,2, Kenichiro Hata1, Tomohiko Kuboyama1, Hidehiko Makino1, Shogo Matsuda1, Takao Kiboshi1, Ayaka Yoshikawa1, Takayasu Suzuka1, Yuri Hiramatsu1, Takaaki Ishida1, Hideyuki Shib1, Youhei Fuji1, Takuya Kotani1, Yoko Matsumura1, Shigeaki Makino1, Tohru Takeuchi1, Shigeki Arawak1
1Department of Internal Medicine IV, Osaka Medical College, 2Department of Rheumatology, Koshokai Aino Hospital, Ibaraki, Osaka, Japan, 3Department of Rheumatology, Osaka Medical College Mishima Minami Hospital
Conflict of interest: None

<Introduction> Long-term inhibition of structural destruction of ADA has been reported, but they are able to improve and maintain the most important physical function (HAQ) in daily life. We study the long-term improvement of HAQ in patients treated with ADA. [Methods] RA patients treated ADA in our hospital from April 2015 to September 2018 were included. We examined disease activity, therapy and HAQ at the time of administration, 6 months, 1 year, and 2 years after. [Results] Average age 59.6 years, disease duration 26 months DAS-ESR 3.67, HAQ 0.875, MTX use 82.6% (8.5mg/week), PSL use 20.7% (2.4mg/day) The ADA continuation rate was 83.5% in 2 years, 1 case was secondary ineffective, 2 were infections, 2 were failed due to lymphadenopathy. DAS-ESR improved significantly after 6 months and the effect was sustained until two years later. HAQ started to improve after the administration and improved significantly after 1 year and improved trend and long term improvement after 2 years. HAQ remission was 65% at baseline, 88% after 6 months, HAQ remission in all cases was achieved after 1 or 2 years. [Conclusion] Continued administration of ADA may maintain long-term sustainable improvement of HAQ. MTX use maintaining, PSL dose reduction, are sufficient merit to continue administering ADA.

P2-117
Treatment with Tocilizumab for elderly patients with rheumatoid arthritis
Katsumitsu Ara1, Junya Ajiro2
1Department of Orthopedic Surgery, Niigata Prefectural Central Hospital, 2Department of Internal Medicine, Niigata Prefectural Central Hospital
Conflict of interest: None

[Object] To assess the safety and efficacy of tocilizumab (TCZ) in elderly (≧65years) rheumatoid arthritis (RA) patients. [Methods] We conducted a retrospective study of TCZ use in twelve RA patients over 65 years in our hospitals between 2010 and 2016. TCZ efficacy was evaluated at Dec 2017 by the DAS28ESR score. We also evaluated drug maintenance and safety, relative to adverse events discontinuation. TCZ retention over time was estimated with the Kaplan-Meier method. [Results] Among 12 RA patients treated with TCZ, 7 cases were after 65 years at the initiation of treatment. Mean age at the evaluation was 73±8.2 years old. There were 7 cases that TCZ was the first DMARD. There were 4
cases that TCZ was second bDMARDs. TCZ retention was 73% at 8 years after the initiation of treatment. Eight cases were treated with TCZ at evaluation point, 5 cases were remission and 3 cases were low disease activity. There was one adverse event discontinuation of TCZ that was suture abscess at total hip arthroplasty (THA), who was second failure of TCZ at THA. [Conclusions] Although there was a bias for the selection of patients treated with TCZ, TCZ seems to be well tolerated in RA patients in elderly patients.

**P2-118**

**Efficacy of Tocilizumab for suppressing radiographic progression of cervical lesions in patients with rheumatoid arthritis comparison with methotrexate therapy; three years of follow-up – A Multicenter Registry Study –

Yasuhide Kanayama1, Toshihisa Kojima2, Yuji Hirano1, Yuichiro Yabe1, Nobunori Takahashi3, Yukiyoshi Oishi4, Naoki Ishiguro2

1Department of Orthopaedic Surgery and Rheumatology, Toyota Kosei Hospital, Toyota, Japan, 2Department of Orthopedic Surgery, Nagoya University, Graduate School of Medicine, Nagoya, Japan, 3Department of Rheumatology, Toyohashi Municipal Hospital, Toyohashi, Japan, 4Department of Rheumatology, JCHO Tokyo Shinjuku Medical Center, Tokyo

Conflict of interest: None

[Objectives] To evaluate the efficacy of Tocilizumab (TCZ) for suppressing the radiographic progression of RA cervical lesions comparison with methotrexate (MTX) for 3 years. [Methods] We used TCZ and MTX for treating each 50 and 75 Japanese patients with active RA for at least 3 years. For evaluation of cervical lesions ADI, SAC and the Ranawat value were measured at initiation and Year 1,2,3. [Results] In the patients receiving TCZ (n=50) and MTX (n=75), the mean age was 58.7 vs 63.6 years old (p=0.046), disease duration was 7.7 vs 8.0 years (p=0.247). The respective changes in cervical lesion parameters after 1 year were as follows: ADI: 0.24 vs 0.27mm (p=0.476), SAC: -0.20 vs -0.17mm (p=0.885) and Ranawat value: -0.16 vs -0.13mm (p=0.679). The respective changes in cervical lesion parameters after 2 years were as follows: ADI: 0.36 vs 0.55mm (p=0.072), SAC: -0.26 vs -0.45mm (p=0.074) and Ranawat value: -0.26 vs -0.33mm (p=0.387). The respective changes in cervical lesion parameters after 3 years were as follows: ADI: 0.46 vs 0.71mm (p=0.044), SAC: -0.34 vs -0.63mm (p=0.027) and Ranawat value: -0.32 vs -0.44mm (p=0.295). [Conclusions] This study suggested that TCZ treatment can be used to suppress the progression of RA cervical lesions.

**P2-119**

**Which DMARDs is better for RA patients who had inadequate response to Tocilizumab?**

Tsuneo Kondo, Yusuake Okada, Akiko Shibata, Kentaro Chino, Takahiko Kurasawa, Hirofumi Takei, Koichi Amano

Department of Rheumatology and Clinical Immunology, Saitama Medical Center, Saitama Medical University

Conflict of interest: None

[Object] To elucidate next treatments for RA patients who had insufficient efficacy of tocilizumab (TCZ). [Methods] The medical records of 23 RA patients who had received another DMARD due to inadequate response to TCZ and had been followed up for more than 24 weeks were retrospectively evaluated. [Results] Background features at the time of discontinuation of TCZ were as follows; female 91% (21 patients), average age 60.8 years, mean disease duration 14 years, stage 4 ratio 56% (13 cases), MTX usage rate 52% (12 cases), the average TCZ administration duration 2.6 years, and the average DAS28-ESR 4.3. Next DMARDs after TCZ discontinuation were as follows; tofacitinib (Tofa) 10 (43%), TNF inhibitors 8 (35%), abatacept (ABT) 5 (22%). TNF inhibitors included 4 infliximab, 2 etanercept and 2 golimumab. LOCF analysis revealed that the changes of DAS28-ESR from baseline to week 24 were from 4.2 to 3.3 for Tofa (P=0.058), 4.2 to 3.8 for TNF inhibitors (P=0.494) and 4.8 to 4.2 for ABT (P=0.676), and the changes of CDAI from baseline to week 24 were from 15.9 to 6.6 for Tofa (P=0.003), 17.3 to 9.9 for TNF inhibitors (P=0.040) and 25.7 to 15.4 for ABT (P=0.143). [Conclusions] This study suggested that switching to Tofa and TNF inhibitors for TCZ inadequate responders could be effective.

**P2-120**

**Clinical results of tocilizumab (TCZ) in elderly RA patients; more than 5 years follow-up**

Hideki Tsutou, Shoichi Kaneshiro

Osaka Rosai Hospital, Sakai, Japan

Conflict of interest: None

[Object] We investigated the efficacy using TCZ more than five years in elderly patients with rheumatoid arthritis. [Methods] 41 RA patients have been continued to treat with tocilizumab in our hospital more than five years. Among them, 26 were less than 65 years old (less 65 group) at the beginning of TCZ, and 15 were more than 65 years old (above 65 group). The average duration of RA were 9.0years/23years (less 65/above 65, respectively). The average DAS28CRP were 4.0/4.1 at the beginning of administration. At the end of this study, we investigated the efficacy of TCZ in both groups, and moreover, we analyzed the reasons of discontinuation in the above 65 group. [Results] At the end point, CRP were 0.05/0.04 (less 65/above 65, respectively), and CDAI were 5.3/6.0. The usage of MTX were 92%/87% at the beginning of TCZ, on the other hand, they were reduced to 31%/47% at the end point. Moreover, the usage of PSL were 65%/80% at the beginning of TCZ, on the other hand, they were reduced to 33.8%/14%. Among 10 patients who have discontinued TCZ, the reason was infectious diseases in 3 patients and malignant diseases in 2 patients. [Conclusions] The treatment with TCZ for elderly patients with RA is safe and it may be useful for elderly RA patients.

**P2-121**

**Efficacy of shortening the dosing interval of subcutaneous tocilizumab to rheumatoid arthritis patients with an inadequate response to subcutaneous tocilizumab every other week**

Hiroomi Watanabe, Shuntaro Miyoshi, Jiro Yamana, Mitsuhiro Iwashashi, Rie Sasaki, Seizo Yamana

Department of Rheumatology, Higashi Hiroshima Memorial Hospital, Higashihiroshima, Japan

Conflict of interest: None

[Object] The dosing interval was shortened up to one week for nine cases of rheumatoid arthritis patients who had an inadequate response to subcutaneous tocilizumab every other week. We investigated the effectiveness of these cases. [Methods] Nine patients with rheumatoid arthritis (RA) who had an inadequate response to subcutaneous tocilizumab every other week preparation were included. The dosing interval was shortened, and the continuation rate and efficacy after 6 months were investigated. Efficacy was evaluated using SDAI and CDAI. [Results] The patient background was 5 women and 4 men, with an average age of 59.7 years (17 - 83). The combination medication were 7 prednisone (2 to 5 mg) and 2 methotrexate (4 mg, 8 mg). The CDAI before shortening the dosing interval was 18.78 ± 13.6. CRP <0.05 mg / dL in all cases after 6 months of shortened dosing. In the clinical evaluation, 4 cases achieved remission, 3 cases achieved low disease activity, and 2 cases did not show improvement. Of the 4 patients with CRP <0.05 mg / dL before the start of shortened dosing, 2 patients improved the clinical evaluation. [Conclusions] Many shortened dosing confirmed improvement in disease activity. It was suggested that shortening administration may be effective even in cases with normal CRP.

**P2-122**

**Clinical experience of sarilumab at the author’s institution**

Yukita Ueki, Toshiyuki Aramaki, Shota Kurushima, Kanako Kojima, Natsumi Kawachi, Kaoru Terada, Katsumi Eguchi

Clinical results of tocilizumab (TCZ) in elderly RA patients; more than 5 years follow-up

Hideki Tsutou, Shoichi Kaneshiro

Osaka Rosai Hospital, Sakai, Japan

Conflict of interest: None

[Object] Approved in September 2017, sarilumab, is a novel anti-rheumatoid drug that is classed biologics. Presently, the postmarketing
clinical surveillance is ongoing, and we await the data on the actual clinical safety and efficacy of this drug. We hereby report the safety and efficacy of sarilumab treatment. [Methods] The subjects were 9 patients (1 in bio-naïve, 8 in the other biologics—sarilumab) that were enrolled in RA patients responding poorly to MTX and other biologics. Safety and efficacy of the treatment were assessed in the 14 weeks. [Results] With regard to safety, there were 6 onsets of adverse events in 4 of the 9 patients; however, all were not serious and the outcome was recovery with no dropout cases. Two of the cases were dropout by no-efficacy. With regard to efficacy, changes in CDAI showed remission for 1 patient, effective for 6 patients, and ineffective for 2 patients at 12 weeks. [Conclusions] Safety is comparatively high if attention is paid to infection and so on. Our study suggests that the usefulness of sarilumab is considered high for patients that respond poorly to MTX and other biologics.

P2-123 Experience of sarilumab therapy for RA patients in our hospital Satoshi Tsutsumi, Daisuke Tomita, Kosuke Okuda, Keiko Funahashi, Tsukasa Matsubara Matsubara Mayflower Hospital Conflict of interest: None

[Object] Sarilumab is a fully human anti-IL-6R monoclonal antibody that blocks IL-6-mediated inflammatory signaling cascade. We examined retention rate, efficacy and safety of sarilumab therapy for RA patients. [Methods] For 7 RA patients in our hospital (3 males and 4 females) at more than 24 weeks after starting sarilumab, we evaluated retention rate, efficacy and safety. [Results] The mean age 70.5 years, the mean disease duration 8.4 years, bio-naïve cases five and bio-switch cases two (one from ETN and one from TCZ). Four patients initially received MTX at mean dose 8.5 mg/w. Four patients were able to continue sarilumab at 24 weeks after starting it (retention rate 57.1%), and mean DAS28-CRP decreased from 3.85 at the start to 1.87 at 24 weeks. Two of the four experienced neutropenia and required transient withdrawal or dose decrease of sarilumab for continued use. Three patients stopped sarilumab because of ineffectiveness (1 case) and thrombocytopenia (2 cases). Thrombocytopenia was recovered within 4 weeks after stopping sarilumab in one case, but in another case resulted from concomitant idiopathic thrombocytopenic purpura. [Conclusions] More than 24-week treatment of RA with sarilumab resulted in obvious efficacy and safety profile consistent with IL-6 blockade.

P2-124 Short-term efficacy of sarilumab therapy in the patients with rheumatoid arthritis Yuko Kimura1, Shuzo Yoshida1, Akitoshi Machida2, Nobuhsia Shibahara3 1Department of Immuno-Rheumatology Center, Arisawa General Hospital, Hirakata, Osaka, Japan, 2Department of Orthopedic Surgery, Arisawa General Hospital, Hirakata, Osaka, Japan, 3Department of Urology, Arisawa General Hospital, Hirakata, Osaka, Japan Conflict of interest: None

[Object] We examined short-term efficacy of sarilumab therapy in the patients with rheumatoid arthritis (RA). [Methods] Ten patients with RA who underwent sarilumab treatment in our hospital between April and October 2018 were examined. We evaluated the disease activity score (DAS) 28-ESR and ultrasound. [Results] Nine patients were females, the average age was 62.8 years ± 20.3 years, and the mean disease duration was 16.5 ± 14.0 years. Seven patients were anti-CCP antibody positive and six patients were RF positive. The mean age 70.5 years, the mean disease duration 8.4 years, bio-naïve case one and bio-switch cases five. Four patients initially received MTX. Four patients were able to continue sarilumab at 24 weeks after starting it (retention rate 66.7%). The mean DAS28-ESR decreased from 5.8 at the start to 2.37 at 24 weeks. The mean SDAI decreased from 31.9 at the start to 5.88 at 24 weeks. Two patients are stopped sarilumab because of rash. They are recovered within 4 weeks after stopping sarilumab. Four patients that continued sarilumab were no adverse effect. And we confirmed efficacy by patients that sarilumab switch tocilizumab and tocilizumab switch sarilumab. One of the eleven experienced neutropenia. Neutropenia was recovered within 28 days. [Conclusions] More than 24 weeks treatment of RA with sarilumab resulted in obvious efficacy. We experienced side effects that are rashes and the patients continued sarilumab were no adverse effect. And we confirmed efficacy by the case of switching during anti-IL-6R monoclonal antibody.

P2-125 Experience of sarilumab therapy for RA patients in our hospital Yasuhiro Terashima1, Ken Takebe1, Koji Tateishi1, Midori Kitayama2, Takashi Yamane2, Yo Ueda1 1Department of Orthopaedic, Kohnan Kakogawa Hospital, 2Department of Rheumatology, Kakogawa City Hospital, 3Department of Immunology, Kobe University Graduate School of Medicine Conflict of interest: None

[Object] We examined efficacy and safety of sarilumab therapy for RA patients. [Methods] For six RA patients within eleven RA patients that treated by sarilumab at more than 24 weeks after having passed, we examined efficacy and safety. [Results] The mean age 68 years (55-77years), bio-naïve case one and bio-switch cases five. Four patients initially received MTX. Four patients were able to continue sarilumab at 24 weeks after starting it (retention rate 66.7%). The mean DAS28-ESR decreased from 5.8 at the start to 2.37 at 24 weeks. The mean SDAI decreased from 31.9 at the start to 5.88 at 24 weeks. Two patients are stopped sarilumab because of rash. They are recovered within 4 weeks after stopping sarilumab. Four patients that continued sarilumab were no adverse effect. And we confirmed efficacy by patients that sarilumab switch tocilizumab and tocilizumab switch sarilumab. One of the eleven experienced neutropenia. Neutropenia was recovered within 28 days. [Conclusions] More than 24 weeks treatment of RA with sarilumab resulted in obvious efficacy. We experienced side effects that are rashes and the patients continued sarilumab were no adverse effect. And we confirmed efficacy by the case of switching during anti-IL-6R monoclonal antibody.

P2-126 A case of early remission of rheumatoid arthritis with eosinophilia induced by tocilizumab Taro Akira1, Michiko Ohashi1, Masashi Okamoto2, Hiroshi Shimagami1, Takehiro Hirayama1, Akira Masa2, Yoshinobu Matsuura1, Akihiko Nakabayashi1, Yoshinori Katada1, Kazushi Konna1 1Division of Rheumatology and Clinical Immunology., Sakai City Medical Center, Sakai, Japan, 2Nephrology, Diabetology and Rheumatology., Sakai City Medical Center, Sakai, Japan Conflict of interest: None

[Case] A 43-year-old woman with polyarthralgia was referred to our hospital 3 years ago. She was diagnosed as RA, 4mg of MTX per week and 3mg of PSL was introduced. After use of tocilizumab, complete remission was achieved and PSL was stopped. 3 months later, since an eosinophilia and leucopenia (WBC 3980/μl, Seg 34.2 %, Eo 14.3 %) developed, presumably due to adverse effect of tocilizumab, both tocilizumab and MTX were stopped. Interestingly, the patient had no symptoms for the next 6 months with no medication. Using sarilumab, she is now in good control. [Discussion] In spite of 3 month use, tocilizumab led a drug-free remission for half a year. As bDMARDs are generally discontinued after several years remission, this is very early remission introduction. After 4 years remission by tocilizumab monotherapy, 10 % of RA patients are described to keep drug-free remission for 1 year (Nishimoto N et al. Modern Rheumatol 2014; 24:17-25.). Notably, our patient had an eosinophilia. Frequency of eosinophilia is reported to be 0.35 % in RA patients treated with tocilizumab (Azuma N et al. Intern Med. 2015;54:1585-1590.). This case suggests a possibility of early induction of drug-free remission by combination of IL-6 blockade and a certain treatment which cause eosinophilia.

P2-127 Two cases in which ETNBS and intra-articular injection of triamcinolone acetonide was co-administered for rheumatoid arthritis with refractory activity Heiseki Yu Touei Internal Medicine and Rheumatology Clinic Conflict of interest: None

[Background] bDMARDs cannot be used for economic reasons even
in the intractable state because of high prices. Two patients who were effective for administration of low cost ETNBS=IAGC with refractory active RA at our clinic will be reported. Casel 67y M visited our clinic with bone destruction at X-ray and joint echo. ACPA629 RF161 CRP2.7 stageIII class2, csDMARDs=IAGC no effective lacks symptoms of pain and rapidly after interruption of treatment for 3M Bone destruction and deformation progression. Even though it was being treated with prostate cancer and stable, so it was effective at simultaneous administration of ETNBS=IAGC. PD on echo disappeared once with administration and is still in remission. Case2 66y F, she refused bio-DMARDs for economic reasons. Articular stiffness, activity, the disease condition suddenly worsened and visited our clinic. StageV class2 ACPA809 CRP3.5, Bone destruction is highly advanced mainly on the two hand joints and echo was also GS3 PD3. MTX+IAGC no effective, effective for two doses of ETNBS=IAGC. Even now it is remission with PD disappearance [discussion] Low cost and extremely economical IAGC=ETNBS in short-term refractory disease symptoms but also careful administration in tumor-bearing condition and bone destruction are remarkable in both cases.

P2-128 Safety of Baricitinib (Bari) under Clinical Settings in Patients (pts) with Rheumatoid Arthritis (RA), Using Data from All-case Post-marketing Surveillance and Spontaneous Reports Hiroaki Matsuno1, Tatsuya Atsumi2, Syuji Takei3, Naoto Tamura4, Masayoshi Harigai5, Takao Fujii6, Shigeki Momohara7, Yuko Takahashi8, Nobuhiro Nariki9, Naoto Tsujimoto10, Atsuko Ishii11, Kazuhiko Yamamoto12, Masataku Kawanami13, Michiaki Takagi14
1Matsumo Clinic for Rheumatic Diseases, 2Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine, Hokkaido University, 3Department of Pediatrics, Graduate School of Medical and Dental Science, Kagoshima University, 4Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, 5Department of Rheumatology, Tokyo Women’s Medical University, 6Department of Rheumatology and Clinical Immunology, Wakayama Medical University, 7Hakkeikai Incorporated Medical Institution, 8Eli Lilly Japan K.K., 9RIKEN Center for Computational Science, Kagoshima University, 10Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, 11Department of Orthopaedic Surgery, Yamagata University Faculty of Medicine

Conflict of interest: Yes

[Objectives] To evaluate efficacy and safety of baricitinib for RA patients who achieved remission or low disease activity in real world data [Methods] All-case post-marketing surveillance of Bari (except pts in clinical studies) collects safety and efficacy data for the first 24 weeks starting in Sep 2017; collection of safety data like SAEs continues for 3 years. This interim report summarizes registration data including pretreatment test rates and AEIs collected in the surveillance and spontaneous reports. [Results] As of Aug 2018, 1288 pts had been enrolled. Registration data were as follows: women, 81%; mean age, 64 years old, mean RA duration, 12 years; Steinbrocker stage II, 32%; stage III or IV, 52%; Bari 4mg, 68%; Bari 2mg 32%; MTX use, 57%; corticosteroid use, 51%; pretreatment test for TB, 93%; HBV, 95%; HCV, 93%; and eGFR, 96%. Of 299 AEs collected, 53 were SAEs. SAEs reported in 2 or more pts were pneumonia (8), fall (4), osteonecrosis (3), HZ (2) and ILD (2). Pulmonary TB (1), lymph node TB (1) and DVT (1) were also reported as SAEs. [Conclusion] Care is needed to ensure that all pretreatment tests be conducted in all pts; although the most pts underwent all tests, some tests were not conducted in some pts. SAEs including infections were reported, and careful monitoring is continuously needed in pts receiving Bari.

P2-129 Dose reduction of baricitinib for rheumatoid arthritis patients who achieved remission or low disease activity in real world data Eiji Torikai, Daisuke Suzuki
Department of Rheumatology, Iwata City Hospital

Conflict of interest: None

[Object] To evaluate efficacy and safety of baricitinib (Bari) for rheumatoid arthritis (RA) patients in real world clinic during 24 weeks. [Methods] We included 21 RA patients (Bio naive (BN): 13 patients and Bio switch: (BS) 8 patients) who started the treatment with Bari between October 2017 and April 2018. Patients were treated with T2T strategies. We evaluated the disease activity, HAQ-DI and adverse events. [Results] At Baseline, the mean ages, the disease duration, CDAI and HAQ-DI of BN were 63.8 years, 5.03 years, 26.2 and 0.81, respectively, and those of BS were 65.5 years, 5.73 years, 35.0 and 1.16, respectively. At 4 weeks, ACR20/50/70 of BN (%) and BS (%) were 85.6/61.5/38.4 and 50.0/25.0/12.5, respectively. HAQ-DI of BN and BS were 0.39 and 0.67, respectively. At 24 weeks, the percentage of remission/LDA/MDA/HDA in BN and BS were 53.8/30.7/15.4/0 and 25.0/37.5/25.0/12.5, respectively. HAQ-DI of BN and BS were 0.39 and 0.67, respectively. One patient discontinued due to no response. Two patients restarted after withdrawal for a while due to a pneumonia and a herpes zoster. Mild adverse events including laboratory abnormalities occurred in 52.4% of them. [Conclusions] Bari treatment with T2T strategies in real world clinic demonstrated beneficial efficacy and safety.

P2-130 Efficacy of baricitinib (bari) for rheumatoid arthritis in patients with an inadequate response (IR) to tofacitinib (tofa) Takashi Yamane, Ayaka Nakagawa, Midori Kitayama, Takuro Maeda, Noriaki Yo, Chihiro Tanaka
Rheumatology Division, Kakogawa Central City Hospital

Conflict of interest: None

[Object] To investigate the efficacy of bari for tofa IR patients. [Methods] There were 7 tofa IR patients who were switched to bari. Their baseline characteristics, continuation rate, and disease activity were retrospectively assessed up to week 12. [Results] Mean age was 56.4, mean disease duration was 9.2 years, all were ACPA - RF positive. The number of prior biologics use was 2.3 (1-4). 3 had concomitant MTX use (mean 3.5 mg (4-6)) and 4 had PSL (mean 3.3 mg (2-5)). Mean SJC/TJC was 5.0 (1-15)/5.3 (1-15), Physician’s/’Patient’sVAS 71 mm (50-90)/73 mm (50-80), CRP/MMP-3 3.1 mg/dl (0.01-4.3)/357.3 mg/dl (27-933). Mean SDAI/CDAI 26.3/24.7, DAS 28-28CRP was 4.5, 57% with MDA, 43% with HDA at baseline. The mean patient’s VAS decreased significantly (P <0.01) at week 2, and at week 4, CDAI/SDAI/DAS28-28CRP showed a significant improvement (P <0.05). 2 were discontinued due to lack of efficacy and ILD, the continuation rate at 71.4%. At week 12, all patients achieved LDA by SDAI/CDAI, 40% achieved MDA, 40% LDA, 20% achieved by DAS28-28CRP (mean 2.6). 3 of 4 patients taking PSL were able to withdraw. [Conclusions] Efficacy of bari seemed to be expected from the early stage even in tofa IR patients. Bari was administered for the case of inadequate improvement of patient’s VAS with tofa.

P2-131 Study of clinical manifestations by Baricitinib Shunichi Imaizumi, Kikuko Gushiken, Ken Hasegawa
1Rheumatoid Arthritis Center, Minami Medical Health Cooperation, 2Meinan Hospital, Department of Orthopaedic Surgery

Conflict of interest: None

[Objective] To study clinical manifestations by Baricitinib (BARI). [Subjects and Methods] Data from 23 patients who were treated with BARI in our hospital after the launch of BARI till Sep 2018 were analyzed (17 showed inadequate response to multiple biologic drugs and 6 chose BARI 2 mg due to financial reasons). The assessment items included morning stiffness (MST), VAS, fatigue, grip strength, DAS28 (ESR), DAS28 (CRP), CDAI, SDAI, and HAQ. [Result] All assessment items rapidly improved 1 week after introduction of BARI treatment. Improvement and maintenance in efficacy were also observed during the subsequent courses. In addition, HAQ tended to improve 6 months after introduction. [Discussion and Conclusion] BARI was effective in the early phase of introduction and in patients with inadequate response even after the introduction of multiple biologic drugs. BARI was effective in 6 patients who chose BARI 2 mg due to financial reasons, suggesting that BARI 2 mg can be effective in patients in whom the introduction of biologic drugs is difficult due to financial reasons. BARI could also be used for improvement of fatigue in patients with RA that has been difficult to treat conventionally. Furthermore, BARI will be beneficial for treatment.
P2-132
Baricitinib administration experience of the elderly, including the super elderly
Tamami Kikuchi1, Takeshi Kuroda1, Ichiei Narita1
1Division of Department of Internal Medicine, Niigata Rosai Hospital, 2Division of Clinical Nephrology and Rheumatology, Niigata University Graduate School of Medical and Dental Sciences

Conflict of interest: None

[Object] Report on the effectiveness of Baricitinib to the elderly and side effects [Methods] Six cases of rheumatoid arthritis patients aged 77 to 90 years. Duration of disease is 2 years to decades or more. I have experienced MTX in all cases, I have never used biologics. Disease activity is moderate to high with SDAI. In all cases, half of Baricitinib (2 mg / day) was administered [Results] Improvement of subjective symptoms was observed from several days to several weeks after administration, and CRP was also lowered. In the evaluation after 1 month, SDAI remission was achieved in 5 out of 6 cases and 1 case was low disease activity. In 1 case of side effects, lower limb vein thrombosis was observed in the same case as serum CK elevation. The continuation rate for 3 months was 100%, for 5 months was 83% [Conclusions] Baricitinib was used for elderly people with MTX resistance. Although 6 cases, small group number and short term observation, Baricitinib was effective in the elderly as sufficient effect by half dose administration throughout the course. Half dose administration of Baricitinib is expected to become an effective treatment option for the elderly rheumatic patients in the future.

P2-133
Treatment with Baricitinib in a Patient with Rheumatoid Arthritis Complicated by Janus Kinase 2 V617F Mutation-positive Essential Thrombocythemia
Makoto Sugihara, Tomohiro Kozuki, Yuji Miyoshi, Miho Ohshima
Department of Rheumatic Diseases, Tama-Hokubu Medical Center, Tokyo Metropolitan Health and Medical Treatment Corporation

Conflict of interest: Yes

[Case] A 75-year-old man, construction company employee, referred to our hospital with arthralgia in his hands and knees. At X-10 years, he was diagnosed with essential thrombocythemia (ET) with JAK2 V617F hetero mutation and followed by hematologist, taking aspirin for thrombophrophylaxis and allopurinol for secondary hyperuricemia. Initial examination revealed the following: TJC 4; SJC 4; WBC 17300/μL; Hb 11.6 g/dL; PLT 607000/μL; RF 92 IU/mL; ACPA >150 U/mL; CRP 0.65 mg/dL; PGA 5 cm; EGA 4 cm; DAS28-ESR 3.44; SDAI 17.65 and HAQ 0.25. The diagnosis was moderately active RA. MTX treatment was started at 8 mg/wk but was ineffective and interfered with his work. At week X+4, baricitinib (BAR) 4 mg/d was administrated. At week X+8, TJC was 0; SJC 0; CRP 0.06 mg/dL; PGA 2 cm; EGA 0.5 cm; DAS28-ESR 1.41; SDAI 2.56, and HAQ 0, he achieved clinical and HAQ remission. His PLT was normalized to 329000/μL. [Discussion] JAK2 V617F mutation is common in myeloproliferative disorders, such as ET. Only 5 cases were included in the present study. The age of the patient was 61 years, and the disease duration was 137 months, StageI/II/III/IV (3/5/3/0), Class1/2/3/4 (7/4/0/0), RF/ACPA positive 82%/82%, MTX73%, PSL36%, tacrolimus55%, Bari2mg 4 cases, Bari4mg 7 cases, DAS28-ESR5.16, SDAI26.3, CDAI23.6, HAQ0.56. Complications: collagen disease, interstitial pneumonitis36%, sinusitits18%, bronchiectasis, pulmonary MAC, HBsAb positive, past history (herpes zoster, MTX-pneumonitis). Efficacy: EULAR good response at 12 weeks was 73%, and 78% at 24 weeks. High rate of remission achievement rate at 12 weeks (DAS45%, SDAI36%, CDAI27%), 24 weeks (DAS56%, SDAI56%, CDAI56%). Adverse events: upper respiratory tract infection, diarrhea, high CK, high Chol. There are no serious adverse events, herpes zoster and malignancy. [Conclusions] Baricitinib is useful even in actual clinical practice, where are many complications unlike clinical trials.

P2-134
Examination of joint ultrasound findings in JAK inhibitor Baricitinib in our clinical practice
Shigekazu Takahashi, Yasushi Nawata, Kazusa Miyachi, Norihiro Mimura, Taiga Ikezawa, Kazuhiro Hamasato, Norihiko Watanabe
Division of Rheumatology / Clinical Immunology, Chibaken Saiseikai Narashino Hospital, Chiba, Japan

Conflict of interest: None

[Object] We assessed RA patients in our hospital who received JAK inhibitor Baricitinib (Bari), and examined the effectiveness in clinical practice using joint ultrasound (US) findings. [Methods] In 13 cases of administration of Bari, 9 cases continued for 6 months or more were evaluated. Effectiveness was evaluated semi-quantitatively with 26 joints of both hands (wrist, MCP, PIP) with GS and PD by joint US, before, 12 and 24 weeks after administration. We also compared it with disease activity index (DAS28-ESR, SDAI). [Results] Background is age 59.4 years, Bari 2 mg 4 cases / 4mg 5cases, pre-administration DAS 5.28, SDAI 28.1. EULAR good response 67% for week 12, 86% for 24 weeks, remission rate was high at 12 weeks (DAS 43%, SDAI 33%), 24 weeks (DAS 57%, SDAI 57%). In the joint US findings, improvement of average total GS and PD was observed consistent with disease activity index. Maximum number of findings when evaluating joints with the OMER- ACT-EULAR composite PDUS score, the average GS / PD combined score improved from 2.11 (before), 1.29 (12 weeks), 0.86 (24 weeks). After 24 weeks we achieved grade 1 or less in all cases. [Conclusions] Even in clinical practice, improvement of clinical and joint US findings was recognized from the early stage of administration of Bari.

P2-135
Baricitinib for rheumatoid arthritis (RA) patients with complications in actual clinical practice
Yasushi Nawata, Shigekazu Takahashi
Center for Rheumatic Diseases, Chibaken Saiseikai Narashino Hospital

Conflict of interest: None

[Object] We examined the efficacy and safety of baricitinib (Bari) in actual clinical practice. [Methods] 11 RA patients who received Bari remission more than 12 weeks were examined. The efficacy of Bari was evaluated by composite measure (DAS28-ESR, CDAI, SDAI), EULAR response, remission/low disease activity achievement rate. [Results] Subjects: 7 Bio-naive (MTX-IR 3, csDMARDs-IR -) and 4 Bio-switch cases (TNFi 2, IL6Ri 1, tofacitinib 1). Background: age 61 years, disease duration 137 months, StageII/III/IV (3/5/3), Class1/2/3/4 (7/4/0/0), RF/ACPA positive 82%/82%, MTX73%, PSL36%, tacrolimus55%, Bari2mg 4 cases, Bari4mg 7 cases, DAS28-ESR5.16, SDAI26.3, CDAI23.6, HAQ0.56. Complications: collagen disease, interstitial pneumonitis36%, sinusitis18%, bronchiectasis, pulmonary MAC, HBsAb positive, past history (herpes zoster, MTX-pneumonitis). Efficacy: EULAR good response at 12 weeks was 73%, and 78% at 24 weeks. High rate of remission achievement rate at 12 weeks (DAS45%, SDAI36%, CDAI27%), 24 weeks (DAS56%, SDAI56%, CDAI56%). Adverse events: upper respiratory tract infection, diarrhea, high CK, high Chol. There are no serious adverse events, herpes zoster and malignancy. [Conclusions] Baricitinib is useful even in actual clinical practice, where are many complications unlike clinical trials.

P2-136
The annual observational research of tofacitinib in patients with rheumatoid arthritis by NinJa2017 cohort
Atsushi Kaneko1, Toshihiro Matsui2, Shotaro Mori3, Yosuke Hattori1, Tomotaro Sato1, Masao Katayama1, Shigeto Tohma1
1Department of Orthopaedic Surgery and Rheumatism, Nagoya Medical Center, 2Department of Rheumatology, Sagamihara National Hospital, 3Department of Collagen Disease and Rheumatology, Nagoya Medical Center, 4Department of Rheumatology, Tokyo Medical Center

Conflict of interest: None

[Object] The purpose of this current study is to research of tofacitinib in patients with rheumatoid arthritis by NinJa2017 cohort. [Methods] We investigated the drug efficacy and safety of tofacitinib in 277 Japanese RA patients by NinJa2017 cohort. [Results] 58 patients were medicated tofacitinib monotherapy, 139 patients were medicated the combined therapy with MTX, 21 patients the combined therapy csDMARD except MTX, and 25 patients the combined therapy with 2 or 3 cs DMARDs. 58 patients were medicated tofacitinib 5mg/day, 212 patients 10mg/day. The BOOLEAN remission reached 59 patients, and SDAI remission were reached 82 patients. The annual hospitalization and/or serious adverse event were occurred 18 patients involving 10 patients complicated with...
[Object] To evaluate the persistence rate of JAK inhibitor in Japanese patients with Rheumatoid Arthritis (RA). [Methods] All patients treated with JAK inhibitor for RA at Kitasato University Medical Center or Shinonoi General Hospital were analyzed. The drug retention rates were compared using Log-rank test. [Results] Fifty patients were treated with JAK inhibitor. The mean age of subjects was 64.6 and the mean duration of disease was 8.7 years. Woman accounted for 37 of the 50 cases. 30 patients were treated with MTX and 30 patients were treated with PSL. At the start of JAK inhibitor, DAS28-CRP was 4.5. Age of the subject, concomitant therapy with MTX, remote biological agents use and anti-CCP antibody value did not correlate with the continuation rate of JAK inhibitor. PSL combination group had a significantly lower persistence rate than the noncombined group. In the cases that DAS28-CRP declined by more than 20% within 4 weeks after JAK inhibitor was started, the persistence rate was significantly better than the case that DAS28-CRP did not decline. [Conclusions] There is a possibility that long-term continuation can be expected in the PSL noncombined group or the case that DAS28-CRP is improved by more than 20% within 4 weeks after JAK inhibitor was started.

P2-138
Change of 22 RA patients treated with tofacitinib for three years in Keiyu Orthopedic Hospital
Keio Ayabe, Akira Inoue, Takuro Okari
Keiyu Orthopedic Hospital Gunma Japan

Conflict of interest: None

[Objectives] Most of the function of cytokines that the biological activity is controlled by tofacitinib (following TOF) relates to the function of lymphocyte. It is thought that TOF and abatacept (following ABT) have similar action for the reports about the restraint action for T cell, B cell and dendritic cell by TOF. So we can expect the effectiveness for the autoantibody-positive RA patients about TOF like ABT reported that is effective for the antiCCP antibody-positive RA patients. This study aims to investigate the change of the antiCCP antibody titer which is poor-prognosis factor for the treatment of RA patients. [Methods] 34 RA patients passed more than three years after the initiation of the treatment with TOF in Keiyu Orthopedic Hospital, and 22 patients (5males,17females) continued the treatment with TOF. We examined the progress such as changes of the disease activity and laboratory data for them. [Results] Mean DAS28CRP was improved (baseline/3 years after dosage: 3.9/2.1). The patients which antiCCP antibody titer decreased were 14 of 22 patients. [Conclusions] We can expect a drop of the antiCCP antibody titer which was a poor-prognosis factor for the treatment of RA patients by the treatment with TOF.

P2-139
Evaluation of the effectiveness of two JAK inhibitors in rheumatoid arthritis treatment at our hospital
Mai Morimoto, Takahiro Yoshikawa, Chie Ogita, Masao Tamura, Tetsuya Furukawa, Teppei Hashimoto, Naoto Azuma, Masayasu Kitano, Kiyoshi Matsui
Division of Rheumatology Department of Internal Medicine, Hyogo College of Medicine

Conflict of interest: None

[Object] We examined the effectiveness of two JAK inhibitors against RA patients in our hospital. [Methods] 26 patients who were observable continuously for more than 6 months in RA patients who received TOF, and 7 patients who had been able to observe continuously for 12 weeks or more and patient background and efficacy was evaluated. [Results] Patient background was TOF treatment group, mean age 56.5 years, disease term 11.61 years, 19 females, 7 males, 22 cases used MTX at the start, DAS 28-ESR 5.17 at the start of treatment, DAS 28-CRP: 4.49, DAS 28-ESR 3.18, DAS 28-CRP 2.41 after 6 months. Meanwhile, the BAR treatment group had an average age of 60.3 years, 6 women, 1 case of man, 6 cases used MTX at the start, all cases of using biologics, DAS 28-ESR 4.99 at the start of treatment. It was DAS 28-CRP 4.36. The DAS 28 - ESR at the 12th week of the BAR treatment group was 3.62, DAS 28 - CRP 2.80, which was almost the same as the DAS 28 - ESR 3.57 and DAS 28 - CRP 2.75 of the TOF at the same time. [Conclusions] The number of types of molecular targeted drugs has increased and establishment of therapeutic strategies that make use of drug characteristics is required. We will investigate the case including additional administration cases thereafter and report its effectiveness.

P2-140
Efficacy of tofacitinib in elderly patients with rheumatoid arthritis (age >70yrs)
Toyomitsu Tsuchida, Rikiai Tanaka, Yoichi Kamiino, Chizuru Shiraiishi
Department of Rheumatology, Tsuchida Clinic, Chiba, Japan

Conflict of interest: None

Introduction Treatment for elderly patients with rheumatoid arthritis (RA) has relied on steroids due to difficulty in introducing biologics or methotrexate. Oral low-molecular-weight JAK inhibitor tofacitinib (TOF) was approved in 2013, but has not been used in elderly patients because of the risk of serious adverse reactions. Objectives In 2013, we treated RA patients aged >70 years with 5 mg dose of TOF. This report summarizes the treatment efficacy as evaluated by MRI. Patients 23 patients (1 male, 22 females) who could continue TOF treatment for >1 year Mean age: 77.4 years Evaluation methods DAS28CRP, MMP-3 The wrist MRI data of 18 patients were retrospectively analyzed for synovitis and osteitis. Results The mean DAS28CRP values before and after 5 years of treatment were 3.23 and 2.00, respectively, and the corresponding MMP-3 values were 140.8 and 38.8. The numbers of patients with and without were 11 and 22 before and 4 and 29 after treatment, respectively; for os teitis, there were 19 and 14 before and 22 and 11 after treatment, respect ively. Discussion The 3 patients who worsened after treatment were treated with single-agent TOF, suggesting insufficiency of single-agent treatment at 5 mg. In conclusion, TOF can be used 5 mg in RA patients aged > 70 years.

P2-141
Effect about switching from ABT to TOF having the similar action of ABT for an effect attenuation antiSS-A antibody-positive RA patients of ABT
Keio Ayabe, Akira Inoue, Takuro Okari
Keiyu Orthopedic Hospital Gunma Japan

Conflict of interest: None

[Objectives] Most of the function of cytokines that the biological activity is controlled by tofacitinib (following TOF) relates to the function of lymphocyte. It is thought that TOF and abatacept (following ABT) have similar action for the reports about the restraint action for T cell, B cell and dendritic cell by TOF. So we can expect the effectiveness for the autoantibody-positive RA patients about TOF like ABT reported that is effective for the antiSS-A antibody-positive RA patients at-
tibody-positive RA patients were effective.

**P2-142**

Clinical experience of JAK inhibitors as a treatment for rheumatoid arthritis with interstitial lung disease

Nobuhito Naito, Hiroshi Kawano, Mayo Kondo, Hirokazu Ogino, Seidai Sato, Yuku Toyoda, Hisatsuji Goto, Yasuhiro Nishioka
Department of Respiratory Medicine & Rheumatology, Graduate School of Biomedical Sciences, Tokushima University

Conflict of interest: None

[Background]Interstitial lung disease (ILD) is a common extra-articular manifestation of rheumatoid arthritis (RA) and is one of the most serious prognostic factors. However, several disease-modifying anti-rheumatic drugs (DMARDs) can be a potential risk for the exacerbation of ILD, and the optimal treatment of RA-ILD has not been established. In the present study, we investigated the effectiveness and safety of JAK inhibitors as a treatment for RA-ILD. [Method] We retrospectively reviewed records of 5 RA-ILD patients treated with JAK inhibitors before October 2018 at our department. [Results]The mean age of the 5 patients was 73.8 years (65-82 years), and 4 patients were female. Of the 5 patients, 3 were administered tofacitinib, and 2 were baricitinib. Median dosing period was 10 months (2-51 months). After the initiation of JAK inhibitors, none of the patients experienced a worsening of ILD. The differences in the mean levels of KL-6 in 5 patients were not statistically significant between baseline and last visit (529.8±263.0 vs. 589.6±371.7 U/mL, p=0.55). Additionally, DAS28-CRP values significantly decreased from baseline to the last visit (529.8±263.0 vs. 589.6±371.7 U/mL, p=0.55). [Conclusion]JAK inhibitors can be a useful treatment option for RA-ILD.

**P2-143**

The study of JAK inhibitor monotherapy in treatment of patients with rheumatoid arthritis

Tatsuo Hirose, Yuji Tasaka
Department of Internal Medicine, Saitama City Hospital

Conflict of interest: None

[Object] The aim of this study was to assess the effect of the monotherapy by JAK inhibitors to achieve the therapeutic goal of D2T. [Methods] The patients with RA who visited our hospital since 2015, and who were ineffective with biologic agents were registered. During treatment these patients with JAK inhibitors monotherapy, if the therapeutic goal was not achieved, we tried MTX combination therapy. We set the therapeutic goal by C-DAI as below 3.2. [Results] In total, 23 patients were registered. 3 cases dropped out from this study, two patients stopped visiting our hospital and one stopped taking JAK inhibitors because of infection. 20 patients remained were analyzed in this study. The patients who did not achieved low disease activity by JAK inhibitor monotherapy, were applied to the treatment with MTX combination therapy. Finally, 10 cases (50%) achieved the therapeutic goal by JAK inhibitor monotherapy, however 10 cases (50%) needed MTX combination therapy. Multivariate analysis showed no significant factors to achieve treatment goal by JAK inhibitor monotherapy. [Conclusions] JAK inhibitor monotherapy was effective in 50% of patients, but failed another 50% of patients with RA. We can not find any factors to achieve therapeutic goal by JAK inhibitor monotherapy.

**P2-144**

Improvement of periodontal disease condition by tofacitinib administration in two cases with rheumatoid arthritis

Tetsuo Kobayashi1, Satoshi Ito2, Akira Murasawa2, Hajime Ishikawa2
1General Dentistry and Clinical Education Unit, Niigata University Medical and Dental Hospital, 2Department of Rheumatology, Niigata Rheumatic Center

Conflict of interest: None

[Object] Overproduction of proinflammatory cytokines has been implicated as a shared risk factor for rheumatoid arthritis (RA) and periodontal disease (PD). We had previously reported the beneficial effect of inhibitors of tumor necrosis factor (TNF) and interleukin-6 (IL-6) receptor on PD condition in patients with RA. Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA and has been suggested to regulate cytokine signaling. Therefore, we aimed to evaluate the effect of tofacitinib on PD condition in patients with RA. [Methods] We compared RA, PD, and serum parameter values before and after 3 months of tofacitinib administration in 2 patients (43- and 51-year-old women) with RA whose informed consents were obtained. [Results] Both patients showed an improvement in RA condition including simplified disease activity index, tender and swollen joint count, and visual analogue scale, as well as in serum levels of TNF-a and IL-6. Likewise, their PD conditions were ameliorated, as in gingival index, % sites with bleeding on probing, and probing pocket depth, although their oral hygiene levels as determined by plaque control record were relatively unchanged. [Conclusions] Tofacitinib may have a beneficial effect on PD condition in patients with RA.

**P2-145**

An Operated Case of Lumbar Disc Herniation In Patient with Rheumatoid Arthritis Using JAK Inhibitor without Drug Holiday in safety

Yoshinori Hashimoto
Department of Orthopaedic Surgery, South Miyagi Medical Center

Conflict of interest: None

We report a successful operated case of lumbar disc herniation in patient with rheumatoid arthritis (RA) using JAK inhibitor (Tofacitinib) and MTX without drug holiday.65years old male suffered from lumbar disc herniation one month ago, and he had paresis rapidly. In MRI, lumbar disc herniation revealed clearly. We decided resection operation of herniation, but he did not desire drug holiday (without holiday). So we operated without drug holiday. In result, he cleared paresis and had no post operated complication and no progression of inflammation. In short time and no impanting operation of RA patient using JAK inhibitor, we can complete without drug holiday in safety.

**P2-146**

Successful treatment with tofacitinib for biology refractory rheumatoid arthritis, which was aggravated after removal of adrenal tumor

Naofumi Yamauchi1, Koji Ibara2
1Department of Rheumatology, Sapporo Kiyota Hospital, 2Department of Internal Medicine, Sapporo Kiyota Hospital

Conflict of interest: None

A 54-year-old male developed rheumatoid arthritis (RA) in February 2013 and was treated with methotrexate (MTX) 6mg/week in our hospital. Lung adenocarcinoma occurred in September 2013 and he was performed a left upper lobectomy. In January 2017, abdominal CT scan revealed a left adrenal tumor and the patient underwent a left adrenalectomy. He was pathologically diagnosed as a metastatic adenocarcinoma. Articular symptoms were aggravated (DAS28-ERP 6.32) after the surgery and the patient was treated with corticosteroid and increasing the dose of MTX. Because the symptoms were continued, abatacept was administered in August. However, it was not effective and switched to golimumab. But the disease activity was not controlled. Therefore, he was administered tofacitinib (TOF) in February 2018 and articular symptoms immediately improved. The low disease activity (DAS28-ERP 3.17) was achieved after 4 weeks of the treatment. Onset or exacerbation of RA after the surgery of Cushing’s syndrome has been reported. It was suggested that the adrenalectomy caused progression of articular symptoms and TOF was effective in a RA patient inadequate response to biologics.

**P2-147**

A case report of successfully treated refractory psoriatic arthritis with tofacitinib

Michinori Ishitoku, Masamoto Funaki
Rheumatology Department, JR Hiroshima Hospital

Conflict of interest: None
A case with bilateral unstable artificial knees treated by constrained total knee arthroplasty

Toshihiro Mata, Aiko Kishida, Yukiko Komano, Ikuko Masuda, Koichiro Ohmura

Center for Rheumatic Diseases, Jujoutakeda Rehabilitation Hospital, Rheumatology and Clinical Immunology, Kyoto University Hospital

Conflict of interest: None

Instability of artificial knee joint is treated with ligament reconstruction and soft tissue repair followed by long-time cast fixation. Instability of bilateral knees is a great matter for patients. We report one case with instability of bilat. artificial knee joints treated by constrained total knee arthroplasty (TKA). [Case]: The patient is 65ys old female. On February 22, 2017 lt. TKA was done. On December 13, 2017 rt. TKA was done. She fell down and suffered bilat. knee instability on March 16, 2018. Rt. Artificial knee was worse damaged than lt. Knee. The patient could only stand up but could not walk even with knee brace or canes. [Operation & Result]: Rt. constrained total knee arthroplasty was done on march 28, 2018. L.t. constrained total knee arthroplasty was done on April 23, 2018. Just after operation she could start walking without cast and brace. On September 18, 2018, she can walk well with cane. [Discussion]: Instability of artificial knee is treated by reconstruction of ligament and soft tissue followed by casting. But bilateral knee casting is against post operative rehabilitation. It is difficult to revise unstable artificial knee with constrained total knee arthroplasty. But stability, mobility and early rehabilitation are obtained by one operation.

A case report: dislocation of PS type TKA with synovial proliferation induced

Hiroaki Hamada
Division of Orthopaedic Surgery, Department of Medicine of Sensory and Mortor Organs, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Conflict of interest: None

70 years old female [chief complaint] the left TKA dislocation [Present history] RA on set in 2001, for 2014/11/17, the left TKA operation (PERSONA PS type commented). In January, 2018, like, with the symp-toms. First dislocation was carried, but an emergency and rescue crew carries with 3 people, it’s said that it fitted in. When twisting the knee inside when standing up from a kotatsu on March 7, 2018, the second dislocation was carried on. [Complication] Interstitial pneumonia Hypothyroidism Hypertension. [RA treatment] TAC 1 mg/day, PSL 6 mg/day [operation view] synovial proliferation was admitted around the bar behind the post, and therefore it seems to have become easy to slip. In scopic view, the post even falls in the level of the bar, and judges a bar as slippery and contrary purpose for a dislocation. We removed the spacer, and the thickness 4 mm, 5 mm higher post were extended. Now, there is no joint instability after an operation, and range of motion is 0-or 140 after half year operation, and she is walking without support. [Consideration] When I looked back to a record after 2014, DAS-28 had range between LDA and MDA around 3 years after an operation, moreover, a CRP average was 1.7 for RA control between it. New synovial proliferation seems to have affected the dislocation.

Two cases that were planned TKA for the knee OA, but elderly onset RA was diagnosed based on a blood test result in preoperation, and canceled their operation

Takeshi Harui
Department of Orthopedic Surgery, Ishikawa Prefectural Central Hospital

Conflict of interest: None

[Case 1] TKA was planned for OA of an 87 y.o. woman, but laboratory data showed elevated CRP (11.7mg/dl). The present illness in detail revealed her symptom to be a polyarthritis. Though the anti-CCP antibody was negative but MMP-3 was high, the diagnosis might be elderly onset RA (EORA). She was started on oral prednisolone (PSL 10mg/day). Then the symptoms were improved immediately, and CRP fell to 0.9 at one week later. PSL was decreased gradually, and EORA was controlled by use of MTX and iguratimod. But on ten months later, TKA was performed because the joint destruction had progressed. [Discussion] Even if EORA develops in the case of the OA of an elderly person introduced for the purpose of TKA, only views of the OA of advanced stage on the X-rays may not notice a rheumatic disease. Enough check is needed in preoperation to evade the situation “un-necessary operations had been performed!”.

Biomechanical analysis of the bone graft for tibial defects in total knee arthroplasty

Koji Totoribe, Etsuo Chosa, Hiroaki Hamada, Takero Sakamoto, Tomohisa Sekimoto
Department of Orthopaedic Surgery, Faculty of Medicine, University of Miyazaki

Conflict of interest: None

[Object] Achieving stability of the tibial implant is essential following cementless total knee arthroplasty with bone grafting. The present study aimed to investigate the effects of bone grafting on the stability of the tibial implant in the immediate postoperative phase. [Methods] Tibial implant models were developed using a finite element method. Geometric data were obtained from CT scans of the right tibia. Based on a pre-prepared template, ten types of bone graft models of varying sizes and material properties were prepared in the medial and postero-medial portion. A compressive force was applied to the postero-medial portion. Each model was loaded, and the micromotion and stress distribution were analyzed and compared. [Results] The medial side of the tibial tray exhibited subsidence, and the opposite lateral side showed liftoff. Compared with the soft bone graft models, the magnitudes of micromotion in the hard bone graft models were significantly lower. Maximum micromotion and excessive stress in the adjacent bone graft area was observed for the large soft bone graft model. [Conclusions] Our results suggested that grafting defects with hard bone is more likely to yield better fixation especially for larger, postero-medial defects.

Aseptic Loosening after Total Knee Arthroplasty in Patients with Rheumatoid Arthritis

Satomi Nagamine, Eriko Ito, Motoki Sonohata, Masaaki Mawatari
Department of Orthopaedic Surgery, Faculty of Medicine Saga University

Conflict of interest: None
Total knee arthroplasty (TKA) in RA patients are known to have a higher risk of postoperative complications than patients with osteoarthritis. It may cause loosening of component with the bone fragility due RA itself or steroidal osteoporosis. Therefore, it is important to evaluate cautious bone quality before surgery. We investigated aseptic loosening after TKA in RA patients at our hospital. [Methods] It was investigated 293 knees were performed TKA in RA patients. The femoral-tibial angle and component installation angle in migration and aseptic loosening cases were measured using plain radiograph. In addition, as osteoporosis evaluation of preoperative, we were measured bone density and bone turnover markers. [Results] Component migration was observed in 7 knees. Progressive loosening was observed in 4 knees and revision were performed. Preoperative knee alignment in 6 knees of the migration cases were valgus deformity. Tibial components were varus and anteversion in all cases. [Results] If it is revision performed, physical and mental burden of the patient is large, and often it is difficult to treatment. To prevent revision, it is necessary to pay close attention to various points such as bone quality evaluation, osteoporosis treatment, implant selection and so on.

P2-153
Total knee arthroplasty without patellar resurfacing for rheumatoid arthritis
Kazue Hayakawa, Hideki Date, Sho Nojiri, Sota Nagai, Harumoto Yamada
Department of Orthopaedics, Fujita Health University, Toyoake, Japan

Conflict of interest: None

[Object] We investigated the outcome of total knee arthroplasty (TKA) without patellar resurfacing in patients with rheumatoid arthritis (RA). [Methods] The subjects were 74 patients with 97 knees. The mean follow-up period was 8 years and 10 months. The items investigated were clinical and plain X-ray findings. [Results] Knee ROM before surgery/at assessment was -12.6°/-1.1° of extension and 120.1°/120.6° of flexion, while the JOA score was 41.5/90.1. At assessment, the incidence of anterior knee pain and discomfort was 0% and 8.2%, respectively. There were no significant differences of knee flexion at assessment (124.4°/119.2°, p=0.09), follow-up period, age, use of biological agents, type of TKA, outside dissociation, ROM, JOA score, and FTA between the patients with patellar findings (26.8%) and those without patellar findings. However, the incidence of discomfort was significantly higher in the patients with patellar findings. Patellar resurfacing was not performed in any of the patients. [Conclusion] The clinical outcome of without patellar resurfacing TKA was generally favorable and was similar between the patients with and without patellar findings. We concluded that without patellar resurfacing TKA was an acceptable procedure in patients with RA.

P2-154
Study of the background and the medication of rheumatic patients who received total knee arthroplasty and total hip arthroplasty
Hiroshi Aonuma1, Takeshi Kashiwagura2, Yoichi Katoaka1, Hiromi Morita1, Wataru Watanabe1, Nobuhiro Ishizawa1, Natsuo Konishi3, Masakazu Uraya1, Moto Kobayashi4,5, Yusuke Sugimura6, Naohisa Miyakoshi1,2, Yoichi Shimada10
1Department of Orthopedic Surgery, Oguchi Central Hospital, Akita, Japan, 2Department of Orthopedic Surgery, Akita University Hospital, Akita, Japan, 3Joto Orthopedic Clinic, Akita, Japan, 4Morita Orthopedic Clinic, Akita, Japan, 5Department of Orthopedic Surgery, Iwate Medical University Akita Hospital, Akita, Japan, 6Department of Orthopedic Surgery, Aizu University Hospital, Akita, Japan, 7Department of Orthopedic Surgery, Iwate Medical University, Akita, Japan, 8Department of Orthopedic Surgery, Akita University Hospital, Akita, Japan, 9Department of Orthopedic Surgery, Akita University Hospital, Akita, Japan, 10Department of Orthopedic Surgery, Akita University Graduate School of Medicine, Akita, Japan

Conflict of interest: None

Objective: To investigate the patient background and the current state of medication and disease activity among RA patients with prior surgery of weight bearing joints of the lower extremities. Method: A total of 2172 RA patients were registered with the Akita Orthopedic Group on rheumatoid Arthritis in 2017. Of these, patients receiving surgery including 181 total knee arthroplasty (TKA), 70 total hip arthroplasty (THA) were evaluated. Result: Mean age at the time of TKA, THA were 65.8 and 61.8 years. Mean disease duration were 12.1 and 13.3 years. High titer (more than 13.5 U/ml) rate of anticyclic citrullinated peptide antibodies were 73.5 and 65.7. Mean age at the final survey among the four group were 63.8 and 61.8 years. Methotrexate and prednisolone were administered in 56.4 and 55.2% of patients with TKA, 62.9 and 52.9% patients with THA. The patients with history of one or more biologics use were including 47.0 and 40.0. Mean DAS28-ERP were 2.65 and 2.62. Conclusion: It was old, and a contraction of a disease period was long, and the lower limbs artificial joint substituted postoperative patient was guessed if there were many examples that joint destruction already went.

Conflict of interest: None

P2-155
Clinical results of PFCsigmaRP total knee arthroplasty in patients with rheumatoid arthritis
Kiyoshi Nakazono, Akira Murasawa, Hajime Ishikawa, Asami Abe, Hiroshi Otani, Shinji Taniguchi, Satoshi Ito, Eriko Hasegawa, Yoichi Kurosawa
Department of Rheumatology, Department of Rheumatology, Niigata Rheumatic Center, Shibata, Japan

Conflict of interest: None

[Object] To demonstrate the clinical results of PFCsigmaRP total knee arthroplasty (TKA) in patients with rheumatoid arthritis (RA). [Methods] One-hundred seventy-two arthroplasties in 132 patients with RA were performed from January 2004 to December 2017 at Rheumatic Center. There were 15 men and 117 women: the mean patients age at the surgery was 65.0 years (range 33–96 years). The mean followed period was 4.1 years (0.1–15.4 years). We measured RA Japanese Orthopedic association (JOA) knee score, presence of loosening and preoperative and postoperative knee ROM. [Results] A fracture was present in three cases, loosening was absent. 15 patients was died. The mean preoperative RA JOA knee score was 44.1, and the score at the final examination was 81.9. [Conclusions] The clinical results of PFCsigmaRP total knee arthroplasty in RA patients was almost good.

P2-156
Bilateral periprosthetic femur fracture in patient with rheumatoid arthritis
Hiroshi Yonezu, Hiroshi Mikami
Department of Orthopaedic Surgery, Yoshinogawa Medical Center

Conflict of interest: None

[Introduction] The incidence of periprosthetic fracture after total hip arthroplasty (THA) or total knee arthroplasty (TKA) has recently increased with increases in the number of operative cases and the aging of the rheumatoid arthritis patients. We report our experience with one case of bilateral periprosthetic femur fracture. [Case] Patient was 82-year-old, woman who underwent for THA and TKA for rheumatoid arthritis. She consulted our hospital after incurring an injury due to a fall. On radiography, we accepted bilateral periprosthetic femur fracture with transposition. Because the instability was accepted, we chose to perform operative treatment. In addition, we started weekly injections of teriparatide after surgery. We confirmed callus formation on CT performed at 2 months after surgery, at which time she started wheelchair movement. At present, she can walk with T-cane. [Clinical Significance] It is reported that a weekly injection of teriparatide has the ability to stimulate bone formation, but there are few reports on its ability to stimulate bone union. We conclude that operative treatment with teriparatide is effective for periprosthetic fracture accompanying transposition.

P2-157
A case of rheumatoid arthritis who underwent bilateral simultaneous total knee arthroplasties for Windsewpt deformity
Shiho Nakano, Arata Nakajima, Masato Sonobe, Hiroshi Takahashi, Manabu Yamada, Koichi Nakagawa
Department of Orthopaedic Surgery, Toho University Sakura Medical
Conflict of interest: None

Objective] The purpose of this study is to determine the outcomes and surgical complications for total hip arthroplasty (THA) in patients with juvenile idiopathic arthritis (JIA). [Methods] Examine the perioperative clinical condition and course of THA in JIA. [Results] This study included 8 hips in 4 patients. Age at THA averaged 35.8 (30-42) years, disease duration averaged 27.3 (21-36) years, the mean time to follow-up is 15.5 (6-34) years. Height averaged 148.6 cm, weight averaged 57.9 kg. Larsen grade IV was observed in 3 hips, grade V was 5 hips. Stelo-Grarze grade I was observed 6 hips, grade II was 2 hips. All operations used cemented implants. We chose an implant of small size with 6 hips for thighbone medullary cavity narrowing. At surgery, difficulty with intubation due to the trismus was found in 2 hips in one patient. The walking ability improved in postoperative all cases. The postoperative dislocation was found in 2 hips in one patient. It were 2 hips in one patient to have need reoperations (tardive deep part infection in the postoperative 27 years and loosening in postoperative 33 years). [Conclusions] It was necessary to consider physique in implant choice. We were thought to need careful follow-up for a long term after surgery.

P2-162
Experience of bilateral simultaneous ALS-THA for RA patient
Koji Asaumi
Department of Orthopaedic Surgery, Yashima General Hospital, Takamatsu, Japan

Conflict of interest: None

Objective] The number of patients who received total hip arthroplasty (THA) is increasing year by year because of stable long-term implant survival. We evaluated the activities of the patients after THA. [Methods] Patients who were performed THA more than one year ago were included in this study. They were asked their daily activities including sports, jobs and hobbies by interview. The Japanese Orthopaedic Association (JOA) hip score was also used to evaluate clinical outcome measure for hip function. [Results] We evaluated 33 patients (47 hips) in rheumatoid arthritis (RA) and 156 patients (212 hips) in osteoarthritis (OA). The average JOA hip score was 86 points for RA and 96 points for OA. More than 90 points in JOA hip score was about 53% in RA and about 90% in OA. Exercises and sports activities were done about one third in RA and two thirds in OA. Most of RA patients were satisfied by normal daily lives and only a few cases played low-impact sports. On the other hand, most of OA patients played low-impact sports and moreover a few patients played high-impact sports. [Conclusions] There will be increasing number of RA patients who anticipate to join in sports activities because of no or less joint pain for extensive medications.

P2-158
Comparative Study of Clinical Outcome after THA in Hemodialysis vs Non-Hemodialysis Patients
Yasumasa Ito
Department of Orthopaedic Surgery, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan

Conflict of interest: None

Objectives] We compared the clinical outcomes after total hip arthroplasty (THA) in hemodialysis (HD) patients and non-HD patients. [Methods] We examined 12 patients (male 4 female 8, 13 hips) who underwent THA with PerFix HA system. The average age at THA was 60.7 years. The average duration of HD before THA was 9.0 years. Clinical outcomes were evaluated preoperatively and at 1 year postoperatively by JOA, D’Aubigne & Postel and Oxford scores. [Results] Preoperatively, the average JOA and Oxford scores in HD/non-HD patients are 41.5/43.5 and 15.2/17.8, respectively, with no significant difference statistically. But, there is significant difference in the average D’Aubigne & Postel score (8.9/10.4) between them. At 1 year postoperatively, the JOA, D’Aubigne & Postel and Oxford scores are 81.8/86.1, 15.5/16.5 and 39.4/43.0, respectively, with no significant difference. In terms of the subscales, only in the D’Aubigne & Postel function (walk) score (3.8/5.2) and Oxford walk score (2.7/3.5), non-HD patients achieved more significant improvement. [Conclusion] Despite poorer long-distance walking ability in HD patients, THA in HD patients is expected to bring good short-term outcomes comparable to those in non-HD patients.

P2-159
Occurrence of dislocation and stability were clearly confirmed in recurrent anterior dislocation after total hip arthroplasty when hip arthroscopy was added to open surgery with posterior lateral approach that was used at total hip arthroplasty
Kanjo Amano, Toshikatsu Kanazawa
Orthopaedic Department, Hiroshima Clinic, Hiroshima, Japan

Conflict of interest: None

A female, 81 years old in 2018, underwent total hip arthroplasty (THA) with posterior lateral approach due to left hip osteoarthritis in 2012. In 2018, she suffered anterior dislocation of the hip joint three times, therefore, she underwent revision arthroplasty (Modular Dual Mobility and 4 mm lengthen of neck) with posterior lateral approach that was used at THA. Arthroscopy revealed dislocation due to an impingement between an implant neck and an elevated rim liner and acquirement of stability in the hip joint after revision. If revision is performed with anterior approach in patients with recurrent anterior dislocation after THA, dislocation can be easily observed. If anterior approach is performed in patients who underwent THA with posterior lateral approach, two open surgeries from two directions cause a lot of invasion of the soft tissues around the hip joint. If revision is performed with the same approach in patients who underwent THA with posterior lateral approach, it causes less invasion. However, the mechanism of the anterior dislocation and the stability of the hip joint after revision are not observed under direct vision during surgery. If arthroscopy is added to open surgery with posterior lateral approach that is used at THA, it solves the dilemma.

P2-210
Total hip arthroplasty in patients with juvenile idiopathic arthritis
Suran Yang, Yuya Takakubo, Hiroharu Oki, Akiko Sasaki, Yasushi Naganuma, Yuta Suzuki, Juji Ito, Kan Sasaki, Michiaki Takagi
Department of Orthopaedic, Yamagata University Faculty of Medicine

Conflict of interest: None

Object] The number of patients who received total hip arthroplasty (THA) is increasing year by year because of stable long-term implant survival. We evaluated the activities of the patients after THA. [Methods] Patients who were performed THA more than one year ago were included in this study. They were asked their daily activities including sports, jobs and hobbies by interview. The Japanese Orthopaedic Association (JOA) hip score was also used to evaluate clinical outcome measure for hip function. [Results] We evaluated 33 patients (47 hips) in rheumatoid arthritis (RA) and 156 patients (212 hips) in osteoarthritis (OA). The average JOA hip score was 86 points for RA and 96 points for OA. More than 90 points in JOA hip score was about 53% in RA and about 90% in OA. Exercises and sports activities were done about one third in RA and two thirds in OA. Most of RA patients were satisfied by normal daily lives and only a few cases played low-impact sports. On the other hand, most of OA patients played low-impact sports and moreover a few patients played high-impact sports. [Conclusions] There will be increasing number of RA patients who anticipate to join in sports activities because of no or less joint pain for extensive medications.

P2-210
Total hip arthroplasty in patients with juvenile idiopathic arthritis
Suran Yang, Yuya Takakubo, Hiroharu Oki, Akiko Sasaki, Yasushi Naganuma, Yuta Suzuki, Juji Ito, Kan Sasaki, Michiaki Takagi
Department of Orthopaedic, Yamagata University Faculty of Medicine

Conflict of interest: None

Object] The purpose of this study is to determine the outcomes and surgical complications for total hip arthroplasty (THA) in patients with juvenile idiopathic arthritis (JIA). [Methods] Examine the perioperative clinical condition and course of THA in JIA. [Results] This study included 8 hips in 4 patients. Age at THA averaged 35.8 (30-42) years, disease duration averaged 27.3 (21-36) years, the mean time to follow-up is 15.5 (6-34) years. Height averaged 148.6 cm, weight averaged 57.9 kg. Larsen grade IV was observed in 3 hips, grade V was 5 hips. Stelo-Grarze grade I was observed 6 hips, grade II was 2 hips. All operations used cemented implants. We chose an implant of small size with 6 hips for thighbone medullary cavity narrowing. At surgery, difficulty with intubation due to the trismus was found in 2 hips in one patient. The walking ability improved in postoperative all cases. The postoperative dislocation was found in 2 hips in one patient. It were 2 hips in one patient to have need reoperations (tardive deep part infection in the postoperative 27 years and loosening in postoperative 33 years). [Conclusions] It was necessary to consider physique in implant choice. We were thought to need careful follow-up for a long term after surgery.
[Object] We report on experiences of bilateral simultaneous ALS-THA for RA patient. [Case] 68 years, woman. Both coxalgia was increased for one year, because a pain aggravated it, it became our department introduction consultation in surgical therapeutic purpose. She had an allergy to metal as a medical history. The diagnosis was both coxarthrosis. It was adaptation of the THA for the pain that was similar to both sides, and the release from an early pain is hoped for even a little and will perform bilateral same time THA. Rheumatoid arthritis was diagnosed in preoperative examination and started medication by MTX postoperatively. In late years we used Dual Mobility Bearing from the viewpoint of dislocation prevention. However, we used Continuum cup because we had an allergy to metal for the cobalt chromium in the disorder. We performed the THA by the ALS approach so that the dislocation had resistance in the small bone diameter of head. The operative time was left 54 minutes, right 53 minutes. We started a walker walk on the second day after surgery and left the hospital without perioperative complications to the home on day 24 after an operation. [Conclusion] I experienced bilateral simultaneous ALS-THA for RA patient and got a good course.

P2-163
Late infection of total hip joint arthroplasty in 3 rheumatoid arthritis patients treated with biologics
Hiroki Wakabayashi, Masahiro Hasegawa, Akihiro Sudo
Department of Orthopaedic Surgery, Mie University Graduate School of Medicine

Conflict of interest: None

[Object] Three cases of late infection of total hip arthroplasty (THA) following biologics therapy in rheumatoid arthritis (RA) patients are reported. [Case] THA were performed in 3 patients with RA. They were received biologics therapy 3 year after THA (patient 1; tocilizumab), 2 month after THA (patient 2; etanercept) and 1 month before THA (patient 3; etanercept). However, they were age at the time of THA infection was 71 male (patient 1) and 64 females (patient 2, 3) years old. The causative organism were shown to be MSSA (patient 1) and Listeria (patient 3), and unknown (patient 2). All patients underwent open debridement and exchange of modular components. Currently, 7 years (patient 1), 11 months (patient 2) and 10 months (patient 3) after the operation, the patient is able to walk without pain, reports no symptoms in the previously infected hips. [Significance] Postoperative infection and delayed healing are a concern during biologics therapy. These cases were late infection from 3 years to 10.5 years after THA operation. Biologics therapy after the total joint arthroplasty also takes possibility of postoperative infection merger into consideration. It seemed necessary to observe carefully.

P2-164
Transition of total hip arthroplasty for RA hip in our department
Junya Mibe1, Kengo Yamamoto2
1Tokyo Metropolitan Ohtsuka Hospital, Tokyo, Japan, 2Tokyo Medical University

Conflict of interest: None

[Object] We investigated all cases of THA in our department. [Methods] We performed one hundred nineteen THA from 1994 to 2018 for RA patients. The operative age was 27 to 85 years old (average 62.3 years old), 17 male 101 female, and we clinically examined. [Results] The number of surgeries and age in every 5 years are 1994 ~ 1998: 27 cases, 59.8 years, 1999 ~ 2003: 34 cases, 59.6 years, 2004 ~ 2008: 13 cases, 67.3 years, 2009 ~ 2013: 13 cases, 67.3 years, 2014 ~ 2018: 15 cases, 65.3 years old. On the acetabular side, we did cement fixation form 1994 to 1999, and cementless fixation from 1999 to 2018. On the femur side, all cases were fixed with cement until 1998, and fixed without cement from 2001. From 2009 we adopted muscle sparing antero-lateral approach, and from 2014 we use X-ray image in supine position, and it is possible to recover promptly without complications due to the progress of drug therapy. [Conclusions] THA is said to be the most successful operation. Prior, high risk of dislocation, fracture, vulnerability, bone loss were pointed out in THA for RA hip, but nowadays, THA can expect a reliable result.

P2-165
Middle and long-term results of ankle arthrodesis using intramedul- lary nail with fin for rheumatoid arthritis
Naoto Yamauchi1, Sadamu Shibata1, Tadashi Okawa1, Kiyoshi Yamauchi2
1Department of Orthopedic Surgery, Kin-ikyo Chuo Hospital, 2Department of Orthopedic Surgery, Kin-ikyo Ichijo Hospital

Conflict of interest: None

[Object] The objective of this study was to evaluate the clinical results and problems associated with ankle arthrodesis using an intramedullary nail with fin for patients with rheumatoid arthritis more than 5 years after surgery. [Methods] Ankle arthrodesis was performed using an intramedullary nail with a fin to treat 16 rheumatoid arthritis patients. The mean age at surgery was 61.0 years and the mean follow-up time was 9 years and 1 months. Clinical evaluation was assessed by the patients’ pain and the union of the tibiotalar and talocalcaneal joints, additional surgery and degeneration of middle foot. [Results] Tibiotalar arthrodesis was achieved after surgery in all patients. Talocalcaneal arthrodesis was not done in 4 cases. Pain occasionally occurred in 5 cases. Additional surgery for implant removal was performed on 3 joints. Also, talocalcaneal arthrodesis was performed on 2 joints. Degeneration of middle foot of 10 joints progressed. [Conclusions] Ankle arthrodesis with an intramedullary nail with a fin was useful for patients requiring union of the tibiotalar and talocalcaneal joints. However careful postoperative observation of the talocalcaneal joint is necessary. Degeneration of the middle foot progressed at 63%, but no additional surgery was required.

P2-166
Investigation of osteoporosis in elderly patients with rheumatoid arthritis
Ken Kumagai, Hyonmin Choe, Shunsuke Yamada, Akiko Nagaoka, Yukuta Inaba
Department of Orthopaedic Surgery, Yokohama City University School of Medicine

Conflict of interest: None

[Object] In recent years, elderly population is increasing in patient with rheumatoid arthritis (RA). We investigated the status of osteoporosis in elderly patients with RA. [Methods] RA patients with 65 years of age or older were extracted in this study. [Results] Twenty-eight percent of patients have a history of fracture. Fracture rate in patients with use of corticosteroid is significantly greater than in patients with no use of corticosteroid. [Conclusions] Elderly patients with use of corticosteroid should be careful about osteoporosis treatment.

P2-167
Insufficiency fractures adjacent joints in patients with rheumatoid arthritis
Hidetoshi Tsushima, Takashi Komatsu, Satoshi Kamura, Kenjiro Fujimura, Hisaaki Miyahara
National Hospital Organization Kyushu Medical Center

Conflict of interest: None

[Object] Patients with long-standing rheumatoid arthritis (RA) tend to represent severe bone fragility, which improved with long-term use of corticosteroids. Usually, atrumatic periarticular symptoms with RA patients may be considered arising from arthritis. This study shows the cases that the causes of pain in adjacent a joint are the insufficiency periarticular fractures in RA patients. [Results] The cases were 8 female RA patients. The mean age at onset was 70 (64 - 79) years and the mean duration of the disease was 17.2 (5-36) years. Three patients complained of gonalgia with proximal tibia fracture and others complained of ankle pain with distal tibia fracture without obvious injuries over the site of involvement. Corticosteroid was used in 7 patients of 8. According to the Steinbrocker stages, 4 patients belonged to stage III and 2 to stage IV. All case represented stable fracture on X-ray and treated conservatively. [Conclu-
sions] They were the group that have the risk factors of osteoporosis including long disease duration, aged female and use of corticosteroid. If a patient with RA, especially have these risk factors, experiences pain without obvious injuries around their joint, you might need also suspect fracture besides arthritis as a cause of pain.

P2-168
Gain of bone mineral density in rheumatoid arthritis patient
Ichiro Yoshii1, Tatsumi Chijiwara2, Naoya Sawada3, Naoki Iwamoto2, Shin-ya Kawashiri2, Naoya Sawada3
1Rheumatologist and Musculoskeletal Medicine, Yoshii Hospital, 2Department of Rheumatology, Kochi Memorial Hospital, 3Department of Rheumatology, Dohgo Spa Hospital

Conflict of interest: None

[Object] Bone mineral density (BMD) gain in rheumatoid arthritis (RA) patient, and factors that affect BMD were investigated. [Methods] From April 2013 to September 2018, BMD had been measured 2596 times. Patients were divided into RA patient group (G-RA) and non-RA group (G-nRA). Patients background, drugs administration, BMD of lumbar spine (LS), femoral neck (FN), whole proximal femur (WF), and greater trochanter (GT) after age was corrected, and their changes were statistically compared between the two groups with Mann Whitney U test, and significant factors in G-RA were compared. [Results] In 918 case of G-RA and 1678 of G-nRA, G-RA demonstrated significantly younger age, and significantly more patient who administered glucocorticoid steroid. There is no other background factors or blood test results that demonstrated significantly different. G-RA demonstrated significantly more BMD in all bones, while significantly higher BMD gain only in GT. G-RA demonstrated significantly less patient who gained BMD only in LS and G-RA demonstrated significantly higher BMD gain in LS. [Conclusions] RA patient demonstrated more BMD than non-RA even age factor was diminished. There is still unclear, however, it is suggested that ADL and GS affect.

P2-169
Osteoporosis treatment of patients with rheumatoid arthritis in our hospital
Norie Yoshikawa1, Koichiro Saisho2, Hiroaki Hamada1, Etsuo Chosa1
1Department of Orthopedics, NHO Miyakonojo Medical Center, 2Taniuma Hospital, 3Department of Orthopedics, Faculty of Medicine, University of Miyazaki

Conflict of interest: None

[Object] We investigated osteoporosis treatment of patients with rheumatoid arthritis in our hospital. [Methods] The contents of osteoporosis treatment examine in 333 RA patients visited in 2017. There were 70 males patients 263 female patients, with mean age of 68.9 years. [Results] 153 (46%) patients were treated for osteoporosis. There were 107 (70%) patients treated bisphosphonate (alendronate in 48 patients, risedronate in 14 patients, minodronate in 25 patients, ibandronate in 17 patients), 14 (9%) patients treated denosumab, 4 (7.5%) patients treated teriparatide, 5 (3%) patients treated SERM, 23 (15%) patients treated vitamin D. The use of teriparatide and ibandronate has increased since 2014. There were 38 patients treated bisphosphonate in 100 patients with steroid osteoporotic fracture risk factor score of over 3. [Conclusions] RA patients with high risk of fracture should be treated appropriately for osteoporotic fracture.

P2-170
A functional polymorphism on ALDH2 gene and bone mass among community-dwelling persons
Kazuhiko Arima1, Naoki Iwamoto1, Shin-ya Kawashiri2, Mami Tamai1, Tomoki Oriyuchi2, Atsushi Kawakami2, Kiyoshi Aoyagi1
1Department of Public Health, Division of Advanced Preventive Medical Sciences, Nagasaki University, 2Department of Immunology and Rheumatology, Nagasaki University

Conflict of interest: None

[Object] To compare the levels of bone and cartilage metabolism markers in the synovial fluid of hip osteoarthritis. [Methods] We studied 70 synovial fluid samples from 57 patients with ONFH, 21 samples from 21 patients with RDA and 20 samples from 20 patients with DDH. The levels of BAP, TRACP-5b, MMP-3 and keratan sulfate were analyzed. [Results] The levels of BAP, MMP-3 and KS were significantly higher in ONFH group than in RDA and DDH groups. The levels of TRACP-5b were highest in RDA group. The levels of BAP in the ONFH group after the development of osteoarthritic changes were significantly lower than those
observed in earlier stages. In the comparisons between the samples obtained from each group with a terminal condition, ONFH samples exhibited significantly higher MMP-3 and KS levels, while the TRACP-5 levels were highest in RDA group. [Conclusions] ONFH patients showed a relatively bone formative condition before the osteoarthritic stage and maintained a higher rate of cartilage turnover throughout several stages compared to RDA and DDH patients. RDA patients were characterized by a significantly high osteoclast activity.

P2-173
The rate of patients with radiological erosive hand OA (EHOA) findings among patients with rheumatoid arthritis, and the effect of DMARDs on the progression of EHOA
Tsuyoshi Nishime1, Takefumi Kato2, Nobunori Takahashi1, Toshisaka Kojima1, Shuji Asai1, Takuya Matsumoto1, Nobuyuki Asai1, Yasumori Sobue1, Mochihito Suzuki1, Yutaka Yokota1, Naoki Ishiguro1
1Nagoya University Orthopedics Department, 2Kato Orthopedics Clinic

Conflict of interest: None

Objective: To investigate the rate of patients with the image findings of EHOA among patients diagnosed as rheumatoid arthritis and the influence of DMARDs in this patient group on the progression of erosive hand OA. <object>1145 patients with rheumatoid arthritis who are visiting Kato orthopedic clinic or Nagoya University hospital. <method>Patients with erosive changes defined by Verbruggen in DIP or PIP joints with the nearest two hands Xp among the subjects were counted. Among them, radiographic changes of the DIP / PIP joints were retrospectively evaluated by the Verbruggen method. <Results> There were 41 patients (40 females, average age 69.4 years) with the findings of EHOA among the 1145 subjects, the complication rate was 3.5% and the seronegative RA was 23 (55%). Among the 35 people (34 females) whose hands Xp were taken over the course of 1 year or more, the Verbruggen score worsened on the Xp image by an average of 3.3 points / year, including 23 people using bDMARDs. <Discussion and Conclusion> Although the incidence of EHOA has been reported to be 2-3%, it was similar in RA patients. From the results of this study, radiographic EHOA changes progressed and it was considered that rheumatoid arthritis treatment including bDMARDs was ineffective.

P2-174
Clinical findings and Pathology of synovitis with combined RA and OA knee
Keita Nagira1, Hiroshi Hagino2, Masako Hayashi1, Daichi Mukanoki1, Chikako Takeda1, Hideki Nagashima1
1Department of Orthopedic Surgery, Faculty of Medicine, Tottori University Hospital, Yonago, Japan, 2School of Health Science, Faculty of Medicine, Tottori University Hospital, Yonago, Japan

Conflict of interest: None

Objective: To compare retrospectively whether there is difference between clinical findings and synovial pathology findings in presence or absence of OA change by X-ray in RA patients who underwent TKA. <Methods> Material was 80 patients with RA who underwent TKA from January 2017 to January 2018. Patients with erosive disease activity of their knee X-ray were divided into two groups. (1) RA knee, (2) OA knee. <Results> Age at onset of RA was 44.3 ± 5.6 years for RA knee and 60.4 ± 12.9 years for OA knee (P=0.001). Age of TKA was 60.0 ± 8.1 years for RA knee, RAOA knee was 68.9 ± 9.3 years (P=0.029). There was no significant difference in therapeutic agent, disease activity, physical findings, synovial pathology findings. <Discussion> Age on set of RA was 44.3 ± 5.6 years for RA knee and 60.4 ± 12.9 years for RAOA knee (P=0.001). Age of TKA was 60.0 ± 8.1 years for RA knee, RAOA knee was 68.9 ± 9.3 years (P=0.029). There was no significant difference in therapeutic agent, disease activity, physical findings, total synovial pathology score between two groups. However, total score was relatively high both of RA knee 7.4 ± 2.3 and RAOA knee 6.5 ± 1.2 points. <Conclusion> In the RAOA knee, RA seems to have occurred concomitantly with the knee which had originally changed OA.

P2-175
Zoledronic Acid Treatment in Patients with Osteoporosis Who Have Various Kinds of Characteristics -Results in 12 months-
Yuji Hirano, Daisuke Kihira
Department of Rheumatology, Toyohashi Municipal Hospital

Conflict of interest: Yes

Objective: The aim of this retrospective study is to investigate efficacy of zoledronic acid (ZOL) in patients with osteoporosis (OP) who have various kinds of characteristics in daily clinical practice. <Methods> 27 OP patients treated with ZOL over 12 months were used. Time-course of BMD, time-course of bone turnover markers (BTM) and frequency of acute phase reaction (APR) were investigated. Comparison between post-menopausal OP patients (PMOP) and RA patients (RAOP) and comparison between bisphosphonate pretreatment patients (BP-G) and no-pretreatment besides vitamin D patients (ND-G) were also performed. <Results> Mean age was 71 years. 48% had previous fracture history. PMOP:n=8, RAOP: n=16. BP-G: n=12, ND-G: n=9. Pretreatment of denosumab: n=5. LS-BMD was increased in +3.4% at 12m and THBMD was increased in +1.1%. Both were statistically significant. BTMs were significantly decreased. APR occurred in 22.6%. <Conclusions> Although ZOL was comparatively effective in LSBMD and RAOP, pretreatment of BP inhibited efficacy of ZOL. Most APR was mild but frequent.

P2-176
Once-yearly zoledronic acid for osteoporosis patients
Taisei Kawamoto1, Satoshi Iida1, Takeshi Umibe2
1Department of Orthopedics, Matsudo City General Hospital, 2Department of Rheumatology, Matsudo City General Hospital

Conflict of interest: None

Objective: Zoledronic acid is a third-generation bisphosphonate that has recently been approved for the treatment of osteoporosis as an annual intravenous infusion. Objective: To evaluate Zoledronic acid to osteoporosis patients for short-term results. <Methods> From January 2017 eleven cases treated with zoledronic acid were evaluated by bone mineral density (BMD). <Results> The BMD in the lumbar spine and femoral neck increased by 8.2% and 4.4% respectively. Most common side effects are post-dose fever, flu-like symptoms, myalgia, arthralgia, and headache which usually occur in the first 3 days after infusion. <Conclusions> The therapy of Zoledronic acid to osteoporosis was effective for short-term results.

P2-178
The efficacy of anti-RANKL monoclonal antibody (Denosumab) under the treatment of connective tissue disease (CTD)
Naofumi Dobashi, Moemi Miyazaki, Kensi Inoue, Kenta Misaki
Department of Rheumatology, Kita-Harima Medical Center

Conflict of interest: None

Objective: We evaluated the efficacy of Denosumab (Dmab) by using BMD and serum TRACP-5b and BAP. <Methods> One hundred forty-four CTD patients under the treatment of Dmab were included. Fifty-six among 144 patients were retrospectively analyzed for 12 months by measuring BMD of lumbar vertebra (L), femoral neck (FN) and the serum TRACP-5b and BAP. <Results> Baseline patient characteristics (n=56) was as follows; Mean age:70.5 years old, ratio of male to female (M:21, F:35), RA (n=21), SLE (n=9), IgG4-RD (n=6), MPA (n=5), GCA (n=4), PM/DM (n=3), SSc (n=2), EGPA (n=1), RS3PE (n=1), others (n=4). In the treatment in all patients, BMD of L was 91.7% vs 94.9% (P=0.0001), L.S-BMD+4.0% (P<0.01), THBMD+1.0% (P=0.05), ND-G: LSBMD+4.6% (P=0.01), THBMD+2.3% (P=0.01). APR occurred in 22.6%. <Conclusions> Although ZOL was comparatively effective in LSBMD and RAOP, pretreatment of BP inhibited efficacy of ZOL. Most APR was mild but frequent.
We evaluated Locomo25, bone mineral density (BMD), and lateral roentgenoxyvitamin D3 longer than 2 years (Group A), and the other (Group B). D3 in ADL. [Methods] 211 female patients, over 65 years old, were into evaluate the efficacy of the administration of 1,25-dihydroxyvitamin hydroxyvitamin D3 in ability of daily life (ADL). In this study, we aimed to demonstrate paradoxically lower score of locomo25 than Group B. In the patients of Locomotive syndrome. However, in this study, Group A demonstrated statistically lower score of locomo25 than Group B. In the patients using DMAb for 2 years. [Methods] 84 patients who had DMAb for osteoporosis from Aug 2013-2018 and were able to follow spinal X-ray for 2 years. For vertebral body fractures, we evaluated by Genant classification. Genant classification grade 2 or more was defined as vertebral body fracture. Evaluation items were age, lumbar bone mineral density (LBMD), rheumatoid arthritis (RA), glucocorticoid (GC) use. From the fourth thoracic vertebra to the fifth lumbar vertebra were evaluated. [Results] The age was 73.6 ± 9.1, LBMD at baseline was 0.636 ± 0.121, 49 cases of RA, 21 cases of GC user. Thirty two cases of new vertebral body fractures (1st year 23 cases, 2nd year 13 cases) were observed. Only age was a significant risk factor in the logistic regression analysis. When we analyzed similarly with focusing on the RA group, only GC use was a significant risk factor. When analysis was made separately for the 1st year and the 2nd year, no significant risk factor was extracted in the 2nd year. [Conclusions] Although RA was not a risk factor for new vertebral body fractures, GC use is a very strong risk factor in the initial stage.

P2-179
Glucocorticoid use in patients with rheumatoid arthritis during administration of denosumab increases the risk of developing new vertebral fractures
Eri Narita1,2, Hitoshi Yoshimura2,3, Syuuji Yamada4, Kazuki Orita5, Shuhe Ueno6, Tatsuya Koike7,8
1Shirahama Hamayu Hospital, 2Search Institute for Bone and Arthritis Disease (SINBAD), 3Taiseikai Nakatsu Hospital, 4Osaka City General Hospital, 5Daito Chuo Hospital, 6Center for Senile Degenerative Disorders (CSDD), Osaka City University Medical School of Medicine

Conflict of interest: None

[Objective] We examined risk factors of new vertebral fracture in patients using DMAbs for 2 years. [Methods] 84 patients who had DMAb for osteoporosis from Aug 2013-2018 and were able to follow spinal X-ray for 2 years. For vertebral body fractures, we evaluated by Genant classification. Genant classification grade 2 or more was defined as vertebral body fracture. Evaluation items were age, lumbar bone mineral density (LBMD), rheumatoid arthritis (RA), glucocorticoid (GC) use. From the fourth thoracic vertebra to the fifth lumbar vertebra were evaluated. [Results] The age was 73.6 ± 9.1, LBMD at baseline was 0.636 ± 0.121, 49 cases of RA, 21 cases of GC user. Thirty two cases of new vertebral body fractures (1st year 23 cases, 2nd year 13 cases) were observed. Only age was a significant risk factor in the logistic regression analysis. When we analyzed similarly with focusing on the RA group, only GC use was a significant risk factor. When analysis was made separately for the 1st year and the 2nd year, no significant risk factor was extracted in the 2nd year. [Conclusions] Although RA was not a risk factor for new vertebral body fractures, GC use is a very strong risk factor in the initial stage.

P2-180
Clinical effect of the administration of 1,25-dihydroxyvitamin D3 longer than 2 years on Locomo25 score
Yusuke Ueda, Hirokuni Takayama, Kei Yamamoto, Norihiro Ichikawa, Ayumu Nishihara
1Department of Orthopedic Surgery, Kansai Medical University Kori Hospital, 2Department of Orthopedic Surgery, Kansai Medical University Medical Center, 3Department of Orthopedic Surgery, Yamamoto the Third Hospital

Conflict of interest: None

[Objective] Previously, a few reports describe the advantages of 1,25-dihydroxyvitamin D3 in ability of daily life (ADL). In this study, we aimed to evaluate the efficacy of the administration of 1,25-dihydroxyvitamin D3 in ADL. [Methods] 211 female patients, over 65 years old, were included, and classified into two groups, one who administered 1,25-dihydroxyvitamin D3 longer than 2 years (Group A), and the other (Group B). We evaluated Locomo25, bone mineral density (BMD), and lateral roentgenogram of thoracic and lumbar spine. Statistically analyses were performed using Mann-Whitney U test and Fisher’s exact test, and we accepted statistical significance at P<0.05. [Results] In Group A, 60 cases, average Locomo25 score was 21.3 points, in Group B, 151 cases, 22.7 points (P=0.65). Osteoporotic vertebral fractures (OVF) were identified in 21 cases in Group A, 26 in Group B, statistically significant differences were detected in existence rate (P=0.005). In BMD, there were no significance between two groups (P=0.64). [Conclusions] OVF is considered to cause of Locomotive syndrome. However, in this study, Group A demonstrated paradoxically lower score of Locomo25 than Group B. In the patients with OVF, administration of 1,25-dihydroxyvitamin D3 suggested to contribute maintaining ADL.

P2-181
The Diagnosis of Atypical Femoral Fracture and Determination of Surgical Intervention by MRI
Koji Nomura1,2, Tomomi Tada4, Takeshi Kaneko2, Kenji Funakoshi2, Shinichiro Nameki2, Jun Fukui3, Takashi Hosokawa2, Hiroshi Fujiwara1
1Department of Orthopedic Surgery, Osaka General Medical Center, Osaka, Japan, 2Division of Rheumatology, Osaka General Medical Center, Osaka, Japan

Conflict of interest: None

[Background] Many patients with rheumatic disease take bisphosphonate to treat glucocorticoid-induced osteoporosis. Recently atypical femoral fracture (AFF) by long-term use of bisphosphonate has become known. As most of it is diagnosed with X-ray alone, we tend to miss the imminent fracture. [Case] 52-year-old female. SLE occurred at the age of 18 and PSL treatment was started. Bisphosphonate treatment was also done for over 12 years. A few months ago she fell a slight pain in her right hip joint and the pain was exacerbated from one month ago. The X-ray showed the ‘beaking’ sign, which was specific to AFF, at the lateral cortex of the bilateral femoral subtrochanteric area. Shortly thereafter, she suddenly felt the weakness of right lower limb and fell down to the right AFF. MRI just before the fracture showed the STIR (T2) high signal at the very site of ‘beaking’ and no signal changes in the bone marrow. Although the similar ‘beaking’ sign was observed at the left femur, there was no significant finding in either MRI or bone scintigraphy and she had no left thigh pain. [Clinical Significance] MRI is very useful in evaluating the imminent fracture of AFF and the prompt surgical intervention will be needed when the abnormal signal is recognized at the ‘beaking’ area.

P2-182
A Seven cases report of the atypical femoral fractures treated surgically
Yukio Mikami, Taisei Kawamoto, Satoshi Ida
Matsudo City General Hospital

Conflict of interest: None

[Object] We investigated seven cases report of the atypical femoral fractures treated with internal fixation. [Methods] We targeted AFF cases who underwent operation from March 2016 to July 2018. We examined items such as age, sex, medication, past history, trauma injury, fracture site, thigh bone shape, bone fusion period, YAM, bone metabolism marker. [Results] The subject was ten limbs in seven cases. All cases were female, the average age was 70.8 years (57 to 88 years old). Complete fractures were five cases. Incomplete fractures were two cases. There were three cases on both sides. Bisphosphonate (BP) formulation was used in six of seven cases, and Denosumab was used in one case. Two out of seven patients were taking steroids for more than ten years. Mean bone fusion period with complete fracture was 8.6 months (7 to 10 months). Bone metabolism marker, YAM did not show a remarkable low value. Surgical treatment was done for incomplete fracture cases. A case of incomplete fracture was able to walk with the cane and shopping in three weeks postoperatively. [Conclusions] Bone fusion period was long with complete fractures. Because there is a high possibility of transitioning to complete fracture, preventive nail insertion for incomplete fracture seems to be effective.

P2-183
Osteonecrosis of the jaw in patients with rheumatoid arthritis treated with denosumab: three cases report
Shinichi Mizuki, Tatsuya Kai, Daisuke Hiroaka, Kenji Yoshida, Hiroko Ikeuchi, Kensuke Oryoji
The Center for Rheumatic Diseases, Matsuyama Red Cross Hospital

Conflict of interest: None

BACKGROUND: Denosumab is now widely used for the treatment of osteoporosis and RA. Osteonecrosis of the jaw (ONJ) is a potentially severe adverse event in patients with osteoporosis treated with anti-erosive drugs. Rheumatoid arthritis (RA) has been hypothesized as a po-
tential risk factor for ONJ. OBJECTIVE: To clarify the clinical features of ONJ in patients with RA treated with denosumab. METHODS: We present three patients with osteoporosis and RA who treated with denosumab. Demographic, pharmacological, and clinical data were collected. Case Presentation: This report describes three patients; a 81-year-old woman, a 77-year-old woman, a 64-year-old man. All patients received treatment with prednisolone, and two were treated with biologic drugs. All patients stopped denosumab, and after the treatment with antibiotics, all patients underwent surgical curettages. Two patients cured. CONCLUSIONS: It should be important to monitor oral environment during denosumab treatment.

P2-184
The role of the nurse for rheumatoid arthritis patients complicated with osteoporosis
Kokoro Takata1, Aya Oshimura1, Takeko Koyama1, Ken Takebe2, Koji Tateishi2, Yasuhiro Terashima2
1Nursing Unit, Japan Hyogo Kohnan Kakogawa Hospital, 2Orthopedic Surgery, Japan Hyogo Kohnan Kakogawa Hospital

Conflict of interest: None

[Object] We examined the present conditions of the everyday life of RA patients and our purpose is reveal that the role of the nurse for RA patients complicated with osteoporosis. [Method] We research 400 patients who received osteoporotic liaison service in our hospital that is separated by the RA group and non-RA group used by an interview vote. We made the current state clear by comparing a medical record of inspection data and PSL internal. [Result] 139 RA patient group (men:12 woman: 127, average ages:70.8 years old, PSL:91 non-PSL:48) a bone fracture career was 47% and twice in the above-mentioned bone fracture career was 32%. An osteoporotic bone fracture was 84% (vertebral fracture:38%, hip fracture:26%, femoral neck fracture:9%, other bone fracture:41%) 261 non-RA patient group (men:10 women: 251, average ages:74.7 years old, non-PSL:247) a bone fracture career was 53% and twice in the above-mentioned bone fracture career was 17%. An osteoporotic bone fracture was 78% [Conclusion] Our result is that a nurse is required to prevent the osteoporotic bone fracture as complications as well as RA treatment, maintain the health of the frame, guide activities of daily living and observe and instruction for treatment continuation.

P2-185
Two cases of tumour-induced osteomalacia treated as RA
Takashi Komatsu, Satoshi Kamura, Hidetoshi Tsushima, Kenjiro Fujimura, Hisaaki Miyahara
Orthopaedic Surgery Rheumatology, National Hospital Organization Kyushu Medical Center

Conflict of interest: None

Tumor-induced osteomalacia (TIO) is overgrown of fibroblast growth factor 23 (FGF23) from tumors. We report that we experienced two cases of tumour-induced osteomalacia treated as RA. Case1 presentation: 37-year-old male, he recognized front chest pain and lower back pain, and treated as seropositive RA. But he was consulted to our hospital because injured for a calcaneus fracture. A serum creatine phosphokinase was 620 IU/L. A serum phosphorus level was 4.0 mg/dL. A serum calcium level was 8.9 mg/dL. A serum alkaline phosphatase level was 629 IU/L. A urinary 17-Ketosteroid level was 5.2 mg/dL. Case2 presentation: 55-year-old female, she recognized seropositive RA, polyarthralgia, and treated as rheumatoid arthritis. But he was consulted to our hospital because of the sacroiliac joint pain and right leg pain. A serum creatine phosphokinase level was 105 IU/L. A serum phosphorus level was 4.0 mg/dL. A serum calcium level was 9.7 mg/dL. A serum alkaline phosphatase level was 364 IU/L. We suspected TIO from increased FGF23, a mass lesion in the left popliteal region was detected in PET-CT. Case2 presentation: A tumor was resected with both cases, as a result, the phosphorus levels increased, and the symptom was improved. There is multiple pain region in TIO, TIO is easy to be mistaken for inflammatory disease such as RA. It is impotent to put TIO in the differentiation in RA with osteomalacia.

P2-186
The clinical outcome of curved intertrochanteric varus osteotomy for osteonecrosis of the femoral head in Chiba University
Satoshi Yoh
Department of Orthopedic, Chiba University Graduate School of Medicine

Conflict of interest: None

[Object] Osteonecrosis will cause osteoarthritis as it progresses. Our university do curved varus osteotomy for adolescence people. We evaluated long term clinical result of this operation. [Methods] Between April 1997 and January 2018, CVO was performed on 40 hips in 33 patients for the treatment of osteonecrosis. The patients included 12 men and 21 women with a mean age of 32.0 years. The mean follow-up was 8.7 years. [Results] The cause of osteonecrosis was steroid-induced in 26 cases, alcohol associated in 3 cases, idiopathic and posttraumatic in 4 cases. The localisation of the necrotic lesion was type B in 4 cases, C1 in 22 cases, and C2 in 10 cases. In these cases, preoperative osteoarthritis was grade 2 in 1 case, 3A in 29 cases, 3B in 4 cases and 4 in 1 case. Average JOA score was 83.0 point at the latest follow-up. We observed joint-space narrowing in 32.5% cases and 12.5% cases converted to THA. Average term to conversion was 11.9 years. [Conclusions] In this study, there is no conversion case to THA in early phase. Although long term follow-up observation is necessary, good clinical result have been obtained. We conclude that CVO is helpful operation for joint preserving.

P2-187
The risk of irreversible renal failure in patients with systemic lupus erythematosus
Mai Yoshida, Kentaro Minowa, Hirofumi Amano, Ken Yamaji, Naoto Tamura
Juntendo University Hospital, Tokyo, Japan

Conflict of interest: None

Lupus nephritis can cause irreversible renal failure with the systemic lupus erythematosus (SLE) patients. The renal prognosis with SLE has been improved during recent years by development of the immunosuppressants. But some of the cases which lead to renal failure has been still present. We studied clinical characteristics of 21 cases in irreversible renal failure with SLE who came to our hospital. [Methods] We extracted 21 patients among 1196 patients between 2007 and 2018 whose serum (s)- Cr level was more than 2.0 in over 3 months and the level continues more than 2.0 at last visit. [Methods] Disease duration between onset and reach to s-Cr 2.0 was 14.1±9.4 years. Period from s-Cr 1.0 to s-Cr 2.0 was 31.2±28.3 months. One case was positive for anti-U1-RNP antibody. The anti-Sm antibody-positive patient was not present. Positive rate of anti-DNA antibody at s-Cr 1.0 and s-Cr 2.0 was 75% and 57%. The cases with either low CH50, C3 or C4 was 64% at the time of s-Cr 1.0. [Conclusions] We observed many cases with hypocomplementemia at time of s-Cr1.0 in the ESRD SLE patients. We should consider the risk of the irreversible renal failure in the case with hypocomplementemia, negative anti-U1-RNP Sm antibodies at the time of s-Cr 1.0.

P2-188
The hydroxylchloroquine use in clinical practice for systemic lupus erythematosus: a cross-sectional study of the LUNA registry
Yumiko Sugiyama1, Ryusuke Yoshimi2, Yosuke Kanishita1, Chiharu Hidekawa1, Natsuki Sakurai1, Masaki Mitsuhashi1, Daiga Kishimoto1, Yuki Iizuka1, Takaaki Komiyari1, Hideo Naga1, Naoki Hamada1, Naomi Tsuchida1, Yuto Soejima1, Reikou Kamiyama2, Kouji Kobayashi1, Yukiko Asami1, Yohei Kirino1
1Center for Rheumatic Disease, Yokohama City University Medical Center, 2Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, 3Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 4Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 5Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced
Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences

Conflict of interest: None

[Object] To investigate the real-world situation of hydroxychloroquine (HCQ) use in the clinical practice of systemic lupus erythematosus (SLE) using a multicenter registry. [Methods] SLE patients registered in the LUNA registry were divided into two groups according to whether HCQ was administered or not. The patient’s demographic, clinical, and laboratory data were compared between the two groups. [Results] Of the 591 patients with SLE, 94 (16%) used HCQ. The mean age was significantly lower in the HCQ user group than in the non-user group (42.4 ± 12.7 vs 46.6 ± 15.5 years old, p = 0.016). In the HCQ user group, the disease activity was significantly higher (SLEDAI 6.3 ± 4.5 vs 4.7 ± 4.8, p = 0.0039), and arthritis and eruption were more frequent (OR 2.04, 95% CI 1.14-3.62, and OR 2.17, 95% CI 1.16-4.04, respectively) as compared with the non-user group. There was no significant difference in the glucocorticoid dose between the HCQ user group and the non-user group (7.6 ± 5.0 vs 6.8 ± 7.3 mg/day, p = 0.32). [Conclusions] HCQ tended to be used in SLE patients with arthritis or rash. HCQ use was not related to the daily glucocorticoid dose. We are planning to assess the relationship between HCQ administration and glucocorticoid dose tapering by a longitudinal observational study.

P2-189
Investigation of hydroxychloroquine (HCQ) therapy for Systemic Lupus Erythematosus (SLE) in our hospital
-Junichiro Kondo, Yu Matsueda, Kazuma Ino, Yasuhiro Hasegawa, Takumi Muramatsu, Takayuki Hoshiyama, Yoshihiro Tono, Yoshiyuki Arinuma, Tatsuo Nagai, Suniaki Tanaka, Kunitomo Yamaoka Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine

Conflict of interest: None

PURPOSE: Last year, we have indicated that HCQ possess the possibility of reducing serum anti-DNA antibody level in SLE patients. We have increased patient number and expanded observation period to clarify the effect of HCQ in Japanese SLE patients. METHODS: Retrospective chart review was performed in 74 patients who fulfilled ACR criteria, observed over 12 months and was initiated HCQ therapy in our hospital during October 2016 to October 2017. Sixteen patients treated with PSL over 15 mg/day or increased immunosuppressants at baseline were excluded. RESULTS: Average age was 42.1 years old, 68 females and PSL average dose was 11.1 mg/day. Seven patients discontinued HCQ for side effect due to nausea or serum Cr elevation, skin symptoms of drug allergy. Serum anti-DNA antibody significantly decreased compared to baseline at month 6 and month 12, respectively (p=0.0220, p=0.0050). Platelet count and serum complement had no remarkable change. CONCLUSION: Our results demonstrate that HCQ should be administer to patients with high or increasing tendency of anti-DNA antibody during PSL tapering.

P2-190
Consideration of Hydroxychloroquine to patients with systemic lupus erythematosus in our hospital
-Motoki Kusano, Ayaka Kato, Hideki Tani, Koichiro Taguchi, Yoshiko Kitada, Takahide Ikeda, Hiroyuki Morita General Medicine, Gifu University Hospital

Conflict of interest: None

[Object] Hydroxychloroquine (HCQ) has been widely used since it was approved in March 2015 as a treatment for SLE. Side effects of HCQ, PSL weight loss effect retrospectively. [Method] Analyzed sex, age, concomitant medication, complications, PSL weight loss of 36 SLE patients treated with HCQ during the period from September 7, 2017 to April 31, 2018, retrospectively compared did. [Results] The average age at the start of administration was 45.4 years and the ratio of males and females was 5 males and females in 31 cases. The complications were 3 of NP SLE, 3 of APS, 14 of lupus nephritis and no organ dysfunction was 16. As concomitant medicine, 29 PSL, 1 CyA 1 Tac, 2 MZR, 3 CPA, 4 AZP, 9 MMF. The average dose of PSL at the start of HCQ administration was 16.2 ± 2.3 mg and the average was 8.1 ±1.6 after 3 months, 5.6 ± 1.4 mg on average after 6 months, PSL weight loss effect was observed, 3 cases were discontinued, all caused by drug eruption. [Conclusions] Although there were cases where HCQ administration was discontinued due to side effects in this survey, there were no cases showing severe side effects and adequate therapeutic effect and PSL weight loss effect were observed.

P2-191
Use results of Belimumab in Hitachinaka General Hospital
-Hidetomo Oguni1, Taichi Hayashi1,2
1Hitachinaka General Hospital, 2University of Tsukuba Rheumatology

Conflict of interest: None

[Object] Belimumab is the biologic drug used for the treatment of systemic lupus erythematosus (SLE) that launched in december, 2017. We searched the SLE patients treated with Belimumab and studied effect of Belimumab. [Methods] We did retrospective study of 15 patients treated with Belimumab in our hospital. [Results] There was 2 male and 13 female patients. 4 patients was under 30 years old, 5 was 31 to 40, 6 was over 41.6 patients was less than 2 years after diagnosed, 4 was 2 to 10 years, 5 was after 10 years. The average dose of Predonisolone was 32.2mg in the group less than 2 years after diagnosed, 11.8mg in the group 2 to 10 years, 19mg in the group after 10 years.9 patients was combined with Tacrolimus, 9 with Hydroxychloroquine, 10 with Mycophenolate mofetil, 4 with Cyclosporine. Hypocomplementaemia was observed in 9 patients, anti-DNA antibody was positive in 4 patients. No patients were interrupted. Every patients with Hypocomplementaemia or anti-DNA anybody positive was improved. Recurrence was occur in 1 patient in the group 2 to 10 years, and 1 in the group after 10 years. [Conclusions] Belimumab is thought to be effective not only in maintain remission but also in induction of remission.

P2-192
A study on the renal prognosis and the usefulness of antiplatelet therapy in antiphospholipid antibody-positive lupus nephritis patients
-Mayumi Itó, Makoto Yamaguchi, Shihō Iwagaisu, Hirohobu Nobata, Takayuki Katsuno, Shogo Banno, Yasuhiko Ito Aichi Medical University

Conflict of interest: None

[Object] We investigated the renal prognosis and the usefulness of antiplatelet therapy in antiphospholipid antibody (aPL)-positive lupus nephritis patients. [Methods] We analyzed 41 cases who underwent renal biopsy at our hospital between November 2009 and October 2018, diagnosed as initial LN. We investigated the change in the period until reaching CR, the relapse-free rate, and the eGFR according to the presence or absence of antiplatelet therapy in 11 cases of aPL positive patients who did not meet the criteria for a diagnosis of APS. [Results] The eGFR was low at 2 years and 3 years after the initiation of therapy, compared to the negative cases in aPL positive cases. A PL positive patients who did not satisfy the diagnostic criteria showed a significant improvement in eGFR after 2 years in the group receiving antithrombotic therapy (p <0.0313). [Conclusions] In LN patients, aPL positive group may have poor renal prognosis compared with negative group. But in addition to conventional immunosuppressive therapy, antiplatelet therapy may be related to improvement of eGFR in aPL positive LN patients who did not meet the criteria for a diagnosis of APS. Further detailed study in the future is needed.

P2-193
Early induction of Hydroxychloroquine inhibits acute skin lesion in patients with Systemic lupus erythematosus
-Nahoko Tanaka, Hirotake Sakuraba, Hiroto Hiraga, Yasuhisa Murai, Rina Watanabe, Shinji Ota, Keisuke Hasui
Conflict of interest: None

[Object] Hydroxychloroquine (HCQ) has been approved as an immunomodulatory drug for treating with SLE. We examined the effect for skin lesions and disease activity and the reduction the dose of prednisolone (PSL). [Methods] Medical records were reviewed until Oct. 2018 in our hospital and 12 SLE cases, who treated with HCQ over 6 months, were enrolled in this study. Labo data, SLEDAI and Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) were assessed before and after treatment of HCQ. [Results] All patients were female, the median age was 41 (26-67) years old and disease duration was 8.0 (1-18) years. As for beginning of therapy and 6 months after treatment of HCQ, the averages of anti ds-DNA antibody were 38±20 and 23±18 (p=0.06), SLEDAI were 3.4±2.2 and 1.6±1.6 (p<0.01), CLASI activity scores were 10±9.6 and 2.6±4.1 (p<0.01), damage scores were 5.5±5.0 and 3.4±4.8 (p<0.05), and the doses of PSL were 12±5.7 and 8.4±5.2 (p<0.05) respectively. The scores of SLEDAI and CLASI were significantly reduced, and the tendency that the dose of PSL decreased as compared with before treatment was observed. [Conclusions] Treatment with HCQ was useful to control the disease activity and early induction of HCQ inhibits acute skin lesion in patients with SLE.

P2-194
Analysis about the positive transformation of the antiU1-RNP antibody in patients with SLE, the antiSm antibody
Kentaro Minowa, Hirofumi Amano, Yuki Asai, Mai Yoshida, Shinya Kawano, Seiichiro Ando, Ken Yamaji, Naoto Tamura
Internal Medicine and Rheumatology, Juntendo University School of Medicine
Conflict of interest: None

[Objectives] In SLE, various autoantibodies such as anti-ENA antibodies, antiphospholipid antibody, and RF are positive in addition to the anti-DNA antibody. In past reports, anti-U1RNP antibody and mild nephropathy or pulmonary hypertension, anti-Sm antibody and tardive nephropathy or central nerve symptom, anti-SS-A antibody and pulmonary hypertension are related to each other. The titers of anti-ENA antibody are poorly changed due to the treatment, they are considered to be unsuitable for evaluating disease activity. However, anti-U1RNP antibody and anti-Sm antibody have turned positive more closely to SLE onset compared with other autoantibodies, and there is a possibility that they are important for early diagnosis of new pathological conditions. [Methods] We extracted the cases that anti-ENA antibodies became positive to negative and analyzed the association between anti-DNA antibodies and complement value at that time. [Results] When they became negative to positive, they had decreased C3 level with a significant difference. [Discussion] When C3 values decrease more than 10%, we consider the possibility that antiU1-RNP antibody, anti-Sm antibody change to positive, and it is recommended that we reexamine the autoantibodies.

P2-195
Actual usage of immunosuppressive medications for lupus nephritis in a university hospital
Kurumi Asako, Takafumi Tomizuka, Takahiro Itamiya, Yoshitaka Kimura, Hiroshi Kiuchki, Zenichiro Honda, Akiteru Takeuchi, Hajime Kono
Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan
Conflict of interest: None

[Object] Immunosuppressive medications are given in addition to steroid therapy to lower the dose of steroids needed and thus spare some of the undesirable side effects of steroid therapy. Actual usage of immunosuppressive medications in our hospital was studied. [Methods] Medical records of 61 patients with lupus nephritis who received immunosuppressive medications in October 2018 were retrospectively reviewed. [Results] 49 patients were female and 12 were male. Mean age was 46±15 year-old. Mean duration of SLE was 10.6±10.2 years. All patients have received corticosteroids. Renal biopsy was performed in 43 patients. IVICY was administered in 10 patients. The number of patients used and the continuation rates were as follows; MMF: 39 patients, 92.3%; Aza: 8 patients, 0%; TAC: 31 patients, 80.6%; HCQ: 17 cases, 88.2%; MZB: 9 cases, 33.3%. PSL was discontinued in 2 patients of class V, one of whom also discontinue immunosuppressives. In remission maintenance phase, 1, 2 or 3 immunosuppressives were given to 21, 23, 6 patients in combination with corticosteroids, respectively. [Conclusions] Continuation of MMF and TAC was higher than others. It seems that MMF will be playing a key role in the induction and maintenance phase of lupus nephritis.

P2-196
Present status of belimumab use in Systemic Lupus Erythematosus at our hospital
Youhei Fujiki1, Tomohiko Kuboyama1, Hidehiko Makino2, Shogo Matsuda1, Takao Kiboshi1, Takaki Ishida1, Yumiko Wada2, Koji Nagai2, Shuzo Yoshida1, Kenichiro Hata1, Takuya Kotani1, Tohru Takeuchi1, Shigeki Makino1, Shigeki Arawaka1
Department of Internal Medicine IV, Osaka Medical College, Takatsuki, Osaka, Japan, 1Department of Rheumatology, Yodogawa Christian Hospital, 2Department of Rheumatology, Arisawa General Hospital, 3Department of Internal Medicine, Osaka Medical College Mishima-Minami Hospital
Conflict of interest: None

[Object] We evaluated the efficacy and safety of belimumab for SLE in our department. [Method] We assessed the serological test, SELENA-SLEDAI, prednisolone (PSL) dose and adverse events of the therapy with add-on belimumab in 7 cases retrospectively. [Result] The following are median values. Age 46 years old, disease duration was 17 years. All cases were female. The reasons for administration were 5 cases of serologic activity remaining and difficulty of steroid dose reduction. While the other 2 cases remained proteinuria of 0.5 g/day and more and remained vasculitis symptoms. C3 level, titer of anti-ds-DNA-antibody and SELENA-SLEDAI before combination were 90 mg/dl, 35.7 IU/ml and 6. PSL dosage was 9 mg/day. Five immunosuppressive agents administered until the addition of belimumab in 3 cases. Five cases were used IVCY and three cases were rituximab before belimumab therapy. Significant differences were not observed in PSL dosage and SELENA-SLEDAI, but C3 levels increased significantly (P=0.03) and anti-ds- DNA antibody titer also significantly decreased (P=0.03) at 12 weeks. One patient had no improvement in arthritis and was discontinued at 17 weeks, but no adverse events were noted. [Conclusion] Belimumab may contribute to improvement of serologic activity as reported.

P2-197
Efficacy of the add-on treatment of hydroxychloroquine for patients with Systemic Lupus Erythematosus during maintenance phase
Takakazu Hasegawa, Mayu Sugiyama, Kahori Oshima, Suyunsuke Yokoi, Kumiko Umemura, Michita Suzuki, Kyoko Takano, Eiji Nagaawara, Nobuyoshi Minemura, Masao Katayama
Division of Rheumatology, Department of Internal Medicine, National Hospital Organization Nagoya Medical Center
Conflict of interest: None

[Object] We evaluated the efficacy of add-on treatment of hydroxychloroquine (HCQ) for patients with Systemic Lupus Erythematosus (SLE) during maintenance phase. [Methods] The subjects were 66 patients with steroid therapy who passed 6 months after remission induction therapy, started HCQ at our hospital between September 2015 and March 2018 and didn’t needed additional therapy from 8 weeks before HCQ treatment to initiation of HCQ. The retention rate of HCQ and the changes of prednisolone (PSL) dose, SLE disease activity index (SLEDAI) and titer of anti-DNA antibody were examined retrospectively at 6 months after treatment of HCQ. [Results] The retention rate is 92.4%. The mean dose of PSL was significantly reduced (mean±SD) (pre-treatment of HCQ:6.3±3.1 mg/day, 6months after treatment of HCQ:5.4±3.2 mg/day, p<0.001) and the mean of SLEDAI was significantly reduced (3.6±2.8 vs...
2.7±2.5, p<0.001). In 25 patients with the high titer of anti-DNA antibody (ELISA) before the treatment of HCQ, the mean of titer was significantly reduced (40±41 IU/ml vs 35±51 IU/ml, p=0.0347). [Conclusions] It was suggested that the add-on treatment of HCQ for patients with SLE during maintenance phase might be enable to improve the disease activity and reduce the dose of PSL.

P2-198
A Case series of Protein losing enteropathy associated with connective tissue diseases
Takao Nagashima, Ayako Kukuzawa, Yoichiyo Akiyama, Akiko Miyangana, Keiske Saito, Natsuki Shima, Takamasa Muroskai, Yasuyuki Kamata, Katsuya Nagatanai, Masahiro Iwamoto, Seiji Minota
Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University Hospital

Conflict of interest: None

[Purpose] To investigate treatment response in patients with protein losing enteropathy (PLE) associated with connective tissue diseases (CTD). [Methods] From January 2006 to March 2018, 7 patients were diagnosed with PLE. PLE was diagnosed by 99mTc-labeled albumin scintigraphy and/or alpha-antitrypsin clearance (AT) test. [Results] 6 were women. Median age was 41 (range: 31-72). Underlying diseases were Sjögren syndrome (SS) in 3; SLE in 2; SS plus SLE in 1; and suspected SLE in 1. Median serum albumin (Alb) was 2.0 g/dL (0.9-2.8). Complement levels were low in all the patients. Median AT test was 56 mg/day (27-281) (n=5). Treatment options other than high-dose glucocorticoid (GC) were mPSL pulse in 5, GC switch in 2, and use of immunosuppressants in 6 (Tacrolimus, IVCY, MMF). Additional treatment was required in 3. Median days from the start of treatment to the day of serum Alb <3 g/dL was 50 (9-73) (n=6). One patient did not achieve remission. Arterial thrombosis and cerebral infarction occurred in one patient each. In patients who achieved early remission (<50 days), serum Alb was higher, total cholesterol and AT test was lower than those who did not; but there was no significant difference. [Conclusions] In severe PLE, intensive therapy may be needed from the beginning.

P2-199
Characterization and Comparison of Valvular Disease, Ischemic Heart Disease, and Aortic Aneurysm in SLE Patients who Have Undergone Cardiovascular Surgery
Toshiro Kawamoto, Hirofumi Amano, Kentaro Minowa, Mai Yoshida, Yuki Asai, Ken Yamaji, Naoto Tamura
Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

Conflict of interest: None

[Object] This study determined whether there was a correlation between the SLE activity and the progress and aggravation of heart disease in each category. Identifying these characteristics is expected to be useful in establishing strategies to prevent the occurrence of heart diseases complicated by SLE, and to treat them. [Methods] 29 cardiovascular with SLE patients were operated in 5years. Indices for SLE activity were anti-dsDNA antibody levels, CH50. Peak and bottom values of these indices before surgery were recorded, and the values obtained during the pre-surgery 180-day period were compared with those that had been determined prior to this period. We also investigated the relationship of anti- phospholipid antibodies to cardiac disease onset and platelet count. [Results] The peak/bottom values for CH50 and anti-DNA antibodies in the pre-surgery 180-day period were different from those obtained prior to this period. The values of anti- phospholipid antibodies were 0.6 for V, 0.28 for I, and 0.33 for A, and thus, higher in the heart valve disease category. [Conclusions] The integrated value for DNA Ab was lower in the heart valve disease category; therefore, the presence of both anti-phospholipid antibodies and thrombocytopenia may be a risk factor for valvular disease.

P2-200
Retrospective observational study for effect of hydroxychloroquine (HCQ) on glucose and lipid metabolism
Yoshinori Masui, Kenichi Hiraga, Leo Yoshikawa, Naonori Tsuda, Toshikazu Kano
Department of Rheumatology, Kohnodai Hospital, National Center for Global Health and Medicine, Ichikawa, Japan

Conflict of interest: None

[Object] Several overseas studies have reported the effect of HCQ improving glucose and lipid metabolism. However, few reports in Japan. We elucidate the effect of HCQ on glucose and lipid metabolism. [Methods] We picked up adult patients prescribed HCQ for more than a month between Sep. 2015 and Aug. 2018. We included the patients who prescribed low-dose PSL. We retrospectively collected patient’s data and metabolic parameters before and after taking HCQ up to 12 months. Comparison between values before and after the start of HCQ was performed by using paired t-test. [Results] Forty adult patients had prescribed HCQ, of which 9 cases had discontinued within a month because of side effect such as fever, diarrhea, drug rash. SLE were 36. Eligible cases were 26. The mean age was 46.5 years and females were 84.6%. Diabetes were 3, and dyslipidemia were 7. HbAlc significantly decreased 0.28±0.33% from baseline at 6 months after its start. TG significantly decreased 45.2±52.7 mg/dL at 2 months. LDL-C significantly decreased 12.5±13.2 mg/dL at 3 months. No significant change in HDL-C. The eligible cases had taken no additional therapeutic drugs of diabetes and dyslipidemia. [Conclusions] It was suggested that HCQ has an effect improving glucose and lipid metabolism in patients in Japan.

P2-201
The short-term effects of belimumab on 3 Japanese SLE cases with resistance to steroid sparing
Hiroshi Kajiyama, Mayumi Matsuda, Takuma Wada, Yoshihiro Yoshida, Kazuhiro Yokota, Yasuto Araki, Kojiro Sato, Yu Funakubo, Toshiihide Mimura
Department of Rheumatology and Applied Immunology, Saitama Medical University

Conflict of interest: None

[Object] There is a paucity of evidence about the optimal condition of Japanese SLE patients for belimumab (BLM) introduction. The purpose of this study is to assess the short-term effects of BLM to SLE patients with resistance to steroid sparing. [Methods] Observational Study. Intravenous BLM 10 mg/kg was introduced to three SLE outpatients on maintenance treatment with resistance to steroid sparing in our department. The changes of serum dsDNA antibody levels, SLEDAl and daily prednisolone doses after BLM introduction were described. [Results] Studied were two female and one male patients. Average age at BLM introduction was 26.7±11.9 (average and standard deviation) years old, and average observational period was 18.7±6.1weeks. Lupus nephritis was previously diagnosed with renal biopsy in two patients. After BLM introduction, serum anti-dsDNA antibody levels were improved from 90.3±77.5 IU/mL to 37.1±46.2 IU/mL, SLEDAl decreased from 7.3±4.2 to 2.0±0.0, and daily prednisolone dose was reduced from 23.7±7.1mg/day to 15.3±1.5 mg/day without any recurrence. No adverse event was seen during the observational period. [Conclusions] BLM might have steroid sparing effects on SLE cases at least during short period after BLM introduction.

P2-202
Bladder carcinoma in situ in a patient with lupus cystitis
Takahiko Akagi, Shunichi Fujita, Mayuko Fukushima, Hiroshi Sawachika, Hiroyasu Hiran, Tomoyuki Mukai, Yosihata Morita
Department of Rheumatology, Kawasaki Medical School, Kurashiki, Japan

Conflict of interest: None

Lupus cystitis is a well-known but rare complication of systemic lupus erythematosus. This manifestation is frequently associated with lupus
enteritis. We report here a case of a 34-year-old man with lupus cystitis and enteritis who presented with diarrhea and bladder storage symptoms such as urinary frequency and nocturia. Serological tests showed positivity for anti-dsDNA, anti-SS-A and anti-SS-B antibodies. Enhanced computed tomography showed diffuse thickening and abnormal enhancement of bowel wall as well as right hydropneumothorax. Cytoscopy revealed bladder trabeculation, a characteristic ribbed appearance, suggesting the presence of lupus cystitis. However, unexpectedly, a biopsy of randomly selected bladder tissue revealed bladder carcinoma in situ. Treatment with prednisolone (50 mg/day) improved abdominal symptoms, while the bladder irritation symptoms remained unchanged. After tapering the prednisolone dose to 20 mg/day, treatment of the bladder carcinoma in situ was started with intravesical Bacillus Calmette-Guérin. To our knowledge, no reports of bladder cancer in association with lupus cystitis have been published to date. It is necessary to be aware of this serious complication when caring for patients with lupus cystitis.

P2-203
Consideration of the clinical feature of 3 examples of male late onset systemic lupus erythematosus
Ruita Kuratani, Rumiko Miyagi, Rina Okita, Satoshi Baba, Shinichiros Tsunoda
Division of Immunology and Rheumatology, Sumitomo Hospital

Conflict of interest: None

[Object] There is a lot of female SLE patients, but there is also late onset SLE. It’s learned that late onset SLE has a high percentage of the man in particular. [Methods] 3 examples of male patient of late onset SLE was considered clinically. [Results] 1) A 61 year old man. He had the symptoms by arthritis, renal dysfunction, pericarditis, cytopenia and antinuclear antibody. Renal pathological is type4. We treat it with a mPSL pulse and PSL50mg, and also with Tac and MMF, there was a colon cancer, and We performed an operation. 2) A 75 year old man. He had the symptoms by the skin, renal dysfunction, pleurisy and anti ds-DNA antibody. Renal pathological is type4. We treat it with a mPSL pulse and PSL40mg, and also with Tac. 3) A 62 year old man. He had the symptoms by arthritis, renal dysfunction, pleurisy, cytopenia and antinuclear antibody. Renal pathological is type3. We treat it with a mPSL pulse and PSL40mg, and also with HCQ. [Conclusions] Case1 had a recurrence lupus nephritis but the treatment reaction was good 3examples. There was also a report that I have few mergers of renal dysfunction in late on set SLE, but 3examples admitted lupus nephritis. It’s more important to reduce the steroid by multiple drug use than early stage for treatment to reduce a side effect with a steroid.

P2-204
Efficacy and complications of Belimumab in 4 patients with systemic lupus erythematosus
Hideyuki Okada, Yoshihiro Uno, Mami Iida
General Internal Medicine, Gifu Prefectural General Medical Center

Conflict of interest: None

Case1: A 24-yo man, who developed systemic lupus erythematosus (SLE) at the age of 15, has lupus nephritis (LN) and pericarditis (PC). Type of LN is ISN/RPS V+III (A). Although he relapsed SLE as he took prednisolone (PSL) less than 15mg, he was able to reduce the dosage of PSL by using Belimumab (BEL) in combination. Case2: A 21-yo man was diagnosed with SLE at the age of 10. She has LN (ISN/RPS IV-G), PC and interstitial pneumonia. She relapsed SLE because of her self-discontinuation of treatment. Due to her resuming treatment with BEI, her disease improved. Case3: A 38-yr woman, who got SLE at the age of 37, has cholecystitis and LN (ISN/RPS IV (A/C)). She complicated pan-cytopenia during induction therapy. But she treated with BEL, her pancytopenia improved. Case4: A 45-yr man, onset at the age of 33, has LN (ISN/RPS IV+V) with 15.8g/day of proteinuria, alveolar hemorrhage, pulmonary hypertension and antiphospholipid syndrome. He treated with steroid pul therapy, he is currently treating by using antibiotics agents. Although it is necessary to pay attention to the occurrence of adverse events, it was considered that BEL could be effectively used in both induction therapy and maintenance therapy.

P2-205
Belimumab administration on SLE, clinical trial cases and post-marketing neuropsychiatric (NP) cases
Yasushi Nawata, Shigekazu Takahashi, Norihiro Mimura, Kazusa Miyachi, Kaori Masujima, Taiga Ikezawa, Kazuhiro Hamasato, Norihiko Watanabe
Center for Rheumatic Diseases, Chibaken Saiseikai Narashino Hospital

Conflict of interest: None

[Object] Anti-BLyS antibody belimumab (BEL) was effective for SLE in clinical trials, but there is little evidence for NP-SLE. We report the experience of the NP-SLE cases. [Methods] 5 BEL cases, 2 clinical trial (BLISS-NEA) (case1,2) and 3 post-marketing NP-SLE (case3,4,5). SELENA-SLEDAI, anti-dsDNA, complements (C3/C4), IgG are evaluated. [Results] Case1) 48 year-old (PSL12.5mg+MIZB), arthritis, alopecia, rash, anti-dsDNA positive, low complement, SLEDAI10. Case2) 35 year-old (PSL10mg+CsA), rash, skin vasculitis, alopecia, anti-dsDNA positive, SLEDAI14. Anti-dsDNA levels decreased by 52 weeks after starting treatment with increased complement levels. Case3) 46 year-old (PSL16mg+CY), abduction/swallowing disturbance, anti-dsDNA positive, anti-cardiolipin J2GP1 positive, SLEDAI10. After starting BEL symptoms improved together with anti-dsDNA/anti-cardiolipin decrease. Case4) 43 year-old (PSL12.5mg+CsA), psychosis, arthritis, anti-dsDNA positive, SLEDAI14. Case5) 57 year-old, consciousness disturbance, SLEDAI124. Steroid pulse and IVCY were temporarily effective. Evaluation of BEL was difficult. Although the effect of BEL on NP symptoms was partially recognized, it is still unclear. [Conclusions] Evidence needs to be accumulated in the evaluation of BEL for SLE including NP symptoms.

P2-206
A case of systemic lupus erythematosus with a relapse and refractory infections after living-donor kidney transplantation
Midori Akagi, Nozomi Iwanaga, Chiieko Kawahara, Yoshiro Horai, Yasumori Izumi, Atsushi Kawakami
1National Hospital Nagasaki Medical Center, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan

Conflict of interest: None

A 35-year-old Japanese woman was diagnosed with systemic lupus erythematosus (SLE) with lupus nephritis at the age of 11. Her SLE was refractory. After cyclosporine (CyA) was started, her urinary protein was reduced. Her creatinine had been around 4 mg/dl. Because of hope of childbirth, she received a kidney transplantation 11 months ago. Steroid pulse was administered and CyA was changed to tacrolimus (TAC) and mycophenolate mofetil. Although she had relapsed with lupus enteritis 7 months ago and was treated with steroid pulse and intravenous cyclophosphamide. Her urine protein increased 5 months ago. Renal biopsy revealed thrombotic microangiopathy caused by TAC. After TAC was changed to CyA, her urine protein gradually decreased. She was admitted to our hospital 4 months later, because of fever and back pain. MRI revealed suggestive spondylitis of Th10-11. Mycobacterium avium was detected by abscess punctured. She was treated with CAM, EB and RFP, and her symptoms resolved. Because most of patients with SLE performed kidney transplantation required dialysis before transplantation, this case is rare. We report the difficulty of the management after the kidney transplantation in patients with SLE.

P2-207
A case of systemic lupus erythematosus successfully treated with belimumab
Masako Furuyama,1 Sosuke Tsuji2, Tomoki Origuchi3, Atsushi Kawakami2
1Department of Rheumatology, Nagasaki Kita Hospital, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, 3Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences

Conflict of interest: None

[Object] Anti-BLyS antibody belimumab (BEL) was effective for SLE in clinical trials, but there is little evidence for NP-SLE. We report the experience of the NP-SLE cases. [Methods] 5 BEL cases, 2 clinical trial (BLISS-NEA) (case1,2) and 3 post-marketing NP-SLE (case3,4,5). SELENA-SLEDAI, anti-dsDNA, complements (C3/C4), IgG are evaluated. [Results] Case1) 48 year-old (PSL12.5mg+MIZB), arthritis, alopecia, rash, anti-dsDNA positive, low complement, SLEDAI10. Case2) 35 year-old (PSL10mg+CsA), rash, skin vasculitis, alopecia, anti-dsDNA positive, SLEDAI14. Anti-dsDNA levels decreased by 52 weeks after starting treatment with increased complement levels. Case3) 46 year-old (PSL16mg+CY), abduction/swallowing disturbance, anti-dsDNA positive, anti-cardiolipin J2GP1 positive, SLEDAI10. After starting BEL symptoms improved together with anti-dsDNA/anti-cardiolipin decrease. Case4) 43 year-old (PSL12.5mg+CsA), psychosis, arthritis, anti-dsDNA positive, SLEDAI14. Case5) 57 year-old, consciousness disturbance, SLEDAI124. Steroid pulse and IVCY were temporarily effective. Evaluation of BEL was difficult.Although the effect of BEL on NP symptoms was partially recognized, it is still unclear. [Conclusions] Evidence needs to be accumulated in the evaluation of BEL for SLE including NP symptoms.

S306
Conflict of interest: None

A case of acquired angioedema associated with SLE
Yohei Takeuchi, Hiromi Hirabayashi, Michiaki Tokuda
Internal Medicine, Saniki Municipal Hospital

Conflict of interest: None

Angioedema (AE) is caused by hypervascular permeability by activating complement system, coagulation fibrinolysis system, kinin-kallikrein system due to deficiency of C1 inhibitor (C1-INH). There are inherited genetic AE, and acquired AE caused by the dysfunction of C1-INH associated with lymphoproliferative diseases and autoimmune diseases. She was 33 year-old, and was diagnosed SLE from X-3 year. In X year, she was urgently hospitalized with sudden eyelids, lips, limbs of edema and abdominal pain. In CT, ascites in abdomen and intestinal wall thickening were observed. All of C3, C4, and CH50 were markedly reduced, C1q was also low, and C1-INH decreased quantitatively. Finally, she was diagnosed as AE, but administration of the C1-INH formulation was ineffective. Because of adult onset, no family history, and ineffectiveness of corticosteroids and cyclophosphamide pulse therapy was performed, the above symptoms and ascites disappeared immediately. Furthermore, serum complement value increased and C1-INH also normalized. Later, no abnormality was observed in the C1-INH gene, suggesting not inherited genetic AE. When accompanied by autoimmune disease, immunosuppressive therapy is thought to be effective.

SLE associated with macrophage activation syndrome and cardiac tamponade brought about acute heart failure: A case report
Kohei Nagaya1, Akimasa Asai2, Asako Kachi2, Masako Koshino2, Nao Asai2, Hirokazu Sugiyama2, Tomomichi Kasagi2, Mayumi Ito2, Hiroshige Kobayashi2, Takeyuki Katsuno2, Shogo Banno3, Yashiko Ito3
1Department of Nephrology, Kizawa Memorial Hospital, 2Department of Nephrology, Rheumatology and Collagen Diseases, Aichi Medical University

Conflict of interest: None

[Case] 49-year-old female [Chief complaint] fever [Present illness] A 49-year-old female patient noticed face erythema 12 years ago. She enter a hospital one month ago because of fever. CT scan showed lymphadenopathy through out the body, therewith the attending doctor suspect malignant lymphoma and introduced her to hematology department of out hospital. On the admission, the physical examination, blood test and CT scan showed depletion, face erythema, pericarditis, pancytopenia, ANA positive, anti-dsDNA antibody positive, low complement. The result suggested a diagnosis of SLE. She was treated with prednisolone 50mg/day, then fever and blood cell count improved. She got acute respiratory insufficiency on 5th day of the treatment. She was diagnosed with acute heart failure and cardiac tamponade. She was intubated, got to be on a mechanical ventilator and treated with steroid pulse therapy. At the same time her ferritin level showed surprising increase, that suggest complicated macrophage activation syndrome (MAS). IVIG therapy was added. Pericardial effusion and ferritin level improved quickly, but cardiac function did slowly. [Conclusions] Probably, not only cardiac tamponade, also high level cytokine caused by MAS was the important factor of heart failure.

Clinical course of systemic patients with digital ulcers treated with bosentan
Takashi Kida, Tomoyo Sagawa, Takuya Inoue, Akiko Kasahara, Shunya Kaneshita, Kazuki Fujioka, Hitotake Nagahara, Makoto Wada, Masataka Kohno, Yutaka Kawahito
Inflammation and Immunology, Kyoto Prefectural University of Medicine

Conflict of interest: None

[Objective] Digital ulcers (DUs) in systemic sclerosis (SSc) is a visible manifestation reflecting the extent of systemic vasculopathy. Because its pathogenesis is diverse and complicated, the management is often challenging. Here, we aimed to investigate the clinical course of SSc patients with DUs treated with bosentan (BOS). [Methods] We retrospectively analyzed the consecutive SSc patients with DUs treated with BOS after April 2013. [Results] A total of 21 patients (13 limited; 8 diffuse; median disease duration 7 years) were detected. Six patients had PAH. Of total, 72.9% (15/21) patients did not develop new DUs within 52 weeks. Also, 42.9% (9/21) patients did not develop new DUs within 52 weeks. Short disease duration, low severity of skin thickness, and concomitant use of alprostadil injection were tended to be associated with healing of existing DUs. PAH was associated with development of new DUs. The most common adverse events were liver damage or adverse hemodynamic effect. Within 52 weeks, 2 patients suffered sudden death and 6 patients discontinued taking BOS. [Discussion] For the optimal management, multidisciplinary treatment including BOS is required. We will discuss based on our experience and literature review.

Analysis of therapeutic target for early systemic sclerosis using of public approval treatments
Hirahito Endo1, Yoshie Kusunoki2, Aki Shoji2, Noriko Tonozuka2
1Department of Rheumatology, Jusendo General Hospital, 2Department of Rheumatology, Akishima Hospital

Conflict of interest: None

[Objective] In real-world clinical state we need the assessment of the efficacy in the standard public approved therapy for early active systemic sclerosis. We analyzed the therapeutic target in these clinical state [Object] 2014–18. 26 patients with SSc, 60.29 ± 1 years old, disease duration 3 ± 2.1 years, dSSc22 LeSSc, Scl70ab 11, ACA 5, RNA polyab 3 cases We defined the therapeutic goal, mRSS improvement: over 5, %VC improvement over 5%, improve HAQ-DI over 0.5 and SF-36. [Results] Patients with SSc with IP were treated by corticosteroids and intravenous cyclophosphamide therapy. Scleroderma overlapped with rheumatoid arthritis treated by Tocilizumab (TOZ) and MTX. Skin sclerosis mRSS were improved 66.6±13.2 to 68.2±15.6, %VC Δ5over improved cases were 56%. In Patients overlapped RA DAS28 improved from 5.020 ± 2.6, 78% patients SSc improved HAQ-DI ±0.5. [Conclusions] Improvement of health related QOL is the most important therapeutic target used the combination of approved therapeutic drugs in era there were only treatment with limited effects.

Comparison of systemic scleroderma group and non-systemic scleroderma group in pulmonary hypertension associated with connective tissue disease
Kenji Sakai, Kaori Ishimura, Hiroki Akazawa, Chisato Ashida, Fusiyo Ikeda, Atsuhiro Yamamoto, Tetsu Itami, Asuka Inoue, Shinaki Ri, Yoshikiko Shiga, Kazuya Kishimoto, Yuji Nozaki, Koji Kinoshita,

Conflict of interest: None
Masanori Funaschi, Itaru Matsumura
Department of Hematology and Rheumatology, Kindai University Faculty of Medicine

Conflict of interest: None

[Background] Inflammation is considered to be involved in the pathology of pulmonary hypertension (PH) accompanying connective tissue disease (CTD), and in case of accompanying active findings of CTD, use of immunosuppressive therapy is recommended. However, the effectiveness at PH associated with SSc is low. The pathogenesis of PH with SSc may be different from that of other CTD. [Methods] We analyzed 20 patients with CTD who underwent right heart catheter and were diagnosed as pulmonary hypertension. Patients were divided into 2 groups by SSc group (n=12), non-SSc group (n=8). The average pulmonary artery pressure, pulmonary artery wedge pressure, systolic right ventricular pressure, cardiac output, cardiac index, pulmonary vascular resistance of the right heart catheter were compared. [Results] There was no significant difference between the 2 groups in the right heart catheter findings. One case was a duplicated example of SSc and dermatomyositis, and improved PH by administration of prednisolone. [Conclusions] A significant tendency in right heart catheter finding was not recognized. This study is suggested that it may be necessary to add immunosuppressive therapy in duplicate cases of other CTD.

P2-213
Consideration of pulmonary hypertension and borderline pulmonary hypertension associated with systemic sclerosis by YKL-40
Tetsuya Furukawa, Masayasu Kitano, Naoto Azuma, Kiyoshi Matsui Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine

Conflict of interest: None

[Object] SSc is an intractable connective tissue disease that causes fibrosis of the skin and various organs and affects the prognosis by complication of PH. PH is diagnosed with mPAP ≥ 25 mmHg by RHC. In recent years, the intervention for the treatment of the borderline PH (mPAP 20 to 24 mmHg), has been discussed. We reported the possibility that YKL-40 correlated with vascular lesions of SSc and YKL-40. We compared this YKL-40 with the PH of the SSc patient at the borderline PH and examined whether or not the early intervention of PH therapy at SSc was made. [Methods] We conducted a retrospective analysis of 19 patients (11 PH, 8 borderline PH) with SSc who were referred to our institution for treatment between August 2014 and April 2017. We measured serum YKL-40 levels by ELISA. [Results] YKL-40 age percentile significantly increased PH (90.2±11.2) and borderline PH (94.8±6.7) from 24.9±17.4 for healthy controls. There was no difference between PH and borderline PH. [Conclusions] Borderline PH in SSc progresses to disease state, more than 2/3 of pulmonary capillary bed is damaged and PH develops. From the results of YKL-40, which is thought to reflect vascular disorders, it may be possible to improve the prognosis by treatment intervention at the borderline PH.

P2-214
Cobblestone appearance in systemic sclerosis
Ikko Kajihara1, Masatoshi Jinnin2, Katsunari Makino1, Takamitsu Makino1, Hironobu Ihn1
1Department of Dermatology, Kumamoto University, 2Department of Dermatology, Wakayama Medical University

Conflict of interest: None

Background: A cobblestone appearance (CSA) is a rare skin manifestation of systemic sclerosis (SSc), which is defined as a lesion with characteristic multiple small papules/nodules due to lymphangiectasia caused by an obstruction of the lymphatic channels during the sclerosing process. However, the frequency and the clinical significance of CSA in SSc patients are still unclear. Objective: This study examined the prevalence of CSA on the affected skin of patients with SSc and investigated the clinical features of SSc patients with CSA retrospectively. Methods All 184 patients with SSc in this clinic were evaluated. Diagnosis for CSA was based on the clinical and histopathological pictures. Results: CSA was found in 3 of 184 patients (1.6%). The CSA patients were all male with diffuse cutaneous SSc, and had significantly higher modified Rodnan’s skin score (m-TSS) than those without CSA. Furthermore, these patients were resistant to treatments for skin sclerosis. Conclusions: CSA may be an indicator of severe skin sclerosis and poor prognosis in SSc patients.

P2-215
An Algorithm to Predict Mean Pulmonary Artery Pressure > 20 mmHg in Patients with Systemic Sclerosis
Keita Ninagawa, Masaru Kato, Hiroyuki Nakamura, Kuniyuki Aso, Taiki Sato, Michihito Kono, Yuichiro Fujieda, Kenji Oku, Toshiyuki Bohgaki, Olga Amengual, Shinsuke Yasuda, Tatsuya Atsumi Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University

Conflict of interest: None

[Object] Early intervention in pulmonary arterial hypertension associated with systemic sclerosis (SSc) may improve its prognosis. We aimed to establish an algorithm to detect mean pulmonary artery pressure (mPAP) > 20 mmHg using non-invasive examinations in patients with SSc. [Methods] This study included 58 SSc patients who underwent right heart catheterization in our hospital during 2010 to 2018. Following variables according to DETECT algorithm were assessed to predict mPAP > 20 mmHg: anti-centromere or U1-RNP antibodies, BNP, serum urate, right axis deviation, FVC/DLco and tricuspid regurgitation velocity. Each cut-off value of these markers was determined by ROC curves, and was compared between mPAP > 20 and ≤ 25 mmHg. In addition, cardiac MRI was evaluated. [Results] FVC/DLco and right axis deviation had high specificity (72% and 96%, respectively) to predict mPAP > 20 mmHg as well as ≥ 25 mmHg. Thus, an algorithm weighted with these two markers showed high AUC of 0.87 (sensitivity: 90% and specificity: 70%). Addition of cardiac MRI increased AUC to 0.89 (sensitivity: 90% and specificity: 70%). [Conclusions] We proposed a pilot algorithm to predict mPAP > 20 mmHg in SSc patients. Weighting FVC/DLco and right axis deviation, and adding cardiac MRI may improve its predictability.

P2-216
Analysis of the relationship between HRCT findings suspecting pulmonary veno-occlusive lesion and clinical factor in pulmonary artery hypertension associated with systemic sclerosis
Kenichiro Hata1, Takuya Kotani1, Takao Kiboshi1, Takayasu Suzuki1, Youhei Fujiuki1, Reiko Wakura1, Daisuke Wakura1, Koji Naga1, Takeshi Shoda1, Tohru Takeuchi1, Shigeki Makino1, Shigeki Arawaka1
1Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical College, Takatsuki, Osaka, Japan, 2Department of Rheumatology, Yodogawa Christian Hospital, Osaka, Japan, 3Department of Internal Medicine, Osaka Medical College Mishima-Minami Hospital

Conflict of interest: None

[Object] To analyse the relationship between HRCT findings suspecting pulmonary veno-occlusive lesion and clinical factor in pulmonary artery hypertension (PAH) associated with systemic sclerosis (SSc). [Methods] We assessed HRCT findings suspecting pulmonary veno-occlusive lesion in 13 cases of systemic sclerosis complicated with PAH. We suspect pulmonary veno-occlusive lesion based on thickened septal lines, centrilobular GGO, and mediastinal lymph node enlargement, and divided into 2 groups defined as satisfied over 2 HRCT findings (Group A, n=4) or less than one (Group B, n=9). [Results] Average age was 71.4±8.0 years old, 7 cases was anti-centromere antibody positive, 7 cases were complicated with ILD. Average %VC, %DLCO, mPAP and PVR were 76.5±16.2%, 24.9±10.0%, 31.7±9.9 mmHg, 5.5±4.1 wood, respectively. Thickened septal lines were shown in 6 cases, centrilobular GGO were 3 cases, mediastinal lymph node enlargement were 5 cases. One case had triad HRCT findings, 3 cases had 2 findings, 5 cases had one, 4 cases had none. All cases in Group A were WHO class 3 and needed oxygen therapy. Group A was higher than Group B in the average of mPAP, PVR and AaDO2. [Conclusions] HRCT findings suspecting pulmonary veno-occlusive lesion and clinical factor in pulmonary artery hypertension (PAH) associated with systemic sclerosis (SSc) may improve its predictability.
veno-occlusive lesion in PAH associated with SSC could reflect clinical severity.

**P2-217**

**Evaluation of the utility of Nailfold videocapillaroscopy (NVC) in anti-centromere antibody (ACA)-positive patients**

Tomohiro Sugimoto¹, Kei Araki¹, Hiroki Kohno¹, Kazutoshi Yukawa¹, Tatsuoji Kuranobu¹, Tadahiro Tokunaga¹, Katsuhiro Ohí¹, Yusuke Yoshida¹, Sho Mokuda¹, Keisuke Oda¹,², Takaki Nojima¹,², Shinataro Hirata¹, Eiji Sugiyama¹

¹Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan, ²Department of Internal Medicine, Hiroshima Clinic, Hiroshima, Japan, ³Nojima Internal Medicine Clinic, Hiroshima, Japan

Conflict of interest: None

[Object] The anti-centromere antibody (ACA) is a specific and frequent marker for systemic sclerosis (SSc) or Sjögren’s syndrome (SS). We divided the clinical features of ACA-positive patients into three groups (SSc, SS, others) and evaluated them using nailfold videocapillaroscopy (NVC). [Methods] We evaluated the ACA-positive patients which we examined NVC test from April 2018 to October 2018, respectively. The 2nd to 5th fingers were observed using NVC and semiquantitatively evaluated the scores of Enlarge, Giant, Hernorrhage, Loss of Capillary, Disorganization, presence of Ramification. Then, subjects were classified into four phases: Normal, Early, Active, Late. [Results] 48 ACA-positive cases fulfilled the entry criteria. All of the cases were women. SSc: 32 cases, SS: 6 cases, others: 10 cases. In patients with SSc, we showed 32 Raynaud phenomenon (RP,100%), 31 NVC abnormality (96.8%, Early 5, Active 14, Late 12) and 32 sclerodactyly (100%, puffy finger-4). In patients with SS, 2 RP (33.3%), no sclerodactyly and 3 NVC abnormalities (50%, Early 2, Active 1) were included. And, we detected 6 RP (60%), 1 sclerodactyly (10%) and no NVC abnormality in patients with others. [Conclusions] In ACA-positive patients, NVC abnormality and RP are useful to distinguish SSc from SS.

**P2-218**

**Overlap syndrome of systemic autoimmune rheumatic diseases (SARD)**

Yuki Inoue, Yuto Takakura, Chihiro Imaizumi, Kennosuke Mizushima, Munetugu Imamura, Sayaka Takenaka, Hideki Ito, Rie Kujime, Norihide Hayashi, Ayako Hirata, Takehisa Ogura, Hideto Kameda

Division of Rheumatology, Toho University Ohashi Medical Center

Conflict of interest: None

[Objective] To analyze the clinical features of patients with SARD. [Method] A total of 952 patients with SARD were included in this study. Applied criteria were: 1997 revised ACR (old) and 2012 SLICC criteria (new) for SLE, 1980 ACR (old) and 2013 ACR/EULAR criteria (new) for SSc, 1987 revised ACR (old) and 2011 ACR/EULAR criteria (new) for RA, and Bohan-Peter (old) and 2017 EULAR/ACR criteria (new) for PM/DM.Overlap syndrome was defined as fulfillment of criteria for ≥2 diseases (old-old or new-new). [Results] Twenty-three and 37 patients were identified as overlap syndrome by old and new criteria sets, respectively, and 7 (5 SLE-SSc and 2 SLE-PM) and 9 (7 SLE-SSc, 1 SLE-PM and 1 SLE-DM), respectively, when those with RA-overlap were excluded. All 11 (old-old or new-new) non-RA-overlap patients showed positive ANA with speckled pattern including 5 with anti-RNP antibody. All SSc patients were limited-cutaneous, and all MCTD patients were SLE-SSc overlap. Ten patients received moderate-dose glucocorticoids. Azathioprine and tacrolimus were predominant immunosuppressants. With the mean observation for 10.7 years, fatal outcome was not observed. [Conclusion] Among patients with overlap syndrome of SARD, RA- and SLE-overlap were predominant and the prognosis was favorable.

**P2-219**

**The Clinical Manifestations In Anti-Ro52 Antibody- Positive Patients With Systemic Sclerosis**

Chihiro Iwao, Shanchi Miyauchi, Masatoshi Kimura, Yuki Rikitake, Kosho Iwao, Mao Rikitate, Ayako Aizawa, Takeshi Kagawuchi, Yumi Kariya, Motohiro Matsuda, Kunihiro Umekita, Katoko Takajo, Ichiro Takajo, Akihiko Okayama

Department of Rheumatology, Infectious Diseases and Laboratory Medicine, Faculty of Medicine, University of Miyazaki, Miyazaki, Japan

Conflict of interest: None

[Objectives] The aim of this study is to clarify the prevalence of anti-Ro52/TRIM21 abs in patients with systemic sclerosis (SSc). [Methods] This study is a retrospective case control study. The medical records of 50 patients who were diagnosed as having SSc admitted to our hospital were reviewed. We evaluated the clinical manifestations at the first-onset of SSc. Co-existing rheumatic diseases were also reviewed. All subjects underwent SSc-associated abs testing using EUROWILE immuno blot assay. The association between clinical features and autoantibody profile was evaluated. [Results] The study group included 6 male and 44 female patients. Twenty-eight patients are limited cutaneous SSc. Twenty-three patients with SSc are positive for anti-Ro52/TRIM21 abs. The prevalence of co-existing rheumatic diseases is tended to be higher in anti-Ro52/TRIM21 abs-positive SSc patients than in negative SSc patients. Unexpectedly, the prevalence of RA was higher in anti-Ro52/TRIM21 abs-negative SSc patients than in positive SSc patients. [Conclusions] The prevalence of anti-Ro52/TRIM21 abs in SSc patients of this study seems to be high compared to other reports. This abs may have potential as a biomarker in SSc patients indicating the existence of other rheumatic diseases.

**P2-220**

**Association study of CD300H gene polymorphisms in systemic sclerosis (SSc)**

Akiko Tochimoto, Yusashi Kagawuchi, Manabu Kawanomoto, Kae Takagi, Yasuhiko Katsumata, Masanori Hanaoka, Hisashi Yamanaka

Institute of Rheumatology, Tokyo Women’s Medical University Hospital

Conflict of interest: None

[Object] SSc is characterized by fibrosis of the skin and internal organs and microvascular injury. Endothelial injury is induced by the actions of free radicals or environmental factors with immune activation. A novel immunoreceptor CD300H is one of CD300 family molecules is expressed on CD16+ monocytes and myeloid dendritic cells, and that mediates neutrophil chemoattractant production. In this study, we examined whether CD300H polymorphisms are associated with SSc and systemic lupus erythematosus (SLE). [Methods] We investigated 329 SSc patients, 373 SLE patients and 346 healthy controls. Single nucleotide polymorphism (SNP) rs905709 was determined using TaqMan SNP genotyping assay. [Results] The frequency of rs905709 A allele was significant higher in SSc than healthy control and SLE (P=7.32e-7, P=0.01). [Conclusions] Our results suggest CD300H polymorphism may associate occurrence of SSc.

**P2-221**

**Superior efficacy of CD34-selected versus unmanipulated autologous haematopoietic stem cell transplantation for severe systemic sclerosis**

Masahiro Ayano¹,², Hiroki Mitoma¹, Hiroshi Tsukamoto³, Yusuke Kashiwado¹, Yasutaka Kimoto³, Mitsuteru Akahoshi¹, Yojiro Arinobu¹, Koichi Akashi¹, Takahiko Horuchi¹, Hiroaki Nitro¹

¹Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ²Department of Stem Cell Biology and Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, ³Department of Rheumatology, Shin-Kokura Hospital, Kitakyushu, Japan, ⁴Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, ⁵Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

Conflict of interest: None

[Object] This study aimed to compare the efficacy and safety of CD34-selected autologous haematopoietic stem cell transplantation (auto-HSCT) with unmanipulated auto-HSCT to treat severe systemic sclerosis
(SSc). [Methods] The subjects were 19 severe SSc patients who received CD34-selected (n=11) or unmanipulated auto-HSCT (UM, n=8). Changes in skin sclerosis and pulmonary function were assessed over an 9-year follow-up period. Differences in the changes, toxicity and overall survival were compared between the two groups. [Results] Improvement of skin sclerosis was significantly greater in the CD34-selected group than in the unmanipulated group. Forced vital capacity in the CD34-selected group continuously increased over 9 years, whereas in the UM group it returned to baseline 3 years after transplantation. Toxicity and viral infections, such as CMV infection and herpes zoster, were more frequently found in the CD34-selected group than in the UM group. No treatment-related deaths occurred in either treatment group. The 9-year overall survival rates of the CD34-selected and UM group were 81.8% and 43.8% respectively. [Conclusions] CD34-selected auto-HSCT may produce favorable effects on improvement of skin sclerosis and pulmonary function compared with unmanipulated auto-HSCT.

P2-222
Effects of platelet-derived growth factor receptor (PDGFR) inhibitor for the fibrosis of systemic sclerosis
Katsunari Makino, Hiroshu Inh
Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
Conflict of interest: None

[Object] Systemic sclerosis (SSc) is an acquired autoimmune disorder that typically results in fibrosis of the skin and internal organs. We examined the role of crenolanib, an inhibitor of PDGFR signaling, in cultured skin fibroblasts and evaluated its antifibrotic effect in the angiotensin II (Ang II)-induced mouse skin and heart fibrosis. [Methods] Healthy control (HC) and SSc dermal fibroblasts were cultured in the presence of crenolanib, TGF-β, PDGF ligands and CTGF. Skin biopsy samples collected from 15 healthy controls and 33 dcSSc were included in the microarray analysis. Ang II was administered by subcutaneous osmotic pumps. [Results] Crenolanib effectively inhibited proliferation of SSc and HC fibroblasts and attenuated basal and TGF-β-induced expression of CTGF and peristin. In contrast to HC fibroblasts, SSc fibroblasts proliferated in response to PDGFAA, while a combination of PDGFAA and CTGF was required to produce a similar response in HC fibroblasts. PDGFRA mRNA correlated with CTGF and other fibrotic markers in the skin of SSc patients. Crenolanib reduced mRNA expression by daily intraperitoneal injections attenuated the skin and heart fibrosis in the Ang II model. [Conclusions] Our data indicate that inhibition of PDGFR signaling presents a new attractive therapeutic approach in SSc.

P2-223
Serum KL-6 level and forced vital capacity are prognostic factor of patients with Systemic Sclerosis
Takayuki Kon, Yoshibuki Abe, Masakazu Matsushita, Michihito Ogasawara, Ken Yamaji, Naoto Tamura
1Department of Rheumatology and Internal Medicine, Juntendo University, Tokyo, Japan, 2Department of Rheumatology and Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan
Conflict of interest: None

[Object] We investigated whether serum KL-6 levels and respiratory function in patients with systemic sclerosis (SSc) are prognostic factors. [Methods] Two-hundred ninety-three patients with SSc hospitalized to Juntendo University Hospital were included. Patients with interstitial lung disease (ILD) (185 patients; group A) and without ILD (108 patients; group B), were investigated for differences in prognosis with normal KL-6 level (n<500 U/mL) and high KL-6 group (n>=500 U/mL), forced vital capacity (% FVC) and diffusing capacity of the lung for carbon monoxide (% Dlco) in the normal and the declining groups. [Results] One-hundred thirty cases (70.3%) in group A and 35 cases (32.4%) in group B. The high KL-6 group was poor prognosis (p=0.007) compared with the normal group, but in the group B, there was no significant difference. In the low %FVC group (<80%), the prognosis was poor (p=0.009) compared with the normal group, but when compared in each of the Group A and B, there was no significant difference. Only 20 cases has normal %Dlco levels, there was no significant difference. [Conclusions] Elevated KL-6 levels in SSc patients withoutILD was not a prognostic factor. For the characteristics of high serum KL-6 levels, further investigation is considered necessary.

P2-224
Nailfold videocapillaroscopic changes in 2 cases of systemic sclerosis renal crisis
Kae Onishi, Naoto Yokogawa, Naoki Tanomogi, Masahiro Iida, Yusuke Nakamichi, Shuhei Sano, Tatsuori Mori, Nanase Honda, Michiru Kira, Eiisuke Takamasu, Takayasu Kise, Yuji Miyoshi, Yoshiki Nagai, Masako Utsunomiya, Kita Shimada, Shoji Sugii
Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center

Conflict of interest: None

[Background] There are few case reports of Nailfold videocapillaroscopy (NVC) findings in scleroderma renal crisis (SRC). [Case1] An 71-year-old female was immediately hospitalized with cardiac failure. She presented the progressive renal dysfunction with erythrocytura and proteinuria, thrombocytopenia and anemia. The renal biopsy presented moderate glomerular ischemic collapse and vascular thrombosis. Further, she was anti-RNA polymerase 3 antibody positivity, thus we diagnosed her with SRC. ACEI, ARB, and CCB was administered, but she progressed oliguria and fluid retention state, and hemodialysis was initiated. The NVC revealed severe avascular areas and the massive busy capillaries. [Case2] An 81-year-old female with anti-RNA polymerase 3 antibody positivity was admitted for renal dysfunction with proteinuria and thrombocytopenia. The renal biopsy revealed the thrombosis in renal arteries, which contributed to the diagnosis of SRC for her. She was treated with ACEI and CCB and improved renal function and platelet counts. The NVC finding revealed mostly normal morphological capillaries and only a few giant capillaries and avascular areas. [Clinical implications] We describe the two valuable SRC cases with references in terms of their NVC findings.

P2-225
Scleroderma renal crisis in a patient with diffuse cutaneous systemic sclerosis after persistent elevation of anti-RNA polymerase III antibody
Hirosi Sawachika, Shunichi Fujita, Mayuko Fukushima, Takahiko Akagi, Hiroyasu Hirano, Tomoyuki Mukai, Yshitaka Morita
Department of Rheumatology, Kawasaki Medical School, Kurashiki, Japan
Conflict of interest: None

A 71-year-old woman was referred to our clinic with Raynaud’s phenomenon in September 2014. She had nailfold capillary abnormalities and puffy fingers without skin sclerosis. Serological tests showed positivity for anti-Scl70 antibody. Skin sclerosis progressed gradually, and we diagnosed diffuse cutaneous systemic sclerosis (SSc) during her follow up visit to the clinic. Her serum creatinine level was 0.6 mg/dl in June 2018, while it was elevated to 3.16 mg/dl in September 2018. She also had thrombocytopenia, hemolytic anemia, and hypertension of 238/134 mmHg with hyperreninemia. She was admitted to hospital with a diagnosis of scleroderma renal crisis (SRC). She then started to receive an angiotensin-converting enzyme inhibitor. However, this treatment was not effective, and hemodialysis was needed on the 12th hospital day. Of note, serum anti-RNA polymerase III antibody levels (index <28: negative, 28-50: gray zone, >50: positive) were elevated from 18.4 in September 2014 to 23.1 in August 2015, and were subsequently increased to 32.9 in September 2018. Clinical significance: The follow up measurements of anti-RNAPIII antibody may contribute to early diagnostic assessment of SRC in SSc patients, and improve their outcomes.

P2-226
Nine cases with giant cell arteritis
Daisuke Nakatsuho, Yoshimasa Hamano, Michihito Katayama, Hitoshi Deguchi

Conflict of interest: None
Department of Immunology, Kinki Central Hospital of Mutual Aid Association of Public Teachers

Conflict of interest: None

[purpose] Giant cell arteritis (GCA) is a rare disease presenting fever and headache. However, without subjective manifestations, some patients might not be diagnosed or treated properly. We examined the diagnostic process of GCA patients in our hospital. [method] Patients diagnosed having GCA in our department from 2013 to 2018 were analyzed retrospectively. [result] Five male and four female patients were diagnosed. Their mean age at diagnosis was 75.2±8.8 year old. One had ocular manifestation, six complicated with polymyalgia rheumatica and one complicated with lupus. Five patients had dilatation or tenderness of temporary artery (TA). Five had wall thickening in ultrasonography and six had histologically positive findings, among seven patients having both ultrasonography and TA biopsy. Among them, two would not be diagnosed according to 1990 ACR criteria without biopsy. PET-CT was performed to seven patients, and five were classified as having large vessel GCA. One patient complicated with malignancy at diagnosis. We also report instructive cases with details. [conclusion] Positive findings in ultrasonography in more than a half of the patients, suggesting it is recommended as a non-invasive examination. Our report investigated false negative in ultrasonography or TA biopsy.

P2-227
Experience of tocilizumab for Giant Cell Arteritis: A single center cohort
Hiromichi Tamaki, Sho Fukui, Haruki Sawada, Yukihiko Ikeda, Ayako Kitada, Masei Suda, Haruyuki Yanoaka, Ryo Rokutanda, Kotakuro Tsuda, Mutsuomasa Kishimoto, Ken-ichi Yamaguchi, Yukio Matsui, Masato Okada
Imuno-Rheumatology Center, St. Luke’s International Hospital

Conflict of interest: None

[Object] Giant Cell Arteritis (GCA) is one of the primary systemic vasculitides, which mainly affects elderly. No effective treatment has been described except for glucocorticoids until the recent clinical trial of tocilizumab (TCZ) for GCA. Now TCZ is approved for GCA in Japan since August 2017. Here our experience with TCZ for GCA is described. [Methods] This is a retrospective study of the patients with GCA treated at St. Luke’s International Hospital who was on TCZ for at least 3 months. [Results] Nine patients were identified. Three are male. The median age at the initiation of TCZ is 71 years. The median duration of follow up is 9 months. TCZ was used for relapse in 8 patients. One patient received TCZ from the beginning due to a history of recurrent compression fracture. The median dose of prednisone at the initiation of TCZ was 15mg and the median dose of prednisone 3 months after TCZ treatment was 6mg (p=0.009, Wilcoxon signed rank test)). Eight patients used TCZ for more than 6 months. The median dose of prednisone at 6 months was 3.5 mg (p=0.014). All of the patients were on prednisone 5mg or less and two discontinued prednisone. Relapse occurred one out of 9 patients. [Conclusions] TCZ appears to have steroid sparing effects in Japanese patients based on our experience.

P2-228
Thinking how to optimize treatment for giant cell arteritis through the experience of three cases
Hideyuki Takahashi, Sayaka Tsuzuki, Fangyi Chin, Keigo Setoguchi
Department of Rheumatology, Tokyo Metropolitan Komagome Hospital

Conflict of interest: None

Background: As for giant cell arteritis (GCA), one of the main purposes of induction therapy is to prevent future relapses and complications, including aneurysm and stenosis. However, it is difficult to evaluate the risk of those events precisely, and to predict the necessity of strong treatment such as tocilizumab. Case: 1.A 64-year-old woman was admitted to our department due to low grade fever, dry cough and backache. She was diagnosed GCA after temporary artery biopsy (TAB), and started to receive mPSL 40mg. During steroid tapering, however, fever and elevation of CRP relapsed when mPSL 20mg was prescribed. Concomitant use of AZP 50mg or MTX 14mg was not effective enough. Finally, the inflammation was maintained after tocilizumab was administered. 2.A 67-year-old woman was diagnosed GCA as well and started to receive mPSL 40mg. Administering MTX 6mg concomitantly, dose of steroid had been tapered to PSL 7mg without any relapse. 3.A 66-year-old woman was diagnosed GCA as well and started to receive PSL 40mg alone. Dose of steroid had been tapered to PSL 20mg without any relapse so far, and tapering has gone on. Three cases above seemed similar at first, but showed different reactivity to therapies. Here, we analyze the cause of this difference with some literature review.

P2-229
Efficacy and safety of Tocilizumab therapy for relapsed cases of giant cell arteritis
Yoichiro Haji1, Takanori Ito1, Mizuki Kato1, Naoho Takizawa2, Tatsu Watanabe1, Hideaki Shimizu1, Yoshiro Fujita2
1Daido Hospital, Nagoya, JAPAN, 2Department of Rheumatology, Chubu Rosai Hospital, Nagoya, Japan

Conflict of interest: None

[Object] To investigate its efficacy and safety of Tocilizumab (TCZ) therapy for relapsed cases of giant cell arteritis (GCA) in spite of standard therapy. [Methods] We retrospectively reviewed GCA cases treated with TCZ which is relapsed in spite of standard therapy. Three cranial GCA and one large vessel GCA were included. Their age, gender, disease duration, average steroid dose, number of steroid cessations, number of relapses, and symptoms when relapsing were collected. [Results] All subjects were female, and its average age was 76.3 years old. Disease duration until TCZ started was 4.9 months. There were 2 cases of successful cessation of steroid, zero case of relapse, and zero case of discontinuation of administration due to adverse event. Regarding safety signals, there were one case of nasopharyngitis, one case of bronchitis, and one case of diabetes exacerbation. [Conclusions] It was suggested that the use of TCZ for relapsed case of giant cell arteritis may contribute to discontinuation of steroids, steroid sparing, and prevention of recurrence.

P2-230
Two cases of giant cell arteritis that treatment with steroids could be discontinued by using tocilizumab
Tatsuya Kai, Kensuke Oyooji, Daisuke Hiraoka, Kenji Yoshida, Hiroko Ikeuchi, Shinichi Mizuki
Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan

Conflict of interest: None

[Case 1] She is a 68-year-old woman. She was diagnosed relapsing polyarthritis and treated with prednisolone (PSL). After that, PSL was discontinued. 6 years after, she felt discomfort in the neck and CRP increased. PET-CT revealed FDG uptake in the common carotid artery and aorta, and giant cell arteritis (GCA) was suspected. After steroid pulse treatment, we treated with oral PSL. When PSL was tapered to 5 mg/day, it had a flare. By using tocilizumab (TCZ), symptoms disappeared and PSL was able to be discontinued. [Case 2] She is a 88-year-old woman. She presented with two-months of fever and headache, and four-days of right visual loss. Her temporal arteries were swollen. We diagnosed as GCA, after steroid pulse treatment, treated with oral PSL. When PSL was tapered to 7.5 mg/day, it had a flare. By using TCZ, symptoms disappeared and PSL was able to be discontinued. [Clinical Significance] Although steroids are used to treat GCA, we also experience cases that it is difficult to reduce or stop steroids. In recent years, the effectiveness of TCZ against GCA has been shown, and there is a possibility that steroid can be reduced or stopped by using TCZ. We also experienced cases that steroids could be discontinued by using TCZ and report with literature consideration.

P2-231
A case of giant cell arteritis presenting with abducens nerve palsy
Yu Katayama, Nobuyuki Shinoda, Hiroshi Wakabayashi
Department of Rheumatology, Okayama City Hospital, Okayama, Japan

Conflict of interest: None

[Object] Giant cell arteritis (GCA) is one of the primary systemic vasculitides, which mainly affects elderly. No effective treatment has been described except for glucocorticoids until the recent clinical trial of tocilizumab (TCZ) for GCA. Now TCZ is approved for GCA in Japan since August 2017. Here our experience with TCZ for GCA is described. [Methods] This is a retrospective study of the patients with GCA treated at St. Luke’s International Hospital who was on TCZ for at least 3 months. [Results] Nine patients were identified. Three are male. The median age at the initiation of TCZ is 71 years. The median duration of follow up is 9 months. TCZ was used for relapse in 8 patients. One patient received TCZ from the beginning due to a history of recurrent compression fracture. The median dose of prednisone at the initiation of TCZ was 15mg and the median dose of prednisone 3 months after TCZ treatment was 6mg (p=0.009, Wilcoxon signed rank test)). Eight patients used TCZ for more than 6 months. The median dose of prednisone at 6 months was 3.5 mg (p=0.014). All of the patients were on prednisone 5mg or less and two discontinued prednisone. Relapse occurred one out of 9 patients. [Conclusions] TCZ appears to have steroid sparing effects in Japanese patients based on our experience.
Conflict of interest: None

[Case] A 77 year old female «Current medical history» Headache, posterior neck pain occurred and a previous doctor was consulted. Using NSAIDs did not improve headaches, but was introduced to our hospital for the purpose of scrutiny. Headache, scalp pain, jaw claudication, shedding disorder, swallowing pain was recognized, and the superficial temporal artery was tactile in the bloodtest, marked inflammatory reaction was observed. Temporal arteritis was suspected from the above, but echocardiography was performed because there was no abnormality in MRI. Echocardiography revealed a circumferential low lumiance thickening image including the vessel wall and a narrowing of the vascular lumen, suspected of temporal arteritis, and biopsy was performed. The lumen narrowing, the destruction image in intima-media infiltrating numerous inflammatory lymphocyte, a large number of giant cells in elastic fibers, led to the diagnosis of temporal arteritis. Steroids and tocilizumab 162 mg / w subcutaneous injection resulted in remission, and subsequent echocardiography improved wall thickening and restored blood flow. «Conclusion» Echo can be obtained noninvasively and accurate biopsy findings. Moreover, it was considered to be useful not only for diagnosis but also for judgment of therapeutic effect.

P2-233 Azathioprine use in a patient with methotrexate-intolerant giant cell arteritis
Kyoichi Nakajima, Yasufumi Shindo
Department of Rheumatology, National Hospital Organization Higashi-Saitama Hospital

Conflict of interest: None

[Background] It is necessary for some glucocorticoid (GC)-resistant giant cell arteritis (GCA) patients to use therapeutic options. The evidence levels of methotrexate (MTX) and tocilizumab (TCZ) are high, while other immunosuppressants are low, such as azathioprine (AZP), cyclosporine, and tacrolimus. I report a case of MTX-intolerant GCA treated with AZP. [Case] A 68-year-old woman had fever, temporal headache, tenderness of temporal artery, and jaw claudication. Her erythrocyte sedimentation rate (ESR) increased to 20 mg daily and 4 mg weekly of MTX was started. PSL dose was decreased to 20 mg daily with 10 mg weekly of MTX, but ESR level was elevated and her hair was lost gradually. MTX was discontinued finally because of her alopecia. After administration of 50 mg daily of AZP, ESR level reduced and PSL was tapered to 11.5 mg daily. AZP has been continued with tapering to 25 mg daily due to liver dysfunction. [Clinical significance] AZP can be used for GC-resistant, MTX-intolerant GCA.

P2-234 A case of temporal arteritis in which echo examination was useful for diagnosis and treatment effect determination
Hiromi Hirabayashi1, Yohei Takeuchi2, Michiaki Tokuda2
1Examination Department, Sanuki Municipal Hospital, 2Department of Rheumatology, Sanuki Municipal Hospital

Conflict of interest: None

«Case» A man in his 70s had cough, sputum, anorexia, malaise and slight fever for five months before hospitalization. Antimicrobial agents didn’t work. He visited our general department three months ago. CRP was prolonged high. PET-CT showed that FDG accumulated in large vessels and temporal artery. He visited our department for examination of large vessel vasculitis. There were no symptoms of headache, scalp pain, side of the head pain, jaw claudication, diplopia, blurred vision, visual field loss and limb claudication. Laboratory results were ESRI 100 mm/h, CRP 4.54 mg/dl, and no swelling or weak beating at palpation. There was halo sign of temporal artery in ultrasonic echo and giant cells founded in vessel wall media at biopsy. There were no eye symptoms but thickened intima and lumen constriction. We treated PSL 30mg/day, tocilizumab 162mg/week and aspirin Day 9. His fever had gone and ESR and CRP decreased Day 22. PSL is now reduced, but there is no reactivation. [Clinical significance] Febrile patients with unknown origin, who had no headache or ischemic cranial symptoms, are sometimes diagnosed as large vessel giant cell arteritis by imaging tests. However, it is very rare that temporal artery involvement is confirmed by imaging test and biopsy in such cases.

P2-235 The effectiveness of tocilizumab to Takayasu arteritis in the real-world
Toshiki Nakajima, Yuniko Nakano, Kohei Tsujimoto, Masaaki Fujita, Yoshitaka Imura
Department of Clinical Immunology and Rheumatology, Tazuke Kofukai Medical Research Institute Kitano Hospital, Osaka, Japan

Conflict of interest: Yes

[Object] Although Japanese Ministry of Health, Labor and Welfare admitted the use of tocilizumab (TCZ) to the patients with Takayasu arteritis (TAK) in August 2017, the effectiveness of TCZ to TAK in the real-world is still unclear. In this survey, we aimed to evaluate the effectiveness of TCZ to TAK. [Methods] We examined the medical records of 19 patients with TAK, who have been treated in our hospital since September 2017, then checked the changes in the treatment of TAK and relapse of TAK between September 2017 and September 2018. [Results] Two of 19 patients with TAK were treated with TCZ. Every patient with TAK except 1 patient was treated with glucocorticoids. The dose of glucocorticoids was reduced in 2 patients treated with TCZ and in 10 patients treated without TCZ. Before the administration of TCZ, patients treated with TCZ used methotrexate, which was discontinued after TCZ administration. No one relapsed in the patients treated with TCZ, whereas 2 patients had relapsed in the patients treated without TCZ. [Conclusions] Patients with TAK, who need immunosuppressant to control their disease, could discontinue immunosuppressant if TCZ is administered. This may suggest that TCZ is effective to the patients with TAK, who are resistant to conventional therapy.
P2-236
A case of severe Takayasu arteritis successfully treated with upfront combination of tocilizumab and conventional immunosuppressive treatment

Natsuko Watanabe, Takako Hashimoto, Masashi Suzuki, Tatsuki Nagana, Ai Umeda, Konomi Ashihara, Megumi Kurumizawa, Daisuke Hirano, Jo Nishino, Shusaku Fukaya, Shunji Yoshida, Hidekata Yasuoka
Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine

Conflict of interest: None

[Case] A 21-years old female firstly suffered from faintness and blurry vision in January, 201X. In March, jaw claudication appeared. In April, she visited a clinic because those symptoms were persisted. Brain MRI showed multiple old cerebral infarction. In June, she visited to the emergency room because she felt the numbness of right upper limb and dysarthria. Cervical MRA revealed an occlusion of the bilateral common carotid artery, and stenosis of the left vertebral artery. An image of carotid US showed swelling of vascular wall and narrow of the lumen. Furthermore, PET-CT found that FDG uptake was detected on the artery wall. Dose of PSL was successfully decreased to 25mg/day on day 86 at admission and she discharged from hospital. [Discussion] For seriously ill cases, upfront combination of tocilizumab and conventional immunosuppressive treatment may be one of the choice which contribute to improvement of prognosis.

P2-237
Therapeutic effect of biologics for Takayasu arteritis with rapid progressive arterial stenosis

Tomoyuki Asano, Makiko Furuya Yashiro, Junpei Temmoku, Yuya Fujita, Naoki Matsuoka, Shuzo Sato, Hiroko Kobayashi, Hiroshi Watanabe, Kyoshi Migita
Department of Rheumatology, Fukushima Medical University

Conflict of interest: None

[Object] We have evaluated effect of biologics for Takayasu arteritis (TA) with progressive arterial stenosis. [Methods] Cases of TA with arterial stenosis were included. Biomarkers, Ankle-Branchial-Index (ABI) and CT images were examined over time. [Results] Case 1: A 20-year-old woman had a diagnosis of TA, because of a history of intermittent claudication and CT images were examined over time. Prednisolone (PSL) and subcutaneous tocilizumab (TCZ) was administered to her. After TCZ therapy, serum IL-6 level was improved from 29.3 to 18.4 pg/mL. ABI was also improved from 0.70/0.60 (right/left) to 0.85/0.81. Stenosis of femoral artery was disappeared significantly. Case 2: A 18-year-old woman had a diagnosis of TA. She had a history of intermittent claudication and gangrenous pyoderma. Stenosis of common carotid artery, descending aorta and femoral artery were shown from CT findings. After PSL therapy, TCZ was added. ABI was remarkably improved from 0.40/0.39 to 0.62/0.79. However, IL-6 level was not reduced. Stenosis of carotid and femoral artery were remarkably improved. [Conclusions] Immunosuppressive treatment in early stage seems to be effective to improve arterial stenosis in patients with TA.

P2-238
A study of Takayasu arteritis treated with the biological preparations

Hiroki Yabe, Eri Watanabe, Chihiro Terai, Tuuyoshi Kobashigawa, Toru Yago, Shigeru Kotake
Division of Rheumatology, Jichi Medical University Saitama Medical Center

Conflict of interest: None

Takayasu arteritis (TA) is LVV which is relatively frequent in young women and Japan. We examined the clinical features of cases using biological products (Bio) against TA at our hospital. Treatment course before and after introduction of Bio was examined in 5 patients with TA who received Bio in 2009-2018 and were followed more than half a year. All cases were females and the age at onset and diagnosis was 17-43 years (average 30 years old). As initial treatment, all patients were treated with steroids with PSL 30-50 mg/day, and the minimum PSL dose before Bio was 3-10 mg/day (avg. 7.6). The PSL dose at introduction of Bio was 10-15 mg/day (avg. 11.7). The immunosuppressive agents before Bio were MTX in 5 cases, TAC in 3, and CyA in 1. The period from the first treatment to Bio was 17 to 82 months (avg. 53), and the first Bio was TOC in 2 cases, ETN in 2, and ADM in 1. ETN was primarily ineffective in 2 cases and switched to TOC after 3 months. At average 36 months (10-70 m.) after Bio-introduction, dose of PSL was decreased to 6.4 mg/day (5-7.5 mg/day). Although this survey is performed in a small number of TA cases, a good persistence rate of Bio and the steroid sparing effect was shown in TOC and ADM.

P2-240
Regulatory mechanism of rice seeds expressing altered peptide ligands against M3 muscarinic acetylcholine receptor (M3R) induced experimental sialadenitis-like Sjögren’s syndrome

Hanea Kudo, Hirotu Tsuibo, Hiromitsu Asashima, Hanae Kudo, Sumida1, Sections of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University

Conflict of interest: None

[Object] We previously reported that T cells specific RORγt transgenic (RORgtTg) mice developed spontaneous sialadenitis like Sjögren’s syndrome in which reduced regulatory T cells and RORγt-overexpressed CD4+T cells contributed to the pathogenesis. The purpose of this study was to clarify suppressive ability and its mechanisms of RORγt antagonists (A213) for sialadenitis of RORgtTg mice. [Methods] 6 weeks (W) aged RORgtTg orally received A213 or PBS every 3 days for 2W. We compared 1) saliva volume, 2) histopathology of salivary glands, 3) expressions of CD25 and Foxp3 in CD4+CD4+ T cells of spleen and cervical lymph nodes (cLN), between treatment groups. [Results] 1) The ratio of saliva volume at 2W to that at baseline was significantly increased in A213 (3.4±1.4) compared with PBS group (1.3±0.3) (p<0.05). 2) The focus score of sialadenitis at 2W was significantly lower in A213 (2.2±0.2) than in PBS group (2.6±0.6) (p<0.05). 3) The percentage of CD25Foxp3+CD4+ T cells in spleen and cLN was comparable between groups. The percentage of CD25Foxp3+CD4+ T cells in cLN was significantly lower in A213 (18±6%) than in PBS group (45±11%) (p<0.05), while similar in spleen. [Conclusions] A213 reduced CD4+CD4+ Foxp3+ T cells in cLN and suppressed sialadenitis in RORγtTg mice.

P2-387
RORgt antagonist suppresses Sjögren’s syndrome like sialadenitis in RORgt transgenic mouse

Yuko Ono1,2, Hiroto Tsuibo1, Masafumi Moriyama2, Hiromitsu Asashima1, Hanyu Kondo1, Saori Abe1, Hiroyuki Takahashi1, Yuya Kondo1, Isao Matsumoto1, Seiji Nakamura2, Takayuki Sumida1

1Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, 2Section of Oral and Maxillofacial Oncology, Division of Maxillofacial Diagnostic and Surgical Sciences, Faculty of Dental Science, Kyushu University

Conflict of interest: None

[Object] We previously reported that T cells specific RORγt transgenic (RORγtTg) mice developed spontaneous sialadenitis like Sjögren’s syndrome in which reduced regulatory T cells and RORγt-overexpressed CD4+T cells contributed to the pathogenesis. The purpose of this study was to clarify suppressive ability and its mechanisms of RORγt antagonists (A213) for sialadenitis of RORγtTg mice. [Methods] 6 weeks (W) aged RORγtTg orally received A213 or PBS every 3 days for 2W. We compared 1) saliva volume, 2) histopathology of salivary glands, 3) expressions of CD25 and Foxp3 in CD4+CD4+ T cells of spleen and cervical lymph nodes (cLN), between treatment groups. [Results] 1) The ratio of saliva volume at 2W to that at baseline was significantly increased in A213 (3.4±1.4) compared with PBS group (1.3±0.3) (p<0.05). 2) The focus score of sialadenitis at 2W was significantly lower in A213 (2.2±0.2) than in PBS group (2.6±0.6) (p<0.05). 3) The percentage of CD25Foxp3+CD4+ T cells in spleen and cLN was comparable between groups. The percentage of CD25Foxp3+CD4+ T cells in cLN was significantly lower in A213 (18±6%) than in PBS group (45±11%) (p<0.05), while similar in spleen. [Conclusions] A213 reduced CD4+CD4+ Foxp3+ T cells in cLN and suppressed sialadenitis in RORγtTg mice.
vary glands were evaluated. 3) M3R specific cytokine production by splenic CD4+ T cells of MIS was compared between rice seeds treated groups in vitro. [Results] 1) Expression of N1 and N1-APL7 were detected in the rice seeds. 2) Saliva volume of N1-APL7 rice group tended to increase compared to N1 and non-transgenic rice group. Focus score of N1-APL7 rice group was significantly lower than those of other groups. 3) M3R specific IFNγ and IL-17 productions by splenic CD4+ T cells were detected. M3R specific IFNg production in N1-APL7 rice group tended to decrease compared with other groups. [Conclusions] Oral administration of N1-APL7-expressing rice suppressed MIS.

P2-241
Analysis of blood Tfh/Tph subsets in primary Sjögren Syndrome
Shotaro Kawanami, Shoichiro Inokuchi, Hiroki Mitoma, Kazuhiko Higashio, Kensuke Irino, Masahiro Ayano, Yasutaka Kimoto, Mitsuteru Akahoshi, Yojiro Arinobu, Takahiko Horii, Hiroaki Niito 1Department of Medicine and Bioisotopic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan, 2Department of Medical Education, Graduate School of Medical Science, Kyushu University, Fukuoka, Japan, 3Department of Internal Medicine, Kyushu University Beppu Hospital, Oita, Japan

Conflict of interest: None

[Objective] Recent reports showed that PD-1+CXCR3+CD4+ T cells in synovium of patients with rheumatoid arthritis poised to promote B-cell responses and antibody production. Interplay between T follicular helper cells and germinal center B cells is essential for the formation and maintenance of germinal centers and for the generation of memory B cells and long-lived plasma cells. Abatacept reduced percentages and numbers of circulating follicular helper T (Tfh) cells, autoantibodies, and serum levels of cytokines. Rituximab reduced circulating Tfh cells. This suggests circulating follicular helper T (Tfh) cells, autoantibodies, and serum levels of cytokines.

[Methods] We analyse Tfh/Tph subsets from pSS patients and healthy controls using flowcytometry. Which may help B cell differentiation in pSS. [Conclusions] Tfh-like cells may be increased in pSS and Tph subsets from pSS patients and healthy controls using flowcytometry. Which may help B cell differentiation in pSS.

P2-242
Novel therapeutic strategy using T-induced pluripotent stem cells (T-iPSCs) derived from M3R-reactive Th1 cell clone of a patient with Sjögren’s syndrome (SS)
Hiroyuki Takahashi1, Hiroto Tsuboi1, Seiji Segawa1, Hiromitsu Asashima1, Saori Abe1, Hanae Kudo1, Yuki Ono1, Fumika Honda1, Yuya Kondo1, Isao Matsumoto1, Makoto Otsu2, Takayuki Sumida3
1Faculty of Medicine, Department of Internal Medicine, University of Tsukuba, 2Division of Stem Cell Processing/Stem Cell Bank, Center for Stem Cell Biology and Regenerative Medicine, The University of Tokyo

Conflict of interest: None

[Objective] To establish antigen-specific CD4+ regulatory T cells for development of a novel treatment via iPSCs generated from antigen-specific T cells in a SS patient. [Methods] 1) We identified peripheral M3R reactive IFN-g-producing CD4+ T cells, which were single cell sorted to establish CD4+ T cell clones, in a primary SS patient. 2) T-iPSCs were generated from CD4+ T cell clones by transfection of Yamanaka’s factors. 3) TCRβ gene rearrangement was compared between the original CD4+ T cell clone and the T-iPSCs. 4) T-iPSC-Sacs were generated by culture on 10T1/2 cells for 14 days, and analyzed for expressions of CD45, CD34, CD43, and CD122 by flow cytometry. 5) We transferred T-iPSC-Sacs cells or CD34+ cells in Sacs into irradiated NSG mice, and analyzed generation of peripheral T cells from T-iPSCs. [Results] 1) We established 35 CD4+ T cell clones. 2) 7 T-iPSCs were generated from CD4+ T cell clones. 3) TCRβ gene rearrangement of the generated T-iPSCs was consistent with that of the original CD4+ T cell clone (TRBV20.1+01-D2*02-J3*01). 4) T-iPSC Sacs cells expressed CD45, CD34 and CD43. 5) We are now analyzing the generation of T cells from T-iPSCs in NSG mice. [Conclusion] We could establish T-iPSCs from M3R-reactive Th1 cell clones of a SS patient, and could generate CD34+ cells from the T-iPSCs.

P2-243
Initial phase of human T-cell leukemia virus type I infection toward salivary gland epithelial cells use biofilm-like structure
Hideki Nakamura, Toshimasa Shimizu, Ayuko Takatani, Atsushi Kawakami
Department of Immunology and Rheumatology, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences

Conflict of interest: Yes

[Object] To examine initial infection manner of human T cell leukemia virus type-I (HTLV-I) toward salivary gland epithelial cells (SGECs).

[Methods] Immunofluorescence (IF) was used when SGECs of patients with Sjögren’s syndrome (SS) and non-SS subjects were co-cultures with HTLV-I infected cell line, HCT-5 or MOLT-4. Scanning and Transmission electron microscope (SEM/TEM) were employed to detect virions. [Results] Extracellular matrix and linker proteins, Galectin-3, Agrin, and Thetherin expressed on the surface of HCT-5. HTLV-I Gag-positive spots were observed on adjacent SGECs after 1h co-culture with HCT-5. Regardless of presence of pSS, Agrin, and Thetherin co-expressed with HTLV-I Gag on SGECs. HTLV-I Gag co-culture with HCT-5. No polarization of HTLV-I Gag and Talin was observed after co-culture with HCT-5. Virion-like particles between HCT-5 and SGECs were detected by SEM, in which HTLV-I virions were found on the surface of HCT. Virions existed at an interspace between HCT-5 and SGECs. TEM image showed that HTLV-I virions with envelope were transmitted to SGECs at the interface of HCT-5 and SGECs. [Conclusions] Initial phase of HTLV-I infection toward SGECs was mediated by not viral synapse, but biofilm-like components.

P2-244
Clinical feature and outcome of juvenile Sjögren’s syndrome; a single center experience
Seira Hattori, Ai Olnihshi, Kenichi Nishimura, Ryoki Hara, Shuichi Ito
Department of Pediatrics, Yokohama City University Graduate School of Medicine

Conflict of interest: None

[Object] To investigate the clinical feature and outcome of juvenile Sjögren’s syndrome (SS). [Methods] We retrospectively assessed the clinical symptom, laboratory data, radiological findings and treatment in 34 children with SS who were diagnosed in our hospital since April 1987 until April 2018. [Results] Thirty patients (88%) were female, and median age of diagnosis was 10.9 (4.6-15.9) years old. Thirteen patients had primary SS, and 21 had the secondary SS, in which 12, 8 and 1 patients were complicated with systemic lupus erythematosus, mixed connective tissue disease and juvenile dermatomyositis, respectively. Primary SS were discovered by ever or rash or arthralgia. No one showed dry mouth and dry eye. Rheumatoid factor, anti SS-A antibody, anti SS-B antibody was positive in 65%, 94%, 50% of the patients, respectively. Schirmer test, Saxon test, lip biopsy abnormality was positive in 15%, 35%, 100% of the patients, and abnormal magnetic resonance sialography and salivary scintigraphy were observed in 69% and 88% of the patients respectively. [Conclusions] In juvenile SS patients, few patients developed dry mouth or dry eye, and primary SS patients were diagnosed with fever or rash or arthralgia. Sicca symptoms had presented over time regardless of whether they were treated or not.

P2-245
A retrospective analysis of clinical manifestation in primary Sjögren’s syndrome -related interstitial lung disease
Eriko Ishioka Takeki1, Katsuya Suzuki1, Naoshi Nishina1, Hidekata Yasuoka2, Tsutomu Takeuchi1
1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, 2Division of Rheumatology, Fujita Health University School of Medicine, Nagoya, Japan
Conflict of interest: None

[Object] Lung involvement is a systemic manifestation of primary Sjögren’s syndrome (pSS). The aim of this study is to investigate patients back ground and clinical course of pSS-interstitial lung disease (ILD). [Methods] Total 300 consecutive patients with pSS diagnosed according to the 1999 revised Japanese criteria for the diagnosis of pSS at our division were enrolled. Clinico-radiographic characteristics were retrospectively investigated and statistically analyzed. [Results] Lung involvements were confirmed in 31.4%. This included ILD (n=23, 9.6%). Radiological patterns of 23 pSS-ILD were followings: 17 for NSIP, 5 for UIP and 1 Organizing pneumonia. 9 were progressive and 17 were stable during observation periods. Comparing ILD-progressive group with stable group, serum IgG level was significantly elevated. Notably, In ILD-progressive group, a serum IgG level in the progressive group of UIP and LIP was significantly higher than a progressive group of NSIP. (p=0.027) [Conclusions] This study demonstrated that there is possibility of involvement of ILD in 10% of pSS patients and UIP patterns with high level of serum IgG needed the follow-up that a lot of progress examples in particular were careful in that.

P2-246
Effective glucocorticoid treatment in a case of pulmonary artery hypertension associated with long-term follow up of Sjögren’s syndrome
Mayuko Koyama1, Masakazu Matsushita1, Taiga Kuga1, Seiichiro Ando1, Takayuki Kon1, Kurisu Tada1, Hirofumi Amano1, Ken Yamaji1, Naoto Tamura1
1Department of Rheumatology and Internal Medicine, Juntendo University School of Medicine, 2Department of Rheumatology and Internal Medicine, Juntendo University Nerima Hospital
Conflict of interest: None

A 47-year-old man with a history of hepatic dysfunction in 11years ago underwent further evaluation. He was positive for anti-SS-A/B antibody and direct/indirect Coombs tests, and also haptoglobin was decreased. The results of liver biopsy and other tests suggested a diagnosis of Sjögren’s syndrome (SS), with autoimmune hemolytic anemia (AIHA) and autoimmune hepatitis (AIH). Two years ago, the patient developed dyspnea on exertion, and the symptom began to worsen, therefore he was hospitalized for evaluation. Right heart catheterization (RHC) revealed a mean pulmonary arterial pressure (mPAP) of 26 mmHg. Pulmonary arterial wedge pressure was 7 mmHg. He had interstitial pneumonia (IP), but lung perfusion scintigraphy showed no abnormality. From these results, the patient was diagnosed with SS complicated by AIHA, AIH, IP and pulmonary arterial hypertension (PAH). Tadalafil was initiated. However, RHC didn’t show a decrease in mPAP. He was thought to have systemic lupus erythematosus (SLE), based on positive anti-Sm antibody, decreased complement and AIHA. Therefore, prednisolone and hydroxychloroquine was initiated. RHC showed an improvement in mPAP at 17 mmHg. Here, we report a case of PAH associated with SS, AIHA, AIH, and SLE that was effectively treated with glucocorticoid.

P2-247
Effectiveness of intravenous cyclophosphamide therapy for connective tissue disease-associated pulmonary hypertension with refractory cardiopulmonary complication: a case report
Norihiko Amano, Soshi Takahashi, Saki Mukohara, Yasuhiro Nohda, Katsukiyo Yoneda, Miwa Nishida, Saori Hatachi, Shinichiro Kumagai Shinko Hospital Kobe Japan
Conflict of interest: None

[Case report] A 61-year-old woman with interstitial lung disease (ILD), who was diagnosed with Sjögren’s syndrome at the age of 56, had treated with prednisolone, mizoribine and tacrolimus. But, progression of ILD was observed and home oxygen therapy was started. February 2018, she presented with worsening dyspnea and edema in her legs. Echocardiography revealed estimated systolic pulmonary artery pressure (esPAP) of 89mmHg and right heart catheterization (RHC) demonstrated mean pulmonary artery pressure (mPAP) of 56mmHg. Though she was treated with diuretics and combination therapy of pulmonary vasodilators after diagnosis with pulmonary hypertension (PH), mPAP improved only to 36mmHg, and progression of ILD and pericardial effusion were observed. Therefore, we initiated Intravenous cyclophosphamide (IVCY) therapy for connective tissue disease-associated pulmonary hypertension (CTD-PH). 2 weeks after IVCY therapy, her clinical condition was smooth improved and mPAP decreased to 25mmHg with mild improvement of ILD and pericardial effusion. So we completed IVCY therapy for total 6 times [Conclusion] This case suggested immunotherapy treatment, such as IVCY, can provide improvement of CTD-PH when conventional treatment, such as pulmonary vasodilators are ineffective.

P2-248
A case of myositis in primary Sjögren syndrome
Rina Okita, Rumiko Miyagi, Satoshi Baba, Ruriko Kuratani, Shinichiro Tsunoda
Division of Immunology and Rheumatology, Sumitomo Hospital
Conflict of interest: None

A 56-year-old female developed right facial numbness and visit our hospital. Her laboratory data showed CK 2370U/L, IgG 2028 mg/dl, antinuclear antibody 40 times and anti SS-A antibody/anti SS-B antibody-positive. She was suspected Sjögren syndrome and myositis and admitted to our hospital. MRI showed high signal STIR in upper and lower limb. Blood test results showed anti-ARS antibody-negative. Muscle biopsy was performed from the right deltoid muscle due to findings in EMG. Biopsy result showed the possibility of immune-mediated necrotic myopathy and we requested measurement of anti-SRP antibody /anti-HMGCR antibody but results were negative. Lip biopsy showed advanced lymphocytic infiltration and we diagnosed myositis in primary Sjögren syndrome. She was treated with mPSL 500 mg pulse therapy and PSL (20mg/day). Her clinical symptoms were not improved and blood test results showed CK 1000U/L, so we increased to PSL 40mg/day and added tacrolimus. Third mPSL 500mg pulse therapy in combination with IVIG and MTX showed effectiveness with decreased CK titer. Frequency of myositis in primary Sjögren syndrome is reported to be 5.6%. In addition, this case is steroid resistant. We discuss about myositis in primary Sjögren syndrome with literature review.

P2-249
Zinc Status andand subjective symptoms in Sjögren’s syndrome
Kumiko Akiya, Misako Konishi, Mari Ushikubo, Keisuke Izumi Internal Medicine, National Hospital Organization Tokyo Medical Center.
Conflict of interest: None

[Purpose] Zinc is an essential trace element for living organisms and their biological processes. Zinc plays a key role in many enzymes and it is involved in cell communication, proliferation, differentiation and survival. Zinc plays also a role in regulating the immune system with implications in pathologies where zinc deficiency. [Method] The subjects received a medical examination from the medical center from April to May of 2018 and received a test of serum zinc concentration. (Sjögren’s syndrome (SS) 162, RA 144). I examined subjective symptoms by interview questionnaire. [Result] Among the Primary SS low serum zinc concentration (30.6%) was significantly higher than RA (18.8%). The serum concentration of zinc, was not correlated to the serum albumin. In subjective symptoms, taste disorder alone was significantly higher in the latent zinc deficient group than in the normal group. [Conclusion] In Primary SS, the risk of low serum zinc was higher than that of RA. Taste disorder in SS is often caused by Zn deficiency and it seems necessary to be careful.

P2-250
Hydroxychloroquine in Japanese children with systemic lupus erythematosus
Toaki Kohagura, Asami Oohara, Daisuke Nishida, Naoki Abe, Haruna Nakaseko, Shinji Kawabe, Naomi Iwata
Department of Infection and Immunology, Aichi Children’s Health and Medical Center
Conflict of interest: None

[Object] To investigate the safety and the efficacy of hydroxychloroquine (HCQ) in Japanese childhood-onset systemic lupus erythematosus (SLE) patients. [Methods] Subjects included 25 children aged over 10 years old (3 male, 22 female) suffering from SLE who received HCQ and were observed for 6-months or more. HCQ efficacy and side effects were retrospectively investigated. [Results] The mean age at introduction of HCQ was 17 years. The mean duration from diagnosis of SLE to start of HCQ was 5.9 years. The mean observation period was 1.4 years. The average HCQ dose was 4.3 mg / ideal body weight kg. The dose of prednisolone (PSL) was reduced in 12 (80%) of 15 patients observed for more than 1 year. The mean PSL dose at the start of HCQ was 0.18 mg / kg / day, and was reduced to 0.11 mg / kg / day after 1 year. Adverse reactions of HCQ were found in 15 of 25 patients; 15 had gastrointestinal symptoms and one had eruptions. Of these 15 patients, five temporarily discontinued HCQ and three reduced HCQ dosage. Four of the five who discontinued HCQ subsequently resumed with a reduced dose. The other received hyposensitization therapy. Finally, all patients were able to continue HCQ. [Conclusions] HCQ was effective and safe in Japanese childhood-onset SLE patients.

P2-251
2 Unique Cases of Thrombotic Microangiopathy (TMA) in Childhood Systemic Lupus Erythematosus (SLE) resistant to Plasma Exchange (PLEX): Thrombotic Thrombocytopenic Purpura (TTP) responsive to Rituximab (RTX) and atypical Hemolytic Uremic Syndrome (aHUS) responsive to Eculizumab (ECU)

Koji Akamine1, Riku Hamada1, Naoto Yokogawa2, Kota Shimada2, Shoji Sugii1, Hiroshi Hataya1,2
1Department of Nephrology, Tokyo Metropolitan Children’s Medical Center, Tokyo, Japan, 2Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan

Conflict of interest: None

Case 1: 18 year old male with SLE and class V lupus nephritis presented with fever, jaundice, vomiting, and headache. Labs revealed hemolytic anemia with schistocytes and thrombocytopenia. PLEX was initiated for presumed TTP but he did not respond. ADAMTS13 activity was undetectable (<0.5%) and its inhibitor was positive. RTX was administered with prompt resolution of symptoms and normalization of his labs.

Case 2 of the U.S.: 18 year old female with SLE and class III lupus nephritis presented with vomiting and headache. Labs revealed hemolytic anemia with schistocytes, thrombocytopenia, and acute kidney injury. She received PLEX and steroids for presumed TTP but she was unresponsive to these treatments. ADAMTS13 activity was normal (97%), thus, we diagnosed her with aHUS. After ECU administration, her labs improved and schistocytes ultimately resolved. We should consider TMA when SLE patients present with microangiopathic hemolytic anemia and thrombocytopenia. ADAMTS13 activity will distinguish between TTP and aHUS. RTX is a chimeric monoclonal antibody to B cells that reduces various autoimmune disorders. On the other hand, ECU is a monoclonal antibody to C5 that blocks the terminal complement cascade. Consider RTX for TTP and ECU for aHUS if the patient does not respond to PLEX.

P2-252
A case of secondary hemophagocytic lymphohistiocytosis in a 15-year-old boy with systemic lupus erythematosus

Kazuzumi Sekine1, Nami Okamoto2, Yako Sugita2, Reisuke Shindo2, Kosuke Shabana2
1General Medicine, Osaka Medical College Hospital, 2Department of Pediatrics, Osaka Medical College Hospital

Conflict of interest: None

Case: A 15-year-old boy with fever and comedo-like erythema on his cheeks, visited a clinic. He was treated with antibiotics making no improvement, and visited another hospital. Bictepotenina and elevated ferritin level (9,968 ng/mL) was found there, and he was hospitalized for suspected HLH. The bone marrow histology showed hemophagocytic macrophages, and he was diagnosed as HLH. On day 15 of admission, mPSL pulse therapy was started, and his symptom improved the next day. Primary HLH was denied from the family and past history, and the blood test to identify the possible cause of secondary HLH revealed positive anti-ds DNA antibody (400 times) and ANA (160 times). He was diagnosed as SLE and was transferred to our hospital after receiving 3 courses of mPSL pulse therapy. Renal pathology showed ISN/RPS class II lupus nephritis. She was considered as severe SLE associated with HLH, and a therapeutic regimen of prednisolone, hydroxychloroquine and cyclosporine was started. Prednisolone was gradually decreased, and he discharged on day 48 of admission. [Consideration] In case of HLH, screening for autoimmune disease is important. Also, we considered that aggressive multi-target therapy from early stage of disease is useful in childhood SLE with severe organ damage.

P2-253
A 13-year-old boy with newly diagnosed SLE who had developed an abscess of the gluteus maximus muscle

Tadayasu Kawaguchi1,2, Yasuji Inamo1,2, Yukihiko Fujita1,2
1Department of Pediatrics and Child Health, Nihon University School of Medicine, 2Department of Pediatrics and Child Health, Nihon University Itabashi Hospital

Conflict of interest: None

[Aim] Patients with SLE are easily infected by an immunodeficiency of the disease during clinical courses. We report a newly diagnosed SLE who had developed an abscess of the gluteus maximus muscle. [Case report] A 13-year-old boy, was admitted to our hospital with complaints of fever, nausea and diarrhea. Laboratory test results were shown pancytopenia, hypocomplementemia, proteinuria, and coombs positive. Abdominal CT revealed edema of small intestine. He was made a diagnosis as SLE, lupus enteritis, lupus nephritis, and hemolytic anemia. He was treated two times methylprednisolone pulse therapy. He complained left hip pain caused by an abscess of the gluteus maximus muscle after second pulse therapy. He was performed incisional drainage and antibiotic therapy. Staphylococcus aureus was detected in the culture of the abscess. The abscess gradually improved by incisinal drainage. [Conclusion] Patients with SLE are easily infected by an immunodeficiency of the disease during clinical courses. However, it is rarely, patients with newly diagnosed SLE developing infections, especially, an abscess of the gluteus maximus muscle.

P2-254
A case of C1q nephritis with autoimmune hemolytic anemia

Noriko Kinjo, Kazuya Hamada, Koichi Nakanishi
Department of Child Health and Welfare (Pediatrics), Graduate School of Medicine, University of the Ryukyus

Conflict of interest: None

[Background] There are few studies of C1q nephropathy with childhood SLE. In this case, autoimmune hemolytic anemia (AIHA) was diagnosed subsequent to C1q nephritis. NS. C1q nephropathy was diagnosed by the renal biopsy. [Case] 14 years old, female. [Present Illness] Two years before the visit, thrombocytopenia observed during the treatment of right knee suppurrative bursitis (50,000/µl). Idiopathic thrombocytopenia, AIHA was suspected. Thereafter, butterfly erythema, hemolytic anemia, lymphocytopenia, thrombocytopenia, hypomyacolonemia were observed. Systemic lupus erythematosus (SLE) was diagnosed, according to the classification criteria. After steroid therapy, the patient visited to our hospital. In our laboratory tests, antinuclear antibodies (ANA) and other autoantibodies were also negative. Anemia and thrombocytopenia improved, subsequently developed NS, diagnosed C1q nephropathy. Urinary protein/urinary creatinin value was improved from 5.0 to 0.6 g/Gr by steroid and cyclosporine combination therapy. [Discussion] We experienced a case of NS during the treatment of AIHA, leading to the diagnosis of C1q nephropathy. The appearance of autoantibodies may change the pathological condition, and it is necessary to carefully observe the course.
P2-255
Clinical features of systemic onset type juvenile idiopathic arthritis presenting chronic articular course in adulthood
Yumi Tani1,3, Takayuki Kishi1,3, Takako Miyamae1,3, Eiichi Tanaka2, Satoru Nagata1, Hisashi Yamanaka1,2
1Pediatric Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University Hospital, 2Department of Rheumatology, Tokyo Women’s Medical University, School of Medicine, 3Department of Pediatrics, Tokyo Women’s Medical University, School of Medicine

Conflict of interest: None

Onishi, Kiyoshi Takasugi
Sawada, Kenichiro Matoba, Akihiro Yamada, Kazuo Jouyama, Makoto Ayuko Sogabe, Yasuaki Okuda, Atsushi Kondo, Yosuke Murata, Naoya

P2-256
A case report: improvement of sternoclavicular joint pain by tonsillectomy for tonsillitis-related reactive arthritis
Mao Suzuki, Yuya Takakubo, Suran Yang, Akiko Sasaki, Yuta Suzuki, Hiroharu Oki, Yasushi Naganuma, Hiroshi Orui, Michiaki Takagi Department of Orthopedic Surgery, Yamagata University Faculty of Medicine

Conflict of interest: None

Tonsillitis-related arthritis has been defined as an acute sterile arthritis developing after or during infection in other parts of the body. Tonsillar tonsillitis is one of effective treatments for tonsillitis-related disease. We have reported a case of 13-year-old woman suffering from reactive arthritis related to tonsillitis. She has complained her sternoclavicular and knee joint pain at the first visit of our hospital. Although she has received NSAIDs, her joint pain and swelling became worse. C-reactive protein was 0.1mg/dl, anti-cyclic citrullinated peptides antibody <0.6 U/ml, anti-nuclear antibody <40, anti-streptolysin O (ASO) < 20 IU/ml at her first visit for our hospital. Her tonsil was swelling since she was 2-year-old. CT scanning revealed the thickening of her right sternoclavicular joint. She was introduced to departments of otolaryngology and pediatrics of our hospital, and diagnosed with chronic tonsillitis. She has received tonsillar tonsillitis. One month after the surgery, her joint pain and swelling have improved. However, one year after the surgery, she has still complained both sternoclavicular joint pain, careful management and observation are required.

P2-257
A Case of Localized Lung Amyloidosis Accompanied by Rheumatoid Arthritis that Required Differentiation from Metastatic Lung Cancer
Ayuko Sogabe, Yasuaki Okuda, Atsushi Kondo, Yosuke Murata, Naoya Sawada, Kenichiro Matoba, Akihiro Yamada, Kazuo Jouyama, Makoto Onishi, Kiyoshi Takasugi Center for Rheumatic Disease, Dohgo Spa Hospital

Conflict of interest: None

Case report: A 81-year-old woman suffering from rheumatoid arthritis and Sjögren’s syndrome for 34 years was hospitalized for rehabilitation. Multiple anti-rheumatic drugs have not been effective, therefore her joint disease progressed gradually. Now she takes tacrolimus 2mg/day and arthritis is well controlled. The screening CT scan showed ileocecal tumor (4cm in size) with enlarged lymph nodes around, and multiple nodules (2.5cm at maximum) in both lung fields. Colonoscopy and biopsy revealed poorly differentiated caecum adenocarcinoma. As for lung nodules, bronchoscopy was carried out in order to distinguish mycosis from metastatic lung cancer. Histological examination showed not malignancy but amyloidosis, and immunostaining proved it type AL amyloidosis. Since there was no symptom or finding to suspect amyloidosis in other organs, it was supposed to be lung localized amyloidosis.

Conclusion: The great majority of lung amyloidosis is type AL, and type AA is very rare. Patients suffering from chronic inflammatory disease sometimes accompany amyloidosis other than type AA. Immunosuppressing was effective in this case.

P2-258
Analysis of AA proteins in amyloid from biopsy samples
Kouhei Kawaguchi1,2, Yasuaki Okuda3, Takeshi Kuroda4, Toshiyuki Yamada1
1Department of Clinical Laboratory Medicine, Jichi Medical University, Tochigi, Japan, 2Biochemical Research Laboratory-1, Eiken Chemical CO., LTD., Tochigi, Japan, 3Department of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Ehime, Japan, 4Health Administration Center, Niigata University, Niigata, Japan

Conflict of interest: None

Object
Systemic inflammation in patients with systemic juvenile idiopathic arthritis (sJIA) is suppressed in a long-term follow up duration, however some patients developed to progressive arthritis without systemic inflammation. To clarify the difference of treatment effect between systemic onset arthritis and rheumatoid arthritis (RA) is important from the viewpoint of transition from pediatric to adult care. [Methods] A retrospective review of functional disability, complications, and efficacy of medication was performed in patients with systemic onset arthritis. [Results] Six patients (3 females) were identified. The median (range) age at onset of sJIA was 4 (0.6-11.0) years, and at evaluation was 29 (20-48) years. All patients received corticosteroid most of the time of follow-up. Four patients received tocilizumab, and 1 received etanercept without effectiveness. Three complicated with hip arthritis could not walk due to severe functional disability. All patients had short stature, 3 patients complicated bone fracture, and 1 died cause of renal amyloidosis. [Conclusions] The pathology of adulthood systemic onset arthritis is different from that of RA and close to that of sJIA. It is desirable to apply medication after consideration.

P2-259
A case of Rosai-Dorfman disease in which steroids responded to protein-losing gastrointestinal disease associated with gastrointestinal amyloidosis
Ryota Okazaki, Yuriko Sueda, Yoshihiro Funaki, Tomoya Harada, Miki Takata, Yasuhiro Tamimoto, Akira Yamasaki Division of Medical Ontology and Molecular Respirology, Tottori University Faculty of Medicine

Conflict of interest: None

Rosai-Dorfman disease (RDD) is a rare non-neoplastic histiocytic proliferative disorder of unknown origin characterized by lymphadenopathy and extranodal lesion. A 63-year old man. In X-3 year, a chest abnormal shadow was pointed out at medical examination. In X-1 year, he visited our hospital because a right lung nodule shadow was increasing in the chest CT examination. PET-CT showed high accumulation in the paranasal sinuses, pulmonary nodule shadows, prostate glands, cervical lymph nodes, and bones. Biopsy of the cervical lymph node, paranasal sinuses, prostate was performed, and revealed histiocyte infiltration S-100 (+), CD68 (+), CD1 (-) by immunohistochemical staining and immunochemistry. We diagnosed with RDD. In X year, he had fever, abdominal pain, diarrhoea, anorexia, and was admitted to our hospital. Both biopsies of small intestine and colon by colonoscopy were positive for Congo red staining and diagnosed as amyloidosis. Protein leakage scintigraphy was diag-
_progression of the sarcopenia.

P2-260
Tocilizumab decreased urinary protein excretion by improving AA amyloidosis secondary to RA and might help to suppress CKD worsening

Daisuke Kanai, Yuji Uzawa, Yuji Yoshioka, Akiko Suda, Shohei Nagaoka
Yokohama Minami Kyousai Hospital

Conflict of interest: None

We report a case of an 81-year-old lady whose RA was diagnosed at 49 years old. She was treated with oral steroids, sulfasalazine and methotrexate, but her disease activity remained high. She was given prophylactic joint replacement operations for both knees and elbows between 51 and 61 years old. At 78 years old, she visited our hospital first time. Her condition of RA was in stage IV and class III, and SDAI was 11.45. She also had CKD, which was in stage G3A2 (eGFR 40.1, urinary protein/creatinine ratio (U-PCR) 0.25g/ger). We started to use goltimib 50mg s.c. every 4 weeks. SDAI decreased to 5.58. One year later from her first visit, she got a left femoral neck fracture during traveling and was admitted to get operated for joint replacement in a hospital there. Goltimub was not used during admission. Four months later, she came back to our hospital, and SDAI increased to 13.91 and her renal function got worse (eGFR 28.2, U-PCR 4.11g/ger). We obtained biopsy samples of her kidney and parotidoduodenal mucosa. AA amyloid deposits were detected in both samples. Systemic AA amyloidosis was diagnosed. Tocilizumab 8mg/kg IV every 4 weeks was started. Four weeks later, serum amyloid A level got to within the normal range, and at 3months SDAI was 0.52, U-PCR 1.88, at 14 months U-PCR 0.77.

P2-261
Assessment of the prevalence of the sarcopenia in rheumatoid arthritis: Influence of disease activity and insulin-like growth factor-1

Tsuneo Watanabe1, Koichi Shinoda1, Masao Takemura2, Takahide Ikeda3, Hiroyuki Morita1
1Division of Clinical Laboratory, Gifu University Hospital, 2Advanced Disease System Research Laboratory, Fujita Health University Graduate School of Health Science, 3Department of General Internal Medicine, Gifu University Hospital

Conflict of interest: None

[Object] The aim of this study was to evaluate the relationship between disease activity, insulin-like growth factor-1 (IGF-1), and prevalence of the sarcopenia in patients with rheumatoid arthritis (RA). [Methods] Twenty-two patients, who met the 2010 ACR/EULAR criteria were enrolled in this study from February 2018 to June 2018. The subjects were classified into two groups according to the DAS28-CRP: remission group (n = 10, 61.5±13.1 years) when DAS28-CRP<2.3, and low disease activity group (n = 10, 61.5±13.1 years) when DAS28-CRP≧2.3. The incidence of sarcopenia increased in the LDA group as compared with the remission group (n = 29 pre-frailty and 4 normal. Stage, class, duration, DAS28CRP and HAQ score were highest in frailty-group and higher in patients with criteria was 6 weight loss, 44 exhaustion, 20 low physical activity, 33 low grip strength, 16 slow walking speed. 26 patients were evaluated as frailty, 29 pre-frailty and 4 normal. Stage, class, duration, DAS28CRP and HAQ score were highest in frailty-group and higher in pre-frailty group than normal group. Prevalence of frailty was 48.7% in patients with DAS28CRP≧2.7. In patients with HAQ≧1, prevalence of frailty was 80% and 95% of frailty cases had exhaustion. [Conclusions] In patients with RA, prevalence of frailty was very high and functional impairment influenced on not only physical frailty but also mental frailty.

P2-262
Investigation of steroid-induced osteonecrosis occurrence site by MRI

Kento Nawata, Junichi Nakamura, Shigeo Hagiwara, Yuya Kawarai, Masahiko Sugano, Kensuke Yoshino, Satoshi Yoh
Department of Orthopaedic Surgery, Graduate School of Medicine Chiba University

Conflict of interest: None

[Object] The purpose of this study was to investigate the site of glucocorticoid-induced osteonecrosis in individual cases and to confirm the effectiveness of the MRI screening method in our hospital. [Methods] We investigated 100 patients with 800 joints who received screening of MRI in all of their hip, knee, shoulder and ankle joints after systemic glucocorticoid therapy from 1986 to 2018. The patient’s age at the time of initial glucocorticoid therapy, the proportions of female patients, the dosage of glucocorticoids, the incidence rate of osteonecrosis and the site of osteonecrosis were investigated. [Results] The patient’s mean age was 36.2 years. The ratio of male, and also the highest daily glucocorticoid dose were significantly higher in osteonecrosis group than in the non-osteonecrosis group. The incidence of osteonecrosis was 67% in the hip, 44% in the knee, 18% in the ankle, and 14% in the shoulder. If osteonecrosis was not observed in neither the hip or knee, osteonecrosis did not occur in neither shoulder or knee. However, when osteonecrosis was observed in the shoulder or foot, osteonecrosis was always observed at least one place in the hip or knee. [Conclusions] MRI imaging of both hip and knee is considered effective as a screening method.

P2-263
Frailty in patients with rheumatoid arthritis

Kazushi Haraguchi
Department of Orthopaedic Surgery, Kenwakai Ootemachi Hospital, Kitakyushu, Japan

Conflict of interest: None

[Object] Recently, frailty came to attract interest widely. Aged patients with RA are increasing and frailty is an important problem in RA. We performed an investigation about frailty in patients with RA. [Methods] 59 patients were performed questionnaire and measurement of physical functions based on Fried’s criteria: (weight loss, exhaustion, low physical activity, low grip strength, slow walking speed). Prevalence of frailty (over 3 criteria), pre-frailty (1 or 2 criteria), normal (no criterion) were evaluated and relations of frailty and Steinbrocker stage and class, duration, DAS28CRP and HAQ score were examined. [Results] Number of patients with criteria was 6 weight loss, 44 exhaustion, 20 low physical activity, 33 low grip strength, 16 slow walking speed. 26 patients were evaluated as frailty, 29 pre-frailty and 4 normal. Stage, class, duration, DAS28CRP and HAQ score were highest in frailty-group and higher in pre-frailty group than normal group. Prevalence of frailty was 48.7% in patients with DAS28CRP≧2.7. In patients with HAQ≧1, prevalence of frailty was 80% and 95% of frailty cases had exhaustion. [Conclusions] In patients with RA, prevalence of frailty was very high and functional impairment influenced on not only physical frailty but also mental frailty.

P2-264
Three azathioprine hypersensitivity syndrome cases without cutaneous manifestation

Yuuske Nakamichi, Naoto Yokogawa, Naoki Tanomogi, Masashi Iida, Shuhei Sano, Michiru Kina, Nanase Honda, Tatsuo Mori, Eisuke Takamasu, Kae Onishi, Yuji Miyoshi, Takayasu Kise, Masako Utsunomiya, Yoshiki Nagai, Kota Shimada, Shoji Sugii
Tokyo Metropolitan Medical Center

Conflict of interest: None

[Introduction] Azathioprine (AZA) Hypersensitivity Syndrome (AHS) is dose independent side effect that presents within few weeks. AHS can present with only systemic symptoms and without cutaneous symptoms. [Case 1] A 42-year-old woman with MCTD admitted with fever and shock without skin symptoms. 16 days before this admission, AZA 50 mg/day was initiated for her worsening of MCTD. The completely resolution after 2 days of AZA discontinuation is suggestive of AHS. [Case 2] A 24-year-old woman with MCTD presented with fever and shock without skin symptoms. 7 days ago, AZA 25 mg/day was started for MCTD maintenance therapy. AZA was discontinued at the time of
the shock. Over the 2 days, her symptoms were disappeared. This made a diagnosis of AHS. [Case 3] A 79-year-old man with ANCA associated vasculitis (AAV) presented with fever and shock without skin symptoms. 5 days ago, AZA 50 mg/day was started for AAV maintenance therapy. One day ago, AZA was discontinued due to allopurinol concomitant. He made an improvement over 24h. The other cause of these symptoms was excluded. A clinical diagnosis of AHS was made. [Discussion] AHS should be considered in a patient presenting with only constitutional symptoms without skin manifestation who starts to take AZA within several weeks.

P2-265
Clinical experience of recombinant thrombomodulin and heparin combination therapy for pediatric patients with disseminated intravascular coagulation

Akira Oshima
Department of Pediatrics, Yokohama City University School of Medicine

Conflict of interest: None

[Object] We investigate the efficacy and safety of recombinant thrombomodulin (rTM) and heparin combination therapy for pediatric patients with disseminated intravascular coagulation (DIC). [Methods] In this single-center, retrospective study, we evaluated 11 patients with DIC, who received rTM and heparin combination therapy between January 2013 and October 2018. DIC was diagnosed according to the acute phase diagnostic criteria established by the Japanese association for acute medicine. We excluded the DIC associated with malignant diseases. [Results] The age at the start of treatment was median (range) 3 (1-10) years and male patients were 4 (50%). There was 7 patients with underlying disease, of which 7 were hemophagocytic lymphohistiocytosis (HLH), 1 was Kawasaki disease. As the cause of HLH, there were 6 infectious diseases, and was 1 paroxysmal cold hemoglobinuria. The rTM administration duration was 4 (1-5) days, and DIC scores before and after treatment were 5 (4-8) and 0 (0-4), respectively. DIC withdrawal rate was 62.5%. One adverse event related to bleeding tendency was mild nasal bleeding. [Conclusions] This study suggested rTM and heparin combination therapy was safe for DIC in pediatric patients. To evaluate efficacy of combination therapy, we need further study.

P2-266
A case report of thoracic hypertrophic pachymeningitis complicated by eosinophilic granulomatosis with polyangiitis

Isao Matsuura
Department of Rheumatology, Tokyo Women’s Medical University

Conflict of interest: None

A 76-year-old male with asthma and chronic sinusitis was referred to our institution complaining fever and right foot drop. Laboratory examination showed high CRP, eosinophilia and MPO-ANCA positive. Motor axonal neuropathy of right peroneal nerve was observed in nerve conduction study and he was diagnosed with eosinophilic granulomatosis with polyangiitis (EGPA). His MMT of right calf was improved after high dose prednisolone and intravenous immunoglobulin therapy. In 10 months, he visited us with chest and back pain at rest and bilateral leg weakness. He had hypoaesthesia below chest and paraparesis. Epidural T2 high signal at the level Th1-2 was observed on MRI. He was diagnosed with epidural abscess. Laminectomy was performed for decompression and thickening of dura mater was observed. Pathology report showed fibrotic hypertrophy of dura mater and he was finally diagnosed with thoracic hypertrophic pachymeningitis (HP). Steroid pulse and cyclophosphamide pulse therapy improved his paralyzsis gradually. We often experience secondary HP following vasculitis, however spinal lesion is relatively rare. Furthermore, a few cases of thoracic lesion were reported in microscopic polyangiitis and granulomatosis with polyangiitis but EGPA. We discuss this case referring to literature.

P2-267
Rheumatoid vasculitis of coronary arteries found by autopsy - a case report-

Tomo Oyakawa, Chintusu Azuma, Fuminori Kanaya
Department of Orthopedics, University of Ryukyus Okinawa Japan

Conflict of interest: None

[Objectives] We report a case with rheumatoid arthritis (RA) of coronary arteries found by autopsy. [Case] A 68-year-old man was suffered from RA for 20 years. He had many medical complications. He was suffered from septic arthritis of the right ankle three months ago. He was transferred to our hospital for the treatment of RA arthritis. [Findings on admission] Das28-ESR:7.81, crp:16.82mg/dl, esr90mm, mmp-3:7.17mg/ml. [Image findings] chest x-ray: both pleural effusion, electrocardiogram: sinus rhythm, heart supersonic wave: left ventricle wall motion was normal. [On admission ra therapy] Prednisolone 8mg/day, salazosulfapyridine 1000 mg/day he could treated with steroid pulbs and abactecept. Unfortunately, he suddenly died at 70 days after hospitalization. Myocardial infarction caused by the rheumatoid vasculitis of coronary arteries was diagnosed by autopsy. There was no evidence of vasculitis in contrast et at 40 days after hospitalization. [Discussion] The coronary vasculitis is difficult to find out with a blood test and the diagnostic imaging. Rheumatoid vasculitis of the coronary arteries could be considered one of cause of sudden death. It is necessary to cure in consideration of a merger of the vasculitis in the ra patients of the high disease activity.

P2-268
A case report of rheumatic meningitis occurring while RA treatment with Golimumab

Masamitsu Natsuneda
Department of Internal Medicine, Rheumatic Disease Center, Mabi Memorial Hospital, Kurashiki, Japan

Conflict of interest: None

A 75-year-old female, she visited our hospital due to exacerbation of polyarticular pain. It was characterized as DAS 28 ESR 4.4 at the first visit, and initiated Golimumab (GLM) 50 mg from February 7. On March 7, the PSL was reduced to 1 mg with the increase in GLM 100 mg. Cognitive dysfunction and right incomplete paralysis appeared on both left and right paralysis on March 15th. Head MRI revealed meningeal FLAIR and DWI high signal on right temporal parietal lobe. Improvement of various symptoms was observed by administration of antibiotics as sterile meningitis. As joint articular swelling and pain worsened in April, tocilizumab (TCZ) 8 mg / kg was administered on April 16 as primary care for rheumatoid arthritis. The slight convulsion of the left half body appears and gradually worsens on May 11. Treatment with steroid pulses was performed twice as treatment of rheumatoid meningitis and very effective. PSL 30mg maintenance therapy was started and returned to our hospital. As a gradual decrease of PSL, multijoint swelling and pain relapsed TCZ subcutaneous injection was performed, but no sign of neurological aggravation was observed. Rheumatic meningitis during administration of biological products is reported with consideration on report.

P2-269
A case of rheumatoid arthritis in which Tocilizumab was effective against necrotizing scleritis

Keichi Yoshimoto, Taro Miyagawa
Department of Internal Medicine, Kurobe City Hospital

Conflict of interest: None

A 50-year-old woman began to complain polyarthralgia from 2012 and was diagnosed as rheumatoid arthritis (RA). She was treated with 6mg/week of Methotrexate (MTX) and 2mg/day of prednisolone (PSL). Although her polyarthralgia was controlled well, In the summer of 2017, she consulted a nearby ophthalmologist with both eyes congested. She was diagnosed as scleritis, and then, received Betamethasone instillation but did not improve, so, she was introduced to our department of ophthalmology. In addition to topical treatment, she received oral administration
of prednisolone 20 mg but did not improve, then, intravenous adminis- 
tration of infliximab (IFX) 3 mg / kg was started. Because sceritis pro-
gressed in spite of administration of IFX, Tocilizumab (TCZ) subcutane-
ous injection was started instead of IFX. As a result, sceritis was 
dramatically improved. Conclusion: Scleritis is a rare but sometimes 
complicated with rheumatoid arthritis. Although severe sceritis presents 
of danger of blindness, recently effectiveness of biological agent were 
reported. In this case, the anti-TNFα inhibitor was ineffective but the anti-
IL6 receptor antibody was effective. This phenomenon is interesting for 
examining the pathogenesis of sceritis related to RA.

P2-270
A case of suspected myelitis during etanercept administration
Daisuke Nakashima, Atsunori Tokushige, Takashi Imagama, Kazushige 
Seki
Department of Orthopaedic Surgery, Yamaguchi University Graduate 
School of Medicine Ube, Yamaguchi, Japan
Conflict of interest: None

[Object] Demyelinating diseases and myelitis are reported as side ef-
cfects of TNF inhibitors. We report the case of bladder and bowel dysfunc-
tion during etanercept administration and it suspected myelitis in spinal 
cord compression site by ossification of posterior longitudinal ligament 
(OPLL). [Case] A 45 year old woman was treated with etanercept to RA. 
She got her right back pain, so she pointed out as OPLL on T3/4. She was 
admitted to our hospital due to CRP:15.19 mg/dl, numbness both legs, 
bladder and bowel dysfunction. High signal intensity change of the spinal 
cord of T3/4 with MRI worsened with symptoms worsening. She was 
discontinued from etanercept administration, bladder and bowel dysfunc-
tion improved after the start of oral administration of PSL:15mg, and 
numbness gradually disappeared. Thereafter the high signal intensity 
change of the spinal cord was relieved with MRI. [Conclusions] In this 
case, clinically isolated syndrome (CIS) and myelitis were suspected be-
cause the high signal intensity change of the spinal cord was relieved by 
stoping etanercept, and there was no relapse of the symptoms without 
abnormalities in MRI of other parts. In the future, careful follow-up ob-
servation is necessary, and treatment of RA other than TNF inhibitor is 
necessary.

P2-271
Autosomal dominant polycystic kidney disease (ADPKD) combined 
with polyarthritis
Juniko Kawata
Kawata-Junko Clinic
Conflict of interest: None

[Case] A 70-year-old woman developed polyarthritis. Her mother and 
her brother had PKD. On physical exam, she had arthritis in the third MP 
joint, both wrists, and both hips and left ankle. Blood pressure was 
133/88mmHg, CRP 9.01mg/dl, GPT 65 U/L, γ-GTP86U/l, 
Crest1.15mg/dl and anti-CCP antibody 10.2U/ml. Urine and blood culture 
enabled fatigue and anasarca. On physical examination, she had a newly el-
levated blood pressure of 164/76 mmHg with new pitting edema of the bi-
ateral lower extremity. Laboratory examinations revealed profound 
proteinuria (9428 mg/day) of nephrotic syndrome. Histopathological ex-
amination of renal biopsy specimens showed minimal change nephoropa-
tic. Proteinuria and anasarca were new. On physical examination, she had a newly el-
levated blood pressure of 164/76 mmHg with new pitting edema of the bi-
ateral lower extremities. Laboratory examinations revealed profound 
proteinuria (9428 mg/day) of nephrotic syndrome. Histopathological ex-
amination of renal biopsy specimens showed minimal change nephropas-
tic. Almost complete resolution of the MCNS was achieved by 
discontinuation of IGU and CZP, and initiation of steroid therapy. Mem-
branous and amyloid nephropathy in RA patients associated with nephrit-
ic syndrome are found in high incidence in literature. There have been no 
reports from Japan of the occurrence of MCNS caused by IGU or CZP 
administration in RA patients. Therefore, this case was considered to be 
very uncommon and worthy of reporting.

P2-274
Is it time to rethink the routine prescription of proton pump inhibi-
tors in rheumatic diseases? : A Retrospective Case Series
Yasuyuki Suyama, Kiyofumi Hagiwara
JR Tokyo General Hospital
Conflict of interest: None

[Object] Steroid is generally not considered to increase the risk of 
gastrointestinal (GI) bleeding except for intensive care unit (ICU) adminis-
tration and concurrent use of nonsteroidal anti-inflammatory drugs 
(NSAIDs) or anticoagulants. On the other hand, in clinical practice, pro-
ton pump inhibitors (PPIs) may be routinely prescribed with or without 
risk factors when initiating steroid therapy. [Methods] We retrospectively 
evaluated patients who were newly diagnosed as having rheumatic dis-
cases and initiated steroid treatment without PPIs from April 2014 to 
March 2018. We defined the day starting the treatment as start date, and 
the 180th to 280th days as the evaluation date. In order to exclude bias 
due to changes in dose of corticosteroids, cases in which were changed 
dose of corticosteroid exceeded 5 mg during the period were excluded. 
[Results] DPP-4 inhibitor group, SGLT-2 inhibitor group, and intensive 
insulin therapy group were included 18, 6, and 13 patients, respectively. 
The median (IQR) of changes of HbA1c were -0.55 (0.54), -0.50 (0.60), 
and -0.95 (1.45), respectively, and there were no statistical difference. 
[Conclusion] DPP-4 inhibitors and SGLT-2 inhibitors decreased -0.5 to 
-0.6 % of HbA1c for steroid diabetes mellitus in patients with rheumatic 
diseases. Too many biases were included in current study, however our 
results showed the possibilities that the effectiveness of DPP-4 inhibitors 
and SGLT-2 inhibitors for steroid diabetes mellitus.

Conflict of interest: None

A 74-year-old female patient has been treated rheumatoid arthritis (RA) 
with iguratimod (IGU) 25mg daily started 2 years prior to presenta-
tion, and certolizumab pegol (CZP) 200mg subcutaneously twice a month 
started 4 years prior to presentation. On the end of August, she had sud-
denly fatigue and anasarca. On physical examination, she had a newly el-
levated blood pressure of 164/76 mmHg with new pitting edema of the bi-
ateral lower extremities. Laboratory examinations revealed profound 
proteinuria (9428 mg/day) of nephrotic syndrome. Histopathological ex-
amination of renal biopsy specimens showed minimal change nephropas-
tic (MCNS). Almost complete resolution of the MCNS was achieved by 
discontinuation of IGU and CZP, and initiation of steroid therapy. Mem-
branous and amyloid nephropathy in RA patients associated with nephrit-
ic syndrome are found in high incidence in literature. There have been no 
reports from Japan of the occurrence of MCNS caused by IGU or CZP 
administration in RA patients. Therefore, this case was considered to be 
very uncommon and worthy of reporting.
per-off was achieved in 53 patients (63.1%). The mean follow-up period was 10.5 months (2-41 months) in total, and 9.6 months (3-27 months) in steroid tapered-off group and 12 months (2-39 months) in steroid contin-
ue group. Finally, there was no complication of gastrointestinal bleeding during the period. [Conclusions] Routine PPIs prescription could not be required when initiating steroid therapy in patients with rheumatic dis-

cases who do not have risk factors of GI bleeding except for steroid use.

P2-275
Parvovirus B19 infection: a rare case of splinter hemorrhage and nodular erythema.
Masahiro Minoda, Kiyoharu Muranaka
Suwa Central Hospital Chino, Nagano, Japan
Conflict of interest: None

[Case] A 57-year old female presented with 7 days of fever and leg pain. She had a 1-week history of fever and cough and 4days history of right ankle joint and left knee joint pain. Physical findings showed arth-
ritis in the right and left knee joints, and tenderness on both elbows. Skin eruption was found splinter hemorrhage accompanied by pain on both fingernails and erythemas with tenderness on the front of both legs were observed. We evaluated it as acute arthritis accompanied by splinter hem-
orrhage and nodular erythema due to a viral infection and infective endo-
carditis. We conducted blood test, blood culture, synovial fluid culture and echocardiography examinations. She was admitted to our hospital and celecoxib was administered. After 5 days, blood test revealed posi-
tive anti-HPVB 19 IgM antibody 5.12 and diagnosed as HPV-B19 infec-
tion. Day 7 hospitalization, symptoms disappeared. All cultivation tests and transthoracic echocardiography were negative. [Clinical Signifi-
cance] In early stage of HPV-B19 infection, it causes a variety of symp-
toms such as fever and headache due to viremia. In late stage, it causes infectious erythema and arthritis due to impair by immune mechanism. We report HPV-B19 is rare conditions characterized by splinter hemor-
rhage and nodular erythema.

P2-276
A case report of myalgia by Human Parechoviruses 1
Fumiya Kitamura, Tatsuya Araai, HiroYuki Yoshida, Yoshihiro Nakamura, Hirotaka Ikai, Tsuyoshi Watanabe, Mari Yamamoto, Yukari Murai, Koji Takahashi, Naohi Takizawa, Waka Kokuryo, Yoshiro Fujita
Department of Rheumatology, Chubu Rosai Hospital
Conflict of interest: None

Introduction: HPeVs have been identified worldwide. HPeVs are re-
sponsible for multiple clinical syndromes involving epidemic myalgia. Case report: A 29-year-old male admitted to the hospital for muscle pain and weakness. On admission day, he also complained diarrhea. He went to Indonesia 6 weeks prior to admission and works in airport. The labora-
tory date showed that WBC count (21,600/μL), CRP (29.35mg/dL) and LFT (GPT 371U/L, ALP 343 U/L) were elevated. GI doctor diagnosed acute bacterial enteritis and treated with cefmetazole followed by levo-
foxacarin His symptoms persisted for one week despite treatment. We were consulted 8 days after admission. At that time, he was still febrile and difficult to move because of muscle pain. All lab tests for infection were negative including blood culture, HBV, HCV, HIV, CMV, EBV, Syphilis. We consider that he was myalgia caused by any virus. We start-
ed enough dose of acetaminophen and stopped using antibiotics. He was afibrile on the next day and his muscle pain was disappeared 4 days later. After He discharged, we received a result of antibody for HPeVs (256). Conclusion: Patients with acute muscle pain should be aware that HPeVs can cause epidemic myalgia. It is also important that rule out any other infection and auto immune disease.

P2-277
The current situation of Pneumocystis pneumonia prevention in sys-
temic lupus erythematosus: A study of the multicenter registry
LUNA
Ryusuke Yoshimi1, Yosuke Kunishita1, Chiharu Hidekawa1, Natsuki Sakurai1, Masaaki Mitsuhashi1, Yamiko Sugiyama2, Daiga Kishimoto2, Yuki Iizuka1, Takakki Komiya1, Hideto Nagai1, Naoki Hamada1, Naomi Tsuvida1, Yutaro Soejima1, Reikou Kamiyama1, Kouji Kobayashi2, Yukiko Asami1, Yohei Kirino1, Nobuyuki Yajima1, Ken-etsu Sada1, Kunihiro Ichinose1, Toshiaki Miyamoto2, Shigeru Ohno2, Hideaki Nakajima1
1Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, 2Center for Rheumatic Disease, Yokohama City University Medical Center, Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Phar-
maceutical Sciences, 2Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, 3Department of Rheumatology, Seirei Hamamatsu General Hospital
Conflict of interest: None

[Object] To investigate the current situation of prophylaxis for Pneumocystis pneumonia (PCP) using a multicenter registry of systemic lupus erythematosus (SLE). [Methods] We collected the data as to the method of PCP prophylaxis from the SLE patients registered in the LUNA registry, and analyzed its relationship with the patient’s back-
ground. [Results] Among 589 patients, PCP prevention was performed in 97 (16%), and ST was used in all cases (ST group). The prednisolone dose was larger in the ST group than in the non-ST group (12.5 ± 10.3 vs 5.8 ± 5.5 mg/day, p = 4.7 x 10^-14). Mycopropholate mofetil, azathioprine and cyclosporine were used more commonly in the ST group. Serum IgG level was significantly lower in the ST group than in the other (1,220 ± 548 vs 1,457 ± 488 mg/dL, p = 4.0 x 10^-14), but there were no differences in the numbers of leucocyte or lymphocyte. One ST tablet was adminis-
tered daily in 32%, every other day in 6.5%, 3 times per week in 29%, twice a week in 13%, and weekly in 19%. BMI was lower in the patients not administered daily as compared with those administered daily (20.2 ± 2.0 vs 24.2 ± 3.3 kg/m², p = 6.7 x 10^-7). [Conclusions] The dose decrease of ST tended to be done in patients with low BMI. We should consider the optimization of PCP prevention.

P2-278
Treatment for Pneumocystis Pneumonia of Patients with Connective Tissue Disease
Kengo Akashi, Sadao Jinno, Motoko Katayama, Mai Yamashita, Yoko Nose, Yoshikazu Fujikawa, Takumi Nagamoto, Yuzuru Yamamoto, Hirokata Yamada, Yoshiside Ichise, Ikuko Naka, Takaichi Okano, Yo Ueda, Sho Sendo, Akira Onishi, Jun Saegusa, Akio Morinobu
Kobe University Graduate School of Medicine, Kobe, Japan
Conflict of interest: None

[Purpose] To review the treatment for pneumocystis pneumonia (PCP) of patients with connective tissue disease (CTD) in our hospital. [Method] We collected the medical charts of the PCP patients with CTD from April 2014 to March 2018. PCP was diagnosed with clinical cours-
es, CT images, serum β-D-glucan elevation. [Result] Twenty-five patients with PCP were investigated. They had been treated with immunosuppres-
sive agents because of rheumatoid arthritis in 13 cases, ANCA-associated vasculitis in 7 cases, dermatomyositis in 3 cases and others in 2 cases. Sixteen cases had co-existing lung disease. Seven patients had fatal clini-
cal courses because of PCP. Glucocorticoid were administered for all pa-
tients as PCP treatment. As anti-fungal agents, sulfamethoxazole/trime-
thoprim (ST) was used in 17 cases, pentamidine (PEN) for 8 cases, and other agents because of rheumatoid arthritis in 13 cases, ANCA-associated vasculitis in 7 cases, dermatomyositis in 3 cases and others in 2 cases. Sixteen cases had co-existing lung disease. Seven patients had fatal clini-
cal courses because of PCP. Glucocorticoid were administered for all pa-
tients as PCP treatment. As anti-fungal agents, sulfamethoxazole/trime-

P2-279
Analysis of discontinuation of trimethoprim/sulfamethoxazole (TMP-SMX) as primary prophylaxis in our Rheumatic division
Rimi Iwamoto1, Ayaka Inoue1, Hiroaki Nakagawa1, Midori Kitayama2, Takuro Maeda1, Noriaki Yo1, Chihiro Tanaka1, Takashi Yamane2
1Department of Pharmacy, Kakogawa Central City Hospital, 2Division of Rheumatology, Kakogawa Central City Hospital

Conflict of interest: None

Object: There are a lot of cases to be forced to change or cancel TMP-SMX by allergy. In order to investigate the possibility of re-administration by hyposensitization therapy as we reported JCRI2018, we now report the continuation rate, the reason for termination and the condition at the time of discontinuation of TMP-SMX. Method: In July 2018, we investigated the continuation rate of TMP-SMX which were administered in July 2016 to October 2017, the reasons for termination, age, primary disease, daily prednisolone dosage, presence or absence of immunosuppressive drugs. The condition at the time of discontinuation of TMP-SMX was examined retrospectively from the medical record. Result: Study included 230 patients. Median age was 70 years old. Discontinuation were 103 cases (55.2%), the reason of discontinuation was 3 allergic cases and 12 other harmful phenomena. In all of these cases, the prophylactic drugs were changed to the others. Though the prophylaxes were finished in 51 cases, there were no cases of PCP development. Conclusion: Since the case of discontinuation due to allergy were not tried to hyposensitization therapy, I intend to introduce the therapy for safe and effective PCP prevention as a pharmacist.

P2-280
Investigation of lethal mycosis cases with collagen disease in our department
Tomoki Hayashi, Ryo Takahashi, Nao Oguro, Mika Hatano
Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

Conflict of interest: None

[Object] Deep seated mycosys is sometimes emergence in hematology and will be lethal. To suppress immunity for the treatment in rheumatology, we rarely experienced emergence before. We investigated lethal cases with deep seated mycosis in our department. [Method] Cases suspected with mycosis were collected from fatal cases hospitalized in our department with medical reports from 2007 to 2017. [Result] Four patients (Three females and one male, the average age 62 years) were identified. Two patients were with rheumatoid arthritis. One was with systemic lupus erythematosus. One was microscopic polyangiitis. The classes of mycosis were one pulmonary aspergillosis, one candida pneumoniae, one disseminated cryptoccocosis, and one candidemia. At diagnosis, glucocorticoid (minimum 15 mg/day prednisolone equivalent) was administered in all for the therapy of underlying disease aggravation. [Conclusion] All lethal cases with mycosis were administered minimum 15mg/day prednisolone equivalent glucocorticoid for therapy of underlying disease. Early differentiation of mycosys and early treatment are needed for patients with glucocorticoid.

P2-281
Infections disease as a complication of systemic lupus erythematosus: a cross-sectional study of LUNA registry
Chiharu Hidekawa1, Yosuke Kunishita1, Ryusuke Yoshimi1, Natsuki Sakurai1, Masaki Mitsushashi1, Yumiyo Sugiyama2, Daiga Kishimoto1, Yuki Iizuka1, Takaaki Komiya1, Hideto Nagai1, Naoki Hamada1, Naomi Tsuchida1, Yutaro Soejima1, Reikou Kamiyama1, Kouji Kobayashi1, Yukiko Asami1, Yohei Kirino1, Nobuyuki Yajima1, Ken-eki Sada1, Kunihito Ichinose1, Shigeru Ohno1, Hideaki Nakajima1
1Department of Hematology and Clinical Immunology, Yokohama City University School of Medicine, 2Center for Rheumatic Disease, Yokohama City University Medical Center, 3Division of Rheumatology, Department of Internal Medicine, Showa University School of Medicine, 4Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, 5Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences

Conflict of interest: None

[Object] To examine the relationship between the frequency of infectious disease and patients’ background in systemic lupus erythematosus (SLE) using a multicenter registry. [Methods] Patients registered in the multicenter SLE registry “LUNA” were divided into two groups by presence (SI group) or absence (NI group) of the history of severe infection requiring hospitalization, and patients’ background parameters were compared between the groups. [Results] Of the 618 SLE patients, 255 (41%) had histories of infection, among whom 97 (16%) were pneumonia as the largest number. Eighty-two (13%) had histories of serious infection requiring hospitalization (SI group). There were no significant differences between the SI and NI groups in use of hydroxychloroquine or glucocorticoid and disease activity. The use of tacrolimus (TAC) was significantly less frequent in the SI group as compared to the NI group (7.4 vs 18%, p = 0.029). The drinking rate was significantly lower (4.9 vs 40%, p = 1.0 x 10^{-11}), and the smoking rate also tended to be lower (6.3 vs 13%, p = 0.13) in the SI group as compared to the NI group. The drinking and smoking rates were lower in such cases, suggesting that serious infection history may improve lifestyle.

P2-282
Usefulness of neutrophil-to-lymphocyte ratio (NLR) at the onset of infection to NLR at the baseline ratio for predicting bacterial infections in patients with rheumatoid arthritis treated with tocilizumab
Yoshiki Naga1, Naoki Tanomogi1, Masahiro Iida1, Shuhei Sano1, Yusuke Nakamichi1, Tatsuo Mori1, Nanase Honda1, Michiru Kina1, Eiisuke Takamasu1, Kae Onishi2, Takayasu Kise1, Yuji Miyoshi1, Masako Utsunomiy1, Naoto Yokogawa1, Koto Shimada1, Shoji Sugii1
Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan

Conflict of interest: None

[Objective] The aim of this study is to describe the usefulness of neutrophil to lymphocyte ratio (NLR) for predicting bacterial infection in patients with rheumatoid arthritis (RA) treated with tocilizumab (TCZ). [Methods] We extracted RA patients treated with TCZ who developed any infections between April 2008 and March 2018 from our hospital database. We divided into two groups: bacterial infection group and non-bacterial infection group. We compared the patient backgrounds, CRP, WBC, NLR at the onset of infection and NLR at the onset of infection (post-NLR)/NLR at the baseline (pre-NLR) ratio between two groups. [Results] Of 198 patients who received TCZ, 21 cases developed bacterial infections and 20 cases developed non-bacterial infections. Median CRP level, WBC count, NLR and post-NLR/pre-NLR ratio in bacterial group were significantly higher than non-bacterial group. In ROC curve analysis for predicting bacterial infection, AUC of CRP, WBC, NLR and post-NLR/pre-NLR ratio were 0.787, 0.857, 0.887 and 0.975 respectively. The cutoff value of 2.25 in post-NLR/pre-NLR showed the greatest sensitivity (90.5%) and specificity (100%). [Conclusion] The post-NLR/pre-NLR ratio may be useful for differentiating bacterial and non-bacterial infections in patients with RA treated with TCZ.

P2-283
Clinical evaluation of RA patients who have severe pneumonia during RA medication using biologics
Kayo Hira1, Hiideki Tsuibo1
Osaka Rosai Hospital, Osaka, Japan

Conflict of interest: None

[Object] To elucidate the clinical background of RA patients using biologics (Bio) who have required hospitalization for severe pneumonia. [Methods] Ten patients with RA treated with Bio, whom diagnosed as severe pneumonia requiring hospitalization, between 2014 and 2018 were enrolled and they were female; 9 and male; 1. The mean age was 44.9
years. We evaluated their baseline characteristics which included ages of development, gender, duration of RA, stages (Steinbrocker’s), comorbidities including chronic lung diseases and diabetes mellitus, moreover, the use of MTX and PSL, serum RF, ACPA, KL-6 (U/mL), and β-D glucan (pg/ml) at the start of Bio treatment. [Results] In four patients, their duration of RA was more than ten years at the onset of severe pneumonia. The age of onset of RA was above 65 years old in 7 patients, on the other hand, one patient was 42 years old. 6 patients showed stages III/IV. Comorbidities of lung disease were IP in six and one was complicated with Mycobacterium avium. 6 patients used MTX and two used PSL. [Conclusions] Although the number of this study was so small, we experienced a severe pneumonia patient who was 42 years old. Our results showed that we have to pay attention to RA patients using Bio if they don’t have any risk factors.

P2-284
The consideration of two infection cases in the rheumatoid arthritis patients with total knee arthroplasty during biological therapy
Hirofumi Taki1, Kazuyuki Tobe1
1Department of Immunology and Collagen Disease, Toyama University Hospital, 2Department of Rheumatology, Saiseikai Takaoka Hospital, 3Department of Orthopaedic Surgery, Japanese Red Cross Kochi Hospital, Kochi, Japan

Conflict of interest: None

[Object] We report two infection cases in rheumatoid arthritis (RA) patients with total knee arthroplasty (TKA) after the introduction of biological therapy. [Case 1] A 68-year-old woman with RA underwent a right revision TKA. After that, she started biological therapy with ETN. She had the pain and swelling in her right knee. In the synovial fluid of her knee, group B streptococcus was detected. After the suspension of MTX and ETN, we performed irrigation and debridement of her right knee. After that, the patient received antibiotic therapy and the infection had been healed. [Case 2] A 47-year-old woman with RA underwent a left TKA. After that, she started biological therapy with ETN. She had the pain and swelling from left knee to lower extremity. In the synovial fluid of her knee, no bacterium was detected. So we think cellulitis led the symptoms. We treated this patient by the suspension of ETN and administration of antibiotics. However, CRP was still high. We thought not only cellulitis but also RA caused a high CRP level and improved RA disease control. Finally, inflammatory reaction disappeared. [Discussion] There were some reports which indicated the biological agents increased the infection risk and so we needed to take care of infection during using biological agents.

P2-285
A purulent arthritis case in which prednisolone introduction is also difficult to treat for polyarthritis mainly of sternal arthritis and skin vasculitis
Masatoshi Kawataka1, Hiroyuki Hounoki1, Miho Yamazaki1, Ryoko Asano1, Maiko Okumura2, Satoshi Yamaguchi1, Koichiro Shinoda1, Hirofumi Taki1, Kazuyuki Tobe1
1Department of Immunology and Collagen Disease, Toyama University Hospital, 2Department of Rheumatology, Saiseikai Takaoka Hospital

Conflict of interest: None

[Case] 65 year old male [chief complaint] Polyarticular pain, purpura [medical history] Eruption appears in the limbs, trunk and head from last year, he was treated steroid ointment but the scabbing erosion remained. Since the sternoclavicular pain appeared from January, he was prescribedloxoprofen, but the pain remained. He received skin biopsy. IgG, IgA, IgM, C3c were deposited along the vessel wall and vasculitis was diagnosed. Prednisolone was started with 10mg but increased to 30mg as shoulder joint and back pain appeared, and CRP elevation didn’t improve. He was difficult to move, and hospitalized. In bone scintigraphy, abnormal accumulation was found the right sternoclavicular joint, Th8, L4/5, and the limb joints, and polyarthritis was suspected. Methylcellulose-resistant Staphylococcus aureus was detected in blood culture, and from L4/5 puncture culture, so he was diagnosed as purulent discitis. Linezolid was started and control was obtained. [Discussion] There was treatment intervention before his visit, pain appeared prior to fever, and skin vasculitis, it was difficult to diagnose. Suppurative sternal arthritis is about 9% of total sternal arthritis, of which healthy people account for 23%, it is always necessary to keep in mind when scrutinizing sternal arthritis.

P2-286
Rice-body formation and tenosynovitis of bilateral hands in patient with anti-ARS antibody: a case report
Atsushi Kitagawa, Tomoko Nakamura, Fumimasa Maruno
Hyogo Prefectural Central Rehabilitation Hospital

Conflict of interest: None

A 67-year-old woman treated for dermatomyositis and interstitial lung disease presented with severe pain and swelling on the dorsal aspect of bilateral hands, wrists, and left forearm which had started 1 year before. Laboratory tests revealed WBC: 10730/µL, ESR: 44mm/H, CRP: 1.32mg/dL, MMP-3: 458.3 ng/mL, KL-6: 904 U/mL, T-spot: TB: negative. There was no sign of lung tuberculosis and nontuberculous mycobacteria. Ultrasonography revealed significant echogenic fluid and magnetic resonance imaging showed tenosynovitis of the extensor tendons and and inflammatory mass lesions. Surgical exploration of the lesion revealed multiple rice bodies and through synovectomy and debridement were performed. Pathologic examination showed epithelioid cell granulomatous synovitis and fibrinoid necrosis. However, PCR for tuberculosis was negative. Four weeks later, the specimen grew Mycobacterium intercellulare and the patient subsequently received ethambutol and Clindamycin. Conclusions: Ricebody formation is a non-specific inflammatory reaction associated with chronic tenosynovitis and atypical mycobacterial infection should be considered in case of the immunosuppressed patient.

P2-287
A case of chronic Pseudomonas aeruginosa arthritis diagnosed by synovial biopsy, which can not be diagnosed by repeated arthrocentesis
Shuhei Sano, Masahiro Iida, Yusuke Nakamichi, Tatsuo Mori, Nanase Honda, Michiru Kina, Eisuke Takamasu, Kae Onishi, Takayas Kise, Yuji Miyoshi, Naoto Yokogawa, Kota Shimada, Shoji Sugii
Department of Rheumatic Disease, Tokyo Metropolitan Tama Medical Center

Conflict of interest: None

[Background] It is experienced that monoarthritis persists and recurs in rheumatoid arthritis (RA) patients. Synovial fluid examination is useful for discrimination of monoarthritis, but we sometimes encounter difficulty in arthrocentesis. [Case] An 86-year-old woman was diagnosed as RA at the age of 60. She had been treated with methotrexate (MTX) 6mg and prednisolone (PSL) 3mg. X-1 year before presentation, right joint ankle pain appeared. She was treated by PSL dose increase and intraarticular steroid injection, but symptoms did not improve. She was referred to our hospital in April X. At the time of initial examination, right foot monoarthritis was observed. Under ultrasonography I attempted arthrocentesis, but could not collect. At a later date, I did again but only a very small amount of synovial fluid could be collected. Fungus and acid-fast bacteria culture test was submitted. It was negative. Synovial biopsy was performed, and Pseudomonas aeruginosa became positive in synovium / synovial fluid culture. She was treated with cefazidime and ciprofloxacin, arthritis improved. [Clinical implication] Synovial biopsy is useful for diagnosis in arthritis where joint puncture is difficult and the treatment response is not suitable.

P2-288
Severe multiple infections after repeating methylprednisolone pulse therapy in collagen-vascular disease; two case reports
Noriko Sakaguchi, Kenichi Ueno, Takanori Ichikawa, Satoru Ushiyama, Dai Kishida, Yasuhiro Shimojima, Yoshihiki Sekijima
The Third Department of Internal Medicine, Shinshu University School of Medicine

Conflict of interest: None

[medical history] Eruption appears in the limbs, trunk and head from last year, he was treated steroid ointment but the scabbing erosion remained. Since the sternoclavicular pain appeared from January, he was prescribedloxoprofen, but the pain remained. He received skin biopsy. IgG, IgA, IgM, C3c were deposited along the vessel wall and vasculitis was diagnosed. Prednisolone was started with 10mg but increased to 30mg as shoulder joint and back pain appeared, and CRP elevation didn’t improve. He was difficult to move, and hospitalized. In bone scintigraphy, abnormal accumulation was found the right sternoclavicular joint, Th8, L4/5, and the limb joints, and polyarthritis was suspected. Methylcellulose-resistant Staphylococcus aureus was detected in blood culture, and from L4/5 puncture culture, so he was diagnosed as purulent discitis. Linezolid was started and control was obtained. [Discussion] There was treatment intervention before his visit, pain appeared prior to fever, and skin vasculitis, it was difficult to diagnose. Suppurative sternal arthritis is about 9% of total sternal arthritis, of which healthy people account for 23%, it is always necessary to keep in mind when scrutinizing sternal arthritis.
A 52-year-old female, who had a 4-year history of interstitial pneumonia (IP) related to dermatomyositis, was administered mPSL because of IP deterioration. However, respiratory failure due to pneumocystis pneumonia appeared, and progressed even after adding mPSL with pentamidine. In our hospital, CMV infection and multidrug-resistant pseudomonas aeruginosa pneumonia was additionally revealed. She was intensively treated under respirator support, and consequently complete remission was achieved.

**Conclusion:** The accumulation of high-dose PSL can induce severe infection. PSL-sparing effect may be expected by concomitant use of immunosuppressant since early phase of disease.

**P2-289**

**Comparative study of prognosis of arthritis rheumatology complicated with interstitial pneumonia and chronic respiratory bacterial infection**

Hiroyuki Nakaya, Kouichiro Takahi, Kazuhiko Imoto

Orthopedics & Rheumatology, National Hospital Organization of Toneyama Hospital

Conflict of interest: None

**[Object]** Therapeutic treatment for Rheumatoid arthritis patient with interstitial pneumonia (IP) or chronic respiratory bacterial infection (such as Pseudomonas aeruginosa and NTM) does not often go well smoothly. In this study we investigated the influence of respiratory disease on patient condition and prognosis comparing two groups. [Methods] Among RA patients followed in our hospital, Patients complicated with IP (IP group) and chronic respiratory infection (especially Pseudomonas aeruginosa and NTM) (CRI group) was compared. investigation was performed from Oct.2015 to Dec.2018. We compared patient background prognosis, medication, ADL (steinblocker classification and m-HAQ), DMARD use (MTX/TAC/b-DMARD) patient condition (ACPA, RF, CRP, MMP-3, DAS28- CRP and modified sharp score) and respiratory function. [Results] IP group 17 patients and CRI 20 patients were included. We found that RA disease duration, ADL, MMP-3/DAS-28/m-sharp score yearly change were dominant in CRI group. We found characteristic use in MTX and TAC and b-DMARD medication in both groups. [Conclusions] In the treatment of RA patient with chronic respiratory infection, RA prognosis was poor because we have to take much care of b-DMARD indication.

**P2-290**

**Autoimmune lymphoproliferative syndrome with somatic mutation of FAS (ALPS-sFAS): A case report**

Shunjiro Kurihara1, Junichi Ishikawa1, Norihiro Mimura1, Hirotoshi Kawashima1, Masaki Hiragi1, Yuzaburo Inoue2

1Rheumatology Department, Narita Red-Cross Hospital, Narita, Japan, 2Division of Clinical Genetics, Chiba University Hospital

Conflict of interest: None

Autoimmune lymphoproliferative syndrome (ALPS) is a rare disease characterized by lymphadenopathy, splenomegaly, and usually complicated autoimmune diseases and malignant lymphoma. It is commonly said most all of ALPS develop in childhood because of its germinal mutation. The present study is a case report of ALPS with somatic mutation of FAS (ALPS-sFAS). The case is a 21-years-old man who presented to the hospital with back pain. CT scan showed splenomegaly and systemic lymphadenopathy. However, lymph node biopsy didn’t indicate malignant lymphoma. Three years later (when he was 24-years-old), a fever brought him to the hospital again. As he had intestinal follicular lymphoid hyperplasia together with splenomegaly, we suspected that he had an immunodeficiency causing lymphoproliferative disorder. Flow cytometry analysis revealed that CD3+TCRαβ+CD4+CD8- lymphocytes increased in CD3+ cell in the peripheral blood (5.2%). We found a frame-shift mutation of the FAS gene (c.585-595del, p. Thr198fs) in 20 % of peripheral blood cells, but did not detect the mutation in buccal mucosa cells. Thus, we diagnosed his illness as ALPS with somatic mutation of FAS (ALPS-sFAS), which is rarely reported in Japan.

**P2-291**

**A case of anti-EJ positive dermatomyositis (DM) and interstitial pneumonia (IP) complicated by nephrotic syndrome (NS) due to membranous nephritis (NE)**

Syoko Tsuobouchi, Fumika Iemura, Kayo Ishii, Takahiro Mizuuchi, Yusuke Yamamoto, Hiroaki Mori, Haeru Hayashi, Koichiro Tahara, Tetsuji Sawada

Department of Rheumatology, Tokyo Medical University Hospital

Conflict of interest: None

A 67-year-old woman with a 10-year history of Raynaud’s phenomenon developed DM at age of 37, and was treated with methotrexate (MTX). At age of 65, she developed swelling of her fingers and fingertip ulcers. She was found to be anti-RNP positive, and prednisolone (PSL) was started. However, at age of 67, she was admitted to our hospital because of worsening ulcers, although PSL was increased prior to admission. Since her digital ulcers were attributed to scleroderma-like phenotype of MCTD, we discontinued MTX and tapered PSL with sympathetic nerve block and vasodilation therapy. Although amputation was required due to infectious complication, digital ulcers were ameliorated. However, she presented with recurrence of DM 4 months later, as diagnosed by anti-EJ positivity, elevated CK, muscle MRI, worsening interstitial pneumonia, and mechanic hands. Concurrently, she developed NS, and renal biopsy revealed immune-positive MN. Anti-dsDNA IgG was slightly elevated, albeit negative anti-DNA Ab (RJA). Both DM and MN were controlled by high-dose PSL and cyclosporin. Simultaneous development of DM and MN suggests causal relationship, although chance occurrence cannot be precluded. Further accumulation of similar cases would thus be warranted to explore common pathogenetic mechanisms.

**P2-292**

**Three cases of probable viral infection referred as collagen diseases**

Shino Fujimoto, Tomoyuki Sakai, Haruka Iwao, Takafumi Kawanami, Shuichi Mizuta, Hiroshi Kawabata, Toshihiro Fukushima, Yasufumi Masaki

Hematology and Immunology, Kanazawa Medical University

Conflict of interest: None

[C2-1] A 54-year-old man manifesting malaise, edema of the hands and feet, polyarthritis, sausage-like fingers, and erythema with desquamation on the extension side of the finger joints was referred to our Hospital under a diagnosis of dermatomyositis. He was taking 10 mg of prednisolone with little effects. The anti-human Parvovirus (HPV) B19 IgM antibody was positive in his serum, and his symptoms spontaneously improved within 4 months. [Case 2] A 62-year-old woman was referred to our hospital with slight fever and polyarthritis under a diagnosis of rheumatoid arthritis. The anti-cytomegalovirus IgM antibody was positive in her serum, and her symptoms spontaneously disappeared in 4 months. [Case 3] A 46-year-old man was referred to our hospital with fever and polyarthritis under a diagnosis of adult Still disease. The HPV B19 IgM antibody was positive in his serum. There was an outbreak of HPV B19 in his hometown. Viral infection-related symptoms, such as malaise, polyarthritis, and fever, are usually transient, but they may persist for months. Therefore, viral infection should be carefully excluded when diagnosing collagen diseases before starting corticosteroids or immunosuppressive therapies.

**P2-293**

**Actual condition of medical treatment of rheumatoid arthritis patients using medical collaboration**

Makoto Onishi, Atsushi Kondo, Ayuko Sugabe, Naoya Sawada, Akihiro Yamada, Yosuke Murata, Kenichiro Matoba, Kazuo Jouyama, Yasuaki
Okuda, Kiyoshi Takesugi
Center for Rheumatic Diseases, Dooho Spa Hospital
Conflict of interest: None

Introduction: Current medical treatment is based on the concept of regional inclusive care that provides medical care throughout the fulfilling region. Our hospital has general wards for disabled people, regional inclusive care wards (RICW) and recovery rehabilitation ward (RRW). PURPOSE: Medical cooperation with acute phase hospital in our hospital and survey on patients using RICW and RRW Method: Investigate the hospitalization purpose, hospital stay, etc for RA using patients who transferred from an acute hospital from January to August 2018 and the RICW ward and RRW RESULTS: There were 61 and 20 RA patients who used the RICW and RRW. 10 transferred to the direct RRW, and 43 were hospitalized in the RICW directly. 21 from outpatient, 22 from other hospitals. T Reasons for which medical treatment was necessary continuously was most the rehabilitation after orthopedic surgical treatment, Treatment continued after complications. CONCLUSION: In RA patients, there is a possibility that it will be difficult to continue the treatment in general hospitals that are in the recovery phase (subacute phase), such as drug management and assessment of ADL, disorders for each patient due to the specificity of disease it is conceivable that.

P2-294
Using social resources in the treatment of rheumatoid arthritis
Satoshi Kashiwagi, Yoshiyko Ohsawa, Hitoshi Nakata, Haruki Imura, Atsushi Saito
Department of Rheumatology, Amagasaki Medical COOP Hospital
Conflict of interest: None

[Object] Rheumatoid arthritis (RA) patients need much money for their treatment. They often use social resources to reduce their payment. We researched the situation in our hospital. [Methods] We researched the number and rate who use social resources such as welfare, medical welfare system and free/low-cost medical project from 2012 to 2017. We also compared them with the situation in other patients. [Results] The number of RA patients increased, whom received welfare were almost same, whom received medical welfare system decreased and whom received free/low-cost medical project increased. The numbers who use social resources in other diseases patients were almost same. In compared with them, the late to use social resources in RA patients were more. [Conclusions] The numbers who used welfare and medical welfare system decreased. On the other hand, the numbers who used free/low-cost medical project increased. RA patients were older and the cost which old patients must pay increased. The total numbers who use social resources will increase by changing the form.

P2-295
A case of elderly-onset eosinophilic temporal arteritis complicated by steroid-responsive occlusion of arteries of upper extremities
Kayo Ishii, Takahiro Mizuuchi, Hiroaki Mori, Mayu Tago, Eri Kato, Haeri Hayashi, Koichiro Tahara, Tetsuji Sawada
Department of Rheumatology, Tokyo Medical University Hospital
Conflict of interest: None

[Abstract] Temporal giant cell arteritis is a large-vessel vasculitis of the elderly, while juvenile temporal arteritis is characterized by eosinophilic infiltration of swollen temporal artery. We describe here a 61-year-old woman with itchy and painful subcutaneous nodules on her forehead who developed digital cyanosis with small nodules on both sides of her fingers. Eosinophil count was 556. Ultrasound examination revealed occlusion of inflamed temporal arteries and corkscrew-like changes of her digital arteries. Temporal-artery-biopsy (TAB) revealed highly inflammatory (transmural) and eosinophilic infiltration without giant cell formation. Angiography revealed occlusion of ulnar and proper palmar digital arteries. Digital cyanosis was ameliorated by low-dose prednisolone, which was reduced over 4 years without recurrence. Eosinophilic inflammation was not observed in the 2nd TBA. Although Burger’s disease involving temporal arteries could be a differential diagnosis, the angio-graphic findings and steroid-responsiveness supported the diagnosis of eosinophilic temporal arteritis involving upper extremity arteries. Further accumulation of similar cases would be warranted given that this type of eosinophilic vasculitis could be a new disease entity.

P2-296
A case of ACNES (anterior cutaneous nerve entrapment syndrome) introduced to department of rheumatic diseases as unknown abdominal pain
Naoki Tanomori1, Kota Shimada1, Masahiro Iida1, Yusuake Nakamichi1, Tatsuo Morii1, Nanase Honda1, Michiru Kina1, Eiisek Takeyasu1, Kae Onishi1, Takayasu Kise1, Naofumi Chinen2, Masako Utsunomiya1, Yoshiki Nagai1, Naoto Yokogawa1, Shoji Sug1i1
1Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, 2Department of Internal Medicine, Tamananbu Chi-iki Hospital
Conflict of interest: None

Introduction ACNES (anterior cutaneous nerve entrapment syndrome) is not generally recognized as a cause of abdominal pain with a few reported cases in Japan. We experienced a case introduced due to abdominal pain of unknown cause, which improved after the Transversus Abdominis Plane Block. A case A 22-year-old woman without past history was hospitalized with infectious enterocolitis. Though, in a few days, diarrhea improved, localized abdominal pain in two points with nausea persisted for 1 month. She could eat nothing. She was transferred to our department because of the abdominal pain. CRP was negative and no abnormal findings were observed in both endoscopy and the enhanced CT. Carnett sign was positive. Considering ACNES, 1% procaine subcutaneous injection was performed, which had little effect. Then we tried TAP block, which resolved pain in one pain points and reduced the other pain to 30%. The nausea disappeared. She got able to take meals and she was discharged on hospital day 15. Clinical significance ACNES causes abdominal wall pain and, if it becomes severe, it may disturb eating. In the case with no test abnormality, localized abdominal pain and positive Carnett signs, we should recall this disease and try trigger point injection or TAP block.

P2-297
A Case of Intravascular Lymphoma Presenting with Proteinuria, Hematuria, Diffuse Pulmonary Infiltrative Shadows, and Positive PR3-ANCA/Anti-GBM Antibodies
Hirooyuki Yoshida1, Naoho Takizawa2, Tatsuya Arai2, Fumiya Kitamura1, Hiroki Ikai2, Tsuyoshi Watanabe2, Mari Yamamoto2, Yukari Murai1, Waka Kokuyo1, Koji Takasugi1, Yoshiro Fujita1
1Department of Nephrology, Chubu Rosai Hospital, Nagoya, Japan, 2Department of Rheumatology, Chubu Rosai Hospital, Nagoya, Japan
Conflict of interest: None

[Case] An 81-year-old woman was hospitalized with influenza and treated for 2 weeks. Chest CT was normal at that time. The patient developed cough and dyspnea after discharge. Two weeks after discharge, she was referred to our hospital because of diffuse pulmonary infiltrations in her chest CT. Her body temperature was 37.7°C and SpO2 was 88%. Laboratory test revealed anemia and thrombocytopenia, high CRP level, LDH 1130 IU/L, positive PR3-ANCA/anti-GBM antibodies, and normal renal function. Her urinalysis showed proteinuria and hematuria. Chest CT revealed bilateral diffuse centrilobular patchy shadows. The bronchoscopy showed no abnormal findings. Serum sIL-2 receptors level was elevated, so we suspected intravascular lymphoma along with elevated LDH levels, cytopenia, and diffuse lung injury. Consequently, a random skin biopsy was performed. Which revealed large CD20-positive lymphocytes in the vessels. She was diagnosed with IVL, and treatment was started. [Discussion] IVL can present with multiple organ failure, including lungs and kidneys, and positive results for autoantibodies. Therefore, physicians should consider possibility of IVL if a patient presents with cytopenia or elevated LDH and ferritin levels when suspecting ANCA associated vasculitis or anti-GBM disease.
P2-298
Risk factors of drug-induced kidney injury due to calcineurin inhibitors: a case-control study
Keiichi Iwanami
Department of Rheumatology, Tokyo Bay Urayasu Ichikawa Medical Center

Conflict of interest: None

[Object] To investigate risk factors of drug-induced kidney injury by calcineurin inhibitors. [Methods] We enrolled 45 patients (male 6, female 39) attending our hospitals regularly as of October 2018 and taking calcineurin inhibitors for more than 1 year. Drug-induced kidney injury (DKI) by calcineurin inhibitors was defined as a decrease of eGFR by more than 10 ml/min/1.73m2 from baseline and a decrease of eGFR to less than 60 ml/min/1.73m2. Age, underlying disease, comorbidity and medication were investigated and risk factors were analyzed. [Results] Of the 45 patients, 15 developed DKI with calcineurin inhibitors. In all cases, the blood concentration of calcineurin inhibitors was in the expected therapeutic range. In univariate analysis, hypertension (odds ratio 6.42, 95% CI: 1.61-25.64), combined use of trimethoprim-sulfamethoxazole (ST) (odds ratio 11.0, 95% CI: 2.54-49.39) was extracted as a risk factor. In multivariate analysis, combined use of ST (odds ratio 13.0, 95% CI: 2.04 - 82.2) was extracted as a risk factor. Age, eGFR at the start of administration did not show any significant difference. [Conclusions] Patients with hypertension and combination with ST have a high risk of developing DKI by calcineurin inhibitors.

P2-299
A case of arthropathy of familial amyloidosis with a clinical suspicion of concomitant with rheumatoid arthritis
Takuya Inoue1,2, Kazuki Fujioka1, Hitdecate Nagahara1, Makoto Wada1, Masataka Kohno1, Yutaka Kawahto1
1Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 2Internal Medicine, Fukuchiyama City Hospital

Conflict of interest: None

A 44-year-old woman presented to our hospital with 6-month history of progressive joint swelling of left 3rd PIP and bilateral wrist joints. She had been diagnosed with familial amyloid polyneuropathy (FAP) due to detection of intravital transthyretin amyloid deposition and systemic involvement (peripheral polyneuropathy, chronic kidney disease, bowel and heart). She also had past history of arthropathy in right 3rd PIP joint and had underwent synovectomy. Histological findings had suggested the joint involvement of FAP. Although her arthropathy hadn’t exacerbated for a few years, she was referred to our facility for evaluation of progressive joint swelling described above. Laboratory testing showed high levels of CRP (1.18 mg/dl), MMP-3 (169 ng/ml), RF (300 U/ml) and anti-CCP antibody (316 IU/ml). Radiographic images and MRI revealed some bone erosions, and active tenosynovitis and synovitis in left 3rd PIP and bilateral wrist joints. We suspected of coincidence of rheumatoid arthritis (RA). As of now, administration of Golimumab for 3 months improved elevated CRP and MMP-3 but her joints remained swollen. Further treatment is under consideration. To our knowledge, there are no reported cases of coincidence of FAP and RA. Here we report this case with some literature review.

P2-300
A case of adult type hypophosphatasia diagnosed as long-term unclassifiable arthritis
Satsuki Aochi1, Rieko Murakami1, Saho Honda1
1Japan Self Defense Forces Sapporo Hospital, 2JR Sapporo Hospital

Conflict of interest: None

Case A 43-year-old female. At the age of 34, she was admitted to other hospital with joint pain and diagnosed reactive arthritis, then she was administered prednisolone 5mg/day for 1 year but it was ineffective. At the age of 39, she visited our hospital for examination and pain on both elbows. laboratory test showed Low ALP and FDG-PET/CT, there was no special matter and did not satisfy the diagnostic criteria of any collagen disease, so As symptomatic treatment as unclassifiable arthritis. At the age of 43 years, a heterozygote of the ALPL gene c.1559delT mutation was found. Think of hypophosphatasia in adults, we started treatment. Clinical Significance Low hypophosphatasia is rare disease caused by ALPL gene mutation. As far as other searches were done in Japan, there is no similar report, and as a rare example report based on overseas literature, with some consideration added.

P2-301
A case of artropathy of familial amyloidosis with a clinical suspicion of concomitant with rheumatoid arthritis
Masataka Kohno1, Yutaka Kawahito1
1Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, 2Internal Medicine, Fukuchiyama City Hospital

Conflict of interest: None

A 44-year-old woman presented to our hospital with 6-month history of progressive joint swelling of left 3rd PIP and bilateral wrist joints. She had been diagnosed with familial amyloid polyneuropathy (FAP) due to detection of intravital transthyretin amyloid deposition and systemic involvement (peripheral polyneuropathy, chronic kidney disease, bowel and heart). She also had past history of arthropathy in right 3rd PIP joint and had underwent synovectomy. Histological findings had suggested the joint involvement of FAP. Although her arthropathy hadn’t exacerbated for a few years, she was referred to our facility for evaluation of progressive joint swelling described above. Laboratory testing showed high levels of CRP (1.18 mg/dl), MMP-3 (169 ng/ml), RF (300 U/ml) and anti-CCP antibody (316 IU/ml). Radiographic images and MRI revealed some bone erosions, and active tenosynovitis and synovitis in left 3rd PIP and bilateral wrist joints. We suspected of coincidence of rheumatoid arthritis (RA). As of now, administration of Golimumab for 3 months improved elevated CRP and MMP-3 but her joints remained swollen. Further treatment is under consideration. To our knowledge, there are no reported cases of coincidence of FAP and RA. Here we report this case with some literature review.

P2-302
Case report: Case of diagnosis of adult onset hypophosphatasia from general pain and pathological fracture
Kenji Yoshida, Tatsuya Kai, Daisuke Hiraoka, Hiroko Ikeuchi, Kensuke Oyoyo, Shinichi Mizuki
Matsuyama Red-Cross Hospital, Matsuyama, Japan

Conflict of interest: None

A 69-year-old man. He injured the right femoral neck fracture in a fall in 2007. In 2009, he injured a left shoulder fracture, both tibial fractures. And, systemic pain has appeared since 2014 and gradually became difficult to walk. In August 2018, he visited the rheumatology department of the hospital. As a result, blood test showed ALP: 97 U / L, it is low. Ca, P, int-PTH, 1-25 Vitamin D was in the normal range. We ordered genetic testing for suspected adult onset hypophosphatasia from pathological fracture history, over 4 years of systemic pain. As a result, the 1375th base of exon 12 of the ALPL gene was replaced by G → A, and the amino acid at position 459 was substituted with valine → methionine. (p.V459M mutation was detected heterozygous.) This mutation has been reported in infant type and Odontohypophosphatasia (tooth limiting type) in the past, and confirmed as adult type hypophosphatasia.

P2-303
A case of palmer fascitis and polyarthritis syndrome associated with ovarian cancer
Shunya Kaneshita, Tomoya Sagawa, Takuya Inoue, Takashi Kida, Kazuki Fujioka, Hitdecate Nagahara, Makoto Wada, Masataka Kohno, Yutaka Kawahto
Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

Conflict of interest: None

A 43-year-old female. At the age of 33, she was admitted to hospital with joint pain and diagnosed reactive arthritis, then she was administered prednisolone 5mg/day for 1 year but it was ineffective. At the age of 39, she visited our hospital for examination and pain on both elbows. Laboratory test showed Low ALP and FDG-PET/CT, there was no special matter and did not satisfy the diagnostic criteria of any collagen disease, so As symptomatic treatment as unclassifiable arthritis. At the age of 43 years, a heterozygote of the ALPL gene c.1559delT mutation was found. Think of hypophosphatasia in adults, we started treatment. Clinical Significance Low hypophosphatasia is rare disease caused by ALPL gene mutation. As far as other searches were done in Japan, there is no similar report, and as a rare example report based on overseas literature, with some consideration added.
P2-304
Acquired factor V inhibitor developing in a patient with interstitial pneumonia
Masanori Seki
Department of Hematology, National Hospital Organization Mito Medical Center, Mito, Japan

Conflict of interest: None

Acquired factor V (FV) inhibitor is a rare hemostatic disorder that presents with hemorrhagic manifestations in the vast majority of patients. In this report, we present a case of acquired FV inhibitor in a patient with interstitial pneumonia who presented with bladder tamponade. A 77-year-old woman had had asymptomatic macroscopic hematuria but was placed under observation. However, she was admitted because of bladder tamponade. Laboratory test showed prolonged prothrombin time and activated partial thromboplastin time. The FV levels decreased and the presence of FV inhibitor was confirmed by Bethesda method. She was managed for bleeding with supportive care, followed by corticosteroid therapy. The bleeding completely stopped 1 week after corticosteroid therapy. The FV levels were normalized, and the inhibitor was successfully eradicated using corticosteroids. The inhibitor disappeared twelve months after the onset. Here, we discuss this rare disorder, its unusual manifestation, and provide a review of the current literature regarding FV inhibitors.

P2-305
Mortality and Risk factors of Death in Patients of Rheumatoid Arthritis in our hospital
Yutaka Chifu1, Yukiko Takeyama1, Rie Suematsu2
1Department of Rheumatic Diseases, Tama-Hokubu Medical Center, Tokyo, Japan, 2Department of Rheumatology, University of Sage, Saga, Japan

Conflict of interest: None

[Objective] To evaluate what factors and comorbidities influence mortality of patients of RA. [Methods] To December 31, 2017, we studied mortality of 143 patients of RA (29 males, 143 females, 63.5years old) who were outpatients in our hospital and registered from January to March in 2014. We also investigated the relationship between total hospitalizations and death from January 1, 2014 to December 31, 2017. [Results] There were ten deaths during the observation period. Five deaths were due to pulmonary disease and two were due to malignant disease, also five were due to infectious disease. The standard mortality ratio during this period was 1.17 for males, 1.56 for females, 1.34 for total. In multivariate analysis, age, male and pulmonary disease were significantly associated with death. During the study period, all hospitalizations were 81, orthopedic disease 23, infectious diseases 27 (pneumonia 16), malignant disease 6. Hospitalization of pneumonia and malignant disease was significantly associated with death. A large part of the causes of death in patients of RA were pulmonary disease, malignant disease and infectious diseases. Control of pulmonary diseases and infectious diseases is important for improving prognosis of patients of RA.

P2-306
Usage survey of immunoglobulin preparations for connective tissue disease
Yasushi Koyama1, Yuto Izumi1,2, Kazuki Hirano1, Yoko Nakagome1, Mai Sugiyama1, Sho Sasaki1, Chihiro Yamada1, Takayoshi Kurabayashi1, Noriko Sasaki2, Takayuki Wakabayashi1, Yasuo Suzuki2, Shinji Sato1
1Division of Rheumatology, Department of Internal Medicine, Tokyo University School of Medicine, 2Division of Rheumatology, Department of Internal Medicine, Tokyo University Hachioji Hospital

Conflict of interest: None

[Objective] To examine the usage of immunoglobulin preparations for connective tissue disease [Methods] One hundred twenty two patients with connective tissue disease (CTD) treated with intravenous immunoglobulin (IV Ig) between January 2016 and September 2018 at Tokai University Hospital were examined retrospectively their backgrounds, diagnosis, application of IV Ig and applied dose and others. [Results] Of 122 patients with CTD, 76 patients are treated for hypogammaglobulinemia, 25 patients for refractory idiopathic inflammatory myopathies (IIM), 11 patients for neuropathies with vasculitis syndrome, and 7 patients for idiopathic thrombocytopenic purpura and 3 patients for other conditions. Of 76 patients treated for hypogammaglobulinemia, 52 patients had no active infection and IV Ig were used for infection prophylaxis. Remaining 18 patients suffers from active infectious diseases. Interestingly, 15 patients had cytomegalovirus infection among those who were complicated with active infection. A large amount of IV Ig (400mg/body for 5 days) was used for refractory IIM in high frequency. [Conclusions] IV Ig therapy was frequently used for infection prophylaxis and cytomegalovirus infection in patients with hypogammaglobulinemia under the treatment for underlying CTD.

P2-307
Clinical manifestations of acute hemorrhagic rectal ulcer (AHRU) in patients(pts) with rheumatic diseases (RD)
Yusuke Yamamoto, Haeru Hayashi, Koichiro Tahara, Tetsuji Sawada
Department of Rheumatology, Tokyo Medical University Hospital

Conflict of interest: None

[Aim] AHRU is an ulcerative lesion restricted to lower rectus, characterized by sudden onset and painless massive hematohoezia in long-term bedridden pts with severe underlying disease. The rapidly aging of Japan prompted us examine the manifestations of AHRU in RD. [Methods] The pts hospitalized from Jan 2017 to Jul 2018 were retrospectively examined. [Results] Eight developed AHRU during the period; Mean age: 72 + 9 (2 male, 6 female), background: 4 with RA, and 1 with MRA, SSc, DM, MCTD, and MPA, respectively, mean PSL: 12.6±6.4 mg/day. The reason of hospitalization was infectious complications in 7 out of 8. AHRU occurred from day 5 to 15 in pts with poor ADL (PS 3 or 4), and hypoalbuminemia (2.2 + 0.3 g/dl) and anemia (Hb 7.9 + 0.9 g/dl). AHRU lesion was solitary in all the 8 pts. Two pts who developed recurrent AHRU and required multiple blood infusions had iliosposas abscess and extensive phlegmon which were treatment-resistant (CRP > 10 mg/dl). [Conclusion] AHRU complicated by RD was prevalent in elderly pts with impaired ADL due to infection. Since AHRU could possibly recur especially in RD pts hospitalized due to infection, it would be important to control underlying diseases and to perform preventive measures, such as frequent repositioning, to circumvent AHRU.

P2-308
Gout presenting as a foramen magnum syndrome
Yuji Miyoshi1, Miho Ohshima1, Makoto Sugihara1, Tomohiro Kozuki1, Takayasu Kise2, Naoto Yokogawa2, Shoji Sugii2
1Department of Rheumatic Diseases, Tama-Hokubu Medical Center, Tokyo, Japan, 2Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center

Conflict of interest: None

[Object] To examine what factors and comorbidities influence mortality of patients of RA. [Methods] To December 31, 2017, we studied mortality of 143 patients of RA (29 males, 143 females, 63.5years old) who were outpatients in our hospital and registered from January to March in 2014. We also investigated the relationship between total hospitalizations and death from January 1, 2014 to December 31, 2017. [Results] There were ten deaths during the observation period. Five deaths were due to pulmonary disease and two were due to malignant disease, also five were due to infectious disease. The standard mortality ratio during this period was 1.17 for males, 1.56 for females, 1.34 for total. In multivariate analysis, age, male and pulmonary disease were significantly associated with death. During the study period, all hospitalizations were 81, orthopedic disease 23, infectious diseases 27 (pneumonia 16), malignant disease 6. Hospitalization of pneumonia and malignant disease was significantly associated with death. A large part of the causes of death in patients of RA were pulmonary disease, malignant disease and infectious diseases. Control of pulmonary diseases and infectious diseases is important for improving prognosis of patients of RA.
P2-309
A case of tophaceous gout with deposition of monosodium urate crystals on the flexor tendon causing flexion contracture of the fingers

Naomi Ito1, Atsuo Taniguchi1, Yohei Seto1,2, Hisashi Yamanaka1
1Institute of Rheumatology, Tokyo Women's Medical University, 2Tokyo Women's Medical University Yachiyo Medical Center

Conflict of interest: None

A tophus is a characteristic sign of advanced gout and develops after long-standing untreated gout as a consequence of excessive deposition of monosodium urate (MSU) crystals on joints, tendons and subcutaneous tissue. We report a case of MSU deposition on the flexor tendon of a 77-year old woman with a history of chronic glomerulonephritis who had developed polyarthritis and subcutaneous nodules since 1994 and visited our hospital in 2014 because of persistent articular pain. The patient had multiple subcutaneous nodules in her hands and right forearm, with the fingers showing flexion contracture. Laboratory tests demonstrated hemoglobin level was 9.5 g/dL, serum urea nitrogen 71.6 mg/dL, serum creatinine 2.59 mg/dL, serum uric acid 10.2 mg/dL, CRP 0.09 mg/dL, while the rheumatoid factor was negative. A plain x-ray of the hand showed punched out lesions in finger and carpal bone. MSU crystals were confirmed in subcutaneous nodules, leading to a diagnosis of gout. Dual-energy CT also demonstrated deposition of MSU in both the macroscopic and microscopic areas. The most interesting finding was that diffuse deposits were found in the flexor tendons, and it appeared that some of the deposits were involved in bone destruction of the medial phalangeal bone trunk.

P2-310
Case report; acute CPP crystal arthritis is complicated by septic arthritis of the knee

Atsushi Goshima, Masataka Nishikawa, Hajime Owaki
Japan Community Health Care Organization Osaka Hospital

Conflict of interest: None

[Object] We present the case of a 86-year-old male who was diagnosed with monoarticular arthritis due to acute calcium pyrophosphate (CPP) crystal arthritis and septic arthritis. [Methods] A 86-year-old man presented to the emergency department complaining of the left knee pain. He was found to have swelling and tenderness of the joint. We performed arthrocentesis of the knee and identified coagulative gouty nodules and areas of bone destruction. An interesting finding was that diffuse deposits were found in the flexor tendons, and it appeared that some of the deposits were involved in bone destruction of the medial phalangeal bone trunk.

P2-311
A 15-year-old boy with gout
Yoshiki Nagai1, Naoto Yokogawa1, Naoki Tanomogi1, Masahiro Iida1, Shuhei Sano1, Yusuke Nakamichi1, Tatsuo Morii1, Nanase Honda1, Michiru Kina1, Eisuke Takamasu1, Kae Onishi1, Takayasu Kise1, Yuji Miyoshi1, Masako Utsunomiya1, Keiji Akamine2, Kota Shimada1, Shoji Sugii1
1Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan, 2Department of Nephrology, Tokyo Metropolitan Children's Medical Center, Tokyo, Japan

Conflict of interest: None

[Background] Juvenile-onset gout is rare. [Case] A 15-year-old boy presented with swelling and pain in his left foot. Two days before presentation, he noticed the pain in his left foot. One day before presentation, he was seen in primary care physician and prescribed antibiotics in the diagnosis of cellulitis. Since his symptom did not improve, he was referred to Tokyo Metropolitan Children’s Medical Center. He had received four surgeries of double-outlet right ventricle, corrected transposition of great arteries, and pulmonary artery blockage at 1, 4, 13 months and 5 years old. He had difficulty in walking because of the pain in left foot. He was referred to our department because the pain and swelling in his left foot did not improve with antibiotics. Blood tests showed an elevated serum uric acid level of 11.4 mg/dL. Musculoskeletal ultrasonography revealed moderate fluid in the first and second MTP joint. He underwent arthrocentesis and gout was diagnosed by isolation of monosodium urate crystals in synovial fluid by polarization microscope. After prednisolone was started at the dose of 15 mg/day, his symptom improved immediately. [Clinical implication] We should consider gout and perform arthrocentesis when we suspect the arthritis in juvenile patient.
P3-002
Elucidation of chronic inflammation of rheumatoid arthritis using three-dimensional electron microscopy analysis
Rie Kurose1,2, Takahiro Ochi1, Miwa Uzuki4, Kenya Murakami1, Yasuyuki Ishibashi5, Takashi Sawai3
1Hiroaki Memorial Hospital, 2Hiroaki University Graduate School of Medicine, 3Osaka Police Hospital, 4Tohoku Bunka Gakuen University, 5Iwate Medical University, 6Tohoku University

Conflict of interest: None

[Object] We focus on nursing phenomenon formed by a complex of synovial dendritic and plasma cells. The objective of this study is to investigate the mechanism of long duration of immunological inflammation in RA using electron microscope technology. [Methods] Synovial tissue collected from RA patients undergoing elbow or knee synovectomy was prepared for this study. From the wide fields of view of synovial tissue, we could easily select areas containing the nursing phenomenon by multiscale electron microscopy, and image 3D features by focused ion beam-scanning electron microscopy and construct the tomography by transmission electron microscopy with double-axis electron microscopy. [Results] Using multiscale electron microscopy, the numbers of synovial dendritic and plasma cells were observed in various areas of the lymphomembranous infiltration. Synovial dendritic cells patronize the plasma cells by the long slender axis, and forming the membranous fusion of the plasma cells. [Conclusions] The meaning of the nursing phenomenon is not yet known, however it may provide a new aspect for analyzing the mechanism of long duration of immunological inflammation in RA.

P3-003
Research of body composition and prevalence of sarcopenia from two regions, in patients with rheumatoid arthritis from the CHIKARA RA study
Koji Mandai1, Yutaro Yamada2,3, Tatsuya Koike4,5, Tadashi Okano5, Noriaki Hidaka1, Masahiro Tada2
1Department of Orthopaedics, Osaka Social Medical Center, 2Department of Orthopaedic, Osaka Social Care Center

Conflict of interest: None

[Object] We investigated the differences in the prevalence of sarcopenia in patients with rheumatoid arthritis (RA) according to the size of the city. [Methods] The data from a prospective observational study (CHIKARA RA study) were used. 190 RA patients were measured by body composition analyzer MC-780A (TANITA). We evaluated the differences in the prevalence of sarcopenia and body composition by region (Metropolitan: group M, Provincial city: group P). [Results] A total of 190 patients (group M:100, group P:90) with rheumatoid arthritis was included. Mean age was 66 years old at group M and 67 years old at group P (p=0.9). Mean disease duration was 5.5 years at group M and 8.5 years at group P (p=0.001). DAS28-ESR was 3.5 at group M and 2.9 years at group P (p=0.001). Mean appendicular skeletal muscle mass index (ASMI) was 6.4kg/m² at group M and 6.2kg/m² at group P (p=0.057). Prevalence of presarcopenia was 29% at group M and 43.3% at group P (p=0.049). Prevalence of sarcopenia was 20% at group M and 32.2% at group P (p=0.068). [Conclusions] RA patients live in provincial city tended to have a higher prevalence of sarcopenia than those who live in metropolis. Further research including living environment and work is necessary.

P3-004
What are the risk factors for developing sarcopenia in patients with rheumatoid arthritis during 2 years? -from the CHIKARA study-
Yutaro Yamada1,2, Masahiro Tada1, Koji Mandai1,4, Noriaki Hidaka1, Kentaro Inui5, Hiroaki Nakamura1
1Department of Orthopedics, Osaka City University Graduate School of Medicine, 2Department of Orthopedics, Yodogawa Christian Hospital, 3Department of Orthopedics, Osaka City General Hospital, 4Department of Orthopedics, Osaka Social Care Center

Conflict of interest: None

[Object] Rheumatoid arthritis (RA) often develops into sarcopenia due to joint dysfunction and chronic inflammation. We reported glucocorticoid use and low body fat were independent risk factors for developing sarcopenia during 1 year in patients with RA. We investigated these during 2 years. [Methods] 100 patients (78 female, average age 68 yo) enrolled in the prospective CHIKARA study (UMIN000023744) were examined their body composition, laboratory data, disease activity, HAQ and treatment condition at baseline and 2-year. Among 64 patients without sarcopenia at baseline, those who developed sarcopenia at 2-year were detected and risk factors were investigated. [Results] 6 patients (9.4%) developed sarcopenia during 2 years. Among them, GC use >5mg was significantly high (p=0.009); MMP3 (p=0.018) and HAQ (p=0.045) elevated during 2 years significantly. Sarcopenia development significantly associated with male sex (r=0.28, p=0.03), age (r=0.27, p=0.03), GC use >5mg (r=0.33, p=0.01), CRP (r=0.33, p=0.01) at baseline, ΔMMP3 (r=0.30, p=0.02) and ΔHAQ (r=0.25, p=0.04) by univariate analysis. Multivariate analysis identified no independent factor. [Conclusions] RA patients with male, old-age, GC use >5mg, high elevation of MMP3 and HAQ associated with developing sarcopenia during 2 years.

P3-005
The sarcopenia and obesity are predictable by measuring thigh muscle and fat thickness using ultrasound in patients with rheumatoid arthritis - from the CHIKARA study -
Yutaro Yamada1,2, Masahiro Tada1, Koji Mandai1,4, Noriaki Hidaka1, Kentaro Inui5, Hiroaki Nakamura1
1Department of Orthopedics, Osaka City University Graduate School of Medicine, 2Department of Orthopedics, Yodogawa Christian Hospital, 3Department of Orthopedics, Osaka City General Hospital, 4Department of Orthopedics, Osaka Social Care Center

Conflict of interest: Yes

[Object] Rheumatoid arthritis (RA) often accompanies sarcopenia. The thickness of quadriceps muscle is known to be related with skeletal muscle mass. We investigated the utility of ultrasound (US) for predicting sarcopenia by examining anterior thigh in patients with RA. [Methods] 94 patients (66 female) enrolled in the prospective CHIKARA study (UMIN000023744) were examined muscle (MT) and fat thickness (FT) at anterior thigh by US. They were also examined muscle and body fat mass by body composition analyzer. We investigated whether MT and FT can predict sarcopenia and obesity. They were diagnosed by Asian Working Group on Sarcopenia and % body fat (%BF). [Results] MT was related with sarcopenia (male r=0.56, p=0.02; female r=0.32, p=0.01). The MT cut-off value for sarcopenia was 24.7 in male, 19.7 in female by ROC analysis. FT showed correlation with %BF (male r=0.66, p=0.01; female r=0.62, p=0.001). %BF was estimated by 2.21FT+7.28 in male, 1.45FT+14.46 in female by single linear regression model. This means FT>8.0 in male, FT>10.7 in female deserves obesity. When assessing the accuracy of these cut-off value, kappa value was 0.54 and 0.469 respectively. [Conclusions] The sarcopenia and obesity are predictable by US at anterior thigh in patients with RA.

P3-006
Investigation of bone mass and bone mineral density in patients with rheumatoid arthritis from the CHIKARA study
Koji Mandai1, Yutaro Yamada1,2, Tatsuya Koike4,5, Tadashi Okano5, Noriaki Hidaka1, Masahiro Tada2
1Department of Orthopedics, Osaka Social Medical Center, 2Department of Orthopedic, Yodogawa Christian Hospital, 3Department of Orthopedics, Osaka City General Hospital

Conflict of interest: None

[Object] Rheumatoid arthritis (RA) often accompanies sarcopenia. The thickness of quadriceps muscle is known to be related with skeletal muscle mass. We investigated the utility of ultrasound (US) for predicting sarcopenia by examining anterior thigh in patients with RA. [Methods] 94 patients (66 female) enrolled in the prospective CHIKARA study (UMIN000023744) were examined muscle (MT) and fat thickness (FT) at anterior thigh by US. They were also examined muscle and body fat mass by body composition analyzer. We investigated whether MT and FT can predict sarcopenia and obesity. They were diagnosed by Asian Working Group on Sarcopenia and % body fat (%BF). [Results] MT was related with sarcopenia (male r=0.56, p=0.02; female r=0.32, p=0.01). The MT cut-off value for sarcopenia was 24.7 in male, 19.7 in female by ROC analysis. FT showed correlation with %BF (male r=0.66, p=0.01; female r=0.62, p=0.001). %BF was estimated by 2.21FT+7.28 in male, 1.45FT+14.46 in female by single linear regression model. This means FT>8.0 in male, FT>10.7 in female deserves obesity. When assessing the accuracy of these cut-off value, kappa value was 0.54 and 0.469 respectively. [Conclusions] The sarcopenia and obesity are predictable by US at anterior thigh in patients with RA.
Does dietary inflammation exist in rheumatoid arthritis?  
Yuto Kobayashi1, Eri Narita1, Kentaro Inui2, Yuko Sugioaka2, Tadashi Okano2, Kenji Mamoto2, Masahiro Tada1, Tatsuya Koike1  
1Shirahama Hamayu Hospital, 2Osaka City University Medical School Hospital, 3Osaka City General Hospital  
Conflict of interest: None  

[Objective] The dietary inflammatory index (DII) is a tool to evaluate the inflammation induced by diet and has been used for predicting low-grade chronic inflammation. We examined whether DII can predict inflammation in rheumatoid arthritis (RA). [Methods] Food nutrition data of 201 RA and age-, sex- matched 201 volunteers (Vo) in a cohort study (TOMORROW, UMIN000003876) were used. DII is a score of nutrients promoting inflammation and the larger value means the higher inflammation. Evaluation items were age, use of biological agents (Bio) or steroid (PSL) and Disease activity score 28 (DAS 28) in RA group. [Results] The mean age was 59.0 y (female 84.6%) in RA, 57.9 (female 84.7%) in Vo. DII was significantly higher in RA compared to Vo (Vo - 1.3 ± 1.92, RA - 0.60 ± 1.90, P = 0.016). Among three groups of Bio user, Bio non-user, and Vo, DII was significantly higher in the Bio user group. Analysis were done using 595 people living in Shika Town, Ishikawa Prefecture using brief-type self-administered diet history questionnaire (BDHQ). Anti - nuclear antibody (ANA), rheumatoid factor (RF), anti - CCP antibody (ACPA), and anti - SSA antibody were measured, and analyzed by binomial logistic analysis whether it relates to specific food and estimated nutrient intake and autoantibody appearance. [Results] Of the 595 patients, 14 ANAs, 24 RFs, 6 ACPAs and 16 anti-SSA antibodies were positive. For foods already reported to be associated with RA such as alcohol, fish intake, vegetables / fruits, meat, salt, etc., there was no consistent and significant association in any of the antibodies. In addition, the number of smokers and smoking duration were not significantly related in this survey. [Conclusions] There was no association between dietary content and the positive rate of autoantibodies. Although there are possibilities that no significant results were obtained due to the small number of cases, other factors may be more important for the appearance of autoantibodies.  

P3-010  
Titer of anti CCP antibody has changed to positive in patients with rheumatoid arthritis: A case report  
Gen Momoyama1, Nobuyuki Suzuki1, Hidekazu Tanaka1, Yasunobu
white blood cells was analyzed by flow cytometry. Peripheral blood mononuclear cells (PBMCs) and naïve CD4+ T cells from healthy controls were stimulated in vitro and FPR2 expression was examined. We also examined the influence of Resolvin D1 on the production of IFNγ from CD4+ T cells in PBMCs by aCD3/aCD28. [Results] The expression of FPR2 on T cells was high in part of RA patients. FPR2 expression of CD4+ T cells from ESR-high RA patients tended to be higher than from ESR-low patients. After PBMCs from healthy controls were stimulated in vitro by aCD3/aCD28, FPR2 expression of CD4+ T cells was elevated. Addition of Resolvin D1 decreased the production of IFN-γ from CD4+ T cells in PBMCs by aCD3/aCD28. naïve CD4+ T cells were differentiated to Th0 and Th1, but FPR2 was not expressed in those cells. [Conclusions] FPR2 CD4+ T cell possibly plays a certain role in RA.

P3-013
Successful use of colchicine for treating a case of polyarthritis with MEFV mutation
Suzu Sugi, Naomi Yoshida, Daisuke Wakasugi, Satoshi Yamashiki, Munetoshi Nakashima
Division of Rheumatology, Kurume University Medical Center, Fukuoka, Japan
Conflict of interest: Yes

An 82-year-old man visited our hospital because of joint swelling of the hand and feet with tenderness in the proximal extremities. Tests for both rheumatoid factor and anti-citrullinated peptide antibody were positive, but synovitis was not observed upon ultrasonographic (US) examination of the joints. He was treated with 20 mg/day of prednisolone (PSL), which relieved his symptoms, and the PSL dose was reduced to 5 mg/day. 1 year and 4 months later, he experienced swollen and tender fingers of both hands. The PSL dose was escalated to 15 mg/day, with no response after 7 months of treatment. He met the EULAR classification criteria for rheumatoid arthritis (RA). Synovitis was detected by US but his symptoms were not typical of RA, as his clinical course was similar to polymyalgia rheumatica and the recurrent arthritis was refractory to 15 mg/day of PSL. We included familial Mediterranean fever as a differential diagnosis and started colchicine, which resolved his symptoms. US examination confirmed the resolution of synovitis. Gene analysis revealed two mutations, P369S/R408Q, in MEFV. Some reports show colchicine or IL-1β blockers are useful for treating RA with MEFV mutations. Our case also suggests that MEFV mutations modulated the RA disease process.

P3-014
Search for RA-susceptibility genes using genetic difference between RA children and non-RA parents
Marowa Hashimoto1, Keiko Funahashi1, Kosuke Okuda2, Koji Fukuda2, Shinya Hayashi2, Tsukasa Matsubara2
1Research Institute of Joint Diseases, Kobe, Japan, 2Matsubara Mayflower Hospital, Kato, Japan, 3Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Kobe, Japan
Conflict of interest: None

[Object] It seems that analyzing genome between parent and child to search for disease-susceptibility genes is useful because of similarity in both genetic backgrounds. In this study, we searched for RA-susceptibility genes by analyzing genome using wide association study (GWAS) among RA children and non-RA parents. [Methods] The subjects were 9 RA children and the each 9 non-RA parents. Illumina HumanHap300K or HumanOmniExpress chip were used for genotyping. SNPs used in this study were common among these chips and were 178,753 SNPs. Case-control study was carried out between RA children and non-RA parents using Chi-Squared test in Recessive Model. [Results] As the result of GWAS, rs959976 (p = 10−12) on TRP1A (Transient Receptor Potential cation channel, subfamily A, member 1) was found among SNPs with comparable lower P value. R959976 on TRP1A was missense mutation with amino acid substitution (p. His1018Arg). [Conclusions] It has been suggested that the expression of TRP1A on peripheral blood leukocytes correlate with RA progression. Thus, rs959976 on...
TRPA1 may also be involved in the onset of RA. We will continue to search for RA-susceptibility genes by increasing sample sizes.

**P3-015**

**Study of the factor which has an influence on the rheumatoid arthritis synovium**

Koji Tateishi¹, Ken Takebe¹, Yasuhiro Terashima¹, Noriaki Yo², Takashi Yamane³, Tepppei Hashimoto⁴

¹Department of Orthopaedic Surgery, Kohnan Kakogawa Hospital, ²Kakogawa City Hospital Organization, ³Hyogo College Of Medicine

Conflict of interest: None

[Object] In late years disease control of the rheumatoid arthritis (following RA) is improved drastically by the spread of biological preparation. It is not a rare case which only a single joint pain remains in even if we gave the medical treatment with any drug are not only rare. Because I weighed the factor which has an influence on the synovium in the arms joint of RA and the lower leg joint, I report it. [Methods] The synovial membrane samples were obtained from 17 wrist joints undergoing wrist synovectomy; 33 knees and 17 knee joints undergoing knee arthroplasty. We evaluated CRP, DAS-28, MMP-3, RF, ACPA, having MTX or not, PSL dose. The evaluation of the RA synovium checks many cell surface antigens emerging on Rooney score and the antigen presenting cell surface. [Results] There was no significant difference between two groups except CD56, CD34. [Conclusions] It has been already reported that sustained positive of the bloodstream in the intraarticular synovium appears except CD56, CD34. [Conclusions] It has been already reported that sustained positive of the bloodstream in the synovium. It is thought that a further study will be necessary in future based on this findings.

**P3-016**

**Role of ADAM12 and regulation by miRNA-29b in synovial cell proliferation of rheumatoid arthritis**

Masahito Watanabe¹, Keiichiro Nishida¹, Yoshihisa Nasu², Ruiyichi Nakahara¹, Hideki Ohashi¹, Shunji Okita¹, Yohei Kiso¹, Minami Matsushahi¹, Toshifumi Ozaki¹

¹Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan, ²Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan, ³Department of Intelligent Orthopaedic System, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

Conflict of interest: None

[Introduction] ADAM12 is a member of a disintegrin and metallo-proteinase family and has been reported to participate in the development of variety of tumors by degrading ECM and shed precursors, thus promoting cell proliferation, invasion and metastasis. ADAM12-L is a direct target of the miR-29 family in breast cancer. In the current study, we investigated the expression of ADAM12-L in synovial tissue of rheumatoid arthritis (RA), and examined the potential role of miRNA-29b in regulation of ADAM12. [Methods] The expression of ADAM12-L in RA synovium was examined by immunohistochemistry. The cultured synovioblasts obtained from RA patients at the surgery (RASF) were stimulated by TNF-α and IL-6, and the expression of ADAM12-L was measured by real-time PCR after miR-29b transfection. [Results] ADAM12-L was highly expressed in RA synovial tissue. Stimulation by TNF-α resulted in upregulation of ADAM12-L, HDAC4 and CDK6 in RASF. Transfection of miR-29b mimics decreased mRNA levels of ADAM12-L, HDAC4 and CDK6 in RASF. [Conclusion] ADAM12-L might be involved in the cell proliferation of RASF. miR-29b might have a role in the reduction of cell proliferation via regulation of ADAM12-L, HDAC4 and CDK6.

**P3-017**

**A case of rheumatoid arthritis on maintenance hemodialysis relapsed with the arteriovenous fistula side arthritis**

Koji Harada

Department of Nephrology, Diabetes and Renal Replacement Therapy, Nishinara Central Hospital, Nara, Japan

Conflict of interest: None

Case report: 76 year-old man was diagnosed as rheumatoid arthritis (RA) at the age of 72 and disease activity was stable with salazosulfapyridine (SASP). Hemodialysis (HD) was initiated due to polycystic kidney disease at the age of 74. Then, SASP was discontinued by skin eruption and prednisolone 7.5 mg/day was administered. Refractory arthritis in arteriovenous fistula (AVF) side was continued and celecoxib was added. Because disease activity management was difficult, abatcept (ABT) was started. After the administration of ABT arthritis was disappeared and prednisolone could be discontinued. However, uncontrolled arthritis in AVF side was appeared after 5 months. ABT was switched to tocilizumab (TOC), however, uncontrolled AVF side arthritis was relapsed 5 months after the switch to TOC. Golimumab was started, and then disease activity has been steady. Conclusion: A case of RA on maintenance HD relapsed with the arteriovenous fistula side arthritis has not been reported previously and we report this case with literature review of clinical feature of dialysis patients with RA.

**P3-018**

**Two cases of Rheumatoid Arthritis Manifested as Monoarthritis**

Hiroomi Hashimoto¹, Kiichi Koumoto¹, Kazuhiro Moriwaki¹, Fumio Otsuka²

¹Internal Medicine, Innoshima General Hospital, Onomichi, Japan, ²Department of Genral Medicine, Okayama University Hospital

Conflict of interest: None

Case 1: 73- yo male had suffered left elbow pain and swelling since Jan 201X. RF: 27 IU/ml, CCL-Ab: 86.8 U/ml, CRP: 1.5 mg/dl. MRI detected bone erosion, bone marrow edema and synovial membrane swelling in the left elbow joint. Ultrasonography showed synovial membrane swelling of the left elbow, meeting classification criteria: 5/10. Since the patient was diagnosed as RA, PSL (15mg), MTX (25mg) and Leflunomide (25mg) were administered. Case 2: 71- yo female had suffered right knee joint pain and swelling, and had left elbow joint and forearm pain since Jun 201X. RF: 15 IU/ml, CCL-Ab: 12.1 U/ml, CRP: 5.2 mg/dl. MRI showed destruction of medial meniscus and anterior cruciate ligament in the right knee and detected bone sclerosis and osteophytes. Ultrasonography showed swelling of synovial membrane in bilateral knee, right 3,4-MCP and 4-PiP joints. She also suffered left knee, right 3,4-MCP and 4-PiP joints pain and swelling, meeting classification criteria: 5-7/10. Since RA, osteoarthritis, destruction of medial meniscus and anterior cruciate ligament were detected, PSL (5mg) and salazosulfapyridine (0.5g) were administered. Conclusion: We report two elderly RA cases manifesting monoarthritis, by showing the differential diagnosis and clinical significance based on the literature.

**P3-019**

**Discrepancy between ultrasound and clinical assessment of enthesis in patients with psoriatic arthritis**

Yutaro Yamada¹, Kentaro Inui¹, Tadashi Okano¹, Koji Mandai¹, Kenji Mamoto¹, Yoko Sugikata¹, Tatsuya Koike¹, Daisuke Tsuruta¹, Hiroaki Nakamura¹

¹Department of Orthopedics, Osaka City University Graduate School of Medicine, ²Department of Orthopedics, Yodogawa Christian Hospital, ³Department of Orthopedics, Osaka Social Care Center, ⁴Center for Senile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, ⁵Department of Dermatology, Osaka City University Graduate School of Medicine

Conflict of interest: None

[Object] Psoriatic arthritis is classified by CASPAR which requires...
Significance of MMP-3 in patients with psoriatic arthritis and inflammatory bowel disease related arthritis
Hitoshi Yoshimura1, Kentaro Inui2, Tadashi Okano2, Koji Mandai5, Yutaro Yamada3, Daiuske Tsuruta4, Chiharu Tateishi4, Yuki Sugioka4, Tatsuya Koike4, Hiroaki Nakamura2
1Department of Orthopaedic Surgery, Osaka Saiseikai Nakatsu Hospital, 2Department of Orthopaedic Surgery, Osaka City University Graduate School of Medicine, 3Department of Orthopaedic Surgery, Center for Senile Degenerative Disorders, Osaka City University Medical School, Osaka, Japan, 4Department of Orthopaedic Surgery, Search Institute for Bone and Arthritis Disease, Wakayama, Japan, 5Department of Orthopaedic, Yodogawa Christian Hospital, Osaka, Japan, 6Department of Dermatology, Osaka City University Graduate School of Medicine, 7Department of Orthopaedic, The Institute of Medical Science The University of Tokyo, Tokyo, Japan, 8Department of Dermatology and Photolaser Medicine, The University of Tokyo Hospital

Conflict of interest: None

Purpose: Although psoriatic arthritis (PsA) and inflammatory bowel disease related arthritis (IBD-SpA) are classified as spondyloarthritis (SpA), difference of clinical features is well understood. The purpose of this study is to compare the clinical features of PsA with IBD-SpA, and to clarify the significance of MMP-3 in SpA.

Methods: One hundred and eighty nine patients with PsA and 81 with IBD-SpA were referred to our department to evaluate musculoskeletal symptoms. Classifications of PsA and IBD-SpA were performed using CAPAR and ASAS criteria with musculoskeletal ultrasounds. Proportion of peripheral, axial and mixed disease, swollen joint counts (SJC), tender joint counts (TJC), DAS28-2CRP and blood examinations (RF, ACPA, MMP-3) were evaluated.

Results: Among referred patients, 116 patients were classified as SpA (PsA: 81, IBD-SpA:35). There was no significant difference between SpA and non-SpA in MMP-3 positivity. Proportion of disease type was significantly different between PsA and IBD-SpA (PsA: per 90.1 ax 8.6, IBD-SpA: per 57.1 ax 17.1%; p<0.01). There was weak but significant correlation between MMP-3 and SJC in PsA. Conclusions: Proportion of peripheral disease was significantly common in patients with PsA. There was significant correlation between MMP-3 and SJC in PsA.

Conflict of interest: Yes

Functiona impairment measurement in psoriatic arthritis in real world
Shoko Tateishi, Hiroko Kanda, Mariko Inoue, Kuniko Ono, Jun Hirose, Ayumi Yoshizaki, Yoshihide Asano, Shinichi Sato, Sakae Tanaka, Keishi Fujio

Department of Immunotherapy Management, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Allergy and Rheumatology, The University of Tokyo Hospital, Department of Joint Surgery, The Institute of Medical Science The University of Tokyo, Department of Orthopaedic Surgery Faculty of Medicine, The University of Tokyo Hospital, Department of Dermatology and Photolaser Medicine, The University of Tokyo Hospital

Conflict of interest: Yes

Object: Use HAQ-DI, BASFI and SF 36 (PCS) to assess functional impairment in Psoriatic arthritis (PsA). But these measurements are not developed for PsA. We evaluated about these functional measurements in PsA in real life.

Methods: Enrolled fifty-four patients with PsA were classified into with (n=26) or without (n=28) biologics. We compared with change rate of clinical assessment: TJC, SJC, enthesitis, dactylitis, skin, ASDAS, BASMI and functional measurements with or without biologics. And we also assessed correlation between clinical feature and functional measurements. Results Clinical feature, skin, peripheral and axial feature were improved with biologics. But three functional measurements were not significantly improved. The strength of correlation was HAQ>BASFI>SF36 (PCS). There was no correlation between CRP, skin, dactylitis and HAQ. Conclusions In real world, HAQ was more useful in functional measurement in PsA.

Object: To evaluate long-term safety and efficacy of secukinumab in psoriasis vulgaris and PsA patients interim analysis
Kazuko Matsumoto, Nobartis Pharma.K.K.

Conflict of interest: Yes

Surveillance objective was to collect partially retrospective data on long-term safety and efficacy of secukinumab subcutaneous injection in clinical use in psoriasis vulgaris (PsV) and PsA patients in whom this product was started before the conclusion of a contract for surveillance. This study included patients with PsV or PsA who were not adequately responding to conventional therapies and then received secukinumab for the first time between the market release and the conclusion of the surveillance contract and until April 30, 2016. Results 167 patients were assessed as safety set (average period of observation=SD: 327±68.25 days). The overall incidence rate of adverse reaction was 19.16%. Nasopharyngitis, oral candidiasis and psoriasis were observed in 4 patients each as most frequent adverse reaction. Serious adverse reactions were noted in 9 (5.39%) of 167 patients in the
A case of acute exacerbating psoriasis vulgaris and onset of psoriatic arthritis by cutaneous infection
Misaki Yoshida, Hiromi Naka, Kunihiro Ogane, Hideo Araki
Department of Nephrology and Rheumatology, Fukui Prefectural Hospital

Conflict of interest: None

A 49-year old man was hospitalized for cutaneous infection, acute exacerbating psoriasis vulgaris and onset of psoriatic arthritis. He was diagnosed as psoriasis vulgaris by skin biopsy 30 years ago. A week after he injured his right leg, he had exacerbated psoriasis and onset of multiple joint pain. He was diagnosed as acute exacerbating psoriasis vulgaris, onset of psoriatic arthritis and cutaneous infection. He was administered antibacterial drugs. After infection improvement, he was administered Steroidal anti-inflammatory drug, Non-steroidal anti-inflammatory drug and PDE4 inhibitor. Psoriasis was improved, but a right shoulder pain persisted, so he was administered Infuliximab. His shoulder pain improved after Infliximab administration and was discharged. This case was stable psoriasis with skin lesion only for 30 years from diagnosis. But he was exacerbated psoriasis and onset of psoriatic arthritis by cutaneous infection. Infection was reported as an environmental factor of psoriasis, and onset of psoriatic arthritis by cutaneous infection. It was suggested that possibility of involvement of TNFα in the acute exacerbated psoriasis vulgaris and onset of psoriatic arthritis after infection. I also report that Therapeutic effect with TNFα inhibitor in this case.

P3-025
High frequency of HLA-B40 (B60, B61), B54 and B46 among 12 patients with axial spondyloarthritsis exhibiting bamboo spine
Akihiro Toujima, Ai Suzue
Department of Internal Medicine, Ananyakoci Hospital Tokushima Prefectural Federation of Agricultural Cooperatives for Health and Welfare
Conflict of interest: None

[Object] We examined the effects of the presence of the HLA-B alleles on the progression of spinal lesions in patients with different types of axial spondyloarthritsis, such as the ankyllosing spondylitis and axial psoriatic arthritis treated at our hospital. [Methods] We examined the clinical features of 12 patients who exhibited bamboo spine and the patients with the same HLA-B variant allele, among 72 patients diagnosed with axial-SpA at our hospital. [Results] Among the 72 patients with axial-SpA, we found 29 with B61, indicating an overall high frequency at 40.2%. Nine out of the 12 patients with bamboo spine were positive for B60 and B61, the major subtypes of B40, whereas 5 patients were positive for B54, and 4 for B46. Among the 72 patients with axial-SpA, HLA-B (54,61) was observed in 6 patients, HLA-B (51,61) in 5 patients, HLA-B (35,61) in 4 patients, and HLA-B (7,51) in 4 patients. These patients were diagnosed with axial PsA or SAPHO syndrome, and bDMARD and NSAIDs were effective in these patients. [Conclusions] Based on our findings, it is possible that HLA-B40 (60, 61), found at a high frequency in axial-SpA, and B51, B54, and B7 that are known to be the susceptibility genes of other autoimmune diseases in Japanese people, may contribute to the severity of spinal lesions.

P3-026
Characteristics of the patients with Spondyloarthritis (SpA) in our division
Hitoshi Kodera, Yoshifuji Matsumoto
Kuwana City Medical Center

Conflict of interest: None

[Background] The prevalence of SpA in Japan is thought to be higher than previously reported. There may be some SpA patients without appropriate diagnosis. [Object] To analysis the characteristics of SpA patients (including SAPHO syndrome) diagnosed in our division. [Results] The axSpA was 23 cases, the average age at diagnosis was 44.3 years old (female 69.6%). The frequency of AS among axSpA was 34.8%, the average age at diagnosis was 36.8 years old (female 37.5%). HLA was checked in 52.2% of patients in the axSpA, of which 75% were positive. The PsA was 8 cases, the average age at diagnosis was 60.1 years old (female 50%). The uSpA was 5 cases, the average age at diagnosis was 50.6 years old (female 80%). The IBD-SpA was 4 cases, the average age at diagnosis was 41 years old (female 50%). The ReA was 2 cases, the average age at diagnosis was 37 years old (female 0%). The SAPHO was 8 cases, the average age at diagnosis was 48.1 years old (female 12.5%). Coexistence of fibromyalgia was found in 26% of all cases. [Conclusions] The clinical feature of the SpA in our division tended to differ from previously reported cases. This may suggest the possibility of some undiagnosed patients in our area, and the necessity of appropriate collaboration among medical divisions.

P3-027
Ankyllosing spondylitis or SAPHO syndrome? A case with remarkable bone erosion and osteoporiferative lesion of the sacroiliac, sternoclavicular joint
Toshioh Shuto
Department of Orthopedics and Rheumatology, Chiyoda Hospital, Miyazaki, Japan
Conflict of interest: None

[Clinical relevance] It is sometime difficult to distinguish SAPHO syndrome from ankyllosing spondylitis (AS) without skin lesion. Here we report a case in which it is difficult to distinguish AS and SAPHO syndrome with remarkable bone erosion and osteoporiferative lesion on both sides of the sacroiliac joint and sternoclavicular joint. [Case] Male in his 30s. complained back pain, bilateral knee and shoulder pain appearing about 3 years before the initial visit to our department. Pain was gradually increased, leading to his disability. Very high inflammatory reaction was pointed out, and he was admitted to our department. He showed restriction of thoracic expansion, restriction of the range of motion of the spine. X-rays/CT showed bone proliferative changes accompanied by marked bone erosion on the sternoclavicular joint and sacroiliac joint, and both sacroiliac joints were ankylosed. In addition, unilateral non-marginal syndesmophyte was found between L1/2 and the facet joints were bilaterally ankylosed with bony hyperostosis, but vertebral body was not ankylosed. He met both the modified New York criteria of AS and the classification criteria of SAPHO of Benhamou. Infliximab with csDMARDS lessened his inflammation, back pain and arthralgia.

P3-028
Respiratory function and human leukocyte antigens in diffuse idiopathic skeletal hyperostosis
Taketoshi Yasuda, Hiraku Motomura, Isao Matsushita, Yoshiharu Kawaguchi, Tomoatsu Kimura
University of Toyama, Faculty of Medicine
Conflict of interest: None

[Object] In the spine, the bone formation in diffuse idiopathic skeletal hyperostosis (DISH) is sometimes resembles ankyllosing spondylitis (AS). The purpose of this study is to investigate the ankylosing level, respiratory function and type of human leukocyte antigen (HLA) in DISH patients to clarify similarities and differences between DISH and AS. [Methods] Nine patients who are satisfied the Resnick criteria for spinal DISH and similar spine ankylosis to AS were enrolled in this study. All cases are male, the average age was 76.3 years old. The level of ankylosis, loss of chest expansion, type of airway disorders and HLA type are investigated in DISH. The respiratory function was examined in % vital capacity (%VC) and forced expiratory volume 1.0 second % (FEV1.0%). [Results] The ankylosing levels were from T2 to L2 in all cases. The loss of chest
over, keys to the correct diagnosis were very suggestive and instructive in nont SpA, we experienced two female cases of Andersson lesion. More-
because of lumbago relieved with corticosteroid was thought to due to lumbar spine. Case2. A 60-year-old female was transferred to our OPD x-ray, abdominal x-ray was taken, it showed Andersson lesion in her normal limit except for decreased chest expansion. In addition to Chest ther exam of subtle CRP elevation. Physical Exam were almost within good condition for four years after two treatments.

P3-029 Ankylosing spondylitis with femoral head osteonecrosis treated by vascularized fibular graft and anti-TNF antibody preparation: a case report Kohsei Naito1, Akihiro Fukui2, Takuro Otsuki2 1Department of Orthopedics, Nishinokyo Hospital, 2Department of Rheumatology, Nishinokyo Hospital Conflict of interest: None

[Introduction] A case report: Ankylosing spondylitis with femoral head osteonecrosis treated by vascularized fibular graft and anti-TNF antibody preparation [Case Presentation] A thirty seven year old male in for consultation due to low back pain and hip pain. X-ray showed ankylosing spondylitis. MRI showed aseptic osteonecrosis of femoral head. He was treated with vascularized fibular graft and anti-TNFα antibody preparation (adalimumab, infliximab) with MTX. Patient keeps good condition for four years after two treatments.

P3-030 Two female cases of Andersson lesion of SpA Kazutkaro Hatta, Hiroyuki Akebo, Hirofumi Miyake, Ryuichi Sada, Hiroyasu Ishimaru Department of General Internal Medicine, Tenri Hospital Conflict of interest: None

Case1. A 59-year-old female came to our OPD clinic because of further exam of subtle CRP elevation. Physical Exam were almost within normal limit except for decrease chest expansion. In addition to Chest x-ray, abdominal x-ray was taken, it showed Andersson lesion in her lumbar spine. Case2. A 60-year-old female was transferred to our OPD because of lumbago relieved with corticosteroid was thought to due to collagen disease. X-ray examination revealed Andersson lesion. Andersson lesion was rare complication of SpA. Among seemingly male dominant SpA, we experienced two female cases of Andersson lesion. Moreover, keys to the correct diagnosis were very suggestive and instructive in real clinical situation in both cases.

P3-031 A case of pustulotic arthro-osteitis who exhibited multiple paradoxical reactions to TNF-alpha inhibitors and was treated with secukinumab Tatsuo Mori, Naoto Yokogawa, Naoki Tanomogi, Masahiro Iida, Yusuke Nakamash, Shuhuei Sano, Michiru Kima, Nanase Honda, Esuke Takamash, Kae Onishii, Yuji Miyoshi, Takayasu Kise, Masako Utsunomiya, Yoshiki Nagai, Kota Shimada, Shoji Sugii Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan Conflict of interest: None

Case: a 53-year-old woman with pustulotic arthro-osteitis. She started infliximab (IFX) at age 49. From the age of 50 parasit-like rash as a paradoxical reaction appeared. IFX was switched to adalimumab (ADA). Multiple oral ulcers, abdominal pain, diarrhea appeared. Gastroscopy revealed longitudinal multiple ulcers at esophagus. Drug-induced inflammatory bowel disease due to ADA was suspected. ADA was stopped and gastrointestinal symptoms relieved. At the age of 52, colitizumab pegol was started against aggravation of arthritis. Multiple oral ulcers again appeared. We started secukinumab for her arthritis. Her axial arthritis and skin rash improved without adverse events. Discussion: Imbalance of cytokines is assumed as a mechanism of paradoxical reaction of biological products (Toussriot et al.) In our case two paradoxical reactions made it difficult to continue TNF-α inhibitors. The second-line biologics against spondyloarthritis (SpA) is IL-17 inhibitor (van der Heijde et al.). There was no report using IL-17 inhibitors for SpA patient who can’t use TNF-α inhibitor due to paradoxical reactions. This case suggests that IL-17 inhibitors are useful option for patients with SpA who can’t use TNF-α inhibitors due to the paradoxical reaction.

P3-032 A case of SAPHO syndrome requiring differentiation from multiple myeloma Masami Ogasawara, Satoshi Inotani, Tatsuki Matsumoto, Yoshiko Shimamura, Kosuke Inoue, Taro Horino, Yoshio Terada Department of Endocrinology, Metabolism and Nephrology, Kochi Medi-
cal School, Kochi University Conflict of interest: None

A 76-year-old Japanese male with half-year history of appetite loss, weight loss and stiffness of hands was admitted to our hospital. When he visited another hospital before admission, MGUS was diagnosed by bone narrow biopsy because of monoclonal gammapathy. Physical examination revealed polyarthralgia in the MP and PIP joints and deformities in the thoracic joints. Laboratory examination revealed the elevated level of CRP (7.5 mg/dL), negative rheumatoid factor and negative anti-CCP antibody. Serum and urine proteinogram detected monoclonal gammapathy (IgGk) and BIP, respectively. Gallium scintigraphy and bone scintigraphy revealed abnormal accumulation in thoracic joints and spinal osteophytes. MRI showed high intensity signal in the thoracic joints. Based on above findings, SAPHO syndrome associated with MGUS was diagnosed. Treatment started with SASP 0.5 g / day and then continued at 1 g / day without relapse. Lots of diseases associated with arthralgia, such as blood diseases and autoimmune diseases, are found in diseases that recognize M protein. However, to our knowledge, there has been no report that M protein was confirmed in SAPHO syndrome. Herein we experienced a rare case of SAPHO syndrome associated with MGUS, so we will report including literature review.

P3-033 Evaluation of patients with psoriatic arthritis in Dermatology and Rheumatology Natsumi Ikumi1,2, Takamasa Nozaki1, Hitadaka Shiraia1, Hitomi Harako1, Noboru Kitamura1, Hideki Fujita2, Masami Takei1 1Department of Rheumatology, Nihon University School of Medicine, 2Department of Dermatology, Nihon University School of Medicine Conflict of interest: Yes

[Object] Psoriatic arthritis (PsA) has recently been seen in various clinical departments including dermatology, rheumatology or orthope-
ds. To determine if there are differences in treatment and disease activi-
ty in each department. [Methods] 36 PsA patients fulfilling the CASPAR criteria and attending a dermatology clinic and/or a rheumatology clinic during December 2017 to May 2018 were recruited. The characteristics, treatments, and disease activity of patients were compared using the Fisher’s Exact test and t test. [Results] 12 patients with PsA in dermatology (D group), 10 patients in rheumatology (R group) and 14 patients in both departments (B group) were evaluated. The duration of psoriasis and PsA, the activity of arthritis were similar. A number of patients with PASI ≥3 in the R group had was significantly (50% vs. 90%, p value 0.04). The rate of achievement of PASI Clear in the B group was significantly lower compared to the D group and the R group (0% vs. 25% and 40%, respectively, p-value 0.02, 0.04). MTX was significantly more common treatment in the R group compared to the D group (42% vs. 90%, p value 0.01). [Conclusions] Although there was no significant difference in the disease activity of arthritis between treatment in dermatology and rheu-
matology in our study.
P3-034
The study of the therapeutic effect of IL-17A inhibitor on psoriatic arthritis
Takuya Izumiyama, Yu Mori, Eiji Itoi
Department of Orthopaedic Surgery, Graduate School of Medicine, Tohoku University, Miyagi, Japan

Conflict of interest: None

[Objective] The aim of this study was to assess the efficacy of IL-17A inhibitors in Japanese patients with active psoriatic arthritis. [Methods] We retrospectively investigated 15 patients who fulfilled the classification criteria for Psoriatic Arthritis (CASPAR) for the efficacy of IL-17A inhibitors. We assessed the visual analog scale (VAS) score, C-reactive protein-based disease activity score in 28 joints (DAS28), swollen joint count (0 - 66), tender joint count (0 - 68), health assessment questionnaire score and C-reactive protein level at baseline, week 24 and week 52. [Results] Of the 15 patients, 8 were male and 7 were female, with a mean age of 55.6±2.6 years. In the group treated with IL-17A inhibitors, the tender joint count declined from 4.7±2.1 to 1.5±0.8 at week 24 and 1.3±0.8 at week 52, the VAS score declined from 34.6±4.2 to 32±7.3 at week 24 and 23±5.6 at week 52, and the DAS28 declined from 2.8±0.5 to 2.1±0.3 and 2.1±0.2 at week 52. [Conclusion] Our study demonstrated IL-17A inhibitors are effective for the treatment of active psoriatic arthritis in Japanese patients.

P3-035
Clinical outcome of the anti-IL-17 inhibitor for patients with psoriatic arthritis
Akiko Suda, Yuji Uzawa, Yuji Yoshioka, Daisuke Kanai, Shohei Nagaoka
Yokohama Minamikyousai Hospital, Japan

Conflict of interest: None

[Object] To evaluate the efficacy and safety of anti-IL-17 monoclonal antibody in psoriatic arthritis (PsA) patients in our hospital. [Methods] Included in the present study were 10 patients followed up for at least 12 weeks of treatment with anti-IL-17 monoclonal antibody from March 2015 in our hospital, including 9 women (mean age: 58.4 years; mean duration of illness: 5.1 years). [Results] Of the 15 patients, 8 were male and 7 were female, with a mean age of 40.3 years, whereas that of articular manifestations occurred at a mean age of 40.3 years, whereas that of articular manifestations occurred at a mean age of 52.2 years. Seven patients were peripheral arthritis types, axial types were 3. The former preceded the latter by a mean of 15.7 years. The laboratory findings at the initial visit included a mean C-reactive protein level of 0.79 mg/dl. Drug therapy had been performed in all patients. The administered drugs were methotrexate in 8 patients, infliximab, adalimumab, and prednisolone in 3, and adalimumab and tocilizumab in 2. Cutaneous manifestations improved in all patients without one. The continuation rate at Weeks 12 and 24 was 72.7% and 54.5%, respectively. It was discontinued in one patient due to inefficacy and in 2 due to side effects, and another one patient due to request of patient. [Conclusions] Therapeutic responses were favorable in a real-world clinical setting.

P3-036
A case of psoriatic arthritis in which syndesmophytes appeared at the cervical spine C1 / 2
Shigeyoshi Tsuji1, Mari Higashiyama2, Jun Hashimoto1, Tetsuya Tomita1
1NHK Osaka Minami Medical Center, 2Nissay Hospital, Osaka University Orthopedic Biomaterial Science

Conflict of interest: None

Case A 58-year-old female with a chief complaint of neck pain visited our department for a 12-month history of neck pain. She was diagnosed with cervical spondylosis and underwent cervical spine surgery with anterior surgery. However, cervical spine surgery did not improve her symptoms. On further examination, she was diagnosed with PsA. She was treated with anti-TNFα agents, and her symptoms improved significantly. [Object] This case report describes a patient with PsA who developed syndesmophytes at the cervical spine C1/2.

P3-037
A case of psoriatic arthritis diagnosed as unexplained or somatoform disorder for a long period of time, with no rash other than nail lesion
Satsuki Aochi1, Rieko Murakami2, Safo Honda3
1Japan Self Defense Forces Sapporo Hospital, 2JR Sapporo Hospital

Conflict of interest: None

Case 24-year-old female had pain in the neck, back, and lumber region exacerbating since teens. She visited various hospitals but it did not lead to the cause. So she was introduced to our department, at first she depressed in the nial of both hands and toes, there was line of the lateral groove, and a tenderness of an adhesion. However there was no typical psoriasis eruption besides the nail. Bone scintigraphy showed bilateral asymmetry accumulation in the tendon attachment part and the sacroiliac joint lower part of 2:3. Think of psoriasis, we took her anti-TNFα formulation. After that, symptoms gradually improved. Clinical Significance Psoriatic symptoms cause ADL disorder, work disorder and markedly lower the patients quality of life. If the skin lesion of psoriasis is confirmed to the nail only as in this example, it is overlooked as unknown cause or mental illness. As a lessonful and rare example, report with some literature consideration.

P3-038
Early childhood-onset ankylosing spondylitis with ankylosis of cervical facet joint
Utako Kaneko1, Naoki Kondo2, Junichi Fujisawa2
1Department of Pediatrics, Niigata University, Niigata, Japan, 2Division of Orthopedic Surgery, Niigata University, Niigata, Japan

Conflict of interest: None

Ankylosing spondylitis (AS) is a chronic rheumatic disease characterized by inflammation and structural changes in the axial skeleton. However, spine and sacroiliac joint involvement are seldom present in childhood and adolescent patients at disease onset. We present a very rare case of early childhood onset AS with rapid progress of ankylosis of cervical facet joint. A 5-years-old Japanese male was referred to our hospital due to neck pain. He was suffering from limited range of motion of cervical right rotation, and retroflexion. There is no abnormal finding on X ray radiography of cervical spine. MRI showed erosion and erosion of right atlanto-occipital joint and dens axis. Laboratory finding showed subtle inflammation. Initial diagnosis was retro-odontoid pseudo tumor, and he was followed by regularly assessment of X ray radiography of cervical spine. At the age of 6, ankylosis of cervical facet joint of C3 to C6 was observed in X ray radiography, and cervical CT scan. Furthermore, X ray radiography of sacroiliac (SI) joint showed osteosclerosis and obsercation. MRI findings of SI joint showed erosion and joint space dilatation. He was diagnosed as having AS, and started adalimumab, which induced improvement of clinical symptom and bone erosion.

P3-039
A clinical study of the assessment of the lesions of peripheral enthesis and sternoclavicular arthritis by ultrasonography
Hirofumi Ohshaki
Internal Medicine, Ohshaki Clinic

Conflict of interest: None

[Object] There are the cases of causing the anterior chest pain in spondyloarthrits (SpA). Enthesitis are common conditions to SpA, but also SpA cases often go with the sternoclavicular arthritis. Therefore, I examined the relevance of Madrid Sonographic Enthesis Index (MASEI) score and sternoclavicular arthritis by ultrasonography. [Methods] The
subjects were SpA or SpA suspected cases (16 males, 79 females) who underwent joint ultrasonographic examination at my clinic from June to Sep-
tember 2018. Tendon structure, bone erosion, bursitis, calcification, Power Doppler signal for peripheral enthesis were examined and the 
MASEI score was calculated and sternoclavicular arthritis was evaluated. 
[Results] The sternoclavicular arthritis positive were 19 cases, the aver-
age MASEI score was 18.1, the score 18 more were 52.6%. On the other 
hand, the cases of the sternoclavicular arthritis negative were 76 cases, 
the average MASEI score was 11.5, score 18 or more was 19.7%. [Con-
cclusions] In this study, the number of cases with a MASEI score of 18 or 
more was 2.7 times that of cases with SpA or SpA suspected and those 
with positive sternoclavicular arthritis compared with negative cases. 
That the sternoclavicular arthritis and the peripheral enthesitis has some 
strong relevance was suggested.

P3-040
SAPHO syndrome complicated with multiple sclerosis successfully treated with IL-17 receptor antagonist, Brodalumab: A Case Report
Masahide Funahiki, Seiko Kondo, Naho Ayzawa, Hidetoshi Yanagida
Department of Rheumatology, National Hospital Organization Utano Hospital, Kyoto, Japan

Conflict of interest: None

Case Report: 40 years-old male with 8-year history of optic neuritis and palmoplantar pustulosis was referred to us for neck pain and polyar-
thralgia persisted for 15 years. He had treated with oral NSAIDs, cortico-
steroid and MTX for 4 years without remission. He consulted our depart-
ment of neurology for cervical cord lesion incidentally found in MRI. At 
the first visit, multiple pustules were observed at palms and soles. Wrists 
and knees were swollen and painful. Cervical ROM was restricted and 
the X-ray showed assimilation of C3-5 vertebrae. In sacroiliac MRI, bone 
marrow edema, JSA and synovial fluid retention were detected. Further, 
bone scintigraphy with 99mTc-HMDP demonstrated avid uptake in stern-
oclavicular joints and lower cervical to lumbar vertebrae. In laboratory 
test, CRP and ESR were elevated, RF and anti-CCP antibody were nega-
tive and HLA-B27 was positive. He was diagnosed with SAPHO syn-
drome complicated with multiple sclerosis (MS). For the presence of MS, 
Brodalumab was introduced. BASDAI improved from 5.3 to 1.3 at the 
50th week after treatment. Aggravation of MS was not observed over the 
period. Conclusions: In case anti-TNFα inhibitor is contraindicated, anti-
IL-17 receptor antagonist could be a potent therapeutic option for 
DMARDs resistant SAPHO syndrome.

P3-041
A case of SAPHO syndrome with the chief complaint of severe head-
ache
Tamao Nakashita, Akira Yoshida, Akira Jibatake, Shinji Motojima
Rheumatology and Allergy, Kamed Medical Center, Kamogawa, Japan

Conflict of interest: None

The well-known osteoarticular lesions of SAPHO syndrome are ster-
noclavicular joint, sacroiliac joint, and pubic joint. However, when skull 
is involved, patients frequently complain of severe headache. We report a 
case of SAPHO syndrome whose chief complaint was severe headache. A case was 45 years-old woman. From half year before consultation she 
noticed low grade fever, weight loss and severe headache of left frontal 
region. She consulted with a neurosurgeon who recognized a subcutane-
ous puncture site and intraperitoneal irrigation drainage again, and free air was observed around the ascending colon mesencephal-
on at CT, suspected of supranuclear puncture, the same day operation was performed. Under intraoperative findings, there was no macro-
scopically apparent puncture site and intraperitoneal irrigation drainage 
was performed, and relief was performed only with conservative treat-
ment. [Discussion] We report literature considerations on vasculitis, HPS and intestinal perforation with SLE.

P3-042
Successful diagnosis and treatment of SAPHO syndrome with Diffuse sclerosing osteomyelitis of the Mandible (DSOM): a case report
Yuichiro Nakashishi1, Takahiro Seno2, Shunya Kaneshita2, Kazuki Fujoka3, Makoto Wada4, Masatako Kohno5, Yutaka Kawahito2
1Internal Medicine, Kumihama Municipal Hospital, Kyoto, Japan, 2In-
flammation and Immunology, Graduate School of Medical Science, Kyoto 
Prefectural University of Medicine, Kyoto, Japan

Conflict of interest: None

[Rationale] A case is presented of SAPHO syndrome in a 39-year-old man suspected to have DSOM who was initially treated with prednis-
alone, and successfully treated with NSAIDs, methotrexate, biophospho-
nate. After intervention and evaluation with the collaboration of physi-
cian and oral surgeon, prednisolone was gradually tapered. [Case] 
39-year-old man was referred for swelling and pain of the right mandibu-
lar area due to osteomyelitis of the mandible. He had no family history of 
rheumatic and inflammatory diseases. Although culture test was negative, infectious osteomyelitis was initially suspected and he underwent a long-
term antibacterial therapy and an oral surgical procedure, but it did not 
effective. After 4 years, he complained of pain and difficulty of swelling 
again. Bone scintigraphy revealed uptake for the right mandibular and the 
first right sternocostal articulation. He had ache, knee and heel and shoul-
der pain due to enthesitis. He was diagnosed as SAPHO syndrome. [Out-
comes] NSAIDs and MTX therapy was started and it was effective, and it 
enabled to taper prednisolone. [Conclusion] Collaboration with dentists 
is important for diagnosis and evaluation of treatment in SAPHO syn-
drome with osteomyelitis of the mandible.

P3-043
A case of SLE that exacerbated with skin vasculitis and resulted in hemophagocytic syndrome and intestinal microperforation during treatment
Shiiori Hiroumi, Yuka Hyodo, Kota Azuma, Yuko Kashihara, Makoto Terada
Itami City Hospital, Hyogo, Japan

Conflict of interest: None

[Case] A 40-year-old woman was diagnosed as SLE at 27-year-old 
and was taking PSL 14 mg/day orally. From early March, exacerbations 
of exanthema were observed. In the biopsy pathology of skin lesions, 
there was clear formation of IgA, IgM, complement, and findings of SLE 
vasculitis were confirmed. Treatment with increasing PSL (20mg/day) 
and HCQ 300mg/day showed a tendency to improve eruption, but on 17 
May, shivering and fever were recognized. There were no findings sup-
porting infectious disease, but pancytopenia and high ferritinemia 
(13407ng/ml) were recognized. We diagnosed HPS associated with SLE 
and started administration of mPSL (500mg/day) and IVCY (500mg/m²). 
Treatment was successful and PSL gradually decreased progressively (PSL30mg/day), but on July 3, fever and shivering were recognized 
again, and free air was observed around the ascending colon mesencephal-
on at CT, suspected of supranuclear puncture, the same day operation was performed. Under intraoperative findings, there was no macro-
scopically apparent puncture site and intraperitoneal irrigation drainage 
was performed, and relief was performed only with conservative treat-
ment. [Discussion] We report literature considerations on vasculitis, HPS 
and intestinal perforation with SLE.

P3-044
A case of autoimmune hypophysitis presenting as central diabetes in-
sipidus associated with Systemic Lupus Erythematosus
Satoshi Kawai, Sho Ishigaki, Mayu Nagata, Yuto Takakura, Yoshiro Kanayama, Ryoei Nagata, Hiroshi Takai, Megumi Iwasaki, Ryo Hazue, 
Hiroaki Taguchi, Yasuo Ohsone, Yutaka Okano
Department of Rheumatology, Kawasaki Municipal Hospital

Conflict of interest: None

A 73-years-old woman noticed polyarthralgia in June X-1. Laborato-
ry studies showed lymphopenia, positive anti-nuclear antibody, anti-DNA
antibody, and hypoocomplementemia. So she was diagnosed as Systemic Lupus Erythematosus (SLE). She received prednisolone (PSL) 10mg/day and hydroxychloroquine 200mg/day and PSL was tapered to 5mg/day. But in April X, the patient admitted to our hospital with polydipsia and nausea. Gastro intestinal endoscopy and abdominal CT Scan didn’t revealed any digestive system disease. After admission, Urine volume was 3900ml/day, and urinary osmotic pressure was 131mOsm/kg. MRI of the head demonstrated thickening of the pituitary stalk. 5% saline load test and vasopressin load test were positive. Because MRI with administration of gadolinium showed no findings of malignancy, we didn’t histopathological examination. On the above mentioned results, we diagnosed autoimmune hypophysis presenting as secondary central diabetes insipidus associated with SLE. The patient received methylprednisolone pulse therapy and followed by PSL 1mg/kg/day and oral desmopressin. Urine volume gradually decreased and this patient was able to discontinued desmopressin. Followed up MRI showed decreased size of the pituitary stalk. Autoimmune hypophysis is rare complication with SLE.

**P3-045**

A case of SLE like symptoms presented during prostate cancer hormone therapy

Masahiro Minoda, Kiyoharu Muranaka
Suwa Central Hospital Chino, Nagano, Japan

Conflict of interest: None

[Case] A 75-year-old man presented to our hospital with facial erythema. He had received hormonal therapy with Leuproin and bicalutamide in the urology department for prostate cancer from 2 months ago. Three weeks before the visit, after working outdoors, he noticed face was flushing. On the patient’s presentation to that hospital, he appeared mild erythema on both cheeks and livedo reticularis on both legs. No other abnormal findings were observed. Urine or blood cell abnormality was not observed, CRP 0.26 mg / dl, ESR 1 hour value 41 mm, no complement reduction, 40 times antinuclear antibody, 21 IU / ml anti-ds-DNA antibody, 8.6 U / ml anti-Sm antibody, SS-A antibody <1.9 U / ml and anti-RNP antibody <2.0 U / ml. Follow up with hormone therapy discontinuation and ray exposure avoidance. After that, the skin eruption gradually improved, and blood test reexamination was carried out 6 months later, anti-ds-DNA antibody <10 IU / ml was negative. [Clinical Significance] It is considered that autoantibody appears by the antiandrogen preparation and GnRH agonist as the suppression of the immune cell activity and that it is activated by light stimulation and transiently exhibited the SLE-like finding. We report SLE-like immune response accompanying prostate cancer hormone therapy.

**P3-046**

A case of recurrent strokes caused by APS and NPSLE

Aiko Hirano, Hiroaki Kusuoka, Hironori Inoue, Kettaro Saito, Aki Sakashita, Yu Isoda, Risa Sagawa, Kazuki Fujioka, Hitetake Nagahara, Makoto Wada, Masataka Kohno, Yutaka Kawahito

Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

Conflict of interest: None

A 62-year-old female diagnosed as SLE was treated with PSL. 5mg/day and mizoribine. After herpes zoster infection, she had spike fever and leg edema. Renal biopsy showed type 3 (A/C)+5 lupus nephritis and ANA positivity (RNP+). Predonisolone and ST were prescribed. Clinical course was improved, but on 9th day these symptoms got worse. Despite of steroid pulse, plasma exchange and MMF administration, clinical course was not improved. When ST was stopped, the symptoms improved on the next day. When ST was prescribed again, the same symptoms appeared within a few hours. [Case 2] A 26-year-old female presented with fever and joint pain. She was diagnosed as SLE with lymphadenopathy, arthritis, pleuritis, lymphopenia and ANA positivity (RNP+). Predonisolone and ST were prescribed. Clinical course was improved, but on 9th day these symptoms got worse. Despite of steroid pulse, plasma exchange and MMF administration, clinical course was not improved. When ST was stopped, the symptoms improved on the next day. This patient had fever, headache and pantalgia intermittently. When ST was stopped, the symptoms improved on the next day. These symptoms have not appeared. [Consideration] The rash and bone marrow suppression are well known by the adverse effect of ST. When the SLE symptom with anti RNP antibody positive may get worse by trimeprprim-sulfamethoxazole admonistration. ST may be the etiology.

**P3-047**

A case of reversibility occipital lobe leukoencephalopathy (PRES) of SLE patient

Takamasa Nozaki, Masashi Oshima, Yutaka Tanikawa, Shoeci Yoshizawa, Hiroshi Tsuzuki, Yosuke Nagasawa, Kaita Sugiyama, Atsuna Nishiwaki, Natsumi Ikumi, Isamu Yokoe, Mitsuhiro Iwata, Hitomi Haraoaka, Noboru Kitamura, Masami Takei

Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine

Conflict of interest: None

The patient is 28 years old woman. Two years ago, she was diagnosed with SLE by lupus nephritis, CNS lupus and pleurisy. She had a cold and legs edema in July. In August Hypertension (sBP150-180) and face edema appeared. She was admitted with renal dysfunction, urine protein, urine occult blood for the medical treatment. Blood chemical analysis showed anti ds-DNA antibody (+), immunocomplex (+), reduce of complement activity and urine protein 5.93g/day. We diagnosed of rapidly progressive glomerulonephritis and nephrotic syndrome. We treated with steroid pulse therapy and prednisolone (PSL) of 1 mg/kg and plasma exchange. She developed convulsive seizure on day 30. MRI revealed abnormal signal level mainly on both sides occipital lobe. We continued same therapy, brain damage was remission on day 40. We diagnosed it with reversibility occipital lobe leukoencephalopathy (PRES) from progression. It was induced by renal damage, hypertension and CY. The patient became remission by mycophenolate mofetil afterwards. PRES is introduced by pregnancy, drug, hypertension, collagen disease, renal damage. There is few case reports which caused PRES treated with CY.

**P3-048**

SLE with anti RNP antibody positive may get worse by trimethoprim-sulfamethoxazole administration : 2 case reports

Tohru Nishizawa, Kai Imai, Minoru Shigemasa, Akira Tsujimoto, Nobuyasu Ishii, Akhiro Tanaka, Keiko Shimamoto, Hideki Amuro, Yosuho Son, Yoshio Ozaki, Shosaku Nomura

1Rheumatology and Clinical Immunology, Kansai Medical University Medical Center, 2Rheumatology and Clinical Immunology, Kansai Medical University Hospital, 31st Department of Internal Medicine, Kansai Medical University

Conflict of interest: None

[Introduction] Trimethoprim-sulfamethoxazole (ST) often prescribe to SLE patients for PCP prevention. Some reports suggest that SLE with anti RNP antibody positive may get worse by ST administration. [Case 1] A 26-year-old female presented with fever and joint pain. She was diagnosed as SLE with lymphadenopathy, arthritis, pleuritis, lymphopenia and ANA positivity (RNP+). Predonisolone and ST were prescribed. Clinical course was improved, but on 9th day these symptoms got worse. Despite of steroid pulse, plasma exchange and MMF administration, clinical course was not improved. When ST was stopped, the symptoms improved on the next day. When ST was prescribed again, the same symptoms appeared within a few hours. [Case 2] A 25-year-old female presented with rash. She was diagnosed as SLE with fever, rash, lymphopenia, hypoocomplementemia and ANA positivity (RNP+). Predonisolone was prescribed, and ST was done on every-other-day. On 8th day, she had fever, headache and pantalgia intermittently. When ST was stopped, the symptoms improved on the next day. These symptoms have not appeared. [Consideration] The rash and bone marrow suppression are well known by the adverse effect of ST. When the SLE symptom with anti RNP antibody positive patient get worse, ST may be the etiology.

**P3-049**

A case of asymptomatic retinal vasculitis with systemic lupus erythematosus

Yumiko Mizuno, Masayuki Nishiide, Akane Watanabe, Yuta Yamaguchi, Mayu Yagit, Yusuke Manabe, Takayoshi Morita, Yuichi Maeda, Hyota Takamatsu, Toru Hirano, Masashi Narazaki, Atsushi Kumanogoh

Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University

Conflict of interest: None
Conflict of interest: None

P3-052
A case of recurrent acute subdural hematoma due to vasculitis in systemic lupus erythematosus and antiphospholipid antibody syndrome

Koichi Kageyama, Kazuma Nishisaka, Shinya Ichikawa, and Fumiaki Kondo

Department of Rheumatology, JA Toride Medical Center and Department of Nephrology, Kanazawa University

Conflict of interest: None

This case was a 53-year-old woman who diagnosed with systemic lupus erythematosus (SLE) and antiphospholipid antibody syndrome (APS) two years ago. Although the activity of thrombocytopenia and renal dysfunction remained even after 40 mg of prednisolone (PSL) was started, this was improved after warfarin was started. She was stable on treatment with PSL 5mg and warfarin (target PT-INR 2 to 3). Eight months ago, she developed the first acute subdural hematoma of the right cerebellar tent. The activity of SLE was not indicated and PT-INR was strictly adjusted to about 2 after this event. However, she repeated hemorrhage at the same site three times. Cerebral angiography examination performed during the course could not identify organic abnormalities such as an aneurysm and vascular malformation. Because FDG-PET/CT showed decreased FDG accumulation in the right occipital lobe and cerebrospinal fluid examination revealed IL-6 elevation (25.7 pg/mL), we assumed vasculitis as a cause of the recurrent hemorrhage and performed additional immunosuppressive therapy (PSL 30mg+IVCY). There was no episode of hemorrhage during the follow-up period of two months. We report a case in whom vasculitis, in addition to thrombocytopenia and APS, was suspected as a cause of cerebral hemorrhage.

P3-053
An autopsy case of catastrophic antiphospholipid syndrome with multiple cerebral infarction, renal failure, acute hepatitis and pancreatitis

Fumiaki Kondo, Fumihito Suzuki

Department of Rheumatology, JA Toride Medical Center

Conflict of interest: None

This was a 62-year-old female who was diagnosed with antiphospholipid syndrome (APS) based on cerebral infarction (CI) and positive antiphospholipid antibodies in 2008. Aspirin was administrated. She admitted to our hospital for further treatment of chronic kidney disease of unknown etiology on 2015. She received hemodialysis since 2016. Her cognitive function declined and gait disorder appeared since February 2017. Brain MRI depicted multiple CI, SPECT revealed cerebral blood flow decrease in ACA-MCA lesion. Since her cognitive dysfunction advanced, she became in need for medical restraint. She was transported to our hospital due to consciousness disturbance on September 2017. Blood test revealed thrombocytopenia and elevated levels of liver enzymes and amylase. Brain MRI depicted multiple acute CI. Under the diagnosis of catastrophic APS (CAPS), methylprednisolone pulse therapy, continuous heparin infusion, oral prednisolone 40mg/day, and intravenous immunoglobulin were administrated. She died with aspiration pneumonia during the clinical course. Autopsy revealed microvascular thrombosis to the multiple organs, indicating CAPS. If multiple organ dysfunction with thrombocytopenia was observed in rheumatic patients, we should consider CAPS.
**P3-054**

**Non-Hodgkin’s Lymphoma in Systemic Lupus Erythematosus; 2 case reports**

Takanori Ichikawa, Noriko Sakaguchi, Satoru Ushiyama, Kenichi Ueno, Dai Kishida, Yasuhiro Shimojima, Yoshide Sekijima

Division of Nurology and Rheumatology, Department of Internal Medicine, Shinsiu University

Conflict of interest: None

We present two patients demonstrating malignant lymphoma (ML) which developed in their clinical course of SLE. Case 1: 34-year-old female with a 7-year history of SLE had repeated relapse despite administration of prednisolone (PSL) together with immune suppressants. Massive lesions with advanced edema in the right frontal lobe was found on brain MRI which was performed when she indicated convulsive seizure. Brain biopsy revealed EB virus positive central nervous system primary B cell lymphoma. Partial remission was obtained after surgical resection as well as radiotherapy and rituximab administration. Case 2: 33-year-old female, who had 10-year history of SLE as well as anti-phospholipid antibody syndrome, had treated with PSL. She had several episodes of severe vascular damage in her visceral organ and extremities. A subcutaneous tumor was found in her abdomen at her 31-year-old. Consecutively, several subcutaneous tumors appeared in her limbs and trunk. Biopsied tissue demonstrated T cell lymphoma. CHOP therapy was administered and remission was achieved. Conclusion: Considering the relationship between high disease activity of SLE and the pathogenesis of ML, it should be concerned that extranodal lymphoma may appear in the long-term and active phase of SLE.

**P3-055**

**The successful treatment for the refractory thrombocytopenia using belimumab in a patient with systemic lupus erythematosus**

Hiroki Kobayashi1, Takuya Tanimoto2, Hiroyuki Maeda1

1Department of Rheumatology, Hiroshima Prefectural Hospital, Hiroshima, Japan, 2Respiratory Medicine, Hiroshima Prefectural Hospital, Hiroshima, Japan

Conflict of interest: None

A fifteen-year-old woman was referred to our hospital because of nasal bleeding and petechial hemorrhage. She was diagnosed as having systemic lupus erythematosus (SLE) by the presence of the butterfly rash, positive anti-nuclear antibody, positive anti-phospholipid antibody, and thrombocytopenia. Oral prednisolone (PSL, 45 mg/day) was administered, resulting in the improvement of thrombocytopenia. The dosage of PSL was gradually tapered. Thereafter, in addition to the decrees of her platelet count, the abdominal pain occurred. Because of positive antiphospholipid antibody, thrombosis of the abdominal artery was suspected. After the aspirin-heparin treatment, her platelet count gradually increased and immunosuppression was switched to the combination of tacrolimus and Mizoribine. After that, PSL was gradually tapered to low-dose without recurrence of lupus myocarditis. [Clinical significance] SLE-related myocarditis is rare, but life-threatening. There are few prospective studies, and management is based on small-series reports. We reported the patient with literatures.

**P3-056**

**A case of linear cutaneous lupus erythematosus treated successfully with hydroxychloroquine**

Ryo Tanaka, Akiko Tanikawa

Department of Dermatology, Keio University Hospital, Tokyo, Japan

Conflict of interest: None

17-year-old woman developed a red streak along the nose ridge in October 2017. She was refractory for oral and topical antibiotics. She visited our hospital. Red pruritic papules were arranged linearly along the nose ridge. Histological examination from the papule showed liquefaction and lymphocytic infiltrates around hair follicles and appendages in a patchy pattern. No extracutaneous symptoms was seen. Anti-ds-DNA antibody, anti-SS-A antibody, anti-SS-B antibody and ANA were negative and blood test and urinalysis was unremarkable. She was diagnosed as linear cutaneous lupus erythematosus. Treatment with topical alremethazone propionate and topical tacrolimus was failed. Hydroxychloroquine was started. One month later, the red papule begins to depigmented gradually. Skin eruption continued to improve over 3 months. In Japan, treatments previously reported for linear cutaneous lupus erythematosus include topical steroid, topical tacrolimus, systemic steroid, diaminodiphenyl sulfone, but no reports using hydroxychloroquine have been made. However, antimalarials are used worldwide for cases refractory for topical steroid or tacrolimus. We summarize previous cases of linear cutaneous lupus erythematosus treated with antimalarials and our case.
**P3-059**
**Combined usage of tacrolimus and rituximab in systemic lupus erythematosus patient with severe immune thrombocytopenia: A case report**
Hideyuki Watanabe, Nobuhisa Hirase
Kyushu Rosai Hospital

Conflict of interest: None

A 65-year-old woman was admitted because of mucocutaneous bleeding involving the skin, oral cavity. Laboratory data revealed thrombocytopenia and immunological abnormalities, suggesting elevated disease activity. She was assessed and diagnosed as having systemic lupus erythematosus based on immune thrombocytopenia, positive antinuclear antibody and antiphospholipid antibody, low C3 levels and direct Coombs test in the absence of hemolytic anemia. Prednisolone, eltrombopag, Helicobacter pylori eradication and intravenous immunoglobulin therapy failed to improve the thrombocytopenia. Tacrolimus at 2-3mg/day and 4 doses of rituximab 375mg/m² weekly were added to the prednisolone regimen. Eventually, the thrombocytopenia improved and prednisolone could be effectively tapered. Combination of tacrolimus and rituximab could be an additional or alternative modality for treating refractory immune thrombocytopenia associated with systemic lupus erythematosus.

**P3-060**
**A case of systemic lupus erythematosus with Pseudo-pseudo Meigs syndrome**
Saki Tsujimoto1,2, Hideki Amuro1,2, Nobuyasu Ishii1,2, Tohru Nishizawa1,2, Shosaku Nomura1
1Rheumatology and Clinical Immunology, Kansai Medical University Medical Center, Moriguchi, Japan, 2First Department of Internal Medicine, Kansai Medical University, Hirakata, Japan

Conflict of interest: None

Case: A 32 year-old female suffered with abdominal bloating and facial edema for a month. She was admitted to our hospital. She had malar rash, leukopenia, renal disorder and positive anti-nuclear antibody and anti-Smith antibody. We made a diagnosis of systemic lupus erythematosus (SLE). Chest and abdominal CT showed pleural effusion and ascites. Pleural effusion increased rapidly, that caused orthopnea. We ruled out SLE serositis, hypoalbuminemia, or gynecological malignancies. So her CA-125 was elevated, we made a diagnosis of Pseudo-pseudo Meigs syndrome (PPMS). The patient was treated with methylprednisolone 1000mg/day for three days, followed by prednisolone 1mg/kg/day. Pleural effusion and ascites were improved, and CA-125 level normalized. PPMS syndrome described as a disease of pleural effusion, ascites, and elevated CA-125 level in patients with SLE. The mechanism of this syndrome has not become clear. PPMS should therefore be considered in the differential diagnosis of a patient presenting with ascites and pleural effusion in patients with SLE.

**P3-061**
**Worsening of central serous chorioretinopathy after steroid administration in a patient with protein-losing gastroenteropathy due to systemic lupus erythematosus**
Arata Hibi, Yuto Kasahara
Department of Nephrology and Rheumatology, Rakuwakai Otowa Hospital, Kyoto, Japan

Conflict of interest: None

A 56-year-old Japanese woman was referred to the hospital because of persistent diarrhea and worsening systemic edema. Computed tomography showed bilateral pleural effusion, ascites, and a small amount of pericardial effusion. Blood test results showed hypoalbuminemia; mild anemia with positive direct Coombs test; thrombocytopenia; as well as positive antinuclear antibody, antiphospholipid antibodies, and anti SS-A antibody. Nephritic syndrome was ruled out using urinalysis. The antrum of the stomach and duodenal bulb were suspected as protein-losing sites with "^{131}I"Te human serum albumin diethylenetriamine pentaacetic acid scintigraphy. As per these test results, protein-losing gastroenteropathy (PLGE) due to systemic lupus erythematosus (SLE) was suspected. Fundoscopy was performed prior to steroid administration and revealed central serous chorioretinopathy (CSC) on the right eye. Although PLGE responded well to steroid therapy, we were required to consider tapering steroids because the CSC worsened after steroid administration. Although PLGE is a rare manifestation of SLE, it generally achieves good therapeutic response to steroid monotherapy. However, in a patient with CSC, we should be aware of the risk of worsening the eye symptoms due to steroid administration.

**P3-062**
**A case of severe lupus myocarditis**
Chizuru Abe1, Nozomi Iwanaga1, Midori Akagi1, Chieko Kawahara1, Yoshiro Horai2, Yasumori Izumi1, Atsushi Kawakami2
1Department of Rheumatology and General Internal Medicine, National Hospital Nagasaki Medical Center, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Science

Conflict of interest: None

A 61-year-old woman with a 20-year history of systemic lupus erythematosus (SLE) and lupus nephritis was admitted to a neighboring hospital due to slight fever, general malaise and renal dysfunction. She developed heart failure and alveolar hemorrhage, for which steroid pulse therapy, tracheal intubation and artificial ventilation were performed. She was then transferred to our hospital. Interdigital erythema with erosion and a positive anti-DNA antibody test reflected SLE disease activity. Elevated Cardiac Troponin T and diffuse high signal intensity of her left ventricular wall revealed by MRI-short inversion time inversion recovery suggested the presence of lupus myocarditis (LM). Steroid pulse therapy was followed by administration of 40 mg/day prednisolone and intravenous cyclophosphamide, which resolved heart failure and alveolar hemorrhage and the tracheal tube was removed. However, she then developed perianal cutaneous vasculitis, lupus colitis, brain infarction due to antiphospholipid syndrome and cytomegalovirus infection. Considering her general condition, we avoided additional immunosuppressive therapy and she died just after the transfer to a palliative care unit. This is a rare case of LM which occurred after the onset of SLE and lupus nephritis.

**P3-063**
**A case of steroid-induced diabetic SLE patient who disclosed a gradual renal dysfunction probably due to the treatment with biguanide**
Yuta Ibayashi1, Tetsushin Murakami1, Yasutaka Kimoto1, Daisuke Oryoji1, Masahiro Ayano1, Yojiro Arinobu2, Hiroaki Niio2, Koichi Akashi3, Takahiko Horiuichi4
1Kyushu University Beppu Hospital Internal Medicine, 2Department of Medicine and Biosystemic Science, Kyushu University Hospital, 3Department of Medical Education, Kyushu University Graduate School of Medical Sciences

Conflict of interest: None

In January of X-31 year, 28 year old woman was hospitalized by unknown fever and dyspnea and was diagnosed as cardiac tamponade accompanying lupus endocarditis. During the course, she got a diagnosis as central nerve lupus, then a temporary remission being observed with steroid therapy thereafter. Since the year of X-7, she has been prescribed the same month. HbA1c was in the range of 6.5 to 6.9%. and GFR formulation was started as type 2 diabetes in X-2 year. From June of X-1 year, Hba1c worsened to 7.1%, so she was introduced to the department of diabetes medicine. Biguanide preparation / DPP-4 inhibitor were added from the same month. Hba1c was stabilized at 6.5%, but gradually worsened the kidney dysfunction. The deterioration of SLE per se was also taken into consideration, probably due to the drug-related nephritis, so we discontinued Metgluco from July X, followed by the prompt improvement of creatinine level. Metgluco is a good indication from the point of view by diabetes medicine, but it might be necessary to consider very carefully when prescribing biguanide in patients with renal dysfunction.
**P3-064**  
Lupus-associated pulmonary hypertension: Long-term response to combination of immunosuppressive and vasoactive therapy  
Koichiro Shinoda, Hiroyuki Hounoki, Reina Tsuda, Hirofumi Taki, Kazuyuki Tobe  
First Department of Internal Medicine, University of Toyama Japan

Conflicts of interest: None

[Case] 34-years-old female was admitted to our hospital, because of dyspnea on effort. She was diagnosed systemic lupus erythematosus (SLE) at the age of 13, and was treated with prednisolone (PSL) 30 mg/day. She complicated with lupus nephritis at the age of 26 and treated with PSL and cyclosporin A [CsA]. She first admitted to our hospital at the age of 33 for exacerbation of lupus nephritis and successfully treated with PSL and tacrolimus [TAC]. UltrasoundCardioGraphy [UCG] demonstrated slightly higher transthracic pressure gradient [TRPG] of 35 mmHg. Her anti-ds-DNA antibody was gradually elevated, and she admitted. ECG detected right heart load findings, TRPG 82.8 mmHg at UCG, mean PAP 53 mmHg, PCWP 6 mmHg at right heart catheter. Pulmonary embolism was never detected by imaging examination. She was diagnosed pulmonary arterial pulmonary hypertension [PAH] complicating with SLE. Oxygen inhalation and steroid pulse therapy were initiated and we changed to azathioprine from TAC. Currently, she is under maintenance therapy with PSL and tacrolimus [TAC]. UltrasoundCardioGraphy [UCG] detected right heart load findings, PAP 82.8 mmHg at right heart catheter. She needed to be punctured her abdomen or to receive cell-free concentrated ascites refusion therapy third times per two weeks. IPH rarely associated with SSc. Pathological findings of liver are very similar to those of skin sclerosis in SSc with IPH: dense fibrosis, and vascular obstruction. When SSc patients develop refractory ascites, we should consider IPH as a differential diagnosis.

**P3-065**  
A case of Systemic Lupus Erythematosus (SLE) treating with Belimumab  
Sachiko Fukumi, Keiichiro Matsunaga  
Department of Internal Medicine, Yokosuka General Hospital Uwamachi

Conflict of interest: None

Fifty-eight years old woman, who was diagnosed as Systemic Lupus erythematosus (SLE) with malar and diskoid rash, photosensitivity and nonerosive arthritis nineteen years ago, was treated with prednisone (PSON). One year later her skin symptoms were worse, so she received adadministration of mizoribine (MZR) and intravenous methyprednisolone (IVMP). Four years later she got renal symptom, so we enforced renal biopsy. The result was ISN/RPS Class III, so she received intravenous cyclophosphamide and we also used PSL, MZR and tacrolimus (TAC) as maintenance therapy. She complicated with hemophagocytic syndrome three years ago and treated with IVMP with intravenous immunoglobulin (IVIG). Until three month ago her symptom was stable, we maintained with PSL and TAC, but her compliment level was decreased and anti-dsDNA Ab was sustained positive, so we introduced belimumab. Belimumab, which is anti-BLyS monoclonal antibody, respond to improvement of clinical symptom. We report and consider our case on basis of literature.

**P3-066**  
HCQ efficacy for comorbidities of SLE  
Junya Ajiro, Katsumitsu Arai  
Niigata Prefectural Central Hospital

Conflict of interest: None

[Object] Prognosis dramatically improved with steroid treatment in SLE patients. On the other hand, there are many comorbidities such as hypertension and femoral head necrosis, improvement of QOL of SLE patients is an important subject. In Japan, HCQ was approved for skin lupus erythematosus, systemic lupus erythematosus indication. HCQ has been approved in more than 70 countries including Europe and is positioned as a standard treatment for SLE abroad, since was approved in the US in 1955 Although the effectiveness of HCQ to SLE is obvious, it is expected that comorbidities caused by steroid administration will be alleviated. We examined the effect of HCQ on comorbidities. [Methods] we investigated steroid dosage, blood pressure, HbA1c, HDL and LDL respectively for SLE patients undergoing maintenance therapy before and after HCQ treatment. [Results] Improvement was found in the reduction of the dosage of steroids and the several items. [Conclusions] In addition to the effect of SLE on the disease itself, HCQ can also be expected to have an effect on indirect co-morbidities.

**P3-067**  
Systemic sclerosis complicated by idiopathic portal hypertension  
Hajime Sanada, Satoshi Hara, Masahiro Konishi, Kazuyuki Suzuki, Takashi Ze, Ichiro Mizushima, Takashi Kawame, Hiroshi Fujii, Kazunori Yamada, Mitsuo Kawano

1Department of Rheumatology, Kanazawa University Hospital, 2Department of Nephrology, Rheumatology, Infection, Toyama Red Cross Hospital

Conflict of interest: None

A 68-year-old woman admitted to our hospital because of hyperglobulinemia 4 years before. A diagnosis of Sjogren’s syndrome was made from sicca syndrome, chronic sialadenitis in lip biopsy, and positive anti-SSA antibodies. In addition, she was also diagnosed with diffuse cutaneous systemic sclerosis (SSc) because of wide range of skin sclerosis and positive anti-centromere antibodies. She has been prescribed pulmonary vasodilators for pulmonary hypertension and estimated pressure of pulmonary artery remained 50 mmHg. She was admitted to our hospital because acute chest pain and dyspnea have developed for 7 days, and diagnosed with pneumothorax. Massive ascites was also observed, and it remained after pneumothorax resolved. Serum-ascites albumin gradient was 1.4 g/dL, so her ascites was transudative and would be caused by portal hypertension (IPH). Her ascites was not responded to diuretics, so she needed to be punctured her abdomen or to receive cell-free concentrated ascites refusion therapy three times per two weeks. IPH rarely associated with SSc. Pathological findings of liver are very similar to those of skin sclerosis in SSc with IPH: dense fibrosis, and vascular obstruction. When SSc patients develop refractory ascites, we should consider IPH as a differential diagnosis.

**P3-068**  
A case of the scleroderma that an ureter cancer and bladder cancer were able to be diagnosed with urinalysis abnormality  
Yasunori Satouchi, Amane Nakabayashi

Division of Internal Medicine, Kyoto Kuramaguchi Medical Center

Conflict of interest: None

[Case] The patient was 73-year-old woman who had a scleroderma. Urine occult bleeding, leukocyte positive lasted. Urine cytodiagnosis was classV, urinary tract epithelial cancer were detected. Abdominal CT showed saft shadow, cranial ureter, renal pelvis expansion in right lower part ureter. She was hospitalized in urology department. Tumors in the right ureter, an ureter oral region bladder were detected by ureteroscopy. Transitional cell carcinoma was diagnosed by biopsy. A transurethral bladder tumor resection was enforced under lumbar anesthesia. Laparoscopic right kidney ureter total extraction was enforced under general anesthesia. After seven years, progress is good without a recurrence and metastasis. [Clinical significance] Kidney crises may cause a renal function disorder on scleroderma, urine occult bleeding and protein become often positive. In this case, occult bleeding was positive, but protein was negative. Urine white blood cell was positive due to hydrophrosis. Urinalysis abnormality became the decisive factor of ureter and bladder cancer diagnosis. When we accept microscopic hematuria without proteinuria in menopause women, even collagen disease except dermatomyositis has to consider the possibility of the malignant tumor of urinary tract origin.
A Case report of multiple tooth resorption in SSc patients
Takumi Memida, Shiningi Matsuda, Kazuhisa Ouhara, Yuskou Yoshida, Shintaro Hirata, Eiji Sugiyama, Hidemi Kurihara
1Department of Periodontitis, Hiroshima University, Hiroshima, Japan, 2Department of Clinical Immunology and Rheumatology, Hiroshima University, Hiroshima, Japan
Conflict of interest: None

A systemic sclerosis (SSc) patient who visited department of periodicontics in Hiroshima university hospital has multiple unexplained tooth resorptions (MUTR). MUTR is first report in Japan, whereas only one case has been reported in Spanish patient in 2017. We examined systemic and oral conditions in SSc patient collaborating with department of Clinical Immunology and Rheumatology. Twenty-four patients participated to the examination, and MUTR were found in 3 patients including first case. Systemic conditions differed in three patients although their maxillofacial conditions were in high homogeneity. One, they have exhibited MUTR, and they have some calcinosis of an anterior nasal spine. In addition, their mouth is limited opening because of facial skin fibrosis. These common points suggest pathologic physiology of 3 patients is similar. The histological analysis of fraction of the tooth in first patient revealed it was bone replacing resorption in tooth. We found novel symptoms, MUTR, in SSc patients. Disease-specific iPSC cells from these patients can be revealed mechanisms of MUTR. In the future, these studies would make understanding the mechanism of pathogenesis of SSc.

P3-073
A case of suspected pulmonary veno-occlusive lesion with centromere positive systemic sclerosis
Ayana Okazaki, Kenichiro Hata, Takao Kiboshi, Hidehiko Makino, Shogo Matsuda, Youhei Fujiki, Reiko Wakura, Takuya Kotani, Tohru Takeuchi, Shigeki Arawaka
Division of Rheumatology, Department of Internal Medicine IV, Osaka Medical College
Conflict of interest: None

76 years old female was diagnosed as systemic sclerosis 10 years ago because of skin sclerosis, anti-centromere antibody positive, Raynoud phenomenon. She suffered from dyspnea on effort one year ago, and dyspnea was gradually worsened. She was suspected pulmonary hypertension because TR-PG was 65mmHg by Echocardiography. Right heart catheterization revealed mean pulmonary artery pressure (mPAP) 52mmHg, pulmonary capillary wedge pressure (PCWP) 6mmHg and pulmonary vascular resistance (PVR) 14.7wood unit. Her HRCT presented thickened septal lines, centriflobular ground-grass opacity, and medias-tinal lymph node enlargement. %DLCO and 6MWD were 16.1% and 70m respectively. She was diagnosed as pulmonary artery hypertension associated with systemic sclerosis, and suspected that pulmonary veno-occlusive lesion was complicated. She was treated with Tadalafil (20mg) and Macitentan (5mg) with diuretic agent. mPAP and PVR improved to 38mmHg and 12 wood unit 4 weeks after the therapy. Three months later, she was admitted to our hospital because of right heart failure. Her symptoms was improved after diuretic agent was added on. We reported a rare case with three CT signs of pulmonary veno-occlusive lesion complicated with systemic sclerosis.

P3-070
A Case of Systemic Sclerosis with Systemic Multiple and Huge Calcinoses
Akitsu Yoshida, Mari Tochihara, Akira Nishino, Shinya Hirahara, Hirokazu Nishina, Masanori Hanaoka, Yasuhiro Katsumata, Yasushi Kawaguchi, Hiohshi Yamanouchi, Tomoko Karita
Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
Conflict of interest: None

A woman in her 40s was diagnosed as diffuse cutaneous systemic sclerosis (SSc) 15 years ago, based on her Raynoud’s phenomenon, skin thickening of the fingers of both hands extending proximal to the metacarpophalangeal joints, interstitial lung disease, and positive anti-Scl-70 antibodies. She was treated for her skin and lung involvement with glucocorticoids, intravenous cyclophosphamide, intravenous immunoglobulin, and tocilizumab, but their effect was limited. Her modified total skin score reached 40 points a year ago. Her pain in the shoulder and hip and their joint range of motion limitations deteriorated several years ago, and her X-ray and CT showed multiple and huge calcinoses around her shoulder and hip joints. Serum level of calcium, phosphate and intact-PTH were within normal ranges. Generally, surgical intervention should be considered for severe, refractory calcinosis. However, it was avoided due to her poor general conditions. [Clinical Significance] Calcinosis affects 25% of SSc patients. Although pathogenesis is unknown, there is evidence supporting local trauma, chronic inflammation, vascular hypoxia, and dysregulation of bone matrix proteins as potential mechanisms. There is a very limited evidence base for the management of calcinosis.
P3-074
The use of nailfold videocapillaroscopy to assess for Raynaud’s phe-
nomenon associated with hand-arm vibration syndrome
Nanase Honda, Naoki Tanomogi, Masahiro Iida, Yusuke Nakamichi, Shuhei Sano, Tatsu Mor, Michiru Kina, Eisuke Takasamu, Kae Onishi, Takayasu Kise, Yui Miyoshi, Masako Utsunomiy, Yoshihki Nagai, Naoto Yokogawa, Kota Shimada, Shoji Sugii
Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center

Conflict of interest: None

[Introduction] Hand-arm vibration syndrome (HAVS) is an occupa-
tional disease affecting workers in multiple industries in which hand-held vibration tools are used. Its vascular component is a type of secondary Raynaud’s phenomenon. [Case] A 42-year-old man had Raynaud’s phe-
nomenon and digital ulcers in his fingers. He had diagnosed as systemic lupus erythematosus. Immunosuppressive and vasodilator therapy had no effect on Raynaud’s phenomenon. In nailfold videocapillaroscopy (NVC), avascular areas without giant capillaries or neangiogenesis were ob-
served in all fingers. At the age of 48, ischemia of the right index finger led to osteomyelitis and the amputation was needed. The occupational history was obtained that the patient was engaged in handling vibration tools for 32 years. Hand-arm vibration syndrome was suspected. Reduc-
tion of vibration exposure and smoking cessation improved Raynard’s phenome
non markedly and then the number and the form of capillaries became normal in NVC. [Discussion] It is important to recognize the possibility of hand-arm vibration syndrome as a potentially curable cause of Raynaud’s phenomenon even in rheumatic diseases. Improvement of microvascular damage was observed in NVC after reduction of vibration exposure.

P3-075
Two cases of treatment-resistant systemic sclerosis-related interstitial lung disease (SSc-ILD) who were treated with mycophenolate mofetil (MMF)
Tamao Nakashita, Akira Yoshida, Akira Jibatake, Shinji Motojima
Rheumatology and Allergy, Kameda Medical Center, Kamogawa, Japan

Conflict of interest: None

ILD is an important cause of death in patients with SSc. Recently, there are reports in which MMF was administered successfully for the treatment of standard -regimen resistant SSc-ILD. We here report 2 cases of severe resistant SSc-ILD for whom MMF was administered. Case 1 is a 61-year-old female with diffuse SSc. The remission induction for ILD was done by the combination of PSL and IVCy and maintenance therapy was done by PSL and AZA. However, AZA was stopped because of hepatotoxicity. Afterwards, ILD exacerbated and IVCy was re-introduced, but stopped because of nausea and others. MMF was introduced with dose of 1g/day and increased to 2g/day. After 21 months use of MMF, FVC and DLCO did not decrease, and HRCT score improved slightly. Case 2 is a 49-years-old female with the initial symptom of severe digital ulcer. The remission induction and the maintenance of SSc-ILD were done by the same regimen as in the Case 1. However, ILD progressed gradually and pneumothorax developed several times. AZA was changed to MMF 1.5g. 

day and the HRCT did not worsen after 12 months. We suggest that MMF can be a treatment option for SSc-ILD.

P3-076
A case of pulmonary arterial hypertension with mixed connective tis-
sue disease
Takafumi Onose, Reina Tsuda, Naonori Sugisita, Miho Yamazaki, Ryoko Asano, Toshiki Kido, Hiroyuki Hounoki, Koichihiro Shinoda, Hirofumi Taki, Kazuyuki Tobe
University of Toyama

Conflict of interest: None

A 58 year old woman was diagnosed as sclerodermia in 2006 and PAH (pulmonary arterial hypertension) in 2015. She had a palpitation and dyspnea in progression. Finally, she could not do any activities of dai-
ly living due to dyspnea. She was diagnosed as exasperation of PAH and referred to our hospital. She was newly diagnosed as MCTD (mixed connective tissue disease) due to elevated anti U1-RNP antibodies and SLE-like symptoms. Echocardiography and right cardiac catheterization showed no evidence of left heart failure and pulmonary perfusion scintig-
raphy denied chronic thromboembolic pulmonary hypertension. There-
fore she was diagnosed PAH, which was IV degree in WHO-PH classifi-
cation, and right heart failure due to MCTD. Vasodilator agents, catecholamine and methylprednisolone pulse therapy made her better im-
mediately. After improvement of PAH and heart failure, she was pre-
scribed IVCy therapy additionally. Combination of vasodilator agent, corticosteroid and immunosuppressive agent can improve progno
sis (Arthritis Rheum. 2008;58 (2):521-31), therefore we should start treatment as soon as possible.

P3-077
A case of Scleroderma Rheumatoid arthritis Systemic lupus erythe-
amatosus overlap syndrome
Mai Yamashita, Takaichi Okano, Yoko Nose, Yu Ueda, Sho Sendo, Kengo Akashi, Akira Onishi, Jun Saegusa, Akio Morinobu
Rheumatology and Allergy, Kobe University Graduate School of Medicine, Kobe, Japan, 3Clinical Laboratory, Kobe University Hospital, Kobe, Japan

Conflict of interest: None

[Background] Overlap syndrome (OS) is difficult, heterogeneous dis-
ease concept. We report a patient who has various symptoms, and ful-
lled criteria of systemic sclerosis (SSc), Rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). [Case description] A 74-year-old man was consulted us for fever and subacute pleuritis. He presented sclerodactyly distal to wrist, nail fold bleeding, NSIP in lower lung. ANA was 2560 fields (homogeneous and nucleolar pattern), and anti-topoisom-
erase -I antibody (Scl-70) was positive. Thus he was diagnosed with SSc. In addition, he had arthralgia one year before, elevated RF (171U/ml), and active synovitis in ultrasonography, so he also diagnosed with RA. Furthermore, he had positive Direct Coombs’test, so he met criteria of SLE. We treated him with prednisolone 0.6mg/kg according to treatment protocol of pleuritis in RA or SLE. Pleuritis decreased, but NSIP didn’t improve, and he needed home oxygen therapy after discharge. [Discussion] In the literature review, 20% in SSc patients are OS. In this case, Scl-70 antibody indicated typical pure SSc, but pleuritis, fever, and arthri-
tis suggested OS. And SSc-RA-SLE OS has not been reported previously. Here we have brief discussion about SSc-RA-SLE OS.

P3-078
A case of systemic sclerosis repeating digital ulcers complicated der-
matomyositis
Yoshinori Harada1, Yasutaka Okita1, Eri Oguro2, Kentaro Kuzuya1, Hidetoshi Matsuoka1, Satoru Teshigawara1, Maiko Yoshimura1, Yui Yoshida1, Kentaro Isoda1, Jun Hashimoto1, Shiro Ohshima1, Yukihiko Sack2
1Department of Rheumatology & Allergology, National Hospital Organi-
sation Osaka Minami Medical Center, 2Department of Clinical Research, National Hospital Organization Osaka Minami Medical Center

Conflict of interest: None

Case: 44-year-old female Course: She presented bilateral digital pain in Dec of 2015 and was diagnosed systemic sclerosis (SSc) with interstitial pneumonia (IP). Digital ulcers worsening, beraprost sodium 0.12mg was started. Transferred to our hospital in Mar of 2016, sarop 栄olate hydrochloride 300mg was added. Digital ulcers worsening in Jan of 2017, alprostadil alfloxide ointment was effective. She presented both thighs and popliteal pain in Mar of 2018, followed by bilateral back pain with diffi-
cult motion. She revealed serum myogenic enzymes increase, fever, my-
algia and positive anti-ARS antibody. She was hospitalized on 6th of Aug. No limb hypotonia, skin ulcers of right ear and right fingers, Got-
tron signs of right elbow and both knees, and mechanic hands were ob-
served. EMG developed myogenic pattern. UCG developed no myocard-
ial dysfunction and no pulmonary hypertension. IP deteriorated by imaging and function. No malignancy was found. Diagnosed dermatomy-
ositis (anti-ARS syndrome), prednisolone 30mg and tacrolimus 2mg was started, with remarkable effect. Prednisolone is gradually decreased visit by visit. Discussion: In case of SSc skin lesion worsening, we should consider not only original disease recurrence but also dermatomyositis complication, and in indication, we should use steroids actively.

P3-079
A case report of successful immunosuppressive therapy for Ogilvie’s syndrome due to scleroderma
Junya Suzuki, Shotaro Kojima, Ayako Matsuki, Kentaro Takahashi, Takeshi Umibe
Matsudo City General Hospital
Conflict of interest: None

A 53-year-old woman with hand swelling and exertional dyspnea during a year, was diagnosed as scleroderma because of sclerotic change from fingers to the elbows, interstitial pneumonia and positive anti-RNA polymerase III antibody half a year before her admission to our hospital. She had a fever and chest discomfort from the previous week, and was diagnosed with pleuritis and pericarditis. Despite administration of PSL 30mg, a new abdominal distension and pain appeared. CT showed luminal dilation of the right seminal colon without obstruction. We diagnosed it was an intestinal pseudo-obstruction. Pleuritis and pericarditis also tended to deteriorate, so we increased PSL dose to 60mg. Transanal decompression was also performed. However, her fever, abdominal symptoms and chest symptoms remained. Therefore, IVCY (cyclophosphamide intravenous therapy) was performed. Her fever fell down quickly and abdominal symptoms disappeared. CT showed improvement of intestinal dilation, pleuritis and pericarditis. Intestinal pseudo-obstruction due to scleroderma is generally a chronic course, and the fibrosis of the intestinal tract is considered to be irreversible. Acute colon pseudo-obstruction is classified as Ogilvie’s syndrome. Little has been reported on Ogilvie’s syndrome due to scleroderma.

P3-080
A Case of Systemic Sclerosis Associated with Nephrotic Syndrome
Masashi Mizuno, Koji Uehara, Taio Naniwa, Michio Fukuda
1Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Graduate School of Medical Sciences, 2Department of Laboratory Medicine, Allegy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences
Conflict of interest: None

A case of 28-year-old man who had suffered from nephrotic syndrome was reported. The patient had developed digital ulcers in 2006 and had been treated methotrexate under diagnosis of systemic sclerosis. However, he then had developed sclerosis of skin. Proteinuria had appeared in June 2018. His blood showed hypoproteinemia. A renal biopsy was judged to be at high risk due to the problem of arthropathy, and considering the acute onset of nephrotic syndrome, steroid treatment (oral prednisolone 50 mg/day) started without histological diagnosis. However, he had an incomplete remission by the steroid therapy. Then a renal biopsy was performed and showed no spiking or bubbling was found on periodic acid methenamine silver staining. His renal biopsy revealed the minimal change glomerular lesion microscopically. Improvement in urinary protein and serum albumin was insufficient, so focal glomerulosclerosis was also presumed from the clinical course. Since such renal diseases were rarely observed in systemic sclerosis, we herein report the interesting case suggesting immune system abnormality.

P3-081
The use of nailfold videocapillaroscopy to assess Raynaud’s phenomenon secondary to dermatomyositis
Nanase Honda, Naoki Tamogami, Masahiro Iida, Yusuke Nakamichi, Shuhei Sano, Tatsuori Mori, Michiru Kina, Isuake Takamatsu, Kae Onishi, Takayasu Kise, Yuji Miyoshi, Masako Usutsumi, Yoshiki Nagai, Naoto Yokogawa, Kota Shimada, Shoji Sugii
Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center
Conflict of interest: None

[Introduction] Nailfold videocapillaroscopy (NVC) is useful in the evaluation of microvascular damage in systemic sclerosis. Recently, the significance of nailfold microvascular abnormalities in dermatomyositis was reported. [Case] A 29-year-old woman with proximal muscle weakness, rash over cheek and neck, periangual erythema and Raynaud’s phenomenon was admitted. Creatine kinase was elevated and myositis-specific antibodies were negative. Electromyography showed signs of myopathy and muscle pathology showed perifascicular atrophy. In NVC, giant capillaries, microhemorrhages and loss of capillary density were observed. The patient was diagnosed as dermatomyositis and started on glucocorticoid and azathioprine. 3 months later, muscle weakness, rash and Raynaud’s phenomenon improved and creatine kinase normalized. 9 months later, NVC showed remarkable bushy and ramifying capillaries with a decrease of giant capillaries and an increase in capillary density. [Discussion] In systemic sclerosis, Raynaud’s phenomenon is refractory and slowly progressive microvascular damage can be observed in NVC. In dermatomyositis, Raynaud’s phenomenon improves and in the presented case the severe microvascularopathy at the onset and the remodeling of microvascular after treatment were observed by NVC.

P3-082
Usefulness of muscle echo in polymyositis and dermatomyositis
Chie Orita, Kazuteru Noguchi, Maki Shimamoto, Mai Nakano, Rei Tadakoroi, Kazuyuki Tsuboi, Mei Tani, Tetsuya Furukawa, Masao Tamura, Takahiro Yoshikawa, Teppei Hashimoto, Mai Morimoto, Naoto Azuma, Masayasu Kitano, Kyoshi Matsui
Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine
Conflict of interest: None

[Objective] MRI has been widely used as a morphological evaluation of neuromuscular diseases, and in recent years the utility of muscle echo has also been reported. Muscle echo is an aid in the diagnosis of inclusion body myositis and myosarcoma. Inflammatory findings of polymyositis (PM) and dermatomyositis (DM) can also be evaluated on muscle echo. This time, we evaluated muscle of inflammatory myopathy using muscle echo. [Methods] We used a high frequency probe (7-12 MHz) and examined the patient in a sitting position. Regardless of the presence or absence of muscle pain or muscle weakness, we made the observation sites of all cases into quadriceps femoris and biceps brachii muscle. We evaluated both short and long axis images. [Results] Compared with healthy muscles at the same site, PM patients showed an increase in muscle brightness, and in short-axis images there was conspicuous irregularity of the muscle bundle. DM Patients had predominantly myofascial thickening and necrotizing myopathy patients had marked muscle atrophy. [Conclusions] Diagnosis of inflammatory myopathy and evaluation of disease condition are possible by using muscle echo. To evaluate accurately it is important to use muscle echo under the same conditions on the same machine.

P3-083
Practice investigation of polymyositis, dermatomyositis in our hospital
Shin Furukawa, Hirohiko Kitakawa
Internal Medicine, Kushiro Red Cross Hospital
Conflict of interest: None

[Objective] In conformity with “polymyositis, dermatomyositis treatment guidelines issued in 2015,” we grasp the practice situation of the case of previously treated polymyositis / dermatomyositis in the past 20 years in this hospital and examine clinical problems. [Methods] We searched polymyositis, dermatomyositis and a diagnosed case (27) on an electronic chart from October, 1998 to October, 2018. In conformity with “the diagnostic criteria, practice guidelines on polymyositis, dermatomyositis,” we received the analysis of various complications, therapies, age, sex, examination data of the target cases. [Results] Sex: Seven men: 20 women, Age at investigation 54.2±13.4 years old, Age at onset 50.1±14.2 years old, Polymyositis / dermatomyositis:11/16, Interstitial pneumo-
P3-086
The study on prognostic factor for anti-MDA5-antibody positive DM patients
Toshiki Kido, Hiyoriuki Hounoki, Takafumi Onose, Naonori Sugishita, Miho Yamazaki, Ryoko Asano, Reina Tsuda, Koichiro Shinoda, Hirofumi Taki, Kazuyuki Tobe
The First Division of Internal Medicine, Toyama University Hospital, Toyama, Japan
Conflict of interest: None

[Object] The aim of this study is to retrospectively review the clinical practice of our institution and to evaluate the clinical manifestation and prognostic factors in patients with interstitial pneumonia (IP) associated with anti-melanoma differentiation-associated gene 5 (MDA5) antibody (Ab) positive dermatomyositis (DM). [Methods] Subject comprised 7 patients who presented with DM positive for anti-MDA5 Ab. Base line characteristics, clinical manifestations, parameters and outcomes were recorded (5 survived, 2 died). [Results] We analysed continuous variables such as highest serum ferritin, LDH, anti-MDA5 Ab titer and age of diagnosis, which had no significance in two groups of survived group and that with fatal outcome. We also considered IP involvement in right middle lobe, bacteremia and pneumomediastinum during treatment course, and we found the last two factors were more frequently in the group with outcome of death. [Conclusions] Bacteremia and pneumomediastinum seems to be important factors which contribute to poor outcome in MDA5 Ab positive DM patients.

P3-088
Clinical characteristics and prognostic factors in patients with anti-MDA5 antibody positive dermatomyositis
Shun Nomura, Ryosuke Haru, Wataru Ishii
Division of Rheumatology, Nagano Red Cross Hospital
Conflict of interest: None

[Object] Anti-MDA5 (melanoma differentiation-associated gene5) antibody positive dermatomyositis patients show rapidly progressive interstitial pneumonia. The aim of this study is to elucidate clinical characteristics and prognostic factors in patients with anti-MDA5 positive dermatomyositis. [Methods] We retrospectively examined clinical data,

P3-084
Predictive serum biomarkers for mortality and relapse in idiopathic inflammatory myopathies-associated interstitial lung disease
Yoko Nakagome, Yasushi Kondo, Kazuki Hirano, Takayoshi Kurabayashi, Sho Sasaki, Yasushi Koyama, Mai Sugiyama, Yuto Izumi, Chippo Yamada, Shinji Sato
Department of Rheumatology, Tokai University
Conflict of interest: None

[Object] To identify predictive serum biomarkers of mortality and recurrence in idiopathic inflammatory myopathies (IIM)-associated ILD. [Methods] A total of 125 of IIM-associated ILD patients were enrolled. The risk of mortality and relapse were examined using the recent predictive model that combined the serum biomarkers (including serum ferritin, CRP, KL-6 levels and anti-MDA5 antibody positivity). [Results] 28 patients were positive for anti-MDA5 antibody and 75 patients had anti-ARS antibody. During the observation period (median 42 months), Death related to ILD was observed in 31 patients. The mortality of ILD was significantly associated with positive numbers of serum biomarkers of predictive risk model for PM/DM-ILD. Univariate analysis showed that serum ferritin and CRP levels were correlated with mortality although they were not associated with recurrence of ILD. Only serum KL-6 level was significantly associated with recurrence of ILD. [Conclusions] The predictive risk model of the combined evaluation of autoantibodies and serum biomarkers is useful for assessing the prediction of mortality in IIM-associated ILD. Only serum KL-6 was associated with relapse of IIM-associated ILD. To identify predictive serum biomarkers of poorer survival and recurrence in myositis-associated ILD.

P3-085
The involvement of type I interferon in pathophysiology of dermatomyositis
Jeong Hoon Park1,2, Hachirou Konakaza1, Eri Iotagawa2, Yasuhiro Kato2,3,4, Hyota Takamatsu2,3, Atsushi Kumanogoh2,3
1Osaka University Faculty of Medicine, 2Department of Immunopathology, World Premier International Research Center Immunology Frontier Research Center, 3Department of Respiratory Medicine and Clinical Immunology, Osaka University Graduate School of Medicine, 4Division of Allergy, Rheumatology and Connective Tissue Disease, NTT West Osaka Hospital
Conflict of interest: None

[Object] Expression of interferon-stimulated genes (ISGs) has been reported in polymyositis/dermatomyositis (PM/DM). However, only a few studies have directly measured type I interferon (IFN-I) in patients. Here, we evaluated IFN-I in the serum of PM/DM and studied its clinical significance. [Methods] Sera from PM/DM (n=40) and healthy controls (HC; n=37) were collected to measure IFN-I bioactivity and ISG-inducing activity using a cell-based reporter system. To identify the molecular mechanisms of IFN-I production, knockout reporter cells were generated. [Results] IFN-I bioactivity and ISG-inducing activity were significantly higher in DM than HC. Elevated IFN-I was observed almost exclusively in DM patients with anti-MDA5 antibody and associated with clinical manifestation. The ISG-inducing activity was completely diminished in IFNAR2-knockout reporter cells. [Conclusions] Anti-MDA5 antibody-positive DM patients with high IFN-I levels tended to have severe disease manifestation. Diminished ISG-inducing activity in IFNAR2-knockout reporter cells suggested that it was induced by IFN-I itself and not by other extracellular factors, implying IFN-I overproduction by cell-intrinsic abnormalities. Our data indicate that IFN-I signaling may be a promising therapeutic target for DM.

P3-087
Initial predictors of poor survival in anti-melanoma differentiation-associated gene 5 antibody-associated dermatomyositis and rapidly progressive interstitial lung disease
Kazuki Hirano, Yasushi Kondo, Yoko Nakagome, Mai Sugiyama, Yuto Izumi, Sho Sasaki, Takayoshi Kurabayashi, Yasushi Koyama, Chippo Yamada, Shinji Sato
Department of Rheumatology, Tokai University
Conflict of interest: None

Initial predictors of poor survival in anti-melanoma differentiation-associated gene 5 antibody-associated dermatomyositis and rapidly progressive interstitial lung disease [Objective] To identify initial predictors of poor survival in patients with anti-melanoma differentiation-associated gene 5 antibody (anti-MDA5 ab) associated dermatomyositis (DM) and rapidly progressive interstitial lung disease (RP-ILD). [Methods] Twenty-eight patients with anti-MDA5ab associated DM and RP-ILD were enrolled. We retrospectively collected clinical data at the time of diagnosis and their outcome. we analyzed associations between them by univariate and multivariate analyses. [Results] The mean age of 28 patients was 56.3±10.4 years. During the observation period (median: 22 months), 14 patients died (50%) due to RP-ILD. Univariate analysis revealed that age at onset, serum levels of ferritin, CRP and SP-D were significantly associated with mortality. Subsequently we performed multi-variate analysis and identified the elevation of serum SP-D as an independent risk factor for mortality due to RP-ILD: (p <0.01; HR 1.02, 95%CI 1.01-1.04) [Conclusion] High serum SP-D concentration at baseline might be an independent predictor of poor survival in patients with anti-MDA5ab associated DM and RP-ILD.
treatment and outcome of anti-MDA5 antibody positive dermatomyositis patients who were admitted to our hospital between April 2015 and October 2018. [Results] Ten patients were enrolled in this study. Six patients survived and 4 patients died. Interval between onset of disease and commencement of treatment was 102 days in survival group and 29 days in fatal group. Serum ferritin, KL-6 and CRP were higher in fatal group than survival group. All patients were treated with oral prednisolone in combination with calcineurin inhibitors. All patients in fatal group were treated with methylprednisolone pulse therapy and intravenous cyclophosphamide (IVCY). On the other hand, only 3 patients in survival group were treated with IVCY. [Conclusions] Anti-MDA5 antibody positive dermatomyositis is fatal disease. Early combination therapy of immunosuppressants improved the prognosis, but it is not enough. We need to find out new effective treatment.

P3-089 Transition of ferritin value during initial treatment in anti-MDA5 antibody positive interstitial pneumonia and anti-synthetase syndrome
Satoshi Omura, Takuya Yanagida, Masatoshi Kadoya, Atsushi Omoto, Wataru Fukuda
Center for Rheumatic Disease, Japanese Red Cross Kyoto Daichi Hospital
Conflict of interest: None

[Object] Although it is known that high levels of ferritin before treatment start with Anti-synthetase syndrome (ASS) and anti-MDA5 antibody-positive interstitial pneumonia become prognostic exacerbating factors, there are few reports reported. We investigated the trend of ferritin value at the beginning of treatment. [Methods] A case of each disease diagnosed at our hospital and receiving initial treatment was taken from January 2007 to October 2018. Patients measuring ferritin levels at least twice before treatment and 1 to 4 weeks after treatment were selected from among them and examined for the course of ferritin values from the start of treatment to 4 weeks. [Results] The each case satisfying the above was 6 cases and 4 cases. The median ferritin values before treatment were 690.5 ng/mL and 564 ng/mL, respectively. Except for one case of ASS, the ferritin value increased after treatment started. In all cases, the ferritin level peaked within 4 weeks. The median peak-out of ferritin levels in 6 surviving cases in total was 14 days and in dead cases it was 2 days. [Conclusions] It was suggested that the length of the period required for peak out of ferritin value may be a factor of prognostic prediction.

P3-090 Necessity of triple therapy for anti-MDA5 antibody positive dermatomyositis
Takayasu Ando, Takeshi Suzuki, Harunobu Iida, Kanako Suzuki, Yutaka Goto, Marina Uchina, Yusa Asari, Hisae Fujimoto, Shoshi Shinagawa, Kana Ishimori, Keiichi Sakurai, Tomo'fumi Kiyokawa, Hiromi Matsushita, Yukiko Takakawa, Kuniko Tonooka, Mitsuru Imamura, Yoshihiko Yamasaki, Seido Ooka, Hiroko Nagafuchi, Kimito Kawahata
Division of Rheumatology and Allergology, St. Marianna University School of Medicine
Conflict of interest: None

[Object] To evaluate necessity of triple therapy for anti-MDA5 antibody (aMDA5 Ab) positive dermatomyositis (DM), [Methods] The data of aMDA5 Ab positive patients were retrospectively collected from clinical records. These patients were classified triple therapy group and double therapy group as induction therapy. We compared both groups of clinical characteristics, prognosis and existence of interstitial pneumonia (IP) recurrence. Rapidly progressive IP (RP-IP) was defined as developing respiratory symptoms within 1 month after its onset. [Results] All 10 patients were female and age was 50.5±10.8 years. Six patients were triple therapy group (IVCY+Tac:4, IVCY+Csa:2) and 4 were double therapy group (PSL+IVCY:2, PSL+Tac:2). Survival rate in all patients was 90%. Baseline characteristics were not significantly different between two groups, but cytoktemaloviriasis was significantly increased in triple therapy group (p<0.01). In double therapy group, 2 patients complicated RP-IP, and one of them died of infections, but another 3 patients survive without recurrence of IP. [Conclusion] Both aMDA5 Ab positive DM patients treated with triple and double therapy had good survival rate compared with previous reports. Triple therapy will not be necessarily for all aMDA5 Ab positive DM patients.

P3-091 Usefulness of Combined Immunosuppressive Therapy in Anti-MDA5-Positive Dermatomyositis with Interstitial Lung Disease
Hideaki Tsuji, Ran Nakashima, Yuji Hosono, Yoshitaka Imura, Masato Yagita, Hajime Yoshifuji, Shintaro Hirata, Takao Nakijima, Eiji Sugiyama, Kazuhiro Hatta, Yoshiho Taguchi, Masaki Katayama, Kiminobu Tanizawa, Tomohiro Handa, Takeshi Kubo, Shuji Akizuki, Kosaku Murakami, Motomu Hashimoto, Masao Tanaka, Koichiro Ohmura, Tsuneyo Mimori
1Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, 2National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, 3Department of Clinical Immunology and Rheumatology, The Tazuke-Kofukai Medical Research Institute, Kitano Hospital, 4Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, 5Department of General Medicine, Tenri Hospital, 6Department of Respiratory Medicine, Tenri Hospital, 7Department of Rheumatology and Clinical Immunology, Osaka Red Cross Hospital, 8Department of Respiratory Medicine, Kyoto University Hospital, 9Department of Diagnostic Imaging and Nuclear Medicine, Kyoto University Hospital, 10Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Hospital
Conflict of interest: None

[Object] Since the standard treatment had not been established for rapidly progressive interstitial lung disease (RP-ILD) in anti-MDA5-positive dermatomyositis (DM), we prospectively evaluated the efficacy of combined immunosuppressive therapy. [Methods] Newly onset adult Japanese anti-MDA5-positive DM patients with ILD received combined immunosuppressive regimen with glucocorticoids, tacrolimus, and intravenous cyclophosphamide (IVCY) and/or plasmapheresis (PE). We set a historical control with step-up treatment of immunosuppressants. The primary endpoint was 6-month survival and 2nd endpoint was analyzing transition of laboratory data during 52 weeks. [Results] Combined immunosuppressive regimen (n=29) received IVCY about 20 days earlier with shorter intervals and received PE more frequently than step-up treatment (n=15). Six-month survival rates were 89% and 33%, respectively (p<0.0001). At week 52, the levels of anti-MDA5, ferritin, and %VC were improved. Cytomegalovirus reactivation was frequently observed during 52 weeks. [Conclusions] Early combined immunosuppressive therapy is effective for anti-MDA5-positive DM with ILD, and in intractable cases, additional effect can be expected in PE. Opportunistic infections should be monitored during treatment.

P3-092 Clinical features of anti-MDA5 antibody positive amyopathic dermatomyositis patients
Kazuma Ino, Takayuki Hoshiyama, Takumi Muramatsu, Yasuhiro Hasegawa, Junichi Kondo, Toshihiro Tono, Yoshiyuki Arinuma, Tatsuo Nagai, Sumiaki Tanaka, Kunihiro Yamaoka
Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Sagamihara, Kanagawa, Japan
Conflict of interest: None

[Object] In order to understand its clinical features, we examined anti-MDA5-5 (melanoma differentiation-associated gene 5) antibody positive amyopathic dermatomyositis (ADM) experienced at our hospital. [Methods] We retrospectively examined initial ADM patients who hospitalized in our department and were confirmed as positive for anti-MDA5 antibody (including anti-CADM140 antibody) after March 2013. (Results) 13 patients had anti-MDA5 5 antibody positive. The mean age was 51.7 years, sex was 4 males and 9 females, all cases had skin rash, 12 cases had interstitial pneumonia, myositis such as muscle weakness were observed in 3 cases. There were 10 surviving and 3 deaths. The average ferritin and KL-6 values were 505 ng/mL and 740.1 U/mL respectively. 11
patients survived and 3 patients were dead. Since October 2016 when anti-MDA-5 antibody measurement was covered in insurance, There were no deaths (n=6). [conclusions] Measurement of anti-MDA-5 antibody may sample the rapid progressive dermatomyositis early and contribute to improvement prognosis by strong immunosuppressive therapy. 

P3-093  
Three cases of hemophagocytic syndrome in dermatomyositis with anti-MDA-5 autoantibody  
Manabu Honda 1, Mayuko Moriyama 1, Masahiro Kondo 1, Shunichi Kumakura 2, Yoshiko Sumita 1, Yohko Murakawa 2  
1Department of Internal Medicine and Rheumatology, Juntendo University, 2Division of Rheumatology, Department of Medicine, Kurume University  

Conflict of interest: None  

Hemophagocytic syndrome (HPS) is a rare complication but exhibits poor prognosis in dermatomyositis (DM). We describe here three cases with HPS in DM with anti-MDA-5 autoantibody. Case 1: A 63-year-old woman was admitted to our hospital with high fever, muscle weakness, Gottron’s papule, mechanic’s hands. Laboratory tests showed elevated serum muscle enzymes, thrombocytopenia and hyperferritinemia. Bone marrow aspiration and biopsy revealed hemophagocytosis. She was diagnosed as DM with HPS. After she died of interstitial pneumonia, it found that anti-MDA5 autoantibody was positive. Case 2: A 37-year-old woman was admitted to our hospital with high fever, dysphagia, facial erythema, mechanic’s hand, leukopenia and hyperferritinemia. Anti-MDA5 autoantibody was positive. He was diagnosed as amyopathic DM. Bone marrow examinations revealed hemophagocytosis. Case 3: A 57-year-old woman was admitted to our hospital with arthralgia, muscle weakness, facial erythema, heliotrope eruption, shawl and V neck signs, elevated serum muscle enzymes, pancytopenia and hyperferritinemia. Anti-MDA5 autoantibody was positive. She was diagnosed as HPS with bone marrow examinations. Thus, our cases indicated that anti-MDA-5 autoantibody might be associated with HPS.  

P3-094  
Three cases with dermatomyositis of anti-MDA5 antibody which followed various processes  
Maki Shibamoto, Mai Morimoto, Tetsuya Furukawa, Kazutera Noguchi, Rei Tadokoro, Kazuyuki Tsuboi, Mei Tani, Chie Ogita, Takahiro Yoshikawa, Masao Tamura, Teppei Hashimoto, Naoto Azuma, Masayasu Kitano, Kiyoshi Matsui  
Division of Rheumatology, Hyogo College of Medicine Department of Internal Medicine  

Conflict of interest: None  

We report three cases with interstitial lung disease (ILD) of anti-MDA5 antibody positive. The first patient was 31-year-old man, who had gottron’s sign and ferritin’s elevation. CT showed ground-glass opacification (GGO) in both lower lungs. He was received methylprednisolone (mPSL) pulse therapy following prednisolone (PSL) 1mg/kg/day, tacrolimus (TAC) and intravenous cyclophosphamide (IVCY). Later, gottron’s sign was disappeared, ferritin level decreased. The second patient was 37-year-old woman, who had gottron’s sign and ferritin’s elevation. CT showed random GGO in both lungs. She was received PSL0.8mg/kg/day, TAC and IVCY. However, she had steroid psychosis and could not receive intravenous treatment. We changed to oral cyclophosphamide, and gottron’s sign and ferritin level decreased. The third patient was 28-year-old man, who had the erythema in finger, elbow joint stretch side and back. CT showed diffuse GGO in both lungs. He was received mPSL pulse therapy following PSL1mg/kg/day, TAC and IVCY. However, he had sigmoid colon piercing and underwent abdominal surgery. After oxygenation had got worse, and he died. We experienced three cases which followed various processes, and report with literature consideration.  

P3-095  
Clinical features of anti-MDA5 antibody-positive clinically amyopathic dermatomyositis that caused repeated aggravation of interstitial pneumonia  
Satoshi Suzuki 1, Takuya Nishi 1, Shota Sakuma 1, Keigo Ikeda 1, Ken Yamaji 1, Naoto Tamura 2, Shinji Morimoto 1  
1Department of Internal Medicine and Rheumatology, Juntendo University, 2Urayasu Hospital, 3Department of Internal Medicine and Rheumatology, Faculty of Medicine, Juntendo University  

Conflict of interest: None  

Anti-MDA5 antibody-positive clinically amyopathic dermatomyositis (CADM) often accompanies rapidly progressive interstitial pneumonia (RP-ILD). However, relapse is reported to be infrequent if the treatment is successful, although the long-term prognosis is unclear. We examined the clinical features of three cases of CADM with recurrences of ILD. In case 1, developed CADM at 44 years of age and was treated with steroid pulse therapy (IVmPSL) and 50 mg/day but was hospitalized with ILD aggravation at 47 and 51 years of age. In case 2, developed CADM at 54 years of age and was treated with IvmPSL and 40 mg/day of PSL with cyclosporin (CyA); ILD was aggravated at 61 years of age and cyclophosphamide pulse therapy (IVCY). ILD was aggravated for the third time at 66 years of age, and the patient died. In case 3, developed CADM at 60 years of age. IvmPSL was initiated with 50 mg/day of PSL; CyA was also added. However, ILD recurred at 67 years of age; thus, CyA was replaced with tacrolimus, and IVCY was introduced. Although cases of recurring CADM are rare, they do exist and can sometimes be fatal. The prognosis for CADM has improved over time owing to its establishment as a disease. However, further accumulation of research is needed to ascertain its long-term prognosis.  

P3-096  
Clinical significance of the early induction of IVCY in patients with anti-MDA5 antibody-positive DM associated with interstitial lung disease  
Takuma Koga, Yumi Yoshida, Makiko Hayashi, Kyoko Fujimoto, Satoshi Sakamoto, Yukiko Hitaka, Masaki Okamoto, Shinjiro Kaieda, Masaki Tominaga, Tomoaki Hoshino, Hiroaki Ida  
Division of Rheumatology, Department of Medicine, Kurume University School of Medicine  

Conflict of interest: None  

Background: Intensive immunosuppressive therapy including steroids, calcinurin inhibitor and IVCY has been reported to be improved poor prognosis in anti-MDA-5 antibody positive DM associated rapidly progressive interstitial lung disease (RP-ILD). We examined whether the early induction of IVCY may improve prognosis. Methods: A total of fifteen patients diagnosed as having anti-MDA-5 antibody-positive DM with ILD from 2007 to 2018 were enrolled. All patients received intensive immunotherapy including IVCY. In addition, respiratory function was analyzed in anti-MDA5-5 ab or anti-ARS ab positive ILD during chronic phase. Results: Seven patients were received IVCY within 28days after ILD diagnosis and only one patient was killed by RP-ILD. Four out of eight patient, who received IVCY after 28 days ILD diagnosis, died. In the chronic phase, forced vital capacity (FVC) tended to be improved in anti-MDA-5 ab positive ILD. In contrast, FVC was decreased in anti-ARS ab-positive ILD in the long observation period. Conclusion: Early induction of IVCY may improve poor prognosis caused by RP-ILD. In the chronic phase of anti-MDA-5 antibody positive DM patients with ILD, pulmonary function test results were well maintained and had a good clinical course.  

P3-097  
Three clinically amyopathic dermatomyositis cases with anti MDA5 antibody who were treated with hydroxychloroquine  
Nobuyuki Ono, Mariko Sakai, Yosiharu Nakao, Yuri Sadanaga, Akihito Maruyama, Syuichi Koarada, Yoshifumi Tada  
Department of Rheumatology, Saga University Hospital  

Conflict of interest: None
The usefulness of hydroxychloroquine (HCQ) has also been reported in dermatomyositis (DM), but its use is limited due to its myotoxicity. We reported three cases using HCQ for anti-MDA5 antibody positive amyopathic dermatomyositis (CADM). Case 1: A 74-year-old male was suffered from skin symptoms with multiple ulcers and subacute interstitial pneumonia with elevated ferritin (948 µg / ml) and anti-MDA 5 antibody. His refractory skin ulcers for the three-drug combination therapy was improved by additional HCQ treatment. Case 2: 82-year-old female with progressive interstitial pneumonia appeared during treatment of NP-SLE was diagnosed as CADM from Gottron’s sign, elevated ferritin (1395 mg / ml), and anti-MDA 5 antibody. The triple combination therapy with HCQ improved her respiratory symptoms. Case 3: A 74-year-old female, with Gottron’s sign, subacute interstitial pneumonia, elevated ferritin (719 mg / ml) and MDA 5 antibody was diagnosed as CADM. The skin symptoms and high ferritinemia were refractory for the triple combination therapy. Additional HCQ treatment improved them. (Discussion) Anti-MDA5 antibody positive dermatomyositis is known to have high type 1-IFN activity, suggesting that HCQ may be useful for the remission induction and maintenance therapy.

P3-098 A case of successful treatment of combination with plasma exchange and rituximab for rapid progressive interstitial lung disease with anti-MDA5 antibody positive dermatomyositis
Hiroshi Hamada, Tadashi Sugiyama, Nobuyoshi Mineura, Eiji Nagasawa, Koji Takano, Michita Suzuki, Kumiho Umemura, Suyensuke Yokoi, Takakazu Hasegawa, Mayu Sugiyama
General Medicine, Nagoya Medical Center, Department of Rheumatology, Nagoya Medical Center

Conflict of interest: None

A 54-year-old female has had rash on face since one month ago, and on both hands from the end of the same month. Since she has had fever and muscle pain in proximal limbs. She saw previous doctor and chest CT revealed ground-glass appearance, so she was suspected of DM. After that She was referred to our hospital for purpose of treatment. After hospitalized we found anti-MDA5 antibody was positive, for Steroid pulse, tacrolimus and endoxan were performed. The interstitial shadow progressed was observed even after additional treatment with Endotoxin adsorption, immunoglobulin therapy. So rituximab and plasma exchange were introduced. So respiratory state improved, and titer of anti-MDA5 antibody and ferritin declined. And she was discharged on 156th day. (Discussion) It is known interstitial lung disease with anti-MDA5 antibody positive DM is refractory to treatment and poor prognosis. There is no definitive treatment, In this case, there was a possibility that plasma exchange and rituximab could lead to good result. Further investigation is necessary in the future.

P3-099 A case of that was able to inhibit progress by IVIg and RTX administration for the immunosuppressive therapy anti-MDA-5 antibody positive treatment-resistant interstitial pneumonia
Masami Mizuno, Ken Takao, Takuo Hirota, Yukio Horikawa
Department of Diabetes and Endocrinology, Gifu University Hospital

Conflict of interest: None

[Case] We report the case of a patient who was hospitalized for dermatomyositis in 2017. The diagnosis was based on the presence of anti-MDA-5 antibody and a mild ground glass shadow appearance on laboratory investigations. Prednisolone 55 mg and tacrolimus were subsequently initiated. Although there was no evidence of exacerbation with the ground glass shadow evaluation, KL-6, lactate dehydrogenase, ferritin, and PaO2 values suggested otherwise. High dose cyclophosphamide was administered intravenously from April. A diagnosis of rapidly progressive interstitial lung disease (RP-ILD) was made by the end of May. The patient was subsequently admitted to our department and steroid pulse therapy was initiated. However, RP-ILD aggravated following which rituximab (RTX) and intravenous immunoglobulin (IVIg) therapy was added. The patient was stable subsequently. Markers such as KL-6, SP-D, and antiMDA-5 antibody suggested improvement. However, RP-ILD aggravated abruptly by June end and the patient succumbed to septic shock. [Discussion] The management of advanced RP-ILD with positive antiMDA-5 antibody is unclear. Although IVIg and RTX were partially effective, further evidence is necessary to prove its safety and efficacy.

P3-100 A case of anti-MDA5 antibody positive amyopathic dermatomyositis with refractory eruption and chronic interstitial lung disease managed by introduction of triple therapy
Yuki Mizutani, Keiho Noda, Naohiro Sugitani, Yasuo Suzuki, Ayako Nakajima
Center for Rheumatic Diseases, Tsu, Japan, Mie University Hospital

Conflict of interest: None

[Case presentation] A 43-years-old female complained fever and joint pain from 1 month before hospitalization. She had no muscle weakness nor elevated CK, but had heliotrope rash and Gottron’s purpura. Biopsy from her hand skin revealed liquefactive degeneration of the epidermis. She was diagnosed as having amyopathic dermatomyositis (CADM). Interstitial lung disease (ILD) was confirmed on CT and the anti-MDA5 antibody titer was 143 index. Since ferritin was slightly high at 222 ng/mL and she had no respiratory symptom at her first visit, treatment with prednisolone 30 mg/day and tacrolimus 3 mg/day was started. Fatigue and joint pain improved, however, erythema remained and ferritin increased. On the 10th day of treatment, she received cyclophosphamide intravenous injection therapy (IVCY). By continuation of IVCY every 2 weeks, ferritin decreased, erythema and lung slightly improved. [Clinical significance] In this case, initial ferritin level was not high enough, however, we needed 3 agents to manage refractory erythema and ILD. We emphasize that it is necessary to treat such patient with 3 agents intensively from the early stage of CADM.

P3-101 Early detection of rapidly progressive interstitial lung disease with anti-MDA5 antibody-positive clinically amyopathic dermatomyositis associated with exacerbation of skin rash
Naoya Matsuoka, Akimasa Asai, Mayumi Ito, Makoto Yamaguchi, Shihito Iwagaito, Hironobu Nobata, Takayuki Katsuno, Shogo Banno, Yasuhiko Ito
Aichi Medical University

Conflict of interest: None

In June 2018, a 57-year-old Japanese woman was diagnosed with hemophagocytic syndrome and clinically amyopathic dermatomyositis (CADM) based on the findings of rash on the fingers and legs, pancytopenia and a high titer of anti-MDA5 antibody (158 index). We administered 500mg of methyl-prednisolone (m-PSL) pulse therapy followed by prednisolone (PSL) 50mg/day with tapering and add on tacrolimus (TAC), and symptoms were improved. However, after three month, she presented exacerbation of erythemas, and a chest computed tomography (CT) showed diffuse ground-glass opacities with path cures of consolidations in both the middle and lower lung fields. We diagnosed rapidly progressive interstitial lung disease (RP-ILD). We successful treated with 500mg of m-PSL pulse and intravenous cyclophosphamide therapy followed by PSL and TAC. The patient’s skin symptoms and lung abnormal shadows decreased. This case suggests that careful physical examinations and monitoring the serum makers are important. Exacerbation of skin rash could be one of the symptoms of early detection of lung involvement with dermatomyositis.

P3-102 A markedly effective multi-agent immunosuppressive therapy and plasma exchange for Clinical Amyopathic Dermatomyositis (CADM) accompanied by interstitial Pneumonia exhibiting anti-MDA5 antibody positivity and high ferritin levels: A Case Report
Kazuyuki Suzuki,1, Kyoko Ito;2, Misaki Yoshida,2, Kunihiro Ogane,2, Masahiro Konishi,2, Hajime Sanada,1, Takeshi Zoshima,1, Satoshi Hara,1, Ichiro Mizushima1, Hiroshi Fujii1, Kazunori Yamada1, Mitsuhiro Kawano1
Conflict of interest: None

A 50-year-old man presented at a local clinic with fever and fatigability. He had had rubefaction around the eyelids erythema of the fingertips from 4 months before. He had typical skin findings such as heliotrope rash and Gottron’s sign. Blood tests revealed no muscular symptoms and elevated CK level. Thus, a diagnosis of CADM was made. Blood test revealed anti-MDA5 antibody positivity and high ferritin levels and CT showed interstitial Pneumonia. Owing to his high risk of RP-ILD, he was treated with 60mg/day PSL, 3mg/day Tac, and IVCY. The interstitial pneumonia shadows improved but reexacerbated with respiratory symptoms after PSL dose attenuation. Owing to the high anti-MDA5 antibody titer levels and persistent markedly high ferritin levels (10,182 ng/ml), he was transferred to our hospital. Plasma exchange (PE) was conducted in addition to the multi-agent immunosuppressive therapy. After PE, anti-MDA5 antibody titer and ferritin levels markedly decreased. His respiratory symptoms improved, and the PSL dose was reduced to 30mg/day. [Discussion] Anti-MDA5 antibody titer and ferritin levels are strongly associated with poor prognosis in CADM accompanied by RP-ILD. Therefore, patients with high anti-MDA5 antibody titer and ferritin levels require early intensive therapy.

P3-103
Successful treatment of single filtration plasmapheresis for anti-MDA5 antibody positive dermatomyositis that developed pneumocystis pneumonia during treatment for rapidly progressive ILD
Masahiro Kogami, Yoshiyuki Abe, Kurisu Tada, Ken Yamaji, Naoto Tamura
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine

Conflict of interest: None

The patient is a 66 years old woman. On May, she presented with finger joint arthralgia, skin rash and dry cough. Because these symptoms weren’t improved, she was hospitalized on June. Anti-MDA5 antibody was positive, and she had Gottron’s sign and rapidly progressive ILD. She received methylprednisolone pulse therapy from day 1 to day 3, and intravenous cyclophosphamide therapy (IVCY) on day 4 and tacrolimus (TAC) from day 5. After these treatments, her respiratory condition was improved but image of CT scan was not improved. We added single filtration plasmapheresis (SFPP) on day 21, however, she complicated with anaphylactic shock for FFP, then SFPP was discontinued. On day 35, her respiratory condition was suddenly worse, it was difficult to distinguish ILD exacerbation from pneumocystis pneumonia by image of CT scan. We resumed methylprednisolone pulse with TMPco, and TAC and IVCY was discontinued. In addition, we started SFPP again to ILD from day 39, and SFPP was done total 16 times. On day 76, oxygen therapy was no longer necessary because of respiratory status improved, and she discharged from hospital on day 101. We report that the effective of SFPP for anti-MDA5 antibody positive dermatomyositis with some literature review.

P3-104
A case of anti-MDA5 antibody-positive dermatomyositis complicating rapidly progressive interstitial lung disease and pneumoemiastinum successfully treated with multidisciplinary therapy including tofacitinib
Manami Kato, Kei Ikeda, Takahiro Kageyama, Tadamichi Kasuya, Takashi Kumagai, Hiroki Furuya, Shunsuke Furuta, Tomohiro Tamachi, Akira Suto, Kotoro Suzuki, Hiroshi Nakajima
Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan

Conflict of interest: None

The prognosis of rapidly progressive interstitial lung disease (ILD) that is associated with anti-MDA5 antibody-positive dermatomyositis is poor and early intervention with high-dose corticosteroids and combined multiple immunosuppressive agents is recommended. However, treatment strategy for refractory cases has not been established. Here, we describe a 44-year-old man with anti-MDA5 antibody-positive dermatomyositis complicating rapidly progressive ILD. His ILD was progressive and accompanied by pneumoemiastinum despite receiving the combination of high-dose corticosteroids, calcineurin inhibitors, and cyclophosphamide. While double filtration plasmapheresis was not effective either, multidisciplinary therapy including plasma exchange and tofacitinib improved his life-threatening conditions. His ILD and dermatomyositis are stable with no signs of infection on prednisolone 5 mg daily, cyclosporine 100 mg twice daily, and tofacitinib 5 mg twice daily one year after discharge. Tofacitinib merits further investigation as a novel treatment option for refractory cases of this disease.

P3-105
Successful treatment with tofacitinib for anti-MDA5 antibody-positive dermatomyositis with interstitial pneumonia complicated with rheumatoid arthritis, and throughout the treatment course tofacitinib could be discontinued
Yuki Ueno1, Katsuhiro Oda1, Koji Nagai2, Hideyuki Shiba1, Masakazu Sugino3
1Department of Internal Medicine, Aino Hospital, Osaka, Japan, 2Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan

Conflict of interest: Yes

[Introduction] In JCR 2018, we reported a case of successful treatment with tofacitinib (TOF) for anti-MDA5 antibody-positive dermatomyositis with acute interstitial pneumonia (DM-AIP) complicated with rheumatoid arthritis (RA). We additionally report that TOF can be discontinued during remission maintenance period. [Case] A 41-year-old female was diagnosed with RA and anti-MDA5 antibody-positive DM-AIP in 2017. She was treated with prednisolone (PDN), cyclosporine (CSA) and intravenous cyclophosphamide pluse therapy. Chest CT showed that consolidation/ground-glass opacity had partially improved. However, her respiratory condition was getting worse. And, she still suffered from polyarthrits. Informed consent was obtained from patient and family, we additionally administered TOF. After the TOF treatment, not only polyarthrits, but also IP improved. The dosage of PDN was decreased to 5mg/day, and we discontinued TOF on 11 months after the TOF administration. After, polyarthrits and IP had not exacerbated. Side effects were renal dysfunction due to CSA, herpex zoster, and skin and soft tissue infection. [discussion] Our case suggest in JCR 2018 and 2019 that TOF may be useful for remission induction treatment and can be discontinued during remission maintenance period.

P3-106
An autopsy case of anti-MDA5 antibody positive dermatomyositis with rapid progressive interstitial pneumonia
Naofumi Chinen1, Tatsuo Mori2
1Department of Internal Medicine, Tamananbu Chi-iki Hospital, 2Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center

Conflict of interest: None

A 78-year old man who had a past history of surgery for gastric and colon cancer was admitted to other hospital with pneumonia. He was treated with antibiotics, but his respiratory condition was worse. After two weeks, he was transferred to our hospital. Gottron’s papules and periungual erythemas were found. He did not complain of arthralgia and periangual erythemas were found. He did not complain of arthralgia and myalgia, but weakness of both quadriceps muscle was recognized. Laboratory findings showed normal CK level (139 U/mL) and slightly elevation of aldolase (10.3 U/L). CT scan showed diffuse ground glass appearance and infiltration in both lung. Skin biopsy from elbow showed vacuolization of dermoepidermal junction and perivascular lymphocytic infiltration. He was diagnosed with dermatomyositis with interstitial pneumonia. He was treated with mPSL pulse therapy, but died of respiratory failure after 7 days. At later date, there was proved to be positive of anti-MDA5 antibody (index 210). Autopsy findings of lung demonstrated diffuse alveolar damage with prominent hyaline membrane lining alveolar sac with edema of alveolar septae. Occasionally intra-alveolar hemorrhage and fibrin thrombi were seen. These findings was compatible to diffuse alveolar damage. Here we report a valuable autopsy case of anti-
Department of Rheumatology, Chubu Rosai Hospital, 2Department of Nephrology, Chubu Rosai Hospital

Conflict of interest: None

[Case] A 72-year-old man presented with three weeks of decreased appetite and one week of erythema with pruritus on his back. He was emergently admitted due to persistent poor dietary intake and difficulty standing. Chest computed tomography revealed consolidation in the left lung and a pneumococcal urinary antigen test was positive. He was admitted with the initial diagnosis of bacterial pneumonia; however, his respiratory status did not improve after 5 days of antibiotics. Physical examination revealed blood blister-like palm papules on his hand and flagellate erythema on his back. We considered dermatomyositis in the differential diagnosis, and pulsed intravenous methylprednisolone and cyclophosphamide with oral tacrolimus were started on day 5. On day 7, the presence of anti-MDA5 antibody was confirmed, and the patient was diagnosed with anti-MDA5 antibody-positive dermatomyositis. His respiratory status worsened rapidly and he died on day 14, despite intensive care. An autopsy was performed. [Clinical significance] In this case, we immediately started combination therapy with immunosuppressant agents for dermatomyositis after failure of antibiotic therapy; however, the patient eventually died. We present this case with the results of autopsy. Conflict of interest: None

A 35-year-old woman was admitted to our hospital with a 3-month history of muscle pain, erythematous eruptions, and dyspnea. A general examination revealed Gottron’s papules, palmar papules, erythemas on the elbows and knees joints. Muscle weakness (MMT4) in the proximal muscles was observed. Fine cracks were noted in the bilateral lower legs. Laboratory findings showed aldolase 8.7 U/L, CK 450 U/L, KL-6 464 U/mL, and ferritin 346 ng/mL. Anti-MDA5 antibody positive was found immediately. Chest high-resolution computed tomography (HRCT) scanning showed linear opacities, consolidations, and ground-glass opacities in the lower lobes. Several lines were diagnosed as having rapid progressive interstitial pneumonia (RPIP). The treatment led her stable disease state, and she kept treatment with 7mg of PSL and 3mg of Tac over a year.

Discussion

Over, we added plasma exchange, rituximab, and IVIg for the deterioration of her lung. The treatment led her stable disease state, and she kept treatment with 7mg of PSL and 3mg of Tac over a year. Discussion MDA5-Ab-positive DM often leads fatal interstitial pneumonia (IP). In our case, the patient was initially diagnosed as anti-synthetase syndrome, but ARS-Ab was negative on RNA precipitation. The positive finding of MDA5-Ab led us induction of early strong immunosuppressive therapy.

Conclusion

We need to consider existence of MDA5-Ab, if ARS-Ab is positive on ELISA assay in a patient with DM-associated IP.

A case of interstitial pneumonia with dermatomyositis. Rapid inspection of anti-MDA 5 antibody is useful for early diagnosis and determination of therapy

Tomohiko Koboyama, Youhei Fujiki, Takuya Kotani, Koji Nagai, Kenichi Hata, Tohru Takeuchi, Shigeki Arawaka
Osaka Medical College Hospital

Conflict of interest: None

A 72-year-old woman was admitted to our hospital with a 3-month history of muscle pain, erythematous eruptions, and dyspnea. A general examination revealed Gottron’s papules, palmar papules, erythemas on the elbows and knees joints. Muscle weakness (MMT4) in the proximal muscles was observed. Fine cracks were noted in the bilateral lower legs. Laboratory findings showed aldolase 8.7 U/L, CK 450 U/L, KL-6 464 U/mL, and ferritin 346 ng/mL. Anti-MDA5 antibody positive was found immediately. Chest high-resolution computed tomography (HRCT) scanning showed linear opacities, consolidations, and ground-glass opacities in the lower lobes. Several lines were diagnosed as having rapid progressive interstitial pneumonia (RPIP) associated with anti-MDA5 antibody-positive dermatomyositis (DM). We started combination therapy including prednisolone, cyclosporine, and intravenous pulse cyclophosphamide (IVCY) on day 1. However, her IP resisted treatment. Antimyositis specific antibodies (MSAs) and myositis-associated antibodies (MAAs). Of the MSAs, anti-signal recognition particle (SRP) antibodies

Conflict of interest: None

[Object] Muscle strength recovery have been reported in dermatomyositis/-polymyositis patients after the start of therapeutic intervention, but no studies compared the recovery from the baseline. We aimed to analyze the muscle strength changes from the baseline until the stage of treatment as outpatient. [Methods] Twelve anti-ARS antibody syndrome patients with muscle weakness and elevated serum muscle enzymes joined the study at the baseline before the therapeutic intervention start. Quadriceps Femoris muscle strength was measured at 4 timeline points: baseline, within 1 week after the start of treatment (<1w), at discharge and as outpatient. We measured the muscle strength using a hand-held dynamometer and obtained the percentage compared to the age-matched data from previous studies in healthy individuals. Serum Creatine Kinase (CK) was also investigated. [Results] The mean muscular strength were 70% (baseline), 75.2% (<1w), 84.7% (discharge), and significantly higher in outpatient point reaching 105.3% (p<0.05). Serum CK mean values were chronologically 2813, 1065, 88.2 and, 54.8. [Conclusions] The muscular strength and CK mean values showed considerable improvement throughout the treatment. The Quadriceps strength was fully recovered based in healthy individuals data.

Coexistence of anti-SRP and anti-SS-A/Ro antibodies in inflammatory myopathy: Does the association occur by chance?

Tadashi Nakamura1, Naoki Shiraishi2, Seiyo Honda1
1Clinical Rheumatology, Sakurayuji Hospital, Kumamoto, Japan, 2Clinical Nephrology, Sakurayuji Hospital, Kumamoto, Japan

Conflict of interest: None

[Object] Myositis-related autoantibodies are tools for the diagnosis in idiopathic inflammatory myopathies and placed into two groups: myositis-specific antibodies (MSAs) and myositis-associated antibodies (MAAs). Of the MSAs, anti-signal recognition particle (SRP) antibodies

Conflict of interest: None

Anti-MDA5 antibody-positive dermatomyositis-associated interstitial pneumonia who had anti-ARS antibody positive on ELISA, but negative on RNA immunoprecipitation: A case report

Yoichi Nakayama1, Saki Minoda1, Hironori Kakebo1, Hirofumi Miyake1, Ryuichi Sada1, Hiroayasu Ishimaru1, Run Nakashima2, Tsuneyo Mimori2, Kazuhiro Hatta1
1Department of General Internal Medicine, Tenri Hospital, Tenri, Japan, 2Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Conflict of interest: None

Case A 54-year-old woman was admitted with bilateral thigh pain and weakness, and erythema of her face, chest, and hands. Physical examinations revealed proximal muscle weakness, heliotrope rash, and inverse Gottron’s papules. Laboratory results were as follows: CK, 402 U/L; aldolase, 23.7 U/L; KL-6, 425 U/mL; and ferritin, 1586 ng/mL. Chest CT showed faint ground opacity (GGO) on the left upper lobe. Anti-ARS antibody (ARS-Ab) and anti-MDA5 antibody (MDA5-Ab) were reported to be positive on day 7 and 14, respectively. Follow-up CT showed exacerbation of GGO. We started multi-immunosuppressive therapy including pulse steroid therapy, IVCY, and tacrolimus (Tac). Moreover, we added plasma exchange, rituximab, and IVIg for the deterioration of her lung. The treatment led her stable disease state, and she kept treatment with 7mg of PSL and 3mg of Tac over a year. Discussion MDA5-Ab-positive DM often leads fatal interstitial pneumonia (IP). In our case, the patient was initially diagnosed as anti-synthetase syndrome, but ARS-Ab was negative on RNA precipitation. The positive finding of MDA5-Ab led us induction of early strong immunosuppressive therapy.

Conclusion We need to consider existence of MDA5-Ab, if ARS-Ab is positive on ELISA assay in a patient with DM-associated IP.

Coexistence of anti-SRP and anti-SS-A/Ro antibodies in inflammatory myopathy: Does the association occur by chance?

Tadashi Nakamura1, Naoki Shiraishi2, Seiyo Honda1
1Clinical Rheumatology, Sakurayuji Hospital, Kumamoto, Japan, 2Clinical Nephrology, Sakurayuji Hospital, Kumamoto, Japan, 3Department of Rheumatology, Honda Clinic Office, Uto, Japan

Conflict of interest: None

Anti-MDA5 antibody-positive dermatomyositis-associated interstitial pneumonia who had anti-ARS antibody positive on ELISA, but negative on RNA immunoprecipitation: A case report

Yoichi Nakayama1, Saki Minoda1, Hironori Kakebo1, Hirofumi Miyake1, Ryuichi Sada1, Hiroayasu Ishimaru1, Run Nakashima2, Tsuneyo Mimori2, Kazuhiro Hatta1
1Department of General Internal Medicine, Tenri Hospital, Tenri, Japan, 2Department of Rheumatology and Clinical Immunology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Conflict of interest: None

Case A 54-year-old woman was admitted with bilateral thigh pain and weakness, and erythema of her face, chest, and hands. Physical examinations revealed proximal muscle weakness, heliotrope rash, and inverse Gottron’s papules. Laboratory results were as follows: CK, 402 U/L; aldolase, 23.7 U/L; KL-6, 425 U/mL; and ferritin, 1586 ng/mL. Chest CT showed faint ground opacity (GGO) on the left upper lobe. Anti-ARS antibody (ARS-Ab) and anti-MDA5 antibody (MDA5-Ab) were reported to be positive on day 7 and 14, respectively. Follow-up CT showed exacerbation of GGO. We started multi-immunosuppressive therapy including pulse steroid therapy, IVCY, and tacrolimus (Tac). Moreover, we added plasma exchange, rituximab, and IVIg for the deterioration of her lung. The treatment led her stable disease state, and she kept treatment with 7mg of PSL and 3mg of Tac over a year. Discussion MDA5-Ab-positive DM often leads fatal interstitial pneumonia (IP). In our case, the patient was initially diagnosed as anti-synthetase syndrome, but ARS-Ab was negative on RNA precipitation. The positive finding of MDA5-Ab led us induction of early strong immunosuppressive therapy.

Conclusion We need to consider existence of MDA5-Ab, if ARS-Ab is positive on ELISA assay in a patient with DM-associated IP.
are found in inflammatory myopathy (anti-SRP myopathy), being said to be an immune-mediated necrotizing myopathy. The significance of the association of MSAs and MAAs in inflammatory myopathies has not yet been discussed, so considering the clinical importance of a coexistence of MSAs and MAAs may be useful. [Methods] Through our experience with anti-SRP myopathy with typical clinical signs and anti-SS-A/Ro antibodies, we reviewed the literature related to this antibody combination and evaluated the coexistence of MSAs and MAAs in inflammatory myopathy. [Results] The prevalence of anti-SRP antibody was 0.45% in a cohort of Japanese patients with autoimmune diseases and anti-SS-A/Ro antibody is the most prevalent MA found in more than 30% of patients. [Conclusions] Our experience with anti-SRP myopathy indicates that clinical investigation of inflammatory myopathy with coexistence of MSAs and MAAs will lead to clarification of clinical subsets and new understanding of the mechanisms of inflammatory myopathy.

P3-112

Two cases of polymyositis/myopathy with anti-signal recognition particle (SRP) antibody complicating interstitial pneumonia
Shuntaro Miyoshi1, Hirofumi Watanabe2, Rie Sasaki1, Mitsuhiro Iwahashi1, Jiro Yamane1, Seizo Yamana1, Hiroki Kobayashi2, Takuya Tanimoto2, Hiroyuki Maeda3
1Hiigasi Hiroshima Memorial Hospital, 2Hiroshima Prefectural Hospital

Conflict of interest: None

In cases of polymyositis with anti-signal recognition particle (SRP) antibody there clinical course are myositis. But those pathological findings are myopathy. There are rarely complicated by interstitial pneumonia. [Case 1] A 56 year old woman saw near doctor because of muscle weakness. Her examination showed CPK high, she was referred and entered our hospital. Her chest CT showed obscure lesion. MRI showed her muscle was caused by the inflammation. The electromyogram also showed low amplitude. So we performed muscle biopsy and that showed no myositis but muscle necrosis. Her blood test showed SRP antibody. We diagnosed polymyositis/myopathy with SRP antibody. [Case 2] A 57 year old man has smoking history. He saw near doctor because of lower limbs muscle weakness. His examination showed CPK high, he was referred and entered our hospital. His chest CT showed fibrotic lesion. MRI showed his muscle was caused by the inflammation. In EUROLINE his blood test showed SRP antibody. We diagnosed polymyositis/myopathy with SRP antibody. They were treated by corticosteroid and immunosuppressive drugs. Their interstitial pneumonia are also not worse. We report those rare cases with some literature review because sometimes this polymyositis are different in terms of treatment progress.

P3-113

Clinical investigation regarding anti-TIF1-gamma antibody in inflammatory myositis patients
Daisuke Hirano, Shusaku Fukaya, Natsuko Watanabe, Masashi Suzuki, Tatsukii Naganaana, Ai Umeda, Kosumi Ashibara, Megumi Karunizawa, Takako Hashimoto, Jo Nishino, Shunji Yoshida, Hidekata Yasuoka
Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine

Conflict of interest: None

[Object] To investigate the clinical significance of anti-TIF1-γ antibody (Ab) in inflammatory myositis (IM). [Methods] In 31 patients with inflammatory myositis diagnosed between October 2016 and October 2018, we investigated clinical features stratified by anti-TIF1-γ Ab. [Results] Anti-TIF1-γ Ab were positive in 4 of the 31 patients. 2 of 4 in the anti-TIF1-γ Ab positive groups complicated of malignancy within 1 year after onset. In the anti-TIF1-γ Ab negative group, malignancy within 1 year after onset was complicated in 5 of 27 cases. In the anti-TIF1-γ Ab positive group, 3 of 4 cases had dysphagia. In the anti-TIF1-γ Ab negative group, only 2 of 27 patients had dysphagia (P=0.008). In the anti-TIF1-γ Ab negative group, 19 of 27 patients had complication of interstitial lung disease (ILD), whereas no patient had complication of ILD in the anti-TIF1-γ Ab positive group. [Conclusions] In patients with anti-TIF1-γ Ab positive IM, dysphagia were many cases. In contrast, it was suggested that ILD is less prevalent in anti-TIF1-γ Ab positive cases (P=0.015).

P3-114

Phenotype and the therapy of anti-TIF1-gamma antibody positive dermatomyositis (TNF1g-DM)
Yoshikazu Fujikawa, Kengo Akashi, Motoko Katayama, May Yamashita, Yoko Nose, Takumi Nagamato, Yuzuru Yamamoto, Hirota Kamada, Yoshhide Ichise, Ikuko Naka, Takaichi Okano, Yo Ueda, Sho Sendo, Akira Onishi, Jun Saegusa, Akio Morinobu
Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan

Conflict of interest: None

[Object] Phenotype and the therapy of anti-TIF1-γ antibody positive dermatomyositis (TNF1g-DM) [Methods] We investigated the phenotype and the outcome of the treatment in the myositis that we treated in our hospital. [Results] We treated 148 cases of idiopathic inflammatory myositis in our hospital, of which 9 were TNF1g-DM. Average age at onset was 63 years old. In all cases, patients had distinctive skin rash and muscle weakness, and in 7 cases, they had dysphagia. In 3 cases with cancer, the average of serum creatine kinase (CK) was 2385U/L. We administered 1mg/kg of predonisonol in 8 cases., Four cases were treated with immuno-suppressants, and seven cases with intravenous immunoglobulin. In 5 of 6 cases with elevated serum CK, serum CK was normalized within a month. But in comparison with serum CK, the improvement of muscle weakness, especially esophageal dismotility, was poor. [Conclusions] In our investigation, TNF1g-DM patients showed good response with treatment in serology, but dysphagia, which was associated with the prognosis, was poorly improved. So it is controversial whether the improvement of elevated levels of muscle enzymes is one of the goals of the treatment in TNF1g-DM. We report our investigation of the phenotype and treatment of TNF1g-DM.

P3-115

The case series study of anti-TIF1gamma antibody-positive patients with dermatomyositis
Masatoshi Kimura, Ayako Aizawa, Kunihiko Umekita, Chihiro Iwao, Yuki Rikitake, Kosho Iwao, Mao Rikitake, Takeshi Kagawuchi, Yumi Kariya, Motohiro Matsuda, Shunichi Miyauchi, Katoko Takajo, Ichiro Akihiko Okano
Department of Rheumatology, Infections Diseases, and Laboratory Medicine, University of Miyazaki, Miyazaki, Japan

Conflict of interest: None

[Object] The aim of this study is to evaluate the clinical characteristics of anti-TIF1γ antibody (TIF1γ ab)-positive patients with dermatomyositis (TIF1γ-DM). [Methods] Five cases were diagnosed as TIF1γ-DM in our department from April 2012 to July 2018. The physical findings, malignancies, therapeutic regimens were evaluated. In addition, we analyzed the changes of TIF1γ ab levels before and after treatment for malignancy. [Results] Four patients were female. The average age was 66 years old at the onset of TIF1γ-DM. All patients showed typical clinical findings of DM such as muscle weakness and skin rash. Four patients showed dysphagia. Three patients had malignant lesion such as laryngeal cancer, breast cancer, and lymphoma, respectively. Immunosuppressive treatment was administrated in TIF1γ-DM patients without malignancy. On the other hands, treatment for malignancies including radiotherapy, surgical operation and chemotherapy was administrated in patients with malignancy-associated DM (DMMD) prior to immunosuppressive treatment. In 2 patients of DMMD, the levels of anti-TIF1γ ab were decreased after treatment for malignancy. [Conclusions] More clinical researches with large number participants are necessary to clarify the characteristics and the pathogenesis of TIF1γ-DM.

P3-116

A case of anti-TIF1-gamma antibody and anti-ARS antibody positive interstitial pneumonia combined with gastric cancer
Akihiro Tanaka1,2, Nobuyasu Ishii3, Keiko Shimamoto2, Hideki Amuro2, Tohru Nishizawa2, Yousu Son2, Yoshio Ozaki2, Tomoki Ito2, Shosaku

Conflict of interest: None

[Object] A case of anti-TIF1-gamma antibody and anti-ARS antibody positive interstitial pneumonia combined with gastric cancer

[Akihiko Tanaka1,2, Nobuyasu Ishii3, Keiko Shimamoto2, Hideki Amuro2, Tohru Nishizawa2, Yousu Son2, Yoshio Ozaki2, Tomoki Ito2, Shosaku]
Successful treatment with tocilizumab for refractory antisynthetase syndrome
Takumi Matsumoto, Takao Katsuragawa, Hitoha Nomura, Hiroaki Tamura
Rheumatology Center, Department of Rheumatology, Kin-ikyo Chuo Hospital

Conflict of interest: None

[Case] An 84-year-old man. He visited a nearby hospital with respiratory distress, and diagnosed as anti-ARS antibody positive interstitial pneumonia. He was introduced to our department for scrutiny and treatment. Treatment started with prednisolone 0.5 mg/kg from the first hospital day, but chest X-ray examination showed decreased permeability of both lungs, and prednisolone 1 mg/kg was started from 4th hospital day. Since new lesions were found in chest CT, steroid pulse therapy was added from the 9th hospital day, but no improvement was observed. Anti-TIF1-gamma antibody was positive, and upper gastrointestinal endoscopy was performed on the 15th hospital day. Gastric tumor was found, and the pathological result was adenocarcinoma. [Discussion] In this case, since it was anti ARS antibody positive, we started treatment of interstitial pneumonia with moderate amount of prednisolone. However, it was refractory to treatment, resulting in anti TIF1-gamma antibody positive and gastric cancer combined. Anti-ARS antibody positive interstitial pneumonia is said to have good steroid reactivity. In cases where initial treatment does not respond or when some anti-TIF1-gamma antibody is positive, screening tests of malignant tumors should be conducted as the condition permits.

P3-119
Double Cancer of the Oropharynx and Prostate Occurring in an Anti-TIF1-gamma Antibody-Positive Dermatomyositis Patient: A Case Report
Yuko Asanuma1, Takayuki Koni2, Kurisu Tada1, Kazuhisa Nozawa1, Ken Yamaji1, Naoto Tamura1
1Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, 2Department of Internal Medicine and Rheumatology, Juntendo University Nerima Hospital, Tokyo, Japan

Conflict of interest: None

A 66-year-old man, who had had radical neck dissection and chemoradiation therapy for oropharyngeal cancer 2 years ago, presented with arthralgia, myalgia and skin rash. He had weakness and tenderness in both upper and lower extremities, and a skin rash on his face and arms that resembled heliotrope rash, Gottron’s papules, V-neck sign and shawl sign. At first, we suspected paraneoplastic syndrome, but after further examination, we found that anti-TIF1-gamma antibody was positive. Also, MRI, electromyography, and skin biopsy showed findings compatible with dermatomyositis, so we diagnosed him as anti-TIF1-gamma antibody-positive dermatomyositis. After we started oral prednisolone (30mg/day), his rash and myalgia improved, so he was discharged. While he was hospitalized, we found that his mediastinal lymph nodes were enlarged, and started chemotherapy for recurrent oropharyngeal cancer. Also, we found adenocarcinoma in his prostate through biopsy, so we started hormone therapy for that as well. This case report shows that it is important to consider the possibility of not only paraneoplastic syndrome, but also recurrent or multiple cancer, when we diagnose anti-TIF1-gamma antibody-positive dermatomyositis.

P3-120
A case of anti-Ro52 antibody positive dermatomyositis complicated with systemic capillary leak syndrome (SCLS)
Motohiko Sato, Daisuke Kawata, Takuji Itakura, Ayaka Maeda, Hiroyuki Hagiyama
Department of Rheumatology, Yokohama City Minato Red Cross Hospital

Conflict of interest: None

A 40-year-old man was referred to our hospital due to fever, walking difficulty, and polyrheumalgia. His physical findings revealed proximal muscle weakness with myalgia, Heliotrope eruption and V-neck sign. Myogenic enzymes were elevated, MRI showed high signal intensity areas with STIR sequences on thigh muscles. Electromyography was compatible with inflammatory myositis. According to the Bohan and Peter criteria, he was diagnosed as dermatomyositis. Prednisolone (PSL) 60mg/day was started. His skin eruptions promptly improved, but CKP level was elevated and muscle strength was further reduced. He became almost bedridden. Although mPSL pulse therapy was added, he suffered from hypovolemic shock, acute respiratory and renal failure, and entered inten-
sive care unit. Furthermore, he developed anasarca especially in the thigh with markedly elevated CPK level (65,000 U/L). He was thought to be in SCLS and compartment syndrome with rhabdomyolysis. Accordingly, we added IVIG and tacrolimus. Then his symptoms gradually improved. After two months of rehabilitation, he can walk by himself, and he was discharged home. We report a rare case of dermatomyositis complicated with SCLS.

P3-121
A case of myositis localized to the neck with positive for the anti-titin antibody induced by pembrolizumab
Saki Mukohara, Soshi Takahashi, Norihiko Amano, Yasuhiro Nobuda, Katsuhiko Yoneda, Miwa Nishida, Saori Hatachi, Shunichi Kumaigai
Department of Rheumatic Disease, Shinko Kinen Hospital
Conflict of interest: None

[Case report] 76-year-old woman, who developed advanced urothelial cancer with focal recurrence and inversion, was treated with pembrolizumab from April 2018. After the three cycles of pembrolizumab, she felt general malaise and laboratory test showed creatine kinase (CK) level of 2537 U/L and she rapidly developed dropped head syndrome. An electromyogram revealed myogenic change in cervical muscles. Magnetic resonance imaging (MRI) demonstrated the presence of focal changes of myositis and fasciitis involving the muscles around the cervical spine. An electrophysiologic did not demonstrate positive waning on repetitive stimulation and she was diagnosed as immune checkpoint inhibitor-related myositis (irMyositis). On laboratory test, only anti-titin antibody, which is one of anti-striated muscle antibody, was positive. From elevation of cardiac enzyme and negative change of T wave in electrocardiogram, we considered that she also developed myocarditis. She received prednisolone therapy and immediately levels of CK was decreased and abnormal wave in ECG improved. [Discussion] There are many unclear points in the immune-related adverse events (irAE). This is the first case of the irMyositis showing anti-titin antibody positive.

P3-122
A case of interstitial pneumonia associated with anti-PL-7 antibody positive dermatomyositis with thrombotic thrombocytopenic purpura
Hidehiko Makino, Kenichiro Hata, Takaaki Ishida, Tomohiko Kuboyma, Shogo Matsuda, Takao Kiboshi, Youhei Fujiki, Koji Nagai, Takuya Kotani, Maki Kagitani, Tohru Takeuchi, Shigeki Arakawa
Department of Internal Medicine IV, Osaka Medical College
Conflict of interest: None

We report a case of 30s-year-old woman, she noticed an itch and erythema of the skin from May of the X year and caused pain of the proximal muscle and intermittent fever of the 37 degrees level from the middle of June. At the end of July she was revealed a rise in CK and liver enzymes when the uterine content removal was performed in the diagnosis of a progressive miscarriage, and she was transported to a former hospital. Although treated with steroids because it did not improve by observation, the interstitial pneumonia in the chest CT in the middle of August and the Gottron’s sign were pointed out, and it became transference to our hospital because the dermatomyositis was suspected. We diagnosed dermatomyositis from anti-ARS Ab positive. The anti-ARS Ab was later found to be an anti-PL-7 Ab. We started treatment with prednisolone, cyclosporine, cyclophosphamide, but on 3rd day the patient showed disturbance of consciousness and TTP was suspected. We used plasma exchange in combination, but the condition did not improve, and the patient died on the 7th day. Anti-PL-7 Ab positive cases have characteristics such as TTP and alveolar hemorrhage may be complicated, and long-term prognosis is bad. However, it is rare to follow a rapid turning point and report it including past cases.

P3-123
A case of anti-Ro-52 antibody positive-dermatomyositis with preceding panniculitis, followed by cutaneous leukocytoclastic vasculitis
Daisuke Nakatsubo, Yoshimasa Hamano, Michihito Katayama, Hitoshi Deguchi
Department of Immunology, Kinki Central Hospital of Mutual Aid Association of Public Teachers
Conflict of interest: None

We report a rare case of 76-year-old female with dermatomyositis having an onset from panniculitis. She consulted the department of dermatology of our hospital due to painful erythema on her right thigh, which was diagnosed as panniculitis, followed by muscles pains and at bilateral upper arms and thighs. She was hospitalized in our department with proximal extremity muscle weakness and polyarthritis. CPK elevation and specific histological findings led to the diagnosis of dermatomyositis with panniculitis. Neither specific skin manifestation nor interstitial pneumonia was observed. Anti-Ro-52 antibody was detected by the comprehensive screening of autoantibodies. Her subjective symptoms and radiological findings were improved by the daily oral corticosteroid therapy (1mg per kg of prednisolone). She tool 20mg of prednisolone per day in gradual decreasing when propable purpura was seen and diagnosed as cutaneous leukocytoclastic vasculitis. The purpura was improved by rest and oral colchicine without re-increasing of corticosteroid. We present this case with some literature review.

P3-124
A case with dermatomyositis positive for anti-NXP2 antibody suggested from granular type of anti-nuclear antibody
Kentaro Noda1, Yuki Mizutani1, Yasuo Suzuki1, Naohiro Sugitani1, Masataka Kuwana1, Ayako Nakajima1
1Center for Rheumatic Diseases, Tsu, Mie, Japan, Mie University Hospital, 2Department of Allergy and Rheumatology, Nippon Medical School, Graduate School of Medicine
Conflict of interest: None

[Case] A 70-year-old female complained muscle weakness and erythema on her upper limbs. The Gottron papule, V sign, shawl sign, and weakness of neck flexor and deltoid muscles with elevated CK at titer of 2491 U/L were detected. The muscle of both upper arms and thigh appeared as hyperintense in T2-weighted MR images. The biopsy of skin showed liquefactive degeneration of epidermis and lymphocyte infiltration around the vasculature. HE staining of a biopsied muscle showed perivascular inflammation. With the diagnosis dermatomyositis, 40 mg/day of PSL and 3 mg/day of TAC were started, resulting good response except muscle weakness of neck flexor. The type of ANA in this patient was granular type and myositis specific antibody was negative. Positivity of Anti-NXP2 antibody was confirmed by immunoprecipitation and immunoblotting. [Clinical Significance] Detection of granular type of ANA itself is rare. Granular pattern is known as atypical speckled and staining pattern of anti-NXP2 antibody is supposed to be atypical speckled. In this case, we supposed anti-NXP2 antibody was positive from this ANA pattern. It is significance that we could expect the presence of anti-NXP2 antibody from the pattern of ANA pattern.

P3-125
Report on treatment experience with high-dose calcineurin inhibitor for acute / subacute interstitial pneumonia associated with dermatomyositis
Takayasu Suzuki1, Takuya Kotani1, Kenichiro Hata1, Youhei Fujiki1, Takaaki Ishida1, Takao Kiboshi1, Hidehiko Makino1, Tomohiko Kuboyma1, Tohru Takeuchi1, Shigeki Makino2, Shigeki Arakawa1
1Department of Internal Medicine IV, Osaka Medical College, 2Osaka Medical College, 3Osaka Medical College Mishima-Minami Hospital
Conflict of interest: None

[Objective] We report a treatment experience with high-dose calcineurin inhibitor for acute/ subacute interstitial pneumonia (A/SIP) associated with dermatomyositis (DM). [Method] 30 patients with DM-A/SIP were treated with calcineurin inhibitor at a high dose in addition to steroids. We assessed the treatment effect in the observation period of 6 months after the start of treatment. The cyclosporine (CSA) dose was adjusted to maintain the peak levels (C2) above 1500 ng/mL, and the tacro-
P3-126 Refractory polymyositis, induction of remission with rituximab for dermatomyositis  
Hisaé Fujimoto, Seido Ooka, Yutaka Goto, Kanako Suzuki, Harunobu Iida, Takayasu Ando, Yusa Asari, Marina Uchida, Kana Ishimori, Hiromi Matsuhashi, Keichi Sakurai, Tomofumi Miyaki, Yukiho Takakawa, Kumiko Tonooka, Takeshi Suzuki, Mitsuru Imamura, Yoshihiko Yasamaki, Hiroko Nagauchi, Kimito Kawahata  
Division of Rheumatology and Allergology, St. Marianna University School of Medicine

Conflict of interest: None

[Background] In dermatomyositis (DM) polymyositis (PM), there are the patients who are resistant to typical treatment. For refractory myositis, we report on four patients using rituximab (RTX). [Case 1] A 33 years old man, with DM. This patients were treated in azathioprine (AZA), tacrolimus (Tac), mycophenolate mofetil (MMF), but were treated with intravenous cyclophosphamide (IVCY) because interstitial pneumonia (ILD) worsened. The myositis was improved by RTX. [Case 2] A 47 years old woman with DM. For ILD, was treated in IVCY, but it is continued by a liver damage. ILD and the myositis were improved by RTX. [Case 3] A 61 years old woman with PM. This patients was treated with AZA, CyA, methotrexate (MTX), MMF, were ineffective. The myositis was improved by RTX. [Case 4] A 55 years old woman with anti-MDA5 antibody-positive DM. This patients was treated in IVCY, and ILD remitted. However, cutaneous ulcer aggravated it in maintenance therapy in Tac. The cutaneous ulcer was improved remarkably by RTX.

P3-127 Clinical features related to cytomegalovirus infection after immunosuppressive therapy in polymyositis and dermatomyositis  
Kenichi Ueno, Satoru Ushiyama, Dai Kishida, Yasuhiro Shimojima, Yoshihiko Sekijima  
Division of Nurology and Rheumatology, Department of Internal Medicine, Shinshu University School of Medicine

Conflict of interest: None

[Objectives] To investigate the clinical characteristics associated with the induction of cytomegalovirus (CMV) infection after initiating immunosuppressive therapy in patients with polymyositis (PM) and dermatomyositis (DM). [Methods] We reviewed the clinical records of 42 patients with PM/DM in whom CMV pp65 antigen test were performed after starting treatment. [Results] CMV infection was shown in 17 patients (CMV positive), and their mean age was 63 ± 13 years; meanwhile, that of patients without CMV infection (CMV negative) was 50 ± 13 years, suggesting patients in CMV positive were elder than those in CMV negative. Serum albumin levels and circulating lymphocyte counts in CMV positive were significantly lower than in CMV negative. Methylprednisolone pulse therapy (mPSL) was administered to 12 patients in CMV positive, whereas 6 patients in CMV negative were treated with mPSL. The complication of other infection was frequently demonstrated in CMV positive. [Conclusion] CMV infection in patients with PM/DM may be implicated in the features including old age, low levels of serum albumin and lymphocytes counts, as well as mPSL administration. It was also concerned that multiple infection could occur in patients having CMV infection.

P3-128 Two cases of myositis syndrome with anti-PM/Scl antibodies  
Hironori Inoue, Hiroaki Kusuoka, Keitaro Saito, Aki Sakashita, Aiko Hirano, Yu Isoda, Risa Sagawa, Kazuki Fujikoa, Hitodake Nagahara, Makoto Wada, Masataka Kohno, Yutaka Kawahito  
Division of Rheumatology and Allergology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

Conflict of interest: None

Background: Anti-PM/Scl antibodies are generally detected in polymyositis/systemic scleroderma overlap syndromes in European and North American patients, but it is rare in Japanese ones. Case 1: A 50-year-old female, suffered from systemic muscle pain especially lower limbs from 4 years ago. Anti-PM/Scl-75 antibody was 1+ and anti-PM/Scl-100 antibody was negative. Muscle weakness was observed but interstitial pneumonia (IP) and skin symptoms were not detected. We started to treat with 50 mg/day of prednisolone (PSL), 6 mg/week of Methotrexate and the symptoms improved. Case 2: A 68-year-old female suffered from fatigue from half a year ago. She complained shortness of breath on exertion. Anti-PM/Scl-75 antibody was 3+ and anti-PM/Scl-100 antibody was 3+. Mechanic’s hands, IP and muscle weakness were observed. We started to treat with 50 mg/day of PSL, 2 mg/day of tacrolimus and the symptoms improved. Discussion: In our two cases, scleroderma-specific skin lesions were not appeared, and muscular weakness dominated ilio-psoas muscle. They had different characteristics from the cases reported from Europe or North America. We report two cases of myositis syndrome with anti-PM/Scl antibodies with some literature review.

P3-129 A case of anti-Ku antibody-positive polymyositis which needed combined modality therapy for hemophagocytic syndrome  
Takuya Nishi1, Satoshi Suzuki1, Mai Yoshida1,2, Yuki Matsuoka1, Keigo Ikeda1, Ken Yamaji1, Naoto Tamura1, Shinni Morimotoin1,2  
1Department of Internal Medicine and Rheumatology, Juntendo University Urayasu Hospital, Chiba, Japan, 2Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

Conflict of interest: None

A 40-years-old man presented arthralgia of both knee, decrease in grip strength on August 2017, anti-nuclear antibody titer over 2560 times and high levels of serum CK on November. Anti-Ku antibody was detected besides high levels of myogenic enzyme, myogenic change, non-destructive arthritis, systemic inflammation, diagnosed polymyositis. Presenting anti-U1-RNP, anti-Sm antibody and leukopenia, overlap syndrome of SLE and myositis was suspected although no nephropathy or cuts symptom. Starting 35 mg of PSL on January 2018, but showed fever, shaking chill, liver dysfunction, thrombocytopenia, high level of serum ferritin, urgently hospitalized. Bone marrow examination showed increase of histiocytes with phagocytosis of all blood corpuscles, diagnosed hemophagocytic syndrome. Not improved though steroid semi-pulse, simple plasma exchange performed for 3 days, with cyclosporine. The treatment succeeded, discharged by tapering PSL to 45 mg. Anti-Ku antibody has high positive rate in overlap syndrome in Japan, shows reactivity to steroid, good prognosis. The case led to HPS, presumed to be caused by overlap of SLE such as anti-Sm antibody and hypocomplementaemia. This case suggested need of systemic examination including searching of other autoantibodies and evaluation of organ complications in these patients.

P3-130 Myositis-specific or -related antibodies were frequently found in patients other than mastitis  
Ryutaro Yamazaki, Kazuhiro Kurasawa, Yuta Takamura, Tomoyuki Miyao, Ayae Tanaka, Satoko Araoi, Takayoshi Owada, Reika Maewa, Masafumi Arima  
Dokkyo Medical University

Conflict of interest: None

Purpose: To clarify the clinical features of patients with myositis-spe-
cific or -related antibodies, particularly underlying diseases. Methods: Subjects were 974 patients whose serum were examined for myositis-specific or -related antibodies using Euroline Myositis profile3. Medical records of patients with positive results were reviewed to examine clinical features. Results: Of 974 patients who were suspected CTD, 145 (14.9%) were positive for anti-ARS, -SRP, -Mi2, KU, and PM-Scl (70 or 100) Abs. Of 68 patients with anti-ARS Ab (anti-OJ; 1, EJ;15, PL-12; 13, PL-7; 8, Jo-1; 31), 38 were myositis (DM; 17, PM21), and idiopathic interstitial pneumonia (IIP) and Sjögren syndrome (pSS) were 14 and 10, respectively. Myositis was found in 9 of 17 anti-SRP Ab+ patients (DM; 4, PM; 5) and in 5 of anti-Mi2 Ab+ patients (DM; 4, PM1). In patients with these Abs, there were RA and IIF. Of 32 patients with anti-KU Ab, 14 were myositis (DM; 6, PM8), 7, 6 and 3were SLE, pSS and IIP, but none were scleroderma. Of 23 patients with anti-PM-Scl Abs, 7 were myositis (DM;4, PM3), RA and pSS were 5, and only 2 cases were SSc. Conclusion: Myositis-specific or -related antibodies were frequently found in patients other than myositis.

P3-131
The improvement of nailfold videocapillaroscopy abnormalities in 2 patients with dermatomyositis
Kei Araki, Hiroki Kohno, Kazutoshi Yukawa, Tatsuomi Kuranobu, Tadahiro Tokunaga, Yusuke Yoshida, Tomohiro Sugimoto, Katsuhiko Ohi, Sho Mokuda, Keisuke Oda, Takaki Nojima, Shintaro Hirata, Eiji Sugiyama
Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital
Conflict of interest: None

[Background] In dermatomyositis (DM) patients, nailfold videocapillaroscopy (NVC) abnormalities are found in some cases, but the change after the treatment is not fully understood. From the beginning of treatment, we observed NVC abnormalities in two DM patients every 2 weeks. [Case1] A 37-year-old man was diagnosed as DM with skin eruption and cough. Blood tests showed elevated creatine phosphokinase (CPK), hyperferritinemia, anti-melanoma differentiation associated gene 5 (MDA5) antibody positive, and computed tomography (CT) revealed interstitial pneumonia. He was treated with three drugs of prednisolone, tacrolimus, cyclophosphamide. [Case2] A 68-year-old woman was diagnosed as DM due to skin eruption, muscle pain and muscle weakness. Blood test showed CK elevation and anti-Mi-2 antibody positive. She was treated with glucocorticoids and azathoprine. In both cases, there were NVC abnormalities at the initiation of treatment, but those changed into almost normal findings after 8 weeks. [Clinical significance] In two cases of DM, NVC abnormalities improved along with underlying diseases. The degree of NVC abnormalities may be related to the severity of myositis, skin eruption, or interstitial pneumonia, and it may be an indicator of the treatment response.

P3-132
Seronegative necrotizing myopathy associated with Rosuvastatin: a case report
Yuto Nakakubo, Masaaki Fujita, Toshiki Nakajima, Yumiko Nakano, Yoshitaka Imura
Department of Clinical Immunology and Rheumatology, The Tazuke-Ko-fukai Medical Research Institute, Kitano Hospital, Osaka, Japan
Conflict of interest: None

[Case] A 41-year-old woman presented with myalgia and reddish urine, 4 months after starting rosuvastatin. Laboratory tests showed a marked increase of creatine kinase: CK (206100U/L), serum myoglobin (19714.1ng/mL). She was hospitalized with diagnosis of labdomyolysis. Although we continued fluid therapy, CK was still elevated remarkably. She was hospitalized with diagnosis of labdomyolysis. Although we continued fluid therapy, CK was still elevated remarkably. Anti-ARS antibody, anti-TIF1-γ antibody, anti-Mi-2 antibody, anti-MDA-5 antibody, anti-HMGCR antibody, anti-mitochondria M2 antibody, and anti-SRP antibody were negative. MRI showed symmetrical STIR high signals in bilateral tibialis anterior muscles, rectus femoris muscles and so on. Biopsy from right rectus femoris supported immune-mediated necrotizing myopathy, with active necrosis of muscle fibers and regenerative changes in HE and expression of HLAABC and MAC depo-
sition on sarcolemmal membrane in immunological staining. Prednisolone 40mg/day (0.6mg/kgBW/day) was started. Because of insufficient CK decrease, we added methotrexate 8mg/week and tacrolimus 3mg/day and CK decreased. [Clinical significance] Anti-HMGCR antibody and Anti-SRP antibody are known as disease-specific antibodies of necrotizing myopathy. However, cases in which no antibody was detected were seldom reported. We report our experience with some literature review

P3-133
A case of Good syndrome complicated with dermatomyositis, Sjögren’s syndrome, and neuromyelitis optica
Shotaro Masuoka, Hiroshi Sato, Keiko Koshiba, Mai Kawazoe, Soichi Yamada, Satoshi Mizutani, Kotohiro Shikano, Sei Muraoka, Toshio Nanki
Division of Rheumatology, Department of Internal Medicine, Toho University School of Medicine
Conflict of interest: None

Good syndrome (GS) is characterized by thymoma with immunocompromised condition. Several cases in GS with autoimmune diseases have been reported. [Case] A 48-year-old male developed GS three years ago. Seven months ago, skin rash, muscle weakness and increase of CK level were observed. MRI and electromyogram revealed myositis findings, and he was diagnosed with dermatomyositis. Sjögren’s syndrome was also suspected because of dry eye and mouse. He was treated with 50 mg/day of prednisolone (PSL), and the symptoms were improved. However, thrombocytopenia and visual loss appeared. Based on the presence of pancytopenia and elevation of ferritin level, hemophagocytic syndrome was suspected. Intravenous glucocorticoid pulse therapy was administered before switching 60 mg/day of PSL and cyclosporine. However, the visual impairment progressed. Lower limb weakness and bladder rectal disturbance also appeared. MRI revealed optic neuritis and myelitis. We then performed plasma exchange and administration of rituximab, nevertheless, the symptoms were not improved. At five months later, he died because of pneumonia. Autopsy revealed demyelination in optic nerve and spinal cord. We reported rare GS case complicated with dermatomyositis, Sjögren’s syndrome and neuromyelitis optica.

P3-134
A case of long-term course of polymyositis confirmed by follow-up FDG-PET-CT after pancreatic cancer surgery
Tatsuki Matsumoto, Taro Horino, Satoshi Inotani, Hirofumi Nishikawa, Yoshiko Shimamura, Kosuke Inoue, Yoshio Terada
Department of Endocrinology, Metabolism, Nephrology, Kochi Medical School, Kochi University
Conflict of interest: None

A 51-year-old Japanese woman presented with myalgia and muscle weakness was admitted to our hospital. Six years before, she was diagnosed with pancreatic tail cancer and resection of pancreatic body and tail was performed. Seven years before, hyper-CPEA-emia had persisted. Although FDG-PET-CT was performed once a year for follow-up after surgery, recurrence of pancreatic cancer was not pointed out. Laboratory examination revealed the elevated levels of CRP, CPK, and positive anti-cytoplasmic antibody. Based on findings of muscle biopsy specimen of biopsies, polymyositis was diagnosed. The levels of CPK and CRP normalized, myalgia also improved with treatment started with PSL 20 mg/day. When confirming the past FDG-PET-CT backwards, they showed that FDG accumulation increased over time to the proximal muscles such as the upper arm, thigh, and so on, from when the elevated levels of CPK was initially observed. Furthermore, after the treatment, disappearance of FDG accumulation was observed. In our case, it was suspected that polymyositis was progressing more slowly than pancreatic tail cancer surgery based on the sequential FDG-PET-CT findings. It was suggested that FDG-PET-CT is effective for diagnosis, follow-up and treatment effect determination of polymyositis.
P3-135
A case of dermatomyositis complicated by rheumatoid arthritis treated with abatacept
Shotaro Kojima, Junya Suzuki, Ayako Matsuki, Kentaro Takahashi, Takeshi Umibe
Matsudo City General Hospital, Matsudo, Japan
Conflict of interest: None

A 56-year-old male was diagnosed with rheumatoid arthritis at previous hospital. He was treated with 5mg/day of prednisolone and 1000mg/day of salazosulfapyridine. In December 2010X-3, he had muscle weakness, muscle pain, and Gottron signs. He was diagnosed as dermatomyositis with an elevation of CK, inflammation findings at MRI and electromyogram. He had no malignancies. He was treated with 60mg/day of prednisolone, 400mg/day of cyclosporine, and intravenous immunoglobulin. Then the symptoms were improved. In April 2011X, when the dose of prednisolone was tapered to 12.5mg/day, he had a relapse of dermatomyositis with an elevation of CK. He was treated with 40mg/day of prednisolone and 10mg/week of methotrexate, but the symptoms were not improved. There were no symptoms which suggest the relapse of rheumatoid arthritis. Alveolar hemorrhage was strongly suspected since bronchoalveolar lavage fluid (BALF) was bloody. Cytologic studies for her BALF detected hemoglobin-laden macrophages. Pulse therapy with methylprednisolone improved alveolar hemorrhage. It is said that patients with dermatomyositis complicate alveolar hemorrhage very rarely. This patient is the rare case of dermatomyositis complicated by alveolar hemorrhage.

P3-136
Alveolar hemorrhage in a patient with dermatomyositis
Yuji Uzawa, Yuji Yoshioka, Daisuke Kanai, Akiko Suda, Shohei Nagaoka
Yokohamaminamikyosai Hospital
Conflict of interest: None

A 66-year-old woman was admitted to our hospital because of dyspnea. She was diagnosed with dermatomyositis based on biopsied specimens and clinical symptoms and positive for anti Jo-1 antibody 12 years ago. Thoracic computed tomography (CT) showed new ground-glass pattern in bilateral lung fields. We did bronchoscopy for diagnosis. Alveolar hemorrhage was strongly suspected since bronchoalveolar lavage fluid (BALF) was bloody. Cytologic studies for her BALF detected hemoglobin-laden macrophages. Pulse therapy with methylprednisolone improved alveolar hemorrhage. It is said that patients with dermatomyositis complicate alveolar hemorrhage very rarely. This patient is the rare case of dermatomyositis complicated with alveolar hemorrhage.

P3-137
A case of focal eosinophilic myositis of the hand
Sayuri Yamashita, Hidenaga Kawasumi, Asako Murota, Makiko Kimura, Manabu Tanabe, Takashi Ogasawara, Mutsoo Tateishi
Department of Rheumatology, Tokyo Metropolitan Ohtsuka Hospital
Conflict of interest: None

A 30-year-old woman with 4-year history of ulcerative colitis was referred to our hospital to evaluate a swollen lesion on the left hand. She noticed a swollen lesion on the first web space of the left hand 2 weeks before her visit. Physical examination showed that vital signs were normal. Her thenar was swollen with no tenderness. She had no skin erosion or muscle weakness. Laboratory studies showed that the white blood cell count was 15,800/μL (reference range, 3,300-8,600/μL) with eosinophils at 66% (reference range 0.2-7.3%). Muscle enzymes were also elevated (CK 262 U/L, aldolase 7.7 U/L). Magnetic resonance imaging of the left hand demonstrated high intensity lesions in adductor pollicis muscle with fat-suppressed T2 weighted image. Muscle biopsy from the left hand demonstrated high intensity lesions in adductor pollicis muscle with fat-suppressed T2 weighted image. Muscle biopsy from the left hand demonstrated high intensity lesions in adductor pollicis muscle with fat-suppressed T2 weighted image. She was diagnosed as having focal eosinophilic myositis. Two months after her first visit, symptoms resolved spontaneously. This case suggests that physicians should consider the possibility of eosinophilic myositis if isolated myositis is seen in patients with peripheral blood eosinophilia.

P3-138
A patient with Takayasu arteritis with right pulmonary artery obstruction and recurrent right lung field infection was safely treated with total right lung resection and tocilizumab administration
Yoshihiro Yoshida, Mayumi Matsuda, Yoshinobu Nako, Takashi Maruyama, Kazuhiro Yokota, Hiroshi Kajiyama, Kojiro Satoh, Yu Funakubo, Toshhide Mimura
Department of Rheumatology and Applied Immunology, Saitama Medical University
Conflict of interest: Yes

Case A 57-year-old female was diagnosed as a right pulmonary infection. The symptom was once improved, but she suffered from the recurrence after 2 months. A chest contrast-enhanced CT scan revealed an occlusion and wall thickening of right main pulmonary artery. Takayasu arteritis was suspected due to a wall thickening of aortic arch. The diagnosis was confirmed by PET-CT. The treatment with prednisolone 0.8mg/kg did not induce favorable response. Additional administration of tacrolimus, steroid pulse, increase amount of prednisolone (1.0 mg/kg) or methotrexate did ameliorate the disease activity. Angioplasty of right pulmonary artery was considered risky because no angiographical information was obtained on the distal side. Finally, because she had pulmonary Aspergillus infection and complicated pneumothorax, total right pulmonary resection was performed after 5 months. Additional Tocilizumab administration caused CRP complete negative and immunosuppressants unnecessary and prednisolone decreased without any adverse events.

Clinical significance Since there have been only a few case-reports describing requirement of total unilateral pulmonary resection for Takayasu arteritis, here along with some literature review we report our case, which is believed educative for rheumatologists.

P3-139
Inflammatory Subclavian artery aneurysm with Takayasu Arthritis: Successful Surgical Treatment with Tocilizumab
Mari Yamamoto
Department of Rheumatology and Nephrology, Chubu-Rosai Hospital, Aichi, Japan
Conflict of interest: None

48-year-old woman presented to our hospital with fever and headache. Same symptoms developed since she was 20-year-old and she was diagnosed with Takayasu arteritis. Since the onset of symptoms prednisolone was started for providing symptomatic relief and she could not reduce prednisolone less than 10mg per day. She had no other past medical history. When she came to our hospital, she took 8mg per day prednisolone. She never takes another immunosuppressive agents. On physical exam, her blood pressure was 110/78mmHg in both arms. A cardiovascularexamination revealed a left subclavial bruit and mild aortic regurgitation. She had also 30mm left subclavian artery aneurysm. Since treatment with methotrexate (MTX) was difficult with PSL dose reduction, tocilizumab (TCZ) combination therapy was started. When she could successful of weaning off PSL 5mg/day, left common carotid artery - left subclavian artery bypass and chest stent graft interoporation were performed and the postoperative course is uneventful. [Discussion] Takayasu arteritis is one of the major vasculitis, causing stenosis of blood vessels and aneurysm. There are only few reports of TCZ therapy with Takayasu’s arteritis aneurysm. We report as a successful surgical treatment case by TCZ combination.
Conflict of interest: None

[Background] In diagnosis of fever of unknown origin, thorough history taking and physical examination are essential but sometimes hints of diagnosis become clinically evident lately. [Case report] The patient was a 48-year-old woman who presented 5 days fever without any associated symptoms. After 3 weeks from onset contrast enhanced CT showed pulmonary infiltrative shadow in the left lingular segment. Antibiotics did not work. Finally, repeated physical examination revealed newly carotid bruit on 4 weeks from onset. She was diagnosed as Takayasu’s arteritis by PET-CT. [Conclusion] Repeated physical examination could give a clue for diagnosis in a patient with fever of unknown origin.

P3-141
Long-term efficacy and safety of abatacept in an elderly patient with large vessel vasculitis
Miki Murata, Atsuo Uefuji, Ryosuke Yoshihara, Natsuko Nakagawa, Yasushi Tanaka, Kazuko Shiozawa
Rheumatology & Collagen Disease Center, Hyogo Prefecture Kakogawa Medical Center

Conflict of interest: None

A 83-year-old female case. It was diagnosed as rheumatoid arthritis in 2012. From around 2013, a strong inflammatory response not related to the degree of arthritis was observed in the blood test. Takayasu arteritis diagnosis with MRI and PET-CT. Aortic dissection also accompanied during the course. High inflammation continued, when combined with Abatacept, inflammatory response and back pain improved. Improvement was also seen in contrast MRI and PET-CT. Even now, there are few reports that large angiitis has been treated with ABT, as it is a rare case, we will examine and report it.

P3-142
Three cases of reactive aortitis appeared after infection
Yoshinobu Nakao, Mariko Sakai, Yuri Sadanaga, Akihito Maruyama, Nobuyuki Ono, Syuichi Koarada, Yoshifumi Tada
Saga University Hospital

Conflict of interest: None

[Case 1] Sixty-eight-year-old man experienced fever, dyspnea and chest pain a week after his improvement of pneumococcus pneumonia. CT scan and MRI showed thickening of the blood vessel wall and fat around the blood vessel from the aortic arch to abdominal aorta. His fever and radiographic changes were improved spontaneously. [Case2] Sixty-six-year-old man experienced fever and dyspnea after the improvement of infectious enteritis. CT scan showed thickening of the blood vessel wall and fat around the blood vessel from the aortic arch to thoracic aorta. His fever and radiographic changes were improved spontaneously. [Case3] Seventy-seven-year-old woman with ovarian cancer had fever and cough after G-CSF treatment during her chemotherapy. After improvement of her bronchitis, she became febrile again. CT scan showed thickening of the blood vessel wall and fat around the blood vessel in the aortic arch. Fever and the inflammatory response were improved spontaneously. [Discussion] We experienced 3 cases of aortitis that developed after infection leading to spontaneous remission. We supposed that these cases were associated with reactive arthritis.

P3-143
A case of Crohn’s disease complicated with large vasculitis with asymptomatic right internal carotid artery occlusion
Koari Ishimura, Yuji Nozaki, Hiroki Akazawa, Chisato Ashida, Fusayo Ikeda, Atsushiro Yamamoto, Tetsu Itami, Kenji Sakai, Asuka Inoue, Shinkai Ri, Toshihiko Shiga, Kazuya Kishimoto, Koji Kinoshita, Masanori Funauchi, Itaru Matsumura
Kindai University Hospital Osaka Japan

Conflict of interest: None

[Case] 14-year old man [Chief complaint] Right brachial pain [History of present illness] He was receiving mesalazine and infliximab on diagnosis of Crohn’s disease. He was referred to our hospital 7 months after diagnosis of Crohn’s disease due to an inflammatory reaction increase and right upper limb pain. [Passage] A difference in left-right blood pressure was recognized, so contrast CT was performed. A stenosis of the right brachial artery was observed and diagnosed as large arteritis. The left internal carotid artery occlusion was confirmed by the carotid pulse echo performed as a screening test, and occlusion was confirmed by the MRA at the origin of the left internal carotid artery. But the flow of the left internal carotid artery from the eight internal carotid artery or vertebral basilar artery was maintained. Prednisolone 30 mg / day and aspirin 100 mg / day started. Inflammatory response and right brachial artery stenosis improved. Azathioprine 25 mg / day was used in combination and discharged. [Consideration] In this case, echo made it possible for him to get medical treatment earlier before cerebrovascular accident occurred. Thus, aggressive blood vessel evaluation using contrast CT, echo and so on regarding systemic vasculitis is important.

P3-144
Abdominal aortitis after using pegfilgrastim during the lung cancer chemotherapy
Nao Oguro, Tomoki Hayashi, Mika Hatao, Ryo Takahashi
Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan

Conflict of interest: None

A 49-year-old man was diagnosed with advanced stage 4 lung small cell carcinoma and started chemotherapy. Patient received 3.6mg pegfilgrastim as prophylaxis for neutropenia. 1 days after the administration of pegfilgrastim, patient developed abdominal pain and high fever. Initial laboratory test revealed white blood cell count of 285800/μl and C-reactive protein 18.52mg/dl. Computed tomography:CT scan showed thickness of the soft tissue around abdominal aorta and Magnetic resonance imaging showed the wall thickness and contrast enhancement. We excluded the Takayasu arteritis and giant cell aortitis from the clinical history and physical examination. There was no elevation of IgG4 and no sign of infection. G-CSF associated aortitis were strongly suspected and 40mg prednisolone was started. High fever and inflammatory marker were rapidly improved. A week after the treatment, CT scan showed complete resolution of soft tissue thickness. There were 6 reported case of G-CSF associated aortitis and 2 of them were induced by pegfilgrastim. Underlying diseases varied, and most of the case treated by corticosteroid and rapidly improved. It seemed to be important to reveal the mechanism, treatment necessity and risk factors of the disease by accumulating the case.

P3-145
A case of aortitis complicated by ischemic colitis
Hiroyuki Teruya, Ko Sudo, Hiroyuki Yano, Mitsuyo Kinjo
Okinawa Chubu Hospital, Okinawa, Japan

Conflict of interest: None

Chief complaint: Abdominal pain, hematochezia
History of present illness: A 86-year-old woman with history of advanced rheumatoid arthritis on low dose prednisone and diabetes, who presented with 2 months duration of headache, and lower abdominal pain associated with hematochezia for one day. Clinical course: An abdominal CT scan with contrast revealed findings suggestive of ischemic colitis in splenic flexure to descending colon, and thickened abdominal aortic wall. As abdominal pain persisted, repeated abdominal CT scan 8 days later revealed expanding inflammation around abdominal wall. Prednisolone 40mg daily was started for large vessel vasculitis. Biopsy of temporal artery was suboptimal. The patient developed steroid psychosis and deferred all oral medications. Subcutaneous tocilizumab successfully controlled her symptoms and inflammation. Clinical significance: Persistent abdominal pain and inflammation were the keys to diagnose aortitis in this case. Aortitis can cause hematochezia by mesenteric ischemia which may be life-threatening. Early detection of vasculitis is important to improve prognosis.
**P3-146**
A case of primary Sjögren Syndrome comorbid with large vessel vasculitis

Takahisa Suzuki¹, Yoshikazu Nakashima², Akitomo Okada², Atsushi Kawakami²
¹Sasebo City General Hospital, Sasebo, Japan, ²Nagasaki Genbaku Hospital, Nagasaki, Japan

Conflict of interest: None

**Case report** The patient was 63-year-old, female. She developed dry eye, dry mouth, and polyarthritides at age 57. She was diagnosed with primary Sjögren Syndrome, on the basis of keratoconjunctivitis sicca and presence of anti-Ro/SS-A antibody and anti-La/SS-B antibody. Because she comorbid interstitial nephritis and arthropathy refractory to NSAIDs treatment, she had a low dose of prednisolone. In X-year mid of June, she visited our hospital and presented with a fever over 38 degrees Celsius continued for a week and myalgia. Plain CT scan could not presented cause of fever. Laboratory test showed elevation of CRP (25.88mg/dL). Since the origin of the fever was still unknown, she was examined by FDG-PET/CT. The exam indicated she developed large vessel vasculitis. Although we planned to remission induction therapy, thereafter she rapidly declined fever, reduced CRP levels, and diminished lymph nodes swelling in the natural course. Follow up FDG-PET / CT exam in mid of July revealed improvement of the large vessel vasculitis.

**Clinical Significance** For the vasculitis associated with Sjogren’s syndrome, large vessel vasculitis considered to be rare. We experienced a case thought to be the large vasculitis taking selfremitting course, so we reported this case with literature review.

**P3-147**
Aortitis associated with SLE

Hiroyuki Akebo, Yoichi Nakayama, Saki Minoda, Hirofumi Miyake, Ryuichi Sada, Hiroyasu Ishimaru, Kazuhiro Hatta
General Internal Medicine, Tenri Hospital

Conflict of interest: None

A 49-year-old female complained of an 1-week history of bilateral shoulder pain followed by a 3-day history of anterior chest pain, dyspnea and fever of 38°C. SLE was diagnosed 35 years ago, followed by 5 times of relapse with pericarditis or pleurisy. She was successfully treated with prednisolone (PSL) 0.5 mg/ kg/ day in those times. On admission to our hospital she was treated with PSL 8 mg/ day. The investigations showed elevated CRP 9.4 mg/ dl, ESR 89 mm/ h and ds-DNA 13 U/ ml, without pleural effusion or pericardial effusion and ECG abnormality. Contrast CT showed aortic wall thickness between ascending region and arch withperiaortic soft tissue inflammation. Two sets of blood culture were negative. There was no sign or symptom suggesting that coexistence of antiphospholipid syndrome, Behcet syndrome and temporal arteritis. She was diagnosed as Lupus aortitis and administered PSL 0.5 mg/ kg/ day. Her symptom, laboratory abnormality and aortic wall thickness improved. She is maintained with PSL 10 mg/ day without relapse. There are only 13 reports of Lupus aortitis. The therapeutic approach is unclear in the situation. In this case, we have retried the regimen of PSL with which her relapse had been controlled, and gotten good response.

**P3-148**
A Case of "Limb Restricted Arteritis": Presenting Large Vessel Giant Cell Arteritis Like Symptoms and Diagnosed by PET-CT

Isao Matsuura¹, Shohi Nakamura¹,², Yohei Seto¹,²
¹Department of Rheumatology, Tokyo Women’s Medical University Yachiyo Medical Center, ²Department of Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University

Conflict of interest: None

A 70-year-old man was referred to our institution for a 20-day history of persistent fever and high level of CRP. He had claudication of lower limb, but denied myalgia, arthralgia and any craniocebral symptom. Large Vessel Giant Cell Arteritis (GCA) was suspected from his age and history. Contrast CT from his neck to pelvis did not show any organ and vessel lesion. PET-CT was performed and increased FDG uptake was not observed in any large arteries but bilateral brachial and femoral arteries. Therefore, he was diagnosed with limb restricted arteritis. Forty mg of predonisolone was commenced and his symptoms were resolved promptly. GCA with extracranial large vessels and with first branches of aorta reportedly occupies 20-30% and 10-20% of total GCA respectively. In contrast, a few studies have reported regarding limb arteritis which is restricted to the arteries distal to aorta and these epidemiological data is scarce. Additionally, limb restricted arteritis distal to first branches of Aorta which are out of CT imaging range may have been much overlooked like our case. Hence, PET-CT and vascular ultrasound would be preferable for diagnosis. We discuss the pathology of limb restricted arteritis and the diagnosis with imaging modalities referring to literature.

**P3-149**
A Case of Microscopic Polyangiitis Complicated by large vessel Lesions

Teppei Kamikawa¹, Akari Kato¹, Teruchika Yamada², Yuichi Handa¹, Masanobu Horikoshi¹
¹Division of Rheumatology, Saitama Red Cross Hospital, ²Oomiya Clinic

Conflict of interest: None

[Case] 62-oy male [Clinical course] The patient was diagnosed with MPA based on IP, RPGN, the high titer of MPO-ANCA in October, X-2. Treatment using PSL and IVCY was administered. In June of the X-1, lung cancer was suspected, and in August of the same year, the right lower lobe was excised. It was diagnosed as pulmonary adenocarcinoma. With postoperative CRP being 4-7 mg / dl, prolongation of inflammatory reaction was observed. In the PET, accumulation promotion was observed on the vessel wall from the abdominal aorta to the bilateral iliac artery, and inflammation of the large artery was suspected. Few subjective symptoms appeared due to the post cancer operative condition. Therefore, the follow-up observation was conducted without treatment. For about one year from that time to the present, symptoms have not been observed. In addition, MRI shows narrowing of vascular lumen has not progressed. [Conclusion] In ANCA-related angiitis, the complication of macrovascular lesions has been considered rare. However, it has been suggested that in the case inflammation of unknown origin is prolonged like in this case, it is necessary to consider it as a disease state requiring differential diagnosis.

**P3-150**
A case of thromboangiitis obliterans in a never-smoking woman of middle age

Natsuki Shima¹, Yoichiro Akiyama¹, Ayako Kokuzawa¹, Katsuya Nagatani², Masahiro Iwamoto¹,², Seiji Minota¹
¹Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University, ²Department of Rheumatology, Tochigi Medical Center Shimotsuga

Conflict of interest: None

A 48-year-old woman with severe pain and numbness in her right leg and foot was admitted to our hospital. Pulsation in the right popliteal artery was normal, whereas that in the right dorsal pedis artery reduced. Pulsations in the left popliteal, left dorsal pedis, bilateral brachial, and radial arteries were normal. White blood cell count was 10,800/µl, CRP was 0.65 mg/dl, lupus anticoagulant was 2.35 and anti-cardiolipin IgG was 11.9 U/ml. MPO-ANCA and other autoantibodies were negative. CT angiography showed obstruction in the right anterior tibial artery and disruption in the right tibial and fibular arteries. Polyaorteritis nodosa and anti-phospholipid syndrome were in the differential diagnosis. The combination therapy with methylprednisolone pulse therapy, intravenous cyclophosphamide, some vasodilators and anticoagulants was ineffective. Gangrene developed in her right toes, and amputation was mandatory. Pathological findings of the amputated leg revealed thromboangiitis obliterans (TAO, Buerger’s disease). She had never smoked, and she had little exposure to passive smoking. We should expand differential diagnosis to TAO in patients who show refractory to conventional therapy for vasculitis even if their clinical characteristics do not match the typical
P3-151
Presence and significance of NETs in the necrotic lesion of ANCA-associated vasculitis
Sakiko Masuda1,2, Yuka Nishibata1, Daigo Nakazawa1, Utano Tomaru1, Tamihiro Kawakami1, Tatsuya Amimiru1, Akihiro Ishizu1
1Department of Medical Laboratory Science, Faculty of Health Sciences, Hokkaido University, 2Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University

[Object] Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is characterized by production of ANCs and systemic necrotizing vasculitis in small vessels. Recent studies have revealed that disordered regulation of neutrophil extracellular traps (NETs) is critically involved in the pathogenesis of AAV. [Methods] We examined the amounts of NETs in formalin-fixed paraffin-embedded tissue sections and compared the results for AAV with the results for diseases that should be distinguished from AAV. [Results] NETs were more abundant in necrotizing vasculitis of AAV than in non-AAV, such as polyarteritis nodosa and cutaneous arteritis, or in granulomatous angiitis of giant cell arteritis. We next focused on pulmonary granulomas in AAV and non-AAV-associated diseases. The amount of NETs was significantly greater in necrotizing granulomas of AAV than in granulomas of sarcoidosis without necrosis. Although NETs were formed in necrotizing granulomas of tuberculosis equivalently to those formed in AAV, they were more susceptible to degradation by DNase I than were NETs in AAV. [Conclusions] In AAV, DNase I-resistant NETs were deposited in necrotic lesions.

Conflict of interest: None

P3-152
Classification of ANCA-associated vasculitis by Epithelial Cell-Derived Cytokines
Kyoko Otsuka1, Kensuke Irino1, Yojiro Arinobu1, Nobuyuki Ono2, Yasushi Inoue1, Masahiro Ayano1,4, Yasutaka Kimoto5, Hiroki Mitoma3, Masahiro Kurosaki, Tamihiro Kawakami4, Tatsuya Atsumi2, Akihiro Ishizu1
1Department of Stem Cell Biology and Medicine, Faculty of Medical Education, Kyushu University, 2Department of Pathology, Faculty of Medicine and Pharmaceutical University

[Object] IL-25 and IL-33 classified as epithelial cell-derived cytokines are produced from vascular endothelial cells and epithelial cells. Recently, serum IL-25 levels were reported to be elevated in active eosinophilic granulomatosis with polyangiitis (EGPA). A correlation between IL-33 and large vessel vasculitis has also been reported. ANCA-associated vasculitis (AAV) has many common clinical signs and it is required to raise the accuracy of diagnosis and disease classification. In this study, we examined the correlation between AAV type or organ involvement and serum IL-25 and IL-33 concentrations. [Methods] We measured serum IL-25, IL-33 concentrations of 22 patients with AAV (8 patients with EGPA, 8 patients with granulomatosis with polyangiitis (GPA), 6 patients with microscopic polyangiitis (MPA)) at the initial examination by Multiplex Assays, and examined relationship with laboratory and clinical findings. [Results] IL-25 levels were elevated in 12 patients, all cases expressed higher levels of IL-33. Factors related to elevation of IL-25 include BVAS score at diagnosis, skin vasculitis, and presence of neurological manifestations. [Conclusions] It is possible that IL-25 is involved in some pathology of AAV and is useful for diagnosis and classification.

P3-153
Five cases of AAV cases in newly established the department of Rheumatology in our hospital
Hideki Shimizu
Funabashi Municipal Medical Center

[Background] ANCA-related vasculitis (AAV) has been gradually recognized as a representative vasculitis. However, initial approach has not been sufficient. [Object/Methods] To examine the actual clinical aspect, we retrospectively summarize the medical records in our 5 cases of AAV. [Results] Total 5 cases of AAV was 2 males and 3 female, and average age was 74.2 ± 11.12 years. Its category was 4 cases of MPA and 1 case of GPA. All cases were positive for MPO-ANCA, and one case was also positive for PR3-ANCA. Disease onset were 8 years in one case, 5 months in 2 cases and initial diagnosed cases were remained 2 cases. Initial approach for AAV patients performed as an each doctors of respiratology, neurology, nephrology and orthopedics. The initial treatments of all cases were mainly selected glucocorticoids, and only one case of an alveolar bleeding were also combined immunosuppressive drugs. [Discussion/conclusions] MPO-ANCA positive cases had not been sufficient for the initial use of immunosuppressive drugs were retained disease activity, except for newly diagnosed cases. AAV is also desirable for early diagnosis, and after then its patients should be selected appropriate immunosuppressive therapy according the degree of disease progression.

P3-154
Analysis of Six Cases of ANCA Associated Vasculitis with Intestinal Perforation in Our Institution
Takamasa Murosaki, Taketo Sato, Akiko Miyama, Ayako Kokuzawa, Yoichiro Akiyama, Katsuya Nagatani, Takao Nagashima, Masahiro Iwamoto, Seiji Minota
Division of Rheumatology and Clinical Immunology, Jichi Medical University

[Object] To investigate the backgrounds of intestinal perforation in ANCA associated vasculitis (AAV) because of the difficulty of judging whether it is derived from vasculitis. [Methods] We examined 162 AAV cases in our division from 2005 to 2016. [Results] Intestinal perforation: n = 6 (3.7%), male: n = 3 (50.0%), age: 67.5 (year, mean), MPO-ANCA positive: n = 5, PR3-ANCA positive: n = 2, MPA: n = 4, GPA: n = 1, EGPA: n = 1, small intestine: n = 2, descending colon: n = 1, sigmoid colon: n = 3. All events occurred after starting glucocorticoid [duration: 18.5 (0.1 - 73.7) [month, median (range)]]. Pathology were examined in four. Two had biopsy-proven vasculitis of small intestine with short duration [0.9 (0.1 - 1.7)]. Four had colon involvement, with no vasculitis, from diverticulum (n = 3), long duration [41.8 (16.6 - 73.7)]. In Swedish cohort with 202 AAV cases; perforation: n = 5, post-medication: n = 4, small intestine: n = 2 (improved after reinforce), ascending colon: n = 1 (pre-medication, biopsy-proven vasculitis, improved), sigmoid colon: n = 2 (dead). [conclusions] In our institution, vasculitidies were proved in small intestine perforations and its duration of medication was short. The cause of perforation is due to vasculitis in small intestine, but various in colon.

P3-155
A case of acute pancreatitis and hemoperitoneum associated with microscopic polyangiitis
Kazuya Tsuji, Kaoru Ario
Japanese Red Cross Kochi Hospital

Conflicts of interest: None

A 54-year-old woman exhibited malaise and reduction of urine output was refered to our hospital because of renal function deterioration with glomerulonephritis feature. After examination, she was suspected rapid progressive glomerulonephritis. She underwent renal biopsy, we diagnosed microscopic polyangiitis (MPA) with MPO-ANCA positive and renal biopsy specimen findings. We administerd prednisolone. She com-
plained epigastric pain after admission and gradually deteriorated. We performed computed tomodraphy (CT), revealed acute pancreatitis (AP). Pancreatic specimen on EUS-FNA showed no malignancy. Considering AP associated with MPA, we selected pulse cyclophosphamide therapy adding to pulse steroid therapy. However she suddenly failed into shock state, she was detected extravasation in pancreas tail’s arteries on contrast CT. We diagnosed hemorrhage in pseudocyst associated with AP caused hemopteritoneum. She underwent emergency transcather arterial embolization, succeeded in hemostasis. After that, abdominal symptoms ameliorated in parallel with nephritis findings. In light of the clinical course, we diagnosed AP associated with MPA. -Conclusion-Symptomatic pancreatic involvement in cases of MPA is rare. We add review of the literatures.

P3-156 Microscopic polyangiitis presenting hemorrhagic shock due to gastric artery aneurysm rupture: A case report

Kenji Funakoshi1, Takeshi Kaneko1, Tomomi Tada1, Shinichiro Nameki1, Jun Fukui1, Takashi Hosokawa1, Yuki Yoshida1, Hiroshi Fujitawa1
1Osaka General Medical Center, 2National Hospital Organization Osaka Minami Medical Center
Conflict of interest: None

A 73-year-old man was admitted to a previous hospital with a 1-month history of fever and a high serum C-reactive protein (CRP) level. Thorough investigation did not reveal infection. He was transferred to our hospital for further examination. We diagnosed him with microscopic polyangiitis from acute progressive glomerulonephritis and a high serum titer of myeloperoxidase anti-neutrophil cytoplasmic antibody. Methylprednisolone pulse therapy followed by the administration of high-dose steroid rapidly improved his fever and lowered the elevated serum CRP levels. On day 5 after initiating treatment, he developed sudden cardiopulmonary arrest; however, successful cardiopulmonary resuscitation was performed. Contrast-enhanced computed tomodraphy (CECT) revealed rupture of a left gastric artery aneurysm and multiple aneurysms of the intra-abdominal arteries. Transcatheter arterial embolization of the left gastric artery stabilized his vital signs. He was treated with intravenous cyclophosphamide pulse therapy in addition to high-dose steroid. CECT performed a month later did not reveal any intra-abdominal aneurysm. Subsequently, his general condition and renal function showed improvement. This case report describes and analyzes the possible causes of gastric artery rupture.

P3-157 A case of ANCA-associated vasculitis with bilateral perirenal hematoma

Masako Kuskabe1, Takaaki Ishida1, Tomohiko Kuboyma1, Takao Kiboshi1, Youhei Fuji1, Kenichiro Hata1, Maki Kagitani1, Tohru Takeuchi1, Shigeki Arawaka1
1Department of Internal Medicine IV, Osaka Medical College, Osaka, Japan
Conflict of interest: None

A 73-year-old woman presented with right secretory otitis media since January and with fever and cough since February. She transferred to our hospital on March 27 and diagnosed with ANCA-associated vasculitis (AAV) due to CRP 13.26 mg/dl, creatinine 4.67 mg/dl, MPO-ANCA 300 U/ml, microscopic hematuria, and proteinuria. Because of rapidly progressive glomerulonephritis, she was treated with prednisolone 60mg, intravenous cyclophosphamide (IVCY), plasma exchange, hemo-dialysis (HD), and intravenous heparin. On April 3, she suddenly complained of right back pain and hematuria. Abdominal CT showed right perirenal hematoma. She discontinued heparin and had blood transfusion. However, in the next morning, she suddenly complained of right back pain and hematuria. Abdominal CT showed left perirenal hematoma. Because of hypotension and depressed level of consciousness, she was admitted to the intensive care unit and treated with steroid pulse therapy and IVCY undergoing continuous hemodialfiltration. Increasingly, her consciousness and renal impairment improved without obviously rebleeding episode, so she discharged on March 18 and transferred on July 27. It is important to consider perirenal hematoma when back pain and hypotension appeared, although AAV with perirenal hematoma is a rare case.

P3-158 Simple plasma exchange therapy for microscopic polyangiitis with diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis: a case report

Shinya Seki
Department of Internal Medicine, Asama General Hospital, Saku, Nagano, Japan
Conflict of interest: None

An 80 years-old male. He was diagnosed with pneumonia and hospitalized on 8th August X. Computer tomography showed ground-glass opacity, consolidation, and patchy shadow on the both lungs. Ampicillin/subactam was started, but it was changed to Levofloxacin and Clindamycin on day 5, and Micafungin was added on day 7. He had blood sputum from day 8, and his renal function declined. On day 16, MPO-ANCA was higher than 300U/ml. I became his doctor on day 17, and diagnosed as microscopic polyangiitis (MPA) with diffuse alveolar hemorrhage and rapidly progressive glomerulonephritis. As his SpO2 was 90 % (reservoir mask oxygen 8L/min), a ventilator was started. Pulse steroid therapy, prednisolone (0.8mg/kg/ day) was started. From day 21, simple plasma exchange therapy was carried out for 3 days. On day 24, intravenous cyclophosphamide (IVCY, 260mg/m2) was carried out. He tended to improve, and withdrew from a ventilator on day 27. eGFR improved from 24 to 81 mL/min/1.73m2. On day 43, he withdrew oxygen therapy and was reduced steroid. On day 55, IVCY was carried out. He didn’t have any infection. On day 71 (abstract registration date), prednisolone is 25mg/day, and rehabilitation is continued to return his home. I report plasma exchange therapy’s possibility of treating severe MPA.

P3-159 2 cases of Hypertrophic pachymeningitis with anti-neutrophil antibody

Hiroyuki Ohashi, Tamaki Sagisaka
Omeazaki Municipal Hospital
Conflict of interest: None

Hypertrophic pachymeningitis is a rare clinical disorder involving thickening of the dura mater which is often associated with ANCA-related vasculitis. Case1: 74-year-old female. She complaints of headache, numbness and edema of both legs, fever and taste disorder. In Aug.,2011, she performed renal biopsy and its result revealed only hypertensive changes. Whereas, IPSL was administered from Oct., 2011. because of high fever. She suffered from a headache and walking disturbance. Her skull MRI showed an extensive hypertrophic pachymeningitis and laboratory data showed CRP 1.37 mg/dl, MPO-ANCA 23.2 U/ml. She treated with PSL+IVCY, then her symptoms improved. Case2: 79 year-old male: He complaints of arthralgia of both fingers, severe headache and taste disturbance in March, 2018. In May his skull MRI showed an extensive hypertrophic pachymeningitis and data showed CRP 9.0 mg/dl and PR3-ANCA 4.3 U/ml. He was treated with PSL+IVCY, and rituximab but not induced a remission. Thus MMF was administered, then he developed a remission. Discussion: ANCA-positive Hypertrophic pachymeningitis is considered a localized of the ANCA-related vasculitis. A combination of PSL+IVCY is reported less recurrence than PSL alone. However, flare up case used with PSL+IVCY is needed by another immunosuppression.

P3-160 Microscopic polyangiitis presenting drooping hands and feet

Takanori Ito, Mizuki Kato, Yoichiro Haji
Rheumatology Department, Daido Hospital
Conflict of interest: None

[Clinical significance] Vasculitic neuropathy (VN) is typically refractory and lower patient’s ADL. Microvascular injury and ischemia pro-
veoke damage of myelinated sensory and motor long tract nerve and cause peripheral VN that presents mononeuritis multiplex or distal symmetric polyneuropathy. In this case, we treated early microscopic polyangiitis (MPA) presenting drooping hands and feet and distal symmetric dysesthesia and hypesthesia by corticosteroid (CS) pulse, intravenous immunoglobulin (IVIG) and intravenous cyclophosphamide (IVCY). The peripheral nerve symptoms and life function are improved dramatically.

[Case presentation] Seventy-year-old woman, she had blood feces and was hospitalized in other as diverticular hemorrhage two days later. It disappeared slowly, but dysesthesia of her hands and feet appeared and had been worse rapidly. Day 4, she had drooping hands and feet and distal symmetric hypesthesia, became bedridden. Day 6, MPO-ANCA was high titer, she was diagnosed with MPA. Day 8, she was transferred our hospital, treated by methylprednisolone pulse and high dose CS, IVIG and IVCY for induction therapy. Her symptoms improved and MPO-ANCA became negative. After four months, we started maintenance therapy by azathioprine, she could walk with support and return home.

P3-163
Two case of elderly patient with ANCA-associated vasculitis
Yukiko Asami
Yokosuka City Hospital, Yokosuka, Japan
Conflict of interest: None

Patient 1 was a 82-year-old woman, suffering from leg edema, fever-up, general fatigue, and difficulty in motion. Renal biopsy showed pauci immune crescentic glomerulonephritis and tubulointerstitial nephritis, leading to a diagnosis of AAV with positive MPO-ANCA serology. She received prednisolone (PSL) therapy, however presented with progressive renal insufficiency. She was added plasma exchange (PE), but suffered from catheter occlusion, deep venous thrombosis, and multiple hemorrhages, and then died from cytomegalovirus (CMV) infection and gastrointestinal perforation. Patient 2 was a 88-year-old woman, developing numbness and weakness in limb with fever-up. She was diagnosed with AAV, following a positive result for MPO-ANCA, interstitial pneumonia, renal dysfunction, and peripheral neuropathy in a ‘stacking-glove’ pattern. During the therapy with PSL and a single dose of rituximab followed by PE, she suffered from renal and hepatic insufficiency and CMV infection, but finally improved. The management of AAV in elderly patients continues to present significant therapeutic challenges, since both prevention of comorbidity and management of complication are difficult. PE with the single RTX injection may improve the prognosis of elderly AAV.

P3-164
A case report of difficult diagnosis in the patient with microscopic polyangiitis
Yuki Mizutani, Mayu Sugiyama, Kahori Oshima, Takakazu Hasegawa, Syunsuke Yokoi, Kumiko Umemura, Michita Suzuki, Kyoko Takano, Eiji Nagasawa, Nobuyoshi Minemura, Masao Katayama
Division of Rheumatology, Department of Internal Medicine, National Hospital Organization Nagoya Medical Center, Nagoya, Japan
Conflict of interest: None

[Case] A 88-year-old female [Chief complaint] Fever [Present illness] She had pneumonia and was administered antibiotics because she had high fever and cough, left chest pain around late July. It was not improved by antibiotics. The serum IgG4 was elevated, so she was transferred to our hospital. She had fever, the elevation of CRP and pleurisy. We suspected drug-induced vasculitis, so we stopped some drugs and changing some drugs. After that, she had high fever once a week. Pleurisy was improved and the serum CRP was decreased. We didn’t find the focus of inflammation and tumor. The serum IgG4 was elevated, but we didn’t find IgG4-related disease. She had arthritis of left hand and ground glass opacity in X-ray. That was not improved by antibiotics. We diagnosed microscopic polyangiitis because urine occult blood, MPO-ANCA and PR3-ANCA were positive. She took prednisolone 30 mg/day, and the symptom was improved. [Discussion] After drugs was stopped and changed, the symptom was improving. We diagnosed microscopic polyangiitis because she had the arthritis, urine occult blood and MPO-ANCA was positive. We reported this noteworthy case because it is difficult to diagnose in the cause of fever of unknown origin.

P3-165
An example of the anti Ku antibody-positive AAV
Kyoko Ozaki, Hirotaka Itoh, Masaki Katayama
Rheumatology and Clinical Immunology, Osaka Red Cross Hospital
Conflict of interest: None

The case is 38 years old, a woman. A cough develops from X-4 ten a
year these past months. We had interstitial pneumonia pointed out in X-2 two a year month and showed CK increase, antiKu antibody positive and diagnosed it with overlap syndrome of myositis scleroderma and were under the medical treatment by steroid mass therapy. After that we tapered a steroid and became the follow-up. Fever develops from the middle of January in X year. MPO-ANCA was positive and, in acknowledgment of interstitial pneumonia exacerbation and multiple mononeuritis, had a diagnosis of AAV and performed medical treatment in steroid mass therapy and a cyclophosphamide pulse. Headache, fever, lingual left side ectopia develop from the end of July in X year. We showed hypertrophic cranial pachymeningitis and the cytography effect augmentation around the left hypoglossal canal by MRI and were under the medical treatment by steroid mass therapy and rituximab administration for multiple mononeuritis and thought, AAV. After medical treatment initiation, the symptom was improved. The disorder plurally included disease-specific autoantibody, and each affected it separately, and myositis clinical condition, pulmonary disease, a neurologic lesion were thought to develop over time, respectively.

P3-166
Role of rheumatoid factor in clinical manifestation of microscopic polyangiitis
Keishi Etori, Yosuke Toda, Yoko Yabe, Kensuke Suga, Takayuki Nakamura, Daisuke Kashiwakuma, Shin-ichiro Kagami
Research Center for Allergy and Clinical Immunology, Asahi General Hospital
Conflict of interest: None

[Object] The aim of this study is to investigate the association between the presence of rheumatoid factor (RF) and clinical features of microscopic polyangiitis (MPA). [Methods] We retrospectively reviewed the medical records of 42 patients who were diagnosed as MPA and measured RF titer from January 2007 to January 2017 in our hospital. Of 42 patients, 28 patients had RF positive (RF-positive group). We compared clinical features including BVAS version 3 and VDI (3, 6 and 12 months later after initial treatment) in RF-positive group and RF-negative group. [Results] There were no significant differences in age, sex and disease duration before initial treatment in both groups. General and nervous manifestation at diagnosis were more frequently involved in the RF-positive group (p=0.036 and p=0.049, respectively). The titer of ANCA at diagnosis had no significant difference. However, the level of CRP was higher in the RF-positive group than RF-negative group (p=0.04). Additional, serum levels of C4, CH50 and Alb had a significant negative correlation with the RF titers (p=0.02 R=-0.35, p=0.02 R=-0.35 and p=0.01 R=-0.36, respectively). VDI at each time point had no differences. [Conclusions] The presence of RF could be associated with general and nervous manifestation in MPA.

P3-167
A Case of Microscopic Polyangiitis Complicated with Established Rheumatoid Arthritis
Kotaro Hashimoto, Mari Tochihara, Hirokazu Nishina, Shinya Hirahara, Akira Nishino, Masanori Hanaoka, Yasuhiro Katsumata, Masayoshi Harigai, Hisashi Yamana
Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan
Conflict of interest: None

[Case] Six months before admission, a woman in her 60’s with rheumatoid arthritis (RA) presented with proteinuria, RBC cast, granular cast and her serum creatinine levels elevated. A month before, she complained of edema of legs and intermittent left chest pain. Consulting a doctor, anemia worsened and consolidation was in left lower lobe on chest X-ray and CT. On admission, physical examination revealed pitting-edema and palpable purpura of her both legs. Laboratory tests showed Cr 1.04 mg/dl, CRP 7.68 mg/dl, MPO-ANCA 804 U/ml and protein-to-creatinine ratio in spot urine 0.57 g/gCr. Rapidly progressive glomerulonephritis was suspected. Hemosiderin-laden macrophages were in bronchoalveolar lavage fluid, so she was diagnosed as pulmonary hemorrhage and received a diagnosis of definite microscopic polyangiitis. By the induction therapy (oral prednisolone 40 mg/day, pulse methylprednisolone 1g and rituximab 375 mg/m2 4 times), her symptoms improved. The dosage of prednisolone was tapered. [Clinical significance] In the review paper about an overlap between RA and ANCA associated vasculitis (AAV), 15 articles were published from 1976 to 2015 and 35 case reports were described. We thought it was worth sharing the rare knowledge that AAV could develop in patients with established RA.

P3-168
Two patients with ANCA-associated vasculitis, showing a decrease in visual acuity
Ryota Takamatsu, Takanori Ichikawa, Masayuki Matsuda
Department of Rheumatology, Saku Central Hospital
Conflict of interest: None

ANCA-associated vasculitis sometimes affects nervous systems. We report 2 patients with ANCA-associated vasculitis, showing a decrease in visual acuity. [Case 1] A 77-year-old man noticed a decrease in the right visual acuity, which gradually worsened in 2 months. After cataract surgery, he lost right visual acuity. MPO-ANCA was positive. MRI revealed diffuse pachymeningitis and an enhancement effect around the right optic nerve and cavernous sinus. After starting steroid therapy, his right visual acuity quickly improved. [Case 2] An 82-year-old woman gradually showed a decrease in the left visual acuity and field defect, while being treated with low-dose steroid for MPO-ANCA positive microscopic polyangiitis. She had a past history of the right ischemic optic neuritis. MRI revealed enhancement effects around the bilateral optic nerves and cavernous sinuses. Her left visual acuity quickly improved after administration of rituximab following steroid pulse therapy. Cranial nerve involvement, such as a decrease in visual acuity, produces a serious damage to activity of daily living in patients with ANCA-associated vasculitis. To avoid neurological sequelae, early treatment including rituximab is important and should be actively considered.

P3-169
Microscopic polyangiitis mimicking Temporal arteritis
Kyoysuke Yamamoto1, Kensuke Nakanishi2
1Okinawa Prefectural Nambu Medical Center & Children’s Medical Center Minamimaidaitou Clinic, 2Department of General Internal Medicine, Okinawa Prefectural Hokubu Hospital
Conflict of interest: None

[Case report] A 69 year-old man with chronic obstructive pulmonary disease, presented with fatigue, dry cough and dyspnea on exertion. 18 days before, he had the influenza. His fever was gone in a few days, but other symptoms did not improve. On examination, his blood pressure was 124/68 mmHg; heart rate,127 beats/min; temperature, 38.0°C; respiratory rate, 24 beats/min; oxygen saturation (on room air) 91%. Auscultation of the chest revealed bibasilar crackles. Laboratory test revealed elevated C-reactive protein and computed tomography showed tractionbronchiectasis and emphysema. Despite of broad-spectrum antibiotics therapy, his fever persisted. Additional history taking and laboratory study revealed bilateral jaw claudication and positive MPO-ANCA. Superficial temporal artery biopsy was performed, which showed small vessel vasculitis, in which inflammation was limited to small periadventitial vessels, with sparing of the temporal artery. We diagnosed with microscopic polyangiitis (MPA) and administered prednisolone 60mg/day. He was discharged on the 20th day without fever or jaw claudication. It was reported that MPA occurred symptoms like temporal arteritis. Detailed history taking and biopsy were useful for diagnosis.

P3-170
A case of ANCA associated vasculitis with GCA like symptoms, clinical course and isolated granulomatous small vessel vasculitis around temporal artery
Keitaro Saito, Hiroaki Kusuoka, Hironori Inoue, Aki Sakashita, Aiko Hirano, Yu Isoda, Risa Sagawa, Kazuki Fujikyo, Hit detect Nagahara, Makoto Wada, Masataka Kohno, Yukata Kawahito
Inflammation and Immunology, Graduate School of Medical Science,
Conflict of interest: None

A 75-year-old female [chief complaint] fever, purpura, shoulder pain, and jaw claudication [Present illness] A 75 years old female presented with fever, purpura, shoulder pain, and jaw claudication, which had continued for 2 months in Nov 2017. Laboratory data showed that WBC was 16000/μL, CRP 17.03 mg/dL, and MPO-ANCA was positive (22.0 U/mL). Ultrasound showed halo sign on the temporal artery, where no specific finding was seen on CTA and 18F-FDG-PET. A biopsy of skin purpura showed neutrophilic and leukocytoclastic vasculitis and temporal artery biopsy provided small vessel vasculitis and aggregation of macrophages, which did not infiltrate into temporal artery although there was intimal hyperplasia in it. This patient might be diagnosed not as GCA but as granulomatosis with polyangiitis (GPA) by CHCC 2012. We commenced high dose of glucocorticoid monotherapy (PSL50 mg/day) and tapered it to maintenance dose without relapse for a year. [Consideration] We report a case of ANCA associated vasculitis (AAV) which had GCA like symptoms with pathological findings which showed isolated granulomatous small vessel vasculitis around the temporal artery. On this case it was difficult to make a differential diagnosis as GCA or AAV.

P3-171
Successful management of a patient developing renal and cardiac amyloidosis during treatment of Microscopic polyangiitis [MPA] with Giant cell arteritis [GCA] with Tocilizumab
Serina Koto1, Sosuke Tsuji1, Yushiro Endo1, Ayuko Takatani1, Takashi Igawa1, Toshimasa Shimizu1, Remi Sumiyoshi1, Tomohiro Koga2, Shin-ya Kawashiri1, Naoki Iwamoto3, Kunihiro Ichinose3, Hideki Nakamura3, Tomoki Oriuchi2, Atsushi Kawakami1
1Department of Immunology and Rheumatology, Unit of Advanced Preventive Medical Sciences, Division of Advanced Preventive Medical Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2Department of Rehabilitation Sciences, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 3Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University, Okayama, Japan

Conflict of interest: None

A 61-year-old woman with conjunctival hyperemia, headache since September X, presented to her primary care physician with engorgement and tenderness of bilateral temporal arteries. She was admitted to our hospital in November X. Gadolinium-enhanced MRI showed an enhancement of blood vessel wall of temporal arteries. Interstitial pneumonia on CT, scleritis, positivity for MPO-ANCA led to the diagnosis of MPA complicated with GCA. Her symptoms and inflammatory reaction improved by prednisolone [PSL] and azathioprine. Almost two years later, her renal function got worse. Furthermore, heart enlargement appeared on Chest X-ray, and echocardiography revealed cardiac hypofunction. Because of renal function getting worse, renal biopsy was performed. Pathological results showed deposition of AA amyloid without vasculitis. Echocardiography showed abnormal myocardial reflectivity of left ventricular wall, and we diagnosed renal and cardiac amyloidosis. Because of her alveolar hemorrhage, she was treated by increase of PSL and Intravenous cyclophosphamide [IVCY]. After 2 course of IVCY, we changed to Tocilizumab. After that it kept renal function, improved inflammatory reaction, and reduced PSL. This case suggested that tocilizumab can have an effect on MPA with GCA and amyloidosis.

P3-172
Multiple ulcerative colitis and uveitis as initial presentations in a patient with HLA-A*26 positive granulomatosis with polyangiitis
Norikazu Hinamoto1, Ken-ke Sada2, Keiji Ohashi1, Yoshinori Matsumoto1
1Department of Medicine, Chugoku Central Hospital, Fukuyama, Hiroshima, Japan, 2Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University, Okayama, Japan

Conflict of interest: None

A 44-year-old man visited a physician because of watery stool for 2 weeks and fever for one week. He was diagnosed with right uveitis, and treated with instillation of steroids 3 months before. Thickening of colon wall at CT scan and high CRP levels were found, so antibiotics was administrated. His symptoms did not improve, and then he was referred to our hospital. He had no aphthous ulcer and erythema nodosum, but each ocular pain and right ptosis developed 2 days before referral. His PR3-ANCA was positive, and HLA A26 was also positive. Orbital mass and multiple ulcers of colon were found, then granulomatosis with polyangiitis (GPA) was made finally. After initiation of daily dose of 70mg of prednisolone after methylprednisolone therapy, his symptoms immediately improved. [Clinical significance] Previous report showed that ocular involvement was found in 30-50% of patients with GPA, and uveitis was 25% of ocular involvements. On the other hands, gastrointestinal involvement was found in 7% of patients with microscopic polyangiitis and GPA were reported and related to fatal outcome. Uveitis and colitis in this patient might relate to HLA-A26 as the disease-susceptibility gene for Bechet disease.

P3-173
One case that we can diagnose by a skin biopsy GPA complicated with systemic sclerodema
Rei Tadokoro, Kazuteru Noguchi, Mai Nakano, Chie Ogita, Masao Tamura, Teppei Hashimoto, Masayasu Kitano, Maki Shimbamoto, Kazuyuki Tsboi, Mei Tani, Mai Morimoto, Tetsuya Furukawa, Takahiro Yoshikawa, Naoto Azuma, Kyoshi Matsui
Division of Rheumatology Department of Internal Medicine Hyogo College of Medicine

Conflict of interest: None

She went to hospital for systemic scleroderma and interstitial pneumonia. She had arthralgia and CRP increased, she began to take PSL5mg. She was hospitalized because MPO-ANCA was positive and CRP was not improved though she took PSL15mg. There were no abnormal findings though we searched an infection and the malignant tumor. She was diagnosed GPA because she had otitis media and interstitial pneumonia, and biopsy of right palmar eruption showed necrotizing granulomatous vasculitis. When we prescribed her PSL30mg inflammatory reaction was improved, so we prescribed her AZP and discharged. But there was exacerbation of nasal soreness, nose mass increase and a cough symptom. We discontinued AZP because drug hepatopathy was detected from June, CRP gradually rose, and so she was hospitalized again. Head CT showed a high absorption range to both maxillary antra, ethmoid sinuses and maxillary sinuses, chest CT showed a large number of nodular shadow to both embryonaly newly and so we diagnosed her with relapse of GPA. We gave RTX to her but CRP was not improved, We added MTX6mg. Then it was showed nose mass reduction, the improvement of the cough symptom. That systemic scleroderma was mixed with GPA is very rare. According to Derrett-Smith, anti U3-RNP antibody may suggest merger of AAV.

P3-174
Granulomatosis with polyangiitis presenting as a renal mass
Ayano Watanabe, Kaneshige Sasaki
Department of Rheumatology Medicine, Kainan Hospital Aichi Prefectural Welfare Federation of Agricultural Cooperatives, Japan

Conflict of interest: None

A 67-year-old man was presented with weight loss, frequent urination. His medical histories were Sjogren’s syndrome, recurrent acute otitis media, hypertension and hyperlipidemia. Computed tomography (CT) showed a left renal abnormal lesion. 8 months later, this lesion had expanded to 65mm and para-aortic lymphadenopathies were revealed. Renal biopsy revealed inflamed tissue comprising mixed inflammatory cells including lymphocytes and plasma cells. Malignant lesions were not observed. A nephrectomy was performed that demonstrated necrotizing granulomatous lesions and vasculitis. MPO-ANCA testing was positive (10.4 U/mL). No pulmonary symptoms were presented. CT of the chest did not detect nodular lesions. Based on these findings, he was diagnosed with granulomatosis with polyangiitis. He received prednisolone (30mg/day), which resulted in improvement of fatigue. The presentation of GPA as a renal mass is rare and about fifteen cases have been reported in the literature. In conclusion, GPA can present as an inflammatory mass in the
P3-175
PR3-ANCA associated vasculitis with secondary membranous nephropathy
Shunichiro Hanai1,2, Yoshiaki Kobayashi1,2, Yurika Tatsuno1,2, Chisaki Ajima1,2, Kimie Hara1,2, Kei Kobayashi1,2, Rei Koh1,2, Daiki Nakagomi1,2, Kenicho Kitamura1,2
1Third Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan, 2Center for Clinical Immunology and Rheumatology, University of Yamanashi Hospital, Yamanashi, Japan

Conflict of interest: None

A 73-year-old woman developed ophthalmalgia and congestion of her left eye a month earlier. She was referred to our hospital for further assessment. Serum creatinine level was 0.91 mg/dL, urine protein/creatinine ratio was 2.6 g/gCr (UPCR), occult blood test and PR3-ANCA was positive. Computed tomography of the lung revealed bilateral ground-glass opacity. Renal biopsy showed membranous nephropathy (MN) with bubbly appearance of basement membrane on the outer surface of the capillary wall by light microscopy. There was no signs of necrotizing vasculitis. Immunofluorescence microscopy revealed granular deposits of IgG along the outer surfaces of all capillary walls. Anti-phospholipase A2 receptor antibody was negative. She was diagnosed with PR3-ANCA associated vasculitis (AAV), and received oral prednisolone 25mg per day, four infusion of rituximab (375mg/m2) at a week interval. UPCR was reduced, and other symptoms were improved immediately. Renal involvement of AAV typically shows pauci-immune glomerulonephritis, but immune-complex glomerulopathy was also reported. Some literatures suggest that MN associated with AAV is a poor prognosis factor of the renal function. Early treatment may be needed for MN associated AAV.

P3-176
A case of otitis media with ANCA associated vasculitis (OMAAV) with anti-aminooacyl tRNA synthetase antibody syndrome
Hiroki Matsuwaza, Kazuaki Katsumata, Tetsuya Hoshi, Satuki Aochi Department of Rheumatology, Teine Keijinkai Hospital

Conflict of interest: None

[Case] A 73-year-old women visited us for consultation due to bilateral shoulder and hip pain of one month. She had been taking prednisolone (PSL) 3mg/day for anti-aminooacyl tRNA synthetase (ARS) antibody syndrome with interstitial lung disease (ILD) for 5 years. Her symptom was evaluated as a flare of anti ARS antibody syndrome, and the dose of PSL was increased to 15mg/day. Then, her symptoms resolved completely. After 3 months, she noticed difficulty of hearing. Laboratory test revealed positive MPO-ANCA (147U/ml), and otoscopy showed right otitis media with granuloma exists in the middle ear, then she was diagnosed with otitis media with ANCA associated vasculitis (OMAAV). Shortly after treatment with PSL 60 mg/day, her ear symptoms disappeared and MPO-ANCA became negative. While PSL was tapered, Azathioprine (AZP) 50mg/day was started, but stopped for agranulocytosis. Since then she has been only on PSL without any relapse. [Clinical importance] OMAAV is a disease concept transmitted from Japan and is one of important differential diseases of refractory otitis media. Although ANCA sometimes becomes positive in dermatomyositis/polymyositis, very few reports showed the occurrence of ANCA associated vasculitis (AAV). Especially this case is probably first report of OMAAV with anti-ARS antibody syndrome.

P3-177
Otitis media with ANCA-associated vasculitis (OMAAV) with extra-axial granulation tissue formed in the left middle cranial fossa
Keisuke Saito, Katsuya Nagatani, Takeo Sato, Yoichihiro Akiyama, Hiroi Kusaka, Ayako Kokuzawa, Akiko Miyangara, Takamasa Murosaki, Masahiro Iwamoto, Seiji Minota Division of Rheumatology and Clinical Immunology, Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan

Conflict of interest: None

[Case] A 65-year-old woman had reported left ear closure and deafness two years earlier and was diagnosed as having left otitis media with effusion at an otolaryngology clinic. She was positive for MPO-ANCA and antibiotic treatment was not effective for her otitis media. Inflammatory granulation tissue was observed in the middle ear biopsy, but findings of vasculitis were not clear. We made the diagnosis of OMAAV, and remission was achieved with PSL and IVCY therapy. 10 days ago she visited our department with dizziness, headache, vomiting. MRI revealed tumor formation in the extra-axial region of the left middle cranial fossa. The pathology examination of the mass in the biopsy showed inflammatory granulation tissue, but no obvious vasculitis was observed. We concluded that her OMAAV had relapsed, and we administered steroid pulse therapy. The tumor clearly shrunk, and remission is maintained at present by rituximab. [Clinical significance] In Japan, only 16% of OMAAV cases manifest the pathological findings of typical vasculitis. At 31% of OMAAV, complications are observed during the course. An early clinical diagnosis of OMAAV should be made and early treatment should be started even if clear pathological findings of vasculitis are not obtained.
P3-180
A case of rapidly progressive glomerulonephritis with double positive MPO-ANCA and anti-glomerular basement membrane antibody: successful treatment with plasma exchange and rituximab

Naonori Sugishita, Hiroyuki Hounoki, Takafram Onose, Miho Yamazaki, Ryoko Asano, Toshiki Kido, Atsushi Matsui, Reina Tsuda, Koichi Shinoda, Hirofumi Taki, Kazuyuki Tobe
University of Toyama, Japan

Conflict of interest: None

[Case] A 69 year old woman introduced our hospital with fever, pulmonary nodule, hematuria and overt proteinuria. We diagnosed rapidly progressive glomerulonephritis (RPGN). MPO-ANCA was positive and steroid therapy was performed prior to renal biopsy as ANCA associated vasculitis. Anti-glomerular basement membrane (GBM) antibody was also positive. Plasma exchange and rituximab were performed, her renal function improved. Renal biopsy was performed, and peritubular capillary flame and the IgG deposition of the linear pattern were confirmed, then both MPO-ANCA and anti-GBM antibody were thought to be involved in clinical condition. [Discussion] It is reported that anti-GBM antibody becomes positive in about 5% in ANCA-related vasculitis. The mechanism by which an immune response to the glomerular basement membrane occurs following the glomerular injury due to ANCA associated vasculitis and anti-GBM antibody appears has been proposed. This is a first case of rituximab in cases with double-positive ANCA and anti-GBM antibody.

P3-181
Three cases suspected of rituximab induced acute thrombocytopenia during remission induction therapy for ANCA-associated vasculitis

Yoko Nose, Yo Ueda, Motoko Katayama, Mai Yamashita, Takaichi Okano, Sho Sendo, Kengo Akashi, Akira Onishi, Jun Saegusa, Akio Morinobu
Department of Rheumatology and Clinical Immunology, Kobe University Hospital, Kobe, Japan

Conflict of interest: None

BACKGROUND: The number of ANCA-associated vasculitis (AAV) patients treated with rituximab (RTX) for remission induction therapy is increasing. Although RTX induced acute thrombocytopenia (RIAT) has been reported as a rare complication in patients with malignant lymphoma (ML), there are few reports about RIAT in patients with AAV. METHODS: We reviewed AAV patients treated with RTX in our department. We clarified the clinical features of suspicious cases of RIAT and compared with those in ML. RESULTS: There were three cases of suspicious cases of RIAT. Among them, thrombocytopenia occurred acutely and severely within several days after third or fourth administration of RTX. Although it needed to distinguish from the reactivation of cytomegalovirus or other drug-induced thrombocytopenia, the rapid decrease after RTX administration and the recovery after discontinuation or extension of next RTX administration were the common feature. Thinking from that most RIAT cases in ML occurred after the first administration of RTX, the mechanism of RIAT may be different between ML and AAV. On the other hand, thrombocytopenia after re-administration of RTX didn’t recur in one patient as well as most cases in ML. CONCLUSIONS: We should pay attention to thrombocytopenia after RTX administration.

P3-182
A case of rituximab induced acute thrombocytopenia (RIAT) in granulomatosis with polyangiitis

Ryoko Asano, Hiroyuki Hounoki, Takafram Onose, Naonori Sugishita, Miho Yamazaki, Toshiki Kido, Atsushi Matsui, Reina Tsuda, Koichiro Shinoda, Hirofumi Taki, Kazuyuki Tobe
First Department of Internal Medicine, University of Toyama

Conflict of interest: None

[Case] A 62 year old man admitted to our hospital because of gait disorder due to hypertrophic lesion in spinal cord. Although anti-neutrophil cytoplasmic antibody (ANCA) was negative, he was diagnosed as granulomatosis with polyangiitis (GPA) because of saddle nose, hypertrrophic spinal pachymeningiitis and necrotizing angiitis on a nasal mucosal biopsy. He improved after methylprednisolone pulse therapy, but he relapsed with sinusitis five months later. We initiated rituximab (RTX) therapy and after third RTX administration, thrombocytopenia and hypocomplemetemia was observed, and we diagnosed rituximab induced acute thrombocytopenia (RIAT). He was improved for a year, but he developed sinusitis again. We determined re-infusion of RTX under his consent, but RIAT was observed after second RTX administration. [Discussion] RIAT develops within several days of RTX administration and has been reported as a rare adverse event occurring during the treatment of lymphoma, on the other hand, there are few reports in the autoimmune disease. Rheumatologists should consider RIAT as we have more opportunities to use RTX. We report our case, along with the relevant literature.

P3-183
A case of single administration of rituximab to ANCA-associatedvasculitis in hemodialysis patients and introducing remission

Tatsuki Amano
Yokkaichi Municipal Hospital

Conflict of interest: None

[Case] A 68-year-old man. In X - 8 year, he was diagnosed with rheumatoid arthritis and remission was maintained by MTX, but he was self - discontinued from November, X - 1. Fever, sore throat, otic pain, eating disorders appeared in April X, and he visited our hospital. Highly renal dysfunction was recognized (Cr 14 mg/dL), and emergency dialysis was introduced. PTX-3 was observed after second RTX administration. [Discussion] RTX was observed after second RTX administration. [Discussion] In introducing remission to ANCA-associated vasculitis in dialysis patients, a single administration of rituximab can be one of safe and effective treatments that enables early loss of steroids.

P3-184
Granulomatosis with polyangiitis (GPA) with multiple tumor lesions in the choroid plexus successfully treated with rituximab

Mai Suhara, Yasushi Kondo, Yoko Nakagome, Kazuki Hirano, Yuto Izumi, Takayoshi Kurabayashi, Sho Sasaki, Yasushi Koyama, Chiho Yamada, Shinji Sato
Tokai University Hospital, Isehara, Japan

Conflict of interest: None

A 36-year-old female had recurrent nasal bleeding with chronic sinusitis since 2003 and developed to nasal septal defect. Mucosal biopsy from sinuses showed noncaseating granuloma and the chest CT demonstrated cavitated lesions in the both lungs. We diagnosed her as granulomatosis with polyangiitis (GPA) and high-dose prednisolone (PSL) with cyclophosphamide (IVCY) was initiated. However, retrobulbar neuritis optica was arisen with PR-3-ANCA positivity after initial remission induction therapy. She suffered frequent relapse of lung and upper tract involvements for many years, although she received intensive treatment.
with combination of PSL, IVCY and MTX. In September 2016, she began to notice headache, nausea, and double vision and head MRI showed multiple, contrast enhanced tumor lesions in the choroid plexus. For the first time, she was introduced received rituximab (RTX) for this refractory disease. Soon after that, and neurological focal signs were resolved and MRI revealed significant regression of choroid plexus lesions. We continued to use RTX as a maintenance therapy and we could reduce the daily PSL dose to 5 mg so far. This case was recurrent and refractory GPA that showed rare neurologic manifestation of choroid plexus lesion and successfully treated and managed with RTX.

P3-185
A study on the number of rituximab initial doses for ANCA-related vasculitis cases in our hospital
Kazuyuki Tsuboi1, Takahiro Yoshikawa1, Chie Ogita1, Mei Tani1, Masao Tamura1, Yuichi Yokoyama2, Masahiro Sekiguchi2, Atsushi Saito2, Akiko Nishioka1, Shinichiro Tsunoda1, Mai Morimoto1, Tepppei Hashimoto1, Naoto Azuma1, Masayasu Kitano1, Hajime Sano1, Kiyoshi Matsui1
1Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, 2Department of Nephrology, Sakai Rumi Clinic

Conflict of interest: None

[Background] Rituximab (RTX) administration method for ANCA-related vasculitis (AAV) is 4 times the initial dose of 375 mg / m2 / week, which is previously confirmed in guidelines for B cell lymphoma. The optimal dosing regimen for AAV is still under discussion. [Purpose] We examined the number of first RTX administration therapy for intractable / recurrent AAV and the presence or absence of relapse of AAV pathology in 3 years after administration. [Object] 29 patients (8 men, 21 females, average age 68.9 ± 12.7 years old). Clinical diagnosis was 16 cases of Granulomatosis with Polyangiitis (GPA), 11 cases of Microscopic Polyangiitis (MPA), 2 cases of Eosinophilic Granulomatosis with Polyangiitis (EGPA). The number of RTX initial doses was 2 times in 8 cases and 4 times in 21 cases. [Methods] We examined the existence of AAV relapse for 3 years after administration in 25 patients excluding 4 cases of death. AAV relapse was defined as clinical symptoms or blood test findings. [Results] 10 cases (2 times in 1 case, 4 times in 9 cases) was relapsed. There was no difference in relapse rate between the two groups in the Kaplan-Meier method. [Conclusion] There was no difference in relapse rate between the first RTX 2 and 4 times for AAV in 3 years.

P3-186
The efficacy and safety of rituximab on relapsing granulomatosis with polyangiitis
Makiko Hayashi, Kyoko Fujimoto, Shinjiro Kaieda, Yumi Yoshida, Suzuna Sugi, Takuma Koga, Yukiko Hidaka, Tomoaki Hoshino, Hiroaki Ida
Division of Respiratory, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, Japan

Conflict of interest: None

[Objectives] To evaluate the efficacy and safety of rituximab (RTX) therapy in patients with relapsing granulomatosis with polyangiitis (GPA) in our hospital. [Methods] Nine patients with GPA were administrated with RTX. Efficacy and safety of RTX were evaluated for six months. The efficacy was determined as follows: 1) reduction of BVAS score was more than 30%, 2) dosage of steroids was reduced. Eight patients with GPA were already given by CY. Five patients relapsed after discontinuation of CY. Three patients were refractory to GPA by conventional therapy including CY. RTX was administrated weekly for consecutive 4 weeks. The average follow-up periods were 18 months. [Results] Five patients treated with RTX achieved clinical remission for all observation period. One patient maintained clinical remission for eighteen months and relapsed. Although two patients developed allergic reactions and discontinued RTX, infectious disease and cytopenia were not observed in all cases.

[Conclusion] Compared to CY therapy, efficacy and safety of RTX therapy for the patients with GPA was indicated. Attention to acute allergic infusion reaction is needed.

P3-187
A case of microscopic polyangiitis which plasma exchange was effective
Yuki Miyaguchi, Shie Ichihara, Norihito Suga
Nagoya City West Medical Center

Conflict of interest: None

[Case] A 69-year-old woman had cough and bilateral joint pain since 1 month before. Although antibiotic drugs were taken, the fever and general malaise continued. As purple spot appeared, she visited our hospital. We diagnosed rapidly progressive glomerulonephritis (RPGN) from proteinuria and hematuria, her serum creatinine (2.46mg/dL). The MPO-ANCA titer increased to 776IU/mL. We started steroid pulse therapy (methylprednisolone 0.5g/day) and oral administration of prednisolone 30mg/day. Histological findings on renal biopsy showed diffuse paucimmune cellular crescentic glomerulonephritis, diagnosed as RPGN by microscopic polyangiitis. Intravenous cyclophosphamide 250mg/day and the second steroid pulse therapy was administered, but since the renal function progressively deteriorates, plasma exchange therapy (PE) was used in combination. Renal function remarkably improved after the start of PE, MPO-ANCA decreased to 5.6IU/mL. [Conclusions] It is expected that PE will be useful in cases where it is difficult to administer immunosuppressive drugs due to side effects or severe cases with progressive organ disorder. This case was a case in which progressive renal dysfunction could be suppressed by combined use of PE.

P3-188
Attainment of steroid free remission in ANCA associated vasculitis
Kouji Kobayashi1, Yumiko Sugiyama1, Shigeru Ohno1, Hideaki Nakajima2
1Center for Rheumatic Diseases, Yokohama City University Medical Center, 2Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine

Conflict of interest: None

[Objectives] To determine the frequency of steroid free remission and to define disease characteristics of ANCA associated vasculitis patients achieving steroid-free remission. Methods: We retrospectively reviewed clinical charts of 44 consecutive patients (age 71.3±13y.o., female 70%, disease duration 8.1±6.7years, MPO-23, EGPA-12, GPA-9) who met each of Ministry of Health, Labor and Welfare Diagnostic Criteria followed in our hospital. Steroid free remission was defined as a 3-month consecutive period of no disease activity without corticosteroid treatment. Clinical characteristics, BVAS, corticosteroid use, immunosuppressant medicines were examined and compared between patients groups with and without present steroid use. Results: 10 patients (22.7%) achieved steroid free remission. There were no differences in onset of age, disease duration, sex, co-administration of immunosuppressants, initial dose of steroid, CRP and ANCA at baseline between two groups. Patients with less than two damaged organs (p=0.001), lower baseline BVAS (p=0.05), and without nephritis (p=0.02) led to higher rates of steroid discontinuation. Conclusion: Steroid-free remission might be a realistic goal in some patients with ANCA associated vasculitis.

P3-189
Clinical features of eosinophilic granulomatosis with polyangiitis
Shinichiro Nameki, Takeshi Kaneko, Tomomi Tada, Kenji Funakoshi, Jun Fukui, Takashi Hosokawa, Hiroshi Fujiwara
Division of Rheumatology, Osaka General Medical Center

Conflict of interest: None

OBJECTIVE: We aimed to determine the clinical features of eosinophilic granulomatosis with polyangiitis (EGPA). METHOD: This retrospective study analyzed data obtained from 11 patients diagnosed with
Eosinophilic granulomatosis with polyangiitis (EGPA) and treated at our center between April 2011 and September 2017. RESULTS: All patients reported a history of bronchial asthma, 7 showed a positive serum myeloperoxidase anti-neutrophil cytoplasmic antibody test, and 5 showed a positive rheumatoid factor test. Neurological and pulmonary involvement occurred in 9 patients each. The Five Factor Score was 0, 1, 2, and 3 in 4, 5, 1, and 1 patient, respectively. The mean Birmingham Vasculitis Activity Score at the time of diagnosis was 14.1. All patients received corticosteroid therapy. Intravenous immunoglobulin, azathioprine, and cyclophosphamide were administered to 5, 4, and 3 patients, respectively. Induction therapy improved ear, nose, throat, and pulmonary features in all patients; however, neurological symptoms persisted in 8 patients. No patient developed relapse or died of vasculitis within a year. CONCLUSIONS: Patients with EGPA tend to develop neurological and/or pulmonary involvement. Residual symptoms persisted in 89% of the patients with neurological involvement a year after induction therapy.

P3-190
Clinical pictures of Eosinophilic Granulomatosis with Polyangiitis patients in our department
Takumi Muramatsu, Kazuma Ino, Yuasuhito Hasegawa, Kunichi Kondo, Yu Matsueda, Takayuki Hoshiyama, Toshihiro Tono, Yoshiyuki Arinuma, Tatsuhiko Wada, Tatsuuo Nagai, Sumiaki Tanaka, Kenihiro Yamaoka
Department of Rheumatology and Infectious Diseases, Kitasato University School of Medicine
Conflict of interest: None

[Object] The aim of this study is to optimize treatment for patients with eosinophilic granulomatosis with polyangiitis (EGPA) by analyzing clinical features of EGPA patients in our university hospital. [Methods] We examined 14 inception EGPA patients admitted to our hospital since December 2012. [Result] 6 patients were positive for myeloperoxidase-anti-neutrophil cytoplasmic antibody (ANCA), 1 patient was positive for proteinase-3-ANCA and 7 patients were negative. All patients had peripheral neuropathy and 11 patients had sinus lesions. In patients positive or negative for ANCA, mean age was 45.3 year-old or 56.4, initial eosinophil count was 9055/μL and 7140, total IgE was 2144 IU/mL and 1073, C-reactive protein was 10.03 mg/dL and 3.70, respectively. 4 patients with ANCA and 2 patients without ANCA had pulmonary lesions. Only 4 patients with ANCA had renal lesions. Cardiac lesions were involved in 3 patients with ANCA and 4 patients without ANCA. Of 5 patients who received intravenous cyclophosphamide treatment (IVCY), 1 patient experienced relapse, while 5 of 9 patients who did not receive IVCY experienced relapse. [Discussion] Pulmonary and renal lesions were related to ANCA positivity. Initial IVCY could reduce relapses.

P3-191
A case of eosinophilic granulomatous polyangiitis complicated by bilateral calcified urethral stenosis
Masaki Higane, Hironoaki Yano, Mitsuyo Kinjo
Department of Rheumatology, Okinawa Chubu Hospital
Conflict of interest: None

Case 39 y.o male Chief complaint Right lower abdominal pain History of present illness Eosinophilic granulomatous polyangiitis (EGPA) was diagnosed 3 months earlier when the patient presented with numbness, weakness in lower extremities, difficulty walking, and eosinophilia with eosinophilic vasculitis in the skin biopsy. He was started on prednisolone 40mg daily. Right lower abdominal pain developed 2 days earlier, and physical examination was remarkable for right lower abdominal tenderness, skin ulcers with necrotic changes in fingertips and legs, asymmetrical distal motor and sensory neuropathy findings consistent with mononeuritis multiplex. Postrenal acute kidney injury was attributed to bilateral urethral stenosis, and the patient underwent bilateral nephropathy with prompt recovery of renal function. Prednisolone increased to 60mg and intravenous cyclophosphamide pulse therapy abated neurological symptoms and skin ulcer. Discussion This case illustrated EGPA with severe dermatological and neurological manifestations complicated by uncommon findings of progressive bilateral calcified urethral stenosis. We reviewed literature on urological presentation of ANCA vasculitis including EGPA.

P3-192
Eosinophilic Granulomatosis with Polyangiitis (EGPA) with Eosinophilic Myocarditis (EMC)-a Case Report
Masahiro Konishi1, Ichiro Mizushima1, Hajime Sanada1, Kazuyuki Suzuki2, Akari Takeji2, Satoshi Hara1, Kiyoko Ito1, Takeshi Kawane1, Hiroshi Fujii2, Kazunori Yamada1, Mitsuiho Kawano1
1Division of Rheumatology, Kanazawa University Hospital, 2Department of Rheumatology, Toyama Red Cross Hospital
Conflict of interest: None

[Case] A 66-year-old woman had received antiasthmatic agents to treat her chronic cough from 3 years before the current admission. Two months before the current admission, dyspnea on exertion appeared. Because her dyspnea was exacerbated and eosinophilia and bilateral lung infiltrates were detected, she was referred to our hospital as suspected eosinophilic pneumonia. On admission, she complained of dysesthesis of legs. Laboratory data showed marked eosinophilia despite the negativities of PR3-ANCA and MPO-ANCA, and CT showed cardiac enlargement, pericardial effusion, and pleural effusion. Skin and myocardial biopsy revealed cutaneous vasculitis with eosinophil infiltration and the findings compatible with eosinophilic myocarditis (EMC), respectively. Based on the diagnosis of EGPA with EMC, 40 mg/day of prednisolone (PSL) was started. Then, the dosage of PSL was gradually tapered. Glucocorticoid improved her dyspnea, laboratory data, and imaging findings. Because improvement of leg dysesthesis was not sufficient, IVCY was added and she was discharged from our hospital. [Discussion] In EGPA cases, the complication of EMC is generally considered to be a factor of poor prognosis. The present case in which EMC was well improved suggested the importance of early treatment.

P3-193
The case of EGPA complicated by serositis
Marina Shinoura1, Satoshi Suzuki2, Takuya Nishi2, Shotya Sakuma2, Keigo Ikeda2, Shinji Morimoto2, Ken Yamaji1, Naoto Tamura1
1Department of Rheumatology, Juntendo University School of Medicine, 2Department of Rheumatology, Juntendo University Urayasu Hospital
Conflict of interest: None

[Case] The patient was a 27-year-old man who had a childhood history of asthma. He presented with a month of tiredness, lower leg edema, skin rash and fever. He first had a feeling of tiredness and edema from scrotum to lower legs in May 201X. From the following month, he developed a fever. At the first visit he had purpura, numbness of whole body. The number of eosinophils in the blood was greatly increased and total serum IgE was elevated. Eosinophilic Granulomatosis with Polyangiitis (EGPA) was suspected, so he was referred to the department of rheumatology. MPO-ANCA was negative. A chest X-ray showed bilateral pleural effusion that was revealed Eosinophilic and exudative by thoracocentesis. The result of skin biopsy was compatible with EGPA. On the 2nd hospital day administration of prednisolone (PSL) 60mg was began, but pleural effusion was increased. So he was treated by steroid semi pulse therapy. Then pleural effusion, the number of eosinophils and purpura were improved. [Conclusion] We experienced the case of EGPA with bilateral pleural effusion responded to corticosteroid therapy. Relatively rare case of EGPA complicated by serositis is reported along with some literature review.

P3-194
A Case of Eosinophilic Granulomatosis with Polyangiitis (Churg-Strauss) with subepidermal blister
Eri Shishido, Yukiya Iimura, Junichi Kurashina, Masahiro Yasumura, Tomoki Tanaka, Seichi Ono, Fusazo Urano, Sadahiro Suzuki Shinonoi General Hospital, Nagano, Japan
Conflict of interest: None

The patient is a 49-year-old man. His past medical history is signifi-
A Case of eosinophilic polyangiitis granulomatosis (EGPA) which was difficult to treat MPO-ANCA positive where propylthiouracil seemed to be a trigger
Hideo Yamanaka, Yusuke Hanioka, Kaori Seki, Ryota Nakamura, Tomoyuki Nakamura, Keiko Yamagami, Hitoshi Goto
Internal Medicine, Osaka City General Hospital
Conflict of interest: None

She was diagnosed as Graves’ disease x-12 years ago and was treated with thiamazole. There was hope of birth and was changed to propylthiouracil from x-3 years after birth. There are numbness and weakness from the left shoulder to the elbow from the middle of April x, and edema of the lower limb increased. EGPA was diagnosed as a history of asthma / sinusitis, eosinophilia, muscle weakness and peripheral neuropathy, MPO - ANCA 196 U / mL. She has been treated with 1000 mg/day of Methylprednisolone and 30mg/day of prednisolone. However, abdominal pain and numbness appeared and the eosinophil count increased. In the lower endoscopic examination, there was a finding of vasculitis and the neurological symptoms were deteriorated. Immunoglobulin high dose therapy (IVIG) 20000 mg / day x 5 days was done. PSL increased to 40 mg / day and azathioprine and tacrolimus were added. There was no increase in eosinophils and abdominal symptoms also improved. PSL was gradually decreased, the immunosuppressant was continued, and eosinophil count did not rise by introducing mepolizumab, but the numbness symptoms remained elapsed. Propylthiouracil has been reported to induce vasculitis and reports that IVIG therapy at the remission phase is effective.

A patient with eosinophilic granulomatosis with polyangiitis treated only with mepolizumab and intravenous immunoglobulin
Yukihiro Ikeda, Hiromichi Yamanaka, Koichi Seki, Ryota Nakamura, Akira Kitada, Mitsuru Watanabe, Seiko Yamagami, Hitoshi Goto
Internal Medicine, Osaka City General Hospital
Conflict of interest: None

(Case) A 46-year-old male was transported to our hospital with respiratory failure. He had polyarthritis, abdominal pain, hemoptysis and hematuria. Purpura was found on his legs, but it had been diagnosed as IgA vasculitis (IgAV) by skin biopsy performed at the previous hospital. Diffuse ground-glass opacity (GGO) observed on chest CT suggested of alveolar hemorrhage. Even after steroid pulse therapy, GGO deteriorated. After these treatments, his symptoms improved rapidly. A renal biopsy revealed IgA deposition in skin and kidney suggested of IgA vasculitis (IgA V). He was discharged on day 42. 

A Case of IgA Vasculitis accompanied with Kidney and Testicular Ischemia
Hideyuki Matsushima, Takayuki Hiirai, Shota Minami, Nobuo Negoro
Clinical Immunology, Osaka City University Hospital
Conflict of interest: None

A Case of IgA Vasculitis accompanied with Kidney and Testicular Ischemia
Hideyuki Matsushima, Takayuki Hiirai, Shota Minami, Nobuo Negoro
Clinical Immunology, Osaka City University Hospital
Conflict of interest: None
A 41-year-old man, having palpable purpura of the lower legs 2 weeks before, abdominal pain and bleeding 3 days before, was admitted to our hospital with suspected IgA vasculitis. Although skin biopsy did not show IgA deposition, EULAR classification criteria (2010) was satisfied, he was diagnosed as IgA vasculitis. Symptoms improved with prednisolone 60 mg / day. However, left testicular pain and microscopic hematuria on day 14 after hospitalization began. Ultrasonography revealed left testicular bleeding. Angiographic examination revealed irregularities and stenosis of left testicular and renal artery. Diagnosis as complication of polyarteritis nodosa, cyclophosphamide pulse therapy was performed. His pain gradually improved and he was discharged. At 240 day after onset of the disease, purpura and hematuria restarted and he was hospitalized. Renal biopsy showed IgA nephropathy (erscetiotic glomerulonephritis, ISKDC classification Grade 3), and IgA vasculitis requiring aggressive treatment was confirmed. Because medium-sized vasculitis is also accompanied, his treatment is strengthened such as azathioprine and tonsilllectomy. The case suggests us that precious diagnosis including biopsies is important to select the better treatment in patient with complicated vasculitis syndrome.

P3-200
Two cases of the elderly with gastrointestinal manifestation complicated IgA vasculitis
Takahiro Yajima1, Rie Yamada2
1Department of Nephrology, Matsunami General Hospital, 2Department of Internal Medicine, Matsunami General Hospital

Conflict of interest: None

[Case 1] A 69-year-old female presented with 3-day palpable purpura on legs. Skin biopsy revealed leukocytoclastic vasculitis. Based on possible diagnosis of IgA vasculitis (IgAV), PSL therapy began orally administered (30mg/day). The purpura disappeared within a week, but recurred on 12th hospital day. She complained of epigastralgia on 15th hospital day. Esophagogastroduodenoscopy (EGD) revealed telangiectasia of stomach and erosion of duodenum. PSL intravenously administered (50mg/day) led disappearance of gastrointestinal symptoms and purpura on 20th hospital day. [Case 2] A 79-year-old male presented with 3-day abdominal pain and purpura on legs. Laboratory data showed elevated inflammatory marker and renal failure. Abdominal CT revealed thickening of the duodenal wall. EGD revealed ulcerative lesions in the duodenum. These findings made the most plausible diagnosis of IgA vasculitis (IgAV). PSL therapy began orally administered (50mg/day) and ameliorated the abdominal pain in a few days. Despite the improvement of EGD findings on 18th hospital day, renal function exacerbated requiring hemodialysis. [Discussion] We report two cases of the elderly gastrointestinal involvement of aged IgAV. Intra- venous injection of steroid preempted successful improvement of abdominal symptoms and EGD findings.

P3-201
Two case reports of the intestinal vasculitis who were not determined the definite diagnosis after the operation of the perforation
Yoshiki Shiohira, Takuya Oshiro, Chiai Nakata, Tomoo Murayama, Eishi Uechi, Masato Oroku
Department of Nephrology and Rheumatology, Tomishiro Central Hospital, Tomigusuku, Okinawa, Japan

Conflict of interest: None

Case 1: 81-year-old woman was diagnosed left renal pelvic carcinoma and left renal ureterectomy and partial cystectomy was performed. Two weeks later ulcer and penetration of descending colon developed and then left hemicolectomy and artificial colostomy was done. Five months later acute lymphocytic leukemia occurred, after that she died. Reconfirmation of the pathology revealed a scarring vasculitis of the colon. We diagnosed this case was polyarteritis nodosa combined with malignancy Case 2 is a 73-year-old woman being treated with hypertension. Abdominal pain persisted and she was admitted to our hospital at department of surgery. On the 23rd hospital day intestinal perforation was suspected, and subtotal colectomy, partial resection of the small intestine, and artificial colostomy were done. Proteinuria, hematuria and renal dysfunction were observed on admission, but 6 years later the renal function deteriorated and was introduced to dialysis. She also complicated a bladder bleeding and abdominal cavity pelvic abscess due to rectal-bladder fistula. Reconfirmation of the pathology of the colon revealed a necrotizing venulitis. It was considered as IgA vasculitis (serum IgA 644 mg/dl). Conclusion: Diagnosis is uncertain Intestinal perforation is caused by vasculitis.

P3-202
A case of IgA vasculitis treated successfully with rituximab
Kazuo Kishimoto1, Takuya Sawabe2, Masahiro Aoyama1, Miki Nakano1, Yasutaka Kimoto1, Hiroki Mitoma1, Mitsuteru Akahoshi2, Yojiro Arinobu1, Koichi Akashi1, Takahiro Horuiuchi1, Hiroaki Niiro2
1Department of Medicine and Bioisystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 2Department of Rheumatology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan, 3Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 4Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

Conflict of interest: None

A 63-year-old man presented to our hospital with arthralgia of the left knee and right ankle joint and palpable purpura of both lower legs. His serum IgA was elevated (629 mg/dl) and coagulation factor XIII activity was decreased (65%). A skin biopsy of the purpura revealed leukocytoclastic vasculitis, and he was diagnosed with IgA vasculitis based on the criteria provided by the American College of Rheumatology in 1990. We started treatment with corticosteroids (PSL 30 mg/day) because his severe arthritis was resistant to non-steroidal anti-inflammatory drugs. We achieved temporary remission; however, he relapsed with new-onset fever, diarrhea, and mild renal dysfunction when the dose of PSL reached 12.5 mg after tapering. We added mizoribine, but the patient’s response was poor. After starting rituximab, he achieved remission and the dose of PSL was tapered to 3 mg/day. The present case demonstrates a good efficacy of RTX for the treatment of IgA vasculitis.

P3-203
Remarkable effect of TNFα inhibitor for refractory lower leg ulcers in patients with malignant rheumatoid arthritis
Asami Akita1, Yukie Yamaguchi1, Nobuaki Ikeda1, Miwa Kanaoka1, Yasushi Ototake1, Michiko Aihara2, Yohsi Kirino2
1Department of Environmental Immuno-Dermatolgy, Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Department of Hematology and Clinical Immunology, Yokohama City University Hospital, Yokohama, Japan

Conflict of interest: None

The first case is a 78-years-old woman, who has been suffering from rheumatoid arthritis (RA) for 33 years being treated with prednisolone and methotrexate (MTX). She visited our hospital due to development of skin ulcers in her leg and toe. DAS28-CRP was 3.09. Skin biopsy revealed necrotizing vasculitis. High dose corticosteroids (CS) and azathioprine were not effective, then Etanercept (ETN) was administrated in combination with L-CAP and negative pressure wound therapy. Finally, the lesion was improved. The second case is a 81-years-old woman, who has been treated of her RA with MTX and salazosulphapyridine for 8 years. Skin biopsy for newly appeared erythema revealed necrotizing vasculitis. High dose CS was failed, then her skin vasculitis got worsen to form deep leg ulcer. DAS28-CRP was 4.05. Finally, the ulcer was improved by ETN. Stasis leg ulcers in RA patients may be commonly observed in daily clinics. However, a refractory leg ulcer may be caused by rheumatoid vasculitis, which sometimes requires aggressive therapy. Even though the disease activity is not high, it may be important to suspect vasculitis in RA patients with a refractory gangrene or ulcers. In addition, a prompt use of TNFα inhibitors may be helpful in cases resistant to CS or immunosuppressive drugs.
**P3-204**

Rapid improvement of microaneurysms in visceral arteries was confirmed by follow-up angiography in a case of polyarteritis nodosa

Yoshinobu Matsuura1, Takehiro Hirayama1, Akihiko Nakabayashi1, Akira Meguro1, Yoshinori Katada1

1Division of Rheumatology and Clinical Immunology, Sakai City Medical Center, Sakai, Japan, 2Nephrology, Diabetology, Rheumatology, Sakai City Medical Center, Sakai, Japan

Conflict of interest: None

[Introduction] Visceral angiography, a valuable examination for the diagnosis of polyarteritis nodosa (PN), is rarely performed as a follow-up examination in the course of treatment. In this case, we had a chance to perform follow-up angiography, and confirmed marked improvement of microaneurysms only 1 week after initiation of immunosuppressive therapy. [Case] A 74-year-old man, who presented with malaia and appetite loss for several days, was admitted to a hospital. He developed retroperitoneal bleeding 13 days after administration, then transferred to our hospital. Visceral angiography revealed microaneurysms, stenosis and obstruction in the branches of both celiac and superior mesenteric artery (SMA). He was treated with coil embolization for aneurysms in the branches of SMA considered as a source of retroperitoneal bleeding. Laboratory tests showed increased CRP (16 mg/dL); MPO-ANCA and PR3-ANCA were negative. He was diagnosed with PN, and treated by corticosteroid pulse therapy and intravenous cyclophosphamide. An enlargement of an aneurysm was confirmed by CT angiography 1 week after corticosteroid pulse therapy, so visceral angiography and coil embolization were performed again, showing dramatically improved microaneurysms, stenosis and obstruction in the visceral arteries.

**P3-205**

A case of polyarteritis nodosa with myalgia and marked edema of lower limbs

Kyoko Takano1, Yuki Mizutani1, Hiroshi Hamada1, Mayu Sugiyama1, Kahori Oshima1, Takakazu Hasegawa1, Syunsuke Yoko1, Kumiko Umemura1, Michita Suzuki1, Eiji Nagasawa1,2, Nobuyoshi Minemura1, Masao Katayama1

1Division of Rheumatology, Department of Internal Medicine, National Hospital Organization Nagoya Medical Center, 2Nagasaki Clinic

Conflict of interest: None

[Case] A 74-year-old woman presented fever and edema and myalgia of bilateral lower limbs. Laboratory tests showed WBC 15200/μL, CRP 15.8mg/dL, ESR 56mm/H, CK 37U/L (normal), aldolase 7U/L (slightly elevated). ANA, MPO-ANCA and PR3-ANCA were all negative. MRI revealed increased signal in the bilateral femoral muscles, pectineus, obturator externus and obturator internus on STIR sequences. She was received femoral muscle biopsy because myositis was suspected. The biopsy revealed perivascular inflammatory infiltrate with lymphocytes and histiocytes and fibrinoid necrotic vasculitis. The fasciitis and myositis findings were not clear. She was diagnosed with polyarteritis nodosa (PN). She was treated with 40mg (1mg/kg/day) of prednisolone and 50mg/day of azathioprine. During the course, she complicated of deep vein thrombosis of the lower limbs, so 30mg/day of edoxaban was used. These treatment resulted in immediate improvement of her symptoms and normalization of serum CRP and ESR values. [Discussion] There are some cases of myalgia without CK increase in PN. We reported a case diagnosed as PN by MRI and muscle biopsy. It is important to suspect PN as one of causes of myalgia of lower limbs. MRI and muscle biopsy may be useful for diagnosis of PN in those cases.

**P3-206**

A case of polyarteritis nodosa begun by meralgia

Shiho Iwagawa1, Hanako Ito, Masayoshi Toda, Hiroya Tanaka1, Naoya Matsuoka, Masako Koshino, Akashi Kachi, Akimasa Asai, Nao Asai, Mayumi Ito, Hirokazu Sugiyama, Makoto Yamaguchi, Hironobu Nobata, Takayuki Katsuno, Shogo Banno, Yasuhiro Ito

Department of Internal Medicine, Division of Rheumatology and Nephrology, Aichi Medical University School of Medicine

Conflict of interest: None

Polyarteritis nodosa (PAN) is a medium vessel vasculitis affecting systemic organs. PAN limited to the muscles is rare and typically muscle lesions often appear on the lower leg. We report a case of PAN begun with meralgia. An 83-year-old male presented with meralgia and branchialgia for 4 months. Low dose prednisolone (PSL) was administered by his primary care physician in the diagnosis of polymyalgia rheumatica. Brachialgia was improved rapidly, but meralgia was persistent. Laboratory testing showed a low level of creatine kinase and an elevated C-reaction protein (CRP) levels of 18 mg/dL. Lower limbs MRI showed muscle atrophy on the ventral side of the femur and STIR high signal was observed at the same site. Enhanced MRI demonstrated hyperintensities on T1 in the femoral muscles. Muscle biopsy was performed from the quadriceps right muscle, the biopsied specimen revealed thickening of the vessel wall with inflammatory cell infiltration. According to these findings, he was diagnosed with PAN and administered with PSL 40 mg/day, the symptoms of PAN were improved rapidly.

**P3-207**

A case of polyarteritis nodosa as rashes like cellulitis and myalgia of lower thighs

Miho Yamazaki, Reina Tsuda, Takafumi Onose, Naonori Sugishita, Ryoko Asano, Toshiki Kido, Hiroyuki Hounoki, Koichiro Shinoda, Hirofumi Taki, Kazuyuki Tobe

Department of Internal Medicine 1, Toyama University Hospital

Conflict of interest: None

[Case] A 74-year-old female with hypertension had fever, pain and swelling of lower thighs 3 months ago. She was admitted as cellulitis and treated with six kinds of antibacterial drugs, but CRP level was remained 6 ~ 7 mg/dL. Her symptoms were improved a few, so she left the hospital 2 months ago. However got worse soon, she was admitted and treated with 2 kinds of antibacterial drugs together and NSAIDs during three weeks. CRP level was improved to 2.7 mg/dL from 16.3 mg/dL, but remained. So she was started treating with PSL 5mg/day, left the hospital a month ago. Thereafter, her symptoms got worse again, so she was introduced and admitted to our hospital. She was only positive for RF among autoantibodies. She was negative for serum HBs-antigen and HBV-DNA, but positive for serum HBs-antibody. She was performed a biopsy on the skin, the muscle and fascia. The biopsy showed small arteritis with infiltrating by neutrophil. She was started treating as polyarteritis nodosa with methylprednisolone 500mg/day for three days. After the three days, She was treated from PSL 20mg (0.5mg/kg/day). Her symptoms were improved, and CRP level became negative. [Clinical significance] We discuss about the case of small arteritis suspected of polyarteritis nodosa with literature review.

**P3-208**

Lower leg myalgia as the initial symptom in systemic vasculitis

Satoru Ushiyama, Noriko Sakaguchi, Takenori Ichikawa, Kenichi Ueno, Dai Kishida, Yasuhiro Shimozima, Yoshiaki Sekijima

The Third Department of Internal Medicine, Shinshu University School of Medicine

Conflict of interest: None

[Object] To investigate the clinical features in patients indicating myalgia as the initial episode of systemic vasculitis. [Methods] By reviewing clinical records of patients with systemic vasculitis, they were classified into two groups dividing patients with or those without myalgia as the initial episode of disease (myalgia or non-myalgia group, respectively). Clinical findings were analyzed between two groups. [Results] We recruited 82 patients (mean age 61±15, 31 men and 51 women), who were classified into eosinophilic granulomatosis with polyangiitis (n = 7), granulomatosis with polyangiitis (n = 20), microscopic polyangiitis (n = 30), and polyarteritis nodosa (n = 21), as well as 4 patients of unclassified. Of them, 22 patients were classified to myalgia group, in which the majority of patients demonstrated lower leg myalgia. Meanwhile, there were no significant differences in mean age and sex distribution between two groups. In myalgia group, administering immunosuppressant togeth-
er with prednisolone (PSL) was required for achieving remission. [Conclusions] Lower leg myalgia can be an initial clinical episode of vasculitis. Even in the case showing myalgia as a principal symptom, concomitant use of immunosuppressive agent may be necessary for achieving favorable outcome.

### P3-209
A case showing polyarteritis nodosa like symptom accompanied with thrombocytopenia
Shota Nakano, Harumichi Suma, Atsushi Tanaka, Takuya Sawabe
Department of Rheumatology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital, Hiroshima, Japan

Conflict of interest: None

A 67-year-old man <Chief complaint> Fever, general malaise, joint pain, muscle pain <Current medical history> On 6 September, a fever of the order of 38 °C Because there was no improvement, he was introduced to his previous doctor on the 18th. Various infectious disease tests and autoantibody tests were performed, but since there was no abnormality, he was treated with SBT / ABPC and MINO as sepsis. On the 26th he was transferred to our hospital, the inflammatory response high value, platelet reduction of the 60000 / ul range, pleural effusion, pericardial effusion was observed, pleural effusion, pleural effusion was exudative. The cause was still unknown, so we administered high-dose steroids and immunosuppression improved. Polyarteritis nodosa usually involves thrombocytosis, but we observed weight loss, hypertension, puppera, joint pain, muscle pain, and neuropathy in the course of scrutiny, We were to administer an immunosuppressive agent as a polyarteritis nodosa when relapsing symptoms. <Discussion> This case is a course that cannot be explained by known single disease, and it is necessary to follow carefully in the future. We report with differentiation such as idiopathic pericarditis, adult onset Still’s disease, TAFRO syndrome etc.

### P3-210
A suspicion case of primary central nervous system vasculitis with emergency surgery due to cerebral hemorrhage after steroid pulse therapy
Yutaka Tanikawa, Marina Hamaguchi, Masashi Oshima, Shohei Yoshizawa, Hiroshi Tsuchi, Yosuke Nagasawa, Kaita Sugiyama, Atsuna Nitta, Natsuru Shimizu, Hitomi Harako, Noboru Kitamura, Masami Takai
Division of Hematology and Rheumatology, Department of Medicine, Nihon University Itabashi Hospital, Nihon University School of Medicine Itabashi Hospital

Conflict of interest: None

A 81-year-old female, who was treated with common cold by antibiotics, recognized extremities weakness in addition to persistent inflammation. She was referred to our hospital for examination and treatment. On the first day after admission to our hospital, head MRI showed multiple strokes in bilateral cerebral cortex. She was treated with heparin. On 13th day of admission, followed-up head MRI showed new multiple strokes in bilateral cerebral cortex on heparin. On 22nd day of admission, head MRI showed cerebral microbleed and subarachnoid hemorrhage. As all the autoantibodies were negative as well as central nervous system lesion had progressed rapidly, which were unable to conduct biopsy, she started to be on steroid pulse therapy with suspicion of primary CNS vasculitis (PCNSV). On 28th day of admission, she had consciousness disturbance, left hemiplegia. Head CT showed right cerebral hemorrhage and she transferred to another hospital for surgery. [Discussion] PCNSV is vasculitis in localized central nervous system. Diagnosis of PCNSV is required to perform brain biopsy. If brain biopsy is unfeasible like this case, it can be considered that treatment at an early stage is required when PCNSV is suspected with progression of central nervous lesion in other examinations.

### P3-211
Three cases of suspected muscle localized vasculitis
Kenichi Hiraga, Yoshinori Masui, Naonori Tsuda, Toshikazu Kano

Conflict of interest: None

A 58-year-old male with diabetes and hypertension due to bilateral renal artery stenosis diagnosed 1.5 year ago was referred to our hospital for refractory PAN. 4 month prior to admission, he stayed at the prior hospital for fever, high CRP weight loss, and acute renal injury (Cre 2.7

### P3-212
A case of cutaneous arteritis without inflammatory response: a case report
Yu Isoda, Hiroaki Kusuoka, Hironori Inoue, Keitaro Saito, Aki Sakashita, Aiko Hirano, Risa Sagawa, Kazuki Fujoka, Hitetake Nagahara, Makoto Wada, Masakatsu Koho, Yutaka Kawahito
Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

Conflict of interest: None

A 37-year-old woman was admitted with paralysis of the ulnar area of the left in year X-10 and her grip strength declined. She was diagnosed with left ulnar nerve paralysis, so underwent neuro-transposition and the symptoms improved. Two years later, similar symptoms appeared in the opposite ulnar area and the transposition also was done. After that the symptoms once again flared in each hand and she had reoperations. In October of year X-1, paresthesias in the hands and lower thigh appeared intermittently. In September year X, numbness and livedo reticularis on the lower leg appeared, so she was hospitalized for further examination in our hospital the next month. At the time of admission, she had the atrophy of the interosseous muscle of the hands, weak grip strength and a nerve conduction study showed mononeuritis multiplex in limbs. The laboratory exam showed no inflammatory reactions nor specific antibodies. But skin biopsy of the lower limbs revealed fibrinoid necrosis and inflammatory cells on the dermic artery wall, so she was diagnosed as cutaneous arteritis (CA). oral steroid therapy with azathioprine improve neurological symptoms promptly. CA sometimes develops negative inflammatory response, so we should keep it in mind in clinical practice.

### P3-213
A Case Report of Angiosarcoma with an Aortic Lesion Diagnosed as Polyarteritis Nodosa Based on Fever, CRP Elevation and Renal Artery Stenosis
Sho Fukui, Hiromichi Tanaki, Haruki Sawada, Mitsuhiro Watanabe, Yukihiro Ikeda, Ayako Kitaeda, Rui Kawato, Masei Suda, Haruyuki Yanoaka, Ryo Rokutanda, Hisanori Shimizu, Tokutaro Tsuda, Mitsu masa Kishimoto, Ken-ichi Yamaguchi, Masato Okada
Immu-no-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan

Conflict of interest: None

A 58-year-old male with diabetes and hypertension due to bilateral renal artery stenosis diagnosed 1.5 year ago was referred to our hospital for refractory PAN. 4 month prior to admission, he stayed at the prior hospital for fever, high CRP weight loss, and acute renal injury (Cre 2.7
were EGPA. 

Conclusions: Although eosinophilia is observed in IgG4-related disease, only 4 cases of IgG4-related disease were found, and most of the IgG4 single increase group. In cases with eosinophils exceeding 2000 / μL, only 4 cases of IgG4-related disease were found, and most of the IgG4 single increase group is rare. IgG4RD was the main disease in IgG4-related disease. In cases with eosinophils exceeding 2000 / μL, only 4 cases of IgG4-related disease were found, and most of the IgG4 single increase group. In cases with eosinophils exceeding 2000 / μL, only 4 cases of IgG4-related disease were found, and most of the IgG4 single increase group is rare.

Methods: In our hospital, cases with IgG4 of more than 135 mg/dl were extracted and diseases, IgG4 levels, peripheral blood eosinophil counts were examined. [Results] We studied 262 cases in which blood IgG4 was above 135 mg/dl. In the past, we had received corticosteroid due to asthma and eosinophilic pneumonia. She also had swelling of her face and erythema of her neck and limbs which lead her to admission. Contrast-enhanced CT had revealed swelling of the pancreas, small nodules and ground-glass opacity of her lung, and swelling of multiple lymph nodes in the mediastinum. They were consistent with IgG4-RD, but skin biopsy had atypical result, which was perivascular eosinophilia with few plasma cells in dermic layer of the skin. She also had eosinophilia (5099/μL) so differential diagnosis such as eosinophilic granulomatosis with polyangiitis (EGPA) should be ruled out. As a result of biopsy from other organs, there was rich infiltration of IgG4-positive plasma cells in her lung (IgG4/IgG ratio >55%), whereas in a submandibular gland and lymph nodes in her mediastinum was not. Consequently, we diagnosed her disease as IgG4-RD. After receiving 30 mg of prednisolone, her symptoms improved. The skin lesions of IgG4-RD sometimes take the form of irregular pattern which causes difficulty of diagnosis. This is the rare case of IgG4-RD case with eosinophilic dermatitis.

Peripheral blood eosinophils in high IgG4 cases
Reika Maezawa, Kazuhiko Kurasawa, Yuta Takamura, Tomoyuki Miyao, Ayae Tanaka, Ryutaro Yamazaki, Masashi Narazaki, Atsushi Kumanogoh
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University

Conflict of interest: None

A 76-year-old female had recognized swelling of submandibular glands with high titer of IgG4 level (740/μg/dl). In the past, we had received corticosteroid due to asthma and eosinophilic pneumonia. She also had swelling of her face and erythema of her neck and limbs which lead her to admission. Contrast-enhanced CT had revealed swelling of the pancreas, small nodules and ground-glass opacity of her lung, and swelling of multiple lymph nodes in the mediastinum. They were consistent with IgG4-RD, but skin biopsy had atypical result, which was perivascular eosinophilia with few plasma cells in dermic layer of the skin. She also had eosinophilia (5099/μL) so differential diagnosis such as eosinophilic granulomatosis with polyangiitis (EGPA) should be ruled out. As a result of biopsy from other organs, there was rich infiltration of IgG4-positive plasma cells in her lung (IgG4/IgG ratio >55%), whereas in a submandibular gland and lymph nodes in her mediastinum was not. Consequently, we diagnosed her disease as IgG4-RD. After receiving 30 mg of prednisolone, her symptoms improved. The skin lesions of IgG4-RD sometimes take the form of irregular pattern which causes difficulty of diagnosis. This is the rare case of IgG4-RD case with eosinophilic dermatitis.

Peripheral blood eosinophils in high IgG4 cases
Reika Maezawa, Kazuhiko Kurasawa, Yuta Takamura, Tomoyuki Miyao, Ayae Tanaka, Ryutaro Yamazaki, Masashi Narazaki, Atsushi Kumanogoh
Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka University

Conflict of interest: None

[Object] We clarify the relationship between IgG4 level and peripheral blood eosinophils. [Methods] In our hospital, cases with IgG4 of more than 135 mg/dl were extracted and diseases, IgG4 levels, peripheral blood eosinophil counts were examined. [Results] We studied 262 cases in which blood IgG4 was above 135 mg/dl. IgG4-RD was 96 cases, and the average IgG4 value was 705.8 ± 604.5 mg/dl. Other diseases were 166 cases, 246.1 ± 456.9 mg/dl. The average number of peripheral blood eosinophils as a whole is 1011.1 ± 3310, the maximum value 29916.6 / μL, the median 194.7 / μL. Met. When examining the relationship between the IgG4 level and the number of eosinophils, it is roughly classified into an IgG4 level and the number of eosinophils, it is roughly classified into an

Conflict of interest: None

A 38-year-old female presented to our hospital with bilateral eyelid swelling, parotid swelling, submaxillary swelling, nasal congestion and chronic sinusitis. On her laboratory examination, serum IgG4 level was elevated (670 mg/dl). A biopsy of right lacrimal gland showed marked infiltration of lymphocytes and plasma cells (IgG4/IgG ratio of 90%) and fibrosis, and she was diagnosed as IgG4-RD. FDG-PET/CT scan demonstrated a high uptake in cervix of uterus as well as in lacrimal gland, parotid gland, submandibular gland, sublingual gland, nasal mucosa, ethmoid sinus and mediastinum/hilar lymph node. After gynecological examination, a cone excision of the cervix was performed. The endocervical tissue also showed histopathologic features suggestive of IgG4-RD (IgG4/IgG ratio of 80%). Treatment was initiated with prednisolone at a dose of 0.6 mg/kg/day (35mg). One month later, her symptoms disappeared almost entirely by physical examination. CT after 7 months revealed resolution of bilateral eyelid swelling and parotid swelling. MRI after 8 months revealed shrinking of the uterine cervical lesion. This is a rare case of IgG4-RD with uterine cervical involvement.

P3-217
A case of IgG4-related disease with uterine cervical involvement
Yusuke Yamauchi, Masahiro Ayano, Yasutaka Kimoto, Hiroki Mitoma, Mitsutera Akahoshi, Yojiro Arinobu, Koichi Akashi, Takahiko Horuchi, Hiroaki Niroy
1Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan, 2Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan, 3Department of Medical Education, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

Conflict of interest: None

A 38-year-old female presented to our hospital with bilateral eyelid swelling, parotid swelling, submaxillary swelling, nasal congestion and chronic sinusitis. On her laboratory examination, serum IgG4 level was elevated (670 mg/dl). A biopsy of right lacrimal gland showed marked infiltration of lymphocytes and plasma cells (IgG4/IgG ratio of 90%) and fibrosis, and she was diagnosed as IgG4-RD. FDG-PET/CT scan demonstrated a high uptake in cervix of uterus as well as in lacrimal gland, parotid gland, submandibular gland, sublingual gland, nasal mucosa, ethmoid sinus and mediastinum/hilar lymph node. After gynecological examination, a cone excision of the cervix was performed. The endocervical tissue also showed histopathologic features suggestive of IgG4-RD (IgG4/IgG ratio of 80%). Treatment was initiated with prednisolone at a dose of 0.6 mg/kg/day (35mg). One month later, her symptoms disappeared almost entirely by physical examination. CT after 7 months revealed resolution of bilateral eyelid swelling and parotid swelling. MRI after 8 months revealed shrinking of the uterine cervical lesion. This is a rare case of IgG4-RD with uterine cervical involvement.

P3-218
Difficulty to differentiate multicentric Castleman’s disease from IgG4-related disease: A case report
Harumichi Suma, Shota Nakano, Atsushi Tanaka, Takuya Sawabe
Department of Rheumatology, Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital

Conflict of interest: None
A female in her seventies showed an elevated C-reactive protein level (CRP) of about 1 mg/dL 8 years ago. She experienced no symptoms at all, and was followed by her primary care doctor. Three years ago, her CRP level was raised by 7 mg/dL, and anemia and renal dysfunction occurred. Simultaneously, she presented a polyclonal hypergammaglobulinemia. She remained asymptomatic, however, anemia and renal dysfunction were getting worse. She was referred to our hospital. At the initial visit, she showed no aberration on physical examination. Her blood tests are as follows: CRP 13.1 mg/dL, hemoglobin 6.6 g/dL, creatinine 1.3 mg/dL, immunoglobulin G 7882 mg/dL, immunoglobulin A 1030 mg/dL, immunoglobulin M 256 mg/dL, and IgE 6 55.6 pg/mL. Whole-body CT scan showed multiple lymphadenopathy of left infraclavicular, bilateral axillary, mediastinal, and bilateral inguinal regions. It is difficult to distinguish multicentric Castleman’s disease (MCD) and IgG4-related disease (IgG4-RD) clinically. Left axillary lymph node biopsy revealed IgG4-positive plasma cell infiltration. We report the characteristics of MCD and IgG4-RD to differentiate themselves, and the course of treatment.

P3-219
A case of “pseudo-meningioma”, which was diagnosed as an IgG4-related disease based on the pathological findings
Hikaru Hirose, Shinya Hirahara, Akira Nishino, Mari Tochihara, Hirokazu Nishina, Masanori Hanaoka, Yasuhiro Katsumata, Hisashi Yamanaka
Department of Rheumatology, Tokyo Women’s Medical University School of Medicine, Tokyo, Japan

Conflict of interest: None

[Case] Ten months ago, a woman had a headache and was detected tumor which was not presented before. It spread along the right tent and pushed the brainstem. Tumor was extracted by neurosurgeon six months ago and oppression was canceled. Meningioma was denied from pathology findings. Invasion of prominent B lymphocytes/plasma cells and fibrosis was observed. It could not evaluate “IgG/IgG positive cells ratio ≥ 40%” due to crushed degeneration. IgG4 positive plasma cells exceeded 10/HPF and serum IgG4 was high as 226 mg/dL. So IgG4 related disease was suspected. IgG4-related disease comprehensive diagnostic criteria was not fulfilled and plasmacyte tumors could not be denied because of large number of κ chain-dominant CD 138 positive plasma cells. Any symptoms disappeared, but a part of the tumor remained, and in consideration of the risk of re-exacerbation without treatment, we started prednisolone at 0.6 mg/kg. Subsequently, the serum IgG4 value rapidly normalized and did it not relapse after the gradual decrease of prednisolone.

[Clinical Significance] As rare IgG4-related disease of central nervous system, there are few reports of tumorous lesions similar to meningiomas as in this example. This case was important considering various disease states of IgG4 related diseases.

P3-220
An example of the IgG4-related disease that merged SLE
Kazusato Hara1, Yoshikazu Nakashima1, Takahisa Suzuki2, Akitomo Okada1, Atsushi Kawakami1
1Department of Rheumatology, Japanese Red Cross Nagasaki Genbaku Hospital, 2Department of Immunology and Rheumatology, Sasebo City General Hospital, 3Department of Immunology and Rheumatology, Nagasaki University Hospital

Conflict of interest: None

A case is a 78 year old man. He admitted to the medical department of Hematology, recognizing the pancytopenia. IgG:7150mg/dL and the immunity electrophoresis test was performed, it was multi-clone. No significant findings were observed in the bone marrow test. CT showed lots of lymphadenopathy and the enhancement of soft shadow in the abdominal aorta and the iliac artery. IgG4:740mg/dL was high and IgG4-related diseases were suspected. Anti-nuclear antibodies and anti-Sm antibody positive, low complement blood and white blood cells, renal dysfunction and urinary findings, so we underwent renal biopsy. Interstitial cell infiltration and Hana-like fibrosis, mesangial cell increase, IgG in fluorescence antibody method, IgA, IgM, C3, deposition of C1q, was admitted deposition of mesangial region in electron microscopy. We diagnosed as IgG4-RD/IgG4-related kidney disease (IgG4-RKD) and systemic lupus erythematosus (SLE)/lupus nephritis (LN) Class II merger. We started prednisolone 40mg for treatment and are decreasing gradually. Both sides submandibular gland swelling and lymphadenopathy, the soft shadow disappear, and IgG4 decreases to the normal range. Also, renal function become normal. The course is good, adding a mycophenolic acid methylfetol.

P3-221
A case of MALT lymphoma diagnosed by biopsy of a growing mass around right kidney during therapy of IgG4-related disease
Kahori Oshima, Masao Katayama, Nobuyoshi Minemura, Eiji Nagasawa, Kyoko Takano, Michita Suzuki, Kumiko Umemura, Syunsuke Yokoi, Takakazu Hasegawa, Mayu Sugiyama
National Hospital Organization Nagoya Medical Center

Conflict of interest: None

A 60-year-old man with a history of diffuse large B-cell lymphoma came to the hospital because of left swelling eyelid and right swelling axially. He was diagnosed as IgG4-related disease because the eyelid biopsy histology confirmed it. According to the enhanced CT scan, many lymph nodes throughout the body, including a small mass around the right kidney, were swelling. PET-CT scan and an additional biopsy of neck lymph node were performed in order to confirm the diagnosis. Because no evidence of malignancy were found, we finally diagnosed with IgG4-related disease and started on PSL 0.6 mg/kg/day. The response to the treatment was remarkable and almost all lesions were disappeared. However, in spite of under treatment and other lesions were improved, the only mass around the right kidney was growing bigger within one year, so malignancy and lymphoma was considered as a differential diagnosis. The biopsy of the mass was procured laparoscopically and its history confirmed MALT lymphoma. We report a case of MALT lymphoma diagnosed by biopsy of a growing mass around right kidney during therapy of IgG4-related disease with some discussion.

P3-222
A case of IgG4-related disease with marked eosinophilia and purpura
Katsunori Nakagawa1, Hiromasa Kawashima1, Ryo Yonezima1, Yoshiaki Tai1, Emiko Tatsumi1, Kiyomi Yoshimoto2, Yasuhiro Akai1,2, Yasuhiro Tanka1, Takashi Fujimoto1, Kenji Nishio1
1Department of General Medicine, Nara Medical University Hospital, 2The Center for Rheumatic Diseases, Nara Medical University Hospital

Conflict of interest: None

A 55-year-old female presented with swelling of salivary and lacrimal glands for 6 months. She was admitted with 10 days history of purpura of lower legs. She had a history of bronchial asthma. Her laboratory results were: peripheral white blood cell count, 17,000 /μL with 72.0% eosinophils (12,000 /μL); ESR, 79 mm; CRP, 0.47 mg/dL; IgG, 3,870 mg/dL; IgG4, 2,200 mg/dL; IgE, 1,675 U/mL; and both PR3-ANCA and MPO-ANCA negative. CT showed mediastinal and paraaortic lymphadenopathy, but no findings suggesting pancreas swelling or retroperitoneal fibrosis. The submandibular gland biopsy revealed lymphoplasmacytic infiltration with 70% of IgG4+/IgG+ cell ratio. The skin biopsy of purpura indicated eosinophilic infiltration, but no apparent findings of vasculitis. She was diagnosed with IgG4-related disease (IgG4-RD), as she had no evidence of vasculitis. She was commenced on 0.6 mg/kg (50 mg daily) of prednisolone (PSL), and the swollen salivary and lacrimal grinds and purpura resolved completely on the 7th day of treatment. IgG4-RD was reported to have eosinophilia with the eosinophil count of up to 2,000 cells/μL. A differential diagnosis between IgG4-RD and eosinophilic granulomatosis with polyangiitis (EGPA) was essential, as she had eosinophilia, purpura and a history of asthma.

P3-223
A case of inflammatory aortic aneurysm which was difficult to decide whether IgG4 related or unrelated
Tohru Michitsuji1, Haruna Matsuou1, Takahisa Suzuki1, Atsushi
A 90-year-old woman presented with fever and loss of appetite. She visited our hospital and was hospitalized. She was pointed out an abdominal aortic aneurysm (AAA) two years ago. AAA didn’t increase but surrounding soft tissue increased. Mammal sign was positive. Her laboratory data showed increase of inflammatory response. We thought it necessary to distinguish IgG4 related disease. Her serum IgG4 levels was not elevated. Gallium scintigraphy showed uptake of gallium in submandibular gland. But she never agreed to biopsy. We judged it necessary to corticosteroid therapy because size of soft tissue was increased at day 20 of the disease. We started Predonisolone 0.6mg/kg/day. Size of soft tissue was reduced and Her C-reactive protein levels was negativeization. Like this case, IAAA without other lesion and not applicable for surgery is difficult to be judged whether IgG4 related or unrelated. We report also including literature considerations.

**P3-224**

A case of IgA vasculitis combined with IgG4 related disease

Koji Uehara1, Shin-ichiro Omura1, Toru Yamabe1, Shinya Tamechika1, Shinji Maeda1, Michio Fukuda2, Taio Naniwa2

1Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Hospital, 2Department of Cardio-Renal Medicine and Hypertension, Nagoya City University Hospital

Conflict of interest: None

[Case] A 50-year-old man was diagnosed IgG4 related disease 5 months ago because of swelling of the submaxillary gland and elevation of IgG4 227 mg/dl. He was observed with no treatment. 20 days before admission, he had a fever, palpable purpura and multiple mononeuropathy. Laboratory data showed creatinine elevation and urine protein increase. CT findings showed thick bronchial thickening, enlargement of bith kidneys and patchy contrast defect. Renal biopsy showed plasmacyte infiltration in interstitium without glomerulonephritis and skin biopsy showed IgA deposition on the vessel wall. We diagnosed as combinaton of IgG4 related disease and IgA vasculitis. We started steroid therapy and he was discharged from hospital. [Clinical significance] There were few reports of the combination of IgG4 related disease and IgA vasculitis. We started steroid and IgA vasculitis, and in the past reports only 2 cases were reported. Both cases had glomerulonephritis and interstitial lesions in the kidneys and palpable purpura of the skin. We report with some literature review on the combination of IgG4 related disease and IgA vasculitis.

**P3-225**

Metabolomic analysis in IgG4-related disease

Takafumi Kawamura, Shino Fujimoto, Yoshimasa Fujita, Hiroshi Kawabata, Yasufumi Masaki

Department of Hematology and Immunology, Kanazawa Medical University

Conflict of interest: None

IgG4-related disease is indicated by increased infiltration of IgG4-positive plasma cells, typically elevated IgG4 serum levels and the formation of lymphoplasmacytic infiltrate in one or more organs. We explored the metabolome of >400 small molecules in serum from 10 matched pair IgG4-related disease subjects prior to (PRE) and following (POST) steroid treatment and contrast these profiles with a cohort of 10 normal non-diseased subjects (NORM). The polyunsaturated fatty acid arachidonate is involved in pro-inflammatory activities through its metabolism to pro-inflammatory prostaglandins via cyclooxygenase activity and HETEs via lipoygenases. Individuals with PRE IgG4-related disease had elevated arachidonate and the 12-lipoxygenase product, 12-HETE, as compared to NORM subjects. The higher levels of the pro-inflammatory arachidonate and 12-HETE was unaffected by steroid treatmen as POST subjects had similar levels of these biochemics as was observed in PRE subjects.

**P3-226**

Usefulness of Serum IgG4 in IgG4-Related Disease

Hiroki Ozaki1, Tomohiro Kameda1, Shusaku Nakashima2, Hiromi Shimada1, Risa Wakiya1, Mikiya Kato1, Taichi Miyagi2, Hiroaki Dobashi1

1Department of Rheumatology, KKR Takamatsu Hospital, 2Department of Internal Medicine, Division of Hematology, Rheumatology and Respiratory Medicine, Faculty of Medicine, Kagawa University

Conflict of interest: None

[Object] We evaluated the usefulness of serum IgG4 in diagnosis of IgG4-related disease (IgG4-RD) and monitoring after treatment. [Methods] This study included 37 patients of IgG4-RD and 9 patients of others who showed high levels of serum IgG4. Laboratory data, image findings and the treatment response were analyzed from their medical records retrospectively. Relapse was defined by the new development or return of abnormal findings on physical examination, laboratory tests or imaging studies. [Results] There were 34 cases in men, 12 cases in females. Serum IgG4 was 614±514 mg/dl for IgG4-RD and 178±59 mg/dl for other diseases. In all 26 cases of IgG4-RD treated for more than 1 year, serum IgG4 was decreased after treatment started. 16 of them fell within the reference value range (<135 mg / dl). Relapse was observed in 12 cases, but there was no relation between normalization and re-elevation of serum IgG4 and relapse. In addition, there was only one case in which re-elevation of serum IgG4 was observed before relapse. [Conclusions] Serum IgG4 levels were useful in the differential diagnosis of IgG4-RD. In addition, serum IgG4 was decreased in all cases by treatment, but there was no relation between the transition of serum IgG4 and the presence or absence of relapse thereafter.

**P3-227**

A case of IgG4-related disease with varied clinical manifestations

Hideaki Sofue, Ken Murakami

Department of Rheumatology, Kyoto Yamashiro General Medical Center

Conflict of interest: None

[Case] 87-year-old man [chief complaint] fever of unknown origin [history] hypertension, chronic obstructive pulmonary disease, history of heavy drinking [current medical history] He was hospitalized due to unknown fever lasting about 1 month. He had leucopenia, normocytic anemia, hyponatremia, hypothyroidism (TSH: 6.49 μU/mL, FT4: 0.50 ng/mL, FT3: 1.6 pg/mL). Thyradin was started as a treatment of primary hypothyroidism that antibiotics were initiated, but these did not response. He was introduced to the department of Rheumatology on the 35th hospital day. He had low Serum complement levels, the high serum IgG4 concentration, renal dysfunction, exocrine pancreatic insufficiency, hypopopituitarism, retropertitoneal fibrosis, left hydronephrosis, periaortitis, interstitial pneumonia and pure red-cell aplasia. We diagnosed possible IgG4-related disease and started 30mg/day of prednisolone (PSL). We changed PSL to hydrocortisone because hyponatremia did not improve and then hydrocortisone responded. He was discharged on the 79th hospital day. [Clinical significance] This case was difficult to be diagnosed because he had various symptoms. We think this case is valuable.

**P3-228**

A case of IgG4-Related Disease with multiple organ involvement

Soichiro Adachi, Kazuo Matsui, Atsushi Noguchi, Yoshiharu Amasaki

Department of Rheumatology, Tonan Hospital

Conflict of interest: None

An eighty-three years old man with swelling of parotid glands and high levels of serum IgG and IgG4 was referred to our hospital in May 2017. He developed weight loss and fatigue gradually and was admitted to our hospital in September 2018. Imaging studies revealed multiple organ involvement and the immunohistochemical staining of the right submandibular gland showed numerous IgG4 positive cells. He was diagno-
nosed with IgG4-related disease with multiple organ involvement and treatment with oral glucocorticoid was started. The characteristics of imaging findings and the indication of systemic treatment of IgG4-related disease will be discussed.

P3-229
Clinical features of Behcet’s disease complicated with joint symptoms
Toshihiro Tono1, Shunsei Hirohata1, Hirotohi Kikuchi2, Tetsuji Sawada2, Mitsuhito Takeno2, Hiroko Nagafuchi2, Yohie Kirino2, Ippei Miyagawa2, Yoshiya Tanaka2, Kumihito Yamaoka1
1Department of Collagen Disease and Infection Internal Medicine, Kitasato University School of Medicine Hospital, 2School of Medicine Medical Course Internal Medicine and Clinical Immunology, Yokohama City University, 3Hospital of the University of Occupation and Environmental Health, Japan

Conflict of interest: None

[Object] Approximately 60% of Behcet’s disease patients have joint symptoms. The present study aimed to clarify the clinical features of these patients in Japan. [Methods] Depending on retrospective medical chart review, 151 cases were collected from 7 cooperative medical institutions treated during 2007 to 2017. Clinical characteristics and treatments regimens were analyzed. [Results] The order of most commonly afflicted joints were, knee, ankle and PIP joints. Among the patients with X-ray imaging joint space narrowing and deformation were observed in 18 joints out of 293 joints. Among those who were treated with steroids as initial treatment, 84% improved and those treated with 10 mg/day or more had 84% improvement. Among those who were treated with colchicine and MTX has the effect of preventing recurrence of joint symptoms in acute phase of Behcet’s disease. In addition, results indicate that PSL should be administered at 10mg or higher for MTX compared to those treated with prednisolone. [Conclusions] These results indicate that PSL should be administered at 10mg or higher for MTX compared to those treated with prednisolone. Among the patients with X-ray imaging joint space narrowing and deformation were observed in 18 joints out of 293 joints. Among those who were treated with steroids as initial treatment, 84% improved and those treated with 10 mg/day or more had 84% improvement. Among those who were treated with colchicine and MTX has the effect of preventing recurrence of joint symptoms in acute phase of Behcet’s disease. In addition, results indicate that PSL should be administered at 10mg or higher for MTX compared to those treated with prednisolone.

P3-230
Management of pregnancy in patients with Behcet’s disease
Shunsuke Uchiyama1, Mitsuhiro Takeno1,2, Takahisa Gono1, Masataka Kuwana1
1Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan, 2Nippon Medical School Musashi Kosugi Hospital, Kanagawa, Japan

Conflict of interest: None

[Object] This study is aimed to investigate clinical outcomes of pregnancy in patients with Behcet’s disease (BD) patients. [Methods] We retrospectively reviewed treatments and outcomes of pregnancy in BD patients between July 2014 and October 2018 in our hospitals. [Results] Seven patients had 8 pregnancies including 6 successful delivery and 2 ongoing. Of them, 3 patients had BD flares. Case 1 was a 23-year-old female who developed chronic progressive neuro-BD after discontinuation of colchicine at pregnancy. Case 2 was a 45-year-old female who had a flare with skin and ocular symptoms after deliveries, which required colchicine and topical steroids. Case 3 was a 28-year-old female who received infliximab (IFX) due to a severe ocular attack at 33 weeks of gestation, though discontinuation of IFX had been planned at 26 weeks. All newborns were fine except suspending live vaccinations for a year in Case 3. [Discussion] Our study suggest that treatment changes are often associated with disease flares during pregnancy in BD patients. Drafts of Japanese guidelines recommend low dose prednisolone, and suggest to use cyclosporine-A, azathioprine, and anti-TNF antibodies if necessary. Colchicine may be used under informed consent. Further study is needed for establishing management for BD during pregnancy.

P3-231
Clinical Features of Our Patients with Behcet’s Disease in Saitama Medical Center Jichi Medical University
Tsuyoshi Kobashigawa, Toru Yago, Eri Watanabe, Hiroki Yabe, Shigeru Kotake
Division of Rheumatology, 1st Department of Comprehensive Medicine, Saitama Medical Center, Jichi Medical University

Conflict of interest: None

[Object] To investigate the clinical features of our Behcet’s Disease (BD). [Methods] We enrolled 27 BD patients (12 males) in our hospital (Saitama Medical Center, Jichi Medical University) who continued arriving at April 1st, 2018 into this study. We analyzed their age, gender, each symptom of BD, diagnosis, treatment, etc, statistically. [Results] The median age was 45 year-old (y/o): quartile, 31 y/o and 56 y/o. The symptoms of BD were as below: oral aphthous ulcers (OU), 26 (96.3%), genital ulcers, 17 (63.0%); skin lesions, 22 (81.5%) with acneciform eruption, 13 (48.1%), erythema nodosum, 14 (51.9%) and phlebitis, 4 (14.8%); uveitis, 13 (48.1%); arthritis, 23 (85.2%); intestinal lesions, 9 (33.3%); neural lesions, 0 (0%); vascular lesions, 6 (22.2%); positive pathergy test, 2 (7.4%); epididymitis, 0 (0%). The treatments were performed with steroid-pulse to 6 (22.2%) cases; mean dose of oral steroid, 3.2 mg/day, 17 cases out of 27 were exactly taken: CyA, 2 cases; MTX, 3; AZT, 3; 5-ASA, 2; SSZ, 2; IVCY, 2; warfarin, 3; none of biologics. [Conclusions] We analyzed our BD patients. A vascular BD case was absent from OU and none was taken biologics.

P3-232
A Clinical Features of Behçet’s Disease Comorbid with MDS with 8 Trisomy: a Review of Literatures
Takahiro Iiamiya, Takafumi Tomizukua, Kurumi Asako, Daisuke Tsukui, Yoshitaka Kimura, Hirotohi Kikuchi, Hiroko Oguchi, Zenichiro Honda, Akiteru Takeuchi, Hajime Kono
Teikyo University Hospital, Tokyo, Japan

Conflict of interest: None

[Object] There have been several reports on patients with Behçet’s disease accompanied with MDS with 8 trisomy. Most of these are reported from Japan, and a high incidence of intestinal legion and a low incidence of uveitis are pointed out. A pathological relationship between Behçet’s disease and MDS with 8 trisomy isn’t still fully understood, and it’s a chicken or egg situation. [Methods] 65 case reports on Behçet’s disease and MDS with 8 trisomy were collected. They were categorized into three groups according to written medical records, Behçet’s disease preceded MDS (30 cases), MDS preceded Behçet’s disease (19 cases), and these two diseases occurred simultaneously (16 cases). [Results] There was no significant difference in the onset age of Behçet’s disease and MDS between the three groups. And there was no significant difference between the three groups in the rate of each symptom or clinical features (oral, genital, skin, uveitis, pathergy, HLA-B51 positive, fever, arthralgia, gastrointestinal, vasculitis, CNS involvement, and sex category). [Conclusions] Regardless of the preceding disease of Behçet’s disease or MDS with 8 trisomy, there were no significant differences in the clinical features of Behçet’s disease.

P3-233
Recurrant fever and panniculitis with trisomy 8
Sho Fujimoto, Naoyasu Ueda, Sanshiro Inoue, Genichi Tanaka, Koichi Mashiba
Miyazaki Prefectural Miyazaki Hospital

Conflict of interest: None

[Case] 84-year-old male [Chief complaint] fever, recurrent painful erythema [Current medical history] He had recurrent fever and painful erythema on his back from around June X-1 year. His blood examination showed anemia, thrombocytopenia and strong inflammation. He was admitted to our hospital on February X year. His symptom and laboratory data improved spontaneously in about 5 days. Histopathology of skin tissue showed panniculitis. After discharge, similar symptoms and blood test showed...
abnormalities repeated every 14-21 days and spontaneously achieved remission in about 5 days. Erythema appeared the upper limbs and the abdomen as well as the back. Some examinations were performed, and bone-marrow examination revealed trisomy 8. 2.8% of blast cell and less than 10% of the morphological abnormality of erythroid cells and megakaryocytic cells was observed; these did not meet the morphological criteria of myelodysplastic syndrome. Ulcerative lesions were found at the terminal ileum by total colonoscopy. [Discussion] Several cases have been reported mainly from Japan about Behcet’s disease-like symptoms coexisting myelodysplastic syndrome with trisomy 8, but it is rare to find trisomy 8 through Behcet’s disease-like symptoms before the onset of myelodysplastic syndrome.

P3-234
A case of intestinal Behcet’s disease associated with myelodysplastic syndrome (Trisomy 8)
Mariko Harada, Yoshiyuki Abe, Eri Hayashi, Kentaro Minowa, Kurisu Tada, Ken Yamaji, Naoto Tamura
Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan

Conflict of interest: None

The patient is a 40-years-old woman. She was diagnosed incomplete Behcet’s disease, since she presented with genital ulceration, oral ulceration, erythema nodosum and elevation of serum IgD level in X-8 year. She was treated with prednisolone and colchicine. In X-1 year, she presented with right lower abdominal pain, and colonoscopy revealed ileocecal ulcers. Because she was diagnosed as MDS (trisomy 8) in X-20 year, we diagnosed her current symptoms as intestinal Behcet’s disease associated with MDS (Trisomy 8). Her first-line therapy with adalimumab was discontinued because of secondary failure. Her second-line therapy with infliximab (IFX) was failed with 300mg of IFX at the first time, however succeeded with 600mg of IFX per 8 weeks after the second time. Since she was relapsed 8 months later, we treated her with extreme high dose IFX (600mg of IFX per 4 weeks), after we confirmed negative of Human Anti-Chimeric Antibody in her serum. In present, she showed remission state with extreme high dose IFX and cyclosporin. This disease is intracetable and TNF inhibitor is only temporarily effective. We also examine three similar cases experienced in our hospital and literature review.

P3-235
Two patients present with autoinflammatory syndrome like manifestation with trisomy 8 not associated to myelodysplastic syndrome (MDS)
Fangyi Chiu, Sayaka Tsuruki, Hideyuki Takahashi, Keigo Setoguchi
Department of Rheumatology, Komagome Hospital Tokyo Japan

Conflict of interest: None

Case1) 21y.o F. Six years before diagnosis, she had fever, pancytopenia, diagnosis of AOSD was made and treated with steroid. Bone marrow aspiration (BMA) reveal chromosomal abnormality (trisomy 8) without any specific disease. Three years before diagnosis, recurrent aphtous stomatitis, genital ulcer appeared. Finally, she developed ileocecal ulcer and with diagnosis of gastrointestinal Behcet disease (GIBD), Infliximab was administered. Since we couldn’t achieve good response, we increment IFX to maximal dose and then she achieved remission. Case2) 51y.o M. The patient present with recurrent fever, pharyngitis, thrombocytopenia and migratory panniculitis four years ago. At that time BMA reveal trisomy 8 without any specific disease. Steroid was used on patient demand at first but during course, inflammation became exacerbated and recurrent multiple gastrointestinal ulcer were developed. We started IFX according to BD treatment but despite increment IFX dose, we can’t achieve remission. Clinical significance) BD associated MDS with trisomy 8 has known to GI predominant feature and refractory to conventional treatment. Our cases are not associated to MDS so it could be good opportunity to examine the influence of trisomy 8.

P3-236
Six cases of seronegative spondyloarthropathy with HLA-B51 positive
Ryosuke Yoshihara, Atsuo Uefuji, Miki Murata, Natsuko Nakagawa, Yasushi Tanaka, Kazuko Shiozawa
Rheumatology & Collagen Disease Center, Hyogo Prefectural Kakogawa Medical Center

Conflict of interest: None

[Object] There are some patients with rheumatic symptoms and HLA-B51 positive, who meet neither diagnostic criteria for Behcet’s disease nor classification criteria for rheumatoid arthritis or spondyloarthritis. We examined the clinical manifestation of such cases. [Methods] We analyzed the clinical findings of six patients. [Results] Two men and four women. Average onset age was 55 years. Clinical symptoms were three cases of low back pain, two cases of sternoclavicular pain, three cases of peripheral joint pain, two cases of Achilles tendon pain, a case of upper and lower limb pain and a case of episcleritis. All cases were negative for rheumatoid factor and anti-CCP antibody. Three cases were CRP positive. HLA-A24 was also positive in five cases. As a result of administration of NSAID to five cases, the two remitted but three did not. One patient remitted after using methotrexate because of steroid resistance. [Conclusion] HLA-B51 may be related not only to Behceht’s disease but also to spondyloarthropathy with relatively good prognosis. However, it is possible that joint symptoms preceded Behcet’s disease. There are also a few similar case reports.

P3-237
Trigeminal neuralgia complicated with acute neuro-Behcet’s disease
Tomohiro Kozuki, Yui Miyoshi, Makoto Sugiura, Miho Oshishima
Department of Rheumatology, Tama-Hokubu Medical Center

Conflict of interest: None

Trigeminal neuralgia (TN) can be seen in autoimmune connective tissue diseases. Headache has been reported to account for 53.9% in acute neuro-Behcet’s disease (NBD) patients. However, few case reports presented with TN have been published. A 48 year-old woman with no past medical history presented fever, poly arthralgia and headache lasting for a week. As for her headache, paroxysmal attacks of her left facial sharp pain lasted for a second, with persistence of aching between paroxysms. She had oral and genital ulcers, polyarthritis and erythema nodosum on bilateral legs. Her left facial muscle spasm occurred on her every attack and the rest of neurological findings were unremarkable. Laboratory test was consistent with moderate inflammation in the serum (CRP 10.09mg/dl) and cerebrospinal fluid (Cell count 246/μl, IL-6 1400pg/ml). She was negative for anti-CCP antibody, ANA, MPO/PR3-ANCA and HSV/VZV-DNA. MRI of her head showed no abnormalities. Acute NBD manifesting aseptic meningitis with TN was clinically diagnosed. She got afebrile and the headache disappeared soon after intravenous prednisolone 50mg/day. We shall be aware of NBD as differential diagnosis of TN with multiple systemic symptoms. Early treatment of corticosteroid is possibly effective for the TN of acute NBD.

P3-238
Successful treatment of neuro-Behcet’s disease with methotrexate and infliximab: a case report
Norikai Yo1, Ayaka Inoue1, Hiroaki Nakagawa1, Midori Kitayama1, Takuro Maeda1, Rimi Iwamoto1, Chihiro Tanaka1, Takashi Yamane1
1Department of Rheumatology, Kakogawa Central Hospital, 2Department of Pharmacy, Kakogawa Central Hospital

Conflict of interest: None

A 50 year-old-Japanese man, his vision was impaired one year before, and was diagnosed as uveitis. He was aware of dizziness 6 months before, developed diplopia and gait ataxia, and visited the other hospital one month before. Neurological examinations showed cerebellar ataxia, magnetic resonance imaging revealed his pons stroke, and he was hospitalized. Lumbar puncture was performed. The cerebrospinal fluid (CSF) showed a elevation of cell count and IL-6 levels, and he was suspected
P3-239
A case of vascular Behçet Disease with an occlusion of right main pulmonary artery
Nozomi Tanaka1, Hajime Yoshifuji1, Ran Nakashima2, Shuji Akizuki1, Kosaku Murakami2, Motomu Hashimoto2, Masao Tanaka2, Koichiro Ohmura1, Tsuneyo Mimori2
1Department of Rheumatology and Clinical Immunology, Kyoto University Hospital, 2Department of Advanced Medicine for Rheumatic Diseases, Kyoto University Hospital

Conflict of interest: None

A 36-year-old woman, who was diagnosed with incomplete Behçet’s disease (BD) 7 years before, has presented with dry cough, exertional dyspnea and bloody sputum for 10 months. Chest CT revealed multiple infiltrates in both lungs. Bloody fluid was collected in bronchoalveolar lavage. Contrast enhanced CT showed thickening of walls on the branches of the aortic arch and occlusion of right main pulmonary artery. She was diagnosed with pulmonary infarction with vascular BD. Serum CRP levels were decreased with high dose glucocorticoids (GC). However, vascular lesions were not improved on CT after 4 weeks, and serum CRP levels were slightly elevated. Then, infliximab (5mg/kg) was added and GC was tapered. Chronic pulmonary thromboembolism, Takayasu arteritis (TAK) and vascular BD can causes pulmonary arterial stenosis. In BD, thromboembolism or arterial aneurysm are common, whereas a few cases with pulmonary arterial stenosis have been reported. In our case, it is controversial whether this patient has both TAK and BD or only BD. We discuss treatments and prognoses of patients with pulmonary arterial stenosis, referring our case series and the literatures.

P3-240
Subclavian Artery Aneurysm with Uveitis revealed Behçet’s Disease without Oral Aphthous Ulcer
Takehiko Manabe, Tsuyoshi Kobashigawa, Eri Watanabe, Hiroki Yabe, Toru Yago, Shigeru Kotake
Division of General Medicine and Division of Rheumatology, Department of Comprehensive Medicine, Saitama Medical Center, Jichi Medical University

Conflict of interest: None

[Case] A 36-year-old male patient with Behçet’s disease (BD) without oral aphthous ulcer was referred to our hospital due to uveitis of his left eye. One month was passed after the operation, reduced visual acuity on his left eye was occurred with vitreous opacity. At the same period, he complained his left neck pain and disability of raise-up motion on his left arm. MRI of neck was performed and was shown his left subclavian artery aneurysm and the size was 60 millimeter. The vitreous surgery against uveitis was performed. The patient with uveitis and subclavian artery aneurysm was referred to our division. According to dermatologists in our hospital, the present patient was having acneiform eruptions on his abdomen. The HLA analysis showed he is double positive B51 and A26 loci. We diagnosed he was a patient with BD by Japanese criteria of BD; interestingly, he was absent from oral aphthous ulcers.

P3-241
Refractory pulmonary thrombosis resolved by adalimumab in a patient with Behçet disease: case report
Shuzo Yoshida1, Yuku Kimura2, Nobuhisa Shibahara2
1Department of Immuno-Rheumatology Center, Arisawa General Hospital, Hirokata, Osaka, Japan, 2Department of Urology, Arisawa General Hospital, Hirokata, Osaka, Japan

Conflict of interest: None

[Case] 80 years old man. He was admitted in our hospital because of uveitis, arthritis, and erythema nodosum. He was diagnosed with Behçet disease based on clinical symptoms and laboratory findings of C-reactive protein (CRP) positive and HLA-B26 positive. He was treated with prednisolone (30 mg/day) and colchicine. His symptoms improved. However, he noticed arthralgia and uveitis again, and CRP elevated 8.33 mg/ml and D-dimer 2.3 μg/dl. Enhance chest CT revealed pulmonary thrombosis. He was treated with heparin and warfarin. However, pulmonary thrombosis was worsened, and D-dimer elevated to 3.2 μg/dl. He was treated adalimumab (ADA), pulmonary thrombosis was improved. [Clinical significance] ADA may effective refractory pulmonary thrombosis in a patient with Behçet disease.

P3-242
A case of multiple colon ulcer with differential diagnosis with intestinal Behçet’s disease or Crohn’s disease
Kenichirou Kubo1, Yoshikata Misaki1, Noriyuki Yamakawa1, Kohei Yoshio1
1Department of Rheumatology, Kyoto Katsura Hospital, Japan, 2Department of Pediatrics, Kyoto Katsura Hospital, Japan

Conflict of interest: None

A 38-year-old female presented with mild fever, arthralgia, abdominal pain and bilateral erythema on lower leg admitted to our hospital in May 20XX. The skin biopsy revealed the pathological findings consistent with erythema nodosum. Her symptoms had improved without therapy until two months, when exacerbated with high fever, arthralgia, abdominal pain, multiple aphthous oral ulcer and genital ulcer. HLA-B27 was negative. She was diagnosed with having Behçet’s disease and was treated with colchicine. Her arthralgia improved but abdominal pain persisted. Although poorly studied on ileocecal and ascending colon because of stenosis, colonoscopy showed entire circumference inflammation on sigmoid and transverse colon accompanied with multiple ulcers of punched-out appearance. Capsule endoscopic examination showed multiple simple ulcer in ileocecal and ascending colon. She was treated with high-dose prednisolone (PSL) 100mg/day and enteric salazosulfapyridine, resulted from clinical improvement. Colonoscopy later revealed residual multiple longitudinal ulcers in ascending colon, suggestive of Crohn’s disease. She had been tapered with PSL without recurrence. We report this case with consideration of multiple colon ulcer diagnosed as Intestinal Behçet’s disease or Crohn’s disease.

P3-243
A case of gastrointestinal Behçet with surgery on refractory ileocecal ulcer
Hiroaki Kusuoka, Keitaro Saito, Hironori Inoue, Aki Sakashita, Aiko Hirano, Yu Isoda, Risa Sagawa, Kazuki Fujikoa, Hitotake Nagahara, Makoto Wada, Masataka Kohno, Yutaka Kawahito
Inflammation and Immunology, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan

Conflict of interest: None

[Case] 25 years old female. [Chief complaint] Abdominal pain [Present illness] She was diagnosed as incomplete type Behçet’s disease (BD) from recurrent aphthous stomatitis, genital ulcer and arthritis when she was 20 years old. Arthritis was getting worse and abdominal pain appeared because of ulcerative lesions at ileocecum, so we diagnosed as
S378
gastrointestinal BD when she was 22 years old. She was treated with ADA, methotrexate, colchicine, mesalazine and PSL, and we gradually decreased the dose of PSL. But her right lower abdominal pain was exacerbated in April 2018, so ADA was changed to IFX. One month later, her symptoms and CRP value worsened, contrast CT revealed the thickening of the ileocecal wall, and colonoscopy showed that ulceration lesions at ileocecum did not change significantly. So laparoscopic ileocoeal resection were performed, and we found that the ulcer was so deep. Abdominal pain and inflammatory response improved after that surgery. [Discussion] Refractory, deep, and punched-out ulcers are typical in gastrointestinal BD and it is thought that intestinal perforation are often caused by these features. Because it is about to perforate in our case, surgical treatment is to considered positively for intestinal lesion which is resistant to medication.

**P3-244**

Two cases of multicentric Castleman disease with pulmonary involvement experienced in our department

Tomoyuki Nakamura, Hideki Yamanaka, Kaori Seki, Yusuke Hanioka, Ryouta Nakamura, Keiko Yamagami, Hitoshi Goto

General Medicine, Osaka City General Hospital

Conflict of interest: None

Multicentric Castleman disease (MCD) is an polyclonal lymphoproliferative disorder with inflammatory symptoms. Dysregulated overproduction of IL-6 by enlarged lymph node is implicated in the pathogenesis of MCD. We experienced two cases of MCD with lung lesion. Case 1: 37 y.o. female was admitted because of anemia and hypergammaglobulinemia. She had IgG (4760mg/dl), CRP (5mg/dl) and no respiratory symptom, but CT showed small ground glass nodule (GGN) and histopathologic findings of lung revealed plasma cell-infiltrated lesion by TBLB and those of inguinal lymph node revealed sheets of plasma cells, therefore she was diagnosed MCD and started prednisolone (PSL) 20mg/day. Case 2: 34 y.o. female was admitted because of fever. She had slight cough, IgG (3873mg/dl) and CRP (20mg/dl). CT showed GGN and histopathologic findings of axillary lymph node revealed sheets of plasma cells, therefore she was diagnosed MCD. She started PSL 30mg/day, because SPO2 decreased to 86% by 6 minutes walk test. About half of MCD cases of Japanese were reported to have progressive lung lesion. However the two cases improved with PSL. It is necessary to consider introduction of anti-IL-6 receptor antibody according to clinical course because cyst formation may cause irreversible respiratory failure.

**P3-245**

Longitudinal analysis of serum cytokine levels in a patient with acute onset neuro-Sweet disease

Hiroi Kusaka, Katsuya Nagatani, Takeo Sato, Seiji Minota

Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University Hospital, Shimotsuke, Tochigi, Japan

Conflict of interest: None

[Object] Sweet disease occasionally affects central nervous system (CNS): neuro-Sweet disease (NSD). Aim of this study is to elucidate the pathophysiology of NSD by analyzing longitudinally serum levels of 27 cytokines in a patient with acute onset NSD. [Methods] The serum levels of 27 cytokines from a 55-year-old male NSD patient at the onset of neurological symptoms and at the remission after 8 months of glucocorticoid treatment is to considered positively for intestinal lesion which is resistant to medication. We experienced two cases of MCD with lung lesion. Case 1: 37 y.o. female was admitted because of anemia and hypergammaglobulinemia. She had IgG (4760mg/dl), CRP (5mg/dl) and no respiratory symptom, but CT showed small ground glass nodule (GGN) and histopathologic findings of lung revealed plasma cell-infiltrated lesion by TBLB and those of inguinal lymph node revealed sheets of plasma cells, therefore she was diagnosed MCD and started prednisolone (PSL) 20mg/day. Case 2: 34 y.o. female was admitted because of fever. She had slight cough, IgG (3873mg/dl) and CRP (20mg/dl). CT showed GGN and histopathologic findings of axillary lymph node revealed sheets of plasma cells, therefore she was diagnosed MCD. She started PSL 30mg/day, because SPO2 decreased to 86% by 6 minutes walk test. About half of MCD cases of Japanese were reported to have progressive lung lesion. However the two cases improved with PSL. It is necessary to consider introduction of anti-IL-6 receptor antibody according to clinical course because cyst formation may cause irreversible respiratory failure.

**P3-246**

A case of Sweet Syndrome characterized by neutrophil infiltration into the muscle with difficulty in distinguishing from Statin-Associated Autoimmune Myopathy

Akihiko Nakabayashi1, Taro Akira2, Hiroshi Shimagami1, Michiko Ohashi1, Masashi Okamoto1, Takehiro Hirayama1, Akira Megata2, Yoshinobu Matsura3, Yoshinori Katada4

1Division of Rheumatology and Clinical Immunology, Sakai City Medical Center, Sakai, Japan, 2Nephrology, Diabetology and Rheumatology., Sakai City Medical Center, Sakai, Japan

Conflict of interest: None

[Case] A 77-year-old man was admitted to a hospital 48 months ago, complaining a high fever and polymyalgia with elevated CK 1317 U/L. He had papular rashs and blisters on flexor aspect of his right lower leg. Skin biopsy showed superficial perivascular dermatitis. As he had been taking pitavastatin for a month, statin-associated autoimmune myopathy was suspected. Pitavastatin was stopped and steroid pulse therapy, 80mg of prednisolone (PSL) and 8mg of methotrexate (MTX) were started. 40 months ago, he visited our department for myalgia in left thigh. Immuno suppressive therapy was intensified, resulting in some response. Both 22 months and 17 months ago, he complained myalgia in his left lower leg. As abscess was suspected by MRI, antibiotic was used. 16 months ago, he had myalgia in both lower legs. Muscle biopsy revealed marked infiltration of inflammatory cells dominated by neutrophils. Re-examination of previous specimens revealed similar finding compatible with sweet syndrome. After 1mg of colchicine was added, no relapse was noted, enabling tapering of PSL and MTX. [Discussion] Sweet syndrome is a rare disease presenting neutrophil infiltration usually into the dermis, neutrophil infiltration into the muscle can occur.

**P3-247**

Three cases of remitting seronegative symmetrical synovitis with pitting edema syndrome (RS3PE)-like symptoms associated with periodontitis

Hirosi Okuno1, Munee Ota2, Hiroaki Ogawa1, Ichiro Kato2, Hisayoshi Inoue1, Akira Hatakeyama1, Katsumi Sato1

1Department of Orthopaedic Surgery, Tohoku Rosai Hospital, 2Department of Rheumatology, Tohoku Rosai Hospital

Conflict of interest: None

[Case 1] A 74 y/o man presented to our hospital with local edema, warmth, and redness in his right hand. After admission, he was found to have polyarthitis and pitting edema in both hands, as well as severe periodontitis. Antibiotic administration, several teeth extraction, and oral care improved his symptoms promptly. [Case 2] A 60 y/o man presented to our hospital with pain, swelling, redness and warmth in his right ankle. He was prescribed a course of antibiotics for cellulitis. Subsequently, he developed pain and swelling in his left foot and pitting edema in his right foot. Though his symptoms seemed to improve with antibiotics, he developed bilateral ankle pain and foot edema and was found to have severe periodontitis. Treatment for periodontitis resulted in prompt symptom remission. [Case 3] A 55 y/o man presented to our hospital with edema and stiffness in his right hand, along with polyarthitis. His laboratory tests showed a high white blood cell count, elevated inflammatory markers, and the presence of anti-streptolysin-o antibodies; he also had severe periodontitis. Extraction of his teeth combined with antibiotic treatment improved his symptoms and inflammatory test results. These cases indicate an association between periodontitis and RS3PE syndrome.

**P3-248**

Serositis and anasarca due to TAFRO syndrome

Satoshi Akao, Hiroyuki Yano, Ko Sudo, Hitoshi Miyasato, Mitsuyo Kinjo

Department of Rheumatology, Okinawa Chubu Hospital

Conflict of interest: None

A 48 year-old woman presented with 3 weeks duration of fatigue and fever. Epigastric and right flank pain associated with watery diarrhea and abdominal distention developed, and she could barely eat and sought medical attention.
Conflict of interest: None

A 72-year-old-man was admitted to our hospital for the swelling in his left leg. Contrast-enhanced CT showed deep venous thrombosis and echocardiography detected intracardiac thrombosis. Blood test revealed eosinophilia (34%, 3,350/μl) and he was diagnosed with hypersino-
philic syndrome/Löffler’s endocarditis. In addition to anticoagulant treat-
ment, he received prednisolone 30 mg/day, which was later increased to 60 mg/day. However, his peripheral blood eosinophil counts did not de-
crease and the intracardiac thrombosis did not significantly improve, ei-
ther. Therefore, treatment with hydroxyurea was started, while prednis-
alone was tapered and discontinued. However, hydroxyurea did not im-
prove his eosinophil count, either. We found that he had had eosino-
philia since his youth and that his father, brother and nephew also had eo-
sinophilia. We diagnosed him with familial eosinophilia. Hydroxyurea
was discontinued due to thrombocytopenia but he has been stable for
months. Familial eosinophilia is a rare disease which has a benign clini-
cal course as opposed to hypersinophilic syndrome. However, when a
life-threatening event occurs like in our case, it can be difficult to decide
to not to treat. Treatment indication of familial eosinophilia will be dis-
cussed with some literature review.

Conflict of interest: None

Among the initiating site of pain in FM cases, there is a notch-recep-
tor. At this site, there are some relevant substances to exploit, ATP, hista-
mine, bradykinin can be picked up. At the vicinity of notochreceptor, mast
cell are exsited. At the mediation of N-adherin, mast cells will be de-
granuated into releasing histamine. The mean titer of histamine in healthy
person was said to be 0.43ng/ml. That mean titer of FM cases was
0.88ng/ml. Between those two showed gap at the point of those two
mean titer, t=5.3, α=0.01. The FM cases with alodenia (9cases) showed
0.98ng/ml at the mean titer. That titer didn’t show gap between
the mean titer of histamine in whole FM cases and the above 0.98ng/ml
of FM cases with alodenia, t=1.3, α=0.1. But the possibility of gap be-
tween the those two groups will be remained in the process at increasing
of examined number. The relative relationship (RR) between histamine
in serum and ARA points (2010), didn’t show significance. The RR
between SDS (self-rating depression scale) and histamine showed α=0.1.
and so the RR between FM cases with over 0.9ng/ml of histamine and ARA
(2010) showed γ=0.43, t=1.72, α=0.1. From the fact, there remains the
possibility of significantRR at FM case with high histamine titer.

Conflict of interest: None

A 77-year-old-woman presented with a floater 8 years ago. The
ophthalmologic examination revealed vitreous opacities compatible
with sarcoidosis (SA) uveitis. Symptoms were stable in topical steroid
and STTA. Six years ago, annular erythema appeared on her finger,
which was diagnosed with cutaneous SA, but disappeared spontaneously.
BHL enlargement was also observed at chest CT. BAL examination
and TBLB showed complementary with pulmonary SA. No active lesions
were observed in the lung field, then, she was followed up without any system-
ic medications. Three months ago, her uveitis relapsed with vitreous
opacities. The topical steroid and oral prednisolone had no effects. Chest
CT revealed nodules in both lung fields with the elevation of serum lyso-
zyme. Adalimumab (ADA) treatment was then started. After 2 weeks,
vitreous opacities were disappeared, and after 6 weeks, serious retinal
detachment was improved with normalization of lysozyme. We continued
maintenance with ADA. (Conclusions) Since 2016, ADA has been available for non-infectious uveitis including SA uveitis. However, the ADA use for refractory SA is still limited in Japan. While TNF-α is the target of SA treatment, TNF-α inhibitor itself can cause SA. We need to carefully select the objects using ADA for SA.

P3-254 A case of idiopathic multicentric castleman’s disease complicated with IgA nephropathy
Tomoya Nishida1, Shoichiro Inokuchi1, Tomofumi Tatsutani1, Koji Mishima1, Yojiro Arinobu1, Masahiro Ayano1, Hiroki Mitoma1, Yasutaka Kimoto1, Mitsuteru Akahoshi1, Koichi Akashi1, Takahiko Horiiuchi1, Hiroaki Niiri1
1Department of Clinical Immunology and Rheumatology/Infectious Disease, Kyushu University, Fukuoka, Japan, 2Department of Medical Education, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan, 3Department of Internal Medicine, Kyushu University Beppu Hospital, Beppu, Japan
Conflict of interest: None

[Case] The patient was 66-year-old male. Two months before he visited our hospital, he presented low-grade fever and weight loss, and blood test showed elevated CRP, creatinine, and γ-globulin. A positive urine occult blood and cellular casts in urine sediment were observed. Computed tomography of whole body showed inguinal lymph node swelling. He was introduced to be admitted to our hospital. Lymph node biopsy showed the feature of plasma cell type of castleman’s disease and kidney biopsy revealed IgA nephropathy (IgAN). As serum IL-6 was 118.6 pg/ml, we diagnosed the patients as idiopathic multicentric castleman’s disease (iMCD) complicated with IgAN. Immunophenotyping examination was performed, and increased memory Th2 cells and CCR6-positive Tfh cells were identified in peripheral blood. Effector CD8-positive cells were increased and activated and a large number of positive Tfh cells were identified in peripheral blood. electric laryngoscopy revealed redness and swelling of tracheal mucosa, observed as the anti-SRP antibody positive necrotizing myopathy is recognized symmetric proximal muscles weakness. In the neck, flexor muscle group are worse than extensor them. However in this case, the defective site was exchanged. There are few similar cases. We think it is important to treat of an inflammatory myopathy.

P3-255 Four cases of TAFRO syndrome
Ayaka Kato, Hideki Tani, Motochika Asano, Koichiro Taguchi, Yoshihiko Kitada, Takahide Ikeda, Hiroyuki Morita
General Medicine, Gifu University Hospital
Conflict of interest: None

[Object] TAFRO syndrome has been described firstly by Takai in Japanese patients. It includes thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly. [Methods] we present 4 cases of TAFRO syndrome. [Results] (CASE 1) A 70-year-old male patient referred to our hospital with thrombocytopenia and renal dysfunction. Methylprednisolone pulse therapy, IVIG, tocilizumab and cyclosporine resulted in improvement. (CASE 2) A man, who is 40 years old, referred to our hospital for fatigue and anasarca with thrombocytopenia and renal dysfunction. Prednisolone and cyclosporine resulted in improvement. (CASE 3) A 55-year-old man visited our hospital due to fatigue and anasarca. He underwent artificial dialysis for renal dysfunction. Methylprednisolone pulse therapy, followed oral prednisolone and azathioprine resulted in improvement. He could get off artificial dialysis. (CASE 4) A 39-year-old man had been diagnosed as having infectious endocarditis and treated with antibiotics. He visited our hospital due to right hypochondrium pain, fever and anasarca with thrombocytopenia and renal dysfunction. Methylprednisolone pulse therapy and followed prednisolone resulted in improvement. [Conclusions] We recomend cyclosporine if prednisolone is no effect.

P3-256 A patient with Necrotic myopathy who exhibited head down condition as the chief symptom
Kazuteru Noguchi, Chie Ogita, Tepppei Hashimoto, Maki Shibamoto, Rei Tadokoro, Mai Nakano, Kazuyuki Tsiboi, Mei Tani, Masao Tamura, Takahiro Yoshikawa, Mai Morimoto, Naoto Azuma, Masayasu Kitano, Kiyoshi Matsui
Hyogo College Of Medicine Nishinomiya Hyogo Japan
Conflict of interest: None

[Case] 63 year-old woman [Chief compliments] head down [Current medical history] She had been healthy. On august X. Her sister came to her for the first time in a year. She made her go to the hospital when she saw her symptom. She was suspected and hospitalized myositis because of her serum CK value was high. [Clinical course] She was done a manual muscle test, so Head extension, iliosposus muscle, Erector Spinae were poor. She had no eruption. MRI revealed Erector Spinae was atrophied. Electromyogram found biceps brachialis, iliosposus muscle, trapezius muscle were abnormal. Biceps brachialis biopsies showed necrotic fibers scattered, and there were no infiltration of inflammatory cells. The antibody against signal recognition particle was detected by immunoprecipitation. The others were negative. Then we diagnosed her a necrotic myopathy. We administered steroid, tacrolimus, IVIG, and improved her serum value, however head down condition had been remained. [discussion] The anti-SRP antibody positive necrotizing myopathy is recognized symmetric proximal muscles weakness. In the neck, flexor muscle group are worse than extensor them. However in this case, the defective site was exchanged. There are few similar cases. We think it is important to treat of an inflammatory myopathy.

A 49 year-old woman presented with dyspnea and hoarseness accompanied with 3 weeks of fever and upper airway symptoms admitted to our hospital. White blood cell count was 11200/µL and C reactive protein (CRP) was 6.6mg/dL. Fiber laryngoscopes revealed swollen subglottic larynx and CT scan showed bronchial wall thickening and stenosis of peripheral bronchi. Though she had no auricular pain, we performed auricular biopsy suspecting relapsing polychondritis (RP) and administered Hydrocortisone 500mg/day with antibiotic therapy targeting acute subglottic laryngitis. As her symptoms and CRP elevation were improved, we tapered steroid rapidly and switched to prednisolone (PSL) 50mg but recur after tapering to PSL10mg/day. Subglottic larynx was not swollen, but bronchoscopy revealed redness and swelling of tracheal mucosa, obstruction of criocoid cartilage and stenosis of peripheral bronchi. As the anti-type II collagen antibody was positive and other diseases were unlikely, we diagnosed her as RP. PSL50mg/day with methotrexate 6mg/week were initiated. Her symptoms improved and inflammatory responses normalized within a week. CT scan showed almost normal bronchi without bronchial wall thickening. We report this case as it is rare to diagnose RP presenting only airway symptoms.

P3-258 A case of relapsing polychondritis with central nerve system involvement
Shotaro Yamamoto, Katsuya Nagatani, Takeo Sato, Keisuke Saito, Yoichiro Akiyama, Masahiro Iwamoto, Seiji Minota
Division of Rheumatology and Clinical Immunology, Department of Medicine, Jichi Medical University
Conflict of interest: None

A 71-year-old man with ulcerative colitis had been diagnosed as re-
lapses polychondritis (RP) based on sensory neural hearing loss, scleritis, and bronchial cartilage inflammation and treated with glucocorticoid, methotrexate, and infliximab. One year later, he developed diplopia, dizziness, paresthesia in the areas of trigeminal nerve, and ocular motility disorder. Brain MRI showed contrast enhancement on the cervicomedulary junction, the cerebellar peduncle, and the pontine tegmentum. *Candida parapsilosis* was cultured from cerebrospinal fluid (CSF) without pleocytosis. Although he was treated with antifungal agents, the treatment response was incomplete. Follow-up CSF study showed pleocytosis, the elevated level of protein and IL-6, and no cultured pathogens. Brain MRI showed contrast enhancement on the surface of the brainstem in addition to the known findings. Therefore, we considered *C. parapsilosis* cultured from the first CSF as contamination, and he was suspected as having RP with central nerve system (CNS) involvement, and his neurological and MRI findings improved with high dose glucocorticoid and intravenous cyclophosphamide. The involvement of CSF in RP is rare. In this case, treatment failure to antifungal agents and repeated brain MRI led to the final diagnosis.

**P3-259**

A case of sarcoidosis presenting acute renal failure

Michiko Ohashi, Akihiko Nakabayashi, Taro Akira, Hiroshi Shimagami, Masashi Okamoto, Takehiro Hirayama, Akira Mega, Yoshinobu Matsuura, Yoshinori Katada

1Division of Rheumatology and Clinical Immunology, Sakai City Medical Center, 2Nephrology, Diabetology and Rheumatology, Sakaki City Medical Center

Conflict of interest: None

**Case**

A 24-year-old woman was referred to our hospital, because of arthralgia, high fever and exertional dyspnea. On admission, she had neither abnormal chest sound, swollen or tender joint, nor rash. Labo data include WBC 9900 /µL, CRP 12.99 mg/dL, Cr 1.24 mg/dL, and ANA <40times, Both RF and ACPA were negative. Chest CT showed diffuse particulate opacity. On the 6th hospital day, serum Cr elevated to 2.35 mg/dL. Urine protein /creatinine 0.32 g/gCr, urine RBC count <1/HP, granular cast 1+, urine β2MG 6599 μg/L, NAG 15.8 IU/L. Renal pathology showed granulomatous interstitial nephritis with multinucleated giant cells, and interstitial fibrosis was 0-5%. ACE 31.6 U/L, sIL-2R 7645 U/mL, lysozyme 40.4 μg/mL. With a diagnosis of sarcoidosis, 50mg (0.8mg/kg) of PSL was started. 1 month later, serum Cr was 0.94 mg/dL. (PSL 50mg) and 5 months later, 0.97 (PSL 10mg). [Discussion] Acute onset sarcoidosis is rare. As our case, patients with milder interstitial fibrosis are likely to recover renal function sufficiently. Data from other 4 case of renal sarcoidosis in our hospital support this finding.

**P3-260**

Toclizumab (TCZ) treatment in the young female patient of Castleman’s disease

Takashi Ogasawara, Manabu Tanabe, Makiko Kimura, Sayuri Yamashita, Atsuko Murota, Yuki Takahashi, Hidenaga Kawasumi, Mutsuto Tateishi

Department of Rheumatology, Tokyo Metropolitan Ohsuka Hospital

Conflict of interest: None

[Castleman disease (CD) is a rare disease of lymph nodes and related tissues, recognized as a lymphoproliferative disorder, and similar in many ways to lymphomas. It was first described by Dr. Benjamin Castleman in the 1950s. It is also known as Castleman’s disease, including angiofollicular lymph node hyperplasia (AFH). Even though CD is not logically a cancer, one form of multicentric Castleman disease acts very much like lymphoma. So CD is often treated with chemotherapy or radiation therapy. CD affects multiple organs and high value of IL-6 in serum. Our patients had once of CD at 27 years old with severe fatigue, polyarthralgia, and sub fever. Her Bood test indicates critical inflammation and anemia. There were almost none improvement of disease by NSAIDS and small amount of predonisolone (PSL). It speeded almost one year till the diagnosis of CD was diagnosed. The level of serum IL-6 was over 450 pg/mL, then we started her treatment with high dose of PSL and tocilizumab. After almost 4years, the disease activity got completely in subjective symptoms and blood tests the we checked her serum level of IL-6, however, it still exists in the high level. Now we have to investigate the management of her CD, because she got married and is having the wish of having childs.]

**P3-261**

A very severe and refractory case of TAFRO syndrome treated with Tacrolimus and Rituximab subsequent to Tocilizumab adding to glucocorticoids

Hidenori Takashashi, Naoto Umeda

Division of Rheumatology, Tsuchiura Kyodo General Hospital, Tsuchiura, Japan

Conflict of interest: None

A 53-year-old man developed fever, fatigue, anasarca, pleural effusion, ascites, thrombocytopenia, anemia, and renal failure. Diagnosis of TAFRO syndrome was made according to the 2015 diagnostic criteria. We administered methyl-prednisolone pulse therapy, high-dose glucocorticoids and cyclosporine A (CsA), however they were ineffective. Renal function worsened and hemodialysis has been administered. After administration of tocilizumab (TCZ) weekly, CRP has decreased. Due to a complication of sepsis, TCZ was discontinued. CsA was discontinued due to no effect. Then he had gradual improvement in renal function. Not only persistence of thrombocytopenia, but also fever and slight elevation of CRP appeared. We added tacrolimus (TAC) resulting in improvements of them. Approximately 5 months later, he developed the recurrence. Re-administration of TCZ was ineffective. He received rituximab (RTX) and increase in dosage of TAC and PSL, which resulted in remission again. The 2015 treatment strategy suggests CsA, TCZ or RTX in refractory cases. In this case adding TAC, TAC and RTX to glucocorticoids was effective. The reports of very severe case treated successfully including recurrence are very rare. We suggest the possibility of efficacy of TAC and/or RTX for refractory TAFRO syndrome.

**P3-262**

Successful treatment of multicentric reticulohistiocytosis with enbrelisys by Secukinumab: a case report

Kei Kobayashi, Daiki Nakagomi, Shunichiro Hanai, Yoshihiro Takayama, Kensuke Koyama, Hirotaka Haro, Kenichiro Kitamura

1Third Department of Internal Medicine, University of Yamanashi Hospital, 2Clinical Immunology and Rheumatology, University of Yamanashi Hospital, 3Department of Orthopaedic Surgery, University of Yamanashi Hospital

Conflict of interest: None

A 55-year-old woman was referred to our hospital complaining of papules without itching or pain on her forearms and polyarthritids for one year. Physical examination revealed pain and tenderness in shoulder, elbow, knee and distal interphalangeal joints, and also found dark red papules on her hands, forearms and elbows. Musculoskeletal ultrasound examination showed enthesis in insertion of the triceps brachialis and quadriceps muscle tendon. Skin biopsy of papules revealed diffuse and nodular multinucleated giant cells infiltrating in the dermis. Finally, we diagnosed multicentric reticulohistiocytosis (MRH). Her symptoms deteriorated although we treated her with methotrexate, tacrolimus and denosumab. Next, we treated the patient with subcutaneous injection of anti-IL-17A antibody (secukinumab) and all the clinical features were significantly improved. MRH is a rare disease characterized by multiple nodular lesions of the skin and destructive arthritis. To our knowledge, anti-IL-17 biological agent therapy has never been applied for MRH. Secukinumab could be useful for the treatment of MRH.

**P3-263**

Elderly Onset Chronic Recurrent Multifocal Osteomyelitis

Kanako Kojima, Toshiyuki Aramaki, Shota Kurushima, Yosihika Tsuji, Natsumi Kawachi, Kaoru Terada, Katsumi Eguchi, Yukitaka Ueki, Atsushi Kawakami

1Rheumatic Collagen Disease Center, Sasebo Chuo Hospital, Sasebo, Nagasaki, Japan, 2Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences
Conflict of interest: None

Introduction: Chronic recurrent multifocal osteomyelitis (CRMO) is an autoinflammatory bone disorder mostly affecting children and adolescents. We recently encountered a patient with elderly onset CRMO. Case Report: A 71-year-old man developed ankle pain and skin pigmentation changes bilaterally three years ago. Blood test showed positive rheumatoid factor and negative anti CCP antibody. Skin biopsy was normal. He was diagnosed with rheumatoid arthritis in his previous hospital. Treatments with methotrexate 6mg/week and salazosulfapyridine 1g/day were started. He had persistent symptoms and elevation of ESR and CRP. The patient was referred to our hospital for further examination. There was no evidence of palmpoplantar pustulosis and chest pain. Ankle CT showed multifocal lytic areas and surrounding sclerosis. Ankle MRI showed marrow edema. Technetium 99m bone scintigraphy showed increased uptake in both legs. Left leg bone biopsy showed osteomyelitis and no malignancy. The findings led to a diagnosis of CRMO. Discussion: CRMO is currently seen as a closely related disorder with SAPHO syndrome. He had no findings suggestive of SAPHO syndrome. There is no consensus about treatment. The patient will need careful follow-up.

P3-264
A case of TAFRO syndrome with a multifocal cerebral infarction
Daisuke Kanai
Department of Nephrology, Kobe City Hospital Organization Kobe City Medical Center West Hospital

Conflict of interest: None

Case: Sixty nine-years-old man who has been hospitalized because recognized edema, fever and proteinuria. After hospitalization, he had persistent fever, severe generalized edema, pleural effusions and ascites, thrombopenia, elevated serum level of ALP, kidney dysfunction. Histopathology of kidney revealed hyper cellular in tubule and swelling of endothelial cells. Bone marrow biopsy showed to fibrosis surrounding trabecular bone. The levels of IL-6 in serum / pleural Effusions are 11.4/1100pg/mL, serum level of VEGF was 190pg/mL. We diagnosed as TAFRO syndrome base on the criteria of 2015. We started medical treatment with steroid and cyclosporine. The fever, the level of CRP, kidney dysfunction ameliorated by treatment, but pleural effusions and ascites had sustained. On the 42th hospital day, he led to impaired consciousness. Brain diffusion-weighted MRI and T2WI/FLAIR showed scattered micro nodule shadows in the lung area on HRCT, BAL showed CD 4/8 ratio of 12.3, TBLB showed granulomas, serum ACE 56.4U/L, sIL-2R 2220U/mL, lypoyme 18.2μg/mL increased was observed. Sarcoidosis uveitis and skin sarcoidosis were point out at the same time, and it was diagnosed as multifocal cerebral infarction. We thought cerebral infarction was due to the TAFRO syndrome. Discussion: Although it has been not clear, it was possible that an intravascular volume depletion with increased vascular permeability and vascular endothelial damage are the etiology of a multifocal cerebral infarction.

P3-265
Adalimumab was effective for uveitis-associated heart sarcoidosis
Takeshi Shoda1, Yumiko Wada1, Junichi Komma1, Natsuko Fukuda2,1
1Clinical Immunology and Rheumatology, Yodogawa Christian Hospital, 2Ophthalmology, Yodogawa Christian Hospital

Conflict of interest: None

Case: A 57-year old female. In 20XX-3, Health examination pointed out BHL on chest X-ray, and scattered micro nodule shadows in the lung area on HRCT, BAL showed CD 4/8 ratio of 12.3, TBLB showed granulomas, serum ACE 56.4U/L, sIL-2R 2220U/mL, lypoyme 18.2μg/mL increased was observed. Sarcoidosis uveitis and skin sarcoidosis were pointed out at the same time, and it was diagnosed as sarcoidosis. Afterwards, it was followed up with local treatment, but uveitis was refractory. In 20XX, retinal uveitis also complicated and repeating injection into Tenon capsule did not improve, so ADA administration was examined, and it was admitted to our hospital in 20XX August. There was appeal of palpitations, delayed enhancement MRI was performed, enhancement was observed in the ventricular septal base and posterior wall, and FDG accumulation was also observed in PET-CT and diagnosed as Heart sarcoidosis. ADA 40mg2w started in September, improved uveitis, ACE 44→16U/L promptly decreased, BHL shrunk, skin symptoms improved. Combined with CsA 100mg from January 20XX+1, and in March the delayed enhancement MRI and PET-CT confirmed the loss of heart lesions. [Clinical Significance] ADA was effective in early stage Heart sarcoidosis.

P3-266
A case of sarcoidosis with large vessel vasculitis
Kimie Harama
Yamanashi Prefectural Central Hospital, Yamanashi, Japan

Conflict of interest: None

Case: The patient was 79-year-old man. He was admitted our hospital presenting anemia for 8 weeks and general malaise, neck chest pain, shortness of breath and wobble for 4 weeks. Although he had slight fever and showed elevated CRP level, the following week he got a high fever, difficult to walk and his CRP increased to 19 mg/dL. Blurred vision and uveitis appeared 5 days after admission, which suggested sarcoidosis. The FDG-PET/CT showed higher FDG uptake in mediastinal lymph nodes, infiltration on both lungs, and wall thickening from the left common carotid to thoracic aorta. While ACE level was within the normal range, soluble IL-2R and CD4/8 ratio in his bronchoalveolar lavage fluid were high. Finally, he was diagnosed as sarcoidosis with eyes, lungs and large vessels. When corticosteroid therapy was started, general symptoms including ocular and pulmonary status were improved. Next, we plan to evaluate blood vessel thickening. [Discussion] Sarcoidosis is idiopathic disease that forms non-casewing epitheloid cell granuloma and exhibits various clinical symptoms. Although it is said that large-scale vasculitis is rare, it may have been overlooked because of lacking FDG-PET studies.

P3-267
Polymyalgia rheumatica and RS3PE syndrome occurring after immune checkpoint inhibitor treatment
Yonsu Son1,2, Akhihiro Tanaka1,2, Saki Tsujimoto1,2, Kai Imai1,2, Minoru Shigesaka1,2, Keiko Shimamoto1,2, Yoshio Ozaki1,2, Shosaku Nomura2
1Department of Rheumatology and Clinical Immunology, Kansai Medical University Hospital, 2First Department of Internal Medicine, Kansai Medical University Hospital

Conflict of interest: None

Case 1] A 76-year-old, man [Clinical course] In January 2016, he was diagnosed as NSCLC. He started treatment with chemotherapy but had no effect, then Nivolmab started. He presented with muscle pain of the lower thighs after 6 courses, and the pain gradually getting worse throughout the course after 9 courses. Grasping pain on the upper arm and femoral region. Ultrasound examination found active bursitis affecting biceps tendon. He was diagnosed of polymyalgia rheumatica. Oral corticosteroid (PSL 20mg) were effective. [Case 2] A 79-year-old, man [Clinical course] In January 2017, he was diagnosed as NSCLC. Since PD-L1 was 50%, Pembrolizumab was started as the first line. He presented with inflammatory arthralgia, synovitis of proximal interphalangeal, wrist and ankle joint, and edema of both hand and forearms. He was diagnosed of RS3PE syndrome. Oral corticosteroid (PSL 10mg) were effective. While immune checkpoint inhibitors (ICIs) have been reported to be effective in cancer treatment, they are recognized as irAE due to concern that autoimmune diseases may be caused by their mechanism of action. We report patients with PMR and RS3PE syndrome, secondary to ICIs.

P3-268
Utilization of imaging procedures for giant cell arteritis according to distribution of affected vascular lesion
Kazutoshi Yukawa, Kei Araki, Hiroki Kohno, Katsuhiro Ohi, Tatsuomi Kuranobu, Tadahiro Tokunaga, Yusuke Yoshida, Tomohiro Sugimoto, Sho Mokuda, Keisuke Oda, Shintaro Hirata, Takaki Nojima, Eiji Sugiyama
Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital
Conflict of interest: None

P3-269
Characteristics of patients with polymyalgia rheumatica; an experience in a general hospital in Japan

Akiko Aoki, Hiroshi Kobayashi, Hiroshi Oka
Department of Rheumatology, Tokyo Medical University Hachioji Medical Center

Conflict of interest: None

[Object] Clinical symptoms of polymyalgia rheumatica (PMR) are improved by low-dose glucocorticoids (GCs), but most patients require long-term GC therapy. We report the clinical characteristics and therapeutic response of PMR patients. [Methods] This was a retrospective study in a single general hospital in Japan. We reviewed the medical records of 87 PMR patients between April 2011 and September 2018. Diagnosis of PMR was based on Bird’s criteria or 2012 provisional classification criteria. Relapse was defined as the reappearance of symptoms associated with elevated C-reactive protein (CRP) levels in patients receiving GCs. Remission was defined as the absence of clinical symptoms and normal CRP with discontinuation of GC. [Results] The Remission rate was achieved in 13% (8/61) after one-year GC therapy. At two-year follow-up, the remission rate was 57% (28/49). Patients were divided into 2 groups; those who achieved remission within 2 years (n=28) and those who required GC therapy for more than 2 years (n=21). No differences were observed in sex, age, and or clinical features at diagnosis. Body mass index was significantly lower and CRP at diagnosis was higher in the early remission group. [Conclusions] According to the guidelines the remission rate in our hospital is not low.

P3-270
A case of a 48-year-old man of multicentric Castleman’s disease (MCD) who developed SLE-like symptoms such as arthralgia, lymphopenia, hypocoomplementemia

Takehiro Hirayama1, Yoshinori Katada1, Taro Akira1, Michiko Ohashi1, Masashi Okamoto2, Hiroshi Shimagami2, Akira Mega2, Yoshinobu Matsura1, Akihiko Nakabayashi1
1Division of Rheumatology and Clinical Immunology, Sakai City Medical Center, Sakai, Japan, 2Nephrology, Diabetology and Rheumatology, Sakai City Medical Center, Sakai, Japan

Conflict of interest: None

We report a case of a 48-year-old man of multicentric Castleman’s disease (MCD) who developed SLE-like symptoms such as arthralgia, lymphopenia, hypocoomplementemia. Some patients with MCD might develop various symptoms and signs, including positive autoantibodies, thrombocytopenia, elevation of ESR, hypoalbuminemia, proteinuria plus hyperγammaglobulinemia. In this case, ANA ×40 (Speckled, Cytoplasmic), U1-RNP Ab, TPO Ab and dsDNA Ab are positive. Interestingly, hypocoomplementemia is also present, suggesting activation of classical pathway. Plasma cell type MCD can satisfy classification criteria of SLE. In the Japanese criteria currently need patients who meet the lupus criteria are excluded from diagnosis of MCD. However, like this case, some patients seem to have both disease simultaneously.

P3-271
A 14-year-old girl who developed polyarthritis 13 years after umbilical cord blood bone marrow transplantation for infantile leukemia

Yoshiyazu Ogata1, Tomoko Mera2, Yukari Mizoguchi2
1Department of Pediatrics, Saga University Faculty of Medicine, 2Department of Pediatrics, Saiseikai Yahata General Hospital

Conflict of interest: None

[Case] 14-year-old girl [HPI] She developed leukemia at 8 months, remitted with umbilical cord blood bone marrow transplantation, and was on a outpatient follow-up. At the age of 14, because of the pain and swelling of the joints of the fingers, wrist joints, ankle joints and knee joints, she was introduced to our outpatient. [Progress] Physical findings confirmed swelling and pain in her joint. In the blood test, white blood cell count was 2800/mm3, RF was negative, CRP was 1.13 mg/dl, and MMP-3 was 64.2 mg/dl. Synovitis were confirmed by MRI, NSAID and MTX was started, but improvement was poor, and MMP-3 increased to 103.8 mg/dl. Tac was added, and MMP-3 became negative. Because the joint symptoms had been calm for 5 years, MTX was discontinued, then recurrence of arthralgia was recognized, and the symptoms improved with resumption of MTX. [Summary] She had no apparent chronic graft-versus-host disease (GVHD) until the onset of arthritis. Despite of polyarthritis, the findings of the declined leukocyte count, the relatively mild MMP-3 elevation and the effectiveness of Tac, were considered that this polyarthritis may be a pathological condition as chronic GVHD. In addition, it was thought that the use of MTX is useful in the chronic GVHD mainly comprising arthritis.
Even after visiting his fever continued and joint pain moved to elbows and shoulders. In a month before admission, erythema in upper limb arose, when laboratory data indicated as CRP 8.93mg/dL, ASO 225U/ml, ASK x10240, ferritin 1773.8ng/mL. Although he received 1g/day of ampicillin, his condition did not improve. Moreover, his right wrist swelled painfully. After he admitted our hospital, we clarified no obvious infection or malignancy, negative value of RF and ANA. His MRI of right wrist joint revealed synovitis, with worsening its clinical symptom. After synovectomy his wrist improved with normalizing ferritin value and decreasing of CRP around 3mg/dL. At this time, a diagnosis of AOSD was evoked. Three month later MXT was started, then up to 8mg. His joint swelling disappeared with the normalization of CRP, ASO, ASK. [Discussion] In this case even diagnosis can be PSRA or RA, we diagnosed as AOSD with the elevated ferritin value and its reactivity to MTX. This is rare case of high ASO with AOSD. 

P3-274
Erdheim-Chester disease, a rare cause of secondary retroperitoneal fibrosis
Shogo Matsuda, Youhei Fujiki, Takaaki Ishida, Hidehiko Makino, Koji Nagai, Kenichiro Hata, Tohru Takeuchi, Shigeki Arakawa
Department of Internal Medicine IV, Osaka Medical College

Conflict of interest: None

Case: A 46-year-old woman presented to the rheumatology department with gradually worsening swollen lower limbs in September 2017. She had elevated serum creatinine levels (1.78 mg/dL). A contrast-enhanced CT scan revealed abnormal tracer uptake in the proximal tibias and lumbar vertebral bodies. Technetium-99m methylene diphosphate bone scintigraphy showed osteosclerotic changes in the thoraco-peritoneal fibrosis (RPF) was unknown, and we diagnosed her as idiopathic RPF. She was treated with glucocorticoid therapy, but she had a partial response. To elucidate the etiology, we further performed radiological examinations. MRI showed osteosclerotic changes in the thoracolumbar vertebral bodies. Technetium-99m methylene diphosphonate bone scintigraphy revealed diffuse fibrotic change in the tissue. IgG4 was negative in immunohistochemistry. Also, there were no cancer in biopsy. The etiology of retroperitoneal fibrosis (RPF) was unknown, and we diagnosed her as idiopathic RPF. She was treated with glucocorticoid therapy, but she had a partial response. To elucidate the etiology, we further performed radiological examinations. MRI showed osteosclerotic changes in the thoracolumbar vertebral bodies. Technetium-99m methylene diphosphonate bone scintigraphy revealed abnormal tracer uptake in the proximal tibias and distal femurs. These findings raised a possibility of Erdheim-Chester disease. It is thought that investigating such a case is also useful for elucidation of the pathology of SLE.

P3-276
Pathological features of lymph node in Adult-onset Still’s disease (AOSD)
Masahiro Iida, Yoshiaki Nagai, Naoki Tanomogi, Shuhei Sanoo, Yusuke Nakamichi, Tatsuo Mori, Nanase Honda, Michiru Kina, Ei suke Takamatsu, Kae Onishi, Takayasu Kise, Yuji Miyoshi, Masako Utsunomiya, Naoto Yokogawa, Kota Shimada, Shoji Sugii
Department of Rheumatic Diseases, Tokyo Metropolitan Tama Medical Center, Tokyo, Japan

Conflict of interest: None

[Objectives] To examine pathological features of lymph node (LN) in Adult-onset Still’s disease (AOSD) and their usefulness in diagnosis in Japan. [Methods] From April 2010 to July 2018, 115 patients visited our department and received LN biopsy. Of these, 12 patients, in whom AOSD was suspected by clinicians, were analyzed retrospectively. [Results] The median age of the 12 (2 males, 10 females) was 60.5 (18-81). Paracortical hyperplasia was shown in 7, follicular hyperplasia in 1, histiocytic necrotizing lymphadenitis (HNL) in 3, and diffuse large B cell lymphoma (DLBCL) in 1. Of 9 who fulfilled Yamaguchi’s criteria (except the item “excluding malignant lymphoma”), TAFRO syndrome was diagnosed in one. As for the other 8, diagnosis of AOSD was made and treated as AOSD. Although 1 of the 8 had pathological features of HNL, we treated her as AOSD because her clinical feature and laboratory data were not compatible with HNL. As for the 3 who did not meet the criteria, the diagnosis was HNL in 2 and DLBCL in 1. [Conclusions] In patient who fulfilled the criteria, many cases showed paracortical hyperplasia in LN as previously reported from outside Japan and no cases had malignant lymphoma. However, in diagnosing AOSD, LN biopsy is needed to exclude AOSD-mimicking malignant lymphoma.

P3-277
A case of pachydermoperiostosis in an elderly patient
Tomoe Kaieda, Hideo Otsubo, Satoru Nakashima, Sanae Shigemizu, Takemasa Matsuda
Department of Rheumatology, Japanese Red Cross Society Kagoshima Hospital

Conflict of interest: None

The patient was a 74-year-old man who was diagnosed with rheumatoid arthritis at around the age of 24. He had been treated with methotrexate and iguratimod since March 2012, but later developed refractory ulcers, anemia, and multiple erosions in the small intestine. Since these symptoms were suspected to have been drug-induced, the medications were discontinued and the patient was referred to our hospital in July 2017. The patient presented with periosteal formation, which was mainly noted around the long bones, as well as deep wrinkles and clubbed fingers. These observations suggested the diagnosis of pachydermoperiostosis, which was confirmed by skin biopsy and genetic testing for SLC20A1 mutations. Gastrointestinal symptoms were likely attributable to chronic enteropathy associated with the SLC20A1 gene (CEAS). Secondary hypertrophic osteoarthropathy causes clubbing of the fingers, periosteal formation of the long bones, and arthritis. Since the patient had a history of basal cell carcinoma, skin biopsy and genetic testing were required to confirm the diagnosis of pachydermoperiostosis. We report the rare case of pachydermoperiostosis in an elderly patient and discuss the literature.

P3-278
A rare case of glycogen storage disease type 5 (McArdle disease) associated with HLA B39 positive spondyloarthritis
Eri Amano, Taro Horino, Satoshi Inotani, Tatsuki Matsumoto, Yoshiko Shimamura, Kosuke Inoue, Yoshiro Terada
Department of Endocrinology, Metabolism and Nephrology, Kochi Medical School, Kochi University

Conflict of interest: None
A 76-year-old woman with myalgia and arthralgia was admitted to our hospital. Physical examination revealed myalgia in upper arm and thigh and polyarthralgia in the shoulder and hip joints. Laboratory examination revealed the elevated levels of CRP (0.64mg/dL), MMP3 (78.3ng/mL) and CPK (1294 U/L). Serological tests were all negative. FDG-PET-CT revealed FDG accumulation in the tendon attachments around shoulder and hip joints. Although myositis could not be confirmed by muscle biopsy specimen, initial treatment with PSL 20 mg/day and Tac 1 mg/day was started. Myalgia and arthralgia improved, but CPK level did not normalized. As a result of retest of muscle biopsy specimen, glycogen storage disease type 5 (McArdle disease) was diagnosed, and PSL was tapered. However, myalgia and arthralgia relapsed. Based on clinical course, findings of FDG-PET-CT and HLA B39 positive, spondyloarthritits (SpA) was diagnosed. Treatment with PSL 10 mg/day was restarted and her symptoms improved. We herein a rare case of McArdle disease with HLA B39 positive SpA. Originally, polymyositis was suspected, and it was diagnosed as McArdle disease, so after discontinuation of steroid, recurrence of tendon adhesion flame was confirmed. We report this rare case because similar cases had never reported so far.

P3-279
Clinical presentation, organ involvement and outcomes of 10 cases with relapsing polychondritis
Hiroki Kohno, Kei Araki, Kazutoshi Yukawa, Tadahiro Tokunaga, Tatsuomi Kuranobu, Katsuhito Ohi, Yusuke Yoshida, Tomohiro Sugimoto, Shok Mokuda, Keisuke Oda, Takaki Nojima, Shintaro Hirata, Eiji Sugiyama
Department of Clinical Immunology and Rheumatology, Hiroshima University Hospital, Hiroshima, Japan

Conflict of interest: None

(Object) Relapsing polychondritis (RP) is a rare disease characterized by systemic inflammation of cartilage. In this study, we report 10 cases with RP. [Methods] We retrospectively assessed clinical manifestations of 10 RP patients who attended our department from January 2009 to September 2018. [Results] Patient background was; age (mean ± SD) 53.9 ± 16.7 years; female 80%; mean time from initial symptom to diagnosis was 4.1 months. As for involved organs / symptoms, auricular chondritis was observed in 9 cases, arthritis in 6, skin lesions in 4, ocular involvement in 3 cases, tracheal involvement in 2, saddled nose, hearing impairment, cardiovascular involvement, and neurological symptoms in 1, respectively. At diagnosis, auricular biopsy was performed in 7 cases, while cartilage inflammation was identified in 5 cases. Ga-scintigraphy was performed in 6 cases. Initial therapy was PSL in 8 cases, and MTX or NSAIDs in one for each. Death and tracheotomy were not identified during observation period. [Conclusions] Female patients was dominant, and tracheal involvement was identified in 20% of the cases. In addition, skin lesions was relatively common.

P3-280
Clinical evaluation of patients with polymyalgia rheumatica in Ogawa Red Cross Hospital
Tatsuya Itō, Takashi Maruyama1, Yuji Akiyama1,2
1Division of Rheumatology, Department of Internal Medicine, Ogawa Red Cross Hospital, 2Department of Rheumatology and Applied Immunology, Saitama Medical University

Conflict of interest: None

(Object) We investigated and examined patients of polymyalgia rheumatica (PMR) during treatment at the Division of Rheumatology, Department of Internal Medicine. (Methods) Examples of PMR patients, it was confirmed that the bird’s standards were met at the start of the treatment. 25 Example (male 12 Cases, women 13 Example). Average Age of onset 74 year (61-89). After commencement of prednisolone (PSL) by medical records 52. We investigated the presence of clinical symptoms, test findings, and adverse events up to the week. Disease activity was determined by CRP. Rheumatoid arthritis (RA) was excluded by the presence of the manual arthritis of classification standards by ACR/eular. (Results) PSL at the beginning of treatmentUsing all cases. Average dosage 11.25mg (5 to 15). The term PSL treatment is good reactivity all Example, 5 cases of flare-up during weight loss and 2 cases of PSL resistance. MTX was used in 2 cases. (Conclusions) PMR Although reactivity was good in a small amount of steroids when it comes to treatment, the cases that cause a flare-up at the time of gradual decrease are difficult to treatment, many cases of steroid withdrawal difficulties have been demanded that treatment method.

P3-281
Long-term treatment course of elderly-onset adult-onset Still's disease
Akihito Maruyama, Mariko Sakai, Yoshinobu Nakao, Yuri Sadanaga, Nobuyuki Ono, Syuichi Koarada, Yoshifumi Tada
Department of Rheumatology, Faculty of Medicine, Saga University

Conflict of interest: None

(Object) Adult onset Still’s disease (AOSD) is a systemic inflammatory disease characterized by fever, rash, and joint pain. On the other hand, elderly-onset AOSD has been increasing in recent years and reported its atypical clinical features. In this study, we evaluated the long-term treatment outcome in elderly-onset AOSD. [Methods] For 49 patients diagnosed with AOSD in our department from February 1994 to June 2018, we investigated continuation / discontinuation of treatment by retrospective survey using electronic medical record. [Results] Twenty-nine of 49 patients (45.9%) had discontinued treatment during the observation period. Among them, fifteen cases (30.6%) of 49 patients with advanced age over 65 years of age and 5 cases (33.3%) of 15 patients with discontinued treatment were admitted. Comparative examination was made between clinical symptoms, examination values, treatment contents, recurrence rate, etc. Only the sex (P=0.0220) and the splenomegaly (P=0.0170) showed a significant difference between the treatment continuation group and the treatment discontinuation group with onset of over 65 years old. [Conclusions] In the elderly-onset AOSD, prediction of the withdrawal of treatment discontinuation before the start of treatment was difficult.

P3-282
Analysis of SAPHO syndrome
Eri Hayashi1, Kurisu Tada2, Shigeto Kobayashi3, Hisashi Inoue2, Ken Yamaji1, Naoto Tamura1
1Internal Medicine and Rheumatology, Juntendo University School of Medicine, 2Internal Medicine, Juntendo Koshigaya Hospital, 3Department of Orthopaedic Surgery, Juntendo University School of Medicine

Conflict of interest: None

(Object) The aim of this study is to evaluate the radiographic progression of patients with SAPHO syndrome by mSASSS (modified Stoke Ankylosing Spondylitis Spinai Score) and analyze the association between mSASSS progression and clinical characteristics. [Methods] There were 25 patients with SAPHO syndrome and we collect data of clinical symptoms, blood examinations, image findings, treatment. [Results] As skin symptoms, palmoplantar pustulosis was found in 14 cases, acne in 3 cases. As musculoskeletal symptoms, swelling and/or pain of the sternal clavicular joint was found in 21 cases, low back pain in 22, peripheral arthritis in 8. As image findings, sternocostoclavicular hyperostosis was found in 14 cases, sacroiliitis in 7 cases osteitis in 13 cases. The spinal ankylosis was observed in 17 cases, 11 of which were followed by X-rays and evaluated by mSASSS. The overall change in mSASSS was 1.9/2 years, and if the progression of mSASSS was more than 2/2 years, the progress cases were 5.1/2 years in 3 cases. Between progressive and non-progressive cases, no significant difference was observed. [Conclusions] We analyzed the association between mSASSS progression and clinical symptoms, inflammation and disease activity, but no significant difference was found between them.

P3-283
A case of hydroxychloroquine-induced generalized pustular psoriasis in systemic lupus erythematosus
Mayu Sugiyama, Masao Katayama, Nobuyoshi Minemura, Eiji Nagasawa, Kyoko Takano, Michita Suzuki, Kumiko Umemura, Syu nossa Yoko, Takakazu Hasegawa, Kahori Oshima

Conflict of interest: None
Department of Rheumatology, National Hospital Organization Nagoya Medical Center

Conflict of interest: None

[Case] A 51-year-old woman who was taking 7.5mg of predonisone (PSL) daily for years with past medical history of systemic lupus erythematosus (SLE) complained of fever and rash lasted for a week. She started to take hydroxychloroquine (HCQ) a month ago. Erythema and pustulae were located in her extremities, face, scalp and torso with fever and general fatigue. No mucosal lesions were identified. The skin feature included acute generalized exanthematous pustulosis (AGEP) or generalized pustular psoriasis (GPP) and we started PSL 1mg/kg/day. Though fever and rash resolved in a couple of days, the rash returned in steroid tapering process. The clinical course was atypical for AGEP and started sekukinumab for GPP induced by HCQ. Sekukinumab improved Psoriasis Area and Severity Index score rapidly and helped steroids tapered steadily. [Discussion] AGEP closely mimics GPP clinically and both would cause similar manifestations consisted of acute non-follicular pustular lesions, fever, leukocytosis and general inflammation. AGEP is mostly induced by drugs as type4 allergic reaction and usually resolved spontaneously after the drugs withdrawn. Although it is difficult to distinguish each other visually and pathologically, it is important for clinicians since their treatments are different.

P3-284
Influence of the bone metabolism on relapsing polychondritis
Kumiko Tonooka, Seido Ooka, Tomofumi Kiyokawa, Yukiko Takakuwa, Hiroshi Matsushita, Keiichi Sakurai, Yusuke Asari, Takayasu Ando, Harunobu lida, Marina Uchida, Kana Ishimori, Hisae Fujimoto, Kanako Suzuki, Yutaka Goto, Mitsuuru Imamura, Takeshi Suzuki, Yoshioki Yamasaki, Kintaro Kawai

Conflict of interest: None

[Object] RP (Relapsing Polychondritis) is a rare disease which causes inflammation to the cartilage tissue. Patients of RP are often complicated with osteoporosis. Although destruction of a cartilage decreases cytokine, such as IL-11 from a cartilage cell, and has a possibility of having control of a bone matrix and maturity of a bone blast cell, we investigated effect on bone cartilage metabolism of RP. [Methods] Eighteen RP patients from January,2010 to May,2018 were retrospectively evaluated with bone metabolism marker (1 type pro collagen Npeptide:P1NP, osteocalcin:OC, Tartrate-resistant acid phosphatase 5b:TRACP-5b, type 1 collagen cross-linked N-telopeptide:NTX) They satisfied classification of Damiani and Michet or MacAdams. As a control, we investigated 243 patients from January 2010 to May 2018. We investigated 243 cases rheumatoid arthritis (RA) and 169 cases systemic lupus erythematoses (SLE). All these cases were treating the osteoporosis. [Results] P1NP which reflected bone matrix formation ability among osteoplasty and NTX which is formed the resolution of the type 1 collagen among bone destruction compared in the RP cases significantly decreased against RA and SLE group. [Conclusions] The decrease in bone metabolism marker is observed in RP patients. The osteoporosis is important in RP patient.

P3-285
HBV related cryoglobulinemia: A case report
Ayako Kitada, Masato Okada
St Luke’s International Hospital, Tokyo, Japan

Conflict of interest: None

[Case] A 37-year-old women who is HBV carrier presented with one week history of fever, epigastric pain and cervical lymphadenopathy. She was admitted and treated with ceftriaxone and azithromycin for five days. She developed conjunctivitis, erythema on the palms and around ankles, auricular inflammation and polyarthritis. She was transferred to our hospital. On the admission day we suspected viral infection because of her fever, liver function abnormality, thrombocytopenia and arthralgia and atypical lymphocyte. She also had hypocoomplementemia and cryoglobulin was positive. We started etodolac. Her skin symptom and arthralgia were getting better. She also had pulmonary edema and ECG showed diffuse negative T wave. It showed atrial ventricular dissociation and accertated ventricular rhythm. We treated her with IVIG for myocarditis. She also has high P-AMY and suspected as having viral pancreatitis. Her liver function abnormality continued in outpatient clinic and her HBV-DNA titer was high which was 5.2 logIU/mL. We decided to treat her with entecavir. After that her liver function test turned to normal limit and arthralgia almost disappeared. [Conclusions] We report a 37-year-old women with HBV related cryoglobulinemia which was treated with entecavir.

P3-286
Treatment as seronegative rheumatoid arthritis, a case diagnosed as recurrent polychondritis later
Keisuke Kamiya, Junichiro Hagita, Kiyomi Koike, Katsushi Koyama Kariya Toyota General Hospital, Kariya, Japan

Conflict of interest: None

[Clinical significance] We reported to have difficulty diagnosing and treating recurrent polychondritis. [Case] 57-year-old man [Chief complaint] Respiratory distress [Current medical history] From X-1 July, He feels conscious pain of some joints. CRP was rising to 16 mg/dL, but RF and ACPA were negative. He was diagnosed seronegative RA, in August prednisolone (PSL) 15 mg/day, then methotrexate (MTX), tocilizumab (TCZ) were sequentially started. But he was introduced to our hospital without improvement. Steroid pulse was started, but the arthritis didn’t improve. In December, left knee resection was performed. He was introduced to the nearby doctor in February X. In July, diagnosed as uveitis. In August, breathing difficulty and wheezing appeared, urgent tracheotomy was performed. He managed with a mechanical ventilator. We diagnosed recurrent polychondritis (RP). Respiratory condition improved with steroid pulse, but tracheal lesions and arthritis findings remained. We treated with biologics and JAK inhibitors. [Consideration] Originally diagnosed as RA, poor therapeutic reactivity, later turned out to be RP. If the response is poor even if strong immunosuppressive treatment is performed in seronegative RA, it is necessary to suspect other diseases including RP.

P3-287
A patient with fever, pleural effusion, ascites, regarded as TAFRO syndrome
Kosuke Ota, Takato Nakadoi, Takahisa Takeyama
1Department of Nephrology, NHO Okayama Medical Center, 2Department of General Medicine, NHO Okayama Medical Center

Conflict of interest: None

[Case] Seventies male [chief complaint] fever, edema [Clinical course] For forty years he was treated of type 1 diabetes mellitus without nephropathy. In a month before admission, he manifested cough and fever of 38 degree. Although he received antibiotics (MEPM, CAM) diagnosed as pneumonia, his symptom was not improved. Complicated with refractory edema, pleural effusion and ascites to diuretics and with renal impairment, he admitted to our hospital. He showed temperature was 37 degree and general edema. Laboratory data indicated as; Hbg 7.9g/dL, Cre 2.7mg/dL, CRP 8.9mg/dL. CT scan revealed ascites, pleural effusion and lymph nodes swelling of mediastium. Bone marrow aspiration indicated hypoplasia without reticulum fiber hypertrophy. Endothelial injury of glomeruli and arterioles was shown in renal biopsy specimen. As serum IL-6 and VEGF values elevated, a diagnosis of TAFRO syndrome could be made. Treated with corticosteroid normalized fever, RBC and Plt, also improved edema and renal impairment. [Discussion] In this case we regarded as TAFRO syndrome from his clinical course and the exclusion of other diseases. Endothelial injury of arterioles in TAFRO syndrome is considered not to be common.

P3-288
Change of thermal disparity among fingers in connective disease patients
Yoshimasa Goto, Shigeko Inokuma, Satoshi Miike, Tadamichi Kasuya

Conflict of interest: None
Internal Medicine, Allergy and Rheumatology, Chiba Central Medical Center, Chiba, Japan

Conflict of interest: None

[Object] In connective tissue diseases (CTDs), blood flow disorder is frequently observed. When seeing it in the periphery of the fingers, not only low temperatures but temperature differences among fingers evaluated by thermographic inspection before and after cold stimulus. [Methods] CTD patients with suspected peripheral circulation disturbance were included. From baseline to 30' after hands immersion in 10°C water for 10'', nailfold temperatures were measured by Thermo. Coefficient of variation (CV: SD/mean) was adopted as the indicator of the disparity. [Results] 47 CTD patients were included. The changing pattern of nailfold temperature was classified into normal, rebound, delayed recovery, persistently low/decline patterns. CV promptly recovered in normal pattern, did relatively soon in rebound pattern, did slowly and finally in delayed recovery, and sustained high in persistently low/decline pattern. [Conclusions] In CTD patients with peripheral circulation disturbance, the nailfold temperature disparity among fingers evaluated adopting CV tended to be high and sustained high after cold stimulus. The remaining disparity seemed to relate to severity of vascular involvement. The temperature disparity would be a characteristic feature of peripheral circulation disturbance in CTD.

P3-289
Clinical analysis of mutations in 22 genes related to autinflammatory syndromes in patients with fever of unknown origin
Kyoko Fujimoto1, Yukiko Hidaka1, Yumi Yoshida1, Makiko Hayashi2, Takuma Koga3, Shinjiro Kaieda3, Satosho Yamasaki3, Tomoaki Hoshino3, Hiroaki Koda3
1Division of Respiratory, Neurology and Rheumatology, Department of Medicine, Kurume University School of Medicine, 2Center for Rheumatic Diseases, Kurume University Medical Center

Conflict of interest: None

[Background] Autoinflammatory syndromes, cause systemic inflammation mainly by innate immunity abnormality and should be distinguishable with fever of unknown origin. Examining gene mutations is valuable for the diagnosis of autoinflammatory syndromes; however, the frequency of gene mutations in patients with fever of unknown origin is not reported in Japan. We comprehensively analyzed genetic mutations related to autoinflammatory syndromes. [Methods] We analyzed mutations of 22 genes related to autoinflammatory syndromes as follows; TNFRSF1A, MEFV, NLRP3, MKV, NOD2, IL1RN, NLRP12, PSTPIP1, PSMB8, PSMB9, PSMA3, PSMB4, POMP, NLR4, PLCG2, HMOX1, CECR1, COPA, TNAIP5, FAM105B, RNF31, RBCK1. In 75 patients with fever of unknown origin from May 2017 to June 2018. Genetic analysis was performed by the next generation sequencer. [Results] 15 genes were identified as having novel or rare variants. The most frequent variants was determined in NLRP12 (8 cases, 6 sites), followed by NLRP3 (7 cases, 4 sites). In addition, mis sense mutations including genetic polymorphisms were observed in MEFV (69.3%). [Conclusions] Novel or rare variants in NLRP12 and NLRP3 were noted in patients with autoinflammatory diseases of fever of unknown origin in our hospital.

P3-290
Ultrasound and biopsy findings of arthritis accompanied by Familial Mediterranean Fever
Yutaro Yamada1,2, Kentaro Inui1, Tadashi Okano1, Koji Mandai1,2, Kenji Mamoto1, Yuko Sugio1, Tatuya Koike2, Daisuke Tsuruta2, Hiroaki Nakamura1
1Department of Orthopedics, Osaka City University Graduate School of Medicine, 2Department of Orthopedics, Yodogawa Christian Hospital, 3Department of Orthopedics, Osaka Social Care Center, 4Center for Se- nile Degenerative Disorders (CSDD), Osaka City University Graduate School of Medicine, 5Department of Dermatology, Osaka City University Graduate School of Medicine

Conflict of interest: None

[Introduction] Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory disease characterized by recurrent fever and serositis. Among patients with FMF in Japan (estimated 300), 31% show arthritis. We report one case with arthritis in which we assessed presence of amyloidosis, known as poor prognostic factor, by ultrasound (US) and biopsy. [Case report] 70-year-old arthritis was consulted because of recurrent fever and di- use rash with tenderness mostly located at lower leg. He was diagnosed as FMF since MEFV gene examination revealed abnormality (not the typical one). The laboratory data for CRP was 3.34mg/dl, ESR 50mm/1h, MMP3 190.7ng/ml, Amyloid-A 251.2ug/ml. Colchicine ther- apy had been started but intolerable. Glucocorticoids and cyclosporine were added, but in vain. All symptoms had disappeared after IL-1 inhibi- tor canakinumab initiation. US showed positive Grey-Scale and negative Power-Doppler at 3 months later. We did biopsy of intraarticular tissue because it was unclear whether it reflects previous arthritis or amyloid deposition. However it showed only collagen proliferation. As arthritis accompanied by FMF typically heals without sequelae, intraarticular tissue with previous inflammation by US did not present amyloid deposi- tion.

P3-291
A case of familial Mediterranean fever complicated with renal amy-loidosis successfully treated with canakinumab accompanied by the changes in proportion of peripheral CD4+ T cell subsets
Yusuke Miyaizaki1, Shingo Nakayamada, Yoshihisa Tanaka1, Tadashi Nakamura1
1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2Sakurajyuji Hos- pital

Conflict of interest: None

Familial Mediterranean fever (FMF) caused by a Mediterranean fe- vergene (MEVF) gene mutation is characterized by IL-1β activation. However, immune cell subsets involved in the pathogenesis of FMF remain unclear. Here, we document a case of 57-year-old male with FMF complicated by renal amyloidosis, who is analyzed the phenotype of immune cell subsets by 8-color flow cytometry (FCM) before and after treatment with canakinumab. The patient had periodic fever, abdominal pain, diarrhea and proteinuria. After 6 months of treatment with canakinumab, those symptoms almost disappeared and the levels of CRP and serum amyloid A was markedly decreased. Phenotype of immune cells in the patient was compared with 12 healthy controls (HC). The proportion of Th1 cells was lower in the patient than in HCs, whereas that of Th17 and activated Th17 cells were higher. The proportion of Treg and Th2 cells was not different between the patient and HCs. At six months after treatment, the proportion of Th1 cells was increased and that of Th17 and activated Th17 cells were decreased. The data suggested that canakinumab could alter the proportion of CD4+ T cell subset and improved disease activity, indicating that activation of Th17 cells induced by IL-1β may be involved in the pathogenesis of FMF.

P3-292
Clinical features of patients that has MEFV gene mutation in our hospital
Miharu Izumikawa1,2, Tomohiro Kameda2, Shusaku Nakashima1, Hiromi Shimada1, Risa Wakiya1, Mikiya Kato1, Taichi Miyag1, Noriyuki Kurata1, Hiroaki Dobashi1
1Department of Internal Medicine, Hematology, Rheumatology and Re- spiratory Medicine, Faculty of Medicine, Kagawa University, 2Tamamori Clinic

Conflict of interest: None

[Object] Familial Mediterranean Fever (FMF) is an autosomal recessive condition due to mutations in MEFV. FMF is characterized by relapsing and remitting 1-3 day episodes of fever, peritonitis, pleuritic, and arthritis. Genotype phenotype correlations studied in Japan suggest that mutations within MEFV exon 10 are associated with a typical FMF phenotype, whereas mutations within exons 2 or 3 are associated with an incomplete FMF phenotype. We investigate genotype-phenotype correlations of patients with MEFV gene mutations. [Methods] We collected the
data of 9 patients with MEFV gene mutations: genotype, the clinical characteristics, and the genetic tests performed. [Results] A genetic investigation of Mediterranean fever (MEFV) detected heterozygosity for the compound mutations E148Q, L110P, E148Q/R306S, E148Q/G304R, E148Q/R406Q, and E148Q/M694I. The average of onset age is 18.3±14.9 years old, the average of duration of attack is 3.9±2.7 day, the average CRP is 9.0±6.5mg/dl and the average SAA is 565±470μg/ml. 3 patients with an MEFV exon 3 mutation presented with incomplete phenotype. [Conclusions] All patients have mutations within exons 2. MEFV exon 3 mutation may relate incomplete phenotype.

P3-293
A Case of Familial Mediterranean fever with Difficulties in Diagnosis
Kaita Sugiyama, Marina Hamaguchi, Yutaka Tanikawa, Shohei Yoshizawa, Masashi Oshima, Hiroshi Tsuzuki, Yusuke Nagasawa, Atsuma Nishiwaki, Natsumi Ikumi, Takamasa Nozaki, Hitomi Haraoka, Yoshihiro Matsukawa, Masami Takei
Nihon University Itabashi Hospital

Conflict of interest: None

[Case] A 27-year-old female. February 2018 during pregnancy, fever, sore throat and cervical lymphadenopathy were observed. She was admitted to our hospital for further examination due to skin rash, thrombocytopenia, hepatic dysfunction and high serum ferritin. After cesarean section at 34 weeks 3 days, there was a complication of respiratory and heart failure. Steroid pulse therapy was performed with symptomatic clinical findings suspected to be diagnosed as hemophagocytic syndrome (HPS). Lymph node and random skin biopsy were performed, but we didn’t have a diagnosis and the therapeutic effect was also poor as HPS. MEFV genetic tests submitted during hospitalization suggested mutations were found in S503C of exon 5, which may be atypical of Familial Mediterranean fever (FMF). We started colchicine and showed improvement. [Discussion] This example didn’t satisfy the diagnostic criteria of typical cases of FMF, and confirmed by therapeutic diagnosis with gene mutation and colchicine. Atypical FMF in which mutation was observed in S503C of exon 5 is one case in the past and only a few reports in the world. Complications related to life prognosis such as amyloidosis may occur, so early diagnosis and treatment may be desired.

P3-294
A case of familial Mediterranean fever (FMF) complicated with IgA deficiency (IgAD) and spondyloarthritis (SpA)
Tamao Nakashita1, Akira Yoshida1, Akira Jibatake1, Takako Miyamae2, Shinji Motojima1
1Rheumatology and Allergy, Kamada Medical Center, Kamogawa, Japan, 2Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan

Conflict of interest: None

Immunodeficiency frequently accompany with autoimmune or auto-inflammatory diseases. We report a case of FMF complicated with IgAD and SpA. Case is a 39-years-old female. She noticed periodic fever of unknown origin from childhood. Fever subsided spontaneously without treatment but complicated by polyarthralgia and chest pain. Afterwards, joint pain and lumber pain developed and persisted without fever. She was referred to our department from orthopedics During the course, polyarthritis, dactilitis, and enthesitis were noticed and sacroiliitis was recognized on XR and CT images resulting in the diagnosis of SpA according to the CASPAR criteria. HLA-B27 was negative but B61 was positive that is one of disease susceptible gene for SpA in Japan. FMF was diagnosed according to the Tel-Hashomer criteria and the autoinflammatory disease guideline in Japan that include search for the MEFV related gene mutations. Specifically, 3 mutations were found. IgA levels were less than 1.0 mg/dl. Drugs that induce IgAD were not used and the genetics of IgAD have not been known at present. SpA is thought to be related to IgAD. Colchicine and SASP were administrated and symptoms are getting better.

P3-295
Case report: Familial Mediterranean fever (FMF) complicated by diagnosis due to cytomegalovirus infection
Takuya Nemoto, Takashi Watanabe, Yusuke Ishibe, Nagachika Sugisaki, Makio Kusaoi, Michihiro Ogasawara, Ken Yamaji, Naoto Tamura
Department of Rheumatology and Internal Medicine, Juntendo University School of Medicine, Tokyo, Japan

Conflict of interest: None

A 45-year-old woman presented on November X-1 with fever and cervical lymph node swelling. She was admitted to another hospital because of Leukocytopenia and thrombocytopenia. The serum ferritin value increased, fever and skin rash, adult still’s disease was suspected. She was treated with Prednisolone 60 mg/day, fever and cytopenia relapsed when PSL was reduced to 30 mg /day. PSL increased to 60 mg /day, but it was no response. She was transferred to our hospital for plasma exchange in February X because cytomegalovirus (CMV) was positive. We diagnosed hemophagocytic syndrome (HPS) and started ganciclovir (GCV) and plasma exchange. She was improved, and discharged in May X after PSL was stopped. But she was admitted again due to high fever in July X. Familial Mediterranean fever (FMF) was suspected, she was treated with colchicine 1 mg / day. pyrexia was quickly resolved. Although MEFV gene analysis was performed and mutations were not observed in exon 10 and 3, we diagnosed FMF. [Clinical Significance] Because of CMV infection, it was valuable case that it was reactive to both antiviral drugs and steroid treatments, and was confused by confirmed diagnosis.

P3-296
Two cases with TNF-receptor associated periodic syndrome treated by canakinumab with extended dose intervals
Junko Yasumura
Department of Pediatrics, Hiroshima University Graduate School of Biomedical & Health Sciences, Hiroshima, Japan

Conflict of interest: None

[Introduction] Although treatment of patient with TNF-receptor associated periodic syndrome (TRAPS) by canakinumab (CAN) is recommended at 4-week dose intervals, it may be able to extend according to the difference of disease severity and it’s blood concentration. We will present two cases with TRAPS treated by CAN with extended dose intervals.

[Case1] 36 years old man. He had been diagnosed with systemic-juvenile idiopathic arthritis, but his daughter was diagnosed with TRAPS (mutation of C43R in TNFRSF1A) when he was 32 years old. Same mutation was also identified in him. He was treated with etanercept, but it was not effective enough, so it was switched to CAN. It was very effective. After he had been started CAN every 4 weeks, the dose intervals were gradually extended until 9 weeks without attacks. [Case2] 4 years old girl. She had been started CAN every 4 weeks, the dose intervals were gradually extended until 6 weeks without attacks. [Conclusions] Dose intervals of CAN for TRAPS may be able to extend.

P3-297
A case of Cryopyrin-Associated Periodic Fever Syndrome that diagnosed at the age of 35
Yuichiro Taguchi1, Ryuehi Ishihara2, Tatsuos Inoue2, Kenji Yamazaki2, Toshiaki Miyamoto2
1Japanese Red Cross Nagoya Daini Hospital, 2Seirei Hamamatsu General Hospital

Conflict of interest: None

A 35-year-old man who suffered from joint pain and skin rash. So even if it is scrutinized at many general hospitals, it does not reach diagnosis and has symptoms for about 30 years. He visited our hospital on February 23, X year. From detailed medical history listening, from No-
vember every year to the beginning of March every year, urticaria without fever, multijoint pain, pruritus. Skin eruption was admitted. In addition, he accepted mild hearing loss since childhood, and similar symptoms were recognized by mother as family history. We suspected cryopyrine-related cyclic fever syndrome from progress, symptoms, family history, etc. I searched for genes and found an NLRP3 gene mutation, which led to the diagnosis of cryopyrine related periodic fever syndrome. Next year, similar symptom appeared from the beginning of November, and it interferes with everyday life, so symptoms were markedly improved after administration of Canakinumab. After that, we used Canakinumab only in winter. Most of the symptoms of Cryopyrine related periodic fever syndrome develop in early childhood, but I experienced a case diagnosed after adult as in this case. Today, genetic tests have developed, since it has become possible to reach diagnosis from symptoms, medical history, etc., we report here.

**P3-298**

Four cases of adult-onset Still’s disease (AOSD), in which severe flare accompanying liver dysfunction and/or disseminated intravascular coagulation (DIC) occurred, and diagnosis of macrophage activation syndrome (MAS) was made, during treatment with tocilizumab (TCZ)

Toru Yamabe, Taio Naniwa, Shin-ichiro Omura, Shinya Tamechika, Shinni Maeda, Koji Uchera

Nagoya City University Hospital

Conflict of interest: None

**Cases**

Case 1: a 21 year-old female patient was started on TCZ. On day 5 she experienced disease flare with liver dysfunction and disseminated intravascular coagulation (DIC). TCZ was switched to etanercept (ETN), and her condition resolved. Case 2: a 42 year-old female patient was started on TCZ. On day 7, she experienced flare with liver dysfunction and DIC. TCZ was switched to certolizumab pegol (CZP), and her condition resolved. Case 3: A 79 year-old female patient was started on TCZ and achieved remission. In week 20 she experienced flare with DIC. With steroid pulse, her condition resolved. TCZ was withdrawn. Case 4: A 56 year-old female patient was started on TCZ and achieved remission. In week 64 she experienced flare with DIC. With steroid pulse, her condition resolved. TCZ was withdrawn. [Conclusion] We have instituted TCZ for 19 AOSD cases, and experienced four cases of severe flare. Two fulfilled the diagnostic criteria for hemophagocytic lymphohistiocytosis (HLH) 2004 criteria. In maintenance-phase cases, there were no clear clinical signs of flare, and blood test abnormalities led to timely diagnosis. In induction-phase cases, switch of biologics was effective. MAS can develop during TCZ treatment for AOSD, and patient’s condition should be closely monitored.

**P3-299**

PYCARD/ASC variant lacking exon2 expressed in Japanese patients with palindromic rheumatism increases IL-1beta secretion

Yumi Suganuma1, Atsuko Yabuuchi1, Fumi Otani2, Koji Inoue2, Shunichi Shiozawa2, Koichiro Komai2

1Department of Biophysics, Graduate School of Health Sciences, Kobe University, Kobe, Japan, 2Shichikawa Arthritis Center, Osaka Rehabilitation Hospital, Hannan, Japan, 3Institute for Rheumatic Diseases, Co., Ltd, Ashiya, Japan

Conflict of interest: None

[Object] Palindromic rheumatism (PR) is a rare periodicity arthritis characterized by relapsing short episodes. Although the pathogenesis of PR is not elucidated, the pathology is similar to that of autoinflammatory diseases in which majority was biologics user. Pregnancy under using biologics might be desirable.

**P3-300**

Risk factors associated with complications during pregnancy and delivery in patients with RA

Yoshino Inoue, Kazuhisa Nakano, Shingo Nakayama, Shigeru Iwata, Kentaro Hanami, Shunsuke Fukuyo, Satoshi Kubo, Ippei Miyagawa, Yusuke Miyazaki, Akio Kawabe, Yoshiya Tanaka

The First Department of Internal Medicine, University of Occupational & Environmental Health, Japan

Conflict of interest: None

[Object] To examine the relationship with perinatal background and pregnancy outcomes in RA female patients who were pregnant during treatment of RA in our hospital. [Methods] We retrospectively analysed pregnancy outcome data from subjects who were pregnant during treatment of RA in our department. The primary endpoint was the rate of full-term birth, and secondary outcomes were patient background, disease activity of RA (CDAI), maternal and neonatal complication. [Results] There were total 23 pregnancies in 16 subjects, 32.0 years of age. The rate of full-term birth was 74%. There were 1 induced abortion and 2 miscarriages in the first trimester, 2 preterm births and 1 stillbirth in the third trimester. Non full-term birth occurred in young women who had unexpected pregnancies and older women who had first pregnancies. Neonatal complications occurred in 5 cases, frequently occurred in mothers who exposed glucocorticoid (GC), in contract hardly occurred in mothers who had drug free. RA relapsed after childbirth in 9 pregnancies, frequently relapsed in patients who exposed GC and were pregnant over 35. [Conclusions] For full-term birth and prevention of neonatal complications, it is important to aim for drug free after achievement and maintain remission of RA without GC.

**P3-301**

Study on pregnancy and joint destruction in patients with rheumatoid arthritis

Eri Narita1, Kentaro Inui1, Yuku Sugioaka4, Kenji Mamoto1, Tadashi Okano2, Masahiro Tada1, Shuhei Ueno25, Tatsuya Koike1,2,4

1Shirahama Hamayu Hospital, 2Search Institute for Bone and Arthritis Disorders (SINBAD), 3Department of Orthopedic Surgery, Osaka City University Medical School of Medicine, 4Center for Senile Degenerative Disorders (CSDD), Osaka City University Medical School of Medicine, 5Osaka City General Hospital

Conflict of interest: None

[Object] We investigated the progress of joint destruction of RA patients who experienced pregnancy activities. [Methods] We examined the age, disease duration and medication of 16 patients. And joint destructive change was evaluated using Sharp/van der Heijde (SvdH) score. [Results] The average of age was 32.4 ± 3.6 years, the disease duration was 8.1 ± 4.8 years, and 9 patients got babies. There was no significant difference in age and duration of illness between a bearing baby group and a non-bearing baby group. In a bearing baby group, 6 used prednisolone only, 2 were drug free, 1 was contingent pregnancies using methotrexate and tocilizumab. In a non-bearing baby group, 5 used both of prednisolone and etanercept, and each one had prednisolone alone and drug free. Total SvdH score significantly deteriorated during the mean follow-up period of 38.5 months, but there was no significant difference between two groups. [Conclusions] Although there was no statistically significant difference, joint destruction did not progress in a non-bearing baby group in which majority was biologics user. Pregnancy activity under using biologics might be desirable.
P3-302
Treatment elapse of 31 examples of pregnancy, birth child’s gross result and problem during joint rheumatism treatment
Tomohiko Yoshida1,2, Naoki Katsuyama1,2, Yoichi Akiyama1,2
1Department of Rheumatology, Setagaya Rheumatology Clinic, 2Department of Rheumatology, Toshin Yoshida Internal Medicine Rheumatology
Conflict of interest: None

[Object] We analyzed the condition of pregnancy, pregnancy, post-partum babies and babies who gave birth in 31 patients who gave birth to pregnancy during rheumatoid arthritis (RA) treatment at our hospital. [Methods] From April 2013 to August 2018, we analyzed the disease activity and treatment method of pregnancy, pregnancy, and childbirth for cases of RA patients who attended our hospital. [Results] The number of cases was 31, the age at pregnancy was 34.8 years, and the mean disease duration was 8.52 years. Before pregnancy treatment, 24 biological products alone, 3 biologics + PSL, 2 SASP + PSL, 1 PSL mono, 1 no med. All cases were low disease activity at birth at pre-pregnancy DAS 28 (median) 1.74, delivery at delivery DAS 28 (median) 2.45. Treatment after childbirth was untreated 10 cases, PSL alone 3 cases, PSL + SASP 2 cases, PSL + biological preparation 12 cases, unknown 4 cases. [Conclusions] Advancement of biological products increases fertility, and safety to pregnant women and fetuses is also increasing. In this study, we reported that we can give birth safely by controlling the disease activity before and after pregnancy to below the low disease.

P3-303
A mutual influence of pregnancy birth on disease flares in patients with systemic lupus erythematosus
Motoko Ishida, Tomoya Miyamura, Makiko Higuchi, Kenji Tamagawa, Tomoaki Iwanaga, Soichiro Takahama, Rumi Minami, Masahiro Yamamoto, Eiichi Suematsu
Department of Internal Medicine and Rheumatology, National Hospital Organization, Kyushu Medical Center
Conflict of interest: None

[Object] Systemic lupus erythematosus (SLE) usually develops in young women at reproductive ages. Previous researches revealed that about 20%-60% of women with SLE experienced a flare during pregnancy. In contrast, others reported that there were no differences. The purpose of this study is to investigate the mutual influence of pregnancy birth on disease flares in patients with SLE, retrospectively. [Method] Twenty-nine patients (44 pregnancies) who have been treated since April 2009 till January 2018 in our center were enrolled. [Results] The average age at pregnancy was 35.4 years old. Forty-one patients were treated with prednisolone (PSL); average 5.6mg/day, 10 patients with immunosuppressive drugs. The average SLEDAI was 6, BILAG was 1. Twenty-four babies were birth in full term, 6 were in premature, 5 were miscarriage and 4 were born dead. The group of patients who had babies in full term birth were treated with lesser doses of PSL (5.0mg/day) than the group in non-full term birth (PSL7.8mg/day). Four patients had moderate flare and recovered by increased PSL. [Conclusion] The disease activity of SLE should be controlled lower and the lower doses of PSL as much as possible is desirable during pregnancy.

P3-304
Study of pregnancy in patients with Sjogren’s Syndrome (SjS)
Kumiko Shimoyama, Shogo Furukawa, Daisuke Suzuki, Noriyoshi Ogawa
Division of Immunology and Rheumatology, Department of Internal Medicine 3, Hamamatsu University School of Medicine
Conflict of interest: None

[Object] We reported the management of pregnancy in rheumatic disease in JCR 2017, 2018. Here, we report the study of pregnancy in Sjögren’s syndrome (SjS). [Methods] Pregnancy was planned in 25 cases (32.1±7.9 y/o) of SjS patients from 2008 to 2018. Information concerning study subjects was retrospectively collected and analyzed. [Results] There were 8 cases of primary SjS (pSjS) 35.1±5.4 y/o, duration 1.3±1.8 y/o, ESSDAI 5.75±7.1), 17 cases of secondary SjS (sSjS) 30.7±7.3 y/o, duration 6.7±6.0 y/o, ESSDAI 0.53±1.1), sSjS consisted of 16 cases of SLE and a case of RA. There was 24.0% (6 cases) of live birth (pSjS) 12.5% (1 case), sSjS 29.4% (5 cases). There were no significant difference between normal delivery group (NDG) and abnormal delivery group (ADG) at age, duration, ESSDAI and autoantibody. In ADG SLEDAI (5.18±2.79) is higher than in NDG (1.60±0.89) in SjS with SLE. Neonatal lupus was not seen. 2 miscarriages, 1 artificial abortion, 1 neonatal death and 1 congenital heart block were noted. The level of anti SS-A antibody was higher than ×256 in a case of neonatal death and congenital heart block. [Conclusions] Further studies are needed in order to management of pregnancy in patients with SjS.

P3-305
Survey of the awareness of transitional Juvenile idiopathic arthritis (JIA) patients and their parents regarding transitional care
Takumi Matsumoto1,2, Mariko Mouri1, Fumio Hirano2,3, Masaki Morii1
1Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 2Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan, 3Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan
Conflict of interest: None

[Object] To understand the awareness of transitional JIA patients and their parents concerning transitional care. [Methods] We conducted a questionnaire survey of transitional care targeted for transitional JIA patients of Tokyo Medical and Dental University hospital and for members of JIA patient’s association. [Results] 80% of transitional patients and 40% of parents did not know the term of transitional care. 50 to 60% did not have the opportunity to talk about transition. 55% of the transitional patients and 80% of the parents had anxiety about transition and transfer, and the biggest anxiety was to establish a relationship of trust with the new physician. Approximately half of the transitional patients wished to continue visiting pediatric rheumatology. Ideally, about half of parents wanted a shift to an adult rheumatology department after establishing a consultation period, but in fact 85% of transferred patients were directly managed by pediatric rheumatology. They wanted to consider transfer timing based on consultation with their doctor, not age. As information that they want to know, data on the course and prognosis of the disease itself, adult medical system, pregnancy and childbirth was required. [Conclusions] Enhancement of transitional medical care is required.

P3-306
Investigation of rheumatoid arthritis cases whose pregnancies were established during treatment using biologics
Masao Sato1, Masao Takemura2, Noriko Iwata1, Tomohisa Tani1, Toshiro Ohashi1,2
1Ohashi-Tani Orthopedics, Gifu, Japan, 2Advanced Diagnostic System Laboratory, Fujita Health University
Conflict of interest: Yes

[Objectives] Rheumatoid arthritis (RA) cases in which pregnancy was established during biologic (BIO) therapy were examined. [Methods] We examined the type of BIO, the course of pregnancy, delivery, etc. for RA cases in which pregnancy was established during treatment using BIO. [Results] A total of 5 pregnancies were established in 4 women. The age at the time of confirmed pregnancy was 25 to 35 years old, average 31.4 years old. The breakdown of pregnancy was 2 cases of first pregnancy, 3 cases of second pregnancy. Tocilizumab (TCZ) was 3 times and Etanercept (ETN) was 2 times as BIO used when pregnancy was established. Three pregnancies that were established during TCZ administration were births with normal childbirth, and there was no problem with both mothers and children. Two cases in which pregnancy was established during ETN administration are currently under observation. Pregnancy cases during ETN administration were planned pregnancies under
patient acknowledgment. One case of pregnancy during ETN administration experienced miscarriage once in the past. [Discussion] Although there are many subjects such as selection of drugs used during pregnancy, control of RA disease activity, securing patient’s mental stability, accumulation of established evidence is desired.

P3-307
Safety of tacrolimus treatment during pregnancy in inflammatory rheumatic disease: Report of three cases
Ran Matsuda1-2, Toshiaki Kaneko1, Ken-yan Yamaji1, Naoto Tamura1
1 Internal Medicine and Rheumatology, Juntendo University, School of Medicine, 2 Tokyo Skytree Station Medical Clinic
Conflict of interest: None

[Objectives] To study safety of pregnancy in inflammatory rheumatic disease (IRD) patients treated with tacrolimus (TAC). [Cases] The cases were two rheumatoid arthritis (RA) and one dermatomyositis (DM) and we gave approval pregnancy because of their disease activity (DA) was controlled. One of the RA patients (case-1: 30 years old) were treated with TAC (3mg/day) and tocilizumab (TCZ) and stopped TCZ when she turned out to be pregnant. We added prednisolone (4mg/day) because her DA got worse through the course of gestation. At 39 weeks, she gave birth to son (3285g) naturally without any complications. Another RA patient (case-2: 31 year old) was treated with TAC (3mg/day) and cetrizumab-pegol (CZP) and stopped CZP when she turned out to be pregnant. Her DA was not worse and fetus growing was no problem. At 39 weeks, she gave birth to son (3285g) naturally without any complications. DM patient (case-3: 36 years old) was treated with TAC (2mg/day) and betamethasone (0.5mg/day) because of insufficient of PSL. She continued both drugs and her DA was not worse. At 37 weeks, she delivered daughter by Caesarean section (2100g). [Conclusion] We experienced three IRD patients treated with TAC during pregnancy. It was suggested that TAC treatment during pregnancy was safety.

P3-308
Generalized Pustular Psoriasis (GPP) was developed during administration of Hydroxychloroquine (HCQ) and improved by Infliximab (IFX) : A case of pregnancy in a patient with Systemic Lupus Erythematosus (SLE)
Shiko Mishima1, Kayoko Kaneko1, Chie Kohno1, Chinatsu Takai1, Mikako Goto1, Misato Kawakami2, Atsuko Murashima2-1
1Division of Maternal Medicine, Center of Maternal-Fetal, Neonatal and Reproductive Medicine, National Center for Child Health and Development, 2Japan Drug Information Institute in Pregnancy, National Center for Child Health and Development
Conflict of interest: None

[Background] GPP is a serious skin disease. It may appear due to pregnancy, and it is poor prognosis for both of mother and fetus. On the other way, there are some reports of GPP by HCQ. [Case] 31 y, first pregnancy, SLE at 23y. She was taking 10mg of PSL before pregnancy. She was presented with hair loss, low complement, thrombocytopenia at the first visit. We started HCQ from the 20 gestational weeks (GW). At 24 GW, erythema appeared in her trunk. We first suspected skin lesion of SLE and increased PSL to 30mg. However, the skin rash further expanded with increasing pustules and erosion. Skin biopsy revealed GPP. We stopped HCQ immediately and administered IFX at 28 GW. The skin lesion remarkably improved the following day, so we tried to reduce PSL. She complained of empyema at 30 GW and could not be treated with IFX. However, there was no recurrence of the eruption. She gave birth to a girl (weight of 998 g). On the next day, a feeling of abdominal fullness appeared, CT showed a remarkable pancreatic swelling and as a pancreatic on day 45 of birth. Discussion: Pancreatic swelling which appeared remarkably improved the following day, so we tried to reduce PSL. She complained of empyema at 30 GW and could not be treated with IFX. However, there was no recurrence of the eruption. She gave birth to a girl (weight of 998 g). On the next day, a feeling of abdominal fullness appeared, CT showed a remarkable pancreatic swelling and ascitc fluid, and I suspected acute pancreatitis. It resulted in oliguria, acute renal injury occurred, strengthened steroid treatment and slow blood filtration dialysis was performed from 3 days after parturition. On the 11th day, diuresis accompanied, withdrawal from dialysis, discharge from hospital on day 45 of birth. Discussion: Pancreatic swelling which appeared the next day after parturition did not show abdominal symptoms or pancreatic enzyme elevation, and it was due to serositis because it responded to steroid therapy.

P3-309
Measurements of tocilizumab concentrations in maternal and umbilical cord blood at the time of delivery and in breast milk of a lactating mother: A case report of Takayasu arteritis
Mayuko Moriyama, Manabu Honda, Masahiro Kondo, Yohko Murakawa
Department of Rheumatology, Faculty of Medicine, Shimane University
Conflict of interest: None

[Case] A 32-year-old woman, who developed Takayasu arteritis (TA) in September 2005, was commenced treatment with 162 mg of tocilizumab (TCZ) s.c. every 2 weeks in April 2016. She attained remission with TCZ, azathioprine, and prednisolone 8 mg/day. In March 2017, azathioprine was discontinued. She became pregnant in December 2017. Although safety of TCZ for pregnancy has not been established yet, the patient and we decided to continue TCZ treatment throughout pregnancy. She had no problems and a girl weighing 3188 g was born at 39 weeks and 4 days by spontaneous delivery. Apgar scores at 1 and 5 minutes were 8 and 9, respectively. No abnormalities except neonatal jaundice were observed. TCZ concentrations in the maternal serum and in umbilical cord blood were 14,146 ng/ml and 1,967 ng/ml, respectively. The concentrations in her breast milk at several points were lower values but still detectable. [Conclusions] A small number of cases have been reported in which patients received TCZ continuously throughout the entire course of pregnancy and lactation. Especially in TA, no case has as yet been reported. TA occurs frequently among younger women whose future pregnancies and births can be a major problem, indicating that our study is extremely significant.

P3-310
A case of lupus nephritis that caused acute kidney injury (AKI) after parturition
Takahiro Onoishi1, Satoshi Hosoi2
1Department of Rheumatology, Ise Red Cross Hospital, 2Orthopedic Surgery, Ise Red Cross Hospital
Conflict of interest: None

Case 30 year old woman In December X-5 she diagnosed SLE with lupus nephritis IV - S (A) and underwent treatment. X-2 December eGFR 90 ml / min / 1.73 m 2, urine protein 0.8 - 1.3 g / g Cr, with hope of birth, X-1 September pregnancy was established. With control of prednisolone 10 mg, hydroxychloroquine 200 mg, aspirin 100 mg, nifedipine CR 20 mg, blood pressure 160 units eGFR 58 ml / min / 1.73 m 2 urine protein 5.98 g / g Cr, and hypertension and renal function decrease were observed at 30 weeks of pregnancy, caesarean section I gave birth to a daughter (weight of 998 g). On the next day, a feeling of abdominal fullness appeared, CT showed a remarkable pancreatic swelling and ascitic fluid, and I suspected acute pancreatitis. It resulted in oliguria, acute renal injury occurred, strengthened steroid treatment and slow blood filtration dialysis was performed from 3 days after parturition. On the 11th day, diuresis accompanied, withdrawal from dialysis, discharge from hospital on day 45 of birth. Discussion: Pancreatic swelling which appeared the next day after parturition did not show abdominal symptoms or pancreatic enzyme elevation, and it was due to serositis because it responded to steroid therapy.

P3-311
A case of severe relapsing polychondritis in a pregnant woman
Mayu Yagita, Masayuki Nishide, Yusuke Manabe, Yumiko Mizuno, Yuta Yamaguchi, Takayoshi Morita, Yuichi Maeda, Hyota Takamatsu, Toru Hirano, Masashi Narazaki, Atsushi Kumanogoh
Department of Respiratory Medicine and Clinical Immunology, Osaka University
Conflict of interest: None

(Case) A 39-year-old Japanese pregnant woman at 37 weeks of gestation was referred to our hospital with acute respiratory failure. She required intubation due to subglottic edema. The patient had experienced nose pain, cough, and wheezing for 3 months and noticed swelling of her left ear for 3 weeks before hospitalization. Upon admission, she presented
with swelling of both ears and saddle nose deformity. Computed tomography (CT) scan showed severe subglottic edema. Biopsy of auricular cartilage revealed the infiltration of T cells. Based on these findings, she was diagnosed as relapsing polychondritis. Fetal growth was normal at the time. Pulse methylprednisolone therapy was performed, followed by oral prednisolone at 60 mg/day. Etanercept 50 mg/week was added on 14th day. As the dose of oral prednisolone carefully tapered, she was started on Azathioprine (50 mg/day). Under these intensive treatments, the disease activity did not get worth and the patient then vaginally delivered a female infant at 36 weeks of gestation. (Discussion) We experienced a case of severe relapsing polychondritis in a pregnant woman. Treatment strategies and clinical courses of acute worsening of relapsing polychondritis during pregnancy were rarely reported, therefore this case may be of interest.

EP1-01
Real-world sensitivity analysis of the 2017 classification criteria of systemic lupus erythematosus
Masei Suda
Immuno-Rheumatology Center, St. Luke’s International Hospital, Japan
Conflict of interest: None

[Object] Two major classification criteria have been used in the clinical trials of systemic lupus erythematosus (SLE). One is the American College of Rheumatology (ACR) criteria first developed in 1982 and revised in 1997 (1997 criteria), and the other is Systemic Lupus International Collaborating Clinics (SLICC) criteria developed in 2012 (2012 criteria). Currently, the new classification criteria of SLE (2017 criteria) have been proposed by steering committee from ACR and the European League Against Rheumatism (EULAR), aiming for better sensitivity and specificity. They were made based on the agreement of expert panel, and have not been validated in the real-world practice. [Methods] We retrospectively reviewed the electronic medical record of the consecutive 100 patients who visited St. Luke’s International Hospital, a tertiary care center in Tokyo, Japan, searching back from November 13, 2017. Patients were included if they are clinically diagnosed as having SLE with board-certified doctors, and excluded if they complicated with other autoimmune disease or if they are under 18-year-old. The patients were evaluated for fulfillment of the 1997, 2012, or 2017 criteria. [Results] Among the 100 cases, the sensitivity of 1997, 2012, 2017 criteria are, 97%, 99%, 92% respectively. The total score that the patients got with the 2017 criteria ranged from 12 to 44 (mean: 27.3). All the cases who were classified as non-SLE with the 2017 criteria had anti-nuclear antibody (ANA) <80. [Conclusions] 2017 criteria for SLE accomplished modestly high sensitivity in the real-world practice, but not as high as 1997 and 2012 criteria. They possibly miss-classify the real SLE cases as non-SLE, especially if patients have low titer (<80) of ANA.

EP1-02
A prospective cohort study of the predictive factors for the development of glucocorticoid-induced diabetes mellitus in patients with rheumatic disease (DIMERD study)
Yosuke Asano, Yoshinori Matsumoto, Ken- ei Sada, Keigo Hayashi, Yuriko Yamamura, Sumie Asano Hiranmu, Michiko Morishita, Keiji Ohashi, Haruki Watanabe, Mariko Narazaki, Tomoko Kawabata, Jun Wada
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Department of Medicine and Clinical Science., Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
Conflict of interest: None

[Object] Osteocalcin (OC) is a protein in the bone matrix which is produced by osteoblasts. Previous studies reported that OC reduced insulin resistance and stimulated pancreatic beta cell proliferation and production of insulin in mice, and undercarboxylated OC (ucOC) regulated glucose metabolism. Additionally, the previous report showed that glucocorticoid (GC) affected serum OC levels. In this clinical study, we prospectively investigate the association between ucOC levels, a complication of diabetes mellitus (DM) and GC usage at enrollment. Statistical analyses were performed by applying student’s t-test, Spearman rank correlation coefficients or chi-square test. [Result] Of 77 patients enrolled in this study, the mean age was 60 years old and 46 (60%) were female. Although the complication of DM was comparable between patients with and without GC (10/33 [30%] vs. 13/44 [30%], p = 0.94), ucOC levels of patients treated with GC were significantly lower than without GC (1.09 vs. 3.32 ng/ml, p < 0.001). Mean daily dose of prednisolone in patients treated with GC was 13.3 mg. Among patients treated with GC, a daily dose of prednisolone was higher in patients with undetectable ucOC levels (<0.38 ng/ml) than those with detectable ucOC levels (19.2 ± 2.1 vs.
EP1-03
Serum tenascin-C levels in patients with idiopathic inflammatory myopathy as a possible biomarker of myocardial injury
Aya Nishiwaki, Toshikiho Komai, Yasuo Nagafuchi, Hirofumi Shoda, Keishi Fujito
Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Conflict of interest: None

[Object] Tenascin-C (TNC) is an extracellular matrix glycoprotein which contributes to tissue remodeling. Serum TNC levels are elevated in patients with cardiac diseases, interstitial pneumonia, and connective tissue diseases such as rheumatoid arthritis (RA) and systemic sclerosis (SSc). The aim of this study is to investigate the relationship between serum TNC levels and clinical disease status of idiopathic inflammatory myopathy (IM). [Methods] Fourteen IM patients and 6 healthy controls (HC) were recruited. As disease control groups, blood samples from patients with RA (n=5), and SSc (n=5) were also analyzed. Serum TNC levels were quantified by ELISA. Clinical characteristics of IM patients were retrospectively collected from medical records to assess whether they could be associated with serum TNC levels. [Results] Serum TNC levels were significantly elevated in IM patients compared to HC (mean, 91.1 ng/ml [95% CI, 71.3-111.0] versus 45.9 ng/ml [15.6-76.2], p=0.0159). The mean serum TNC levels of RA and SSc patient were 66.4 ng/ml [33.2-99.6], and 95.6 ng/ml [62.4-128.8], respectively. TNC was positively correlated with cardiac biomarkers such as troponin I (r=0.725, p=0.0033) and CK-MB (r=0.596, p=0.0246), but not with total CPK, LDH, SP-A, SP-D, and CRP. Among clinical disease status of IM, the presence of anti-Mi-2 autoantibody was associated with higher serum TNC levels. [Conclusions] Our findings indicate that serum TNC levels are high and specifically correlated with cardiac enzymes in IM patients especially with anti-Mi-2 antibody. TNC could be a useful cardiac-specific biomarker in IM.

EP1-04
Five cases of IgG4-related disease in nasal mucosa and sinus disease
Masanobu Ueno, Kazuhsisa Nakano, Ippei Miyagawa, Shingo Nakayamada, Shigeru Iwata, Satoshi Kobo, Akio Kawabe, Yusuke Miyazaki, Yoshiya Tanaka
The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan

Conflict of interest: None

IgG4-related disease (IgG4-RD) is frequently associated with allergic diseases. Recently, chronic sinusitis with IgG4-RD has also been reported. In such cases, characteristic pathological findings of IgG4-RD can be observed from nasal mucosa biopsy. We report five cases of IgG4-RD with nasal mucosa and sinus lesions. Five cases were all female and the mean age was 56.4 ± 15.1 years old. All cases presented with nasal obstructions. Of them, four had bilateral eyelid swelling and three had oral dryness. Two had been diagnosed as allergic rhinitis and two as chronic sinusitis. The allergic rhinitis and chronic sinusitis were refractory. The mean serum IgG value was 2091.2 ± 561.1 mg/dL and IgG4 value was 791.4 ± 489.5 mg/dL. In the CT images, sinusitis and bilateral eyelid swellings were observed in all cases and in four cases, respectively. We performed lip biopsy in four cases and nasal mucosal biopsy in all cases. Two cases had histopathological findings that met the IgG4-RD comprehensive diagnostic criteria in both lip and nasal mucosa biopsy. There was one case each satisfying the criteria by lip biopsy or mucosa biopsy. One case without having done a lip biopsy had histopathological finding in nasal mucosa biopsy. We started treatment with medium dose of oral glucocorticoid (GC) therapy (PSL 0.5-0.6 mg/kg/day) in four cases and their nasal obstruction was improved promptly. We confirmed improvement of sinusitis and bilateral eyelid swelling in two cases from CT images after treatment. In one case who had advanced obesity, mild sinusitis findings on CT images and no other organ involvement, corticosteroid nasal drops were used and nasal obstruction improved without oral GC. We suggested that nasal mucosal biopsy may be useful for diagnosis as IgG4-RD with nasal and parasanal lesions. In refractory allergic rhinitis and chronic sinusitis, the possibility of nasal and parasanal lesions as an organ disorder of IgG4-RD should be considered.

EP1-05
The efficacy of Classical Indian Yoga in the treatment of Fibromyalgia: A Randomized Controlled Trial
Vikas Trivedi, Panna Mishra
Era’s Lucknow Medical College, Era University, Lucknow, India

Conflict of interest: None

Purpose: Fibromyalgia (FM) is a complex musculoskeletal disorder treated with multidisciplinary therapies. Classical Indian Yoga is an ancient life style healing technique which has an integrated mind-body approach to enhance both physical and mental health. [Methods] 6 months, single-blind, randomized trial of Classical Indian Yoga (50 patients) versus attention control group (stretching and wellness education) of 50 patients for Fibromyalgia. [Results] The classical Indian Yoga involved 60-minute group sessions thrice-weekly. The primary outcome measure was change in the FM Impact Questionnaire (FIQ) score at 1 year. Secondary outcome measures were tender point count, patient and physician global assessments, sleep quality (PSQI), 10-minute walk, timed chair stand, grip strength, depression and quality of life. These outcome measures were repeated at 1 year to test durability of response. Both groups were compared using an intent-to-treat analysis. [Results] The mean age of 100 patients was 55 years (SD 11), disease duration 10 years (SD 7) and BMI 30 kg/m2 (SD 8). 90 patients were females. 80 patients baseline expectancies of benefit from an exercise intervention were similar: Classical Yoga = 4.1 and the controls = 4.3. After 6 months patients in the classical Yoga group had a significantly greater improvement in FIQ score: between-group change -20, 95% CI (-24.0 to -8.8); P= 0.0005). The Yoga group patients also had significant improvement in secondary outcome measures: reduction in pain scale (VAS), improved patient global assessment, physical function, depression, and health status. After 1 year patients compliant with the classical Yoga had sustained and durable benefits in FIQ score quality of sleep and quality of life. In the control group, 2 groups did not differ in medication usage. No adverse events were noted. Conclusion: Classical Indian Yoga appears to be highly effective in the management of FM having a positive impact on physical, psychological and social aspects.

EP1-06
Perinatal exposures and risks for coronary artery lesion formation and IVIG resistance in Kawasaki disease
Kuo Ho-chang
Kaohsiung Chang Gung Memorial Hospital, Taiwan

Conflict of interest: Yes

[KObject] Kawasaki disease (KD) is featured by acute febrile systemic vasculitis and most affect children less than five years old. Nowadays the mean maternal age of giving birth is increasing in most countries in recent three decades. The effect of maternal age in KD has been reported before. This study was conducted to survey patients’ potential perinatal exposures and clinical outcome of KD. [Methods] A total of 185 KD patients and caregiver dyads were enrolled in this study through questionnaires in Kaohsiung Chang Gung Memorial Hospital. Questionnaire content included two categories: (1) children’s characteristics: age at disease onset (years), gender, gestational age at delivery, birth body weight, delivery methods (vaginal/cesarean), and breast-feeding; (2) caregivers’ characteristics: caregiver (parents/non-parents), education levels (senior high school/university), maternal age of giving birth to the KD patient, total number of offspring born to each patient’s mother, and family income. CAL formation and IVIG treatment response of KD were analyzed with these factors retrospectively. [Results] KD with CAL formation had higher maternal age than non-CAL patients (32.49 ± 3.42 vs. 31.01 ± 3.92 years, p = 0.016). We also found that group of maternal age ≥ 32 years
had higher rate to have KD patients with CAL (39/81 vs. 24/74, p = 0.047) when compared with group of maternal age < 32 years. KD patients with male gender had higher incidence of CAL formation than female (56/112 vs. 19/73, p = 0.001). Group of maternal age ≥ 35 years had higher rate to have KD patients with IVIG resistance (6/31 vs. 6/116, p = 0.01). [Conclusions] The present study first reported that increasing maternal age is significant associated with CAL and IVIG resistance in KD. We suggested that maternal age less than 32 and 35 years will be benefit for coronary artery status and IVIG response in KD offspring, respectively.

EP1-07
Serum Aldolase as a Diagnostic Marker and Indicator of Disease Activity in Patients with Adult-onset Still's Disease
Shinji Izuka, Hiroyuki Yamashita, Sotaro Nakajima, Toshiaki Kobayashi, Hiroshi Kaneko
National Center for Global Health and Medicine, Shinjuku, Tokyo, Japan

Conflict of interest: None

[Object] Adult-onset Still's disease (AOSD) is an acute systemic inflammatory disorder that is commonly diagnosed using Yamaguchi's criteria. AOSD is difficult to diagnose, and it is hard to determine whether it is active or inactive. A few studies have reported that serum aldolase (ALD) increases in AOSD patients. However, the specific relationship between AOSD and serum ALD has not been clarified. The aim of this study was to address the possible role of serum ALD as a biomarker for differential diagnosis and disease activity in patients with AOSD. [Methods] Blood samples and symptom data were collected from 8 patients with AOSD, 28 patients with rheumatic arthritis (RA) who have active arthritis with positive C-reactive protein, 34 patients with Sjögren's syndrome (SjS) who did not take glucocorticoids or immunosuppressants, 19 patients with systemic lupus erythematosus (SLE) whose SLE Disease Activity Index was higher than 8, and 12 patients with systemic sclerosis (SSc) who did not take glucocorticoids or immunosuppressants. Follow-up samples of all patients with AOSD were collected after resolution of disease activity. Correlations were performed between serum ALD and Pouchot’s score, ferritin, and other enzymes in patients with AOSD. [Results] Serum levels of ALD in AOSD patients were higher than in the control groups (RA, SjS, SLE, and SSc patients; all p-values were <0.001). The sensitivities and specificities for the diagnosis of AOSD were 87.5%/100%, 88%/95%, 87.5%/100%, and 87.5%/100%, respectively. All cutoff values were 8.9 U/L. Serum ALD was found to be decreased after disease activity was resolved in the follow-up of AOSD patients (p=0.02). In addition, serum ALD was correlated with Pouchot’s score and ferritin levels among AOSD patients (r = 0.71, p=0.003 and r = 0.6, p=0.02). [Conclusions] The data suggest that serum ALD may be a useful biomarker for diagnosis and evaluating disease activity in patients with AOSD.

EP1-08
Can cancer trigger autoimmune disease? Features of autoimmune disorder of patients with cancer
Sayaka Tsuzuki, Hideyuki Takahashi, Fangyi Chin, Keigo Setoguchi
Systemic Immunological Disease, Tokyo Metropolitan Cancer and Infectious Disease Center Komagome Hospital, Japan

Conflict of interest: None

[Object] Association between cancer and autoimmune diseases are reconsidered by frequent use of immune checkpoint inhibitor. In previous research, the childhood cancer patients have the higher possibility of developing autoimmune disease than general population. In this study, we examine the autoimmune diseases that appear after the cancer onset. [Methods] Date on clinical characteristics, laboratory features, and treatment from 107 patients with autoimmune disease in our hospital retrospective survey were analyzed. [Results] 107 patients were included; their median duration of follow-up was 39 months. The period of diagnosing cancer from autoimmune disease was 17 months, and age of the patients with autoimmune diseases at diagnosis was 68 years. Baseline manifestations included rheumatoid arthritis (RA) 43%, polymyalgia rheumatica (PMR) 20%, systemic sclerosis (SSc) 9%, Sjögren syndrome (SjS) 8%, IgG4-related disease 7%, vasculitis 6%, interstitial pneumonia 4%, polymyositis and dermatomyositis 3%. In patients with RA, 53% were positive for both rheumatoid factor (RF) and anti-CCP antibody (median RF 155U/mL, CCP antibody 380U/mL). The median age of diagnosis was 68 years, and 51% were female. The average serum C-reactive protein (CRP) was 1.7 mg/dL. Treatments used were MTX in 34%, SASP in 29%, PSL alone in 8%. The response to therapy was 70% overall. In PMR, all cases were seronegative. The median age of diagnosis was 71 years, and 63% were female. The average CRP was 5.4 mg/dL. All cases started treatment using PSL 15mg and responded to treatment. They all tapered PSL. In SSc, 77% had centromere antibody and the median titer of the antibody were 1280. Interestingly, even in SjS patients, the same antibody was positive in 50%. Seeing from cancer side, 19% had colon cancer, 16% had breast cancer, 11% had lung cancer, 9% had gastric cancer. [Conclusions] Patients with cancer developed autoimmune diseases, and had different characteristics from primary autoimmune disease.

EP1-09
Preliminary report on genetic analysis for an immune-related adverse event caused by immune checkpoint inhibitors
Naoki Hamada1, Yohei Kirino1, Ryusuke Yoshimi1, Yukie Yamaguchi2, Michiko Aihara2, Hideaki Nakajima1
1Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Japan, 2Department of Environmental Immuno-Dermatology, Yokohama City University Graduate School of Medicine, Japan

Conflict of interest: None

[Background] Immune checkpoint inhibitors (ICI) have shown marked efficacy in multiple cancers. However, an immune-related adverse event (irAE) may occur in any organ at any time point. Search for biomarkers to predict irAE is highly needed. [Object] To identify susceptibility gene polymorphisms of onset of specific irAE. [Methods] ICI monitoring committee including immunologist was established in our hospital. Since Sep 2014, cancer patients who received approval of ICI treatment (nivolumab, pembrolizumab, atezolizumab, ipilimumab) participated in our study. Clinical information was obtained from the electronic medical record. Genotypes of genetic polymorphisms associated with autoimmune diseases such as HLA and CTLA-4 were determined by next-generation sequencer using genomic DNA extracted from the saliva or whole blood. We analyzed the association between the onset of irAE and their genetic polymorphism. [Results] 100 patients who underwent ICI therapy (malignant melanoma; n=19, non-small cell lung cancer; n=22, head and neck cancer; n=24, renal cell carcinoma; n=21) participated in the study. As an adverse event, diarrhea, thyroid dysfunction, and a rash appeared in about 20% of all patients, respectively. Interstitial pneumonia and arthralgia were found in 10% of cases. Genetic analysis is currently underway. [Conclusions] Genetic factors may be involved in the onset of irAE. Further study of the large cohort in Japan can lead to elucidation of the genetic risk of irAE and appropriate use of ICI.

EP1-10
Association of Serum MMP-3 Concentrations with Disease Progression after the Onset of Rapidly Destructive Coxopathy
Tadashi Yasuda
Department of Orthopaedic Surgery, Kobe City General Hospital Medical Center, Kobe, Japan

Conflict of interest: None

[Object] Rapidly destructive coxopathy (RDC) is an unusual subset of osteoarthritis. It is characterized by rapid joint space loss, chondrolysis, and sometimes marked femoral head and acetabular destruction as a late finding. Although the exact pathogenetic mechanism is unknown, potential causes of RDC include high serum levels of matrix metalloproteinase (MMP)-3 as biological factors. No previous study has investigated MMP-3 in association with the disease progression of RDC. This study was aimed to elucidate association of MMP-3 with the time course after the onset of RDC. [Methods] Of female patients who visited our
hospital with hip pain from 2012 through 2018, this study enrolled female patients with the clinical records including the onset of hip pain, a series of radiographs during the period of ≥12 months from the onset of hip pain, and hematological data of MMP-3. We found the hip joints of 30 patients meet the diagnostic criteria of RDC; chondrolysis >2 mm with subsequent femoral head destruction in one year. Serum MMP-3 was measured with blood samples within one year after the onset. This study excluded male patients because RDC occurs mainly in elderly females and the reference intervals (RIs) of MMP-3 are different between males and females. [Results] When the approximate curve obtained from the scatter diagram of serum MMP-3 concentrations obtained from 30 patients with RDC were plotted in association with the duration between the onset of hip pain and MMP-3 determination, we found a significant exponential decrease in MMP-3 with time (R²=0.304, P<0.002). MMP-3 kept higher levels over >59.7 ng/ml, the upper limit of RI, within 10 months after the onset in every patient with RDC. [Conclusions] In female patients with RDC, serum MMP-3 may stay at increased levels during the period of chondrolysis after the onset of hip pain and thereafter decrease with time.

EP1-12
Effectiveness of tocilizumab and impact of cancer for large-vessel giant cell arteritis developing recurrent ischemic stroke: a case report
Masashi Watanabe
Department of Neurology, Ehime Prefectural Central Hospital, Matsuyama, Japan
Conflict of interest: None

[Object] Here we report a rare case of large-vessel GCA (LV-GCA) refractory to antithrombotic drugs and corticosteroid (CS) with adrenal cancer. [Methods] We analyzed its clinical course retrospectively. [Results] A 76-years-old woman has had recurrent cerebral embolisms 6 times for 2 years despite optimal antithrombotic treatments. She presented with right-side dominant tetraparesis with frontal releasing signs. Cardiovascular tests detected neither atrial fibrillation nor arterial stenosis. Brain MRI showed multiple cortical and subcortical high intensity lesions in both anterior and posterior circulations. Blood investigations indicated only elevated erythrocyte sedimentation rate and d-dimer without abnormal findings associated with cerebral embolisms. Contrast CT and FDG-PET/CT showed abnormal enhancement in the thoracic aorta with its branches suggesting vasculitis and left adrenal tumor without hormonal abnormality. Urologists and Radiologists diagnosed it as benign adenoma then. Biopsy of left temporal artery showed no findings of vasculitis. We diagnosed her as LV-GCA with recurrent ischemic stroke based on scan findings. Treatment with CS, aspirin, and apixaban temporarily prevented ischemic attacks for only 2 months. Combination of tocilizumab (TCZ) with CS completely resolved recurrence for several months. However, serial CT showed increase in the adrenal tumor with invasion to surrounding tissues and systemic metastases. Carcinoma was detected from gingival biopsy. After that, she suffered from frequent ischemic attacks due to Trousseau’s syndrome and died of sepsis due to duodenal perforation caused by tumor invasion. [Conclusions] CS treatment alone was reduced with time.

EP1-13
Cervical lymphadenopathy uncovered: Kikuchi-Fujimoto Disease as initial presentation of mixed connective tissue disease
Maeflor Q Oñilas, Maria Roselle E Guzman, Joseph Patrick N Patricio Ilocos Training and Regional Medical Center, San Fernando City, La Union, Philippines
Conflict of interest: None

Kikuchi-Fujimoto Disease is a rare, benign, self-limiting systemic lymphadenitis with unknown etiology presenting with lymphadenopathy, fever and leukopenia. It can be associated with Systemic Lupus Erythematous and Mixed Connective Tissue Disease (MCTD). We report a 36-year old female, initially presenting with posterior neck lymphadenopathy, fever, arthralgia, leukocytosis managed with series of antibiotics. There was no decrease in lymph node size which warranted ruling out tuberculosis and lymphoma with negative Tuberculin skin test and IGRA. Lymph node biopsy revealed lymphoid tissue fragments with interfollicular histiocytes and necroinflammatory lymphadenitis characteristic of KFD. Immunohistochemical stain results were positive for CD20, CD3, Ki67, and CD68; EBER were negative. Ruling in connective tissue disease, Immunologic profile showed ANA 1:5120 (speckled pattern), elevated Anti-U1RNP antibodies, normal complement 3. She was managed as case of MCTD with Methylprednisolone and Hydroxychloroquine rendering resolution of symptoms. This case supports the idea that KFD and MCTD may share common pathogenesis.

EP2-01
Comparison of clinical efficacy and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis in our department
Shunta Kaneko, Hiroyuki Yamashita, Shijii Iizuka, Sotaro Nakajima, Toshiaki Kobayashi, Kyoko Motomura, Nanami Mino, Yuko Takahashi, Hiroshi Kaneko
Division of Rheumatic Disease, National Center for Global Health and Medicine, Japan
Conflict of interest: None

[Object] Few studies have directly compared the Janus kinase (JAK) inhibitors tofacitinib and baricitinib in terms of their effects in, and safety for, patients with rheumatoid arthritis (RA); we retrospectively report our departmental experience with this topic. [Methods] We evaluated the therapeutic effects and safety of tofacitinib and baricitinib in 17 and 9 patients, respectively, after 4 and 12 weeks of treatment. [Results] The characteristics of the two treatment groups such as swollen and tender joints and C-reactive protein (CRP) levels did not differ. Improvements in joint symptoms and significant decreases in CRP levels were observed at 4 weeks (tofacitinib: -3.36 ± 3.35 mg/dL, p<0.01, baricitinib: -3.44 ± 3.23 mg/dL, p<0.01) and 12 weeks (tofacitinib: -3.18 ± 3.10 mg/dL, p<0.01, baricitinib: -3.77 ± 3.28 mg/dL, p<0.01). In patients taking tofacitinib, the higher the anti-cyclic citrullinated peptide (CCP) antibody titer, the less the change in CRP level after 4 weeks (p=0.83, p>0.05). On the other hand, in patients given baricitinib, effects were evident regardless of the anti-CCP antibody titer. No patient discontinued baricitinib within 3 months, but six discontinued tofacitinib because of infection or lymphocytopenia; the difference was significant (p=0.05). [Conclusions] The anti-inflammatory effects of the two JAK inhibitors in RA patients varied by the anti-CCP antibody titer.

EP2-02
The role of methotrexate monotherapy along with high dose vitamin D in newly diagnosed rheumatoid arthritis
Vikas Trivedi, Yashavsi Bansal
Era’s Lucknow Medical College, Era University, Lucknow, India
Conflict of interest: None

Introduction: Rheumatoid arthritis is a very common chronic inflammatory and autoimmune disease affecting approximately 1-2% of Indian population. The subsequent inflammatory changes lead to cartilage and bone destruction and the corresponding systemic inflammation may result in disorders of multiple organ systems. AIM: To study the role of methotrexate monotherapy along with high dose vitamin D in newly diagnosed cases of rheumatoid arthritis. Materials and Methods: This is a prospective randomized controlled study. It comprised of two groups each having 50 patients of RA each. One group only methotrexate subcutaneously was given and in another group along with methotrexate, Vitamin D in a high loading dose was given. The dosage of Methotrexate was 25mg/week and 0.6 million IU Vitamin D was given. The maximum follow up was of about 3 years which was done by clinical evaluation, ACR and DAS28 scoring. RESULTS: On the basis of this study it was found that patients who were given vitamin D along with subcutaneous methotrexate injection therapy, the relief to the symptoms was early, significant (P<0.05) and more dramatic as compared to patients receiving only subcutaneous methotrexate. A significant association between vitamin D levels
and ACR scores, CRP levels and ESR was observed. Lower vitamin D levels were associated with higher ACR scores, CRP levels and ESR.

Conclusions: 1. Vitamin D deficiency was quite common in patients with rheumatoid arthritis and vitamin D deficiency was significantly associated with disease activity. 2. Vitamin D supplementation helped to improve the outcome of methotrexate therapy among early cases of rheumatoid arthritis and also helped to eradicate the vitamin D deficiency in the targeted group. 3. These findings suggest subcutaneous Injection Methotrexate monotherapy along with high dose Vitamin D is an excellent and highly cost effective treatment regime for adult patients diagnosed with early RA.

**EP2-03**

**Comparison between Denosumab and Teriparatide treatments for osteoporosis in patients with Japanese rheumatoid arthritis; 18 months of follow-up**

Takotaro Okawa\(^1\), Shaihe Ueno\(^2\), Eri Narita\(^3\), Tatsuya Koike\(^2,3\)

\(^1\) Okawa Orthopedic Surgery Hospital, Japan, \(^2\)Search Institute for Bone and Arthritis Disease, Shiraamaha Foundation for Health and Welfare, Japan, \(^3\)Center for Senile Degenerative Disorders, Osaka City University Medical School, Japan

Conflict of interest: None

[Background] DMB and TPTD are well known as a great useful treatment medication in OP. Comparison between these medications for OP in RA patients is not well addressed previously. [Object] In this retrospective study, we compared BMD changes with DMB and TPTD treatment for OP in Japanese RA patients for 18 months of follow-up. [Methods] Patients with a diagnosis of RA according to the 2010 ACR/EULAR criteria. All patients were postmenopausal women with OP who were OP treatment naive. The DMB dose was 60mg at once every six months with daily native vitamin D. The TPTD included 20µg daily or 56.5µg weekly by subcutaneous injection. BMD was measured with DXA for lumbar spine (LS), femoral neck (FN) and total hip (TH) at baseline and months 6, 12, 18 during treatment. We assessed the TBS (trabecular bone score) at the same regions used for LS DXA scans, using TBS iNsight Software v.2.2 at baseline and months 12 and 18. [Results] DMB (n=30) and TPTD (n=13) were enrolled. Patients’ characteristics of DMB and TPTD. The Mean age 72.0 and 70.6 years old. The body mass index 19.7 and 20.4. Baseline LS-BMD 0.647 and 0.655. The LS-BMD change from baseline to 6, 12 and 18 months were each 0.671 vs 0.649 (p<0.05) at 6 months, 0.686 vs 0.650 (p<0.01) at 12 month and 0.694 vs 0.655 (p=0.05) at 18 month. Baseline FN-BMD 0.435 and 0.449. The FN-BMD from baseline to 6, 12 and 18 months were each 0.441 vs 0.435 (N.S.,no significant) at 6 month, 0.443 vs 0.434 (p<0.05) at 12 month and 0.444 vs 0.436 (N.S.) at 18 month. Baseline TH-BMD 0.566 and 0.561. The change of TH-BMD from baseline to 6, 12 and 18 months were each 0.579 vs 0.548 (p<0.05) at 6 month, 0.586 vs 0.549 (p<0.01) at 12 month and 0.586 vs 0.557 (p<0.05) at 18 month. Baseline TBS 1.266 and 1.273. The change of TBS from baseline to 12 and 18 months were each 1.267 vs 1.274 (N.S.) at 12 months and 1.268 vs 1.269 (N.S.) at 18 months. [Conclusions] This study shows that DMB was more useful to increase BMD than TPTD in OP of RA patients.

**EP2-04**

**The relationship between the precise region of ultrasound joint synovitis and joint examination findings in the wrist joints of patients with rheumatoid arthritis**

Norihide Hayashi\(^1\), Takehisa Ogura\(^1\), Ayako Hirata\(^1\), Rie Kujime\(^1\), Hideki Ito\(^2\), Sayaka Takenaka\(^2\), Munetsugu Imamura\(^2\), Yuki Inoue\(^2\), Chihiro Imaizumi\(^1\), Yuto Takakura\(^1\), Hideto Kameda\(^1\)

\(^1\) Division of Rheumatology, Department of Internal Medicine Toho University Ohashi Medical Center, Tokyo, Japan, \(^2\)Medical Corporation Syurinkai Yoshihi Hospital, Japan

Conflict of interest: None

[Object] Joint examination is the core assessment of the clinical evaluation of rheumatoid arthritis (RA). We have previously demonstrated a limited concordance between ultrasound (US) joint synovitis and joint examination by swelling and tenderness in various joints of patients with RA. The aim of this study was to elucidate the precise localization of US joint synovitis in wrist joints which are the most frequently involved in RA and anatomically complex, and its importance in the concordance with joint examination. [Methods] We enrolled 208 RA patients who were examined for the presence of arthritis in wrist joints by physical examination and US in this study. Clinical joint assessment determined the presence of tenderness alone (T), swelling alone (S), both (TS) or none (N) of them. US evaluation was performed in radial, median and ulnar regions of the dorsal side by longitudinal and transverse scans. US synovitis was defined as gray-scale (GS) imaging score ≥2 (graded 0-3) or a synovial power Doppler (PD) signal score ≥1 (graded 0-3) for each region of wrist joints. Binominal data were examined by Fisher’s exact test. [Results] Among total wrist joints assessed, US synovitis was observed in 95 of 285 N joints (33%), 11 of 20 T joints (55%, p=0.056 versus N joints), 37 of 52 S joints (71%, p<0.001 versus N joints) and 51 of 59 TS joints (86%, p<0.001 versus N joints), respectively. US synovitis was observed in 28% of radial, 38% of median, and 30% of ulnar regions, respectively. When US synovitis was confined to only one of three regions, clinical examination was positive (other than N joint) only in 33% (26 of 79 joints), while it was positive in 69% (61 of 89 joints) when US synovitis was found in all the three regions of the wrist. [Conclusion] The detection rate of arthritis by joint examination is decreased when RA synovitis is confined to a particular region of the wrist joint.

**EP2-05**

**The Clinical Features and Outcome of Native Vertebral Osteomyelitis in Patients with Rheumatoid Arthritis**

Ming-Li Hung\(^1\), Chang-youth Tsai\(^2\)

\(^1\) Kuanshan Tzu Chi Hospital, Taitung, Taiwan, \(^2\) Division of Allergy, Immunology, & Rheumatology, Department of Medicine, Taipei Veterans General Hospital, Taiwan

Conflict of interest: None

Objective: The clinical features and outcomes of native vertebral osteomyelitis diseases in patients with rheumatoid arthritis are unknown. We analyzed such the relevant data in from a medical center in Taiwan. Methods: We retrospectively reviewed the medical records of patients with RA diagnosed with NVO between 2006 and 2016 in Taipei Veterans General Hospital, Taiwan. Clinical presentations, laboratory parameters, and treatment outcomes were analyzed. Results: Twelve eligible patients with 26 NVO episodes were enrolled and separated into groups of primary episodes (12) and recurrent episodes (14). The median age of the cohort was 70 years, and 8 (67%) were female. The spinal pain was the most common presenting symptom (100%). The lumbar to sacral spine was the most common site of NVO (85%), followed by the thoracic spine (19%) and cervical spine (8%). The most common organisms organism was methicillin-sensitive Staphylococcus aureus (19% of bacteremia), followed by methicillin-resistant Staphylococcus aureus (8% of bacteremia) and 8% of biopsy specimens. The median duration of the parenteral antibiotic course was 53 days (interquartile range, 30 to 67 days). Recurrence developed in 75% of patients developed recurrence, and the median time to recurrence after completing treatment was 37 days (interquartile range, 14 to18 days). Vertebral osteomyelitis developed in 58% of patients developed vertebral osteomyelitis after an invasive spinal procedure, and six patients experienced the recurrence. Conclusions: The recurrence of native vertebral osteomyelitis in patients with rheumatoid arthritis is relatively high. Back pain is the most common presentation and the can provide a hint for diagnosis.

**EP2-06**

**Cartilage oligomeric matrix protein, a biomarker of arthritis, could be useful for predicting the response to biologic therapy in Rheumatoid Arthritis?**

Claudia S Ciofu, Macovei Liviu, Victor Stoica, Ioan Ancuta, Mihai Bojinca, Bogdan I Gavrila

Department of Internal Medicine and Rheumatology “Dr. I. Cantacuzino” Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Conflict of interest: None
alterations compared to healthy individuals, which may lead to higher structure. [Conclusions] Patients with RA have BMD and microstructural related to lower vBMD, trabecular number and impaired microstructure. A total of 81 RA patients (69 women, aged 57.9±8.7y, duration 5.7 (IQR 1.4-11.2)y) and 81 healthy controls were included. Compared to healthy controls (91.7±219.94 ng/ml) vs moderate responders (1042.7±193.117 ng/ml). Grouping patients in 2 categories (responders/nonresponders) there were no differences between groups at 6 months (p=0.227) or 12 months (p=0.9753). Following the status pretreatment of COMP and EULAR response at 6 months, we identified differences between groups (p=0.0001), all 7 patients declared nonresponders were COMP positive and only 13/19 (68.4%) of good responders were tested positive. At 12 months there were no differences between groups (p=0.2805). [Conclusions] COMP could be one of the biomarkers for identifying pretreatment the patients who will respond to anti-TNF therapy in RA.

EP2-07 Bone mineral density and microarchitecture among Chinese patients with rheumatoid arthritis Shangyi Jin1, Evelyn Hsieh2, Mengtao Li3, Weibo Xia1, Qian Wang1, Xiaofeng Zeng3
1Department of Rheumatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Beijing, China, 2Section of Rheumatology, Yale School of Medicine, USA, 3Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, Peking Union Medical College Hospital, Chinese Academy of Medical Science, Beijing, China

Conflict of interest: None

[Object] To evaluate risk factors associated with alterations in bone mineral density and microarchitecture in patients with rheumatoid arthri-
tis. [Methods] In this case-control study, patients with RA were recruited from the Chinese Registry of rhEumatoID arthritis (CREDIT). The pri-
mary outcomes were HRpQCT at distal radius and tibia (Scanco Xtrem-
ecT II), and data from age- and sex-matched healthy controls were in-
cluded for comparison. In the RA group, data was also collected regarding demographic and clinical characteristics, OP risk factors, RA histo-
ry, thoracolumbar X-ray, and central DXA. Correlation between HRpQCT and covariates were analyzed using linear regression models.
[Results] A total of 81 RA patients (69 women, aged 57.9±8.7y, duration 5.7 (IQR 1.4-11.2)y) and 81 healthy controls were included. Compared with controls, patients had larger bone area and lower vBMD at the distal radius and tibia. HRpQCT at the distal tibia also showed lower cortical bone thickness in patients. Among those with RA, aBMD at lumbar spine and total hip positively correlated with vBMD, trabecular bone volume fraction, trabecular number and cortical thickness, and negatively corre-
lated with trabecular separation and inhomogeneity. vBMD correlated positively with BMI, grip strength, HCQ and correlated negatively with age, RA duration and DAS28. Parameters reflecting impairment of mi-
crostructure negatively correlated with BMI and grip strength, and posi-
tively correlated with age, disease duration and activity. Current GCs was related to lower vBMD, trabecular number and impaired microstructure. Patients with fragility fractures had lower vBMD in both trabecular and cortical bone, thinner cortical bone and impaired trabecular bone micro-
structure. [Conclusions] Patients with RA have BMD and microstructural alterations compared to healthy individuals, which may lead to higher fracture risk. Both traditional and RA-related factors should be consid-
ered in bone quality assessment in RA.

EP2-08 The role of low socio-economic status, education and occupation in patients with Rheumatoid arthritis Panna Mishra, Vikas Trivedi Era’s Lucknow Medical College, Era University, Lucknow, India

Conflict of interest: None

Background: There are few studies evaluating community poverty association with RA especially in an emerging economy like India. In other chronic diseases, the poverty rate of one’s community was found to be associated with disease prevalence and health status outcomes inde-
pendent of a person’s education level. Purpose: The aim of this study is to critically evaluate associations between education, occupation, and community poverty with rheumatoid knee symptoms and radiographic knee RA parameters. Method: A cross-sectional analysis was conducted on 500 patients with RA who resided in a district setting comprising of low income and high income groups. Education (less than High School) and occupation (physically demanding or not) were used as individual measures. The annual income of 1000 USD is used as defining criteria for community poverty with about 250 patients selected with < 1000 USD annual income and rest 250 above it. Covariates included age, gen-
der, number of dependents and current smoking. Three outcomes were assigned as a finding in one or both knee joints: r RA defined as Larsen grade 2 and rheumatoid knee symptoms (pain, swelling and stiffness). Multivariate analyses were also performed adjusting for the covariates. Results: In bivariate analyses with education and the covariates, less than High School was significantly associated with r RA (OR equal to 1.3, CI 1.3, 1.5), symptoms (OR equal to 1.6, CI 1.5,1.9), and sypp RA (OR equal to 1.6, CI 1.3,2.0). In an urban group with >20% poverty was sig-
ificantly associated with r RA (OR equal to 1.8, CI 1.3,2.5) and symp RA (OR equal tol.5 CI 1.1, 2.1) in bivariate analyses. Conclusion: The community and individual Socio-economic status (SES) measures were independently associated with knee RA in this population-based study of individuals from a urban community.

EP2-09 Importance of the sites of affected joint in clinical assessment of rheumatoid arthritis Hideki Ito, Takehisu Ogura, Chihiro Imazumi, Yuki Inoue, Sayaka Takenaka, Norihide Hayashi, Ayako Hirata, Hitoko Kameda Division of Rheumatology, Department of Internal Medicine Toho Uni-
erity Ohashi Medical Center, Japan

Conflict of interest: None

[Object] Current assessment of rheumatoid arthritis (RA) is primarily based on the evaluation of affected joint counts. The aim of this study was to examine the importance of the sites of affected joint in clinical assess-
ment of patients with RA. [Methods] A total of 305 patients with RA were enrolled in this cross-sectional study. All the patients met 1987 American College of Rheumatology (ACR) and/or 2010 ACR/European League Against Rheumatism classification criteria, and visited our center between May 2014 and March 2015. Their medical records were re-
viewed for tender, swollen, and/or subjectively painful joint sites, as well as pa-
tient’s and physician’s global assessments (PtGa and PhGa, respec-
tively), health assessment questionnaire-disability index (HAQ-DI), se-
rum level of C-reactive protein (CRP) and RA treatments received. A stepwise regression analysis was performed for a multivariate analysis of factors determining each clinical assessment. [Results] Simplified disease activity index (SDAI) remission rate was 49.8% in our patients. Tender joint count (TJC) and swollen joint count (SJC) mainly depended on the small joints, as expected, while HAQ-DI and CRP depended on the large joints (Figure 1). Interestingly, the determinant factors of HAQ-DI and PtGa did not overlap with those of SJC and CRP, both of which have been demonstrated to be closely associated with the radiographic pro-
gression evaluated by hand and foot X-rays. In addition, patients with large joint predominance (large swollen joint count > small swollen joint count) showed a higher rate of receiving biological agents than the other
patients (55.2% vs. 34.1%, respectively, p=0.03) despite smaller number of total swollen joints in patients with large joint predominance than others (median 1 vs. 2, respectively, p=0.002). [Conclusions] Consideration of the sites of diseased joint is important in clinical evaluation of patients with RA.

EP2-10
The Study of Predictors of Osteoporotic Fracture in Rheumatoid Arthritis
Panna Mishra, Vikas Trivedi
Era’s Lucknow Medical College, Era University, Lucknow, India
Conflict of interest: None

Purpose: Osteoporosis and osteoporotic fractures are commonly associated with Rheumatoid Arthritis (RA). We assessed the association between osteoporotic fractures and RA clinical features, other organ damage and the impact of treatment, especially corticosteroids. Method: This is a large prospective cohort study of 500 RA patients, there were 200 osteoporotic fractures. Variables evaluated were sociodemographic data, disease variables, clinical features, Uveitis, the use of corticosteroids and other complications. Clinical associates of fractures were determined by univariate and multivariate analyses. Results: In the best multivariable model, More than 3 major joint involvement, smoking ever, uveitis, prednisone ever, pulse steroid ever and obesity remained significant. (Detailed results will be presented in the ICR meeting) Conclusion: This study identified multiple risk factors for osteoporotic fracture in RA. Corticosteroid use (ever, current, pulse) was a strong risk factor. This new study also identifies smoking, uveitis and polyarticular involvement as additional risk factors.

EP2-11
Prescriber Attitudes and Beliefs about Triple Therapy for Patients with Rheumatoid Arthritis: Knowledge Exchange in Internet Forums and Social Media
Maria A Lopez-olivo, Jude K Des Bordes, Gregory Pratt, Maria E Suarez-almazor
The University of Texas, MD Anderson Cancer Center, USA
Conflict of interest: None

[Objective] Several forums on the internet serve as repositories of personal experiences and exchange of health information. Online discussions among healthcare providers about management of patients with rheumatoid arthritis occur on a regular basis. Therefore, we explored and characterized the discussions about the use of triple therapy (methotrexate, sulfasalazine, hydroxychloroquine) on Internet forums, as differences in utilization among countries have been reported. [Methods] Online discussions were collected from three “leading edge” forums (ResearchGate, Medscape, and Twitter). Threads of discussion were systematically examined and interpreted to reveal recurring topics and patterns. Each post was coded and arranged into broader categories, which were combined into overarching themes. [Results] Twelve threads with 96 posts were identified. Seventy-nine of the posts were categorized. Seventeen were discarded because they were questions or comments unrelated to the topic discussed in the original thread. Four themes emerged during the analysis: (i) effectiveness, (ii) costs, (iii) safety, and (iv) adherence. The first theme dealt primarily with the effectiveness of triple therapy compared with tumor necrosis factor inhibitors. The second theme focused on the costs. Although the majority agreed that it is a cost-saving alternative, especially in developing countries, some believed that biosimilars will be cost-saving and more effective. The third theme involved a multitude of safety and tolerance concerns. The last theme covered the use of multiple drugs, which minimizes adherence. [Conclusions] The discussions in online forums showed extensive and cumulative discussions on attitudes and beliefs exchanged about triple therapy. Main concerns included radiographic progression, safety, and adherence which could partially explain low utilization of triple therapy in some countries.

EP2-12
Short to mid-term outcomes of Golimumab for rheumatoid arthritis in our hospital
Junichi Fujisawa1, Naoko Kondo2, Takehiro Murai2, Naoko Kudo2, Naoto Endo2
1Carrier Support Center for Resident, Niigata University Medical and Dental Hospital, Niigata, Japan, 2Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
Conflict of interest: None

[Object] To investigate short to mid-term outcomes of Golimumab for rheumatoid arthritis in our hospital [Methods] Fifty-eight cases of rheumatoid arthritis who introduced Golimumab between February 2012 and August 2018 in our hospital were included in this study. The average age at the start of administration was 66-year-old. The average observation period was 1.2 year. The examination items consist of 1) Changes in DAS28 from the start up to 12 months after the administration 2) Cumulative survival rate of Kaplan-Meier method 3) Combined use rate and dose of MTX at the start of administration 4) DAS28 and survival rate in combined with or without MTX 5) DAS28 and survival rate of each bio-naïve and switch cases. [Results] DAS28 was 4.4 at the start, 3.4 at 3 months, 3.3 at 6 months, 2.8 at 9 months and 2.7 at 12 months after the administration. The cumulative survival rate was 60% for 1 year and 46% for 2 years. The case of concomitant use of MTX at the start of administration was 44 cases (76%) and the average dose was 7.4 mg/week. There was no significant difference in the transition of DAS28 with or without MTX combination and survival rate was 63% for 1 year, 52% for 2 year in combination cases, 51% for 1 year, 25% for 2 year in non-combination cases. By comparing the bio-naïve and switch cases, the DAS28 declining rate from the start, the naïve case was significantly higher. The survival rate was 71% for 1 year, 56% for 2 year in bio-naïve cases, and 33% for 1 year in bio-switch cases. [Conclusions] Administering Golimumab for rheumatoid arthritis at our hospital showed a trend towards gradual improvement over the course of 12 months for disease activity. Although there was no significant difference in the transition of disease activity with or without MTX combination, survival rate was significantly higher in MTX combination cases. The rate of decline in disease activity and the survival rate were also significantly higher in the bio-naïve cases.

EP2-13
The clinical outcome of tofacitinib in patients with rheumatoid arthritis
Naoko Kondo1, Naoko Kudo2, Junichi Fujisawa1, Naoto Endo1
1Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Katsumi Othopedic Clinic, Japan
Conflict of interest: None

[Object] To evaluate the efficacy and safety of tofacitinib (TOF) in patients with rheumatoid arthritis (RA). [Methods] Twenty-four RA patients (23 females and 1 male) who were administered with TOF and could be followed more than 3 months were recruited. Of 24 patients, 19 cases (79%) had been treated with biological DMARDs more than 1 agent. The mean age was 66±9.9 years old (43 to 85) and the average RA disease duration was 16.3±13.3 years. The mean dose of methotrexate was 3.0±4.0 mg/week (0 to 12) at TOF administration. The mean follow up duration was 7.9±10 months. Disease activity score 28 (DAS28) and clinical disease activity index (CDAI) were evaluated and the retention rate was examined. The cessation cases were examined. The statistical analysis was performed with Student-t test and p-values less than 0.05 were defined as significant difference. [Results] The average DAS28 was 4.02 at the administration of TOF, and significantly decreased to 3.43, 3.24, and 2.77 at 1, 3, and 6 months after TOF administration. The average CDAI was 20 at the administration of TOF, and significantly decreased to 15, 11, and 6.3 at 1, 3, and 6 months after TOF administration. The retention rate was 79% at 1-year. Five case were ceased with TOF because of 3 cases of no efficacy and 2 cases of adverse events such as herpes zoster and dysphoria. [Conclusions] Although the almost subjects were refractory RA, TOF demonstrated good efficacy.
EP2-14
Our experience of administering Sarilumab for rheumatoid arthritis: Three cases report
Junichi Fujisawa¹, Naoki Kondo², Takehiro Murai², Naoko Kudo², Naoto Endo²
¹Carrier Support Center for Resident, Niigata University Medical and Dental Hospital, Niigata, Japan, ²Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan

Conflict of interest: None

[Object] To report three cases of administering Sarilumab for rheumatoid arthritis in our department. [Case 1] A 54-year-old female. After Abatacept became secondary ineffective, changing to Tocilizumab, but it became secondary ineffective. [Case 2] A 64-year-old female. Tocilizumab started at the age of 55. Although low disease activity was obtained, RF and MPP-3 gradually increased. Thereafter, disease activity scores also increased, and at the age of 64, even when changing to Golimumab, it was primary ineffective. [Case 3] A 56-year-old female. Patient global assessment was 10.0, CRP 7.48, RR 53.3, MPP-3 712.1, DAS28 (4)-ESR 6.08, SDAI 35.48, CDAI 28.0. Then changing to Sarilumab, seven weeks later, patient global assessment was 2.0, CRP 0.45, RR 351.3, MPP-3 534.2, DAS28 (4)-ESR 31.4, SDAI 8.45, CDAI 8.0. [Case 3] A 65-year-old man. At the age of 54, Etanercept was started. But it became secondary ineffective, changed to Tocilizumab at the age of 57. At the age of 64, the disease activity of rheumatoid arthritis was increased and it changed to Golimumab, but it became secondary ineffective. [Case 2] A 64-year-old female. Patient global assessment was 6.0, CRP 3.01, RR 222.7, MPP-3 199.0, DAS28 (4)-ESR 5.28, SDAI 31.01, CDAI 28.0. Then changing to Sarilumab, five weeks later, patient global assessment was 2.5, CRP 0.03, RR 221.0, MPP-3 55.5, DAS28 (4)-ESR 2.32, SDAI 13.03, CDAI 13.0. [Conclusions] We reported three cases of administering Sarilumab for rheumatoid arthritis in our department. All cases were bio-switch cases, but both patient global assessment and disease activity were improved from a relatively early stage.

Conflict of interest: None

EP2-02
A culture engineering strategy to enhance mesenchymal stromal cells for treatment of osteoarthritis
Kevin P Robb¹, Alejandro Gómez-aristizábal², Shashank Bhatt¹, Rajiv Gandhi¹, Sowmya Viswanathan¹,²
¹The Arthritis Program, University Health Network, Canada, ²Institute of Biomaterials and Biomedical Engineering, University of Toronto, Canada

Conflict of interest: None

Osteoarthritis (OA) is a progressive joint disease linked to chronic inflammation for which mesenchymal stromal cells (MSCs) have been investigated as a promising therapy. We hypothesize that enhanced MSCs (eMSCs) by 3D culture using a proprietary method (US62/397,572) and hypoxic stimulation will augment their ability to reduce inflammation, fibrosis, and cartilage degradation relative to naïve MSC (nMSC) controls within ex vivo and animal OA models. In 24 h licensing experiments with the pro-inflammatory cytokine TNFα, eMSCs displayed a 5-fold increase in transcript levels of the anti-inflammatory MSC potency marker TSG-6 versus nMSCs as measured by qPCR. After stimulation with the pro-inflammatory cytokine IFNγ, eMSCs also showed reduced gene expression of the pro-inflammatory markers CXCL8 and COX2, as well as the fibrostatic marker TGFβ relative to nMSCs suggesting that eMSCs could help to mitigate the inflammatory and fibrotic microenvironment in OA. Co-culture studies with human monocytes or CD4+ T cells revealed that the eMSCs caused a modest increase in the expression of the homeostatic monocyte/macrophage marker CD163 after 48 h with a reduction in the pro-inflammatory phenotypic marker CD86 observed in parallel by flow cytometry. In terms of expressing CFSE-labeled CD4+ T helper cell proliferation, preliminary results show that eMSCs are equivalent to nMSCs under fresh conditions, but that after cryopreservation and thawing, eMSCs are much more effective than nMSCs. In conclusion, eMSCs have improved immunomodulatory characteristics relative to nMSCs and may therefore be more clinically effective in OA. In ongoing work, we are investigating mechanism of action of eMSCs through mRNA profiling with RNA-sequencing and by examining cartilage gene expression changes as well as glycosaminoglycan content after co-culture of the eMSCs with human osteoarthritic cartilage and synovium.

Conflict of interest: Yes

EP3-03
Interleukin-6 Receptor Blocker Increases Revascularization and New Bone Formation in a Murine Model of Ischemic Osteonecrosis
Gen Kuroyanagi¹,²,³, Naoko Kudo¹,³, Sowmya Viswanathan¹,², Naoto Endo¹,³
¹Department of Orthopaedic Surgery, Nagoya City University Graduate School of Medical Sciences, Japan, ²Department of Rehabilitation Medicine, Nagoya City University Graduate School of Medical Sciences, Japan, ³Department of Joint Surgery for Rheumatic Diseases, Nagoya City University Graduate School of Medical Sciences, Japan

Conflict of interest: None

[Background] Ischemic osteonecrosis of femoral head includes chronic synovitis, increased bone resorption and decreased bone formation.

[Object] To report three cases of administering Sarilumab for rheumatoid arthritis. [Case 1] A 54-year-old female. After Abatacept became secondary ineffective, changing to Tocilizumab, but it became secondary ineffective. [Case 2] A 64-year-old female. Tocilizumab started at the age of 55. Although low disease activity was obtained, RF and MPP-3 gradually increased. Thereafter, disease activity scores also increased, and at the age of 64, even when changing to Golimumab, it was primary ineffective. [Case 3] A 65-year-old man. At the age of 54, Etanercept was started. But it became secondary ineffective, changed to Tocilizumab at the age of 57. At the age of 64, the disease activity of rheumatoid arthritis was increased and it changed to Golimumab, but it became secondary ineffective. [Case 2] A 64-year-old female. Patient global assessment was 6.0, CRP 3.01, RR 222.7, MPP-3 199.0, DAS28 (4)-ESR 5.28, SDAI 31.01, CDAI 28.0. Then changing to Sarilumab, five weeks later, patient global assessment was 2.5, CRP 0.03, RR 221.0, MPP-3 55.5, DAS28 (4)-ESR 2.32, SDAI 13.03, CDAI 13.0. [Conclusions] We reported three cases of administering Sarilumab for rheumatoid arthritis in our department. All cases were bio-switch cases, but both patient global assessment and disease activity were improved from a relatively early stage.

Conflict of interest: None

Osteoarthritis (OA) is a progressive joint disease linked to chronic inflammation for which mesenchymal stromal cells (MSCs) have been investigated as a promising therapy. We hypothesize that enhanced MSCs (eMSCs) by 3D culture using a proprietary method (US62/397,572) and hypoxic stimulation will augment their ability to reduce inflammation, fibrosis, and cartilage degradation relative to naïve MSC (nMSC) controls within ex vivo and animal OA models. In 24 h licensing experiments with the pro-inflammatory cytokine TNFα, eMSCs displayed a 5-fold increase in transcript levels of the anti-inflammatory MSC potency marker TSG-6 versus nMSCs as measured by qPCR. After stimulation with the pro-inflammatory cytokine IFNγ, eMSCs also showed reduced gene expression of the pro-inflammatory markers CXCL8 and COX2, as well as the fibrostatic marker TGFβ relative to nMSCs suggesting that eMSCs could help to mitigate the inflammatory and fibrotic microenvironment in OA. Co-culture studies with human monocytes or CD4+ T cells revealed that the eMSCs caused a modest increase in the expression of the homeostatic monocyte/macrophage marker CD163 after 48 h with a reduction in the pro-inflammatory phenotypic marker CD86 observed in parallel by flow cytometry. In terms of expressing CFSE-labeled CD4+ T helper cell proliferation, preliminary results show that eMSCs are equivalent to nMSCs under fresh conditions, but that after cryopreservation and thawing, eMSCs are much more effective than nMSCs. In conclusion, eMSCs have improved immunomodulatory characteristics relative to nMSCs and may therefore be more clinically effective in OA. In ongoing work, we are investigating mechanism of action of eMSCs through mRNA profiling with RNA-sequencing and by examining cartilage gene expression changes as well as glycosaminoglycan content after co-culture of the eMSCs with human osteoarthritic cartilage and synovium.

Conflict of interest: Yes

EP3-03
Interleukin-6 Receptor Blocker Increases Revascularization and New Bone Formation in a Murine Model of Ischemic Osteonecrosis
Gen Kuroyanagi¹,²,³, Naoko Kudo¹,³, Sowmya Viswanathan¹,², Naoto Endo¹,³
¹Department of Orthopaedic Surgery, Nagoya City University Graduate School of Medical Sciences, Japan, ²Department of Rehabilitation Medicine, Nagoya City University Graduate School of Medical Sciences, Japan, ³Department of Joint Surgery for Rheumatic Diseases, Nagoya City University Graduate School of Medical Sciences, Japan

Conflict of interest: None

[Background] Ischemic osteonecrosis of femoral head includes chronic synovitis, increased bone resorption and decreased bone formation.
Recently, patients with juvenile ischemic femoral head osteonecrosis shows significant elevation of the pro-inflammatory cytokine interleukin-6 (IL-6) in the synovial fluid. Thus, IL-6 is implicated in playing important pathological roles in increasing bone formation and decreasing bone resorption following ischemic osteonecrosis. [Object] The purpose of this study was to investigate whether IL-6 receptor inhibition prevents bone loss and healing process in a mouse model of ischemic osteonecrosis. [Methods] Ischemic osteonecrosis was surgically induced in the distal femoral epiphysis by vessels cauterization. Anti-mouse IL-6 receptor antibody (MR16-1) or saline was administered after the surgery. MR16-1 effects on bone formation, bone resorption, and healing response were assessed at 2 weeks and 4 weeks after the surgery using histologic, histomorphometric and micro-CT methods. [Results] IL-6 immunohistochemistry showed increased IL-6 immunostaining in the distal femoral epiphysis after ischemic osteonecrosis induction. Histologic assessment showed significantly increased revascularization and restoration of the necrotic marrow with new hematopoietic marrow in the MR16-1 group at 2 and 4 weeks after the surgery. Micro-CT assessment showed significantly increased bone volume in the osteonecrosis side of the MR16-1 group at 4 weeks following ischemic osteonecrosis compared to the saline group. Histomorphometric assessment showed significantly increased osteoblast number/bone surface, bone formation rate, and mineral apposition rate in the MR16-1 group. However, the number of osteoclast/bone surface was also increased in the MR16-1 group. [Conclusions] IL-6 receptor inhibition increases revascularization and restoration of the hematopoietic bone marrow, and stimulates new bone formation following ischemic osteonecrosis.

**EP3-05**

4-Phenylbutyric Acid Mediates Therapeutic Effect in Systemic Lupus Erythematosus: Observations in an Experimental Murine Lupus Model

Yunjung Choi1, Eunkyeong Lee1, Ji-hyeon Jeong2, Wan-hee Yoo1,2 1Division of Internal Medicine, Chonbuk National University Hospital, Jeonju, Korea, 2Research Institute of Clinical Medicine of Chonbuk National University-Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, Korea

Conflict of interest: None

[Object] Recently, several studies have revealed the pathological role of endoplasmic reticulum (ER) stress in the autoimmune and inflammatory diseases. The purpose of the present study was to investigate whether ER stress inhibition by 4-phenylbutyric acid (4-PBA) ameliorates arthritis in an experimental model and the effect of ER stress inhibition by 4-PBA on interleukin-1β-induced proliferation and inflammatory response of rheumatoid synovial fibroblasts (RASFs). [Methods] The proliferation of RASFs was evaluated in the presence of IL-1β with/without 4-PBA. The expression of ER stress markers and matrix metalloproteinases were examined. The in vivo effects of 4-PBA were investigated using DBA/1 mice with collagen-induced arthritis (CIA). [Results] 4-PBA markedly attenuated the severity of arthritis in CIA mice, such as ameliorated joint swelling and reduced bone erosion and destruction. Furthermore, the level of proinflammatory cytokines including IL-1β, IL-6 and TNF-α in joint extracts were suppressed in the CIA model treated with 4-PBA. In vitro, the elevated level of GRP78 was detected in IL-1β-stimulated RASFs. 4-PBA treatment suppressed the IL-1β-induced proliferation, production of proinflammatory cytokines and metalloproteinase (MMP-1, MMP-3) in IL-1β-stimulated RASFs [Conclusions] These findings suggest that 4-PBA ameliorates experimental arthritis by inhibition of ER stress in RASFs. 4-PBA could be a therapeutic option for the treatment of RA.

**EP3-06**

The accumulation of microdamage is the most related factor than biopsy-proven severely suppressed bone turnover (SSBT) in bisphosphonate-associated atypical femoral fractures

Naoki Kondo1, Hiroe Sato2, Naoto Endo1 1Division of Orthopedic Surgery, Department of Regenerative and Transplant Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan, 2Health Center, Niigata University, Niigata, Japan

Conflict of interest: None

[Objective] The pathogenesis of atypical femoral fractures (AFF) remains unknown. The accumulation of microdamage, SSBT, and the bone metabolism decreases are supposed to be the critical factors for the incidence of bisphosphate (BP)-related AFFs. In this study, we determined which factors was the most related for the incidence of AFFs. [Methods] Twenty-five patients of BP-associated atypical femoral fractures were registered. Most patients were primary osteoporosis (n=15). The others were SLE (4 cases), RA (3 cases), angitis (2 cases), and PMR (1 case). BP duration was 6.2 years on average. Age was 72 years old (range: 49-93) on average, and 1 male and 24 females. The site of fractures was subtrochanteric in 14 and diaphyseal in 11 cases. Iliac bones were harvested and subjected bone histomorphometric findings. Fracture sites were harvested and the cortex was stained with bulk or Villaneuva bone staining. When bone histomorphometric findings demonstrate that bone formation (osteoid) parameters were low and bone resorption parameters were low, the situation was defined as SSBT. The former specimens were the quantitative analysis of microcracks. The crack density (Cr. Dn: N/mm²) and the crack surface density (Cr.S. Dn: μm/mm²) were measured. The latter ones were the quantitative analysis of the densities of empty lacunae and osteocyte. Then in the cases of the empty lacunae density was superior to the osteocyte density, the situation was defined as “the decreased state of bone metabolism”. The incidences were calculated. [Results] SSBT was detected in 3 cases (16%). Microcracks were detected in the all 17 cases (100%), and the average Cr. Dn was 1.56 and the average Cr.S. Dn was 154, respectively. Empty lacuna density was more elevated than osteocyte density in 14 cases (64%). [Conclusions] Microdamage was the most related factor in the incidence of atypical femoral fractures, followed by the bone metabolism decreases and SSBT in order.

**EP3-07**

Biomarker discovery in early knee osteoarthritis using microRNA-sequencing

Shabana A Ali, Konstantin Sheshtopoloff, Rajiv Gandhi, Mohit Kapoor Krembil Research Institute, University Health Network, Toronto, Canada

Conflict of interest: None

[Objectives] Despite extensive research, there is still a lack of specific OA biomarkers that can be used in a therapeutic, prognostic, or diagnostic manner. Since microRNAs are promising biomarkers for several diseases, we previously used microRNA PCR-arrays and identified a panel of microRNAs in the synovial fluid that differentiate between early- and late-stage radiographic knee OA. We also performed microRNA microarrays and identified 2 microRNAs as mediators of cartilage degeneration. However, the gold standard approach in identifying biomarkers is next generation sequencing (NGS) because it offers the sensitivity and specificity to detect novel and low abundance microRNAs that are unique to early versus late OA. Here, we use NGS to identify signatures of circulating microRNAs as biomarkers for knee OA. [Methods] Patient cohorts include healthy donors with no history of musculoskeletal disease (N=100), Kellgren-Lawrence grade-I for early OA (N=100), and Kellgren-Lawrence grade-III/IV for late OA (N=750). In a pilot experiment, 5 plasma samples from each group with a particular age, sex, body mass index, ethnicity, and comorbidity status were subjected to NGS using Illumina NextSeq500. Bioinformatic and statistical analyses were performed to filter and interpret the results. [Results] The most differentially expressed microRNAs were identified based on false discovery rate less than 0.05, log counts per million greater than 2, and log fold change greater than 1.5. Hierarchical clustering of these microRNAs revealed a distinct pattern where 60 microRNAs were upregulated only in early OA samples. Among these are 4 novel putative microRNAs that have not previously been identified. We are currently repeating sequencing experiments in each group to validate and establish a clear microRNA signature for early knee OA. [Conclusion] Our pilot data suggest that NGS is a powerful approach for identifying differentially expressed circulating microRNAs as biomarkers for knee OA.
**EP3-08**

Inhibitor of DNA binding 1 protein is expressed in rheumatoid arthritis

Takeo Isozaki, Masahiro Hosonuma, Airi Nishimi, Shinichiro Nishimi, Sho Ishit, Takahiro Tokunaga, Yuzo Ikari, Hidekazu Furuya, Kuninobu Wakabayashi, Tsuyoshi Kasama

Division of Rheumatology, Showa University School of Medicine, Japan

Conflict of interest: None

[Object] Angiogenesis is one of the important reaction in rheumatoid arthritis (RA) pathology. Inhibitor of DNA Binding 1 (Id1) is a transcription factor unique to endothelial progenitor cells (EPCs) that influences cell maturation. In this study, we showed Id1 expression in RA.

[Methods] The levels of Id1 in RA and healthy controls serum were measured with enzyme-linked immunosorbent assays (ELISA). In order to investigate the relationship of disease activity, we measured correlations between Id1 and DAS28 (ESR) or MMP-3. In addition, to examine the differences of Id1 in RA serum with infliximab treatment, ELISA was used. Finally, to clarify the Id1 expression in RA synovium, immunohistochemistry was performed.

[Results] Id1 in RA was significantly higher compared with that in healthy controls (mean ± SE; 102 ± 20 pg/ml and 40 ± 15 pg/ml, p<0.05, respectively). Id1 in RA was also positively correlated with DAS28 (ESR) and MMP-3. The levels of Id1 decreased after treatment with infliximab (pre: 102 ± 20 pg/ml and post: 58 ± 9 pg/ml, p<0.05, respectively). Finally, we found that Id1 was expressed in RA synovial tissues. [Conclusions] Id1 is expressed on RA synovium and is correlated with disease activity.

**EP3-09**

Beclin-1 activator induces severe synovial fibrosis and does not protect cartilage from degeneration in a mouse model of OA

Jason S Rockel¹, Brian Wu¹, Sayaka Nakamura¹, Mohit Kapoor²,³

¹Krembil Research Institute, University Health Network, Toronto, Ontario, Canada, ²Department of Surgery, University of Toronto, Ontario, Canada, ³Department of Laboratory Medicine and Pathobiology, University of Toronto, Ontario, Canada

Conflict of interest: None

[Object] Beclin-1 is a component of the autophagy pathway necessary for formation of autophagosomes, contributing to autophagy-mediated cellular homeostasis. Enhancing autophagy through inhibition of mTOR activity, either via genetic deletion in chondrocytes or intra-articular injection of rapamycin, attenuates progression of surgically-induced models of osteoarthritis (OA). For this study, we sought to determine if a potent, soluble activator of Beclin-1 could also attenuate OA in a mouse model.

[Methods] Nine-week old C57BL/6 mice underwent destabilization of the medial meniscus (DMM) surgery to induce OA, or sham surgery as a control. Mice were injected intra-articularly with retro-inverso TAT-Beclin-1 (2mg/kg in 5μl) twice weekly for 9 weeks. Mice were sacrificed at 10-weeks post-surgery. Knee joints were stained with safranin-O/fast green to evaluate cartilage degeneration and Masson’s trichrome to determine degree of synovitis using OARSI scoring for mice. Sections were stained for α-SMA (myofibroblast) and CD45 (hematopoietic-origin cell).

[Results] TAT-Beclin-1-treated mice showed no difference in the degree of articular cartilage degeneration in the tibia or femur of DMM surgical mice as compared to PBS-injected DMM mice. Surprisingly, in both sham and DMM mice, TAT-Beclin-1 treatment induced a pronounced thickening of the synovium with increased cell numbers and collagen deposition compared to PBS-treated mice. The increased number of synovial cells did not show substantial expression of α-SMA⁺ or CD45⁺ cells.

[Conclusions] Contrary to our expected results, TAT-Beclin-1 did not attenuate cartilage degeneration. Rather, it exacerbated synovial thickening likely through cell proliferation and collagen deposition, resulting in a severe fibrotic phenotype independent of myofibroblast differentiation or inflammation. We are evaluating alternate injection and dosing strategies to determine if OA may be modified by TAT-Beclin-1 treatment.
## AUTHORS’ INDEX

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>PL</td>
<td>Presidential Lecture</td>
</tr>
<tr>
<td>PS</td>
<td>Presidential Symposium</td>
</tr>
<tr>
<td>SS</td>
<td>Special Symposium</td>
</tr>
<tr>
<td>S</td>
<td>Symposium</td>
</tr>
<tr>
<td>EL</td>
<td>Educational Lecture</td>
</tr>
<tr>
<td>MTE</td>
<td>Meet the Expert</td>
</tr>
<tr>
<td>LS</td>
<td>Luncheon Seminar</td>
</tr>
<tr>
<td>ES</td>
<td>Evening Seminar</td>
</tr>
<tr>
<td>ACL-LS</td>
<td>Annual Course Lecture Luncheon Seminar</td>
</tr>
<tr>
<td>W</td>
<td>Workshop</td>
</tr>
<tr>
<td>ICW</td>
<td>International Concurrent Workshop</td>
</tr>
<tr>
<td>P</td>
<td>Poster Session</td>
</tr>
<tr>
<td>EP</td>
<td>English Poster Session</td>
</tr>
</tbody>
</table>

**Bold Abstract No.** ........ Presenting Author
<table>
<thead>
<tr>
<th>A</th>
<th>B</th>
<th>C</th>
<th>D</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abe, Asami</td>
<td><strong>S11-3</strong>, W25-4, W65-3, ICW2-2, P1-085, P1-088, P1-144, P1-170, P2-019, P2-155</td>
<td><strong>Akihiro, Nakamura</strong></td>
<td><strong>ICW13-2</strong></td>
</tr>
<tr>
<td>Abe, Chizuru</td>
<td><strong>P3-062</strong></td>
<td><strong>Akioka, Shinji</strong></td>
<td><strong>W7-4</strong></td>
</tr>
<tr>
<td>Abe, Fumito</td>
<td><strong>P2-066</strong></td>
<td><strong>Akira, Taro</strong></td>
<td><strong>P2-097, P2-126, P3-246, P3-259, P3-270</strong></td>
</tr>
<tr>
<td>Abe, Hidekazu</td>
<td>S3-3, W24-2, P1-003, P1-086, P2-171</td>
<td><strong>Aki, Asami</strong></td>
<td><strong>W6-9, P3-203</strong></td>
</tr>
<tr>
<td>Abe, Kazuya</td>
<td><strong>P3-251</strong></td>
<td><strong>Aki, Shosuke</strong></td>
<td><strong>W2-8, W5-0, W7-3, P1-149</strong></td>
</tr>
<tr>
<td>Abe, Koki</td>
<td><strong>EL24-1</strong></td>
<td><strong>Akiya, Kumi</strong></td>
<td><strong>W1-5, W5-9, P3-249, P3-293</strong></td>
</tr>
<tr>
<td>Abe, Kyosuke</td>
<td>P3-050</td>
<td><strong>Akiyama, Haruhiko</strong></td>
<td><strong>P1-148</strong></td>
</tr>
<tr>
<td>Abe, May</td>
<td>W36-1, W37-4, <strong>W70-1</strong>, W70-7, P1-001</td>
<td><strong>Akiyama, Yuichi</strong></td>
<td><strong>W2-8, P2-198, P3-150, P3-154, P3-177, P3-258, P3-302</strong></td>
</tr>
<tr>
<td>Abe, Masanori</td>
<td>W40-2</td>
<td><strong>Akiyama, Yuji</strong></td>
<td><strong>W4-5, W5-5, P1-082, P3-280</strong></td>
</tr>
<tr>
<td>Abe, Naoki</td>
<td>P2-250</td>
<td><strong>Akizuki, Shuji</strong></td>
<td><strong>W9-5, W32-1, W78-6, P3-012, P3-091, P3-239</strong></td>
</tr>
<tr>
<td>Abe, Nobuya</td>
<td>W31-2-5, ICW4-3, ICW8-5, <strong>ICW10-2</strong></td>
<td><strong>Akutsu, Yuko</strong></td>
<td><strong>W7-3</strong></td>
</tr>
<tr>
<td>Abe, Takeo</td>
<td><strong>P2-020</strong></td>
<td><strong>Ali, Shabana A</strong></td>
<td><strong>EP6-3</strong></td>
</tr>
<tr>
<td>Adeichi, Nobuo</td>
<td>S3-4</td>
<td><strong>Alten, Rieke</strong></td>
<td><strong>P3-278</strong></td>
</tr>
<tr>
<td>Adachi, Soichiro</td>
<td><strong>P3-228</strong></td>
<td><strong>Amano, Eri</strong></td>
<td><strong>P2-159</strong></td>
</tr>
<tr>
<td>Agarwal, Vikas</td>
<td>ICW20-6</td>
<td><strong>Amano, Hirofumi</strong></td>
<td><strong>W2-6, P3-004, P2-187, P2-194, P2-199, P2-246</strong></td>
</tr>
<tr>
<td>Agarwal, Amita</td>
<td>ICW8-2, ICW20-6</td>
<td><strong>Amano, Kanzo</strong></td>
<td><strong>W2-5, W3-5, P3-203, W3-3, W35-4, W39-4, W6-5, W6-8, ICW6-2, ICW6-6, ICW7-3, ICW17-3, ICW20-5, P2-119</strong></td>
</tr>
<tr>
<td>Ahmed, Sakir</td>
<td>ICW20-6</td>
<td><strong>Amano, Koichi</strong></td>
<td><strong>W3-5, W5-1, W7-7, <strong>P2-247</strong>, P3-121</strong></td>
</tr>
<tr>
<td>Aihara, Michiko</td>
<td>W69-5, P3-203, EP-09</td>
<td><strong>Amano, Tatsuki</strong></td>
<td><strong>P3-183</strong></td>
</tr>
<tr>
<td>Aita, Tetsushi</td>
<td>W31-1-1, W31-2-4, W36-5, W73-5, P1-064, P2-060</td>
<td><strong>Amano, Yuichiro</strong></td>
<td><strong>P2-137</strong></td>
</tr>
<tr>
<td>Aizaki, Yoshimi</td>
<td>W17-5, ICW2-5, P2-006</td>
<td><strong>Amsaki, Yoshihara</strong></td>
<td><strong>W3-5, W47-4, P1-096, P3-228</strong></td>
</tr>
<tr>
<td>Aizawa, Ayako</td>
<td>W34-3, P1-235, P2-219, P3-115</td>
<td><strong>Amengual, Olga</strong></td>
<td><strong>W6-4, ICW3-5, ICW4-3, ICW4-4, ICW8-5, ICW10-2, ICW16-6, ICW19-4, P2-215, EP3-01</strong></td>
</tr>
<tr>
<td>Aizawa, Toshiaki</td>
<td>S3-3, W24-2, P1-003, P1-086, P2-094, P2-115, P2-171</td>
<td><strong>Amin, Shreyasee</strong></td>
<td><strong>ICW17-4</strong></td>
</tr>
<tr>
<td>Ajima, Chisaki</td>
<td>W35-2, P2-073, P3-175</td>
<td><strong>Amuro, Hideki</strong></td>
<td><strong>W1-8, W36-6, W51-5, W55-2, W55-6, W75-2, ICW6-1, ICW7-4, P3-213, P2-052, P3-007, P3-048, P3-060, P3-116</strong></td>
</tr>
<tr>
<td>Ajiro, Junya</td>
<td>P2-117, P3-066</td>
<td><strong>Ando, Fumihiro</strong></td>
<td><strong>ICW5-6</strong></td>
</tr>
<tr>
<td>Akagawa, Manabu</td>
<td>S3-3</td>
<td><strong>Ando, Kiichiro</strong></td>
<td><strong>An, Di</strong></td>
</tr>
<tr>
<td>Akagi, Midori</td>
<td>P2-206, P3-062</td>
<td><strong>Ando, Seiichiro</strong></td>
<td><strong>Anciauta, Ioan</strong></td>
</tr>
<tr>
<td>Akagi, Takahiko</td>
<td>W73-2, P1-063, P2-202, P2-225</td>
<td><strong>Ando, Takayas</strong></td>
<td><strong>ICW5-6, EP-06</strong></td>
</tr>
<tr>
<td>Akahoshi, Mitsuteru</td>
<td>W26-4, W33-2, W34-5, W65-1, ICW11-4, ICW14-6, P1-203, P2-037, P2-072, P2-221, P2-241, P3-052, P3-152, P3-202, P3-217, P3-254</td>
<td><strong>Ando, Fumihiro</strong></td>
<td><strong>P1-080</strong></td>
</tr>
<tr>
<td>Akai, Yasuhiro</td>
<td>P2-052, P3-222</td>
<td><strong>Ando, Seiichiro</strong></td>
<td><strong>P2-194, P2-246</strong></td>
</tr>
<tr>
<td>Akamine, Keiji</td>
<td>P2-251, P2-311</td>
<td><strong>Ando, Takayas</strong></td>
<td><strong>W3-9, W59-4, W64-6, W65-5, P2-105, P3-090, P3-126, P3-284</strong></td>
</tr>
<tr>
<td>Akao, Satoshi</td>
<td>P3-248</td>
<td><strong>Aono, Hiroshi</strong></td>
<td><strong>W1-4</strong></td>
</tr>
<tr>
<td>Akasaka, Yukio</td>
<td>W26-2, ICW19-5, P1-065, P2-172</td>
<td><strong>Aoki, Akiko</strong></td>
<td><strong>W10-2, W5-5</strong></td>
</tr>
<tr>
<td>Akashi, Kengo</td>
<td>W75-2, ICW6-1, ICW7-4, P1-107, P1-231, P2-052, P2-278, P2-299, P3-077, P3-114, P3-181</td>
<td><strong>Aoki, Kazutoshi</strong></td>
<td><strong>S21-3</strong></td>
</tr>
<tr>
<td>Akashi, Koichi</td>
<td>W26-4, W33-2, W34-5, W65-1, ICW11-4, ICW14-6, P1-203, P2-037, P2-072, P2-221, P3-052, P3-063, P3-152, P3-202, P3-217, P3-254</td>
<td><strong>Aoki, Naoko</strong></td>
<td><strong>P1-006</strong></td>
</tr>
<tr>
<td>Akashi, Yoshihiro</td>
<td>P1-100</td>
<td><strong>Aoki, Sadao</strong></td>
<td><strong>P1-014, P1-048, P1-057</strong></td>
</tr>
<tr>
<td>Akazawa, Hiroki</td>
<td>W20-5, W22-6, W28-2, P1-208, P2-212, P2-143, P3-178</td>
<td><strong>Aoki, Yuu</strong></td>
<td><strong>P2-001</strong></td>
</tr>
<tr>
<td>Akebo, Hiroyuki</td>
<td>**ICW4-3, ICW8-5, <strong>ICW10-2</strong></td>
<td><strong>Aonuma, Hiroshi</strong></td>
<td><strong>S3-3, W24-2, P1-003, P1-086,</strong></td>
</tr>
</tbody>
</table>
Blanco, Ricardo W 38-2
Bohgaki, Miyuki W 10-3
Bohgaki, Toshiyuki W 62-4, ICW 3-5, ICW 4-2, ICW 5-1
Bojinca, Mihai ICW 5-6, EP 2-06
Bono, Stephanie ICW 17-4
Borada, Kaushik H ICW 22-5
Brockett, Robert ICW 5-1
Bruce, Ian ICW 31-1-7
Burns, Ariel ICW 4-6
Buyon, Jill P ICW 17-4
Byers, Nicole ICW 38-6
Cai, Zhihong P 104
Camp, Heidi S ICW 38-3
Cardiel, Mario W 31-1-7
Carlier, Hilde ICW 44-2
Chae, Jin-nyeong ICW 13-1
Chan, Mable Wing Yan ICW 22-3
Chang, Song Ho ICW 1-73
Chen, Hua ICW 14-2
Chen, Jen-hao ICW 4-2
Chen, Lei ICW 38-6
Chen, Ming-han ICW 13-3
Chen, Su ICW 8-3
Chen, Weijia ICW 6-6, W 22-5, P 1-005
Chen, Yi-Hsing ICW 38-4
Chen, Zhilei ICW 14-2
Chen, Zhu ICW 8-6
Cheng, Sue ICW 70-6
Chia, Jean-san ICW 8-6
Chiba, Asako ICW 26-3, W 79-3, W 79-5, P 1-020
Chiba, Junji ICW 103, P 115
Chiba, Ko ICW 48-5, W 48-6, P 1-070
Chiba, Noriyuki ICW 10-5, W 34-1
Chien-chih, Lai ICW 9-6
Chifu, Yutaka ICW 8-5
Chijiwa, Tatsumi ICW 6-1, W 6-2, P 1-009, P 1-038, P 1-133, P 2-028, P 2-065, P 2-168
Chikuda, Hirotaka ICW 14-3
Chin, Fangyi ICW 43-5, P 2-228, ICW 235, EP 1-08
Chinen, Naofumi ICW 296, P 10-6, P 3-106
Chinone, Orie ICW 31-4
Cho Hee, Bang ICW 22-4
Cho, Soo-kyung ICW 7-5
Choe, Hyomin ICW 50-2, W 75-6, P 2-166
Choi, Seongmi ICW 7-5
Choi, Sung Jae ICW 22-4
Choi, Yunjung ICW 3-5, P 2-05, P 2-191
Chosa, Etsuo ICW 17-4
Chowdhury, Vaidini R ICW 2-2, W 9-4, W 11-5, W 31-1-6, W 32-2, W 32-6, W 33-5, W 48-5
<table>
<thead>
<tr>
<th>Name</th>
<th>ICW/ICW-</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ernst, Floranne C</td>
<td>ICW17-4</td>
</tr>
<tr>
<td>Eshiro, Hisako</td>
<td>P2-047</td>
</tr>
<tr>
<td>Etani, Yuki</td>
<td>ICW2-1</td>
</tr>
<tr>
<td>Etori, Keishi</td>
<td>P3-166</td>
</tr>
<tr>
<td>Ezawa, Kazuhiko</td>
<td>S1-3, W66-5,</td>
</tr>
<tr>
<td></td>
<td>P1-079</td>
</tr>
<tr>
<td>Favio, Enriquez-sosa</td>
<td>ICW6-3</td>
</tr>
<tr>
<td>Feser, Marie</td>
<td>PS-2</td>
</tr>
<tr>
<td>Friedman, Alan</td>
<td>W38-2, W38-3</td>
</tr>
<tr>
<td>Fujibayashi, Takayoshi</td>
<td>W28-1, W71-7,</td>
</tr>
<tr>
<td></td>
<td>P2-051</td>
</tr>
<tr>
<td>Fujieda, Yuichiro</td>
<td>W35-3, W47-4,</td>
</tr>
<tr>
<td></td>
<td>W54-5, W62-4,</td>
</tr>
<tr>
<td></td>
<td>ICW3-5, ICW4-3,</td>
</tr>
<tr>
<td></td>
<td>ICW8-5, ICW10-2,</td>
</tr>
<tr>
<td></td>
<td>ICW16-6, ICW19-4,</td>
</tr>
<tr>
<td></td>
<td>P2-215, EP3-01</td>
</tr>
<tr>
<td>Fujii, Asami</td>
<td>S2-4</td>
</tr>
<tr>
<td>Fujii, Hiroshi</td>
<td>W20-6, W27-2,</td>
</tr>
<tr>
<td></td>
<td>W72-5, ICW20-4</td>
</tr>
<tr>
<td>Fujii, Hiroshi</td>
<td>W42-1, W43-6,</td>
</tr>
<tr>
<td></td>
<td>W56-6, W61-5,</td>
</tr>
<tr>
<td></td>
<td>P3-009, P3-067,</td>
</tr>
<tr>
<td></td>
<td>P3-102, P3-192</td>
</tr>
<tr>
<td>Fujii, Ryoji</td>
<td>P2-001</td>
</tr>
<tr>
<td>Fujii, Takao</td>
<td>MTE15, ES8-2,</td>
</tr>
<tr>
<td></td>
<td>W30-1, P2-018,</td>
</tr>
<tr>
<td></td>
<td>P2-041, P2-128</td>
</tr>
<tr>
<td>Fukikawa, Keita</td>
<td>W9-4, W32-2,</td>
</tr>
<tr>
<td></td>
<td>W33-5, P1-053</td>
</tr>
<tr>
<td>Fukikawa, Satoshi</td>
<td>W7-2</td>
</tr>
<tr>
<td>Fukikawa, Yoshikazu</td>
<td>ICW7-4, P1-098,</td>
</tr>
<tr>
<td></td>
<td>P1-107, P2-278,</td>
</tr>
<tr>
<td></td>
<td>P3-114</td>
</tr>
<tr>
<td>Fujiki, Youhei</td>
<td>W1-6, W2-1,</td>
</tr>
<tr>
<td></td>
<td>W13-4, W58-6,</td>
</tr>
<tr>
<td></td>
<td>P2-058, P2-116,</td>
</tr>
<tr>
<td></td>
<td>P2-196, P2-216,</td>
</tr>
<tr>
<td></td>
<td>P3-073, P3-108,</td>
</tr>
<tr>
<td></td>
<td>P3-122, P3-125,</td>
</tr>
<tr>
<td></td>
<td>P3-157, P3-274</td>
</tr>
<tr>
<td>Fujimaki, Hiroshi</td>
<td>W74-2</td>
</tr>
<tr>
<td>Fujimori, Misuzu</td>
<td>S1-3, W66-5,</td>
</tr>
<tr>
<td></td>
<td>P1-079</td>
</tr>
<tr>
<td>Fujimoto, Hisae</td>
<td>W12-4, W39-3,</td>
</tr>
<tr>
<td></td>
<td>W59-4, W64-6,</td>
</tr>
<tr>
<td></td>
<td>W65-5, P1-046,</td>
</tr>
<tr>
<td></td>
<td>P2-105, P3-090,</td>
</tr>
<tr>
<td></td>
<td>P3-126, P3-284</td>
</tr>
<tr>
<td>Fujimoto, Kyoko</td>
<td>W54-1, P3-096,</td>
</tr>
<tr>
<td></td>
<td>P3-186, P3-289</td>
</tr>
<tr>
<td>Fujimoto, Manabu</td>
<td>S7-4, W58-1</td>
</tr>
<tr>
<td>Fujimoto, Minoru</td>
<td>W2-4</td>
</tr>
<tr>
<td>Fujimoto, Shino</td>
<td>S21-2, S21-3,</td>
</tr>
<tr>
<td></td>
<td>P2-292, P3-225</td>
</tr>
<tr>
<td>Fujimoto, Sho</td>
<td>P3-233</td>
</tr>
<tr>
<td>Fujimoto, Takashi</td>
<td>P1-247, P2-052,</td>
</tr>
<tr>
<td></td>
<td>P3-222</td>
</tr>
<tr>
<td>Fujimura, Kenjiro</td>
<td>P1-150, P1-151,</td>
</tr>
<tr>
<td></td>
<td>P1-165, P2-161,</td>
</tr>
<tr>
<td></td>
<td>P2-167, P2-185</td>
</tr>
<tr>
<td>Fujimura, Takanori</td>
<td>W9-2, P1-247</td>
</tr>
<tr>
<td>Fujinaga, Hiroshi</td>
<td>W19-4, P1-141</td>
</tr>
<tr>
<td>Fujio, Keishi</td>
<td>S5-2, ES15-1,</td>
</tr>
<tr>
<td></td>
<td>ES7-2, W1-5,</td>
</tr>
<tr>
<td></td>
<td>W9-6, W30-1,</td>
</tr>
<tr>
<td></td>
<td>W52-1, W52-5,</td>
</tr>
<tr>
<td></td>
<td>W64-3, W72-1,</td>
</tr>
<tr>
<td></td>
<td>W78-5, ICW1-2,</td>
</tr>
<tr>
<td></td>
<td>ICW1-4, ICW6-4,</td>
</tr>
<tr>
<td></td>
<td>ICW7-3, ICW11-3,</td>
</tr>
<tr>
<td></td>
<td>ICW18-1, ICW18-4,</td>
</tr>
<tr>
<td></td>
<td>ICW21-1, P1-201,</td>
</tr>
<tr>
<td></td>
<td>P1-234, P3-022,</td>
</tr>
<tr>
<td></td>
<td>EP1-03</td>
</tr>
<tr>
<td>Fujioka, Kazuki</td>
<td>W18-2, W27-6,</td>
</tr>
<tr>
<td></td>
<td>W33-3, W60-6,</td>
</tr>
<tr>
<td></td>
<td>W77-1, P2-087,</td>
</tr>
<tr>
<td></td>
<td>P2-210, P2-301,</td>
</tr>
<tr>
<td></td>
<td>P2-303, P3-042,</td>
</tr>
<tr>
<td></td>
<td>P3-046, P3-128,</td>
</tr>
<tr>
<td></td>
<td>P3-170, P3-212,</td>
</tr>
<tr>
<td></td>
<td>P3-243</td>
</tr>
<tr>
<td>Fujioka, Kei</td>
<td>W63-3, P1-077,</td>
</tr>
<tr>
<td></td>
<td>P3-071</td>
</tr>
<tr>
<td>Fujisawa, Junichi</td>
<td>ICW13-4, ICW22-2, P3-038, EP2-12, EP2-13, EP2-14</td>
</tr>
<tr>
<td>Fujisawa, Yuhei</td>
<td>W61-5, P3-009</td>
</tr>
<tr>
<td>Fujishiro, Daisuke</td>
<td>W31-1-2</td>
</tr>
<tr>
<td>Fujita, Hideki</td>
<td>P3-033</td>
</tr>
<tr>
<td>Fujita, Kazuyuki</td>
<td>W60-2</td>
</tr>
<tr>
<td>Fujita, Masaaki</td>
<td>P2-235, P3-132</td>
</tr>
<tr>
<td>Fujita, Shinichiro</td>
<td>S1-3, W66-5</td>
</tr>
<tr>
<td>Fujita, Shinichi</td>
<td>W73-2, ICW1-6,</td>
</tr>
<tr>
<td></td>
<td>P1-063, P2-202,</td>
</tr>
<tr>
<td></td>
<td>P2-225</td>
</tr>
<tr>
<td>Fujita, Takayuki</td>
<td>W40-2</td>
</tr>
<tr>
<td>Fujita, Yoko</td>
<td>W20-6, W72-5</td>
</tr>
<tr>
<td>Fujita, Yoshimasa</td>
<td>P3-225</td>
</tr>
<tr>
<td>Fujita, Yoshiro</td>
<td>W13-1, P1-054,</td>
</tr>
<tr>
<td></td>
<td>P1-226, P2-229,</td>
</tr>
<tr>
<td></td>
<td>P2-274, P2-297,</td>
</tr>
<tr>
<td></td>
<td>P3-107</td>
</tr>
<tr>
<td>Fujita, Yukihiko</td>
<td>P2-253</td>
</tr>
<tr>
<td>Fujita, Yuya</td>
<td>W29-2, W43-2,</td>
</tr>
<tr>
<td></td>
<td>W43-4, W55-1,</td>
</tr>
<tr>
<td></td>
<td>W63-5, ICW3-4,</td>
</tr>
<tr>
<td></td>
<td>ICW15-4, P1-021,</td>
</tr>
<tr>
<td></td>
<td>P1-183, P1-204,</td>
</tr>
<tr>
<td></td>
<td>P2-237</td>
</tr>
<tr>
<td>Fujiwara, Hiroshi</td>
<td>W46-4, W47-3,</td>
</tr>
<tr>
<td></td>
<td>P2-049, P2-181,</td>
</tr>
<tr>
<td></td>
<td>P3-156, P3-189</td>
</tr>
<tr>
<td>Fujiwara, Kazuo</td>
<td>P1-068</td>
</tr>
<tr>
<td>Fujiwara, Michio</td>
<td>W31-1-4</td>
</tr>
<tr>
<td>Fujiwara, Yoshifumi</td>
<td>W26-2, ICW19-5,</td>
</tr>
<tr>
<td></td>
<td>P1-041, P1-065,</td>
</tr>
<tr>
<td></td>
<td>P2-172</td>
</tr>
<tr>
<td>Fukae, Jun</td>
<td>P1-131, P1-222</td>
</tr>
<tr>
<td>Fukasawa, Chikako</td>
<td>W58-2</td>
</tr>
<tr>
<td>Fukaya, Naoki</td>
<td>P1-066</td>
</tr>
<tr>
<td>Fukaya, Shinji</td>
<td>W11-7, W35-3</td>
</tr>
<tr>
<td>Fukaya, Shusaku</td>
<td>W2-2, W12-6, W77-6, P2-236, P3-113</td>
</tr>
<tr>
<td>Fukuda, Koji</td>
<td>W8-6, W15-1, W51-4, P1-029, P1-035, P1-090, P2-042, P2-089, P3-014</td>
</tr>
<tr>
<td>Fukuda, Michio</td>
<td>P3-080, P3-224</td>
</tr>
<tr>
<td>Fukuda, Natsuko</td>
<td>P3-265</td>
</tr>
<tr>
<td>Fukuda, Takaaki</td>
<td>W37-2</td>
</tr>
<tr>
<td>Fukuda, Wataru</td>
<td>W34-4, W44-5, W73-3, P1-236, P2-077, P3-089</td>
</tr>
<tr>
<td>Fukue, Ryosuke</td>
<td>W8-2</td>
</tr>
<tr>
<td>Fukuhara, Shunichi</td>
<td>S17-1</td>
</tr>
<tr>
<td>Fukui, Akihiro</td>
<td>P3-029</td>
</tr>
<tr>
<td>Fukui, Jun</td>
<td>W46-4, W47-3,</td>
</tr>
<tr>
<td></td>
<td>P2-049, P2-181,</td>
</tr>
<tr>
<td></td>
<td>P3-156, P3-189</td>
</tr>
<tr>
<td>Fukui, Naoshi</td>
<td>W26-6, P2-011</td>
</tr>
<tr>
<td>Fukui, Sho</td>
<td>P2-227, P3-196,</td>
</tr>
<tr>
<td></td>
<td>P3-213</td>
</tr>
<tr>
<td>Fukumi, Sachiko</td>
<td>P3-065</td>
</tr>
<tr>
<td>Fukuoka, Kazuhiro</td>
<td>W40-5, W41-1, W60-1, P1-125</td>
</tr>
<tr>
<td>Fukuishi, Junichi</td>
<td>W26-2, ICW19-5, P1-065, P2-172</td>
</tr>
<tr>
<td>Fukushima, Mayuko</td>
<td>W73-2, P1-063,</td>
</tr>
<tr>
<td></td>
<td>P2-202, P2-225</td>
</tr>
<tr>
<td>Fukushima, Toshihiro</td>
<td>P2-292</td>
</tr>
<tr>
<td>Fukuyo, Shunsuke</td>
<td>W4-1, W13-2, W51-2, W55-1, ICW6-5, ICW7-1, ICW8-1, ICW9-4, ICW12-1, ICW12-2, ICW12-6,</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Hamada, Kazuya</td>
<td>P2-254</td>
</tr>
<tr>
<td>Hamada, Naoki</td>
<td>W31-2-2, ICW3-2, ICW12-3, P1-034, P1-179, P2-188, P2-277, P2-281, <strong>EP1-09</strong></td>
</tr>
<tr>
<td>Hamada, Riku</td>
<td>P2-251</td>
</tr>
<tr>
<td>Hamaguchi, Marina</td>
<td>W59-3, ICW10-4, ICW10-5, P1-211, P3-210, P3-293</td>
</tr>
<tr>
<td>Hamano, Ryoko</td>
<td>W43-6</td>
</tr>
<tr>
<td>Hamano, Yoshimasa</td>
<td>P2-226, P3-123</td>
</tr>
<tr>
<td>Hamasato, Kazuhiro</td>
<td>P2-134, P2-205</td>
</tr>
<tr>
<td>Hamatani, Hiroko</td>
<td>W32-4, P2-012</td>
</tr>
<tr>
<td>Hammer, Anne</td>
<td>W76-3</td>
</tr>
<tr>
<td>Hanabayashi, Masahiro</td>
<td>W71-7</td>
</tr>
<tr>
<td>Hanai, Shinichi</td>
<td>W4-3, P3-175, P3-262</td>
</tr>
<tr>
<td>Hanami, Kentaro</td>
<td>W13-2, W51-2, W55-1, ICW6-5, ICW7-1, ICW8-1, ICW12-1, ICW12-2, ICW12-6, ICW13-5, ICW14-5, ICW17-2, ICW17-6, ICW21-5, P3-300</td>
</tr>
<tr>
<td>Hanada, Hideki</td>
<td>W29-6, P1-128</td>
</tr>
<tr>
<td>Hanada, Hironari</td>
<td>W11-3, W20-2, W31-2-1, <strong>W31-2-6</strong>, W33-6, P1-135</td>
</tr>
<tr>
<td>Hanada, Masanori</td>
<td>W79-4, P1-186, P1-206, P2-071, P2-220, P2-232, P3-070, P3-167, P3-219</td>
</tr>
<tr>
<td>Hanada, Ryosuke</td>
<td>P2-070</td>
</tr>
<tr>
<td>Handa, Norio</td>
<td>W1-5, W52-5, <strong>ICW11-3</strong></td>
</tr>
<tr>
<td>Handa, Tomohiro</td>
<td>P3-091</td>
</tr>
<tr>
<td>Handa, Yūichi</td>
<td>W33-4, W34-4, P1-236, P3-149, P3-216</td>
</tr>
<tr>
<td>Hanioka, Yusuke</td>
<td>P3-195, P3-244</td>
</tr>
<tr>
<td>Hanly, John G</td>
<td>S4-1, ICW4-6</td>
</tr>
<tr>
<td>Hanyu, Tadamasu</td>
<td>W34-4, ICW22-2, P1-162, P1-236</td>
</tr>
<tr>
<td>Hara, Akinori</td>
<td>P2-068</td>
</tr>
<tr>
<td>Hara, Kazusato</td>
<td>P3-220</td>
</tr>
<tr>
<td>Hara, Ryoki</td>
<td>W3-4, W57-1, P2-244, P2-265</td>
</tr>
<tr>
<td>Hara, Ryosuke</td>
<td>P1-215, P3-088</td>
</tr>
<tr>
<td>Hara, Ryota</td>
<td>S3-5, W9-2, W36-6, W51-5, W55-2, W55-6, W75-2, ICW6-1, ICW7-4, P1-231, P1-247, <strong>P2-052</strong>, P3-007</td>
</tr>
<tr>
<td>Hara, Satoshi</td>
<td>W42-1, W43-6, W56-6, P3-009, P3-067, P3-102, P3-192</td>
</tr>
<tr>
<td>Harada, Hiroaki</td>
<td>W1-5</td>
</tr>
<tr>
<td>Harada, Koji</td>
<td>P3-017</td>
</tr>
<tr>
<td>Harada, Mariko</td>
<td>P3-234</td>
</tr>
<tr>
<td>Harada, Ryozo</td>
<td>S1-3, S11-2, <strong>W66-5</strong>, P1-079</td>
</tr>
<tr>
<td>Harada, Tomoya</td>
<td>W11-4, P1-012, P2-259</td>
</tr>
<tr>
<td>Harada, Toshihiko</td>
<td>P1-153</td>
</tr>
<tr>
<td>Harada, Yoshinori</td>
<td>W28-5, W61-3, W73-1, ICW9-1, ICW9-2, P1-061, P2-036, P2-067, <strong>P3-078</strong>, P3-118</td>
</tr>
<tr>
<td>Haraguchi, Akihisa</td>
<td>W26-2, P1-041</td>
</tr>
<tr>
<td>Haraguchi, Kazushi</td>
<td>P2-263</td>
</tr>
<tr>
<td>Harai, Hiroaki</td>
<td><strong>LS17</strong></td>
</tr>
<tr>
<td>Harama, Kimie</td>
<td>W4-3, P3-175, P3-266</td>
</tr>
<tr>
<td>Haraoka, Hitomi</td>
<td>W54-5, W59-3, ICW6-6, ICW10-4, ICW10-5, P1-211, P3-033, P3-047, P3-210, P3-293</td>
</tr>
<tr>
<td>Harigae, Hideo</td>
<td>W20-6, W27-2, W72-5, ICW20-4</td>
</tr>
<tr>
<td>Harigane, Kengo</td>
<td><strong>W75-6</strong></td>
</tr>
<tr>
<td>Haro, Hirotaka</td>
<td>P1-155, P3-262</td>
</tr>
<tr>
<td>Harvey, Nicholas C</td>
<td>S8-5</td>
</tr>
<tr>
<td>Hase, Kayoko</td>
<td>W27-3</td>
</tr>
<tr>
<td>Hasegawa, Eiko</td>
<td>W21-6, W53-4, P1-055</td>
</tr>
<tr>
<td>Hasegawa, Eriko</td>
<td>W25-4, W65-3, ICW2-2, <strong>P1-085</strong>, P1-088, P1-144, P2-019, P2-155</td>
</tr>
<tr>
<td>Hasegawa, Hitoshi</td>
<td>W21-3, W41-2, W47-6, P1-052</td>
</tr>
<tr>
<td>Hasegawa, Ken</td>
<td><strong>W57-5</strong>, P2-030, P2-131</td>
</tr>
<tr>
<td>Hasegawa, Kiminori</td>
<td>P1-096, P1-119</td>
</tr>
<tr>
<td>Hasegawa, Masahiro</td>
<td>P2-074, P2-163</td>
</tr>
<tr>
<td>Hasegawa, Minoru</td>
<td>W58-1</td>
</tr>
<tr>
<td>Hasegawa, Takakazu</td>
<td>P2-197, P3-098, P3-164, P3-205, P3-221, P3-283</td>
</tr>
<tr>
<td>Hasegawa, Yasuhiro</td>
<td>W31-1-3, P2-189, P3-092, P3-190</td>
</tr>
<tr>
<td>Hashiba, Yayoi</td>
<td>W29-4, W34-3, W57-6</td>
</tr>
<tr>
<td>Hashiguchi, Tomomitsu</td>
<td><strong>W5-6</strong></td>
</tr>
<tr>
<td>Hashimoto, Atsushi</td>
<td>W10-5, W16-2, W34-1, W55-5, W71-1, P1-008, P1-043, P2-011</td>
</tr>
<tr>
<td>Hashimoto, Hiro</td>
<td>P3-018</td>
</tr>
<tr>
<td>Hashimoto, Hiroshi</td>
<td>W41-6</td>
</tr>
<tr>
<td>Hashimoto, Jun</td>
<td>S3-2, S11-5, <strong>MTE2</strong>, W28-5, W49-1, W49-6, W50-6, W61-3, W73-1, ICW9-1, ICW9-2, P1-061, P1-149, P2-036, P2-067, P3-036, P3-078</td>
</tr>
<tr>
<td>Hashimoto, Keisuke</td>
<td>P1-010, P1-011</td>
</tr>
<tr>
<td>Hashimoto, Kotaro</td>
<td><strong>P3-167</strong></td>
</tr>
<tr>
<td>Hashimoto, Marowa</td>
<td>W8-6, W51-4, P1-035, P1-090, P2-089, <strong>P3-014</strong></td>
</tr>
<tr>
<td>Hashimoto, Masahiro</td>
<td><strong>ICW10-1</strong></td>
</tr>
<tr>
<td>Hashimoto, Motomu</td>
<td><strong>LS27, ES10-2</strong>, W7-4, W9-5, W32-1, W36-6, W50-6, W51-3, W51-5, W55-2, W55-6, W75-2, W78-6, ICW6-1, ICW7-4, ICW16-1, P1-058, P1-231, P1-240, P2-052, P3-007, P3-012, P3-091, P3-239</td>
</tr>
<tr>
<td>Hashimoto, Naoaki</td>
<td><strong>W54-3</strong></td>
</tr>
<tr>
<td>Hashimoto, Takako</td>
<td>W2-2, W12-6, W77-6, P2-236, P3-113</td>
</tr>
<tr>
<td>Hashimoto, Takenori</td>
<td>P5-2-096</td>
</tr>
<tr>
<td>Hashimoto, Teppie</td>
<td>W41-3, W47-5, W51-6, P2-107, P2-139, P3-015, P3-082, P3-094, P3-173, P3-185, P3-249, P3-256</td>
</tr>
<tr>
<td>Hashimoto, Yoshinori</td>
<td>P2-145</td>
</tr>
<tr>
<td>Hashiramoto, Akira</td>
<td>W17-6, W37-6, W41-3, P1-030, P1-033</td>
</tr>
<tr>
<td>Hasui, Keisuke</td>
<td>W1-2, P1-128, P2-193</td>
</tr>
<tr>
<td>Hata, Kenichiro</td>
<td>W1-6, W23-4, W51-5, W52-6, W58-6, W61-4, W75-2, P2-058, P2-116, P2-196, <strong>P2-216</strong>, P3-073, P3-108, P3-122, P3-125, P3-157, P3-274</td>
</tr>
</tbody>
</table>
Inui, Kentaro
W2-4, W5-1, W16-5, W16-6, W23-6, W36-3, W37-1, W44-6, W68-1, W70-6, P2-023, P2-062, P3-004, P3-005, P3-008, P3-019, P3-020, P3-021, P3-290, P3-301

Inui, Saori
W63-3, P2-023, P3-004, P3-005, P3-008, P3-019, P3-020, P3-021, P3-290, P3-301

Irabu, Hitoshi
W7-6

Irino, Kensuke
P2-241, P3-152

Isaacs, John D
LS8

Iseki, Masako
LS33-2

Iseki, Masanori
ICW1-6, ICW15-2

Ishibashi, Mika
P1-239, P1-241

Ishibashi, Yasuyuki
P3-295

Ishibe, Yusuke
P3-295

Ishida, Motoko
P1-212, P2-025, P3-161, P3-253, P3-303

Ishida, Takaaki
W1-6, W2-4, W13-4, W58-4, W58-6, P2-058, P2-116, P2-196, P3-122, P3-125, P3-157, P3-274

Ishie, Shinichiro
W51-3

Ishigaki, Kazuyoshi
W63-3, P1-077, P3-071

Ishigaki, Sho
W10-1, P3-044

Ishigaki, Yasuhito
S21-3

Ishigatsubo, Yoshiaki
S14-2, W72-4

Ishiguro, Naoki

Ishiguro, Yoh
W12-1

Ishihara, Katsuhiko
ICW1-6

Ishihara, Ryuhei
W19-6, W28-4, W71-2, P1-116, P1-137, P2-046, P2-088, P3-297

Ishihara, Yoshihiro
P1-176

Ishii, Kayo
P2-291, P2-295

Ishii, Koji
W1-4, W9-6, ICW5-2

Ishii, Naoto
P1-027

Ishii, Nobuyasu
P3-048, P3-060, P3-116

Ishii, Sho
W17-2, W34-6, P1-024, P1-032, P2-002, P2-034, P3-191

Ishii, Taeko
W31-1-7, W39-1, P2-128

Ishii, Takanori
S6-2, W20-6, W27-2, W37-2, W47-2, W72-5, ICW20-4

Ishii, Wataru
P1-215, P3-088

Ishijima, Kazuyuki
W33-1, P1-039, P1-233

Ishikawa, Eiji
P1-181

Ishikawa, Hajime
S20-2, W10-6, W25-4, W49-6, W65-3, ICW2-2, P1-085, P1-088, P1-144, P1-170, P2-019, P2-144, P2-155

Ishikawa, Hisato
W71-7

Ishikawa, Junichi
W42-4, P2-290

Ishikawa, Osamu
W52-4, W58-1, ICW21-2

Ishikawa, Yuichi
W31-1-4

Ishikawa, Yuki
ICW16-1

Ishimaru, Hiroyasuo
W42-6, W53-1, P3-030, P3-109, P3-147

Ishimori, Kana
W12-4, W33-6, W39-3, W59-4, W64-6, W65-5, P1-046, P2-105, P3-090, P3-126, P3-284

Ishimura, Kaori
W20-5, W22-6, P1-208, P2-212, P3-143, P3-178

Ishioka Takei, Eriko
P2-245

Ishitoku, Michinori
P1-147

Ishizaka, Kosuke
P1-003, P2-115, P2-154

Ishizu, Tatsuo
ICW13, P3-151

Ito, Eriko
P1-190

Ito, Gen
P1-206

Ito, Haruko
W14-1

Ito, Haruyasu
W8-4

Ito, Hiroki
S3-3, W24-2, P1-003, P1-086, P2-171

Ito, Hiromu
W5-4, W9-5, W6-1, ICW6-6, W49-3, P3-054, P3-178

Ito, Hideki

Ito, Hiroshi
P1-229

Ito, Ikko
P1-232

Ito, Kiyoki
P1-226

Ito, Mayumi
W59-2, P2-192, P2-209, P3-101, P3-206

Ito, Nobuki
P1-240, P3-007

Ito, Nobuaki
P2-20, P1-135

Ito, Satoshi
P2-160

Ito, Satoshi
P2-140, P2-144, P2-155

Ito, Satosabu
P2-142, P2-144, P2-155

Ito, Shuichi
P2-244, P2-265

Ito, Takeshi
P1-014, P1-048, P1-057

Ito, Tatsuya
P3-280
Kawano, Mika  W36-1, W37-4, W70-1, W70-7, P1-001
Kawano, Mitsuhiro  S21-6, W38-1, W42-1, W43-6, W54-5, W61-5, P1-001, P3-009, P3-067, P3-102, P3-110, P3-140, P3-192
Kawano, Shinya  P2-194, P3-257
Kawano, Tetsuya  S3-3, W24-2, P1-003, P1-086, P2-094, P2-115, P2-171
Kawano, Yutaka  W63-6, ICW3-6
Kawarai, Yuya  W50-1, P2-262
Kawasaki, Aya  W41-6
Kawasaki, Makoto  P1-031
Kawasaki, Masashi  P2-051
Kawasaki, Yoshiko  W17-6, W37-6, P1-030, P1-033
Kawashima, Hiromasa  P3-222
Kawashima, Hirotoshi  W40-6, W42-4, P2-290
Kawashima, Soko  W40-5, W41-1, W43-1, W60-1
Kawasumi, Hidenaga  W79-4, P3-137, P3-260
Kawata, Daisuke  P3-120
Kawata, Junko  P2-271
Kawata, Masatoshi  P2-285
Kawato, Rui  P3-196, P3-213
Kawazoe, Mai  W74-4, P3-133
Keeling, Stephanie  ICW3-3
Kelly, Colleen  ICW4-6
Kerr, Lisa  W22-1
Kiboshi, Takao  W13-4, W52-6, W58-6, P2-058, P2-116, P2-196, P2-216, P3-073, P3-122, P3-125, P3-157
Kida, Daihei  W65-2, P1-154, P2-051
Kida, Issei  W14-6
Kida, Takashi  W18-2, W33-3, W60-6, W77-1, P2-087, P2-210, P2-303
Kido, Akira  P2-052
Kido, Toshiki  P3-076, P3-086, P3-180, P3-182, P3-207
Kihira, Daisuke  W19-3, P1-049, P1-075, P2-102, P2-175
Kijima, Takeshi  P1-170
Kikuchi, Eigo  W10-2, W55-4, P1-147
Kikuchi, Hirotoshi  S14-2, ES3-2, P2-195, P3-229, P3-232
Kikuchi, Jun  W31-2-1, ICW10-1, P1-200
Kikuchi, Tamami  P2-132
Kikuta, Junichi  S12-5
Kim, Harry  EP3-03
Kim, Hyoungyoung  ICW7-5
Kim, Jong-seo  ICW13-1
Kim, Sang-hyon  ICW13-1
Kim, Tae-hwan  ICW13-1
Kim, Viha  W13-4, W52-6, W58-6, P2-058, P2-116, P2-196, P2-216, P3-073, P3-122, P3-125, P3-157
Kimoto, Yasutaka  W26-4, W33-2, W34-5, W59-5, W60-5, W65-1, ICW11-4, ICW14-6, P1-203, P2-037, P2-072, P2-221, P2-241, P3-052, P3-063, P3-152, P3-202, P3-217, P3-254
Kimura, Fumihiro  W67-2, W67-6
Kimura, Junko  P1-094
Kimura, Makiko  P3-137, P3-260
Kimura, Naoki  P2-219, P3-115
Kimura, Tomoatsu  LS18, W19-4, W49-6, P3-028
Kimura, Yoshitaka  S3-3
Kimura, Yuko  P1-042, P1-250, P2-057, P2-124, P3-241
Kinoshi, Koji  W20-5, W22-6, W28-2, W35-6, W46-2, W65-4, P1-095, P1-207, P1-208, P2-054, P2-090, P2-212, P3-143, P3-178
Kiso, Yohei  W13-4, W31-2-2, W72-3, W72-4, ICW3-2, ICW11-1, ICW12-3, P1-034, P1-179, P1-188, P2-277, P2-281, P3-198, P3-203, P3-229, EP1-09
Kita, Yasuhiko  W7-2, W7-4, ICW8-4, P2-255
Kira, Tsutomu  P2-052
Kirino, Yohei  S14-2, W31-2-2, W72-3, W72-4, ICW3-2, ICW11-1, ICW12-3, P1-034, P1-179, P1-188, P2-277, P2-281, P3-198, P3-203, P3-229, EP1-09
Kitada, Ayako  W20-5, W22-6, W28-2, W35-6, W46-2, W65-4, P1-095, P1-207, P1-208, P2-054, P2-090, P2-212, P3-143, P3-178
Kitada, Yoshiko  W24-5
Kishida, Aiko  W12-1, W46-1, P1-026, P2-288, P3-054, P3-127, P3-208
Kishida, Dai  W12-1, W46-1, P1-026, P2-288, P3-054, P3-127, P3-208
Kishimoto, Daiga  W31-2-2, ICW3-2, ICW11-1, ICW12-3, P1-034, P1-179, P1-188, P2-277, P2-281, P3-198
Kishimoto, Hiroki  P1-064
Kishimoto, Kazuya  W20-5, W22-6, W28-2, W35-6, W46-2, W65-4, P1-208, P2-054, P2-212, P3-143, P3-178
Kishimoto, Kenji  ES1-1, ES13-1, W44-1, W72-6, P2-227, P3-196, P3-213
Kishimoto, Mitsumasu  ES1-1, ES13-1, W44-1, W72-6, P2-227, P3-196, P3-213
Kito, Yohei  P1-059, P1-168, P3-016
Kita, Yasuhiro  W31-1-4
Kitada, Ayako  P2-227, P3-196, P3-213, P3-285
Kitada, Yoshiko  W35-5, W78-1, P2-190, P3-255
Kitade, Makoto  P1-160
<table>
<thead>
<tr>
<th>Name</th>
<th>Pages</th>
<th>Name</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kitagawa, Akiko</td>
<td>P1-126, P1-189</td>
<td>Kobayashi, Takashi</td>
<td>ICW5-2</td>
</tr>
<tr>
<td>Kitagawa, Atsushi</td>
<td>P2-286</td>
<td>Kobayashi, Tatsuya</td>
<td>P1-164</td>
</tr>
<tr>
<td>Kitahara, Hideyuki</td>
<td>P1-141</td>
<td>Kobayashi, Tetsuo</td>
<td>S20-2, P2-144</td>
</tr>
<tr>
<td>Kitajima, Shinji</td>
<td>P2-068</td>
<td>Kobayashi, Toshiaki</td>
<td>W4-6, W69-4, P1-178, EP1-07, EP2-01</td>
</tr>
<tr>
<td>Kitajima, Susumu</td>
<td>W43-6</td>
<td>Kobayashi, Yoshiaki</td>
<td>P3-175</td>
</tr>
<tr>
<td>Kitakawa, Hirohiko</td>
<td>P3-083</td>
<td>Kobayashi, Yoshihisa</td>
<td>P3-251</td>
</tr>
<tr>
<td>Kitamura, Fumiya</td>
<td>P1-054, P1-226, P2-276, P2-297, P3-107</td>
<td>Kobayashi, Yuto</td>
<td>P3-008</td>
</tr>
<tr>
<td>Kitamura, Kenichiro</td>
<td>W4-3, P2-073, P3-175, P3-262</td>
<td>Koboyama, Tomohiko</td>
<td>S5-2, S5-5, W64-3, ICW1-2, P1-201</td>
</tr>
<tr>
<td>Kitamura, Noboru</td>
<td>S10-4, W40-2, W59-3, ICW10-4, ICW10-5, P1-211, P3-033, P3-047, P3-210, P3-293</td>
<td>Kochi, Yuta</td>
<td>W16-2, P1-043</td>
</tr>
<tr>
<td>Kitamura, Susumu</td>
<td>W22-2, W38-1</td>
<td>Kodama, Kako</td>
<td>W31-1-2</td>
</tr>
<tr>
<td>Kitani, Atsushi</td>
<td>ICW5-5</td>
<td>Kodama, Satoru</td>
<td>W1-4</td>
</tr>
<tr>
<td>Kitano, Akemi</td>
<td>P1-014, P1-048, P1-057</td>
<td>Kodama, Shogo</td>
<td>W76-1, P3-026</td>
</tr>
<tr>
<td>Kitano, Masayasu</td>
<td>W9-2, W47-5, W51-6, W54-3, W54-4, P2-107, P2-139, P2-213, P3-082, P3-094, P3-173, P3-185, P3-249, P3-256</td>
<td>Kodera, Hitoshi</td>
<td>W62-2</td>
</tr>
<tr>
<td>Kiyokawa, Shigeto</td>
<td>W54-4</td>
<td>Kodera, Masanari</td>
<td>W27-2, P37-2, P2-086</td>
</tr>
<tr>
<td>Kiyokawa, Tomofumi</td>
<td>W39-3, W59-4, W64-6, W65-5, P2-105, P3-090, P3-126, P3-284</td>
<td>Koenuma, Naoko</td>
<td>P1-163, P1-169</td>
</tr>
<tr>
<td>Kizaki, Kazuha</td>
<td>W74-6</td>
<td>Koga, Keiko</td>
<td>W8-1</td>
</tr>
<tr>
<td>Koarada, Syuichi</td>
<td>W18-3, W22-4, W59-5, W60-5, P3-097, P3-142, P3-281</td>
<td>Koga, Takuma</td>
<td>W54-1, W69-3, P3-096, P3-186, P3-289</td>
</tr>
<tr>
<td>Kobashi, Yasuko</td>
<td>P1-201, P1-011</td>
<td>Kogami, Masahiro</td>
<td>P3-103</td>
</tr>
<tr>
<td>Kobashigawa, Tsuyoshi</td>
<td>P1-087, P2-015, P2-238, P3-231, P3-240</td>
<td>Koh, Rei</td>
<td>P3-175</td>
</tr>
<tr>
<td>Kobayakawa, Tomonori</td>
<td>W71-7</td>
<td>Kohagura, Toaki</td>
<td>P2-250</td>
</tr>
<tr>
<td>Kobayashi, Atsushi</td>
<td>W31-1-2</td>
<td>Kohno, Chie</td>
<td>W13-1, W13-6, P3-308</td>
</tr>
<tr>
<td>Kobashigawa, Tsuyoshi</td>
<td>P3-240</td>
<td>Kohnosaka, Hitoshi</td>
<td>W30-1, W62-6, W64-5, ICW8-3, P1-022</td>
</tr>
<tr>
<td>Kobayakawa, Tomonori</td>
<td>W71-7</td>
<td>Koide, Yohei</td>
<td>W11-5</td>
</tr>
<tr>
<td>Kobayashi, Moto</td>
<td>S3-3, W24-2, P1-003, P1-086, P2-115, P2-154, P2-171</td>
<td>Koike, Taka</td>
<td>W30-4, P1-014, P1-048, P1-057</td>
</tr>
<tr>
<td>Kobayashi, Satomi</td>
<td>W52-1, W52-5, W64-3, W72-1, ICW21-1</td>
<td>Koizumi, Sayaka</td>
<td>P2-070</td>
</tr>
<tr>
<td>Kobayashi, Seiji</td>
<td>W3-1, W21-4, W23-2, W54-6, W69-1, W69-2, P1-229, P3-010</td>
<td>Koizumi, Yasuhiko</td>
<td>W31-1-4</td>
</tr>
<tr>
<td>Kobayashi, Shigeto</td>
<td>S18-1, W14-6, W41-6, W44-1, W44-3, P3-282</td>
<td>Kojima, Kanako</td>
<td>W34-2, W62-1, P2-122, P3-263</td>
</tr>
<tr>
<td>Kitaoki, Toshio</td>
<td>S21-2</td>
<td>Kojima, Masayo</td>
<td>W49-6, W70-3</td>
</tr>
<tr>
<td>Kitayama, Midori</td>
<td>P1-118, P1-230, P1-237, P2-098, P2-125, P2-130, P2-279, P3-238</td>
<td>Kojima, Mina</td>
<td>P1-245</td>
</tr>
<tr>
<td>Kiyokawa, Tomofumi</td>
<td>W39-3, W59-4, W64-6, W65-5, P2-105, P3-090, P3-126, P3-284</td>
<td>Kojima, Sachiko</td>
<td>P1-135</td>
</tr>
<tr>
<td>Kiyokawa, Tomofumi</td>
<td>W39-3, W59-4, W64-6, W65-5, P2-105, P3-090, P3-126, P3-284</td>
<td>Kojima, Shotaro</td>
<td>P3-079, P3-135</td>
</tr>
<tr>
<td>Koda, Kiyomi</td>
<td>P1-135</td>
<td>Kojima, Toshihisa</td>
<td>S11-1, MTE18, W5-3, W14-2, W24-5, W28-1, W30-1, W49-6,</td>
</tr>
</tbody>
</table>
Kuhn, Kristine A PS-2
Kujime, Rie W36-4, P1-188, P2-218, EP2-04
Kukimoto, Hitaru W43-1
Kumagai, Ken W50-2, W75-6, P2-166
Kumagai, Shinichi W3-5, W51-1, W77-4, ICW1-1, P2-247, P3-121
Kumagai, Takashi P1-050, P3-104
Kumakura, Shunichi P3-093
Kumano, Kotaro W53-5
Kumanogoh, Atsushi S5-3, W45-4, W48-3, W51-5, W72-2, ICW16-5, ICW20-1, P2-008, P3-049, P3-214, P3-311
Kunder, Rebecca ICW6-3
Kunishita, Yosuke W31-2-2, ICW3-2, ICW11-1, ICW12-3, P1-034, P1-179, P2-188, P2-277, P2-281
Kunugiza, Yasuo S3-2, S11-5, W18-4, W49-1, P2-031
Kuo, Yu-min ICW4-2
Kurabayashi, Takayoshi W56-5, P1-180, P2-306, P3-084, P3-087, P3-184
Kuramoto, Nobuo P2-018, P2-041
Kuroda, Hiroshi W29-4, W57-6
Kurihara, Hidemi P1-036, P3-072
Kurihara, Shunjiro W42-4, P2-290
Kurihara, Yuko P3-058
Kurita, Takashi W35-3, W47-4
Kuroda, Hiroshi W29-4, W57-6
Kuroda, Ryosuke W15-1, W51-4, P1-029, P1-035, P1-090, P2-042, P2-089
Kuroe, Yuriko S1-6
Kurokawa, Hiroaki S3-5
Kurokawa, Manae P2-017
Kuroki, Keiko P1-245
Kuroasaki, Nami W73-2
Kuroasawa, Michiko W72-3, W72-4
Kuroasawa, Yoichi W25-4, W65-3, ICW2-2, P1-085, P1-088, P1-144, P2-019, P2-155
Kurose, Nozomu S21-2, S21-3
Kurose, Rie P2-027, P3-002
Kuroyanagi, Gen P1-124, EP3-03
Kurumizawa, Megumi W2-2, W12-6, W77-6, P2-236, P3-111
Kurushina, Shota W34-2, W62-1, P2-122, P3-263
Kusaba, Atsushi P1-140
Kusaka, Hiroi P3-177, P3-245
Kusakabe, Masako P3-157
Kusanagi, Yasuyoshi W67-2, W67-6
Kusaoi, Makio P3-069, P3-295
Kusayama, Yoshihiro W74-2
Kushida, Taketoshi P1-138
Kusunoki, Natsuko W52-2
Kusunoki, Yoshie P2-038, P2-211
Kusuoka, Hiroyuki P3-046, P3-128, P3-170, P3-212, P3-243
Kuwabara, Satoshi S21-5
Kuytaris, Vasileios C ICW5-3
Lagaras, David ICW21-3
Lawrence, Able ICW8-2, ICW20-6
Lee, Eunkyong EP3-05
Lee, Hyeryong W43-1
Lee, Hyunho P1-144, P1-170
Lee, Ji-hyun ICW13-1
Lee, Wen Shi W62-4, ICW16-6, ICW19-4, EP3-01
Li, Mengtao ICW3-1, ICW4-1, ICW19-3, ICW19-6, EP2-07
Li, Xianpei ICW8-6, ICW14-1, ICW14-3, ICW18-6
Li, Xiaomei ICW8-6, ICW14-1, ICW14-3, ICW18-6
Li, Yang ICW3-1
Lian, Chaofeng ICW14-2
Lin, Yen-chun ICW4-2
Lin, Yong W30-3
Liu, Suying ICW14-2
Liu, Yang ICW15-5
Liu, Yi ICW3-1
Liu, Ziwei ICW19-6
Liviu, Macovei EP2-06
Loomis, Cynthia A ICW17-4
Lopez-olivo, Maria A EP2-11
Lotz, Martin K ICW2-6
Ly, Thai Yen ICW4-6
Mabuchi, Mayuko S1-5
Machida, Akitoshi P1-042, P1-250, P2-124
Machiyama, Tomoaki W72-5
<table>
<thead>
<tr>
<th>Name</th>
<th>ICW</th>
<th>W/C</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macias, William</td>
<td>ICW5-6</td>
<td>MA</td>
</tr>
<tr>
<td>Macovei, Liviu</td>
<td>ICW5-6</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Ayaka</td>
<td>W12-3, P3-120</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Hiroyuki</td>
<td>P3-055, P3-112</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Junko</td>
<td>ICW5-1, W52-1, W64-3, W72-1</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Kayaho</td>
<td>P1-216</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Shinji</td>
<td>P2-032, P3-224, P3-298</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Takuro</td>
<td>P1-118, P1-230, P1-237, P2-098, P2-130, P2-279, P3-238</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Tomoyo</td>
<td>P2-032</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Toshihisa</td>
<td>ICW5-1, P1-029</td>
<td>MA</td>
</tr>
<tr>
<td>Macias, William</td>
<td>W38-6</td>
<td>MA</td>
</tr>
<tr>
<td>Macovei, Liviu</td>
<td>ICW5-6</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Ayaka</td>
<td>W12-3, P3-120</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Hiroyuki</td>
<td>P3-055, P3-112</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Junko</td>
<td>ICW5-1, W52-1, W64-3, W72-1</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Kayaho</td>
<td>P1-216</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Shinji</td>
<td>P2-032, P3-224, P3-298</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Takuro</td>
<td>P1-118, P1-230, P1-237, P2-098, P2-130, P2-279, P3-238</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Tomoyo</td>
<td>P2-032</td>
<td>MA</td>
</tr>
<tr>
<td>Maeda, Toshihisa</td>
<td>ICW5-1, P1-029</td>
<td>MA</td>
</tr>
<tr>
<td>Maeshima, Keisuke</td>
<td>W1-4, ICW5-2</td>
<td>MA</td>
</tr>
<tr>
<td>Maeyama, Akira</td>
<td>P1-171</td>
<td>MA</td>
</tr>
<tr>
<td>Maeyama, Akira</td>
<td>W1-4, ICW5-2</td>
<td>MA</td>
</tr>
<tr>
<td>Maeyama, Akira</td>
<td>P1-171</td>
<td>MA</td>
</tr>
<tr>
<td>Makino, Hirofumi</td>
<td>W41-5, W41-6</td>
<td>MA</td>
</tr>
<tr>
<td>Makino, Katsunari</td>
<td>P2-214, P2-222</td>
<td>MA</td>
</tr>
<tr>
<td>Makino, Takamitsu</td>
<td>P2-214</td>
<td>MA</td>
</tr>
<tr>
<td>Makino, Yuichi</td>
<td>W31-1-2</td>
<td>MA</td>
</tr>
<tr>
<td>Makita, Sohei</td>
<td>P1-050</td>
<td>MA</td>
</tr>
<tr>
<td>Makiiyama, Akayo</td>
<td>W79-5, P1-020</td>
<td>MA</td>
</tr>
<tr>
<td>Makol, Ashima</td>
<td>ICW17-4</td>
<td>MA</td>
</tr>
<tr>
<td>Maldonado-cocco, José Antonio</td>
<td>W30-3</td>
<td>MA</td>
</tr>
<tr>
<td>Mamoto, Kenji</td>
<td>W9-2, W16-5, W23-6, W37-1, W68-1, W70-6, P2-023, P2-062, P3-008, P3-019, P3-290, P3-301</td>
<td>MA</td>
</tr>
<tr>
<td>Manningrova, Guhnara</td>
<td>ICW8-4</td>
<td>MA</td>
</tr>
<tr>
<td>Manabe, Miho</td>
<td>W74-5</td>
<td>MA</td>
</tr>
<tr>
<td>Manabe, Takehiko</td>
<td>P3-240</td>
<td>MA</td>
</tr>
<tr>
<td>Manabe, Yusuake</td>
<td>W45-4, W51-5, P3-049, P3-214, P3-311</td>
<td>MA</td>
</tr>
<tr>
<td>Mandai, Koji</td>
<td>S2-4, W16-5, W16-6, W37-1, W44-6, W68-1, ICW22-6, P3-001, P3-003, P3-004, P3-005, P3-006, P3-019, P3-020, P3-021, P3-290</td>
<td>MA</td>
</tr>
<tr>
<td>Marnami, Kenji</td>
<td>P1-114</td>
<td>MA</td>
</tr>
<tr>
<td>Marnami, Makoto</td>
<td>P1-114</td>
<td>MA</td>
</tr>
<tr>
<td>Marshall, Wayne</td>
<td>ICW22-3</td>
<td>MA</td>
</tr>
<tr>
<td>Maruno, Fumimasa</td>
<td>P2-286</td>
<td>MA</td>
</tr>
<tr>
<td>Maruyama, Akihito</td>
<td>W18-3, W22-4, W59-5, W60-5, P3-097, P3-142, P3-281</td>
<td>MA</td>
</tr>
<tr>
<td>Name</td>
<td>Contributions</td>
<td></td>
</tr>
<tr>
<td>-----------------------------</td>
<td>-------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>Matsumoto, Akihiko</td>
<td>W1-5</td>
<td></td>
</tr>
<tr>
<td>Matsumoto, Kazuko</td>
<td><strong>W63-4</strong>, P3-023</td>
<td></td>
</tr>
<tr>
<td>Matsumoto, Kazuya</td>
<td>W3-2, <strong>W32-3</strong>, P1-056</td>
<td></td>
</tr>
<tr>
<td>Matsumoto, Takumi</td>
<td><strong>S3-1</strong>, S9-7, EL12, W68-2, W75-5, ICW10-6, ICW22-1, P1-134, P1-173, P1-242, P3-117, <strong>P3-305</strong>, W43-3, W54-5, W76-2, ICW12-4, ICW14-4, ICW16-3, P2-005, P2-007, P2-009, P2-111, P2-239, P2-240, P2-242</td>
<td></td>
</tr>
<tr>
<td>Matsumoto, Takuya</td>
<td>W5-3, W14-2, W21-3, W24-5, W41-2, <strong>W47-6</strong>, W50-4, W71-7, ICW7-2, P1-052, P2-021, P2-173</td>
<td></td>
</tr>
<tr>
<td>Matsumoto, Tatsuki</td>
<td>W40-3, W58-3, P1-185, P3-032, <strong>P3-134</strong>, P3-278</td>
<td></td>
</tr>
<tr>
<td>Matsumoto, Yoshifugi</td>
<td>W76-1, P3-026</td>
<td></td>
</tr>
<tr>
<td>Matsumoto, Yoshinori</td>
<td>W40-1, <strong>ICW2-4</strong>, P2-024, P3-172, EP1-02</td>
<td></td>
</tr>
<tr>
<td>Matsumoto, Yuki</td>
<td>P1-050</td>
<td></td>
</tr>
<tr>
<td>Matsumura, Itaru</td>
<td>W20-5, W22-6, W28-2, W35-6, W46-2, W65-4, W75-1, P1-095, P1-207, P2-054, P2-090, P2-212, P3-143, P3-178</td>
<td></td>
</tr>
<tr>
<td>Matsumura, Ryutaro</td>
<td><strong>W33-1</strong>, W34-1, ICW18-2, P1-039, P1-233, P2-022</td>
<td></td>
</tr>
<tr>
<td>Matsumura, Yoko</td>
<td>W23-4, W75-2, P2-058, P2-116</td>
<td></td>
</tr>
<tr>
<td>Matsunaga, Keichiro</td>
<td>P3-065</td>
<td></td>
</tr>
<tr>
<td>Matsunaga, Takahiro</td>
<td>P1-210, P3-009</td>
<td></td>
</tr>
<tr>
<td>Matsuno, Hiroaki</td>
<td><strong>LS13-2</strong>, ES14, W8-6, <strong>P2-128</strong></td>
<td></td>
</tr>
<tr>
<td>Matsuo, Haruna</td>
<td>P3-223</td>
<td></td>
</tr>
<tr>
<td>Matsuo, Takashi</td>
<td>W36-6, P1-231</td>
<td></td>
</tr>
<tr>
<td>Matsuoka, Hidetoshi</td>
<td>W28-5, W61-3, W73-1, ICW9-1, ICW9-2, P1-061, P2-036, P2-067, P3-078, P3-118</td>
<td></td>
</tr>
<tr>
<td>Matsuoka, Naoya</td>
<td>W59-2, <strong>P3-101</strong>, P3-206</td>
<td></td>
</tr>
<tr>
<td>Matsuoka, Yuki</td>
<td>P3-129</td>
<td></td>
</tr>
<tr>
<td>Matsushima, Hideyuki</td>
<td>P3-199</td>
<td></td>
</tr>
<tr>
<td>Matsushita, Hiromi</td>
<td>W12-4, W39-3, W59-4, W64-6, W65-5, P1-046, P2-105, P3-090, P3-126, P3-284</td>
<td></td>
</tr>
<tr>
<td>Matsushita, Isao</td>
<td><strong>LS18</strong>, W19-4, P3-028</td>
<td></td>
</tr>
<tr>
<td>Matsushita, Masakazu</td>
<td>W3-6, P2-223, P2-246</td>
<td></td>
</tr>
<tr>
<td>Matsushita, Takashi</td>
<td>P3-110</td>
<td></td>
</tr>
<tr>
<td>Matsushita, Takayuki</td>
<td>P1-025</td>
<td></td>
</tr>
<tr>
<td>Matsuura, Isao</td>
<td>W18-6, <strong>P2-266</strong>, <strong>P3-148</strong></td>
<td></td>
</tr>
<tr>
<td>Matsuura, Mio</td>
<td>P1-081</td>
<td></td>
</tr>
<tr>
<td>Matsuura, Takunori</td>
<td>P1-031</td>
<td></td>
</tr>
<tr>
<td>Matsuura, Yoshinobu</td>
<td>W9-2, P2-097, P2-126, <strong>P3-204</strong>, P3-246, P3-259, P3-270</td>
<td></td>
</tr>
<tr>
<td>Matsuyama, Tsuyoshi</td>
<td>W7-2</td>
<td></td>
</tr>
<tr>
<td>Matsuyama, Yukihiro</td>
<td>W49-5, P1-044</td>
<td></td>
</tr>
<tr>
<td>Matsuzaki, Tomoko</td>
<td>P1-214</td>
<td></td>
</tr>
<tr>
<td>Matsuzawa, Hiroki</td>
<td><strong>P3-176</strong></td>
<td></td>
</tr>
<tr>
<td>Matsuzawa, Yasuo</td>
<td><strong>W53-5</strong></td>
<td></td>
</tr>
<tr>
<td>Matzkes, Franziska</td>
<td>ICW6-2</td>
<td></td>
</tr>
<tr>
<td>Meawatari, Masaaki</td>
<td>P2-152</td>
<td></td>
</tr>
<tr>
<td>Meawatari, Noriko</td>
<td>S1-4</td>
<td></td>
</tr>
<tr>
<td>Mayumi, Norihiro</td>
<td><strong>P2-074</strong></td>
<td></td>
</tr>
<tr>
<td>Mazur, Minodora</td>
<td>ICW6-3</td>
<td></td>
</tr>
<tr>
<td>McInnes, Iain</td>
<td>W38-6</td>
<td></td>
</tr>
<tr>
<td>Md Yusof, Md Yuzafu</td>
<td>ICW17-5</td>
<td></td>
</tr>
<tr>
<td>Meerwein, Sebastian</td>
<td>W38-1</td>
<td></td>
</tr>
<tr>
<td>Mega, Akira</td>
<td>P2-097, P2-126, P3-204, P3-246, P3-259, P3-270</td>
<td></td>
</tr>
<tr>
<td>Memida, Takumi</td>
<td><strong>P3-072</strong></td>
<td></td>
</tr>
<tr>
<td>Mera, Tomoko</td>
<td>P3-271</td>
<td></td>
</tr>
<tr>
<td>Meuleners, Luc</td>
<td>ICW6-3</td>
<td></td>
</tr>
<tr>
<td>Mezzano, Valeria</td>
<td>ICW17-4</td>
<td></td>
</tr>
<tr>
<td>Mibe, Junya</td>
<td><strong>P2-164</strong></td>
<td></td>
</tr>
<tr>
<td>Migita, Kiyoshi</td>
<td><strong>P3-223</strong></td>
<td></td>
</tr>
<tr>
<td>Miller, Frederick W</td>
<td>ICW8-4</td>
<td></td>
</tr>
<tr>
<td>Mimori, Tsuneyo</td>
<td>S21-2, W9-5, W30-4, W32-1, W36-6, W50-5, W51-3, W54-5, W78-6, ICW7-3, ICW16-1, P1-058, P1-094, P1-240, P3-007, P3-012, P3-091, P3-109, P3-239</td>
<td></td>
</tr>
<tr>
<td>Minami, Rumi</td>
<td>P1-111</td>
<td></td>
</tr>
<tr>
<td>Minami, Runa</td>
<td>P1-199</td>
<td></td>
</tr>
<tr>
<td>Minami, Shota</td>
<td>P1-049</td>
<td></td>
</tr>
<tr>
<td>Minamoto, Hiroko</td>
<td>W9-4</td>
<td></td>
</tr>
<tr>
<td>Mine, Masanobu</td>
<td><strong>P2-253</strong>, P3-303</td>
<td></td>
</tr>
<tr>
<td>Minemura, Nobuyoshi</td>
<td>P2-197, P3-098, P3-164, P3-205, P3-221, P3-283</td>
<td></td>
</tr>
<tr>
<td>Minoda, Masahiro</td>
<td><strong>P2-275</strong>, <strong>P3-045</strong></td>
<td></td>
</tr>
<tr>
<td>Minoda, Saki</td>
<td>W53-1, P3-109, P3-147</td>
<td></td>
</tr>
<tr>
<td>Minoda, Seiji</td>
<td>P1-004, P2-198, P3-150, P3-154, P3-177, P3-245, P3-258</td>
<td></td>
</tr>
<tr>
<td>Minowa, Kentaro</td>
<td>P1-129, P2-187, <strong>P2-194</strong>, P2-199, P3-234</td>
<td></td>
</tr>
<tr>
<td>Misaki, Kenta</td>
<td><strong>S2-1</strong>, MTE24, LS7-1, LS37-1, ICW1-1, P1-040, P1-193, P2-178</td>
<td></td>
</tr>
<tr>
<td>Misaki, Yoshikata</td>
<td>P3-242</td>
<td></td>
</tr>
<tr>
<td>Mishima, Koji</td>
<td>W34-5, <strong>P3-052</strong>, P3-254</td>
<td></td>
</tr>
<tr>
<td>Mishima, Shuko</td>
<td>W13-1, W13-6, <strong>P3-308</strong></td>
<td></td>
</tr>
<tr>
<td>Misra, Durga</td>
<td>EP1-05, <strong>EP2-08</strong>, <strong>EP2-10</strong></td>
<td></td>
</tr>
<tr>
<td>Misra, Ramnath</td>
<td>ICW20-6</td>
<td></td>
</tr>
<tr>
<td>Mitoma, Hiroki</td>
<td>ICW8-2, ICW20-6</td>
<td></td>
</tr>
<tr>
<td>W26-4, W33-2, W34-5, W65-1,</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

S422
<table>
<thead>
<tr>
<th>Name</th>
<th>Code(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Othman, Ahmed A</td>
<td>W38-1, W38-3</td>
</tr>
<tr>
<td>Oto, Yohsuke</td>
<td>W8-4, P1-025</td>
</tr>
<tr>
<td>Otsuka, Fumio</td>
<td>P3-018</td>
</tr>
<tr>
<td>Otsuka, Kyoko</td>
<td>W59-5, W60-5, P3-152</td>
</tr>
<tr>
<td>Otsuka, Mizuna</td>
<td>W31-1-6, W32-6, W33-5, W48-5, W62-5, P1-037, P1-069</td>
</tr>
<tr>
<td>Otsubo, Makoto</td>
<td>P2-242</td>
</tr>
<tr>
<td>Ototake, Yasushi</td>
<td>W69-5, P3-203</td>
</tr>
<tr>
<td>Otomo, Kotaro</td>
<td>W31-2-1</td>
</tr>
<tr>
<td>Otomo, Makoto</td>
<td>P2-242</td>
</tr>
<tr>
<td>Otsuka, Fumio</td>
<td>P3-018</td>
</tr>
<tr>
<td>Otsuka, Mizuna</td>
<td>W31-1-6, W32-6, W33-5, W48-5, W62-5, P1-037, P1-069</td>
</tr>
<tr>
<td>Otsuka, Yukimi</td>
<td>P2-037</td>
</tr>
<tr>
<td>Ouhara, Kazuhisa</td>
<td>P1-036, P3-072</td>
</tr>
<tr>
<td>Owada, Takayoshi</td>
<td>W2-3, W23-1, W23-5, W61-1, W64-4, P2-050, P3-130, P3-215</td>
</tr>
<tr>
<td>Otsuka, Yuko</td>
<td>P1-127, P2-310</td>
</tr>
<tr>
<td>Oya, Yoshihiro</td>
<td>W33-1, ICW18-2, P1-039, P1-233</td>
</tr>
<tr>
<td>Oyabu, Hideaki</td>
<td>W74-6</td>
</tr>
<tr>
<td>Oyakawa, Tomo</td>
<td>P1-213, P2-267</td>
</tr>
<tr>
<td>Oyama, Junji</td>
<td>P3-179</td>
</tr>
<tr>
<td>Ozaki, Hiroki</td>
<td>P3-226</td>
</tr>
<tr>
<td>Ozaki, Kyoko</td>
<td>P3-165</td>
</tr>
<tr>
<td>Ozaki, Shoichi</td>
<td>W17-4, W41-6</td>
</tr>
<tr>
<td>Ozaki, Takashi</td>
<td>W1-4, ICW5-2</td>
</tr>
<tr>
<td>Ozaki, Takuro</td>
<td>P3-029</td>
</tr>
<tr>
<td>Ozaki, Yoshio</td>
<td>W18-4, P1-138, P1-231, P3-048, P3-116, P3-267</td>
</tr>
<tr>
<td>Ozawa, Yuko</td>
<td>W40-5</td>
</tr>
<tr>
<td>Sada, Eiji</td>
<td>W21-3, W41-2, W47-6, P1-052</td>
</tr>
<tr>
<td>Sada, Ken- ei</td>
<td>LS2-1, W31-1-6, W31-2-2, W32-6, W40-1, W41-5, W41-6, ICW2-4, ICW3-2, P1-179, P1-182, P1-187, P1-191, P2-024, P2-188, P2-277, P2-281, P3-172, EP1-02</td>
</tr>
<tr>
<td>Sada, Ryuichi</td>
<td>W42-6, W53-1, P3-030, P3-109, P3-147</td>
</tr>
<tr>
<td>Sagawa, Akira</td>
<td>W8-6, W35-3, P1-010, P1-011, P1-096, P2-043</td>
</tr>
<tr>
<td>Sagawa, Tomoya</td>
<td>W18-2, W77-1, P2-087, P3-046, P3-128, P3-170, P3-212, P3-243</td>
</tr>
<tr>
<td>Sagisaka, Tamaki</td>
<td>P3-159</td>
</tr>
<tr>
<td>Sahara, Kagayaki</td>
<td>W75-6</td>
</tr>
<tr>
<td>Saito, Atsushi</td>
<td>P2-062</td>
</tr>
<tr>
<td>Saito, Keisuke</td>
<td>P3-046, P3-128, P3-170, P3-212, P3-243</td>
</tr>
<tr>
<td>Saito, Keitaro</td>
<td>P2-198, P3-177, P3-258</td>
</tr>
<tr>
<td>Saito, Koichiro</td>
<td>W19-1</td>
</tr>
<tr>
<td>Sairyo, Koichi</td>
<td>P1-132, P2-029</td>
</tr>
<tr>
<td>Saito, Kuniki</td>
<td>W67-4</td>
</tr>
<tr>
<td>Saito, Masaya</td>
<td>P2-066</td>
</tr>
<tr>
<td>Saito, Mayu</td>
<td>W65-6, P1-105, P1-182, P1-192</td>
</tr>
<tr>
<td>Saito, Mitsuru</td>
<td>P1-161</td>
</tr>
<tr>
<td>Saito, Mayu</td>
<td>W65-6, P1-105, P1-182, P1-192</td>
</tr>
<tr>
<td>Saito, Keitaro</td>
<td>P3-046, P3-128, P3-170, P3-212, P3-243</td>
</tr>
<tr>
<td>Saito, Koichiro</td>
<td>W34-1, P1-008, P2-011, P2-169</td>
</tr>
<tr>
<td>Saito, Atsushi</td>
<td>P2-294, P3-185</td>
</tr>
<tr>
<td>Saito, Keisuke</td>
<td>P2-198, P3-177, P3-258</td>
</tr>
<tr>
<td>Saito, Keitaro</td>
<td>P3-046, P3-128, P3-170, P3-212, P3-243</td>
</tr>
<tr>
<td>Saito, Kuniki</td>
<td>W67-4</td>
</tr>
<tr>
<td>Saito, Masaya</td>
<td>P2-066</td>
</tr>
<tr>
<td>Saito, Mayu</td>
<td>W65-6, P1-105, P1-182, P1-192</td>
</tr>
<tr>
<td>Saito, Mitsuru</td>
<td>P1-161</td>
</tr>
</tbody>
</table>
Sawabe, Kazuma  P1-111
Sawabe, Takuya  W59-5, W60-5, P3-202, P3-209, P3-218
Sawachika, Hiroshi  W73-2, P1-063, P2-202, P2-225
Sawada, Haruki  P2-227, P3-196, P3-213
Sawada, Tetsuji  P1-016, P1-017, P2-291, P2-295, P2-307, P3-229
Sawai, Takashi  P3-002
Sawamukai, Norifumi  P1-014, P1-048, P1-057
Schett, Georg  ICW18-5
Schlichting, Douglas  W38-6
Segawa, Seiji  P2-242
Seida, Yuka  P1-249
Seifert, Jennifer  PS-2
Seki, Iwao  P2-001
Seki, Kaori  W12-1, P3-195, P3-244
Seki, Kazushige  P2-270
Seki, Masanori  P2-304
Seki, Shinya  P3-158
 Sekiguchi, Akiko  W72-4
 Sekiguchi, Masahiro  W42-5, W54-4, P3-185
 Sekiguchi, Masayuki  W24-1
 Sekiguchi, Yukio  W53-3
 Sekijima, Yoshiki  W46-1, P1-026, P2-288, P3-054, P3-127, P3-208
 Sekimoto, Tomohisa  P2-151
 Sekine, Akinari  W21-6, W53-4, P1-055
 Sekine, Kazuomi  P2-252
Selvaraj, Shanmugapriya  ICW17-4
Sendo, Sho  W9-2, ICW7-4, P1-107, P2-278, P2-299, P3-077, P3-114, P3-181
Seno, Takahiro  P3-042
Seo, Kenichi  W5-6
Seri, Yu  W45-6
Seto, Nickie  PS-2, ICW16-2
Seto, Yohei  W18-6, W66-3, P2-266, P2-309, P3-148
Setoguchi, Keigo  W43-5, P2-228, P3-235, EP1-08
Shabana, Kosuke  W7-1, W13-4, P1-015, P2-252
Shao, Tihong  ICW14-2
Shestopaloff, Konstantin  EP3-07
Shevach, Ethan  ICW18-2
Shiba, Hideyuki  P1-239, P1-241, P2-058, P2-116, P3-105
Shiba, Takeshi  W63-2
Shibahara, Nobuhisa  P1-042, P1-250, P2-057, P2-124, P3-241
Shibamoto, Maki  W51-6, P3-082, P3-094, P3-173, P3-256
Shibanuma, Nao  W17-6, W37-6, P1-030, P1-033, P2-042
Shibata, Hirofumi  W63-2
Shibata, Horiyuki  W1-4, ICW5-2
Shibata, Sadamu  P2-165
Shibata, Toshiko  P1-190
Shibata, Yuhei  W62-4
Shibuto, Nobuyuki  P2-231
Shibuya, Hitoshi  S2-5
Shibuya, Takaaki  P2-082
Shich, Daisuke  W11-1, W11-2, W11-6
Shiga, Toshikiko  W20-5, W22-6, W28-2, W35-6, W46-2, W65-4, P1-208, P2-212, P3-143, P3-178
Shigemizu, Sanae  P3-277
Shigesaka, Minoru  P3-048, P3-267
Shiigi, Eiichi  P1-067
Shikano, Kotaro  W74-4, P3-133
Shima, Natsuki  P2-198, P3-150
Shimada, Kota  W66-2, P1-184, P1-224, P2-011, P2-224, P2-251, P2-264, P2-282, P2-287, P2-296, P2-311, P3-031, P3-074, P3-081, P3-276
Shimada, Yosuke  S3-3, W24-2, P1-003, P1-086, P2-094, P2-115, P2-154, P2-171
Shimada, Yuki  P2-272
Shimagami, Hiroshi  P2-097, P2-126, P3-246, P3-259, P3-270
Shimamura, Yoshiko  W14-3, W15-2, W15-6
Shimamura, Yoshiko  W18-4, P3-048, P3-116, P3-267
Shimura, Yoshiko  W40-3, W58-3, P1-185, P3-032, P3-134, P3-278
Shimane, Kenichi  W24-3, P1-145, P2-055
Shimane, Kenichi  P1-239, P1-241
Shimaoka, Erina  P2-229
Shimizu, Hideaki  P3-153
Shimizu, Hisanori  P3-196, P3-213
Shimizu, Jun  W45-1
Shimizu, Masaki  MTE6, W7-1, W7-6
Shimizu, Masamu  W1-2, W17-3, W20-3, W76-2, W76-5, ICW12-4, P2-009, P2-111
Shimizu, Masato  P1-014, P1-048, P1-057
Shimizu, Miho  P2-068
Shimizu, Takako  ICW10-4
Shimizu, Yuko  W47-4, ICW3-5
Shimono, Naoki  P2-052
Shimogori, Kei  P1-102, P1-232
Shimojima, Yasuhiro  W46-1, P1-026, P2-288, P3-054, P3-127, P3-208
Suzuki, Yasuo ACL-LS, W6-3, W44-4, W46-6, P1-181, P2-040, P2-306, P3-100, P3-124

Suzuki, Yukari P1-250

Suzuki, Yuta W18-5, ICW18-3, P2-079, P2-110, P2-160, P2-256

Szombati, Istvan ICW6-3

Tabata, Kayoko P2-018, P2-041

Tabuchi, Yuya W9-5, W32-1, W78-6

Tachibana, Masahiro W8-5

Tachihara, Miho P1-132, P2-029

Tada, Hitoshi P1-131, P1-222

Tada, Kurisu S18-2, W44-3, P1-097, P2-246, P2-272, P3-103, P3-119, P3-234, P3-257, P3-282

Tada, Masahiro W5-1, W9-2, W16-5, W16-6, W23-6, W36-3, W68-1, W70-6, ICW22-6, P2-023, P2-062, P3-001, P3-003, P3-004, P3-005, P3-006, P3-008, P3-021, P3-301

Tada, Tomomi W46-4, W47-3, P2-049, P2-181, P3-156, P3-189

Tada, Yoshifumi W18-3, W22-4, W78-5, P1-097, P3-142, P3-281

Tadokoro, Rei W51-6, P3-082, P3-094, P3-173, P3-249, P3-256

Tagawa, Yasuhiro P1-022

Tago, Mayu P1-016, P1-017, P2-295

Taguchi, Hiroaki W10-1, P3-044

Taguchi, Koichiro W35-5, W63-3, W78-1, P2-190, P3-255

Taguchi, Yoshio P3-091

Taguchi, Yuichiro P3-297

Takahara, Koichiro W78-5, P1-016, P1-017, P2-291, P2-295, P3-207

Tai, Yoshiaki P3-222

Tajima, Setsuko P1-132, P2-029

Takahayashi, Katsuhiro LS20-2, W29-6, P1-128

Takada, Hideto W68-4, P2-071

Takagi, Haruki W19-4, P1-108, P1-110, P1-167

Takagi, Hideki P1-076, P1-227

Takagi, Ikuyo W3-1

Takagi, Kaoru W58-2, P1-073, P1-115, P2-220, P3-275

Takagi, Kasumi W3-1

Takagi, Michiaki S11-4, W18-5, ICW18-3, P2-013, P2-016, P2-079, P2-110, P2-128, P2-160, P2-256

Takahama, Soichiro P1-212, P2-025, P3-161, P3-253, P3-303

Takahashi, Chihiro ICW10-1

Takahashi, Haruka W1-5

Takahashi, Hidenori P3-261

Takahashi, Hideyuki W43-5, P2-228, P3-235, EP1-08

Takahashi, Hiroki W42-2, W58-1

Takahashi, Hiroshi W5-5, W24-1, W56-1, W56-2, W14-3, P1-081
<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Takamura, Akito</td>
<td>W12-3</td>
</tr>
<tr>
<td>Takamura, Yoshiko</td>
<td>P1-243</td>
</tr>
<tr>
<td>Takamure, Hiroshi</td>
<td>ICW10-6</td>
</tr>
<tr>
<td>Takamashi, Satoshi</td>
<td>ICW10-1</td>
</tr>
<tr>
<td>Takamashi, Tetsumi</td>
<td>W35-1</td>
</tr>
<tr>
<td>Takano, Kyoko</td>
<td>P2-197, P3-098, P3-164, P3-205, P3-221, P3-283</td>
</tr>
<tr>
<td>Takao, Ken</td>
<td>P3-099</td>
</tr>
<tr>
<td>Takaori-Kondo, Akifumi</td>
<td>S21-2</td>
</tr>
<tr>
<td>Takasaki, Minoru</td>
<td>P1-218</td>
</tr>
<tr>
<td>Takasaki, Yoshinari</td>
<td>W54-5</td>
</tr>
<tr>
<td>Takasawa, Naruhiko</td>
<td>W53-3</td>
</tr>
<tr>
<td>Takashima, Yoshinori</td>
<td>W51-4, P1-035, P1-090, P2-089</td>
</tr>
<tr>
<td>Takasu, Hiroshi</td>
<td>P1-150, P1-165, P2-161</td>
</tr>
<tr>
<td>Takasugi, Kiyoshi</td>
<td>W15-6, W70-2, P1-018, P1-217, P2-257, P2-293</td>
</tr>
<tr>
<td>Takasugi, Koji</td>
<td>S1-3, W66-5, P1-079</td>
</tr>
<tr>
<td>Takasugi, Koji</td>
<td>P1-054, P1-226, P2-276, P2-297, P3-107</td>
</tr>
<tr>
<td>Takata, Kokoro</td>
<td>P1-248, P2-184</td>
</tr>
<tr>
<td>Takata, Miki</td>
<td>W11-4, P1-012, P2-259</td>
</tr>
<tr>
<td>Takatori, Kyohi</td>
<td>W31-1-2</td>
</tr>
<tr>
<td>Takatori, Sayaka</td>
<td>W31-1-2</td>
</tr>
<tr>
<td>Takatsuka, Kazutaka</td>
<td>P1-108, P1-110, P1-167</td>
</tr>
<tr>
<td>Takayama, Hirokuni</td>
<td>P2-180</td>
</tr>
<tr>
<td>Takayama, Yoshihiro</td>
<td>P1-155, P3-262</td>
</tr>
<tr>
<td>Takebe, Ken</td>
<td>P1-248, P2-125, P2-184, P3-015</td>
</tr>
<tr>
<td>Takeda, Chikako</td>
<td>P1-146, P2-100, P2-174</td>
</tr>
<tr>
<td>Takeda, Ryutaro</td>
<td>P1-173</td>
</tr>
<tr>
<td>Takeda, Setsuko</td>
<td>S2-4</td>
</tr>
<tr>
<td>Takeda, Tomofumi</td>
<td>W63-3, P1-077, P3-071</td>
</tr>
<tr>
<td>Takeda, Tomoki</td>
<td>P2-086</td>
</tr>
<tr>
<td>Takeda, Tsuyoshi</td>
<td>W35-3</td>
</tr>
<tr>
<td>Takehara, Kazuhiko</td>
<td>W58-1, W58-5, P3-110</td>
</tr>
<tr>
<td>Takehisa, Tomoko</td>
<td>P1-244</td>
</tr>
<tr>
<td>Takei, Hiroshi</td>
<td>W10-1, W31-2-6, ICW10-1, ICW21-4, P3-044</td>
</tr>
<tr>
<td>Takei, Masami</td>
<td>W40-2, W54-5, W59-3, ICW10-4, ICW10-5, P1-211, P3-033, P3-047, P3-210, P3-293</td>
</tr>
<tr>
<td>Takei, Reoto</td>
<td>W1-3</td>
</tr>
<tr>
<td>Takei, Syuji</td>
<td>S14-5, W76-3, P2-128</td>
</tr>
<tr>
<td>Takei, Yoshinori</td>
<td>W32-4</td>
</tr>
<tr>
<td>Takeji, Akari</td>
<td>W42-1, W43-6, P3-009, P3-192</td>
</tr>
<tr>
<td>Takekomi, Chiomato</td>
<td>W19-2</td>
</tr>
<tr>
<td>Takemoto, Miyuki</td>
<td>P1-246, P2-268</td>
</tr>
<tr>
<td>Takemoto, Toki</td>
<td>W71-7, W75-4, P1-166, P2-051</td>
</tr>
<tr>
<td>Takemura, Masao</td>
<td>W37-3, W67-4, P1-221, P2-103, P2-106, P2-261, P3-306</td>
</tr>
<tr>
<td>Takemura, Tamiko</td>
<td>S19-4</td>
</tr>
<tr>
<td>Takenaka, Katsuto</td>
<td>W21-3, W41-2, W47-6, P1-052</td>
</tr>
<tr>
<td>Takenouchi, Seiji</td>
<td>P1-102, P1-232</td>
</tr>
<tr>
<td>Takeshima, Yusuke</td>
<td>W52-1, W64-3, W72-1, ICW1-2, ICW1-4, ICW18-1, ICW21-1, P1-201</td>
</tr>
<tr>
<td>Takeshita, Masaru</td>
<td>W8-1, ICW1-5</td>
</tr>
<tr>
<td>Takeshita, Miki</td>
<td>P2-086</td>
</tr>
<tr>
<td>Taketomi, Shuji</td>
<td>S5-2</td>
</tr>
<tr>
<td>Takeuchi, Akiteru</td>
<td>P2-195, P3-232</td>
</tr>
<tr>
<td>Takeuchi, Kaoru</td>
<td>W35-3</td>
</tr>
<tr>
<td>Takeuchi, Masaki</td>
<td>S7-2, S14-2</td>
</tr>
<tr>
<td>Takeuchi, Yohei</td>
<td>P2-208, P2-234</td>
</tr>
<tr>
<td>Takeda, Yamahina</td>
<td>P3-273, P3-287</td>
</tr>
<tr>
<td>Takeda, Yukinami</td>
<td>W59-5, W60-5, P2-305</td>
</tr>
<tr>
<td>Takekayama, Munichiro</td>
<td>W7-4</td>
</tr>
<tr>
<td>Taki, Hirofumi</td>
<td>W19-4, P1-023, P2-285, P3-064, P3-076, P3-086, P3-180, P3-182, P3-207</td>
</tr>
<tr>
<td>Taigaka, Naohide</td>
<td>P2-047</td>
</tr>
<tr>
<td>Takiguchi, Maiko</td>
<td>W8-1, ICW1-5</td>
</tr>
<tr>
<td>Takiguchi, Mitsuko</td>
<td>P1-239, P1-241</td>
</tr>
<tr>
<td>Takita, Yusashi</td>
<td>W31-1-7, W38-6, W39-1</td>
</tr>
<tr>
<td>Takizawa, Naoho</td>
<td>P1-054, P1-226, P2-229, P2-276, P2-297, P3-107</td>
</tr>
<tr>
<td>Takizawa, Tsutomu</td>
<td>W66-6</td>
</tr>
<tr>
<td>Takizawa, Yasunobu</td>
<td>P3-010</td>
</tr>
<tr>
<td>Tamachi, Tomihito</td>
<td>P1-205, P3-104</td>
</tr>
<tr>
<td>Tamagawa, Kenji</td>
<td>P1-212, P2-025, P3-161, P3-253, P3-303</td>
</tr>
<tr>
<td>Tamai, Hiroshi</td>
<td>ICW10-1, ICW15-3</td>
</tr>
<tr>
<td>Tamai, Hiroya</td>
<td>MTE23</td>
</tr>
<tr>
<td>Name</td>
<td>Page Numbers</td>
</tr>
<tr>
<td>-----------------------</td>
<td>--------------</td>
</tr>
<tr>
<td>Tasaka, Yuji</td>
<td>P2-143</td>
</tr>
<tr>
<td>Tashiro, Yuka</td>
<td>P1-135</td>
</tr>
<tr>
<td>Tasset, Chantal</td>
<td>ICW6-2</td>
</tr>
<tr>
<td>Tateishi, Chiharu</td>
<td>P3-019, P3-020, P3-021</td>
</tr>
<tr>
<td>Tateishi, Koji</td>
<td>P1-030, P1-033, P1-248, P2-125, P2-184, P3-015</td>
</tr>
<tr>
<td>Tateishi, Mutsumi</td>
<td>P3-137, P3-260</td>
</tr>
<tr>
<td>Tateishi, Shoko</td>
<td>W9-6, ICW6-4, P3-022</td>
</tr>
<tr>
<td>Tatsumi, Emiko</td>
<td>P3-222</td>
</tr>
<tr>
<td>Tatsu, Yurika</td>
<td>P3-175</td>
</tr>
<tr>
<td>Tatsutani, Tomofumi</td>
<td>W34-5, P3-052, P3-254</td>
</tr>
<tr>
<td>Tawada, Kaneki</td>
<td>P2-096, P2-114</td>
</tr>
<tr>
<td>Temmoku, Jumpei</td>
<td>W43-2, W63-5, ICW15-4, P1-021, P1-183, P1-204, P2-237</td>
</tr>
<tr>
<td>Ten Brinck, Robin</td>
<td>W48-2</td>
</tr>
<tr>
<td>Terabe, Kenya</td>
<td>W65-2, P1-154</td>
</tr>
<tr>
<td>Terada, Kaoru</td>
<td>W34-2, W62-1, P2-122, P3-263</td>
</tr>
<tr>
<td>Terada, Makoto</td>
<td>P1-112, P3-043</td>
</tr>
<tr>
<td>Terada, Yoshio</td>
<td>W40-3, W58-3, P1-185, P3-032, P3-134, P3-278</td>
</tr>
<tr>
<td>Terai, Chihiro</td>
<td>W69-1, W69-2, P1-087, P2-238</td>
</tr>
<tr>
<td>Teranishi, Tsuyoshi</td>
<td>W18-4</td>
</tr>
<tr>
<td>Terao, Chiaki</td>
<td>EL21, ICW16-1</td>
</tr>
<tr>
<td>Terashima, Yasuhiro</td>
<td>P1-030, P1-033, P1-118, P1-248, P2-125, P2-184, P3-015</td>
</tr>
<tr>
<td>Terui, Tadashi</td>
<td>LS19-2</td>
</tr>
<tr>
<td>Teruya, Hiroyuki</td>
<td>P3-145</td>
</tr>
<tr>
<td>Teshigawara, Satoru</td>
<td>W28-5, W61-3, W73-1, ICW9-1, ICW9-2, P1-061, P2-036, P2-067, P3-078, P3-118</td>
</tr>
<tr>
<td>Teshima, Takenori</td>
<td>S2-5</td>
</tr>
<tr>
<td>Thomas, Stacey M</td>
<td>ICW16-2</td>
</tr>
<tr>
<td>Tian, Lu</td>
<td>ICW5-1</td>
</tr>
<tr>
<td>Tian, Zhuang</td>
<td>ICW3-1</td>
</tr>
<tr>
<td>Tobe, Kazuhiro</td>
<td>P1-023, P2-285, P3-064, P3-076, P3-086, P3-180, P3-182, P3-207</td>
</tr>
<tr>
<td>Tobimatsu, Haruki</td>
<td>S3-6, W49-4, P1-169</td>
</tr>
<tr>
<td>Tochihara, Mari</td>
<td>W31-2-3, P1-186, P1-206, P2-071, P2-232, P3-070, P3-167, P3-219</td>
</tr>
<tr>
<td>Tochimoto, Akiko</td>
<td>W58-2, P2-220</td>
</tr>
<tr>
<td>Toda, Masayoshi</td>
<td>P3-206</td>
</tr>
<tr>
<td>Toda, Yusuke</td>
<td>ICW9-5, P1-223, P3-166</td>
</tr>
<tr>
<td>Todoroki, Yasuyuki</td>
<td>ICW3-4, ICW8-1, ICW11-2, ICW21-5</td>
</tr>
<tr>
<td>Toguchida, Junya</td>
<td>W26-1</td>
</tr>
<tr>
<td>Tohdo, Satoshi</td>
<td>P1-100</td>
</tr>
<tr>
<td>Toi, Norikazu</td>
<td>W53-6</td>
</tr>
<tr>
<td>Toko, Hirofumi</td>
<td>W1-2, W20-3, W76-2, W76-5, ICW12-4, P2-111</td>
</tr>
<tr>
<td>Tokuda, Hitsoshi</td>
<td>S19-5</td>
</tr>
<tr>
<td>Tokuda, Michiaki</td>
<td>P2-208, P2-234</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name</th>
<th>Page Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tokunaga, Kenjiro</td>
<td>W20-1</td>
</tr>
<tr>
<td>Tokunaga, Tadahiro</td>
<td>W4-5, W5-7-4, P2-010, P2-217, P3-131, P3-268, P3-279</td>
</tr>
<tr>
<td>Tokunaga, Takahiro</td>
<td>W17-2, W34-6, P1-024, P1-032, P2-002, P2-034, EP3-08</td>
</tr>
<tr>
<td>Tokura, Masami</td>
<td>W64-2</td>
</tr>
<tr>
<td>Tokuhashi, Atsunori</td>
<td>P2-270</td>
</tr>
<tr>
<td>Toma, Tomoko</td>
<td>W63-3</td>
</tr>
<tr>
<td>Tomaru, Utano</td>
<td>P3-151</td>
</tr>
<tr>
<td>Tomita, Minako</td>
<td>S1-4-5</td>
</tr>
<tr>
<td>Tominaga, Akiyo</td>
<td>W16-2, P1-043</td>
</tr>
<tr>
<td>Tominaga, Masaki</td>
<td>P3-096</td>
</tr>
<tr>
<td>Tomita, Daisuke</td>
<td>W20-5, W22-6, W75-1, P1-095, P2-123</td>
</tr>
<tr>
<td>Tomita, Tetsuya</td>
<td>S18-4, W44-2, P3-036</td>
</tr>
<tr>
<td>Tomita, Tomoko</td>
<td>W45-3</td>
</tr>
<tr>
<td>Tomizawa, Takaya</td>
<td>W5-4, W49-3, W51-3</td>
</tr>
<tr>
<td>Tomizuka, Takaumi</td>
<td>P2-195, P3-232</td>
</tr>
<tr>
<td>Tomozawa, Sho</td>
<td>W46-5</td>
</tr>
<tr>
<td>Tono, Midori</td>
<td>P1-143</td>
</tr>
<tr>
<td>Tono, Toshihiro</td>
<td>S14-2, W31-1-3, P2-189, P3-092, P3-190, P3-229</td>
</tr>
<tr>
<td>Tonoooka, Kumiko</td>
<td>W12-4, W39-3, W59-4, W64-6, W65-5, P2-105, P3-090, P3-126, P3-284</td>
</tr>
<tr>
<td>Torigoe, Masataka</td>
<td>W1-4, ICW11-5</td>
</tr>
<tr>
<td>Torikai, Eiji</td>
<td>W39-2, W49-5, P1-044, P2-129</td>
</tr>
<tr>
<td>Torisu-Itakura, Hitoe</td>
<td>W22-1</td>
</tr>
<tr>
<td>Totoribe, Koji</td>
<td>P2-151</td>
</tr>
<tr>
<td>Toujima, Akihiro</td>
<td>ICW16-2</td>
</tr>
<tr>
<td>Toyama, Tadashi</td>
<td>P2-068</td>
</tr>
<tr>
<td>Toyoda, Yuko</td>
<td>P2-142</td>
</tr>
<tr>
<td>Toyohara, Isakua</td>
<td>P1-170</td>
</tr>
<tr>
<td>Toyota, Tsuyoshi</td>
<td>W66-6</td>
</tr>
<tr>
<td>Trivedi, Vikas</td>
<td>EP1-05, EP2-02, EP2-08, EP2-10</td>
</tr>
<tr>
<td>Tsai, Chang-youh</td>
<td>ICW13-3, EP2-05</td>
</tr>
<tr>
<td>Tsukos, George C</td>
<td>ICW5-3</td>
</tr>
<tr>
<td>Tsuboi, Hideki</td>
<td>S3-2, S11-5, W49-1, P1-139, P1-149, P2-120, P2-283</td>
</tr>
<tr>
<td>Tsuboi, Kazuhiro</td>
<td>W51-6, P2-107, P3-082, P3-094, P3-173, P3-185, P3-249, P3-256</td>
</tr>
<tr>
<td>Tsuboi, Masahiko</td>
<td>W32-2</td>
</tr>
<tr>
<td>Tsubouchi, Shiio</td>
<td>P1-248</td>
</tr>
<tr>
<td>Tsubouchi, Syoko</td>
<td>P2-291</td>
</tr>
<tr>
<td>Tsubouchi, Yasunori</td>
<td>P3-068</td>
</tr>
<tr>
<td>Tsuchida, Masahiko</td>
<td>W31-2-2, ICW3-2, ICW12-3, P1-034, P1-179, P2-188, P2-277, P2-281</td>
</tr>
<tr>
<td>Tsuchida, Takahiro</td>
<td>P2-069</td>
</tr>
</tbody>
</table>
You, Hanxiao  ICW4-1
Younan, Carolen  ICW22-5
Yu, Heiseki  W9-2,  P2-127
Yuan, Xiang  ICW14-1, ICW18-6
Yudoh, Kazuo  P2-001
Yukawa, Kazutoshi  W4-5, W57-4, P2-010, P2-217, P3-131,  P3-268, P3-279
Yukawa, Naoichiro  P2-041
Yukioka, Masao  ES9-3, W49-6, P2-082
Yumoto, Taeko  P1-207
Yu-sheng, Chang  ICW9-6

Z

Zaiss, Mario  ICW18-5
Zanwar, Abhishek  ICW20-6
Zeisbrich, Markus  ICW5-1
Zeng, Fanxing  ICW13-2
Zeng, Xiaofeng  ICW3-1, ICW4-1, ICW19-3, ICW19-6, EP2-07
Zhang, Fengchun  ICW14-2
Zhang, Haoze  ICW14-2
Zhang, Hui  ICW5-1
Zhang, Miaojia  ICW3-1
Zhang, Mingling  ICW11-2, ICW17-1
Zhang, Mingzeng  ICW11-5,  ICW11-6
Zhang, Wei  ICW3-1
Zhang, Xian  P1-204
Zhang, Xiao  ICW3-1
Zhang, Ying  W38-3
Zhang, Zhuoli  ICW3-1
Zhao, Fangyi  W44-2
Zhao, Jiuliang  ICW3-1, ICW4-1, ICW19-3
Zhao, Qianzi  ICW15-5
Zheng, Pan  ICW15-5
Zheng, Xu  ICW14-1, ICW18-6
Zheng, Yi  ICW3-1
Zhou, Yijie  W38-1
Zhou, Ying-bo  ICW18-6
Zhu, Ping  ICW3-1
Zoshima, Takeshi  P3-009, P3-067, P3-102
Zuo, Xiaoxia  ICW3-1